query_name	uniprot.hit_name	E value	bit score	coverage	identical	description
GN000007.1	sp|K1PU09|K1PU09_CRAGI	1.2e-29	135.6	91.67%	40.70%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000089.1	sp|K1PGV3|K1PGV3_CRAGI	9.6e-15	86.3	62.03%	38.51%	Putative short transient receptor potential channel 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003684|	GO:0000012|
GN000694.1	sp|A0A210QE43|A0A210QE43_MIZYE	7.7e-22	110.2	97.26%	29.66%	Cholecystokinin receptor type A;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000695.1	sp|K1QWA4|K1QWA4_CRAGI	6.0e-35	152.9	97.06%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000696.1	sp|K1PMM4|K1PMM4_CRAGI	1.2e-79	302.4	98.46%	51.84%	Beta-4C adrenergic receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000698.1	sp|K1PX07|K1PX07_CRAGI	1.9e-232	810.4	99.57%	86.80%	Adenylosuccinate lyase;OS=Crassostrea;PE=3;SV=1	GO:0070626|GO:0004018|	GO:0044208|GO:0006189|
GN000699.1	sp|K1RC63|K1RC63_CRAGI	2.8e-14	84.0	99.27%	32.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000090.1	sp|J9LXN4|J9LXN4_ACYPI	2.8e-11	74.3	91.48%	26.71%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2	GO:0000943|	GO:0003676|	GO:0015074|
GN000702.1	sp|K1RA63|K1RA63_CRAGI	2.1e-25	120.9	77.14%	55.05%	Transmembrane protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000703.1	sp|K1PIZ5|K1PIZ5_CRAGI	5.0e-160	570.1	85.55%	54.82%	Endo-1,4-beta-xylanase A;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0045493|
GN000705.1	sp|K1QMJ6|K1QMJ6_CRAGI	4.2e-235	819.7	100.00%	77.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000707.1	sp|K1QJQ8|K1QJQ8_CRAGI	4.5e-81	308.9	24.12%	50.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000708.1	sp|K1P959|K1P959_CRAGI	2.4e-125	453.8	100.00%	91.87%	Vacuolar-sorting protein SNF8;OS=Crassostrea;PE=3;SV=1	GO:0000814|	GO:0043328|
GN000710.1	sp|K1QFV0|K1QFV0_CRAGI	7.9e-73	279.6	95.86%	48.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000712.1	sp|K1R650|K1R650_CRAGI	2.4e-77	294.3	93.75%	62.28%	Plexin-B2;OS=Crassostrea;PE=4;SV=1	GO:0017154|
GN000713.1	sp|K1PFB7|K1PFB7_CRAGI	4.3e-86	323.6	92.63%	64.49%	DnaJ-like protein subfamily B member 3;OS=Crassostrea;PE=4;SV=1
GN000091.1	sp|A0A210QG44|A0A210QG44_MIZYE	2.1e-156	558.1	94.84%	54.69%	Sodium/potassium/calcium exchanger 5;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0055085|
GN000714.1	sp|B0YIL0|B0YIL0_CRAGI	3.1e-105	387.5	95.54%	55.36%	Bindin 4 repeat variant;OS=Crassostrea;PE=2;SV=1
GN000715.1	sp|D8VNK2|D8VNK2_9BIVA	2.6e-17	93.2	83.33%	63.08%	Bindin;OS=Crassostrea;PE=2;SV=1
GN000716.1	sp|E7BJ58|E7BJ58_CRASI	1.1e-12	78.6	59.38%	54.67%	Bindin;OS=Crassostrea;PE=2;SV=1
GN000717.1	sp|K1QWY2|K1QWY2_CRAGI	4.2e-14	84.3	27.74%	53.33%	alpha-1,2-Mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004571|	GO:0008152|
GN000718.1	sp|K1Q2U1|K1Q2U1_CRAGI	7.2e-137	492.3	100.00%	78.62%	Mitochondrial GTPase 1;OS=Crassostrea;PE=3;SV=1	GO:0005743|	GO:0005525|
GN000720.1	sp|K1Q9S6|K1Q9S6_CRAGI	3.0e-267	927.2	79.84%	65.18%	RING finger protein nhl-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN000721.1	sp|K1R9Q1|K1R9Q1_CRAGI	6.3e-201	705.7	100.00%	75.85%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN000723.1	sp|A0A210PGN3|A0A210PGN3_MIZYE	4.4e-77	293.5	88.12%	58.95%	Post-GPI attachment to proteins factor 3;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0006506|
GN000724.1	sp|K1Q2U4|K1Q2U4_CRAGI	2.0e-143	515.0	97.51%	83.58%	Uncharacterized protein C2orf77;OS=Crassostrea;PE=4;SV=1
GN000725.1	sp|K1PV73|K1PV73_CRAGI	7.5e-106	389.0	96.09%	69.39%	Pyridoxal phosphate phosphatase PHOSPHO2;OS=Crassostrea;PE=4;SV=1	GO:0016791|
GN000726.1	sp|K1QQY1|K1QQY1_CRAGI	3.8e-100	370.2	100.00%	63.94%	Cytochrome P450 20A1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0016705|
GN000727.1	sp|K1QX53|K1QX53_CRAGI	5.9e-32	142.1	89.47%	77.38%	Cytochrome P450 20A1;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN000728.1	sp|C3YRP4|C3YRP4_BRAFL	5.7e-54	217.2	93.32%	38.06%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN000729.1	sp|C3ZUM2|C3ZUM2_BRAFL	6.8e-29	134.0	64.00%	32.75%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN000731.1	sp|K1Q019|K1Q019_CRAGI	1.1e-282	977.6	95.34%	74.02%	Beta-galactosidase;OS=Crassostrea;PE=3;SV=1	GO:0004565|	GO:0005975|
GN000732.1	sp|K1PP75|K1PP75_CRAGI	2.9e-17	94.7	46.85%	45.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000092.1	sp|K1R4C3|K1R4C3_CRAGI	3.0e-38	163.3	95.61%	71.30%	Receptor-type tyrosine-protein phosphatase alpha;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN000733.1	sp|K1QWI9|K1QWI9_CRAGI	2.4e-177	627.1	99.74%	74.27%	Polypeptide N-acetylgalactosaminyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN000734.1	sp|A0A1S3GY56|A0A1S3GY56_LINUN	1.6e-85	322.8	98.22%	30.89%	kelch-like protein 41;OS=Lingula;PE=4;SV=1
GN000735.1	sp|K1QX53|K1QX53_CRAGI	1.8e-33	147.1	89.47%	79.76%	Cytochrome P450 20A1;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN000736.1	sp|K1PWI6|K1PWI6_CRAGI	4.8e-79	299.3	93.59%	90.34%	Apoptosis regulator R1;OS=Crassostrea;PE=4;SV=1	GO:0006915|GO:0042981|
GN000737.1	sp|C3S7I4|C3S7I4_CRAGI	9.9e-66	255.0	95.97%	83.80%	Predicted Bcl-2 protein;OS=Crassostrea;PE=2;SV=1	GO:0006915|GO:0042981|
GN000738.1	sp|K1P828|K1P828_CRAGI	2.3e-121	441.0	91.64%	64.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000739.1	sp|K1RIM7|K1RIM7_CRAGI	9.1e-20	102.1	47.24%	76.27%	Methionine aminopeptidase 2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0046872|GO:0070006|	GO:0070084|
GN000740.1	sp|K1PPF0|K1PPF0_CRAGI	5.9e-113	413.3	87.22%	67.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000741.1	sp|K1R699|K1R699_CRAGI	6.5e-87	325.9	87.38%	79.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000742.1	sp|K1Q0E7|K1Q0E7_CRAGI	2.3e-69	266.9	98.52%	88.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000743.1	sp|K1QZX9|K1QZX9_CRAGI	2.3e-163	580.5	100.00%	65.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN000744.1	sp|K1R175|K1R175_CRAGI	1.5e-66	258.8	92.24%	44.15%	Carbonic anhydrase 7;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|
GN000747.1	sp|K1PGW4|K1PGW4_CRAGI	3.4e-235	820.8	100.00%	51.18%	Myoneurin;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000748.1	sp|K1PAM0|K1PAM0_CRAGI	1.5e-234	817.8	92.29%	75.10%	Fatty-acid amide hydrolase 1;OS=Crassostrea;PE=4;SV=1	GO:0004040|
GN000749.1	sp|K1Q7N1|K1Q7N1_CRAGI	8.6e-39	167.2	28.39%	63.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000750.1	sp|A0A210R1C7|A0A210R1C7_MIZYE	7.7e-25	120.9	94.41%	22.64%	E3 ubiquitin-protein ligase TRIM56;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN000751.1	sp|K1Q1X2|K1Q1X2_CRAGI	4.4e-77	293.5	93.18%	60.41%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003906|GO:0003950|	GO:0006302|
GN000752.1	sp|K1Q1X2|K1Q1X2_CRAGI	2.4e-75	287.7	100.00%	68.82%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003906|GO:0003950|	GO:0006302|
GN000753.1	sp|A0A210PRE0|A0A210PRE0_MIZYE	7.0e-215	753.1	99.56%	47.78%	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1;OS=Mizuhopecten;PE=3;SV=1	GO:0036310|GO:0005524|	GO:0006281|GO:0031297|
GN000095.1	sp|K1RNC3|K1RNC3_CRAGI	5.7e-63	246.1	70.81%	87.69%	ADP-ribosylation factor H;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN000756.1	sp|K1QFU9|K1QFU9_CRAGI	3.1e-32	143.7	72.03%	58.82%	Brorin;OS=Crassostrea;PE=4;SV=1
GN000758.1	sp|K1QE55|K1QE55_CRAGI	0.0e+00	1337.4	98.92%	90.33%	Methylmalonyl-CoA mutase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0031419|GO:0046872|GO:0004494|
GN000759.1	sp|K1PCG7|K1PCG7_CRAGI	1.4e-223	781.2	87.86%	78.59%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN000760.1	sp|K1R190|K1R190_CRAGI	5.9e-13	79.7	85.71%	45.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000763.1	sp|A0A1X7T0L5|A0A1X7T0L5_AMPQE	2.5e-63	248.8	97.51%	31.41%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN000764.1	sp|A7RPZ5|A7RPZ5_NEMVE	1.8e-21	108.2	68.33%	43.44%	Predicted protein;OS=Nematostella;PE=4;SV=1	GO:0005694|GO:0005737|GO:0005634|	GO:0005524|GO:0043140|GO:0003677|GO:0009378|	GO:0032508|GO:0006310|GO:0006281|GO:0000724|
GN000765.1	sp|C3YMK5|C3YMK5_BRAFL	7.4e-28	129.4	95.45%	40.00%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005694|GO:0005737|GO:0005634|	GO:0005524|GO:0043140|GO:0003677|GO:0009378|	GO:0032508|GO:0006310|GO:0006281|GO:0000724|
GN000766.1	sp|W4YMP2|W4YMP2_STRPU	1.6e-24	118.6	70.78%	49.69%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN000767.1	sp|K1QC44|K1QC44_CRAGI	5.8e-151	539.7	99.08%	64.45%	Synaptosomal-associated protein 47;OS=Crassostrea;PE=4;SV=1
GN000768.1	sp|A0A210QIP8|A0A210QIP8_MIZYE	1.6e-148	531.6	100.00%	63.17%	3-ketoacyl-CoA thiolase B, peroxisomal;OS=Mizuhopecten;PE=3;SV=1	GO:0016747|
GN000769.1	sp|K1PG67|K1PG67_CRAGI	1.1e-234	818.1	98.93%	75.58%	Sodium/nucleoside cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005337|
GN000771.1	sp|K1QPY5|K1QPY5_CRAGI	2.1e-185	654.8	97.93%	48.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN000774.1	sp|A0A2B4RZW9|A0A2B4RZW9_STYPI	4.6e-16	90.5	53.99%	33.33%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0008270|
GN000775.1	sp|K1QFG2|K1QFG2_CRAGI	0.0e+00	2473.0	98.62%	55.79%	Telomere-associated protein RIF1;OS=Crassostrea;PE=4;SV=1
GN000776.1	sp|K1Q066|K1Q066_CRAGI	6.3e-155	552.7	94.17%	65.89%	Growth/differentiation factor 8;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008083|
GN000779.1	sp|K1QAX7|K1QAX7_CRAGI	1.3e-28	132.9	32.34%	58.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000781.1	sp|K1PCI8|K1PCI8_CRAGI	7.8e-73	279.3	73.00%	85.06%	Cullin-2;OS=Crassostrea;PE=3;SV=1	GO:0031461|	GO:0031625|	GO:0006511|
GN000782.1	sp|K1Q728|K1Q728_CRAGI	1.6e-44	186.0	95.97%	30.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000097.1	sp|A0A210PWC3|A0A210PWC3_MIZYE	1.1e-10	71.6	49.04%	70.00%	Short-chain dehydrogenase TIC 32, chloroplastic;OS=Mizuhopecten;PE=4;SV=1
GN000784.1	sp|K1QTT0|K1QTT0_CRAGI	0.0e+00	1220.7	99.61%	77.82%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008376|
GN000785.1	sp|A0A210R6H1|A0A210R6H1_MIZYE	4.5e-93	348.2	86.12%	29.93%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000786.1	sp|K1QF05|K1QF05_CRAGI	2.6e-233	813.5	93.97%	75.29%	Beta,beta-carotene 15,15'-monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0046872|GO:0004497|GO:0016702|
GN000787.1	sp|K1Q6Z4|K1Q6Z4_CRAGI	1.1e-192	679.1	87.10%	49.43%	Beta-1,3-galactosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0008378|	GO:0006486|
GN000788.1	sp|K1RIZ9|K1RIZ9_CRAGI	0.0e+00	1084.3	96.88%	70.23%	Band 4.1-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005856|GO:0016021|	GO:0005524|GO:0016887|
GN000789.1	sp|K1PNG2|K1PNG2_CRAGI	6.1e-27	126.7	86.67%	39.18%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1
GN000790.1	sp|K1R643|K1R643_CRAGI	3.0e-32	144.4	87.60%	50.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000795.1	sp|K1QI65|K1QI65_CRAGI	8.5e-156	555.4	97.49%	76.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000796.1	sp|K1QVD1|K1QVD1_CRAGI	4.1e-32	144.1	45.02%	48.17%	Kielin/chordin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0030414|
GN000797.1	sp|K1RNF3|K1RNF3_CRAGI	1.5e-98	365.2	99.40%	50.44%	Steroid 17-alpha-hydroxylase/17,20 lyase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0016829|GO:0004497|GO:0016705|
GN000798.1	sp|K1QQF6|K1QQF6_CRAGI	4.0e-18	97.1	55.75%	48.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000801.1	sp|A0A1S3IV22|A0A1S3IV22_LINUN	9.5e-15	85.5	79.56%	39.45%	uncharacterized protein LOC106167536;OS=Lingula;PE=4;SV=1	GO:0008270|
GN000802.1	sp|A0A147BID2|A0A147BID2_IXORI	1.0e-29	136.3	67.01%	40.50%	Putative phage-type endonuclease;OS=Ixodes;PE=4;SV=1	GO:0004519|
GN000803.1	sp|V4AGJ7|V4AGJ7_LOTGI	6.4e-14	83.2	76.22%	37.14%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN000804.1	sp|K1Q2Z6|K1Q2Z6_CRAGI	1.1e-226	791.6	97.55%	65.71%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN000805.1	sp|K1Q2Z6|K1Q2Z6_CRAGI	1.1e-221	775.0	96.05%	64.64%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN000806.1	sp|K1Q2Z6|K1Q2Z6_CRAGI	8.6e-219	765.4	97.56%	63.93%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN000807.1	sp|K1Q2Z6|K1Q2Z6_CRAGI	7.8e-228	795.4	97.39%	65.89%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN000808.1	sp|K1R0Z9|K1R0Z9_CRAGI	8.3e-107	392.9	67.16%	67.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000009.1	sp|K1PU09|K1PU09_CRAGI	1.8e-25	121.7	93.03%	37.19%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000100.1	sp|W4XWS8|W4XWS8_STRPU	2.6e-09	67.8	77.19%	28.57%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0046872|
GN000809.1	sp|K1QVT0|K1QVT0_CRAGI	1.4e-186	657.9	100.00%	96.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN000810.1	sp|K1QA06|K1QA06_CRAGI	1.3e-59	235.0	99.46%	64.48%	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN000812.1	sp|K1PFQ4|K1PFQ4_CRAGI	1.3e-12	78.2	47.06%	58.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000814.1	sp|K1PX51|K1PX51_CRAGI	3.1e-30	136.3	98.88%	79.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000821.1	sp|K1PSU4|K1PSU4_CRAGI	6.3e-70	270.0	92.43%	43.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN000103.1	sp|V3ZMP6|V3ZMP6_LOTGI	4.4e-59	234.2	70.96%	44.66%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN000824.1	sp|K1QE14|K1QE14_CRAGI	3.5e-55	221.5	42.02%	63.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000825.1	sp|K1REY6|K1REY6_CRAGI	6.0e-60	236.9	99.69%	41.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000827.1	sp|K1RT71|K1RT71_CRAGI	1.2e-24	119.0	59.42%	48.36%	Transmembrane protein 19;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000828.1	sp|K1QY88|K1QY88_CRAGI	4.3e-18	98.2	93.51%	27.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN000830.1	sp|K1RDJ9|K1RDJ9_CRAGI	4.2e-170	603.6	89.78%	71.23%	Sphingosine 1-phosphate receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000831.1	sp|O02622|O02622_CRAGI	5.1e-288	995.3	89.26%	88.74%	Alpha-amylase;OS=Crassostrea;PE=2;SV=1	GO:0004556|GO:0103025|GO:0043169|	GO:0005975|
GN000832.1	sp|K1Q686|K1Q686_CRAGI	3.8e-131	473.4	99.37%	72.61%	Hydroxysteroid 17-beta dehydrogenase 6;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN000833.1	sp|A0A210R344|A0A210R344_MIZYE	4.7e-130	469.9	94.99%	64.12%	L-galactose dehydrogenase;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN000834.1	sp|K1R6W8|K1R6W8_CRAGI	0.0e+00	1177.5	88.39%	61.65%	Integrin alpha-PS3;OS=Crassostrea;PE=3;SV=1	GO:0008305|	GO:0007155|GO:0007229|
GN000835.1	sp|K1PIV5|K1PIV5_CRAGI	7.9e-311	1072.0	99.15%	45.25%	Estrogen sulfotransferase;OS=Crassostrea;PE=3;SV=1	GO:0008305|	GO:0008146|	GO:0007155|GO:0007229|
GN000837.1	sp|K1R7B9|K1R7B9_CRAGI	2.6e-103	381.7	73.25%	49.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000838.1	sp|K1QWV7|K1QWV7_CRAGI	1.9e-106	391.3	87.66%	69.57%	Transforming growth factor-beta-induced protein ig-h3;OS=Crassostrea;PE=4;SV=1
GN000840.1	sp|A0A210QP02|A0A210QP02_MIZYE	4.3e-39	167.2	97.07%	40.25%	Cation-dependent mannose-6-phosphate receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN000842.1	sp|K1Q4J6|K1Q4J6_CRAGI	1.9e-181	641.0	97.95%	75.00%	Corticotropin-releasing factor receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN000843.1	sp|K1PSQ5|K1PSQ5_CRAGI	4.6e-34	151.8	98.47%	23.95%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN000844.1	sp|K1RU35|K1RU35_CRAGI	1.2e-90	338.2	100.00%	81.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000106.1	sp|W4XWS8|W4XWS8_STRPU	6.3e-10	70.5	53.68%	29.05%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0046872|
GN000846.1	sp|K1QBH4|K1QBH4_CRAGI	0.0e+00	1223.4	100.00%	86.18%	ATP-dependent RNA helicase DDX42;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN000848.1	sp|K1QK00|K1QK00_CRAGI	2.2e-216	756.9	100.00%	95.54%	Zinc finger CCCH domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN000010.1	sp|K1PU09|K1PU09_CRAGI	4.8e-27	126.7	97.71%	34.50%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000851.1	sp|K1QE86|K1QE86_CRAGI	1.9e-12	78.6	40.37%	43.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000852.1	sp|K1QE86|K1QE86_CRAGI	3.9e-43	180.6	43.32%	76.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000853.1	sp|K1RFC1|K1RFC1_CRAGI	2.3e-143	514.2	91.42%	73.18%	Melatonin-related receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008502|
GN000855.1	sp|K1S2H7|K1S2H7_CRAGI	3.7e-87	327.0	100.00%	57.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000856.1	sp|K1QX89|K1QX89_CRAGI	6.3e-93	346.7	97.88%	47.48%	Complement C1q-like protein 2;OS=Crassostrea;PE=4;SV=1
GN000857.1	sp|K1R4K4|K1R4K4_CRAGI	5.6e-18	97.4	46.54%	35.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000109.1	sp|K1QSX2|K1QSX2_CRAGI	5.0e-20	102.4	68.13%	83.61%	Dehydrogenase/reductase SDR family member 13;OS=Crassostrea;PE=3;SV=1
GN000859.1	sp|A0A210PJC7|A0A210PJC7_MIZYE	1.8e-74	285.4	91.21%	48.44%	Embryonic protein UVS.2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN000860.1	sp|K1PHG9|K1PHG9_CRAGI	3.1e-09	68.9	8.10%	97.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000861.1	sp|K1P3L8|K1P3L8_CRAGI	5.3e-79	299.3	100.00%	91.28%	Amino acid transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015293|
GN000863.1	sp|K1PMC5|K1PMC5_CRAGI	3.0e-36	158.3	34.83%	60.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000865.1	sp|K1RB12|K1RB12_CRAGI	5.1e-30	136.7	39.18%	92.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008191|	GO:1904684|GO:0060828|GO:0001944|
GN000868.1	sp|K1QVW8|K1QVW8_CRAGI	2.6e-189	667.2	97.67%	73.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000869.1	sp|K1R2M4|K1R2M4_CRAGI	2.6e-136	491.1	78.83%	69.41%	Secretin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN000870.1	sp|K1PLC5|K1PLC5_CRAGI	9.1e-98	363.6	73.00%	36.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000871.1	sp|K1RCG2|K1RCG2_CRAGI	1.4e-50	204.9	97.18%	58.29%	ATP-dependent DNA helicase tlh2;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN000872.1	sp|K1Q9J4|K1Q9J4_CRAGI	1.8e-61	242.3	51.34%	53.81%	Zinc finger CW-type PWWP domain protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0008270|
GN000873.1	sp|K1RT67|K1RT67_CRAGI	0.0e+00	1264.6	98.33%	75.77%	Partitioning defective 3-like protein;OS=Crassostrea;PE=4;SV=1
GN000874.1	sp|V4AE92|V4AE92_LOTGI	3.0e-86	325.1	74.48%	41.36%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN000875.1	sp|A0A210QF09|A0A210QF09_MIZYE	1.1e-29	137.5	52.32%	29.52%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000876.1	sp|K1RIT6|K1RIT6_CRAGI	0.0e+00	1346.6	91.69%	89.41%	NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0009055|GO:0051536|GO:0008137|	GO:0042773|
GN000883.1	sp|A0A210Q1J5|A0A210Q1J5_MIZYE	4.6e-12	77.0	92.51%	35.08%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000884.1	sp|A0A210PJT7|A0A210PJT7_MIZYE	2.5e-09	68.6	53.36%	33.13%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000886.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	2.6e-20	104.8	50.21%	41.67%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN000887.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	3.0e-106	392.1	82.58%	33.52%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN000895.1	sp|A0A1X7THR6|A0A1X7THR6_AMPQE	2.8e-55	221.9	97.81%	32.97%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|
GN000896.1	sp|K1PRV0|K1PRV0_CRAGI	5.2e-47	193.7	44.29%	78.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN000897.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN000113.1	sp|K1RM61|K1RM61_CRAGI	1.5e-50	205.7	96.88%	37.06%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN000899.1	sp|K1QNW0|K1QNW0_CRAGI	8.0e-15	85.5	99.13%	72.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000900.1	sp|V4A8A4|V4A8A4_LOTGI	3.1e-18	97.4	85.55%	35.37%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN000902.1	sp|K1QMQ3|K1QMQ3_CRAGI	1.2e-136	492.3	98.75%	58.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000903.1	sp|K1QTT5|K1QTT5_CRAGI	1.9e-184	651.0	93.72%	74.54%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN000904.1	sp|V3ZX45|V3ZX45_LOTGI	2.3e-79	302.0	88.16%	40.09%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN000907.1	sp|K1QNZ5|K1QNZ5_CRAGI	7.1e-28	129.8	79.19%	40.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000908.1	sp|K1PHJ6|K1PHJ6_CRAGI	1.9e-132	479.6	79.24%	33.27%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN000011.1	sp|K1PU09|K1PU09_CRAGI	8.9e-29	133.7	47.99%	33.51%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000909.1	sp|K1PHJ6|K1PHJ6_CRAGI	4.1e-146	525.4	57.15%	36.45%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN000910.1	sp|K1QFL5|K1QFL5_CRAGI	2.4e-21	110.5	28.36%	25.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000912.1	sp|K1QFL5|K1QFL5_CRAGI	1.4e-16	92.8	46.52%	38.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000913.1	sp|K1REY4|K1REY4_CRAGI	1.2e-56	225.7	96.19%	43.31%	Replication factor A protein 1;OS=Crassostrea;PE=4;SV=1
GN000914.1	sp|A0A210Q124|A0A210Q124_MIZYE	1.3e-13	82.0	78.57%	39.39%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000915.1	sp|K1PMC5|K1PMC5_CRAGI	1.5e-25	120.9	98.06%	56.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000917.1	sp|K1S0K2|K1S0K2_CRAGI	1.2e-150	538.5	96.38%	67.34%	Secernin-1;OS=Crassostrea;PE=4;SV=1	GO:0016805|
GN000918.1	sp|K1RM80|K1RM80_CRAGI	8.5e-227	791.6	92.13%	94.96%	Citrate synthase;OS=Crassostrea;PE=3;SV=1	GO:0004108|	GO:0006099|
GN000920.1	sp|W4XUP0|W4XUP0_STRPU	3.8e-15	87.4	40.58%	45.74%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004842|
GN000922.1	sp|W4YZM0|W4YZM0_STRPU	5.5e-42	176.4	100.00%	45.41%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|	GO:0015074|
GN000012.1	sp|K1PU09|K1PU09_CRAGI	5.2e-25	120.2	91.67%	37.19%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000134.1	sp|K1QSX2|K1QSX2_CRAGI	1.3e-118	432.2	71.04%	64.83%	Dehydrogenase/reductase SDR family member 13;OS=Crassostrea;PE=3;SV=1
GN000135.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	1.2e-46	192.2	83.11%	47.06%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN000136.1	sp|K1QN00|K1QN00_CRAGI	2.0e-104	384.4	82.37%	76.32%	Uracil-DNA glycosylase;OS=Crassostrea;PE=3;SV=1	GO:0005739|GO:0005634|	GO:0004844|	GO:0006284|
GN000137.1	sp|A0A210QFP7|A0A210QFP7_MIZYE	1.0e-182	646.0	90.30%	49.49%	F-box/LRR-repeat protein 18;OS=Mizuhopecten;PE=4;SV=1
GN000013.1	sp|K1PU09|K1PU09_CRAGI	3.9e-62	245.0	98.76%	28.71%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000144.1	sp|K1PEP3|K1PEP3_CRAGI	1.8e-21	107.8	75.56%	51.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000014.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	2.8e-34	151.0	88.89%	42.47%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000145.1	sp|K1S0A7|K1S0A7_CRAGI	6.0e-286	990.7	59.38%	35.17%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0016787|GO:0005044|
GN000147.1	sp|A0A2B4RQ39|A0A2B4RQ39_STYPI	2.5e-67	261.2	85.61%	52.81%	Putative nuclease HARBI1;OS=Stylophora;PE=4;SV=1
GN000015.1	sp|A0A2B4R9F6|A0A2B4R9F6_STYPI	4.6e-61	241.9	51.59%	35.25%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN000148.1	sp|A0A1S3I398|A0A1S3I398_LINUN	5.9e-17	93.2	60.23%	41.51%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN000149.1	sp|A0A2B4R9F6|A0A2B4R9F6_STYPI	6.5e-23	113.6	91.27%	30.53%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN000150.1	sp|K1RC81|K1RC81_CRAGI	3.1e-61	240.4	100.00%	65.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000152.1	sp|K1Q330|K1Q330_CRAGI	3.6e-82	311.2	78.16%	47.72%	Dihydrolipoyl dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0005623|GO:0016021|	GO:0004148|GO:0050660|GO:0004930|	GO:0045454|GO:0007166|
GN000016.1	sp|K1PU09|K1PU09_CRAGI	1.0e-74	286.6	98.21%	34.12%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000153.1	sp|K1RB32|K1RB32_CRAGI	1.3e-34	152.1	78.14%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000154.1	sp|K1Q178|K1Q178_CRAGI	1.5e-51	208.0	100.00%	53.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000017.1	sp|K1PU09|K1PU09_CRAGI	3.0e-92	345.1	97.10%	33.58%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000155.1	sp|K1Q178|K1Q178_CRAGI	9.8e-100	369.0	99.68%	54.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000156.1	sp|K1QIE5|K1QIE5_CRAGI	1.1e-23	115.2	100.00%	47.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000158.1	sp|K1QLS5|K1QLS5_CRAGI	2.0e-127	460.7	100.00%	85.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000159.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN000160.1	sp|K1QAP7|K1QAP7_CRAGI	5.2e-15	85.1	89.47%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000161.1	sp|K1Q3D9|K1Q3D9_CRAGI	4.0e-13	79.0	80.65%	79.59%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000018.1	sp|K1PU09|K1PU09_CRAGI	2.2e-28	131.3	88.61%	35.20%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000162.1	sp|K1Q3D9|K1Q3D9_CRAGI	1.8e-10	70.9	64.71%	87.69%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000163.1	sp|A0A2H4PXG3|A0A2H4PXG3_CRAVI	3.1e-10	69.3	81.67%	70.83%	Caltractin;OS=Crassostrea;PE=2;SV=1	GO:0005509|
GN000165.1	sp|Q70SJ4|Q70SJ4_CRAGI	1.2e-220	771.2	98.67%	82.25%	Calcitonin-like receptor;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN000019.1	sp|K1PU09|K1PU09_CRAGI	3.8e-79	301.2	97.88%	39.44%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000166.1	sp|K1PZS6|K1PZS6_CRAGI	4.5e-166	589.7	100.00%	83.50%	Dynactin subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0005869|	GO:0007017|
GN000167.1	sp|K1PCI5|K1PCI5_CRAGI	1.3e-193	681.8	98.47%	59.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000169.1	sp|K1RZJ5|K1RZJ5_CRAGI	7.5e-229	798.9	86.00%	72.55%	Alba-like protein C9orf23-like protein;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0003676|GO:0016491|
GN000171.1	sp|A0A210QLH6|A0A210QLH6_MIZYE	6.6e-82	310.5	96.76%	36.35%	Organic cation transporter protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN000172.1	sp|K1QTN8|K1QTN8_CRAGI	2.0e-44	185.7	93.07%	28.35%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000173.1	sp|A0A0N5DS64|A0A0N5DS64_TRIMR	7.9e-21	106.7	78.31%	29.30%	Uncharacterized protein;OS=Trichuris;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN000174.1	sp|K1PKU7|K1PKU7_CRAGI	1.2e-103	382.1	96.45%	59.94%	Neuromedin-U receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN000020.1	sp|K1PU09|K1PU09_CRAGI	2.2e-28	131.3	88.61%	35.20%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000175.1	sp|K1PP75|K1PP75_CRAGI	4.6e-48	196.8	98.59%	44.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000176.1	sp|K1RUW2|K1RUW2_CRAGI	2.3e-169	600.9	87.90%	77.70%	5-hydroxytryptamine receptor;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0004993|
GN000178.1	sp|K1QNQ6|K1QNQ6_CRAGI	1.2e-246	857.8	99.81%	80.56%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|	GO:0006302|GO:0006471|
GN000179.1	sp|K1QNQ6|K1QNQ6_CRAGI	4.6e-96	356.7	98.94%	63.70%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|	GO:0006302|GO:0006471|
GN000180.1	sp|K1PQI1|K1PQI1_CRAGI	3.6e-181	639.8	91.25%	90.99%	Uncharacterized protein C7orf26-like protein;OS=Crassostrea;PE=4;SV=1
GN000181.1	sp|A0A0B6Z6X5|A0A0B6Z6X5_9EUPU	1.3e-139	501.9	80.00%	72.14%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0003676|GO:0008270|
GN000021.1	sp|K1PU09|K1PU09_CRAGI	5.5e-78	297.4	97.88%	39.22%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000182.1	sp|K1Q4V9|K1Q4V9_CRAGI	4.7e-295	1018.8	99.84%	81.03%	Rac GTPase-activating protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0035556|
GN000183.1	sp|K1QUM1|K1QUM1_CRAGI	1.5e-47	195.3	98.31%	46.72%	Receptor-type tyrosine-protein phosphatase N2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN000186.1	sp|V3ZZR2|V3ZZR2_LOTGI	3.5e-71	273.9	91.73%	54.13%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN000022.1	sp|K1PU09|K1PU09_CRAGI	3.8e-28	130.6	88.61%	34.64%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000187.1	sp|V3ZX45|V3ZX45_LOTGI	3.0e-87	327.8	95.99%	47.85%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN000023.1	sp|K1PU09|K1PU09_CRAGI	3.0e-73	281.6	96.90%	38.34%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000188.1	sp|K1QTH6|K1QTH6_CRAGI	1.4e-26	125.6	57.02%	56.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN000189.1	sp|K1PSD1|K1PSD1_CRAGI	5.5e-39	166.0	96.30%	66.67%	Organic cation transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN000190.1	sp|K1PSD1|K1PSD1_CRAGI	3.3e-127	460.7	86.92%	63.69%	Organic cation transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN000191.1	sp|K1PSD1|K1PSD1_CRAGI	2.5e-185	654.1	89.69%	71.52%	Organic cation transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN000192.1	sp|K1PYV3|K1PYV3_CRAGI	0.0e+00	2587.0	100.00%	80.38%	E3 ubiquitin-protein ligase HECW2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN000193.1	sp|K1Q9S4|K1Q9S4_CRAGI	1.4e-73	282.0	100.00%	54.61%	Apolipoprotein L3;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0008289|	GO:0006869|GO:0042157|
GN000194.1	sp|K1QK08|K1QK08_CRAGI	1.1e-69	269.2	80.63%	54.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000024.1	sp|K1PU09|K1PU09_CRAGI	8.8e-57	226.9	94.30%	30.22%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000195.1	sp|K1Q9S4|K1Q9S4_CRAGI	9.4e-67	259.2	96.63%	52.75%	Apolipoprotein L3;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0008289|	GO:0006869|GO:0042157|
GN000197.1	sp|K1PF13|K1PF13_CRAGI	3.0e-162	578.6	76.31%	41.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000198.1	sp|K1P8V9|K1P8V9_CRAGI	1.8e-190	671.4	98.71%	62.03%	One cut domain family member;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|
GN000199.1	sp|A0A210Q1G5|A0A210Q1G5_MIZYE	7.5e-187	659.4	100.00%	56.09%	Sodium/nucleoside cotransporter;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005337|
GN000200.1	sp|A0A210QPW7|A0A210QPW7_MIZYE	6.8e-197	692.2	99.76%	85.54%	26S proteasome non-ATPase regulatory subunit 11;OS=Mizuhopecten;PE=4;SV=1	GO:0000502|	GO:0043248|
GN000025.1	sp|K1PU09|K1PU09_CRAGI	1.4e-85	322.8	98.70%	35.47%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000201.1	sp|K1QA08|K1QA08_CRAGI	4.2e-150	537.3	98.58%	67.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000202.1	sp|A0A210QIQ8|A0A210QIQ8_MIZYE	7.4e-92	342.8	84.64%	61.54%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000203.1	sp|K1QLK4|K1QLK4_CRAGI	2.4e-66	258.5	100.00%	38.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000204.1	sp|A0A210PKX9|A0A210PKX9_MIZYE	1.0e-24	118.2	96.19%	55.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN000206.1	sp|K1RSG4|K1RSG4_CRAGI	2.6e-21	108.6	95.89%	30.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000207.1	sp|K1PWT4|K1PWT4_CRAGI	1.7e-10	70.9	77.55%	41.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000026.1	sp|K1PU09|K1PU09_CRAGI	3.1e-33	147.5	96.65%	34.91%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000208.1	sp|A0A1B6C052|A0A1B6C052_9HEMI	3.1e-14	84.0	95.45%	35.62%	Uncharacterized protein;OS=Clastoptera;PE=4;SV=1	GO:0003676|
GN000209.1	sp|K1RFU6|K1RFU6_CRAGI	4.3e-34	150.6	97.13%	34.84%	Proteasome activator complex subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0008537|
GN000210.1	sp|K1Q1K4|K1Q1K4_CRAGI	3.4e-80	303.9	99.64%	56.25%	Ankyrin repeat and SOCS box protein 3;OS=Crassostrea;PE=4;SV=1
GN000212.1	sp|K1PV26|K1PV26_CRAGI	2.8e-18	97.8	76.70%	39.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000215.1	sp|K1PHV6|K1PHV6_CRAGI	3.7e-79	300.4	76.03%	70.79%	Sorcin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000216.1	sp|K1QI90|K1QI90_CRAGI	2.6e-170	604.7	97.91%	56.91%	Integrin beta;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0007155|GO:0007229|
GN000218.1	sp|K1R5I8|K1R5I8_CRAGI	2.1e-115	421.0	92.26%	73.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000219.1	sp|K1QZW6|K1QZW6_CRAGI	1.5e-96	358.6	60.29%	83.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000222.1	sp|A0A210QZG7|A0A210QZG7_MIZYE	3.8e-92	344.4	85.81%	42.14%	Neuronal acetylcholine receptor subunit alpha-10;OS=Mizuhopecten;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN000224.1	sp|A0A210R1W6|A0A210R1W6_MIZYE	3.8e-114	416.8	100.00%	68.03%	Cyclin-dependent kinase 5 activator 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016533|	GO:0061575|GO:0016301|
GN000225.1	sp|K1QSN7|K1QSN7_CRAGI	2.3e-26	123.6	100.00%	66.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000226.1	sp|K1R242|K1R242_CRAGI	0.0e+00	1392.5	97.93%	86.05%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000227.1	sp|K1PU09|K1PU09_CRAGI	6.3e-12	77.4	47.60%	25.91%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000229.1	sp|K1R242|K1R242_CRAGI	3.5e-102	376.7	98.72%	81.90%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000230.1	sp|K1R242|K1R242_CRAGI	1.0e-100	372.1	92.06%	73.58%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000231.1	sp|K1PU09|K1PU09_CRAGI	2.7e-36	158.3	98.77%	30.11%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000233.1	sp|K1PU09|K1PU09_CRAGI	4.2e-20	104.4	83.62%	27.24%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000234.1	sp|K1R242|K1R242_CRAGI	1.1e-70	271.6	100.00%	84.42%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000029.1	sp|K1PU09|K1PU09_CRAGI	1.2e-31	142.9	92.45%	33.00%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000235.1	sp|K1R242|K1R242_CRAGI	1.5e-86	324.7	98.68%	73.54%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000236.1	sp|K1R242|K1R242_CRAGI	3.2e-267	926.4	89.97%	84.38%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000238.1	sp|K1R242|K1R242_CRAGI	6.2e-47	192.2	94.87%	71.85%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000239.1	sp|K1R242|K1R242_CRAGI	1.5e-24	118.2	39.87%	91.94%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000240.1	sp|K1R242|K1R242_CRAGI	2.3e-205	720.3	100.00%	84.20%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000242.1	sp|K1PEP3|K1PEP3_CRAGI	6.0e-77	293.1	95.26%	57.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000030.1	sp|K1PU09|K1PU09_CRAGI	7.8e-58	230.3	98.87%	33.18%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000244.1	sp|K1R242|K1R242_CRAGI	0.0e+00	1773.8	100.00%	82.92%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN000245.1	sp|K1R5S8|K1R5S8_CRAGI	3.7e-272	942.6	99.44%	88.35%	Formimidoyltransferase-cyclodeaminase;OS=Crassostrea;PE=4;SV=1	GO:0005542|GO:0016740|	GO:0044237|
GN000246.1	sp|K1QQB3|K1QQB3_CRAGI	8.8e-45	185.3	74.45%	89.11%	Glycyl-tRNA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0004820|	GO:0006426|
GN000248.1	sp|K1QQB3|K1QQB3_CRAGI	1.2e-241	840.9	99.77%	92.20%	Glycyl-tRNA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0004820|	GO:0006426|
GN000249.1	sp|K1QKG4|K1QKG4_CRAGI	3.9e-162	576.6	96.72%	73.04%	Probable tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0046872|GO:0004222|GO:0061711|	GO:0002949|
GN000250.1	sp|K1QSW4|K1QSW4_CRAGI	3.6e-65	253.8	97.93%	70.76%	Glucocorticoid-induced transcript 1 protein;OS=Crassostrea;PE=4;SV=1
GN000251.1	sp|K1QZM0|K1QZM0_CRAGI	1.2e-105	388.3	96.55%	87.95%	Vesicle-trafficking protein SEC22a;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN000031.1	sp|V3ZX45|V3ZX45_LOTGI	1.0e-100	372.9	93.97%	48.42%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN000252.1	sp|K1QK28|K1QK28_CRAGI	1.1e-216	758.1	96.26%	75.00%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|GO:0005507|GO:0016491|	GO:0006004|
GN000253.1	sp|K1Q3Q5|K1Q3Q5_CRAGI	2.3e-19	99.8	100.00%	73.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000255.1	sp|A0A1X7T231|A0A1X7T231_AMPQE	3.7e-09	68.9	35.29%	27.59%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN000256.1	sp|K1PVI5|K1PVI5_CRAGI	6.3e-135	486.1	99.72%	66.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000032.1	sp|V3ZZR2|V3ZZR2_LOTGI	5.0e-70	270.0	91.63%	54.13%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN000257.1	sp|K1QCA3|K1QCA3_CRAGI	6.0e-36	157.9	40.85%	41.82%	Parathyroid hormone/parathyroid hormone-related peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN000260.1	sp|K1RR26|K1RR26_CRAGI	3.1e-09	66.6	89.25%	41.67%	Transcription factor E3;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0006959|GO:0045893|
GN000261.1	sp|K1Q4G7|K1Q4G7_CRAGI	2.8e-241	839.7	97.74%	94.25%	Tubulin gamma chain;OS=Crassostrea;PE=3;SV=1	GO:0000930|GO:0005874|	GO:0005525|GO:0003924|	GO:0031122|GO:0007020|
GN000033.1	sp|K1PU09|K1PU09_CRAGI	4.1e-50	204.5	94.21%	34.39%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000262.1	sp|K1QBQ7|K1QBQ7_CRAGI	2.3e-174	617.5	100.00%	71.62%	Serine/threonine-protein kinase 17A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN000263.1	sp|K1QXH1|K1QXH1_CRAGI	9.0e-229	798.5	95.91%	72.98%	Bifunctional coenzyme A synthase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004140|	GO:0015937|
GN000264.1	sp|K1PZD2|K1PZD2_CRAGI	5.6e-151	541.2	30.94%	69.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000265.1	sp|K1PS37|K1PS37_CRAGI	5.9e-96	355.9	97.20%	85.51%	Adenylate cyclase type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004016|GO:0000166|	GO:0006171|GO:0035556|
GN000266.1	sp|K1QH90|K1QH90_CRAGI	1.1e-40	172.2	96.46%	61.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000001.1	sp|K1PU09|K1PU09_CRAGI	4.8e-80	304.3	98.22%	33.96%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000267.1	sp|K1QB04|K1QB04_CRAGI	4.7e-245	852.4	92.25%	95.04%	26S proteasome non-ATPase regulatory subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0000502|	GO:0030234|	GO:0042176|
GN000268.1	sp|K1R7E0|K1R7E0_CRAGI	1.4e-87	328.9	81.34%	55.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000270.1	sp|K1PGG5|K1PGG5_CRAGI	1.7e-53	215.3	74.75%	46.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000035.1	sp|K1PU09|K1PU09_CRAGI	1.5e-37	162.5	93.15%	33.05%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000272.1	sp|A0A210QRF8|A0A210QRF8_MIZYE	4.4e-70	270.0	95.43%	64.29%	Homologous-pairing protein 2-like;OS=Mizuhopecten;PE=4;SV=1	GO:0007131|
GN000273.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	6.0e-21	107.1	39.33%	42.99%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN000275.1	sp|K1PP75|K1PP75_CRAGI	1.1e-152	545.8	98.98%	47.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000036.1	sp|K1PU09|K1PU09_CRAGI	1.1e-88	333.2	98.73%	35.81%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000278.1	sp|K1QE60|K1QE60_CRAGI	5.6e-216	756.1	100.00%	86.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN000279.1	sp|K1R998|K1R998_CRAGI	4.2e-67	261.9	46.58%	37.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000281.1	sp|K1QF66|K1QF66_CRAGI	1.0e-292	1012.3	52.13%	65.90%	Uncharacterized protein in xynA 3'region;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|
GN000282.1	sp|K1RQZ1|K1RQZ1_CRAGI	3.1e-114	416.8	100.00%	80.95%	Glutathione S-transferase P 2;OS=Crassostrea;PE=3;SV=1	GO:0016740|
GN000283.1	sp|K1R542|K1R542_CRAGI	4.1e-311	1072.4	98.48%	56.71%	L-ascorbate oxidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0016491|
GN000284.1	sp|K1QY77|K1QY77_CRAGI	4.8e-36	156.4	99.34%	54.30%	Uncharacterized protein C7orf36;OS=Crassostrea;PE=4;SV=1
GN000037.1	sp|K1PU09|K1PU09_CRAGI	8.4e-43	179.5	97.06%	38.36%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000286.1	sp|K1QGH8|K1QGH8_CRAGI	8.8e-64	248.8	99.46%	60.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000289.1	sp|K1PGE8|K1PGE8_CRAGI	8.7e-56	222.6	68.33%	68.79%	Calmodulin-5/6/7/8;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000290.1	sp|K1PA81|K1PA81_CRAGI	6.8e-82	309.7	81.67%	61.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000291.1	sp|K1RLS0|K1RLS0_CRAGI	7.9e-46	189.1	78.09%	70.71%	Polypeptide N-acetylgalactosaminyltransferase 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN000038.1	sp|K1PU09|K1PU09_CRAGI	1.6e-09	68.2	65.71%	46.15%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000292.1	sp|K1PRK0|K1PRK0_CRAGI	0.0e+00	1309.3	100.00%	82.85%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN000293.1	sp|K1QZH9|K1QZH9_CRAGI	3.9e-286	989.6	100.00%	68.42%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN000294.1	sp|K1QDK9|K1QDK9_CRAGI	2.4e-51	207.2	95.30%	74.47%	Pancreas transcription factor 1 subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000295.1	sp|K1RCQ4|K1RCQ4_CRAGI	1.1e-156	559.7	46.87%	65.24%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN000297.1	sp|K1QAA3|K1QAA3_CRAGI	1.5e-165	588.2	94.00%	59.96%	Dipeptidase;OS=Crassostrea;PE=3;SV=1	GO:0031225|GO:0016021|	GO:0016805|GO:0008239|GO:0020037|GO:0046872|GO:0008235|GO:0004601|	GO:0006979|
GN000039.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	1.7e-31	141.4	99.39%	45.12%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000299.1	sp|K1R2D9|K1R2D9_CRAGI	3.3e-79	300.8	99.68%	47.02%	Eosinophil peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN000300.1	sp|K1QW43|K1QW43_CRAGI	1.8e-192	678.3	92.05%	61.99%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B;OS=Crassostrea;PE=4;SV=1
GN000301.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	4.2e-11	72.4	100.00%	48.53%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN000302.1	sp|K1RGZ5|K1RGZ5_CRAGI	9.2e-102	375.6	71.27%	85.13%	Peptidoglycan-recognition protein;OS=Crassostrea;PE=3;SV=1	GO:0008745|GO:0042834|GO:0008270|	GO:0045087|GO:0009253|
GN000303.1	sp|K1PKY6|K1PKY6_CRAGI	0.0e+00	1928.7	99.91%	80.17%	DNA-directed RNA polymerase subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003899|GO:0032549|	GO:0006351|
GN000304.1	sp|K1PU13|K1PU13_CRAGI	1.7e-122	444.5	99.31%	72.41%	UPF0565 protein C2orf69-like protein;OS=Crassostrea;PE=4;SV=1
GN000040.1	sp|K1PU09|K1PU09_CRAGI	1.2e-87	329.7	98.73%	35.64%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000305.1	sp|A0A210PU30|A0A210PU30_MIZYE	4.5e-68	263.8	89.91%	48.44%	Methylmalonic aciduria and homocystinuria type D-like;OS=Mizuhopecten;PE=4;SV=1	GO:0009235|
GN000306.1	sp|K1QDT6|K1QDT6_CRAGI	9.0e-11	72.8	36.60%	38.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000307.1	sp|K1P4Q4|K1P4Q4_CRAGI	5.4e-58	230.7	67.00%	51.84%	Insulin-like growth factor-binding protein complex acid labile chain;OS=Crassostrea;PE=4;SV=1
GN000310.1	sp|K1RKX3|K1RKX3_CRAGI	3.4e-119	433.3	100.00%	87.15%	Putative cytochrome b561;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055114|
GN000311.1	sp|K1PG67|K1PG67_CRAGI	3.3e-225	786.9	91.04%	65.40%	Sodium/nucleoside cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005337|
GN000312.1	sp|K1Q2V4|K1Q2V4_CRAGI	2.2e-244	850.5	98.40%	70.39%	Sodium/nucleoside cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005337|
GN000313.1	sp|K1Q2V4|K1Q2V4_CRAGI	5.0e-237	825.9	98.10%	81.12%	Sodium/nucleoside cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005337|
GN000314.1	sp|K1R7H5|K1R7H5_CRAGI	5.5e-42	175.6	100.00%	72.64%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN000041.1	sp|K1PU09|K1PU09_CRAGI	6.4e-43	179.9	97.06%	38.36%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000315.1	sp|K1R7H5|K1R7H5_CRAGI	3.5e-237	826.2	97.53%	79.66%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN000316.1	sp|K1R7H5|K1R7H5_CRAGI	1.1e-83	315.1	100.00%	63.22%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN000317.1	sp|K1R7H5|K1R7H5_CRAGI	7.2e-207	725.3	100.00%	78.55%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN000318.1	sp|K1QZJ7|K1QZJ7_CRAGI	8.4e-132	476.9	100.00%	38.33%	MAP kinase kinase kinase win1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN000319.1	sp|K1Q7B8|K1Q7B8_CRAGI	4.1e-134	483.4	93.31%	71.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000042.1	sp|K1PU09|K1PU09_CRAGI	1.6e-09	68.2	65.71%	46.15%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000320.1	sp|K1P526|K1P526_CRAGI	4.0e-265	919.5	99.69%	79.10%	Sodium/nucleoside cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005337|
GN000321.1	sp|K1QB30|K1QB30_CRAGI	4.4e-160	570.5	71.68%	64.32%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN000322.1	sp|K1R924|K1R924_CRAGI	7.1e-209	732.3	100.00%	74.25%	RNA-binding protein 45;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN000323.1	sp|K1QTJ9|K1QTJ9_CRAGI	1.5e-41	174.9	83.63%	57.04%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000043.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	2.1e-32	144.4	99.39%	45.73%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000324.1	sp|K1QSX2|K1QSX2_CRAGI	1.7e-20	104.0	68.13%	83.61%	Dehydrogenase/reductase SDR family member 13;OS=Crassostrea;PE=3;SV=1
GN000327.1	sp|K1Q5V3|K1Q5V3_CRAGI	1.5e-126	458.4	100.00%	64.78%	DnaJ-like protein subfamily C member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005634|	GO:0003677|
GN000329.1	sp|K1PHH3|K1PHH3_CRAGI	1.8e-57	228.8	68.59%	53.59%	Galanin receptor type 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000044.1	sp|K1PU09|K1PU09_CRAGI	4.0e-46	191.0	98.52%	34.33%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000045.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	2.4e-24	117.5	92.36%	44.44%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000331.1	sp|R7VLQ6|R7VLQ6_CAPTE	1.5e-66	257.7	98.60%	82.86%	Uncharacterized protein;OS=Capitella;PE=3;SV=1	GO:0005525|
GN000333.1	sp|K1Q1J1|K1Q1J1_CRAGI	3.6e-12	77.0	63.45%	48.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000334.1	sp|K1Q1J1|K1Q1J1_CRAGI	6.5e-21	107.1	98.29%	34.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000337.1	sp|K1PRP1|K1PRP1_CRAGI	3.7e-61	241.9	53.26%	42.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000338.1	sp|K1PZ57|K1PZ57_CRAGI	2.7e-104	384.4	98.92%	49.60%	L-ascorbate oxidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0016491|
GN000046.1	sp|K1PU09|K1PU09_CRAGI	1.9e-43	181.8	98.47%	37.31%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000339.1	sp|K1QMU2|K1QMU2_CRAGI	1.7e-251	874.0	95.87%	82.55%	Protein Malvolio;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0046873|
GN000340.1	sp|K1QGK1|K1QGK1_CRAGI	8.8e-139	498.8	95.81%	71.47%	Fibrillin-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|	GO:0007160|
GN000341.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	3.3e-59	234.2	86.30%	48.74%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN000344.1	sp|K1PX91|K1PX91_CRAGI	1.5e-142	511.9	93.32%	53.26%	Cytochrome P450 2D4;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN000345.1	sp|K1PHE2|K1PHE2_CRAGI	5.3e-55	219.5	98.83%	76.44%	TAR DNA-binding protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003723|
GN000047.1	sp|K1PU09|K1PU09_CRAGI	1.6e-09	68.2	65.71%	46.15%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000346.1	sp|K1S5W9|K1S5W9_CRAGI	5.3e-56	222.6	91.03%	79.39%	Heparan-alpha-glucosaminide N-acetyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005765|	GO:0015019|
GN000348.1	sp|K1RAN3|K1RAN3_CRAGI	0.0e+00	1291.6	83.74%	60.20%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000048.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	2.4e-24	117.5	92.36%	44.44%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000361.1	sp|K1RAN3|K1RAN3_CRAGI	2.0e-29	134.8	55.45%	60.36%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000049.1	sp|K1PU09|K1PU09_CRAGI	2.7e-78	298.5	98.05%	35.36%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000366.1	sp|K1RAN3|K1RAN3_CRAGI	5.3e-113	414.8	48.30%	46.08%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000367.1	sp|K1RAN3|K1RAN3_CRAGI	5.2e-113	415.6	28.53%	46.27%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000368.1	sp|K1RAN3|K1RAN3_CRAGI	4.9e-112	412.5	25.98%	46.08%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000369.1	sp|K1RAN3|K1RAN3_CRAGI	1.1e-34	152.1	98.30%	49.72%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000371.1	sp|K1RAN3|K1RAN3_CRAGI	1.2e-23	115.9	40.55%	50.00%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0005576|
GN000050.1	sp|K1PU09|K1PU09_CRAGI	1.9e-43	181.8	98.47%	37.31%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000373.1	sp|K1R455|K1R455_CRAGI	6.8e-211	738.8	99.12%	77.48%	Glycylpeptide N-tetradecanoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004379|	GO:0006499|
GN000374.1	sp|K1QX74|K1QX74_CRAGI	3.9e-90	336.3	100.00%	93.06%	EF-hand calcium-binding domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000375.1	sp|K1PT58|K1PT58_CRAGI	8.4e-25	118.6	93.86%	55.66%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN000376.1	sp|K1QPG4|K1QPG4_CRAGI	3.1e-78	297.4	91.01%	56.79%	Cytochrome P450 2U1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN000377.1	sp|K1RAM5|K1RAM5_CRAGI	3.4e-119	434.1	98.10%	56.52%	UPF0712 protein C7orf64-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008270|
GN000051.1	sp|K1PU09|K1PU09_CRAGI	1.6e-09	68.2	65.71%	46.15%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000378.1	sp|K1Q5G7|K1Q5G7_CRAGI	2.0e-49	201.1	100.00%	53.37%	Sarcoplasmic calcium-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000380.1	sp|K1P3Z1|K1P3Z1_CRAGI	2.0e-115	422.9	35.20%	53.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN000381.1	sp|K1PPU7|K1PPU7_CRAGI	0.0e+00	3207.2	96.92%	54.71%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN000382.1	sp|K1PHQ2|K1PHQ2_CRAGI	6.3e-42	176.0	96.30%	61.01%	Cation-dependent mannose-6-phosphate receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000383.1	sp|K1P3Y7|K1P3Y7_CRAGI	0.0e+00	2757.2	98.85%	80.75%	Deleted in lung and esophageal cancer protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008285|
GN000384.1	sp|K1P7C3|K1P7C3_CRAGI	4.5e-140	504.2	78.97%	68.42%	F-box/LRR-repeat protein 20;OS=Crassostrea;PE=4;SV=1
GN000385.1	sp|K1QJU0|K1QJU0_CRAGI	6.7e-113	413.3	96.96%	53.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN000386.1	sp|K1PRN2|K1PRN2_CRAGI	2.4e-271	940.6	89.75%	66.47%	Ankyrin repeat and zinc finger domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN000052.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	2.4e-24	117.5	92.36%	44.44%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000387.1	sp|D7PD35|D7PD35_APLCA	3.0e-67	260.4	82.72%	79.62%	NAD-dependent protein deacylase;OS=Aplysia;PE=2;SV=1	GO:0005739|	GO:0070403|GO:0034979|GO:0036054|GO:0036055|GO:0008270|
GN000388.1	sp|K1QTN8|K1QTN8_CRAGI	5.1e-48	197.6	92.36%	30.29%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000389.1	sp|K1Q394|K1Q394_CRAGI	1.1e-243	848.6	81.50%	67.07%	Testis-expressed sequence 10-like protein;OS=Crassostrea;PE=4;SV=1
GN000392.1	sp|K1PV00|K1PV00_CRAGI	1.8e-38	165.2	57.65%	55.48%	Putative ATP-dependent DNA helicase recS;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN000393.1	sp|K1PLC5|K1PLC5_CRAGI	1.5e-110	405.6	97.37%	44.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000394.1	sp|K1QXZ2|K1QXZ2_CRAGI	5.8e-12	76.3	53.28%	55.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000053.1	sp|K1PU09|K1PU09_CRAGI	3.3e-81	308.1	98.62%	34.87%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000397.1	sp|V4B4J6|V4B4J6_LOTGI	8.2e-16	89.0	69.47%	43.48%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0031436|	GO:0043065|GO:0016567|
GN000398.1	sp|V4AE92|V4AE92_LOTGI	6.4e-89	334.0	76.13%	41.32%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN000399.1	sp|K1QY17|K1QY17_CRAGI	4.0e-33	147.9	77.01%	32.71%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000400.1	sp|A0A0P4WGA4|A0A0P4WGA4_9EUCA	3.8e-48	197.6	82.08%	40.31%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN000003.1	sp|K1PU09|K1PU09_CRAGI	1.8e-25	121.7	93.03%	37.19%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000054.1	sp|K1PU09|K1PU09_CRAGI	5.1e-77	294.3	98.66%	33.87%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000401.1	sp|K1RNJ2|K1RNJ2_CRAGI	2.9e-36	157.5	40.20%	88.61%	Hydroxyacylglutathione hydrolase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0004416|	GO:0019243|
GN000402.1	sp|K1QT12|K1QT12_CRAGI	3.3e-17	94.0	77.06%	38.93%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000403.1	sp|K1PVI5|K1PVI5_CRAGI	2.7e-127	460.7	99.71%	60.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000404.1	sp|A0A210QT19|A0A210QT19_MIZYE	1.5e-54	221.9	11.83%	39.26%	Breast cancer type 1 susceptibility protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0004842|GO:0008270|	GO:0006281|
GN000404.1	sp|A0A210QT19|A0A210QT19_MIZYE	3.7e-16	94.4	4.39%	50.93%	Breast cancer type 1 susceptibility protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0004842|GO:0008270|	GO:0006281|
GN000405.1	sp|K1Q4R1|K1Q4R1_CRAGI	2.4e-126	457.6	91.69%	54.39%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN000055.1	sp|K1PU09|K1PU09_CRAGI	1.4e-76	292.7	98.54%	34.75%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000408.1	sp|K1QDJ4|K1QDJ4_CRAGI	0.0e+00	1176.4	95.62%	84.09%	Dpy-19-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0000030|
GN000409.1	sp|K1Q5G4|K1Q5G4_CRAGI	1.4e-119	434.5	100.00%	88.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000410.1	sp|K1Q5G4|K1Q5G4_CRAGI	1.3e-38	164.9	63.45%	84.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000411.1	sp|A0A210Q7B6|A0A210Q7B6_MIZYE	5.8e-52	210.7	77.23%	34.24%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008375|
GN000412.1	sp|K1RCJ9|K1RCJ9_CRAGI	2.5e-28	131.3	38.70%	62.50%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000413.1	sp|K1QSD1|K1QSD1_CRAGI	2.3e-60	238.4	94.63%	62.87%	Coiled-coil domain-containing protein 89;OS=Crassostrea;PE=4;SV=1
GN000414.1	sp|A0A210PU67|A0A210PU67_MIZYE	3.0e-138	497.7	98.43%	50.49%	WD repeat-containing protein mio-B;OS=Mizuhopecten;PE=4;SV=1
GN000415.1	sp|K1QQJ9|K1QQJ9_CRAGI	5.3e-82	309.3	100.00%	82.68%	GTP-binding protein Di-Ras2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN000416.1	sp|V4A2Z2|V4A2Z2_LOTGI	1.9e-84	318.9	61.15%	49.06%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN000417.1	sp|K1Q136|K1Q136_CRAGI	3.1e-40	171.4	69.40%	43.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000418.1	sp|K1Q4B7|K1Q4B7_CRAGI	8.3e-58	229.2	85.05%	61.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN000419.1	sp|K1Q4B7|K1Q4B7_CRAGI	2.4e-206	724.2	74.76%	72.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN000420.1	sp|K1Q4B7|K1Q4B7_CRAGI	1.7e-207	728.0	74.76%	72.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN000421.1	sp|K1R3U5|K1R3U5_CRAGI	1.0e-86	325.9	73.49%	60.66%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN000422.1	sp|K1RAA4|K1RAA4_CRAGI	3.4e-100	369.8	100.00%	86.89%	Endoglucanase;OS=Crassostrea;PE=4;SV=1
GN000423.1	sp|K1PMG4|K1PMG4_CRAGI	3.4e-34	149.8	97.39%	73.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000424.1	sp|K1PWL1|K1PWL1_CRAGI	1.2e-185	655.2	80.40%	73.83%	Putative methyltransferase NSUN5;OS=Crassostrea;PE=3;SV=1	GO:0008168|GO:0003723|
GN000425.1	sp|A0A210PVK8|A0A210PVK8_MIZYE	2.5e-96	357.8	97.10%	47.90%	Oxidoreductase YrbE;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN000426.1	sp|K1QX83|K1QX83_CRAGI	7.1e-80	303.5	75.91%	48.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000057.1	sp|K1PU09|K1PU09_CRAGI	2.5e-104	385.2	98.83%	38.26%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000428.1	sp|K1P3I0|K1P3I0_CRAGI	2.6e-26	123.6	100.00%	64.41%	Structural maintenance of chromosomes flexible hinge domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005694|	GO:0005524|	GO:0051276|GO:0006302|
GN000430.1	sp|K1QED2|K1QED2_CRAGI	8.4e-189	665.6	100.00%	69.85%	Nuclear receptor subfamily 1 group D member 2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN000058.1	sp|K1PU09|K1PU09_CRAGI	3.1e-22	110.5	97.44%	34.07%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000432.1	sp|K1PE45|K1PE45_CRAGI	3.1e-10	70.5	64.93%	43.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000433.1	sp|A0A210QG49|A0A210QG49_MIZYE	1.4e-23	115.2	83.43%	48.30%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|GO:0008270|
GN000434.1	sp|K1RW77|K1RW77_CRAGI	1.4e-113	415.2	70.67%	70.63%	Neuropeptide FF receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN000435.1	sp|K1PE31|K1PE31_CRAGI	2.4e-49	201.1	74.29%	65.81%	G-protein coupled receptor 54;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000437.1	sp|K1QIJ4|K1QIJ4_CRAGI	1.7e-42	177.6	100.00%	71.09%	Corepressor interacting with RBPJ 1;OS=Crassostrea;PE=4;SV=1	GO:0003714|
GN000438.1	sp|K1PJY6|K1PJY6_CRAGI	7.1e-17	92.4	84.80%	44.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000059.1	sp|K1PU09|K1PU09_CRAGI	1.3e-27	128.6	95.11%	42.86%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000439.1	sp|K1QLN9|K1QLN9_CRAGI	2.8e-245	854.0	76.65%	60.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000440.1	sp|K1PMM4|K1PMM4_CRAGI	1.3e-71	275.4	98.94%	52.86%	Beta-4C adrenergic receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000442.1	sp|K1Q4I9|K1Q4I9_CRAGI	9.0e-225	785.0	98.16%	83.96%	D-3-phosphoglycerate dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN000443.1	sp|K1RCA4|K1RCA4_CRAGI	9.2e-171	605.1	100.00%	88.29%	Amino acid transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015293|
GN000444.1	sp|K1RCA4|K1RCA4_CRAGI	2.1e-86	323.9	100.00%	88.17%	Amino acid transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015293|
GN000445.1	sp|K1Q556|K1Q556_CRAGI	3.4e-199	699.9	91.18%	87.24%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000447.1	sp|W4YJ40|W4YJ40_STRPU	1.6e-31	141.7	85.15%	45.61%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|
GN000448.1	sp|A0A2G8JMN3|A0A2G8JMN3_STIJA	8.7e-55	219.9	100.00%	30.42%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN000449.1	sp|K1QCN5|K1QCN5_CRAGI	3.5e-200	704.1	63.88%	70.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000061.1	sp|K1PU09|K1PU09_CRAGI	2.3e-30	137.9	95.45%	34.25%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000451.1	sp|K1QA16|K1QA16_CRAGI	6.2e-21	107.5	100.00%	28.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000452.1	sp|K1Q2Z1|K1Q2Z1_CRAGI	2.0e-136	490.7	100.00%	83.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000454.1	sp|Q0KJW4|Q0KJW4_CRAVI	3.5e-78	296.6	97.70%	79.29%	Dominin;OS=Crassostrea;PE=2;SV=1	GO:0046872|	GO:0006801|
GN000455.1	sp|I6LKX0|I6LKX0_OSTED	7.5e-117	425.6	100.00%	95.83%	Extracellular Cu-Zn superoxide dismutase;OS=Ostrea;PE=2;SV=1	GO:0046872|	GO:0006801|
GN000456.1	sp|A0A210R3J5|A0A210R3J5_MIZYE	7.7e-101	372.1	100.00%	87.32%	Proteasome subunit beta;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|GO:0005634|GO:0019774|	GO:0004298|	GO:0043161|
GN000457.1	sp|K1QZ69|K1QZ69_CRAGI	2.0e-110	404.8	84.02%	59.94%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|	GO:0006915|
GN000062.1	sp|K1PU09|K1PU09_CRAGI	8.3e-34	149.4	98.11%	41.35%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000459.1	sp|K1QST7|K1QST7_CRAGI	2.9e-16	90.1	81.73%	51.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000462.1	sp|K1QIT2|K1QIT2_CRAGI	6.5e-193	679.1	96.95%	72.30%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN000463.1	sp|K1QIT2|K1QIT2_CRAGI	1.1e-51	208.8	87.86%	51.10%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN000464.1	sp|K1QIT2|K1QIT2_CRAGI	1.8e-150	538.1	97.58%	61.31%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN000465.1	sp|K1QMB1|K1QMB1_CRAGI	1.7e-23	114.4	96.75%	43.70%	Atrial natriuretic peptide receptor A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0000166|GO:0016849|GO:0004672|	GO:0009190|GO:0035556|
GN000004.1	sp|K1PU09|K1PU09_CRAGI	2.3e-60	238.8	68.00%	36.31%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000466.1	sp|K1QMB1|K1QMB1_CRAGI	1.5e-22	111.3	96.75%	42.02%	Atrial natriuretic peptide receptor A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0000166|GO:0016849|GO:0004672|	GO:0009190|GO:0035556|
GN000469.1	sp|W4YX27|W4YX27_STRPU	1.7e-24	117.9	100.00%	48.12%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004190|
GN000470.1	sp|K1S395|K1S395_CRAGI	1.3e-26	124.8	67.69%	64.37%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN000471.1	sp|K1PZ37|K1PZ37_CRAGI	2.3e-102	377.1	100.00%	94.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN000472.1	sp|K1RCW8|K1RCW8_CRAGI	0.0e+00	1311.6	89.90%	72.47%	Ubiquitin carboxyl-terminal hydrolase 40;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN000473.1	sp|K1RCW8|K1RCW8_CRAGI	7.2e-22	110.5	27.65%	57.14%	Ubiquitin carboxyl-terminal hydrolase 40;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN000474.1	sp|K1R6Y1|K1R6Y1_CRAGI	3.4e-36	156.8	70.29%	75.00%	UPF0538 protein C2orf76-like protein;OS=Crassostrea;PE=4;SV=1
GN000478.1	sp|K1QRL8|K1QRL8_CRAGI	2.5e-09	67.4	82.81%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000481.1	sp|A0A2T7PSN4|A0A2T7PSN4_POMCA	6.9e-57	226.5	99.63%	40.88%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005524|GO:0004672|
GN000063.1	sp|K1PU09|K1PU09_CRAGI	1.2e-22	112.1	96.49%	31.53%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000482.1	sp|K1QTN8|K1QTN8_CRAGI	1.2e-41	176.4	93.05%	28.91%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000483.1	sp|K1PKU7|K1PKU7_CRAGI	3.1e-107	394.0	96.48%	59.94%	Neuromedin-U receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN000484.1	sp|K1R5D8|K1R5D8_CRAGI	3.5e-73	280.0	100.00%	72.63%	Sarcoplasmic calcium-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN000487.1	sp|K1QCA1|K1QCA1_CRAGI	9.6e-102	375.9	94.91%	59.83%	Inhibin beta A chain;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008083|
GN000488.1	sp|K1PPT6|K1PPT6_CRAGI	1.7e-33	147.9	66.01%	66.00%	Aggrecan core protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN000489.1	sp|K1PX39|K1PX39_CRAGI	0.0e+00	1645.2	100.00%	87.23%	Formin-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|GO:0008360|
GN000064.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	4.5e-34	151.4	51.03%	39.18%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000490.1	sp|K1RJC1|K1RJC1_CRAGI	4.1e-14	84.0	51.96%	50.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000491.1	sp|A0A210PWC4|A0A210PWC4_MIZYE	8.8e-204	715.3	96.74%	73.05%	4-trimethylaminobutyraldehyde dehydrogenase;OS=Mizuhopecten;PE=3;SV=1	GO:0016620|
GN000492.1	sp|K1QMA6|K1QMA6_CRAGI	1.8e-140	504.2	99.29%	86.33%	Aquaporin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN000493.1	sp|K1RA04|K1RA04_CRAGI	3.5e-132	476.9	89.78%	75.78%	Putative aquaporin-10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015267|
GN000495.1	sp|A0A2G8L4X1|A0A2G8L4X1_STIJA	9.6e-46	189.5	92.20%	36.99%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN000498.1	sp|K1PHH3|K1PHH3_CRAGI	1.2e-58	232.6	68.30%	52.89%	Galanin receptor type 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN000065.1	sp|K1PU09|K1PU09_CRAGI	2.5e-18	97.1	95.45%	42.31%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000499.1	sp|K1RPE5|K1RPE5_CRAGI	1.2e-39	169.5	36.25%	65.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000500.1	sp|K1Q7M3|K1Q7M3_CRAGI	7.1e-34	148.7	79.44%	77.38%	Proline iminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004177|
GN000501.1	sp|A0A0D2X245|A0A0D2X245_CAPO3	2.9e-17	92.4	98.04%	79.59%	Proline iminopeptidase;OS=Capsaspora;PE=3;SV=1	GO:0005737|	GO:0004177|
GN000502.1	sp|K1PMP6|K1PMP6_CRAGI	1.1e-99	369.0	76.44%	64.15%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000503.1	sp|K1PMP6|K1PMP6_CRAGI	4.0e-97	360.5	73.89%	63.40%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000504.1	sp|A0A210Q7S4|A0A210Q7S4_MIZYE	1.4e-146	524.6	98.44%	72.29%	Proline iminopeptidase;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0004177|
GN000505.1	sp|K1RF73|K1RF73_CRAGI	5.5e-92	342.8	99.56%	72.77%	Fer3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000506.1	sp|K1RF73|K1RF73_CRAGI	2.5e-89	334.0	99.56%	70.98%	Fer3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000507.1	sp|K1QUY1|K1QUY1_CRAGI	2.2e-47	194.5	93.78%	58.74%	Fer3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000066.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	4.3e-30	136.7	99.39%	44.51%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000508.1	sp|K1QNU4|K1QNU4_CRAGI	1.0e-204	718.8	100.00%	78.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000510.1	sp|K1QDL5|K1QDL5_CRAGI	1.2e-221	775.0	81.44%	72.43%	Peroxisomal carnitine O-octanoyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016746|
GN000511.1	sp|K1R3Q0|K1R3Q0_CRAGI	2.9e-71	274.2	88.41%	48.36%	Carbohydrate sulfotransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN000513.1	sp|K1QLI2|K1QLI2_CRAGI	1.8e-47	196.1	87.40%	30.88%	Toll-like receptor 6;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN000514.1	sp|K1QLI2|K1QLI2_CRAGI	8.1e-21	106.3	57.94%	42.40%	Toll-like receptor 6;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN000516.1	sp|K1QLI2|K1QLI2_CRAGI	4.7e-61	241.9	77.24%	28.81%	Toll-like receptor 6;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN000517.1	sp|K1RH02|K1RH02_CRAGI	5.4e-51	206.5	69.85%	73.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000518.1	sp|K1QST7|K1QST7_CRAGI	1.7e-175	621.7	87.34%	55.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000519.1	sp|A0A182ILJ9|A0A182ILJ9_9DIPT	5.5e-10	70.1	61.88%	34.82%	Uncharacterized protein;OS=Anopheles;PE=4;SV=1	GO:0016021|
GN000520.1	sp|M4VR96|M4VR96_MYTGA	3.0e-09	68.6	49.41%	27.06%	Toll-like receptor W;OS=Mytilus;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN000068.1	sp|K1PU09|K1PU09_CRAGI	1.8e-108	399.1	96.71%	36.54%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000525.1	sp|K1R525|K1R525_CRAGI	5.4e-99	366.3	100.00%	63.12%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN000069.1	sp|K1PU09|K1PU09_CRAGI	4.2e-127	461.1	99.13%	37.65%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000527.1	sp|K1Q637|K1Q637_CRAGI	2.0e-33	148.3	91.11%	40.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000528.1	sp|W4XHS4|W4XHS4_STRPU	2.5e-27	127.5	95.45%	39.73%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0008270|
GN000530.1	sp|K1QDT8|K1QDT8_CRAGI	2.9e-35	154.1	78.02%	50.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000531.1	sp|K1QK28|K1QK28_CRAGI	2.4e-165	587.0	100.00%	76.78%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|GO:0005507|GO:0016491|	GO:0006004|
GN000532.1	sp|K1QK28|K1QK28_CRAGI	2.2e-50	204.1	78.66%	71.09%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|GO:0005507|GO:0016491|	GO:0006004|
GN000070.1	sp|K1PU09|K1PU09_CRAGI	9.4e-64	250.4	65.10%	33.57%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000534.1	sp|K1RCZ4|K1RCZ4_CRAGI	1.4e-186	657.9	100.00%	84.67%	5-hydroxytryptamine receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN000535.1	sp|C3ZH72|C3ZH72_BRAFL	5.6e-14	83.6	49.76%	44.76%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN000005.1	sp|K1PU09|K1PU09_CRAGI	3.0e-59	235.0	76.00%	35.69%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000536.1	sp|A0A131XQ81|A0A131XQ81_IXORI	1.3e-48	199.9	90.93%	30.88%	Putative is4eu-1 dr;OS=Ixodes;PE=2;SV=1	GO:0008270|
GN000537.1	sp|V4AGJ7|V4AGJ7_LOTGI	7.7e-21	105.5	52.10%	72.13%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN000541.1	sp|K1R6I8|K1R6I8_CRAGI	1.6e-78	297.7	100.00%	85.25%	Twist-related protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000542.1	sp|K1PXG7|K1PXG7_CRAGI	1.7e-15	89.7	14.85%	58.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000543.1	sp|K1PX51|K1PX51_CRAGI	7.4e-34	150.2	59.13%	47.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000544.1	sp|K1QPI9|K1QPI9_CRAGI	2.1e-60	237.7	100.00%	68.32%	Twist-related protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000545.1	sp|K1R9G8|K1R9G8_CRAGI	6.8e-38	162.5	98.04%	51.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN000546.1	sp|R7U7Z8|R7U7Z8_CAPTE	2.2e-11	73.9	53.77%	58.93%	Uncharacterized protein;OS=Capitella;PE=4;SV=1	GO:0000350|
GN000547.1	sp|K1PRH1|K1PRH1_CRAGI	5.7e-22	108.6	96.00%	71.83%	ABC transporter G family member 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000548.1	sp|K1RD95|K1RD95_CRAGI	2.0e-176	625.2	42.33%	86.93%	Phosphatidylinositol-5-phosphate 4-kinase type-2 beta;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016307|
GN000549.1	sp|A0A210QIQ6|A0A210QIQ6_MIZYE	9.7e-122	441.8	98.82%	79.28%	tRNA-dihydrouridine(47) synthase [NAD(P)(+)];OS=Mizuhopecten;PE=3;SV=1	GO:0050660|GO:0046872|GO:0017150|
GN000550.1	sp|K1Q3M6|K1Q3M6_CRAGI	4.0e-137	493.8	87.34%	55.07%	Cytochrome P450 3A9;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN000551.1	sp|K1Q900|K1Q900_CRAGI	7.8e-96	356.3	94.84%	52.81%	Galectin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN000552.1	sp|K1QT37|K1QT37_CRAGI	3.2e-156	557.8	96.91%	46.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000553.1	sp|K1QVE4|K1QVE4_CRAGI	1.6e-58	233.0	25.46%	80.00%	Inner centromere protein;OS=Crassostrea;PE=4;SV=1	GO:0000070|GO:1902412|
GN000554.1	sp|K1QT37|K1QT37_CRAGI	7.0e-159	566.6	96.92%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000555.1	sp|A0A0L8FN67|A0A0L8FN67_OCTBM	9.7e-11	73.2	50.55%	32.17%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN000556.1	sp|K1QK28|K1QK28_CRAGI	1.3e-140	504.6	95.93%	82.56%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|GO:0005507|GO:0016491|	GO:0006004|
GN000557.1	sp|K1RFW2|K1RFW2_CRAGI	1.8e-100	372.1	45.77%	78.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000558.1	sp|K1QSI3|K1QSI3_CRAGI	1.8e-68	264.2	100.00%	73.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000559.1	sp|K1QZA8|K1QZA8_CRAGI	3.5e-131	473.4	100.00%	76.19%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN000560.1	sp|K1RIV9|K1RIV9_CRAGI	2.5e-70	270.4	100.00%	77.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000561.1	sp|K1PVU0|K1PVU0_CRAGI	1.6e-29	134.8	97.56%	41.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000562.1	sp|A0A210PVG4|A0A210PVG4_MIZYE	1.1e-54	219.9	82.64%	30.98%	E3 ubiquitin-protein ligase TRIM33;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN000565.1	sp|K1QHB0|K1QHB0_CRAGI	8.0e-22	110.2	45.87%	44.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000566.1	sp|A0A2G8KYC6|A0A2G8KYC6_STIJA	7.7e-24	117.5	64.10%	28.53%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0008270|
GN000567.1	sp|K1QB30|K1QB30_CRAGI	1.6e-53	216.1	81.59%	31.89%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN000568.1	sp|K1PD38|K1PD38_CRAGI	1.9e-215	754.2	86.86%	68.43%	Succinate-semialdehyde dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN000570.1	sp|K1Q0L9|K1Q0L9_CRAGI	5.0e-32	143.3	82.49%	48.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000572.1	sp|K1RED4|K1RED4_CRAGI	1.7e-13	80.9	99.02%	48.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000573.1	sp|K1PSN6|K1PSN6_CRAGI	6.2e-41	173.3	97.54%	43.04%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000073.1	sp|K1QBI2|K1QBI2_CRAGI	4.8e-15	85.9	93.33%	50.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000574.1	sp|K1QL92|K1QL92_CRAGI	5.5e-21	105.5	96.47%	59.26%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000575.1	sp|K1Q136|K1Q136_CRAGI	8.4e-39	166.8	40.85%	50.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000577.1	sp|K1QB30|K1QB30_CRAGI	5.2e-55	221.1	97.17%	29.42%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN000578.1	sp|C7T5D1|C7T5D1_9BIVA	5.5e-110	402.5	95.33%	93.69%	Insulin-induced protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN000579.1	sp|A0A210QP14|A0A210QP14_MIZYE	1.7e-46	190.7	100.00%	80.70%	Transcription factor 15;OS=Mizuhopecten;PE=4;SV=1	GO:0046983|
GN000580.1	sp|A0A210QG50|A0A210QG50_MIZYE	3.8e-116	424.1	94.64%	48.13%	Integrin alpha-9;OS=Mizuhopecten;PE=3;SV=1	GO:0008305|	GO:0007155|GO:0007229|
GN000074.1	sp|K1Q7B8|K1Q7B8_CRAGI	7.2e-94	349.4	91.37%	69.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000583.1	sp|A0A210Q1E9|A0A210Q1E9_MIZYE	5.1e-81	306.6	85.66%	64.34%	Tankyrase-2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN000586.1	sp|Unreviewed|A0A087U9K1_9ARAC	3.3e-10	70.1	94.50%	36.89%	Uncharacterized protein;OS=Stegodyphus;PE=4;SV=1
GN000587.1	sp|K1QLM4|K1QLM4_CRAGI	4.6e-118	430.3	90.82%	59.24%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0005230|GO:0043565|GO:0004888|	GO:0006355|
GN000588.1	sp|K1QLM4|K1QLM4_CRAGI	1.2e-102	379.0	90.93%	51.80%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0005230|GO:0043565|GO:0004888|	GO:0006355|
GN000590.1	sp|K1QLM4|K1QLM4_CRAGI	7.2e-90	336.3	84.54%	61.05%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0005230|GO:0043565|GO:0004888|	GO:0006355|
GN000591.1	sp|K1QLM4|K1QLM4_CRAGI	4.1e-100	370.5	93.96%	50.84%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0005230|GO:0043565|GO:0004888|	GO:0006355|
GN000592.1	sp|K1QLM4|K1QLM4_CRAGI	3.3e-108	397.5	92.96%	54.30%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0005230|GO:0043565|GO:0004888|	GO:0006355|
GN000593.1	sp|K1PDX6|K1PDX6_CRAGI	1.7e-233	813.9	99.36%	88.82%	Ecdysone receptor;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0035100|GO:0004879|GO:0043565|GO:0003707|GO:0008270|	GO:0035076|
GN000597.1	sp|K1RIW4|K1RIW4_CRAGI	1.1e-86	326.6	87.24%	33.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000076.1	sp|A0A210QJ55|A0A210QJ55_MIZYE	1.1e-33	149.1	92.69%	39.09%	Histone-lysine N-methyltransferase set-1;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN000598.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	2.4e-36	158.7	73.99%	35.79%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN000599.1	sp|K1PI38|K1PI38_CRAGI	4.9e-58	229.6	98.80%	68.86%	Helix-loop-helix protein 13;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000601.1	sp|K1PP42|K1PP42_CRAGI	3.5e-41	173.7	79.78%	59.86%	Glutamate receptor delta-1 subunit;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN000077.1	sp|K1PU09|K1PU09_CRAGI	1.6e-23	115.5	99.60%	29.54%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000603.1	sp|K1RIW4|K1RIW4_CRAGI	4.8e-85	321.2	87.24%	33.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000604.1	sp|A0A1X7U2S0|A0A1X7U2S0_AMPQE	2.2e-37	162.5	75.70%	29.76%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0005524|GO:0008026|GO:0003676|	GO:0006310|
GN000605.1	sp|K1PI38|K1PI38_CRAGI	4.1e-60	236.5	98.80%	70.83%	Helix-loop-helix protein 13;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN000606.1	sp|K1QNS0|K1QNS0_CRAGI	2.9e-303	1046.2	87.52%	88.58%	Ubiquitin-conjugating enzyme E2 6;OS=Crassostrea;PE=4;SV=1
GN000607.1	sp|K1QFG7|K1QFG7_CRAGI	5.2e-247	859.4	70.88%	82.98%	Galactocerebrosidase;OS=Crassostrea;PE=4;SV=1	GO:0004336|	GO:0006683|
GN000608.1	sp|K1RUW9|K1RUW9_CRAGI	9.5e-125	451.8	100.00%	86.77%	Enkurin;OS=Crassostrea;PE=4;SV=1
GN000609.1	sp|K1RBB5|K1RBB5_CRAGI	5.4e-112	409.5	100.00%	81.71%	TCF3 fusion partner-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN000610.1	sp|K1R4T0|K1R4T0_CRAGI	2.1e-214	751.1	99.72%	58.37%	Zinc finger SWIM domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0061630|GO:0008270|
GN000611.1	sp|K1QXX9|K1QXX9_CRAGI	2.1e-55	220.3	94.83%	90.83%	Cytochrome c;OS=Crassostrea;PE=3;SV=1	GO:0005739|GO:0070469|	GO:0009055|GO:0020037|GO:0046872|
GN000078.1	sp|K1PU09|K1PU09_CRAGI	3.9e-52	212.2	60.10%	28.82%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000612.1	sp|K1RBB0|K1RBB0_CRAGI	2.5e-164	583.6	100.00%	88.58%	Cell division protein kinase 5;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0051301|
GN000613.1	sp|A0A210Q2S0|A0A210Q2S0_MIZYE	7.7e-36	156.4	56.25%	55.97%	ATP-dependent DNA helicase PIF1;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|
GN000614.1	sp|A0A2C9LWQ6|A0A2C9LWQ6_BIOGL	1.7e-23	114.8	94.27%	39.46%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003677|
GN000616.1	sp|K1Q5G1|K1Q5G1_CRAGI	1.1e-161	575.1	100.00%	79.78%	Tachykinin-like peptide receptor 86C;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN000617.1	sp|K1PUT5|K1PUT5_CRAGI	3.7e-28	130.2	56.67%	65.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000618.1	sp|K1PZG0|K1PZG0_CRAGI	2.5e-17	94.7	97.75%	35.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN000620.1	sp|A0A210QQK0|A0A210QQK0_MIZYE	3.0e-267	926.0	100.00%	99.78%	Tubulin alpha chain;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN000621.1	sp|K1Q7K3|K1Q7K3_CRAGI	2.1e-111	407.9	93.91%	62.46%	Integrin alpha-4;OS=Crassostrea;PE=3;SV=1	GO:0008305|	GO:0007155|GO:0007229|
GN000622.1	sp|K1RCE3|K1RCE3_CRAGI	5.6e-22	109.0	88.42%	63.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000623.1	sp|K1PBH4|K1PBH4_CRAGI	1.8e-32	146.0	68.87%	30.03%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000624.1	sp|K1PBH4|K1PBH4_CRAGI	4.1e-31	141.4	72.21%	31.18%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000625.1	sp|K1PBH4|K1PBH4_CRAGI	1.1e-31	143.3	72.21%	31.18%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000626.1	sp|K1PBH4|K1PBH4_CRAGI	5.8e-33	147.5	74.49%	30.38%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000627.1	sp|K1PBH4|K1PBH4_CRAGI	2.0e-26	125.2	98.44%	29.76%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000628.1	sp|K1QSF2|K1QSF2_CRAGI	7.9e-22	109.4	90.86%	41.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000629.1	sp|K1QSF2|K1QSF2_CRAGI	7.8e-33	147.9	97.81%	31.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000630.1	sp|K1PUB3|K1PUB3_CRAGI	9.2e-38	162.5	94.15%	50.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN000631.1	sp|K1QSF2|K1QSF2_CRAGI	2.9e-51	209.1	99.29%	29.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000632.1	sp|A0A210PW35|A0A210PW35_MIZYE	3.5e-63	246.9	98.47%	59.90%	COMM domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0006814|
GN000081.1	sp|K1PU09|K1PU09_CRAGI	1.1e-85	323.6	99.08%	28.86%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000634.1	sp|K1PI18|K1PI18_CRAGI	0.0e+00	3117.4	94.08%	86.00%	E3 ubiquitin-protein ligase UBR3;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|GO:0008270|	GO:0071596|
GN000638.1	sp|K1R0V6|K1R0V6_CRAGI	4.4e-112	410.2	89.61%	57.01%	Ficolin-2;OS=Crassostrea;PE=4;SV=1
GN000639.1	sp|K1QEY1|K1QEY1_CRAGI	2.2e-154	551.2	84.76%	67.44%	ABC transporter G family member 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016887|
GN000082.1	sp|K1PU09|K1PU09_CRAGI	1.9e-59	235.3	97.99%	39.53%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN000640.1	sp|K1QCN5|K1QCN5_CRAGI	5.0e-31	139.0	100.00%	74.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000641.1	sp|K1RJG2|K1RJG2_CRAGI	3.6e-25	120.2	96.45%	51.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000642.1	sp|K1QCN5|K1QCN5_CRAGI	3.7e-34	149.4	100.00%	78.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000643.1	sp|K1QCN5|K1QCN5_CRAGI	1.1e-43	181.4	100.00%	74.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000644.1	sp|K1QCN5|K1QCN5_CRAGI	1.5e-185	655.6	65.42%	60.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000645.1	sp|K1QCN5|K1QCN5_CRAGI	3.8e-91	340.1	95.87%	73.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000646.1	sp|K1PND9|K1PND9_CRAGI	1.0e-22	111.7	89.57%	53.92%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN000649.1	sp|A0A1X7V8P5|A0A1X7V8P5_AMPQE	2.5e-22	112.5	43.97%	32.68%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003676|
GN000651.1	sp|K1Q0Z1|K1Q0Z1_CRAGI	3.1e-217	760.0	94.07%	84.97%	Putative sodium-coupled neutral amino acid transporter 11;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000652.1	sp|V4AKX4|V4AKX4_LOTGI	5.2e-27	125.9	91.96%	58.65%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN000653.1	sp|K1QTH9|K1QTH9_CRAGI	2.4e-21	107.5	44.68%	80.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000655.1	sp|A0A2T7NAT5|A0A2T7NAT5_POMCA	3.1e-21	107.8	79.06%	37.31%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0004252|
GN000656.1	sp|K1Q237|K1Q237_CRAGI	8.5e-60	236.1	77.82%	54.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000658.1	sp|K1RK81|K1RK81_CRAGI	6.4e-18	95.5	91.67%	53.85%	Chorion peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN000659.1	sp|K1QCR2|K1QCR2_CRAGI	1.2e-131	475.3	97.47%	59.59%	Chorion peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN000666.1	sp|K1QCI2|K1QCI2_CRAGI	1.1e-275	954.5	100.00%	72.54%	Polypeptide N-acetylgalactosaminyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN000667.1	sp|A0A210PU74|A0A210PU74_MIZYE	3.4e-93	347.1	99.25%	66.18%	Interferon-inducible double stranded RNA-dependent protein kinase activator A-like A;OS=Mizuhopecten;PE=4;SV=1	GO:0003725|GO:0008047|GO:0016301|	GO:0030422|
GN000668.1	sp|K1RG64|K1RG64_CRAGI	1.1e-232	811.6	92.32%	70.63%	Polypeptide N-acetylgalactosaminyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN000086.1	sp|A0A210QYP1|A0A210QYP1_MIZYE	3.8e-34	152.1	94.39%	23.32%	Transmembrane protein ORF68;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN000670.1	sp|K1QPF5|K1QPF5_CRAGI	5.2e-15	89.0	49.82%	32.06%	Zonadhesin;OS=Crassostrea;PE=4;SV=1
GN000671.1	sp|K1Q0M2|K1Q0M2_CRAGI	0.0e+00	1607.0	95.77%	75.47%	Ras-associated and pleckstrin-like protein domains-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN000673.1	sp|K1Q7V3|K1Q7V3_CRAGI	4.0e-60	236.9	91.08%	59.49%	AIG2-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0061929|
GN000674.1	sp|K1QZH4|K1QZH4_CRAGI	9.0e-92	342.0	84.02%	93.99%	Ras-related protein Ral-A;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN000676.1	sp|A0A210QNU3|A0A210QNU3_MIZYE	2.0e-10	70.5	82.95%	50.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000677.1	sp|A0A210R559|A0A210R559_MIZYE	1.2e-55	222.2	96.69%	46.84%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000679.1	sp|A7S4E4|A7S4E4_NEMVE	2.7e-22	110.9	49.13%	57.14%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN000683.1	sp|K1QBK6|K1QBK6_CRAGI	0.0e+00	2041.5	99.48%	94.90%	Splicing factor 3B subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0003729|	GO:0000245|
GN000684.1	sp|K1R646|K1R646_CRAGI	5.3e-75	285.8	100.00%	85.23%	Coenzyme Q-binding protein COQ10-like protein B, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN000685.1	sp|A0A385NFS7|A0A385NFS7_PINFU	2.0e-237	827.4	95.18%	73.38%	Insulin-like growth factor 2 mRNA binding protein 1;OS=Pinctada;PE=2;SV=1	GO:0003723|
GN001612.1	sp|K1R1E4|K1R1E4_CRAGI	1.8e-230	803.9	100.00%	83.40%	Serine/threonine-protein kinase Chk2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001613.1	sp|K1QUK1|K1QUK1_CRAGI	3.2e-22	111.3	23.79%	82.54%	Ubiquitin fusion degradation protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0006511|
GN001617.1	sp|K1P9Y6|K1P9Y6_CRAGI	6.3e-35	152.1	100.00%	75.00%	Tyrosine-protein kinase PR2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004713|
GN001619.1	sp|A0A2T7PR27|A0A2T7PR27_POMCA	5.1e-28	132.1	57.63%	25.97%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN001621.1	sp|K1R0A3|K1R0A3_CRAGI	1.1e-127	462.6	44.05%	92.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016627|	GO:0006629|
GN001622.1	sp|K1Q720|K1Q720_CRAGI	2.8e-14	82.8	95.24%	59.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000986.1	sp|A0A1X7STM2|A0A1X7STM2_AMPQE	1.2e-15	88.2	93.52%	40.00%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0005524|GO:0008026|GO:0003676|	GO:0006310|
GN001624.1	sp|C3ZG36|C3ZG36_BRAFL	4.8e-60	237.7	74.66%	39.76%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0015074|GO:0006310|GO:0009299|
GN001625.1	sp|K1QI60|K1QI60_CRAGI	1.5e-141	508.1	100.00%	69.32%	D-aspartate oxidase;OS=Crassostrea;PE=4;SV=1	GO:0003884|GO:0071949|	GO:0046416|
GN001626.1	sp|K1RPE5|K1RPE5_CRAGI	2.6e-64	251.1	100.00%	49.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001627.1	sp|K1Q7N1|K1Q7N1_CRAGI	6.7e-50	203.4	58.98%	54.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001628.1	sp|K1RRD7|K1RRD7_CRAGI	6.6e-123	446.4	69.63%	62.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001629.1	sp|K1QDG0|K1QDG0_CRAGI	2.6e-42	177.2	91.39%	66.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN001630.1	sp|K1QDG0|K1QDG0_CRAGI	3.7e-95	354.0	84.70%	65.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN000987.1	sp|K1Q5B6|K1Q5B6_CRAGI	6.5e-220	770.0	63.80%	48.85%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN001631.1	sp|K1Q5C2|K1Q5C2_CRAGI	2.3e-187	660.6	93.26%	82.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001633.1	sp|K1PXZ7|K1PXZ7_CRAGI	1.1e-130	472.2	98.39%	53.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001635.1	sp|K1QDG0|K1QDG0_CRAGI	2.6e-42	177.2	91.39%	66.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN000988.1	sp|K1PVQ2|K1PVQ2_CRAGI	2.7e-75	287.0	100.00%	78.49%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001640.1	sp|K1PE80|K1PE80_CRAGI	4.3e-68	263.5	82.83%	63.59%	Uncharacterized protein C3orf38-like protein;OS=Crassostrea;PE=4;SV=1
GN001641.1	sp|K1PTI1|K1PTI1_CRAGI	1.2e-255	887.9	99.83%	73.22%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN001643.1	sp|K1QHK2|K1QHK2_CRAGI	4.5e-40	170.2	96.23%	44.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000989.1	sp|K1QXK8|K1QXK8_CRAGI	7.4e-66	255.8	98.95%	72.11%	Tyramine receptor ser-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|GO:0004983|
GN001645.1	sp|K1RBQ1|K1RBQ1_CRAGI	2.3e-308	1063.1	100.00%	85.71%	Serine/threonine-protein kinase Nek11;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001646.1	sp|K1QC49|K1QC49_CRAGI	4.6e-195	686.0	100.00%	88.10%	Phosphatidylinositol glycan anchor biosynthesis class U protein;OS=Crassostrea;PE=4;SV=1	GO:0042765|	GO:0016255|
GN001647.1	sp|K1QRM1|K1QRM1_CRAGI	0.0e+00	1075.1	99.15%	91.91%	Nuclear pore protein;OS=Crassostrea;PE=3;SV=1	GO:0016020|GO:0005643|	GO:0017056|	GO:0051028|GO:0015031|
GN001648.1	sp|K1QRM1|K1QRM1_CRAGI	8.2e-123	445.3	100.00%	93.28%	Nuclear pore protein;OS=Crassostrea;PE=3;SV=1	GO:0016020|GO:0005643|	GO:0017056|	GO:0051028|GO:0015031|
GN001649.1	sp|K1RBQ6|K1RBQ6_CRAGI	0.0e+00	1134.8	100.00%	83.27%	Ankyrin repeat domain-containing protein 12;OS=Crassostrea;PE=4;SV=1
GN001650.1	sp|K1Q4N2|K1Q4N2_CRAGI	3.5e-124	450.7	99.76%	57.87%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001651.1	sp|K1PIS2|K1PIS2_CRAGI	2.7e-27	127.9	62.33%	46.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001652.1	sp|K1PXV6|K1PXV6_CRAGI	2.3e-160	570.5	100.00%	84.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001653.1	sp|A0A210Q6H6|A0A210Q6H6_MIZYE	9.3e-174	615.9	99.36%	57.59%	T-box transcription factor TBX2-B;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN001654.1	sp|K1PXU8|K1PXU8_CRAGI	2.6e-296	1023.1	99.53%	86.03%	T-box transcription factor TBX2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN001655.1	sp|K1PQB1|K1PQB1_CRAGI	0.0e+00	1506.5	98.16%	86.89%	Breast carcinoma-amplified sequence 3-like protein;OS=Crassostrea;PE=4;SV=1
GN001657.1	sp|K1S3Y9|K1S3Y9_CRAGI	2.5e-58	230.7	86.02%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001659.1	sp|K1QY43|K1QY43_CRAGI	7.4e-68	262.3	98.32%	72.16%	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003854|GO:0016853|	GO:0006694|
GN001660.1	sp|K1QY43|K1QY43_CRAGI	5.1e-75	286.2	96.83%	71.98%	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003854|GO:0016853|	GO:0006694|
GN000991.1	sp|K1RFE1|K1RFE1_CRAGI	1.3e-87	329.3	83.61%	41.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001662.1	sp|K1QT12|K1QT12_CRAGI	5.0e-27	127.1	95.40%	32.17%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000992.1	sp|K1QPX1|K1QPX1_CRAGI	4.9e-137	493.4	100.00%	80.32%	ATPase family AAA domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0005524|	GO:0007005|
GN001665.1	sp|A0A2B4RME3|A0A2B4RME3_STYPI	5.4e-09	67.4	26.98%	35.14%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN001666.1	sp|K1PRB2|K1PRB2_CRAGI	4.5e-19	99.4	62.50%	84.75%	O-acyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0004144|	GO:0019432|
GN001667.1	sp|K1PYJ1|K1PYJ1_CRAGI	6.5e-124	449.1	98.90%	83.27%	TBC1 domain family member 20;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001668.1	sp|K1QRJ9|K1QRJ9_CRAGI	6.8e-31	139.4	96.45%	48.15%	Heat shock transcription factor, Y-linked;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN001669.1	sp|A0A210QMB4|A0A210QMB4_MIZYE	2.1e-93	348.2	92.43%	50.88%	HAUS augmin-like complex subunit 4;OS=Mizuhopecten;PE=4;SV=1	GO:0070652|	GO:0007098|GO:0051225|
GN000993.1	sp|F5A8D5|F5A8D5_CRAGI	9.9e-26	122.9	90.84%	30.07%	Inhibitor of apoptosis protein;OS=Crassostrea;PE=2;SV=1
GN001670.1	sp|K1PJJ5|K1PJJ5_CRAGI	0.0e+00	1187.9	92.53%	88.02%	Conserved oligomeric Golgi complex subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0017119|	GO:0006886|
GN001671.1	sp|A0A1I8J146|A0A1I8J146_9PLAT	3.5e-19	99.8	76.53%	58.11%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN001672.1	sp|W4ZF66|W4ZF66_STRPU	2.3e-24	117.5	87.32%	51.61%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN001673.1	sp|K1QMF9|K1QMF9_CRAGI	1.2e-74	285.8	92.77%	42.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN001674.1	sp|A0A210Q9B2|A0A210Q9B2_MIZYE	7.8e-13	79.3	66.88%	40.38%	Ninjurin-2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007155|GO:0042246|
GN000994.1	sp|F5A8D5|F5A8D5_CRAGI	3.5e-26	124.4	82.81%	31.15%	Inhibitor of apoptosis protein;OS=Crassostrea;PE=2;SV=1
GN001677.1	sp|K1RLN7|K1RLN7_CRAGI	5.2e-18	96.7	53.45%	47.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001678.1	sp|A0A1Y1MQL2|A0A1Y1MQL2_PHOPY	5.0e-30	136.7	96.86%	37.84%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN001679.1	sp|A0A210PJW7|A0A210PJW7_MIZYE	1.8e-15	89.0	53.36%	39.74%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001681.1	sp|W4ZKT7|W4ZKT7_STRPU	1.2e-13	83.6	50.43%	32.76%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN001683.1	sp|A0A3M6U5M9|A0A3M6U5M9_9CNID	6.5e-32	142.9	99.44%	42.86%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN001684.1	sp|K1PXX6|K1PXX6_CRAGI	4.5e-30	138.3	89.00%	26.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0002218|GO:0032481|GO:0007165|
GN000995.1	sp|A0A3L5TRA6|A0A3L5TRA6_MYTGA	2.3e-18	99.8	28.09%	31.31%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN001686.1	sp|W4YR48|W4YR48_STRPU	1.8e-45	189.1	60.74%	41.83%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN001689.1	sp|A0A2G8JK74|A0A2G8JK74_STIJA	2.4e-44	184.5	100.00%	42.25%	Putative 52 kDa repressor of the inhibitor of the protein kinase-like;OS=Stichopus;PE=4;SV=1	GO:0016301|GO:0046983|
GN000996.1	sp|K1Q8Z7|K1Q8Z7_CRAGI	1.2e-115	422.5	57.42%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN001692.1	sp|K1RGG7|K1RGG7_CRAGI	4.6e-25	119.0	77.78%	88.71%	ATP-dependent DNA helicase Q4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN001693.1	sp|K1RGG7|K1RGG7_CRAGI	1.2e-32	146.4	92.86%	34.66%	ATP-dependent DNA helicase Q4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN001694.1	sp|K1Q919|K1Q919_CRAGI	5.5e-106	389.8	91.22%	69.39%	Protein deadpan;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN001695.1	sp|K1QPZ3|K1QPZ3_CRAGI	0.0e+00	1141.3	99.64%	73.02%	Protein phosphatase 1E;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN001696.1	sp|K1R7Y8|K1R7Y8_CRAGI	6.1e-194	682.6	89.33%	80.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001698.1	sp|K1R1N2|K1R1N2_CRAGI	7.9e-71	272.7	71.48%	68.23%	S-crystallin SL11;OS=Crassostrea;PE=4;SV=1
GN001699.1	sp|K1R1N2|K1R1N2_CRAGI	6.2e-60	236.1	100.00%	51.60%	S-crystallin SL11;OS=Crassostrea;PE=4;SV=1
GN001700.1	sp|K1R1N2|K1R1N2_CRAGI	3.7e-71	273.5	100.00%	56.00%	S-crystallin SL11;OS=Crassostrea;PE=4;SV=1
GN001703.1	sp|K1REF7|K1REF7_CRAGI	5.3e-72	276.6	98.40%	54.88%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN001704.1	sp|J9KQR3|J9KQR3_ACYPI	1.5e-43	182.6	98.37%	30.60%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2
GN001705.1	sp|A0A2B4RZW9|A0A2B4RZW9_STYPI	5.1e-16	90.1	63.19%	33.33%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0008270|
GN001706.1	sp|K1REF7|K1REF7_CRAGI	2.3e-226	791.2	83.92%	53.70%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN001707.1	sp|K1REF7|K1REF7_CRAGI	5.1e-255	886.3	92.87%	55.32%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN001708.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	1.8e-14	85.5	65.27%	31.98%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001709.1	sp|K1Q922|K1Q922_CRAGI	3.5e-221	773.5	91.38%	68.66%	Solute carrier family 13 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030170|GO:0005215|	GO:0006520|GO:0006814|GO:0055085|
GN001710.1	sp|A0A0U5AKI6|A0A0U5AKI6_CRAGI	2.5e-131	473.8	98.20%	83.82%	Serine racemase;OS=Crassostrea;PE=2;SV=1	GO:0030170|	GO:0006520|
GN001711.1	sp|K1QPZ3|K1QPZ3_CRAGI	1.2e-13	82.0	73.20%	48.65%	Protein phosphatase 1E;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN001712.1	sp|K1QBZ7|K1QBZ7_CRAGI	1.1e-23	114.4	81.25%	79.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001713.1	sp|K1RJE3|K1RJE3_CRAGI	3.8e-49	200.7	93.82%	48.77%	Protein jagged-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN001714.1	sp|K1RJE3|K1RJE3_CRAGI	2.4e-198	697.2	92.66%	74.15%	Protein jagged-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN001715.1	sp|K1RJE3|K1RJE3_CRAGI	0.0e+00	3536.1	99.86%	81.61%	Protein jagged-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN001716.1	sp|K1RJE3|K1RJE3_CRAGI	0.0e+00	1987.2	99.39%	72.38%	Protein jagged-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN001717.1	sp|K1Q5E6|K1Q5E6_CRAGI	2.9e-211	740.0	100.00%	91.73%	Forkhead box protein J3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN001718.1	sp|K1QJR1|K1QJR1_CRAGI	0.0e+00	1332.0	100.00%	67.65%	DIS3-like exonuclease 2;OS=Crassostrea;PE=3;SV=1	GO:0000932|	GO:0000175|GO:0046872|GO:0003723|	GO:0034427|GO:1990074|
GN001719.1	sp|K1R5C4|K1R5C4_CRAGI	0.0e+00	1375.5	100.00%	70.70%	Golgin subfamily A member 3;OS=Crassostrea;PE=4;SV=1	GO:0090498|	GO:0007283|
GN001720.1	sp|K1QDI2|K1QDI2_CRAGI	6.0e-218	762.3	100.00%	79.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001721.1	sp|K1Q5E8|K1Q5E8_CRAGI	5.7e-132	476.9	59.40%	82.70%	Leucine-rich repeat-containing protein 47;OS=Crassostrea;PE=4;SV=1	GO:0004826|GO:0003723|
GN001722.1	sp|K1PY12|K1PY12_CRAGI	1.8e-169	601.3	77.83%	80.77%	TWiK family of potassium channels protein 7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN001723.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	10919.2	79.99%	81.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001724.1	sp|K1QBP4|K1QBP4_CRAGI	1.4e-172	612.1	69.47%	61.57%	Cytochrome P450 4F22;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN001725.1	sp|K1QJR7|K1QJR7_CRAGI	1.9e-266	923.7	97.56%	80.29%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008810|	GO:0030245|
GN001726.1	sp|K1QJR7|K1QJR7_CRAGI	1.2e-38	164.5	89.62%	68.42%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008810|	GO:0030245|
GN001727.1	sp|K1QDI5|K1QDI5_CRAGI	1.6e-160	571.2	92.20%	85.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001728.1	sp|K1QJR7|K1QJR7_CRAGI	0.0e+00	1279.6	99.35%	79.42%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008810|	GO:0030245|
GN001731.1	sp|K1R5D0|K1R5D0_CRAGI	1.5e-61	241.5	63.96%	86.40%	Leukotriene-B4 omega-hydroxylase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN001734.1	sp|A0A2B4SP29|A0A2B4SP29_STYPI	3.4e-15	87.4	58.38%	40.00%	Zinc finger protein 862;OS=Stylophora;PE=4;SV=1
GN000930.1	sp|A0A2T7NHN0|A0A2T7NHN0_POMCA	7.4e-21	107.1	79.82%	24.76%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN001735.1	sp|A2FIL1|A2FIL1_TRIVA	7.2e-12	75.9	82.31%	29.01%	Uncharacterized protein;OS=Trichomonas;PE=4;SV=1
GN001736.1	sp|K1R0E3|K1R0E3_CRAGI	5.1e-22	109.4	100.00%	51.28%	Apoptosis inhibitor IAP;OS=Crassostrea;PE=4;SV=1
GN001737.1	sp|W4Y5B2|W4Y5B2_STRPU	1.5e-39	168.7	83.40%	40.19%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|	GO:0015074|
GN001741.1	sp|K1RYB1|K1RYB1_CRAGI	1.9e-121	441.0	97.92%	73.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001742.1	sp|K1R2N4|K1R2N4_CRAGI	1.8e-269	933.7	99.82%	83.13%	Ankyrin repeat domain-containing protein 13B;OS=Crassostrea;PE=4;SV=1
GN001743.1	sp|K1R8Q3|K1R8Q3_CRAGI	4.9e-67	259.2	99.29%	96.38%	Golgi SNAP receptor complex member 1;OS=Crassostrea;PE=3;SV=1	GO:0005801|GO:0000139|GO:0016021|	GO:0006888|GO:0015031|
GN001744.1	sp|A0A210Q0I0|A0A210Q0I0_MIZYE	1.4e-192	678.3	93.02%	60.30%	Uncharacterized protein;OS=Mizuhopecten;PE=3;SV=1
GN001745.1	sp|K1QJQ0|K1QJQ0_CRAGI	2.8e-181	640.6	97.78%	78.92%	IQ domain-containing protein D;OS=Crassostrea;PE=4;SV=1
GN001746.1	sp|K1QB68|K1QB68_CRAGI	1.7e-13	80.5	71.62%	75.00%	dCTP pyrophosphatase 1;OS=Crassostrea;PE=4;SV=1	GO:0047429|	GO:0009143|
GN001747.1	sp|A0A293LJS4|A0A293LJS4_ORNER	5.3e-12	75.5	70.27%	68.63%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0047429|	GO:0009143|
GN001748.1	sp|A0A210Q891|A0A210Q891_MIZYE	5.7e-42	176.4	83.25%	53.09%	Protein unc-93-like A;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN001749.1	sp|A0A210Q891|A0A210Q891_MIZYE	3.4e-141	507.3	97.39%	55.56%	Protein unc-93-like A;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN001750.1	sp|K1RF99|K1RF99_CRAGI	5.7e-264	915.6	90.79%	80.84%	Solute carrier family 15 member 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN001751.1	sp|A0A210PV03|A0A210PV03_MIZYE	2.1e-17	95.9	97.51%	27.23%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN000999.1	sp|A0A210Q6D7|A0A210Q6D7_MIZYE	1.7e-62	244.6	97.84%	64.48%	RWD domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1
GN001752.1	sp|A0A210Q7W0|A0A210Q7W0_MIZYE	1.3e-129	468.8	96.53%	50.78%	Transporter MCH1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001754.1	sp|K1PQQ5|K1PQQ5_CRAGI	5.5e-20	103.2	67.06%	49.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001000.1	sp|K1QH15|K1QH15_CRAGI	0.0e+00	1536.5	99.78%	80.86%	UPF0636 protein C4orf41-like protein;OS=Crassostrea;PE=4;SV=1
GN001759.1	sp|K1PK06|K1PK06_CRAGI	1.1e-16	92.8	52.87%	40.31%	Myb-related transcription factor, partner of profilin;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN001760.1	sp|A0A1S3JYC9|A0A1S3JYC9_LINUN	7.0e-78	296.6	98.87%	44.76%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN001761.1	sp|V4AE92|V4AE92_LOTGI	1.5e-88	332.0	86.00%	51.67%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN001001.1	sp|K1QH15|K1QH15_CRAGI	3.0e-89	333.6	95.05%	81.68%	UPF0636 protein C4orf41-like protein;OS=Crassostrea;PE=4;SV=1
GN001762.1	sp|A0A210R1E9|A0A210R1E9_MIZYE	3.3e-23	113.6	98.54%	44.03%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001002.1	sp|K1PWX2|K1PWX2_CRAGI	9.7e-66	257.7	55.70%	29.24%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001772.1	sp|K1PLG1|K1PLG1_CRAGI	3.5e-76	289.7	99.32%	96.53%	Putative ribosomal RNA methyltransferase NOP2;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0008757|	GO:0006364|
GN001774.1	sp|K1PFD5|K1PFD5_CRAGI	6.4e-165	585.5	100.00%	92.98%	Spermidine synthase;OS=Crassostrea;PE=3;SV=1	GO:0016740|	GO:0006596|
GN001775.1	sp|K1PYV9|K1PYV9_CRAGI	2.8e-20	103.2	100.00%	89.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001776.1	sp|K1Q933|K1Q933_CRAGI	1.6e-82	310.8	100.00%	91.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001777.1	sp|K1QDF2|K1QDF2_CRAGI	4.2e-293	1012.7	92.65%	71.17%	DnaJ-like protein subfamily C member 16;OS=Crassostrea;PE=4;SV=1
GN001779.1	sp|A0A210PL30|A0A210PL30_MIZYE	8.1e-189	665.6	97.79%	70.16%	ATP-dependent RNA helicase DDX19A;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN001003.1	sp|A0A210R559|A0A210R559_MIZYE	5.1e-44	183.3	97.14%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001780.1	sp|K1QZ85|K1QZ85_CRAGI	2.3e-214	751.5	77.97%	51.60%	Pleckstrin-like protein domain-containing family M member 3;OS=Crassostrea;PE=4;SV=1
GN001781.1	sp|K1PRC3|K1PRC3_CRAGI	2.1e-119	435.3	62.91%	57.41%	U5 small nuclear ribonucleoprotein 40 kDa protein;OS=Crassostrea;PE=4;SV=1	GO:0019013|
GN001782.1	sp|K1Q6C5|K1Q6C5_CRAGI	2.7e-207	726.9	100.00%	85.43%	Nuclear receptor subfamily 0 group B member 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003707|	GO:0006355|
GN001783.1	sp|K1QY88|K1QY88_CRAGI	1.6e-45	188.3	74.54%	62.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN001784.1	sp|K1QNJ7|K1QNJ7_CRAGI	1.7e-76	292.0	73.96%	57.20%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0005975|
GN001785.1	sp|A0A1W4XKH3|A0A1W4XKH3_AGRPL	3.8e-21	107.8	34.60%	55.24%	uncharacterized protein LOC108742291 isoform X1;OS=Agrilus;PE=4;SV=1
GN001786.1	sp|K1P6C4|K1P6C4_CRAGI	2.0e-127	462.6	52.32%	46.29%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN001004.1	sp|K1QH15|K1QH15_CRAGI	3.1e-116	424.5	100.00%	74.90%	UPF0636 protein C4orf41-like protein;OS=Crassostrea;PE=4;SV=1
GN001787.1	sp|A0A210Q934|A0A210Q934_MIZYE	1.4e-84	319.7	99.24%	24.54%	Ankyrin-1;OS=Mizuhopecten;PE=4;SV=1
GN001788.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	6.2e-81	307.0	96.24%	36.72%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN001790.1	sp|K1P6C4|K1P6C4_CRAGI	1.3e-63	250.4	40.42%	39.88%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN001791.1	sp|K1QCB5|K1QCB5_CRAGI	1.3e-51	208.0	95.56%	75.00%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN001792.1	sp|K1RPU6|K1RPU6_CRAGI	1.8e-86	324.3	100.00%	79.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001793.1	sp|K1QZ14|K1QZ14_CRAGI	1.8e-61	240.7	93.38%	91.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001795.1	sp|K1QN19|K1QN19_CRAGI	6.2e-208	730.7	50.37%	50.99%	Tyrosine-protein kinase Abl;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001005.1	sp|K1Q8Z3|K1Q8Z3_CRAGI	9.2e-139	498.4	100.00%	88.01%	Putative L-aspartate dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0033735|GO:0050661|	GO:0009435|GO:0006742|
GN001796.1	sp|K1QN19|K1QN19_CRAGI	5.1e-119	433.3	86.06%	65.00%	Tyrosine-protein kinase Abl;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001797.1	sp|A0A210Q9Y7|A0A210Q9Y7_MIZYE	5.2e-86	324.3	60.58%	43.09%	Jerky protein homolog-like;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN001799.1	sp|K1R0B5|K1R0B5_CRAGI	5.8e-51	206.5	100.00%	55.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001800.1	sp|K1PSA2|K1PSA2_CRAGI	1.9e-65	256.1	46.37%	50.45%	Leucine-rich repeat and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN001801.1	sp|K1Q760|K1Q760_CRAGI	1.2e-258	897.5	98.73%	90.32%	Phosphoenolpyruvate carboxykinase, cytosolic [GTP];OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0016301|GO:0004613|	GO:0006094|
GN001802.1	sp|K1Q760|K1Q760_CRAGI	3.0e-19	99.0	100.00%	91.84%	Phosphoenolpyruvate carboxykinase, cytosolic [GTP];OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0016301|GO:0004613|	GO:0006094|
GN001804.1	sp|A0A162EDT1|A0A162EDT1_9CRUS	2.3e-38	165.2	91.96%	33.76%	Uncharacterized protein;OS=Daphnia;PE=4;SV=1	GO:0003676|GO:0004523|
GN000931.1	sp|K1QRL9|K1QRL9_CRAGI	3.6e-60	236.9	97.91%	65.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0070072|
GN001006.1	sp|K1RGF0|K1RGF0_CRAGI	4.4e-243	845.9	100.00%	84.89%	Solute carrier family 46 member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001805.1	sp|K1QEA6|K1QEA6_CRAGI	1.0e-298	1030.8	100.00%	77.13%	Phosphoenolpyruvate carboxykinase [GTP];OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0016301|GO:0004613|	GO:0006094|
GN001807.1	sp|K1Q762|K1Q762_CRAGI	0.0e+00	1172.9	93.11%	78.93%	Wilms tumor protein 1-interacting-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN001808.1	sp|K1QEB0|K1QEB0_CRAGI	1.3e-75	288.1	85.79%	79.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001809.1	sp|K1PZN3|K1PZN3_CRAGI	1.0e-234	818.1	99.42%	78.17%	Protein G7c;OS=Crassostrea;PE=4;SV=1
GN001810.1	sp|K1Q4X5|K1Q4X5_CRAGI	6.1e-153	546.2	97.40%	74.15%	Iroquois-class homeodomain protein IRX-6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN001815.1	sp|K1QR19|K1QR19_CRAGI	2.8e-209	733.4	100.00%	78.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001816.1	sp|K1PJ05|K1PJ05_CRAGI	1.0e-299	1035.0	96.06%	53.75%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN001818.1	sp|K1QIC0|K1QIC0_CRAGI	4.8e-109	401.0	53.20%	52.62%	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN001819.1	sp|K1PJ05|K1PJ05_CRAGI	0.0e+00	1431.0	99.38%	62.14%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN001821.1	sp|V4A8A4|V4A8A4_LOTGI	4.8e-22	110.2	89.67%	34.76%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001822.1	sp|V4A8A4|V4A8A4_LOTGI	9.9e-98	363.2	98.60%	38.49%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001823.1	sp|K1Q4I0|K1Q4I0_CRAGI	8.0e-112	409.5	65.45%	79.12%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN001824.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	3.9e-84	317.4	84.25%	63.52%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN001825.1	sp|K1PV75|K1PV75_CRAGI	1.5e-90	338.2	98.04%	67.47%	Prostacyclin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN001826.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	1.2e-17	95.5	87.85%	36.02%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001828.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	1.2e-17	95.5	87.85%	36.02%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001829.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	3.9e-84	317.4	84.25%	63.52%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN001830.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	1.4e-64	252.3	85.07%	42.81%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN001832.1	sp|K1QVJ8|K1QVJ8_CRAGI	0.0e+00	1308.5	86.49%	74.97%	Piwi-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003676|	GO:0031047|
GN001833.1	sp|K1RDS3|K1RDS3_CRAGI	4.5e-37	159.5	100.00%	58.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001834.1	sp|K1QXG4|K1QXG4_CRAGI	7.9e-46	189.1	86.52%	54.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001835.1	sp|K1R586|K1R586_CRAGI	1.4e-88	331.6	82.81%	79.15%	Vesicle-associated membrane protein/synaptobrevin-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|
GN001836.1	sp|A0A210QP62|A0A210QP62_MIZYE	1.1e-264	918.3	98.98%	59.72%	Anaphase-promoting complex subunit 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005680|
GN001837.1	sp|A0A210PGL0|A0A210PGL0_MIZYE	3.5e-29	133.7	68.79%	49.61%	Protein C8orf37-like;OS=Mizuhopecten;PE=4;SV=1
GN001838.1	sp|K1R7N6|K1R7N6_CRAGI	6.3e-126	455.7	99.19%	95.88%	Eukaryotic translation initiation factor 6;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0016021|GO:0005730|	GO:0043023|GO:0043022|GO:0003743|	GO:0042256|GO:0042273|
GN001839.1	sp|K1RLT5|K1RLT5_CRAGI	0.0e+00	1147.5	97.92%	74.64%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN001840.1	sp|K1R2H1|K1R2H1_CRAGI	0.0e+00	1139.4	99.33%	76.86%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN001841.1	sp|A0A210QXS7|A0A210QXS7_MIZYE	4.3e-197	693.3	90.73%	62.64%	Guanylate cyclase soluble subunit beta-2;OS=Mizuhopecten;PE=3;SV=1	GO:0004383|GO:0020037|GO:0000166|	GO:0035556|
GN001842.1	sp|K1PCM2|K1PCM2_CRAGI	6.1e-132	476.1	100.00%	66.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001843.1	sp|K1P0H4|K1P0H4_CRAGI	1.1e-53	216.1	61.49%	54.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001010.1	sp|K1Q188|K1Q188_CRAGI	1.4e-24	118.2	72.73%	69.90%	BEN domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN001844.1	sp|K1QRR4|K1QRR4_CRAGI	3.3e-113	413.7	77.59%	81.47%	ADP-ribose pyrophosphatase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047631|
GN001846.1	sp|K1QYY1|K1QYY1_CRAGI	1.6e-157	561.2	97.81%	78.37%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN001848.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-21	108.2	97.56%	47.06%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN001849.1	sp|V3ZI82|V3ZI82_LOTGI	4.5e-55	221.5	81.52%	36.42%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0012505|GO:0005634|	GO:0035497|GO:0003700|	GO:0030968|GO:0006357|
GN001850.1	sp|A0A210PN67|A0A210PN67_MIZYE	2.9e-13	80.5	83.33%	39.82%	Cyclin-D1-binding protein 1-like;OS=Mizuhopecten;PE=4;SV=1	GO:0051726|
GN001851.1	sp|K1RI10|K1RI10_CRAGI	1.6e-32	144.4	90.55%	86.09%	Programmed cell death protein 5;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0003677|
GN001852.1	sp|K1RI10|K1RI10_CRAGI	1.1e-63	249.2	60.00%	71.28%	Programmed cell death protein 5;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0003677|
GN001854.1	sp|K1R582|K1R582_CRAGI	6.2e-78	297.0	92.93%	44.36%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN001855.1	sp|K1RPQ0|K1RPQ0_CRAGI	1.4e-136	491.5	92.97%	77.38%	Testis-specific serine/threonine-protein kinase 4;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN001856.1	sp|A0A210Q8N2|A0A210Q8N2_MIZYE	2.0e-57	228.8	99.48%	54.81%	Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN001858.1	sp|A0A1Q1NMJ6|A0A1Q1NMJ6_CRAGI	7.7e-289	998.0	99.46%	81.64%	Cryptochrome-like protein;OS=Crassostrea;PE=2;SV=1
GN001859.1	sp|K1QRM4|K1QRM4_CRAGI	2.2e-148	530.8	98.61%	74.58%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001863.1	sp|K1QYY1|K1QYY1_CRAGI	1.6e-157	561.2	97.81%	78.37%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN001867.1	sp|C3ZM17|C3ZM17_BRAFL	5.6e-13	79.7	55.41%	44.44%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003677|
GN001868.1	sp|K1P6C4|K1P6C4_CRAGI	1.5e-149	536.2	45.00%	56.71%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN001869.1	sp|K1P6C4|K1P6C4_CRAGI	2.2e-149	535.8	42.31%	54.41%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN001870.1	sp|K1QPC4|K1QPC4_CRAGI	3.0e-225	786.9	100.00%	75.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001871.1	sp|K1RVF6|K1RVF6_CRAGI	8.5e-177	625.5	75.11%	90.96%	T-box transcription factor TBX20;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN001872.1	sp|K1R5E5|K1R5E5_CRAGI	2.6e-18	97.8	49.74%	55.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000932.1	sp|K1RAZ7|K1RAZ7_CRAGI	1.4e-291	1007.3	100.00%	81.36%	F-box only protein 42;OS=Crassostrea;PE=4;SV=1
GN001014.1	sp|K1R786|K1R786_CRAGI	9.6e-29	132.1	89.19%	58.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001873.1	sp|K1RBY5|K1RBY5_CRAGI	1.9e-178	630.9	100.00%	73.17%	T-box transcription factor TBX20;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005634|	GO:0003677|GO:0003700|
GN001875.1	sp|K1PCB6|K1PCB6_CRAGI	8.4e-16	89.0	52.63%	65.22%	Arginine-glutamic acid dipeptide repeats protein;OS=Crassostrea;PE=4;SV=1	GO:0003682|
GN001876.1	sp|K1PJR9|K1PJR9_CRAGI	6.8e-119	434.1	36.37%	82.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001878.1	sp|K1R141|K1R141_CRAGI	4.3e-42	178.3	32.35%	49.71%	Tetranectin;OS=Crassostrea;PE=4;SV=1
GN001879.1	sp|K1PEN9|K1PEN9_CRAGI	3.9e-301	1038.9	99.27%	87.73%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0008810|GO:0030247|	GO:0030245|
GN001880.1	sp|K1QLK4|K1QLK4_CRAGI	3.2e-27	128.3	65.19%	38.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001881.1	sp|K1PDV3|K1PDV3_CRAGI	4.3e-161	573.5	88.78%	60.00%	RSM22-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008168|	GO:0006412|
GN001882.1	sp|K1QL98|K1QL98_CRAGI	1.1e-88	332.0	99.19%	63.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN001883.1	sp|K1PLP4|K1PLP4_CRAGI	6.7e-25	119.0	93.22%	48.73%	Ankyrin repeat and SAM domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN001884.1	sp|K1QL98|K1QL98_CRAGI	1.3e-102	378.3	99.23%	66.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN001885.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	1.0e-14	86.7	27.16%	42.22%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN001889.1	sp|K1PMQ8|K1PMQ8_CRAGI	0.0e+00	1132.9	82.76%	78.85%	Membrane metallo-endopeptidase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|
GN001890.1	sp|V4CB32|V4CB32_LOTGI	9.7e-68	264.6	59.97%	27.31%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005524|GO:0003676|
GN001891.1	sp|A0A210PX54|A0A210PX54_MIZYE	1.2e-155	555.8	91.56%	56.06%	7SK snRNA methylphosphate capping enzyme;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN001892.1	sp|K1RKX6|K1RKX6_CRAGI	7.6e-140	503.1	84.16%	65.21%	Macrophage mannose receptor 1;OS=Crassostrea;PE=4;SV=1
GN001894.1	sp|K1QDE6|K1QDE6_CRAGI	1.9e-194	684.1	98.35%	77.46%	Agrin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN001895.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	8.6e-39	166.0	100.00%	44.34%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN001896.1	sp|K1QDE6|K1QDE6_CRAGI	0.0e+00	1361.3	99.66%	71.46%	Agrin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN001897.1	sp|K1PY24|K1PY24_CRAGI	3.5e-192	676.4	99.47%	91.73%	B1 bradykinin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN001901.1	sp|K1QUV7|K1QUV7_CRAGI	5.8e-49	199.5	100.00%	47.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001902.1	sp|K1QFS0|K1QFS0_CRAGI	6.6e-140	503.1	79.15%	94.34%	Transcription elongation factor spt6;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003746|	GO:0006139|GO:0032968|
GN001903.1	sp|K1QFS0|K1QFS0_CRAGI	0.0e+00	2038.5	83.32%	93.61%	Transcription elongation factor spt6;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003746|	GO:0006139|GO:0032968|
GN001904.1	sp|K1QUW3|K1QUW3_CRAGI	1.6e-240	837.8	100.00%	75.14%	Protein phosphatase 1 regulatory inhibitor subunit 16B;OS=Crassostrea;PE=4;SV=1
GN001905.1	sp|K1QUV7|K1QUV7_CRAGI	5.0e-72	276.2	98.89%	75.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001906.1	sp|K1QFT2|K1QFT2_CRAGI	7.9e-76	288.9	94.74%	76.68%	Phosphorylase b kinase regulatory subunit;OS=Crassostrea;PE=3;SV=1	GO:0005886|	GO:0005516|GO:0016301|	GO:0005977|
GN001907.1	sp|A0A210R2F7|A0A210R2F7_MIZYE	4.8e-26	122.1	94.37%	84.85%	Phosphorylase b kinase regulatory subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0005886|	GO:0005516|GO:0016301|	GO:0005977|
GN001908.1	sp|A0A210R2F7|A0A210R2F7_MIZYE	0.0e+00	1206.0	98.96%	68.42%	Phosphorylase b kinase regulatory subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0005886|	GO:0005516|GO:0016301|	GO:0005977|
GN001909.1	sp|K1P6V3|K1P6V3_CRAGI	3.0e-46	191.4	34.91%	76.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001910.1	sp|K1PLG5|K1PLG5_CRAGI	4.9e-48	196.8	61.14%	67.86%	rRNA methyltransferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008173|	GO:0006396|
GN001912.1	sp|K1Q8G3|K1Q8G3_CRAGI	1.9e-114	417.5	100.00%	88.21%	Coiled-coil domain-containing protein 92;OS=Crassostrea;PE=4;SV=1
GN001913.1	sp|K1Q1B7|K1Q1B7_CRAGI	4.4e-248	862.8	100.00%	66.31%	Protein deltex-4;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0007219|GO:0016567|
GN001914.1	sp|K1R8E3|K1R8E3_CRAGI	1.4e-124	451.8	99.45%	66.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0035240|GO:0004930|GO:0072544|GO:0072545|	GO:0007166|
GN001915.1	sp|K1R545|K1R545_CRAGI	8.8e-139	498.4	100.00%	94.53%	Pre-mRNA-processing-splicing factor 8;OS=Crassostrea;PE=4;SV=1	GO:0005681|	GO:0030623|GO:0017070|	GO:0000398|
GN001916.1	sp|K1R545|K1R545_CRAGI	5.6e-147	525.8	91.34%	100.00%	Pre-mRNA-processing-splicing factor 8;OS=Crassostrea;PE=4;SV=1	GO:0005681|	GO:0030623|GO:0017070|	GO:0000398|
GN001917.1	sp|K1R545|K1R545_CRAGI	0.0e+00	1725.7	100.00%	97.68%	Pre-mRNA-processing-splicing factor 8;OS=Crassostrea;PE=4;SV=1	GO:0005681|	GO:0030623|GO:0017070|	GO:0000398|
GN001918.1	sp|J9Q409|J9Q409_OSTED	5.0e-81	306.2	78.00%	95.48%	Transmembrane protein 70;OS=Ostrea;PE=2;SV=1	GO:0016021|
GN001919.1	sp|K1QB92|K1QB92_CRAGI	3.5e-273	946.0	98.92%	84.52%	Selenocysteine-specific elongation factor;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0003746|
GN001920.1	sp|K1PQW3|K1PQW3_CRAGI	3.6e-78	297.4	98.69%	69.08%	OTU domain-containing protein 6B;OS=Crassostrea;PE=4;SV=1
GN001018.1	sp|K1R786|K1R786_CRAGI	6.9e-40	170.2	85.31%	41.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001921.1	sp|K1PIS9|K1PIS9_CRAGI	1.2e-103	381.7	96.97%	74.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001922.1	sp|A0A210QXL8|A0A210QXL8_MIZYE	1.3e-100	371.7	99.27%	65.07%	Inositol-1-monophosphatase;OS=Mizuhopecten;PE=3;SV=1	GO:0008934|GO:0052832|GO:0052833|GO:0046872|	GO:0006021|GO:0046855|GO:0046854|
GN001923.1	sp|K1Q9P2|K1Q9P2_CRAGI	1.3e-103	381.7	100.00%	72.99%	Transcription factor HES-1-B;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN001924.1	sp|K1Q2Q3|K1Q2Q3_CRAGI	5.3e-117	426.4	100.00%	72.05%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN001925.1	sp|K1R9L1|K1R9L1_CRAGI	2.2e-129	467.6	100.00%	73.57%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046983|	GO:0006355|
GN001926.1	sp|K1PW31|K1PW31_CRAGI	8.4e-105	386.0	96.17%	54.60%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001927.1	sp|K1PW31|K1PW31_CRAGI	4.0e-74	283.9	97.31%	51.20%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001928.1	sp|K1PW31|K1PW31_CRAGI	5.7e-96	356.7	97.18%	53.47%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001929.1	sp|K1PW31|K1PW31_CRAGI	9.6e-102	375.9	95.20%	53.91%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001930.1	sp|K1PW31|K1PW31_CRAGI	8.1e-115	419.5	99.00%	54.04%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001931.1	sp|K1RIW4|K1RIW4_CRAGI	1.5e-62	245.4	98.29%	42.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001932.1	sp|K1RS80|K1RS80_CRAGI	2.4e-57	227.3	98.17%	68.75%	Glycolipid transfer protein domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN001933.1	sp|K1R813|K1R813_CRAGI	8.9e-100	368.6	100.00%	79.53%	Glycolipid transfer protein domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN001934.1	sp|A0A2T7PDX7|A0A2T7PDX7_POMCA	2.6e-40	170.6	75.16%	66.67%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN001935.1	sp|K1R3B3|K1R3B3_CRAGI	1.1e-94	352.1	99.63%	63.24%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001936.1	sp|A0A210QXT8|A0A210QXT8_MIZYE	0.0e+00	1583.9	83.27%	77.84%	Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN001019.1	sp|K1PXH1|K1PXH1_CRAGI	3.7e-22	110.2	84.40%	51.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001937.1	sp|K1PY06|K1PY06_CRAGI	1.9e-199	700.7	100.00%	88.89%	UPF0183 protein C16orf70-like protein;OS=Crassostrea;PE=4;SV=1
GN001938.1	sp|K1PMI0|K1PMI0_CRAGI	4.7e-88	329.7	88.84%	89.50%	Charged multivesicular body protein 4b;OS=Crassostrea;PE=3;SV=1	GO:0007034|
GN001939.1	sp|A0A267G047|A0A267G047_9PLAT	1.4e-25	121.7	92.45%	45.27%	Uncharacterized protein;OS=Macrostomum;PE=3;SV=1	GO:0005747|	GO:0006120|
GN001940.1	sp|K1R5B5|K1R5B5_CRAGI	1.0e-76	292.0	100.00%	90.14%	Ras-responsive element-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001941.1	sp|K1QDH0|K1QDH0_CRAGI	3.5e-192	676.4	95.03%	84.81%	Group XV phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0008374|	GO:0006629|
GN001942.1	sp|K1QDH0|K1QDH0_CRAGI	1.6e-23	114.0	97.70%	67.82%	Group XV phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0008374|	GO:0006629|
GN001945.1	sp|K1QM32|K1QM32_CRAGI	5.0e-28	129.0	97.83%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001946.1	sp|K1QM32|K1QM32_CRAGI	1.2e-42	177.9	100.00%	74.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001949.1	sp|K1QDG7|K1QDG7_CRAGI	0.0e+00	1161.0	100.00%	88.16%	Rhophilin-2-B;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN001950.1	sp|K1Q5D3|K1Q5D3_CRAGI	8.7e-159	565.1	100.00%	95.50%	GMP reductase;OS=Crassostrea;PE=3;SV=1	GO:1902560|	GO:0003920|GO:0046872|	GO:0006144|GO:0006163|
GN001951.1	sp|K1PY00|K1PY00_CRAGI	0.0e+00	1536.9	99.45%	86.92%	Calcium-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0005388|
GN001952.1	sp|K1PQT9|K1PQT9_CRAGI	5.3e-31	139.0	79.21%	81.01%	Protein disulfide-isomerase TMX3;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0016853|	GO:0045454|
GN001953.1	sp|K1PY49|K1PY49_CRAGI	1.7e-79	301.2	87.02%	84.44%	Angiopoietin-2;OS=Crassostrea;PE=4;SV=1
GN001020.1	sp|K1QHM1|K1QHM1_CRAGI	1.0e-10	72.0	38.58%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001954.1	sp|K1Q5J9|K1Q5J9_CRAGI	1.0e-58	231.9	78.03%	82.84%	Protein disulfide-isomerase TMX3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016853|
GN001955.1	sp|K1QYE8|K1QYE8_CRAGI	1.8e-59	236.1	47.40%	47.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001956.1	sp|A0A2R3SK02|A0A2R3SK02_ARGIR	1.2e-68	266.2	97.76%	35.95%	Toll-like receptor 1;OS=Argopecten;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN001957.1	sp|A0A2R3SK02|A0A2R3SK02_ARGIR	1.8e-22	111.3	76.28%	49.58%	Toll-like receptor 1;OS=Argopecten;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN001958.1	sp|K1QXX2|K1QXX2_CRAGI	1.4e-78	298.9	43.61%	89.10%	Ubiquitin-conjugating enzyme E2 Q2;OS=Crassostrea;PE=4;SV=1
GN001959.1	sp|K1R483|K1R483_CRAGI	2.9e-76	292.4	41.37%	65.54%	Zinc finger CCCH domain-containing protein 3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|GO:0046872|
GN001960.1	sp|K1R483|K1R483_CRAGI	3.4e-87	327.4	100.00%	76.92%	Zinc finger CCCH domain-containing protein 3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|GO:0046872|
GN001021.1	sp|K1PPP6|K1PPP6_CRAGI	3.7e-69	267.7	42.20%	79.49%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN001961.1	sp|U5PZB3|U5PZB3_CRAGI	2.5e-87	328.9	97.73%	32.04%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN001962.1	sp|U5PZB3|U5PZB3_CRAGI	8.2e-84	317.0	96.19%	33.48%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN001963.1	sp|A0A210PMZ8|A0A210PMZ8_MIZYE	2.7e-105	389.0	95.60%	32.03%	von Willebrand factor A domain-containing protein 7;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN001965.1	sp|K1P388|K1P388_CRAGI	9.4e-123	445.7	94.40%	61.01%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN001966.1	sp|K1Q9W7|K1Q9W7_CRAGI	1.6e-103	381.7	74.35%	67.70%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN001967.1	sp|K1P388|K1P388_CRAGI	4.6e-110	403.3	99.68%	66.12%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN001968.1	sp|K1Q9W7|K1Q9W7_CRAGI	1.9e-134	484.6	86.22%	68.87%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN001969.1	sp|A0A2H5INK5|A0A2H5INK5_CRAHO	3.4e-44	184.1	97.91%	71.24%	Y-box binding protein YB-1;OS=Crassostrea;PE=2;SV=1	GO:0003676|
GN001970.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.8e-152	546.2	71.04%	37.95%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN001974.1	sp|K1PQK8|K1PQK8_CRAGI	1.8e-105	387.5	94.88%	92.61%	CDP-diacylglycerol--inositol 3-phosphatidyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016780|	GO:0008654|
GN001975.1	sp|K1P7J0|K1P7J0_CRAGI	1.7e-40	171.4	60.47%	76.23%	Rab5 GDP/GTP exchange factor;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN001976.1	sp|K1PXX4|K1PXX4_CRAGI	2.3e-173	614.0	97.79%	77.89%	Rab5 GDP/GTP exchange factor;OS=Crassostrea;PE=4;SV=1
GN001977.1	sp|K1QSX7|K1QSX7_CRAGI	2.0e-09	67.0	97.50%	48.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001978.1	sp|A0A3L8DL29|A0A3L8DL29_OOCBI	2.7e-18	97.1	99.15%	43.48%	Uncharacterized protein;OS=Ooceraea;PE=4;SV=1
GN001979.1	sp|W4YR48|W4YR48_STRPU	7.7e-25	120.2	32.23%	53.13%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN001022.1	sp|K1R007|K1R007_CRAGI	1.9e-57	227.6	95.12%	67.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001980.1	sp|K1QGA2|K1QGA2_CRAGI	1.5e-139	501.5	99.47%	79.68%	Flotillin-2;OS=Crassostrea;PE=4;SV=1
GN001981.1	sp|Q70MN7|Q70MN7_CRAGI	5.8e-81	305.8	88.20%	93.59%	Actin-related protein 2/3 complex subunit 3;OS=Crassostrea;PE=2;SV=1	GO:0005885|GO:0005737|	GO:0003779|	GO:0034314|
GN001982.1	sp|K1QXM4|K1QXM4_CRAGI	8.2e-154	548.5	100.00%	95.04%	GPN-loop GTPase 3;OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0016787|
GN001983.1	sp|K1RNB9|K1RNB9_CRAGI	1.9e-272	943.7	100.00%	85.48%	Peroxisomal targeting signal 1 receptor;OS=Crassostrea;PE=4;SV=1
GN001985.1	sp|K1QGA7|K1QGA7_CRAGI	1.0e-96	358.6	96.17%	74.22%	Kynurenine formamidase;OS=Crassostrea;PE=4;SV=1	GO:0004061|	GO:0019441|
GN001986.1	sp|K1QGA7|K1QGA7_CRAGI	3.3e-101	374.0	68.84%	70.83%	Kynurenine formamidase;OS=Crassostrea;PE=4;SV=1	GO:0004061|	GO:0019441|
GN001023.1	sp|K1PKG1|K1PKG1_CRAGI	9.5e-227	791.6	100.00%	82.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001992.1	sp|K1Q7M8|K1Q7M8_CRAGI	1.3e-220	771.9	86.97%	55.36%	Acid trehalase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN001994.1	sp|K1R413|K1R413_CRAGI	1.4e-146	526.2	66.92%	46.25%	Metabotropic glutamate receptor 8;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|
GN001024.1	sp|K1PIF9|K1PIF9_CRAGI	1.4e-199	701.4	100.00%	73.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001995.1	sp|K1R413|K1R413_CRAGI	6.2e-284	982.6	78.33%	63.54%	Metabotropic glutamate receptor 8;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|
GN001996.1	sp|K1QIB3|K1QIB3_CRAGI	3.7e-59	233.4	100.00%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001997.1	sp|K1QBS6|K1QBS6_CRAGI	1.0e-53	216.1	76.92%	48.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001998.1	sp|K1PW83|K1PW83_CRAGI	1.7e-136	491.5	100.00%	62.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001999.1	sp|K1PZN4|K1PZN4_CRAGI	1.3e-65	255.8	87.39%	41.84%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002001.1	sp|K1PZN4|K1PZN4_CRAGI	6.7e-62	243.4	90.50%	38.59%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002002.1	sp|K1Q300|K1Q300_CRAGI	6.7e-33	146.7	90.11%	33.47%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002003.1	sp|K1PZN4|K1PZN4_CRAGI	5.0e-35	153.7	89.67%	28.94%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN001025.1	sp|K1PQ52|K1PQ52_CRAGI	1.7e-193	681.4	100.00%	71.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002004.1	sp|K1PZN4|K1PZN4_CRAGI	5.0e-46	190.7	96.60%	34.08%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002005.1	sp|K1S3T7|K1S3T7_CRAGI	6.0e-35	152.9	94.05%	49.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002007.1	sp|K1RVX3|K1RVX3_CRAGI	0.0e+00	1226.5	61.99%	71.50%	Exoglucanase xynX;OS=Crassostrea;PE=4;SV=1	GO:0000813|	GO:0004553|	GO:0005975|
GN002008.1	sp|F2TZY9|F2TZY9_SALR5	6.2e-26	124.0	82.49%	27.74%	Uncharacterized protein;OS=Salpingoeca;PE=4;SV=1
GN002010.1	sp|K1RGK1|K1RGK1_CRAGI	3.6e-84	316.6	100.00%	83.67%	Mitochondrial import inner membrane translocase subunit Tim22;OS=Crassostrea;PE=4;SV=1	GO:0042721|	GO:0045039|
GN000933.1	sp|K1RUM2|K1RUM2_CRAGI	4.2e-89	333.2	93.61%	90.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0072546|
GN001026.1	sp|K1Q4I2|K1Q4I2_CRAGI	8.2e-249	865.5	93.20%	74.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002011.1	sp|K1QQZ0|K1QQZ0_CRAGI	5.1e-231	807.0	75.99%	52.49%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN002012.1	sp|K1QH98|K1QH98_CRAGI	1.2e-264	917.9	95.68%	77.22%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN002013.1	sp|A0A1C9U2X0|A0A1C9U2X0_MIZYE	2.6e-80	305.4	87.22%	32.57%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN002015.1	sp|A0A1C9U2W5|A0A1C9U2W5_MIZYE	3.3e-82	312.0	73.14%	33.21%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN002016.1	sp|A0A1C9U302|A0A1C9U302_MIZYE	5.5e-54	217.2	91.39%	35.73%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN001027.1	sp|K1QQJ4|K1QQJ4_CRAGI	1.0e-178	631.7	100.00%	75.96%	Abhydrolase domain-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN002017.1	sp|K1QAG5|K1QAG5_CRAGI	1.9e-21	109.4	25.65%	47.27%	Signal peptide, CUB and EGF-like domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002018.1	sp|K1RQJ5|K1RQJ5_CRAGI	2.4e-127	461.5	99.81%	61.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002019.1	sp|K1PU81|K1PU81_CRAGI	5.6e-158	562.8	97.63%	74.66%	Protocadherin Fat 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN002020.1	sp|K1Q645|K1Q645_CRAGI	6.3e-169	599.0	93.49%	91.43%	Ribose-phosphate pyrophosphokinase 3, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016301|GO:0000287|GO:0004749|	GO:0009116|GO:0009165|
GN001028.1	sp|K1PIG7|K1PIG7_CRAGI	6.6e-171	605.9	84.85%	81.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005892|
GN002021.1	sp|K1PYW2|K1PYW2_CRAGI	0.0e+00	1514.6	99.47%	91.36%	WD repeat-containing protein 67;OS=Crassostrea;PE=4;SV=1
GN002022.1	sp|K1R606|K1R606_CRAGI	6.7e-131	472.2	100.00%	89.72%	Derlin;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|
GN002023.1	sp|A0A210PEF9|A0A210PEF9_MIZYE	3.6e-111	406.8	98.88%	71.10%	Alpha-ketoglutarate-dependent 2,4-dichlorophenoxyacetate dioxygenase;OS=Mizuhopecten;PE=4;SV=1	GO:0051213|
GN002024.1	sp|K1R1S7|K1R1S7_CRAGI	1.1e-256	891.3	100.00%	73.72%	Matrix metalloproteinase-17;OS=Crassostrea;PE=3;SV=1	GO:0031012|GO:0016021|	GO:0004222|GO:0008270|
GN002025.1	sp|A0A151WPL7|A0A151WPL7_9HYME	1.1e-75	289.7	61.71%	51.07%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN001029.1	sp|A0A210QV75|A0A210QV75_MIZYE	2.0e-37	161.4	85.79%	47.62%	Translation machinery-associated protein 16;OS=Mizuhopecten;PE=4;SV=1
GN002028.1	sp|A0A1S3JB19|A0A1S3JB19_LINUN	1.8e-38	165.6	55.14%	46.15%	uncharacterized protein PF11_0207;OS=Lingula;PE=4;SV=1
GN002029.1	sp|K1R1T3|K1R1T3_CRAGI	1.1e-116	425.6	100.00%	65.97%	CD2 antigen cytoplasmic tail-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005682|
GN002031.1	sp|K1PYV6|K1PYV6_CRAGI	4.6e-117	426.4	100.00%	85.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002032.1	sp|K1PDH0|K1PDH0_CRAGI	0.0e+00	1768.4	100.00%	83.33%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN002033.1	sp|E2C2L3|E2C2L3_HARSA	7.2e-21	108.2	16.53%	43.22%	Uncharacterized protein;OS=Harpegnathos;PE=4;SV=1	GO:0003676|GO:0004523|
GN002035.1	sp|K1QJS0|K1QJS0_CRAGI	6.9e-148	530.0	59.22%	66.50%	Ubiquitin carboxyl-terminal hydrolase 30;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN002036.1	sp|K1RHZ9|K1RHZ9_CRAGI	3.1e-141	507.7	99.28%	52.45%	MAP kinase-activated protein kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN002037.1	sp|K1QAS9|K1QAS9_CRAGI	2.3e-113	413.7	100.00%	93.30%	Ras-like protein family member 10B;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN002038.1	sp|K1QRN2|K1QRN2_CRAGI	3.8e-296	1022.3	100.00%	86.89%	Cysteine sulfinic acid decarboxylase;OS=Crassostrea;PE=3;SV=1	GO:0016831|GO:0030170|	GO:0019752|
GN002039.1	sp|K1QY37|K1QY37_CRAGI	0.0e+00	2292.3	100.00%	74.77%	Telomerase-binding protein EST1A;OS=Crassostrea;PE=4;SV=1
GN002040.1	sp|K1RI04|K1RI04_CRAGI	7.6e-179	632.1	99.74%	80.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002041.1	sp|K1QAT4|K1QAT4_CRAGI	2.5e-173	614.0	100.00%	71.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002042.1	sp|A0A210R6Y0|A0A210R6Y0_MIZYE	2.2e-33	147.9	82.81%	43.04%	Interleukin-17D;OS=Mizuhopecten;PE=4;SV=1	GO:0005576|	GO:0005125|
GN002043.1	sp|K1QJ93|K1QJ93_CRAGI	4.2e-15	87.0	83.05%	39.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN002044.1	sp|A0A2C9JH48|A0A2C9JH48_BIOGL	5.0e-11	73.9	35.15%	53.01%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003700|
GN002045.1	sp|K1RCR8|K1RCR8_CRAGI	8.7e-124	448.7	96.79%	78.15%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN002047.1	sp|K1RI14|K1RI14_CRAGI	1.1e-127	461.5	100.00%	94.96%	Putative rRNA methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0008649|	GO:0000453|
GN002048.1	sp|K1RI14|K1RI14_CRAGI	8.3e-107	392.9	100.00%	56.72%	Putative rRNA methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0008649|	GO:0000453|
GN002049.1	sp|K1QRP4|K1QRP4_CRAGI	1.5e-43	180.6	95.83%	90.11%	Putative NADH dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN002050.1	sp|K1QJ95|K1QJ95_CRAGI	3.7e-80	303.1	100.00%	83.33%	tRNA-specific adenosine deaminase 2;OS=Crassostrea;PE=4;SV=1	GO:0008251|GO:0008270|	GO:0002100|
GN002051.1	sp|K1Q554|K1Q554_CRAGI	1.4e-79	301.6	74.09%	92.68%	Mediator of RNA polymerase II transcription subunit 19;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0016592|	GO:0003712|	GO:0006357|
GN001031.1	sp|K1Q326|K1Q326_CRAGI	8.8e-240	835.1	95.93%	78.78%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN002052.1	sp|K1QJA3|K1QJA3_CRAGI	3.8e-46	190.3	93.68%	54.24%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN002053.1	sp|A0A2B4S577|A0A2B4S577_STYPI	1.6e-31	142.5	78.81%	32.96%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN001032.1	sp|A0A210Q5J9|A0A210Q5J9_MIZYE	6.1e-241	838.6	100.00%	96.08%	26S protease regulatory subunit 7;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0008233|GO:0036402|	GO:0030163|
GN002054.1	sp|K1RIW4|K1RIW4_CRAGI	9.6e-63	245.7	99.58%	52.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002055.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	1.3e-23	115.5	64.68%	45.80%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN002056.1	sp|K1QJA3|K1QJA3_CRAGI	7.1e-244	849.4	99.44%	52.81%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN002057.1	sp|K1PIB6|K1PIB6_CRAGI	0.0e+00	1095.9	86.23%	75.79%	Endothelin-converting enzyme 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0016486|
GN002059.1	sp|K1P833|K1P833_CRAGI	9.6e-33	144.4	96.05%	95.83%	Eukaryotic initiation factor 4A-II;OS=Crassostrea;PE=4;SV=1	GO:0004004|GO:0003743|
GN001033.1	sp|K1PHP5|K1PHP5_CRAGI	0.0e+00	1115.1	99.85%	90.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002065.1	sp|K1PV86|K1PV86_CRAGI	1.0e-132	478.4	99.65%	79.86%	Phosphoglycerate mutase family member 5;OS=Crassostrea;PE=4;SV=1
GN002066.1	sp|A0A0B7A8C9|A0A0B7A8C9_9EUPU	4.6e-26	123.6	70.79%	45.77%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0003735|
GN002067.1	sp|K1S1I6|K1S1I6_CRAGI	1.0e-223	783.1	100.00%	43.42%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002068.1	sp|V3ZLM2|V3ZLM2_LOTGI	2.8e-164	583.9	94.58%	71.77%	Transporter;OS=Lottia;PE=3;SV=1	GO:0016021|	GO:0005328|
GN001034.1	sp|K1PPT4|K1PPT4_CRAGI	6.0e-115	419.5	75.00%	89.14%	Protein-S-isoprenylcysteine O-methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0004671|
GN002069.1	sp|K1PQG1|K1PQG1_CRAGI	1.4e-230	804.3	100.00%	86.99%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002070.1	sp|K1Q8C6|K1Q8C6_CRAGI	2.4e-176	624.0	100.00%	71.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002071.1	sp|K1PXT6|K1PXT6_CRAGI	1.6e-33	148.3	85.16%	55.84%	Coiled-coil domain-containing protein 63;OS=Crassostrea;PE=4;SV=1
GN002072.1	sp|K1PXT6|K1PXT6_CRAGI	3.0e-51	207.6	65.20%	64.81%	Coiled-coil domain-containing protein 63;OS=Crassostrea;PE=4;SV=1
GN002073.1	sp|K1PIW0|K1PIW0_CRAGI	1.1e-121	442.6	90.25%	53.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002074.1	sp|A0A210R4Q5|A0A210R4Q5_MIZYE	2.7e-110	404.1	83.55%	73.64%	Microprocessor complex subunit DGCR8;OS=Mizuhopecten;PE=4;SV=1	GO:0070877|	GO:0020037|GO:0042802|GO:0003723|	GO:0031053|
GN002075.1	sp|K1PQF6|K1PQF6_CRAGI	2.1e-178	630.9	89.92%	85.51%	Ankyrin repeat domain-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN000934.1	sp|A0A1L3GTQ4|A0A1L3GTQ4_CRAHO	1.3e-102	379.0	96.90%	52.57%	Tumor necrosis factor receptor 5;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN002076.1	sp|K1QT61|K1QT61_CRAGI	5.0e-115	419.5	86.69%	92.52%	NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0051537|GO:0046872|GO:0016491|
GN002077.1	sp|K1QCE8|K1QCE8_CRAGI	1.8e-219	767.7	78.13%	77.43%	RNA pseudouridylate synthase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN002078.1	sp|K1QKI2|K1QKI2_CRAGI	8.2e-282	975.3	95.67%	67.88%	Annulin;OS=Crassostrea;PE=4;SV=1	GO:0003810|	GO:0018149|
GN002079.1	sp|K1QKI2|K1QKI2_CRAGI	1.3e-125	455.3	96.90%	59.38%	Annulin;OS=Crassostrea;PE=4;SV=1	GO:0003810|	GO:0018149|
GN002080.1	sp|K1QKI2|K1QKI2_CRAGI	3.4e-75	287.0	93.61%	53.51%	Annulin;OS=Crassostrea;PE=4;SV=1	GO:0003810|	GO:0018149|
GN002082.1	sp|K1RC12|K1RC12_CRAGI	2.0e-97	360.9	97.01%	83.77%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN001035.1	sp|K1P3Y3|K1P3Y3_CRAGI	1.1e-59	235.7	92.22%	78.23%	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN002086.1	sp|K1R5H6|K1R5H6_CRAGI	9.0e-45	186.8	61.58%	46.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002087.1	sp|K1Q1J5|K1Q1J5_CRAGI	2.1e-56	224.6	93.61%	58.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002089.1	sp|K1QKI4|K1QKI4_CRAGI	8.3e-270	934.9	94.99%	88.34%	Lysine--tRNA ligase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004824|GO:0003676|	GO:0006430|
GN002090.1	sp|K1Q700|K1Q700_CRAGI	7.2e-20	102.8	82.46%	39.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN002092.1	sp|K1PX51|K1PX51_CRAGI	4.0e-58	231.1	58.88%	60.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN002093.1	sp|A0A210R738|A0A210R738_MIZYE	8.6e-98	362.5	99.66%	59.25%	UPF0392 protein F59C6.8;OS=Mizuhopecten;PE=4;SV=1
GN002094.1	sp|K1QBK9|K1QBK9_CRAGI	4.9e-180	636.3	98.07%	67.88%	Interferon regulatory factor 8;OS=Crassostrea;PE=4;SV=1	GO:0003700|GO:0044212|
GN002095.1	sp|K1PDM3|K1PDM3_CRAGI	8.5e-94	352.1	9.41%	81.59%	Uncharacterized protein C5orf4-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005506|GO:0016491|	GO:0008610|
GN002098.1	sp|W4YMP2|W4YMP2_STRPU	2.3e-24	117.9	86.11%	49.69%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN002099.1	sp|K1QL33|K1QL33_CRAGI	1.9e-185	654.1	97.72%	86.79%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN002100.1	sp|K1QQX9|K1QQX9_CRAGI	1.1e-76	292.0	96.30%	65.70%	Retinol-binding protein 4;OS=Crassostrea;PE=4;SV=1
GN002101.1	sp|K1QZ05|K1QZ05_CRAGI	3.7e-233	813.1	97.30%	77.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002102.1	sp|K1PYL5|K1PYL5_CRAGI	5.3e-185	652.5	100.00%	87.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002103.1	sp|K1R5T3|K1R5T3_CRAGI	5.1e-73	279.3	92.36%	93.75%	DNA replication complex GINS protein PSF2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0006260|
GN002104.1	sp|A0A210Q8N9|A0A210Q8N9_MIZYE	6.7e-66	257.3	96.80%	35.78%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001036.1	sp|K1PHP8|K1PHP8_CRAGI	1.6e-83	314.7	96.43%	68.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002106.1	sp|K1RGD8|K1RGD8_CRAGI	1.2e-111	409.1	95.12%	50.00%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN002107.1	sp|K1RGD8|K1RGD8_CRAGI	1.5e-22	111.7	95.65%	42.59%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN002108.1	sp|K1QG95|K1QG95_CRAGI	1.9e-81	308.5	80.54%	49.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002109.1	sp|J9KMQ1|J9KMQ1_ACYPI	2.0e-56	225.3	87.29%	34.84%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2
GN002111.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	2.9e-35	154.5	90.38%	41.20%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002112.1	sp|K1QD09|K1QD09_CRAGI	1.2e-151	542.0	99.77%	63.32%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001037.1	sp|K1PPU2|K1PPU2_CRAGI	1.9e-44	185.7	30.61%	72.27%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN002114.1	sp|A0A2B4SNB7|A0A2B4SNB7_STYPI	2.3e-19	101.3	61.41%	44.64%	Dipeptidyl peptidase 8;OS=Stylophora;PE=3;SV=1	GO:0008236|
GN002115.1	sp|A0A1X7TIM2|A0A1X7TIM2_AMPQE	2.3e-15	88.6	50.90%	32.64%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0016021|
GN002116.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	7.2e-15	86.3	92.09%	37.80%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN002118.1	sp|A0A210PSN9|A0A210PSN9_MIZYE	3.4e-48	197.6	98.91%	37.86%	Alpha-1A adrenergic receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002124.1	sp|K1RMH6|K1RMH6_CRAGI	6.6e-196	689.1	97.73%	71.25%	Alpha-protein kinase vwkA;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN002125.1	sp|K1QFC8|K1QFC8_CRAGI	1.4e-72	278.5	74.49%	77.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002127.1	sp|C3ZH72|C3ZH72_BRAFL	2.5e-108	397.9	100.00%	47.39%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN002128.1	sp|K1PU80|K1PU80_CRAGI	3.4e-157	560.1	97.44%	77.42%	Aldose 1-epimerase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|GO:0016853|	GO:0005975|
GN002130.1	sp|K1QS08|K1QS08_CRAGI	1.9e-41	174.1	98.45%	86.51%	Ankyrin repeat domain-containing protein 54;OS=Crassostrea;PE=4;SV=1
GN002131.1	sp|K1RC44|K1RC44_CRAGI	1.1e-175	622.1	99.81%	65.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002132.1	sp|K1R6J1|K1R6J1_CRAGI	4.0e-11	73.9	41.97%	42.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002133.1	sp|K1PV63|K1PV63_CRAGI	2.3e-110	404.4	94.69%	60.62%	Alpha-(1,3)-fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0005509|GO:0008417|	GO:0006486|
GN002135.1	sp|A0A2B4SLZ4|A0A2B4SLZ4_STYPI	9.1e-09	67.4	27.47%	31.78%	Down syndrome cell adhesion molecule-like;OS=Stylophora;PE=4;SV=1	GO:0016021|
GN001038.1	sp|K1PPU2|K1PPU2_CRAGI	3.9e-216	757.7	49.80%	61.43%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN002137.1	sp|K1RB32|K1RB32_CRAGI	1.4e-33	148.7	81.95%	45.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002138.1	sp|K1R6J1|K1R6J1_CRAGI	4.0e-11	73.9	41.97%	42.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002139.1	sp|K1QQI5|K1QQI5_CRAGI	2.5e-93	347.4	87.65%	72.00%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN002141.1	sp|A0A210QD55|A0A210QD55_MIZYE	0.0e+00	1500.3	80.45%	78.11%	WD repeat-containing protein 66;OS=Mizuhopecten;PE=4;SV=1
GN002142.1	sp|A0A210QDA1|A0A210QDA1_MIZYE	1.0e-88	332.0	100.00%	67.37%	Nucleolar complex protein 4-like B;OS=Mizuhopecten;PE=4;SV=1	GO:0042254|
GN002143.1	sp|A0A210QD71|A0A210QD71_MIZYE	0.0e+00	2463.0	90.24%	60.15%	E1A-binding protein p400;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|
GN002144.1	sp|V4ADJ9|V4ADJ9_LOTGI	1.7e-16	91.3	65.93%	45.45%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002146.1	sp|K1Q8E9|K1Q8E9_CRAGI	2.3e-30	138.7	35.89%	74.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002147.1	sp|A0A2Z6G1B4|A0A2Z6G1B4_PINFU	2.2e-119	434.9	94.79%	47.33%	Matrix metalloproteinase;OS=Pinctada;PE=2;SV=1	GO:0031012|	GO:0004222|GO:0008270|
GN002148.1	sp|K1RDQ0|K1RDQ0_CRAGI	7.4e-33	145.6	94.62%	59.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002150.1	sp|A0A1S3K4X7|A0A1S3K4X7_LINUN	1.6e-114	419.5	97.02%	36.53%	uncharacterized protein LOC106178715;OS=Lingula;PE=4;SV=1	GO:0005509|
GN002151.1	sp|A0A210Q0J5|A0A210Q0J5_MIZYE	1.3e-106	391.3	100.00%	83.71%	Cell cycle checkpoint protein RAD1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0000077|
GN002152.1	sp|A0A210PG26|A0A210PG26_MIZYE	7.0e-224	782.3	98.80%	62.80%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001040.1	sp|K1PPU2|K1PPU2_CRAGI	1.8e-44	185.3	65.48%	46.99%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN002154.1	sp|A0A210PG26|A0A210PG26_MIZYE	1.2e-220	771.9	76.42%	61.20%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002155.1	sp|K1QS12|K1QS12_CRAGI	0.0e+00	1492.2	100.00%	83.12%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN002156.1	sp|A0A0F7YYU8|A0A0F7YYU8_CRAGI	3.2e-293	1012.7	99.49%	87.56%	TAp63alpha;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003700|GO:0044212|	GO:0006915|GO:0051262|
GN002157.1	sp|K1PNU4|K1PNU4_CRAGI	3.0e-158	563.9	92.04%	71.63%	Potassium voltage-gated channel subfamily B member 2;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN002158.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	3.8e-21	107.1	97.09%	35.91%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN002159.1	sp|K1QBH6|K1QBH6_CRAGI	1.3e-45	189.5	39.05%	64.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002161.1	sp|K1PFV1|K1PFV1_CRAGI	5.1e-111	406.8	100.00%	75.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002163.1	sp|K1PFK7|K1PFK7_CRAGI	4.5e-50	203.8	62.93%	57.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002164.1	sp|A0A210Q5L0|A0A210Q5L0_MIZYE	2.1e-270	937.6	100.00%	53.33%	tRNA pseudouridine(38/39) synthase;OS=Mizuhopecten;PE=3;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN002165.1	sp|K1QJW6|K1QJW6_CRAGI	1.7e-80	304.3	93.75%	96.95%	Translocon-associated protein subunit gamma;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016021|	GO:0006614|
GN002166.1	sp|K1QTQ7|K1QTQ7_CRAGI	6.1e-72	276.2	100.00%	65.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002167.1	sp|K1R0U1|K1R0U1_CRAGI	7.0e-94	349.0	100.00%	83.09%	Glycolipid transfer protein domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN002168.1	sp|A0A210PXQ8|A0A210PXQ8_MIZYE	4.1e-152	543.5	92.95%	65.70%	Selenocysteine lyase;OS=Mizuhopecten;PE=4;SV=1	GO:0016829|
GN002171.1	sp|K1RYR5|K1RYR5_CRAGI	4.6e-127	459.5	100.00%	76.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002172.1	sp|K1QTN6|K1QTN6_CRAGI	0.0e+00	1135.9	98.78%	80.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002173.1	sp|K1R365|K1R365_CRAGI	0.0e+00	1162.9	99.73%	75.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001042.1	sp|K1PPU2|K1PPU2_CRAGI	2.6e-114	419.1	61.01%	39.18%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN002174.1	sp|K1QN90|K1QN90_CRAGI	6.0e-25	120.6	39.29%	44.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047961|
GN002175.1	sp|K1RFP4|K1RFP4_CRAGI	2.5e-27	127.9	100.00%	38.24%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002176.1	sp|K1RYR7|K1RYR7_CRAGI	0.0e+00	2197.2	99.15%	80.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002177.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	5.1e-44	183.3	97.12%	41.95%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN002178.1	sp|K1R369|K1R369_CRAGI	5.5e-149	533.1	78.49%	79.88%	Ficolin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002179.1	sp|K1R970|K1R970_CRAGI	4.1e-94	350.5	72.68%	64.86%	F-box only protein 21;OS=Crassostrea;PE=4;SV=1
GN002180.1	sp|K1RFP6|K1RFP6_CRAGI	1.6e-190	671.0	100.00%	92.79%	Tektin-1;OS=Crassostrea;PE=4;SV=1
GN002181.1	sp|K1Q7N8|K1Q7N8_CRAGI	3.2e-189	667.2	98.77%	57.93%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002182.1	sp|K1RYS1|K1RYS1_CRAGI	3.2e-100	370.5	73.40%	79.72%	JmjC domain-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN002183.1	sp|K1QTP2|K1QTP2_CRAGI	3.5e-221	773.1	99.38%	83.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001043.1	sp|K1PPU2|K1PPU2_CRAGI	4.2e-128	464.9	64.39%	41.15%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN002184.1	sp|K1RFP8|K1RFP8_CRAGI	2.4e-125	453.8	100.00%	82.93%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN002185.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN002186.1	sp|K1QNW1|K1QNW1_CRAGI	5.3e-66	256.5	100.00%	59.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002187.1	sp|K1QWR6|K1QWR6_CRAGI	1.3e-308	1063.9	99.51%	82.76%	Beta-glucuronidase;OS=Crassostrea;PE=3;SV=1	GO:0005764|	GO:0004566|	GO:0005975|
GN002188.1	sp|K1R976|K1R976_CRAGI	0.0e+00	2487.6	100.00%	90.44%	Phosphoinositide 3-kinase regulatory subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001044.1	sp|K1PPU2|K1PPU2_CRAGI	2.6e-92	345.5	79.38%	36.38%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN002189.1	sp|K1RYS7|K1RYS7_CRAGI	1.9e-22	111.3	80.89%	53.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002190.1	sp|K1QTP9|K1QTP9_CRAGI	1.9e-52	211.1	72.94%	85.37%	Centromere protein M;OS=Crassostrea;PE=4;SV=1
GN002191.1	sp|K1RQD8|K1RQD8_CRAGI	3.7e-126	456.4	100.00%	89.47%	5-hydroxytryptamine receptor 1B;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002192.1	sp|K1R381|K1R381_CRAGI	3.9e-120	436.8	100.00%	72.59%	Cholecystokinin receptor type A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002193.1	sp|K1RFQ2|K1RFQ2_CRAGI	6.7e-51	206.8	79.50%	57.89%	Protein polyglycylase TTLL10;OS=Crassostrea;PE=4;SV=1	GO:0006464|
GN001045.1	sp|K1QQK3|K1QQK3_CRAGI	4.4e-144	518.1	92.41%	45.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002194.1	sp|K1R976|K1R976_CRAGI	0.0e+00	2487.6	100.00%	90.44%	Phosphoinositide 3-kinase regulatory subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN002195.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN002197.1	sp|H9LJ32|H9LJ32_CRAAR	2.5e-105	387.1	95.45%	89.47%	Triosephosphate isomerase;OS=Crassostrea;PE=2;SV=1	GO:0004807|	GO:0006094|GO:0006096|
GN002198.1	sp|K1PVU0|K1PVU0_CRAGI	2.4e-28	131.0	97.56%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002200.1	sp|A0A210Q5P4|A0A210Q5P4_MIZYE	5.9e-142	510.0	76.20%	58.69%	DNA damage-binding protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0080008|GO:0005634|	GO:0003684|	GO:0006281|
GN002201.1	sp|K1QKM1|K1QKM1_CRAGI	3.3e-105	387.5	98.44%	57.00%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002202.1	sp|K1QKM1|K1QKM1_CRAGI	1.6e-104	385.2	98.44%	56.74%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002203.1	sp|K1QKM1|K1QKM1_CRAGI	9.8e-94	349.7	98.79%	40.81%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002204.1	sp|K1S2N7|K1S2N7_CRAGI	7.1e-72	275.4	96.69%	93.79%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0019901|GO:0019887|GO:0043022|	GO:0006811|GO:0033674|GO:0006417|
GN002205.1	sp|A0A1S3J244|A0A1S3J244_LINUN	7.1e-64	250.4	91.78%	36.97%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN002206.1	sp|K1S2N7|K1S2N7_CRAGI	2.3e-40	170.2	100.00%	78.85%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0019901|GO:0019887|GO:0043022|	GO:0006811|GO:0033674|GO:0006417|
GN002207.1	sp|V4AU19|V4AU19_LOTGI	6.2e-31	139.4	96.75%	53.38%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002208.1	sp|K1PII2|K1PII2_CRAGI	2.4e-142	510.8	98.87%	69.54%	Inositol polyphosphate 5-phosphatase K;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0046856|
GN002209.1	sp|K1QQK5|K1QQK5_CRAGI	0.0e+00	1405.6	100.00%	72.72%	Metabotropic glutamate receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN001046.1	sp|K1PXG6|K1PXG6_CRAGI	1.8e-197	693.7	100.00%	99.70%	Serine/threonine-protein phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0000164|	GO:0046872|GO:0004722|
GN002210.1	sp|K1Q4J2|K1Q4J2_CRAGI	0.0e+00	1835.5	100.00%	73.19%	Active breakpoint cluster region-related protein;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0005089|	GO:0035556|GO:0035023|
GN002211.1	sp|S5MNM5|S5MNM5_BOMMO	2.3e-95	354.8	97.33%	47.06%	Actin-4;OS=Bombyx;PE=2;SV=1	GO:0005524|
GN002212.1	sp|L8HCZ7|L8HCZ7_ACACA	1.4e-132	478.4	98.16%	60.75%	Actin-1, putative;OS=Acanthamoeba;PE=3;SV=1	GO:0005524|
GN002213.1	sp|K1R4W9|K1R4W9_CRAGI	1.4e-119	435.3	83.95%	66.46%	Actin-1;OS=Crassostrea;PE=3;SV=1
GN002214.1	sp|K1S0M5|K1S0M5_CRAGI	3.4e-232	810.1	86.37%	68.95%	Membrane metallo-endopeptidase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0004222|
GN002215.1	sp|A0A210PXB1|A0A210PXB1_MIZYE	1.0e-18	97.8	93.33%	55.07%	Pleckstrin homology domain-containing family B member 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN002216.1	sp|K1QN24|K1QN24_CRAGI	4.4e-188	662.9	87.56%	86.07%	Carboxypeptidase B;OS=Crassostrea;PE=4;SV=1	GO:0004181|GO:0008270|
GN002217.1	sp|K1QEX1|K1QEX1_CRAGI	5.6e-29	132.1	87.36%	70.67%	Macrophage mannose receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002218.1	sp|K1QNF5|K1QNF5_CRAGI	0.0e+00	1334.7	100.00%	91.25%	Lon protease homolog 2, peroxisomal;OS=Crassostrea;PE=3;SV=1	GO:0005782|	GO:0005524|GO:0004176|GO:0043565|GO:0004252|	GO:0016558|GO:0016485|GO:0006515|
GN000936.1	sp|K1PWT5|K1PWT5_CRAGI	5.1e-13	78.6	90.00%	67.92%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0097200|	GO:0042981|
GN002219.1	sp|A0A210QXY5|A0A210QXY5_MIZYE	1.9e-86	325.9	86.85%	53.05%	Leucine-rich repeat-containing protein 29;OS=Mizuhopecten;PE=4;SV=1
GN002220.1	sp|K1QW86|K1QW86_CRAGI	9.8e-92	342.0	96.62%	70.18%	THO complex subunit 6-like protein;OS=Crassostrea;PE=4;SV=1
GN002222.1	sp|A0A210PH43|A0A210PH43_MIZYE	8.3e-267	925.2	99.86%	69.14%	Inositol 1,4,5-trisphosphate receptor type 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005783|GO:0016021|	GO:0070679|GO:0005220|
GN002223.1	sp|K1RM49|K1RM49_CRAGI	9.5e-82	308.9	100.00%	61.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002224.1	sp|K1RYQ8|K1RYQ8_CRAGI	5.0e-99	366.7	100.00%	63.66%	Ankyrin repeat domain-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN002225.1	sp|K1RYQ8|K1RYQ8_CRAGI	5.4e-147	526.6	100.00%	61.88%	Ankyrin repeat domain-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN002226.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN002227.1	sp|A7SKP6|A7SKP6_NEMVE	9.6e-43	179.5	78.23%	45.45%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN002228.1	sp|C3YG19|C3YG19_BRAFL	3.5e-12	77.0	82.98%	37.50%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN002229.1	sp|K1R8H1|K1R8H1_CRAGI	6.3e-114	417.2	66.40%	49.32%	Testis-specific serine/threonine-protein kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN002230.1	sp|V5HHA0|V5HHA0_IXORI	5.7e-11	72.4	73.40%	52.94%	Uncharacterized protein;OS=Ixodes;PE=2;SV=1
GN002231.1	sp|K1PM89|K1PM89_CRAGI	1.0e-15	89.4	47.39%	40.40%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN002233.1	sp|K1RC96|K1RC96_CRAGI	3.8e-24	116.7	62.50%	70.24%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002234.1	sp|K1PHB3|K1PHB3_CRAGI	1.6e-53	216.5	100.00%	31.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002235.1	sp|K1PR06|K1PR06_CRAGI	6.0e-161	572.8	84.89%	73.65%	Uncharacterized protein C18orf51;OS=Crassostrea;PE=4;SV=1
GN002236.1	sp|K1QY08|K1QY08_CRAGI	4.5e-158	563.5	99.23%	73.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002238.1	sp|K1PWF7|K1PWF7_CRAGI	0.0e+00	1225.3	99.69%	76.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001047.1	sp|K1PIH3|K1PIH3_CRAGI	1.1e-103	382.1	99.32%	69.28%	Potassium voltage-gated channel subfamily B member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0034765|
GN002240.1	sp|A0A210QN14|A0A210QN14_MIZYE	4.9e-88	331.3	96.88%	30.92%	Regulator of G-protein signaling protein-like;OS=Mizuhopecten;PE=4;SV=1
GN002241.1	sp|A0A210QN14|A0A210QN14_MIZYE	2.4e-44	185.7	90.27%	30.82%	Regulator of G-protein signaling protein-like;OS=Mizuhopecten;PE=4;SV=1
GN002242.1	sp|A0A210QQ47|A0A210QQ47_MIZYE	1.4e-65	255.8	97.44%	40.79%	Centromere protein N;OS=Mizuhopecten;PE=4;SV=1	GO:0007059|GO:0051382|
GN002243.1	sp|K1Q2W4|K1Q2W4_CRAGI	3.8e-36	158.7	91.36%	23.35%	Transcription intermediary factor 1-alpha;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002244.1	sp|A0A210QHC9|A0A210QHC9_MIZYE	5.3e-177	625.9	91.44%	86.80%	V-type proton ATPase subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0033179|	GO:0015078|	GO:0015991|
GN002245.1	sp|K1PHB6|K1PHB6_CRAGI	4.8e-137	492.7	100.00%	93.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002246.1	sp|K1R3L1|K1R3L1_CRAGI	7.7e-73	280.0	61.94%	55.82%	C-type lectin isoform 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN001048.1	sp|K1R4J8|K1R4J8_CRAGI	2.3e-218	763.8	99.43%	75.38%	Caspase-2;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN001049.1	sp|K1QIY1|K1QIY1_CRAGI	4.7e-107	393.3	99.34%	64.00%	GDP-fucose transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0005457|	GO:0036085|
GN002253.1	sp|K1P9K3|K1P9K3_CRAGI	2.7e-311	1072.8	99.58%	86.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002254.1	sp|K1PGU3|K1PGU3_CRAGI	7.2e-238	828.6	100.00%	78.23%	Beta-1,3-glucosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0016757|
GN002255.1	sp|K1PNL8|K1PNL8_CRAGI	0.0e+00	1473.0	97.15%	80.65%	Serine/threonine-protein kinase ULK2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN002256.1	sp|K1Q9L2|K1Q9L2_CRAGI	5.8e-234	816.2	99.10%	64.72%	A kinase anchor protein 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005739|	GO:0016301|GO:0034237|GO:0003723|	GO:0010738|
GN002258.1	sp|A0A210R2S1|A0A210R2S1_MIZYE	6.4e-41	173.7	84.29%	38.35%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002259.1	sp|K1P9K9|K1P9K9_CRAGI	1.5e-134	485.0	99.49%	64.36%	Defects in morphology protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0045145|
GN001050.1	sp|K1QCF9|K1QCF9_CRAGI	6.8e-165	585.5	100.00%	84.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016810|	GO:0005975|
GN002261.1	sp|K1PNM1|K1PNM1_CRAGI	1.0e-51	208.8	98.43%	57.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0031005|	GO:0061572|GO:0061181|
GN002262.1	sp|K1PGU7|K1PGU7_CRAGI	5.2e-40	170.2	40.74%	83.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016598|
GN002263.1	sp|K1PNM6|K1PNM6_CRAGI	9.4e-47	193.7	24.86%	74.22%	Zinc finger protein 64-like protein, isoforms 1 and 2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002264.1	sp|K1PNM6|K1PNM6_CRAGI	5.6e-12	77.4	30.85%	50.50%	Zinc finger protein 64-like protein, isoforms 1 and 2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002266.1	sp|K1Q9M0|K1Q9M0_CRAGI	0.0e+00	1117.1	93.20%	78.79%	tRNA (Cytosine-5-)-methyltransferase NSUN2;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0016428|
GN002267.1	sp|A0A210PNC6|A0A210PNC6_MIZYE	1.1e-170	605.5	100.00%	63.02%	Kelch domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1
GN001051.1	sp|K1Q4N0|K1Q4N0_CRAGI	9.7e-63	245.0	100.00%	94.33%	Protein LZIC;OS=Crassostrea;PE=4;SV=1	GO:0008013|
GN002268.1	sp|K1PYC4|K1PYC4_CRAGI	6.8e-84	316.2	67.49%	75.26%	SRR1-like protein;OS=Crassostrea;PE=4;SV=1
GN002269.1	sp|K1QYN2|K1QYN2_CRAGI	0.0e+00	1293.5	100.00%	92.41%	E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|	GO:0006511|
GN002270.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN002273.1	sp|K1QBH6|K1QBH6_CRAGI	6.1e-46	190.7	33.17%	69.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002274.1	sp|K1QZH7|K1QZH7_CRAGI	4.4e-181	641.3	34.99%	64.76%	Putative metabotropic glutamate receptor mgl-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002275.1	sp|K1RCS4|K1RCS4_CRAGI	3.5e-129	466.8	100.00%	97.44%	Coiled-coil domain-containing protein 42-like protein;OS=Crassostrea;PE=4;SV=1
GN001052.1	sp|K1PWY8|K1PWY8_CRAGI	5.7e-102	377.1	89.21%	46.45%	Protein SpAN;OS=Crassostrea;PE=4;SV=1
GN002276.1	sp|A0A210QQ84|A0A210QQ84_MIZYE	2.6e-137	495.4	98.08%	35.73%	Neurochondrin;OS=Mizuhopecten;PE=4;SV=1
GN002277.1	sp|K1QZJ2|K1QZJ2_CRAGI	0.0e+00	1310.8	99.84%	69.08%	Zinc finger protein ZFAT;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002278.1	sp|K1QW92|K1QW92_CRAGI	2.0e-69	268.5	99.14%	52.46%	CREB/ATF bZIP transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN002279.1	sp|K1RBW9|K1RBW9_CRAGI	9.0e-14	82.8	20.40%	97.50%	Leucine-rich repeat-containing protein 69;OS=Crassostrea;PE=4;SV=1
GN002280.1	sp|C3YWQ8|C3YWQ8_BRAFL	3.2e-49	201.4	95.16%	34.07%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN002281.1	sp|K1R5X3|K1R5X3_CRAGI	0.0e+00	1341.6	99.91%	61.34%	Transmembrane and coiled-coil domain-containing protein 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001053.1	sp|K1R4J3|K1R4J3_CRAGI	1.7e-117	427.6	97.82%	93.72%	Putative ribosome biogenesis protein NEP1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN002282.1	sp|K1RBX4|K1RBX4_CRAGI	9.0e-78	295.8	100.00%	51.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN002283.1	sp|K1RBX4|K1RBX4_CRAGI	2.8e-17	93.6	97.22%	45.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN002284.1	sp|K1RHY4|K1RHY4_CRAGI	2.4e-64	252.3	78.21%	48.34%	Endothelial cells scavenger receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001054.1	sp|K1QCF5|K1QCF5_CRAGI	0.0e+00	1079.3	99.29%	94.60%	Fumarate hydratase class I, aerobic;OS=Crassostrea;PE=4;SV=1	GO:0004333|	GO:0006091|
GN002285.1	sp|K1QLK3|K1QLK3_CRAGI	2.0e-24	117.5	92.56%	53.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002286.1	sp|K1QLK3|K1QLK3_CRAGI	1.8e-93	348.6	99.25%	47.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002287.1	sp|A0A024J5R7|A0A024J5R7_CRAGI	4.1e-12	78.2	24.73%	47.92%	Feeding circuit activating peptide;OS=Crassostrea;PE=2;SV=1	GO:0005184|
GN001055.1	sp|W6NXN7|W6NXN7_HAECO	5.3e-09	66.6	69.81%	35.45%	Transposase domain containing protein;OS=Haemonchus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006313|
GN002289.1	sp|K1PYN4|K1PYN4_CRAGI	2.4e-221	773.9	99.82%	68.14%	DnaJ-like protein subfamily C member 11;OS=Crassostrea;PE=4;SV=1
GN002290.1	sp|K1QKK5|K1QKK5_CRAGI	3.5e-27	126.7	92.31%	52.94%	Vacuolar protein sorting-associated protein 4B;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|
GN002291.1	sp|K1QKK5|K1QKK5_CRAGI	6.1e-196	689.1	99.32%	92.06%	Vacuolar protein sorting-associated protein 4B;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|
GN002292.1	sp|K1PSK5|K1PSK5_CRAGI	1.7e-170	605.5	41.98%	80.12%	Vacuolar protein sorting-associated protein 4B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003810|	GO:0018149|
GN002293.1	sp|K1PDB3|K1PDB3_CRAGI	0.0e+00	1360.1	100.00%	62.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001056.1	sp|K1Q4M6|K1Q4M6_CRAGI	9.4e-215	751.5	100.00%	83.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN002296.1	sp|K1QKJ7|K1QKJ7_CRAGI	1.3e-41	175.3	47.94%	94.57%	Translocation protein SEC62;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0015031|
GN002297.1	sp|K1PYM7|K1PYM7_CRAGI	0.0e+00	4415.1	98.87%	92.49%	Serine/threonine-protein kinase TOR;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|GO:0044877|
GN002298.1	sp|K1QKI8|K1QKI8_CRAGI	0.0e+00	1435.2	99.91%	63.99%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN002300.1	sp|K1RIM3|K1RIM3_CRAGI	3.1e-44	183.7	68.71%	79.28%	Glycolipid transfer protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN002301.1	sp|K1QBA3|K1QBA3_CRAGI	5.0e-115	419.5	99.59%	83.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002302.1	sp|K1R1P2|K1R1P2_CRAGI	0.0e+00	1651.0	81.07%	73.28%	Citron Rho-interacting kinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0046872|	GO:0035556|
GN001057.1	sp|K1Q4M6|K1Q4M6_CRAGI	3.4e-123	446.8	89.75%	85.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN002303.1	sp|K1QJU8|K1QJU8_CRAGI	2.7e-22	109.4	100.00%	74.58%	Putative phospholipase B-like 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|	GO:0000281|
GN002304.1	sp|K1QSA0|K1QSA0_CRAGI	3.3e-127	460.7	100.00%	66.19%	X-box-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN002305.1	sp|K1Q8J7|K1Q8J7_CRAGI	2.8e-247	859.8	100.00%	86.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002307.1	sp|A0A210Q1R5|A0A210Q1R5_MIZYE	3.9e-76	291.6	95.23%	35.06%	X-box-binding protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003700|
GN002312.1	sp|K1R1S1|K1R1S1_CRAGI	1.6e-123	449.5	71.22%	42.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002313.1	sp|K1PTT2|K1PTT2_CRAGI	1.0e-131	475.7	97.48%	76.67%	Transcriptional repressor scratch 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002314.1	sp|K1QIV3|K1QIV3_CRAGI	2.1e-30	138.3	84.03%	36.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002315.1	sp|K1PCN1|K1PCN1_CRAGI	9.9e-73	278.9	92.64%	67.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002316.1	sp|K1QTU9|K1QTU9_CRAGI	0.0e+00	1611.3	97.73%	80.83%	Mediator of RNA polymerase II transcription subunit 24;OS=Crassostrea;PE=4;SV=1	GO:0016592|
GN002317.1	sp|K1QMS7|K1QMS7_CRAGI	1.7e-140	504.6	93.61%	72.02%	Malonyl CoA-acyl carrier protein transacylase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN002318.1	sp|K1REG6|K1REG6_CRAGI	3.4e-98	363.2	96.43%	88.00%	DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0003678|	GO:0006270|
GN002319.1	sp|A0A0B7ADT3|A0A0B7ADT3_9EUPU	4.0e-132	476.5	99.65%	84.56%	Uncharacterized protein;OS=Arion;PE=3;SV=1	GO:0042555|	GO:0005524|GO:0003677|GO:0003678|	GO:0006270|
GN002320.1	sp|K1RY25|K1RY25_CRAGI	2.3e-21	108.6	73.84%	29.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004842|
GN002321.1	sp|K1QMS1|K1QMS1_CRAGI	0.0e+00	2169.0	99.63%	86.52%	Protein fantom;OS=Crassostrea;PE=4;SV=1
GN002324.1	sp|K1RA49|K1RA49_CRAGI	5.8e-87	327.0	97.88%	39.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002325.1	sp|K1RA49|K1RA49_CRAGI	4.8e-60	237.7	66.82%	40.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002326.1	sp|K1RA49|K1RA49_CRAGI	4.1e-59	234.6	66.82%	41.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002327.1	sp|K1RA49|K1RA49_CRAGI	4.1e-59	234.6	66.82%	41.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002328.1	sp|K1QPX8|K1QPX8_CRAGI	8.2e-289	998.0	100.00%	81.49%	Alkyl/aryl-sulfatase BDS1;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN002329.1	sp|V4A8A4|V4A8A4_LOTGI	2.6e-90	339.0	59.16%	40.31%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002330.1	sp|C3Z7Z4|C3Z7Z4_BRAFL	6.6e-122	444.9	77.36%	30.41%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN002331.1	sp|K1RI74|K1RI74_CRAGI	0.0e+00	1386.3	100.00%	94.91%	Epithelial splicing regulatory protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN002332.1	sp|K1Q1X1|K1Q1X1_CRAGI	5.5e-32	143.7	68.09%	46.07%	Putative potassium channel regulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN002333.1	sp|K1QNI0|K1QNI0_CRAGI	1.2e-12	79.3	34.30%	47.56%	GTP-binding protein GEM;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN002334.1	sp|K1R3P4|K1R3P4_CRAGI	2.1e-307	1060.4	100.00%	77.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002335.1	sp|K1RN39|K1RN39_CRAGI	4.3e-278	962.2	99.61%	85.13%	N-acetylgalactosamine-6-sulfatase;OS=Crassostrea;PE=4;SV=1	GO:0043890|
GN001061.1	sp|K1QR55|K1QR55_CRAGI	2.0e-217	760.4	98.52%	90.50%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002336.1	sp|K1RHT2|K1RHT2_CRAGI	1.5e-34	152.1	68.92%	44.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002337.1	sp|K1QJW8|K1QJW8_CRAGI	1.1e-40	172.2	75.65%	57.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002339.1	sp|K1P775|K1P775_CRAGI	2.9e-206	723.8	97.56%	82.26%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0005328|
GN000938.1	sp|K1PWT5|K1PWT5_CRAGI	9.6e-110	403.3	69.29%	53.08%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0097200|	GO:0042981|
GN001062.1	sp|K1QR55|K1QR55_CRAGI	2.0e-217	760.4	98.52%	90.50%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002342.1	sp|K1QWJ0|K1QWJ0_CRAGI	0.0e+00	1157.1	94.45%	74.39%	Nuclear mitotic apparatus protein 1;OS=Crassostrea;PE=4;SV=1
GN002343.1	sp|A0A210QXW2|A0A210QXW2_MIZYE	1.8e-86	326.2	82.27%	39.83%	Zinc finger protein 668;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN002344.1	sp|K1R9Z7|K1R9Z7_CRAGI	1.4e-249	867.5	96.91%	86.78%	Oxidative stress-induced growth inhibitor 2;OS=Crassostrea;PE=4;SV=1
GN002345.1	sp|K1RTU4|K1RTU4_CRAGI	2.1e-164	584.7	100.00%	86.32%	Bardet-Biedl syndrome 4 protein;OS=Crassostrea;PE=4;SV=1
GN002346.1	sp|K1R3J0|K1R3J0_CRAGI	5.8e-46	190.3	50.69%	71.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002348.1	sp|K1R417|K1R417_CRAGI	1.7e-44	185.7	90.60%	33.54%	Pumilio domain-containing protein C14orf21;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN001063.1	sp|K1QR55|K1QR55_CRAGI	2.0e-217	760.4	98.52%	90.50%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002350.1	sp|K1RA59|K1RA59_CRAGI	3.1e-177	628.6	85.64%	57.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN002351.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	2.2e-36	157.5	98.03%	53.69%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN002352.1	sp|K1RFV5|K1RFV5_CRAGI	2.9e-66	256.5	100.00%	94.49%	ATP-dependent RNA helicase DDX1;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN002353.1	sp|K1RM04|K1RM04_CRAGI	1.9e-171	607.4	100.00%	83.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002354.1	sp|A0A2S2P439|A0A2S2P439_SCHGA	7.2e-15	87.0	57.43%	29.71%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN001064.1	sp|K1QR55|K1QR55_CRAGI	2.0e-217	760.4	98.52%	90.50%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002355.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	3.7e-19	100.1	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN002356.1	sp|K1PQE3|K1PQE3_CRAGI	3.5e-75	286.6	99.42%	85.80%	RNA-binding protein Raly;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN002357.1	sp|K1PQE3|K1PQE3_CRAGI	3.7e-37	159.8	99.21%	69.05%	RNA-binding protein Raly;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN002358.1	sp|A0A0L8G191|A0A0L8G191_OCTBM	1.6e-59	234.6	99.43%	65.52%	ER membrane protein complex subunit 4;OS=Octopus;PE=3;SV=1	GO:0016021|
GN002359.1	sp|K1PIC5|K1PIC5_CRAGI	1.1e-11	77.4	9.50%	74.07%	Transmembrane protein 85;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002360.1	sp|K1P4P1|K1P4P1_CRAGI	0.0e+00	1486.1	83.12%	86.23%	Solute carrier family 12 member 4;OS=Crassostrea;PE=4;SV=1	GO:0005887|	GO:0015379|	GO:0071477|
GN002362.1	sp|K1Q6H1|K1Q6H1_CRAGI	1.9e-37	161.0	83.11%	68.55%	Uncharacterized protein C16orf7-like protein;OS=Crassostrea;PE=4;SV=1
GN002363.1	sp|A0A1X7V731|A0A1X7V731_AMPQE	5.0e-15	86.7	83.65%	37.31%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN002364.1	sp|K1Q6H1|K1Q6H1_CRAGI	1.2e-67	262.7	94.82%	50.71%	Uncharacterized protein C16orf7-like protein;OS=Crassostrea;PE=4;SV=1
GN002365.1	sp|A0A1D1VGL3|A0A1D1VGL3_RAMVA	5.3e-41	172.6	95.93%	69.23%	Peptidyl-prolyl cis-trans isomerase;OS=Ramazzottius;PE=3;SV=1	GO:0003755|	GO:0006457|
GN002366.1	sp|K1R1H8|K1R1H8_CRAGI	1.1e-87	328.6	93.33%	74.43%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|
GN001066.1	sp|K1QR55|K1QR55_CRAGI	2.0e-217	760.4	98.52%	90.50%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002368.1	sp|A0A210QDG4|A0A210QDG4_MIZYE	3.0e-25	120.9	50.49%	57.84%	Uncharacterized protein K02A2.6;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|	GO:0015074|
GN002369.1	sp|K1R1I1|K1R1I1_CRAGI	6.9e-10	70.1	24.35%	63.16%	PAP-associated domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0004652|GO:0003723|	GO:0043631|
GN002370.1	sp|K1R1I1|K1R1I1_CRAGI	7.3e-177	625.5	94.37%	83.97%	PAP-associated domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0004652|GO:0003723|	GO:0043631|
GN002371.1	sp|K1R862|K1R862_CRAGI	2.7e-170	604.7	88.35%	59.94%	ATM interactor;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002374.1	sp|K1QPB3|K1QPB3_CRAGI	0.0e+00	1115.9	99.58%	74.54%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN002375.1	sp|A0A2B4SMG7|A0A2B4SMG7_STYPI	1.0e-71	276.6	98.53%	34.11%	Zinc finger protein 862;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0008270|
GN002376.1	sp|A0A1S3HE30|A0A1S3HE30_LINUN	1.9e-21	107.5	86.24%	50.49%	zinc finger protein 862-like;OS=Lingula;PE=4;SV=1	GO:0046983|
GN002377.1	sp|K1RA01|K1RA01_CRAGI	1.1e-200	704.9	98.07%	90.61%	Homeobox protein caupolican;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN002378.1	sp|K1Q6G7|K1Q6G7_CRAGI	1.3e-82	313.5	82.84%	42.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002379.1	sp|K1RDW8|K1RDW8_CRAGI	5.6e-245	852.4	86.05%	77.50%	Golgi apparatus protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|
GN002380.1	sp|K1RDW8|K1RDW8_CRAGI	1.9e-233	813.9	100.00%	77.52%	Golgi apparatus protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|
GN002385.1	sp|K1Q6G7|K1Q6G7_CRAGI	5.2e-271	940.3	94.05%	46.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002386.1	sp|K1RDW8|K1RDW8_CRAGI	1.3e-86	324.7	95.29%	83.43%	Golgi apparatus protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|
GN002387.1	sp|K1QMH7|K1QMH7_CRAGI	1.1e-157	561.6	99.07%	84.86%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN002388.1	sp|K1PSA8|K1PSA8_CRAGI	0.0e+00	1281.9	100.00%	75.06%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN002390.1	sp|A0A194AME6|A0A194AME6_PINFU	3.4e-54	216.5	96.15%	85.48%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1	GO:0016021|
GN002391.1	sp|K1R6F6|K1R6F6_CRAGI	0.0e+00	1802.3	99.85%	72.36%	Lysine-specific demethylase 2B;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0005506|GO:0008168|GO:0008270|
GN002392.1	sp|K1S249|K1S249_CRAGI	6.3e-137	492.7	82.53%	84.98%	Clathrin heavy chain 1;OS=Crassostrea;PE=4;SV=1	GO:0030132|GO:0030130|	GO:0005198|	GO:0006886|GO:0016192|
GN002393.1	sp|A0A210R302|A0A210R302_MIZYE	1.6e-54	217.6	100.00%	89.39%	Intraflagellar transport protein 20-like B;OS=Mizuhopecten;PE=4;SV=1	GO:0031514|
GN002394.1	sp|A0A210R319|A0A210R319_MIZYE	4.6e-136	489.6	100.00%	84.72%	BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0051260|
GN002396.1	sp|K1QWR7|K1QWR7_CRAGI	6.4e-92	343.2	84.48%	58.90%	Zona pellucida sperm-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002397.1	sp|K1S245|K1S245_CRAGI	3.7e-134	483.4	97.82%	85.03%	Calcium-dependent protein kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016301|
GN002399.1	sp|K1RCI1|K1RCI1_CRAGI	1.4e-194	685.6	54.60%	78.08%	Transcription initiation factor TFIID subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005669|	GO:0003700|GO:0046982|GO:0003743|	GO:0006352|
GN002400.1	sp|K1S241|K1S241_CRAGI	4.1e-81	307.8	98.31%	46.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002402.1	sp|K1QWF8|K1QWF8_CRAGI	1.5e-229	801.2	95.96%	69.24%	Purple acid phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003993|GO:0046872|
GN002403.1	sp|K1Q996|K1Q996_CRAGI	7.3e-143	512.7	93.45%	64.51%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN000939.1	sp|K1PVX6|K1PVX6_CRAGI	1.9e-128	464.5	94.22%	62.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002404.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	5.8e-18	97.1	40.48%	45.54%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN002405.1	sp|K1Q6G5|K1Q6G5_CRAGI	1.0e-103	381.7	100.00%	91.98%	60S ribosomal protein L13;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN002406.1	sp|A0A0L8HE49|A0A0L8HE49_OCTBM	9.6e-55	221.1	34.48%	42.09%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN002407.1	sp|K1PSA8|K1PSA8_CRAGI	0.0e+00	1282.3	100.00%	75.06%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN002408.1	sp|K1QMH7|K1QMH7_CRAGI	4.4e-139	499.6	100.00%	84.15%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN002409.1	sp|A0A210R4V0|A0A210R4V0_MIZYE	2.1e-71	274.6	99.23%	54.74%	G-protein coupled receptor Mth2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN002411.1	sp|A0A1S3JQA7|A0A1S3JQA7_LINUN	7.9e-18	94.7	100.00%	65.28%	prohibitin-2;OS=Lingula;PE=4;SV=1	GO:0016021|
GN001071.1	sp|K1Q4M3|K1Q4M3_CRAGI	4.7e-228	795.8	100.00%	90.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008502|
GN002412.1	sp|A0A151JWE2|A0A151JWE2_9HYME	9.6e-59	231.9	94.37%	81.33%	Prohibitin-2;OS=Trachymyrmex;PE=4;SV=1	GO:0016020|
GN002413.1	sp|K1RCJ5|K1RCJ5_CRAGI	1.4e-53	214.9	93.72%	63.44%	39S ribosomal protein L47, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005761|	GO:0003735|	GO:0006412|
GN002414.1	sp|K1PZK4|K1PZK4_CRAGI	5.6e-25	120.6	45.33%	51.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002415.1	sp|K1S256|K1S256_CRAGI	4.6e-15	86.7	95.97%	88.73%	Coiled-coil-helix-coiled-coil-helix domain-containing protein 2, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN002416.1	sp|A0A0B7BKQ1|A0A0B7BKQ1_9EUPU	2.6e-70	271.6	94.13%	39.75%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0009976|
GN002418.1	sp|K1P2F2|K1P2F2_CRAGI	4.9e-30	135.6	90.48%	85.33%	Phosphatase PTC7-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN002419.1	sp|K1P2G0|K1P2G0_CRAGI	6.0e-72	275.8	92.12%	87.50%	Strawberry notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006355|
GN002420.1	sp|K1QFD9|K1QFD9_CRAGI	2.1e-33	148.7	76.51%	42.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002421.1	sp|A0A210QBW7|A0A210QBW7_MIZYE	2.6e-294	1016.9	89.28%	63.27%	Sterile alpha and TIR motif-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0035591|	GO:0034128|GO:0048678|GO:0007165|
GN001072.1	sp|K1QIX2|K1QIX2_CRAGI	3.6e-132	477.6	58.04%	79.53%	CUE domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN002423.1	sp|K1PNB8|K1PNB8_CRAGI	9.7e-19	97.4	96.36%	80.77%	Ubiquitin-associated and SH3 domain-containing protein B;OS=Crassostrea;PE=4;SV=1
GN002424.1	sp|A0A210QB58|A0A210QB58_MIZYE	5.1e-32	142.5	97.20%	60.19%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN002425.1	sp|K1QGN7|K1QGN7_CRAGI	2.2e-48	198.7	66.41%	46.12%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN002426.1	sp|K1R6H6|K1R6H6_CRAGI	8.2e-70	268.5	100.00%	87.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001073.1	sp|K1RAZ4|K1RAZ4_CRAGI	1.4e-224	784.3	100.00%	83.85%	Abhydrolase domain-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN002429.1	sp|K1QWW6|K1QWW6_CRAGI	2.3e-14	83.6	50.57%	93.02%	N-acetylated-alpha-linked acidic dipeptidase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002433.1	sp|K1S280|K1S280_CRAGI	8.8e-99	365.9	86.10%	89.08%	Transmembrane protein 26;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002434.1	sp|K1QWV9|K1QWV9_CRAGI	1.4e-299	1033.9	98.58%	79.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002435.1	sp|A0A210QY05|A0A210QY05_MIZYE	1.3e-23	115.9	93.53%	27.72%	Carbohydrate sulfotransferase 5;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016740|
GN002436.1	sp|K1R6H0|K1R6H0_CRAGI	0.0e+00	2149.0	100.00%	83.23%	Zinc finger protein castor-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0006355|
GN002437.1	sp|A0A210Q7Y3|A0A210Q7Y3_MIZYE	1.4e-69	268.9	94.34%	50.88%	Potassium voltage-gated channel subfamily A member 2;OS=Mizuhopecten;PE=3;SV=1	GO:0008076|	GO:0005249|
GN002438.1	sp|K1S267|K1S267_CRAGI	2.2e-143	514.2	100.00%	72.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002439.1	sp|K1RCK0|K1RCK0_CRAGI	1.3e-136	491.9	99.01%	67.91%	Tyrosine-protein phosphatase non-receptor type 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN002442.1	sp|K1R6G0|K1R6G0_CRAGI	3.0e-28	130.2	88.62%	54.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002443.1	sp|K1R6G0|K1R6G0_CRAGI	2.5e-23	114.4	65.75%	55.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002444.1	sp|K1R6G5|K1R6G5_CRAGI	2.4e-78	297.4	88.04%	84.70%	Transmembrane protein C2orf18;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|	GO:0015165|
GN002445.1	sp|K1PND7|K1PND7_CRAGI	1.1e-87	328.6	100.00%	69.47%	Fatty acid synthase;OS=Crassostrea;PE=3;SV=1	GO:0016788|GO:0016740|	GO:0009058|
GN001074.1	sp|A0A0L8I5V8|A0A0L8I5V8_OCTBM	2.7e-13	80.5	79.51%	47.42%	Uncharacterized protein;OS=Octopus;PE=3;SV=1	GO:0005840|	GO:0019843|GO:0003735|	GO:0006412|
GN002446.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN002449.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	5.5e-29	134.4	27.21%	56.64%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001075.1	sp|K1RH70|K1RH70_CRAGI	1.2e-130	471.5	95.74%	93.50%	6-phosphogluconate dehydrogenase, decarboxylating;OS=Crassostrea;PE=3;SV=1	GO:0050661|GO:0004616|	GO:0019521|GO:0006098|
GN002450.1	sp|K1QFZ6|K1QFZ6_CRAGI	2.3e-26	124.8	57.53%	45.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002451.1	sp|V4A526|V4A526_LOTGI	1.1e-09	69.3	35.21%	39.19%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002452.1	sp|K1Q9E6|K1Q9E6_CRAGI	5.2e-74	284.3	31.30%	91.14%	Serine/arginine repetitive matrix protein 2;OS=Crassostrea;PE=4;SV=1
GN002454.1	sp|K1P2H1|K1P2H1_CRAGI	1.9e-60	237.3	100.00%	89.31%	Fatty acid-binding protein, adipocyte;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN002455.1	sp|K1Q9F0|K1Q9F0_CRAGI	6.7e-97	360.5	63.21%	51.70%	RNA methyltransferase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0015288|GO:0003723|GO:0008173|	GO:0034219|GO:0006396|
GN002456.1	sp|K1P2H6|K1P2H6_CRAGI	5.4e-131	473.0	100.00%	74.00%	Potassium voltage-gated channel protein Shaw;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN002458.1	sp|K1P986|K1P986_CRAGI	2.4e-24	118.2	93.55%	58.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002460.1	sp|K1PGK5|K1PGK5_CRAGI	4.8e-37	160.2	97.67%	44.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000940.1	sp|K1PGS9|K1PGS9_CRAGI	3.8e-74	283.5	98.62%	62.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002461.1	sp|K1QY88|K1QY88_CRAGI	9.3e-79	299.3	100.00%	47.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN002462.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-35	156.0	58.22%	47.37%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN001076.1	sp|K1RH67|K1RH67_CRAGI	1.7e-64	250.8	91.11%	86.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002464.1	sp|K1RGC1|K1RGC1_CRAGI	8.5e-57	225.3	92.72%	71.94%	ATP-dependent DNA helicase hus2/rqh1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN001077.1	sp|K1RH67|K1RH67_CRAGI	2.9e-140	503.8	97.49%	75.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002468.1	sp|K1RF74|K1RF74_CRAGI	2.0e-19	102.1	33.93%	55.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002472.1	sp|K1QS69|K1QS69_CRAGI	5.1e-40	169.9	93.41%	48.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001078.1	sp|K1RH67|K1RH67_CRAGI	3.2e-134	483.4	95.42%	88.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002473.1	sp|A0A1X7V8P5|A0A1X7V8P5_AMPQE	3.8e-11	75.1	23.17%	39.36%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003676|
GN002474.1	sp|K1QGN5|K1QGN5_CRAGI	1.2e-73	282.0	94.94%	79.91%	Zinc finger CCHC domain-containing protein 8;OS=Crassostrea;PE=4;SV=1
GN002476.1	sp|W4ZHM1|W4ZHM1_STRPU	3.7e-17	94.4	97.20%	27.57%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0016021|
GN001079.1	sp|K1RAY8|K1RAY8_CRAGI	3.6e-64	250.8	89.16%	51.18%	F-box/WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN002477.1	sp|A0A1S3I398|A0A1S3I398_LINUN	2.8e-48	197.6	71.95%	53.97%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN002478.1	sp|A0A2P8Y7J4|A0A2P8Y7J4_BLAGE	5.8e-18	97.1	92.40%	28.63%	Uncharacterized protein;OS=Blattella;PE=4;SV=1
GN001080.1	sp|K1RAY8|K1RAY8_CRAGI	1.7e-13	80.9	48.45%	76.09%	F-box/WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN002484.1	sp|K1R3B2|K1R3B2_CRAGI	6.5e-13	78.6	55.26%	82.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002485.1	sp|A0A1S3HAE1|A0A1S3HAE1_LINUN	1.8e-36	157.9	100.00%	46.30%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN001081.1	sp|K1PS23|K1PS23_CRAGI	2.7e-130	471.1	95.62%	53.30%	F-box/WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN002486.1	sp|K1R5R4|K1R5R4_CRAGI	0.0e+00	2774.2	98.49%	93.34%	Dynein heavy chain 10, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0015629|GO:0030286|	GO:0003779|GO:0005524|GO:0003777|GO:0003951|	GO:0030042|GO:0007018|
GN002487.1	sp|K1R645|K1R645_CRAGI	4.2e-14	83.6	75.00%	41.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001082.1	sp|K1QSK1|K1QSK1_CRAGI	2.2e-262	910.2	100.00%	86.44%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002491.1	sp|Unreviewed|A0A087T6J7_9ARAC	3.6e-31	140.2	98.03%	48.65%	Uncharacterized protein;OS=Stegodyphus;PE=4;SV=1
GN002492.1	sp|X1WW30|X1WW30_ACYPI	1.2e-22	112.1	84.80%	40.28%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1	GO:0003677|
GN001083.1	sp|K1PKK9|K1PKK9_CRAGI	7.1e-131	472.6	96.61%	68.42%	TWiK family of potassium channels protein 7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN002494.1	sp|K1QSY2|K1QSY2_CRAGI	5.4e-204	716.1	96.30%	71.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002495.1	sp|K1RD27|K1RD27_CRAGI	8.1e-73	280.8	79.86%	35.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002496.1	sp|K1RIJ0|K1RIJ0_CRAGI	5.2e-173	612.8	98.09%	73.52%	Ileal sodium/bile acid cotransporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002498.1	sp|K1QDJ2|K1QDJ2_CRAGI	8.4e-204	715.3	97.86%	77.87%	Sodium-dependent glucose transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008643|GO:0055085|
GN001084.1	sp|K1R0H4|K1R0H4_CRAGI	0.0e+00	1225.3	92.06%	76.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007099|
GN002501.1	sp|K1QDT6|K1QDT6_CRAGI	9.0e-11	72.8	36.60%	38.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002503.1	sp|K1RIH6|K1RIH6_CRAGI	8.0e-36	155.2	99.11%	70.00%	Fatty acid-binding protein, intestinal;OS=Crassostrea;PE=3;SV=1	GO:0005504|
GN002505.1	sp|K1RCQ4|K1RCQ4_CRAGI	7.0e-213	746.1	93.62%	63.73%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN002506.1	sp|K1QLA2|K1QLA2_CRAGI	1.1e-72	278.9	100.00%	55.43%	Peptidase inhibitor 16;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN002507.1	sp|K1RIM7|K1RIM7_CRAGI	3.8e-18	97.1	39.39%	72.31%	Methionine aminopeptidase 2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0046872|GO:0070006|	GO:0070084|
GN000941.1	sp|K1PGS9|K1PGS9_CRAGI	5.9e-51	206.5	88.48%	50.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002508.1	sp|K1PY30|K1PY30_CRAGI	1.0e-181	641.7	93.98%	90.64%	Septin-2;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN002509.1	sp|K1Q5H0|K1Q5H0_CRAGI	2.5e-161	574.3	68.74%	79.60%	Septin-4;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN002509.1	sp|K1Q5H0|K1Q5H0_CRAGI	6.7e-130	469.9	54.17%	82.01%	Septin-4;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN002511.1	sp|K1QDJ9|K1QDJ9_CRAGI	3.2e-211	740.0	81.68%	86.82%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN002512.1	sp|K1QJT1|K1QJT1_CRAGI	1.8e-113	414.5	92.11%	82.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035591|	GO:0007165|
GN002513.1	sp|R7T5B4|R7T5B4_CAPTE	4.1e-22	110.5	55.61%	44.25%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN001086.1	sp|K1QX67|K1QX67_CRAGI	4.9e-09	67.4	26.29%	49.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002514.1	sp|K1QY27|K1QY27_CRAGI	2.4e-129	467.6	99.73%	65.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002515.1	sp|K1PGZ5|K1PGZ5_CRAGI	1.2e-69	269.6	61.44%	40.75%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN002516.1	sp|K1Q0D3|K1Q0D3_CRAGI	5.8e-55	220.3	66.36%	51.64%	Protein FAN;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002517.1	sp|K1PD84|K1PD84_CRAGI	8.8e-83	312.0	100.00%	77.08%	Phosphatidylglycerol/phosphatidylinositol transfer protein;OS=Crassostrea;PE=4;SV=1
GN002518.1	sp|K1QD88|K1QD88_CRAGI	1.0e-58	231.9	82.56%	76.60%	15-hydroxyprostaglandin dehydrogenase [NAD+];OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN002519.1	sp|K1P761|K1P761_CRAGI	2.1e-54	217.2	99.26%	79.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002520.1	sp|K1PKV4|K1PKV4_CRAGI	5.7e-259	899.0	97.25%	72.67%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002521.1	sp|K1PSU7|K1PSU7_CRAGI	6.4e-51	207.6	66.98%	69.89%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN002522.1	sp|K1QD97|K1QD97_CRAGI	7.6e-174	615.5	92.93%	89.22%	Forkhead box protein F1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN002523.1	sp|K1P767|K1P767_CRAGI	1.6e-86	324.7	86.81%	79.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN002524.1	sp|K1Q7Q3|K1Q7Q3_CRAGI	6.4e-37	158.3	97.37%	100.00%	Testis, prostate and placenta-expressed protein;OS=Crassostrea;PE=4;SV=1
GN002525.1	sp|K1PR70|K1PR70_CRAGI	0.0e+00	2434.1	100.00%	85.17%	WD repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN001087.1	sp|K1RWY5|K1RWY5_CRAGI	1.2e-52	212.6	98.44%	40.94%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN002527.1	sp|K1QBL7|K1QBL7_CRAGI	8.4e-293	1011.1	100.00%	91.71%	RCC1 and BTB domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN002528.1	sp|A7T6V0|A7T6V0_NEMVE	4.0e-20	104.4	70.14%	28.23%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN002530.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	1.6e-69	269.6	78.01%	32.53%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN002531.1	sp|K1P5K7|K1P5K7_CRAGI	7.7e-208	728.8	75.15%	94.02%	Beta-1-syntrophin;OS=Crassostrea;PE=4;SV=1	GO:0016010|GO:0005664|	GO:0005198|	GO:0006260|GO:0050808|
GN002532.1	sp|K1PBQ2|K1PBQ2_CRAGI	6.1e-73	279.3	92.97%	74.27%	Gamma-glutamylcyclotransferase;OS=Crassostrea;PE=4;SV=1	GO:0003839|GO:0016740|
GN002533.1	sp|K1PJ16|K1PJ16_CRAGI	6.4e-83	312.4	100.00%	86.63%	ADP-ribosylation factor-like protein 2-binding protein;OS=Crassostrea;PE=4;SV=1
GN002534.1	sp|K1RRD7|K1RRD7_CRAGI	3.3e-52	211.5	36.41%	69.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001088.1	sp|K1RWY5|K1RWY5_CRAGI	4.7e-89	333.2	96.31%	72.77%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN002537.1	sp|K1PXJ9|K1PXJ9_CRAGI	3.7e-41	175.6	18.99%	56.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN002538.1	sp|K1RLY3|K1RLY3_CRAGI	5.6e-260	902.1	100.00%	83.89%	Inositol-3-phosphate synthase 1-B;OS=Crassostrea;PE=4;SV=1	GO:0004512|	GO:0006021|GO:0008654|
GN002539.1	sp|K1R4W3|K1R4W3_CRAGI	1.5e-123	449.1	96.35%	47.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002540.1	sp|V4AE92|V4AE92_LOTGI	1.5e-104	385.6	95.31%	44.17%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN002541.1	sp|K1QVB2|K1QVB2_CRAGI	0.0e+00	1122.1	41.60%	69.01%	Protein ELYS;OS=Crassostrea;PE=4;SV=1
GN002542.1	sp|K1RH49|K1RH49_CRAGI	2.4e-121	443.0	66.04%	50.81%	Zinc finger CCCH domain-containing protein 18;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN002543.1	sp|K1PIS2|K1PIS2_CRAGI	2.6e-43	181.8	84.01%	38.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002544.1	sp|K1RAW3|K1RAW3_CRAGI	1.3e-205	721.1	100.00%	93.67%	Beta-catenin-like protein 1;OS=Crassostrea;PE=4;SV=1
GN002545.1	sp|K1R4V7|K1R4V7_CRAGI	2.1e-40	170.6	93.65%	72.65%	Chromosome transmission fidelity protein 8-like protein;OS=Crassostrea;PE=4;SV=1	GO:0031390|	GO:0007064|
GN002547.1	sp|K1Q4K9|K1Q4K9_CRAGI	3.2e-160	570.5	83.81%	77.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002548.1	sp|A0A210PE70|A0A210PE70_MIZYE	5.7e-140	503.8	88.43%	46.12%	Eukaryotic translation initiation factor 2-alpha kinase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|GO:0003743|
GN002549.1	sp|K1R0J4|K1R0J4_CRAGI	2.1e-62	245.4	95.72%	43.96%	Putative ribosome-binding factor A, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0006364|
GN002550.1	sp|K1RAV9|K1RAV9_CRAGI	7.1e-262	908.7	77.81%	89.36%	Transcription factor 25;OS=Crassostrea;PE=4;SV=1
GN002551.1	sp|K1R0K6|K1R0K6_CRAGI	0.0e+00	1737.2	64.50%	74.34%	Suppressor of presenilin protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002552.1	sp|A0A210R0Z3|A0A210R0Z3_MIZYE	2.4e-48	197.6	97.87%	55.19%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN002553.1	sp|A0A210R0M0|A0A210R0M0_MIZYE	9.7e-149	531.9	99.13%	73.55%	Cysteine and histidine-rich protein 1-B;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN002554.1	sp|X4YT24|X4YT24_CRAGI	2.5e-133	480.7	92.33%	73.57%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN002555.1	sp|A0A210PE47|A0A210PE47_MIZYE	3.1e-10	70.1	84.47%	48.84%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002556.1	sp|K1S640|K1S640_CRAGI	0.0e+00	1167.1	97.50%	85.22%	Protein flp;OS=Crassostrea;PE=4;SV=1
GN002557.1	sp|R7VED2|R7VED2_CAPTE	3.0e-43	181.0	93.83%	42.98%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN002558.1	sp|K1P976|K1P976_CRAGI	7.6e-27	127.5	39.08%	39.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002559.1	sp|K1R0K8|K1R0K8_CRAGI	0.0e+00	2485.3	100.00%	61.46%	Tudor domain-containing protein 12;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003676|
GN002560.1	sp|K1QS31|K1QS31_CRAGI	6.4e-64	250.4	70.92%	56.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002562.1	sp|K1RMQ6|K1RMQ6_CRAGI	4.6e-187	659.4	99.50%	81.22%	F-box/LRR-repeat protein 8;OS=Crassostrea;PE=4;SV=1
GN002564.1	sp|K1RMQ6|K1RMQ6_CRAGI	4.6e-187	659.4	99.50%	81.22%	F-box/LRR-repeat protein 8;OS=Crassostrea;PE=4;SV=1
GN002566.1	sp|K1P847|K1P847_CRAGI	1.7e-71	274.2	100.00%	88.05%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN001090.1	sp|K1R0I2|K1R0I2_CRAGI	5.3e-266	922.5	83.96%	72.62%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN002569.1	sp|K1QJG3|K1QJG3_CRAGI	1.8e-73	282.7	58.10%	45.58%	Transient receptor potential cation channel subfamily V member 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN002570.1	sp|K1QJG3|K1QJG3_CRAGI	1.4e-62	245.4	96.12%	52.02%	Transient receptor potential cation channel subfamily V member 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN002571.1	sp|K1RCQ3|K1RCQ3_CRAGI	7.1e-283	978.4	99.84%	75.20%	Double-stranded RNA-specific adenosine deaminase;OS=Crassostrea;PE=4;SV=1	GO:0004000|GO:0003723|	GO:0006396|
GN002572.1	sp|K1RNK4|K1RNK4_CRAGI	6.1e-40	169.5	99.40%	48.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002573.1	sp|K1RNK4|K1RNK4_CRAGI	6.1e-40	169.5	99.40%	48.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002574.1	sp|K1PK43|K1PK43_CRAGI	9.3e-10	68.2	67.90%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001091.1	sp|K1RWY5|K1RWY5_CRAGI	8.2e-71	271.9	96.15%	90.00%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN002575.1	sp|W4ZKT7|W4ZKT7_STRPU	1.7e-18	99.8	48.75%	32.48%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN002576.1	sp|W8JCY2|W8JCY2_CRAGI	0.0e+00	2474.5	96.33%	76.72%	Complement component 3;OS=Crassostrea;PE=2;SV=1	GO:0005615|	GO:0004866|
GN002577.1	sp|K1R1N1|K1R1N1_CRAGI	4.8e-98	363.2	100.00%	67.38%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046983|	GO:0006355|
GN002578.1	sp|K1PK49|K1PK49_CRAGI	0.0e+00	1852.0	97.55%	89.28%	Myosin-Ic;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0003779|GO:0005524|GO:0003774|
GN002580.1	sp|K1PRU9|K1PRU9_CRAGI	7.4e-106	389.8	98.38%	57.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002581.1	sp|C3ZK91|C3ZK91_BRAFL	1.1e-79	303.5	71.13%	38.60%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN002582.1	sp|K1PBV0|K1PBV0_CRAGI	8.7e-257	891.3	100.00%	90.61%	UDP-glucose 6-dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0003979|
GN001092.1	sp|A0A210Q6B7|A0A210Q6B7_MIZYE	8.1e-33	146.0	98.94%	45.74%	Transmembrane protein 134;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN002583.1	sp|K1QRB9|K1QRB9_CRAGI	8.9e-20	102.8	94.79%	32.35%	DnaJ-like protein subfamily C member 5;OS=Crassostrea;PE=4;SV=1
GN002584.1	sp|V4BM07|V4BM07_LOTGI	4.3e-45	188.0	68.36%	36.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002585.1	sp|K1PRU9|K1PRU9_CRAGI	1.2e-51	209.1	72.30%	58.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002586.1	sp|A0A210PTQ1|A0A210PTQ1_MIZYE	1.3e-131	474.6	98.32%	93.99%	Protein gustavus;OS=Mizuhopecten;PE=4;SV=1
GN002587.1	sp|K1Q677|K1Q677_CRAGI	0.0e+00	1322.0	100.00%	75.51%	DNA ligase 3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0003910|GO:0008270|	GO:0051103|GO:0006310|
GN002588.1	sp|A0A210PXL5|A0A210PXL5_MIZYE	1.4e-89	335.5	99.16%	50.14%	G-protein coupled receptor B0563.6;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002589.1	sp|K1RBG5|K1RBG5_CRAGI	9.8e-253	877.9	100.00%	91.47%	4-hydroxybutyrate coenzyme A transferase;OS=Crassostrea;PE=4;SV=1	GO:0016740|	GO:0006084|
GN002590.1	sp|A0A1S3KAA9|A0A1S3KAA9_LINUN	8.1e-56	223.4	91.60%	37.29%	uncharacterized protein LOC106180092;OS=Lingula;PE=4;SV=1	GO:0008270|
GN002591.1	sp|K1PK57|K1PK57_CRAGI	0.0e+00	1296.6	99.63%	81.61%	ATP-binding cassette sub-family B member 10, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN002592.1	sp|K1PZA1|K1PZA1_CRAGI	6.6e-97	359.0	100.00%	85.15%	AH receptor-interacting protein;OS=Crassostrea;PE=4;SV=1
GN002593.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	1.9e-19	102.1	85.98%	27.92%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN002594.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	8.5e-109	400.6	81.35%	33.93%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN002595.1	sp|K1Q688|K1Q688_CRAGI	5.8e-40	169.1	86.07%	76.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002596.1	sp|K1QI87|K1QI87_CRAGI	2.2e-09	67.4	74.34%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002598.1	sp|K1RFE9|K1RFE9_CRAGI	6.6e-26	123.2	45.91%	58.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002599.1	sp|K1QS31|K1QS31_CRAGI	3.8e-39	167.9	66.38%	43.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002600.1	sp|K1PRV6|K1PRV6_CRAGI	6.5e-28	129.0	67.23%	80.00%	WD repeat-containing protein 33;OS=Crassostrea;PE=4;SV=1
GN002602.1	sp|K1PRV6|K1PRV6_CRAGI	7.1e-32	141.4	94.03%	100.00%	WD repeat-containing protein 33;OS=Crassostrea;PE=4;SV=1
GN002604.1	sp|K1PZA7|K1PZA7_CRAGI	2.1e-95	354.0	89.34%	97.14%	RNA polymerase II subunit A C-terminal domain phosphatase SSU72;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0004721|	GO:0006397|
GN002605.1	sp|K1QS31|K1QS31_CRAGI	3.4e-38	164.1	100.00%	43.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002607.1	sp|A0A2B4SWT4|A0A2B4SWT4_STYPI	8.9e-16	89.7	82.23%	31.82%	Putative DNA polymerase;OS=Stylophora;PE=4;SV=1	GO:0003677|GO:0003887|GO:0000166|	GO:0006260|
GN002608.1	sp|K1Q688|K1Q688_CRAGI	5.8e-40	169.1	86.07%	76.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002609.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	2.7e-28	132.1	27.21%	55.75%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001095.1	sp|K1RDR5|K1RDR5_CRAGI	0.0e+00	1090.9	41.69%	56.95%	A disintegrin and metalloproteinase with thrombospondin motifs 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN002611.1	sp|A0A1X7THR6|A0A1X7THR6_AMPQE	2.3e-52	212.2	96.44%	31.43%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|
GN002614.1	sp|A0A2B4RG89|A0A2B4RG89_STYPI	1.3e-31	141.7	92.07%	42.67%	Gypsy retrotransposon integrase-like protein 1;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0004803|	GO:0015074|GO:0006313|
GN002616.1	sp|K1R525|K1R525_CRAGI	1.2e-37	161.4	93.55%	60.00%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN002620.1	sp|K1PFY6|K1PFY6_CRAGI	5.1e-25	119.4	81.36%	55.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002621.1	sp|K1R2T4|K1R2T4_CRAGI	2.6e-18	97.4	86.49%	43.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002622.1	sp|K1QHB0|K1QHB0_CRAGI	1.1e-27	128.6	75.64%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001098.1	sp|K1QR55|K1QR55_CRAGI	1.6e-219	767.7	77.99%	90.35%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002626.1	sp|K1RYR2|K1RYR2_CRAGI	4.1e-95	353.6	81.88%	65.43%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN002627.1	sp|K1Q4I6|K1Q4I6_CRAGI	2.6e-24	117.9	58.13%	59.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002628.1	sp|A0A210R2H9|A0A210R2H9_MIZYE	9.5e-37	159.8	80.55%	35.66%	Adenosine receptor A2b;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002629.1	sp|K1R1C5|K1R1C5_CRAGI	3.8e-77	293.1	95.38%	87.80%	Signal recognition particle receptor subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002630.1	sp|K1S1T7|K1S1T7_CRAGI	2.2e-26	125.2	80.28%	32.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002631.1	sp|K1R7T4|K1R7T4_CRAGI	4.3e-63	246.9	98.33%	52.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001099.1	sp|K1R0I9|K1R0I9_CRAGI	4.0e-219	766.1	100.00%	84.60%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN002632.1	sp|A0A210R2H9|A0A210R2H9_MIZYE	1.4e-29	135.6	90.61%	36.68%	Adenosine receptor A2b;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN002633.1	sp|K1R1C5|K1R1C5_CRAGI	2.3e-76	290.4	99.39%	88.82%	Signal recognition particle receptor subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002634.1	sp|K1R7T4|K1R7T4_CRAGI	2.4e-32	143.7	100.00%	69.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002635.1	sp|K1P890|K1P890_CRAGI	7.5e-136	489.2	99.72%	83.61%	Cholecystokinin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002636.1	sp|K1PMU0|K1PMU0_CRAGI	6.1e-53	213.0	100.00%	46.70%	Synaptosomal-associated protein;OS=Crassostrea;PE=3;SV=1	GO:0004222|
GN001100.1	sp|K1R7A4|K1R7A4_CRAGI	8.7e-204	715.3	97.73%	77.00%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN002640.1	sp|K1RC99|K1RC99_CRAGI	5.4e-62	242.7	98.10%	72.73%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN002641.1	sp|K1R5P6|K1R5P6_CRAGI	1.1e-243	847.8	90.76%	86.93%	Protein RCC2;OS=Crassostrea;PE=4;SV=1
GN002642.1	sp|K1QPJ7|K1QPJ7_CRAGI	3.3e-264	916.4	96.21%	70.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001101.1	sp|A0A1S3H322|A0A1S3H322_LINUN	7.2e-150	536.2	92.96%	56.03%	bleomycin hydrolase;OS=Lingula;PE=4;SV=1	GO:0004197|
GN002644.1	sp|K1R645|K1R645_CRAGI	1.2e-16	92.8	84.29%	33.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002647.1	sp|K1QS32|K1QS32_CRAGI	6.8e-35	154.5	29.08%	47.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002647.1	sp|K1QS32|K1QS32_CRAGI	1.4e-16	93.6	14.90%	48.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002648.1	sp|K1QLJ2|K1QLJ2_CRAGI	5.9e-34	150.6	79.04%	34.55%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN002649.1	sp|K1QCH7|K1QCH7_CRAGI	4.5e-55	221.1	83.22%	40.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002650.1	sp|K1RRH1|K1RRH1_CRAGI	0.0e+00	2569.7	92.85%	89.14%	Chromodomain-helicase-DNA-binding protein Mi-2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0004386|GO:0046872|
GN002651.1	sp|K1R776|K1R776_CRAGI	0.0e+00	2845.8	99.91%	66.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002652.1	sp|K1R0T6|K1R0T6_CRAGI	4.2e-136	490.7	80.14%	56.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002653.1	sp|K1QTQ2|K1QTQ2_CRAGI	4.6e-13	79.7	31.97%	100.00%	Retinal homeobox protein Rx;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN001102.1	sp|K1R5R4|K1R5R4_CRAGI	7.9e-75	285.8	82.22%	74.46%	Dynein heavy chain 10, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0015629|GO:0030286|	GO:0003779|GO:0005524|GO:0003777|GO:0003951|	GO:0030042|GO:0007018|
GN002654.1	sp|K1QTQ2|K1QTQ2_CRAGI	7.0e-37	158.7	88.07%	81.05%	Retinal homeobox protein Rx;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN002655.1	sp|K1QJW1|K1QJW1_CRAGI	1.9e-134	485.0	99.17%	62.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002656.1	sp|K1QSW5|K1QSW5_CRAGI	5.1e-238	828.9	100.00%	92.59%	Protein BANP;OS=Crassostrea;PE=4;SV=1
GN002657.1	sp|K1QZW3|K1QZW3_CRAGI	0.0e+00	1630.2	100.00%	70.48%	Zinc finger protein ush;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0001085|	GO:0006357|
GN002658.1	sp|K1R685|K1R685_CRAGI	3.8e-99	367.1	100.00%	66.46%	Zinc transporter ZIP1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN002659.1	sp|K1RQS2|K1RQS2_CRAGI	1.2e-210	738.4	96.92%	68.20%	Bifunctional polynucleotide phosphatase/kinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN002660.1	sp|K1R247|K1R247_CRAGI	0.0e+00	1791.2	93.52%	76.95%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN002661.1	sp|K1QQ21|K1QQ21_CRAGI	2.8e-12	77.0	86.84%	35.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002662.1	sp|K1R247|K1R247_CRAGI	1.8e-21	107.5	89.62%	57.45%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN002663.1	sp|K1R247|K1R247_CRAGI	1.8e-21	107.5	89.62%	57.45%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN002664.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	4.2e-11	72.4	100.00%	48.53%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN002665.1	sp|K1R247|K1R247_CRAGI	5.3e-21	105.9	89.62%	56.38%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN002666.1	sp|K1R247|K1R247_CRAGI	5.5e-97	359.4	100.00%	84.40%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN001103.1	sp|K1R0J8|K1R0J8_CRAGI	1.7e-147	527.7	99.69%	80.00%	Polymerase delta-interacting protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN002667.1	sp|K1PT58|K1PT58_CRAGI	2.8e-39	167.5	91.09%	46.99%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN002668.1	sp|K1PT58|K1PT58_CRAGI	4.1e-40	170.2	96.35%	43.48%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN002669.1	sp|K1QXC3|K1QXC3_CRAGI	6.3e-51	206.1	98.32%	55.11%	Cytochrome P450 1A1;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN002670.1	sp|K1QPG4|K1QPG4_CRAGI	2.3e-138	498.0	89.04%	50.97%	Cytochrome P450 2U1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN002671.1	sp|A0A210QNQ0|A0A210QNQ0_MIZYE	2.1e-38	165.6	81.28%	30.47%	Carbohydrate sulfotransferase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008146|
GN002672.1	sp|K1Q8D1|K1Q8D1_CRAGI	6.9e-286	988.4	95.89%	82.24%	BRCA1-associated protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002673.1	sp|K1RG03|K1RG03_CRAGI	0.0e+00	1437.2	100.00%	63.45%	Eukaryotic translation initiation factor 4E transporter;OS=Crassostrea;PE=4;SV=1	GO:0003743|
GN002674.1	sp|K1QEK7|K1QEK7_CRAGI	0.0e+00	1481.1	99.87%	89.08%	Ubiquitin carboxyl-terminal hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0004843|GO:0008270|	GO:0016579|GO:0006511|
GN002675.1	sp|K1PUD9|K1PUD9_CRAGI	4.0e-80	303.5	100.00%	73.58%	Cell division cycle-associated protein 3;OS=Crassostrea;PE=4;SV=1	GO:0051301|
GN002676.1	sp|A0A210R588|A0A210R588_MIZYE	3.8e-57	227.6	88.62%	46.23%	Peroxisomal membrane protein PEX14;OS=Mizuhopecten;PE=4;SV=1	GO:0005778|	GO:0016560|
GN002677.1	sp|K1RJK1|K1RJK1_CRAGI	2.2e-84	317.4	100.00%	80.00%	DNAation factor subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0006915|
GN002678.1	sp|K1S333|K1S333_CRAGI	0.0e+00	1082.0	95.95%	88.42%	Double C2-like domain-containing protein beta;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016020|	GO:0046872|GO:0017137|	GO:0006886|
GN002679.1	sp|H9LHW6|H9LHW6_CRAAR	5.0e-42	176.4	96.99%	54.37%	X-box binding protein-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN002680.1	sp|Unreviewed|A0A087U9X2_9ARAC	4.4e-12	77.8	35.18%	40.00%	Zinc finger protein with KRAB and SCAN domains 2;OS=Stegodyphus;PE=4;SV=1
GN002681.1	sp|K1RJK6|K1RJK6_CRAGI	4.1e-63	246.9	95.20%	53.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN002682.1	sp|J9Q432|J9Q432_OSTED	6.1e-46	189.9	44.40%	93.14%	Uncharacterized protein;OS=Ostrea;PE=2;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN002683.1	sp|J9Q432|J9Q432_OSTED	4.5e-41	173.7	44.78%	84.31%	Uncharacterized protein;OS=Ostrea;PE=2;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN002684.1	sp|A0A210R559|A0A210R559_MIZYE	1.1e-43	182.2	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002685.1	sp|A0A3L8DL29|A0A3L8DL29_OOCBI	2.1e-18	97.4	99.15%	43.97%	Uncharacterized protein;OS=Ooceraea;PE=4;SV=1
GN002687.1	sp|K1RDP6|K1RDP6_CRAGI	2.8e-44	184.1	96.45%	45.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002688.1	sp|A0A210PT16|A0A210PT16_MIZYE	3.5e-243	846.3	100.00%	78.20%	Tubulin polyglutamylase TTLL9;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|	GO:0006464|
GN001104.1	sp|K1PAB1|K1PAB1_CRAGI	7.0e-20	103.2	33.94%	67.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001105.1	sp|K1S1K6|K1S1K6_CRAGI	5.3e-80	303.5	96.32%	46.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002689.1	sp|K1RGY4|K1RGY4_CRAGI	1.3e-34	152.5	64.03%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002690.1	sp|K1QX46|K1QX46_CRAGI	2.4e-23	114.0	76.69%	56.44%	Solute carrier family 2, facilitated glucose transporter member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004222|GO:0022857|GO:0008270|	GO:0008643|
GN002691.1	sp|K1QBP6|K1QBP6_CRAGI	2.1e-202	710.7	99.38%	77.15%	Ileal sodium/bile acid cotransporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002692.1	sp|K1RIA6|K1RIA6_CRAGI	0.0e+00	2213.3	100.00%	79.20%	Protein hedgehog;OS=Crassostrea;PE=4;SV=1	GO:0007267|
GN002693.1	sp|K1QYH7|K1QYH7_CRAGI	9.6e-53	212.2	77.55%	71.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002694.1	sp|K1QYH7|K1QYH7_CRAGI	0.0e+00	1234.6	99.48%	79.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002695.1	sp|K1QAX7|K1QAX7_CRAGI	1.9e-69	268.9	41.09%	70.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002698.1	sp|K1Q4T6|K1Q4T6_CRAGI	8.8e-23	112.8	67.74%	47.13%	Plexin-A2;OS=Crassostrea;PE=4;SV=1	GO:0017154|
GN002699.1	sp|A0A210QD89|A0A210QD89_MIZYE	2.3e-298	1030.4	98.66%	64.12%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002700.1	sp|K1PI41|K1PI41_CRAGI	1.2e-179	634.8	92.04%	94.51%	Flap endonuclease 1;OS=Crassostrea;PE=3;SV=1	GO:0005739|GO:0005730|GO:0005654|	GO:0008409|GO:0017108|GO:0003677|GO:0000287|	GO:0006284|GO:0006260|GO:0043137|
GN002701.1	sp|K1PXR2|K1PXR2_CRAGI	3.3e-188	663.3	100.00%	88.29%	Serine/threonine-protein kinase H1-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN002702.1	sp|K1PXR2|K1PXR2_CRAGI	3.9e-142	510.0	89.44%	85.20%	Serine/threonine-protein kinase H1-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN002703.1	sp|K1PXR2|K1PXR2_CRAGI	1.4e-22	110.9	100.00%	93.33%	Serine/threonine-protein kinase H1-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN001108.1	sp|K1QQ85|K1QQ85_CRAGI	5.4e-149	533.1	92.79%	78.45%	Cholecystokinin receptor type A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002704.1	sp|K1RDQ4|K1RDQ4_CRAGI	2.6e-210	736.9	100.00%	84.10%	Small conductance calcium-activated potassium channel protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005516|GO:0016286|
GN002705.1	sp|K1Q6C9|K1Q6C9_CRAGI	0.0e+00	1338.2	100.00%	83.81%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN002706.1	sp|K1QIQ8|K1QIQ8_CRAGI	2.1e-142	511.5	89.26%	55.33%	F-box only protein 30;OS=Crassostrea;PE=4;SV=1	GO:0061630|GO:0008270|
GN002707.1	sp|K1QE57|K1QE57_CRAGI	0.0e+00	1176.4	100.00%	79.97%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN002708.1	sp|K1QMD1|K1QMD1_CRAGI	9.3e-305	1051.2	98.81%	74.56%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|GO:0046872|GO:0016491|	GO:0006030|
GN001109.1	sp|A0A210QB58|A0A210QB58_MIZYE	7.5e-27	126.3	50.47%	57.55%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN002715.1	sp|A0A2B4R3C4|A0A2B4R3C4_STYPI	1.9e-68	265.0	92.93%	49.82%	Tetratricopeptide repeat protein 38;OS=Stylophora;PE=4;SV=1	GO:0008270|
GN002717.1	sp|K1QTE5|K1QTE5_CRAGI	2.1e-44	183.7	98.20%	76.85%	Apolipoprotein D;OS=Crassostrea;PE=3;SV=1	GO:0008289|	GO:0007568|GO:0006869|
GN002719.1	sp|K1QTE5|K1QTE5_CRAGI	6.0e-89	332.4	100.00%	84.62%	Apolipoprotein D;OS=Crassostrea;PE=3;SV=1	GO:0008289|	GO:0007568|GO:0006869|
GN001110.1	sp|A0A1W5BJ07|A0A1W5BJ07_CIOIN	3.5e-47	193.7	98.46%	47.94%	uncharacterized protein LOC108950671;OS=Ciona;PE=4;SV=1	GO:0008270|
GN002721.1	sp|K1QTE5|K1QTE5_CRAGI	2.9e-44	183.3	90.83%	78.70%	Apolipoprotein D;OS=Crassostrea;PE=3;SV=1	GO:0008289|	GO:0007568|GO:0006869|
GN002723.1	sp|K1RDQ9|K1RDQ9_CRAGI	2.6e-53	213.4	100.00%	83.05%	Apolipoprotein D;OS=Crassostrea;PE=3;SV=1	GO:0008289|	GO:0007568|GO:0006869|
GN002724.1	sp|K1Q6D2|K1Q6D2_CRAGI	2.5e-214	750.0	100.00%	92.23%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN002725.1	sp|K1S066|K1S066_CRAGI	2.8e-35	155.2	36.69%	58.45%	ATP-binding cassette sub-family A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN002726.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	2445.2	64.43%	65.09%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN002727.1	sp|K1Q534|K1Q534_CRAGI	6.0e-16	89.7	82.82%	34.21%	Starch-binding domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:2001070|
GN002728.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	2427.1	77.34%	60.32%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN002730.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	2278.4	82.21%	70.82%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN002732.1	sp|A0A210R0T2|A0A210R0T2_MIZYE	4.4e-154	550.1	93.65%	65.38%	G1/S-specific cyclin-E;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|
GN002733.1	sp|K1QDZ8|K1QDZ8_CRAGI	7.9e-57	226.9	45.61%	62.37%	Uncharacterized protein F13E9.13, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN002734.1	sp|A0A210QMC2|A0A210QMC2_MIZYE	2.2e-39	167.2	93.39%	63.39%	Guanine nucleotide exchange factor MSS4;OS=Mizuhopecten;PE=4;SV=1	GO:0005085|	GO:0007264|
GN002735.1	sp|K1PDV0|K1PDV0_CRAGI	2.2e-223	780.4	100.00%	75.96%	DNA ligase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003910|	GO:0051103|GO:0006310|
GN002736.1	sp|K1P7R7|K1P7R7_CRAGI	8.0e-204	715.3	86.52%	89.58%	Glycosylphosphatidylinositol anchor attachment 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0042765|
GN002737.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	4.6e-89	334.0	95.12%	42.56%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN002738.1	sp|K1QDZ5|K1QDZ5_CRAGI	5.0e-147	526.2	100.00%	76.76%	Cytochrome c1, heme protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0009055|GO:0020037|GO:0046872|
GN002739.1	sp|K1PTI6|K1PTI6_CRAGI	5.6e-256	888.6	99.58%	89.03%	Glucose-6-phosphate isomerase;OS=Crassostrea;PE=3;SV=1	GO:0004347|	GO:0006094|GO:0006096|
GN002740.1	sp|K1QDY9|K1QDY9_CRAGI	2.5e-226	790.4	96.61%	77.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002741.1	sp|K1PTI3|K1PTI3_CRAGI	8.6e-76	288.9	73.91%	84.87%	Glucose-fructose oxidoreductase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN002742.1	sp|K1QWT8|K1QWT8_CRAGI	2.4e-31	142.1	53.32%	40.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002743.1	sp|K1QWT8|K1QWT8_CRAGI	2.4e-31	142.1	53.32%	40.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001111.1	sp|V4AU73|V4AU73_LOTGI	5.0e-32	144.4	36.18%	44.44%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004842|
GN002744.1	sp|A0A210PT23|A0A210PT23_MIZYE	1.1e-124	451.8	100.00%	72.82%	Glucose-fructose oxidoreductase domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN002745.1	sp|A0A3M6U6Z7|A0A3M6U6Z7_9CNID	6.3e-49	199.5	95.31%	51.10%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN002746.1	sp|K1PZZ8|K1PZZ8_CRAGI	3.9e-174	616.7	69.32%	92.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002747.1	sp|K1Q7I9|K1Q7I9_CRAGI	5.4e-50	202.6	94.20%	72.73%	Metallophosphoesterase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|	GO:0006506|
GN002748.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	1807.3	96.04%	53.16%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN002750.1	sp|K1Q041|K1Q041_CRAGI	6.9e-59	233.0	92.97%	51.26%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN002751.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	2.9e-87	328.2	96.98%	36.81%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN002752.1	sp|V3YXA0|V3YXA0_LOTGI	4.3e-104	383.6	98.26%	51.88%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001112.1	sp|A0A2B4R6Y7|A0A2B4R6Y7_STYPI	1.2e-31	142.5	78.54%	36.84%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN002753.1	sp|K1QF17|K1QF17_CRAGI	3.3e-12	78.2	90.51%	27.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002754.1	sp|K1R602|K1R602_CRAGI	1.1e-20	105.1	89.68%	45.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002755.1	sp|K1R8V8|K1R8V8_CRAGI	6.5e-259	898.7	100.00%	75.69%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN002756.1	sp|K1Q637|K1Q637_CRAGI	1.5e-52	212.2	88.14%	43.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002757.1	sp|K1RFS0|K1RFS0_CRAGI	7.1e-206	722.2	97.33%	68.50%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN002758.1	sp|A0A3M6THP8|A0A3M6THP8_9CNID	1.3e-166	591.3	100.00%	83.58%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN002759.1	sp|K1R7M8|K1R7M8_CRAGI	3.1e-97	360.1	99.52%	76.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002760.1	sp|K1RU89|K1RU89_CRAGI	1.0e-274	951.0	98.10%	91.86%	Synaptic vesicle 2-related protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN002761.1	sp|A0A2C9KZ92|A0A2C9KZ92_BIOGL	3.3e-28	131.3	97.67%	53.36%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN001114.1	sp|A0A210PDC7|A0A210PDC7_MIZYE	4.0e-43	180.6	91.70%	37.23%	Master replication protein;OS=Mizuhopecten;PE=4;SV=1
GN002762.1	sp|K1RAG9|K1RAG9_CRAGI	1.6e-38	166.0	94.32%	37.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002763.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	1.8e-29	134.8	87.91%	42.86%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN002764.1	sp|K1R3Z8|K1R3Z8_CRAGI	1.1e-106	391.7	88.40%	86.82%	Chloride intracellular channel protein 6;OS=Crassostrea;PE=4;SV=1
GN002765.1	sp|K1QX15|K1QX15_CRAGI	1.0e-58	232.3	60.44%	86.67%	Transcription initiation factor TFIID subunit 10;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003743|	GO:0006352|
GN002766.1	sp|A0A1S3K8F2|A0A1S3K8F2_LINUN	4.1e-51	208.4	63.49%	34.67%	G-protein coupled receptor 161-like;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002767.1	sp|K1QN14|K1QN14_CRAGI	1.9e-66	257.3	93.71%	90.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002768.1	sp|K1PHB3|K1PHB3_CRAGI	1.7e-30	139.8	96.03%	30.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002769.1	sp|K1RAG6|K1RAG6_CRAGI	0.0e+00	1085.9	100.00%	72.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002770.1	sp|K1R3Z4|K1R3Z4_CRAGI	0.0e+00	2513.8	100.00%	69.79%	5'-3' exoribonuclease 1;OS=Crassostrea;PE=4;SV=1	GO:0004527|GO:0003676|
GN001115.1	sp|K1QNY3|K1QNY3_CRAGI	9.8e-111	406.4	99.28%	46.21%	BEN domain-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN002771.1	sp|K1QX12|K1QX12_CRAGI	9.6e-165	585.1	98.55%	81.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002773.1	sp|K1QN08|K1QN08_CRAGI	3.4e-40	169.9	75.00%	84.62%	Methylenetetrahydrofolate reductase;OS=Crassostrea;PE=3;SV=1	GO:0004489|	GO:0006555|GO:0035999|
GN002774.1	sp|K1RU83|K1RU83_CRAGI	0.0e+00	1098.2	100.00%	75.37%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0004553|	GO:0005975|
GN002775.1	sp|K1RAG0|K1RAG0_CRAGI	3.8e-136	490.0	99.04%	78.71%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN002776.1	sp|K1R593|K1R593_CRAGI	1.1e-119	435.3	98.75%	67.40%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN002777.1	sp|K1QGZ7|K1QGZ7_CRAGI	6.2e-137	492.7	83.54%	84.98%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN002780.1	sp|K1QAG5|K1QAG5_CRAGI	3.4e-28	130.2	74.82%	59.62%	Signal peptide, CUB and EGF-like domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002781.1	sp|A0A2B4S664|A0A2B4S664_STYPI	2.1e-13	82.4	83.43%	26.38%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN001117.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	1.8e-19	101.3	65.54%	45.83%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN002784.1	sp|K1QAG7|K1QAG7_CRAGI	9.8e-229	798.1	99.36%	75.80%	Phosphatidylinositide phosphatase SAC1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0042578|
GN002785.1	sp|K1RHL5|K1RHL5_CRAGI	7.3e-78	295.4	97.58%	86.88%	Mpv17-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN002786.1	sp|K1QXI2|K1QXI2_CRAGI	5.7e-256	889.0	82.32%	89.40%	Sodium/hydrogen exchanger;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015385|	GO:0006885|
GN002787.1	sp|A0A210R0T8|A0A210R0T8_MIZYE	6.8e-195	686.0	99.83%	57.53%	Endonuclease/exonuclease/phosphatase family domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|GO:0004519|GO:0004527|	GO:0006281|
GN002788.1	sp|K1QNG5|K1QNG5_CRAGI	1.0e-66	259.6	97.61%	37.93%	Cholecystokinin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002789.1	sp|Q2MCN4|Q2MCN4_HYDVU	0.0e+00	1862.0	88.45%	44.61%	HyTSR1 protein;OS=Hydra;PE=2;SV=3
GN001118.1	sp|A0A2G8LDZ4|A0A2G8LDZ4_STIJA	1.1e-18	99.0	94.48%	32.57%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN002791.1	sp|K1R1Y2|K1R1Y2_CRAGI	3.8e-110	403.7	99.09%	68.20%	Dysbindin;OS=Crassostrea;PE=4;SV=1	GO:0005737|
GN002793.1	sp|K1QVB9|K1QVB9_CRAGI	1.2e-122	444.9	99.61%	81.10%	Proteasome assembly chaperone 2;OS=Crassostrea;PE=4;SV=1	GO:0000502|
GN002794.1	sp|K1Q9J5|K1Q9J5_CRAGI	0.0e+00	1712.2	96.23%	85.63%	Importin-4;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0008536|	GO:0006606|
GN002795.1	sp|A0A210PEB1|A0A210PEB1_MIZYE	3.2e-68	264.2	100.00%	47.30%	Gamma-soluble NSF attachment protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005623|	GO:0006886|
GN002796.1	sp|K1QUX6|K1QUX6_CRAGI	1.0e-238	831.2	100.00%	87.45%	4-hydroxybutyrate coenzyme A transferase;OS=Crassostrea;PE=4;SV=1	GO:0016740|	GO:0006084|
GN002797.1	sp|K1PPW8|K1PPW8_CRAGI	1.3e-80	305.4	88.10%	53.28%	Coatomer subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0030117|	GO:0005198|	GO:0006886|GO:0016192|
GN002798.1	sp|A0A226D3L7|A0A226D3L7_FOLCA	3.0e-38	164.5	81.78%	40.28%	Putative nuclease HARBI1;OS=Folsomia;PE=4;SV=1
GN002799.1	sp|A0A2R2MN13|A0A2R2MN13_LINUN	4.9e-69	266.9	98.96%	46.08%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN002800.1	sp|V4ARM3|V4ARM3_LOTGI	7.6e-12	76.3	50.56%	45.56%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002801.1	sp|K1PVV3|K1PVV3_CRAGI	2.1e-104	386.0	57.21%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002802.1	sp|A0A2B4RZW9|A0A2B4RZW9_STYPI	8.8e-16	89.4	63.19%	32.46%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0008270|
GN002803.1	sp|K1RUD6|K1RUD6_CRAGI	2.0e-83	314.3	85.20%	80.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0002218|GO:0032481|
GN001120.1	sp|A0A1S3H0I4|A0A1S3H0I4_LINUN	2.1e-66	257.7	98.07%	58.13%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN002806.1	sp|K1Q4L2|K1Q4L2_CRAGI	1.8e-107	394.0	100.00%	90.26%	Hyaluronidase;OS=Crassostrea;PE=3;SV=1	GO:0004415|	GO:0005975|
GN002807.1	sp|K1QC31|K1QC31_CRAGI	2.7e-84	317.0	95.85%	90.76%	Aquaporin-4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN002808.1	sp|K1QK20|K1QK20_CRAGI	4.3e-73	279.6	86.13%	93.92%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN000945.1	sp|K1PEP3|K1PEP3_CRAGI	9.3e-25	118.6	80.16%	53.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002811.1	sp|K1P6P1|K1P6P1_CRAGI	1.4e-70	272.3	87.99%	48.38%	Amidase;OS=Crassostrea;PE=4;SV=1	GO:0004040|
GN002812.1	sp|K1QC11|K1QC11_CRAGI	0.0e+00	1386.3	100.00%	84.35%	AP-1 complex subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0030121|	GO:0006886|GO:0016192|
GN002813.1	sp|K1Q498|K1Q498_CRAGI	0.0e+00	1104.4	99.88%	72.79%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN002814.1	sp|K1PWH1|K1PWH1_CRAGI	8.0e-68	261.9	100.00%	80.27%	Placental protein 11;OS=Crassostrea;PE=4;SV=1	GO:0004521|
GN002815.1	sp|K1R481|K1R481_CRAGI	3.1e-83	313.5	95.94%	74.47%	Epimerase family protein SDR39U1;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN002816.1	sp|K1R481|K1R481_CRAGI	2.2e-65	255.4	41.47%	70.43%	Epimerase family protein SDR39U1;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN002817.1	sp|K1QIH5|K1QIH5_CRAGI	4.3e-37	164.1	89.00%	26.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN002818.1	sp|K1QC09|K1QC09_CRAGI	4.2e-151	540.0	87.04%	74.37%	GPI mannosyltransferase 1;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0016758|	GO:0006506|
GN002819.1	sp|K1QYT3|K1QYT3_CRAGI	2.1e-60	237.7	67.89%	86.72%	28S ribosomal protein S17, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005763|	GO:0003735|	GO:0006412|
GN002820.1	sp|K1S426|K1S426_CRAGI	6.5e-17	92.0	67.05%	84.48%	Charged multivesicular body protein 1a;OS=Crassostrea;PE=3;SV=1	GO:0007034|
GN002821.1	sp|A0A210QUY0|A0A210QUY0_MIZYE	1.6e-80	305.4	99.73%	74.66%	Ankyrin repeat protein;OS=Mizuhopecten;PE=4;SV=1	GO:0035556|
GN002822.1	sp|K1S422|K1S422_CRAGI	1.2e-197	695.7	82.25%	86.15%	Katanin p80 WD40 repeat-containing subunit B1;OS=Crassostrea;PE=3;SV=1	GO:0005813|GO:0008352|GO:0005874|GO:0000922|	GO:0008017|	GO:0007049|GO:0051301|GO:0051013|
GN002823.1	sp|K1RKL6|K1RKL6_CRAGI	5.5e-111	406.4	100.00%	63.55%	Serine/threonine-protein kinase Nek6;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN002824.1	sp|A0A076VA15|A0A076VA15_MYTED	2.6e-45	186.8	88.79%	85.29%	DNA-directed RNA polymerase II polypeptide C;OS=Mytilus;PE=2;SV=1	GO:0003677|GO:0003899|GO:0046983|	GO:0006351|
GN001123.1	sp|W4XJS0|W4XJS0_STRPU	2.0e-66	258.8	69.23%	42.90%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN002825.1	sp|K1REH8|K1REH8_CRAGI	8.3e-125	453.0	57.94%	81.85%	Regulation of nuclear pre-mRNA domain-containing protein 1B;OS=Crassostrea;PE=4;SV=1
GN002827.1	sp|K1REH7|K1REH7_CRAGI	2.9e-127	460.3	98.57%	76.36%	Cytochrome b5 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN002828.1	sp|K1R8Q7|K1R8Q7_CRAGI	8.3e-47	194.9	11.55%	77.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002828.1	sp|K1R8Q7|K1R8Q7_CRAGI	6.6e-12	79.0	5.87%	57.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002829.1	sp|K1QYS3|K1QYS3_CRAGI	6.3e-119	432.6	100.00%	84.50%	Voltage-gated hydrogen channel 1;OS=Crassostrea;PE=4;SV=1	GO:0005887|	GO:0030171|
GN002830.1	sp|K1S411|K1S411_CRAGI	0.0e+00	3778.8	99.21%	77.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0051298|GO:0090222|GO:0071539|
GN002831.1	sp|K1RKK3|K1RKK3_CRAGI	0.0e+00	1703.0	100.00%	78.66%	Myotubularin-related protein 4;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004725|
GN002832.1	sp|K1PYC2|K1PYC2_CRAGI	2.4e-23	114.8	52.44%	45.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002833.1	sp|K1QS32|K1QS32_CRAGI	1.6e-39	169.9	34.43%	28.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002834.1	sp|K1Q0U9|K1Q0U9_CRAGI	1.5e-26	125.6	50.41%	53.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002836.1	sp|K1RE99|K1RE99_CRAGI	9.4e-46	189.5	44.93%	71.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN002840.1	sp|V4A1F7|V4A1F7_LOTGI	2.4e-28	131.7	95.36%	32.72%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002842.1	sp|K1QYS1|K1QYS1_CRAGI	0.0e+00	1680.2	99.89%	87.81%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN002843.1	sp|V4AE92|V4AE92_LOTGI	1.5e-75	289.3	73.97%	45.01%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN002844.1	sp|K1QYR6|K1QYR6_CRAGI	2.1e-264	917.1	100.00%	62.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002845.1	sp|K1REG7|K1REG7_CRAGI	1.4e-151	541.6	97.93%	75.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN002846.1	sp|K1REG7|K1REG7_CRAGI	1.4e-151	541.6	97.93%	75.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN002847.1	sp|A0A1S3IU22|A0A1S3IU22_LINUN	3.8e-16	90.5	93.26%	31.40%	uncharacterized protein LOC106167464;OS=Lingula;PE=4;SV=1
GN002848.1	sp|K1QBX2|K1QBX2_CRAGI	8.6e-182	642.1	75.17%	92.84%	2-(3-amino-3-carboxypropyl)histidine synthase subunit 1;OS=Crassostrea;PE=3;SV=1	GO:0016740|	GO:0017183|
GN002849.1	sp|K1PRE7|K1PRE7_CRAGI	0.0e+00	1483.0	100.00%	90.11%	Tuftelin-interacting protein 11;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN002850.1	sp|K1PJ87|K1PJ87_CRAGI	0.0e+00	1683.3	100.00%	87.70%	Calsyntenin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007156|
GN002852.1	sp|K1QWT8|K1QWT8_CRAGI	1.6e-30	138.7	88.09%	38.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002854.1	sp|K1RGD1|K1RGD1_CRAGI	1.3e-277	960.7	100.00%	81.95%	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003842|GO:0016620|	GO:0010133|
GN002855.1	sp|A0A210PKZ7|A0A210PKZ7_MIZYE	1.7e-36	158.3	85.22%	46.24%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002856.1	sp|K1RKI7|K1RKI7_CRAGI	4.6e-92	342.8	97.92%	93.58%	Pre-mRNA-splicing factor SPF27;OS=Crassostrea;PE=4;SV=1	GO:0006397|
GN002857.1	sp|K1S3Z7|K1S3Z7_CRAGI	0.0e+00	1115.9	100.00%	93.11%	Gametogenetin-binding protein 2;OS=Crassostrea;PE=4;SV=1
GN002858.1	sp|A0A2B4RF51|A0A2B4RF51_STYPI	3.1e-32	144.4	89.16%	36.94%	Zinc finger BED domain-containing protein 1;OS=Stylophora;PE=4;SV=1	GO:0003677|GO:0046983|
GN002859.1	sp|K1QWT8|K1QWT8_CRAGI	1.8e-32	146.0	47.97%	41.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002860.1	sp|K1PJA2|K1PJA2_CRAGI	7.8e-178	629.0	72.84%	92.58%	Cyclin-L1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0000079|GO:0006355|GO:0006396|
GN002861.1	sp|K1PRG1|K1PRG1_CRAGI	7.1e-133	479.2	99.09%	78.53%	45 kDa calcium-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN002862.1	sp|K1QS81|K1QS81_CRAGI	0.0e+00	2034.2	100.00%	94.22%	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit;OS=Crassostrea;PE=3;SV=1	GO:0016303|GO:0005524|GO:0046934|	GO:0048015|
GN002863.1	sp|K1RXN7|K1RXN7_CRAGI	2.3e-189	668.3	77.44%	63.80%	Zinc finger matrin-type protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN002864.1	sp|R7UCN5|R7UCN5_CAPTE	5.0e-13	80.5	57.59%	35.61%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN002865.1	sp|K1R8Z3|K1R8Z3_CRAGI	1.6e-21	107.5	100.00%	50.55%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN002866.1	sp|K1R8Z3|K1R8Z3_CRAGI	1.8e-241	840.9	98.72%	64.90%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN002867.1	sp|K1RRD7|K1RRD7_CRAGI	8.2e-13	80.1	20.28%	64.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002870.1	sp|K1RA17|K1RA17_CRAGI	1.9e-18	96.7	77.78%	91.67%	Tetraspanin-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN002871.1	sp|K1QZQ2|K1QZQ2_CRAGI	6.3e-185	652.5	94.59%	72.04%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 6;OS=Crassostrea;PE=4;SV=1	GO:0005886|	GO:0047390|
GN001128.1	sp|K1QMR7|K1QMR7_CRAGI	5.0e-27	125.6	96.39%	68.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002872.1	sp|V4B9H4|V4B9H4_LOTGI	2.4e-20	104.4	72.62%	43.80%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002873.1	sp|W4XJS0|W4XJS0_STRPU	3.8e-42	176.8	92.07%	55.92%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN002874.1	sp|K1PE19|K1PE19_CRAGI	1.0e-52	212.2	96.08%	51.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002875.1	sp|K1Q136|K1Q136_CRAGI	2.1e-09	68.2	33.70%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002876.1	sp|K1S5B1|K1S5B1_CRAGI	8.1e-110	402.5	86.03%	71.11%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 6;OS=Crassostrea;PE=4;SV=1	GO:0005886|	GO:0047390|
GN002876.1	sp|K1S5B1|K1S5B1_CRAGI	1.8e-40	172.2	28.89%	78.89%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 6;OS=Crassostrea;PE=4;SV=1	GO:0005886|	GO:0047390|
GN002877.1	sp|A0A210QNF7|A0A210QNF7_MIZYE	4.3e-169	600.1	100.00%	56.87%	Solute carrier family 13 member 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN002878.1	sp|K1RQR9|K1RQR9_CRAGI	2.0e-27	129.4	20.13%	61.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002879.1	sp|A0A2B4STZ7|A0A2B4STZ7_STYPI	2.1e-45	188.3	67.40%	50.82%	Toxin PsTX-60B;OS=Stylophora;PE=4;SV=1
GN002881.1	sp|K1Q099|K1Q099_CRAGI	7.4e-98	362.8	87.50%	59.72%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN002882.1	sp|K1QLK4|K1QLK4_CRAGI	3.0e-22	109.8	94.19%	58.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002883.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN002884.1	sp|K1QLD6|K1QLD6_CRAGI	5.4e-34	151.0	28.18%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002885.1	sp|A0A2B4RIG1|A0A2B4RIG1_STYPI	1.3e-116	426.4	82.66%	36.83%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN002886.1	sp|K1PCE3|K1PCE3_CRAGI	6.1e-68	262.3	100.00%	84.93%	TNF receptor-associated factor 3;OS=Crassostrea;PE=4;SV=1
GN002888.1	sp|K1QQB7|K1QQB7_CRAGI	2.1e-179	634.0	99.75%	80.90%	FMRFamide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002889.1	sp|K1PI67|K1PI67_CRAGI	1.4e-66	257.7	97.89%	86.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002890.1	sp|K1Q5Y4|K1Q5Y4_CRAGI	3.9e-50	203.4	75.88%	89.06%	Small nuclear ribonucleoprotein-associated protein B;OS=Crassostrea;PE=4;SV=1	GO:0019013|
GN002892.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	4.7e-18	97.8	36.18%	37.30%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN002893.1	sp|K1QQR5|K1QQR5_CRAGI	9.8e-11	74.3	9.64%	68.97%	Centromere protein T;OS=Crassostrea;PE=4;SV=1	GO:0000776|GO:0005634|	GO:0003677|GO:0046872|GO:0046982|	GO:0051382|
GN002894.1	sp|K1PMG4|K1PMG4_CRAGI	1.1e-15	87.8	74.07%	72.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN002895.1	sp|K1QJ51|K1QJ51_CRAGI	3.8e-295	1019.2	97.43%	77.55%	Proteasome subunit beta type-8;OS=Crassostrea;PE=4;SV=1	GO:0005839|	GO:0004298|GO:0008270|	GO:0051603|
GN002896.1	sp|A0A210PWG1|A0A210PWG1_MIZYE	1.0e-67	262.7	82.97%	50.19%	NADH dehydrogenase (Ubiquinone) complex I, assembly factor 6;OS=Mizuhopecten;PE=4;SV=1
GN002898.1	sp|K1RGG2|K1RGG2_CRAGI	6.2e-44	183.7	27.79%	85.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002899.1	sp|A0A210QXM5|A0A210QXM5_MIZYE	0.0e+00	1223.0	99.11%	63.74%	Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN002900.1	sp|K1R752|K1R752_CRAGI	8.7e-203	711.8	99.77%	80.23%	E3 ubiquitin-protein ligase MYLIP;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0016874|
GN002901.1	sp|K1R0S1|K1R0S1_CRAGI	1.9e-174	617.8	100.00%	98.97%	Growth arrest-specific protein 8;OS=Crassostrea;PE=4;SV=1	GO:0031514|	GO:0008017|GO:0017137|	GO:0048870|
GN002902.1	sp|K1QTN2|K1QTN2_CRAGI	1.6e-191	674.5	98.88%	72.36%	Steroid 17-alpha-hydroxylase/17,20 lyase;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0016829|GO:0004497|GO:0016705|
GN002903.1	sp|K1RRE8|K1RRE8_CRAGI	5.6e-17	94.4	96.26%	27.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002904.1	sp|K1R742|K1R742_CRAGI	1.1e-129	468.4	100.00%	85.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN002905.1	sp|K1PEV9|K1PEV9_CRAGI	8.4e-93	345.5	92.89%	85.58%	2,4-dienoyl-CoA reductase, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN002906.1	sp|K1PA33|K1PA33_CRAGI	9.5e-201	705.7	86.57%	62.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002907.1	sp|K1PG91|K1PG91_CRAGI	9.0e-233	811.6	100.00%	81.84%	Alkaline phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0004035|
GN002908.1	sp|H6BD26|H6BD26_OSTED	1.2e-58	231.9	57.50%	96.49%	Endonuclease/reverse transcriptase;OS=Ostrea;PE=2;SV=1	GO:0004519|GO:0003964|
GN002909.1	sp|W4XYW4|W4XYW4_STRPU	8.0e-117	426.0	92.93%	55.23%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0016021|	GO:0008422|	GO:0005975|
GN002910.1	sp|A0A2T7PCL9|A0A2T7PCL9_POMCA	3.5e-133	481.5	99.12%	31.30%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0004553|	GO:0005975|
GN002911.1	sp|A0A2C9JIJ8|A0A2C9JIJ8_BIOGL	4.1e-64	250.0	86.46%	64.46%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0004553|	GO:0005975|
GN002912.1	sp|A0A210QWH6|A0A210QWH6_MIZYE	1.5e-18	97.8	92.98%	44.44%	Lactase-phlorizin hydrolase;OS=Mizuhopecten;PE=4;SV=1	GO:0004553|	GO:0005975|
GN001132.1	sp|K1R9M2|K1R9M2_CRAGI	0.0e+00	1835.8	100.00%	92.28%	Integrator complex subunit 8;OS=Crassostrea;PE=4;SV=1	GO:0034472|
GN002913.1	sp|A0A1S3I117|A0A1S3I117_LINUN	1.8e-51	208.8	94.15%	30.47%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN002915.1	sp|K1Q4A7|K1Q4A7_CRAGI	7.3e-54	217.2	97.48%	34.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002916.1	sp|K1PPX7|K1PPX7_CRAGI	2.6e-78	297.4	98.21%	61.99%	Thiopurine S-methyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0008119|
GN002917.1	sp|K1QQB7|K1QQB7_CRAGI	2.1e-179	634.0	99.75%	80.90%	FMRFamide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN002919.1	sp|K1R754|K1R754_CRAGI	3.9e-198	696.0	100.00%	95.94%	Arylacetamide deacetylase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0052689|
GN002920.1	sp|K1QXI3|K1QXI3_CRAGI	7.6e-248	861.7	100.00%	84.22%	Cytochrome P450 2J6;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN002921.1	sp|K1P1T5|K1P1T5_CRAGI	6.1e-51	207.6	28.01%	70.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001133.1	sp|K1Q9Q6|K1Q9Q6_CRAGI	2.5e-173	614.0	85.62%	78.28%	Synaptic vesicle membrane protein VAT-1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN002923.1	sp|K1S2P6|K1S2P6_CRAGI	4.8e-109	399.4	100.00%	85.14%	Glutathione peroxidase;OS=Crassostrea;PE=3;SV=1	GO:0004602|	GO:0006979|
GN002924.1	sp|K1RJ18|K1RJ18_CRAGI	1.2e-120	438.3	92.04%	79.25%	Alpha-amylase;OS=Crassostrea;PE=3;SV=1	GO:0004556|GO:0103025|GO:0043169|GO:0004602|	GO:0005975|GO:0006979|
GN002926.1	sp|K1RD51|K1RD51_CRAGI	1.1e-106	391.7	95.28%	83.71%	U8 snoRNA-decapping enzyme;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN002927.1	sp|K1S2P4|K1S2P4_CRAGI	1.4e-88	331.6	91.94%	71.93%	Protein CASP;OS=Crassostrea;PE=3;SV=1	GO:0030173|	GO:0006891|
GN002931.1	sp|K1R8C0|K1R8C0_CRAGI	1.5e-43	183.0	98.91%	28.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002932.1	sp|K1R8C0|K1R8C0_CRAGI	3.4e-127	460.7	91.67%	60.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002933.1	sp|A0A2R2MQ64|A0A2R2MQ64_LINUN	7.1e-25	119.8	91.08%	37.75%	uncharacterized protein LOC112042203;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001134.1	sp|A0A210R5Y9|A0A210R5Y9_MIZYE	0.0e+00	1225.3	99.89%	39.14%	Macrophage mannose receptor 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0030246|
GN002935.1	sp|K1R1B6|K1R1B6_CRAGI	6.9e-296	1021.5	100.00%	81.99%	D-glucuronyl C5-epimerase;OS=Crassostrea;PE=4;SV=1	GO:0047464|	GO:0015012|
GN002936.1	sp|K1RXG3|K1RXG3_CRAGI	5.2e-124	449.5	98.95%	73.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002937.1	sp|K1RXG3|K1RXG3_CRAGI	3.9e-137	493.4	84.66%	73.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002938.1	sp|K1QRW0|K1QRW0_CRAGI	2.9e-45	186.8	100.00%	71.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002939.1	sp|K1R1B9|K1R1B9_CRAGI	3.0e-66	257.7	59.45%	70.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002940.1	sp|K1RXG6|K1RXG6_CRAGI	0.0e+00	1873.6	96.68%	76.51%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN002941.1	sp|A0A210QUT3|A0A210QUT3_MIZYE	4.5e-91	339.7	97.29%	71.50%	Uncharacterized protein C15orf41;OS=Mizuhopecten;PE=4;SV=1
GN002942.1	sp|K1R1C3|K1R1C3_CRAGI	1.2e-119	434.9	97.19%	85.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002943.1	sp|K1PE25|K1PE25_CRAGI	4.3e-30	137.1	48.61%	60.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002944.1	sp|A0A1X7U990|A0A1X7U990_AMPQE	4.2e-18	97.4	53.75%	41.48%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|
GN002947.1	sp|B6EY03|B6EY03_CRAGI	9.8e-252	874.8	100.00%	85.95%	Beta-glucan recognition protein 1;OS=Crassostrea;PE=2;SV=1	GO:0030246|GO:0004553|	GO:0005975|
GN002948.1	sp|K1PQR9|K1PQR9_CRAGI	0.0e+00	1312.7	87.91%	90.59%	Squamous cell carcinoma antigen recognized by T-cells 3;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006396|
GN002949.1	sp|K1PBL0|K1PBL0_CRAGI	1.5e-163	581.3	83.43%	86.05%	Phosphatidylserine decarboxylase proenzyme;OS=Crassostrea;PE=4;SV=1	GO:0004609|	GO:0008654|
GN002951.1	sp|K1PQ56|K1PQ56_CRAGI	1.4e-62	247.3	40.51%	36.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002952.1	sp|K1PQ56|K1PQ56_CRAGI	2.5e-133	481.5	94.86%	48.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002953.1	sp|K1PQ56|K1PQ56_CRAGI	8.9e-14	82.4	86.84%	47.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002954.1	sp|K1QXW6|K1QXW6_CRAGI	1.1e-206	725.7	46.80%	94.35%	PITSLRE serine/threonine-protein kinase CDC2L1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN002956.1	sp|K1Q4W6|K1Q4W6_CRAGI	1.4e-192	677.9	86.95%	82.07%	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0031418|GO:0008475|
GN002957.1	sp|K1Q4W6|K1Q4W6_CRAGI	3.5e-169	599.7	99.37%	84.98%	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0031418|GO:0008475|
GN002958.1	sp|S5GAI1|S5GAI1_MERMT	2.6e-61	240.0	100.00%	100.00%	GABAA receptor-associated protein;OS=Meretrix;PE=2;SV=1	GO:0005737|	GO:0006914|
GN002959.1	sp|K1PQ51|K1PQ51_CRAGI	1.7e-63	248.1	75.60%	69.57%	Neurocan core protein;OS=Crassostrea;PE=4;SV=1
GN002960.1	sp|K1QXW1|K1QXW1_CRAGI	9.4e-65	252.3	74.89%	67.07%	Macrophage mannose receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN002961.1	sp|K1RAV0|K1RAV0_CRAGI	4.7e-120	436.8	99.74%	56.43%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN002962.1	sp|K1RAV0|K1RAV0_CRAGI	1.8e-208	731.1	98.80%	62.82%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN002963.1	sp|K1PN63|K1PN63_CRAGI	1.8e-54	219.5	96.86%	27.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001135.1	sp|K1R5Y9|K1R5Y9_CRAGI	1.8e-139	500.7	90.87%	97.48%	Retroviral integration site protein Fli-1-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN002964.1	sp|K1QHT3|K1QHT3_CRAGI	2.4e-14	85.5	63.93%	24.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002965.1	sp|A0A3L8E2T2|A0A3L8E2T2_OOCBI	1.8e-11	74.7	80.95%	33.05%	Uncharacterized protein;OS=Ooceraea;PE=4;SV=1
GN002966.1	sp|K1PVP0|K1PVP0_CRAGI	2.6e-72	277.3	89.42%	70.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002967.1	sp|K1PQR3|K1PQR3_CRAGI	1.6e-200	705.7	57.82%	67.88%	Nuclear receptor corepressor 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN002968.1	sp|K1PQR3|K1PQR3_CRAGI	3.1e-61	240.0	93.53%	89.15%	Nuclear receptor corepressor 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN002969.1	sp|K1PQR3|K1PQR3_CRAGI	3.4e-32	142.9	95.70%	81.82%	Nuclear receptor corepressor 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN002970.1	sp|K1R9G8|K1R9G8_CRAGI	1.2e-99	369.4	48.23%	73.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN002971.1	sp|K1RAV0|K1RAV0_CRAGI	1.7e-59	234.6	92.97%	63.74%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN002974.1	sp|A0A3L8E2T2|A0A3L8E2T2_OOCBI	6.2e-12	76.3	80.95%	33.90%	Uncharacterized protein;OS=Ooceraea;PE=4;SV=1
GN002975.1	sp|A0A210QP64|A0A210QP64_MIZYE	3.9e-51	207.2	97.55%	41.25%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN002976.1	sp|K1PVP0|K1PVP0_CRAGI	3.2e-40	169.9	100.00%	71.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002977.1	sp|K1RAV0|K1RAV0_CRAGI	3.5e-123	447.2	99.74%	57.48%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN002978.1	sp|K1QHT3|K1QHT3_CRAGI	2.6e-12	79.3	39.92%	23.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN002979.1	sp|A0A210QP64|A0A210QP64_MIZYE	2.5e-50	204.5	97.55%	41.25%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001137.1	sp|V3ZVA0|V3ZVA0_LOTGI	1.1e-39	169.5	97.59%	48.03%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN002980.1	sp|K1PQR3|K1PQR3_CRAGI	0.0e+00	2838.1	81.21%	75.87%	Nuclear receptor corepressor 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN002981.1	sp|A0A1X7VAJ5|A0A1X7VAJ5_AMPQE	6.8e-12	75.5	60.64%	51.79%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0008270|
GN002982.1	sp|K1PXI3|K1PXI3_CRAGI	1.9e-103	381.3	97.16%	67.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002983.1	sp|K1QIQ7|K1QIQ7_CRAGI	0.0e+00	1113.6	100.00%	87.32%	Midline-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN002996.1	sp|K1QLR7|K1QLR7_CRAGI	2.8e-34	151.4	85.87%	36.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN002997.1	sp|K1QTV1|K1QTV1_CRAGI	0.0e+00	2774.6	98.33%	87.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|GO:0016021|	GO:0004866|GO:0020037|GO:0005506|GO:0016705|
GN002998.1	sp|K1RZ11|K1RZ11_CRAGI	3.1e-18	97.1	100.00%	35.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003000.1	sp|K1R3H9|K1R3H9_CRAGI	0.0e+00	1194.5	99.90%	64.19%	Pleckstrin-like protein domain-containing family M member 2;OS=Crassostrea;PE=4;SV=1
GN003001.1	sp|K1R6J1|K1R6J1_CRAGI	1.8e-10	72.0	77.38%	25.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003002.1	sp|C3Z7Z4|C3Z7Z4_BRAFL	1.0e-149	537.3	87.56%	30.03%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN003004.1	sp|K1QTV1|K1QTV1_CRAGI	2.5e-215	753.4	95.54%	86.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|GO:0016021|	GO:0004866|GO:0020037|GO:0005506|GO:0016705|
GN003005.1	sp|K1R9D0|K1R9D0_CRAGI	1.4e-237	827.8	99.64%	80.04%	Short transient receptor potential channel 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005262|
GN003006.1	sp|K1R3D9|K1R3D9_CRAGI	3.4e-285	986.9	99.06%	55.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003007.1	sp|K1S636|K1S636_CRAGI	7.6e-266	922.2	98.61%	66.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005814|	GO:0007268|GO:0060271|GO:0007005|
GN003008.1	sp|K1Q8S9|K1Q8S9_CRAGI	2.7e-41	176.0	39.97%	33.45%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003009.1	sp|K1RFJ0|K1RFJ0_CRAGI	1.7e-116	424.9	88.08%	70.20%	Cadherin EGF LAG seven-pass G-type receptor 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007156|
GN003010.1	sp|A0A210PWC5|A0A210PWC5_MIZYE	5.6e-178	629.4	96.06%	76.33%	Pachytene checkpoint protein 2-like;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|
GN003011.1	sp|K1Q7Z9|K1Q7Z9_CRAGI	1.5e-224	784.6	92.94%	74.66%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN003012.1	sp|K1QVB7|K1QVB7_CRAGI	5.5e-248	862.4	100.00%	80.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003013.1	sp|K1Q804|K1Q804_CRAGI	4.1e-110	403.3	92.70%	76.28%	Alkaline phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0004035|
GN003014.1	sp|A0A210QN12|A0A210QN12_MIZYE	4.1e-26	125.2	14.89%	80.52%	Protein SSXT;OS=Mizuhopecten;PE=4;SV=1	GO:0003713|
GN003015.1	sp|K1RFK4|K1RFK4_CRAGI	3.5e-253	879.4	100.00%	86.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003017.1	sp|K1Q5V5|K1Q5V5_CRAGI	2.1e-187	660.6	99.24%	83.55%	Leucine-rich glioma-inactivated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003018.1	sp|K1RCX7|K1RCX7_CRAGI	4.7e-123	446.8	99.75%	67.25%	Leucine-rich repeat-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003019.1	sp|K1QST4|K1QST4_CRAGI	5.6e-145	519.6	100.00%	79.03%	Slit-like protein 3 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003020.1	sp|K1QLM7|K1QLM7_CRAGI	2.7e-171	607.1	92.11%	79.50%	Leucine-rich repeat-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003021.1	sp|K1QDD9|K1QDD9_CRAGI	5.6e-156	556.2	99.01%	70.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003022.1	sp|K1Q5U9|K1Q5U9_CRAGI	5.4e-167	592.8	91.87%	78.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003023.1	sp|K1RCX1|K1RCX1_CRAGI	9.5e-134	482.3	100.00%	75.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001140.1	sp|K1QSE3|K1QSE3_CRAGI	1.5e-260	904.4	73.58%	77.70%	Protein-glutamine gamma-glutamyltransferase K;OS=Crassostrea;PE=4;SV=1	GO:0003810|	GO:0018149|
GN003024.1	sp|K1QDD4|K1QDD4_CRAGI	3.4e-139	500.0	97.92%	86.52%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN003025.1	sp|K1Q5U4|K1Q5U4_CRAGI	1.1e-186	658.3	99.32%	73.35%	Pantetheinase;OS=Crassostrea;PE=4;SV=1	GO:0016811|	GO:0006807|
GN003026.1	sp|K1RCW5|K1RCW5_CRAGI	9.3e-305	1051.2	94.38%	85.89%	Eukaryotic translation initiation factor 4 gamma 3;OS=Crassostrea;PE=4;SV=1	GO:0003729|GO:0003743|
GN003027.1	sp|K1PIB7|K1PIB7_CRAGI	3.9e-269	932.6	96.50%	81.27%	Phenylalanyl-tRNA synthetase beta chain;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0000287|GO:0004826|GO:0003723|	GO:0006432|
GN003028.1	sp|K1PQD7|K1PQD7_CRAGI	0.0e+00	2552.7	100.00%	84.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003030.1	sp|A0A210R5A8|A0A210R5A8_MIZYE	6.3e-143	512.7	95.53%	70.72%	D-2-hydroxyglutarate dehydrogenase, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0071949|GO:0016491|
GN001141.1	sp|K1QUE9|K1QUE9_CRAGI	0.0e+00	2486.1	100.00%	83.17%	PH domain leucine-rich repeat-containing protein phosphatase 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN003031.1	sp|K1QLL0|K1QLL0_CRAGI	3.3e-166	590.1	99.47%	74.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003032.1	sp|K1PY09|K1PY09_CRAGI	2.2e-255	886.7	100.00%	86.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003033.1	sp|K1R5B9|K1R5B9_CRAGI	3.1e-216	758.1	75.25%	46.03%	DNA-directed RNA polymerase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003899|	GO:0006351|
GN003034.1	sp|K1QJQ5|K1QJQ5_CRAGI	5.6e-120	436.8	62.39%	77.62%	TRAF-interacting protein;OS=Crassostrea;PE=4;SV=1
GN003036.1	sp|K1R100|K1R100_CRAGI	3.9e-112	409.8	96.67%	85.28%	Metaxin-2;OS=Crassostrea;PE=4;SV=1	GO:0001401|
GN003037.1	sp|A0A210Q702|A0A210Q702_MIZYE	3.6e-73	280.0	96.83%	68.13%	Phosphopantothenoylcysteine decarboxylase;OS=Mizuhopecten;PE=4;SV=1	GO:0003824|
GN003038.1	sp|K1S6F6|K1S6F6_CRAGI	4.5e-70	270.8	100.00%	95.54%	Leucine-rich repeat-containing protein 34;OS=Crassostrea;PE=4;SV=1
GN003039.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	4.4e-19	100.5	56.34%	41.80%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN003040.1	sp|K1RGT8|K1RGT8_CRAGI	7.4e-33	146.4	50.67%	68.14%	Kinesin-like protein KIF20A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN003041.1	sp|K1RGT8|K1RGT8_CRAGI	1.2e-22	114.4	28.23%	51.27%	Kinesin-like protein KIF20A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN003042.1	sp|K1RN44|K1RN44_CRAGI	1.8e-52	212.2	69.11%	43.31%	Apelin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN003043.1	sp|K1QQ00|K1QQ00_CRAGI	0.0e+00	1075.1	90.03%	88.62%	Phosphorylated CTD-interacting factor 1;OS=Crassostrea;PE=4;SV=1
GN003044.1	sp|K1QZD7|K1QZD7_CRAGI	3.6e-45	186.4	98.37%	72.95%	Acyl-CoA synthetase family member 3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN003045.1	sp|K1QZD7|K1QZD7_CRAGI	3.8e-188	663.3	79.66%	83.51%	Acyl-CoA synthetase family member 3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN003047.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	3.8e-45	188.3	22.86%	70.18%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN003048.1	sp|K1PMC5|K1PMC5_CRAGI	7.0e-45	186.4	78.01%	54.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001144.1	sp|K1PUA1|K1PUA1_CRAGI	1.2e-142	513.1	89.40%	37.98%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003049.1	sp|K1QAF3|K1QAF3_CRAGI	1.6e-264	917.1	94.97%	88.98%	Alanine aminotransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0030170|GO:0008483|	GO:0009058|
GN003050.1	sp|K1QMP2|K1QMP2_CRAGI	1.7e-76	292.4	92.76%	37.07%	Acetylcholine receptor subunit alpha-like 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN003051.1	sp|K1QIP7|K1QIP7_CRAGI	8.4e-129	465.7	90.03%	77.60%	AKT-interacting protein;OS=Crassostrea;PE=4;SV=1
GN003052.1	sp|K1R1Z0|K1R1Z0_CRAGI	1.0e-79	303.1	91.18%	36.38%	Acetylcholine receptor subunit alpha-type acr-16;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN003053.1	sp|K1QV75|K1QV75_CRAGI	1.4e-81	309.3	92.02%	38.69%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN003054.1	sp|A0A2G8KDS6|A0A2G8KDS6_STIJA	1.8e-13	82.4	72.70%	26.67%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|GO:0008270|
GN001145.1	sp|K1PTN2|K1PTN2_CRAGI	6.5e-183	646.0	97.56%	65.34%	Putative cytochrome P450 CYP44;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN003059.1	sp|K1QGJ4|K1QGJ4_CRAGI	2.5e-50	203.8	91.61%	73.08%	Cytidine deaminase;OS=Crassostrea;PE=3;SV=1	GO:0004126|GO:0008270|
GN003061.1	sp|K1QBR3|K1QBR3_CRAGI	3.5e-179	634.4	89.08%	69.64%	Polyhomeotic-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008270|
GN003062.1	sp|K1P5Q1|K1P5Q1_CRAGI	3.0e-35	154.8	74.38%	46.27%	Crossover junction endonuclease MUS81;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004519|GO:0008270|
GN003063.1	sp|K1PJ53|K1PJ53_CRAGI	9.9e-100	368.2	100.00%	95.29%	Cdc42-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN003064.1	sp|K1PBU4|K1PBU4_CRAGI	0.0e+00	1083.6	99.60%	53.61%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016849|GO:0004672|	GO:0009190|GO:0035556|
GN003066.1	sp|K1P5R2|K1P5R2_CRAGI	1.8e-29	134.0	85.05%	67.78%	Phosphate-binding protein pstS;OS=Crassostrea;PE=4;SV=1
GN003067.1	sp|K1PMG4|K1PMG4_CRAGI	4.8e-36	156.0	97.39%	71.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN003068.1	sp|A0A2B4R6Q7|A0A2B4R6Q7_STYPI	6.2e-24	116.7	80.18%	38.98%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|GO:0008270|
GN003069.1	sp|K1QTQ3|K1QTQ3_CRAGI	3.1e-38	164.5	52.11%	62.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003070.1	sp|K1PBU4|K1PBU4_CRAGI	0.0e+00	1445.6	98.86%	72.65%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016849|GO:0004672|	GO:0009190|GO:0035556|
GN003071.1	sp|K1QRG9|K1QRG9_CRAGI	7.9e-224	781.9	99.80%	97.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000974|	GO:0061630|	GO:0006281|GO:0000398|
GN003072.1	sp|K1QBU1|K1QBU1_CRAGI	2.7e-18	96.7	61.54%	83.64%	Glycerophosphodiester phosphodiesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008081|	GO:0006629|
GN001146.1	sp|A0A210R0W9|A0A210R0W9_MIZYE	1.9e-237	827.8	96.59%	53.11%	G-protein coupled receptor 158-like protein;OS=Mizuhopecten;PE=4;SV=1
GN003073.1	sp|K1PBC1|K1PBC1_CRAGI	2.1e-32	144.1	100.00%	56.69%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN003074.1	sp|K1QU23|K1QU23_CRAGI	6.5e-50	202.2	100.00%	74.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003075.1	sp|K1QU23|K1QU23_CRAGI	2.7e-42	176.8	99.14%	73.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003077.1	sp|A0A2B4RJF9|A0A2B4RJF9_STYPI	2.5e-12	77.0	69.61%	49.30%	Leucine-rich repeat-containing protein 1;OS=Stylophora;PE=4;SV=1	GO:0046983|
GN003078.1	sp|K1QU23|K1QU23_CRAGI	5.2e-39	166.0	100.00%	65.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003079.1	sp|K1R625|K1R625_CRAGI	7.7e-20	103.2	32.77%	54.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003080.1	sp|C3XZ04|C3XZ04_BRAFL	1.0e-98	365.9	95.45%	46.91%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0043240|	GO:0004842|	GO:0036297|
GN003081.1	sp|K1PBU9|K1PBU9_CRAGI	2.1e-10	70.9	50.43%	56.90%	RNA pseudouridylate synthase domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN003084.1	sp|A0A210PG30|A0A210PG30_MIZYE	1.9e-23	116.3	99.23%	26.36%	Protein Spindly-A;OS=Mizuhopecten;PE=4;SV=1
GN003085.1	sp|K1P5S0|K1P5S0_CRAGI	3.4e-100	370.9	87.68%	50.77%	tRNA pseudouridine synthase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN003086.1	sp|A0A210R539|A0A210R539_MIZYE	3.3e-39	166.8	93.48%	62.02%	PDZ and LIM domain protein Zasp;OS=Mizuhopecten;PE=4;SV=1
GN003087.1	sp|K1PJ58|K1PJ58_CRAGI	4.7e-20	102.8	77.48%	55.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003088.1	sp|A0A2B4R6Q7|A0A2B4R6Q7_STYPI	1.7e-35	155.6	97.35%	32.73%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|GO:0008270|
GN003089.1	sp|K1QTQ3|K1QTQ3_CRAGI	3.1e-38	164.5	52.11%	62.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003090.1	sp|K1PBU4|K1PBU4_CRAGI	0.0e+00	1445.6	98.86%	72.65%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016849|GO:0004672|	GO:0009190|GO:0035556|
GN003091.1	sp|A0A210PGK4|A0A210PGK4_MIZYE	1.8e-66	258.8	80.20%	52.94%	DNA repair protein XRCC1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003684|	GO:0000012|
GN003093.1	sp|K1QXV4|K1QXV4_CRAGI	1.0e-180	638.3	98.09%	79.11%	Carboxypeptidase D;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004181|GO:0008270|
GN001148.1	sp|A0A3L5TT48|A0A3L5TT48_MYTGA	1.1e-61	241.9	92.55%	63.07%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN003094.1	sp|K1RHT2|K1RHT2_CRAGI	1.3e-65	255.4	95.63%	52.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003095.1	sp|K1RHT2|K1RHT2_CRAGI	3.5e-71	273.9	94.12%	54.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003097.1	sp|K1QXU3|K1QXU3_CRAGI	9.7e-89	332.0	79.82%	91.16%	Thyrotropin-releasing hormone receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004997|
GN003098.1	sp|A0A2T7NNK9|A0A2T7NNK9_POMCA	4.4e-42	178.7	80.41%	24.25%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0016021|	GO:0016788|	GO:0045087|GO:0007165|
GN003100.1	sp|A0A210R2K7|A0A210R2K7_MIZYE	1.9e-55	221.1	97.83%	55.31%	Apolipoprotein D;OS=Mizuhopecten;PE=3;SV=1	GO:0008289|	GO:0007568|GO:0006869|
GN003101.1	sp|A0A210QTR8|A0A210QTR8_MIZYE	7.8e-186	656.0	88.67%	58.97%	AarF domain-containing protein kinase 5;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016301|
GN003102.1	sp|A0A210PE48|A0A210PE48_MIZYE	1.3e-73	282.7	99.30%	39.39%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003103.1	sp|K1RHT2|K1RHT2_CRAGI	2.5e-69	267.7	95.65%	53.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003105.1	sp|A0A210QH49|A0A210QH49_MIZYE	0.0e+00	2514.6	100.00%	45.53%	Metabotropic glutamate receptor 8;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN003106.1	sp|K1PP60|K1PP60_CRAGI	2.0e-46	192.2	83.07%	33.02%	Acetylcholine receptor subunit delta;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN003107.1	sp|A0A1Y1KDD6|A0A1Y1KDD6_PHOPY	2.1e-42	178.3	83.33%	38.36%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN003108.1	sp|A0A210QMR0|A0A210QMR0_MIZYE	6.6e-39	167.5	27.70%	60.77%	Uncharacterized protein C01G6.5;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN003109.1	sp|K1QRF3|K1QRF3_CRAGI	1.9e-126	457.2	100.00%	97.21%	Cytochrome b5 domain-containing protein 1;OS=Crassostrea;PE=3;SV=1
GN003110.1	sp|A0A194ANC0|A0A194ANC0_PINFU	1.1e-36	157.9	99.03%	73.53%	Putative N-alpha-acetyltransferase 38, NatC auxiliary subunit-like protein;OS=Pinctada;PE=4;SV=1	GO:0031417|	GO:0016740|
GN001150.1	sp|K1PD78|K1PD78_CRAGI	1.6e-173	615.1	56.58%	83.92%	G2/mitotic-specific cyclin-B;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0019901|	GO:0000079|GO:0010389|
GN001150.1	sp|K1PD78|K1PD78_CRAGI	1.1e-07	64.3	11.29%	56.34%	G2/mitotic-specific cyclin-B;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0019901|	GO:0000079|GO:0010389|
GN003111.1	sp|K1RHS1|K1RHS1_CRAGI	6.6e-101	374.4	30.06%	79.25%	Putative defense protein 3;OS=Crassostrea;PE=4;SV=1
GN003112.1	sp|K1QAN1|K1QAN1_CRAGI	1.4e-64	251.9	99.60%	54.55%	Putative defense protein Hdd11-like protein;OS=Crassostrea;PE=4;SV=1
GN003113.1	sp|K1QIZ1|K1QIZ1_CRAGI	0.0e+00	1783.1	99.11%	80.24%	Ephrin type-A receptor 4;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005524|GO:0005003|
GN003116.1	sp|K1QY88|K1QY88_CRAGI	8.4e-90	337.4	54.66%	42.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN003118.1	sp|K1PPU2|K1PPU2_CRAGI	6.1e-55	219.5	96.95%	53.65%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN001151.1	sp|K1P752|K1P752_CRAGI	3.6e-74	283.1	100.00%	90.38%	UPF0195 protein FAM96B;OS=Crassostrea;PE=4;SV=1	GO:0016226|
GN003119.1	sp|A0A210QMR0|A0A210QMR0_MIZYE	7.4e-39	167.5	24.49%	60.77%	Uncharacterized protein C01G6.5;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN003119.1	sp|A0A210QMR0|A0A210QMR0_MIZYE	3.2e-18	99.0	11.40%	61.67%	Uncharacterized protein C01G6.5;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN003120.1	sp|K1QIY8|K1QIY8_CRAGI	6.7e-48	196.1	71.04%	68.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003121.1	sp|K1QRF3|K1QRF3_CRAGI	1.9e-126	457.2	100.00%	97.21%	Cytochrome b5 domain-containing protein 1;OS=Crassostrea;PE=3;SV=1
GN003122.1	sp|K1RHS1|K1RHS1_CRAGI	1.9e-100	372.9	29.72%	78.87%	Putative defense protein 3;OS=Crassostrea;PE=4;SV=1
GN003123.1	sp|K1QAN1|K1QAN1_CRAGI	9.1e-64	249.2	99.60%	54.15%	Putative defense protein Hdd11-like protein;OS=Crassostrea;PE=4;SV=1
GN003124.1	sp|K1QWK3|K1QWK3_CRAGI	1.0e-113	415.6	99.72%	58.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003125.1	sp|K1RDH8|K1RDH8_CRAGI	1.5e-42	179.1	65.93%	40.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001152.1	sp|K1QD73|K1QD73_CRAGI	0.0e+00	1497.3	100.00%	91.00%	Ankyrin and armadillo repeat-containing protein;OS=Crassostrea;PE=4;SV=1
GN003126.1	sp|K1RDH8|K1RDH8_CRAGI	2.2e-104	384.4	89.25%	66.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003127.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	1.8e-22	112.1	92.05%	34.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003128.1	sp|K1QXU2|K1QXU2_CRAGI	3.1e-296	1022.7	100.00%	84.02%	Alkyl/aryl-sulfatase BDS1;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN003131.1	sp|K1QNI0|K1QNI0_CRAGI	1.8e-149	534.3	100.00%	84.31%	GTP-binding protein GEM;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN003132.1	sp|K1QGZ2|K1QGZ2_CRAGI	1.2e-57	228.8	99.15%	58.19%	GTP-binding protein GEM;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN001153.1	sp|K1PST3|K1PST3_CRAGI	3.3e-52	211.1	82.06%	45.00%	Polypyrimidine tract-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN003134.1	sp|K1Q1Y3|K1Q1Y3_CRAGI	1.5e-78	298.5	99.65%	59.11%	GTP-binding protein REM 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN003136.1	sp|K1Q136|K1Q136_CRAGI	2.5e-39	167.9	84.39%	45.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003137.1	sp|K1RXY7|K1RXY7_CRAGI	3.2e-64	250.4	89.90%	66.67%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN003138.1	sp|K1Q3Q1|K1Q3Q1_CRAGI	8.7e-82	308.9	99.55%	64.91%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN003139.1	sp|K1R8V1|K1R8V1_CRAGI	1.8e-128	465.3	93.64%	50.74%	Puratrophin-1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN003140.1	sp|K1R8V1|K1R8V1_CRAGI	1.5e-53	214.2	98.31%	89.57%	Puratrophin-1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN003141.1	sp|A0A210PN94|A0A210PN94_MIZYE	7.1e-75	286.6	99.71%	50.28%	Puratrophin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0005089|	GO:0035023|
GN001154.1	sp|K1PD72|K1PD72_CRAGI	0.0e+00	1574.3	100.00%	85.90%	Breast cancer anti-estrogen resistance protein 1;OS=Crassostrea;PE=4;SV=1
GN003142.1	sp|K1Q1Z0|K1Q1Z0_CRAGI	0.0e+00	3641.3	79.05%	85.61%	Chromodomain-helicase-DNA-binding protein 9;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0004386|
GN003143.1	sp|K1QGZ6|K1QGZ6_CRAGI	1.7e-56	224.9	59.47%	82.84%	DNA repair protein RAD51-like protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008094|	GO:0006281|
GN003144.1	sp|K1RHR4|K1RHR4_CRAGI	0.0e+00	1513.0	46.72%	74.83%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0005665|GO:0000439|	GO:0003677|GO:0003950|	GO:0006289|GO:0006471|GO:0006355|GO:0006366|
GN003144.1	sp|K1RHR4|K1RHR4_CRAGI	9.1e-27	129.4	6.93%	43.71%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0005665|GO:0000439|	GO:0003677|GO:0003950|	GO:0006289|GO:0006471|GO:0006355|GO:0006366|
GN003145.1	sp|A0A210Q849|A0A210Q849_MIZYE	1.9e-51	207.2	100.00%	84.48%	Translation initiation factor eIF-2B subunit alpha;OS=Mizuhopecten;PE=3;SV=1	GO:0003743|
GN003146.1	sp|K1QRE5|K1QRE5_CRAGI	1.9e-89	334.7	96.50%	57.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003147.1	sp|K1QIY0|K1QIY0_CRAGI	7.0e-94	349.0	99.52%	82.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003148.1	sp|K1QRE5|K1QRE5_CRAGI	2.2e-157	560.8	99.50%	70.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003149.1	sp|A0A210Q849|A0A210Q849_MIZYE	1.4e-128	465.3	68.78%	78.22%	Translation initiation factor eIF-2B subunit alpha;OS=Mizuhopecten;PE=3;SV=1	GO:0003743|
GN003150.1	sp|K1RHR4|K1RHR4_CRAGI	0.0e+00	2052.7	55.49%	74.60%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0005665|GO:0000439|	GO:0003677|GO:0003950|	GO:0006289|GO:0006471|GO:0006355|GO:0006366|
GN003150.1	sp|K1RHR4|K1RHR4_CRAGI	1.0e-26	129.4	6.14%	43.71%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0005665|GO:0000439|	GO:0003677|GO:0003950|	GO:0006289|GO:0006471|GO:0006355|GO:0006366|
GN003151.1	sp|K1QRE5|K1QRE5_CRAGI	2.2e-157	560.8	99.50%	70.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003152.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	1.2e-90	339.7	98.42%	34.33%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN001155.1	sp|V3ZK49|V3ZK49_LOTGI	6.3e-103	380.2	99.14%	42.70%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN003153.1	sp|A0A2B4SNB7|A0A2B4SNB7_STYPI	1.1e-17	96.3	48.13%	41.48%	Dipeptidyl peptidase 8;OS=Stylophora;PE=3;SV=1	GO:0008236|
GN003155.1	sp|K1PE19|K1PE19_CRAGI	2.2e-52	211.1	96.08%	50.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003156.1	sp|K1QAX7|K1QAX7_CRAGI	3.3e-46	191.4	39.67%	59.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003157.1	sp|K1PE19|K1PE19_CRAGI	2.2e-52	211.1	96.08%	50.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003159.1	sp|K1RA05|K1RA05_CRAGI	2.9e-135	487.3	100.00%	71.28%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN003160.1	sp|K1RTV5|K1RTV5_CRAGI	3.4e-136	490.3	100.00%	71.82%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN003162.1	sp|K1PT52|K1PT52_CRAGI	2.2e-11	73.9	95.19%	43.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003163.1	sp|A0A0L7KXS8|A0A0L7KXS8_9NEOP	2.2e-10	70.9	84.00%	36.45%	Uncharacterized protein;OS=Operophtera;PE=4;SV=1
GN003164.1	sp|W4XXE5|W4XXE5_STRPU	1.7e-93	349.7	69.74%	33.70%	Uncharacterized protein;OS=Strongylocentrotus;PE=3;SV=1	GO:0046872|GO:0036459|	GO:0016579|GO:0006511|
GN003165.1	sp|W4ZDS2|W4ZDS2_STRPU	3.1e-26	124.4	57.08%	46.21%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0030117|GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|GO:0006886|GO:0016192|
GN003167.1	sp|K1RYA9|K1RYA9_CRAGI	3.4e-20	104.0	49.17%	57.61%	Cornifelin-like protein;OS=Crassostrea;PE=4;SV=1
GN003168.1	sp|K1R8N6|K1R8N6_CRAGI	0.0e+00	2068.9	100.00%	78.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003169.1	sp|K1R2M3|K1R2M3_CRAGI	1.3e-50	206.1	99.46%	39.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003170.1	sp|K1R2M3|K1R2M3_CRAGI	1.2e-46	193.4	72.67%	35.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003171.1	sp|K1QT63|K1QT63_CRAGI	3.4e-136	490.0	100.00%	85.77%	Hydroxysteroid dehydrogenase-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN003173.1	sp|K1QH35|K1QH35_CRAGI	3.3e-115	421.8	96.75%	38.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003174.1	sp|A0A210QH13|A0A210QH13_MIZYE	2.5e-44	183.7	97.06%	65.65%	Methyltransferase-like protein 9;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN003175.1	sp|K1QA00|K1QA00_CRAGI	7.3e-78	295.4	89.76%	92.57%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005328|
GN003176.1	sp|K1QA00|K1QA00_CRAGI	1.5e-47	194.1	100.00%	84.55%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005328|
GN003177.1	sp|K1Q2F8|K1Q2F8_CRAGI	2.5e-122	443.7	99.19%	98.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003178.1	sp|K1PUX5|K1PUX5_CRAGI	1.6e-213	747.3	100.00%	96.37%	Casein kinase II subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN003179.1	sp|K1R2T7|K1R2T7_CRAGI	3.0e-107	393.3	100.00%	99.48%	UPF0468 protein C16orf80-like protein;OS=Crassostrea;PE=4;SV=1
GN003180.1	sp|K1QH31|K1QH31_CRAGI	3.9e-228	796.2	91.13%	85.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003181.1	sp|K1Q9Z6|K1Q9Z6_CRAGI	1.5e-98	364.8	75.90%	95.21%	26S proteasome non-ATPase regulatory subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0005838|
GN003182.1	sp|K1Q268|K1Q268_CRAGI	1.8e-66	258.1	96.46%	78.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003183.1	sp|A0A210QWK6|A0A210QWK6_MIZYE	2.8e-35	154.1	98.30%	46.67%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN003184.1	sp|K1QRB9|K1QRB9_CRAGI	3.0e-20	104.4	94.79%	31.19%	DnaJ-like protein subfamily C member 5;OS=Crassostrea;PE=4;SV=1
GN003185.1	sp|K1Q9D5|K1Q9D5_CRAGI	0.0e+00	2826.2	100.00%	77.16%	Zinc finger homeobox protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|GO:0008270|	GO:0006355|
GN003187.1	sp|K1QV62|K1QV62_CRAGI	0.0e+00	1472.6	97.22%	84.11%	Zinc finger homeobox protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN003188.1	sp|K1PN69|K1PN69_CRAGI	4.1e-130	470.3	97.57%	62.47%	Thiamine-triphosphatase;OS=Crassostrea;PE=4;SV=1	GO:0050333|
GN003189.1	sp|K1QK13|K1QK13_CRAGI	5.0e-100	369.4	99.03%	88.18%	Putative phosphoethanolamine N-methyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN003190.1	sp|K1QRI8|K1QRI8_CRAGI	9.3e-224	782.3	100.00%	80.10%	RNA polymerase II subunit A C-terminal domain phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008420|	GO:0070940|
GN003191.1	sp|K1Q4K8|K1Q4K8_CRAGI	1.8e-49	201.1	84.47%	72.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003193.1	sp|V3ZFN5|V3ZFN5_LOTGI	1.7e-18	98.6	94.93%	30.95%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004190|
GN003194.1	sp|T1I8R4|T1I8R4_RHOPR	1.4e-35	156.0	96.48%	31.36%	Uncharacterized protein;OS=Rhodnius;PE=4;SV=1
GN003196.1	sp|K1RLR4|K1RLR4_CRAGI	1.0e-82	311.6	98.29%	80.12%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN003197.1	sp|A0A210PE54|A0A210PE54_MIZYE	8.1e-26	123.6	86.97%	26.37%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN003198.1	sp|K1QTM7|K1QTM7_CRAGI	3.2e-74	285.4	25.50%	77.65%	AN1-type zinc finger protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003199.1	sp|K1R357|K1R357_CRAGI	6.0e-264	915.2	100.00%	88.93%	Cyclic nucleotide-binding domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN003200.1	sp|K1R958|K1R958_CRAGI	4.6e-150	537.0	95.60%	58.80%	UPF0489 protein C5orf22-like protein;OS=Crassostrea;PE=4;SV=1
GN001158.1	sp|V4AE92|V4AE92_LOTGI	2.0e-56	224.6	96.26%	52.88%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN003201.1	sp|K1RFN6|K1RFN6_CRAGI	1.5e-105	388.7	90.02%	75.74%	Protein escargot;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003203.1	sp|A0A151WPL7|A0A151WPL7_9HYME	2.5e-38	164.1	88.12%	54.29%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN003206.1	sp|K1QAH8|K1QAH8_CRAGI	0.0e+00	2285.0	92.60%	80.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|	GO:0004866|GO:0003723|
GN003207.1	sp|K1RLR4|K1RLR4_CRAGI	1.0e-82	311.6	98.29%	80.12%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN003208.1	sp|K1RLR4|K1RLR4_CRAGI	5.3e-74	283.5	99.34%	55.91%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN003209.1	sp|K1RLR4|K1RLR4_CRAGI	5.5e-233	812.8	99.85%	63.43%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN001159.1	sp|K1QTH9|K1QTH9_CRAGI	5.3e-68	263.1	100.00%	63.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000947.1	sp|K1QY88|K1QY88_CRAGI	1.3e-85	323.6	55.26%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN003220.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	5.5e-16	89.0	97.70%	51.76%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN003225.1	sp|K1QVK1|K1QVK1_CRAGI	1.3e-39	168.7	78.33%	53.80%	Ankyrin repeat domain-containing protein 46;OS=Crassostrea;PE=4;SV=1
GN003227.1	sp|K1RB68|K1RB68_CRAGI	1.1e-114	419.1	98.58%	64.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003228.1	sp|A0A210PV11|A0A210PV11_MIZYE	8.0e-49	198.4	99.08%	84.11%	60S ribosome subunit biogenesis protein NIP7 homolog;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0003723|	GO:0042255|
GN003229.1	sp|K1QQ63|K1QQ63_CRAGI	2.1e-123	448.4	97.02%	47.34%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003230.1	sp|K1Q441|K1Q441_CRAGI	2.4e-39	167.2	96.18%	64.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003231.1	sp|K1RL35|K1RL35_CRAGI	2.6e-144	516.9	98.21%	91.21%	Solute carrier family 25 member 36;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN001162.1	sp|K1QBH6|K1QBH6_CRAGI	1.2e-45	189.5	37.25%	70.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003232.1	sp|K1S0Y7|K1S0Y7_CRAGI	5.0e-35	153.7	68.18%	54.27%	Protein rogdi;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003233.1	sp|K1S0Y7|K1S0Y7_CRAGI	1.8e-136	491.9	86.41%	54.04%	Protein rogdi;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003234.1	sp|K1QP57|K1QP57_CRAGI	3.3e-256	890.2	91.84%	81.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003235.1	sp|K1Q9J0|K1Q9J0_CRAGI	2.0e-161	574.3	84.84%	77.17%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN003236.1	sp|K1PCN1|K1PCN1_CRAGI	2.6e-28	130.6	91.24%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003238.1	sp|F5A8D9|F5A8D9_CRAGI	4.9e-166	589.7	99.77%	71.66%	Caspase-2;OS=Crassostrea;PE=2;SV=1	GO:0004197|	GO:0042981|
GN003240.1	sp|W4YZ12|W4YZ12_STRPU	2.0e-70	272.7	99.70%	28.98%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN003241.1	sp|A0A1X7U2C0|A0A1X7U2C0_AMPQE	2.8e-52	212.2	98.58%	30.19%	ATP-dependent DNA helicase;OS=Amphimedon;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN003243.1	sp|V4AV15|V4AV15_LOTGI	4.8e-230	802.7	98.93%	69.60%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0016831|GO:0030170|	GO:0006520|
GN003244.1	sp|A0A210R5P4|A0A210R5P4_MIZYE	8.3e-94	349.4	93.48%	53.49%	Dopamine beta-hydroxylase;OS=Mizuhopecten;PE=4;SV=1	GO:0005507|GO:0016715|
GN003245.1	sp|C3ZZB5|C3ZZB5_BRAFL	2.6e-26	124.8	90.84%	33.90%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN003246.1	sp|C3YVP9|C3YVP9_BRAFL	3.3e-31	141.7	96.56%	29.24%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN003248.1	sp|K1R9G6|K1R9G6_CRAGI	6.0e-41	172.2	92.52%	88.78%	cAMP-responsive element-binding protein-like 2;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN003249.1	sp|E3P7F4|E3P7F4_LEPCI	2.4e-33	146.7	90.53%	83.53%	Ribosomal protein L22;OS=Lepidochitona;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN003250.1	sp|K1PKK7|K1PKK7_CRAGI	2.4e-237	826.6	100.00%	97.95%	AP-2 complex subunit mu-1;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0006886|GO:0016192|
GN003251.1	sp|K1PD17|K1PD17_CRAGI	5.5e-122	444.1	88.90%	57.95%	Ecotropic virus integration site 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0006355|
GN003252.1	sp|K1QEG5|K1QEG5_CRAGI	7.9e-11	72.4	98.46%	40.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003253.1	sp|K1QWN3|K1QWN3_CRAGI	1.9e-15	88.6	77.12%	26.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN003254.1	sp|K1P700|K1P700_CRAGI	3.2e-57	226.9	91.57%	68.87%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN003255.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	1.4e-21	109.8	31.47%	39.02%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN003256.1	sp|K1R780|K1R780_CRAGI	7.2e-26	122.9	89.13%	38.04%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN003260.1	sp|K1Q1V8|K1Q1V8_CRAGI	1.5e-84	318.5	97.00%	58.05%	Caspase;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN003261.1	sp|K1RCW5|K1RCW5_CRAGI	6.3e-78	296.6	57.86%	78.69%	Eukaryotic translation initiation factor 4 gamma 3;OS=Crassostrea;PE=4;SV=1	GO:0003729|GO:0003743|
GN003262.1	sp|K1Q907|K1Q907_CRAGI	1.1e-233	814.7	100.00%	79.11%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003263.1	sp|K1QUU3|K1QUU3_CRAGI	4.9e-243	845.9	99.28%	80.58%	Paxillin;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0046872|	GO:0007160|
GN003264.1	sp|K1Q1W7|K1Q1W7_CRAGI	1.7e-68	264.2	96.82%	87.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003265.1	sp|K1Q912|K1Q912_CRAGI	6.4e-72	275.8	89.77%	85.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003269.1	sp|K1Q918|K1Q918_CRAGI	0.0e+00	2093.9	95.02%	65.68%	Titin;OS=Crassostrea;PE=4;SV=1
GN003270.1	sp|K1PMX2|K1PMX2_CRAGI	1.6e-54	219.5	46.24%	85.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003272.1	sp|K1Q924|K1Q924_CRAGI	4.4e-34	150.2	99.47%	64.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003273.1	sp|K1QE87|K1QE87_CRAGI	1.3e-34	152.9	91.58%	28.34%	Octopressin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN003276.1	sp|K1QUW2|K1QUW2_CRAGI	2.5e-15	90.9	34.66%	25.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003277.1	sp|K1PMX8|K1PMX8_CRAGI	1.0e-223	781.6	75.58%	90.75%	TNF receptor-associated factor 4;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0042981|GO:0007165|
GN003278.1	sp|K1R9C6|K1R9C6_CRAGI	8.5e-72	275.4	97.78%	70.86%	Phytanoyl-CoA hydroxylase-interacting protein;OS=Crassostrea;PE=4;SV=1
GN003279.1	sp|K1QMS1|K1QMS1_CRAGI	1.6e-70	271.2	94.94%	82.14%	Protein fantom;OS=Crassostrea;PE=4;SV=1
GN003280.1	sp|K1QHE7|K1QHE7_CRAGI	7.3e-14	82.8	77.16%	38.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003281.1	sp|K1PR08|K1PR08_CRAGI	1.5e-207	727.6	99.30%	81.37%	3-oxoacyl-[acyl-carrier-protein] synthase;OS=Crassostrea;PE=3;SV=1	GO:0016747|	GO:0006633|
GN000948.1	sp|K1QQX1|K1QQX1_CRAGI	4.2e-60	236.5	100.00%	66.28%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003282.1	sp|V4A0T0|V4A0T0_LOTGI	6.9e-108	396.4	91.51%	58.74%	Proline dehydrogenase;OS=Lottia;PE=3;SV=1	GO:0005509|GO:0004657|	GO:0006562|
GN003283.1	sp|K1PPV3|K1PPV3_CRAGI	0.0e+00	1109.4	99.87%	94.49%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN003284.1	sp|K1QXG1|K1QXG1_CRAGI	0.0e+00	2045.4	99.91%	84.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003285.1	sp|V4A1M7|V4A1M7_LOTGI	8.9e-73	279.3	80.07%	59.72%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN003286.1	sp|K1QBP7|K1QBP7_CRAGI	5.6e-70	269.2	80.61%	96.21%	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1;OS=Crassostrea;PE=4;SV=1	GO:0000228|	GO:0006338|
GN003287.1	sp|K1Q4F5|K1Q4F5_CRAGI	4.2e-54	217.2	95.26%	54.62%	NFATC2-interacting protein;OS=Crassostrea;PE=4;SV=1
GN003288.1	sp|K1PSA8|K1PSA8_CRAGI	0.0e+00	1935.6	96.56%	81.48%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN003289.1	sp|K1PN97|K1PN97_CRAGI	1.2e-131	475.3	99.50%	78.30%	Gigaxonin;OS=Crassostrea;PE=4;SV=1	GO:0007010|
GN003290.1	sp|K1P2C3|K1P2C3_CRAGI	2.2e-170	604.0	99.48%	76.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003291.1	sp|K1PGD6|K1PGD6_CRAGI	3.1e-310	1069.3	100.00%	82.41%	Putative ubiquitin carboxyl-terminal hydrolase CYLD;OS=Crassostrea;PE=4;SV=1	GO:0036459|	GO:0016579|
GN003292.1	sp|K1PNA2|K1PNA2_CRAGI	8.2e-111	405.2	100.00%	96.12%	Repressor of RNA polymerase III transcription MAF1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0016480|
GN003293.1	sp|K1Q9C1|K1Q9C1_CRAGI	2.0e-184	651.4	83.78%	64.83%	Zinc finger protein 64-like protein, isoforms 1 and 2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003294.1	sp|V9HX25|V9HX25_OSTED	6.5e-31	139.8	88.94%	40.84%	Complement component 1;OS=Ostrea;PE=2;SV=1
GN003295.1	sp|A0A0J7K3R1|A0A0J7K3R1_LASNI	1.1e-28	132.5	68.81%	43.23%	Uncharacterized protein;OS=Lasius;PE=4;SV=1
GN003296.1	sp|K1P2E3|K1P2E3_CRAGI	4.0e-58	230.3	100.00%	59.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003297.1	sp|A0A210PT58|A0A210PT58_MIZYE	1.2e-56	225.7	72.57%	55.14%	CAP-Gly domain-containing linker protein 2;OS=Mizuhopecten;PE=4;SV=1
GN003298.1	sp|K1PNB1|K1PNB1_CRAGI	3.1e-168	596.7	99.40%	87.39%	Tetratricopeptide repeat protein 5;OS=Crassostrea;PE=4;SV=1
GN001167.1	sp|A0A100XKG4|A0A100XKG4_9BIVA	1.2e-110	407.9	18.50%	49.60%	Shell matrix protein;OS=Bathymodiolus;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003299.1	sp|K1QFN7|K1QFN7_CRAGI	2.8e-122	444.5	96.61%	49.24%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN003300.1	sp|K1Q9D1|K1Q9D1_CRAGI	5.2e-231	806.2	75.89%	90.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003301.1	sp|A0A210PMY9|A0A210PMY9_MIZYE	6.2e-26	125.6	33.01%	31.73%	Ankyrin repeat protein;OS=Mizuhopecten;PE=4;SV=1
GN003302.1	sp|K1P2E7|K1P2E7_CRAGI	6.5e-26	123.2	58.99%	52.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN003303.1	sp|A0A210Q5K8|A0A210Q5K8_MIZYE	5.1e-303	1045.4	100.00%	77.04%	Tripartite motif-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0008270|
GN003304.1	sp|K1Q9B2|K1Q9B2_CRAGI	3.0e-110	404.4	66.36%	72.41%	Transcription factor AP-2 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|
GN003305.1	sp|K1RXP9|K1RXP9_CRAGI	1.4e-22	110.5	97.18%	80.88%	Ventricular zone-expressed PH domain-containing-like protein 1;OS=Crassostrea;PE=4;SV=1
GN003306.1	sp|K1REH1|K1REH1_CRAGI	1.9e-72	278.1	60.55%	75.97%	Low affinity immunoglobulin epsilon Fc receptor;OS=Crassostrea;PE=4;SV=1
GN003310.1	sp|K1PVU0|K1PVU0_CRAGI	1.3e-26	125.2	93.98%	39.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003311.1	sp|D6WYB2|D6WYB2_TRICA	2.6e-70	271.2	95.52%	49.46%	Putative nuclease HARBI1-like Protein;OS=Tribolium;PE=4;SV=1
GN003312.1	sp|A0A226ELX1|A0A226ELX1_FOLCA	2.0e-15	88.6	52.10%	39.84%	Myb/SANT-like DNA-binding domain-containing protein 3;OS=Folsomia;PE=4;SV=1	GO:0003677|
GN003313.1	sp|K1PCS8|K1PCS8_CRAGI	3.1e-54	217.2	96.52%	57.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003315.1	sp|K1PCS8|K1PCS8_CRAGI	3.1e-54	217.2	96.52%	57.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003316.1	sp|K1QWA2|K1QWA2_CRAGI	1.0e-88	332.0	90.76%	75.33%	Tumor protein p53-inducible nuclear protein 1;OS=Crassostrea;PE=4;SV=1
GN003317.1	sp|A0A2C9KRQ3|A0A2C9KRQ3_BIOGL	4.8e-27	126.7	54.24%	68.42%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN003318.1	sp|K1QZJ0|K1QZJ0_CRAGI	4.3e-24	120.2	11.60%	38.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003319.1	sp|K1RRD7|K1RRD7_CRAGI	9.5e-84	315.8	63.00%	75.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001169.1	sp|A0A3M6UCM7|A0A3M6UCM7_9CNID	1.9e-76	292.4	98.65%	34.04%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN003320.1	sp|K1RS90|K1RS90_CRAGI	3.3e-101	373.6	87.40%	74.56%	Metallophosphoesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN003321.1	sp|K1R824|K1R824_CRAGI	1.1e-165	588.6	98.43%	67.96%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN003322.1	sp|K1R824|K1R824_CRAGI	6.2e-172	609.4	99.33%	70.07%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN003323.1	sp|K1R824|K1R824_CRAGI	8.0e-172	609.0	99.33%	70.07%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN003324.1	sp|K1R824|K1R824_CRAGI	1.7e-44	184.5	73.08%	71.68%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN003325.1	sp|K1RS90|K1RS90_CRAGI	2.1e-62	244.6	82.61%	63.16%	Metallophosphoesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN003326.1	sp|A0A2T7PE18|A0A2T7PE18_POMCA	7.7e-80	303.1	90.68%	44.21%	Metalloendopeptidase;OS=Pomacea;PE=4;SV=1	GO:0016020|	GO:0004222|GO:0008270|
GN003327.1	sp|A0A210PVA4|A0A210PVA4_MIZYE	1.3e-32	145.2	97.22%	49.72%	Protein DGCR14;OS=Mizuhopecten;PE=4;SV=1
GN001170.1	sp|K1Q925|K1Q925_CRAGI	1.3e-112	412.9	46.51%	62.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003328.1	sp|A0A210PVA4|A0A210PVA4_MIZYE	1.2e-105	388.7	99.68%	65.16%	Protein DGCR14;OS=Mizuhopecten;PE=4;SV=1
GN003329.1	sp|K1RS85|K1RS85_CRAGI	8.0e-158	563.1	83.43%	84.01%	Switch-associated protein 70;OS=Crassostrea;PE=4;SV=1
GN003330.1	sp|K1R819|K1R819_CRAGI	1.1e-90	338.6	81.07%	76.53%	UPF0516 protein C12orf72-like protein;OS=Crassostrea;PE=4;SV=1
GN003331.1	sp|A0A210PXW2|A0A210PXW2_MIZYE	2.5e-99	367.5	100.00%	63.70%	E3 ubiquitin-protein ligase NRDP1;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN003332.1	sp|K1PRJ1|K1PRJ1_CRAGI	5.1e-55	220.7	89.65%	38.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003333.1	sp|K1PRJ1|K1PRJ1_CRAGI	1.3e-78	299.7	74.38%	40.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003334.1	sp|K1RXP6|K1RXP6_CRAGI	1.4e-163	582.0	76.76%	67.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN003335.1	sp|K1RXP6|K1RXP6_CRAGI	2.8e-168	597.8	97.35%	51.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN003336.1	sp|K1QS88|K1QS88_CRAGI	1.6e-152	545.4	91.43%	49.84%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN000949.1	sp|K1QXK8|K1QXK8_CRAGI	7.4e-66	255.8	98.95%	72.11%	Tyramine receptor ser-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|GO:0004983|
GN003337.1	sp|A0A210PQ26|A0A210PQ26_MIZYE	1.7e-72	278.1	96.98%	58.04%	Thioredoxin-like protein AAED1;OS=Mizuhopecten;PE=4;SV=1	GO:0055114|
GN003338.1	sp|K1PVU0|K1PVU0_CRAGI	1.3e-26	125.2	93.98%	39.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003341.1	sp|K1QD94|K1QD94_CRAGI	4.0e-63	246.5	77.78%	90.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003342.1	sp|K1RKQ0|K1RKQ0_CRAGI	3.2e-232	809.7	99.78%	86.37%	Noelin-3;OS=Crassostrea;PE=4;SV=1
GN003343.1	sp|A0A2C9LJV3|A0A2C9LJV3_BIOGL	1.2e-46	192.6	98.63%	33.43%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN003344.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.1e-57	228.8	94.55%	55.98%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN003345.1	sp|K1PPT3|K1PPT3_CRAGI	2.9e-51	208.4	58.58%	37.46%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN001171.1	sp|K1PLZ9|K1PLZ9_CRAGI	0.0e+00	1562.0	99.74%	75.55%	L-ascorbate oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN003347.1	sp|K1R171|K1R171_CRAGI	0.0e+00	1770.0	100.00%	73.21%	GAS2-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008017|
GN003348.1	sp|K1QLX2|K1QLX2_CRAGI	5.4e-131	473.8	58.40%	71.43%	Sodium/nucleoside cotransporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005337|
GN003349.1	sp|Q70MM3|Q70MM3_CRAGI	2.4e-84	317.0	100.00%	90.06%	Ferritin;OS=Crassostrea;PE=2;SV=1	GO:0005623|	GO:0008199|GO:0004322|	GO:0006879|GO:0006826|
GN003350.1	sp|K1R167|K1R167_CRAGI	7.5e-49	200.3	81.44%	39.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003354.1	sp|K1P6L6|K1P6L6_CRAGI	6.7e-119	432.6	94.50%	76.36%	Potassium voltage-gated channel protein Shaw;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN003355.1	sp|K1P6L6|K1P6L6_CRAGI	1.8e-121	441.0	100.00%	84.78%	Potassium voltage-gated channel protein Shaw;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN003356.1	sp|K1QCL3|K1QCL3_CRAGI	5.1e-33	145.6	97.80%	69.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035098|	GO:0016571|
GN003357.1	sp|K1PCL9|K1PCL9_CRAGI	3.3e-168	597.0	97.60%	71.11%	Solute carrier family 28 member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005337|
GN003358.1	sp|K1PS44|K1PS44_CRAGI	1.9e-200	704.5	99.67%	70.03%	Protein HIRA;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0006325|GO:0006355|GO:0006351|
GN003359.1	sp|K1PS44|K1PS44_CRAGI	4.2e-38	162.9	76.61%	86.17%	Protein HIRA;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0006325|GO:0006355|GO:0006351|
GN003360.1	sp|W4YT04|W4YT04_STRPU	2.7e-15	85.9	94.12%	72.34%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000775|GO:0000417|GO:0000790|	GO:0003714|	GO:0030702|GO:0006336|GO:0000070|GO:0031935|GO:0006351|
GN003362.1	sp|K1PS44|K1PS44_CRAGI	7.9e-35	151.4	92.21%	94.29%	Protein HIRA;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0006325|GO:0006355|GO:0006351|
GN003369.1	sp|K1QWS5|K1QWS5_CRAGI	1.1e-301	1040.8	97.10%	88.44%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN003370.1	sp|K1RH18|K1RH18_CRAGI	8.8e-212	741.9	91.45%	87.95%	Sarcalumenin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005525|
GN003371.1	sp|K1Q9K7|K1Q9K7_CRAGI	1.8e-87	327.8	97.78%	75.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN003372.1	sp|K1QHZ5|K1QHZ5_CRAGI	7.2e-62	242.7	76.30%	96.25%	NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0051539|GO:0016651|
GN003373.1	sp|K1RH23|K1RH23_CRAGI	6.9e-240	835.1	100.00%	87.87%	Tubulin delta chain;OS=Crassostrea;PE=3;SV=1	GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN003374.1	sp|A0A1Z5L4K9|A0A1Z5L4K9_ORNMO	7.6e-11	73.2	44.60%	37.23%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0008270|
GN001174.1	sp|K1PXT9|K1PXT9_CRAGI	7.6e-16	90.5	38.64%	40.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003375.1	sp|A0A1Z5L4K9|A0A1Z5L4K9_ORNMO	7.6e-11	73.2	44.60%	37.23%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0008270|
GN003376.1	sp|K1Q9L1|K1Q9L1_CRAGI	5.7e-81	306.2	97.36%	66.67%	39S ribosomal protein L50, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|GO:0005840|
GN003377.1	sp|A0A210QHL1|A0A210QHL1_MIZYE	0.0e+00	1524.2	86.80%	74.85%	EF-hand calcium-binding domain-containing protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN003378.1	sp|Q8MY13|Q8MY13_CRAGI	1.1e-107	395.2	99.62%	79.39%	PAR domain subfamily bZIP;OS=Crassostrea;PE=2;SV=1	GO:0003700|	GO:0006357|
GN003379.1	sp|K1QQK0|K1QQK0_CRAGI	4.8e-43	181.0	27.48%	76.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003380.1	sp|K1QQK0|K1QQK0_CRAGI	9.2e-21	104.8	98.80%	64.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003381.1	sp|A0A210QHL1|A0A210QHL1_MIZYE	0.0e+00	1443.7	98.98%	75.29%	EF-hand calcium-binding domain-containing protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN001175.1	sp|K1R5Y1|K1R5Y1_CRAGI	0.0e+00	1091.6	97.76%	85.41%	Metabotropic glutamate receptor 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|GO:0008378|	GO:0006486|
GN003385.1	sp|K1RUP5|K1RUP5_CRAGI	1.6e-32	143.7	100.00%	88.00%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0004383|	GO:0035556|
GN003386.1	sp|K1R4G7|K1R4G7_CRAGI	5.9e-143	512.7	97.30%	73.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003390.1	sp|K1RUP5|K1RUP5_CRAGI	1.6e-32	143.7	100.00%	88.00%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0004383|	GO:0035556|
GN003391.1	sp|K1RUP5|K1RUP5_CRAGI	0.0e+00	1115.9	98.88%	91.64%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0004383|	GO:0035556|
GN003392.1	sp|K1RGW2|K1RGW2_CRAGI	4.2e-209	733.4	91.95%	62.87%	Serine/threonine-protein kinase PINK1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001176.1	sp|K1R5Y1|K1R5Y1_CRAGI	6.4e-48	195.7	77.78%	85.58%	Metabotropic glutamate receptor 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|GO:0008378|	GO:0006486|
GN003399.1	sp|K1QXL2|K1QXL2_CRAGI	8.5e-162	575.5	98.44%	78.31%	Solute carrier family 35 member C2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003400.1	sp|K1QQC3|K1QQC3_CRAGI	1.0e-90	339.3	97.32%	60.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003401.1	sp|K1RGV7|K1RGV7_CRAGI	3.6e-163	580.1	93.73%	75.87%	Diphosphomevalonate decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0005524|GO:0004163|	GO:0019287|
GN003405.1	sp|K1R3E8|K1R3E8_CRAGI	4.2e-24	115.5	97.01%	82.81%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN003406.1	sp|K1R9D4|K1R9D4_CRAGI	1.4e-245	854.4	100.00%	80.47%	N6-adenosine-methyltransferase 70 kDa subunit;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0016422|
GN003407.1	sp|K1QTV5|K1QTV5_CRAGI	9.1e-114	415.6	100.00%	85.71%	Transcriptional repressor scratch 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000950.1	sp|K1PVQ2|K1PVQ2_CRAGI	4.0e-71	273.1	100.00%	76.74%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003408.1	sp|K1QST7|K1QST7_CRAGI	7.2e-26	122.1	95.33%	59.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003410.1	sp|A0A0A1UA62|A0A0A1UA62_ENTIV	2.5e-37	163.3	34.30%	34.50%	ATP-dependent DNA helicase;OS=Entamoeba;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN003411.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	3.1e-99	368.2	79.04%	42.42%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN003412.1	sp|K1S4P3|K1S4P3_CRAGI	1.3e-172	612.1	66.61%	75.70%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN003413.1	sp|K1P9P0|K1P9P0_CRAGI	4.7e-38	162.9	89.86%	59.35%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN003414.1	sp|K1P9P0|K1P9P0_CRAGI	4.5e-193	679.9	96.83%	67.05%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN003415.1	sp|K1QMY7|K1QMY7_CRAGI	1.2e-31	141.4	70.43%	83.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003416.1	sp|K1R8B6|K1R8B6_CRAGI	6.0e-223	778.9	100.00%	85.40%	Putative sodium-coupled neutral amino acid transporter 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003417.1	sp|K1S4P3|K1S4P3_CRAGI	1.3e-172	612.1	66.61%	75.70%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN003418.1	sp|A0A3M6UX53|A0A3M6UX53_9CNID	3.4e-30	137.5	59.46%	45.93%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN003419.1	sp|K1Q179|K1Q179_CRAGI	2.3e-86	323.9	100.00%	81.54%	Docking protein 5;OS=Crassostrea;PE=4;SV=1
GN003420.1	sp|K1Q9N7|K1Q9N7_CRAGI	5.5e-135	486.5	99.76%	75.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016459|	GO:0003774|
GN003421.1	sp|K1QHP3|K1QHP3_CRAGI	1.7e-184	651.0	100.00%	83.62%	TAR DNA-binding protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003723|
GN003422.1	sp|K1S0V2|K1S0V2_CRAGI	8.6e-16	89.4	72.47%	38.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003423.1	sp|A0A1X7UG29|A0A1X7UG29_AMPQE	8.2e-20	102.8	91.33%	30.34%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN003424.1	sp|A0A076KXK6|A0A076KXK6_CRAGI	1.1e-215	755.4	97.52%	52.78%	Putative tyrosinase;OS=Crassostrea;PE=2;SV=1	GO:0046872|GO:0004503|
GN003425.1	sp|K1PAV4|K1PAV4_CRAGI	1.2e-183	648.7	92.39%	60.11%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN003426.1	sp|K1QAP4|K1QAP4_CRAGI	8.3e-165	585.9	100.00%	55.94%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN003428.1	sp|K1PQ94|K1PQ94_CRAGI	1.4e-79	301.6	97.85%	65.94%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN003429.1	sp|K1PI56|K1PI56_CRAGI	5.0e-62	243.4	97.20%	52.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN001177.1	sp|K1PHD8|K1PHD8_CRAGI	2.2e-09	68.2	24.49%	63.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003430.1	sp|K1PI56|K1PI56_CRAGI	4.5e-81	307.0	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003431.1	sp|K1PI56|K1PI56_CRAGI	3.7e-80	303.9	84.39%	59.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003432.1	sp|K1PI56|K1PI56_CRAGI	6.9e-82	309.7	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003433.1	sp|K1PI56|K1PI56_CRAGI	2.6e-81	307.8	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003434.1	sp|K1PQ94|K1PQ94_CRAGI	7.1e-79	299.3	97.42%	65.35%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN003436.1	sp|K1PI56|K1PI56_CRAGI	5.0e-62	243.4	97.20%	52.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003437.1	sp|K1PI56|K1PI56_CRAGI	4.5e-81	307.0	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003438.1	sp|K1PI56|K1PI56_CRAGI	9.8e-81	305.8	84.39%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003439.1	sp|K1PI56|K1PI56_CRAGI	9.8e-81	305.8	84.39%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN001178.1	sp|K1PX79|K1PX79_CRAGI	3.5e-74	285.0	64.48%	38.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003440.1	sp|K1PI56|K1PI56_CRAGI	5.9e-81	306.6	83.01%	59.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003441.1	sp|K1PI56|K1PI56_CRAGI	2.6e-81	307.8	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003442.1	sp|K1PQ94|K1PQ94_CRAGI	3.5e-69	266.9	98.09%	63.59%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN003443.1	sp|K1PI56|K1PI56_CRAGI	7.7e-63	246.1	97.20%	52.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003444.1	sp|K1PI56|K1PI56_CRAGI	3.9e-65	253.8	80.52%	58.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003445.1	sp|K1PI56|K1PI56_CRAGI	5.3e-82	310.1	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN003446.1	sp|A0A210Q1D5|A0A210Q1D5_MIZYE	7.6e-23	113.6	74.29%	26.98%	Alpha-protein kinase vwkA;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004674|
GN003447.1	sp|K1P4D1|K1P4D1_CRAGI	1.8e-120	438.3	97.71%	54.44%	Mitochondrial inner membrane protein OXA1L;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0032977|
GN003448.1	sp|K1RC63|K1RC63_CRAGI	2.1e-12	77.4	85.59%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003449.1	sp|K1QAN2|K1QAN2_CRAGI	8.1e-96	356.3	90.60%	59.94%	Protein SLC7A6OS;OS={ECO:0000313|EMBL:EKC18541.1};;PE=4;SV=1
GN003450.1	sp|K1PI43|K1PI43_CRAGI	2.4e-54	218.0	66.42%	62.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003451.1	sp|K1PAU1|K1PAU1_CRAGI	1.1e-120	438.7	93.75%	60.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003452.1	sp|K1PAU1|K1PAU1_CRAGI	7.1e-163	578.9	100.00%	75.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003453.1	sp|K1P4C3|K1P4C3_CRAGI	2.5e-102	377.5	83.09%	76.96%	Transmembrane protein with metallophosphoesterase domain;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN003454.1	sp|K1QAM7|K1QAM7_CRAGI	5.7e-228	795.8	92.86%	70.26%	Copine-7;OS=Crassostrea;PE=4;SV=1
GN003455.1	sp|K1PQ79|K1PQ79_CRAGI	8.9e-256	888.3	98.10%	77.99%	Copine-3;OS=Crassostrea;PE=4;SV=1
GN003456.1	sp|R7TDX6|R7TDX6_CAPTE	8.3e-172	609.4	99.67%	50.08%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN003457.1	sp|K1QL12|K1QL12_CRAGI	2.1e-178	630.6	99.17%	83.52%	Meiotic recombination protein SPO11;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0005524|GO:0003824|GO:0003677|	GO:0000737|
GN003458.1	sp|K1QD68|K1QD68_CRAGI	1.9e-207	727.6	100.00%	80.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN003459.1	sp|K1PSS5|K1PSS5_CRAGI	9.0e-33	146.4	61.40%	90.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN003460.1	sp|K1PKR9|K1PKR9_CRAGI	0.0e+00	1174.5	100.00%	72.82%	Protein tiptop;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0048749|GO:0048730|GO:0000122|
GN003462.1	sp|K1PD67|K1PD67_CRAGI	0.0e+00	1640.2	100.00%	79.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN003463.1	sp|K1P739|K1P739_CRAGI	1.6e-146	524.2	98.57%	85.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003464.1	sp|K1QD63|K1QD63_CRAGI	3.0e-112	410.2	98.36%	84.10%	GTP-binding protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0000287|
GN003465.1	sp|K1QBR4|K1QBR4_CRAGI	2.8e-88	330.5	95.15%	80.00%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN003466.1	sp|K1QRV3|K1QRV3_CRAGI	1.4e-36	157.9	95.38%	69.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003467.1	sp|K1QRV3|K1QRV3_CRAGI	5.7e-67	259.2	88.34%	88.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003468.1	sp|K1QJR0|K1QJR0_CRAGI	1.0e-267	928.7	58.83%	79.19%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN003469.1	sp|K1PUH3|K1PUH3_CRAGI	7.2e-49	201.4	22.54%	57.65%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0016021|
GN003470.1	sp|K1QYC9|K1QYC9_CRAGI	5.3e-24	117.5	30.41%	59.38%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1
GN003472.1	sp|A0A210QQ57|A0A210QQ57_MIZYE	7.0e-43	179.1	75.50%	71.68%	ATPase WRNIP1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006281|GO:0006260|
GN003473.1	sp|A0A210QQ57|A0A210QQ57_MIZYE	8.4e-58	229.6	73.31%	55.16%	ATPase WRNIP1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006281|GO:0006260|
GN001182.1	sp|K1PX79|K1PX79_CRAGI	5.8e-81	306.6	86.75%	53.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003474.1	sp|A0A210QQ57|A0A210QQ57_MIZYE	2.6e-20	104.8	81.55%	35.74%	ATPase WRNIP1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006281|GO:0006260|
GN003475.1	sp|T1PQT0|T1PQT0_ANABR	6.4e-29	134.4	59.76%	27.36%	Bactericidal permeability-increasing protein/lipopolysaccharide-binding protein;OS=Anadara;PE=2;SV=1	GO:0005615|	GO:0008289|
GN003476.1	sp|C4NY69|C4NY69_CRAGI	1.7e-157	561.2	99.22%	71.47%	Bactericidal permeability increasing protein;OS=Crassostrea;PE=2;SV=1	GO:0005615|	GO:0001530|	GO:0050829|GO:0006955|
GN003477.1	sp|C4NY81|C4NY81_CRAGI	3.4e-55	219.9	100.00%	75.52%	Bactericidal permeability increasing protein;OS=Crassostrea;PE=2;SV=1	GO:0005615|	GO:0001530|	GO:0050829|GO:0006955|
GN003478.1	sp|K1R8L0|K1R8L0_CRAGI	8.6e-155	552.0	100.00%	78.05%	Dehydrogenase/reductase SDR family member 1;OS=Crassostrea;PE=4;SV=1
GN003479.1	sp|K1RKE8|K1RKE8_CRAGI	2.6e-307	1059.7	100.00%	77.38%	Cirhin;OS=Crassostrea;PE=4;SV=1
GN003480.1	sp|K1PPS0|K1PPS0_CRAGI	8.0e-34	149.8	51.13%	48.92%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN003481.1	sp|J9Q392|J9Q392_OSTED	2.4e-94	350.5	84.62%	94.86%	Omega class glutathione S transferase;OS=Ostrea;PE=2;SV=1	GO:0005737|	GO:0004364|
GN003482.1	sp|G8XUN4|G8XUN4_CRAAR	9.4e-242	841.3	100.00%	93.53%	Adenosylhomocysteinase;OS=Crassostrea;PE=2;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003483.1	sp|K1RW85|K1RW85_CRAGI	1.2e-123	448.0	98.71%	95.20%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003484.1	sp|K1RW85|K1RW85_CRAGI	1.3e-91	341.3	96.74%	90.40%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003485.1	sp|K1RW85|K1RW85_CRAGI	5.2e-40	169.1	81.65%	92.05%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003486.1	sp|K1RW85|K1RW85_CRAGI	1.2e-123	448.0	98.71%	95.20%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003487.1	sp|K1RW85|K1RW85_CRAGI	3.1e-93	346.7	96.74%	91.53%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003488.1	sp|K1RW85|K1RW85_CRAGI	2.3e-40	170.2	81.65%	92.05%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003489.1	sp|K1RW85|K1RW85_CRAGI	2.2e-135	487.3	90.22%	95.16%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003490.1	sp|K1RW85|K1RW85_CRAGI	3.1e-93	346.7	96.74%	91.53%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003491.1	sp|K1RW85|K1RW85_CRAGI	2.3e-40	170.2	81.65%	92.05%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003492.1	sp|K1RW85|K1RW85_CRAGI	8.9e-72	275.0	100.00%	90.21%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003493.1	sp|K1RW85|K1RW85_CRAGI	2.1e-41	173.7	81.65%	94.32%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003494.1	sp|K1RW85|K1RW85_CRAGI	3.8e-51	206.5	77.14%	95.33%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003495.1	sp|K1RW85|K1RW85_CRAGI	5.8e-18	94.7	94.12%	100.00%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003496.1	sp|K1RW85|K1RW85_CRAGI	1.3e-91	341.3	96.74%	90.40%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003497.1	sp|K1RW85|K1RW85_CRAGI	1.0e-40	171.4	81.65%	93.18%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003498.1	sp|K1RW85|K1RW85_CRAGI	2.7e-107	393.7	100.00%	83.41%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN003499.1	sp|K1RA42|K1RA42_CRAGI	9.3e-61	238.8	96.83%	80.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003500.1	sp|K1QZT8|K1QZT8_CRAGI	1.6e-182	644.4	94.16%	84.46%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003501.1	sp|K1S5C5|K1S5C5_CRAGI	9.4e-36	154.8	100.00%	79.00%	Leydig cell tumor 10 kDa-like protein;OS=Crassostrea;PE=4;SV=1
GN003503.1	sp|K1RFS3|K1RFS3_CRAGI	2.0e-294	1016.9	98.14%	71.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001185.1	sp|K1PX79|K1PX79_CRAGI	1.2e-86	325.5	97.61%	53.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003504.1	sp|K1QPB8|K1QPB8_CRAGI	5.8e-186	656.0	79.07%	89.94%	NAD kinase;OS=Crassostrea;PE=3;SV=1	GO:0003951|	GO:0019674|GO:0006741|
GN003505.1	sp|K1QFR8|K1QFR8_CRAGI	1.4e-123	449.5	99.60%	44.86%	Protein SIX6OS1;OS=Crassostrea;PE=4;SV=1
GN003506.1	sp|K1RMU7|K1RMU7_CRAGI	4.5e-57	226.5	93.85%	80.84%	Espin;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0051017|
GN003507.1	sp|K1RMU7|K1RMU7_CRAGI	1.3e-106	392.5	77.41%	60.73%	Espin;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0051017|
GN003510.1	sp|K1RV58|K1RV58_CRAGI	2.7e-28	132.5	16.30%	74.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003512.1	sp|K1RV58|K1RV58_CRAGI	1.1e-31	143.3	24.50%	72.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001186.1	sp|K1QH89|K1QH89_CRAGI	2.3e-113	414.1	77.37%	88.63%	SCO1-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005743|	GO:0005507|	GO:0006878|GO:0006825|GO:0008535|
GN003515.1	sp|K1R8Z3|K1R8Z3_CRAGI	1.2e-225	788.1	100.00%	68.17%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN003516.1	sp|A0A210R2S7|A0A210R2S7_MIZYE	6.0e-149	532.7	96.41%	79.08%	Solute carrier family 35 member E2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN003517.1	sp|K1RMV4|K1RMV4_CRAGI	3.9e-278	962.6	100.00%	77.16%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003518.1	sp|K1R3I6|K1R3I6_CRAGI	4.7e-113	413.3	75.54%	86.01%	Nucleolar complex protein 2-like protein;OS=Crassostrea;PE=4;SV=1
GN003519.1	sp|K1QX33|K1QX33_CRAGI	2.1e-59	234.6	64.86%	83.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001187.1	sp|K1PQ78|K1PQ78_CRAGI	1.3e-104	385.2	98.67%	55.89%	Substrate-specific endoprotease Tex31;OS=Crassostrea;PE=3;SV=1	GO:0008233|
GN003520.1	sp|K1PS17|K1PS17_CRAGI	3.5e-154	551.6	100.00%	36.66%	Protein G7c;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003521.1	sp|K1QPD6|K1QPD6_CRAGI	0.0e+00	1807.7	77.69%	85.62%	Ubiquitin conjugation factor E4 B;OS=Crassostrea;PE=4;SV=1	GO:0000151|	GO:0034450|	GO:0006511|
GN003522.1	sp|K1QX37|K1QX37_CRAGI	7.6e-104	382.1	96.68%	94.09%	Enolase;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0000015|	GO:0000287|GO:0004634|	GO:0006096|
GN003523.1	sp|K1QFS9|K1QFS9_CRAGI	2.5e-66	259.2	28.37%	69.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003524.1	sp|A0A2C9JTU3|A0A2C9JTU3_BIOGL	2.3e-193	681.0	98.34%	58.68%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|	GO:0022857|	GO:0006865|
GN003525.1	sp|K1R3J2|K1R3J2_CRAGI	0.0e+00	1121.7	99.77%	71.63%	Paired box protein Pax-2-A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN003526.1	sp|K1R3J2|K1R3J2_CRAGI	3.6e-95	353.6	89.10%	80.67%	Paired box protein Pax-2-A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN003529.1	sp|K1RMW3|K1RMW3_CRAGI	0.0e+00	1113.2	39.49%	89.37%	Protein kinase C;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004697|	GO:0007163|GO:0035556|
GN003530.1	sp|A0A1S3HLK8|A0A1S3HLK8_LINUN	2.2e-129	467.2	100.00%	86.59%	F-actin-capping protein subunit beta;OS=Lingula;PE=3;SV=1	GO:0005737|GO:0008290|	GO:0003779|	GO:0030036|GO:0051016|
GN003531.1	sp|K1QFT4|K1QFT4_CRAGI	7.9e-45	185.3	86.18%	90.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN003532.1	sp|K1QFT4|K1QFT4_CRAGI	2.7e-148	530.4	100.00%	83.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN003533.1	sp|K1QPF0|K1QPF0_CRAGI	2.2e-38	165.2	58.44%	50.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001188.1	sp|K1PQ78|K1PQ78_CRAGI	6.3e-182	642.5	84.11%	78.18%	Substrate-specific endoprotease Tex31;OS=Crassostrea;PE=3;SV=1	GO:0008233|
GN003534.1	sp|K1R3J5|K1R3J5_CRAGI	5.6e-42	176.4	96.79%	54.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003535.1	sp|K1QJE3|K1QJE3_CRAGI	0.0e+00	1748.8	99.71%	80.92%	Forkhead-associated domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN003536.1	sp|K1QD31|K1QD31_CRAGI	5.3e-217	759.6	100.00%	76.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003537.1	sp|A0A210Q0K6|A0A210Q0K6_MIZYE	1.6e-250	871.7	98.79%	44.01%	Transmembrane protein 132C;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN003538.1	sp|K1R4Y6|K1R4Y6_CRAGI	0.0e+00	2170.2	99.27%	75.57%	Carboxypeptidase D;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004181|GO:0008270|
GN003539.1	sp|K1PXL9|K1PXL9_CRAGI	4.1e-133	480.7	58.21%	77.26%	Williams-Beuren syndrome chromosomal region 14 protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN003540.1	sp|K1PXL9|K1PXL9_CRAGI	3.4e-136	490.3	99.45%	75.27%	Williams-Beuren syndrome chromosomal region 14 protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN003541.1	sp|K1R4Z3|K1R4Z3_CRAGI	4.0e-145	519.6	100.00%	92.86%	Malate dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0030060|	GO:0005975|GO:0006099|
GN003542.1	sp|K1PUH6|K1PUH6_CRAGI	5.5e-97	359.4	100.00%	78.18%	Abhydrolase domain-containing protein 11;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN003543.1	sp|K1P8D2|K1P8D2_CRAGI	0.0e+00	1435.6	100.00%	90.37%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN003544.1	sp|K1QEN1|K1QEN1_CRAGI	0.0e+00	1708.7	100.00%	90.16%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN003545.1	sp|K1PVV3|K1PVV3_CRAGI	1.4e-77	296.2	80.27%	37.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003546.1	sp|K1PVV3|K1PVV3_CRAGI	4.5e-73	281.2	78.89%	37.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003547.1	sp|K1QL84|K1QL84_CRAGI	1.2e-75	290.0	70.31%	34.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003548.1	sp|K1RTQ6|K1RTQ6_CRAGI	8.8e-168	595.1	100.00%	91.05%	Fructose-bisphosphate aldolase;OS=Crassostrea;PE=3;SV=1	GO:0004332|	GO:0006096|
GN003549.1	sp|K1QMC1|K1QMC1_CRAGI	5.1e-114	417.5	85.67%	50.59%	DNA excision repair protein ERCC-6-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN000952.1	sp|K1QMQ3|K1QMQ3_CRAGI	1.1e-22	112.5	60.00%	48.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001191.1	sp|K1PHE2|K1PHE2_CRAGI	3.8e-225	786.2	100.00%	89.13%	TAR DNA-binding protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003723|
GN003550.1	sp|K1QMC1|K1QMC1_CRAGI	0.0e+00	1232.2	85.93%	75.41%	DNA excision repair protein ERCC-6-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN003551.1	sp|K1R8R6|K1R8R6_CRAGI	2.1e-194	683.7	100.00%	93.94%	Fructose-bisphosphate aldolase;OS=Crassostrea;PE=3;SV=1	GO:0004332|	GO:0006096|
GN003552.1	sp|K1Q8S8|K1Q8S8_CRAGI	0.0e+00	1237.2	95.82%	85.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001192.1	sp|K1PP00|K1PP00_CRAGI	4.3e-22	109.8	64.52%	63.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003553.1	sp|K1QGV6|K1QGV6_CRAGI	5.2e-275	952.2	94.94%	78.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003554.1	sp|K1R8Q5|K1R8Q5_CRAGI	1.1e-61	241.5	100.00%	80.00%	Coactosin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN003555.1	sp|K1Q8T5|K1Q8T5_CRAGI	6.6e-99	367.9	40.94%	53.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001193.1	sp|A0A210Q5T0|A0A210Q5T0_MIZYE	4.4e-50	203.8	80.00%	48.74%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001194.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	1.2e-12	77.8	93.98%	53.25%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003572.1	sp|K1PTZ9|K1PTZ9_CRAGI	3.3e-15	87.0	97.83%	41.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003575.1	sp|A0A2S2QV27|A0A2S2QV27_9HEMI	1.9e-41	175.6	98.92%	29.19%	Putative RNA-directed DNA polymerase;OS=Sipha;PE=4;SV=1	GO:0003676|GO:0003964|GO:0004523|
GN003576.1	sp|K1RLN7|K1RLN7_CRAGI	3.3e-18	97.8	42.04%	45.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001195.1	sp|K1QPH8|K1QPH8_CRAGI	1.6e-98	365.2	100.00%	57.69%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN003578.1	sp|C3XT18|C3XT18_BRAFL	3.3e-21	106.7	92.98%	48.65%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN001196.1	sp|K1Q3X1|K1Q3X1_CRAGI	1.5e-119	434.5	100.00%	91.32%	Y+L amino acid transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN003580.1	sp|C3XT18|C3XT18_BRAFL	3.3e-21	106.7	92.98%	48.65%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN003581.1	sp|K1QXP3|K1QXP3_CRAGI	0.0e+00	1105.1	100.00%	77.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003582.1	sp|K1QQ11|K1QQ11_CRAGI	3.0e-78	297.4	78.85%	78.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003583.1	sp|K1QQQ6|K1QQQ6_CRAGI	6.1e-226	789.6	100.00%	51.69%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN001197.1	sp|K1PND9|K1PND9_CRAGI	8.5e-25	118.6	91.30%	56.19%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN003586.1	sp|K1QBH6|K1QBH6_CRAGI	2.2e-34	150.2	100.00%	71.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003587.1	sp|K1QQQ6|K1QQQ6_CRAGI	5.4e-246	857.1	62.07%	51.45%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN003588.1	sp|V3Z3P3|V3Z3P3_LOTGI	1.8e-10	70.9	86.00%	39.80%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN003596.1	sp|K1R8G0|K1R8G0_CRAGI	5.6e-120	436.4	94.89%	65.31%	Uncharacterized protein C1orf93-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055114|
GN003600.1	sp|K1QBH6|K1QBH6_CRAGI	2.2e-34	150.2	100.00%	71.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003601.1	sp|K1PJ05|K1PJ05_CRAGI	5.5e-181	641.0	57.47%	43.98%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN003605.1	sp|K1QBH6|K1QBH6_CRAGI	2.2e-34	150.2	100.00%	71.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003606.1	sp|K1QQQ6|K1QQQ6_CRAGI	5.4e-246	857.1	62.07%	51.45%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN003608.1	sp|K1QIH9|K1QIH9_CRAGI	9.5e-130	468.8	98.17%	76.88%	Suppressor of tumorigenicity protein 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003609.1	sp|K1QC17|K1QC17_CRAGI	2.0e-77	293.9	98.74%	82.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003610.1	sp|K1QIH9|K1QIH9_CRAGI	4.7e-117	426.4	100.00%	77.46%	Suppressor of tumorigenicity protein 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000953.1	sp|K1QXK8|K1QXK8_CRAGI	7.0e-53	212.2	92.25%	76.92%	Tyramine receptor ser-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|GO:0004983|
GN001198.1	sp|K1QI80|K1QI80_CRAGI	1.3e-100	371.3	97.57%	91.50%	Cell division protein kinase 10;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0051301|
GN003611.1	sp|K1QQQ6|K1QQQ6_CRAGI	4.0e-38	162.9	96.61%	64.91%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN003612.1	sp|K1QIH9|K1QIH9_CRAGI	9.5e-130	468.8	98.17%	76.88%	Suppressor of tumorigenicity protein 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003613.1	sp|K1QQQ6|K1QQQ6_CRAGI	4.0e-38	162.9	96.61%	64.91%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN003614.1	sp|K1RLN7|K1RLN7_CRAGI	3.3e-18	97.8	42.04%	45.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003615.1	sp|K1Q5B6|K1Q5B6_CRAGI	1.6e-72	279.3	66.26%	42.69%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN001199.1	sp|K1QBV5|K1QBV5_CRAGI	2.1e-39	167.5	84.31%	69.53%	Cytochrome b-245 light chain;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|
GN003620.1	sp|C3XT18|C3XT18_BRAFL	2.1e-18	97.4	79.83%	50.00%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN003621.1	sp|K1QIH9|K1QIH9_CRAGI	4.7e-117	426.4	100.00%	77.46%	Suppressor of tumorigenicity protein 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003626.1	sp|K1QLK4|K1QLK4_CRAGI	4.0e-88	331.3	94.12%	38.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003629.1	sp|K1QRF1|K1QRF1_CRAGI	5.7e-198	695.7	100.00%	88.40%	Suppressor of cytokine signaling 6;OS=Crassostrea;PE=4;SV=1	GO:0035556|GO:0016567|GO:0040008|
GN003630.1	sp|K1Q5A9|K1Q5A9_CRAGI	3.0e-149	533.9	85.89%	70.74%	39S ribosomal protein L38, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN003631.1	sp|K1PYD5|K1PYD5_CRAGI	8.9e-44	181.8	100.00%	82.40%	CCAAT/enhancer-binding protein gamma;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN003632.1	sp|K1PR50|K1PR50_CRAGI	1.6e-118	431.4	100.00%	73.65%	CCAAT/enhancer-binding protein delta;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN003633.1	sp|K1PJD8|K1PJD8_CRAGI	1.3e-97	361.7	100.00%	78.60%	CCAAT/enhancer-binding protein delta;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN003634.1	sp|K1QRF0|K1QRF0_CRAGI	2.0e-85	321.6	74.35%	70.11%	CCAAT/enhancer-binding protein delta;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN003635.1	sp|K1PR59|K1PR59_CRAGI	1.3e-117	428.3	97.41%	75.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003638.1	sp|K1PXW2|K1PXW2_CRAGI	7.5e-153	545.8	92.25%	78.32%	SET domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN003639.1	sp|K1QI52|K1QI52_CRAGI	1.6e-199	700.7	100.00%	89.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001201.1	sp|K1QPI8|K1QPI8_CRAGI	1.5e-149	535.4	97.97%	75.30%	Zinc finger protein 83;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003642.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	5.5e-29	134.4	27.21%	56.64%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003644.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	3.1e-16	90.5	100.00%	38.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003646.1	sp|K1Q5B2|K1Q5B2_CRAGI	2.1e-225	786.9	100.00%	85.25%	Tyrosine aminotransferase;OS=Crassostrea;PE=4;SV=1	GO:0004838|GO:0030170|	GO:0009072|GO:0009058|
GN001202.1	sp|K1Q3F8|K1Q3F8_CRAGI	1.4e-254	884.8	98.37%	83.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN003647.1	sp|K1PYD8|K1PYD8_CRAGI	8.4e-64	250.4	28.19%	76.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003648.1	sp|K1PR53|K1PR53_CRAGI	5.2e-192	676.0	100.00%	79.30%	5-hydroxytryptamine receptor 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN003649.1	sp|K1QRF7|K1QRF7_CRAGI	5.9e-77	292.7	98.54%	76.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003651.1	sp|A0A210PLM5|A0A210PLM5_MIZYE	1.7e-98	366.3	81.88%	32.38%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN003652.1	sp|A0A210PLM5|A0A210PLM5_MIZYE	3.5e-99	368.6	81.88%	32.52%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN003653.1	sp|A0A210PLM5|A0A210PLM5_MIZYE	1.9e-102	379.4	86.07%	33.48%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN003654.1	sp|K1RGX2|K1RGX2_CRAGI	1.0e-75	289.3	86.24%	59.44%	A kinase anchor protein 10, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN003655.1	sp|K1QWN4|K1QWN4_CRAGI	1.1e-74	285.0	91.53%	82.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003656.1	sp|K1QTS2|K1QTS2_CRAGI	6.1e-85	318.9	100.00%	93.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003659.1	sp|K1R9A6|K1R9A6_CRAGI	8.1e-50	201.8	99.18%	81.67%	HEAT repeat-containing protein 7A;OS=Crassostrea;PE=4;SV=1
GN003660.1	sp|K1R9A6|K1R9A6_CRAGI	5.4e-12	75.1	74.14%	83.33%	HEAT repeat-containing protein 7A;OS=Crassostrea;PE=4;SV=1
GN003661.1	sp|K1QBH6|K1QBH6_CRAGI	4.2e-46	190.3	61.32%	71.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003662.1	sp|A0A210QDU7|A0A210QDU7_MIZYE	0.0e+00	1353.6	97.99%	29.98%	D-galactoside-specific lectin;OS=Mizuhopecten;PE=4;SV=1	GO:0030246|
GN003663.1	sp|A0A210PNF3|A0A210PNF3_MIZYE	5.3e-87	327.0	96.35%	50.13%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001203.1	sp|K1PP10|K1PP10_CRAGI	9.1e-19	97.8	88.06%	74.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003664.1	sp|K1QTR9|K1QTR9_CRAGI	6.2e-39	166.0	72.08%	82.73%	Matrilin-2;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003666.1	sp|K1QTR9|K1QTR9_CRAGI	1.8e-122	444.5	81.79%	83.14%	Matrilin-2;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003667.1	sp|A0A1S3HJ12|A0A1S3HJ12_LINUN	1.0e-29	137.1	70.04%	30.16%	uncharacterized protein LOC106155695;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0005319|
GN001204.1	sp|K1PP10|K1PP10_CRAGI	7.8e-137	492.7	92.01%	65.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003668.1	sp|H6BD87|H6BD87_OSTED	3.5e-62	243.0	94.12%	85.04%	Putative cytochrome c oxidase subunit VIa;OS=Ostrea;PE=2;SV=1	GO:0005751|	GO:0004129|
GN003671.1	sp|A0A3M6UPQ8|A0A3M6UPQ8_9CNID	3.9e-105	387.9	95.99%	39.56%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN003673.1	sp|K1R9A1|K1R9A1_CRAGI	1.1e-212	744.6	96.98%	93.77%	Putative serine/threonine-protein kinase F31E3.2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003674.1	sp|A0A210QQW1|A0A210QQW1_MIZYE	7.9e-43	181.0	56.72%	33.87%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0042981|
GN003678.1	sp|K1R2T4|K1R2T4_CRAGI	2.1e-18	97.4	99.16%	45.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000954.1	sp|K1PVQ2|K1PVQ2_CRAGI	3.1e-71	273.5	100.00%	76.74%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001205.1	sp|K1Q6R1|K1Q6R1_CRAGI	4.8e-50	204.5	76.86%	35.54%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003683.1	sp|K1QXQ0|K1QXQ0_CRAGI	4.4e-86	322.8	100.00%	95.83%	Exosome complex exonuclease RRP41;OS=Crassostrea;PE=4;SV=1	GO:0004527|
GN003684.1	sp|K1QQ16|K1QQ16_CRAGI	0.0e+00	1685.6	100.00%	93.45%	AP complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0030276|	GO:0006886|GO:0016192|
GN003686.1	sp|K1RDD5|K1RDD5_CRAGI	7.4e-146	522.3	93.43%	79.49%	SCF E3 ubiquitin ligase complex F-box protein grrA;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0016772|	GO:0006388|
GN003687.1	sp|K1RWP3|K1RWP3_CRAGI	5.3e-79	299.3	100.00%	84.97%	Peptidyl-tRNA hydrolase 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004045|
GN003688.1	sp|K1Q9V7|K1Q9V7_CRAGI	1.6e-93	347.8	98.17%	78.87%	Transmembrane emp24 domain-containing protein 6;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN003689.1	sp|A0A210QYL9|A0A210QYL9_MIZYE	1.5e-59	236.9	99.11%	48.61%	Vacuolar protein sorting-associated protein 33A;OS=Mizuhopecten;PE=4;SV=1	GO:0003729|GO:0000340|
GN003690.1	sp|A0A210PZY1|A0A210PZY1_MIZYE	3.9e-175	620.2	91.20%	65.13%	Peptidyl-prolyl cis-trans isomerase-like 2;OS=Mizuhopecten;PE=4;SV=1	GO:0003755|GO:0004842|	GO:0006457|
GN003691.1	sp|K1QNV5|K1QNV5_CRAGI	1.5e-62	244.2	100.00%	90.63%	Nucleoporin GLE1;OS=Crassostrea;PE=4;SV=1	GO:0005643|	GO:0016973|
GN003692.1	sp|K1RWP0|K1RWP0_CRAGI	1.7e-111	408.3	86.44%	64.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001206.1	sp|K1Q3E4|K1Q3E4_CRAGI	0.0e+00	3979.5	100.00%	66.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003698.1	sp|A0A1S3I117|A0A1S3I117_LINUN	2.7e-74	284.6	95.09%	42.55%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN003703.1	sp|K1QDI6|K1QDI6_CRAGI	6.3e-77	295.0	25.96%	51.22%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN003704.1	sp|A0A210QRZ2|A0A210QRZ2_MIZYE	1.3e-38	166.4	99.06%	29.67%	Caspase-2;OS=Mizuhopecten;PE=3;SV=1	GO:0004197|	GO:0042981|
GN003705.1	sp|K1RDC5|K1RDC5_CRAGI	0.0e+00	2168.3	99.86%	78.02%	Neuralized-like protein 4;OS=Crassostrea;PE=4;SV=1
GN003706.1	sp|K1R6X7|K1R6X7_CRAGI	2.0e-76	291.2	100.00%	90.98%	Inhibitor of growth protein;OS=Crassostrea;PE=3;SV=1	GO:0070776|	GO:0046872|	GO:0016573|GO:0008285|
GN003707.1	sp|K1R042|K1R042_CRAGI	1.2e-117	428.7	99.14%	62.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003708.1	sp|K1QQR1|K1QQR1_CRAGI	0.0e+00	1392.5	100.00%	94.75%	Major vault protein;OS=Crassostrea;PE=4;SV=1
GN003709.1	sp|K1RWN4|K1RWN4_CRAGI	0.0e+00	1476.1	98.89%	50.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003710.1	sp|A0A210Q826|A0A210Q826_MIZYE	1.6e-249	869.8	89.91%	28.18%	RE1-silencing transcription factor;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN003713.1	sp|K1QQQ5|K1QQQ5_CRAGI	1.6e-77	294.3	92.68%	93.38%	Replication factor C subunit 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006260|
GN003714.1	sp|K1RWN0|K1RWN0_CRAGI	1.5e-276	957.6	98.92%	72.10%	Kinase suppressor of Ras 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003715.1	sp|K1R6W7|K1R6W7_CRAGI	2.3e-28	131.7	92.00%	41.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003716.1	sp|K1R034|K1R034_CRAGI	4.3e-208	729.2	100.00%	94.10%	Endochitinase;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003717.1	sp|A0A210QYD6|A0A210QYD6_MIZYE	1.4e-145	521.9	83.30%	74.88%	Notchless protein-like 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005730|
GN003718.1	sp|K1QEK4|K1QEK4_CRAGI	4.7e-59	233.0	98.28%	66.28%	39S ribosomal protein L18, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN003719.1	sp|A0A0L8FQG0|A0A0L8FQG0_OCTBM	7.0e-30	136.7	33.21%	74.71%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN003720.1	sp|K1QLP9|K1QLP9_CRAGI	4.2e-216	756.5	97.19%	78.45%	Max-binding protein MNT;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN003722.1	sp|A0A210QL72|A0A210QL72_MIZYE	2.7e-19	100.9	47.06%	54.43%	Poly(U)-binding-splicing factor PUF60;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN003723.1	sp|K1PW03|K1PW03_CRAGI	3.3e-241	839.7	91.34%	92.56%	MORC family CW-type zinc finger protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003724.1	sp|K1PW03|K1PW03_CRAGI	9.2e-16	90.1	37.80%	69.60%	MORC family CW-type zinc finger protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003725.1	sp|A0A210QTV7|A0A210QTV7_MIZYE	8.5e-56	222.2	92.74%	78.18%	MORC family CW-type zinc finger protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0008270|
GN003726.1	sp|K1QG03|K1QG03_CRAGI	5.7e-278	961.8	96.37%	91.47%	T-box transcription factor TBX2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN003727.1	sp|A0A2T7PEA8|A0A2T7PEA8_POMCA	1.4e-54	219.5	85.43%	33.85%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005525|GO:0003723|
GN003728.1	sp|K1QEH8|K1QEH8_CRAGI	2.6e-170	603.6	92.26%	93.94%	Signal peptide peptidase-like 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004190|
GN003729.1	sp|K1QTM4|K1QTM4_CRAGI	9.0e-49	199.1	77.99%	70.55%	Sin3 histone deacetylase corepressor complex component SDS3;OS=Crassostrea;PE=4;SV=1
GN003730.1	sp|K1Q6I1|K1Q6I1_CRAGI	1.8e-73	280.8	99.36%	79.44%	Ubiquitin-conjugating enzyme E2 L3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN003731.1	sp|K1QEI2|K1QEI2_CRAGI	5.8e-210	735.7	93.65%	84.07%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN003732.1	sp|K1QMJ9|K1QMJ9_CRAGI	0.0e+00	1228.8	100.00%	77.91%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN001209.1	sp|K1PWJ9|K1PWJ9_CRAGI	1.8e-164	584.3	98.14%	83.15%	Orexin receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN003733.1	sp|A0A2T7PDC1|A0A2T7PDC1_POMCA	2.8e-26	126.7	42.08%	26.41%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN003734.1	sp|K1QTM6|K1QTM6_CRAGI	0.0e+00	1414.1	100.00%	76.55%	Histone-lysine N-methyltransferase SETD1B-A;OS=Crassostrea;PE=4;SV=1	GO:0048188|	GO:0018024|GO:0003723|	GO:0051568|
GN003735.1	sp|K1RE00|K1RE00_CRAGI	0.0e+00	2752.2	98.51%	87.48%	Ubiquitin carboxyl-terminal hydrolase 32;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0004843|	GO:0016579|GO:0006511|
GN003736.1	sp|A0A210Q6H5|A0A210Q6H5_MIZYE	5.1e-61	240.0	96.55%	59.73%	Ran-specific GTPase-activating protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005623|	GO:0046907|
GN003737.1	sp|K1S2R4|K1S2R4_CRAGI	5.1e-270	935.6	98.67%	72.80%	Putative all-trans-retinol 13,14-reductase;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003738.1	sp|K1S2R4|K1S2R4_CRAGI	1.2e-311	1073.5	98.89%	81.45%	Putative all-trans-retinol 13,14-reductase;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003739.1	sp|K1QXK1|K1QXK1_CRAGI	6.2e-229	799.3	100.00%	60.79%	F-box/WD repeat-containing protein 8;OS=Crassostrea;PE=4;SV=1
GN003740.1	sp|K1R777|K1R777_CRAGI	1.2e-26	127.1	79.83%	26.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003742.1	sp|K1QTN7|K1QTN7_CRAGI	3.3e-251	873.6	73.16%	72.80%	RING finger protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003743.1	sp|K1QJL7|K1QJL7_CRAGI	2.0e-264	917.5	99.42%	54.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004573|	GO:0009311|
GN003744.1	sp|K1Q470|K1Q470_CRAGI	8.9e-47	191.8	79.07%	83.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003745.1	sp|T1I8R4|T1I8R4_RHOPR	1.8e-36	159.1	95.15%	30.73%	Uncharacterized protein;OS=Rhodnius;PE=4;SV=1
GN003746.1	sp|K1QR29|K1QR29_CRAGI	3.1e-299	1033.1	69.76%	91.26%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN003747.1	sp|K1QJL2|K1QJL2_CRAGI	0.0e+00	1135.6	90.80%	89.54%	CCR4-NOT transcription complex subunit 10;OS=Crassostrea;PE=4;SV=1	GO:0030014|
GN003748.1	sp|K1QBM0|K1QBM0_CRAGI	4.6e-131	474.2	98.64%	44.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003749.1	sp|A0A1S3K3H4|A0A1S3K3H4_LINUN	2.1e-65	254.6	77.73%	63.24%	Phosphatidylinositol-4,5-bisphosphate 4-phosphatase;OS=Lingula;PE=4;SV=1	GO:0016021|GO:0031902|GO:0005765|	GO:0034597|	GO:0046856|
GN003750.1	sp|K1Q462|K1Q462_CRAGI	5.4e-58	230.3	90.29%	49.82%	Putative arginyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0004814|GO:0005524|	GO:0006420|
GN000955.1	sp|K1R3X8|K1R3X8_CRAGI	1.1e-137	495.7	98.35%	50.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001210.1	sp|K1PP05|K1PP05_CRAGI	1.8e-48	201.1	16.49%	45.72%	Transcription factor HES-1-B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046983|	GO:0006355|
GN003751.1	sp|K1RB85|K1RB85_CRAGI	9.9e-99	365.2	97.71%	81.60%	Glutathione S-transferase theta-1;OS=Crassostrea;PE=3;SV=1	GO:0016740|
GN003752.1	sp|K1RJY3|K1RJY3_CRAGI	0.0e+00	2657.1	100.00%	88.43%	TRS85-like protein;OS=Crassostrea;PE=4;SV=1
GN003753.1	sp|K1R0A6|K1R0A6_CRAGI	0.0e+00	1790.0	94.45%	86.77%	Membrane-bound transcription factor site-1 protease;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004252|
GN003754.1	sp|K1QTG6|K1QTG6_CRAGI	0.0e+00	1370.9	98.78%	71.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003755.1	sp|K1QL10|K1QL10_CRAGI	4.1e-166	590.1	87.63%	69.95%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN003756.1	sp|K1QCB6|K1QCB6_CRAGI	0.0e+00	1126.3	100.00%	86.68%	Translin-associated factor X-interacting protein 1;OS=Crassostrea;PE=4;SV=1
GN003757.1	sp|K1R359|K1R359_CRAGI	6.2e-269	931.8	100.00%	92.48%	Ran-binding protein 9;OS=Crassostrea;PE=4;SV=1
GN003758.1	sp|A0A2R2MRT7|A0A2R2MRT7_LINUN	1.3e-13	81.3	94.12%	44.21%	ribonuclease P protein subunit p29;OS=Lingula;PE=4;SV=1
GN003759.1	sp|K1QT68|K1QT68_CRAGI	1.3e-311	1073.9	99.56%	76.61%	Protein arginine N-methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0008168|	GO:0006479|
GN003760.1	sp|K1R074|K1R074_CRAGI	1.9e-124	451.1	100.00%	76.39%	Suppressor of tumorigenicity protein 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003762.1	sp|K1RR19|K1RR19_CRAGI	5.5e-203	712.2	100.00%	92.33%	Protein NDRG3;OS=Crassostrea;PE=4;SV=1
GN003763.1	sp|A0A210PII7|A0A210PII7_MIZYE	6.8e-171	605.5	98.83%	87.80%	Bardet-Biedl syndrome 5 protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0034464|
GN003764.1	sp|K1R079|K1R079_CRAGI	6.3e-68	262.3	100.00%	85.53%	TP53-regulating kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN001211.1	sp|K1PW36|K1PW36_CRAGI	0.0e+00	1748.4	98.25%	82.46%	Unc-13-like protein D;OS=Crassostrea;PE=4;SV=1
GN003765.1	sp|K1R6K4|K1R6K4_CRAGI	1.1e-159	568.2	100.00%	86.34%	Ganglioside-induced differentiation-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003766.1	sp|K1QT78|K1QT78_CRAGI	7.8e-250	868.2	99.79%	93.04%	Hepatocyte nuclear factor 4-alpha;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN003767.1	sp|K1R2Q9|K1R2Q9_CRAGI	9.5e-209	731.5	100.00%	89.31%	Aspartate aminotransferase;OS=Crassostrea;PE=4;SV=1	GO:0004069|GO:0030170|	GO:0009058|GO:0006520|
GN001212.1	sp|K1Q3W3|K1Q3W3_CRAGI	4.6e-130	469.5	100.00%	81.41%	NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0008137|
GN003770.1	sp|K1QHL1|K1QHL1_CRAGI	1.0e-57	229.6	64.81%	70.00%	Ankyrin-2;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN001213.1	sp|K1QBK7|K1QBK7_CRAGI	1.8e-93	347.8	97.93%	75.85%	Synaptosomal-associated protein 29;OS=Crassostrea;PE=4;SV=1
GN003771.1	sp|A0A210PKZ0|A0A210PKZ0_MIZYE	1.7e-24	117.9	100.00%	41.67%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003773.1	sp|K1QSD3|K1QSD3_CRAGI	0.0e+00	1090.9	91.98%	79.67%	cAMP-dependent protein kinase regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN003774.1	sp|K1QFE5|K1QFE5_CRAGI	3.1e-196	690.6	78.73%	62.73%	T-cell immunomodulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003775.1	sp|R7TJR4|R7TJR4_CAPTE	4.6e-86	323.9	89.87%	48.46%	Uncharacterized protein;OS=Capitella;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN003776.1	sp|K1QFF0|K1QFF0_CRAGI	0.0e+00	1351.3	100.00%	95.62%	Vacuolar protein sorting-associated protein 35;OS=Crassostrea;PE=4;SV=1	GO:0005829|GO:0030906|	GO:0015031|GO:0042147|
GN003777.1	sp|K1QNH8|K1QNH8_CRAGI	1.8e-56	223.8	100.00%	95.50%	Protein SYS1 homolog;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0015031|
GN003778.1	sp|A0A0U2V6W6|A0A0U2V6W6_9MAXI	2.3e-29	134.8	70.04%	48.77%	Cytochrome c oxidase polypeptide IV;OS=Pseudodiaptomus;PE=2;SV=1	GO:0004129|
GN003779.1	sp|K1QUJ5|K1QUJ5_CRAGI	4.9e-122	443.4	98.93%	69.73%	Uncharacterized protein C20orf96;OS=Crassostrea;PE=4;SV=1
GN001214.1	sp|K1QI79|K1QI79_CRAGI	3.0e-194	683.3	99.50%	88.13%	Orexin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN003780.1	sp|K1RET9|K1RET9_CRAGI	0.0e+00	2169.0	98.78%	68.42%	RING finger protein 31;OS=Crassostrea;PE=4;SV=1	GO:0071797|	GO:0046872|GO:0004842|
GN003781.1	sp|K1Q279|K1Q279_CRAGI	1.6e-271	941.0	100.00%	64.59%	Targeting protein for Xklp2;OS=Crassostrea;PE=4;SV=1	GO:0005874|GO:0005819|	GO:0032147|GO:0060236|
GN003782.1	sp|K1PUR4|K1PUR4_CRAGI	5.3e-130	469.5	100.00%	77.27%	Anamorsin homolog;OS=Crassostrea;PE=3;SV=1	GO:0005758|	GO:0051537|GO:0051539|GO:0009055|GO:0046872|GO:0008168|	GO:0016226|
GN003783.1	sp|K1QV69|K1QV69_CRAGI	1.0e-55	221.5	100.00%	84.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003784.1	sp|K1Q9E1|K1Q9E1_CRAGI	3.8e-247	859.4	89.05%	93.15%	Putative D-lactate dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0016491|
GN003785.1	sp|K1Q273|K1Q273_CRAGI	3.3e-61	240.0	97.35%	85.03%	60S ribosomal protein L14;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003723|GO:0003735|	GO:0006412|
GN003786.1	sp|K1QC18|K1QC18_CRAGI	2.8e-177	626.7	100.00%	96.66%	E3 ubiquitin-protein ligase RING2-A;OS=Crassostrea;PE=4;SV=1	GO:0035102|	GO:0016874|
GN003787.1	sp|K1R6C2|K1R6C2_CRAGI	9.3e-179	631.7	100.00%	86.94%	Peroxisomal 3,2-trans-enoyl-CoA isomerase;OS=Crassostrea;PE=4;SV=1	GO:0000062|GO:0016853|
GN003788.1	sp|K1RCG3|K1RCG3_CRAGI	1.5e-205	721.8	63.83%	83.54%	Chromodomain Y-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN003789.1	sp|K1RIF0|K1RIF0_CRAGI	9.9e-234	815.1	100.00%	65.97%	E3 ubiquitin-protein ligase TRAF7;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|
GN001215.1	sp|K1R3V9|K1R3V9_CRAGI	2.4e-93	347.4	83.06%	91.00%	Small G protein signaling modulator 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|
GN003791.1	sp|K1RCF8|K1RCF8_CRAGI	1.6e-54	218.8	67.85%	63.03%	Protein escargot;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003792.1	sp|K1RIE6|K1RIE6_CRAGI	1.0e-63	248.4	98.78%	75.78%	Small conductance calcium-activated potassium channel protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016286|
GN003793.1	sp|K1S222|K1S222_CRAGI	6.5e-193	679.1	100.00%	77.01%	Small conductance calcium-activated potassium channel protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005516|GO:0016286|
GN003794.1	sp|K1QWP3|K1QWP3_CRAGI	1.9e-235	820.5	98.57%	88.96%	Small conductance calcium-activated potassium channel protein;OS=Crassostrea;PE=4;SV=1	GO:0008076|	GO:0005516|GO:0016286|GO:0005249|
GN003795.1	sp|K1QVZ7|K1QVZ7_CRAGI	7.5e-156	555.4	100.00%	82.48%	Dehydrogenase/reductase SDR family member 1;OS=Crassostrea;PE=4;SV=1
GN003796.1	sp|L7M2P4|L7M2P4_9ACAR	2.6e-23	114.0	94.41%	40.14%	Uncharacterized protein;OS=Rhipicephalus;PE=2;SV=1	GO:0016021|
GN003797.1	sp|A0A210QJM6|A0A210QJM6_MIZYE	1.1e-56	225.3	98.48%	58.25%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003798.1	sp|K1RTB0|K1RTB0_CRAGI	2.0e-271	940.3	99.83%	76.53%	NudC domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN003799.1	sp|K1R9G5|K1R9G5_CRAGI	1.8e-197	694.9	91.87%	56.12%	Ankyrin repeat and protein kinase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003800.1	sp|K1QVZ2|K1QVZ2_CRAGI	1.8e-54	218.8	80.54%	43.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003801.1	sp|A0A210QJ40|A0A210QJ40_MIZYE	2.1e-09	68.2	94.57%	27.32%	Receptor-interacting serine/threonine-protein kinase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|	GO:0007165|
GN003802.1	sp|K1RTA4|K1RTA4_CRAGI	4.5e-106	390.2	78.40%	74.34%	NF-kappa-B inhibitor epsilon;OS=Crassostrea;PE=4;SV=1
GN003803.1	sp|K1RVK3|K1RVK3_CRAGI	8.9e-288	995.3	89.51%	65.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN003804.1	sp|K1R6B8|K1R6B8_CRAGI	7.0e-38	162.5	92.95%	53.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN003805.1	sp|K1RVK3|K1RVK3_CRAGI	9.4e-30	137.5	27.80%	39.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN003807.1	sp|K1RCF4|K1RCF4_CRAGI	6.0e-109	399.4	100.00%	92.34%	Translocon-associated protein subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|
GN003808.1	sp|K1RIE3|K1RIE3_CRAGI	9.3e-263	911.4	100.00%	86.73%	Ataxin-1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN003810.1	sp|K1S216|K1S216_CRAGI	2.3e-179	634.4	74.40%	73.56%	Cytoplasmic tRNA 2-thiolation protein 2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0016779|GO:0000049|	GO:0035556|GO:0032447|GO:0034227|GO:0002098|
GN003811.1	sp|K1S216|K1S216_CRAGI	3.6e-119	433.3	100.00%	81.44%	Cytoplasmic tRNA 2-thiolation protein 2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0016779|GO:0000049|	GO:0035556|GO:0032447|GO:0034227|GO:0002098|
GN003813.1	sp|K1R6L2|K1R6L2_CRAGI	0.0e+00	1312.4	92.61%	41.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030374|GO:0004540|GO:0003723|
GN003814.1	sp|K1R6L2|K1R6L2_CRAGI	2.6e-74	283.9	97.97%	73.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030374|GO:0004540|GO:0003723|
GN003815.1	sp|A0A2B4RIG1|A0A2B4RIG1_STYPI	1.7e-141	509.2	77.41%	40.97%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN003817.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	9.8e-88	329.7	96.98%	36.81%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN001216.1	sp|V4A8A4|V4A8A4_LOTGI	2.7e-18	97.8	74.00%	35.37%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN003818.1	sp|K1QNY3|K1QNY3_CRAGI	5.9e-54	215.7	96.97%	78.63%	BEN domain-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN003819.1	sp|A0A2B4S595|A0A2B4S595_STYPI	3.5e-09	67.4	73.03%	35.11%	PiggyBac transposable element-derived protein 5;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN003822.1	sp|K1RF74|K1RF74_CRAGI	4.0e-09	66.6	73.33%	42.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003823.1	sp|K1QN01|K1QN01_CRAGI	1.8e-243	847.4	100.00%	87.02%	Merlin;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0003779|	GO:0008285|
GN003824.1	sp|A0A210Q629|A0A210Q629_MIZYE	9.4e-51	207.2	93.09%	25.40%	E3 ubiquitin-protein ligase TRIM33;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0046872|
GN003825.1	sp|Q70J57|Q70J57_CRAGI	2.8e-69	266.9	97.56%	82.39%	Glycine cleavage system H protein;OS=Crassostrea;PE=2;SV=1	GO:0005960|GO:0005739|	GO:0019464|
GN003826.1	sp|K1RLN1|K1RLN1_CRAGI	2.7e-148	530.4	99.70%	75.07%	NIF3-like protein 1;OS=Crassostrea;PE=3;SV=1
GN003827.1	sp|K1QEC4|K1QEC4_CRAGI	1.4e-139	501.1	100.00%	87.13%	BTB/POZ domain-containing protein KCTD7;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN003828.1	sp|K1QMZ3|K1QMZ3_CRAGI	7.4e-188	662.5	84.10%	70.77%	Putative proline dehydrogenase 2;OS=Crassostrea;PE=4;SV=1	GO:0004657|	GO:0006562|
GN003829.1	sp|K1PQ56|K1PQ56_CRAGI	3.4e-25	122.9	46.29%	25.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003837.1	sp|K1R2A7|K1R2A7_CRAGI	4.2e-16	89.4	62.07%	73.58%	Mitochondrial 18 kDa protein;OS=Crassostrea;PE=4;SV=1
GN003838.1	sp|K1RLN8|K1RLN8_CRAGI	1.6e-37	161.0	96.77%	73.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0031110|
GN003839.1	sp|A0A210Q629|A0A210Q629_MIZYE	2.1e-50	206.1	93.09%	25.22%	E3 ubiquitin-protein ligase TRIM33;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0046872|
GN003840.1	sp|K1QVI8|K1QVI8_CRAGI	3.1e-161	573.5	80.43%	90.30%	Protein-tyrosine sulfotransferase;OS=Crassostrea;PE=3;SV=1	GO:0008476|	GO:0006478|
GN001218.1	sp|K1QBP4|K1QBP4_CRAGI	2.7e-227	793.5	96.55%	73.51%	Cytochrome P450 4F22;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN003843.1	sp|K1R489|K1R489_CRAGI	7.8e-243	845.1	99.81%	77.65%	G patch domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0039536|GO:0032480|
GN003844.1	sp|K1RLP1|K1RLP1_CRAGI	1.6e-296	1024.2	65.12%	89.24%	Calcium/calmodulin-dependent protein kinase kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003846.1	sp|K1PU09|K1PU09_CRAGI	2.7e-138	498.8	96.94%	32.17%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN003847.1	sp|K1PU09|K1PU09_CRAGI	6.0e-127	461.1	96.85%	31.08%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN003848.1	sp|K1PU09|K1PU09_CRAGI	6.0e-127	461.1	96.85%	31.08%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN003849.1	sp|K1PU09|K1PU09_CRAGI	6.0e-127	461.1	96.85%	31.08%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN003851.1	sp|A0A2B4STW4|A0A2B4STW4_STYPI	3.5e-73	281.2	90.75%	42.78%	Zinc finger protein 862;OS=Stylophora;PE=4;SV=1
GN003852.1	sp|K1PU09|K1PU09_CRAGI	1.2e-137	496.9	83.16%	32.07%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN001219.1	sp|K1RJ06|K1RJ06_CRAGI	6.0e-196	689.1	100.00%	72.60%	Cytochrome P450 4F8;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN003855.1	sp|A0A210Q306|A0A210Q306_MIZYE	7.3e-39	166.8	94.17%	32.55%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003856.1	sp|K1QCD4|K1QCD4_CRAGI	6.8e-74	282.7	100.00%	67.38%	Myeloid leukemia factor 1;OS=Crassostrea;PE=4;SV=1
GN003857.1	sp|K1QCF8|K1QCF8_CRAGI	5.4e-16	90.5	43.15%	42.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001220.1	sp|K1R288|K1R288_CRAGI	2.9e-47	193.4	92.62%	86.73%	Coiled-coil domain-containing protein 28B;OS=Crassostrea;PE=4;SV=1
GN003860.1	sp|A0A210PZ49|A0A210PZ49_MIZYE	5.2e-19	100.9	91.08%	23.87%	Serine/threonine-protein kinase pats1;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|GO:0016301|	GO:0007165|
GN003866.1	sp|A0A210PZ49|A0A210PZ49_MIZYE	1.5e-17	95.9	98.31%	24.51%	Serine/threonine-protein kinase pats1;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|GO:0016301|	GO:0007165|
GN003867.1	sp|K1RJ39|K1RJ39_CRAGI	9.6e-250	868.6	97.37%	58.78%	Tetratricopeptide repeat protein 22;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN003868.1	sp|K1RD74|K1RD74_CRAGI	0.0e+00	2538.5	100.00%	90.04%	Tetratricopeptide repeat protein 28;OS=Crassostrea;PE=4;SV=1
GN001221.1	sp|K1QVG6|K1QVG6_CRAGI	3.3e-96	359.0	45.55%	41.90%	Mediator of RNA polymerase II transcription subunit 14;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN003870.1	sp|A0A210QE36|A0A210QE36_MIZYE	3.5e-59	234.6	91.10%	35.33%	Solute carrier family 46 member 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN003871.1	sp|A0A2G8LDZ4|A0A2G8LDZ4_STIJA	2.5e-14	84.3	95.73%	37.18%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN003873.1	sp|A0A210QE36|A0A210QE36_MIZYE	1.0e-58	233.0	91.10%	35.61%	Solute carrier family 46 member 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001222.1	sp|K1Q3I0|K1Q3I0_CRAGI	3.9e-32	142.9	94.34%	70.71%	Reticulon-4-interacting protein 1-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0016491|GO:0008270|
GN003875.1	sp|F8WKQ7|F8WKQ7_CRAGI	1.7e-186	657.9	100.00%	68.48%	Heat shock transcription factor 1h;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN003876.1	sp|K1QS34|K1QS34_CRAGI	1.4e-296	1024.2	98.31%	72.96%	Low-density lipoprotein receptor-related protein 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003877.1	sp|K1PK61|K1PK61_CRAGI	1.7e-39	168.7	77.74%	49.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003879.1	sp|V3ZKL9|V3ZKL9_LOTGI	1.4e-19	102.4	90.23%	30.67%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN001223.1	sp|A0A210QN24|A0A210QN24_MIZYE	2.8e-120	438.0	97.23%	43.29%	BTB/POZ domain-containing protein 17;OS=Mizuhopecten;PE=4;SV=1
GN003883.1	sp|K1QHT3|K1QHT3_CRAGI	8.7e-25	119.8	52.29%	42.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003885.1	sp|K1PXN3|K1PXN3_CRAGI	4.7e-09	67.4	52.89%	34.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003886.1	sp|K1PLF0|K1PLF0_CRAGI	1.4e-10	72.0	82.49%	36.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003887.1	sp|K1QDI7|K1QDI7_CRAGI	2.1e-143	514.2	96.57%	73.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001224.1	sp|K1PEF3|K1PEF3_CRAGI	3.8e-178	629.8	99.21%	87.04%	Transcription factor E2F5;OS=Crassostrea;PE=3;SV=1	GO:0005634|GO:0005667|	GO:0003677|GO:0003700|GO:0046983|	GO:0051726|
GN003888.1	sp|K1QH86|K1QH86_CRAGI	8.1e-147	526.2	99.81%	54.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003890.1	sp|K1PJC8|K1PJC8_CRAGI	3.4e-163	580.1	100.00%	79.53%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN003892.1	sp|K1PYC3|K1PYC3_CRAGI	3.4e-133	480.3	84.70%	83.50%	Protein CBFA2T1;OS=Crassostrea;PE=4;SV=1	GO:0003700|GO:0046872|GO:0003714|	GO:0045892|
GN003893.1	sp|K1PYC3|K1PYC3_CRAGI	5.0e-34	150.2	61.75%	61.65%	Protein CBFA2T1;OS=Crassostrea;PE=4;SV=1	GO:0003700|GO:0046872|GO:0003714|	GO:0045892|
GN003894.1	sp|K1QRB7|K1QRB7_CRAGI	9.5e-175	618.2	100.00%	96.23%	UDP-glucuronic acid decarboxylase 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN003895.1	sp|K1PJ99|K1PJ99_CRAGI	0.0e+00	1489.9	99.46%	73.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN003896.1	sp|K1PR16|K1PR16_CRAGI	2.9e-46	193.7	13.60%	50.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003897.1	sp|K1Q586|K1Q586_CRAGI	3.8e-248	864.4	81.82%	43.37%	2-5A-dependent ribonuclease;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003898.1	sp|K1PY91|K1PY91_CRAGI	1.8e-79	301.6	81.69%	65.37%	Uncharacterized protein C18orf19-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003901.1	sp|K1QJA5|K1QJA5_CRAGI	2.8e-32	143.7	94.53%	66.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003902.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	1.4e-51	209.1	97.35%	34.02%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN003904.1	sp|A0A210QNI3|A0A210QNI3_MIZYE	1.8e-62	244.6	92.93%	59.02%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003905.1	sp|A0A210QY37|A0A210QY37_MIZYE	1.5e-24	117.5	95.51%	63.10%	Transmembrane protein 107;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN003906.1	sp|V4BQF1|V4BQF1_LOTGI	0.0e+00	1283.5	93.00%	82.88%	Coatomer subunit beta';OS=Lottia;PE=3;SV=1	GO:0030663|GO:0000139|GO:0030117|	GO:0005198|	GO:0006886|GO:0016192|
GN003907.1	sp|K1QE21|K1QE21_CRAGI	0.0e+00	1876.7	100.00%	62.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003908.1	sp|K1PTV1|K1PTV1_CRAGI	4.2e-119	433.7	52.96%	99.53%	Splicing factor 3B subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN003909.1	sp|K1R507|K1R507_CRAGI	2.4e-42	177.2	97.79%	61.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003911.1	sp|K1QMC6|K1QMC6_CRAGI	1.4e-59	236.1	65.03%	38.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003912.1	sp|K1QMM5|K1QMM5_CRAGI	8.8e-18	95.9	31.58%	81.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003913.1	sp|A0A194AJW9|A0A194AJW9_PINFU	2.0e-28	131.3	98.31%	44.07%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1
GN003914.1	sp|A0A194AJW9|A0A194AJW9_PINFU	8.6e-31	139.4	89.15%	44.50%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1
GN003915.1	sp|K1PRD4|K1PRD4_CRAGI	2.0e-144	517.7	78.23%	85.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003916.1	sp|K1PYX7|K1PYX7_CRAGI	0.0e+00	3051.5	95.34%	74.34%	Zinc finger protein 64;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003917.1	sp|A0A210QXK5|A0A210QXK5_MIZYE	1.2e-121	442.2	100.00%	62.21%	DnaJ-like subfamily A member 2;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0031072|GO:0046872|GO:0051082|	GO:0006457|GO:0009408|
GN003918.1	sp|K1P5L8|K1P5L8_CRAGI	2.1e-147	527.7	100.00%	62.88%	Nucleoside diphosphate-linked moiety X motif 19, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN003919.1	sp|A0A210QXP0|A0A210QXP0_MIZYE	8.3e-226	788.5	99.60%	75.30%	Xaa-Pro dipeptidase;OS=Mizuhopecten;PE=3;SV=1	GO:0004177|GO:0030145|
GN003920.1	sp|K1PJ25|K1PJ25_CRAGI	2.3e-30	138.3	98.07%	36.43%	Proto-oncogene tyrosine-protein kinase MER;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003921.1	sp|K1PR80|K1PR80_CRAGI	5.0e-184	650.2	91.49%	49.31%	Macrophage colony-stimulating factor 1 receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003922.1	sp|K1RWM6|K1RWM6_CRAGI	3.6e-244	849.7	91.50%	87.59%	Pescadillo homolog;OS=Crassostrea;PE=3;SV=1	GO:0005730|GO:0005654|GO:0030687|	GO:0043021|	GO:0000466|GO:0000463|
GN003923.1	sp|H6BD05|H6BD05_OSTED	3.0e-70	270.4	78.46%	96.71%	60S ribosomal protein L7/L12;OS=Ostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN003924.1	sp|K1R6W1|K1R6W1_CRAGI	2.2e-211	741.5	45.66%	81.65%	Cytochrome P450 4F22;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN003925.1	sp|A7SQT4|A7SQT4_NEMVE	1.7e-38	165.6	98.15%	35.26%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN003926.1	sp|K1PR86|K1PR86_CRAGI	2.5e-79	300.8	93.80%	67.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001225.1	sp|K1PUG5|K1PUG5_CRAGI	0.0e+00	1341.6	72.21%	89.25%	Beta-hexosaminidase subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004563|	GO:0005975|
GN003927.1	sp|K1PJ31|K1PJ31_CRAGI	7.4e-176	622.5	100.00%	72.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0019902|	GO:0010923|
GN003928.1	sp|A0A194APN5|A0A194APN5_PINFU	5.3e-102	375.9	97.07%	85.93%	Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial;OS=Pinctada;PE=3;SV=1	GO:0005743|	GO:0051537|GO:0051538|GO:0051539|GO:0009055|GO:0046872|GO:0008177|	GO:0006099|
GN003929.1	sp|K1P5M3|K1P5M3_CRAGI	3.5e-166	590.1	96.30%	78.68%	OTU domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN003930.1	sp|K1QBN6|K1QBN6_CRAGI	1.3e-101	374.8	100.00%	90.99%	Caltractin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN003931.1	sp|K1Q2H8|K1Q2H8_CRAGI	5.1e-123	446.4	98.79%	70.64%	Atrial natriuretic peptide receptor A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004383|	GO:0035556|
GN003932.1	sp|K1PR80|K1PR80_CRAGI	5.8e-263	913.3	82.92%	46.35%	Macrophage colony-stimulating factor 1 receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003933.1	sp|K1PJ25|K1PJ25_CRAGI	1.2e-204	719.5	72.97%	44.75%	Proto-oncogene tyrosine-protein kinase MER;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003934.1	sp|K1R0H0|K1R0H0_CRAGI	6.8e-92	342.0	100.00%	93.94%	Glutamine synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004356|	GO:0006542|
GN001226.1	sp|K1QEM4|K1QEM4_CRAGI	4.1e-277	959.1	91.75%	85.93%	GPI transamidase component PIG-T;OS=Crassostrea;PE=4;SV=1	GO:0042765|	GO:0016255|
GN003935.1	sp|K1R0H0|K1R0H0_CRAGI	6.8e-92	342.0	100.00%	93.94%	Glutamine synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004356|	GO:0006542|
GN003936.1	sp|K1R0H0|K1R0H0_CRAGI	4.7e-141	506.1	84.03%	94.19%	Glutamine synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004356|	GO:0006542|
GN003937.1	sp|K1QY88|K1QY88_CRAGI	2.4e-20	105.9	94.41%	25.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN003938.1	sp|A0A151IU93|A0A151IU93_9HYME	4.3e-15	86.7	95.68%	36.84%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN003940.1	sp|A0A1I8H434|A0A1I8H434_9PLAT	3.9e-44	184.9	57.54%	38.21%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1	GO:0016021|	GO:0003677|GO:0005452|GO:0046872|	GO:0015074|GO:0006310|
GN003941.1	sp|K1QS32|K1QS32_CRAGI	6.4e-74	284.3	55.36%	35.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003942.1	sp|K1RQJ0|K1RQJ0_CRAGI	3.9e-96	357.1	96.83%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003944.1	sp|K1QLI2|K1QLI2_CRAGI	2.2e-38	166.0	83.09%	28.73%	Toll-like receptor 6;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN003945.1	sp|A0A210PQ57|A0A210PQ57_MIZYE	1.3e-63	248.1	90.91%	75.17%	Rho-associated protein kinase 2;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0017049|GO:0046872|GO:0004674|	GO:2000114|GO:0051492|GO:0007266|
GN003946.1	sp|K1QKH0|K1QKH0_CRAGI	5.8e-28	129.0	91.43%	63.54%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN003948.1	sp|K1R034|K1R034_CRAGI	4.3e-208	729.2	100.00%	94.10%	Endochitinase;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003949.1	sp|K1R6W7|K1R6W7_CRAGI	2.3e-28	131.7	92.00%	41.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000957.1	sp|K1RNA5|K1RNA5_CRAGI	1.2e-97	361.7	92.86%	85.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003950.1	sp|K1RDB8|K1RDB8_CRAGI	8.3e-70	268.9	77.01%	91.61%	UPF0420 protein C16orf58-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN003951.1	sp|K1QQQ5|K1QQQ5_CRAGI	4.1e-131	473.0	94.70%	92.77%	Replication factor C subunit 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006260|
GN003953.1	sp|A0A210Q826|A0A210Q826_MIZYE	1.6e-249	869.8	89.91%	28.18%	RE1-silencing transcription factor;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN003954.1	sp|K1RWN4|K1RWN4_CRAGI	3.5e-75	287.0	100.00%	71.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003955.1	sp|K1RWN4|K1RWN4_CRAGI	0.0e+00	1185.2	99.87%	47.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003956.1	sp|K1QQR1|K1QQR1_CRAGI	0.0e+00	1392.5	100.00%	94.75%	Major vault protein;OS=Crassostrea;PE=4;SV=1
GN003957.1	sp|K1R042|K1R042_CRAGI	1.2e-117	428.7	99.14%	62.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001227.1	sp|K1QKG9|K1QKG9_CRAGI	2.8e-194	683.3	100.00%	83.78%	Cysteine desulfurase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0031071|GO:0030170|	GO:0044571|
GN003958.1	sp|K1RDC5|K1RDC5_CRAGI	0.0e+00	2168.3	99.86%	78.02%	Neuralized-like protein 4;OS=Crassostrea;PE=4;SV=1
GN003959.1	sp|A0A210QRZ2|A0A210QRZ2_MIZYE	1.3e-38	166.4	99.06%	29.67%	Caspase-2;OS=Mizuhopecten;PE=3;SV=1	GO:0004197|	GO:0042981|
GN003960.1	sp|K1QDI6|K1QDI6_CRAGI	1.4e-76	293.9	25.39%	52.36%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN003966.1	sp|K1RWP0|K1RWP0_CRAGI	1.4e-108	398.7	92.37%	57.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003967.1	sp|K1QRB9|K1QRB9_CRAGI	5.3e-13	80.1	59.34%	37.38%	DnaJ-like protein subfamily C member 5;OS=Crassostrea;PE=4;SV=1
GN003969.1	sp|K1RDD5|K1RDD5_CRAGI	6.7e-33	145.6	75.63%	76.40%	SCF E3 ubiquitin ligase complex F-box protein grrA;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0016772|	GO:0006388|
GN003970.1	sp|K1RWP3|K1RWP3_CRAGI	8.8e-79	298.9	79.45%	84.97%	Peptidyl-tRNA hydrolase 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004045|
GN003971.1	sp|A0A210QYL9|A0A210QYL9_MIZYE	9.5e-59	234.2	99.11%	48.61%	Vacuolar protein sorting-associated protein 33A;OS=Mizuhopecten;PE=4;SV=1	GO:0003729|GO:0000340|
GN003972.1	sp|A0A210PZY1|A0A210PZY1_MIZYE	3.9e-175	620.2	91.20%	65.13%	Peptidyl-prolyl cis-trans isomerase-like 2;OS=Mizuhopecten;PE=4;SV=1	GO:0003755|GO:0004842|	GO:0006457|
GN003973.1	sp|K1QNV5|K1QNV5_CRAGI	1.1e-174	619.4	100.00%	51.52%	Nucleoporin GLE1;OS=Crassostrea;PE=4;SV=1	GO:0005643|	GO:0016973|
GN003975.1	sp|H6BD87|H6BD87_OSTED	3.5e-62	243.0	94.12%	85.04%	Putative cytochrome c oxidase subunit VIa;OS=Ostrea;PE=2;SV=1	GO:0005751|	GO:0004129|
GN001228.1	sp|K1QVF0|K1QVF0_CRAGI	1.1e-145	521.9	97.33%	71.62%	Matrix metalloproteinase-19;OS=Crassostrea;PE=3;SV=1	GO:0031012|	GO:0004222|GO:0008270|
GN003978.1	sp|A0A3M6UPQ8|A0A3M6UPQ8_9CNID	3.9e-105	387.9	95.99%	39.56%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN003980.1	sp|K1R9A1|K1R9A1_CRAGI	1.1e-212	744.6	96.98%	93.77%	Putative serine/threonine-protein kinase F31E3.2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN003981.1	sp|A0A210QQW1|A0A210QQW1_MIZYE	7.9e-43	181.0	56.72%	33.87%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0042981|
GN003985.1	sp|A0A3L5TV44|A0A3L5TV44_MYTGA	7.2e-46	191.0	68.03%	29.70%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN001229.1	sp|K1PK98|K1PK98_CRAGI	7.1e-209	732.3	100.00%	84.49%	Coiled-coil domain-containing protein 65;OS=Crassostrea;PE=4;SV=1	GO:0005858|	GO:0070286|
GN003986.1	sp|K1RAR3|K1RAR3_CRAGI	3.9e-167	593.2	99.47%	75.99%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN003988.1	sp|K1QBH6|K1QBH6_CRAGI	4.2e-46	190.3	61.32%	71.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN003989.1	sp|A0A210QDU7|A0A210QDU7_MIZYE	1.2e-249	869.8	97.85%	28.26%	D-galactoside-specific lectin;OS=Mizuhopecten;PE=4;SV=1	GO:0030246|
GN003990.1	sp|A0A210PNF3|A0A210PNF3_MIZYE	5.3e-87	327.0	96.35%	50.13%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN003991.1	sp|K1RYV3|K1RYV3_CRAGI	5.6e-44	183.7	48.48%	62.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN003992.1	sp|K1QTR9|K1QTR9_CRAGI	6.2e-39	166.0	72.08%	82.73%	Matrilin-2;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003994.1	sp|K1QTR9|K1QTR9_CRAGI	0.0e+00	2603.5	99.50%	72.27%	Matrilin-2;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN003995.1	sp|A0A210PLM5|A0A210PLM5_MIZYE	3.5e-99	368.6	81.88%	32.52%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN003996.1	sp|A0A210PLM5|A0A210PLM5_MIZYE	1.9e-102	379.4	86.07%	33.48%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN001230.1	sp|K1QA61|K1QA61_CRAGI	4.9e-36	157.5	73.75%	33.71%	Histone-lysine N-methyltransferase PRDM9;OS=Crassostrea;PE=4;SV=1	GO:0008168|	GO:0035556|
GN003997.1	sp|K1QWN4|K1QWN4_CRAGI	1.1e-74	285.0	91.53%	82.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN003998.1	sp|K1QTS2|K1QTS2_CRAGI	6.1e-85	318.9	100.00%	93.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004001.1	sp|K1QRF1|K1QRF1_CRAGI	5.7e-198	695.7	100.00%	88.40%	Suppressor of cytokine signaling 6;OS=Crassostrea;PE=4;SV=1	GO:0035556|GO:0016567|GO:0040008|
GN001231.1	sp|K1R1E0|K1R1E0_CRAGI	8.4e-164	582.0	100.00%	79.83%	Cyclic nucleotide-gated olfactory channel;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN004002.1	sp|K1PYD5|K1PYD5_CRAGI	8.9e-44	181.8	100.00%	82.40%	CCAAT/enhancer-binding protein gamma;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN004003.1	sp|K1PR50|K1PR50_CRAGI	1.6e-118	431.4	100.00%	73.65%	CCAAT/enhancer-binding protein delta;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN004004.1	sp|K1PJD8|K1PJD8_CRAGI	1.3e-97	361.7	100.00%	78.60%	CCAAT/enhancer-binding protein delta;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN004005.1	sp|K1QRF0|K1QRF0_CRAGI	2.0e-85	321.6	74.35%	70.11%	CCAAT/enhancer-binding protein delta;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN004006.1	sp|A0A1D1WBZ4|A0A1D1WBZ4_RAMVA	1.1e-16	91.7	92.31%	42.99%	Uncharacterized protein;OS=Ramazzottius;PE=4;SV=1
GN004008.1	sp|K1QXQ0|K1QXQ0_CRAGI	4.4e-86	322.8	100.00%	95.83%	Exosome complex exonuclease RRP41;OS=Crassostrea;PE=4;SV=1	GO:0004527|
GN004009.1	sp|K1QQ16|K1QQ16_CRAGI	0.0e+00	1702.2	100.00%	95.06%	AP complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0030276|	GO:0006886|GO:0016192|
GN004010.1	sp|K1QGD2|K1QGD2_CRAGI	8.4e-162	575.5	90.03%	79.01%	Peroxisome assembly protein 12;OS=Crassostrea;PE=3;SV=1	GO:0005779|	GO:0008022|GO:0008270|	GO:0006625|
GN000958.1	sp|K1Q7B2|K1Q7B2_CRAGI	3.3e-67	260.0	98.15%	73.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004011.1	sp|K1QQ16|K1QQ16_CRAGI	2.3e-35	153.3	95.24%	88.61%	AP complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0030276|	GO:0006886|GO:0016192|
GN004012.1	sp|K1QQ16|K1QQ16_CRAGI	1.2e-159	568.2	94.91%	93.99%	AP complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0030276|	GO:0006886|GO:0016192|
GN004013.1	sp|K1QQ16|K1QQ16_CRAGI	1.0e-140	505.0	100.00%	92.83%	AP complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0030276|	GO:0006886|GO:0016192|
GN004014.1	sp|K1RNE5|K1RNE5_CRAGI	2.3e-242	844.3	94.70%	59.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004015.1	sp|K1R402|K1R402_CRAGI	3.3e-252	876.7	97.63%	69.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004016.1	sp|K1Q5B6|K1Q5B6_CRAGI	6.0e-23	113.2	59.38%	44.25%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN004017.1	sp|K1Q5B6|K1Q5B6_CRAGI	1.6e-72	279.3	66.26%	42.69%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN001234.1	sp|A0A1I8G553|A0A1I8G553_9PLAT	8.6e-30	137.1	60.70%	31.94%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN004030.1	sp|K1Q8S8|K1Q8S8_CRAGI	0.0e+00	1237.2	95.82%	85.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004031.1	sp|K1QGV6|K1QGV6_CRAGI	2.2e-239	833.6	100.00%	77.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004033.1	sp|K1QND1|K1QND1_CRAGI	1.4e-64	251.5	100.00%	67.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004035.1	sp|K1Q1S7|K1Q1S7_CRAGI	1.5e-103	382.1	75.86%	63.96%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005544|	GO:0006887|
GN004039.1	sp|K1Q8T5|K1Q8T5_CRAGI	6.3e-46	191.0	28.89%	60.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001236.1	sp|K1RU46|K1RU46_CRAGI	0.0e+00	2400.2	98.27%	78.38%	Formin-2;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN004041.1	sp|A0A210PL16|A0A210PL16_MIZYE	2.5e-116	424.1	98.01%	71.48%	Ski oncogene;OS=Mizuhopecten;PE=4;SV=1	GO:0046332|
GN004043.1	sp|K1Q1T7|K1Q1T7_CRAGI	1.2e-233	815.8	82.72%	44.37%	Brain-specific angiogenesis inhibitor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004044.1	sp|K1QNE1|K1QNE1_CRAGI	0.0e+00	1087.0	100.00%	71.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004045.1	sp|K1R8R6|K1R8R6_CRAGI	2.1e-194	683.7	100.00%	93.94%	Fructose-bisphosphate aldolase;OS=Crassostrea;PE=3;SV=1	GO:0004332|	GO:0006096|
GN001237.1	sp|K1R3W0|K1R3W0_CRAGI	5.9e-102	376.3	95.65%	60.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004046.1	sp|K1QGW8|K1QGW8_CRAGI	3.6e-42	176.8	99.37%	50.32%	Glutathione S-transferase theta-1;OS=Crassostrea;PE=3;SV=1	GO:0016740|
GN004047.1	sp|K1QMC1|K1QMC1_CRAGI	1.8e-17	94.7	42.50%	68.66%	DNA excision repair protein ERCC-6-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN004048.1	sp|K1QMC1|K1QMC1_CRAGI	5.9e-70	269.6	91.67%	63.84%	DNA excision repair protein ERCC-6-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN004050.1	sp|K1R9W0|K1R9W0_CRAGI	4.2e-108	396.7	98.65%	65.41%	Mitochondrial ubiquitin ligase activator of NFKB 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0004842|	GO:0006996|
GN004052.1	sp|K1QL84|K1QL84_CRAGI	1.2e-75	290.0	70.31%	34.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004053.1	sp|K1QY88|K1QY88_CRAGI	3.0e-49	200.3	90.20%	70.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN001238.1	sp|A0A210R559|A0A210R559_MIZYE	5.1e-44	183.3	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN004056.1	sp|K1QL84|K1QL84_CRAGI	1.5e-73	283.1	69.02%	34.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004058.1	sp|K1QY88|K1QY88_CRAGI	2.5e-37	160.2	100.00%	66.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN004059.1	sp|K1QY88|K1QY88_CRAGI	8.7e-159	565.8	98.99%	62.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN004062.1	sp|K1PVV3|K1PVV3_CRAGI	1.4e-77	296.2	80.27%	37.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004063.1	sp|K1PFK0|K1PFK0_CRAGI	5.4e-21	107.1	41.32%	46.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001239.1	sp|K1RBV6|K1RBV6_CRAGI	3.7e-82	310.5	71.33%	73.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004064.1	sp|K1QEN1|K1QEN1_CRAGI	0.0e+00	1708.7	100.00%	90.16%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004065.1	sp|K1P8D2|K1P8D2_CRAGI	0.0e+00	1435.6	100.00%	90.37%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004066.1	sp|K1PEG5|K1PEG5_CRAGI	3.3e-215	753.1	100.00%	86.70%	Arylacetamide deacetylase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016787|	GO:0006260|
GN004067.1	sp|A0A210QCW6|A0A210QCW6_MIZYE	8.1e-45	186.4	98.92%	85.14%	Lissencephaly-1 homolog;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|GO:0005874|GO:0005875|GO:0005815|	GO:0070840|	GO:0051301|GO:0000132|GO:0051012|
GN004068.1	sp|K1PM64|K1PM64_CRAGI	4.0e-188	663.7	93.97%	58.25%	U6 small nuclear RNA (adenine-(43)-N(6))-methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0008168|
GN004071.1	sp|A0A1S3I398|A0A1S3I398_LINUN	3.6e-15	87.4	51.52%	41.18%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN004072.1	sp|K1PUH6|K1PUH6_CRAGI	4.9e-125	453.0	98.63%	76.04%	Abhydrolase domain-containing protein 11;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN001240.1	sp|A0A1I8G553|A0A1I8G553_9PLAT	3.0e-30	138.7	60.70%	32.32%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN004073.1	sp|B6RB76|B6RB76_HALDI	6.5e-70	269.2	77.20%	91.22%	RAB protein;OS=Haliotis;PE=2;SV=1	GO:0005525|GO:0003924|
GN004074.1	sp|A0A210PKY0|A0A210PKY0_MIZYE	6.9e-62	243.0	69.06%	61.78%	BTB and MATH domain-containing protein 38;OS=Mizuhopecten;PE=4;SV=1
GN004075.1	sp|K1P8D7|K1P8D7_CRAGI	1.9e-94	352.4	59.90%	55.82%	Coiled-coil domain-containing protein 64-like protein;OS=Crassostrea;PE=4;SV=1
GN004076.1	sp|K1PEH0|K1PEH0_CRAGI	2.2e-81	308.5	61.59%	63.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004077.1	sp|K1PM68|K1PM68_CRAGI	1.3e-18	99.0	30.48%	82.54%	Vacuolar protein sorting-associated protein 37C;OS=Crassostrea;PE=4;SV=1	GO:0000813|	GO:0032509|
GN004079.1	sp|K1QEP2|K1QEP2_CRAGI	2.3e-46	190.7	82.31%	79.17%	Mitochondrial 2-oxoglutarate/malate carrier protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN004080.1	sp|K1PEH6|K1PEH6_CRAGI	0.0e+00	2487.6	100.00%	71.24%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004081.1	sp|K1PM70|K1PM70_CRAGI	4.4e-57	226.1	100.00%	75.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004082.1	sp|K1R4Z3|K1R4Z3_CRAGI	4.0e-145	519.6	100.00%	92.86%	Malate dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0030060|	GO:0005975|GO:0006099|
GN001241.1	sp|A0A267FX98|A0A267FX98_9PLAT	1.5e-26	126.3	63.40%	29.86%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN004083.1	sp|K1QJG1|K1QJG1_CRAGI	1.0e-110	404.8	100.00%	91.54%	Serine/threonine/tyrosine-interacting-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008138|
GN004084.1	sp|K1Q541|K1Q541_CRAGI	2.3e-150	537.7	82.02%	71.81%	Transducin beta-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004085.1	sp|K1PXL9|K1PXL9_CRAGI	1.1e-135	488.8	85.85%	75.62%	Williams-Beuren syndrome chromosomal region 14 protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN004086.1	sp|K1R4Y6|K1R4Y6_CRAGI	0.0e+00	2170.2	99.27%	75.57%	Carboxypeptidase D;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004181|GO:0008270|
GN004087.1	sp|A0A210Q0K6|A0A210Q0K6_MIZYE	1.6e-250	871.7	98.79%	44.01%	Transmembrane protein 132C;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN004088.1	sp|K1QD39|K1QD39_CRAGI	3.6e-99	366.7	100.00%	80.52%	Tctex1 domain-containing protein 1-B;OS=Crassostrea;PE=4;SV=1
GN004089.1	sp|A0A210Q872|A0A210Q872_MIZYE	7.1e-55	220.7	39.03%	55.66%	Arginine/serine-rich coiled-coil protein 2;OS=Mizuhopecten;PE=4;SV=1
GN004090.1	sp|K1PXK9|K1PXK9_CRAGI	2.5e-20	104.4	57.14%	52.73%	Uncharacterized protein C1orf86-like protein;OS=Crassostrea;PE=4;SV=1	GO:0043130|
GN004091.1	sp|A0A210PL31|A0A210PL31_MIZYE	3.8e-205	719.9	98.28%	67.95%	Acetyl-coenzyme A transporter 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008521|
GN001242.1	sp|K1PEP8|K1PEP8_CRAGI	5.6e-173	612.5	100.00%	90.32%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004092.1	sp|K1QJE9|K1QJE9_CRAGI	2.4e-298	1030.8	49.03%	78.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004093.1	sp|K1Q527|K1Q527_CRAGI	4.0e-201	706.8	98.26%	57.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004094.1	sp|K1PXK1|K1PXK1_CRAGI	1.5e-19	100.9	80.43%	63.01%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1
GN004096.1	sp|K1PXK1|K1PXK1_CRAGI	6.2e-91	339.3	98.71%	71.37%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1
GN004097.1	sp|K1R4X7|K1R4X7_CRAGI	0.0e+00	1192.2	99.86%	85.49%	Sodium/myo-inositol cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN004098.1	sp|K1QJE3|K1QJE3_CRAGI	0.0e+00	1748.8	99.71%	80.92%	Forkhead-associated domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN001243.1	sp|R7UCN5|R7UCN5_CAPTE	8.6e-10	69.7	52.51%	33.90%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004099.1	sp|K1QX46|K1QX46_CRAGI	7.7e-216	755.4	97.97%	81.78%	Solute carrier family 2, facilitated glucose transporter member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004222|GO:0022857|GO:0008270|	GO:0008643|
GN004100.1	sp|K1QX46|K1QX46_CRAGI	2.9e-80	304.3	100.00%	57.14%	Solute carrier family 2, facilitated glucose transporter member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004222|GO:0022857|GO:0008270|	GO:0008643|
GN004101.1	sp|K1QPF0|K1QPF0_CRAGI	2.2e-38	165.2	58.44%	50.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004102.1	sp|K1QFT4|K1QFT4_CRAGI	2.7e-148	530.4	100.00%	83.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN004103.1	sp|A0A1S3HLK8|A0A1S3HLK8_LINUN	1.7e-135	487.6	100.00%	86.45%	F-actin-capping protein subunit beta;OS=Lingula;PE=3;SV=1	GO:0005737|GO:0008290|	GO:0003779|	GO:0030036|GO:0051016|
GN004104.1	sp|K1RMW3|K1RMW3_CRAGI	0.0e+00	1108.2	100.00%	89.32%	Protein kinase C;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004697|	GO:0007163|GO:0035556|
GN001244.1	sp|K1RCR8|K1RCR8_CRAGI	9.4e-126	455.3	98.58%	77.26%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN004107.1	sp|K1QX41|K1QX41_CRAGI	0.0e+00	1566.6	100.00%	75.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004108.1	sp|A0A2C9JTU3|A0A2C9JTU3_BIOGL	2.3e-193	681.0	98.34%	58.68%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|	GO:0022857|	GO:0006865|
GN004110.1	sp|K1QFS9|K1QFS9_CRAGI	7.1e-67	259.2	100.00%	69.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004111.1	sp|K1QX37|K1QX37_CRAGI	4.2e-170	602.8	98.76%	93.71%	Enolase;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0000015|	GO:0000287|GO:0004634|	GO:0006096|
GN001245.1	sp|K1Q7A2|K1Q7A2_CRAGI	7.2e-76	288.9	98.85%	78.36%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN004112.1	sp|A0A210R2S7|A0A210R2S7_MIZYE	6.0e-149	532.7	96.41%	79.08%	Solute carrier family 35 member E2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN004113.1	sp|K1RMV4|K1RMV4_CRAGI	3.9e-278	962.6	100.00%	77.16%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004114.1	sp|K1R3I6|K1R3I6_CRAGI	4.7e-113	413.3	75.54%	86.01%	Nucleolar complex protein 2-like protein;OS=Crassostrea;PE=4;SV=1
GN004115.1	sp|K1QX33|K1QX33_CRAGI	2.1e-59	234.6	64.86%	83.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004116.1	sp|K1QE86|K1QE86_CRAGI	1.8e-43	182.2	31.85%	77.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001246.1	sp|K1Q7A2|K1Q7A2_CRAGI	7.2e-76	288.9	98.85%	78.36%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN004117.1	sp|K1PS17|K1PS17_CRAGI	3.5e-154	551.6	100.00%	36.66%	Protein G7c;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004118.1	sp|K1R3I3|K1R3I3_CRAGI	7.2e-135	486.5	100.00%	51.49%	TRAF-type zinc finger domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004119.1	sp|K1QX29|K1QX29_CRAGI	0.0e+00	1193.3	99.62%	74.24%	Alpha-L-iduronidase;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0005975|
GN004120.1	sp|K1QPB8|K1QPB8_CRAGI	1.3e-171	607.8	100.00%	89.82%	NAD kinase;OS=Crassostrea;PE=3;SV=1	GO:0003951|	GO:0019674|GO:0006741|
GN004121.1	sp|K1QFR8|K1QFR8_CRAGI	6.7e-92	344.0	98.06%	43.40%	Protein SIX6OS1;OS=Crassostrea;PE=4;SV=1
GN004122.1	sp|K1RMU7|K1RMU7_CRAGI	4.5e-57	226.5	93.85%	80.84%	Espin;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0051017|
GN004123.1	sp|K1RMU7|K1RMU7_CRAGI	6.9e-106	389.8	91.81%	60.21%	Espin;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0051017|
GN004125.1	sp|K1RV58|K1RV58_CRAGI	2.7e-28	132.5	16.30%	74.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001247.1	sp|K1QY88|K1QY88_CRAGI	3.3e-86	325.1	72.30%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN004127.1	sp|K1RV58|K1RV58_CRAGI	1.1e-31	143.3	24.50%	72.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004130.1	sp|K1R8Z3|K1R8Z3_CRAGI	1.2e-21	107.8	100.00%	49.45%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN004131.1	sp|K1RFS3|K1RFS3_CRAGI	2.0e-294	1016.9	98.14%	71.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004132.1	sp|A0A2B4SLE6|A0A2B4SLE6_STYPI	1.2e-12	79.7	38.32%	39.37%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN004133.1	sp|K1RLX6|K1RLX6_CRAGI	7.8e-66	255.8	100.00%	63.68%	Ras-like GTP-binding protein RYL1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN004136.1	sp|K1RA42|K1RA42_CRAGI	9.3e-61	238.8	96.83%	80.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004137.1	sp|K1RW85|K1RW85_CRAGI	1.0e-129	468.4	100.00%	83.83%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN004138.1	sp|K1RW85|K1RW85_CRAGI	2.6e-54	216.9	83.72%	97.20%	Adenosylhomocysteinase;OS=Crassostrea;PE=3;SV=1	GO:0004013|GO:0051287|	GO:0006730|GO:0019510|
GN004139.1	sp|K1PPS0|K1PPS0_CRAGI	8.0e-34	149.8	51.13%	48.92%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN004140.1	sp|K1RKE8|K1RKE8_CRAGI	2.6e-307	1059.7	100.00%	77.38%	Cirhin;OS=Crassostrea;PE=4;SV=1
GN001249.1	sp|A0A210QTJ8|A0A210QTJ8_MIZYE	1.1e-136	492.3	93.86%	58.93%	Potassium voltage-gated channel protein egl-36;OS=Mizuhopecten;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004141.1	sp|K1REC9|K1REC9_CRAGI	0.0e+00	2535.0	100.00%	90.43%	Cleavage and polyadenylation specificity factor subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003676|
GN004142.1	sp|K1R8L0|K1R8L0_CRAGI	8.6e-155	552.0	100.00%	78.05%	Dehydrogenase/reductase SDR family member 1;OS=Crassostrea;PE=4;SV=1
GN004143.1	sp|F8RP10|F8RP10_CRAGI	4.9e-199	699.5	98.13%	73.67%	Bactericidal permeability increasing protein;OS=Crassostrea;PE=2;SV=1	GO:0005615|	GO:0001530|	GO:0050829|GO:0006955|
GN001250.1	sp|K1P8Q8|K1P8Q8_CRAGI	1.1e-131	474.9	100.00%	83.70%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN004145.1	sp|A0A210QQ57|A0A210QQ57_MIZYE	2.6e-20	104.8	81.55%	35.74%	ATPase WRNIP1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006281|GO:0006260|
GN004146.1	sp|A0A210QQ57|A0A210QQ57_MIZYE	1.1e-128	465.3	99.71%	63.29%	ATPase WRNIP1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0003677|	GO:0006281|GO:0006260|
GN004147.1	sp|K1QWE6|K1QWE6_CRAGI	1.3e-13	83.6	22.95%	40.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004148.1	sp|K1QRV3|K1QRV3_CRAGI	0.0e+00	2531.5	100.00%	84.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004149.1	sp|K1QBR4|K1QBR4_CRAGI	1.5e-41	174.5	96.95%	72.22%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN004150.1	sp|K1QD63|K1QD63_CRAGI	2.2e-138	497.7	85.90%	78.66%	GTP-binding protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0000287|
GN004151.1	sp|K1P739|K1P739_CRAGI	2.9e-13	79.3	91.38%	69.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004152.1	sp|K1PD67|K1PD67_CRAGI	0.0e+00	1640.2	100.00%	79.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN004153.1	sp|K1PKR9|K1PKR9_CRAGI	0.0e+00	1174.5	100.00%	72.82%	Protein tiptop;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0048749|GO:0048730|GO:0000122|
GN004154.1	sp|K1PSS5|K1PSS5_CRAGI	6.2e-35	153.3	80.87%	70.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN004155.1	sp|K1QD68|K1QD68_CRAGI	1.9e-207	727.6	100.00%	80.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN004156.1	sp|K1QL12|K1QL12_CRAGI	2.1e-178	630.6	99.17%	83.52%	Meiotic recombination protein SPO11;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0005524|GO:0003824|GO:0003677|	GO:0000737|
GN004157.1	sp|R7TDX6|R7TDX6_CAPTE	8.3e-172	609.4	99.67%	50.08%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004158.1	sp|K1PQ79|K1PQ79_CRAGI	1.5e-104	384.4	99.07%	88.63%	Copine-3;OS=Crassostrea;PE=4;SV=1
GN004159.1	sp|K1QAM7|K1QAM7_CRAGI	5.7e-228	795.8	92.86%	70.26%	Copine-7;OS=Crassostrea;PE=4;SV=1
GN004160.1	sp|K1P4C3|K1P4C3_CRAGI	2.5e-102	377.5	83.09%	76.96%	Transmembrane protein with metallophosphoesterase domain;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN004161.1	sp|K1PAU1|K1PAU1_CRAGI	7.1e-163	578.9	100.00%	75.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004162.1	sp|K1PAU1|K1PAU1_CRAGI	1.1e-120	438.7	93.75%	60.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004163.1	sp|K1PI43|K1PI43_CRAGI	8.1e-55	219.5	66.67%	63.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004164.1	sp|K1PQ88|K1PQ88_CRAGI	0.0e+00	1510.4	85.68%	72.44%	Cyclic nucleotide-gated cation channel beta-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN004165.1	sp|K1QAN2|K1QAN2_CRAGI	5.4e-29	132.5	99.08%	71.82%	Protein SLC7A6OS;OS={ECO:0000313|EMBL:EKC18541.1};;PE=4;SV=1
GN004166.1	sp|K1PI56|K1PI56_CRAGI	5.3e-82	310.1	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN004167.1	sp|K1PI56|K1PI56_CRAGI	3.9e-65	253.8	80.52%	58.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN004168.1	sp|K1PI56|K1PI56_CRAGI	7.7e-63	246.1	97.20%	52.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN004169.1	sp|K1PQ94|K1PQ94_CRAGI	3.5e-69	266.9	98.09%	63.59%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN004170.1	sp|K1PI56|K1PI56_CRAGI	2.6e-81	307.8	83.01%	59.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN004171.1	sp|K1PI56|K1PI56_CRAGI	5.9e-81	306.6	83.01%	59.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN004173.1	sp|K1QAP4|K1QAP4_CRAGI	4.5e-107	393.7	99.73%	53.09%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004174.1	sp|K1PAV4|K1PAV4_CRAGI	8.2e-112	409.5	89.51%	59.72%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004175.1	sp|A0A1X7UG29|A0A1X7UG29_AMPQE	8.2e-20	102.8	91.33%	30.34%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN004176.1	sp|K1S0V2|K1S0V2_CRAGI	8.6e-16	89.4	72.47%	38.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004177.1	sp|K1QHP3|K1QHP3_CRAGI	3.4e-94	350.1	99.55%	85.00%	TAR DNA-binding protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003723|
GN004178.1	sp|K1Q2P9|K1Q2P9_CRAGI	2.9e-34	149.8	95.88%	71.74%	Adenine phosphoribosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0009116|
GN004179.1	sp|K1S4P3|K1S4P3_CRAGI	1.5e-239	834.7	73.30%	74.81%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN001251.1	sp|K1QLU8|K1QLU8_CRAGI	2.3e-37	160.6	92.59%	64.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004181.1	sp|K1QST7|K1QST7_CRAGI	7.2e-26	122.1	95.33%	59.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004182.1	sp|K1R9D4|K1R9D4_CRAGI	1.4e-245	854.4	100.00%	80.47%	N6-adenosine-methyltransferase 70 kDa subunit;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0016422|
GN004183.1	sp|K1QTV9|K1QTV9_CRAGI	2.6e-43	179.9	92.71%	81.82%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN001252.1	sp|K1QLU8|K1QLU8_CRAGI	1.0e-26	124.4	94.81%	80.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004184.1	sp|K1QTV9|K1QTV9_CRAGI	3.7e-280	969.5	99.72%	77.45%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN004185.1	sp|K1QTV9|K1QTV9_CRAGI	7.5e-273	946.0	58.77%	84.56%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN004186.1	sp|W4Y8Y6|W4Y8Y6_STRPU	2.0e-51	208.8	86.85%	40.31%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN004188.1	sp|A0A210Q8Q0|A0A210Q8Q0_MIZYE	9.6e-142	509.6	99.38%	44.01%	HEAT repeat-containing protein 3;OS=Mizuhopecten;PE=4;SV=1
GN001253.1	sp|K1QLU8|K1QLU8_CRAGI	6.2e-35	152.5	92.59%	62.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004189.1	sp|K1QWM6|K1QWM6_CRAGI	3.1e-218	763.1	99.76%	84.49%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN004190.1	sp|K1QWM6|K1QWM6_CRAGI	8.5e-35	151.4	98.78%	83.75%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN004191.1	sp|K1QWM6|K1QWM6_CRAGI	0.0e+00	1634.0	98.06%	90.01%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN004192.1	sp|K1QWM6|K1QWM6_CRAGI	1.4e-195	688.0	86.05%	84.15%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN004193.1	sp|K1QWM6|K1QWM6_CRAGI	4.1e-32	144.8	19.81%	84.34%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN004194.1	sp|K1RGW2|K1RGW2_CRAGI	4.2e-209	733.4	91.95%	62.87%	Serine/threonine-protein kinase PINK1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001254.1	sp|K1QLU8|K1QLU8_CRAGI	1.2e-27	127.5	94.81%	81.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004202.1	sp|K1QXL2|K1QXL2_CRAGI	8.5e-162	575.5	98.44%	78.31%	Solute carrier family 35 member C2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001255.1	sp|K1QF99|K1QF99_CRAGI	1.4e-166	591.3	100.00%	87.36%	Transmembrane protein 64;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004204.1	sp|K1QQK0|K1QQK0_CRAGI	4.8e-43	181.0	27.48%	76.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004205.1	sp|K1QQK0|K1QQK0_CRAGI	9.2e-21	104.8	98.80%	64.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004206.1	sp|K1QI03|K1QI03_CRAGI	0.0e+00	1678.3	98.27%	69.22%	Phosphatase Slingshot-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0004725|GO:0008138|	GO:0030036|
GN004207.1	sp|A0A210QHL1|A0A210QHL1_MIZYE	0.0e+00	1443.7	98.98%	75.29%	EF-hand calcium-binding domain-containing protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN004208.1	sp|K1QQJ1|K1QQJ1_CRAGI	4.4e-103	379.4	100.00%	97.31%	Ubiquitin-protein ligase E3B;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN004209.1	sp|K1PRB8|K1PRB8_CRAGI	4.2e-25	121.7	98.76%	23.15%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004210.1	sp|K1QHZ5|K1QHZ5_CRAGI	7.2e-62	242.7	76.30%	96.25%	NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0051539|GO:0016651|
GN004211.1	sp|K1Q9K7|K1Q9K7_CRAGI	1.7e-79	301.2	87.96%	78.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004212.1	sp|K1QWS5|K1QWS5_CRAGI	1.1e-301	1040.8	97.10%	88.44%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN000924.1	sp|K1PEN9|K1PEN9_CRAGI	1.8e-125	454.1	97.17%	87.03%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0008810|GO:0030247|	GO:0030245|
GN001256.1	sp|K1R720|K1R720_CRAGI	7.7e-164	582.0	87.35%	100.00%	Casein kinase I isoform alpha;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN004229.1	sp|K1PCL9|K1PCL9_CRAGI	9.1e-125	452.2	97.20%	77.39%	Solute carrier family 28 member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005337|
GN004230.1	sp|K1PCL9|K1PCL9_CRAGI	3.3e-168	597.0	97.60%	71.11%	Solute carrier family 28 member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005337|
GN004231.1	sp|K1PS39|K1PS39_CRAGI	8.0e-238	828.9	87.20%	65.24%	Leucine-rich repeat and WD repeat-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004233.1	sp|K1PK44|K1PK44_CRAGI	2.9e-67	260.0	99.29%	83.45%	Alkylated DNA repair protein alkB-like protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016491|	GO:0070988|
GN004234.1	sp|K1P6L6|K1P6L6_CRAGI	1.8e-121	441.0	100.00%	84.78%	Potassium voltage-gated channel protein Shaw;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004235.1	sp|K1P6L6|K1P6L6_CRAGI	6.7e-119	432.6	94.50%	76.36%	Potassium voltage-gated channel protein Shaw;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004239.1	sp|K1R167|K1R167_CRAGI	7.5e-49	200.3	81.44%	39.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004240.1	sp|K1RKP3|K1RKP3_CRAGI	0.0e+00	1462.2	100.00%	69.14%	AP1 subunit gamma-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN004241.1	sp|Q70MM3|Q70MM3_CRAGI	2.4e-84	317.0	100.00%	90.06%	Ferritin;OS=Crassostrea;PE=2;SV=1	GO:0005623|	GO:0008199|GO:0004322|	GO:0006879|GO:0006826|
GN004242.1	sp|K1R171|K1R171_CRAGI	0.0e+00	1376.7	95.94%	69.66%	GAS2-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008017|
GN004243.1	sp|K1R171|K1R171_CRAGI	5.3e-110	402.5	99.04%	97.07%	GAS2-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008017|
GN004245.1	sp|K1PPT3|K1PPT3_CRAGI	1.4e-59	236.1	59.15%	38.08%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN004246.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.1e-57	228.8	94.55%	55.98%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN004247.1	sp|K1RKQ0|K1RKQ0_CRAGI	3.2e-232	809.7	99.78%	86.37%	Noelin-3;OS=Crassostrea;PE=4;SV=1
GN004251.1	sp|K1PVU0|K1PVU0_CRAGI	1.3e-26	125.2	93.98%	39.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004252.1	sp|K1RBP0|K1RBP0_CRAGI	5.9e-13	78.2	88.68%	76.09%	Ceramide kinase;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN004253.1	sp|D6WYB2|D6WYB2_TRICA	2.6e-70	271.2	95.52%	49.46%	Putative nuclease HARBI1-like Protein;OS=Tribolium;PE=4;SV=1
GN004254.1	sp|K1PCS8|K1PCS8_CRAGI	3.1e-54	217.2	96.52%	57.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004256.1	sp|K1PCS8|K1PCS8_CRAGI	3.1e-54	217.2	96.52%	57.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004257.1	sp|K1QWA2|K1QWA2_CRAGI	1.0e-88	332.0	90.76%	75.33%	Tumor protein p53-inducible nuclear protein 1;OS=Crassostrea;PE=4;SV=1
GN004258.1	sp|K1RRD7|K1RRD7_CRAGI	9.5e-84	315.8	63.00%	75.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004259.1	sp|K1RS90|K1RS90_CRAGI	8.8e-79	298.9	85.52%	72.34%	Metallophosphoesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN004260.1	sp|K1R824|K1R824_CRAGI	1.3e-166	591.7	98.43%	68.42%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004261.1	sp|K1R824|K1R824_CRAGI	7.3e-173	612.5	99.33%	70.29%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004262.1	sp|K1R824|K1R824_CRAGI	1.2e-172	611.7	99.33%	70.29%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004263.1	sp|K1R824|K1R824_CRAGI	2.0e-45	187.6	73.08%	72.57%	Potassium voltage-gated channel subfamily D member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004264.1	sp|K1RS90|K1RS90_CRAGI	2.1e-62	244.6	82.61%	63.16%	Metallophosphoesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN001258.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	4.5e-52	210.7	98.74%	34.80%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN004265.1	sp|V4AUS0|V4AUS0_LOTGI	3.8e-20	102.8	94.51%	59.34%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004266.1	sp|K1RS85|K1RS85_CRAGI	8.0e-158	563.1	83.43%	84.01%	Switch-associated protein 70;OS=Crassostrea;PE=4;SV=1
GN004267.1	sp|K1R819|K1R819_CRAGI	1.1e-90	338.6	81.07%	76.53%	UPF0516 protein C12orf72-like protein;OS=Crassostrea;PE=4;SV=1
GN004268.1	sp|A0A210PXW2|A0A210PXW2_MIZYE	2.5e-99	367.5	100.00%	63.70%	E3 ubiquitin-protein ligase NRDP1;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN004269.1	sp|K1PRJ1|K1PRJ1_CRAGI	5.1e-55	220.7	89.65%	38.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004270.1	sp|K1PRJ1|K1PRJ1_CRAGI	1.3e-78	299.7	74.38%	40.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001259.1	sp|A0A210PN90|A0A210PN90_MIZYE	2.3e-253	880.2	99.27%	76.06%	Centrosomal protein of 76 kDa;OS=Mizuhopecten;PE=4;SV=1
GN004271.1	sp|K1RXP6|K1RXP6_CRAGI	1.4e-163	582.0	76.76%	67.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN004272.1	sp|K1RXP6|K1RXP6_CRAGI	1.9e-54	218.4	51.09%	75.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN004273.1	sp|K1RXP6|K1RXP6_CRAGI	2.8e-168	597.8	97.35%	51.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN004274.1	sp|K1QS88|K1QS88_CRAGI	1.6e-152	545.4	91.43%	49.84%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN004275.1	sp|K1R1R5|K1R1R5_CRAGI	0.0e+00	1813.1	97.60%	68.46%	SH3 domain-containing guanine exchange factor;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN004276.1	sp|K1REH1|K1REH1_CRAGI	1.9e-72	278.1	60.55%	75.97%	Low affinity immunoglobulin epsilon Fc receptor;OS=Crassostrea;PE=4;SV=1
GN004277.1	sp|K1Q9B2|K1Q9B2_CRAGI	3.0e-110	404.4	66.36%	72.41%	Transcription factor AP-2 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|
GN004278.1	sp|A0A210Q5K8|A0A210Q5K8_MIZYE	5.1e-303	1045.4	100.00%	77.04%	Tripartite motif-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0008270|
GN004279.1	sp|K1P2E3|K1P2E3_CRAGI	4.0e-58	230.3	100.00%	59.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004280.1	sp|K1PNB1|K1PNB1_CRAGI	2.1e-141	507.3	99.64%	88.17%	Tetratricopeptide repeat protein 5;OS=Crassostrea;PE=4;SV=1
GN004281.1	sp|K1QFN7|K1QFN7_CRAGI	2.8e-122	444.5	96.61%	49.24%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN004282.1	sp|K1PNA7|K1PNA7_CRAGI	4.7e-61	240.0	83.18%	90.40%	WD repeat-containing protein 88;OS=Crassostrea;PE=4;SV=1
GN001260.1	sp|K1RB36|K1RB36_CRAGI	1.3e-63	249.2	97.17%	38.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004283.1	sp|K1PGE1|K1PGE1_CRAGI	4.6e-126	456.4	92.23%	85.02%	E3 ubiquitin-protein ligase MARCH6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|
GN004285.1	sp|A0A1S3H413|A0A1S3H413_LINUN	3.1e-32	143.7	95.89%	53.90%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN004286.1	sp|H9LHX4|H9LHX4_CRAAR	1.9e-85	320.9	99.48%	80.21%	Ras-like GTP-binding protein Rho1 isoform 1;OS=Crassostrea;PE=2;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN004287.1	sp|H9LHX4|H9LHX4_CRAAR	7.5e-82	308.9	100.00%	77.20%	Ras-like GTP-binding protein Rho1 isoform 1;OS=Crassostrea;PE=2;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN004288.1	sp|A0A210QNK1|A0A210QNK1_MIZYE	3.9e-28	131.0	98.52%	38.79%	Src kinase-associated phosphoprotein 2-A;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN004289.1	sp|K1Q9B6|K1Q9B6_CRAGI	3.1e-295	1020.0	95.13%	56.05%	RanBP-type and C3HC4-type zinc finger-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004290.1	sp|K1PNA2|K1PNA2_CRAGI	2.4e-130	470.3	100.00%	96.68%	Repressor of RNA polymerase III transcription MAF1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0016480|
GN004291.1	sp|K1PGD6|K1PGD6_CRAGI	0.0e+00	1705.3	100.00%	86.62%	Putative ubiquitin carboxyl-terminal hydrolase CYLD;OS=Crassostrea;PE=4;SV=1	GO:0036459|	GO:0016579|
GN004292.1	sp|K1P2C3|K1P2C3_CRAGI	3.1e-195	686.8	100.00%	73.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004293.1	sp|K1Q9B2|K1Q9B2_CRAGI	8.6e-110	402.9	68.42%	71.24%	Transcription factor AP-2 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|
GN004294.1	sp|K1PN97|K1PN97_CRAGI	5.1e-233	812.8	99.68%	77.88%	Gigaxonin;OS=Crassostrea;PE=4;SV=1	GO:0007010|
GN004295.1	sp|K1PGD2|K1PGD2_CRAGI	3.1e-276	956.1	100.00%	90.00%	Putative aminopeptidase NPEPL1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0004177|GO:0030145|GO:0008235|
GN004297.1	sp|K1P2B8|K1P2B8_CRAGI	6.7e-151	538.9	96.94%	91.20%	GDP-mannose 4,6 dehydratase;OS=Crassostrea;PE=3;SV=1	GO:0008446|	GO:0019673|
GN004298.1	sp|K1Q9A9|K1Q9A9_CRAGI	1.8e-172	610.9	100.00%	79.02%	Forkhead box protein L1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN004299.1	sp|K1Q195|K1Q195_CRAGI	6.2e-29	132.5	96.83%	54.92%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN004300.1	sp|K1PGC6|K1PGC6_CRAGI	6.6e-223	778.9	100.00%	79.28%	Forkhead box protein C2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN004301.1	sp|K1P913|K1P913_CRAGI	8.9e-114	415.6	87.83%	73.31%	Arylacetamide deacetylase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN000959.1	sp|K1QQX1|K1QQX1_CRAGI	4.2e-60	236.5	100.00%	66.28%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001261.1	sp|A0A210QTT9|A0A210QTT9_MIZYE	3.5e-105	388.3	73.35%	58.02%	Nuclear receptor coactivator 5;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN004302.1	sp|A0A210PLK8|A0A210PLK8_MIZYE	1.1e-93	349.0	99.70%	56.97%	Bromodomain-containing protein 7;OS=Mizuhopecten;PE=4;SV=1
GN004304.1	sp|K1Q9A4|K1Q9A4_CRAGI	2.0e-143	514.2	98.80%	76.74%	Purine nucleoside phosphorylase;OS=Crassostrea;PE=3;SV=1	GO:0004731|	GO:0009116|
GN004305.1	sp|K1PJD9|K1PJD9_CRAGI	1.3e-53	215.7	72.79%	51.44%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN004306.1	sp|A0A210PJJ5|A0A210PJJ5_MIZYE	2.3e-61	240.7	89.83%	71.07%	Dihydroorotate dehydrogenase (quinone), mitochondrial;OS=Mizuhopecten;PE=3;SV=1	GO:0005743|	GO:0004152|	GO:0006207|GO:0044205|
GN004307.1	sp|K1PSA8|K1PSA8_CRAGI	0.0e+00	1937.2	93.36%	81.43%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN001262.1	sp|K1QCE7|K1QCE7_CRAGI	3.9e-254	883.2	94.74%	59.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004309.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	1.9e-93	348.6	98.42%	41.06%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN004311.1	sp|K1QJC9|K1QJC9_CRAGI	5.7e-65	253.4	99.66%	52.68%	Polysialoglycoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004312.1	sp|K1RPE5|K1RPE5_CRAGI	6.5e-77	294.3	48.63%	49.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001263.1	sp|K1QKH8|K1QKH8_CRAGI	3.7e-149	533.5	92.25%	75.35%	NF-kappa-B inhibitor-like protein 2;OS=Crassostrea;PE=4;SV=1
GN004314.1	sp|A0A210R2G6|A0A210R2G6_MIZYE	1.3e-56	225.3	96.61%	49.78%	Serine-enriched protein;OS=Mizuhopecten;PE=4;SV=1
GN004315.1	sp|V4AUG6|V4AUG6_LOTGI	7.2e-171	605.9	99.57%	61.19%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0005623|	GO:0009055|GO:0050660|GO:0004791|	GO:0045454|
GN004316.1	sp|K1QTZ6|K1QTZ6_CRAGI	2.6e-126	458.0	88.98%	60.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004317.1	sp|A0A0L8HHW4|A0A0L8HHW4_OCTBM	8.3e-104	383.3	91.25%	40.04%	Uncharacterized protein;OS=Octopus;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN004318.1	sp|V4A1M7|V4A1M7_LOTGI	8.9e-73	279.3	80.07%	59.72%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004319.1	sp|K1QXG1|K1QXG1_CRAGI	0.0e+00	2045.4	99.91%	84.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004321.1	sp|K1PPV3|K1PPV3_CRAGI	0.0e+00	1301.6	97.91%	93.57%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN004322.1	sp|K1R9C6|K1R9C6_CRAGI	4.1e-74	283.1	97.78%	72.57%	Phytanoyl-CoA hydroxylase-interacting protein;OS=Crassostrea;PE=4;SV=1
GN004323.1	sp|K1R9C6|K1R9C6_CRAGI	8.5e-72	275.4	97.78%	70.86%	Phytanoyl-CoA hydroxylase-interacting protein;OS=Crassostrea;PE=4;SV=1
GN004324.1	sp|K1QHE7|K1QHE7_CRAGI	7.3e-14	82.8	77.16%	38.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004325.1	sp|K1QYV4|K1QYV4_CRAGI	0.0e+00	1719.1	100.00%	90.16%	Ankyrin repeat and FYVE domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004326.1	sp|K1PR08|K1PR08_CRAGI	1.5e-207	727.6	99.30%	81.37%	3-oxoacyl-[acyl-carrier-protein] synthase;OS=Crassostrea;PE=3;SV=1	GO:0016747|	GO:0006633|
GN001264.1	sp|K1QKH8|K1QKH8_CRAGI	8.0e-53	212.2	88.27%	74.65%	NF-kappa-B inhibitor-like protein 2;OS=Crassostrea;PE=4;SV=1
GN004327.1	sp|A0A1S3KEW9|A0A1S3KEW9_LINUN	1.1e-72	279.3	87.12%	50.34%	Proline dehydrogenase;OS=Lingula;PE=3;SV=1	GO:0004657|	GO:0006562|
GN004328.1	sp|A0A210Q6E0|A0A210Q6E0_MIZYE	2.2e-220	770.4	95.41%	73.80%	TNF receptor-associated factor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008270|	GO:0042981|GO:0007165|
GN004329.1	sp|K1QUW2|K1QUW2_CRAGI	9.0e-15	89.0	36.43%	24.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004332.1	sp|K1QE87|K1QE87_CRAGI	1.3e-34	152.9	91.58%	28.34%	Octopressin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN004333.1	sp|K1Q924|K1Q924_CRAGI	1.2e-24	119.8	24.86%	76.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004333.1	sp|K1Q924|K1Q924_CRAGI	1.7e-07	62.8	9.67%	82.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004334.1	sp|K1PMX2|K1PMX2_CRAGI	2.1e-54	219.2	45.11%	85.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001265.1	sp|K1QRY1|K1QRY1_CRAGI	1.2e-58	232.6	93.22%	43.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004338.1	sp|K1Q912|K1Q912_CRAGI	6.4e-72	275.8	89.77%	85.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004339.1	sp|K1Q1W1|K1Q1W1_CRAGI	1.4e-68	265.4	98.98%	49.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004573|	GO:0009311|
GN004342.1	sp|K1PUG4|K1PUG4_CRAGI	0.0e+00	2366.3	94.99%	74.67%	ATP-binding cassette transporter sub-family C member 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN004343.1	sp|K1QUU3|K1QUU3_CRAGI	5.2e-36	155.6	95.79%	90.00%	Paxillin;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0046872|	GO:0007160|
GN004344.1	sp|K1Q1V8|K1Q1V8_CRAGI	1.1e-35	156.4	31.96%	65.22%	Caspase;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN001266.1	sp|K1RC08|K1RC08_CRAGI	9.0e-97	359.4	100.00%	61.33%	Transcriptional repressor scratch 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN004345.1	sp|K1PUG0|K1PUG0_CRAGI	5.5e-95	353.6	97.76%	49.53%	Serum paraoxonase/arylesterase 1;OS=Crassostrea;PE=3;SV=1	GO:0004064|GO:0004197|
GN004347.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	1.4e-21	109.8	31.47%	39.02%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN004348.1	sp|K1P700|K1P700_CRAGI	3.2e-57	226.9	91.57%	68.87%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN001267.1	sp|K1QCE8|K1QCE8_CRAGI	5.8e-282	975.7	77.53%	90.58%	RNA pseudouridylate synthase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN004349.1	sp|K1QWN3|K1QWN3_CRAGI	1.9e-15	88.6	77.12%	26.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004350.1	sp|K1QEG5|K1QEG5_CRAGI	7.9e-11	72.4	98.46%	40.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004351.1	sp|K1PD17|K1PD17_CRAGI	5.6e-122	444.1	87.31%	57.95%	Ecotropic virus integration site 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0006355|
GN004352.1	sp|K1PKK7|K1PKK7_CRAGI	2.4e-237	826.6	100.00%	97.95%	AP-2 complex subunit mu-1;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0006886|GO:0016192|
GN004353.1	sp|E3P7F4|E3P7F4_LEPCI	3.0e-48	196.8	86.96%	81.67%	Ribosomal protein L22;OS=Lepidochitona;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN004355.1	sp|C3YVP9|C3YVP9_BRAFL	3.3e-31	141.7	96.56%	29.24%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN004356.1	sp|C3ZZB5|C3ZZB5_BRAFL	2.6e-26	124.8	90.84%	33.90%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN004357.1	sp|A0A210R5P4|A0A210R5P4_MIZYE	1.1e-93	349.0	93.48%	53.49%	Dopamine beta-hydroxylase;OS=Mizuhopecten;PE=4;SV=1	GO:0005507|GO:0016715|
GN004358.1	sp|F5A8D9|F5A8D9_CRAGI	7.6e-34	149.1	61.74%	81.32%	Caspase-2;OS=Crassostrea;PE=2;SV=1	GO:0004197|	GO:0042981|
GN004360.1	sp|F5A8D9|F5A8D9_CRAGI	4.5e-114	416.8	84.16%	74.56%	Caspase-2;OS=Crassostrea;PE=2;SV=1	GO:0004197|	GO:0042981|
GN004362.1	sp|W4ZIR1|W4ZIR1_STRPU	4.2e-59	234.6	83.52%	33.18%	ATP-dependent DNA helicase;OS=Strongylocentrotus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN004363.1	sp|A0A1X7U2C0|A0A1X7U2C0_AMPQE	2.8e-52	212.2	98.58%	30.19%	ATP-dependent DNA helicase;OS=Amphimedon;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN004365.1	sp|K1QHJ5|K1QHJ5_CRAGI	1.8e-237	827.8	100.00%	63.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004366.1	sp|K1Q9J0|K1Q9J0_CRAGI	2.0e-161	574.3	84.84%	77.17%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN004367.1	sp|A0A210Q0H0|A0A210Q0H0_MIZYE	3.2e-143	513.5	90.06%	89.79%	SAGA-associated factor 29-like;OS=Mizuhopecten;PE=4;SV=1	GO:0000124|
GN004368.1	sp|K1QP57|K1QP57_CRAGI	3.3e-256	890.2	91.84%	81.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004369.1	sp|K1QHJ3|K1QHJ3_CRAGI	2.7e-20	102.8	90.77%	82.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004370.1	sp|K1S0Y7|K1S0Y7_CRAGI	1.8e-18	97.8	93.28%	51.56%	Protein rogdi;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004371.1	sp|K1S0Y7|K1S0Y7_CRAGI	8.4e-09	67.8	6.43%	94.29%	Protein rogdi;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004372.1	sp|K1QDL4|K1QDL4_CRAGI	1.1e-107	395.6	92.90%	59.18%	28S ribosomal protein S22, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN004373.1	sp|K1P725|K1P725_CRAGI	5.4e-158	562.8	99.45%	78.63%	Solute carrier family 25 member 36;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN004374.1	sp|K1Q441|K1Q441_CRAGI	2.4e-39	167.2	96.18%	64.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004375.1	sp|K1QQ63|K1QQ63_CRAGI	1.5e-123	448.7	98.79%	47.34%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004376.1	sp|A0A210PV11|A0A210PV11_MIZYE	8.0e-49	198.4	99.08%	84.11%	60S ribosome subunit biogenesis protein NIP7 homolog;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0003723|	GO:0042255|
GN004377.1	sp|K1RB68|K1RB68_CRAGI	1.1e-114	419.1	98.58%	64.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001269.1	sp|K1R0Q4|K1R0Q4_CRAGI	7.0e-39	165.6	100.00%	60.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001270.1	sp|K1RRD7|K1RRD7_CRAGI	1.3e-154	552.0	69.48%	74.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004390.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	5.5e-16	89.0	97.70%	51.76%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN004394.1	sp|K1RLR4|K1RLR4_CRAGI	1.0e-82	311.6	98.29%	80.12%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004395.1	sp|K1RLR4|K1RLR4_CRAGI	5.3e-74	283.5	99.34%	55.91%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004396.1	sp|K1RE87|K1RE87_CRAGI	1.2e-15	88.2	98.25%	44.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004397.1	sp|A0A210PE54|A0A210PE54_MIZYE	8.1e-26	123.6	86.97%	26.37%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN004398.1	sp|K1QVN0|K1QVN0_CRAGI	6.7e-59	234.6	50.34%	51.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001272.1	sp|K1PZN2|K1PZN2_CRAGI	2.5e-09	68.2	48.61%	30.88%	t-SNARE domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN004400.1	sp|K1RFN6|K1RFN6_CRAGI	5.3e-106	390.2	90.02%	76.01%	Protein escargot;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN004402.1	sp|A0A151WPL7|A0A151WPL7_9HYME	2.5e-38	164.1	88.12%	54.29%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN004405.1	sp|K1QAH8|K1QAH8_CRAGI	0.0e+00	2285.0	92.60%	80.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|	GO:0004866|GO:0003723|
GN004406.1	sp|K1Q493|K1Q493_CRAGI	4.1e-155	554.7	84.98%	54.78%	Ankyrin repeat domain-containing protein 27;OS=Crassostrea;PE=4;SV=1
GN004409.1	sp|V3ZFN5|V3ZFN5_LOTGI	1.7e-18	98.6	94.93%	30.95%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004190|
GN001273.1	sp|V4AWX3|V4AWX3_LOTGI	1.8e-19	101.7	87.83%	37.58%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004410.1	sp|K1QRI8|K1QRI8_CRAGI	7.0e-186	656.4	100.00%	78.79%	RNA polymerase II subunit A C-terminal domain phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008420|	GO:0070940|
GN004411.1	sp|K1QK13|K1QK13_CRAGI	2.8e-258	896.3	100.00%	89.57%	Putative phosphoethanolamine N-methyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN004412.1	sp|K1PN69|K1PN69_CRAGI	1.7e-131	474.9	97.34%	62.65%	Thiamine-triphosphatase;OS=Crassostrea;PE=4;SV=1	GO:0050333|
GN004413.1	sp|K1Q268|K1Q268_CRAGI	1.8e-66	258.1	96.46%	78.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001274.1	sp|K1QDT8|K1QDT8_CRAGI	2.2e-35	154.5	78.02%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004414.1	sp|K1Q9Z6|K1Q9Z6_CRAGI	1.4e-149	534.6	84.15%	95.27%	26S proteasome non-ATPase regulatory subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0005838|
GN004415.1	sp|K1R2T7|K1R2T7_CRAGI	2.3e-53	213.4	100.00%	98.06%	UPF0468 protein C16orf80-like protein;OS=Crassostrea;PE=4;SV=1
GN004416.1	sp|K1Q2F8|K1Q2F8_CRAGI	8.2e-114	415.6	96.77%	94.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004417.1	sp|K1QA00|K1QA00_CRAGI	2.6e-190	670.2	100.00%	83.46%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005328|
GN004418.1	sp|K1QA00|K1QA00_CRAGI	7.3e-78	295.4	89.76%	92.57%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005328|
GN004419.1	sp|K1QH38|K1QH38_CRAGI	7.7e-36	156.0	68.85%	64.84%	F-box only protein 31;OS=Crassostrea;PE=4;SV=1	GO:0019005|	GO:0030332|	GO:0031571|GO:0031146|
GN004422.1	sp|A0A2S2QV10|A0A2S2QV10_9HEMI	4.9e-10	69.7	83.20%	37.50%	Uncharacterized protein;OS=Sipha;PE=4;SV=1
GN004423.1	sp|W4XXE5|W4XXE5_STRPU	1.7e-93	349.7	69.74%	33.70%	Uncharacterized protein;OS=Strongylocentrotus;PE=3;SV=1	GO:0046872|GO:0036459|	GO:0016579|GO:0006511|
GN004424.1	sp|W4ZDS2|W4ZDS2_STRPU	3.1e-26	124.4	57.08%	46.21%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0030117|GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|GO:0006886|GO:0016192|
GN004427.1	sp|K1R8N6|K1R8N6_CRAGI	0.0e+00	2068.9	100.00%	78.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004428.1	sp|K1R2M3|K1R2M3_CRAGI	1.3e-50	206.1	99.46%	39.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN004429.1	sp|K1R2M3|K1R2M3_CRAGI	3.6e-46	191.8	72.88%	35.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN004430.1	sp|K1QT63|K1QT63_CRAGI	1.2e-31	141.0	100.00%	86.59%	Hydroxysteroid dehydrogenase-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN004432.1	sp|K1Q3Q1|K1Q3Q1_CRAGI	8.7e-82	308.9	99.55%	64.91%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN004433.1	sp|K1R8J3|K1R8J3_CRAGI	2.8e-87	327.8	69.25%	67.08%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004434.1	sp|K1Q136|K1Q136_CRAGI	2.9e-39	167.9	74.07%	45.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000960.1	sp|K1PVQ2|K1PVQ2_CRAGI	4.5e-70	269.6	100.00%	76.16%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001277.1	sp|A0A1X7TDZ9|A0A1X7TDZ9_AMPQE	3.4e-21	107.8	41.22%	44.86%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|
GN004435.1	sp|K1PU72|K1PU72_CRAGI	6.0e-68	263.5	69.78%	56.05%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0005975|
GN004437.1	sp|K1Q1Y3|K1Q1Y3_CRAGI	1.5e-78	298.5	99.65%	59.11%	GTP-binding protein REM 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN004439.1	sp|K1QGZ2|K1QGZ2_CRAGI	2.0e-24	117.9	59.01%	69.47%	GTP-binding protein GEM;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN004440.1	sp|K1QNI0|K1QNI0_CRAGI	1.8e-149	534.3	100.00%	84.31%	GTP-binding protein GEM;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN001278.1	sp|A0A0A9WBJ7|A0A0A9WBJ7_LYGHE	2.1e-33	148.3	93.00%	38.86%	Exonuclease;OS=Lygus;PE=4;SV=1	GO:0004527|
GN004443.1	sp|K1R8V1|K1R8V1_CRAGI	0.0e+00	1630.2	94.47%	70.79%	Puratrophin-1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN004443.1	sp|K1R8V1|K1R8V1_CRAGI	3.7e-31	143.3	5.61%	89.19%	Puratrophin-1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN004444.1	sp|K1Q1Z0|K1Q1Z0_CRAGI	7.5e-85	321.2	33.00%	76.92%	Chromodomain-helicase-DNA-binding protein 9;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0004386|
GN004445.1	sp|K1Q1Z0|K1Q1Z0_CRAGI	0.0e+00	2434.4	98.87%	87.32%	Chromodomain-helicase-DNA-binding protein 9;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0004386|
GN004449.1	sp|K1QY88|K1QY88_CRAGI	1.3e-88	334.3	28.12%	42.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN004451.1	sp|K1QRF3|K1QRF3_CRAGI	1.9e-126	457.2	100.00%	97.21%	Cytochrome b5 domain-containing protein 1;OS=Crassostrea;PE=3;SV=1
GN004452.1	sp|K1RHS1|K1RHS1_CRAGI	6.6e-101	374.4	30.06%	79.25%	Putative defense protein 3;OS=Crassostrea;PE=4;SV=1
GN004453.1	sp|K1QAN1|K1QAN1_CRAGI	1.4e-64	251.9	99.60%	54.55%	Putative defense protein Hdd11-like protein;OS=Crassostrea;PE=4;SV=1
GN004454.1	sp|A0A210QH49|A0A210QH49_MIZYE	1.8e-250	871.7	99.92%	37.80%	Metabotropic glutamate receptor 8;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004455.1	sp|A0A210QH49|A0A210QH49_MIZYE	0.0e+00	1375.9	99.70%	52.17%	Metabotropic glutamate receptor 8;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004456.1	sp|A0A210PXB7|A0A210PXB7_MIZYE	1.1e-17	95.5	91.57%	28.48%	Neuronal acetylcholine receptor subunit beta-3;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN004457.1	sp|K1QXU3|K1QXU3_CRAGI	9.7e-89	332.0	79.82%	91.16%	Thyrotropin-releasing hormone receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004997|
GN001279.1	sp|K1PVP0|K1PVP0_CRAGI	1.0e-24	117.9	100.00%	71.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004458.1	sp|K1RHS6|K1RHS6_CRAGI	2.5e-263	913.3	96.26%	87.38%	B(0,+)-type amino acid transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN004459.1	sp|A0A2T7NNK9|A0A2T7NNK9_POMCA	1.1e-43	184.1	80.41%	24.58%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0016021|	GO:0016788|	GO:0045087|GO:0007165|
GN004461.1	sp|A0A210QTR8|A0A210QTR8_MIZYE	1.7e-185	654.8	88.67%	58.79%	AarF domain-containing protein kinase 5;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016301|
GN004462.1	sp|K1QIZ7|K1QIZ7_CRAGI	3.9e-83	313.2	100.00%	83.68%	Programmed cell death protein 6;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN004463.1	sp|K1RHT2|K1RHT2_CRAGI	3.5e-71	273.9	94.12%	54.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004464.1	sp|K1RHT2|K1RHT2_CRAGI	1.0e-25	121.7	94.17%	55.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004465.1	sp|K1RHT6|K1RHT6_CRAGI	2.0e-242	843.6	90.22%	98.07%	Mitogen-activated protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004707|
GN001280.1	sp|K1QNU2|K1QNU2_CRAGI	1.4e-49	202.2	82.02%	54.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004466.1	sp|A0A210PGK4|A0A210PGK4_MIZYE	3.1e-137	494.6	96.60%	50.53%	DNA repair protein XRCC1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003684|	GO:0000012|
GN004467.1	sp|K1QRG9|K1QRG9_CRAGI	9.9e-38	161.4	83.84%	96.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000974|	GO:0061630|	GO:0006281|GO:0000398|
GN004468.1	sp|K1QRG9|K1QRG9_CRAGI	5.0e-110	403.3	79.15%	96.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000974|	GO:0061630|	GO:0006281|GO:0000398|
GN004469.1	sp|K1QBU1|K1QBU1_CRAGI	4.8e-43	179.1	99.03%	83.17%	Glycerophosphodiester phosphodiesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008081|	GO:0006629|
GN004470.1	sp|K1QU23|K1QU23_CRAGI	4.2e-49	199.5	100.00%	74.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004471.1	sp|K1QU23|K1QU23_CRAGI	6.5e-50	202.2	100.00%	74.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004472.1	sp|K1QU23|K1QU23_CRAGI	2.7e-42	176.8	99.14%	73.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004474.1	sp|A7S6J7|A7S6J7_NEMVE	1.4e-09	67.8	74.74%	45.07%	Predicted protein;OS=Nematostella;PE=4;SV=1	GO:0046983|
GN004475.1	sp|K1QU23|K1QU23_CRAGI	5.2e-39	166.0	100.00%	65.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004476.1	sp|C3XZ04|C3XZ04_BRAFL	1.0e-98	365.9	95.45%	46.91%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0043240|	GO:0004842|	GO:0036297|
GN004477.1	sp|K1PBU9|K1PBU9_CRAGI	2.1e-10	70.9	50.43%	56.90%	RNA pseudouridylate synthase domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN004480.1	sp|R7U2Y8|R7U2Y8_CAPTE	9.5e-17	92.8	93.15%	31.43%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004481.1	sp|K1P5S0|K1P5S0_CRAGI	1.4e-76	292.0	93.62%	56.82%	tRNA pseudouridine synthase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN004482.1	sp|A0A210R539|A0A210R539_MIZYE	3.3e-39	166.8	93.48%	62.02%	PDZ and LIM domain protein Zasp;OS=Mizuhopecten;PE=4;SV=1
GN004483.1	sp|K1PMG4|K1PMG4_CRAGI	4.4e-34	149.4	97.32%	70.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN004484.1	sp|K1PBU4|K1PBU4_CRAGI	0.0e+00	1083.9	99.60%	53.71%	Guanylate cyclase 2G;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016849|GO:0004672|	GO:0009190|GO:0035556|
GN004485.1	sp|K1P5Q1|K1P5Q1_CRAGI	2.8e-35	154.8	81.14%	46.27%	Crossover junction endonuclease MUS81;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004519|GO:0008270|
GN004486.1	sp|K1QBR3|K1QBR3_CRAGI	2.4e-175	621.7	89.48%	66.79%	Polyhomeotic-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008270|
GN004490.1	sp|K1R1Z0|K1R1Z0_CRAGI	1.0e-79	303.1	91.18%	36.38%	Acetylcholine receptor subunit alpha-type acr-16;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN004491.1	sp|K1QIP7|K1QIP7_CRAGI	8.4e-129	465.7	90.03%	77.60%	AKT-interacting protein;OS=Crassostrea;PE=4;SV=1
GN004492.1	sp|K1QMP2|K1QMP2_CRAGI	8.8e-78	296.6	92.76%	37.56%	Acetylcholine receptor subunit alpha-like 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN004493.1	sp|K1QAF3|K1QAF3_CRAGI	1.3e-166	591.3	92.35%	89.78%	Alanine aminotransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0030170|GO:0008483|	GO:0009058|
GN004494.1	sp|K1QAF3|K1QAF3_CRAGI	3.2e-66	256.5	100.00%	84.89%	Alanine aminotransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0030170|GO:0008483|	GO:0009058|
GN001284.1	sp|K1QQX2|K1QQX2_CRAGI	1.1e-37	161.4	82.41%	93.18%	Sodium-dependent multivitamin transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN004495.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	3.8e-45	188.3	22.86%	70.18%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN000961.1	sp|K1PHG2|K1PHG2_CRAGI	6.0e-67	259.2	100.00%	72.67%	Amine oxidase;OS=Crassostrea;PE=3;SV=1	GO:0016491|GO:0008270|
GN004499.1	sp|K1QZD7|K1QZD7_CRAGI	3.6e-45	186.4	98.37%	72.95%	Acyl-CoA synthetase family member 3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN004500.1	sp|K1QZD7|K1QZD7_CRAGI	8.4e-53	211.8	98.46%	77.95%	Acyl-CoA synthetase family member 3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN004501.1	sp|K1QZD7|K1QZD7_CRAGI	6.6e-59	233.0	54.88%	83.70%	Acyl-CoA synthetase family member 3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN004502.1	sp|K1RN44|K1RN44_CRAGI	9.5e-64	250.0	70.27%	42.77%	Apelin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN004503.1	sp|K1RGU6|K1RGU6_CRAGI	5.0e-31	139.8	98.77%	48.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004504.1	sp|K1RB90|K1RB90_CRAGI	9.3e-55	218.4	96.32%	82.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004506.1	sp|K1S6F6|K1S6F6_CRAGI	4.5e-70	270.8	100.00%	95.54%	Leucine-rich repeat-containing protein 34;OS=Crassostrea;PE=4;SV=1
GN004507.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	4.4e-19	100.5	56.34%	41.80%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN004508.1	sp|K1RGT8|K1RGT8_CRAGI	4.5e-197	693.7	81.27%	64.98%	Kinesin-like protein KIF20A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN004509.1	sp|K1RGT8|K1RGT8_CRAGI	1.2e-22	114.4	28.23%	51.27%	Kinesin-like protein KIF20A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN004510.1	sp|K1QJQ5|K1QJQ5_CRAGI	3.5e-111	406.8	100.00%	80.16%	TRAF-interacting protein;OS=Crassostrea;PE=4;SV=1
GN004511.1	sp|A0A2H8U0G5|A0A2H8U0G5_9HEMI	3.5e-12	77.4	95.65%	28.57%	TRAF-interacting protein;OS=Melanaphis;PE=4;SV=1
GN004512.1	sp|K1R5B9|K1R5B9_CRAGI	3.1e-216	758.1	75.25%	46.03%	DNA-directed RNA polymerase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003899|	GO:0006351|
GN004513.1	sp|K1PY09|K1PY09_CRAGI	2.2e-255	886.7	100.00%	86.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004514.1	sp|K1QSS9|K1QSS9_CRAGI	4.3e-122	443.4	87.84%	54.46%	Acyl-coenzyme A thioesterase 8;OS=Crassostrea;PE=4;SV=1	GO:0047617|	GO:0006637|
GN004515.1	sp|K1QDD9|K1QDD9_CRAGI	5.6e-156	556.2	99.01%	70.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004516.1	sp|K1QLM7|K1QLM7_CRAGI	7.5e-160	568.9	91.41%	81.76%	Leucine-rich repeat-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004517.1	sp|K1QST4|K1QST4_CRAGI	5.6e-145	519.6	100.00%	79.03%	Slit-like protein 3 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004518.1	sp|K1RCX7|K1RCX7_CRAGI	4.7e-123	446.8	99.75%	67.25%	Leucine-rich repeat-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001285.1	sp|K1RLF1|K1RLF1_CRAGI	2.1e-23	113.6	80.90%	77.46%	Nicotinate-nucleotide pyrophosphorylase [carboxylating];OS=Crassostrea;PE=3;SV=1	GO:0004514|	GO:0009435|
GN004519.1	sp|K1Q5V5|K1Q5V5_CRAGI	2.1e-187	660.6	99.24%	83.55%	Leucine-rich glioma-inactivated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004521.1	sp|K1RFK4|K1RFK4_CRAGI	3.5e-253	879.4	100.00%	86.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004522.1	sp|A0A210QN12|A0A210QN12_MIZYE	4.1e-26	125.2	14.89%	80.52%	Protein SSXT;OS=Mizuhopecten;PE=4;SV=1	GO:0003713|
GN004523.1	sp|K1Q7Z9|K1Q7Z9_CRAGI	3.7e-123	446.8	99.68%	77.02%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN004524.1	sp|A0A210PWC5|A0A210PWC5_MIZYE	3.2e-120	436.8	99.22%	85.49%	Pachytene checkpoint protein 2-like;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|
GN004525.1	sp|K1Q8S9|K1Q8S9_CRAGI	2.7e-41	176.0	39.97%	33.45%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004526.1	sp|K1QTV1|K1QTV1_CRAGI	0.0e+00	2737.6	98.88%	88.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|GO:0016021|	GO:0004866|GO:0020037|GO:0005506|GO:0016705|
GN004527.1	sp|K1RZ11|K1RZ11_CRAGI	3.1e-18	97.1	100.00%	35.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004528.1	sp|K1RFT6|K1RFT6_CRAGI	3.9e-97	363.2	12.44%	88.26%	Polyamine-modulated factor 1-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN004529.1	sp|K1QTU8|K1QTU8_CRAGI	0.0e+00	1310.4	100.00%	83.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004530.1	sp|K1R3H9|K1R3H9_CRAGI	0.0e+00	1194.5	99.90%	64.19%	Pleckstrin-like protein domain-containing family M member 2;OS=Crassostrea;PE=4;SV=1
GN004531.1	sp|C3Z7Z4|C3Z7Z4_BRAFL	1.0e-149	537.3	87.56%	30.03%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN004536.1	sp|A0A1W4XKH3|A0A1W4XKH3_AGRPL	2.2e-19	102.4	21.73%	59.09%	uncharacterized protein LOC108742291 isoform X1;OS=Agrilus;PE=4;SV=1
GN004537.1	sp|A0A147BBG1|A0A147BBG1_IXORI	3.8e-20	104.0	84.50%	32.76%	Putative transposon ty3-i gag-pol polyprotein;OS=Ixodes;PE=4;SV=1	GO:0003676|	GO:0015074|
GN001286.1	sp|K1QE15|K1QE15_CRAGI	4.7e-30	136.0	87.74%	75.27%	Ataxin-2;OS=Crassostrea;PE=4;SV=1
GN004547.1	sp|K1PQ56|K1PQ56_CRAGI	1.4e-62	247.3	40.22%	36.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004548.1	sp|K1PQ56|K1PQ56_CRAGI	2.5e-133	481.5	94.86%	48.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004549.1	sp|K1PQ56|K1PQ56_CRAGI	8.9e-14	82.4	86.84%	47.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001287.1	sp|K1QMQ1|K1QMQ1_CRAGI	3.4e-203	713.0	100.00%	89.03%	TBC1 domain family member 10B;OS=Crassostrea;PE=4;SV=1
GN004550.1	sp|K1QXW6|K1QXW6_CRAGI	1.1e-206	725.7	46.80%	94.35%	PITSLRE serine/threonine-protein kinase CDC2L1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN004551.1	sp|K1PQ51|K1PQ51_CRAGI	1.7e-63	248.1	75.60%	69.57%	Neurocan core protein;OS=Crassostrea;PE=4;SV=1
GN004552.1	sp|K1RAV0|K1RAV0_CRAGI	4.7e-120	436.8	99.74%	56.43%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN004553.1	sp|K1RAV0|K1RAV0_CRAGI	7.4e-126	456.1	99.74%	58.01%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN004554.1	sp|K1PN63|K1PN63_CRAGI	1.8e-54	219.5	96.86%	27.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001288.1	sp|K1R1Z7|K1R1Z7_CRAGI	0.0e+00	1855.1	100.00%	87.34%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|	GO:0042981|
GN004555.1	sp|K1QHT3|K1QHT3_CRAGI	2.4e-14	85.5	63.93%	24.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004556.1	sp|A0A3L8E2T2|A0A3L8E2T2_OOCBI	1.8e-11	74.7	80.95%	33.05%	Uncharacterized protein;OS=Ooceraea;PE=4;SV=1
GN004557.1	sp|K1PVP0|K1PVP0_CRAGI	2.6e-72	277.3	89.42%	70.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004558.1	sp|K1PQR3|K1PQR3_CRAGI	0.0e+00	2828.5	81.31%	75.34%	Nuclear receptor corepressor 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN004559.1	sp|A0A1X7VAJ5|A0A1X7VAJ5_AMPQE	7.5e-11	72.0	60.64%	50.00%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0008270|
GN004560.1	sp|K1PBL0|K1PBL0_CRAGI	2.0e-163	580.9	77.84%	86.05%	Phosphatidylserine decarboxylase proenzyme;OS=Crassostrea;PE=4;SV=1	GO:0004609|	GO:0008654|
GN004561.1	sp|K1PQR9|K1PQR9_CRAGI	0.0e+00	1313.5	93.83%	90.59%	Squamous cell carcinoma antigen recognized by T-cells 3;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006396|
GN004562.1	sp|B6EY03|B6EY03_CRAGI	9.8e-252	874.8	100.00%	85.95%	Beta-glucan recognition protein 1;OS=Crassostrea;PE=2;SV=1	GO:0030246|GO:0004553|	GO:0005975|
GN004563.1	sp|K1Q8K2|K1Q8K2_CRAGI	7.3e-160	569.3	91.13%	67.62%	Importin subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0061608|	GO:0006606|
GN004565.1	sp|A0A3L5TQN3|A0A3L5TQN3_MYTGA	2.6e-22	109.8	97.40%	78.38%	Meiotic nuclear division protein 1;OS=Mytilus;PE=4;SV=1
GN001290.1	sp|K1RLF4|K1RLF4_CRAGI	3.5e-10	71.6	56.59%	33.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004568.1	sp|K1R7T0|K1R7T0_CRAGI	5.5e-90	336.3	96.30%	72.53%	GMP synthase [glutamine-hydrolyzing];OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003922|GO:0016462|	GO:0006541|GO:0006177|
GN004569.1	sp|K1R1C3|K1R1C3_CRAGI	4.9e-103	379.4	99.52%	84.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004570.1	sp|A0A210QUT3|A0A210QUT3_MIZYE	4.5e-91	339.7	97.29%	71.50%	Uncharacterized protein C15orf41;OS=Mizuhopecten;PE=4;SV=1
GN004571.1	sp|K1RXG6|K1RXG6_CRAGI	7.7e-140	502.7	83.41%	59.75%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004572.1	sp|K1RXG6|K1RXG6_CRAGI	1.2e-20	104.4	96.30%	62.34%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004573.1	sp|K1QRW0|K1QRW0_CRAGI	2.9e-45	186.8	100.00%	71.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001291.1	sp|K1QE19|K1QE19_CRAGI	7.9e-238	828.6	100.00%	66.11%	Kelch-like protein 13;OS=Crassostrea;PE=4;SV=1
GN004574.1	sp|K1RXG3|K1RXG3_CRAGI	5.2e-124	449.5	98.95%	73.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004575.1	sp|K1RE88|K1RE88_CRAGI	0.0e+00	1454.1	59.39%	84.76%	Pleckstrin-like protein domain-containing family G member 5;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN004576.1	sp|K1R1B6|K1R1B6_CRAGI	6.9e-296	1021.5	100.00%	81.99%	D-glucuronyl C5-epimerase;OS=Crassostrea;PE=4;SV=1	GO:0047464|	GO:0015012|
GN004579.1	sp|K1R754|K1R754_CRAGI	3.9e-198	696.0	100.00%	95.94%	Arylacetamide deacetylase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0052689|
GN004580.1	sp|K1P1T5|K1P1T5_CRAGI	6.1e-51	207.6	28.01%	70.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001292.1	sp|K1QMQ5|K1QMQ5_CRAGI	2.8e-87	327.8	98.26%	58.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004582.1	sp|K1S2P6|K1S2P6_CRAGI	4.8e-109	399.4	100.00%	85.14%	Glutathione peroxidase;OS=Crassostrea;PE=3;SV=1	GO:0004602|	GO:0006979|
GN004583.1	sp|K1RJ18|K1RJ18_CRAGI	1.2e-120	438.3	92.04%	79.25%	Alpha-amylase;OS=Crassostrea;PE=3;SV=1	GO:0004556|GO:0103025|GO:0043169|GO:0004602|	GO:0005975|GO:0006979|
GN004585.1	sp|K1R751|K1R751_CRAGI	1.4e-36	157.5	91.92%	76.67%	Nuclear pore complex protein Nup88;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0017056|	GO:0000055|GO:0000056|
GN004586.1	sp|K1QXI0|K1QXI0_CRAGI	0.0e+00	1894.4	100.00%	84.43%	Homeobox protein cut-like;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN001293.1	sp|K1QV89|K1QV89_CRAGI	3.1e-258	896.3	99.82%	81.85%	Transcription factor RFX4;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|
GN004587.1	sp|R7TXP7|R7TXP7_CAPTE	1.7e-22	111.7	70.90%	43.70%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004589.1	sp|W4XYW4|W4XYW4_STRPU	8.0e-117	426.0	92.93%	55.23%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0016021|	GO:0008422|	GO:0005975|
GN004590.1	sp|A0A1S3I9G2|A0A1S3I9G2_LINUN	8.8e-114	416.0	91.12%	53.59%	lactase-phlorizin hydrolase-like;OS=Lingula;PE=4;SV=1	GO:0004553|	GO:0005975|
GN004591.1	sp|A0A023F7E6|A0A023F7E6_TRIIF	6.3e-46	190.3	57.41%	47.12%	Putative beta-glucosidase lactase phlorizinhydrolase;OS=Triatoma;PE=2;SV=1	GO:0004553|	GO:0005975|
GN004592.1	sp|V4AX82|V4AX82_LOTGI	2.4e-29	134.0	62.59%	70.93%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004553|	GO:0005975|
GN004593.1	sp|A0A210QWH6|A0A210QWH6_MIZYE	1.5e-18	97.8	92.98%	44.44%	Lactase-phlorizin hydrolase;OS=Mizuhopecten;PE=4;SV=1	GO:0004553|	GO:0005975|
GN004594.1	sp|A0A210QWH6|A0A210QWH6_MIZYE	2.8e-91	340.9	98.06%	52.58%	Lactase-phlorizin hydrolase;OS=Mizuhopecten;PE=4;SV=1	GO:0004553|	GO:0005975|
GN004595.1	sp|K1RH56|K1RH56_CRAGI	4.2e-36	157.1	65.18%	51.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004597.1	sp|K1Q4A7|K1Q4A7_CRAGI	7.3e-54	217.2	97.48%	34.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004598.1	sp|K1PPX7|K1PPX7_CRAGI	2.6e-78	297.4	98.21%	61.99%	Thiopurine S-methyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0008119|
GN004599.1	sp|K1Q4B0|K1Q4B0_CRAGI	1.8e-261	907.1	92.33%	83.66%	Putative ATP-dependent RNA helicase DHX35;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|
GN001294.1	sp|A0A0A9WBJ7|A0A0A9WBJ7_LYGHE	2.2e-41	175.3	90.85%	36.21%	Exonuclease;OS=Lygus;PE=4;SV=1	GO:0004527|
GN004601.1	sp|K1QQB7|K1QQB7_CRAGI	2.1e-179	634.0	99.75%	80.90%	FMRFamide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004602.1	sp|K1QQC1|K1QQC1_CRAGI	9.7e-36	155.2	60.29%	97.53%	Dynein light chain roadblock;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005868|GO:0005874|	GO:0045505|GO:0003774|	GO:0007018|
GN004603.1	sp|K1PX85|K1PX85_CRAGI	1.6e-100	370.9	100.00%	91.37%	BTB/POZ domain-containing protein kctd15;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN004604.1	sp|K1PPQ0|K1PPQ0_CRAGI	8.6e-32	141.7	94.29%	63.37%	BEN domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005720|	GO:0003677|	GO:0000183|
GN001295.1	sp|K1RLF8|K1RLF8_CRAGI	0.0e+00	2346.2	99.83%	96.27%	Splicing factor 3B subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003676|
GN004607.1	sp|A0A2G8LMM1|A0A2G8LMM1_STIJA	1.8e-26	125.6	61.03%	38.64%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN004608.1	sp|K1PMG4|K1PMG4_CRAGI	1.1e-15	87.8	74.07%	72.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN004609.1	sp|A0A194AP54|A0A194AP54_PINFU	1.1e-134	485.0	100.00%	85.40%	Proteasome subunit beta;OS=Pinctada;PE=3;SV=1	GO:0005737|GO:0005634|GO:0005839|	GO:0004298|	GO:0043161|
GN004610.1	sp|K1QJ51|K1QJ51_CRAGI	3.8e-295	1019.2	97.43%	77.55%	Proteasome subunit beta type-8;OS=Crassostrea;PE=4;SV=1	GO:0005839|	GO:0004298|GO:0008270|	GO:0051603|
GN001296.1	sp|K1QJ48|K1QJ48_CRAGI	1.9e-72	277.3	95.97%	91.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004612.1	sp|K1RGG2|K1RGG2_CRAGI	6.2e-44	183.7	27.79%	85.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004613.1	sp|K1PMB2|K1PMB2_CRAGI	1.1e-76	292.0	84.12%	65.09%	Ribonuclease P protein subunit p40;OS=Crassostrea;PE=4;SV=1
GN004615.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	2.3e-30	137.9	96.48%	41.45%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN004616.1	sp|A0A210QXM5|A0A210QXM5_MIZYE	3.2e-231	806.6	99.44%	69.78%	Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN004617.1	sp|K1R752|K1R752_CRAGI	8.7e-203	711.8	99.77%	80.23%	E3 ubiquitin-protein ligase MYLIP;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0016874|
GN004618.1	sp|K1R0S1|K1R0S1_CRAGI	1.9e-174	617.8	100.00%	98.97%	Growth arrest-specific protein 8;OS=Crassostrea;PE=4;SV=1	GO:0031514|	GO:0008017|GO:0017137|	GO:0048870|
GN004619.1	sp|K1R742|K1R742_CRAGI	1.1e-129	468.4	100.00%	85.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN000963.1	sp|K1PVQ2|K1PVQ2_CRAGI	1.6e-72	277.7	100.00%	77.33%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004620.1	sp|K1QG39|K1QG39_CRAGI	5.8e-82	309.7	98.84%	61.02%	Ceramide kinase;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN004621.1	sp|K1PA33|K1PA33_CRAGI	4.5e-228	796.6	98.11%	63.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004622.1	sp|K1PG91|K1PG91_CRAGI	3.4e-199	699.9	96.59%	81.60%	Alkaline phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0004035|
GN004623.1	sp|H6BD26|H6BD26_OSTED	3.2e-59	233.8	57.50%	97.37%	Endonuclease/reverse transcriptase;OS=Ostrea;PE=2;SV=1	GO:0004519|GO:0003964|
GN004625.1	sp|A0A210PZW9|A0A210PZW9_MIZYE	9.1e-95	352.8	91.30%	51.48%	Thyrotropin-releasing hormone receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004627.1	sp|K1Q099|K1Q099_CRAGI	7.4e-98	362.8	87.50%	59.72%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN004628.1	sp|K1RQR9|K1RQR9_CRAGI	2.1e-27	129.4	19.24%	61.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004629.1	sp|K1S5B1|K1S5B1_CRAGI	1.0e-126	459.1	81.19%	43.84%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 6;OS=Crassostrea;PE=4;SV=1	GO:0005886|	GO:0047390|
GN004630.1	sp|K1PE19|K1PE19_CRAGI	1.0e-52	212.2	96.08%	51.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004631.1	sp|W4XJS0|W4XJS0_STRPU	6.5e-42	176.8	53.17%	55.92%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN004632.1	sp|V4B9H4|V4B9H4_LOTGI	2.4e-20	104.4	72.62%	43.80%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004633.1	sp|V4AE92|V4AE92_LOTGI	4.3e-98	364.4	75.49%	43.74%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN004634.1	sp|K1QZQ2|K1QZQ2_CRAGI	6.3e-185	652.5	94.59%	72.04%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 6;OS=Crassostrea;PE=4;SV=1	GO:0005886|	GO:0047390|
GN004635.1	sp|K1RA17|K1RA17_CRAGI	4.2e-309	1065.4	99.33%	86.73%	Tetraspanin-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN001299.1	sp|K1QV80|K1QV80_CRAGI	0.0e+00	1839.7	62.32%	89.91%	Myosin-XVIIIa;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0051015|GO:0005524|GO:0003774|
GN004638.1	sp|K1RRD7|K1RRD7_CRAGI	5.9e-23	114.0	24.15%	59.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004639.1	sp|K1R8Z3|K1R8Z3_CRAGI	1.8e-241	840.9	98.72%	64.90%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN004640.1	sp|K1R8Z3|K1R8Z3_CRAGI	1.7e-215	754.6	98.88%	59.08%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN004641.1	sp|R7UCN5|R7UCN5_CAPTE	5.0e-13	80.5	57.59%	35.61%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004642.1	sp|K1RXN7|K1RXN7_CRAGI	4.0e-50	203.0	100.00%	85.82%	Zinc finger matrin-type protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN004643.1	sp|K1RXN7|K1RXN7_CRAGI	2.3e-87	328.9	76.83%	53.41%	Zinc finger matrin-type protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN004644.1	sp|K1QS81|K1QS81_CRAGI	0.0e+00	2034.2	100.00%	94.22%	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit;OS=Crassostrea;PE=3;SV=1	GO:0016303|GO:0005524|GO:0046934|	GO:0048015|
GN004645.1	sp|K1PRG1|K1PRG1_CRAGI	2.7e-135	487.3	99.14%	76.68%	45 kDa calcium-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN001300.1	sp|K1R1Z3|K1R1Z3_CRAGI	5.3e-132	476.5	83.95%	80.73%	Myosin-XVIIIa;OS=Crassostrea;PE=4;SV=1
GN004646.1	sp|K1PJA2|K1PJA2_CRAGI	7.8e-178	629.0	72.84%	92.58%	Cyclin-L1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0000079|GO:0006355|GO:0006396|
GN004647.1	sp|K1QWT8|K1QWT8_CRAGI	1.4e-32	146.4	47.97%	41.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004648.1	sp|K1PRF2|K1PRF2_CRAGI	1.2e-10	72.8	20.16%	62.75%	Serine protease inhibitor dipetalogastin;OS=Crassostrea;PE=4;SV=1	GO:0008233|
GN004649.1	sp|K1P5V7|K1P5V7_CRAGI	2.5e-310	1069.7	86.12%	93.68%	Eukaryotic translation initiation factor 3 subunit C;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0005852|	GO:0003743|GO:0031369|	GO:0001732|
GN004650.1	sp|H6BD59|H6BD59_OSTED	1.2e-75	288.5	76.17%	93.83%	Translation intiation factor 3 subunit S8;OS=Ostrea;PE=2;SV=1	GO:0005852|	GO:0003743|GO:0031369|
GN004651.1	sp|K1QBX2|K1QBX2_CRAGI	5.0e-182	642.9	75.17%	92.84%	2-(3-amino-3-carboxypropyl)histidine synthase subunit 1;OS=Crassostrea;PE=3;SV=1	GO:0016740|	GO:0017183|
GN004652.1	sp|K1PRE7|K1PRE7_CRAGI	0.0e+00	1483.0	100.00%	90.11%	Tuftelin-interacting protein 11;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN004653.1	sp|K1PJ87|K1PJ87_CRAGI	0.0e+00	1683.3	100.00%	87.70%	Calsyntenin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007156|
GN001301.1	sp|K1RLF1|K1RLF1_CRAGI	3.7e-138	496.5	100.00%	86.21%	Nicotinate-nucleotide pyrophosphorylase [carboxylating];OS=Crassostrea;PE=3;SV=1	GO:0004514|	GO:0009435|
GN004656.1	sp|K1RGD1|K1RGD1_CRAGI	1.0e-59	235.0	94.41%	80.60%	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003842|GO:0016620|	GO:0010133|
GN004657.1	sp|K1RKI7|K1RKI7_CRAGI	4.6e-92	342.8	97.92%	93.58%	Pre-mRNA-splicing factor SPF27;OS=Crassostrea;PE=4;SV=1	GO:0006397|
GN004658.1	sp|K1S3Z7|K1S3Z7_CRAGI	0.0e+00	1115.9	100.00%	93.11%	Gametogenetin-binding protein 2;OS=Crassostrea;PE=4;SV=1
GN001302.1	sp|K1QE15|K1QE15_CRAGI	7.9e-111	406.8	97.75%	55.54%	Ataxin-2;OS=Crassostrea;PE=4;SV=1
GN004660.1	sp|K1QW33|K1QW33_CRAGI	6.6e-16	90.5	42.67%	38.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004661.1	sp|K1RKJ5|K1RKJ5_CRAGI	1.5e-242	844.7	84.56%	72.84%	Potassium voltage-gated channel subfamily C member 2;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN004662.1	sp|K1QYS1|K1QYS1_CRAGI	0.0e+00	1680.2	99.89%	87.81%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN004663.1	sp|K1RKK3|K1RKK3_CRAGI	0.0e+00	1703.0	100.00%	78.66%	Myotubularin-related protein 4;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004725|
GN001303.1	sp|K1QE15|K1QE15_CRAGI	3.7e-29	132.9	95.88%	74.19%	Ataxin-2;OS=Crassostrea;PE=4;SV=1
GN004664.1	sp|K1S411|K1S411_CRAGI	0.0e+00	3778.4	100.00%	77.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0051298|GO:0090222|GO:0071539|
GN004665.1	sp|K1QYS3|K1QYS3_CRAGI	6.3e-119	432.6	100.00%	84.50%	Voltage-gated hydrogen channel 1;OS=Crassostrea;PE=4;SV=1	GO:0005887|	GO:0030171|
GN004666.1	sp|K1REH7|K1REH7_CRAGI	4.5e-128	463.0	98.57%	76.73%	Cytochrome b5 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN004668.1	sp|K1RKL1|K1RKL1_CRAGI	0.0e+00	1137.9	96.42%	94.27%	Tyrosine-protein phosphatase non-receptor type 11;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN004669.1	sp|K1R8R1|K1R8R1_CRAGI	1.2e-226	791.2	95.17%	84.55%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004670.1	sp|K1REH8|K1REH8_CRAGI	3.3e-158	563.9	71.34%	84.33%	Regulation of nuclear pre-mRNA domain-containing protein 1B;OS=Crassostrea;PE=4;SV=1
GN001304.1	sp|K1QE15|K1QE15_CRAGI	5.0e-166	590.5	97.87%	57.70%	Ataxin-2;OS=Crassostrea;PE=4;SV=1
GN004672.1	sp|K1S422|K1S422_CRAGI	5.0e-191	673.7	81.35%	85.80%	Katanin p80 WD40 repeat-containing subunit B1;OS=Crassostrea;PE=3;SV=1	GO:0005813|GO:0008352|GO:0005874|GO:0000922|	GO:0008017|	GO:0007049|GO:0051301|GO:0051013|
GN004673.1	sp|A0A210QUY0|A0A210QUY0_MIZYE	1.6e-63	248.8	91.84%	77.39%	Ankyrin repeat protein;OS=Mizuhopecten;PE=4;SV=1	GO:0035556|
GN004675.1	sp|K1S426|K1S426_CRAGI	7.1e-29	132.1	73.39%	88.61%	Charged multivesicular body protein 1a;OS=Crassostrea;PE=3;SV=1	GO:0007034|
GN004676.1	sp|K1QYT3|K1QYT3_CRAGI	2.1e-60	237.7	67.89%	86.72%	28S ribosomal protein S17, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005763|	GO:0003735|	GO:0006412|
GN004677.1	sp|K1QC09|K1QC09_CRAGI	3.0e-149	533.9	87.47%	73.80%	GPI mannosyltransferase 1;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0016758|	GO:0006506|
GN004678.1	sp|A0A210PE59|A0A210PE59_MIZYE	4.0e-53	214.2	96.08%	45.26%	E3 ubiquitin-protein ligase AMFR;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016874|
GN004679.1	sp|K1QIH5|K1QIH5_CRAGI	7.1e-40	173.3	87.84%	25.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN004680.1	sp|A0A210PE59|A0A210PE59_MIZYE	6.2e-122	443.0	93.89%	63.17%	E3 ubiquitin-protein ligase AMFR;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016874|
GN004681.1	sp|K1R481|K1R481_CRAGI	4.9e-65	254.2	41.47%	69.89%	Epimerase family protein SDR39U1;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN001305.1	sp|K1RLF1|K1RLF1_CRAGI	3.0e-86	323.6	85.57%	91.81%	Nicotinate-nucleotide pyrophosphorylase [carboxylating];OS=Crassostrea;PE=3;SV=1	GO:0004514|	GO:0009435|
GN004682.1	sp|K1R481|K1R481_CRAGI	1.5e-100	371.3	96.22%	73.68%	Epimerase family protein SDR39U1;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN004683.1	sp|K1QC11|K1QC11_CRAGI	0.0e+00	1326.6	92.42%	84.33%	AP-1 complex subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0030121|	GO:0006886|GO:0016192|
GN004684.1	sp|K1RUD6|K1RUD6_CRAGI	2.2e-96	358.2	92.59%	35.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0002218|GO:0032481|
GN004685.1	sp|K1QL84|K1QL84_CRAGI	7.5e-120	437.2	59.27%	45.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001306.1	sp|K1R1Z3|K1R1Z3_CRAGI	5.3e-132	476.5	83.95%	80.73%	Myosin-XVIIIa;OS=Crassostrea;PE=4;SV=1
GN001307.1	sp|K1QV80|K1QV80_CRAGI	7.5e-127	459.1	94.46%	78.57%	Myosin-XVIIIa;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0051015|GO:0005524|GO:0003774|
GN004687.1	sp|A0A2T7NJ57|A0A2T7NJ57_POMCA	1.3e-09	68.2	100.00%	36.61%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005623|	GO:0006886|
GN004688.1	sp|K1QUX6|K1QUX6_CRAGI	1.0e-238	831.2	100.00%	87.45%	4-hydroxybutyrate coenzyme A transferase;OS=Crassostrea;PE=4;SV=1	GO:0016740|	GO:0006084|
GN004689.1	sp|K1PPW8|K1PPW8_CRAGI	1.3e-80	305.4	88.10%	53.28%	Coatomer subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0030117|	GO:0005198|	GO:0006886|GO:0016192|
GN004690.1	sp|A0A226D3L7|A0A226D3L7_FOLCA	3.0e-38	164.5	81.78%	40.28%	Putative nuclease HARBI1;OS=Folsomia;PE=4;SV=1
GN004691.1	sp|K1Q6Q8|K1Q6Q8_CRAGI	8.7e-53	211.8	82.22%	81.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004692.1	sp|K1QIR0|K1QIR0_CRAGI	3.5e-155	553.9	99.80%	68.35%	Iroquois-class homeodomain protein IRX-6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN004694.1	sp|K1RHL5|K1RHL5_CRAGI	7.3e-78	295.4	97.58%	86.88%	Mpv17-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN004695.1	sp|K1QXI2|K1QXI2_CRAGI	5.7e-256	889.0	82.32%	89.40%	Sodium/hydrogen exchanger;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015385|	GO:0006885|
GN004696.1	sp|A0A210R0T8|A0A210R0T8_MIZYE	6.8e-195	686.0	99.83%	57.53%	Endonuclease/exonuclease/phosphatase family domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|GO:0004519|GO:0004527|	GO:0006281|
GN004697.1	sp|K1QNG5|K1QNG5_CRAGI	1.0e-66	259.6	97.61%	37.93%	Cholecystokinin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004700.1	sp|K1QGZ7|K1QGZ7_CRAGI	6.2e-137	492.7	83.54%	84.98%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN001308.1	sp|K1PUT5|K1PUT5_CRAGI	2.6e-29	134.0	56.67%	67.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004701.1	sp|K1R593|K1R593_CRAGI	1.1e-119	435.3	98.75%	67.40%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN004702.1	sp|K1RAG0|K1RAG0_CRAGI	3.8e-136	490.0	99.04%	78.71%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN004703.1	sp|K1RU83|K1RU83_CRAGI	0.0e+00	1098.2	100.00%	75.37%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0004553|	GO:0005975|
GN004704.1	sp|K1QX12|K1QX12_CRAGI	3.7e-77	293.9	57.44%	83.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004705.1	sp|K1R3Z4|K1R3Z4_CRAGI	0.0e+00	2439.8	100.00%	69.33%	5'-3' exoribonuclease 1;OS=Crassostrea;PE=4;SV=1	GO:0004527|GO:0003676|
GN004706.1	sp|K1RU87|K1RU87_CRAGI	3.3e-248	863.6	94.51%	60.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004707.1	sp|K1PHB3|K1PHB3_CRAGI	1.2e-23	116.7	97.97%	31.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004708.1	sp|K1QN14|K1QN14_CRAGI	2.9e-119	433.7	82.01%	91.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004709.1	sp|A0A1S3K8F2|A0A1S3K8F2_LINUN	1.9e-51	209.5	63.34%	33.88%	G-protein coupled receptor 161-like;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004710.1	sp|K1QX15|K1QX15_CRAGI	8.3e-59	231.9	97.84%	86.67%	Transcription initiation factor TFIID subunit 10;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003743|	GO:0006352|
GN004711.1	sp|K1R3Z8|K1R3Z8_CRAGI	1.1e-106	391.7	88.40%	86.82%	Chloride intracellular channel protein 6;OS=Crassostrea;PE=4;SV=1
GN004712.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	1.8e-29	134.8	87.91%	42.86%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN004713.1	sp|L7M4D9|L7M4D9_9ACAR	1.3e-24	119.4	96.96%	35.27%	Putative leukocyte receptor cluster member 1;OS=Rhipicephalus;PE=2;SV=1
GN004714.1	sp|K1PKW0|K1PKW0_CRAGI	1.0e-208	731.5	100.00%	84.14%	Short transient receptor potential channel 6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN004716.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	2.9e-87	328.2	96.98%	36.81%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN004717.1	sp|V3YXA0|V3YXA0_LOTGI	4.3e-104	383.6	98.26%	51.88%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004718.1	sp|K1QF17|K1QF17_CRAGI	3.3e-12	78.2	90.51%	27.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004719.1	sp|K1R602|K1R602_CRAGI	1.1e-20	105.1	89.68%	45.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004720.1	sp|K1RFS0|K1RFS0_CRAGI	7.1e-206	722.2	97.33%	68.50%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN004722.1	sp|A0A210R0T2|A0A210R0T2_MIZYE	4.4e-154	550.1	93.65%	65.38%	G1/S-specific cyclin-E;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|
GN004723.1	sp|K1QDZ8|K1QDZ8_CRAGI	8.3e-57	226.9	43.49%	62.37%	Uncharacterized protein F13E9.13, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN004724.1	sp|K1P7R7|K1P7R7_CRAGI	8.0e-204	715.3	86.52%	89.58%	Glycosylphosphatidylinositol anchor attachment 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0042765|
GN004725.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	4.6e-89	334.0	95.12%	42.56%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN004726.1	sp|K1QDZ5|K1QDZ5_CRAGI	5.0e-147	526.2	100.00%	76.76%	Cytochrome c1, heme protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0009055|GO:0020037|GO:0046872|
GN001311.1	sp|K1PAG5|K1PAG5_CRAGI	7.5e-153	545.4	99.02%	84.82%	Solute carrier family 25 member 35;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN004727.1	sp|K1PTI6|K1PTI6_CRAGI	5.6e-256	888.6	99.58%	89.03%	Glucose-6-phosphate isomerase;OS=Crassostrea;PE=3;SV=1	GO:0004347|	GO:0006094|GO:0006096|
GN004728.1	sp|K1QDY9|K1QDY9_CRAGI	2.5e-226	790.4	96.61%	77.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004729.1	sp|K1QWT8|K1QWT8_CRAGI	2.4e-31	142.1	53.32%	40.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004731.1	sp|A0A210PT23|A0A210PT23_MIZYE	1.1e-124	451.8	100.00%	72.82%	Glucose-fructose oxidoreductase domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN004732.1	sp|A0A3M6U6Z7|A0A3M6U6Z7_9CNID	6.3e-49	199.5	95.31%	51.10%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN004733.1	sp|K1PZZ8|K1PZZ8_CRAGI	3.9e-174	616.7	69.32%	92.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001312.1	sp|K1R1Y6|K1R1Y6_CRAGI	0.0e+00	1146.7	99.69%	91.05%	Cationic amino acid transporter 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN004734.1	sp|K1Q7I9|K1Q7I9_CRAGI	2.4e-50	203.8	94.93%	72.93%	Metallophosphoesterase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|	GO:0006506|
GN004735.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	1807.3	96.04%	53.16%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN004736.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	2387.8	67.90%	61.49%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN004738.1	sp|K1QH19|K1QH19_CRAGI	0.0e+00	2445.2	64.43%	65.09%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase mog-5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|GO:0016740|
GN004739.1	sp|K1PIH9|K1PIH9_CRAGI	1.1e-12	79.0	83.72%	37.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004740.1	sp|K1S066|K1S066_CRAGI	2.8e-35	155.2	36.69%	58.45%	ATP-binding cassette sub-family A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN004741.1	sp|K1Q6D2|K1Q6D2_CRAGI	2.5e-214	750.0	100.00%	92.23%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN004743.1	sp|K1QMD1|K1QMD1_CRAGI	2.4e-253	880.2	98.63%	72.74%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|GO:0046872|GO:0016491|	GO:0006030|
GN004744.1	sp|K1QE57|K1QE57_CRAGI	0.0e+00	1176.4	100.00%	79.97%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004745.1	sp|K1QIQ8|K1QIQ8_CRAGI	2.1e-142	511.5	89.26%	55.33%	F-box only protein 30;OS=Crassostrea;PE=4;SV=1	GO:0061630|GO:0008270|
GN004746.1	sp|K1Q6C9|K1Q6C9_CRAGI	0.0e+00	1345.1	100.00%	84.17%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004747.1	sp|K1RDQ4|K1RDQ4_CRAGI	2.6e-210	736.9	100.00%	84.10%	Small conductance calcium-activated potassium channel protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005516|GO:0016286|
GN004748.1	sp|K1PBQ9|K1PBQ9_CRAGI	4.3e-39	167.2	74.79%	50.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN000965.1	sp|K1RH02|K1RH02_CRAGI	7.4e-20	102.4	57.46%	65.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001313.1	sp|A0A210R590|A0A210R590_MIZYE	8.1e-82	309.3	95.27%	63.87%	Transmembrane protein 26;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN004750.1	sp|K1Q4T6|K1Q4T6_CRAGI	8.8e-23	112.8	67.74%	47.13%	Plexin-A2;OS=Crassostrea;PE=4;SV=1	GO:0017154|
GN004751.1	sp|A0A210QD89|A0A210QD89_MIZYE	2.3e-298	1030.4	98.66%	64.12%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN004753.1	sp|K1P4N7|K1P4N7_CRAGI	1.2e-110	404.8	98.26%	85.33%	DNAation factor subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0004536|	GO:0006309|
GN004754.1	sp|K1PB10|K1PB10_CRAGI	1.4e-171	607.8	99.14%	89.31%	DDI1-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0004190|GO:0043130|
GN004758.1	sp|K1PQE2|K1PQE2_CRAGI	4.8e-35	154.8	50.78%	52.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004759.1	sp|K1QYH7|K1QYH7_CRAGI	0.0e+00	3293.8	92.23%	56.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004760.1	sp|K1QYH7|K1QYH7_CRAGI	0.0e+00	1406.0	97.94%	73.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001314.1	sp|K1PPQ1|K1PPQ1_CRAGI	3.1e-128	463.4	100.00%	94.42%	14-3-3 protein gamma;OS=Crassostrea;PE=3;SV=1	GO:0019904|
GN004761.1	sp|K1QYH7|K1QYH7_CRAGI	9.6e-53	212.2	77.55%	71.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004762.1	sp|A0A210QI76|A0A210QI76_MIZYE	4.3e-27	127.1	91.87%	31.61%	EGF-like module-containing mucin-like hormone receptor-like 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN004763.1	sp|K1RIA6|K1RIA6_CRAGI	0.0e+00	2213.3	100.00%	79.20%	Protein hedgehog;OS=Crassostrea;PE=4;SV=1	GO:0007267|
GN004765.1	sp|K1QBP6|K1QBP6_CRAGI	1.2e-199	701.4	99.34%	80.36%	Ileal sodium/bile acid cotransporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004766.1	sp|K1Q6H9|K1Q6H9_CRAGI	7.9e-24	114.8	98.65%	77.78%	N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001315.1	sp|K1PHM8|K1PHM8_CRAGI	4.0e-104	383.3	100.00%	86.75%	14-3-3 protein zeta;OS=Crassostrea;PE=3;SV=1	GO:0019904|
GN004767.1	sp|K1RB32|K1RB32_CRAGI	1.0e-34	152.9	58.33%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004768.1	sp|K1PRI7|K1PRI7_CRAGI	1.4e-10	74.3	7.45%	67.69%	FYVE and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004768.1	sp|K1PRI7|K1PRI7_CRAGI	7.0e-10	72.0	6.77%	61.02%	FYVE and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004769.1	sp|K1Q6H4|K1Q6H4_CRAGI	4.0e-152	543.5	99.77%	68.24%	Excitatory amino acid transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015293|
GN004770.1	sp|K1QTD5|K1QTD5_CRAGI	2.8e-106	390.2	100.00%	89.25%	Low-density lipoprotein receptor-related protein 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004772.1	sp|A0A1X7T780|A0A1X7T780_AMPQE	2.2e-48	198.4	99.33%	37.67%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046983|
GN001316.1	sp|K1P3V3|K1P3V3_CRAGI	1.7e-91	342.4	99.81%	41.85%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|	GO:0006915|GO:0042981|
GN004773.1	sp|A0A3M6TME7|A0A3M6TME7_9CNID	4.9e-15	88.2	21.98%	45.45%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN004775.1	sp|K1QQ46|K1QQ46_CRAGI	0.0e+00	4541.9	99.57%	84.68%	Inositol 1,4,5-trisphosphate receptor type 1;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0016021|	GO:0070679|GO:0005220|
GN004776.1	sp|A0A210PT16|A0A210PT16_MIZYE	6.4e-241	839.0	87.18%	78.34%	Tubulin polyglutamylase TTLL9;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|	GO:0006464|
GN004777.1	sp|A0A210PT46|A0A210PT46_MIZYE	1.3e-88	332.8	98.87%	35.55%	tRNA-specific adenosine deaminase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004000|GO:0003723|	GO:0006396|
GN004778.1	sp|K1QGH6|K1QGH6_CRAGI	4.0e-209	734.2	35.03%	96.23%	Serine/threonine-protein kinase PRP4-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN004779.1	sp|U5PYN6|U5PYN6_CRAGI	8.3e-221	772.7	99.66%	66.06%	Toll-like receptor 3;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN004780.1	sp|K1RNH6|K1RNH6_CRAGI	9.5e-37	159.8	81.71%	35.25%	Toll-like receptor 3;OS=Crassostrea;PE=3;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN004781.1	sp|U5PYN6|U5PYN6_CRAGI	1.1e-52	213.0	87.02%	48.54%	Toll-like receptor 3;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN004782.1	sp|U5PYN6|U5PYN6_CRAGI	6.7e-106	391.0	96.20%	43.48%	Toll-like receptor 3;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN004783.1	sp|K1RNH2|K1RNH2_CRAGI	7.3e-27	127.5	34.50%	44.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004784.1	sp|K1QXS0|K1QXS0_CRAGI	7.7e-31	139.8	100.00%	42.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004785.1	sp|K1PUT5|K1PUT5_CRAGI	2.1e-26	124.4	56.58%	62.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004786.1	sp|K1QGF9|K1QGF9_CRAGI	2.9e-288	998.0	95.08%	86.27%	Rootletin;OS=Crassostrea;PE=4;SV=1
GN004787.1	sp|K1RNG6|K1RNG6_CRAGI	3.9e-216	756.1	92.04%	91.58%	Serine--pyruvate aminotransferase;OS=Crassostrea;PE=3;SV=1	GO:0008453|GO:0004760|
GN004788.1	sp|K1R421|K1R421_CRAGI	0.0e+00	1633.2	66.03%	80.73%	Rho guanine nucleotide exchange factor 10;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN004789.1	sp|V4A2Z2|V4A2Z2_LOTGI	3.2e-35	154.1	92.46%	41.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN004790.1	sp|K1R416|K1R416_CRAGI	4.3e-199	699.9	100.00%	57.58%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004791.1	sp|K1QEK7|K1QEK7_CRAGI	0.0e+00	1481.1	99.87%	89.08%	Ubiquitin carboxyl-terminal hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0004843|GO:0008270|	GO:0016579|GO:0006511|
GN004792.1	sp|H9LHW6|H9LHW6_CRAAR	5.0e-42	176.4	96.99%	54.37%	X-box binding protein-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN004793.1	sp|Unreviewed|A0A087U9X2_9ARAC	4.4e-12	77.8	35.18%	40.00%	Zinc finger protein with KRAB and SCAN domains 2;OS=Stegodyphus;PE=4;SV=1
GN004794.1	sp|K1RJK6|K1RJK6_CRAGI	4.1e-63	246.9	95.20%	53.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN004795.1	sp|J9Q432|J9Q432_OSTED	6.1e-46	189.9	44.40%	93.14%	Uncharacterized protein;OS=Ostrea;PE=2;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN004796.1	sp|J9Q432|J9Q432_OSTED	4.5e-41	173.7	44.78%	84.31%	Uncharacterized protein;OS=Ostrea;PE=2;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN004797.1	sp|A0A210R559|A0A210R559_MIZYE	1.1e-43	182.2	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN004798.1	sp|A0A1Y1K254|A0A1Y1K254_PHOPY	1.6e-52	211.8	99.20%	42.16%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN004800.1	sp|K1RDP6|K1RDP6_CRAGI	2.8e-44	184.1	96.45%	45.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004801.1	sp|K1QZW3|K1QZW3_CRAGI	0.0e+00	1630.2	100.00%	70.48%	Zinc finger protein ush;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0001085|	GO:0006357|
GN001317.1	sp|K1R1G5|K1R1G5_CRAGI	6.5e-125	452.6	99.33%	75.76%	Gamma-glutamyltranspeptidase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0036374|	GO:0006751|
GN004802.1	sp|K1R685|K1R685_CRAGI	3.8e-99	367.1	100.00%	66.46%	Zinc transporter ZIP1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN004803.1	sp|K1R247|K1R247_CRAGI	0.0e+00	1791.2	93.52%	76.95%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN004804.1	sp|K1QQ21|K1QQ21_CRAGI	2.8e-12	77.0	86.84%	35.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004805.1	sp|K1R247|K1R247_CRAGI	5.3e-21	105.9	89.62%	56.38%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN004806.1	sp|K1R247|K1R247_CRAGI	0.0e+00	2179.4	93.59%	85.03%	Condensin complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007076|
GN004807.1	sp|K1PT58|K1PT58_CRAGI	4.1e-40	170.2	96.35%	43.48%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN001318.1	sp|K1R1G5|K1R1G5_CRAGI	1.2e-269	934.5	100.00%	78.90%	Gamma-glutamyltranspeptidase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0036374|	GO:0006751|
GN004808.1	sp|K1QXC3|K1QXC3_CRAGI	6.3e-51	206.1	98.32%	55.11%	Cytochrome P450 1A1;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN004809.1	sp|K1PT58|K1PT58_CRAGI	2.4e-40	171.0	96.84%	45.90%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN004810.1	sp|K1QPG4|K1QPG4_CRAGI	4.9e-127	460.3	93.89%	48.51%	Cytochrome P450 2U1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN004811.1	sp|K1QVP6|K1QVP6_CRAGI	2.4e-191	673.7	87.34%	96.87%	Developmentally-regulated GTP-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN004812.1	sp|K1QJW1|K1QJW1_CRAGI	1.9e-134	485.0	99.17%	62.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004813.1	sp|K1QTQ2|K1QTQ2_CRAGI	2.8e-172	610.9	100.00%	60.91%	Retinal homeobox protein Rx;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN004814.1	sp|K1R0T6|K1R0T6_CRAGI	4.6e-136	490.7	73.75%	56.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004815.1	sp|K1R776|K1R776_CRAGI	0.0e+00	2775.7	99.91%	65.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000966.1	sp|K1QST7|K1QST7_CRAGI	3.1e-60	237.3	83.94%	60.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004817.1	sp|K1RRH1|K1RRH1_CRAGI	8.2e-191	671.8	97.51%	98.01%	Chromodomain-helicase-DNA-binding protein Mi-2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0004386|GO:0046872|
GN004818.1	sp|K1R6A4|K1R6A4_CRAGI	1.3e-77	295.0	99.12%	62.67%	Dermal papilla-derived protein 6-like protein;OS=Crassostrea;PE=4;SV=1	GO:0033588|	GO:0002098|
GN004819.1	sp|A0A210PL21|A0A210PL21_MIZYE	2.3e-57	228.0	81.41%	52.75%	Nucleoside diphosphate-linked moiety X motif 8, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016787|
GN004820.1	sp|V4A916|V4A916_LOTGI	1.2e-63	248.4	100.00%	65.35%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003824|
GN004822.1	sp|K1RC93|K1RC93_CRAGI	6.3e-193	679.1	88.06%	85.90%	N-acetylglucosaminyl-phosphatidylinositol biosynthetic protein;OS=Crassostrea;PE=4;SV=1	GO:0000506|	GO:0017176|	GO:0006506|
GN004823.1	sp|K1RC99|K1RC99_CRAGI	5.1e-39	166.4	61.21%	82.00%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN004824.1	sp|K1P890|K1P890_CRAGI	9.8e-136	488.8	99.72%	83.61%	Cholecystokinin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN004826.1	sp|K1R525|K1R525_CRAGI	1.2e-37	161.4	93.55%	60.00%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN004828.1	sp|K1R2T4|K1R2T4_CRAGI	2.6e-18	97.4	86.49%	43.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004829.1	sp|K1QHB0|K1QHB0_CRAGI	3.2e-27	127.1	75.64%	56.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004833.1	sp|K1RYR2|K1RYR2_CRAGI	5.3e-95	353.2	81.88%	65.43%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN004834.1	sp|K1R4K3|K1R4K3_CRAGI	7.0e-89	332.4	94.88%	79.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004835.1	sp|K1QV25|K1QV25_CRAGI	7.2e-56	221.9	100.00%	98.26%	Transcription elongation factor B polypeptide 2;OS=Crassostrea;PE=4;SV=1	GO:0070449|GO:0030891|	GO:0003746|	GO:0006368|
GN004836.1	sp|K1S0A4|K1S0A4_CRAGI	1.6e-199	702.2	99.50%	49.70%	Mitogen-activated protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004707|
GN001320.1	sp|K1QPZ9|K1QPZ9_CRAGI	5.6e-116	422.9	98.68%	95.99%	Amyloid protein-binding protein 2;OS=Crassostrea;PE=4;SV=1
GN004840.1	sp|K1PK64|K1PK64_CRAGI	5.3e-78	295.8	99.36%	97.42%	Zinc finger MYND domain-containing protein 12;OS=Crassostrea;PE=4;SV=1
GN004841.1	sp|V3ZMP6|V3ZMP6_LOTGI	7.8e-50	203.4	74.19%	41.41%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004844.1	sp|K1Q688|K1Q688_CRAGI	8.7e-23	112.5	84.15%	45.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001321.1	sp|K1QWD4|K1QWD4_CRAGI	3.1e-101	373.6	100.00%	74.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004845.1	sp|K1Q688|K1Q688_CRAGI	5.8e-40	169.1	86.07%	76.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004846.1	sp|K1PRV6|K1PRV6_CRAGI	6.1e-245	853.2	68.11%	77.22%	WD repeat-containing protein 33;OS=Crassostrea;PE=4;SV=1
GN004847.1	sp|K1Q681|K1Q681_CRAGI	0.0e+00	2336.6	99.47%	90.76%	Clustered mitochondria protein homolog;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0003723|	GO:0048312|
GN004848.1	sp|K1QS35|K1QS35_CRAGI	7.3e-214	748.8	97.41%	74.44%	Alkaline phosphatase, tissue-nonspecific isozyme;OS=Crassostrea;PE=3;SV=1	GO:0016791|
GN004849.1	sp|K1Q677|K1Q677_CRAGI	0.0e+00	1322.0	100.00%	75.51%	DNA ligase 3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0003910|GO:0008270|	GO:0051103|GO:0006310|
GN004850.1	sp|A0A210PTQ1|A0A210PTQ1_MIZYE	1.3e-131	474.6	98.32%	93.99%	Protein gustavus;OS=Mizuhopecten;PE=4;SV=1
GN004851.1	sp|K1PLU8|K1PLU8_CRAGI	9.8e-56	223.4	90.65%	30.68%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004852.1	sp|K1Q669|K1Q669_CRAGI	0.0e+00	1380.2	81.11%	62.86%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN004853.1	sp|K1R1N1|K1R1N1_CRAGI	4.8e-98	363.2	100.00%	67.38%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046983|	GO:0006355|
GN004854.1	sp|W4ZKT7|W4ZKT7_STRPU	1.7e-18	99.8	48.75%	32.48%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN001323.1	sp|K1QMA9|K1QMA9_CRAGI	2.5e-66	256.9	100.00%	84.14%	Cytoglobin-2;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN004855.1	sp|K1RNK4|K1RNK4_CRAGI	6.1e-40	169.5	99.40%	48.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004856.1	sp|K1RNK4|K1RNK4_CRAGI	6.1e-40	169.5	99.40%	48.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004857.1	sp|K1RCQ3|K1RCQ3_CRAGI	1.3e-274	951.0	99.86%	68.60%	Double-stranded RNA-specific adenosine deaminase;OS=Crassostrea;PE=4;SV=1	GO:0004000|GO:0003723|	GO:0006396|
GN004858.1	sp|K1QJG3|K1QJG3_CRAGI	1.8e-73	282.7	58.10%	45.58%	Transient receptor potential cation channel subfamily V member 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN001324.1	sp|K1R392|K1R392_CRAGI	4.3e-108	396.7	90.23%	65.58%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN004861.1	sp|K1RGG5|K1RGG5_CRAGI	4.6e-173	614.0	77.20%	49.69%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN004862.1	sp|K1QS31|K1QS31_CRAGI	6.4e-64	250.4	70.92%	56.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004863.1	sp|K1R0K8|K1R0K8_CRAGI	0.0e+00	2485.3	100.00%	61.46%	Tudor domain-containing protein 12;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003676|
GN004864.1	sp|K1S648|K1S648_CRAGI	4.5e-53	213.0	100.00%	73.08%	M-phase phosphoprotein 6;OS=Crassostrea;PE=4;SV=1
GN000925.1	sp|K1R141|K1R141_CRAGI	5.1e-43	181.0	41.71%	49.71%	Tetranectin;OS=Crassostrea;PE=4;SV=1
GN000967.1	sp|K1QST7|K1QST7_CRAGI	1.4e-68	265.0	94.01%	62.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004865.1	sp|R7VED2|R7VED2_CAPTE	3.0e-43	181.0	93.83%	42.98%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004866.1	sp|K1RGG1|K1RGG1_CRAGI	0.0e+00	1739.5	100.00%	89.53%	Alanyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004813|GO:0005524|GO:0005525|GO:0003743|GO:0000049|GO:0008270|	GO:0006419|
GN004867.1	sp|A0A210R0Z3|A0A210R0Z3_MIZYE	2.4e-48	197.6	97.87%	55.19%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN004868.1	sp|A0A210R0M0|A0A210R0M0_MIZYE	9.7e-149	531.9	99.13%	73.55%	Cysteine and histidine-rich protein 1-B;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN004869.1	sp|X4YT24|X4YT24_CRAGI	2.5e-133	480.7	92.33%	73.57%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN004870.1	sp|A0A210PE47|A0A210PE47_MIZYE	3.1e-10	70.1	84.47%	48.84%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN004871.1	sp|K1S640|K1S640_CRAGI	0.0e+00	1167.1	97.50%	85.22%	Protein flp;OS=Crassostrea;PE=4;SV=1
GN004872.1	sp|K1R0J4|K1R0J4_CRAGI	1.1e-17	96.3	95.14%	34.28%	Putative ribosome-binding factor A, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0006364|
GN004873.1	sp|K1QFS1|K1QFS1_CRAGI	1.3e-71	274.6	97.53%	87.26%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN004874.1	sp|K1QFS1|K1QFS1_CRAGI	1.6e-39	167.2	97.75%	86.05%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN004875.1	sp|K1PVS2|K1PVS2_CRAGI	1.3e-69	268.5	65.92%	81.51%	Putative epidermal cell surface receptor;OS=Crassostrea;PE=4;SV=1
GN004878.1	sp|K1Q4K9|K1Q4K9_CRAGI	3.2e-160	570.5	83.81%	77.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004880.1	sp|K1R4W3|K1R4W3_CRAGI	1.3e-48	199.1	91.06%	50.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004881.1	sp|K1R4W3|K1R4W3_CRAGI	9.6e-65	252.7	99.32%	51.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004882.1	sp|V3ZSH9|V3ZSH9_LOTGI	2.9e-38	164.1	98.44%	46.28%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN004883.1	sp|A0A210PX57|A0A210PX57_MIZYE	0.0e+00	1441.0	59.59%	51.15%	Protein ELYS;OS=Mizuhopecten;PE=4;SV=1
GN004885.1	sp|K1S0L8|K1S0L8_CRAGI	0.0e+00	1448.0	94.04%	79.07%	Actin filament-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN004886.1	sp|K1RAW3|K1RAW3_CRAGI	4.8e-38	162.5	86.92%	92.39%	Beta-catenin-like protein 1;OS=Crassostrea;PE=4;SV=1
GN004887.1	sp|K1Q1X1|K1Q1X1_CRAGI	4.2e-32	144.1	68.09%	46.07%	Putative potassium channel regulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN004888.1	sp|K1RAW3|K1RAW3_CRAGI	2.9e-42	176.4	98.97%	94.74%	Beta-catenin-like protein 1;OS=Crassostrea;PE=4;SV=1
GN004889.1	sp|V4APD7|V4APD7_LOTGI	1.8e-108	398.3	98.37%	51.89%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN004890.1	sp|K1PBP8|K1PBP8_CRAGI	6.0e-113	412.9	64.24%	98.51%	C-Maf-inducing protein;OS=Crassostrea;PE=4;SV=1
GN004891.1	sp|A0A210PWF2|A0A210PWF2_MIZYE	6.0e-47	193.0	97.44%	46.56%	Speriolin;OS=Mizuhopecten;PE=4;SV=1
GN004893.1	sp|K1PR60|K1PR60_CRAGI	1.1e-69	268.5	86.49%	83.65%	CKLF-like MARVEL transmembrane domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004895.1	sp|K1QBL7|K1QBL7_CRAGI	8.4e-293	1011.1	100.00%	91.71%	RCC1 and BTB domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN004896.1	sp|A7T6V0|A7T6V0_NEMVE	2.7e-39	168.3	75.22%	36.15%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN004898.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	1.6e-69	269.6	78.01%	32.53%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN004899.1	sp|K1P5K7|K1P5K7_CRAGI	5.0e-82	309.3	98.82%	88.02%	Beta-1-syntrophin;OS=Crassostrea;PE=4;SV=1	GO:0016010|GO:0005664|	GO:0005198|	GO:0006260|GO:0050808|
GN004900.1	sp|K1PJ16|K1PJ16_CRAGI	6.4e-83	312.4	100.00%	86.63%	ADP-ribosylation factor-like protein 2-binding protein;OS=Crassostrea;PE=4;SV=1
GN004901.1	sp|A0A210QHF2|A0A210QHF2_MIZYE	1.4e-68	265.0	73.45%	82.53%	Partitioning defective 6-like gamma;OS=Mizuhopecten;PE=4;SV=1
GN004902.1	sp|A0A210QHF7|A0A210QHF7_MIZYE	3.0e-97	360.1	100.00%	79.61%	Testis, prostate and placenta-expressed protein;OS=Mizuhopecten;PE=4;SV=1
GN004903.1	sp|K1P767|K1P767_CRAGI	1.8e-34	150.6	84.62%	81.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN004904.1	sp|K1QD97|K1QD97_CRAGI	7.6e-174	615.5	92.93%	89.22%	Forkhead box protein F1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN004905.1	sp|K1PKV4|K1PKV4_CRAGI	5.7e-259	899.0	97.25%	72.67%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004906.1	sp|K1P761|K1P761_CRAGI	5.0e-104	383.3	99.68%	65.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004907.1	sp|K1QD88|K1QD88_CRAGI	4.9e-113	412.9	99.61%	77.65%	15-hydroxyprostaglandin dehydrogenase [NAD+];OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN004908.1	sp|H6BD21|H6BD21_OSTED	1.8e-17	93.6	65.71%	100.00%	Dolichol-phosphate mannosyltransferase subunit 1;OS=Ostrea;PE=2;SV=1	GO:0016021|	GO:0016757|
GN004909.1	sp|R7VED2|R7VED2_CAPTE	1.2e-39	169.1	87.55%	42.29%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN004910.1	sp|K1QJT1|K1QJT1_CRAGI	1.8e-113	414.5	92.11%	82.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035591|	GO:0007165|
GN004912.1	sp|K1R5E2|K1R5E2_CRAGI	3.3e-106	390.2	80.56%	94.55%	SH2B adapter protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035591|	GO:0007165|
GN004914.1	sp|K1QSY2|K1QSY2_CRAGI	5.4e-204	716.1	96.30%	71.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004915.1	sp|K1RD27|K1RD27_CRAGI	3.8e-34	151.8	64.50%	36.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004917.1	sp|A0A0L7KSN0|A0A0L7KSN0_9NEOP	1.1e-17	95.1	99.21%	40.80%	Uncharacterized protein;OS=Operophtera;PE=4;SV=1	GO:0003677|
GN001327.1	sp|K1P724|K1P724_CRAGI	4.2e-203	712.6	98.90%	94.97%	Ceramide glucosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016757|
GN004918.1	sp|K1QLA2|K1QLA2_CRAGI	3.8e-25	119.4	89.66%	71.43%	Peptidase inhibitor 16;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN004920.1	sp|X1WW30|X1WW30_ACYPI	1.2e-22	112.1	84.80%	40.28%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1	GO:0003677|
GN004921.1	sp|Unreviewed|A0A087T6J7_9ARAC	3.6e-31	140.2	98.03%	48.65%	Uncharacterized protein;OS=Stegodyphus;PE=4;SV=1
GN004923.1	sp|K1RED4|K1RED4_CRAGI	6.0e-14	82.4	99.02%	49.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000968.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	1.9e-160	572.0	54.09%	67.15%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN004924.1	sp|K1R645|K1R645_CRAGI	4.2e-14	83.6	75.00%	41.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004927.1	sp|K1PS59|K1PS59_CRAGI	5.2e-74	283.9	42.24%	84.94%	Transcriptional repressor CTCF;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003676|
GN001329.1	sp|K1PD48|K1PD48_CRAGI	4.4e-51	206.1	96.83%	83.47%	Beta-ureidopropionase;OS=Crassostrea;PE=4;SV=1	GO:0006807|
GN001330.1	sp|K1PKP6|K1PKP6_CRAGI	9.3e-46	188.7	65.00%	86.41%	Zinc finger SWIM domain-containing protein 7;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN004932.1	sp|K1R3B2|K1R3B2_CRAGI	6.5e-13	78.6	55.26%	82.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001331.1	sp|K1PSQ8|K1PSQ8_CRAGI	0.0e+00	1394.0	100.00%	85.11%	Cytospin-A;OS=Crassostrea;PE=4;SV=1
GN004933.1	sp|K1QS69|K1QS69_CRAGI	5.1e-40	169.9	93.41%	48.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001332.1	sp|K1P730|K1P730_CRAGI	3.0e-180	637.1	86.54%	77.99%	Protein SMG9;OS=Crassostrea;PE=4;SV=1	GO:0000184|
GN004935.1	sp|K1R8H7|K1R8H7_CRAGI	1.2e-50	204.5	97.39%	90.09%	Coiled-coil domain-containing protein 74A;OS=Crassostrea;PE=4;SV=1
GN004938.1	sp|K1R8H7|K1R8H7_CRAGI	4.3e-42	176.0	92.66%	90.00%	Coiled-coil domain-containing protein 74A;OS=Crassostrea;PE=4;SV=1
GN001333.1	sp|K1PKQ5|K1PKQ5_CRAGI	5.5e-171	605.9	100.00%	81.56%	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;OS=Crassostrea;PE=3;SV=1	GO:0003854|GO:0016853|	GO:0006694|
GN004943.1	sp|K1QXV2|K1QXV2_CRAGI	4.6e-20	104.4	31.87%	47.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004945.1	sp|K1P9A5|K1P9A5_CRAGI	7.6e-240	835.9	100.00%	68.04%	Splicing factor, arginine/serine-rich 8;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006396|
GN001334.1	sp|K1PSR5|K1PSR5_CRAGI	1.9e-33	147.5	68.99%	77.27%	Fatty acid-binding protein, heart;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN004946.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-35	156.0	58.22%	47.37%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN004947.1	sp|K1QY88|K1QY88_CRAGI	9.3e-79	299.3	100.00%	47.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN004949.1	sp|K1PGK5|K1PGK5_CRAGI	4.8e-37	160.2	97.67%	44.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001335.1	sp|K1QD57|K1QD57_CRAGI	4.8e-139	500.0	96.28%	70.48%	Protein phosphatase 1D;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN001336.1	sp|K1QD57|K1QD57_CRAGI	1.0e-100	371.7	98.07%	88.61%	Protein phosphatase 1D;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN004950.1	sp|A0A210Q0G2|A0A210Q0G2_MIZYE	1.9e-19	102.8	89.18%	24.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN004951.1	sp|K1QLL9|K1QLL9_CRAGI	3.7e-227	793.1	98.17%	75.14%	Short transient receptor potential channel 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN004952.1	sp|A0A210Q7W9|A0A210Q7W9_MIZYE	6.2e-107	393.3	99.50%	51.61%	Short transient receptor potential channel 7;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005262|
GN004953.1	sp|K1QGN7|K1QGN7_CRAGI	2.2e-48	198.7	66.41%	46.12%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN004954.1	sp|K1PNB8|K1PNB8_CRAGI	1.1e-146	525.0	99.67%	79.34%	Ubiquitin-associated and SH3 domain-containing protein B;OS=Crassostrea;PE=4;SV=1
GN000969.1	sp|A0A210Q2Z4|A0A210Q2Z4_MIZYE	2.8e-60	237.7	64.48%	70.48%	ATP-dependent DNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN004955.1	sp|A0A210QBW7|A0A210QBW7_MIZYE	2.6e-294	1016.9	89.28%	63.27%	Sterile alpha and TIR motif-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0035591|	GO:0034128|GO:0048678|GO:0007165|
GN001337.1	sp|K1PKR1|K1PKR1_CRAGI	4.8e-110	402.9	100.00%	85.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN004956.1	sp|K1PZK4|K1PZK4_CRAGI	5.6e-25	120.6	45.33%	51.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN004957.1	sp|A0A151JWE2|A0A151JWE2_9HYME	9.6e-59	231.9	94.37%	81.33%	Prohibitin-2;OS=Trachymyrmex;PE=4;SV=1	GO:0016020|
GN004958.1	sp|A0A1S3JQA7|A0A1S3JQA7_LINUN	7.9e-18	94.7	100.00%	65.28%	prohibitin-2;OS=Lingula;PE=4;SV=1	GO:0016021|
GN004960.1	sp|A0A3M6TYK9|A0A3M6TYK9_9CNID	1.5e-24	119.0	46.95%	47.58%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN004961.1	sp|K1S261|K1S261_CRAGI	1.7e-112	412.5	96.43%	62.92%	Leucine-, glutamate-and lysine-rich protein 1;OS=Crassostrea;PE=4;SV=1
GN004962.1	sp|A0A194AME6|A0A194AME6_PINFU	3.4e-54	216.5	96.15%	85.48%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1	GO:0016021|
GN004963.1	sp|K1RCJ2|K1RCJ2_CRAGI	4.6e-13	78.6	81.48%	86.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001339.1	sp|A0A2B4RVZ9|A0A2B4RVZ9_STYPI	1.4e-10	71.2	75.73%	42.86%	PiggyBac transposable element-derived protein 1;OS=Stylophora;PE=4;SV=1
GN004966.1	sp|K1QWR7|K1QWR7_CRAGI	6.4e-92	343.2	84.48%	58.90%	Zona pellucida sperm-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004968.1	sp|C3Z7H3|C3Z7H3_BRAFL	4.8e-33	146.0	97.30%	55.14%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0004597|	GO:0042264|
GN004969.1	sp|K1S245|K1S245_CRAGI	4.7e-115	419.5	100.00%	86.32%	Calcium-dependent protein kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016301|
GN004970.1	sp|K1QWF8|K1QWF8_CRAGI	1.3e-57	228.0	89.93%	70.70%	Purple acid phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003993|GO:0046872|
GN004971.1	sp|K1QWF8|K1QWF8_CRAGI	1.0e-31	142.1	100.00%	63.35%	Purple acid phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003993|GO:0046872|
GN004972.1	sp|K1Q996|K1Q996_CRAGI	7.3e-143	512.7	93.45%	64.51%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN004973.1	sp|K1RDW4|K1RDW4_CRAGI	1.0e-265	921.4	90.52%	80.14%	Protein 5NUC;OS=Crassostrea;PE=3;SV=1	GO:0016787|GO:0000166|	GO:0009166|
GN004974.1	sp|K1Q6G5|K1Q6G5_CRAGI	1.0e-22	110.9	100.00%	89.55%	60S ribosomal protein L13;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN004975.1	sp|A0A0L8HE49|A0A0L8HE49_OCTBM	9.6e-55	221.1	34.48%	42.09%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN004976.1	sp|K1PSA8|K1PSA8_CRAGI	0.0e+00	1282.3	100.00%	75.06%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN004977.1	sp|K1QMH7|K1QMH7_CRAGI	4.4e-139	499.6	100.00%	84.15%	Choline dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0008812|GO:0050660|GO:0016787|	GO:0019285|
GN004978.1	sp|K1Q333|K1Q333_CRAGI	0.0e+00	2310.8	100.00%	87.68%	5-oxoprolinase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN001340.1	sp|K1RGH8|K1RGH8_CRAGI	1.0e-172	611.7	100.00%	78.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004979.1	sp|K1RA01|K1RA01_CRAGI	1.1e-200	704.9	98.07%	90.61%	Homeobox protein caupolican;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN004982.1	sp|K1QPB3|K1QPB3_CRAGI	0.0e+00	1112.1	99.58%	74.26%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN004983.1	sp|K1R862|K1R862_CRAGI	6.5e-171	606.7	96.71%	60.08%	ATM interactor;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN004984.1	sp|K1R1I1|K1R1I1_CRAGI	1.9e-177	627.5	98.44%	82.54%	PAP-associated domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0004652|GO:0003723|	GO:0043631|
GN004985.1	sp|K1R1I1|K1R1I1_CRAGI	6.9e-10	70.1	24.35%	63.16%	PAP-associated domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0004652|GO:0003723|	GO:0043631|
GN004986.1	sp|K1QUQ5|K1QUQ5_CRAGI	9.2e-179	631.7	100.00%	80.74%	Abhydrolase domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN004987.1	sp|K1R1H8|K1R1H8_CRAGI	1.1e-87	328.6	93.33%	74.43%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|
GN004988.1	sp|A0A1D1VGL3|A0A1D1VGL3_RAMVA	5.3e-41	172.6	95.93%	69.23%	Peptidyl-prolyl cis-trans isomerase;OS=Ramazzottius;PE=3;SV=1	GO:0003755|	GO:0006457|
GN004989.1	sp|K1Q6H1|K1Q6H1_CRAGI	1.2e-67	262.7	94.82%	50.71%	Uncharacterized protein C16orf7-like protein;OS=Crassostrea;PE=4;SV=1
GN004990.1	sp|A0A1X7V731|A0A1X7V731_AMPQE	5.0e-15	86.7	83.65%	37.31%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN004994.1	sp|K1PQE3|K1PQE3_CRAGI	3.1e-130	470.3	98.39%	81.76%	RNA-binding protein Raly;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN004995.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	2.2e-36	157.5	98.03%	53.69%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN004996.1	sp|K1R3J0|K1R3J0_CRAGI	2.4e-14	84.7	39.20%	66.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN004997.1	sp|A0A210R0J2|A0A210R0J2_MIZYE	3.9e-102	377.1	94.01%	57.91%	Bardet-Biedl syndrome 4 protein;OS=Mizuhopecten;PE=4;SV=1
GN004998.1	sp|K1R9Z7|K1R9Z7_CRAGI	1.4e-249	867.5	96.91%	86.78%	Oxidative stress-induced growth inhibitor 2;OS=Crassostrea;PE=4;SV=1
GN004999.1	sp|K1R3I0|K1R3I0_CRAGI	1.5e-45	188.0	89.33%	62.28%	Protein cappuccino;OS=Crassostrea;PE=4;SV=1
GN005000.1	sp|A0A210QXW2|A0A210QXW2_MIZYE	2.7e-93	349.0	97.06%	35.78%	Zinc finger protein 668;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN005001.1	sp|K1QWJ0|K1QWJ0_CRAGI	0.0e+00	1157.1	94.45%	74.39%	Nuclear mitotic apparatus protein 1;OS=Crassostrea;PE=4;SV=1
GN005003.1	sp|K1P775|K1P775_CRAGI	5.3e-59	233.0	96.95%	63.35%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0005328|
GN005004.1	sp|A0A210QQ43|A0A210QQ43_MIZYE	1.9e-111	407.9	92.16%	65.00%	Transporter;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005328|
GN005005.1	sp|K1P775|K1P775_CRAGI	6.4e-65	252.3	96.00%	86.21%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0005328|
GN005007.1	sp|K1P775|K1P775_CRAGI	0.0e+00	1231.5	99.28%	87.28%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0005328|
GN005008.1	sp|K1P775|K1P775_CRAGI	6.4e-86	322.8	78.05%	74.87%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0005328|
GN005010.1	sp|K1PDA4|K1PDA4_CRAGI	2.6e-193	680.2	93.80%	89.61%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0062023|	GO:0005201|
GN005011.1	sp|K1PDA4|K1PDA4_CRAGI	7.1e-147	525.4	98.89%	87.27%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0062023|	GO:0005201|
GN005012.1	sp|K1PDA4|K1PDA4_CRAGI	0.0e+00	1191.4	99.71%	75.74%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0062023|	GO:0005201|
GN000970.1	sp|K1PX35|K1PX35_CRAGI	8.6e-83	312.8	82.04%	58.21%	ATP-dependent DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN005013.1	sp|K1PDA4|K1PDA4_CRAGI	1.6e-78	297.7	99.44%	93.22%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0062023|	GO:0005201|
GN005014.1	sp|K1QJW8|K1QJW8_CRAGI	1.1e-40	172.2	75.65%	57.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005015.1	sp|K1RN39|K1RN39_CRAGI	1.7e-97	360.9	100.00%	87.11%	N-acetylgalactosamine-6-sulfatase;OS=Crassostrea;PE=4;SV=1	GO:0043890|
GN005016.1	sp|K1R3P4|K1R3P4_CRAGI	2.1e-307	1060.4	100.00%	77.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005018.1	sp|K1Q1X1|K1Q1X1_CRAGI	5.5e-32	143.7	68.09%	46.07%	Putative potassium channel regulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN005019.1	sp|K1QPX8|K1QPX8_CRAGI	3.3e-265	919.5	100.00%	84.51%	Alkyl/aryl-sulfatase BDS1;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN005020.1	sp|K1QHX6|K1QHX6_CRAGI	1.7e-40	171.0	88.81%	70.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005021.1	sp|K1RA49|K1RA49_CRAGI	4.9e-60	237.7	66.37%	40.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005022.1	sp|K1RA49|K1RA49_CRAGI	5.8e-87	327.0	97.88%	39.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005023.1	sp|A6YRK7|A6YRK7_CRAGI	1.6e-224	784.3	99.20%	71.63%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN005024.1	sp|K1RY25|K1RY25_CRAGI	2.3e-21	108.6	73.84%	29.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004842|
GN005025.1	sp|V9PCY2|V9PCY2_9BIVA	1.6e-216	757.3	100.00%	97.09%	G protein a subunit;OS=Crassostrea;PE=2;SV=1	GO:0031683|GO:0005525|GO:0003924|	GO:0007186|
GN005026.1	sp|A0A210PIE3|A0A210PIE3_MIZYE	0.0e+00	1416.7	100.00%	80.40%	DNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0003678|	GO:0006270|
GN005027.1	sp|K1QMS7|K1QMS7_CRAGI	1.7e-140	504.6	93.61%	72.02%	Malonyl CoA-acyl carrier protein transacylase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN005028.1	sp|K1QTU9|K1QTU9_CRAGI	0.0e+00	1611.3	97.73%	80.83%	Mediator of RNA polymerase II transcription subunit 24;OS=Crassostrea;PE=4;SV=1	GO:0016592|
GN005029.1	sp|K1QIV3|K1QIV3_CRAGI	2.1e-30	138.3	84.03%	36.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005030.1	sp|K1PTT2|K1PTT2_CRAGI	1.0e-131	475.7	97.48%	76.67%	Transcriptional repressor scratch 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005031.1	sp|K1R1S1|K1R1S1_CRAGI	9.5e-113	412.9	82.83%	51.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005034.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	3.9e-11	75.1	29.93%	33.61%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN005036.1	sp|K1QFQ6|K1QFQ6_CRAGI	8.0e-20	102.4	80.82%	66.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005038.1	sp|A0A210QJQ4|A0A210QJQ4_MIZYE	2.7e-117	427.9	100.00%	48.24%	Palmitoyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0019706|
GN005039.1	sp|K1Q8J7|K1Q8J7_CRAGI	3.7e-172	609.8	93.48%	88.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005040.1	sp|K1QSA0|K1QSA0_CRAGI	3.3e-127	460.7	100.00%	66.19%	X-box-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN005041.1	sp|K1QJU8|K1QJU8_CRAGI	4.9e-236	822.4	100.00%	80.30%	Putative phospholipase B-like 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|	GO:0000281|
GN005042.1	sp|K1QBA3|K1QBA3_CRAGI	5.0e-115	419.5	99.59%	83.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005043.1	sp|K1QKI8|K1QKI8_CRAGI	0.0e+00	1435.2	99.91%	63.99%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN005044.1	sp|K1PYM7|K1PYM7_CRAGI	0.0e+00	4415.1	98.87%	92.49%	Serine/threonine-protein kinase TOR;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|GO:0044877|
GN005045.1	sp|K1QKJ7|K1QKJ7_CRAGI	1.3e-41	175.3	47.94%	94.57%	Translocation protein SEC62;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0015031|
GN001347.1	sp|K1Q3L0|K1Q3L0_CRAGI	1.1e-80	305.8	55.56%	76.92%	Retinol dehydrogenase 12;OS=Crassostrea;PE=4;SV=1
GN005047.1	sp|K1PYN4|K1PYN4_CRAGI	4.6e-115	419.9	99.66%	69.39%	DnaJ-like protein subfamily C member 11;OS=Crassostrea;PE=4;SV=1
GN005048.1	sp|K1PYN4|K1PYN4_CRAGI	1.3e-88	331.6	99.57%	70.94%	DnaJ-like protein subfamily C member 11;OS=Crassostrea;PE=4;SV=1
GN005049.1	sp|K1QE43|K1QE43_CRAGI	4.3e-36	156.4	92.54%	63.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005050.1	sp|K1PSK5|K1PSK5_CRAGI	1.7e-170	605.5	41.98%	80.12%	Vacuolar protein sorting-associated protein 4B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003810|	GO:0018149|
GN005051.1	sp|K1PDB3|K1PDB3_CRAGI	1.5e-192	677.9	100.00%	65.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005052.1	sp|K1S1J4|K1S1J4_CRAGI	4.5e-237	826.2	95.54%	68.25%	SAM domain and HD domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN005053.1	sp|K1QW92|K1QW92_CRAGI	2.0e-69	268.5	99.14%	52.46%	CREB/ATF bZIP transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN001348.1	sp|K1QTC7|K1QTC7_CRAGI	2.4e-252	876.7	97.90%	86.74%	Spinster-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN005054.1	sp|K1RBW9|K1RBW9_CRAGI	9.0e-14	82.8	20.40%	97.50%	Leucine-rich repeat-containing protein 69;OS=Crassostrea;PE=4;SV=1
GN005055.1	sp|K1RHY2|K1RHY2_CRAGI	1.2e-53	214.9	91.87%	72.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005056.1	sp|C3YWQ8|C3YWQ8_BRAFL	3.2e-49	201.4	95.16%	34.07%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN005057.1	sp|K1R5X3|K1R5X3_CRAGI	0.0e+00	1341.6	99.91%	61.34%	Transmembrane and coiled-coil domain-containing protein 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005058.1	sp|K1RBX4|K1RBX4_CRAGI	9.0e-78	295.8	100.00%	51.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN005059.1	sp|K1RBX4|K1RBX4_CRAGI	2.8e-17	93.6	97.22%	45.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN005060.1	sp|K1RHY4|K1RHY4_CRAGI	1.5e-64	252.7	96.53%	48.34%	Endothelial cells scavenger receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005061.1	sp|K1QLK3|K1QLK3_CRAGI	4.7e-94	350.5	98.51%	47.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005065.1	sp|A0A024J5R7|A0A024J5R7_CRAGI	4.1e-12	78.2	24.73%	47.92%	Feeding circuit activating peptide;OS=Crassostrea;PE=2;SV=1	GO:0005184|
GN001349.1	sp|K1P828|K1P828_CRAGI	2.3e-121	441.0	91.64%	64.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005069.1	sp|K1RBX7|K1RBX7_CRAGI	3.6e-285	986.1	100.00%	70.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005070.1	sp|K1RHY6|K1RHY6_CRAGI	4.0e-114	416.4	98.70%	81.66%	Sigma 1-type opioid receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005072.1	sp|K1QBH6|K1QBH6_CRAGI	6.1e-46	190.7	33.17%	69.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001350.1	sp|K1R5H6|K1R5H6_CRAGI	2.7e-10	72.0	30.50%	46.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005074.1	sp|K1QZH7|K1QZH7_CRAGI	3.0e-181	641.3	52.27%	64.76%	Putative metabotropic glutamate receptor mgl-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005075.1	sp|K1RCS4|K1RCS4_CRAGI	3.5e-129	466.8	100.00%	97.44%	Coiled-coil domain-containing protein 42-like protein;OS=Crassostrea;PE=4;SV=1
GN005076.1	sp|K1RW45|K1RW45_CRAGI	3.4e-41	174.5	32.78%	84.54%	NipSnap-like protein 2;OS=Crassostrea;PE=4;SV=1
GN005077.1	sp|K1S1G9|K1S1G9_CRAGI	4.7e-26	122.9	94.12%	49.55%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN005078.1	sp|K1QZJ2|K1QZJ2_CRAGI	0.0e+00	1310.8	99.84%	69.08%	Zinc finger protein ZFAT;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN000971.1	sp|K1PVQ2|K1PVQ2_CRAGI	6.7e-74	282.3	100.00%	78.49%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001351.1	sp|A0A210R0Z2|A0A210R0Z2_MIZYE	3.6e-24	118.2	41.78%	41.56%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005079.1	sp|V5HHA0|V5HHA0_IXORI	5.7e-11	72.4	73.40%	52.94%	Uncharacterized protein;OS=Ixodes;PE=2;SV=1
GN005081.1	sp|K1RC96|K1RC96_CRAGI	3.8e-24	116.7	62.50%	70.24%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005083.1	sp|K1PR06|K1PR06_CRAGI	6.0e-161	572.8	84.89%	73.65%	Uncharacterized protein C18orf51;OS=Crassostrea;PE=4;SV=1
GN005084.1	sp|K1PR06|K1PR06_CRAGI	1.5e-35	155.2	97.60%	35.21%	Uncharacterized protein C18orf51;OS=Crassostrea;PE=4;SV=1
GN005085.1	sp|A0A210PE65|A0A210PE65_MIZYE	5.4e-109	400.6	95.26%	40.41%	Protein asteroid-like 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004518|	GO:0006281|
GN005086.1	sp|K1PHB3|K1PHB3_CRAGI	1.6e-25	123.2	98.46%	28.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005087.1	sp|K1PHB3|K1PHB3_CRAGI	1.2e-20	104.8	92.73%	50.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005088.1	sp|K1PWF7|K1PWF7_CRAGI	0.0e+00	1225.3	99.69%	76.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005090.1	sp|A0A210QN14|A0A210QN14_MIZYE	7.2e-35	154.1	79.65%	27.75%	Regulator of G-protein signaling protein-like;OS=Mizuhopecten;PE=4;SV=1
GN005091.1	sp|A0A210QQ47|A0A210QQ47_MIZYE	5.1e-22	109.4	98.23%	49.09%	Centromere protein N;OS=Mizuhopecten;PE=4;SV=1	GO:0007059|GO:0051382|
GN005092.1	sp|K1Q2W4|K1Q2W4_CRAGI	3.8e-36	158.7	91.36%	23.35%	Transcription intermediary factor 1-alpha;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005093.1	sp|A0A210QHC9|A0A210QHC9_MIZYE	2.4e-131	473.8	100.00%	86.49%	V-type proton ATPase subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0033179|	GO:0015078|	GO:0015991|
GN005094.1	sp|K1PHB6|K1PHB6_CRAGI	4.8e-137	492.7	100.00%	93.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005095.1	sp|K1R3L1|K1R3L1_CRAGI	7.7e-73	280.0	61.94%	55.82%	C-type lectin isoform 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN005097.1	sp|K1PNL2|K1PNL2_CRAGI	1.6e-53	216.1	96.99%	33.33%	Protein FAM92B;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005098.1	sp|A0A3G1WSA4|A0A3G1WSA4_RUDPH	4.2e-30	137.1	94.71%	45.54%	Peritrophin;OS=Ruditapes;PE=2;SV=1
GN005099.1	sp|K1P9K3|K1P9K3_CRAGI	9.2e-135	485.3	95.11%	81.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005100.1	sp|K1PGU3|K1PGU3_CRAGI	8.0e-86	322.0	100.00%	82.42%	Beta-1,3-glucosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0016757|
GN005102.1	sp|A0A210R2S1|A0A210R2S1_MIZYE	6.4e-41	173.7	84.29%	38.35%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005103.1	sp|K1P9K9|K1P9K9_CRAGI	1.5e-134	485.0	99.49%	64.36%	Defects in morphology protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0045145|
GN005104.1	sp|K1PGU7|K1PGU7_CRAGI	5.2e-40	170.2	40.74%	83.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016598|
GN005105.1	sp|K1PNM1|K1PNM1_CRAGI	1.0e-51	208.8	98.43%	57.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0031005|	GO:0061572|GO:0061181|
GN005106.1	sp|K1QMI7|K1QMI7_CRAGI	1.4e-15	88.2	85.27%	42.61%	CUB and sushi domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005107.1	sp|K1Q9L6|K1Q9L6_CRAGI	2.2e-81	307.4	100.00%	76.56%	Dual specificity phosphatase DUPD1;OS=Crassostrea;PE=3;SV=1	GO:0004725|GO:0008138|
GN005108.1	sp|K1PNM6|K1PNM6_CRAGI	3.8e-71	276.2	34.86%	72.31%	Zinc finger protein 64-like protein, isoforms 1 and 2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005109.1	sp|K1Q9M0|K1Q9M0_CRAGI	0.0e+00	1117.1	93.20%	78.79%	tRNA (Cytosine-5-)-methyltransferase NSUN2;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0016428|
GN005110.1	sp|A0A210PNC6|A0A210PNC6_MIZYE	1.1e-170	605.5	100.00%	63.02%	Kelch domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1
GN005111.1	sp|K1PYC4|K1PYC4_CRAGI	6.8e-84	316.2	67.49%	75.26%	SRR1-like protein;OS=Crassostrea;PE=4;SV=1
GN005112.1	sp|K1Q5V4|K1Q5V4_CRAGI	2.9e-107	395.6	38.14%	63.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035091|	GO:0000902|
GN005113.1	sp|K1QYN2|K1QYN2_CRAGI	4.0e-42	177.2	62.83%	87.32%	E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|	GO:0006511|
GN005114.1	sp|A0A210PNH1|A0A210PNH1_MIZYE	8.0e-96	356.3	99.47%	57.11%	RNA-binding protein NOB1;OS=Mizuhopecten;PE=4;SV=1	GO:0004521|GO:0046872|	GO:0000469|GO:0042274|
GN005115.1	sp|K1RYQ8|K1RYQ8_CRAGI	5.4e-147	526.6	100.00%	61.88%	Ankyrin repeat domain-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN005116.1	sp|K1RYQ8|K1RYQ8_CRAGI	5.0e-99	366.7	100.00%	63.66%	Ankyrin repeat domain-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN005117.1	sp|K1QTN0|K1QTN0_CRAGI	3.4e-28	129.4	86.25%	80.88%	Beta-hexosaminidase subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0004563|GO:0003676|	GO:0005975|
GN005118.1	sp|K1RM49|K1RM49_CRAGI	9.5e-82	308.9	100.00%	61.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005120.1	sp|A0A210QXY5|A0A210QXY5_MIZYE	1.9e-86	325.9	86.85%	53.05%	Leucine-rich repeat-containing protein 29;OS=Mizuhopecten;PE=4;SV=1
GN005121.1	sp|K1QNF5|K1QNF5_CRAGI	0.0e+00	1523.8	100.00%	91.64%	Lon protease homolog 2, peroxisomal;OS=Crassostrea;PE=3;SV=1	GO:0005782|	GO:0005524|GO:0004176|GO:0043565|GO:0004252|	GO:0016558|GO:0016485|GO:0006515|
GN005122.1	sp|K1QEX1|K1QEX1_CRAGI	2.7e-13	80.9	96.20%	45.10%	Macrophage mannose receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005123.1	sp|K1RAW7|K1RAW7_CRAGI	2.6e-186	656.8	100.00%	92.96%	General transcription factor IIH subunit;OS=Crassostrea;PE=3;SV=1	GO:0000439|GO:0005675|	GO:0003676|GO:0008270|	GO:0006289|GO:0006351|
GN005124.1	sp|A0A210PXB1|A0A210PXB1_MIZYE	1.5e-45	188.0	95.92%	55.71%	Pleckstrin homology domain-containing family B member 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN005125.1	sp|K1S0M5|K1S0M5_CRAGI	4.2e-108	396.7	91.55%	65.54%	Membrane metallo-endopeptidase-like 1;OS=Crassostrea;PE=4;SV=1	GO:0004222|
GN005126.1	sp|K1R4W9|K1R4W9_CRAGI	1.4e-119	435.3	83.95%	66.46%	Actin-1;OS=Crassostrea;PE=3;SV=1
GN005127.1	sp|L8HCZ7|L8HCZ7_ACACA	1.4e-132	478.4	98.16%	60.75%	Actin-1, putative;OS=Acanthamoeba;PE=3;SV=1	GO:0005524|
GN005128.1	sp|S5MNM5|S5MNM5_BOMMO	2.3e-95	354.8	97.33%	47.06%	Actin-4;OS=Bombyx;PE=2;SV=1	GO:0005524|
GN005129.1	sp|K1Q4J2|K1Q4J2_CRAGI	0.0e+00	1835.5	100.00%	73.19%	Active breakpoint cluster region-related protein;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0005089|	GO:0035556|GO:0035023|
GN005130.1	sp|K1QQK5|K1QQK5_CRAGI	0.0e+00	1411.0	99.39%	72.80%	Metabotropic glutamate receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005131.1	sp|K1PII2|K1PII2_CRAGI	1.4e-150	538.1	98.27%	73.16%	Inositol polyphosphate 5-phosphatase K;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0046856|
GN001354.1	sp|K1PRF6|K1PRF6_CRAGI	1.2e-09	68.6	35.82%	63.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005132.1	sp|K1RJ07|K1RJ07_CRAGI	3.2e-278	962.6	100.00%	95.52%	Ribosomal protein S6 kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0007165|
GN005133.1	sp|A0A210Q876|A0A210Q876_MIZYE	0.0e+00	3416.7	100.00%	65.53%	Translational activator GCN1;OS=Mizuhopecten;PE=4;SV=1	GO:0019901|GO:0019887|GO:0043022|	GO:0033674|GO:0006417|
GN005134.1	sp|K1QKM1|K1QKM1_CRAGI	6.2e-104	383.3	98.44%	56.49%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005135.1	sp|K1QKM1|K1QKM1_CRAGI	1.3e-60	239.6	94.24%	36.11%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005136.1	sp|K1PU80|K1PU80_CRAGI	1.4e-159	568.2	93.51%	75.35%	Aldose 1-epimerase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|GO:0016853|	GO:0005975|
GN005139.1	sp|K1QQI5|K1QQI5_CRAGI	2.5e-93	347.4	87.65%	72.00%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN005142.1	sp|A0A210QD55|A0A210QD55_MIZYE	0.0e+00	1500.3	80.45%	78.11%	WD repeat-containing protein 66;OS=Mizuhopecten;PE=4;SV=1
GN005143.1	sp|A0A210QD71|A0A210QD71_MIZYE	0.0e+00	1286.9	99.30%	45.16%	E1A-binding protein p400;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|
GN005144.1	sp|V4ADJ9|V4ADJ9_LOTGI	2.7e-14	84.0	65.93%	44.32%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN005146.1	sp|K1Q8E9|K1Q8E9_CRAGI	9.9e-31	139.8	27.19%	84.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005147.1	sp|A0A2Z6G1B4|A0A2Z6G1B4_PINFU	1.0e-119	436.0	94.79%	47.55%	Matrix metalloproteinase;OS=Pinctada;PE=2;SV=1	GO:0031012|	GO:0004222|GO:0008270|
GN001356.1	sp|K1PLC5|K1PLC5_CRAGI	3.4e-26	124.4	98.41%	34.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005149.1	sp|A0A1S3K4X7|A0A1S3K4X7_LINUN	2.7e-114	418.7	97.02%	36.57%	uncharacterized protein LOC106178715;OS=Lingula;PE=4;SV=1	GO:0005509|
GN005150.1	sp|A0A210Q0J5|A0A210Q0J5_MIZYE	1.3e-106	391.3	100.00%	83.71%	Cell cycle checkpoint protein RAD1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0000077|
GN005151.1	sp|A0A210PG26|A0A210PG26_MIZYE	7.0e-224	782.3	98.80%	62.80%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005153.1	sp|K1QKM1|K1QKM1_CRAGI	3.8e-41	173.3	84.00%	68.25%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005154.1	sp|K1QS12|K1QS12_CRAGI	0.0e+00	1492.2	100.00%	83.12%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN005155.1	sp|A0A0F7YYU8|A0A0F7YYU8_CRAGI	3.2e-293	1012.7	99.49%	87.56%	TAp63alpha;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003700|GO:0044212|	GO:0006915|GO:0051262|
GN001357.1	sp|K1PLC5|K1PLC5_CRAGI	4.9e-16	89.4	96.08%	42.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005157.1	sp|A0A210QTI6|A0A210QTI6_MIZYE	1.8e-17	93.2	100.00%	75.47%	WD repeat-containing protein WRAP73;OS=Mizuhopecten;PE=4;SV=1
GN005158.1	sp|K1PNU4|K1PNU4_CRAGI	3.0e-158	563.9	92.04%	71.63%	Potassium voltage-gated channel subfamily B member 2;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN005159.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	3.8e-21	107.1	97.09%	35.91%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN005160.1	sp|K1QBH6|K1QBH6_CRAGI	1.3e-45	189.5	39.05%	64.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005162.1	sp|K1PFV1|K1PFV1_CRAGI	5.1e-111	406.8	100.00%	75.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005163.1	sp|K1PFK7|K1PFK7_CRAGI	4.5e-50	203.8	62.93%	57.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005164.1	sp|K1PZX9|K1PZX9_CRAGI	1.4e-40	171.0	100.00%	74.77%	Glutathione S-transferase theta-1;OS=Crassostrea;PE=3;SV=1	GO:0016740|
GN005166.1	sp|A0A1S3I5V0|A0A1S3I5V0_LINUN	2.7e-24	117.1	93.70%	50.81%	type-1 angiotensin II receptor-associated protein-like isoform X1;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0038166|
GN005167.1	sp|K1QTQ7|K1QTQ7_CRAGI	8.7e-61	238.8	99.44%	68.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005168.1	sp|K1R0U1|K1R0U1_CRAGI	7.0e-94	349.0	100.00%	83.09%	Glycolipid transfer protein domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN005169.1	sp|K1RRD7|K1RRD7_CRAGI	1.6e-51	209.1	36.41%	68.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005170.1	sp|A0A210PXQ8|A0A210PXQ8_MIZYE	4.1e-152	543.5	92.95%	65.70%	Selenocysteine lyase;OS=Mizuhopecten;PE=4;SV=1	GO:0016829|
GN005171.1	sp|K1RFP1|K1RFP1_CRAGI	4.6e-219	766.1	95.62%	74.80%	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit;OS=Crassostrea;PE=3;SV=1	GO:0016303|GO:0005524|GO:0046934|	GO:0048015|
GN005174.1	sp|K1RYR5|K1RYR5_CRAGI	6.2e-65	252.3	93.10%	81.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005175.1	sp|K1QTN6|K1QTN6_CRAGI	0.0e+00	1135.9	98.78%	80.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005176.1	sp|K1R365|K1R365_CRAGI	0.0e+00	1162.9	99.73%	75.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005177.1	sp|K1QN90|K1QN90_CRAGI	6.0e-25	120.6	39.29%	44.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047961|
GN005178.1	sp|K1RFP4|K1RFP4_CRAGI	2.5e-27	127.9	100.00%	38.24%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005179.1	sp|K1RYR7|K1RYR7_CRAGI	0.0e+00	2087.8	98.72%	81.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005180.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	5.1e-44	183.3	97.12%	41.95%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN005181.1	sp|K1R369|K1R369_CRAGI	2.0e-59	234.2	98.77%	73.91%	Ficolin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005182.1	sp|K1R970|K1R970_CRAGI	4.4e-107	394.0	99.58%	46.23%	F-box only protein 21;OS=Crassostrea;PE=4;SV=1
GN005183.1	sp|K1RFP6|K1RFP6_CRAGI	1.6e-190	671.0	100.00%	92.79%	Tektin-1;OS=Crassostrea;PE=4;SV=1
GN005184.1	sp|K1Q7N8|K1Q7N8_CRAGI	3.2e-189	667.2	98.77%	57.93%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005185.1	sp|K1RYS1|K1RYS1_CRAGI	3.2e-100	370.5	73.40%	79.72%	JmjC domain-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN005186.1	sp|K1R976|K1R976_CRAGI	0.0e+00	1341.3	100.00%	93.14%	Phosphoinositide 3-kinase regulatory subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005187.1	sp|K1RIS8|K1RIS8_CRAGI	1.4e-130	472.6	68.89%	51.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005188.1	sp|K1R976|K1R976_CRAGI	0.0e+00	1152.9	98.51%	87.44%	Phosphoinositide 3-kinase regulatory subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005189.1	sp|K1RFQ2|K1RFQ2_CRAGI	5.0e-191	673.3	99.84%	69.03%	Protein polyglycylase TTLL10;OS=Crassostrea;PE=4;SV=1	GO:0006464|
GN005191.1	sp|K1RYS7|K1RYS7_CRAGI	1.9e-22	111.3	80.89%	53.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005193.1	sp|K1QZG3|K1QZG3_CRAGI	4.6e-68	262.7	99.31%	81.82%	A disintegrin and metalloproteinase with thrombospondin motifs 16;OS=Crassostrea;PE=4;SV=1	GO:0004222|	GO:0007229|
GN005194.1	sp|K1RQD8|K1RQD8_CRAGI	3.7e-126	456.4	100.00%	89.47%	5-hydroxytryptamine receptor 1B;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005195.1	sp|W4XIZ8|W4XIZ8_STRPU	7.8e-21	107.1	65.90%	28.94%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0004190|GO:0003676|	GO:0015074|
GN005196.1	sp|K1R381|K1R381_CRAGI	3.9e-120	436.8	100.00%	72.59%	Cholecystokinin receptor type A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005200.1	sp|A0A0B7BT80|A0A0B7BT80_9EUPU	9.1e-35	152.9	62.02%	45.91%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN005201.1	sp|A0A210PSN9|A0A210PSN9_MIZYE	3.4e-48	197.6	98.91%	37.86%	Alpha-1A adrenergic receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005203.1	sp|A0A1S3HY27|A0A1S3HY27_LINUN	6.7e-41	174.1	65.34%	33.89%	uncharacterized protein LOC106158895;OS=Lingula;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN005204.1	sp|A0A1X7TIM2|A0A1X7TIM2_AMPQE	2.3e-15	88.6	50.90%	32.64%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0016021|
GN005205.1	sp|A0A2B4SNB7|A0A2B4SNB7_STYPI	2.3e-19	101.3	61.41%	44.64%	Dipeptidyl peptidase 8;OS=Stylophora;PE=3;SV=1	GO:0008236|
GN005206.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.6e-109	401.4	88.89%	49.00%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN005207.1	sp|K1P6Z5|K1P6Z5_CRAGI	2.8e-167	593.6	99.45%	85.00%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005209.1	sp|K1P6Z5|K1P6Z5_CRAGI	5.3e-31	139.0	75.25%	96.00%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005210.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	2.9e-35	154.5	90.38%	41.20%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005212.1	sp|J9KMQ1|J9KMQ1_ACYPI	2.0e-56	225.3	87.29%	34.84%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2
GN005213.1	sp|K1RGD8|K1RGD8_CRAGI	1.5e-22	111.7	95.65%	42.59%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN005214.1	sp|K1RGD8|K1RGD8_CRAGI	1.2e-111	409.1	95.12%	50.00%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN005215.1	sp|K1Q3Z8|K1Q3Z8_CRAGI	3.0e-25	120.9	65.02%	44.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN005217.1	sp|K1QTD7|K1QTD7_CRAGI	8.5e-15	85.9	45.91%	54.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001362.1	sp|K1QJU6|K1QJU6_CRAGI	0.0e+00	1116.3	96.15%	71.35%	Putative RNA-binding protein 19;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN005218.1	sp|K1Q3Z8|K1Q3Z8_CRAGI	2.5e-29	134.4	69.23%	53.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN005220.1	sp|A0A210Q8N9|A0A210Q8N9_MIZYE	6.7e-66	257.3	96.80%	35.78%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005221.1	sp|K1QBF3|K1QBF3_CRAGI	0.0e+00	1459.9	100.00%	94.81%	Trpc4-associated protein;OS=Crassostrea;PE=4;SV=1	GO:0031464|	GO:0006511|
GN005222.1	sp|K1QJE2|K1QJE2_CRAGI	7.0e-30	136.3	96.08%	33.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005501|GO:0034632|
GN005223.1	sp|K1QQX9|K1QQX9_CRAGI	1.1e-34	151.4	96.08%	67.01%	Retinol-binding protein 4;OS=Crassostrea;PE=4;SV=1
GN005224.1	sp|K1QZ05|K1QZ05_CRAGI	3.7e-233	813.1	97.30%	77.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005225.1	sp|K1PYL5|K1PYL5_CRAGI	2.1e-229	800.4	95.25%	84.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005226.1	sp|K1R5T3|K1R5T3_CRAGI	5.8e-92	342.4	100.00%	91.85%	DNA replication complex GINS protein PSF2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0006260|
GN001363.1	sp|K1QDK7|K1QDK7_CRAGI	1.6e-14	84.7	36.76%	79.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005227.1	sp|K1QE30|K1QE30_CRAGI	0.0e+00	1143.6	99.35%	73.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005228.1	sp|K1QL33|K1QL33_CRAGI	2.2e-147	527.3	100.00%	85.45%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN005229.1	sp|W4YMP2|W4YMP2_STRPU	2.3e-24	117.9	86.11%	49.69%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN005231.1	sp|K1PK48|K1PK48_CRAGI	3.5e-31	139.4	91.95%	78.48%	Y+L amino acid transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN005232.1	sp|K1PDM3|K1PDM3_CRAGI	8.5e-94	352.1	9.41%	81.59%	Uncharacterized protein C5orf4-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005506|GO:0016491|	GO:0008610|
GN005234.1	sp|K1PWW5|K1PWW5_CRAGI	4.5e-45	185.7	100.00%	97.80%	Mediator of RNA polymerase II transcription subunit 10;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN005235.1	sp|K1Q484|K1Q484_CRAGI	3.4e-61	240.0	92.86%	80.28%	TIM21-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005744|	GO:0030150|
GN005236.1	sp|K1QBK9|K1QBK9_CRAGI	4.2e-179	633.3	98.09%	67.67%	Interferon regulatory factor 8;OS=Crassostrea;PE=4;SV=1	GO:0003700|GO:0044212|
GN005237.1	sp|K1RC12|K1RC12_CRAGI	2.0e-97	360.9	97.01%	83.77%	GTP-binding protein RAD;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN005241.1	sp|K1R5H6|K1R5H6_CRAGI	9.0e-45	186.8	61.58%	46.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005242.1	sp|K1Q1J5|K1Q1J5_CRAGI	2.1e-56	224.6	93.61%	58.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005244.1	sp|K1QCE8|K1QCE8_CRAGI	5.9e-44	182.6	100.00%	61.64%	RNA pseudouridylate synthase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN005245.1	sp|K1QCE8|K1QCE8_CRAGI	4.3e-61	239.6	88.00%	83.97%	RNA pseudouridylate synthase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN005247.1	sp|K1QT61|K1QT61_CRAGI	5.0e-115	419.5	86.69%	92.52%	NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0051537|GO:0046872|GO:0016491|
GN001366.1	sp|K1RCG2|K1RCG2_CRAGI	7.6e-49	199.1	97.18%	56.00%	ATP-dependent DNA helicase tlh2;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN005248.1	sp|V3ZVC6|V3ZVC6_LOTGI	5.3e-53	213.4	93.78%	46.90%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0005840|	GO:0019843|GO:0003735|	GO:0006412|
GN005249.1	sp|K1Q4T3|K1Q4T3_CRAGI	6.4e-237	825.9	99.12%	67.79%	Microprocessor complex subunit DGCR8;OS=Crassostrea;PE=4;SV=1	GO:0070877|	GO:0020037|GO:0042802|GO:0003723|	GO:0031053|
GN005250.1	sp|K1PIW0|K1PIW0_CRAGI	1.1e-121	442.6	90.25%	53.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005251.1	sp|K1PXT6|K1PXT6_CRAGI	6.1e-134	483.4	83.36%	60.76%	Coiled-coil domain-containing protein 63;OS=Crassostrea;PE=4;SV=1
GN005252.1	sp|K1PQG1|K1PQG1_CRAGI	1.4e-230	804.3	100.00%	86.99%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005253.1	sp|V3ZLM2|V3ZLM2_LOTGI	8.5e-170	602.4	96.63%	61.38%	Transporter;OS=Lottia;PE=3;SV=1	GO:0016021|	GO:0005328|
GN001367.1	sp|K1PLC5|K1PLC5_CRAGI	6.1e-144	516.9	75.77%	52.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005254.1	sp|K1S1I6|K1S1I6_CRAGI	1.0e-223	783.1	100.00%	43.42%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005255.1	sp|A0A0B7A8C9|A0A0B7A8C9_9EUPU	4.6e-26	123.6	70.79%	45.77%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0003735|
GN005256.1	sp|A0A346M701|A0A346M701_PINMT	2.8e-106	391.0	96.44%	51.83%	Beta,beta-carotene-15,15'-dioxygenase;OS=Pinctada;PE=2;SV=1	GO:0046872|GO:0016702|
GN005257.1	sp|K1PV86|K1PV86_CRAGI	1.0e-132	478.4	99.65%	79.86%	Phosphoglycerate mutase family member 5;OS=Crassostrea;PE=4;SV=1
GN005265.1	sp|A0A2B4S577|A0A2B4S577_STYPI	1.6e-31	142.5	78.81%	32.96%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN005266.1	sp|K1RIW4|K1RIW4_CRAGI	9.6e-63	245.7	99.58%	52.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005267.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	1.3e-23	115.5	64.68%	45.80%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN005269.1	sp|K1QJA3|K1QJA3_CRAGI	2.0e-60	238.0	93.59%	59.63%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN005270.1	sp|K1Q554|K1Q554_CRAGI	4.1e-82	310.1	73.73%	89.71%	Mediator of RNA polymerase II transcription subunit 19;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0016592|	GO:0003712|	GO:0006357|
GN005271.1	sp|A0A0L8HBJ8|A0A0L8HBJ8_OCTBM	9.3e-09	65.9	96.32%	41.05%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0031011|	GO:0006338|
GN005272.1	sp|K1QAT7|K1QAT7_CRAGI	1.5e-160	571.6	98.07%	65.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005273.1	sp|K1QRP4|K1QRP4_CRAGI	4.1e-208	729.9	70.85%	85.37%	Putative NADH dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN005274.1	sp|K1RI14|K1RI14_CRAGI	4.7e-15	85.1	100.00%	80.39%	Putative rRNA methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0008649|	GO:0000453|
GN005276.1	sp|K1Q7A2|K1Q7A2_CRAGI	8.0e-75	285.4	98.86%	76.16%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN005277.1	sp|A0A2C9JH48|A0A2C9JH48_BIOGL	5.0e-11	73.9	35.15%	53.01%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003700|
GN005280.1	sp|K1QJ93|K1QJ93_CRAGI	4.2e-15	87.0	83.05%	39.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN005281.1	sp|A0A210R6Y0|A0A210R6Y0_MIZYE	3.7e-33	147.1	82.81%	43.04%	Interleukin-17D;OS=Mizuhopecten;PE=4;SV=1	GO:0005576|	GO:0005125|
GN005283.1	sp|K1QAT4|K1QAT4_CRAGI	2.5e-173	614.0	100.00%	71.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001372.1	sp|K1QY88|K1QY88_CRAGI	6.5e-90	337.8	55.26%	41.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN005284.1	sp|K1RI04|K1RI04_CRAGI	7.6e-179	632.1	99.74%	80.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005285.1	sp|K1QY37|K1QY37_CRAGI	0.0e+00	2245.7	99.41%	74.68%	Telomerase-binding protein EST1A;OS=Crassostrea;PE=4;SV=1
GN005286.1	sp|K1QRN2|K1QRN2_CRAGI	3.8e-296	1022.3	100.00%	86.89%	Cysteine sulfinic acid decarboxylase;OS=Crassostrea;PE=3;SV=1	GO:0016831|GO:0030170|	GO:0019752|
GN005287.1	sp|K1QJ87|K1QJ87_CRAGI	4.0e-197	694.1	99.79%	45.49%	Armadillo repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN005288.1	sp|K1QAS9|K1QAS9_CRAGI	2.3e-113	413.7	100.00%	93.30%	Ras-like protein family member 10B;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN005289.1	sp|K1RHZ9|K1RHZ9_CRAGI	2.2e-56	224.2	97.75%	67.05%	MAP kinase-activated protein kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005290.1	sp|K1QJS0|K1QJS0_CRAGI	6.9e-148	530.0	59.22%	66.50%	Ubiquitin carboxyl-terminal hydrolase 30;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN005292.1	sp|K1PSU9|K1PSU9_CRAGI	6.6e-57	226.1	90.55%	64.17%	28S ribosomal protein S23, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN005293.1	sp|K1REH4|K1REH4_CRAGI	4.4e-229	799.3	100.00%	92.36%	LIM/homeobox protein Lhx5;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0043565|	GO:0006355|
GN005294.1	sp|K1R1S7|K1R1S7_CRAGI	1.1e-256	891.3	100.00%	73.72%	Matrix metalloproteinase-17;OS=Crassostrea;PE=3;SV=1	GO:0031012|GO:0016021|	GO:0004222|GO:0008270|
GN005295.1	sp|A0A151WPL7|A0A151WPL7_9HYME	1.1e-75	289.7	61.71%	51.07%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN005296.1	sp|K1RXQ7|K1RXQ7_CRAGI	3.9e-65	253.1	100.00%	70.70%	Protein trunk;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN005299.1	sp|A0A1S3JB19|A0A1S3JB19_LINUN	1.8e-38	165.6	55.14%	46.15%	uncharacterized protein PF11_0207;OS=Lingula;PE=4;SV=1
GN005300.1	sp|K1QSA8|K1QSA8_CRAGI	5.5e-131	473.0	82.49%	77.47%	Group 3 secretory phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0004623|	GO:0050482|GO:0006644|
GN005301.1	sp|K1R1T3|K1R1T3_CRAGI	1.1e-116	425.6	100.00%	65.97%	CD2 antigen cytoplasmic tail-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005682|
GN005303.1	sp|K1QE83|K1QE83_CRAGI	0.0e+00	4075.8	87.09%	87.08%	CCR4-NOT transcription complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0030015|	GO:0006417|
GN005304.1	sp|A0A210PEF9|A0A210PEF9_MIZYE	3.6e-111	406.8	98.88%	71.10%	Alpha-ketoglutarate-dependent 2,4-dichlorophenoxyacetate dioxygenase;OS=Mizuhopecten;PE=4;SV=1	GO:0051213|
GN005305.1	sp|K1R606|K1R606_CRAGI	6.7e-131	472.2	100.00%	89.72%	Derlin;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|
GN005306.1	sp|K1PYW2|K1PYW2_CRAGI	1.1e-248	864.4	100.00%	93.24%	WD repeat-containing protein 67;OS=Crassostrea;PE=4;SV=1
GN005307.1	sp|K1PG94|K1PG94_CRAGI	7.7e-126	455.7	99.67%	80.40%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN005308.1	sp|K1PYW2|K1PYW2_CRAGI	7.6e-165	585.9	98.92%	88.89%	WD repeat-containing protein 67;OS=Crassostrea;PE=4;SV=1
GN005309.1	sp|K1Q645|K1Q645_CRAGI	6.3e-169	599.0	93.49%	91.43%	Ribose-phosphate pyrophosphokinase 3, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016301|GO:0000287|GO:0004749|	GO:0009116|GO:0009165|
GN005310.1	sp|A0A210QQ56|A0A210QQ56_MIZYE	8.1e-85	319.7	65.05%	66.39%	Protein FAM92A1;OS=Mizuhopecten;PE=4;SV=1
GN005311.1	sp|K1QE88|K1QE88_CRAGI	2.0e-224	783.9	92.59%	81.34%	Sphingomyelin phosphodiesterase 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0050290|
GN005312.1	sp|K1PU81|K1PU81_CRAGI	5.6e-158	562.8	97.63%	74.66%	Protocadherin Fat 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN005313.1	sp|K1RQJ5|K1RQJ5_CRAGI	7.9e-137	493.0	98.90%	62.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005314.1	sp|A0A210PQW7|A0A210PQW7_MIZYE	1.2e-23	114.8	86.61%	54.17%	tRNA (Uracil-O(2)-)-methyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|GO:0008168|
GN005315.1	sp|A0A1C9U302|A0A1C9U302_MIZYE	5.5e-54	217.2	91.39%	35.73%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN005316.1	sp|A0A3L5TS90|A0A3L5TS90_MYTGA	6.4e-60	237.3	95.08%	31.49%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN005317.1	sp|A0A1C9U2X0|A0A1C9U2X0_MIZYE	2.6e-80	305.4	87.22%	32.57%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN005318.1	sp|K1QH98|K1QH98_CRAGI	1.2e-264	917.9	95.68%	77.22%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN005319.1	sp|A0A210Q0Q3|A0A210Q0Q3_MIZYE	4.5e-164	583.2	99.53%	75.18%	Flotillin-2;OS=Mizuhopecten;PE=4;SV=1
GN005320.1	sp|Q70MN7|Q70MN7_CRAGI	5.8e-81	305.8	88.20%	93.59%	Actin-related protein 2/3 complex subunit 3;OS=Crassostrea;PE=2;SV=1	GO:0005885|GO:0005737|	GO:0003779|	GO:0034314|
GN005321.1	sp|K1QXM4|K1QXM4_CRAGI	2.3e-24	116.3	100.00%	93.44%	GPN-loop GTPase 3;OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0016787|
GN005322.1	sp|K1RNB9|K1RNB9_CRAGI	1.9e-272	943.7	100.00%	85.48%	Peroxisomal targeting signal 1 receptor;OS=Crassostrea;PE=4;SV=1
GN001378.1	sp|V9IR24|V9IR24_9BIVA	9.5e-78	295.4	97.67%	59.22%	3-beta hydroxysteroid dehydrogenase;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0003854|	GO:0006694|
GN005324.1	sp|K1Q7M8|K1Q7M8_CRAGI	5.5e-141	506.9	75.92%	57.31%	Acid trehalase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN001379.1	sp|K1PY41|K1PY41_CRAGI	0.0e+00	1104.0	95.75%	88.83%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN005325.1	sp|K1R413|K1R413_CRAGI	6.2e-284	982.6	78.33%	63.54%	Metabotropic glutamate receptor 8;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|
GN005326.1	sp|K1QIB3|K1QIB3_CRAGI	3.7e-59	233.4	100.00%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005327.1	sp|K1QBS6|K1QBS6_CRAGI	1.0e-53	216.1	76.92%	48.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005328.1	sp|K1PW83|K1PW83_CRAGI	1.7e-136	491.5	100.00%	62.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005329.1	sp|K1R412|K1R412_CRAGI	1.1e-72	278.5	93.65%	82.39%	Uncharacterized protein C1orf50-like protein;OS=Crassostrea;PE=4;SV=1
GN005330.1	sp|K1PZN4|K1PZN4_CRAGI	1.3e-65	255.8	87.39%	41.84%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005332.1	sp|K1PZN4|K1PZN4_CRAGI	6.7e-62	243.4	90.50%	38.59%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005333.1	sp|K1PZN4|K1PZN4_CRAGI	2.2e-46	191.8	91.95%	35.23%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005334.1	sp|K1PZN4|K1PZN4_CRAGI	4.1e-64	250.8	92.15%	38.91%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005335.1	sp|K1S3T7|K1S3T7_CRAGI	6.0e-35	152.9	94.05%	49.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005336.1	sp|K1PIZ5|K1PIZ5_CRAGI	1.6e-26	124.0	85.56%	71.05%	Endo-1,4-beta-xylanase A;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0045493|
GN005338.1	sp|K1RVX3|K1RVX3_CRAGI	1.1e-197	694.9	96.41%	74.65%	Exoglucanase xynX;OS=Crassostrea;PE=4;SV=1	GO:0000813|	GO:0004553|	GO:0005975|
GN005339.1	sp|K1RVX3|K1RVX3_CRAGI	8.2e-105	387.1	32.75%	75.10%	Exoglucanase xynX;OS=Crassostrea;PE=4;SV=1	GO:0000813|	GO:0004553|	GO:0005975|
GN005340.1	sp|K1PFD7|K1PFD7_CRAGI	2.1e-28	130.6	77.19%	68.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005341.1	sp|K1PQK8|K1PQK8_CRAGI	1.8e-105	387.5	94.88%	92.61%	CDP-diacylglycerol--inositol 3-phosphatidyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016780|	GO:0008654|
GN005345.1	sp|K1PP34|K1PP34_CRAGI	1.1e-42	177.9	95.24%	82.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005346.1	sp|K1Q9W7|K1Q9W7_CRAGI	1.9e-134	484.6	86.22%	68.87%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN005347.1	sp|K1P388|K1P388_CRAGI	4.6e-110	403.3	99.68%	66.12%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN005348.1	sp|K1Q9W7|K1Q9W7_CRAGI	1.6e-103	381.7	74.35%	67.70%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN005349.1	sp|K1P388|K1P388_CRAGI	9.4e-123	445.7	94.40%	61.01%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN005351.1	sp|A0A3L5TWL7|A0A3L5TWL7_MYTGA	3.0e-11	73.2	86.75%	48.00%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN005352.1	sp|U5PZB3|U5PZB3_CRAGI	4.4e-121	441.0	96.78%	38.69%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN005353.1	sp|U5PZB3|U5PZB3_CRAGI	2.5e-87	328.9	97.73%	32.04%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN005354.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	5.3e-23	113.2	97.09%	37.57%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN005356.1	sp|A0A2R3SK02|A0A2R3SK02_ARGIR	1.1e-68	266.2	98.49%	36.13%	Toll-like receptor 1;OS=Argopecten;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN005357.1	sp|K1QXX2|K1QXX2_CRAGI	2.4e-85	320.5	89.25%	89.70%	Ubiquitin-conjugating enzyme E2 Q2;OS=Crassostrea;PE=4;SV=1
GN005358.1	sp|K1R483|K1R483_CRAGI	2.8e-76	292.0	56.20%	65.26%	Zinc finger CCCH domain-containing protein 3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|GO:0046872|
GN005359.1	sp|K1R483|K1R483_CRAGI	3.4e-87	327.4	100.00%	76.92%	Zinc finger CCCH domain-containing protein 3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|GO:0046872|
GN005360.1	sp|K1RNM4|K1RNM4_CRAGI	3.6e-93	346.7	96.74%	82.13%	WW domain-containing oxidoreductase;OS=Crassostrea;PE=4;SV=1
GN005362.1	sp|K1PY49|K1PY49_CRAGI	1.7e-79	301.2	87.02%	84.44%	Angiopoietin-2;OS=Crassostrea;PE=4;SV=1
GN001381.1	sp|K1Q5H6|K1Q5H6_CRAGI	9.2e-261	905.2	80.96%	91.63%	FACT complex subunit SSRP1;OS=Crassostrea;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0003677|	GO:0006281|GO:0006260|
GN005363.1	sp|K1PY49|K1PY49_CRAGI	7.1e-93	345.9	79.20%	81.73%	Angiopoietin-2;OS=Crassostrea;PE=4;SV=1
GN005364.1	sp|K1R5A9|K1R5A9_CRAGI	0.0e+00	1130.9	99.24%	47.03%	Ficolin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005365.1	sp|K1Q5D3|K1Q5D3_CRAGI	7.0e-101	372.1	100.00%	98.40%	GMP reductase;OS=Crassostrea;PE=3;SV=1	GO:1902560|	GO:0003920|GO:0046872|	GO:0006144|GO:0006163|
GN005367.1	sp|K1QDH0|K1QDH0_CRAGI	1.6e-23	114.0	97.70%	67.82%	Group XV phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0008374|	GO:0006629|
GN001382.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	3.4e-74	285.4	82.00%	28.81%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN005368.1	sp|K1QDH0|K1QDH0_CRAGI	3.5e-192	676.4	95.03%	84.81%	Group XV phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0008374|	GO:0006629|
GN005369.1	sp|K1R5B5|K1R5B5_CRAGI	0.0e+00	2368.2	87.39%	85.04%	Ras-responsive element-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005371.1	sp|K1PMI0|K1PMI0_CRAGI	4.7e-88	329.7	88.84%	89.50%	Charged multivesicular body protein 4b;OS=Crassostrea;PE=3;SV=1	GO:0007034|
GN005372.1	sp|A0A1V0QB21|A0A1V0QB21_PINMT	2.4e-71	274.2	63.00%	86.62%	CBFbeta isoform 1;OS=Pinctada;PE=2;SV=1	GO:0005634|	GO:0003713|
GN005373.1	sp|A0A210QXT8|A0A210QXT8_MIZYE	0.0e+00	1583.9	83.27%	77.84%	Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN005374.1	sp|K1R3B3|K1R3B3_CRAGI	1.4e-172	611.7	85.16%	69.34%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN005375.1	sp|K1PVG9|K1PVG9_CRAGI	1.5e-79	301.2	100.00%	89.73%	Malectin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN005376.1	sp|K1QUK9|K1QUK9_CRAGI	2.5e-35	154.8	58.82%	52.83%	Migration and invasion-inhibitory protein;OS=Crassostrea;PE=4;SV=1	GO:0030336|GO:0010972|
GN001383.1	sp|A0A0B7A0T5|A0A0B7A0T5_9EUPU	7.3e-13	78.2	77.27%	66.00%	FACT complex subunit SSRP1;OS=Arion;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0003677|	GO:0006281|GO:0006260|
GN005377.1	sp|K1RS80|K1RS80_CRAGI	1.1e-57	228.4	98.17%	69.37%	Glycolipid transfer protein domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN005379.1	sp|K1QWR3|K1QWR3_CRAGI	3.4e-31	140.2	100.00%	48.59%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN005380.1	sp|K1PW31|K1PW31_CRAGI	2.1e-55	221.1	97.50%	56.19%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN001384.1	sp|A0A2C9KAU5|A0A2C9KAU5_BIOGL	4.6e-13	80.1	41.67%	57.75%	FACT complex subunit SSRP1;OS=Biomphalaria;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0003677|	GO:0006281|GO:0006260|
GN005381.1	sp|K1PW31|K1PW31_CRAGI	1.2e-114	419.1	86.62%	54.04%	Monocarboxylate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN005382.1	sp|K1R3V0|K1R3V0_CRAGI	0.0e+00	3989.1	100.00%	87.64%	CAD protein;OS=Crassostrea;PE=3;SV=1	GO:0016597|GO:0004070|GO:0005524|GO:0004088|GO:0016812|GO:0046872|	GO:0006207|GO:0006541|
GN005383.1	sp|K1Q2Q3|K1Q2Q3_CRAGI	5.3e-117	426.4	100.00%	72.05%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN005384.1	sp|K1Q9P2|K1Q9P2_CRAGI	1.3e-103	381.7	100.00%	72.99%	Transcription factor HES-1-B;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN005385.1	sp|K1PQW3|K1PQW3_CRAGI	1.5e-24	118.6	99.03%	61.84%	OTU domain-containing protein 6B;OS=Crassostrea;PE=4;SV=1
GN005386.1	sp|K1PIS9|K1PIS9_CRAGI	5.5e-81	306.2	96.36%	71.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005387.1	sp|A0A210QXL8|A0A210QXL8_MIZYE	1.3e-100	371.7	99.27%	65.07%	Inositol-1-monophosphatase;OS=Mizuhopecten;PE=3;SV=1	GO:0008934|GO:0052832|GO:0052833|GO:0046872|	GO:0006021|GO:0046855|GO:0046854|
GN001385.1	sp|K1PY38|K1PY38_CRAGI	1.7e-30	137.1	100.00%	70.93%	NADPH oxidoreductase A;OS=Crassostrea;PE=4;SV=1	GO:0010181|GO:0016491|
GN005389.1	sp|K1P597|K1P597_CRAGI	2.4e-26	124.0	97.01%	48.94%	Ribosome biogenesis protein BOP1 homolog;OS=Crassostrea;PE=3;SV=1	GO:0005730|GO:0005654|GO:0030687|	GO:0043021|	GO:0000466|GO:0000463|
GN005390.1	sp|K1R8E3|K1R8E3_CRAGI	2.1e-125	454.5	99.45%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0035240|GO:0004930|GO:0072544|GO:0072545|	GO:0007166|
GN005391.1	sp|K1Q1B7|K1Q1B7_CRAGI	2.6e-207	727.2	98.78%	63.12%	Protein deltex-4;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0007219|GO:0016567|
GN005392.1	sp|K1Q8G3|K1Q8G3_CRAGI	2.9e-141	506.9	100.00%	89.15%	Coiled-coil domain-containing protein 92;OS=Crassostrea;PE=4;SV=1
GN005393.1	sp|A0A210QIX0|A0A210QIX0_MIZYE	1.9e-10	70.9	86.24%	40.00%	rRNA methyltransferase 1, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|GO:0008173|	GO:0006396|
GN005395.1	sp|K1PLG5|K1PLG5_CRAGI	3.6e-48	197.2	63.93%	67.86%	rRNA methyltransferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008173|	GO:0006396|
GN005396.1	sp|K1P0P6|K1P0P6_CRAGI	2.8e-156	558.1	52.24%	73.18%	RING finger protein 10;OS=Crassostrea;PE=4;SV=1
GN005397.1	sp|K1P6V3|K1P6V3_CRAGI	1.7e-43	181.8	47.66%	76.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005398.1	sp|A0A210R2F7|A0A210R2F7_MIZYE	0.0e+00	1488.4	97.99%	67.84%	Phosphorylase b kinase regulatory subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0005886|	GO:0005516|GO:0016301|	GO:0005977|
GN005399.1	sp|K1Q7K4|K1Q7K4_CRAGI	1.2e-95	355.1	97.60%	67.62%	Werner syndrome ATP-dependent helicase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0004386|GO:0003676|
GN005400.1	sp|K1QUW3|K1QUW3_CRAGI	1.7e-242	844.3	100.00%	75.77%	Protein phosphatase 1 regulatory inhibitor subunit 16B;OS=Crassostrea;PE=4;SV=1
GN005401.1	sp|K1QNT4|K1QNT4_CRAGI	2.2e-239	833.6	99.38%	85.16%	Anoctamin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN005402.1	sp|K1QNT4|K1QNT4_CRAGI	1.5e-19	100.5	95.89%	76.81%	Anoctamin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN005403.1	sp|K1QFS5|K1QFS5_CRAGI	7.1e-115	420.2	97.32%	66.61%	Carboxypeptidase N subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004180|
GN005404.1	sp|K1Q7J8|K1Q7J8_CRAGI	1.7e-89	334.7	79.22%	77.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005405.1	sp|K1PY24|K1PY24_CRAGI	3.5e-192	676.4	99.47%	91.73%	B1 bradykinin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN001386.1	sp|A0A210PGM6|A0A210PGM6_MIZYE	1.0e-61	242.7	99.66%	42.90%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN005407.1	sp|K1R9G8|K1R9G8_CRAGI	4.4e-76	289.7	94.48%	77.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN005409.1	sp|K1QDE6|K1QDE6_CRAGI	6.0e-168	595.9	96.57%	77.26%	Agrin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN005410.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	8.6e-39	166.0	100.00%	44.34%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN005411.1	sp|K1QDE6|K1QDE6_CRAGI	0.0e+00	1121.3	100.00%	55.13%	Agrin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN005412.1	sp|K1QDE6|K1QDE6_CRAGI	4.2e-29	132.9	72.32%	68.67%	Agrin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN005414.1	sp|A0A210PX54|A0A210PX54_MIZYE	4.1e-156	557.4	90.64%	56.60%	7SK snRNA methylphosphate capping enzyme;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN001387.1	sp|K1R5E8|K1R5E8_CRAGI	2.7e-297	1026.2	99.30%	85.44%	Calpain-A;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN005415.1	sp|V4CB32|V4CB32_LOTGI	2.7e-68	265.8	98.87%	27.32%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005524|GO:0003676|
GN005416.1	sp|K1RK96|K1RK96_CRAGI	4.5e-18	98.2	44.70%	32.37%	Neural cell adhesion molecule 1;OS=Crassostrea;PE=4;SV=1
GN005417.1	sp|K1Q1Q8|K1Q1Q8_CRAGI	1.3e-48	198.4	89.83%	58.23%	Endothelin-converting enzyme 1;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|GO:0004222|	GO:0007160|
GN005421.1	sp|K1QYI8|K1QYI8_CRAGI	6.4e-138	496.5	78.44%	68.91%	Sorting nexin-16;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN005422.1	sp|K1QPC4|K1QPC4_CRAGI	8.6e-52	209.5	98.89%	52.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005423.1	sp|K1RBZ2|K1RBZ2_CRAGI	9.8e-228	794.7	99.52%	92.11%	Protein LCHN;OS=Crassostrea;PE=4;SV=1
GN005426.1	sp|K1RVF6|K1RVF6_CRAGI	8.5e-177	625.5	75.11%	90.96%	T-box transcription factor TBX20;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN005427.1	sp|K1RBY5|K1RBY5_CRAGI	1.9e-178	630.9	100.00%	73.17%	T-box transcription factor TBX20;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005634|	GO:0003677|GO:0003700|
GN005428.1	sp|K1QYI1|K1QYI1_CRAGI	4.3e-140	503.4	95.74%	65.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005429.1	sp|K1QPB7|K1QPB7_CRAGI	1.7e-49	202.2	67.54%	76.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005433.1	sp|K1P6C4|K1P6C4_CRAGI	2.2e-149	535.8	42.31%	54.41%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN001390.1	sp|K1PY33|K1PY33_CRAGI	1.1e-113	415.6	98.40%	60.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005434.1	sp|K1RED4|K1RED4_CRAGI	4.6e-39	167.2	100.00%	44.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005438.1	sp|A0A210QJQ0|A0A210QJQ0_MIZYE	7.4e-17	93.6	31.27%	47.25%	THAP domain-containing protein 1 A;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN005439.1	sp|K1Q014|K1Q014_CRAGI	5.2e-138	496.9	99.04%	47.61%	Solute carrier family 22 member 21;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN005440.1	sp|U5PZB3|U5PZB3_CRAGI	4.3e-56	223.0	94.77%	71.53%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN005442.1	sp|V3ZI82|V3ZI82_LOTGI	4.5e-55	221.5	81.52%	36.42%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0012505|GO:0005634|	GO:0035497|GO:0003700|	GO:0030968|GO:0006357|
GN005443.1	sp|A0A210PN67|A0A210PN67_MIZYE	2.9e-13	80.5	83.33%	39.82%	Cyclin-D1-binding protein 1-like;OS=Mizuhopecten;PE=4;SV=1	GO:0051726|
GN001391.1	sp|K1QHV0|K1QHV0_CRAGI	1.2e-145	521.9	90.75%	64.78%	Putative cytochrome P450 CYP44;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN005446.1	sp|K1R582|K1R582_CRAGI	3.1e-43	180.6	86.80%	49.41%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN005447.1	sp|K1RPQ0|K1RPQ0_CRAGI	1.4e-136	491.5	92.97%	77.38%	Testis-specific serine/threonine-protein kinase 4;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN005448.1	sp|A0A210Q8N2|A0A210Q8N2_MIZYE	2.0e-57	228.8	99.48%	54.81%	Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 2 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN005450.1	sp|A0A1Q1NMJ6|A0A1Q1NMJ6_CRAGI	7.7e-289	998.0	99.46%	81.64%	Cryptochrome-like protein;OS=Crassostrea;PE=2;SV=1
GN005451.1	sp|K1QRM4|K1QRM4_CRAGI	2.2e-148	530.8	98.61%	74.58%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005455.1	sp|K1QYY1|K1QYY1_CRAGI	1.6e-157	561.2	97.81%	78.37%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005456.1	sp|K1QCA9|K1QCA9_CRAGI	1.9e-35	154.1	100.00%	56.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005457.1	sp|K1RDS3|K1RDS3_CRAGI	4.5e-37	159.5	100.00%	58.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005458.1	sp|K1QXG4|K1QXG4_CRAGI	7.9e-46	189.1	86.52%	54.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005459.1	sp|K1R586|K1R586_CRAGI	1.4e-88	331.6	82.81%	79.15%	Vesicle-associated membrane protein/synaptobrevin-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|
GN005460.1	sp|A0A210QP62|A0A210QP62_MIZYE	1.1e-264	918.3	98.98%	59.72%	Anaphase-promoting complex subunit 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005680|
GN001393.1	sp|A0A210QF60|A0A210QF60_MIZYE	2.6e-31	142.1	71.43%	30.23%	Acetylcholine receptor subunit alpha-type acr-16;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN005461.1	sp|K1R7N6|K1R7N6_CRAGI	6.3e-126	455.7	99.19%	95.88%	Eukaryotic translation initiation factor 6;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0016021|GO:0005730|	GO:0043023|GO:0043022|GO:0003743|	GO:0042256|GO:0042273|
GN005462.1	sp|K1RLT5|K1RLT5_CRAGI	0.0e+00	1236.9	96.14%	75.16%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN005463.1	sp|K1R2H1|K1R2H1_CRAGI	0.0e+00	1302.3	99.42%	76.17%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN005464.1	sp|K1PCM2|K1PCM2_CRAGI	1.4e-131	474.9	100.00%	66.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005465.1	sp|K1P0H4|K1P0H4_CRAGI	1.1e-53	216.1	61.49%	54.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005466.1	sp|K1QRR4|K1QRR4_CRAGI	3.6e-113	413.7	72.73%	81.47%	ADP-ribose pyrophosphatase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047631|
GN005467.1	sp|K1QVJ8|K1QVJ8_CRAGI	2.0e-17	94.4	41.18%	74.55%	Piwi-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003676|	GO:0031047|
GN005468.1	sp|K1QVJ8|K1QVJ8_CRAGI	1.7e-20	103.6	82.61%	82.14%	Piwi-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003676|	GO:0031047|
GN005469.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	3.9e-84	317.4	84.25%	63.52%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN005470.1	sp|K1QVJ8|K1QVJ8_CRAGI	2.1e-41	173.3	97.59%	95.00%	Piwi-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003676|	GO:0031047|
GN005471.1	sp|K1R7F2|K1R7F2_CRAGI	1.3e-51	207.6	100.00%	88.79%	Piwi-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005472.1	sp|K1QVJ8|K1QVJ8_CRAGI	4.8e-64	249.6	84.39%	78.62%	Piwi-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003676|	GO:0031047|
GN005473.1	sp|K1QVJ8|K1QVJ8_CRAGI	4.0e-24	115.5	100.00%	84.13%	Piwi-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003676|	GO:0031047|
GN005474.1	sp|K1Q4I0|K1Q4I0_CRAGI	8.0e-112	409.5	65.45%	79.12%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005477.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	1.2e-17	95.5	87.85%	36.02%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001394.1	sp|K1QDI6|K1QDI6_CRAGI	9.7e-69	267.7	28.14%	48.75%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN001394.1	sp|K1QDI6|K1QDI6_CRAGI	5.3e-14	85.9	10.12%	40.40%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN005478.1	sp|K1PJ05|K1PJ05_CRAGI	0.0e+00	1105.1	97.06%	54.75%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN001395.1	sp|K1QW30|K1QW30_CRAGI	7.4e-205	719.2	71.17%	85.68%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN005479.1	sp|K1QR19|K1QR19_CRAGI	3.3e-112	410.2	100.00%	76.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005481.1	sp|K1PXY4|K1PXY4_CRAGI	1.9e-73	281.2	92.00%	63.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005486.1	sp|K1Q4X5|K1Q4X5_CRAGI	6.1e-153	546.2	97.40%	74.15%	Iroquois-class homeodomain protein IRX-6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN005487.1	sp|K1PZN3|K1PZN3_CRAGI	1.0e-38	165.2	82.31%	71.67%	Protein G7c;OS=Crassostrea;PE=4;SV=1
GN000926.1	sp|K1PEN9|K1PEN9_CRAGI	1.4e-226	790.8	98.35%	87.26%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0008810|GO:0030247|	GO:0030245|
GN001396.1	sp|K1R7C1|K1R7C1_CRAGI	3.3e-66	256.9	99.47%	65.05%	Neurocalcin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN005488.1	sp|K1QEB0|K1QEB0_CRAGI	1.3e-75	288.1	85.79%	79.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005489.1	sp|K1PSA2|K1PSA2_CRAGI	6.2e-30	136.0	62.32%	87.06%	Leucine-rich repeat and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN005490.1	sp|A0A0K0PUU4|A0A0K0PUU4_PLADU	9.6e-73	279.6	81.46%	46.65%	Orphan G-protein coupled receptor 28;OS=Platynereis;PE=2;SV=1	GO:0016021|	GO:0004930|
GN001397.1	sp|K1QNC6|K1QNC6_CRAGI	3.5e-137	493.4	92.72%	84.25%	Aquaporin-4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN005491.1	sp|K1PSA2|K1PSA2_CRAGI	3.3e-42	177.2	73.54%	72.46%	Leucine-rich repeat and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN005492.1	sp|K1R0B5|K1R0B5_CRAGI	5.8e-51	206.5	100.00%	55.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005494.1	sp|A0A210Q9Y7|A0A210Q9Y7_MIZYE	5.2e-86	324.3	60.58%	43.09%	Jerky protein homolog-like;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN005495.1	sp|K1QN19|K1QN19_CRAGI	5.1e-119	433.3	86.06%	65.00%	Tyrosine-protein kinase Abl;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005496.1	sp|K1QN19|K1QN19_CRAGI	6.2e-208	730.7	50.37%	50.99%	Tyrosine-protein kinase Abl;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005497.1	sp|K1RPU6|K1RPU6_CRAGI	6.7e-65	252.3	92.36%	84.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005498.1	sp|K1P6C4|K1P6C4_CRAGI	1.3e-63	250.4	41.07%	39.88%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN005500.1	sp|A0A210Q934|A0A210Q934_MIZYE	1.4e-84	319.7	99.24%	24.54%	Ankyrin-1;OS=Mizuhopecten;PE=4;SV=1
GN001398.1	sp|K1QES5|K1QES5_CRAGI	2.1e-101	374.4	100.00%	63.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005501.1	sp|K1P6C4|K1P6C4_CRAGI	2.0e-127	462.6	52.32%	46.29%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN005503.1	sp|K1QNJ7|K1QNJ7_CRAGI	1.7e-76	292.0	73.96%	57.20%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0005975|
GN005504.1	sp|K1QY88|K1QY88_CRAGI	5.6e-76	290.0	99.67%	52.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN005505.1	sp|K1QY88|K1QY88_CRAGI	1.6e-45	188.3	74.54%	62.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN005506.1	sp|A0A2B4R6Q7|A0A2B4R6Q7_STYPI	3.1e-10	69.7	65.38%	52.00%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|GO:0008270|
GN005507.1	sp|A0A1S3I117|A0A1S3I117_LINUN	2.1e-51	208.0	93.24%	49.28%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN001399.1	sp|K1QES5|K1QES5_CRAGI	1.5e-99	368.2	93.62%	65.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005508.1	sp|K1QZ85|K1QZ85_CRAGI	2.3e-214	751.5	77.97%	51.60%	Pleckstrin-like protein domain-containing family M member 3;OS=Crassostrea;PE=4;SV=1
GN005509.1	sp|A0A210PL30|A0A210PL30_MIZYE	3.2e-192	677.2	90.08%	66.36%	ATP-dependent RNA helicase DDX19A;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN005511.1	sp|K1QDF2|K1QDF2_CRAGI	6.1e-43	178.7	95.05%	89.47%	DnaJ-like protein subfamily C member 16;OS=Crassostrea;PE=4;SV=1
GN005512.1	sp|K1QDF2|K1QDF2_CRAGI	4.3e-125	453.4	95.00%	70.50%	DnaJ-like protein subfamily C member 16;OS=Crassostrea;PE=4;SV=1
GN001400.1	sp|K1RM00|K1RM00_CRAGI	3.0e-112	410.6	96.55%	69.90%	Aquaporin-4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN005513.1	sp|K1Q933|K1Q933_CRAGI	1.6e-82	310.8	100.00%	91.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005514.1	sp|K1Q6B9|K1Q6B9_CRAGI	1.8e-14	83.6	52.94%	97.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005515.1	sp|K1PYV9|K1PYV9_CRAGI	2.8e-20	103.2	100.00%	89.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005516.1	sp|K1PLG1|K1PLG1_CRAGI	7.2e-17	93.6	18.09%	96.00%	Putative ribosomal RNA methyltransferase NOP2;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0008757|	GO:0006364|
GN005522.1	sp|K1PE19|K1PE19_CRAGI	8.8e-33	145.6	96.79%	46.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001402.1	sp|K1R2P3|K1R2P3_CRAGI	1.7e-139	501.5	71.08%	85.57%	VAC14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070772|	GO:0006661|
GN005524.1	sp|A0A210R1E9|A0A210R1E9_MIZYE	3.3e-23	113.6	98.54%	44.03%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005525.1	sp|V4AE92|V4AE92_LOTGI	1.5e-88	332.0	86.00%	51.67%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN001403.1	sp|K1R2P3|K1R2P3_CRAGI	5.9e-60	236.9	95.61%	50.33%	VAC14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070772|	GO:0006661|
GN005531.1	sp|K1PQQ5|K1PQQ5_CRAGI	5.5e-20	103.2	67.06%	49.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005534.1	sp|K1PPP8|K1PPP8_CRAGI	0.0e+00	2229.9	100.00%	90.38%	Vigilin;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN001404.1	sp|A0A1X7V8P5|A0A1X7V8P5_AMPQE	4.1e-30	138.3	65.36%	28.13%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003676|
GN005535.1	sp|A0A210QD97|A0A210QD97_MIZYE	2.8e-42	177.6	81.99%	45.09%	WAP four-disulfide core domain protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005576|	GO:0030414|
GN005536.1	sp|A0A2T7PT61|A0A2T7PT61_POMCA	1.7e-10	71.6	87.12%	34.62%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN005537.1	sp|A0A210PV03|A0A210PV03_MIZYE	2.1e-17	95.9	97.51%	27.23%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005538.1	sp|A0A0L8G5W9|A0A0L8G5W9_OCTBM	3.3e-09	67.0	81.25%	34.82%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0016021|
GN005539.1	sp|K1RYB1|K1RYB1_CRAGI	1.9e-121	441.0	97.92%	73.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005540.1	sp|K1R8Q3|K1R8Q3_CRAGI	4.9e-67	259.2	99.29%	96.38%	Golgi SNAP receptor complex member 1;OS=Crassostrea;PE=3;SV=1	GO:0005801|GO:0000139|GO:0016021|	GO:0006888|GO:0015031|
GN005541.1	sp|A0A210Q0I0|A0A210Q0I0_MIZYE	1.4e-192	678.3	93.02%	60.30%	Uncharacterized protein;OS=Mizuhopecten;PE=3;SV=1
GN005542.1	sp|K1QJQ0|K1QJQ0_CRAGI	4.2e-22	109.4	88.30%	80.49%	IQ domain-containing protein D;OS=Crassostrea;PE=4;SV=1
GN001405.1	sp|K1R2P3|K1R2P3_CRAGI	1.8e-34	150.6	83.65%	88.37%	VAC14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070772|	GO:0006661|
GN005543.1	sp|K1QJQ0|K1QJQ0_CRAGI	6.3e-144	516.2	97.72%	83.85%	IQ domain-containing protein D;OS=Crassostrea;PE=4;SV=1
GN005544.1	sp|K1QB68|K1QB68_CRAGI	3.8e-53	213.4	85.06%	67.32%	dCTP pyrophosphatase 1;OS=Crassostrea;PE=4;SV=1	GO:0047429|	GO:0009143|
GN005545.1	sp|K1QB68|K1QB68_CRAGI	2.1e-45	187.6	86.59%	63.12%	dCTP pyrophosphatase 1;OS=Crassostrea;PE=4;SV=1	GO:0047429|	GO:0009143|
GN005546.1	sp|K1QJQ9|K1QJQ9_CRAGI	8.6e-67	258.5	99.31%	85.92%	Fatty acid-binding protein, heart;OS=Crassostrea;PE=3;SV=1	GO:0008289|
GN005548.1	sp|K1PY19|K1PY19_CRAGI	1.8e-166	590.9	98.58%	80.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005549.1	sp|K1QDI5|K1QDI5_CRAGI	1.6e-160	571.2	92.20%	85.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005550.1	sp|K1PY17|K1PY17_CRAGI	2.4e-14	83.6	89.13%	51.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005551.1	sp|K1R5C8|K1R5C8_CRAGI	0.0e+00	1523.1	98.39%	84.18%	Solute carrier family 12 member 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006811|GO:0055085|
GN001406.1	sp|K1QEJ3|K1QEJ3_CRAGI	3.9e-64	250.4	79.34%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006302|
GN005552.1	sp|K1R5C4|K1R5C4_CRAGI	0.0e+00	1375.5	100.00%	70.70%	Golgin subfamily A member 3;OS=Crassostrea;PE=4;SV=1	GO:0090498|	GO:0007283|
GN005553.1	sp|K1QDI0|K1QDI0_CRAGI	3.5e-177	626.7	100.00%	76.76%	Transmembrane protein 49;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005554.1	sp|K1Q5E6|K1Q5E6_CRAGI	2.9e-211	740.0	100.00%	91.73%	Forkhead box protein J3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN005556.1	sp|K1QBZ7|K1QBZ7_CRAGI	2.6e-22	110.5	48.06%	80.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005560.1	sp|K1R7Y8|K1R7Y8_CRAGI	6.1e-194	682.6	89.33%	80.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005562.1	sp|K1R1N2|K1R1N2_CRAGI	5.7e-30	135.6	79.38%	78.95%	S-crystallin SL11;OS=Crassostrea;PE=4;SV=1
GN005563.1	sp|K1QS71|K1QS71_CRAGI	5.5e-20	102.4	95.00%	51.06%	Glutathione S-transferase;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN005567.1	sp|A0A2B4RK55|A0A2B4RK55_STYPI	3.7e-80	304.7	89.98%	40.59%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN005568.1	sp|K1R861|K1R861_CRAGI	7.1e-80	302.8	99.61%	47.92%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN005569.1	sp|K1REF7|K1REF7_CRAGI	1.0e-53	215.7	91.38%	51.89%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN005570.1	sp|K1REF7|K1REF7_CRAGI	6.0e-250	869.4	97.17%	55.50%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN001407.1	sp|K1R7L1|K1R7L1_CRAGI	0.0e+00	1265.0	100.00%	80.76%	SET and MYND domain-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN005571.1	sp|K1PZ18|K1PZ18_CRAGI	1.6e-25	122.1	47.66%	51.79%	Multiple epidermal growth factor-like domains 11;OS=Crassostrea;PE=4;SV=1
GN005572.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	1.8e-14	85.5	65.27%	31.98%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005573.1	sp|K1Q922|K1Q922_CRAGI	3.5e-221	773.5	91.38%	68.66%	Solute carrier family 13 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030170|GO:0005215|	GO:0006520|GO:0006814|GO:0055085|
GN005574.1	sp|A0A0U5AKI6|A0A0U5AKI6_CRAGI	3.3e-131	473.4	97.50%	83.82%	Serine racemase;OS=Crassostrea;PE=2;SV=1	GO:0030170|	GO:0006520|
GN005575.1	sp|K1QPZ3|K1QPZ3_CRAGI	1.7e-157	561.6	98.29%	65.77%	Protein phosphatase 1E;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN005576.1	sp|K1QPZ3|K1QPZ3_CRAGI	1.5e-165	587.8	95.32%	84.62%	Protein phosphatase 1E;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN005577.1	sp|K1Q919|K1Q919_CRAGI	5.5e-106	389.8	91.22%	69.39%	Protein deadpan;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN001408.1	sp|K1RE34|K1RE34_CRAGI	3.5e-161	574.3	99.16%	50.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005578.1	sp|K1PXX6|K1PXX6_CRAGI	4.5e-30	138.3	89.00%	26.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0002218|GO:0032481|GO:0007165|
GN005580.1	sp|W4ZKT7|W4ZKT7_STRPU	1.3e-13	83.6	47.44%	32.76%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN005582.1	sp|K1RLN7|K1RLN7_CRAGI	1.7e-21	109.0	87.46%	30.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001409.1	sp|K1RE34|K1RE34_CRAGI	8.5e-71	271.9	95.71%	79.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005586.1	sp|K1R7S0|K1R7S0_CRAGI	1.3e-279	968.0	98.18%	68.44%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0004842|GO:0008270|
GN005587.1	sp|K1QMF9|K1QMF9_CRAGI	1.2e-74	285.8	92.77%	42.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN005588.1	sp|K1QMF9|K1QMF9_CRAGI	3.0e-129	467.2	100.00%	58.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN005589.1	sp|K1PFZ5|K1PFZ5_CRAGI	1.2e-63	249.2	66.28%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN001410.1	sp|K1RXA8|K1RXA8_CRAGI	1.0e-107	395.2	100.00%	77.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005594.1	sp|K1PRB2|K1PRB2_CRAGI	5.5e-235	818.9	100.00%	84.85%	O-acyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0004144|	GO:0019432|
GN005595.1	sp|K1PYJ1|K1PYJ1_CRAGI	2.6e-166	590.5	89.14%	82.67%	TBC1 domain family member 20;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005596.1	sp|A0A210QMB4|A0A210QMB4_MIZYE	2.1e-93	348.2	92.43%	50.88%	HAUS augmin-like complex subunit 4;OS=Mizuhopecten;PE=4;SV=1	GO:0070652|	GO:0007098|GO:0051225|
GN005597.1	sp|K1PJJ5|K1PJJ5_CRAGI	0.0e+00	1179.5	95.38%	88.48%	Conserved oligomeric Golgi complex subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0017119|	GO:0006886|
GN001411.1	sp|W5XLJ9|W5XLJ9_MYTGA	5.7e-15	87.0	100.00%	34.57%	Receptor-interacting protein kinase-like protein;OS=Mytilus;PE=2;SV=1	GO:0016301|	GO:0007165|
GN005598.1	sp|A0A1I8J146|A0A1I8J146_9PLAT	3.5e-19	99.8	76.53%	58.11%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN005599.1	sp|W4ZF66|W4ZF66_STRPU	2.3e-24	117.5	87.32%	51.61%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN005601.1	sp|K1PXV6|K1PXV6_CRAGI	2.9e-123	446.8	100.00%	87.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005602.1	sp|K1QCH5|K1QCH5_CRAGI	1.5e-98	365.5	71.13%	72.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005603.1	sp|A0A210Q6H6|A0A210Q6H6_MIZYE	5.9e-91	339.3	88.24%	80.51%	T-box transcription factor TBX2-B;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN001412.1	sp|K1PHZ1|K1PHZ1_CRAGI	2.1e-77	295.0	84.38%	51.13%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN005605.1	sp|K1PXU8|K1PXU8_CRAGI	2.6e-296	1023.1	99.53%	86.03%	T-box transcription factor TBX2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN005606.1	sp|K1PQB1|K1PQB1_CRAGI	0.0e+00	1506.5	98.16%	86.89%	Breast carcinoma-amplified sequence 3-like protein;OS=Crassostrea;PE=4;SV=1
GN005608.1	sp|A0A2G8K3T4|A0A2G8K3T4_STIJA	2.1e-73	281.6	90.60%	45.64%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0008270|
GN005609.1	sp|A0A2G8JZY6|A0A2G8JZY6_STIJA	1.6e-19	101.7	68.05%	42.02%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN005610.1	sp|K1PT97|K1PT97_CRAGI	1.5e-11	75.5	95.22%	27.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005611.1	sp|K1S3Y9|K1S3Y9_CRAGI	1.4e-52	212.2	97.93%	43.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005612.1	sp|K1QBH6|K1QBH6_CRAGI	3.2e-45	187.2	67.37%	71.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001413.1	sp|K1QRN6|K1QRN6_CRAGI	5.7e-153	546.2	97.21%	75.92%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005614.1	sp|K1QN93|K1QN93_CRAGI	8.0e-34	148.7	93.33%	69.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005615.1	sp|K1R8P2|K1R8P2_CRAGI	1.8e-130	471.1	100.00%	83.33%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN005617.1	sp|K1QC54|K1QC54_CRAGI	6.7e-09	66.2	26.62%	80.00%	Atonal-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN005618.1	sp|K1PIS2|K1PIS2_CRAGI	2.7e-27	127.9	62.33%	46.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005619.1	sp|K1Q4N2|K1Q4N2_CRAGI	3.5e-124	450.7	99.76%	57.87%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005620.1	sp|K1QRM1|K1QRM1_CRAGI	0.0e+00	1528.5	100.00%	92.71%	Nuclear pore protein;OS=Crassostrea;PE=3;SV=1	GO:0016020|GO:0005643|	GO:0017056|	GO:0051028|GO:0015031|
GN005621.1	sp|K1QK42|K1QK42_CRAGI	2.7e-232	810.1	99.61%	79.06%	tRNA-dihydrouridine synthase 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0050660|GO:0017150|
GN005622.1	sp|K1QC49|K1QC49_CRAGI	1.2e-91	341.3	98.88%	94.29%	Phosphatidylinositol glycan anchor biosynthesis class U protein;OS=Crassostrea;PE=4;SV=1	GO:0042765|	GO:0016255|
GN005623.1	sp|K1Q4M8|K1Q4M8_CRAGI	3.3e-88	330.1	100.00%	77.50%	Dual specificity protein phosphatase 3;OS=Crassostrea;PE=3;SV=1	GO:0004725|GO:0008138|
GN005624.1	sp|A0A2T7NHL0|A0A2T7NHL0_POMCA	3.6e-27	128.3	79.90%	28.44%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN001414.1	sp|K1R137|K1R137_CRAGI	1.5e-158	564.7	97.86%	79.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005626.1	sp|K1PTI1|K1PTI1_CRAGI	1.2e-255	887.9	99.83%	73.22%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN005628.1	sp|K1PE80|K1PE80_CRAGI	5.6e-93	346.7	99.40%	53.15%	Uncharacterized protein C3orf38-like protein;OS=Crassostrea;PE=4;SV=1
GN005629.1	sp|K1QKE2|K1QKE2_CRAGI	6.1e-34	149.1	89.92%	67.92%	Ganglioside-induced differentiation-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005632.1	sp|K1P9Y6|K1P9Y6_CRAGI	6.3e-35	152.1	100.00%	75.00%	Tyrosine-protein kinase PR2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004713|
GN001415.1	sp|K1R7L3|K1R7L3_CRAGI	4.1e-22	110.5	42.65%	60.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005633.1	sp|A0A2T7PR27|A0A2T7PR27_POMCA	5.1e-28	132.1	57.63%	25.97%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN005634.1	sp|A0A2B4RUA7|A0A2B4RUA7_STYPI	6.9e-29	133.3	74.37%	38.20%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|
GN005636.1	sp|K1Q720|K1Q720_CRAGI	2.8e-14	82.8	95.24%	59.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005639.1	sp|C3ZG36|C3ZG36_BRAFL	4.8e-60	237.7	74.66%	39.76%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0015074|GO:0006310|GO:0009299|
GN005640.1	sp|K1QI60|K1QI60_CRAGI	1.5e-141	508.1	100.00%	69.32%	D-aspartate oxidase;OS=Crassostrea;PE=4;SV=1	GO:0003884|GO:0071949|	GO:0046416|
GN005643.1	sp|K1QPS1|K1QPS1_CRAGI	1.3e-28	130.6	100.00%	93.94%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|	GO:0006471|
GN005644.1	sp|A0A210QN48|A0A210QN48_MIZYE	1.7e-166	592.0	74.19%	55.95%	Poly [ADP-ribose] polymerase;OS=Mizuhopecten;PE=4;SV=1	GO:0003950|GO:0008270|	GO:0006471|
GN005645.1	sp|K1RPE5|K1RPE5_CRAGI	2.6e-64	251.1	100.00%	49.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005646.1	sp|K1Q7N1|K1Q7N1_CRAGI	6.7e-50	203.4	58.98%	54.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005648.1	sp|K1RRD7|K1RRD7_CRAGI	6.6e-123	446.4	69.63%	62.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005649.1	sp|K1QDG0|K1QDG0_CRAGI	2.6e-42	177.2	91.39%	66.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005650.1	sp|K1QDG0|K1QDG0_CRAGI	3.7e-95	354.0	84.70%	65.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005651.1	sp|K1QTH6|K1QTH6_CRAGI	2.3e-22	110.9	80.79%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN005652.1	sp|K1Q5C2|K1Q5C2_CRAGI	1.2e-35	154.8	65.35%	87.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005653.1	sp|K1Q5C2|K1Q5C2_CRAGI	3.2e-141	506.9	100.00%	81.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005655.1	sp|K1PXZ7|K1PXZ7_CRAGI	1.1e-130	472.2	98.39%	53.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005656.1	sp|K1Q6H4|K1Q6H4_CRAGI	9.4e-66	256.1	97.48%	45.66%	Excitatory amino acid transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015293|
GN005657.1	sp|A0A210PWY2|A0A210PWY2_MIZYE	2.6e-121	440.7	99.34%	69.33%	Cell division control protein 45-like;OS=Mizuhopecten;PE=4;SV=1	GO:0051301|GO:0006270|
GN005658.1	sp|K1Q4J8|K1Q4J8_CRAGI	9.2e-18	95.1	94.29%	46.94%	Proton myo-inositol cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN005659.1	sp|K1QUK1|K1QUK1_CRAGI	2.2e-72	277.3	94.86%	82.18%	Ubiquitin fusion degradation protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0006511|
GN005660.1	sp|K1R1E4|K1R1E4_CRAGI	9.7e-16	87.8	92.75%	76.19%	Serine/threonine-protein kinase Chk2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005661.1	sp|K1R1E4|K1R1E4_CRAGI	4.7e-95	352.8	93.53%	88.24%	Serine/threonine-protein kinase Chk2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005662.1	sp|K1R1E4|K1R1E4_CRAGI	5.4e-11	72.4	55.06%	74.00%	Serine/threonine-protein kinase Chk2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN005664.1	sp|K1QKQ7|K1QKQ7_CRAGI	0.0e+00	1904.0	98.96%	84.56%	Endo-1,3(4)-beta-glucanase 1;OS=Crassostrea;PE=4;SV=1	GO:0052861|
GN005665.1	sp|K1QTY0|K1QTY0_CRAGI	6.2e-25	119.4	85.92%	61.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005666.1	sp|K1QKQ7|K1QKQ7_CRAGI	4.5e-81	307.4	65.67%	58.27%	Endo-1,3(4)-beta-glucanase 1;OS=Crassostrea;PE=4;SV=1	GO:0052861|
GN005667.1	sp|K1Q358|K1Q358_CRAGI	1.5e-26	124.4	61.95%	89.86%	60S acidic ribosomal protein P2;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006414|
GN005668.1	sp|A0A210Q101|A0A210Q101_MIZYE	9.6e-47	191.8	100.00%	69.78%	Mediator of RNA polymerase II transcription subunit 21;OS=Mizuhopecten;PE=4;SV=1	GO:0016592|
GN005669.1	sp|K1PNR3|K1PNR3_CRAGI	0.0e+00	3200.2	100.00%	96.90%	Clathrin heavy chain;OS=Crassostrea;PE=3;SV=1	GO:0030132|GO:0030130|GO:0071439|	GO:0032051|GO:0005198|	GO:0048268|GO:0006886|GO:0016192|
GN005671.1	sp|K1RHB3|K1RHB3_CRAGI	2.5e-162	577.0	99.69%	89.88%	Phosphoenolpyruvate phosphomutase;OS=Crassostrea;PE=4;SV=1	GO:0050188|
GN005672.1	sp|K1QX28|K1QX28_CRAGI	8.8e-75	285.8	96.00%	64.58%	Solute carrier family 13 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN005673.1	sp|K1QQW3|K1QQW3_CRAGI	2.0e-59	234.2	88.10%	85.71%	Solute carrier family 13 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN005674.1	sp|K1QA01|K1QA01_CRAGI	0.0e+00	1151.7	100.00%	72.51%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005675.1	sp|A0A1X7U934|A0A1X7U934_AMPQE	3.0e-35	155.2	67.62%	32.39%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN005676.1	sp|K1RHA7|K1RHA7_CRAGI	1.6e-260	904.0	98.81%	73.84%	Aspartyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004812|GO:0005524|GO:0003676|	GO:0006418|
GN005677.1	sp|V4A0N7|V4A0N7_LOTGI	2.8e-15	88.6	86.92%	28.52%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001417.1	sp|K1PKF0|K1PKF0_CRAGI	9.9e-29	133.3	48.24%	46.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005678.1	sp|K1QX22|K1QX22_CRAGI	7.4e-184	649.8	99.12%	51.36%	4-hydroxyphenylpyruvate dioxygenase;OS=Crassostrea;PE=4;SV=1	GO:0003868|GO:0005524|GO:0003678|	GO:0009072|GO:0006260|
GN005680.1	sp|K1QX22|K1QX22_CRAGI	5.7e-87	326.6	68.03%	72.35%	4-hydroxyphenylpyruvate dioxygenase;OS=Crassostrea;PE=4;SV=1	GO:0003868|GO:0005524|GO:0003678|	GO:0009072|GO:0006260|
GN005684.1	sp|K1QEB9|K1QEB9_CRAGI	2.3e-133	481.1	95.54%	61.65%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN005685.1	sp|K1QX18|K1QX18_CRAGI	2.3e-128	464.5	82.68%	70.29%	E3 ubiquitin-protein ligase CHFR;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN005686.1	sp|K1QX18|K1QX18_CRAGI	2.0e-132	478.4	100.00%	47.03%	E3 ubiquitin-protein ligase CHFR;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN005687.1	sp|K1P3B0|K1P3B0_CRAGI	1.6e-191	674.5	95.11%	71.08%	Alkaline phosphatase, tissue-nonspecific isozyme;OS=Crassostrea;PE=3;SV=1	GO:0016791|
GN005689.1	sp|K1PH90|K1PH90_CRAGI	3.3e-35	152.9	97.85%	83.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005690.1	sp|K1P9Y6|K1P9Y6_CRAGI	0.0e+00	2438.3	100.00%	85.58%	Tyrosine-protein kinase PR2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004713|
GN001419.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	1.5e-88	332.0	88.70%	64.59%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN005691.1	sp|K1PH85|K1PH85_CRAGI	1.7e-217	762.3	99.31%	44.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005692.1	sp|K1P9Y2|K1P9Y2_CRAGI	2.3e-41	173.7	94.02%	82.57%	Activated CDC42 kinase 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004713|
GN005693.1	sp|K1P392|K1P392_CRAGI	2.5e-142	510.8	100.00%	74.87%	Activated CDC42 kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN005694.1	sp|K1Q9X0|K1Q9X0_CRAGI	3.9e-70	270.0	100.00%	88.66%	Ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1
GN005695.1	sp|K1PP43|K1PP43_CRAGI	3.4e-51	207.6	70.25%	67.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0016491|
GN005696.1	sp|K1R8Q9|K1R8Q9_CRAGI	3.1e-48	196.4	100.00%	84.40%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN005698.1	sp|K1Q7G7|K1Q7G7_CRAGI	0.0e+00	3168.6	74.90%	72.80%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN001420.1	sp|K1RNK4|K1RNK4_CRAGI	4.4e-35	153.3	97.52%	48.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005700.1	sp|K1QNM6|K1QNM6_CRAGI	5.0e-50	202.6	100.00%	73.23%	IL17-5;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0005125|
GN005701.1	sp|K1QFK5|K1QFK5_CRAGI	6.1e-26	122.9	96.77%	46.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001421.1	sp|A0A0A9WBJ7|A0A0A9WBJ7_LYGHE	2.2e-34	152.1	64.17%	38.46%	Exonuclease;OS=Lygus;PE=4;SV=1	GO:0004527|
GN005708.1	sp|K1RAB0|K1RAB0_CRAGI	7.2e-17	91.3	100.00%	78.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005709.1	sp|K1R020|K1R020_CRAGI	1.3e-33	147.9	98.18%	65.74%	Cytochrome P450 4F22;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN005710.1	sp|K1S5M9|K1S5M9_CRAGI	3.3e-15	86.3	92.68%	55.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001422.1	sp|K1QBS1|K1QBS1_CRAGI	2.0e-88	331.6	99.45%	50.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005715.1	sp|A0A2B4RYI2|A0A2B4RYI2_STYPI	1.1e-25	122.5	92.20%	35.48%	THAP domain-containing protein 11;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN005718.1	sp|V4AHI7|V4AHI7_LOTGI	1.0e-13	81.6	88.00%	53.41%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN005721.1	sp|K1PH91|K1PH91_CRAGI	4.9e-28	131.3	25.40%	51.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005725.1	sp|A0A3M6UWC0|A0A3M6UWC0_9CNID	1.2e-92	345.9	98.82%	45.31%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN005727.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	2.5e-121	441.4	97.77%	45.31%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN005728.1	sp|K1QF23|K1QF23_CRAGI	0.0e+00	1573.1	100.00%	81.96%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN005730.1	sp|K1QNG9|K1QNG9_CRAGI	7.7e-46	189.1	58.38%	93.00%	60S ribosomal protein L23a;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN005731.1	sp|V3ZWK8|V3ZWK8_LOTGI	1.2e-16	90.5	100.00%	72.22%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005525|GO:0003924|
GN005732.1	sp|V3ZWK8|V3ZWK8_LOTGI	8.0e-24	115.2	95.92%	58.51%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005525|GO:0003924|
GN005733.1	sp|R7UT05|R7UT05_CAPTE	2.1e-31	140.6	84.48%	62.89%	Uncharacterized protein;OS=Capitella;PE=4;SV=1	GO:0005623|	GO:0045454|
GN005734.1	sp|K1PT59|K1PT59_CRAGI	1.3e-49	201.1	90.35%	86.27%	Nucleoredoxin;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN005735.1	sp|K1QPZ6|K1QPZ6_CRAGI	1.7e-17	94.7	70.27%	52.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005736.1	sp|A0A2B4STN1|A0A2B4STN1_STYPI	3.8e-16	90.1	92.65%	35.20%	Putative RNA-directed DNA polymerase from transposon X-element;OS=Stylophora;PE=4;SV=1	GO:0003964|
GN005738.1	sp|K1R3B2|K1R3B2_CRAGI	6.5e-13	78.6	55.26%	82.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005740.1	sp|K1RNC7|K1RNC7_CRAGI	7.7e-145	519.2	97.07%	84.63%	Thyrotropin-releasing hormone receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005742.1	sp|K1QV93|K1QV93_CRAGI	9.7e-54	215.7	78.08%	63.37%	Low-density lipoprotein receptor-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005743.1	sp|K1QV93|K1QV93_CRAGI	1.5e-49	201.1	98.45%	75.40%	Low-density lipoprotein receptor-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001423.1	sp|K1R6Q7|K1R6Q7_CRAGI	2.2e-264	917.5	60.50%	92.93%	DNA topoisomerase I;OS=Crassostrea;PE=3;SV=1	GO:0005694|	GO:0003677|GO:0003917|	GO:0006265|
GN005744.1	sp|K1QV93|K1QV93_CRAGI	2.6e-54	217.2	83.43%	68.57%	Low-density lipoprotein receptor-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005745.1	sp|K1PGR2|K1PGR2_CRAGI	0.0e+00	1075.5	87.69%	63.98%	G patch domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003723|	GO:0006397|
GN005746.1	sp|K1QXN5|K1QXN5_CRAGI	0.0e+00	1157.9	96.10%	75.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005747.1	sp|U5PZB3|U5PZB3_CRAGI	5.8e-97	360.1	99.00%	47.36%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN005748.1	sp|A0A1S3I117|A0A1S3I117_LINUN	3.9e-29	134.0	95.59%	31.01%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN005750.1	sp|K1R417|K1R417_CRAGI	1.3e-10	70.9	94.44%	53.73%	Pumilio domain-containing protein C14orf21;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN005751.1	sp|A0A2B4R3C4|A0A2B4R3C4_STYPI	1.8e-81	308.5	98.09%	42.24%	Tetratricopeptide repeat protein 38;OS=Stylophora;PE=4;SV=1	GO:0008270|
GN005754.1	sp|K1R417|K1R417_CRAGI	9.4e-221	771.9	98.12%	61.64%	Pumilio domain-containing protein C14orf21;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN005757.1	sp|K1QH24|K1QH24_CRAGI	1.4e-34	152.1	55.95%	57.81%	DnaJ-like protein subfamily C member 30;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005758.1	sp|K1QEE2|K1QEE2_CRAGI	0.0e+00	1143.3	93.72%	81.97%	Integrator complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0032039|	GO:0016180|
GN000973.1	sp|A0A210PRN3|A0A210PRN3_MIZYE	0.0e+00	1086.2	99.17%	71.55%	Acyl-coenzyme A oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0005777|	GO:0003997|GO:0071949|	GO:0006635|
GN001425.1	sp|K1QEX3|K1QEX3_CRAGI	9.5e-24	115.5	45.03%	80.60%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005759.1	sp|K1QEE2|K1QEE2_CRAGI	4.1e-36	156.0	93.81%	87.78%	Integrator complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0032039|	GO:0016180|
GN005760.1	sp|K1QRW0|K1QRW0_CRAGI	3.0e-37	161.0	55.41%	62.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005761.1	sp|K1QRW0|K1QRW0_CRAGI	1.0e-39	169.5	45.71%	65.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005763.1	sp|K1QN06|K1QN06_CRAGI	1.1e-275	956.4	72.34%	44.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN005764.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN005767.1	sp|K1R2B5|K1R2B5_CRAGI	6.4e-82	308.9	100.00%	88.76%	T-box transcription factor TBX1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN005768.1	sp|K1R2B5|K1R2B5_CRAGI	3.0e-86	323.2	99.34%	100.00%	T-box transcription factor TBX1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN001426.1	sp|K1QEX3|K1QEX3_CRAGI	7.8e-143	512.3	88.50%	77.59%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005769.1	sp|K1R2B5|K1R2B5_CRAGI	1.0e-47	194.9	98.41%	78.05%	T-box transcription factor TBX1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN005770.1	sp|K1RLP6|K1RLP6_CRAGI	0.0e+00	1342.0	100.00%	81.49%	Oxysterol-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN005771.1	sp|K1QN10|K1QN10_CRAGI	2.4e-94	351.3	98.89%	51.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005773.1	sp|K1R4K0|K1R4K0_CRAGI	2.4e-76	291.6	96.56%	47.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005775.1	sp|K1RNZ2|K1RNZ2_CRAGI	3.1e-303	1046.6	100.00%	72.48%	Metastasis suppressor protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003779|	GO:0007009|
GN005776.1	sp|K1QH37|K1QH37_CRAGI	1.5e-161	576.6	30.91%	75.10%	RNA-binding protein 12;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN005778.1	sp|K1QQR8|K1QQR8_CRAGI	1.1e-243	848.2	83.17%	84.92%	Meckelin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0036038|	GO:0060271|GO:0010826|
GN001427.1	sp|K1QEX3|K1QEX3_CRAGI	3.7e-47	193.0	96.64%	78.07%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005781.1	sp|K1QAX4|K1QAX4_CRAGI	4.1e-58	229.9	100.00%	66.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005782.1	sp|K1QAX4|K1QAX4_CRAGI	1.6e-09	68.6	95.63%	31.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005783.1	sp|K1PNL5|K1PNL5_CRAGI	3.8e-250	870.2	95.24%	52.11%	Protein IMPACT-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005784.1	sp|K1PNL5|K1PNL5_CRAGI	4.7e-242	843.2	96.26%	52.99%	Protein IMPACT-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN005785.1	sp|K1PNL5|K1PNL5_CRAGI	2.1e-110	404.4	95.83%	63.33%	Protein IMPACT-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001428.1	sp|K1QEX3|K1QEX3_CRAGI	7.1e-96	355.9	90.31%	71.55%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005786.1	sp|K1Q319|K1Q319_CRAGI	5.5e-145	519.2	96.58%	86.48%	Coiled-coil domain-containing protein 90B, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN005788.1	sp|K1Q319|K1Q319_CRAGI	9.3e-65	252.7	74.30%	68.57%	Coiled-coil domain-containing protein 90B, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN005789.1	sp|K1P9M0|K1P9M0_CRAGI	8.5e-25	118.6	94.78%	61.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005790.1	sp|K1QFZ0|K1QFZ0_CRAGI	1.2e-33	149.8	62.90%	35.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005791.1	sp|K1QFZ0|K1QFZ0_CRAGI	1.9e-61	241.1	87.43%	69.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005792.1	sp|A0A2T7NJV8|A0A2T7NJV8_POMCA	8.5e-28	128.3	98.90%	74.16%	Transcription and mRNA export factor ENY2;OS=Pomacea;PE=3;SV=1	GO:0071819|GO:0005643|GO:0000124|GO:0070390|	GO:0003713|	GO:0016578|GO:0006406|GO:0045893|GO:0006368|
GN005793.1	sp|K1QA98|K1QA98_CRAGI	0.0e+00	1766.5	89.40%	91.71%	ATP-dependent RNA helicase A-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003723|
GN005794.1	sp|K1QA98|K1QA98_CRAGI	4.4e-104	382.9	100.00%	89.81%	ATP-dependent RNA helicase A-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003723|
GN001429.1	sp|A0A210QQ94|A0A210QQ94_MIZYE	4.3e-99	368.2	97.77%	29.61%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN005795.1	sp|K1QW41|K1QW41_CRAGI	0.0e+00	1282.3	100.00%	89.78%	Leucine-zipper-like transcriptional regulator 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008094|GO:0046872|GO:0003723|	GO:0006281|
GN005797.1	sp|K1QW41|K1QW41_CRAGI	2.8e-142	510.4	98.45%	81.07%	Leucine-zipper-like transcriptional regulator 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008094|GO:0046872|GO:0003723|	GO:0006281|
GN005798.1	sp|V3ZUX7|V3ZUX7_LOTGI	6.0e-82	309.7	99.25%	60.46%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN005800.1	sp|K1QRH7|K1QRH7_CRAGI	0.0e+00	2538.1	100.00%	86.23%	Nitric oxide synthase, brain;OS=Crassostrea;PE=4;SV=1	GO:0005516|GO:0050660|GO:0010181|GO:0020037|GO:0046872|GO:0050661|GO:0004517|	GO:0006809|
GN005801.1	sp|A0A2G8KTI2|A0A2G8KTI2_STIJA	6.9e-29	132.1	99.06%	53.85%	Putative 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2-like;OS=Stichopus;PE=4;SV=1	GO:0005506|GO:0031418|GO:0016705|
GN005803.1	sp|K1QG74|K1QG74_CRAGI	4.0e-37	160.6	100.00%	47.50%	Acyl-coenzyme A thioesterase 9, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001430.1	sp|K1QEX3|K1QEX3_CRAGI	1.1e-24	117.5	100.00%	82.09%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005804.1	sp|K1PG51|K1PG51_CRAGI	1.2e-36	157.9	83.93%	83.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005805.1	sp|K1PM99|K1PM99_CRAGI	1.2e-26	125.9	81.10%	35.58%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN005810.1	sp|K1PP29|K1PP29_CRAGI	1.2e-235	821.2	97.29%	80.54%	Lipoma-preferred partner-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN001431.1	sp|K1QEX3|K1QEX3_CRAGI	2.3e-120	437.6	91.14%	69.34%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005811.1	sp|K9J9V0|K9J9V0_SCYPA	1.0e-52	211.8	100.00%	63.69%	Eukaryotic translation initiation factor 5A;OS=Scylla;PE=2;SV=1	GO:0043022|GO:0003746|GO:0003743|	GO:0045901|GO:0045905|GO:0006452|
GN005812.1	sp|K1PIZ3|K1PIZ3_CRAGI	1.9e-89	334.7	73.52%	79.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005813.1	sp|K1QA57|K1QA57_CRAGI	1.3e-202	711.1	100.00%	92.91%	Protein pelota homolog;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0004519|GO:0046872|	GO:0070966|GO:0070481|GO:0071025|
GN005816.1	sp|K1QVZ3|K1QVZ3_CRAGI	1.9e-161	573.9	98.31%	89.66%	PR domain zinc finger protein 14;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005817.1	sp|K1RFV9|K1RFV9_CRAGI	0.0e+00	1402.9	94.95%	57.18%	M-phase phosphoprotein 9;OS=Crassostrea;PE=4;SV=1
GN005818.1	sp|K1PR10|K1PR10_CRAGI	4.9e-38	162.9	91.61%	66.15%	Uncharacterized protein C12orf65-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|GO:0003747|
GN005819.1	sp|K1PR10|K1PR10_CRAGI	7.7e-63	245.7	95.81%	63.74%	Uncharacterized protein C12orf65-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|GO:0003747|
GN001432.1	sp|K1QEX3|K1QEX3_CRAGI	6.5e-65	253.4	96.45%	45.70%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005821.1	sp|C3Y2X9|C3Y2X9_BRAFL	3.5e-41	174.1	84.98%	39.39%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN005822.1	sp|K1QL99|K1QL99_CRAGI	0.0e+00	8923.1	100.00%	89.00%	Hydrocephalus-inducing-like protein;OS=Crassostrea;PE=4;SV=1
GN005823.1	sp|K1QTU2|K1QTU2_CRAGI	3.6e-83	313.5	99.13%	79.82%	Slowmo-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005758|
GN005824.1	sp|K1R0N1|K1R0N1_CRAGI	0.0e+00	1163.3	95.65%	56.84%	MOG interacting and ectopic P-granules protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005825.1	sp|K1RK76|K1RK76_CRAGI	5.3e-66	255.8	100.00%	88.24%	Uncharacterized protein C5orf49-like protein;OS=Crassostrea;PE=4;SV=1
GN005826.1	sp|A0A210R2Q9|A0A210R2Q9_MIZYE	5.0e-116	423.3	98.03%	61.47%	RING finger and SPRY domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN001433.1	sp|K1QEX3|K1QEX3_CRAGI	6.9e-62	243.0	94.01%	49.60%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005830.1	sp|A0A210PN63|A0A210PN63_MIZYE	6.0e-44	183.0	89.95%	52.07%	Sorting nexin-20;OS=Mizuhopecten;PE=4;SV=1	GO:0035091|	GO:0015031|
GN005831.1	sp|K1RK79|K1RK79_CRAGI	8.8e-103	380.2	99.85%	64.04%	Zinc finger and BTB domain-containing protein 24;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005832.1	sp|K1QCR0|K1QCR0_CRAGI	0.0e+00	1225.7	94.60%	78.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005833.1	sp|K1QCR0|K1QCR0_CRAGI	6.1e-53	212.6	98.77%	53.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005834.1	sp|K1QEX3|K1QEX3_CRAGI	6.9e-62	243.0	94.01%	49.60%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005835.1	sp|K1QEX3|K1QEX3_CRAGI	6.5e-65	253.4	96.45%	45.70%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005836.1	sp|K1QEX3|K1QEX3_CRAGI	1.9e-178	630.9	93.52%	72.21%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN001434.1	sp|K1QCR0|K1QCR0_CRAGI	0.0e+00	1160.6	100.00%	76.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005837.1	sp|K1PQH5|K1PQH5_CRAGI	1.7e-94	352.8	82.96%	35.66%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN005838.1	sp|K1QEX3|K1QEX3_CRAGI	7.1e-96	355.9	90.31%	71.55%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005839.1	sp|K1QEX3|K1QEX3_CRAGI	5.6e-101	372.9	84.88%	78.44%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005841.1	sp|K1QEX3|K1QEX3_CRAGI	3.3e-24	115.9	100.00%	80.60%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0050660|GO:0005525|GO:0003924|GO:0004499|GO:0050661|	GO:0007165|
GN005843.1	sp|K1R6Q7|K1R6Q7_CRAGI	2.2e-264	917.5	60.50%	92.93%	DNA topoisomerase I;OS=Crassostrea;PE=3;SV=1	GO:0005694|	GO:0003677|GO:0003917|	GO:0006265|
GN005844.1	sp|K1Q6W5|K1Q6W5_CRAGI	0.0e+00	1104.0	82.00%	94.06%	FACT complex subunit spt16;OS=Crassostrea;PE=4;SV=1	GO:0035101|
GN005845.1	sp|A0A2H4FUQ3|A0A2H4FUQ3_CRAHO	2.6e-208	729.9	99.73%	96.99%	Mitogen-activated protein kinase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004707|
GN005846.1	sp|K1QBS1|K1QBS1_CRAGI	2.0e-88	331.6	99.45%	50.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005847.1	sp|K1RNK4|K1RNK4_CRAGI	4.4e-35	153.3	97.52%	48.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005848.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	1.5e-88	332.0	88.70%	64.59%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN005850.1	sp|K1PKF0|K1PKF0_CRAGI	9.9e-29	133.3	48.24%	46.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005852.1	sp|K1R137|K1R137_CRAGI	1.5e-158	564.7	97.86%	79.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN005853.1	sp|K1QRM5|K1QRM5_CRAGI	3.4e-26	125.2	36.89%	50.31%	GTPase SLIP-GC;OS=Crassostrea;PE=4;SV=1
GN001436.1	sp|K1QCR0|K1QCR0_CRAGI	0.0e+00	1167.1	100.00%	75.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005854.1	sp|K1QRM5|K1QRM5_CRAGI	5.8e-217	760.4	93.34%	46.21%	GTPase SLIP-GC;OS=Crassostrea;PE=4;SV=1
GN005855.1	sp|K1QRM5|K1QRM5_CRAGI	2.4e-54	219.9	56.95%	31.23%	GTPase SLIP-GC;OS=Crassostrea;PE=4;SV=1
GN005856.1	sp|A0A210QL72|A0A210QL72_MIZYE	3.3e-18	100.5	4.88%	55.84%	Poly(U)-binding-splicing factor PUF60;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN005857.1	sp|K1QEJ3|K1QEJ3_CRAGI	3.9e-64	250.4	79.34%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006302|
GN005858.1	sp|K1RA72|K1RA72_CRAGI	1.1e-09	68.6	38.21%	57.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005859.1	sp|K1QW23|K1QW23_CRAGI	4.5e-202	711.1	73.56%	62.31%	Protein spire;OS=Crassostrea;PE=4;SV=1	GO:0003779|	GO:0045010|GO:0016192|
GN005860.1	sp|K1R2P3|K1R2P3_CRAGI	1.1e-25	120.9	92.00%	86.76%	VAC14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070772|	GO:0006661|
GN005861.1	sp|A0A1X7V8P5|A0A1X7V8P5_AMPQE	4.1e-30	138.3	65.36%	28.13%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003676|
GN005862.1	sp|A0A0L8HRF1|A0A0L8HRF1_OCTBM	1.0e-48	199.5	81.94%	46.90%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0070772|	GO:0006661|
GN001437.1	sp|K1QLA1|K1QLA1_CRAGI	2.7e-70	270.4	88.07%	88.89%	Serine/threonine-protein phosphatase 4 regulatory subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0030289|	GO:0019888|	GO:0007165|
GN005863.1	sp|K1R2P3|K1R2P3_CRAGI	1.7e-139	501.5	71.08%	85.57%	VAC14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070772|	GO:0006661|
GN005865.1	sp|K1RM00|K1RM00_CRAGI	3.0e-112	410.6	96.55%	69.90%	Aquaporin-4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN005866.1	sp|K1QES5|K1QES5_CRAGI	1.5e-99	368.2	93.62%	65.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005867.1	sp|K1QES5|K1QES5_CRAGI	2.1e-101	374.4	100.00%	63.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005868.1	sp|K1QNC6|K1QNC6_CRAGI	3.5e-137	493.4	92.72%	84.25%	Aquaporin-4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN005869.1	sp|K1QW30|K1QW30_CRAGI	6.5e-208	729.6	64.10%	77.91%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN005870.1	sp|K1Q5H6|K1Q5H6_CRAGI	1.0e-210	738.8	78.83%	90.87%	FACT complex subunit SSRP1;OS=Crassostrea;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0003677|	GO:0006281|GO:0006260|
GN005871.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	3.4e-74	285.4	82.00%	28.81%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN005872.1	sp|A0A2C9KAU5|A0A2C9KAU5_BIOGL	5.7e-13	78.6	79.10%	69.23%	FACT complex subunit SSRP1;OS=Biomphalaria;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0003677|	GO:0006281|GO:0006260|
GN001438.1	sp|K1QLA1|K1QLA1_CRAGI	5.5e-177	626.3	100.00%	67.03%	Serine/threonine-protein phosphatase 4 regulatory subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0030289|	GO:0019888|	GO:0007165|
GN005873.1	sp|A0A210PGM6|A0A210PGM6_MIZYE	1.0e-61	242.7	99.66%	42.90%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN005874.1	sp|K1R5E8|K1R5E8_CRAGI	1.0e-52	212.6	38.60%	92.31%	Calpain-A;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN005875.1	sp|K1R5E8|K1R5E8_CRAGI	2.4e-13	79.7	71.43%	72.73%	Calpain-A;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN005876.1	sp|K1R5F0|K1R5F0_CRAGI	5.9e-132	476.1	94.43%	74.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005877.1	sp|K1R9G8|K1R9G8_CRAGI	2.0e-75	287.7	76.39%	79.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN001439.1	sp|K1QLA1|K1QLA1_CRAGI	4.4e-61	239.6	98.68%	79.87%	Serine/threonine-protein phosphatase 4 regulatory subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0030289|	GO:0019888|	GO:0007165|
GN005880.1	sp|K1PLC5|K1PLC5_CRAGI	6.1e-144	516.9	75.77%	52.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005883.1	sp|K1QD57|K1QD57_CRAGI	1.0e-100	371.7	98.07%	88.61%	Protein phosphatase 1D;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN005884.1	sp|K1QD57|K1QD57_CRAGI	7.3e-140	502.7	96.28%	70.48%	Protein phosphatase 1D;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN005885.1	sp|A0A210Q9E5|A0A210Q9E5_MIZYE	2.4e-43	181.4	83.65%	44.14%	CST complex subunit STN1;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN005886.1	sp|K1PKQ5|K1PKQ5_CRAGI	5.5e-171	605.9	100.00%	81.56%	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1;OS=Crassostrea;PE=3;SV=1	GO:0003854|GO:0016853|	GO:0006694|
GN005887.1	sp|K1PSQ8|K1PSQ8_CRAGI	0.0e+00	1443.7	100.00%	84.43%	Cytospin-A;OS=Crassostrea;PE=4;SV=1
GN005888.1	sp|K1PKP6|K1PKP6_CRAGI	2.2e-46	190.3	95.41%	87.38%	Zinc finger SWIM domain-containing protein 7;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005889.1	sp|A0A1S3IRB8|A0A1S3IRB8_LINUN	1.3e-114	417.9	99.56%	85.78%	beta-ureidopropionase-like;OS=Lingula;PE=4;SV=1	GO:0006807|
GN005890.1	sp|K1QD45|K1QD45_CRAGI	3.3e-174	618.6	97.22%	61.18%	CAP-Gly domain-containing linker protein 1;OS=Crassostrea;PE=4;SV=1
GN001440.1	sp|K1R0N4|K1R0N4_CRAGI	3.0e-138	497.3	72.24%	80.85%	Carboxypeptidase B;OS=Crassostrea;PE=4;SV=1	GO:0004181|GO:0008270|
GN005892.1	sp|A0A210Q866|A0A210Q866_MIZYE	3.1e-104	384.4	100.00%	52.09%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|	GO:0007165|
GN005894.1	sp|A0A2B4RVZ9|A0A2B4RVZ9_STYPI	1.4e-10	71.2	75.73%	42.86%	PiggyBac transposable element-derived protein 1;OS=Stylophora;PE=4;SV=1
GN005895.1	sp|K1R392|K1R392_CRAGI	4.3e-108	396.7	90.23%	65.58%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN005896.1	sp|K1QMA9|K1QMA9_CRAGI	2.5e-66	256.9	100.00%	84.14%	Cytoglobin-2;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN005897.1	sp|K1QWD4|K1QWD4_CRAGI	3.1e-101	373.6	100.00%	74.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005898.1	sp|A0A210Q6C8|A0A210Q6C8_MIZYE	5.9e-46	190.3	97.95%	66.21%	Eukaryotic translation initiation factor 4H;OS=Mizuhopecten;PE=4;SV=1	GO:0003743|
GN005899.1	sp|K1Q441|K1Q441_CRAGI	2.6e-44	184.9	90.94%	37.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005900.1	sp|K1QW94|K1QW94_CRAGI	1.2e-50	205.3	74.40%	84.31%	Myb-binding protein 1A-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005730|	GO:0003677|GO:0008134|	GO:0006355|
GN005901.1	sp|K1RGH8|K1RGH8_CRAGI	1.0e-172	611.7	100.00%	78.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001442.1	sp|A0A210PN63|A0A210PN63_MIZYE	2.5e-74	284.6	93.77%	50.17%	Sorting nexin-20;OS=Mizuhopecten;PE=4;SV=1	GO:0035091|	GO:0015031|
GN005906.1	sp|K1PHM4|K1PHM4_CRAGI	2.2e-88	330.5	98.34%	85.31%	Glutathione S-transferase kappa 1;OS=Crassostrea;PE=4;SV=1	GO:0015035|GO:0016740|
GN005907.1	sp|K1P3V3|K1P3V3_CRAGI	1.7e-91	342.4	99.81%	41.85%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|	GO:0006915|GO:0042981|
GN005908.1	sp|K1PHM8|K1PHM8_CRAGI	4.0e-104	383.3	100.00%	86.75%	14-3-3 protein zeta;OS=Crassostrea;PE=3;SV=1	GO:0019904|
GN005909.1	sp|K1PPQ1|K1PPQ1_CRAGI	3.1e-128	463.4	100.00%	94.42%	14-3-3 protein gamma;OS=Crassostrea;PE=3;SV=1	GO:0019904|
GN001443.1	sp|K1RK79|K1RK79_CRAGI	8.8e-103	380.2	99.85%	64.04%	Zinc finger and BTB domain-containing protein 24;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005910.1	sp|K1QE15|K1QE15_CRAGI	3.6e-91	340.9	100.00%	44.27%	Ataxin-2;OS=Crassostrea;PE=4;SV=1
GN005911.1	sp|K1R1Z0|K1R1Z0_CRAGI	5.6e-176	622.9	96.98%	66.52%	Acetylcholine receptor subunit alpha-type acr-16;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN005913.1	sp|K1RLE6|K1RLE6_CRAGI	4.4e-73	279.6	100.00%	80.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030544|GO:0008270|
GN005914.1	sp|K1R1Y6|K1R1Y6_CRAGI	0.0e+00	1146.7	99.69%	91.05%	Cationic amino acid transporter 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN005915.1	sp|K1QMQ1|K1QMQ1_CRAGI	5.4e-21	105.5	83.33%	75.36%	TBC1 domain family member 10B;OS=Crassostrea;PE=4;SV=1
GN005916.1	sp|K1R1Z7|K1R1Z7_CRAGI	0.0e+00	1854.3	100.00%	87.25%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|	GO:0042981|
GN005917.1	sp|K1R1Z7|K1R1Z7_CRAGI	9.6e-11	70.9	100.00%	66.04%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|	GO:0042981|
GN005918.1	sp|K1RLF4|K1RLF4_CRAGI	2.0e-10	72.4	56.59%	33.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000974.1	sp|K1PJL2|K1PJL2_CRAGI	9.6e-44	181.4	98.06%	81.00%	Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0000030|
GN001444.1	sp|K1QCR0|K1QCR0_CRAGI	0.0e+00	1336.6	100.00%	78.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005919.1	sp|K1QE19|K1QE19_CRAGI	3.4e-97	360.1	91.30%	83.73%	Kelch-like protein 13;OS=Crassostrea;PE=4;SV=1
GN005920.1	sp|K1QE19|K1QE19_CRAGI	2.8e-37	160.2	80.16%	65.00%	Kelch-like protein 13;OS=Crassostrea;PE=4;SV=1
GN005921.1	sp|A0A0A9WBJ7|A0A0A9WBJ7_LYGHE	2.2e-41	175.3	90.85%	36.21%	Exonuclease;OS=Lygus;PE=4;SV=1	GO:0004527|
GN005922.1	sp|K1QE24|K1QE24_CRAGI	0.0e+00	1378.2	100.00%	81.47%	SNF-related serine/threonine-protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN001445.1	sp|A0A210R2Q9|A0A210R2Q9_MIZYE	1.4e-26	124.8	72.46%	55.45%	RING finger and SPRY domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN005923.1	sp|K1PIV4|K1PIV4_CRAGI	1.1e-157	562.4	67.85%	75.85%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN005925.1	sp|K1QDT8|K1QDT8_CRAGI	9.9e-36	155.6	78.02%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005928.1	sp|V4AWX3|V4AWX3_LOTGI	1.8e-19	101.7	87.83%	37.58%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN005930.1	sp|K1RRD7|K1RRD7_CRAGI	1.3e-154	552.0	69.48%	74.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005933.1	sp|K1QCE8|K1QCE8_CRAGI	8.0e-296	1021.5	92.70%	90.89%	RNA pseudouridylate synthase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN005936.1	sp|K1Q4W8|K1Q4W8_CRAGI	2.9e-24	117.5	30.29%	100.00%	Junctophilin-2;OS=Crassostrea;PE=4;SV=1	GO:0030314|
GN005937.1	sp|K1RC08|K1RC08_CRAGI	9.0e-97	359.4	100.00%	61.33%	Transcriptional repressor scratch 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005938.1	sp|K1QRY1|K1QRY1_CRAGI	1.2e-58	232.6	93.22%	43.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005939.1	sp|K1QKH8|K1QKH8_CRAGI	8.0e-53	212.2	88.27%	74.65%	NF-kappa-B inhibitor-like protein 2;OS=Crassostrea;PE=4;SV=1
GN005940.1	sp|A0A210R0I1|A0A210R0I1_MIZYE	1.3e-44	186.4	95.66%	29.61%	Bardet-Biedl syndrome 10 protein-like;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|
GN005941.1	sp|K1QWS9|K1QWS9_CRAGI	2.2e-80	304.7	81.31%	62.99%	Bifunctional protein hldE;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|	GO:0009058|
GN005942.1	sp|K1QCE7|K1QCE7_CRAGI	3.9e-254	883.2	94.74%	59.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005945.1	sp|A0A210QTT9|A0A210QTT9_MIZYE	3.5e-105	388.3	73.35%	58.02%	Nuclear receptor coactivator 5;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN005946.1	sp|A0A210PN90|A0A210PN90_MIZYE	2.3e-253	880.2	99.27%	76.06%	Centrosomal protein of 76 kDa;OS=Mizuhopecten;PE=4;SV=1
GN005947.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	4.5e-52	210.7	98.74%	34.80%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN005949.1	sp|K1QF95|K1QF95_CRAGI	4.2e-66	257.3	98.41%	48.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005950.1	sp|K1R720|K1R720_CRAGI	7.7e-164	582.0	87.35%	100.00%	Casein kinase I isoform alpha;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN001448.1	sp|A0A210R2Q9|A0A210R2Q9_MIZYE	5.0e-116	423.3	98.03%	61.47%	RING finger and SPRY domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN005951.1	sp|K1PZZ6|K1PZZ6_CRAGI	1.3e-280	971.1	94.87%	74.57%	Kinesin-like protein KIFC3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008569|GO:0008017|	GO:0007018|
GN005952.1	sp|K1QF99|K1QF99_CRAGI	1.4e-166	591.3	100.00%	87.36%	Transmembrane protein 64;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005953.1	sp|A0A1S3J188|A0A1S3J188_LINUN	3.9e-17	92.8	83.33%	60.81%	uncharacterized protein K02A2.6;OS=Lingula;PE=4;SV=1
GN005954.1	sp|K1QLU8|K1QLU8_CRAGI	1.2e-27	127.5	94.81%	81.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005955.1	sp|K1QLU8|K1QLU8_CRAGI	6.2e-35	152.5	92.59%	62.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005956.1	sp|K1QLU8|K1QLU8_CRAGI	2.3e-37	160.6	92.59%	64.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005957.1	sp|K1P8Q8|K1P8Q8_CRAGI	1.4e-134	484.6	100.00%	85.51%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN001449.1	sp|K1RK76|K1RK76_CRAGI	1.2e-63	248.1	100.00%	83.33%	Uncharacterized protein C5orf49-like protein;OS=Crassostrea;PE=4;SV=1
GN005958.1	sp|K1P8Q8|K1P8Q8_CRAGI	1.1e-131	474.9	100.00%	83.70%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN005959.1	sp|A0A210QTJ8|A0A210QTJ8_MIZYE	1.1e-136	492.3	93.86%	58.93%	Potassium voltage-gated channel protein egl-36;OS=Mizuhopecten;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN005961.1	sp|K1QY88|K1QY88_CRAGI	3.3e-86	325.1	72.30%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN005962.1	sp|K1RCR8|K1RCR8_CRAGI	7.4e-120	435.6	97.79%	77.27%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN005963.1	sp|K1RCR8|K1RCR8_CRAGI	3.7e-119	433.3	97.79%	76.52%	Carbonyl reductase [NADPH] 1;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN005964.1	sp|A0A267FX98|A0A267FX98_9PLAT	1.5e-26	126.3	63.40%	29.86%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN005965.1	sp|A0A1I8G553|A0A1I8G553_9PLAT	3.0e-30	138.7	60.70%	32.32%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN005966.1	sp|K1RBV6|K1RBV6_CRAGI	3.7e-82	310.5	71.33%	73.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001450.1	sp|K1R0N1|K1R0N1_CRAGI	0.0e+00	1163.3	95.65%	56.84%	MOG interacting and ectopic P-granules protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005967.1	sp|A0A210R559|A0A210R559_MIZYE	5.1e-44	183.3	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN005968.1	sp|K1R3W0|K1R3W0_CRAGI	5.9e-102	376.3	95.65%	60.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005969.1	sp|K1RU46|K1RU46_CRAGI	0.0e+00	2496.5	100.00%	77.00%	Formin-2;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN005971.1	sp|A0A1I8G553|A0A1I8G553_9PLAT	8.6e-30	137.1	60.70%	31.94%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN005974.1	sp|K1R1E0|K1R1E0_CRAGI	8.4e-164	582.0	100.00%	79.83%	Cyclic nucleotide-gated olfactory channel;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN005975.1	sp|K1PK98|K1PK98_CRAGI	7.1e-209	732.3	100.00%	84.49%	Coiled-coil domain-containing protein 65;OS=Crassostrea;PE=4;SV=1	GO:0005858|	GO:0070286|
GN005976.1	sp|K1QVF0|K1QVF0_CRAGI	1.7e-98	364.4	95.02%	78.95%	Matrix metalloproteinase-19;OS=Crassostrea;PE=3;SV=1	GO:0031012|	GO:0004222|GO:0008270|
GN005977.1	sp|K1QKG9|K1QKG9_CRAGI	2.8e-194	683.3	100.00%	83.78%	Cysteine desulfurase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0031071|GO:0030170|	GO:0044571|
GN005978.1	sp|K1QEM4|K1QEM4_CRAGI	1.8e-280	970.3	91.81%	86.50%	GPI transamidase component PIG-T;OS=Crassostrea;PE=4;SV=1	GO:0042765|	GO:0016255|
GN005979.1	sp|K1PUG5|K1PUG5_CRAGI	0.0e+00	1341.6	72.21%	89.25%	Beta-hexosaminidase subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004563|	GO:0005975|
GN001452.1	sp|K1QTU2|K1QTU2_CRAGI	3.7e-83	313.5	97.86%	79.82%	Slowmo-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005758|
GN005980.1	sp|A0A210QN24|A0A210QN24_MIZYE	2.8e-120	438.0	97.23%	43.29%	BTB/POZ domain-containing protein 17;OS=Mizuhopecten;PE=4;SV=1
GN005981.1	sp|K1PEF3|K1PEF3_CRAGI	1.0e-45	188.0	100.00%	91.09%	Transcription factor E2F5;OS=Crassostrea;PE=3;SV=1	GO:0005634|GO:0005667|	GO:0003677|GO:0003700|GO:0046983|	GO:0051726|
GN005982.1	sp|K1P8C2|K1P8C2_CRAGI	4.0e-91	339.7	92.93%	85.25%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005983.1	sp|K1RCY3|K1RCY3_CRAGI	2.6e-21	106.7	78.02%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN005985.1	sp|A0A0K0YB25|A0A0K0YB25_MYTCO	4.9e-68	263.8	76.30%	51.88%	Nacrein-like protein-2;OS=Mytilus;PE=2;SV=1	GO:0004089|GO:0008270|
GN000975.1	sp|K1PRD5|K1PRD5_CRAGI	2.1e-287	993.4	99.67%	81.02%	Trifunctional purine biosynthetic protein adenosine-3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004637|GO:0004641|GO:0004644|	GO:0006189|GO:0009113|
GN001453.1	sp|K1QL99|K1QL99_CRAGI	0.0e+00	3653.6	99.37%	92.22%	Hydrocephalus-inducing-like protein;OS=Crassostrea;PE=4;SV=1
GN005988.1	sp|A0A210QYW0|A0A210QYW0_MIZYE	4.5e-298	1028.9	100.00%	81.73%	Small G protein signaling modulator 1;OS=Mizuhopecten;PE=3;SV=1	GO:0006904|
GN005989.1	sp|K1QBV5|K1QBV5_CRAGI	2.1e-39	167.5	84.31%	69.53%	Cytochrome b-245 light chain;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|
GN001454.1	sp|K1QL99|K1QL99_CRAGI	4.9e-27	125.2	100.00%	98.36%	Hydrocephalus-inducing-like protein;OS=Crassostrea;PE=4;SV=1
GN005990.1	sp|K1PHF4|K1PHF4_CRAGI	3.2e-310	1069.7	99.05%	67.38%	GPI ethanolamine phosphate transferase 1;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|	GO:0051377|	GO:0006506|
GN005992.1	sp|K1QPI8|K1QPI8_CRAGI	1.5e-149	535.4	97.97%	75.30%	Zinc finger protein 83;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN005993.1	sp|K1Q3F8|K1Q3F8_CRAGI	1.4e-254	884.8	98.37%	83.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN005994.1	sp|K1PP10|K1PP10_CRAGI	7.8e-137	492.7	92.01%	65.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN005995.1	sp|K1Q6R1|K1Q6R1_CRAGI	4.8e-50	204.5	76.86%	35.54%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN005996.1	sp|K1Q3E4|K1Q3E4_CRAGI	0.0e+00	3988.0	100.00%	65.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001455.1	sp|K1QL99|K1QL99_CRAGI	0.0e+00	1238.8	100.00%	85.76%	Hydrocephalus-inducing-like protein;OS=Crassostrea;PE=4;SV=1
GN005997.1	sp|K1PWJ9|K1PWJ9_CRAGI	1.8e-164	584.3	98.14%	83.15%	Orexin receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN005998.1	sp|K1QPH8|K1QPH8_CRAGI	1.4e-25	125.6	10.61%	36.33%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN005999.1	sp|K1QPH8|K1QPH8_CRAGI	2.9e-102	377.9	100.00%	54.85%	Transcription factor HES-1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006355|
GN001456.1	sp|K1QL99|K1QL99_CRAGI	0.0e+00	2845.1	98.54%	83.33%	Hydrocephalus-inducing-like protein;OS=Crassostrea;PE=4;SV=1
GN006000.1	sp|A0A210Q5T0|A0A210Q5T0_MIZYE	4.4e-50	203.8	80.00%	48.74%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN006002.1	sp|K1PP00|K1PP00_CRAGI	4.2e-22	109.8	65.57%	63.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006003.1	sp|K1PHE2|K1PHE2_CRAGI	3.8e-225	786.2	100.00%	89.13%	TAR DNA-binding protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003723|
GN006004.1	sp|K1PX79|K1PX79_CRAGI	3.5e-74	285.0	64.48%	38.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006007.1	sp|K1PX79|K1PX79_CRAGI	5.8e-81	306.6	86.75%	53.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001457.1	sp|K1QL99|K1QL99_CRAGI	1.6e-194	684.1	100.00%	96.57%	Hydrocephalus-inducing-like protein;OS=Crassostrea;PE=4;SV=1
GN006009.1	sp|K1PX79|K1PX79_CRAGI	1.6e-09	67.8	62.50%	45.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006010.1	sp|K1PX79|K1PX79_CRAGI	1.2e-86	325.5	97.61%	53.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006011.1	sp|K1PQ78|K1PQ78_CRAGI	1.3e-104	385.2	98.67%	55.89%	Substrate-specific endoprotease Tex31;OS=Crassostrea;PE=3;SV=1	GO:0008233|
GN006012.1	sp|K1PHI1|K1PHI1_CRAGI	1.5e-73	283.1	43.56%	52.76%	Cysteine-rich secretory protein Mr30;OS=Crassostrea;PE=4;SV=1
GN001458.1	sp|C3Y2X9|C3Y2X9_BRAFL	3.5e-41	174.1	84.98%	39.39%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN006013.1	sp|K1PQ78|K1PQ78_CRAGI	6.3e-182	642.5	84.11%	78.18%	Substrate-specific endoprotease Tex31;OS=Crassostrea;PE=3;SV=1	GO:0008233|
GN006014.1	sp|K1PX89|K1PX89_CRAGI	6.0e-84	315.8	95.26%	85.56%	Equinatoxin-5;OS=Crassostrea;PE=4;SV=1	GO:0046930|	GO:0015267|	GO:0006812|GO:0052331|GO:0046931|
GN006015.1	sp|K1QH95|K1QH95_CRAGI	3.6e-95	353.2	90.55%	85.71%	Cathepsin F;OS=Crassostrea;PE=3;SV=1	GO:0008234|
GN006016.1	sp|K1PXT9|K1PXT9_CRAGI	7.6e-16	90.5	38.64%	40.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006024.1	sp|A0A100XKG4|A0A100XKG4_9BIVA	1.2e-110	407.9	18.46%	49.60%	Shell matrix protein;OS=Bathymodiolus;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN006026.1	sp|A0A210PT61|A0A210PT61_MIZYE	1.4e-26	125.2	58.72%	58.42%	Dual specificity protein phosphatase 22;OS=Mizuhopecten;PE=3;SV=1	GO:0008138|
GN006027.1	sp|A0A210R0W9|A0A210R0W9_MIZYE	4.4e-217	760.4	75.94%	51.95%	G-protein coupled receptor 158-like protein;OS=Mizuhopecten;PE=4;SV=1
GN006029.1	sp|K1P752|K1P752_CRAGI	3.6e-74	283.1	100.00%	90.38%	UPF0195 protein FAM96B;OS=Crassostrea;PE=4;SV=1	GO:0016226|
GN006030.1	sp|K1QD73|K1QD73_CRAGI	2.5e-35	153.7	100.00%	87.10%	Ankyrin and armadillo repeat-containing protein;OS=Crassostrea;PE=4;SV=1
GN001460.1	sp|A0A2T7PD46|A0A2T7PD46_POMCA	8.6e-69	266.2	67.11%	56.72%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016787|
GN006031.1	sp|K1QD73|K1QD73_CRAGI	0.0e+00	1298.1	100.00%	92.12%	Ankyrin and armadillo repeat-containing protein;OS=Crassostrea;PE=4;SV=1
GN006032.1	sp|K1PD72|K1PD72_CRAGI	0.0e+00	1574.3	100.00%	85.90%	Breast cancer anti-estrogen resistance protein 1;OS=Crassostrea;PE=4;SV=1
GN006033.1	sp|K1P746|K1P746_CRAGI	4.8e-16	89.0	72.73%	80.36%	Glutathione synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0043295|GO:0004363|GO:0000287|GO:0042803|
GN006034.1	sp|V3ZK49|V3ZK49_LOTGI	6.3e-103	380.2	99.14%	42.70%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN006035.1	sp|A0A0B7BSW7|A0A0B7BSW7_9EUPU	4.2e-13	80.1	50.00%	52.11%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN006037.1	sp|A0A210PXP9|A0A210PXP9_MIZYE	6.6e-197	693.3	95.80%	41.07%	Acid-sensing ion channel 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005272|
GN001461.1	sp|K1PR10|K1PR10_CRAGI	4.9e-38	162.9	91.61%	66.15%	Uncharacterized protein C12orf65-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|GO:0003747|
GN006038.1	sp|K1PUA1|K1PUA1_CRAGI	9.6e-144	516.9	80.27%	37.55%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006039.1	sp|K1QUE9|K1QUE9_CRAGI	0.0e+00	2486.1	100.00%	83.17%	PH domain leucine-rich repeat-containing protein phosphatase 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN006040.1	sp|K1PRM4|K1PRM4_CRAGI	8.0e-99	365.9	96.35%	75.42%	Actin-binding protein anillin;OS=Crassostrea;PE=4;SV=1
GN006041.1	sp|A0A0K8RP19|A0A0K8RP19_IXORI	5.9e-12	77.4	43.31%	32.37%	Putative piggybac;OS=Ixodes;PE=2;SV=1
GN006042.1	sp|K1PJU2|K1PJU2_CRAGI	1.2e-279	968.0	86.89%	72.73%	Transcriptional regulator Erg;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN006043.1	sp|K1R5Y9|K1R5Y9_CRAGI	1.8e-139	500.7	90.87%	97.48%	Retroviral integration site protein Fli-1-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN006044.1	sp|V4BDF6|V4BDF6_LOTGI	1.1e-17	95.5	85.03%	39.44%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0008270|
GN006046.1	sp|V3ZVA0|V3ZVA0_LOTGI	1.1e-39	169.5	97.59%	48.03%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006047.1	sp|K1RQJ6|K1RQJ6_CRAGI	8.7e-25	118.2	71.11%	92.06%	Enhancer of mRNA-decapping protein 4;OS=Crassostrea;PE=4;SV=1
GN006048.1	sp|K1RQJ6|K1RQJ6_CRAGI	1.8e-71	275.4	98.67%	73.78%	Enhancer of mRNA-decapping protein 4;OS=Crassostrea;PE=4;SV=1
GN006049.1	sp|K1RQJ6|K1RQJ6_CRAGI	2.4e-87	327.8	88.85%	84.41%	Enhancer of mRNA-decapping protein 4;OS=Crassostrea;PE=4;SV=1
GN006052.1	sp|K1QNF8|K1QNF8_CRAGI	4.1e-14	85.1	34.58%	33.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006053.1	sp|K1QIM4|K1QIM4_CRAGI	1.3e-24	119.4	90.20%	36.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006054.1	sp|A0A210QQ62|A0A210QQ62_MIZYE	8.9e-20	102.4	87.73%	38.78%	Glycosyltransferase-like domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016757|
GN001463.1	sp|K1RFV9|K1RFV9_CRAGI	1.6e-294	1018.1	90.72%	56.44%	M-phase phosphoprotein 9;OS=Crassostrea;PE=4;SV=1
GN006055.1	sp|A0A210R5Y9|A0A210R5Y9_MIZYE	3.9e-57	227.3	91.01%	54.55%	Macrophage mannose receptor 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0030246|
GN006057.1	sp|K1Q9Q6|K1Q9Q6_CRAGI	2.5e-173	614.0	85.62%	78.28%	Synaptic vesicle membrane protein VAT-1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN006058.1	sp|K1R9M2|K1R9M2_CRAGI	0.0e+00	1835.8	100.00%	92.28%	Integrator complex subunit 8;OS=Crassostrea;PE=4;SV=1	GO:0034472|
GN006066.1	sp|W4XJS0|W4XJS0_STRPU	3.4e-66	258.8	40.69%	42.90%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN006069.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	1.8e-19	101.3	65.54%	45.83%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN006071.1	sp|K1QNY3|K1QNY3_CRAGI	3.8e-55	221.1	38.67%	82.01%	BEN domain-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN006072.1	sp|A0A210PDC7|A0A210PDC7_MIZYE	4.0e-43	180.6	91.70%	37.23%	Master replication protein;OS=Mizuhopecten;PE=4;SV=1
GN006073.1	sp|K1RA81|K1RA81_CRAGI	2.8e-15	87.4	26.45%	87.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006074.1	sp|A0A2B4R6Y7|A0A2B4R6Y7_STYPI	1.3e-31	142.5	72.70%	36.84%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN006075.1	sp|V4AU73|V4AU73_LOTGI	5.6e-32	144.4	32.51%	44.44%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004842|
GN006076.1	sp|K1S5S8|K1S5S8_CRAGI	7.2e-19	99.0	76.47%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN006077.1	sp|A0A1W5BJ07|A0A1W5BJ07_CIOIN	3.5e-47	193.7	98.46%	47.94%	uncharacterized protein LOC108950671;OS=Ciona;PE=4;SV=1	GO:0008270|
GN006078.1	sp|A0A210QB58|A0A210QB58_MIZYE	7.6e-27	125.6	85.60%	57.55%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN006079.1	sp|K1QQ85|K1QQ85_CRAGI	5.4e-149	533.1	92.79%	78.45%	Cholecystokinin receptor type A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN006081.1	sp|K1S1K6|K1S1K6_CRAGI	5.3e-80	303.5	96.32%	46.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006082.1	sp|K1R007|K1R007_CRAGI	1.9e-57	227.6	95.12%	67.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001464.1	sp|K1Q4W4|K1Q4W4_CRAGI	6.7e-196	688.7	98.66%	92.93%	Protein pelota homolog;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0004519|GO:0046872|	GO:0070966|GO:0070481|GO:0071025|
GN006083.1	sp|K1PPP6|K1PPP6_CRAGI	3.7e-69	267.7	42.20%	79.49%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN006084.1	sp|K1QHM1|K1QHM1_CRAGI	1.0e-10	72.0	38.58%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006085.1	sp|K1QHM1|K1QHM1_CRAGI	1.2e-34	152.9	39.04%	54.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006086.1	sp|K1PXH1|K1PXH1_CRAGI	1.0e-21	109.8	40.89%	51.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006089.1	sp|K1PKG1|K1PKG1_CRAGI	9.5e-227	791.6	100.00%	82.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006090.1	sp|K1PIF9|K1PIF9_CRAGI	1.4e-199	701.4	100.00%	73.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006091.1	sp|K1PQ52|K1PQ52_CRAGI	1.7e-193	681.4	100.00%	71.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006092.1	sp|K1Q4I2|K1Q4I2_CRAGI	6.1e-249	865.9	96.77%	73.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006093.1	sp|K1QQJ4|K1QQJ4_CRAGI	3.3e-174	616.7	100.00%	76.25%	Abhydrolase domain-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN006094.1	sp|K1PIG7|K1PIG7_CRAGI	6.6e-171	605.9	84.85%	81.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005892|
GN006095.1	sp|K1Q4I5|K1Q4I5_CRAGI	4.6e-225	786.2	90.73%	76.56%	Ankyrin repeat domain-containing protein 27;OS=Crassostrea;PE=4;SV=1
GN006096.1	sp|K1PIH3|K1PIH3_CRAGI	1.1e-103	382.1	99.32%	69.28%	Potassium voltage-gated channel subfamily B member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0034765|
GN006098.1	sp|K1PQ61|K1PQ61_CRAGI	0.0e+00	1447.6	100.00%	89.97%	Ankyrin repeat domain-containing protein 55;OS=Crassostrea;PE=4;SV=1
GN006099.1	sp|K1PXG6|K1PXG6_CRAGI	1.8e-197	693.7	100.00%	99.70%	Serine/threonine-protein phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0000164|	GO:0046872|GO:0004722|
GN006101.1	sp|K1PPU2|K1PPU2_CRAGI	1.8e-44	185.3	65.48%	46.99%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN006102.1	sp|K1PPU2|K1PPU2_CRAGI	2.8e-154	550.8	99.59%	57.82%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN001465.1	sp|K9J9V0|K9J9V0_SCYPA	1.0e-52	211.8	100.00%	63.69%	Eukaryotic translation initiation factor 5A;OS=Scylla;PE=2;SV=1	GO:0043022|GO:0003746|GO:0003743|	GO:0045901|GO:0045905|GO:0006452|
GN006103.1	sp|K1PHP8|K1PHP8_CRAGI	7.1e-67	259.2	84.73%	73.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006105.1	sp|K1P3Y3|K1P3Y3_CRAGI	1.5e-27	127.5	93.48%	68.24%	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN006106.1	sp|K1P3Y3|K1P3Y3_CRAGI	1.4e-121	442.6	74.28%	72.26%	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN006107.1	sp|A0A0C5PRK1|A0A0C5PRK1_MYTGA	6.0e-46	189.1	100.00%	62.69%	Fibrinogen-related protein 11;OS=Mytilus;PE=2;SV=1
GN006108.1	sp|K1QAB8|K1QAB8_CRAGI	1.0e-118	431.8	100.00%	80.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006109.1	sp|K1PHP5|K1PHP5_CRAGI	0.0e+00	1115.1	99.85%	90.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006110.1	sp|A0A210Q5J9|A0A210Q5J9_MIZYE	6.1e-241	838.6	100.00%	96.08%	26S protease regulatory subunit 7;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0008233|GO:0036402|	GO:0030163|
GN001466.1	sp|K1P384|K1P384_CRAGI	0.0e+00	1872.8	83.44%	84.01%	Cation-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0016887|GO:0046872|	GO:0006812|
GN006112.1	sp|K1Q326|K1Q326_CRAGI	9.0e-55	218.8	73.26%	86.40%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN006117.1	sp|K1QIX2|K1QIX2_CRAGI	3.6e-132	477.6	58.04%	79.53%	CUE domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN006118.1	sp|K1Q4M6|K1Q4M6_CRAGI	0.0e+00	2137.1	100.00%	81.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN006119.1	sp|W6NXN7|W6NXN7_HAECO	5.3e-09	66.6	69.81%	35.45%	Transposase domain containing protein;OS=Haemonchus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006313|
GN006120.1	sp|K1QCF5|K1QCF5_CRAGI	0.0e+00	1092.8	100.00%	94.01%	Fumarate hydratase class I, aerobic;OS=Crassostrea;PE=4;SV=1	GO:0004333|	GO:0006091|
GN006121.1	sp|K1R4J3|K1R4J3_CRAGI	1.7e-117	427.6	97.82%	93.72%	Putative ribosome biogenesis protein NEP1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN006122.1	sp|K1PWY8|K1PWY8_CRAGI	1.8e-77	295.0	50.49%	83.77%	Protein SpAN;OS=Crassostrea;PE=4;SV=1
GN006123.1	sp|K1PWY8|K1PWY8_CRAGI	1.2e-37	162.2	52.76%	70.19%	Protein SpAN;OS=Crassostrea;PE=4;SV=1
GN006124.1	sp|K1QIY1|K1QIY1_CRAGI	4.7e-107	393.3	99.34%	64.00%	GDP-fucose transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0005457|	GO:0036085|
GN001468.1	sp|K1PP29|K1PP29_CRAGI	7.6e-108	396.0	95.28%	70.53%	Lipoma-preferred partner-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN006125.1	sp|K1R4J8|K1R4J8_CRAGI	1.1e-283	981.1	99.85%	77.29%	Caspase-2;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN006126.1	sp|K1S0P7|K1S0P7_CRAGI	0.0e+00	3153.2	99.61%	87.07%	Mediator of RNA polymerase II transcription subunit 13;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN006127.1	sp|K1S0P7|K1S0P7_CRAGI	4.0e-122	443.0	93.59%	91.74%	Mediator of RNA polymerase II transcription subunit 13;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN006129.1	sp|K1RAY8|K1RAY8_CRAGI	2.8e-167	594.0	99.79%	61.57%	F-box/WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN006130.1	sp|K1QSK1|K1QSK1_CRAGI	3.7e-251	872.8	97.28%	86.59%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006131.1	sp|K1PKK9|K1PKK9_CRAGI	4.2e-131	473.4	96.61%	68.42%	TWiK family of potassium channels protein 7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN006132.1	sp|K1R0H4|K1R0H4_CRAGI	0.0e+00	1256.5	82.60%	78.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007099|
GN001469.1	sp|W4XP46|W4XP46_STRPU	2.2e-71	275.0	94.07%	44.84%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN006135.1	sp|K1QR55|K1QR55_CRAGI	1.6e-219	767.7	77.99%	90.35%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN006136.1	sp|K1R0I9|K1R0I9_CRAGI	4.0e-219	766.1	100.00%	84.60%	G protein-activated inward rectifier potassium channel 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN006137.1	sp|K1RWZ1|K1RWZ1_CRAGI	7.2e-09	65.1	63.51%	63.04%	Fibropellin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006138.1	sp|K1RWZ1|K1RWZ1_CRAGI	4.7e-81	307.0	89.13%	51.40%	Fibropellin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006139.1	sp|K1RWZ1|K1RWZ1_CRAGI	9.9e-61	239.2	87.12%	51.53%	Fibropellin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006140.1	sp|K1QT64|K1QT64_CRAGI	3.3e-24	116.7	89.83%	53.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN006141.1	sp|K1R5R4|K1R5R4_CRAGI	3.8e-25	119.4	82.95%	77.78%	Dynein heavy chain 10, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0015629|GO:0030286|	GO:0003779|GO:0005524|GO:0003777|GO:0003951|	GO:0030042|GO:0007018|
GN006142.1	sp|K1RBP0|K1RBP0_CRAGI	3.4e-25	119.4	96.15%	75.68%	Ceramide kinase;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN006143.1	sp|K1PAB1|K1PAB1_CRAGI	5.2e-20	103.2	45.40%	67.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006144.1	sp|A0A1S3K5K2|A0A1S3K5K2_LINUN	1.1e-92	346.7	85.78%	37.67%	uncharacterized protein LOC106179004;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0000166|GO:0016849|	GO:0009190|GO:0035556|
GN006147.1	sp|A0A1X7STM2|A0A1X7STM2_AMPQE	1.2e-15	88.2	93.52%	40.00%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0005524|GO:0008026|GO:0003676|	GO:0006310|
GN006148.1	sp|C3ZG36|C3ZG36_BRAFL	2.9e-55	221.5	84.64%	36.07%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0015074|GO:0006310|GO:0009299|
GN006153.1	sp|K1PBC1|K1PBC1_CRAGI	1.5e-46	191.0	100.00%	69.29%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN006156.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	9.6e-87	327.0	91.54%	30.60%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN006161.1	sp|K1R786|K1R786_CRAGI	9.6e-29	132.1	94.59%	53.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006162.1	sp|K1Q188|K1Q188_CRAGI	9.6e-26	122.1	72.73%	70.87%	BEN domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN006163.1	sp|K1QS32|K1QS32_CRAGI	2.0e-39	167.9	93.12%	43.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006164.1	sp|K1R786|K1R786_CRAGI	9.6e-29	132.1	89.19%	58.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006168.1	sp|K1Q188|K1Q188_CRAGI	1.4e-24	118.2	72.73%	69.90%	BEN domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN006172.1	sp|K1QW49|K1QW49_CRAGI	5.7e-268	928.7	100.00%	87.18%	Anaphase-promoting complex subunit 7;OS=Crassostrea;PE=4;SV=1
GN001474.1	sp|K1PM99|K1PM99_CRAGI	1.2e-26	125.9	81.10%	35.58%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN006173.1	sp|K1RGF0|K1RGF0_CRAGI	1.1e-244	851.3	100.00%	84.81%	Solute carrier family 46 member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN006174.1	sp|K1QH15|K1QH15_CRAGI	3.1e-116	424.5	100.00%	74.90%	UPF0636 protein C4orf41-like protein;OS=Crassostrea;PE=4;SV=1
GN006175.1	sp|A0A210R559|A0A210R559_MIZYE	5.1e-44	183.3	97.14%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN006176.1	sp|K1PWX2|K1PWX2_CRAGI	9.7e-66	257.7	55.70%	29.24%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006177.1	sp|K1QH15|K1QH15_CRAGI	0.0e+00	1857.4	99.07%	81.28%	UPF0636 protein C4orf41-like protein;OS=Crassostrea;PE=4;SV=1
GN006179.1	sp|K1QPX1|K1QPX1_CRAGI	4.9e-137	493.4	100.00%	80.32%	ATPase family AAA domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0005524|	GO:0007005|
GN006180.1	sp|K1PCA9|K1PCA9_CRAGI	7.4e-35	152.5	97.48%	48.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000927.1	sp|K1PEN9|K1PEN9_CRAGI	1.5e-62	244.2	96.97%	88.19%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0008810|GO:0030247|	GO:0030245|
GN001475.1	sp|K1PG51|K1PG51_CRAGI	1.2e-36	157.9	83.93%	83.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006185.1	sp|K1PVQ2|K1PVQ2_CRAGI	6.7e-74	282.3	100.00%	78.49%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006186.1	sp|K1PX35|K1PX35_CRAGI	8.6e-83	312.8	82.04%	58.21%	ATP-dependent DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN006187.1	sp|A0A210Q2S0|A0A210Q2S0_MIZYE	6.9e-38	162.9	66.34%	58.65%	ATP-dependent DNA helicase PIF1;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|
GN006188.1	sp|A0A210Q2Z4|A0A210Q2Z4_MIZYE	8.6e-66	256.1	67.93%	65.33%	ATP-dependent DNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN006189.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	1.9e-160	572.0	54.09%	67.15%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN006191.1	sp|K1PVQ2|K1PVQ2_CRAGI	1.6e-72	277.7	100.00%	77.33%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006193.1	sp|K1QQX1|K1QQX1_CRAGI	4.2e-60	236.5	100.00%	66.28%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006194.1	sp|K1Q5F8|K1Q5F8_CRAGI	1.4e-87	330.5	17.26%	79.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006195.1	sp|W4YYN8|W4YYN8_STRPU	2.6e-18	97.4	65.33%	49.49%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005813|GO:0005694|GO:0000781|GO:0005737|GO:0005654|GO:0005634|GO:0035861|	GO:0008408|GO:0070337|GO:1905773|GO:0043140|GO:0000405|GO:0003682|GO:0003677|GO:0061749|GO:0000400|GO:0009378|GO:0000287|GO:0030145|GO:0042803|GO:0044877|GO:0061821|GO:0000403|	GO:0006284|GO:0007569|GO:0071480|GO:0009267|GO:0008340|GO:0032508|GO:0006310|GO:0006281|GO:0000731|GO:0000724|GO:0044806|GO:0010259|GO:0051345|GO:0098530|GO:0042981|GO:0031297|GO:0001302|GO:0006979|GO:0010225|GO:0061820|
GN006196.1	sp|K1Q7B2|K1Q7B2_CRAGI	3.3e-67	260.0	98.15%	73.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006197.1	sp|K1QY88|K1QY88_CRAGI	1.3e-85	323.6	55.26%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN006198.1	sp|K1QQX1|K1QQX1_CRAGI	4.2e-60	236.5	100.00%	66.28%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001476.1	sp|K1QG74|K1QG74_CRAGI	4.0e-37	160.6	100.00%	47.50%	Acyl-coenzyme A thioesterase 9, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN006199.1	sp|K1PVQ2|K1PVQ2_CRAGI	4.0e-71	273.1	100.00%	76.74%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006200.1	sp|K1QXK8|K1QXK8_CRAGI	7.0e-53	212.2	92.25%	76.92%	Tyramine receptor ser-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|GO:0004983|
GN006201.1	sp|K1R3X8|K1R3X8_CRAGI	1.1e-137	495.7	98.35%	50.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001477.1	sp|A0A2G8KTI2|A0A2G8KTI2_STIJA	6.9e-29	132.1	99.06%	53.85%	Putative 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2-like;OS=Stichopus;PE=4;SV=1	GO:0005506|GO:0031418|GO:0016705|
GN006208.1	sp|K1PGS9|K1PGS9_CRAGI	5.9e-51	206.5	88.48%	50.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006209.1	sp|K1PGS9|K1PGS9_CRAGI	3.8e-74	283.5	98.62%	62.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006210.1	sp|K1PVX6|K1PVX6_CRAGI	1.9e-128	464.5	94.22%	62.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006211.1	sp|K1PWT5|K1PWT5_CRAGI	5.3e-132	476.9	98.80%	54.79%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0097200|	GO:0042981|
GN001478.1	sp|K1QRH7|K1QRH7_CRAGI	0.0e+00	2538.1	100.00%	86.23%	Nitric oxide synthase, brain;OS=Crassostrea;PE=4;SV=1	GO:0005516|GO:0050660|GO:0010181|GO:0020037|GO:0046872|GO:0050661|GO:0004517|	GO:0006809|
GN006214.1	sp|A0A1L3GTQ4|A0A1L3GTQ4_CRAHO	7.5e-103	379.8	96.90%	52.57%	Tumor necrosis factor receptor 5;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN006215.1	sp|K1QRL9|K1QRL9_CRAGI	3.6e-60	236.9	97.91%	65.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0070072|
GN006216.1	sp|A0A2T7NHN0|A0A2T7NHN0_POMCA	7.4e-21	107.1	79.82%	24.76%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN006218.1	sp|K1PYM6|K1PYM6_CRAGI	3.7e-180	636.3	100.00%	82.03%	Sulfatase-modifying factor 2;OS=Crassostrea;PE=4;SV=1
GN006219.1	sp|K1PRD5|K1PRD5_CRAGI	0.0e+00	1614.0	99.80%	79.66%	Trifunctional purine biosynthetic protein adenosine-3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004637|GO:0004641|GO:0004644|	GO:0006189|GO:0009113|
GN006220.1	sp|K1PJL2|K1PJL2_CRAGI	5.6e-44	182.2	98.06%	82.00%	Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0000030|
GN006221.1	sp|K1PJL2|K1PJL2_CRAGI	8.1e-153	545.4	96.69%	82.19%	Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0000030|
GN001481.1	sp|K1QFZ0|K1QFZ0_CRAGI	1.6e-33	149.4	64.48%	35.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001482.1	sp|K1QA98|K1QA98_CRAGI	0.0e+00	2152.1	92.82%	91.41%	ATP-dependent RNA helicase A-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003723|
GN001483.1	sp|K1QW41|K1QW41_CRAGI	5.4e-167	592.4	99.36%	89.61%	Leucine-zipper-like transcriptional regulator 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008094|GO:0046872|GO:0003723|	GO:0006281|
GN001484.1	sp|K1QW41|K1QW41_CRAGI	9.7e-143	511.9	98.45%	81.07%	Leucine-zipper-like transcriptional regulator 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008094|GO:0046872|GO:0003723|	GO:0006281|
GN001485.1	sp|V3ZUX7|V3ZUX7_LOTGI	1.1e-63	248.8	100.00%	59.28%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001487.1	sp|K1Q319|K1Q319_CRAGI	6.7e-159	565.5	96.94%	92.61%	Coiled-coil domain-containing protein 90B, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN001488.1	sp|K1Q319|K1Q319_CRAGI	1.8e-48	197.2	97.25%	82.86%	Coiled-coil domain-containing protein 90B, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN001489.1	sp|K1Q319|K1Q319_CRAGI	2.8e-71	273.5	87.66%	94.78%	Coiled-coil domain-containing protein 90B, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN001490.1	sp|J9Q399|J9Q399_OSTED	1.1e-20	105.9	33.94%	69.86%	THAP domain-containing protein;OS=Ostrea;PE=2;SV=1
GN001491.1	sp|K1R417|K1R417_CRAGI	3.7e-25	120.2	93.06%	46.27%	Pumilio domain-containing protein C14orf21;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN001492.1	sp|K1Q7W6|K1Q7W6_CRAGI	1.1e-13	82.0	80.43%	40.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001493.1	sp|K1Q4H9|K1Q4H9_CRAGI	2.9e-12	76.3	91.43%	56.06%	Limulus clotting factor C;OS=Crassostrea;PE=4;SV=1
GN001494.1	sp|K1R417|K1R417_CRAGI	9.4e-221	771.9	98.12%	61.64%	Pumilio domain-containing protein C14orf21;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN001496.1	sp|K1QRW0|K1QRW0_CRAGI	1.4e-39	169.1	43.69%	65.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001498.1	sp|K1QN06|K1QN06_CRAGI	1.1e-275	956.4	72.34%	44.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN001499.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN001500.1	sp|K1R2B5|K1R2B5_CRAGI	7.3e-245	851.7	99.56%	89.93%	T-box transcription factor TBX1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN001501.1	sp|K1RLP6|K1RLP6_CRAGI	0.0e+00	1340.5	100.00%	81.37%	Oxysterol-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN001502.1	sp|K1QEE6|K1QEE6_CRAGI	3.2e-12	77.0	34.62%	86.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001503.1	sp|K1QN10|K1QN10_CRAGI	8.4e-95	352.8	98.89%	51.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001505.1	sp|K1R4K0|K1R4K0_CRAGI	8.4e-16	88.6	58.82%	59.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN001506.1	sp|K1RNZ2|K1RNZ2_CRAGI	3.1e-303	1046.6	100.00%	72.48%	Metastasis suppressor protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003779|	GO:0007009|
GN001507.1	sp|K1QH37|K1QH37_CRAGI	1.5e-161	576.6	30.91%	75.10%	RNA-binding protein 12;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN001508.1	sp|A0A2C9KCT3|A0A2C9KCT3_BIOGL	1.6e-19	101.7	79.55%	39.57%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0036038|	GO:0060271|GO:0010826|
GN001510.1	sp|K1QQR8|K1QQR8_CRAGI	1.2e-56	224.9	99.37%	67.95%	Meckelin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0036038|	GO:0060271|GO:0010826|
GN001511.1	sp|K1QQR8|K1QQR8_CRAGI	1.2e-204	718.0	98.59%	85.44%	Meckelin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0036038|	GO:0060271|GO:0010826|
GN001512.1	sp|K1PVM1|K1PVM1_CRAGI	1.4e-44	184.9	81.48%	68.70%	AP-2 complex subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0016021|GO:0036038|	GO:0060271|GO:0006886|GO:0010826|GO:0016192|
GN001514.1	sp|K1Q3A7|K1Q3A7_CRAGI	1.2e-54	219.5	64.84%	44.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001516.1	sp|K1QAX4|K1QAX4_CRAGI	4.1e-58	229.9	100.00%	66.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001517.1	sp|K1PNL5|K1PNL5_CRAGI	7.8e-131	473.0	92.69%	52.54%	Protein IMPACT-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001518.1	sp|K1PNL5|K1PNL5_CRAGI	5.8e-89	333.2	95.70%	53.61%	Protein IMPACT-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN001519.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	1.3e-127	462.2	98.36%	47.20%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN001520.1	sp|A0A3M6UAZ4|A0A3M6UAZ4_9CNID	5.3e-17	93.6	44.02%	47.42%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN001522.1	sp|U5PZB3|U5PZB3_CRAGI	5.8e-97	360.1	99.00%	47.36%	Toll-like receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN001523.1	sp|K1QXN5|K1QXN5_CRAGI	2.0e-31	140.6	74.31%	77.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001524.1	sp|K1PGR2|K1PGR2_CRAGI	9.0e-304	1048.5	86.28%	63.71%	G patch domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003723|	GO:0006397|
GN001525.1	sp|K1QF23|K1QF23_CRAGI	0.0e+00	2207.6	82.41%	81.86%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN001528.1	sp|K1QNG9|K1QNG9_CRAGI	8.6e-46	188.7	100.00%	71.43%	60S ribosomal protein L23a;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN001529.1	sp|V3ZWK8|V3ZWK8_LOTGI	3.3e-104	383.6	99.62%	69.55%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005525|GO:0003924|
GN001530.1	sp|V4AWI9|V4AWI9_LOTGI	1.3e-152	545.0	99.28%	59.38%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005623|	GO:0045454|
GN001531.1	sp|K1R3B2|K1R3B2_CRAGI	6.5e-13	78.6	55.26%	82.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001532.1	sp|K1QR23|K1QR23_CRAGI	8.1e-88	328.9	96.88%	71.30%	3,2-trans-enoyl-CoA isomerase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016853|
GN001533.1	sp|K1QR23|K1QR23_CRAGI	1.9e-66	257.7	94.62%	68.57%	3,2-trans-enoyl-CoA isomerase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016853|
GN001534.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	2.5e-121	441.4	97.77%	45.31%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN001538.1	sp|K1PH91|K1PH91_CRAGI	4.8e-28	131.3	25.81%	51.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000928.1	sp|K1Q5J8|K1Q5J8_CRAGI	2.5e-113	415.6	36.47%	89.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001539.1	sp|V4AHI7|V4AHI7_LOTGI	9.8e-14	82.0	69.29%	53.41%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001547.1	sp|A0A210R549|A0A210R549_MIZYE	1.9e-09	68.2	36.14%	50.85%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001549.1	sp|C5KB40|C5KB40_PERM5	5.7e-33	148.3	50.92%	31.53%	ATP-dependent DNA helicase;OS=Perkinsus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN001559.1	sp|K1QNM6|K1QNM6_CRAGI	5.0e-50	202.6	100.00%	73.23%	IL17-5;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0005125|
GN001560.1	sp|K1QNM6|K1QNM6_CRAGI	5.0e-50	202.6	100.00%	73.23%	IL17-5;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0005125|
GN001562.1	sp|K1R2P0|K1R2P0_CRAGI	3.6e-15	85.9	97.01%	68.75%	Inosine-uridine preferring nucleoside hydrolase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN001563.1	sp|K1R2P0|K1R2P0_CRAGI	1.4e-138	498.0	99.37%	75.72%	Inosine-uridine preferring nucleoside hydrolase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN001567.1	sp|K1RYB5|K1RYB5_CRAGI	2.3e-90	337.4	100.00%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN000982.1	sp|C3ZG36|C3ZG36_BRAFL	2.9e-55	221.5	84.64%	36.07%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0015074|GO:0006310|GO:0009299|
GN001568.1	sp|K1RFA6|K1RFA6_CRAGI	4.6e-210	736.9	100.00%	51.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001569.1	sp|K1QDC7|K1QDC7_CRAGI	8.8e-38	162.9	50.58%	57.36%	Jumonji-C domain-containing protein KDM4B;OS=Crassostrea;PE=2;SV=1	GO:0016021|GO:0005634|	GO:0046872|GO:0008168|
GN001570.1	sp|K1Q7G7|K1Q7G7_CRAGI	0.0e+00	3172.5	74.77%	72.85%	Neural-cadherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN001571.1	sp|Q5QGY6|Q5QGY6_CRAGI	2.3e-52	211.1	78.74%	70.37%	Fatty acid binding protein;OS=Crassostrea;PE=2;SV=1	GO:0008289|
GN001572.1	sp|K1P3B0|K1P3B0_CRAGI	6.0e-33	145.6	95.28%	72.00%	Alkaline phosphatase, tissue-nonspecific isozyme;OS=Crassostrea;PE=3;SV=1	GO:0016791|
GN001573.1	sp|K1Q9X6|K1Q9X6_CRAGI	6.9e-45	186.0	66.67%	67.72%	Tomoregulin-2;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN001574.1	sp|K1PH90|K1PH90_CRAGI	3.3e-35	152.9	97.85%	83.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001575.1	sp|K1P9Y6|K1P9Y6_CRAGI	0.0e+00	2438.3	100.00%	85.58%	Tyrosine-protein kinase PR2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004713|
GN000983.1	sp|K1PAB1|K1PAB1_CRAGI	5.2e-20	103.2	45.40%	67.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001576.1	sp|K1P3A0|K1P3A0_CRAGI	0.0e+00	2082.4	98.93%	72.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001577.1	sp|A0A210Q2U6|A0A210Q2U6_MIZYE	2.1e-49	201.1	86.02%	58.49%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN001578.1	sp|K1PH85|K1PH85_CRAGI	2.0e-218	765.4	99.31%	44.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001579.1	sp|A0A210Q7Y5|A0A210Q7Y5_MIZYE	7.2e-286	989.2	100.00%	48.70%	Activated CDC42 kinase 1;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004713|
GN001580.1	sp|K1Q9X0|K1Q9X0_CRAGI	6.5e-111	406.0	96.79%	86.67%	Ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1
GN001581.1	sp|K1PP43|K1PP43_CRAGI	3.4e-51	207.6	70.25%	67.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0016491|
GN001582.1	sp|K1R2P0|K1R2P0_CRAGI	3.6e-15	85.9	97.01%	68.75%	Inosine-uridine preferring nucleoside hydrolase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN001584.1	sp|K1RFA6|K1RFA6_CRAGI	1.5e-208	731.9	100.00%	51.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN001585.1	sp|K1QDC7|K1QDC7_CRAGI	8.8e-38	162.9	50.39%	57.36%	Jumonji-C domain-containing protein KDM4B;OS=Crassostrea;PE=2;SV=1	GO:0016021|GO:0005634|	GO:0046872|GO:0008168|
GN001586.1	sp|K1QX18|K1QX18_CRAGI	2.3e-128	464.5	82.68%	70.29%	E3 ubiquitin-protein ligase CHFR;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN001588.1	sp|K1Q773|K1Q773_CRAGI	2.2e-106	391.3	96.73%	58.47%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN000984.1	sp|K1QDA0|K1QDA0_CRAGI	3.3e-19	100.9	77.03%	39.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008234|
GN001592.1	sp|K1QX22|K1QX22_CRAGI	0.0e+00	1600.5	90.47%	83.76%	4-hydroxyphenylpyruvate dioxygenase;OS=Crassostrea;PE=4;SV=1	GO:0003868|GO:0005524|GO:0003678|	GO:0009072|GO:0006260|
GN001594.1	sp|K1QX22|K1QX22_CRAGI	4.0e-229	800.4	94.14%	54.77%	4-hydroxyphenylpyruvate dioxygenase;OS=Crassostrea;PE=4;SV=1	GO:0003868|GO:0005524|GO:0003678|	GO:0009072|GO:0006260|
GN001595.1	sp|V4A0N7|V4A0N7_LOTGI	2.8e-15	88.6	86.92%	28.52%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN001596.1	sp|K1RHA7|K1RHA7_CRAGI	6.5e-186	655.6	99.74%	79.17%	Aspartyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004812|GO:0005524|GO:0003676|	GO:0006418|
GN001597.1	sp|A0A1X7U934|A0A1X7U934_AMPQE	3.0e-35	155.2	67.62%	32.39%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN001598.1	sp|K1QA01|K1QA01_CRAGI	0.0e+00	1151.7	100.00%	72.51%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN001599.1	sp|K1QIB6|K1QIB6_CRAGI	1.7e-79	301.6	94.44%	59.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN001600.1	sp|K1QQW3|K1QQW3_CRAGI	2.2e-238	830.5	98.95%	76.86%	Solute carrier family 13 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN001601.1	sp|K1RHB3|K1RHB3_CRAGI	2.5e-162	577.0	99.69%	89.88%	Phosphoenolpyruvate phosphomutase;OS=Crassostrea;PE=4;SV=1	GO:0050188|
GN001602.1	sp|K1QA13|K1QA13_CRAGI	0.0e+00	1875.1	96.75%	94.38%	Calcium-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0033017|	GO:0005524|GO:0005388|
GN001604.1	sp|K1QX28|K1QX28_CRAGI	1.6e-35	154.8	94.05%	58.86%	Solute carrier family 13 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN001605.1	sp|K1RHB3|K1RHB3_CRAGI	2.5e-162	577.0	99.69%	89.88%	Phosphoenolpyruvate phosphomutase;OS=Crassostrea;PE=4;SV=1	GO:0050188|
GN001606.1	sp|K1QA13|K1QA13_CRAGI	0.0e+00	1882.5	96.73%	94.95%	Calcium-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0033017|	GO:0005524|GO:0005388|
GN001607.1	sp|K1PVE0|K1PVE0_CRAGI	7.0e-34	149.1	59.12%	82.50%	RPE-spondin;OS=Crassostrea;PE=4;SV=1	GO:0030247|GO:0005044|	GO:0006955|
GN001609.1	sp|K1Q358|K1Q358_CRAGI	1.5e-26	124.4	61.95%	89.86%	60S acidic ribosomal protein P2;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006414|
GN001610.1	sp|K1QKQ7|K1QKQ7_CRAGI	1.6e-159	567.8	98.26%	78.55%	Endo-1,3(4)-beta-glucanase 1;OS=Crassostrea;PE=4;SV=1	GO:0052861|
GN001611.1	sp|K1QKQ7|K1QKQ7_CRAGI	8.9e-92	341.7	100.00%	92.73%	Endo-1,3(4)-beta-glucanase 1;OS=Crassostrea;PE=4;SV=1	GO:0052861|
GN006309.1	sp|A0A210PML6|A0A210PML6_MIZYE	1.5e-43	181.8	89.40%	45.96%	Hermansky-Pudlak syndrome 3 protein-like;OS=Mizuhopecten;PE=4;SV=1
GN006915.1	sp|K1PAT4|K1PAT4_CRAGI	0.0e+00	1398.3	95.64%	79.25%	MutS-like protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0030983|	GO:0006298|
GN006918.1	sp|A0A1X7T7W9|A0A1X7T7W9_AMPQE	1.4e-30	138.7	99.50%	37.12%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN006919.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	2.6e-21	108.6	31.01%	42.20%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN006920.1	sp|K1Q6X7|K1Q6X7_CRAGI	5.3e-233	812.4	94.33%	82.23%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016747|	GO:0009058|
GN006923.1	sp|Q5K4M1|Q5K4M1_CRAGI	1.4e-198	697.6	98.07%	86.72%	Glutamine synthetase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004356|	GO:0006542|
GN006924.1	sp|K1Q7D5|K1Q7D5_CRAGI	4.6e-72	276.2	99.40%	85.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006311.1	sp|K1R427|K1R427_CRAGI	4.9e-124	449.5	99.63%	85.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006925.1	sp|K1QEG9|K1QEG9_CRAGI	4.2e-173	613.6	89.81%	67.96%	Spermatogenesis-and oogenesis-specific basic helix-loop-helix-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0048477|GO:0006355|GO:0007283|
GN006930.1	sp|K1PSG4|K1PSG4_CRAGI	8.0e-80	302.4	86.43%	80.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006931.1	sp|K1Q7E2|K1Q7E2_CRAGI	8.6e-205	718.4	100.00%	81.91%	Sperm motility kinase X;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN006932.1	sp|K1QT23|K1QT23_CRAGI	5.2e-271	940.3	55.69%	62.53%	Histone-lysine N-methyltransferase, H3 lysine-9 specific 5;OS=Crassostrea;PE=4;SV=1	GO:0018024|GO:0002039|
GN006933.1	sp|K1Q072|K1Q072_CRAGI	3.3e-131	473.8	98.61%	70.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006934.1	sp|K1QT28|K1QT28_CRAGI	4.4e-155	552.7	99.65%	88.46%	Ectoine hydroxylase;OS=Crassostrea;PE=4;SV=1
GN006936.1	sp|W4YMP2|W4YMP2_STRPU	6.6e-24	116.3	85.08%	49.37%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN006937.1	sp|K1R769|K1R769_CRAGI	3.2e-231	806.6	100.00%	74.50%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN006938.1	sp|K1R0T1|K1R0T1_CRAGI	4.4e-21	106.3	100.00%	86.21%	V-type proton ATPase subunit G;OS=Crassostrea;PE=3;SV=1	GO:0016471|	GO:0042626|	GO:1902600|
GN006312.1	sp|K1QN40|K1QN40_CRAGI	0.0e+00	1793.9	100.00%	81.79%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN006939.1	sp|K1QTP6|K1QTP6_CRAGI	0.0e+00	2138.2	100.00%	89.85%	Cation-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0016887|GO:0046872|	GO:0006812|
GN006940.1	sp|K1QJV5|K1QJV5_CRAGI	5.2e-231	805.8	99.03%	74.39%	Spinster-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN006941.1	sp|K1RRF9|K1RRF9_CRAGI	5.0e-188	662.9	100.00%	84.77%	Homeobox protein extradenticle;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN006942.1	sp|K1RDM4|K1RDM4_CRAGI	4.8e-40	170.6	35.27%	78.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006943.1	sp|K1PP14|K1PP14_CRAGI	2.2e-154	551.6	100.00%	54.11%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006944.1	sp|K1RI47|K1RI47_CRAGI	8.2e-72	276.2	89.12%	51.88%	Fibrinogen-like protein A;OS=Crassostrea;PE=4;SV=1
GN006945.1	sp|K1Q0H5|K1Q0H5_CRAGI	0.0e+00	1320.1	98.86%	64.83%	Suppressor of cytokine signaling 7;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN006947.1	sp|K1Q7N6|K1Q7N6_CRAGI	0.0e+00	2072.7	93.44%	81.49%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN006948.1	sp|K1R5X2|K1R5X2_CRAGI	3.7e-27	126.7	77.78%	54.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006950.1	sp|K1Q6A9|K1Q6A9_CRAGI	8.5e-64	249.2	76.17%	59.44%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN006951.1	sp|K1Q7N6|K1Q7N6_CRAGI	3.8e-87	327.0	100.00%	63.64%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN006313.1	sp|K1R127|K1R127_CRAGI	1.4e-66	258.1	92.70%	73.17%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006952.1	sp|K1Q7N6|K1Q7N6_CRAGI	6.1e-10	68.6	97.10%	62.50%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN006953.1	sp|K1Q7N6|K1Q7N6_CRAGI	3.8e-87	327.0	100.00%	63.64%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN006954.1	sp|K1Q6A9|K1Q6A9_CRAGI	7.5e-64	249.2	86.89%	59.44%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN006955.1	sp|K1Q7N6|K1Q7N6_CRAGI	1.6e-79	300.8	98.72%	93.46%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN006956.1	sp|K1Q7N6|K1Q7N6_CRAGI	4.7e-108	396.7	99.70%	64.13%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN006957.1	sp|K1Q6A9|K1Q6A9_CRAGI	7.5e-64	249.2	86.89%	59.44%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN006959.1	sp|A0A210QT29|A0A210QT29_MIZYE	1.3e-09	69.7	71.56%	25.91%	Glucose-dependent insulinotropic receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN006960.1	sp|A0A210QT29|A0A210QT29_MIZYE	4.4e-12	77.8	89.14%	27.59%	Glucose-dependent insulinotropic receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN006314.1	sp|K1R127|K1R127_CRAGI	3.0e-28	130.6	96.27%	54.19%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006961.1	sp|K1PLD1|K1PLD1_CRAGI	5.9e-212	743.4	73.25%	59.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006962.1	sp|K1RN18|K1RN18_CRAGI	1.2e-217	761.5	85.89%	82.44%	Kinesin-like protein KIF14;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN006963.1	sp|K1RN18|K1RN18_CRAGI	0.0e+00	1337.4	99.02%	81.22%	Kinesin-like protein KIF14;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN006964.1	sp|K1QFY4|K1QFY4_CRAGI	4.5e-35	152.9	96.85%	77.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006965.1	sp|K1QFY4|K1QFY4_CRAGI	4.5e-35	152.9	96.85%	77.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006966.1	sp|K1RN18|K1RN18_CRAGI	3.4e-33	146.4	90.38%	86.02%	Kinesin-like protein KIF14;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN006968.1	sp|K1RN18|K1RN18_CRAGI	3.4e-56	223.4	85.99%	86.03%	Kinesin-like protein KIF14;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN006315.1	sp|K1QU28|K1QU28_CRAGI	4.4e-208	729.9	90.66%	73.67%	HAUS augmin-like complex subunit 5;OS=Crassostrea;PE=4;SV=1	GO:0070652|	GO:0051225|
GN006969.1	sp|A0A210QRM4|A0A210QRM4_MIZYE	0.0e+00	1088.6	100.00%	70.21%	Glycerol-3-phosphate dehydrogenase;OS=Mizuhopecten;PE=3;SV=1	GO:0009331|	GO:0005509|GO:0052591|	GO:0006072|
GN006970.1	sp|K1PNT6|K1PNT6_CRAGI	1.8e-239	835.1	86.51%	54.39%	Protein CASC3;OS=Crassostrea;PE=4;SV=1	GO:0035145|	GO:0003723|	GO:0006397|
GN006972.1	sp|K1R432|K1R432_CRAGI	2.1e-18	98.2	57.00%	38.02%	Cysteine dioxygenase type 1;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0016702|
GN006973.1	sp|A0A210Q009|A0A210Q009_MIZYE	1.8e-85	322.0	85.40%	54.34%	Lupus La protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|GO:1990904|	GO:0003723|	GO:0006396|
GN006975.1	sp|K1QG34|K1QG34_CRAGI	2.6e-107	394.4	91.03%	60.18%	Titin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006976.1	sp|K1QUL2|K1QUL2_CRAGI	6.1e-111	406.0	95.45%	75.30%	Fibropellin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN006977.1	sp|K1QNJ1|K1QNJ1_CRAGI	3.1e-90	337.0	100.00%	77.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006978.1	sp|K1QFG0|K1QFG0_CRAGI	1.5e-124	451.1	100.00%	97.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006979.1	sp|K1QTT9|K1QTT9_CRAGI	2.6e-54	218.0	96.89%	55.36%	Ankycorbin;OS=Crassostrea;PE=4;SV=1
GN006981.1	sp|K1RJ89|K1RJ89_CRAGI	1.3e-67	261.5	93.16%	71.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006233.1	sp|K1QIF3|K1QIF3_CRAGI	6.1e-153	546.2	76.54%	78.57%	UPF0609 protein C4orf27;OS=Crassostrea;PE=4;SV=1
GN006983.1	sp|K1QMM9|K1QMM9_CRAGI	4.6e-77	293.1	98.10%	66.99%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016888|
GN006985.1	sp|V4B0L3|V4B0L3_LOTGI	3.7e-16	90.1	88.55%	39.50%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006986.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	7.0e-23	112.8	97.09%	37.02%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN006988.1	sp|K1R1W5|K1R1W5_CRAGI	5.5e-73	280.4	46.13%	76.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006989.1	sp|W4XV69|W4XV69_STRPU	2.4e-33	147.9	82.16%	42.53%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|	GO:0015074|
GN006990.1	sp|K1QEB1|K1QEB1_CRAGI	6.8e-14	82.4	51.30%	65.52%	Uncharacterized protein C5orf4-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005506|GO:0016491|	GO:0008610|
GN006991.1	sp|K1Q684|K1Q684_CRAGI	1.6e-51	208.8	82.46%	50.96%	Bone morphogenetic protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006992.1	sp|K1RKC1|K1RKC1_CRAGI	1.1e-207	728.8	100.00%	89.36%	Far upstream element-binding protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006355|
GN006993.1	sp|A0A2T7NM51|A0A2T7NM51_POMCA	4.3e-122	443.4	88.07%	67.60%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0008146|
GN006994.1	sp|K1Q005|K1Q005_CRAGI	7.6e-136	489.6	99.79%	58.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006995.1	sp|K1Q723|K1Q723_CRAGI	1.4e-180	637.9	90.53%	89.80%	Rhomboid-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004252|
GN006996.1	sp|K1PWZ8|K1PWZ8_CRAGI	2.4e-310	1069.7	96.77%	74.00%	Ras-specific guanine nucleotide-releasing factor RalGPS1;OS=Crassostrea;PE=4;SV=1	GO:0005085|	GO:0007264|
GN006997.1	sp|K1PH74|K1PH74_CRAGI	1.7e-159	567.8	94.82%	84.15%	Gamma-aminobutyric acid receptor subunit gamma-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006998.1	sp|K1PPY9|K1PPY9_CRAGI	7.7e-61	238.8	99.36%	74.21%	Putative 39S ribosomal protein L24, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN006999.1	sp|V4A8V4|V4A8V4_LOTGI	1.9e-89	334.7	99.29%	53.57%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016757|
GN007001.1	sp|K1QH06|K1QH06_CRAGI	6.6e-51	207.6	36.21%	47.74%	Neural cell adhesion molecule 2;OS=Crassostrea;PE=4;SV=1
GN007002.1	sp|K1QH46|K1QH46_CRAGI	2.1e-95	354.8	98.82%	47.62%	Beta-(1,2)-xylosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016757|
GN007003.1	sp|K1QH06|K1QH06_CRAGI	1.2e-51	209.5	53.68%	48.24%	Neural cell adhesion molecule 2;OS=Crassostrea;PE=4;SV=1
GN006317.1	sp|K1S1G0|K1S1G0_CRAGI	1.5e-106	392.5	60.50%	66.67%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN007006.1	sp|K1QRD6|K1QRD6_CRAGI	1.5e-38	165.2	93.69%	41.06%	Exonuclease 3'-5' domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003676|
GN007007.1	sp|K1P4A9|K1P4A9_CRAGI	2.6e-100	371.3	98.55%	48.40%	Exonuclease 3'-5' domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003676|
GN007008.1	sp|K1P4A9|K1P4A9_CRAGI	3.0e-174	617.1	99.12%	68.01%	Exonuclease 3'-5' domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003676|
GN007009.1	sp|K1P4A9|K1P4A9_CRAGI	8.7e-95	352.4	100.00%	60.49%	Exonuclease 3'-5' domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003676|
GN007010.1	sp|A0A2T7NM65|A0A2T7NM65_POMCA	1.3e-65	255.4	85.21%	53.67%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005576|	GO:0008061|GO:0098599|	GO:0006030|
GN007011.1	sp|K1QHS5|K1QHS5_CRAGI	4.2e-60	237.3	93.22%	50.36%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN006318.1	sp|K1Q5X3|K1Q5X3_CRAGI	5.1e-132	477.2	74.15%	50.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016787|	GO:0016042|
GN007012.1	sp|K1Q297|K1Q297_CRAGI	1.7e-20	104.8	84.62%	35.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007014.1	sp|K1RSS9|K1RSS9_CRAGI	2.2e-22	112.5	19.76%	66.25%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN007015.1	sp|K1R8X0|K1R8X0_CRAGI	1.9e-115	421.8	64.64%	68.69%	Acidic mammalian chitinase;OS=Crassostrea;PE=3;SV=1	GO:0005615|GO:0016021|	GO:0008061|GO:0004553|	GO:0005975|GO:0045766|
GN007016.1	sp|K1QLB1|K1QLB1_CRAGI	9.6e-159	565.1	99.38%	85.22%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN007017.1	sp|K1RSS7|K1RSS7_CRAGI	9.4e-94	348.6	100.00%	79.72%	Death-associated protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN007018.1	sp|K1PIY5|K1PIY5_CRAGI	1.7e-232	810.4	100.00%	94.84%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN007020.1	sp|K1PE19|K1PE19_CRAGI	2.6e-53	214.2	96.08%	52.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006319.1	sp|K1RE87|K1RE87_CRAGI	5.7e-28	130.2	84.91%	38.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007022.1	sp|K1PYX2|K1PYX2_CRAGI	3.8e-120	436.4	100.00%	84.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016790|	GO:0006633|
GN007023.1	sp|K1PYX2|K1PYX2_CRAGI	3.8e-120	436.4	100.00%	84.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016790|	GO:0006633|
GN007024.1	sp|A0A2T7NGI6|A0A2T7NGI6_POMCA	0.0e+00	1532.7	96.56%	27.95%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN007025.1	sp|K1PRD0|K1PRD0_CRAGI	4.2e-215	755.0	66.55%	32.12%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN007026.1	sp|A0A2T7NGI6|A0A2T7NGI6_POMCA	7.6e-214	750.7	99.95%	29.48%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN007029.1	sp|K1PXN3|K1PXN3_CRAGI	3.7e-09	67.8	51.22%	33.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007030.1	sp|K1PQR4|K1PQR4_CRAGI	3.4e-162	577.0	98.00%	62.56%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN007032.1	sp|K1QA61|K1QA61_CRAGI	4.5e-226	789.3	99.12%	84.96%	Histone-lysine N-methyltransferase PRDM9;OS=Crassostrea;PE=4;SV=1	GO:0008168|	GO:0035556|
GN007033.1	sp|K1PYF4|K1PYF4_CRAGI	1.1e-32	146.0	57.48%	51.03%	Putative ankyrin repeat protein L93;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN007034.1	sp|K1P0Z3|K1P0Z3_CRAGI	3.1e-91	340.5	80.54%	78.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|
GN007035.1	sp|K1P486|K1P486_CRAGI	2.0e-300	1036.6	100.00%	86.75%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007036.1	sp|K1PAR0|K1PAR0_CRAGI	0.0e+00	1142.5	99.91%	58.43%	PDZ domain-containing protein 8;OS=Crassostrea;PE=4;SV=1	GO:0044233|GO:0005739|	GO:0051560|GO:1990456|
GN007038.1	sp|K1PMB3|K1PMB3_CRAGI	1.1e-46	191.4	100.00%	72.22%	Amiloride-sensitive cation channel 5;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN007039.1	sp|K1PSL6|K1PSL6_CRAGI	1.6e-29	136.0	43.43%	50.99%	Usher syndrome type-1G-like protein;OS=Crassostrea;PE=4;SV=1
GN007041.1	sp|K1QYN5|K1QYN5_CRAGI	0.0e+00	1330.1	97.68%	70.74%	Sorting nexin-25;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0035091|	GO:0000350|GO:0030512|
GN007042.1	sp|K1R4Z0|K1R4Z0_CRAGI	6.2e-82	309.7	63.87%	83.52%	Protein Star;OS=Crassostrea;PE=4;SV=1
GN007044.1	sp|K1RPF7|K1RPF7_CRAGI	1.6e-155	554.3	100.00%	92.03%	60S ribosomal protein L5;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0008097|GO:0003735|	GO:0006412|
GN007045.1	sp|K1QHJ9|K1QHJ9_CRAGI	5.1e-237	827.4	97.98%	72.84%	Coiled-coil domain-containing protein 18;OS=Crassostrea;PE=4;SV=1
GN007046.1	sp|A0A210Q8P4|A0A210Q8P4_MIZYE	3.9e-37	162.2	86.66%	24.71%	Cyclic GMP-AMP synthase;OS=Mizuhopecten;PE=4;SV=1
GN007047.1	sp|A0A210Q8P4|A0A210Q8P4_MIZYE	2.9e-34	152.5	91.31%	24.18%	Cyclic GMP-AMP synthase;OS=Mizuhopecten;PE=4;SV=1
GN007048.1	sp|A0A210PTU1|A0A210PTU1_MIZYE	1.3e-21	107.8	84.47%	53.49%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN007049.1	sp|K1QRC1|K1QRC1_CRAGI	2.9e-54	216.9	88.28%	79.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN007054.1	sp|K1PLY0|K1PLY0_CRAGI	3.3e-266	923.3	99.48%	62.37%	Zer-1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0031462|
GN007057.1	sp|K1PZL9|K1PZL9_CRAGI	1.0e-238	831.6	98.85%	66.39%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007058.1	sp|K1QZA6|K1QZA6_CRAGI	1.7e-231	807.7	92.00%	67.30%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007059.1	sp|K1RLE2|K1RLE2_CRAGI	1.4e-180	638.3	99.59%	62.83%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007060.1	sp|K1S4S8|K1S4S8_CRAGI	8.1e-56	222.6	97.31%	53.18%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007068.1	sp|K1Q730|K1Q730_CRAGI	1.1e-53	215.3	100.00%	56.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007069.1	sp|K1QPQ0|K1QPQ0_CRAGI	2.8e-48	197.2	94.74%	56.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007070.1	sp|A0A210Q4E4|A0A210Q4E4_MIZYE	7.1e-89	333.2	98.38%	39.35%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007071.1	sp|A0A210Q4E4|A0A210Q4E4_MIZYE	2.0e-122	444.9	88.09%	55.08%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007072.1	sp|K1RGG5|K1RGG5_CRAGI	2.4e-147	528.9	76.56%	39.69%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN007073.1	sp|K1QJ14|K1QJ14_CRAGI	8.1e-197	692.6	94.18%	61.24%	Histone H4 transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007074.1	sp|K1QYV7|K1QYV7_CRAGI	6.8e-74	282.7	66.96%	84.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007075.1	sp|K1PUD3|K1PUD3_CRAGI	4.1e-17	93.2	51.64%	70.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007076.1	sp|K1PUD3|K1PUD3_CRAGI	4.1e-17	93.2	51.64%	70.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007077.1	sp|K1PUD3|K1PUD3_CRAGI	1.4e-17	94.7	51.64%	72.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007078.1	sp|K1RA88|K1RA88_CRAGI	2.8e-14	84.3	55.56%	36.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007079.1	sp|K1RU68|K1RU68_CRAGI	3.5e-31	139.8	91.96%	62.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007080.1	sp|K1PP23|K1PP23_CRAGI	1.4e-82	312.0	89.23%	56.67%	Chymotrypsin-like serine proteinase;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN007081.1	sp|K1PP23|K1PP23_CRAGI	1.4e-82	312.0	89.23%	56.67%	Chymotrypsin-like serine proteinase;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN007082.1	sp|K1PP23|K1PP23_CRAGI	2.2e-82	311.2	93.97%	56.67%	Chymotrypsin-like serine proteinase;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN006321.1	sp|K1Q5X3|K1Q5X3_CRAGI	6.7e-133	479.9	87.12%	49.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016787|	GO:0016042|
GN007084.1	sp|K1PP23|K1PP23_CRAGI	9.2e-68	262.7	89.97%	50.00%	Chymotrypsin-like serine proteinase;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN007085.1	sp|K1QXE7|K1QXE7_CRAGI	2.0e-97	361.7	93.13%	55.59%	Orexin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN007086.1	sp|K1PH66|K1PH66_CRAGI	1.8e-87	328.9	99.18%	37.84%	Fibrinolytic enzyme, isozyme C;OS=Crassostrea;PE=4;SV=1	GO:0004252|
GN007087.1	sp|K1PSW7|K1PSW7_CRAGI	2.1e-149	534.3	99.47%	68.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN007088.1	sp|K1P9X1|K1P9X1_CRAGI	0.0e+00	1781.5	93.41%	77.72%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN007089.1	sp|K1P371|K1P371_CRAGI	2.1e-225	786.9	98.83%	88.18%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN007090.1	sp|K1P9W8|K1P9W8_CRAGI	0.0e+00	2822.0	46.55%	79.74%	Supervillin;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0007010|
GN007091.1	sp|K1QWT8|K1QWT8_CRAGI	2.7e-32	145.2	89.76%	33.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007092.1	sp|T1KE54|T1KE54_TETUR	3.3e-211	739.6	100.00%	93.88%	Uncharacterized protein;OS=Tetranychus;PE=3;SV=1	GO:0005524|
GN007093.1	sp|T1KE54|T1KE54_TETUR	2.8e-210	736.5	100.00%	93.35%	Uncharacterized protein;OS=Tetranychus;PE=3;SV=1	GO:0005524|
GN007094.1	sp|K1QWP8|K1QWP8_CRAGI	2.6e-211	740.0	100.00%	93.88%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN007097.1	sp|V4BNP4|V4BNP4_LOTGI	9.1e-86	324.3	42.37%	43.98%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN007098.1	sp|K1Q9V3|K1Q9V3_CRAGI	0.0e+00	1239.2	100.00%	95.13%	V-type proton ATPase catalytic subunit A;OS=Crassostrea;PE=3;SV=1	GO:0033180|	GO:0005524|GO:0046961|	GO:0015991|GO:0046034|
GN007099.1	sp|K1PP09|K1PP09_CRAGI	2.9e-80	303.9	87.29%	69.23%	3-oxo-5-alpha-steroid 4-dehydrogenase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016627|	GO:0006629|
GN007100.1	sp|K1QL29|K1QL29_CRAGI	5.6e-20	102.8	86.57%	51.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007101.1	sp|K1PV26|K1PV26_CRAGI	1.9e-26	124.8	82.87%	44.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007103.1	sp|K1PH59|K1PH59_CRAGI	3.1e-240	836.6	100.00%	82.34%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007104.1	sp|K1Q9V3|K1Q9V3_CRAGI	7.6e-255	885.2	99.83%	77.85%	V-type proton ATPase catalytic subunit A;OS=Crassostrea;PE=3;SV=1	GO:0033180|	GO:0005524|GO:0046961|	GO:0015991|GO:0046034|
GN006322.1	sp|K1R2G8|K1R2G8_CRAGI	0.0e+00	1325.8	92.96%	85.80%	Titin;OS=Crassostrea;PE=4;SV=1
GN007105.1	sp|A0A1X7UEV0|A0A1X7UEV0_AMPQE	1.8e-47	196.8	77.78%	25.19%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046872|
GN007107.1	sp|K1QJA6|K1QJA6_CRAGI	2.6e-18	97.4	43.45%	77.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007108.1	sp|K1Q8V0|K1Q8V0_CRAGI	3.7e-68	264.2	86.39%	55.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007109.1	sp|K1QU93|K1QU93_CRAGI	2.8e-33	148.3	37.89%	52.89%	Oncoprotein-induced transcript 3 protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN007111.1	sp|K1RMR8|K1RMR8_CRAGI	2.2e-257	893.6	85.93%	83.82%	WD repeat-containing protein 46;OS=Crassostrea;PE=4;SV=1
GN007112.1	sp|K1PTS2|K1PTS2_CRAGI	1.2e-127	461.8	99.70%	67.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN007113.1	sp|K1QFN5|K1QFN5_CRAGI	5.4e-202	709.5	98.36%	62.45%	Sushi repeat-containing protein SRPX2;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016491|
GN007114.1	sp|K1QFN5|K1QFN5_CRAGI	1.2e-75	288.5	90.09%	67.84%	Sushi repeat-containing protein SRPX2;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016491|
GN007115.1	sp|K1QFP9|K1QFP9_CRAGI	2.4e-103	380.9	67.79%	87.06%	Ectoine hydroxylase;OS=Crassostrea;PE=4;SV=1
GN006234.1	sp|K1PVI2|K1PVI2_CRAGI	3.6e-44	185.7	35.27%	41.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007116.1	sp|A0A3M6TME7|A0A3M6TME7_9CNID	1.2e-18	100.5	25.09%	39.44%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN007117.1	sp|K1RJU5|K1RJU5_CRAGI	5.9e-49	198.7	100.00%	86.54%	Mannan endo-1,4-beta-mannosidase;OS=Crassostrea;PE=4;SV=1
GN007118.1	sp|A0A2G8KHR3|A0A2G8KHR3_STIJA	2.1e-36	157.9	74.21%	53.57%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0016021|
GN006323.1	sp|K1QEI3|K1QEI3_CRAGI	1.9e-199	700.7	100.00%	82.42%	Myosin light chain kinase, smooth muscle;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN007121.1	sp|K1P828|K1P828_CRAGI	2.3e-121	441.0	91.64%	64.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007122.1	sp|K1QJF7|K1QJF7_CRAGI	0.0e+00	1432.5	98.16%	79.40%	Coronin;OS=Crassostrea;PE=3;SV=1	GO:0005794|
GN007123.1	sp|K1QQZ1|K1QQZ1_CRAGI	2.2e-176	624.4	89.77%	67.65%	DnaJ-like protein subfamily A member 3, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0031072|GO:0046872|GO:0051082|	GO:0006457|GO:0009408|
GN007125.1	sp|K1QBI1|K1QBI1_CRAGI	0.0e+00	1132.5	89.96%	91.46%	CAS1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007126.1	sp|K1R600|K1R600_CRAGI	0.0e+00	2083.1	100.00%	71.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007127.1	sp|K1QKS0|K1QKS0_CRAGI	5.0e-78	297.0	62.12%	68.63%	mTERF domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003690|	GO:0006355|
GN006324.1	sp|K1QVQ0|K1QVQ0_CRAGI	2.0e-46	191.4	61.23%	65.22%	PR domain zinc finger protein 12;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007128.1	sp|K1PXU3|K1PXU3_CRAGI	6.9e-53	212.6	98.37%	56.11%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN007129.1	sp|K1PXU3|K1PXU3_CRAGI	2.8e-40	170.2	98.47%	58.59%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN007131.1	sp|K1PI86|K1PI86_CRAGI	3.9e-258	896.3	100.00%	75.66%	Translation initiation factor eIF-2B subunit epsilon;OS=Crassostrea;PE=4;SV=1	GO:0016779|GO:0003743|
GN007132.1	sp|K1PBV0|K1PBV0_CRAGI	1.5e-264	917.1	97.79%	93.20%	UDP-glucose 6-dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0003979|
GN007133.1	sp|K1QG34|K1QG34_CRAGI	9.3e-23	113.2	88.29%	32.36%	Titin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007134.1	sp|K1QI20|K1QI20_CRAGI	2.3e-10	71.6	21.27%	65.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007135.1	sp|K1QT26|K1QT26_CRAGI	1.2e-255	889.4	46.05%	69.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006325.1	sp|K1QN37|K1QN37_CRAGI	4.4e-20	104.4	18.54%	85.45%	WD repeat-containing protein 38;OS=Crassostrea;PE=4;SV=1
GN007136.1	sp|K1RQY2|K1RQY2_CRAGI	0.0e+00	1987.2	100.00%	74.75%	Helicase SKI2W;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003723|GO:0003724|	GO:0006401|
GN007140.1	sp|K1RUI7|K1RUI7_CRAGI	3.7e-17	93.6	62.33%	53.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007141.1	sp|W4YMP2|W4YMP2_STRPU	6.3e-22	109.8	77.47%	48.28%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN006326.1	sp|K1QW35|K1QW35_CRAGI	5.8e-95	353.2	85.58%	60.57%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007142.1	sp|K1R4A6|K1R4A6_CRAGI	1.4e-74	285.8	49.75%	63.86%	Basement membrane-specific heparan sulfate proteoglycan core protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007143.1	sp|K1QXC5|K1QXC5_CRAGI	3.1e-161	573.9	97.94%	59.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007145.1	sp|K1RUI2|K1RUI2_CRAGI	1.4e-130	472.2	66.99%	63.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN007146.1	sp|K1R4A2|K1R4A2_CRAGI	0.0e+00	2162.1	100.00%	68.37%	Pericentriolar material 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0005813|	GO:0060271|GO:0034454|GO:0071539|
GN007147.1	sp|K1QXC0|K1QXC0_CRAGI	1.6e-278	964.5	99.89%	55.36%	Exonuclease 3'-5' domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008408|GO:0003676|
GN007148.1	sp|K1QNA7|K1QNA7_CRAGI	2.6e-222	776.9	100.00%	90.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007149.1	sp|K1RAT7|K1RAT7_CRAGI	0.0e+00	1733.8	99.66%	76.15%	Inverted formin-2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN007151.1	sp|K1QXB5|K1QXB5_CRAGI	2.1e-263	914.1	83.02%	90.43%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006327.1	sp|K1QW35|K1QW35_CRAGI	9.3e-116	422.5	98.46%	56.36%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007152.1	sp|K1QNA0|K1QNA0_CRAGI	0.0e+00	1367.1	99.80%	82.93%	Inverted formin-2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN007153.1	sp|K1Q9C3|K1Q9C3_CRAGI	2.1e-190	670.6	100.00%	92.44%	Transcription factor Sp8;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007154.1	sp|K1QHD9|K1QHD9_CRAGI	1.0e-149	535.4	77.25%	83.82%	Transcription factor Sp8;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007155.1	sp|K1R8Y1|K1R8Y1_CRAGI	2.4e-215	753.4	100.00%	91.46%	Obg-like ATPase 1;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0016887|GO:0005525|GO:0043023|GO:0043022|
GN007156.1	sp|K1RST5|K1RST5_CRAGI	0.0e+00	2660.6	99.73%	76.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007157.1	sp|K1R277|K1R277_CRAGI	5.6e-86	322.8	95.87%	72.12%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN007159.1	sp|K1QVH7|K1QVH7_CRAGI	0.0e+00	1936.4	95.24%	71.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007160.1	sp|K1R281|K1R281_CRAGI	1.3e-44	186.8	20.71%	71.90%	RNA (Guanine-9-)-methyltransferase domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN007160.1	sp|K1R281|K1R281_CRAGI	7.2e-11	74.7	21.90%	50.78%	RNA (Guanine-9-)-methyltransferase domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN007161.1	sp|K1R8Y8|K1R8Y8_CRAGI	3.0e-129	466.8	91.51%	89.88%	Nucleotide-binding-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN007162.1	sp|K1RSU3|K1RSU3_CRAGI	2.0e-97	361.3	83.33%	70.38%	N-glycosylase/DNA lyase;OS=Crassostrea;PE=4;SV=1	GO:0003684|GO:0016829|GO:0008534|	GO:0006284|GO:0006289|
GN007163.1	sp|A0A210R137|A0A210R137_MIZYE	6.6e-241	839.3	99.88%	58.32%	Leucine-rich repeat and IQ domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1
GN006329.1	sp|K1QW35|K1QW35_CRAGI	4.6e-118	430.3	99.00%	54.41%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007164.1	sp|K1QVI0|K1QVI0_CRAGI	1.8e-188	664.1	95.38%	90.84%	Isocitrate dehydrogenase [NAD] subunit, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0004449|GO:0000287|GO:0051287|GO:0008233|	GO:0006099|
GN007167.1	sp|K1RSU8|K1RSU8_CRAGI	1.7e-15	86.7	96.36%	75.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006330.1	sp|K1QW35|K1QW35_CRAGI	9.3e-116	422.5	98.46%	56.36%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007169.1	sp|A0A2C9KNJ8|A0A2C9KNJ8_BIOGL	1.7e-28	131.0	100.00%	57.26%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN007170.1	sp|K1QVI7|K1QVI7_CRAGI	1.3e-206	725.3	61.56%	80.18%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN007171.1	sp|A0A210QEF3|A0A210QEF3_MIZYE	8.1e-60	235.7	76.53%	69.80%	Deoxycytidylate deaminase;OS=Mizuhopecten;PE=4;SV=1	GO:0004132|GO:0008270|	GO:0006220|
GN007172.1	sp|K1PIP9|K1PIP9_CRAGI	5.6e-81	305.8	98.82%	85.03%	Deoxycytidylate deaminase;OS=Crassostrea;PE=4;SV=1	GO:0004132|GO:0008270|	GO:0006220|
GN007173.1	sp|A0A210PNL8|A0A210PNL8_MIZYE	4.5e-162	577.0	100.00%	74.66%	Protein Red;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0007094|
GN007175.1	sp|K1QB58|K1QB58_CRAGI	2.2e-278	964.1	97.72%	81.04%	Oral-facial-digital syndrome 1 protein;OS=Crassostrea;PE=4;SV=1
GN007176.1	sp|K1PQR1|K1PQR1_CRAGI	0.0e+00	1328.9	95.04%	70.15%	Cyclin-dependent kinase-like 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN006235.1	sp|K1Q371|K1Q371_CRAGI	8.9e-259	898.3	100.00%	76.55%	Cysteine/serine-rich nuclear protein 3;OS=Crassostrea;PE=4;SV=1
GN006331.1	sp|K1QW35|K1QW35_CRAGI	1.5e-116	425.2	99.00%	55.81%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007177.1	sp|K1PBC4|K1PBC4_CRAGI	0.0e+00	2038.5	100.00%	84.07%	WD repeat-containing protein 17;OS=Crassostrea;PE=4;SV=1
GN007178.1	sp|A0A210QVT7|A0A210QVT7_MIZYE	1.8e-41	175.6	74.71%	47.10%	Gem-associated protein 8;OS=Mizuhopecten;PE=4;SV=1	GO:0032797|	GO:0000387|
GN007180.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	6.7e-12	76.3	73.42%	33.91%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN007181.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	6.4e-19	99.4	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN007182.1	sp|K1PFG1|K1PFG1_CRAGI	3.9e-190	669.8	98.89%	69.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN006332.1	sp|K1QS80|K1QS80_CRAGI	5.9e-13	80.5	49.43%	32.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007183.1	sp|K1QBR5|K1QBR5_CRAGI	2.3e-112	410.6	99.60%	83.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN007184.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	1419.4	96.09%	58.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN007185.1	sp|K1QBR5|K1QBR5_CRAGI	8.9e-79	299.3	91.07%	54.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN007186.1	sp|K1PFG1|K1PFG1_CRAGI	6.8e-53	214.2	95.43%	46.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN007187.1	sp|K1PFG1|K1PFG1_CRAGI	0.0e+00	1323.5	99.53%	58.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN007188.1	sp|K1QZM7|K1QZM7_CRAGI	2.1e-175	620.5	93.02%	94.98%	Cell division protein kinase 9;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0051301|
GN007189.1	sp|K1QDN4|K1QDN4_CRAGI	1.1e-83	314.7	100.00%	97.53%	UPF0428 protein CXorf56;OS=Crassostrea;PE=4;SV=1
GN007191.1	sp|K1PIP2|K1PIP2_CRAGI	6.4e-61	239.2	90.53%	76.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004521|
GN007192.1	sp|K1PIP2|K1PIP2_CRAGI	1.5e-29	134.0	80.90%	84.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004521|
GN006333.1	sp|K1QEI0|K1QEI0_CRAGI	8.2e-59	232.6	95.26%	54.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007193.1	sp|K1PIP2|K1PIP2_CRAGI	3.7e-117	426.8	99.66%	70.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004521|
GN007194.1	sp|K1PBC0|K1PBC0_CRAGI	5.6e-248	862.4	100.00%	83.57%	Non-neuronal cytoplasmic intermediate filament protein;OS=Crassostrea;PE=3;SV=1	GO:0005882|	GO:0005198|
GN007195.1	sp|K1QB49|K1QB49_CRAGI	2.8e-167	594.3	99.67%	54.57%	RNA polymerase II-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0043175|GO:0008420|	GO:0070940|
GN007196.1	sp|V4CE76|V4CE76_LOTGI	9.9e-39	165.6	51.87%	85.42%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0046982|
GN007198.1	sp|V4AKX4|V4AKX4_LOTGI	1.7e-33	148.3	78.24%	47.71%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN007199.1	sp|K1R9U9|K1R9U9_CRAGI	3.0e-26	124.0	72.19%	48.76%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN007200.1	sp|K1RJU5|K1RJU5_CRAGI	5.9e-49	198.7	100.00%	86.54%	Mannan endo-1,4-beta-mannosidase;OS=Crassostrea;PE=4;SV=1
GN007202.1	sp|A0A210Q029|A0A210Q029_MIZYE	2.6e-117	427.2	100.00%	78.97%	Prohibitin;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|
GN007206.1	sp|K1R9K0|K1R9K0_CRAGI	0.0e+00	2364.0	93.69%	91.17%	Vacuolar protein sorting-associated protein 8-like protein;OS=Crassostrea;PE=4;SV=1
GN007207.1	sp|K1R2V1|K1R2V1_CRAGI	0.0e+00	1537.3	84.88%	77.27%	Importin subunit beta-1;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0008536|	GO:0006606|
GN007208.1	sp|K1QCC1|K1QCC1_CRAGI	2.4e-117	427.2	100.00%	91.36%	Phosphoglycerate kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004618|	GO:0006096|
GN007209.1	sp|K1PWV7|K1PWV7_CRAGI	1.8e-216	758.8	42.40%	88.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN007210.1	sp|A0A210QE83|A0A210QE83_MIZYE	5.4e-81	306.6	96.82%	53.17%	L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase;OS=Mizuhopecten;PE=4;SV=1	GO:0008897|GO:0000287|
GN007211.1	sp|K1QP18|K1QP18_CRAGI	1.2e-249	868.2	99.06%	66.94%	Activating signal cointegrator 1 complex subunit 2;OS=Crassostrea;PE=4;SV=1
GN007212.1	sp|K1PBX2|K1PBX2_CRAGI	8.0e-70	270.0	47.77%	66.20%	BUD13-like protein;OS=Crassostrea;PE=4;SV=1
GN007213.1	sp|A0A210Q2G0|A0A210Q2G0_MIZYE	0.0e+00	1179.9	99.64%	56.86%	Ubiquitin carboxyl-terminal hydrolase 25;OS=Mizuhopecten;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN007214.1	sp|K1RA28|K1RA28_CRAGI	0.0e+00	1734.9	99.62%	54.09%	Abnormal spindle-like microcephaly-associated-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007051|
GN007215.1	sp|A0A210R194|A0A210R194_MIZYE	1.2e-68	266.5	47.02%	53.14%	Influenza virus NS1A-binding protein-like;OS=Mizuhopecten;PE=4;SV=1
GN007216.1	sp|A0A2C9L3L9|A0A2C9L3L9_BIOGL	7.0e-234	815.8	98.04%	58.05%	Uncharacterized protein;OS=Biomphalaria;PE=3;SV=1
GN007218.1	sp|A0A2T7PLS3|A0A2T7PLS3_POMCA	0.0e+00	1387.5	78.10%	61.21%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0007064|
GN007219.1	sp|K1Q363|K1Q363_CRAGI	0.0e+00	1364.7	100.00%	88.53%	Anaphase-promoting complex subunit 2;OS=Crassostrea;PE=3;SV=1	GO:0031625|	GO:0006511|
GN007220.1	sp|A0A210PY39|A0A210PY39_MIZYE	0.0e+00	2259.2	85.83%	72.13%	WD repeat-containing protein 52;OS=Mizuhopecten;PE=4;SV=1
GN007221.1	sp|K1QPV1|K1QPV1_CRAGI	1.8e-190	671.8	99.00%	55.85%	Protein-associating with the carboxyl-terminal domain of ezrin;OS=Crassostrea;PE=4;SV=1
GN007224.1	sp|K1Q982|K1Q982_CRAGI	0.0e+00	1328.5	88.81%	83.32%	Malignant fibrous histiocytoma-amplified sequence 1;OS=Crassostrea;PE=4;SV=1
GN007225.1	sp|K1Q1V1|K1Q1V1_CRAGI	3.9e-91	340.1	99.21%	71.88%	Glutamate decarboxylase 1;OS=Crassostrea;PE=3;SV=1	GO:0016831|GO:0030170|	GO:0019752|
GN007226.1	sp|K1R296|K1R296_CRAGI	5.6e-100	369.8	98.36%	72.67%	Ankyrin repeat domain-containing protein 33B;OS=Crassostrea;PE=4;SV=1
GN007227.1	sp|K1RLU6|K1RLU6_CRAGI	9.8e-189	665.2	96.97%	71.59%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN007228.1	sp|K1QEK6|K1QEK6_CRAGI	3.0e-11	73.2	52.94%	77.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007229.1	sp|V3ZVN5|V3ZVN5_LOTGI	1.3e-81	308.9	100.00%	90.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN007230.1	sp|K1QVT5|K1QVT5_CRAGI	2.6e-198	697.2	99.60%	66.87%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007231.1	sp|K1R2J0|K1R2J0_CRAGI	1.4e-243	847.4	99.79%	88.09%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007232.1	sp|K1R2J0|K1R2J0_CRAGI	5.9e-50	202.2	92.24%	90.57%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007233.1	sp|K1S3V3|K1S3V3_CRAGI	1.2e-19	102.1	58.79%	50.00%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007234.1	sp|K1R2J0|K1R2J0_CRAGI	2.5e-51	208.4	99.16%	31.92%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007235.1	sp|K1PIA1|K1PIA1_CRAGI	0.0e+00	1625.9	64.82%	71.72%	CAP-Gly domain-containing linker protein 1;OS=Crassostrea;PE=4;SV=1
GN007236.1	sp|K1PR40|K1PR40_CRAGI	0.0e+00	1371.7	100.00%	69.98%	Sterol regulatory element-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046983|	GO:0006355|
GN006236.1	sp|K1Q8K0|K1Q8K0_CRAGI	0.0e+00	1285.4	100.00%	85.02%	Vacuolar protein sorting-associated protein 53-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005829|GO:0000938|	GO:0042147|
GN007237.1	sp|K1QI43|K1QI43_CRAGI	5.2e-107	393.3	99.70%	66.48%	Sequestosome-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007238.1	sp|K1QIL7|K1QIL7_CRAGI	1.6e-166	591.7	92.60%	83.37%	Tetratricopeptide repeat protein 29;OS=Crassostrea;PE=4;SV=1
GN007240.1	sp|K1PIU6|K1PIU6_CRAGI	7.2e-11	72.8	43.23%	57.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007241.1	sp|K1PRN7|K1PRN7_CRAGI	2.0e-145	520.8	100.00%	87.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007242.1	sp|K1PU74|K1PU74_CRAGI	0.0e+00	1168.3	99.87%	85.96%	AMY-1-associating protein expressed in testis 1;OS=Crassostrea;PE=4;SV=1
GN007243.1	sp|K1Q1J3|K1Q1J3_CRAGI	1.8e-195	687.6	91.20%	87.84%	Homeobox protein PKNOX2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN007244.1	sp|A0A210PYS2|A0A210PYS2_MIZYE	5.0e-22	110.5	54.44%	46.43%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007246.1	sp|A0A384T7F7|A0A384T7F7_CRAHO	1.2e-118	432.6	97.21%	46.61%	Apoptosis 1 inhibitor;OS=Crassostrea;PE=2;SV=1
GN007247.1	sp|K1PIJ3|K1PIJ3_CRAGI	1.9e-98	364.4	94.67%	77.83%	Lamin-B receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016628|
GN007248.1	sp|K1PB82|K1PB82_CRAGI	2.7e-127	460.3	99.61%	90.94%	Electron transfer flavoprotein subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0009055|
GN006336.1	sp|K1QE87|K1QE87_CRAGI	1.1e-150	538.5	97.15%	77.29%	Octopressin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007250.1	sp|K1S395|K1S395_CRAGI	6.7e-33	145.6	83.19%	64.08%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN007251.1	sp|K1QJN2|K1QJN2_CRAGI	2.6e-24	116.3	100.00%	81.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN006337.1	sp|K1PTY6|K1PTY6_CRAGI	7.0e-292	1008.8	99.33%	79.40%	Serine/threonine-protein phosphatase 1 regulatory subunit 10;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046872|
GN007256.1	sp|K1QHE3|K1QHE3_CRAGI	3.3e-249	866.7	89.36%	64.87%	L-ascorbate oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN007257.1	sp|K1QQ39|K1QQ39_CRAGI	3.9e-77	294.7	44.27%	61.72%	Ras-related protein RHA1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN007259.1	sp|K1QQ39|K1QQ39_CRAGI	1.4e-73	281.6	78.90%	77.96%	Ras-related protein RHA1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN007260.1	sp|K1QWE4|K1QWE4_CRAGI	2.7e-192	677.2	94.40%	71.28%	Tyrosine-protein kinase Fps85D;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN007261.1	sp|K1RGM5|K1RGM5_CRAGI	1.3e-148	531.6	97.26%	72.32%	Tubulin polyglutamylase TTLL11;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0006464|
GN007262.1	sp|K1Q984|K1Q984_CRAGI	6.9e-49	198.7	100.00%	79.51%	Tubulin polyglutamylase TTLL11;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0006464|
GN007263.1	sp|K1QHE8|K1QHE8_CRAGI	5.3e-63	246.5	100.00%	53.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007264.1	sp|K1QQ41|K1QQ41_CRAGI	1.2e-79	302.0	92.42%	66.67%	Short transient receptor potential channel 7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN007267.1	sp|K1QHF2|K1QHF2_CRAGI	1.4e-175	620.9	100.00%	93.61%	Protein Wnt;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0005102|	GO:0007275|GO:0016055|
GN006339.1	sp|G4VGX6|G4VGX6_SCHMA	3.8e-17	93.6	79.73%	38.98%	Uncharacterized protein;OS=Schistosoma;PE=3;SV=1	GO:0005739|GO:0005840|	GO:0003735|	GO:0032543|
GN007269.1	sp|K1PDM5|K1PDM5_CRAGI	4.3e-62	244.2	83.06%	83.66%	Surfeit locus protein 6;OS=Crassostrea;PE=4;SV=1
GN007270.1	sp|K1PT87|K1PT87_CRAGI	0.0e+00	3279.2	100.00%	56.44%	Histone-lysine N-methyltransferase MLL4;OS=Crassostrea;PE=4;SV=1	GO:0071339|	GO:0003677|GO:0042800|GO:0046872|
GN006340.1	sp|K1PLX0|K1PLX0_CRAGI	4.9e-272	943.0	100.00%	63.40%	Hamartin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007271.1	sp|K1PLG8|K1PLG8_CRAGI	7.8e-97	359.0	99.17%	77.18%	Brain-specific homeobox-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN007272.1	sp|R7TMT4|R7TMT4_CAPTE	7.5e-17	92.0	97.03%	41.24%	Uncharacterized protein;OS=Capitella;PE=4;SV=1	GO:0003676|
GN007275.1	sp|K1QPY5|K1QPY5_CRAGI	4.5e-169	599.7	99.52%	71.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN006341.1	sp|K1PE33|K1PE33_CRAGI	4.9e-246	855.9	100.00%	79.31%	Radial spoke head protein 4-like protein A;OS=Crassostrea;PE=4;SV=1
GN007277.1	sp|K1R253|K1R253_CRAGI	1.5e-78	297.7	100.00%	86.14%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN007278.1	sp|K1R8W8|K1R8W8_CRAGI	4.7e-75	286.2	96.57%	78.29%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN007279.1	sp|K1RSS3|K1RSS3_CRAGI	0.0e+00	1511.1	43.35%	86.61%	Myosin heavy chain, striated muscle;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0051015|GO:0005524|GO:0003774|
GN007281.1	sp|K1QHI2|K1QHI2_CRAGI	6.1e-29	132.1	97.87%	68.13%	Heterogeneous nuclear ribonucleoprotein L;OS=Crassostrea;PE=4;SV=1	GO:0005634|GO:0019013|	GO:0003723|	GO:0006397|
GN006342.1	sp|K1P7Z6|K1P7Z6_CRAGI	1.8e-33	147.5	100.00%	68.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007284.1	sp|K1Q6T5|K1Q6T5_CRAGI	2.0e-52	211.8	49.35%	63.58%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN007287.1	sp|W4XY62|W4XY62_STRPU	5.5e-23	114.0	74.67%	33.04%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0016788|GO:0003676|GO:0008270|	GO:0015074|
GN007289.1	sp|A0A1X7UA26|A0A1X7UA26_AMPQE	5.7e-24	116.7	72.28%	42.18%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN007290.1	sp|A0A210Q2M1|A0A210Q2M1_MIZYE	1.4e-27	128.3	86.58%	47.92%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|
GN007292.1	sp|C3YY91|C3YY91_BRAFL	1.1e-11	76.6	32.26%	38.18%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN006237.1	sp|K1QAR1|K1QAR1_CRAGI	6.0e-287	991.9	99.50%	84.53%	Protein PTHB1;OS=Crassostrea;PE=4;SV=1	GO:0034464|
GN007293.1	sp|A0A1X7TSC4|A0A1X7TSC4_AMPQE	5.1e-22	109.8	70.75%	46.09%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN007294.1	sp|A0A1S3H413|A0A1S3H413_LINUN	2.1e-27	127.5	97.01%	47.73%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN007296.1	sp|K1PI99|K1PI99_CRAGI	2.7e-91	340.5	94.71%	80.47%	Tyrosine-protein kinase transmembrane receptor Ror;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004713|
GN007297.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.0e-101	375.6	61.12%	49.60%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN007298.1	sp|A0A2B4SGV1|A0A2B4SGV1_STYPI	4.5e-32	142.9	86.89%	64.76%	Zinc finger BED domain-containing protein 1;OS=Stylophora;PE=4;SV=1	GO:0008234|GO:0003677|GO:0046983|
GN006344.1	sp|K1QF49|K1QF49_CRAGI	9.7e-118	431.8	57.91%	26.12%	Putative E3 ubiquitin-protein ligase HERC1;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN007300.1	sp|A0A210PGI8|A0A210PGI8_MIZYE	2.8e-16	92.4	67.84%	24.17%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN007301.1	sp|K1RJ97|K1RJ97_CRAGI	7.3e-178	628.6	100.00%	90.03%	Multifunctional protein ADE2;OS=Crassostrea;PE=3;SV=1	GO:0004639|	GO:0006189|
GN007303.1	sp|K1RDC9|K1RDC9_CRAGI	2.3e-105	387.1	100.00%	92.54%	Amidophosphoribosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004044|GO:0051536|GO:0046872|	GO:0006189|GO:0009116|GO:0009113|
GN007304.1	sp|K1R7C7|K1R7C7_CRAGI	1.1e-75	288.1	99.38%	91.19%	Gem-associated protein 5;OS=Crassostrea;PE=4;SV=1
GN007305.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	2.5e-29	135.6	27.21%	56.64%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007307.1	sp|R7URW4|R7URW4_CAPTE	1.4e-14	84.7	99.16%	36.97%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN007308.1	sp|K1QZL8|K1QZL8_CRAGI	4.5e-36	156.8	92.39%	49.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007309.1	sp|K1QKH0|K1QKH0_CRAGI	1.9e-28	131.0	75.56%	58.82%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN007312.1	sp|A0A1S3J188|A0A1S3J188_LINUN	3.4e-32	143.3	94.17%	58.04%	uncharacterized protein K02A2.6;OS=Lingula;PE=4;SV=1
GN007314.1	sp|A0A210QDG4|A0A210QDG4_MIZYE	2.1e-13	81.3	44.72%	56.94%	Uncharacterized protein K02A2.6;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|	GO:0015074|
GN007315.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	3.5e-53	213.8	98.05%	49.75%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN006345.1	sp|A0A1S3J1V0|A0A1S3J1V0_LINUN	2.5e-12	78.2	90.71%	29.39%	uncharacterized protein LOC106169495;OS=Lingula;PE=4;SV=1	GO:0003676|
GN007317.1	sp|K1Q9U3|K1Q9U3_CRAGI	0.0e+00	1884.0	78.44%	75.06%	FH2 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN007318.1	sp|K1QQT4|K1QQT4_CRAGI	2.6e-88	330.5	94.69%	81.03%	Exosome complex exonuclease RRP43;OS=Crassostrea;PE=4;SV=1	GO:0000178|	GO:0004527|	GO:0006401|GO:0006396|
GN007320.1	sp|K1QI88|K1QI88_CRAGI	2.4e-138	497.3	99.37%	79.37%	Zwilch-like protein;OS=Crassostrea;PE=4;SV=1	GO:1990423|	GO:0007093|
GN007326.1	sp|A0A210QWK6|A0A210QWK6_MIZYE	5.1e-150	536.6	98.44%	58.84%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN007327.1	sp|K1PZL0|K1PZL0_CRAGI	1.4e-212	744.6	83.17%	84.78%	B-box type zinc finger protein ncl-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007328.1	sp|K1PZL0|K1PZL0_CRAGI	0.0e+00	1211.1	99.35%	96.20%	B-box type zinc finger protein ncl-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007329.1	sp|K1PSB1|K1PSB1_CRAGI	2.9e-110	403.7	98.81%	75.39%	Glycerol-3-phosphate dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0009331|	GO:0005524|GO:0052591|	GO:0006072|
GN007330.1	sp|A0A210Q8S4|A0A210Q8S4_MIZYE	3.4e-109	401.0	75.83%	56.77%	Transmembrane protein 144;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0015144|
GN007331.1	sp|K1QTC1|K1QTC1_CRAGI	3.8e-165	587.8	100.00%	82.77%	Paramyosin;OS=Crassostrea;PE=4;SV=1	GO:0016459|	GO:0003774|
GN007332.1	sp|K1PTU1|K1PTU1_CRAGI	0.0e+00	1474.5	97.28%	76.91%	DNA-binding protein SMUBP-2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008270|
GN006348.1	sp|K1R4G1|K1R4G1_CRAGI	0.0e+00	1542.7	97.20%	57.05%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0016021|	GO:0005509|
GN007333.1	sp|K1Q6C2|K1Q6C2_CRAGI	2.3e-45	187.6	97.77%	64.57%	Male-specific lethal 3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006325|GO:0006355|
GN007334.1	sp|K1Q6C2|K1Q6C2_CRAGI	9.8e-93	346.7	65.53%	50.91%	Male-specific lethal 3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006325|GO:0006355|
GN007335.1	sp|K1RDP3|K1RDP3_CRAGI	2.2e-49	201.8	57.75%	48.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005783|	GO:0016702|GO:0004656|
GN007336.1	sp|K1Q6B8|K1Q6B8_CRAGI	0.0e+00	1639.4	100.00%	85.52%	Linear gramicidin synthetase subunit D;OS=Crassostrea;PE=4;SV=1	GO:0016491|GO:0031177|
GN007337.1	sp|K1Q9H9|K1Q9H9_CRAGI	0.0e+00	1676.8	97.00%	86.40%	Serine/threonine-protein kinase PLK4;OS=Crassostrea;PE=4;SV=1	GO:0005814|	GO:0005524|GO:0004674|	GO:0007099|
GN007338.1	sp|K1QP49|K1QP49_CRAGI	3.6e-93	347.1	100.00%	64.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007339.1	sp|K1R9F7|K1R9F7_CRAGI	4.5e-250	869.4	99.51%	83.36%	Progesterone-induced-blocking factor 1;OS=Crassostrea;PE=4;SV=1
GN007340.1	sp|K1Q890|K1Q890_CRAGI	4.3e-49	199.5	96.18%	78.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007341.1	sp|K1R904|K1R904_CRAGI	2.3e-174	617.1	100.00%	92.05%	Transcription factor AP-4;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN007342.1	sp|K1R292|K1R292_CRAGI	1.4e-192	677.9	99.77%	81.04%	Magnesium transporter NIPA2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015095|
GN007343.1	sp|K1R076|K1R076_CRAGI	7.0e-187	660.2	89.01%	54.48%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1	GO:0005669|	GO:0006367|
GN006350.1	sp|K1PUC1|K1PUC1_CRAGI	9.7e-17	92.4	50.00%	53.57%	Zinc finger protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003676|
GN007344.1	sp|K1RJV4|K1RJV4_CRAGI	1.0e-275	954.5	99.31%	79.41%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007345.1	sp|K1QC94|K1QC94_CRAGI	8.9e-86	323.9	68.19%	40.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007346.1	sp|K1PU25|K1PU25_CRAGI	3.6e-69	268.1	97.88%	38.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007347.1	sp|K1PKZ6|K1PKZ6_CRAGI	5.0e-206	723.0	100.00%	71.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007348.1	sp|K1PET8|K1PET8_CRAGI	1.8e-145	521.5	99.57%	59.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007349.1	sp|K1PET8|K1PET8_CRAGI	2.2e-54	219.5	30.36%	48.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007350.1	sp|K1PNP1|K1PNP1_CRAGI	3.1e-235	820.1	99.01%	66.83%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN006238.1	sp|K1QAR1|K1QAR1_CRAGI	3.3e-162	576.6	100.00%	85.93%	Protein PTHB1;OS=Crassostrea;PE=4;SV=1	GO:0034464|
GN007351.1	sp|V4BNP4|V4BNP4_LOTGI	1.2e-45	189.5	57.42%	50.24%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN007352.1	sp|K1RZF1|K1RZF1_CRAGI	8.0e-41	173.7	23.60%	81.25%	Lymphoid-specific helicase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|
GN007353.1	sp|A0A1S3HPF6|A0A1S3HPF6_LINUN	1.2e-105	388.7	95.82%	64.78%	lymphocyte-specific helicase isoform X1;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0004386|
GN007354.1	sp|K1QIS5|K1QIS5_CRAGI	2.0e-183	647.9	100.00%	58.06%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007355.1	sp|K1R4G4|K1R4G4_CRAGI	1.5e-184	651.7	76.08%	67.01%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007357.1	sp|K1RRP1|K1RRP1_CRAGI	1.7e-63	248.4	75.55%	60.19%	EGF-like domain-containing protein 8;OS=Crassostrea;PE=4;SV=1
GN006352.1	sp|A0A210QA55|A0A210QA55_MIZYE	2.3e-129	468.0	83.15%	57.48%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0008375|
GN007359.1	sp|K1RKT7|K1RKT7_CRAGI	1.6e-27	128.3	55.62%	73.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007360.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	4.2e-68	263.5	100.00%	56.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007361.1	sp|K1QK74|K1QK74_CRAGI	4.1e-162	578.2	37.67%	65.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007362.1	sp|K1R103|K1R103_CRAGI	7.5e-78	295.4	100.00%	85.29%	Dual specificity protein phosphatase 19;OS=Crassostrea;PE=3;SV=1	GO:0008138|
GN007363.1	sp|K1R7G7|K1R7G7_CRAGI	8.5e-58	228.8	85.71%	75.52%	Phosphatase Slingshot-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008138|
GN007364.1	sp|K1RRP4|K1RRP4_CRAGI	3.5e-80	303.5	96.73%	71.36%	Dual specificity protein phosphatase 19;OS=Crassostrea;PE=3;SV=1	GO:0004725|GO:0008138|
GN007366.1	sp|K1QK78|K1QK78_CRAGI	1.0e-70	271.6	100.00%	83.89%	Dual specificity protein phosphatase 19;OS=Crassostrea;PE=3;SV=1	GO:0017017|
GN007367.1	sp|K1QU03|K1QU03_CRAGI	3.1e-40	170.6	54.55%	85.15%	Inhibitor of growth protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007368.1	sp|K1R105|K1R105_CRAGI	2.2e-92	344.7	98.56%	68.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007369.1	sp|K1R7H0|K1R7H0_CRAGI	7.9e-75	287.7	70.76%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007370.1	sp|A0A0L8I8P3|A0A0L8I8P3_OCTBM	7.7e-48	196.8	53.46%	75.00%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005681|	GO:0003676|GO:0008270|	GO:0000398|
GN007371.1	sp|K1RRP7|K1RRP7_CRAGI	2.2e-155	555.1	73.37%	74.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007372.1	sp|K1QK81|K1QK81_CRAGI	3.8e-221	773.5	95.31%	72.62%	Sodium-and chloride-dependent GABA transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005328|
GN007373.1	sp|K1QU07|K1QU07_CRAGI	1.2e-110	405.6	99.23%	54.85%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007374.1	sp|A0A210R629|A0A210R629_MIZYE	8.5e-147	525.8	97.86%	61.35%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN006353.1	sp|A0A210Q665|A0A210Q665_MIZYE	7.8e-119	432.6	92.01%	67.10%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007375.1	sp|K1QK86|K1QK86_CRAGI	2.8e-137	493.4	100.00%	92.13%	Sprouty-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0007275|GO:0009966|
GN007376.1	sp|A0A0L8GKS6|A0A0L8GKS6_OCTBM	1.8e-97	362.5	93.12%	35.42%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0016021|	GO:0003824|
GN007377.1	sp|K1R8P6|K1R8P6_CRAGI	2.1e-281	973.4	92.36%	91.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007378.1	sp|K1QYR1|K1QYR1_CRAGI	3.7e-55	220.7	45.39%	81.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007379.1	sp|K1S3Z3|K1S3Z3_CRAGI	4.5e-245	852.8	87.78%	70.96%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007380.1	sp|K1PPP6|K1PPP6_CRAGI	2.7e-16	90.5	74.02%	44.09%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN007381.1	sp|W4Z9W9|W4Z9W9_STRPU	3.1e-28	132.1	43.70%	38.65%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN007382.1	sp|A0A210Q652|A0A210Q652_MIZYE	1.3e-09	69.7	81.68%	28.29%	Protein inturned;OS=Mizuhopecten;PE=4;SV=1	GO:0060271|GO:0001736|
GN007383.1	sp|A0A210Q651|A0A210Q651_MIZYE	4.6e-59	233.0	88.30%	74.00%	Allene oxide synthase-lipoxygenase protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004096|GO:0020037|GO:0046872|GO:0016702|
GN007384.1	sp|K1P4U3|K1P4U3_CRAGI	1.2e-99	368.6	96.33%	66.90%	PDZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0060271|GO:0001736|
GN007385.1	sp|K1QFR2|K1QFR2_CRAGI	4.1e-173	614.4	58.17%	88.55%	Calnexin;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0016021|	GO:0005509|GO:0051082|	GO:0006457|
GN007386.1	sp|K1R409|K1R409_CRAGI	3.3e-128	463.8	95.52%	64.39%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007387.1	sp|K1PTS3|K1PTS3_CRAGI	8.1e-46	189.1	98.90%	49.26%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007388.1	sp|K1RZR7|K1RZR7_CRAGI	1.4e-239	835.9	44.64%	65.30%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007389.1	sp|K1PRX6|K1PRX6_CRAGI	1.1e-265	922.5	64.43%	52.72%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007390.1	sp|K1PRX6|K1PRX6_CRAGI	1.4e-182	646.4	66.64%	41.03%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007391.1	sp|K1RGD3|K1RGD3_CRAGI	7.1e-261	905.6	100.00%	60.89%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN007392.1	sp|K1QUG4|K1QUG4_CRAGI	8.8e-49	198.7	88.54%	64.75%	Nanos-like protein 2;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0008270|	GO:0006417|
GN007393.1	sp|K1RZQ3|K1RZQ3_CRAGI	1.2e-281	974.5	82.63%	85.11%	Rho GTPase-activating protein 10-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005096|	GO:0007165|
GN007394.1	sp|K1QMI1|K1QMI1_CRAGI	1.7e-109	401.7	88.89%	42.71%	Amiloride-sensitive cation channel 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN007396.1	sp|K1QTK1|K1QTK1_CRAGI	6.9e-162	576.6	99.86%	49.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016300|	GO:0002098|
GN006355.1	sp|K1R3Y4|K1R3Y4_CRAGI	1.8e-254	884.4	100.00%	82.34%	Transcription factor Sp4;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007400.1	sp|K1QLK0|K1QLK0_CRAGI	1.6e-27	129.8	67.56%	33.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007401.1	sp|K1RCR4|K1RCR4_CRAGI	4.7e-142	510.8	40.17%	80.92%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN006356.1	sp|I3ZR77|I3ZR77_CRAGI	0.0e+00	1357.0	100.00%	95.86%	Beta-catenin;OS=Crassostrea;PE=2;SV=1	GO:0045296|	GO:0007155|
GN007402.1	sp|K1PW26|K1PW26_CRAGI	0.0e+00	1947.9	99.79%	71.66%	Multidrug resistance-associated protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN007403.1	sp|A0A210R268|A0A210R268_MIZYE	9.8e-73	280.4	96.26%	30.31%	Cubilin;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007404.1	sp|K1Q1F0|K1Q1F0_CRAGI	9.1e-127	458.8	85.67%	88.28%	Transient-receptor-potential-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN007405.1	sp|K1PU42|K1PU42_CRAGI	9.3e-36	156.8	57.11%	48.21%	Transcription factor IIIA;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007406.1	sp|K1QUF4|K1QUF4_CRAGI	2.4e-81	307.8	97.13%	68.98%	WW domain-binding protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|	GO:0000398|
GN006357.1	sp|K1QWZ8|K1QWZ8_CRAGI	1.4e-111	408.3	100.00%	90.03%	Catenin beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0045296|	GO:0007155|
GN007407.1	sp|K1Q8H5|K1Q8H5_CRAGI	0.0e+00	1444.9	97.34%	85.01%	MBT domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008270|	GO:0006355|
GN007408.1	sp|A0A0B7BNB5|A0A0B7BNB5_9EUPU	4.5e-22	110.5	42.15%	54.84%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN007409.1	sp|K1REI0|K1REI0_CRAGI	1.8e-201	708.0	82.44%	76.48%	NEDD8 ultimate buster 1;OS=Crassostrea;PE=4;SV=1
GN007410.1	sp|K1PTM5|K1PTM5_CRAGI	1.3e-275	954.1	86.78%	86.75%	Dopamine beta-hydroxylase;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN007411.1	sp|K1QTY4|K1QTY4_CRAGI	2.5e-38	164.9	84.95%	62.50%	Prolow-density lipoprotein receptor-related protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007412.1	sp|K1QX14|K1QX14_CRAGI	3.2e-15	87.4	28.00%	75.00%	Low-density lipoprotein receptor-related protein 1;OS=Crassostrea;PE=4;SV=1
GN007413.1	sp|K1R3G7|K1R3G7_CRAGI	7.9e-162	575.5	100.00%	78.15%	Uncharacterized protein C7orf57-like protein;OS=Crassostrea;PE=4;SV=1
GN007414.1	sp|K1RMT6|K1RMT6_CRAGI	3.5e-88	330.1	97.70%	76.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007415.1	sp|A0A210PHB0|A0A210PHB0_MIZYE	1.2e-118	432.2	79.15%	61.39%	JmjC domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1
GN007416.1	sp|K1QP96|K1QP96_CRAGI	0.0e+00	1453.3	100.00%	79.21%	Rab3 GTPase-activating protein catalytic subunit;OS=Crassostrea;PE=4;SV=1	GO:0005096|
GN007417.1	sp|A0A0B7BUV6|A0A0B7BUV6_9EUPU	3.3e-21	106.3	95.40%	59.76%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN007418.1	sp|A0A0B7BVM1|A0A0B7BVM1_9EUPU	3.5e-09	66.2	88.75%	48.10%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN007420.1	sp|K1QFR0|K1QFR0_CRAGI	4.8e-157	560.1	96.81%	57.28%	Fibrocystin-L;OS=Crassostrea;PE=4;SV=1
GN007421.1	sp|A0A0P6EKY0|A0A0P6EKY0_9CRUS	1.2e-12	80.9	28.85%	29.82%	Reverse transcriptase/ribonuclease h/methyltransferase;OS=Daphnia;PE=4;SV=1	GO:0005882|	GO:0003677|GO:0008168|GO:0003964|GO:0005198|	GO:0015074|GO:0006310|
GN007422.1	sp|K1P720|K1P720_CRAGI	3.6e-74	283.5	83.98%	81.82%	Kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|	GO:0032958|
GN006358.1	sp|K1PX73|K1PX73_CRAGI	6.2e-31	140.2	79.54%	40.87%	Complement component 1 Q subcomponent-binding protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005759|
GN007426.1	sp|V4AE92|V4AE92_LOTGI	9.2e-86	322.8	82.35%	51.00%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN007427.1	sp|K1R3H2|K1R3H2_CRAGI	6.0e-56	222.6	96.34%	66.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007428.1	sp|V4AE92|V4AE92_LOTGI	3.7e-87	327.4	82.35%	51.33%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN007429.1	sp|A0A210PI28|A0A210PI28_MIZYE	5.2e-91	340.5	70.00%	60.52%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007430.1	sp|W4YMP2|W4YMP2_STRPU	2.5e-23	114.4	86.11%	48.43%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN006359.1	sp|K1QBE4|K1QBE4_CRAGI	4.6e-111	406.0	97.50%	96.39%	Serine/threonine-protein phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0004721|
GN007432.1	sp|K1QGU7|K1QGU7_CRAGI	2.8e-70	270.4	86.49%	81.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007433.1	sp|K1RNR3|K1RNR3_CRAGI	1.3e-81	308.1	100.00%	66.26%	Transmembrane protein 41A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007434.1	sp|K1QWY2|K1QWY2_CRAGI	1.1e-164	585.9	98.92%	52.82%	alpha-1,2-Mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004571|	GO:0008152|
GN006360.1	sp|K1QQH3|K1QQH3_CRAGI	2.8e-28	131.3	74.40%	39.20%	NEDD8-conjugating enzyme ubc12;OS=Crassostrea;PE=4;SV=1
GN007437.1	sp|K1PT98|K1PT98_CRAGI	7.9e-271	938.3	87.68%	85.18%	Ankyrin repeat and SOCS box protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007438.1	sp|R7URM3|R7URM3_CAPTE	4.8e-35	153.7	87.55%	40.29%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN007439.1	sp|A0A210QJN0|A0A210QJN0_MIZYE	0.0e+00	1117.1	96.47%	58.98%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007440.1	sp|K1PZU1|K1PZU1_CRAGI	5.0e-38	164.5	36.88%	85.81%	Hsc70-interacting protein;OS=Crassostrea;PE=4;SV=1
GN007441.1	sp|K1PTW9|K1PTW9_CRAGI	6.8e-25	120.2	68.05%	37.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007442.1	sp|K1QK24|K1QK24_CRAGI	7.5e-187	660.2	42.39%	66.81%	Putative Xaa-Pro aminopeptidase 3;OS=Crassostrea;PE=3;SV=1	GO:0004177|GO:0030145|
GN007443.1	sp|K1PDZ9|K1PDZ9_CRAGI	8.0e-187	658.7	98.51%	87.66%	Parafibromin;OS=Crassostrea;PE=4;SV=1	GO:0016593|	GO:0016570|GO:0006368|
GN007444.1	sp|K1PKD7|K1PKD7_CRAGI	2.3e-102	377.1	100.00%	85.57%	6-phosphogluconolactonase;OS=Crassostrea;PE=3;SV=1	GO:0017057|	GO:0005975|GO:0006098|
GN007445.1	sp|K1S5N7|K1S5N7_CRAGI	5.0e-182	642.5	99.11%	93.09%	Cell division protein kinase 7;OS=Crassostrea;PE=3;SV=1	GO:0070985|	GO:0005524|GO:0008353|	GO:0051301|
GN007447.1	sp|K1RAB7|K1RAB7_CRAGI	1.7e-37	161.8	80.00%	49.71%	A-kinase anchor protein 7 isoform gamma;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN007448.1	sp|K1Q1U2|K1Q1U2_CRAGI	2.0e-27	127.5	98.39%	53.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007449.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	4.7e-16	90.5	47.69%	47.06%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007451.1	sp|K1R6K7|K1R6K7_CRAGI	2.3e-60	238.0	85.87%	46.96%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN007452.1	sp|A0A210QCN4|A0A210QCN4_MIZYE	1.9e-77	294.3	87.37%	87.27%	Flotillin-1;OS=Mizuhopecten;PE=4;SV=1
GN007453.1	sp|A0A2C9JIT5|A0A2C9JIT5_BIOGL	3.9e-33	147.5	100.00%	82.76%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN007454.1	sp|K1Q9C4|K1Q9C4_CRAGI	0.0e+00	1271.9	97.97%	77.22%	SH2 domain-containing protein 3C;OS=Crassostrea;PE=4;SV=1	GO:0005085|	GO:0007264|
GN007455.1	sp|K1Q262|K1Q262_CRAGI	0.0e+00	1075.1	100.00%	94.72%	Negative elongation factor B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003746|	GO:0045892|
GN007456.1	sp|K1PUP9|K1PUP9_CRAGI	1.5e-174	619.4	35.08%	85.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007456.1	sp|K1PUP9|K1PUP9_CRAGI	1.9e-09	70.9	5.06%	70.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007458.1	sp|K1Q9B7|K1Q9B7_CRAGI	2.4e-36	157.1	100.00%	72.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006361.1	sp|K1PT25|K1PT25_CRAGI	1.5e-31	141.4	83.45%	62.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007459.1	sp|K1Q257|K1Q257_CRAGI	4.0e-30	136.3	71.55%	79.27%	Carnitine O-acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016746|
GN007460.1	sp|K1Q257|K1Q257_CRAGI	8.5e-233	811.6	100.00%	83.01%	Carnitine O-acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016746|
GN007461.1	sp|K1PUP5|K1PUP5_CRAGI	1.0e-117	428.3	94.58%	88.94%	Phytanoyl-CoA dioxygenase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0051213|
GN007463.1	sp|K1R5G4|K1R5G4_CRAGI	4.8e-114	416.8	98.91%	64.74%	60S ribosomal protein L31;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN007464.1	sp|K1R5G4|K1R5G4_CRAGI	2.9e-59	233.4	82.39%	94.83%	60S ribosomal protein L31;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN007465.1	sp|K1PY57|K1PY57_CRAGI	7.0e-57	225.3	100.00%	91.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007466.1	sp|K1QDM1|K1QDM1_CRAGI	9.6e-56	221.9	100.00%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007467.1	sp|K1QJW3|K1QJW3_CRAGI	1.4e-285	987.3	99.83%	83.13%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007468.1	sp|K1PY61|K1PY61_CRAGI	4.8e-143	513.1	89.24%	82.48%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN006362.1	sp|K1PZM0|K1PZM0_CRAGI	3.4e-94	350.9	75.73%	56.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007469.1	sp|K1P308|K1P308_CRAGI	0.0e+00	1131.7	76.60%	85.69%	Glutamate receptor 3;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN007470.1	sp|K1Q9Q8|K1Q9Q8_CRAGI	0.0e+00	1643.6	99.58%	62.08%	Phosphodiesterase;OS=Crassostrea;PE=3;SV=1	GO:0004114|GO:0046872|	GO:0007165|
GN007471.1	sp|K1P9R1|K1P9R1_CRAGI	5.3e-188	662.5	99.48%	79.90%	Anhydro-N-acetylmuramic acid kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016301|GO:0016773|	GO:0006040|GO:0009254|
GN007472.1	sp|A0A210QQY1|A0A210QQY1_MIZYE	1.4e-105	388.7	98.66%	50.39%	Hexosyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN007473.1	sp|K1PNS4|K1PNS4_CRAGI	0.0e+00	1126.3	89.89%	55.99%	Inverted formin-2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN007474.1	sp|K1QP54|K1QP54_CRAGI	4.3e-87	328.2	100.00%	57.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007475.1	sp|K1QHI9|K1QHI9_CRAGI	5.6e-236	822.8	89.19%	67.94%	Rab proteins geranylgeranyltransferase component A 1;OS=Crassostrea;PE=4;SV=1	GO:0005968|	GO:0005092|GO:0016740|	GO:0006886|GO:0018344|GO:0007264|
GN007476.1	sp|K1Q9Q3|K1Q9Q3_CRAGI	0.0e+00	1618.2	100.00%	86.79%	TBC domain-containing protein kinase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN006363.1	sp|K1PZM0|K1PZM0_CRAGI	1.8e-97	361.7	90.60%	60.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007477.1	sp|K1PNR7|K1PNR7_CRAGI	5.1e-132	476.1	97.50%	84.93%	N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN007478.1	sp|K1PGY8|K1PGY8_CRAGI	8.4e-55	219.2	77.99%	69.51%	Beta-1,4-mannosyltransferase egh;OS=Crassostrea;PE=4;SV=1	GO:0043240|GO:0016021|	GO:0019187|	GO:0036297|
GN007479.1	sp|K1PGY8|K1PGY8_CRAGI	1.6e-140	504.6	93.31%	78.10%	Beta-1,4-mannosyltransferase egh;OS=Crassostrea;PE=4;SV=1	GO:0043240|GO:0016021|	GO:0019187|	GO:0036297|
GN007480.1	sp|K1P2Z7|K1P2Z7_CRAGI	6.6e-281	972.2	76.86%	83.47%	Prestin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008271|
GN007481.1	sp|A0A1X7SZ30|A0A1X7SZ30_AMPQE	7.5e-59	233.0	98.19%	43.48%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046983|
GN007482.1	sp|K1PGY4|K1PGY4_CRAGI	6.9e-42	176.0	80.68%	59.63%	Neuropeptide capa receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN006364.1	sp|K1QJX5|K1QJX5_CRAGI	2.7e-31	141.0	66.49%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007483.1	sp|K1P2Z2|K1P2Z2_CRAGI	2.6e-54	218.8	86.99%	32.79%	Lysosomal Pro-X carboxypeptidase;OS=Crassostrea;PE=4;SV=1	GO:0004180|GO:0004867|GO:0008236|
GN007484.1	sp|K1Q9P6|K1Q9P6_CRAGI	4.4e-113	414.1	44.92%	80.35%	Hemolymph lipopolysaccharide-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0030246|
GN007485.1	sp|K1PWU1|K1PWU1_CRAGI	9.2e-199	698.7	99.81%	65.03%	Aggrecan core protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0030246|
GN007486.1	sp|K1PPE5|K1PPE5_CRAGI	3.0e-21	106.7	75.96%	62.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007487.1	sp|K1QJT7|K1QJT7_CRAGI	4.5e-151	540.8	93.35%	55.33%	Protein ovo;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007488.1	sp|K1PDI7|K1PDI7_CRAGI	9.9e-105	385.2	97.44%	77.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005179|
GN007489.1	sp|K1PIW2|K1PIW2_CRAGI	0.0e+00	1366.7	100.00%	70.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006365.1	sp|K1QJX5|K1QJX5_CRAGI	1.9e-78	298.1	74.18%	73.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007490.1	sp|K1RLH8|K1RLH8_CRAGI	1.5e-243	848.2	97.31%	67.90%	RNA-binding protein 26;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003723|
GN007491.1	sp|K1RLH8|K1RLH8_CRAGI	5.2e-36	156.8	85.38%	57.78%	RNA-binding protein 26;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003723|
GN006366.1	sp|K1PU25|K1PU25_CRAGI	7.1e-36	157.1	57.98%	40.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007497.1	sp|K1PN26|K1PN26_CRAGI	1.4e-25	121.7	93.55%	50.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007501.1	sp|K1QF71|K1QF71_CRAGI	2.2e-129	468.0	97.71%	55.09%	Potassium voltage-gated channel protein Shaw;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN007502.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	5.3e-94	350.5	96.54%	40.36%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN007503.1	sp|A0A210QJQ0|A0A210QJQ0_MIZYE	1.7e-16	92.0	39.39%	46.15%	THAP domain-containing protein 1 A;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN007504.1	sp|K1PF16|K1PF16_CRAGI	0.0e+00	1781.5	99.63%	80.45%	Low-density lipoprotein receptor-related protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006367.1	sp|K1RFC9|K1RFC9_CRAGI	7.4e-37	160.2	69.58%	38.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007506.1	sp|K1QAP9|K1QAP9_CRAGI	3.3e-68	265.0	99.61%	35.26%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN007507.1	sp|K1RID2|K1RID2_CRAGI	2.2e-49	201.4	83.40%	48.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006353|
GN007508.1	sp|K1RLK4|K1RLK4_CRAGI	3.1e-137	493.4	99.29%	79.06%	Ectoine hydroxylase;OS=Crassostrea;PE=4;SV=1
GN007509.1	sp|A0A210QCL9|A0A210QCL9_MIZYE	2.1e-144	517.7	99.20%	64.34%	Uncharacterized protein UNK4.17;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN006368.1	sp|A0A210QJI0|A0A210QJI0_MIZYE	1.1e-30	139.8	72.70%	34.73%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007510.1	sp|K1R8X8|K1R8X8_CRAGI	7.8e-177	625.5	98.08%	94.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007511.1	sp|A0A210R1Z7|A0A210R1Z7_MIZYE	1.7e-56	225.3	87.07%	46.59%	DNA repair protein XRCC2;OS=Mizuhopecten;PE=4;SV=1	GO:0033063|GO:0005657|	GO:0005524|GO:0003677|GO:0008094|	GO:0000724|
GN007512.1	sp|K1RER2|K1RER2_CRAGI	1.2e-109	401.4	99.53%	88.26%	E3 ubiquitin-protein ligase RFWD2;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN007513.1	sp|A0A210QIJ8|A0A210QIJ8_MIZYE	1.6e-143	515.8	94.15%	40.86%	Fibroleukin;OS=Mizuhopecten;PE=4;SV=1
GN007514.1	sp|K1RER2|K1RER2_CRAGI	0.0e+00	1517.7	99.55%	73.19%	E3 ubiquitin-protein ligase RFWD2;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN007515.1	sp|K1RKW2|K1RKW2_CRAGI	6.9e-161	573.2	76.51%	63.69%	Monocarboxylate transporter 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN007516.1	sp|K1QTN3|K1QTN3_CRAGI	2.9e-281	973.0	100.00%	75.75%	Glycosyltransferase 25 family member 1;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN007517.1	sp|J9Q4N1|J9Q4N1_OSTED	5.6e-42	175.6	86.24%	93.68%	Rolly protein;OS=Ostrea;PE=2;SV=1
GN006369.1	sp|K1PUD6|K1PUD6_CRAGI	2.8e-09	68.6	43.61%	33.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007518.1	sp|K1QG51|K1QG51_CRAGI	0.0e+00	1085.9	94.92%	77.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007519.1	sp|K1R226|K1R226_CRAGI	0.0e+00	5640.8	100.00%	85.24%	Unc-80-like protein;OS=Crassostrea;PE=4;SV=1
GN007520.1	sp|K1PU44|K1PU44_CRAGI	1.8e-167	594.0	100.00%	91.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007521.1	sp|K1Q1L6|K1Q1L6_CRAGI	0.0e+00	1127.1	100.00%	77.68%	Transient receptor potential cation channel subfamily V member 6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005216|
GN007522.1	sp|A0A210R5E3|A0A210R5E3_MIZYE	0.0e+00	1120.9	91.70%	81.16%	Kinesin-associated protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005871|	GO:0019894|
GN007523.1	sp|A0A210R100|A0A210R100_MIZYE	5.7e-18	95.9	90.00%	57.00%	Protein phosphatase 1 regulatory subunit 11;OS=Mizuhopecten;PE=4;SV=1	GO:0004865|
GN007524.1	sp|K1PU39|K1PU39_CRAGI	8.1e-79	299.3	97.37%	53.41%	Histamine H4 receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007526.1	sp|K1PU39|K1PU39_CRAGI	1.1e-131	475.3	97.97%	71.22%	Histamine H4 receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN006370.1	sp|K1PUD6|K1PUD6_CRAGI	1.1e-52	212.2	90.22%	49.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007527.1	sp|K1R221|K1R221_CRAGI	7.2e-117	426.0	93.33%	66.77%	Histamine H3 receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007528.1	sp|K1R221|K1R221_CRAGI	2.9e-129	467.2	92.49%	71.79%	Histamine H3 receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007529.1	sp|K1QG47|K1QG47_CRAGI	0.0e+00	1101.3	87.43%	74.77%	Diaphanous-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0007015|
GN007530.1	sp|K1PNS7|K1PNS7_CRAGI	0.0e+00	1605.9	100.00%	86.93%	Acyl-CoA synthetase family member 4;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0003824|GO:0017048|	GO:0007015|
GN007531.1	sp|A0A210QAN6|A0A210QAN6_MIZYE	5.2e-96	357.8	50.07%	59.42%	Tudor domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0003723|	GO:0006397|
GN007532.1	sp|K1PNS7|K1PNS7_CRAGI	1.9e-224	785.0	73.11%	54.74%	Acyl-CoA synthetase family member 4;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0003824|GO:0017048|	GO:0007015|
GN007533.1	sp|K1QVY7|K1QVY7_CRAGI	1.5e-103	380.9	100.00%	98.38%	Anaphase-promoting complex subunit 10;OS=Crassostrea;PE=3;SV=1	GO:0005680|	GO:0031145|GO:0007049|GO:0051301|
GN007534.1	sp|K1QA53|K1QA53_CRAGI	4.3e-137	493.0	100.00%	79.93%	Methionine adenosyltransferase 2 subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN007535.1	sp|K1PVG3|K1PVG3_CRAGI	1.5e-101	375.2	96.51%	56.19%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007536.1	sp|K1Q1C0|K1Q1C0_CRAGI	6.0e-151	539.7	97.74%	61.11%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN006371.1	sp|A0A210QP33|A0A210QP33_MIZYE	1.8e-47	195.7	96.61%	32.61%	Cholecystokinin receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN007537.1	sp|K1Q1C0|K1Q1C0_CRAGI	4.8e-217	759.6	98.97%	63.83%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007538.1	sp|K1Q1C0|K1Q1C0_CRAGI	1.0e-133	482.3	99.27%	57.99%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007539.1	sp|K1PWS4|K1PWS4_CRAGI	2.2e-43	180.3	97.14%	84.16%	Neogenin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007540.1	sp|A0A0P5K029|A0A0P5K029_9CRUS	1.3e-39	169.9	80.31%	31.13%	Reverse transcriptase/ribonuclease h/methyltransferase;OS=Daphnia;PE=4;SV=1	GO:0005882|	GO:0008168|GO:0003964|GO:0005198|
GN007543.1	sp|K1PBV0|K1PBV0_CRAGI	2.5e-88	330.5	97.56%	81.50%	UDP-glucose 6-dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0003979|
GN007544.1	sp|K1QCJ5|K1QCJ5_CRAGI	3.1e-89	333.6	89.67%	88.42%	Transforming growth factor-beta-induced protein ig-h3;OS=Crassostrea;PE=4;SV=1
GN007545.1	sp|K1PXW8|K1PXW8_CRAGI	5.3e-114	416.4	100.00%	72.40%	Transforming growth factor-beta-induced protein ig-h3;OS=Crassostrea;PE=4;SV=1
GN007546.1	sp|V4BTR7|V4BTR7_LOTGI	1.8e-67	261.2	100.00%	60.62%	Uncharacterized protein;OS=Lottia;PE=3;SV=1
GN007547.1	sp|A0A194ANN6|A0A194ANN6_PINFU	9.1e-111	406.0	86.26%	50.00%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1	GO:0016020|	GO:0005044|
GN007548.1	sp|K1Q5K0|K1Q5K0_CRAGI	7.9e-175	619.4	96.97%	55.09%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007549.1	sp|K1PNS3|K1PNS3_CRAGI	5.5e-38	162.9	100.00%	53.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|	GO:0055114|
GN007550.1	sp|K1QJ27|K1QJ27_CRAGI	2.8e-119	433.7	93.58%	79.35%	Cathepsin L;OS=Crassostrea;PE=3;SV=1	GO:0008234|
GN007551.1	sp|K1QJ27|K1QJ27_CRAGI	3.7e-71	273.1	100.00%	79.49%	Cathepsin L;OS=Crassostrea;PE=3;SV=1	GO:0008234|
GN007552.1	sp|K1Q4R4|K1Q4R4_CRAGI	3.4e-19	101.7	22.87%	67.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007554.1	sp|K1QCJ9|K1QCJ9_CRAGI	3.9e-259	899.8	100.00%	69.24%	SH3 domain-containing RING finger protein 3;OS=Crassostrea;PE=4;SV=1
GN007555.1	sp|K1PX18|K1PX18_CRAGI	0.0e+00	1175.6	88.53%	74.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007556.1	sp|K1R4L8|K1R4L8_CRAGI	0.0e+00	1104.0	91.69%	93.24%	Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004174|
GN007557.1	sp|K1QCJ4|K1QCJ4_CRAGI	0.0e+00	1091.6	99.69%	81.76%	GH3 domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007558.1	sp|U5Q295|U5Q295_CRAGI	4.0e-260	902.9	99.70%	63.36%	Toll-like receptor 1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN007559.1	sp|K1QXH6|K1QXH6_CRAGI	1.4e-195	688.0	99.78%	81.76%	Sodium/glucose cotransporter 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN007561.1	sp|K1RJ11|K1RJ11_CRAGI	2.8e-41	173.3	82.14%	90.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0043240|GO:0016021|	GO:0036297|
GN007562.1	sp|K1RJ11|K1RJ11_CRAGI	3.9e-137	494.6	58.86%	54.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0043240|GO:0016021|	GO:0036297|
GN007563.1	sp|A0A1W7RAU2|A0A1W7RAU2_9SCOR	3.1e-34	151.0	93.86%	43.93%	Charged multivesicular body protein 4c;OS=Hadrurus;PE=3;SV=1	GO:0007034|
GN006374.1	sp|A0A210QJK2|A0A210QJK2_MIZYE	2.9e-79	300.8	94.12%	58.20%	Neuronal membrane glycoprotein M6-b;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007565.1	sp|K1PRP9|K1PRP9_CRAGI	1.6e-139	501.5	96.61%	80.05%	Pleckstrin-like protein domain-containing family A member 8;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0120013|
GN007567.1	sp|A0A210PLN2|A0A210PLN2_MIZYE	7.7e-107	392.5	99.31%	60.84%	Ectoine hydroxylase;OS=Mizuhopecten;PE=4;SV=1
GN007568.1	sp|K1QDQ6|K1QDQ6_CRAGI	4.9e-39	166.4	71.97%	61.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007569.1	sp|K1RMX4|K1RMX4_CRAGI	7.4e-13	80.5	75.98%	24.63%	Pyroglutamylated RFamide peptide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN007570.1	sp|K1PRM0|K1PRM0_CRAGI	7.7e-82	309.7	51.33%	79.19%	Integrator complex subunit 9;OS=Crassostrea;PE=4;SV=1	GO:0032039|	GO:0016180|
GN007571.1	sp|K1PJG5|K1PJG5_CRAGI	4.8e-158	563.1	100.00%	72.30%	RNA-binding protein 40;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN007572.1	sp|K1PC44|K1PC44_CRAGI	4.2e-223	780.0	100.00%	86.22%	Cell division cycle protein 27-like protein;OS=Crassostrea;PE=4;SV=1	GO:0051301|
GN007573.1	sp|Q5QGY5|Q5QGY5_CRAGI	0.0e+00	1094.3	100.00%	91.91%	Sodium/glucose cotransporter;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0022857|
GN007574.1	sp|K1PRL3|K1PRL3_CRAGI	7.6e-282	974.9	99.67%	75.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007575.1	sp|K1PTZ6|K1PTZ6_CRAGI	7.1e-126	456.4	91.77%	51.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007576.1	sp|K1PTZ6|K1PTZ6_CRAGI	4.9e-196	689.5	92.70%	74.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007577.1	sp|K1PTZ6|K1PTZ6_CRAGI	2.3e-241	841.3	95.59%	50.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007578.1	sp|K1Q0N9|K1Q0N9_CRAGI	0.0e+00	1330.1	86.33%	88.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN007579.1	sp|K1PEQ3|K1PEQ3_CRAGI	3.8e-133	479.9	86.42%	87.69%	Multivesicular body subunit 12B;OS=Crassostrea;PE=4;SV=1	GO:0000813|
GN007580.1	sp|K1RCM5|K1RCM5_CRAGI	2.7e-269	932.9	100.00%	93.27%	Large neutral amino acids transporter small subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN007581.1	sp|K1R632|K1R632_CRAGI	2.8e-45	188.7	20.04%	87.50%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN007582.1	sp|A0A210PJS2|A0A210PJS2_MIZYE	2.5e-53	214.9	87.92%	36.00%	von Willebrand factor D and EGF domain-containing protein;OS=Mizuhopecten;PE=4;SV=1
GN007584.1	sp|A0A210PJS2|A0A210PJS2_MIZYE	5.8e-242	843.2	95.58%	43.68%	von Willebrand factor D and EGF domain-containing protein;OS=Mizuhopecten;PE=4;SV=1
GN007585.1	sp|K1PPL0|K1PPL0_CRAGI	7.1e-34	149.1	97.84%	55.80%	Group XVI phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007586.1	sp|K1QB45|K1QB45_CRAGI	3.1e-58	230.7	79.04%	83.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007587.1	sp|K1PPL0|K1PPL0_CRAGI	2.9e-72	276.9	98.88%	71.19%	Group XVI phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007589.1	sp|K1PPL0|K1PPL0_CRAGI	1.5e-70	271.2	97.69%	72.02%	Group XVI phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007591.1	sp|K1PXH5|K1PXH5_CRAGI	8.0e-31	139.8	49.03%	56.39%	Putative saccharopine dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN007592.1	sp|K1QDT8|K1QDT8_CRAGI	9.6e-39	165.6	78.02%	52.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007593.1	sp|K1Q3Y2|K1Q3Y2_CRAGI	1.1e-114	418.7	74.20%	81.03%	Polypeptide N-acetylgalactosaminyltransferase 5;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN007595.1	sp|K1QQ29|K1QQ29_CRAGI	1.4e-57	228.4	84.54%	73.71%	Uncharacterized protein C21orf70;OS=Crassostrea;PE=4;SV=1	GO:0030686|GO:0005730|GO:0030688|	GO:0000462|
GN007596.1	sp|K1PHT1|K1PHT1_CRAGI	1.0e-93	348.6	82.13%	90.10%	Ubiquitin-conjugating enzyme E2 E3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN007598.1	sp|K1QTG2|K1QTG2_CRAGI	3.4e-31	140.2	95.77%	69.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007599.1	sp|K1QJM6|K1QJM6_CRAGI	1.7e-150	538.5	99.09%	74.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007600.1	sp|K1QTG8|K1QTG8_CRAGI	3.5e-204	716.8	100.00%	75.52%	DnaJ-like protein subfamily B member 1;OS=Crassostrea;PE=4;SV=1
GN007601.1	sp|K1R0J7|K1R0J7_CRAGI	1.3e-177	628.6	99.34%	51.72%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN007602.1	sp|K1R0J7|K1R0J7_CRAGI	2.3e-244	850.5	96.78%	67.35%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN006375.1	sp|K1PU66|K1PU66_CRAGI	5.5e-74	283.1	83.06%	72.50%	ADAM 17-like protease;OS=Crassostrea;PE=4;SV=1	GO:0004222|
GN007604.1	sp|A0A1X7TS12|A0A1X7TS12_AMPQE	2.4e-16	90.9	97.92%	42.14%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN007606.1	sp|V5NCQ8|V5NCQ8_PINMT	1.9e-135	488.8	93.45%	42.15%	Toll-like protein;OS=Pinctada;PE=2;SV=1	GO:0016021|	GO:0007165|
GN007607.1	sp|A0A2T7NHL0|A0A2T7NHL0_POMCA	7.6e-28	131.0	74.19%	25.87%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN007609.1	sp|K1R0K5|K1R0K5_CRAGI	0.0e+00	1269.6	95.03%	81.54%	Histone-lysine N-methyltransferase E(Z);OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN007610.1	sp|K1R6Z4|K1R6Z4_CRAGI	4.8e-41	172.6	100.00%	83.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007611.1	sp|K1RRA8|K1RRA8_CRAGI	9.0e-247	859.0	54.81%	88.55%	Tetratricopeptide repeat protein 25;OS=Crassostrea;PE=4;SV=1
GN007612.1	sp|K1QJN7|K1QJN7_CRAGI	7.8e-151	538.9	99.71%	78.64%	Prolyl 4-hydroxylase subunit alpha-1;OS=Crassostrea;PE=4;SV=1	GO:0005783|	GO:0016702|GO:0004656|
GN007613.1	sp|K1QTI0|K1QTI0_CRAGI	2.5e-31	143.7	9.27%	64.04%	Matrilin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007614.1	sp|K1R0L2|K1R0L2_CRAGI	2.1e-63	248.4	47.76%	81.76%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0062023|GO:0016021|	GO:0005201|
GN007615.1	sp|K1R6Z9|K1R6Z9_CRAGI	0.0e+00	2546.9	95.94%	77.27%	Nck-associated protein 5;OS=Crassostrea;PE=4;SV=1
GN007616.1	sp|A0A210PVD7|A0A210PVD7_MIZYE	5.8e-41	172.2	100.00%	79.41%	Pterin-4-alpha-carbinolamine dehydratase;OS=Mizuhopecten;PE=3;SV=1	GO:0008124|	GO:0006729|
GN007617.1	sp|A0A210Q6K5|A0A210Q6K5_MIZYE	3.4e-246	857.8	85.53%	38.66%	Chitin synthase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016758|
GN007618.1	sp|K1PE45|K1PE45_CRAGI	1.0e-42	179.5	73.33%	43.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN007619.1	sp|A0A210Q6K5|A0A210Q6K5_MIZYE	9.7e-241	839.7	79.97%	40.91%	Chitin synthase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016758|
GN006376.1	sp|K1RAI0|K1RAI0_CRAGI	1.1e-105	389.0	77.09%	68.12%	Serum paraoxonase/arylesterase 1;OS=Crassostrea;PE=4;SV=1	GO:0004064|
GN007621.1	sp|K1QJH7|K1QJH7_CRAGI	8.7e-307	1058.9	58.91%	74.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007623.1	sp|A0A210QD31|A0A210QD31_MIZYE	1.6e-63	250.0	29.29%	58.59%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN007624.1	sp|K1RMU1|K1RMU1_CRAGI	1.4e-70	271.6	99.50%	64.50%	C-type lectin domain family 4 member G;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN007625.1	sp|K1QYF5|K1QYF5_CRAGI	1.4e-229	801.2	98.90%	76.94%	Apoptosis-inducing factor 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0050660|GO:0016491|GO:0046983|
GN007626.1	sp|K1R4R5|K1R4R5_CRAGI	6.4e-32	142.1	92.23%	67.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007627.1	sp|K1RP71|K1RP71_CRAGI	1.8e-188	664.1	100.00%	87.96%	Vacuolar protein-sorting-associated protein 36;OS=Crassostrea;PE=4;SV=1	GO:0000814|	GO:0032266|GO:0043130|	GO:0032509|
GN007628.1	sp|K1QU69|K1QU69_CRAGI	2.5e-292	1010.0	99.72%	70.89%	Glutathione S-transferase C-terminal domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN007629.1	sp|A0A109NI19|A0A109NI19_CRAGI	1.0e-243	847.8	100.00%	90.51%	Mothers against decapentaplegic homolog;OS=Crassostrea;PE=2;SV=1	GO:0005737|GO:0005634|GO:0005667|	GO:0003677|GO:0003700|	GO:0007179|
GN006377.1	sp|K1R3A9|K1R3A9_CRAGI	3.3e-37	162.2	51.68%	35.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007630.1	sp|T2MDY9|T2MDY9_HYDVU	1.6e-12	78.6	93.62%	26.14%	Kelch-like ECH-associated protein 1;OS=Hydra;PE=2;SV=1
GN007631.1	sp|K1QQU9|K1QQU9_CRAGI	4.8e-103	379.8	97.79%	70.19%	Abhydrolase domain-containing protein 14A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN007632.1	sp|K1RWQ9|K1RWQ9_CRAGI	1.5e-144	518.1	86.27%	79.48%	Serine/threonine-protein phosphatase 2A activator;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0003755|GO:0019211|
GN007633.1	sp|K1R702|K1R702_CRAGI	1.2e-102	378.3	100.00%	79.37%	Body wall muscle protein HR-29;OS=Crassostrea;PE=3;SV=1
GN007634.1	sp|K1R067|K1R067_CRAGI	4.8e-27	125.9	100.00%	69.23%	Putative RNA-binding protein 18;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN007635.1	sp|A0A0K2JZM6|A0A0K2JZM6_PINFU	5.9e-139	501.1	89.38%	35.24%	STAT;OS=Pinctada;PE=2;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0007165|
GN007638.1	sp|K1RI97|K1RI97_CRAGI	1.7e-231	808.1	99.17%	68.13%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN007639.1	sp|K1RI97|K1RI97_CRAGI	8.2e-290	1001.5	98.01%	82.63%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN007640.1	sp|K1S1W4|K1S1W4_CRAGI	3.9e-278	962.6	96.71%	84.36%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN007641.1	sp|K1RIA1|K1RIA1_CRAGI	1.7e-165	588.2	90.66%	66.59%	Potassium voltage-gated channel protein Shab;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN007642.1	sp|K1R686|K1R686_CRAGI	2.3e-235	820.5	98.97%	69.90%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007643.1	sp|K1RCB8|K1RCB8_CRAGI	0.0e+00	1231.9	100.00%	84.52%	NF-X1-type zinc finger protein NFXL1;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005634|	GO:0003700|GO:0008270|
GN007644.1	sp|K1RIA5|K1RIA5_CRAGI	0.0e+00	1121.3	67.83%	89.37%	Ubiquitin-protein ligase E3A;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN007645.1	sp|K1S1X3|K1S1X3_CRAGI	0.0e+00	1788.9	97.85%	91.43%	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0016589|	GO:0005524|GO:0016887|GO:0003677|GO:0004386|GO:0031491|	GO:0043044|
GN007646.1	sp|K1S1X3|K1S1X3_CRAGI	3.3e-122	444.1	77.41%	66.57%	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0016589|	GO:0005524|GO:0016887|GO:0003677|GO:0004386|GO:0031491|	GO:0043044|
GN006378.1	sp|K1RAI0|K1RAI0_CRAGI	2.3e-115	421.0	90.83%	68.69%	Serum paraoxonase/arylesterase 1;OS=Crassostrea;PE=4;SV=1	GO:0004064|
GN007647.1	sp|K1RI75|K1RI75_CRAGI	2.5e-29	134.4	97.40%	64.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007648.1	sp|K1RC77|K1RC77_CRAGI	6.7e-40	171.4	93.14%	48.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007649.1	sp|A0A210PJH3|A0A210PJH3_MIZYE	5.0e-189	666.8	99.85%	45.86%	Uncharacterized protein;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004553|	GO:0005975|
GN007650.1	sp|K1RCC1|K1RCC1_CRAGI	1.2e-95	355.5	100.00%	53.18%	NF-kappa-B inhibitor-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0007249|
GN007651.1	sp|K1RIA8|K1RIA8_CRAGI	3.7e-262	910.6	77.22%	53.69%	F-box only protein 38;OS=Crassostrea;PE=4;SV=1
GN007652.1	sp|V4A2Z2|V4A2Z2_LOTGI	4.3e-35	154.5	42.78%	47.33%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN007653.1	sp|K1Q1X1|K1Q1X1_CRAGI	8.8e-32	142.9	73.22%	46.07%	Putative potassium channel regulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN006379.1	sp|A0A2R2MKC9|A0A2R2MKC9_LINUN	4.5e-10	70.1	52.00%	39.74%	uncharacterized protein LOC112041543;OS=Lingula;PE=4;SV=1
GN007655.1	sp|K1S1X4|K1S1X4_CRAGI	1.1e-259	901.0	100.00%	89.52%	Aromatic-L-amino-acid decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0016831|GO:0030170|	GO:0006520|
GN007656.1	sp|K1Q6W4|K1Q6W4_CRAGI	9.0e-62	241.9	100.00%	85.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007657.1	sp|A0A1S3I8L2|A0A1S3I8L2_LINUN	7.3e-198	696.0	98.93%	54.85%	alpha-1,2-Mannosidase;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004571|	GO:0008152|
GN007658.1	sp|A0A210QUI4|A0A210QUI4_MIZYE	5.2e-24	117.1	53.91%	44.36%	Sortilin-related receptor;OS=Mizuhopecten;PE=4;SV=1
GN007659.1	sp|Q75W49|Q75W49_CRAGI	0.0e+00	1228.0	100.00%	96.37%	78kDa glucose regulated protein;OS=Crassostrea;PE=2;SV=1	GO:0005524|
GN007660.1	sp|K1RHM2|K1RHM2_CRAGI	0.0e+00	1962.2	100.00%	79.74%	Low-density lipoprotein receptor-related protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006380.1	sp|A0A2B4RK55|A0A2B4RK55_STYPI	1.5e-79	302.8	83.64%	40.87%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN007662.1	sp|K1R2L5|K1R2L5_CRAGI	5.2e-16	90.9	99.04%	27.05%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007664.1	sp|K1R2L5|K1R2L5_CRAGI	1.3e-12	79.3	69.08%	34.22%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007665.1	sp|K1R2L5|K1R2L5_CRAGI	1.9e-14	85.1	84.58%	34.76%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006381.1	sp|K1RAI0|K1RAI0_CRAGI	1.0e-105	389.0	82.06%	66.67%	Serum paraoxonase/arylesterase 1;OS=Crassostrea;PE=4;SV=1	GO:0004064|
GN007667.1	sp|A0A210PSQ9|A0A210PSQ9_MIZYE	2.0e-47	194.5	87.30%	53.89%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004521|
GN007670.1	sp|A0A210PSQ9|A0A210PSQ9_MIZYE	8.2e-41	172.6	87.37%	51.79%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004521|
GN007671.1	sp|A0A210PSQ9|A0A210PSQ9_MIZYE	7.1e-80	303.1	87.24%	49.16%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004521|
GN006382.1	sp|K1R406|K1R406_CRAGI	5.9e-44	182.2	100.00%	86.11%	Death-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN007672.1	sp|K1QMH8|K1QMH8_CRAGI	1.9e-104	386.0	46.71%	53.19%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN007677.1	sp|A0A210PXS1|A0A210PXS1_MIZYE	1.3e-57	228.0	99.32%	73.29%	Malignant T-cell-amplified sequence 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005737|	GO:0003723|
GN007678.1	sp|K1QIS4|K1QIS4_CRAGI	2.7e-83	315.5	36.36%	67.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007679.1	sp|K1QR98|K1QR98_CRAGI	3.0e-225	786.6	100.00%	97.05%	Integrin-linked protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|	GO:0007229|
GN007680.1	sp|K1QXK7|K1QXK7_CRAGI	1.2e-110	404.8	99.12%	84.00%	40 kDa peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|	GO:0006457|
GN007682.1	sp|A0A2C9JC58|A0A2C9JC58_BIOGL	2.0e-80	303.9	99.36%	91.61%	Uncharacterized protein;OS=Biomphalaria;PE=3;SV=1	GO:0005524|GO:0016740|
GN007683.1	sp|K1QAI2|K1QAI2_CRAGI	1.2e-229	802.4	51.81%	69.71%	Ufm1-specific protease 2;OS=Crassostrea;PE=4;SV=1	GO:0008233|
GN007684.1	sp|A0A210QAL8|A0A210QAL8_MIZYE	3.2e-189	666.8	92.36%	77.39%	Tyrosine-protein kinase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004715|	GO:0035556|
GN007685.1	sp|K1QIS8|K1QIS8_CRAGI	3.1e-41	174.1	58.94%	71.31%	Tyrosine-protein kinase Tec;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004713|	GO:0035556|
GN007686.1	sp|K1QKH4|K1QKH4_CRAGI	2.1e-120	437.2	100.00%	98.17%	Mediator of RNA polymerase II transcription subunit 7;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN007687.1	sp|K1QCT4|K1QCT4_CRAGI	0.0e+00	1621.7	96.05%	74.80%	Ankyrin repeat and LEM domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0051721|	GO:0007084|GO:0035307|
GN006383.1	sp|K1R401|K1R401_CRAGI	0.0e+00	4499.9	100.00%	94.93%	Spectrin alpha chain;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN007688.1	sp|K1QDN0|K1QDN0_CRAGI	0.0e+00	1610.1	93.15%	74.53%	Uncharacterized protein K03H1.5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN007689.1	sp|K1P7I7|K1P7I7_CRAGI	0.0e+00	1249.6	98.40%	68.07%	Uncharacterized protein K03H1.5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007160|
GN007690.1	sp|K1PDK0|K1PDK0_CRAGI	0.0e+00	1147.1	98.06%	81.61%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN007691.1	sp|K1PDK0|K1PDK0_CRAGI	3.0e-80	303.5	100.00%	79.68%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN006384.1	sp|V3ZR40|V3ZR40_LOTGI	9.2e-230	802.4	71.60%	63.39%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0004252|
GN007694.1	sp|A0A2B4RIG1|A0A2B4RIG1_STYPI	1.3e-85	322.4	99.47%	44.53%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN007695.1	sp|K1R994|K1R994_CRAGI	2.0e-75	288.1	74.22%	66.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006385.1	sp|K1QK28|K1QK28_CRAGI	1.6e-202	711.1	96.75%	69.44%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|GO:0005507|GO:0016491|	GO:0006004|
GN007696.1	sp|A0A210PLD1|A0A210PLD1_MIZYE	7.2e-86	322.8	90.71%	69.11%	Protein YIPF;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN007697.1	sp|J9Q4I9|J9Q4I9_OSTED	1.7e-99	367.5	100.00%	97.86%	Ribosomal protein L9;OS=Ostrea;PE=2;SV=1	GO:0005840|	GO:0019843|GO:0003735|	GO:0006412|
GN007698.1	sp|A0A210PXU0|A0A210PXU0_MIZYE	6.6e-32	143.7	80.33%	33.60%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007700.1	sp|K1PE45|K1PE45_CRAGI	2.0e-38	165.6	83.51%	33.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN006386.1	sp|K1QWK0|K1QWK0_CRAGI	1.4e-301	1040.8	85.93%	74.01%	Laccase-1;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016491|
GN007703.1	sp|A0A1X7SS55|A0A1X7SS55_AMPQE	2.6e-25	120.6	88.15%	51.69%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN006387.1	sp|K1R9U9|K1R9U9_CRAGI	1.4e-26	125.2	78.21%	43.17%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN007704.1	sp|K1Q4C8|K1Q4C8_CRAGI	3.0e-28	131.0	56.52%	55.17%	Neuroendocrine convertase 2;OS=Crassostrea;PE=4;SV=1	GO:0004252|
GN007706.1	sp|K1R2J0|K1R2J0_CRAGI	1.9e-160	571.6	97.82%	49.83%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007707.1	sp|K1Q0I6|K1Q0I6_CRAGI	1.5e-108	399.1	99.63%	39.45%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN007708.1	sp|K1PI81|K1PI81_CRAGI	7.4e-188	662.1	99.03%	80.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007709.1	sp|A0A210PHH9|A0A210PHH9_MIZYE	9.3e-37	160.2	83.61%	33.24%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN006388.1	sp|K1QWK0|K1QWK0_CRAGI	3.2e-265	919.8	91.20%	69.17%	Laccase-1;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016491|
GN007710.1	sp|K1PF07|K1PF07_CRAGI	0.0e+00	2717.2	100.00%	82.39%	von Willebrand factor A domain-containing protein 3B;OS=Crassostrea;PE=4;SV=1
GN007711.1	sp|K1PV46|K1PV46_CRAGI	0.0e+00	1372.1	99.02%	71.91%	Thrombospondin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007712.1	sp|A0A1S3HU90|A0A1S3HU90_LINUN	3.1e-182	644.0	96.41%	53.90%	kelch-like protein 12;OS=Lingula;PE=4;SV=1
GN007713.1	sp|A0A1S3K3W5|A0A1S3K3W5_LINUN	2.7e-29	133.7	93.33%	56.76%	5-hydroxyisourate hydrolase;OS=Lingula;PE=3;SV=1	GO:0033971|	GO:0006144|
GN007714.1	sp|A0A1X7THR6|A0A1X7THR6_AMPQE	8.0e-80	303.9	89.46%	31.65%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|
GN007716.1	sp|A0A1X7UEV0|A0A1X7UEV0_AMPQE	4.3e-47	194.9	61.99%	32.83%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046872|
GN007719.1	sp|K1S1B9|K1S1B9_CRAGI	1.7e-46	191.4	88.48%	64.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007720.1	sp|K1RHP9|K1RHP9_CRAGI	7.6e-130	468.8	100.00%	83.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007721.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	2.3e-25	122.1	92.71%	26.52%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN007723.1	sp|K1RBL6|K1RBL6_CRAGI	7.8e-271	938.3	95.99%	79.41%	Solute carrier family 23 member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN007724.1	sp|K1QQS0|K1QQS0_CRAGI	5.8e-166	589.3	99.74%	70.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006390.1	sp|K1PVB6|K1PVB6_CRAGI	1.4e-14	85.1	53.21%	51.22%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN007726.1	sp|A0A210PHY7|A0A210PHY7_MIZYE	1.6e-235	821.6	100.00%	50.06%	Tripartite motif-containing protein 45;OS=Mizuhopecten;PE=4;SV=1	GO:0008270|
GN007728.1	sp|K1Q687|K1Q687_CRAGI	4.2e-241	839.7	100.00%	72.73%	Lariat debranching enzyme A;OS=Crassostrea;PE=4;SV=1	GO:0016788|	GO:0006397|
GN007731.1	sp|K1PPX4|K1PPX4_CRAGI	3.4e-87	327.0	100.00%	62.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007732.1	sp|K1PX29|K1PX29_CRAGI	9.6e-96	355.5	100.00%	66.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007736.1	sp|W4YPX2|W4YPX2_STRPU	3.2e-15	89.0	94.87%	21.43%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004190|GO:0003676|GO:0008270|
GN007737.1	sp|K1QXJ6|K1QXJ6_CRAGI	2.2e-215	753.8	99.38%	77.62%	Neuronal acetylcholine receptor subunit alpha-9-I;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007738.1	sp|K1PPX6|K1PPX6_CRAGI	9.5e-90	335.5	100.00%	67.06%	39S ribosomal protein L17, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN007739.1	sp|K1PX33|K1PX33_CRAGI	9.0e-109	399.4	93.46%	49.61%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN007740.1	sp|K1QSD9|K1QSD9_CRAGI	5.1e-23	113.2	49.08%	63.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007741.1	sp|K1PKE9|K1PKE9_CRAGI	4.3e-149	533.1	100.00%	76.68%	PIH1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN007742.1	sp|K1RDK5|K1RDK5_CRAGI	2.4e-82	310.8	76.05%	82.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007744.1	sp|K1Q8M4|K1Q8M4_CRAGI	1.2e-30	138.7	62.71%	73.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007745.1	sp|K1QXC4|K1QXC4_CRAGI	2.6e-129	468.4	99.25%	39.70%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN007746.1	sp|K1R2H7|K1R2H7_CRAGI	2.5e-49	200.3	93.02%	85.71%	Transforming growth factor-beta-induced protein ig-h3;OS=Crassostrea;PE=4;SV=1
GN006392.1	sp|K1R941|K1R941_CRAGI	0.0e+00	2129.4	84.97%	49.80%	Erythronolide synthase, modules 3 and 4;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN007748.1	sp|K1Q124|K1Q124_CRAGI	1.3e-25	121.7	96.64%	47.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007749.1	sp|K1PYI7|K1PYI7_CRAGI	2.8e-267	926.8	99.58%	62.70%	Vitrin;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN007750.1	sp|K1PVK7|K1PVK7_CRAGI	5.1e-183	646.7	82.53%	60.54%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN007751.1	sp|K1PSG7|K1PSG7_CRAGI	4.7e-178	629.4	95.62%	88.51%	Toll-like receptor 4;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN007753.1	sp|K1Q136|K1Q136_CRAGI	1.4e-12	78.6	65.84%	35.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007754.1	sp|A0A210PZE3|A0A210PZE3_MIZYE	3.4e-47	194.5	75.62%	42.46%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007755.1	sp|K1RLP8|K1RLP8_CRAGI	5.3e-57	227.3	36.01%	82.17%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN007756.1	sp|K1QVS8|K1QVS8_CRAGI	1.3e-22	112.1	97.30%	39.38%	Poly [ADP-ribose] polymerase 14;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN007757.1	sp|A0A210QV36|A0A210QV36_MIZYE	1.0e-123	449.1	89.76%	54.97%	Lipase;OS=Mizuhopecten;PE=3;SV=1	GO:0016788|	GO:0016042|
GN007758.1	sp|K1PJV5|K1PJV5_CRAGI	0.0e+00	1161.0	100.00%	85.80%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007759.1	sp|A0A210Q2Z4|A0A210Q2Z4_MIZYE	4.6e-27	127.1	71.30%	43.75%	ATP-dependent DNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN007760.1	sp|A0A2G8JSW5|A0A2G8JSW5_STIJA	1.4e-85	323.2	44.94%	48.93%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN007761.1	sp|A0A210PHM1|A0A210PHM1_MIZYE	1.4e-28	131.3	83.74%	57.84%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007762.1	sp|K1QTS3|K1QTS3_CRAGI	4.8e-59	233.8	80.20%	49.19%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0004197|GO:0020037|GO:0005506|GO:0016705|
GN007763.1	sp|K1QTS3|K1QTS3_CRAGI	2.7e-23	117.1	28.39%	30.73%	Cytochrome P450 1A1;OS=Crassostrea;PE=3;SV=1	GO:0004197|GO:0020037|GO:0005506|GO:0016705|
GN007764.1	sp|K1QVX4|K1QVX4_CRAGI	1.1e-213	748.8	52.18%	97.64%	Glycogen synthase kinase-3 beta;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN007765.1	sp|K1S6W3|K1S6W3_CRAGI	0.0e+00	1188.7	99.88%	78.00%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007766.1	sp|K1RIW4|K1RIW4_CRAGI	1.8e-45	188.0	99.44%	53.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007767.1	sp|K1S6W3|K1S6W3_CRAGI	0.0e+00	1257.7	99.88%	77.49%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007769.1	sp|K1RIW4|K1RIW4_CRAGI	5.8e-47	193.0	98.40%	53.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007770.1	sp|K1PUB3|K1PUB3_CRAGI	1.5e-57	228.0	87.43%	76.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN007771.1	sp|K1S6W3|K1S6W3_CRAGI	2.2e-91	340.9	100.00%	69.48%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007774.1	sp|K1S6W3|K1S6W3_CRAGI	3.1e-179	633.6	100.00%	74.29%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007777.1	sp|K1S6W3|K1S6W3_CRAGI	1.3e-152	545.0	99.74%	71.98%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007778.1	sp|K1RNI9|K1RNI9_CRAGI	3.3e-53	214.5	99.10%	70.43%	Leucine-rich repeat-containing protein 59;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007779.1	sp|C3XWL2|C3XWL2_BRAFL	1.1e-24	119.0	65.63%	52.80%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005744|	GO:0030150|
GN007780.1	sp|K1RHD2|K1RHD2_CRAGI	1.3e-199	701.4	99.80%	71.60%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN007781.1	sp|A0A210PZE3|A0A210PZE3_MIZYE	4.6e-46	191.0	61.11%	40.48%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN007782.1	sp|K1S6V9|K1S6V9_CRAGI	3.1e-84	317.4	97.89%	60.07%	Transcriptional regulator ATRX;OS=Crassostrea;PE=4;SV=1	GO:0000786|	GO:0005524|GO:0003677|GO:0046872|	GO:0006334|
GN007783.1	sp|K1S6V9|K1S6V9_CRAGI	0.0e+00	1325.8	68.85%	83.39%	Transcriptional regulator ATRX;OS=Crassostrea;PE=4;SV=1	GO:0000786|	GO:0005524|GO:0003677|GO:0046872|	GO:0006334|
GN007784.1	sp|K1RBQ4|K1RBQ4_CRAGI	6.2e-40	169.9	97.73%	43.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007785.1	sp|K1R1M5|K1R1M5_CRAGI	1.6e-194	685.3	81.37%	60.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007786.1	sp|A0A210R115|A0A210R115_MIZYE	2.2e-39	167.2	100.00%	59.50%	RING finger protein 44;OS=Mizuhopecten;PE=4;SV=1
GN007788.1	sp|K1PLQ6|K1PLQ6_CRAGI	4.4e-19	100.9	78.39%	34.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007790.1	sp|K1PVH2|K1PVH2_CRAGI	1.5e-204	717.6	100.00%	75.72%	Arylsulfatase B;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN007791.1	sp|A0A210Q4S7|A0A210Q4S7_MIZYE	1.9e-93	348.2	100.00%	55.15%	Sodium/potassium-transporting ATPase subunit alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007792.1	sp|K1QAK5|K1QAK5_CRAGI	2.9e-121	441.0	99.55%	47.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007793.1	sp|K1PRY0|K1PRY0_CRAGI	7.0e-167	592.8	97.90%	71.85%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN007795.1	sp|K1RED4|K1RED4_CRAGI	6.0e-14	82.4	99.02%	49.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007797.1	sp|K1P6H6|K1P6H6_CRAGI	1.1e-32	145.6	88.54%	54.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007798.1	sp|K1PCH4|K1PCH4_CRAGI	9.7e-210	735.7	97.62%	77.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007799.1	sp|A0A210PJH0|A0A210PJH0_MIZYE	5.2e-107	393.7	98.16%	49.30%	Acylglycerol kinase, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0003951|
GN007800.1	sp|V9HX25|V9HX25_OSTED	8.3e-70	268.5	100.00%	92.96%	Complement component 1;OS=Ostrea;PE=2;SV=1
GN007801.1	sp|K1P6I1|K1P6I1_CRAGI	3.8e-42	176.0	100.00%	88.42%	Glyoxylate reductase/hydroxypyruvate reductase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN007802.1	sp|K1PCH8|K1PCH8_CRAGI	3.9e-205	719.9	75.14%	89.03%	Nucleoporin p54;OS=Crassostrea;PE=4;SV=1	GO:0005643|
GN007803.1	sp|K1PK07|K1PK07_CRAGI	8.3e-61	239.6	47.93%	80.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007805.1	sp|A0A2G8JJY5|A0A2G8JJY5_STIJA	6.2e-21	106.7	75.94%	30.00%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|	GO:0015074|
GN007806.1	sp|A0A0B6ZCF6|A0A0B6ZCF6_9EUPU	1.8e-292	1010.7	99.55%	58.08%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0000145|	GO:0006887|
GN007807.1	sp|K1R2D5|K1R2D5_CRAGI	8.1e-163	578.6	100.00%	87.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007808.1	sp|A0A210QYC7|A0A210QYC7_MIZYE	8.2e-257	892.1	98.31%	58.24%	LON peptidase N-terminal domain and RING finger protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN007809.1	sp|A0A210QYG1|A0A210QYG1_MIZYE	3.5e-54	216.9	93.79%	64.85%	COMM domain-containing protein 5;OS=Mizuhopecten;PE=4;SV=1
GN007810.1	sp|K1QGX0|K1QGX0_CRAGI	1.3e-46	191.0	93.81%	81.90%	Inactive carboxypeptidase-like protein X2;OS=Crassostrea;PE=4;SV=1	GO:0004180|
GN006393.1	sp|K1R0E9|K1R0E9_CRAGI	6.8e-14	83.2	43.65%	42.35%	PHD finger protein 2;OS=Crassostrea;PE=4;SV=1	GO:0048188|	GO:0046872|
GN007814.1	sp|A0A0L8ICQ2|A0A0L8ICQ2_OCTBM	6.5e-11	72.8	62.86%	44.83%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005634|	GO:0006915|
GN007815.1	sp|K1QLQ8|K1QLQ8_CRAGI	2.8e-135	488.8	45.03%	67.97%	Myoneurin;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007816.1	sp|K1RT49|K1RT49_CRAGI	1.2e-12	80.9	61.90%	28.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007817.1	sp|K1R9B8|K1R9B8_CRAGI	0.0e+00	1230.3	99.91%	68.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN007818.1	sp|K1R2K3|K1R2K3_CRAGI	6.3e-193	679.5	82.90%	80.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007819.1	sp|K1QVV1|K1QVV1_CRAGI	3.8e-120	436.4	99.15%	90.99%	Ribose-5-phosphate isomerase;OS=Crassostrea;PE=4;SV=1	GO:0004751|	GO:0009052|
GN007820.1	sp|A0A0F7G5J3|A0A0F7G5J3_CRAGI	2.9e-239	833.2	100.00%	85.22%	Nuclear receptor 8;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN007821.1	sp|K1R9B4|K1R9B4_CRAGI	0.0e+00	1119.0	100.00%	87.36%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN007822.1	sp|K1QVU8|K1QVU8_CRAGI	1.5e-103	381.7	72.62%	73.62%	Archaemetzincin-2;OS=Crassostrea;PE=4;SV=1	GO:0008237|GO:0008270|
GN007823.1	sp|K1QLP8|K1QLP8_CRAGI	1.0e-232	811.6	88.28%	93.75%	Vang-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0007275|
GN007824.1	sp|K1R9B1|K1R9B1_CRAGI	3.2e-137	493.8	76.41%	78.87%	Phytanoyl-CoA dioxygenase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0051213|
GN007825.1	sp|K1QBB7|K1QBB7_CRAGI	4.2e-187	659.8	93.40%	72.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007830.1	sp|K1QK08|K1QK08_CRAGI	5.3e-54	216.5	91.09%	57.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007831.1	sp|K1PY55|K1PY55_CRAGI	1.6e-45	188.0	86.62%	68.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007833.1	sp|K1QZ17|K1QZ17_CRAGI	6.8e-09	66.2	44.23%	57.35%	Homeobox protein HD1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN006243.1	sp|Q70ML8|Q70ML8_CRAGI	1.4e-107	394.4	100.00%	97.06%	Ribosomal protein S5;OS=Crassostrea;PE=2;SV=1	GO:0015935|	GO:0003723|GO:0003735|	GO:0006412|
GN006395.1	sp|K1QRW2|K1QRW2_CRAGI	7.9e-20	102.4	92.31%	41.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0016042|
GN007834.1	sp|K1R3B2|K1R3B2_CRAGI	7.1e-12	75.1	55.26%	80.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007836.1	sp|K1PY55|K1PY55_CRAGI	1.1e-112	412.1	74.02%	81.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007837.1	sp|K1PQW1|K1PQW1_CRAGI	1.9e-191	675.2	100.00%	53.59%	DC-STAMP domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007838.1	sp|K1PJ50|K1PJ50_CRAGI	3.0e-104	383.6	81.07%	92.86%	DnaJ-like protein subfamily C member 27-A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN007839.1	sp|K1QR73|K1QR73_CRAGI	1.4e-89	334.7	99.08%	73.83%	DnaJ-like protein subfamily C member 22;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007841.1	sp|K1PY43|K1PY43_CRAGI	0.0e+00	1409.8	100.00%	76.01%	Roundabout-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007842.1	sp|K1PQV2|K1PQV2_CRAGI	4.1e-216	756.1	96.46%	81.38%	Cytochrome P450 3A24;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN007844.1	sp|K1QR65|K1QR65_CRAGI	6.6e-106	389.8	95.34%	63.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007845.1	sp|K1PY35|K1PY35_CRAGI	2.2e-305	1053.5	96.13%	79.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007846.1	sp|K1QR58|K1QR58_CRAGI	1.5e-112	411.4	98.88%	80.38%	Mechanosensory protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007847.1	sp|K1RCK1|K1RCK1_CRAGI	1.6e-83	314.7	100.00%	73.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007848.1	sp|K1QR01|K1QR01_CRAGI	1.9e-26	124.8	69.40%	55.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007849.1	sp|K1QR58|K1QR58_CRAGI	1.2e-130	471.5	98.50%	95.04%	Mechanosensory protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007850.1	sp|K1Q525|K1Q525_CRAGI	9.2e-121	438.7	87.41%	93.57%	Mechanosensory protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007852.1	sp|A0A210R421|A0A210R421_MIZYE	2.1e-109	401.0	92.55%	79.23%	Stomatin-2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN007853.1	sp|K1PZ36|K1PZ36_CRAGI	3.9e-74	283.5	73.99%	83.23%	Protein phosphatase 1 regulatory subunit 16A;OS=Crassostrea;PE=4;SV=1
GN007854.1	sp|K1PJI8|K1PJI8_CRAGI	6.6e-117	426.4	98.74%	56.62%	Asialoglycoprotein receptor 2;OS=Crassostrea;PE=4;SV=1
GN007855.1	sp|K1PSG7|K1PSG7_CRAGI	4.0e-98	364.0	57.43%	77.41%	Toll-like receptor 4;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN007856.1	sp|K1Q5V0|K1Q5V0_CRAGI	1.7e-251	874.4	57.57%	97.86%	E3 ubiquitin-protein ligase CBL-B;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016874|GO:0001784|GO:0004842|	GO:0007166|GO:0023051|
GN007857.1	sp|A0A210QHS6|A0A210QHS6_MIZYE	1.0e-117	429.1	99.25%	53.55%	Protein AAR2-like;OS=Mizuhopecten;PE=4;SV=1
GN007858.1	sp|A0A1X7TSC4|A0A1X7TSC4_AMPQE	9.7e-17	92.0	85.50%	43.10%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN007862.1	sp|K1QAM6|K1QAM6_CRAGI	1.9e-262	910.2	100.00%	86.65%	Protein BAT5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007863.1	sp|K1QHL4|K1QHL4_CRAGI	6.1e-112	409.8	96.32%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007864.1	sp|K1QHL4|K1QHL4_CRAGI	2.0e-34	150.2	89.77%	87.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007865.1	sp|K1R395|K1R395_CRAGI	4.6e-66	256.1	97.42%	76.00%	Box C/D snoRNA protein 1;OS=Crassostrea;PE=4;SV=1
GN007866.1	sp|K1Q341|K1Q341_CRAGI	2.7e-131	473.8	78.60%	90.60%	Protein FAM78B;OS=Crassostrea;PE=4;SV=1
GN006396.1	sp|K1RLW8|K1RLW8_CRAGI	0.0e+00	1140.6	56.26%	73.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007868.1	sp|K1QJP2|K1QJP2_CRAGI	3.6e-75	287.7	69.11%	53.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007869.1	sp|K1R3A0|K1R3A0_CRAGI	8.0e-174	615.1	100.00%	97.18%	Transcription initiation factor IIB;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0017025|GO:0003743|	GO:0006355|GO:0070897|
GN007870.1	sp|K1PVG1|K1PVG1_CRAGI	3.7e-142	510.0	100.00%	75.54%	Endonuclease G, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004519|GO:0046872|GO:0003676|
GN007872.1	sp|K1Q348|K1Q348_CRAGI	6.6e-246	855.5	99.00%	72.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN007873.1	sp|K1QAP2|K1QAP2_CRAGI	6.3e-21	104.8	89.47%	98.00%	Cyclic nucleotide-gated olfactory channel;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN007874.1	sp|Unreviewed|A0A087T3I4_9ARAC	2.5e-13	82.0	61.03%	28.85%	Retrovirus-related Pol polyprotein from transposon 412;OS=Stegodyphus;PE=4;SV=1	GO:0004190|GO:0003677|	GO:0015074|GO:0006313|
GN007875.1	sp|C4NWI5|C4NWI5_9BIVA	6.9e-116	422.2	100.00%	86.36%	Peroxiredoxin 6;OS=Saccostrea;PE=2;SV=1	GO:0005623|	GO:0004601|GO:0051920|	GO:0045454|
GN007876.1	sp|K1Q4P2|K1Q4P2_CRAGI	0.0e+00	1720.7	94.16%	61.19%	BAT2 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN007877.1	sp|A0A2G8KX79|A0A2G8KX79_STIJA	4.6e-47	192.6	99.13%	78.76%	Putative nuclease HARBI1;OS=Stichopus;PE=4;SV=1
GN007878.1	sp|A0A210QIF6|A0A210QIF6_MIZYE	4.4e-77	293.9	85.09%	55.67%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN007880.1	sp|K1PXN4|K1PXN4_CRAGI	2.8e-195	688.0	99.24%	43.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007881.1	sp|K1PQB0|K1PQB0_CRAGI	7.8e-263	912.9	100.00%	57.68%	Large proline-rich protein BAT3;OS=Crassostrea;PE=4;SV=1
GN007882.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	1.0e-79	302.8	76.52%	51.26%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN007883.1	sp|K1PIP8|K1PIP8_CRAGI	3.7e-64	249.6	100.00%	96.18%	Proteasome subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|GO:0005839|	GO:0004298|	GO:0051603|
GN007884.1	sp|K1QQR6|K1QQR6_CRAGI	2.7e-195	687.2	100.00%	88.48%	U4/U6 small nuclear ribonucleoprotein Prp4;OS=Crassostrea;PE=4;SV=1	GO:0019013|
GN007885.1	sp|K1QCZ6|K1QCZ6_CRAGI	4.3e-166	590.5	79.48%	56.55%	Proprotein convertase subtilisin/kexin type 4;OS=Crassostrea;PE=4;SV=1	GO:0004252|
GN007887.1	sp|K1QSZ5|K1QSZ5_CRAGI	7.6e-19	99.0	88.89%	49.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007891.1	sp|K1QZR6|K1QZR6_CRAGI	3.0e-47	193.0	98.97%	100.00%	U6 snRNA-associated Sm-like protein LSm2;OS=Crassostrea;PE=4;SV=1	GO:0006397|
GN007892.1	sp|K1RJD2|K1RJD2_CRAGI	1.4e-136	491.1	98.80%	92.68%	Ubiquinone biosynthesis protein COQ4 homolog, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0031314|	GO:0006744|
GN006397.1	sp|K1QEM7|K1QEM7_CRAGI	0.0e+00	1103.2	100.00%	85.87%	Ankyrin repeat and SAM domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN007893.1	sp|K1RJD9|K1RJD9_CRAGI	1.6e-228	798.5	100.00%	51.17%	Histone-lysine N-methyltransferase MLL3;OS=Crassostrea;PE=4;SV=1	GO:0008168|GO:0003676|
GN007894.1	sp|K1Q812|K1Q812_CRAGI	0.0e+00	1090.5	73.46%	41.47%	NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016651|GO:0048038|
GN007895.1	sp|K1Q812|K1Q812_CRAGI	2.2e-228	797.0	97.44%	83.77%	NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016651|GO:0048038|
GN007896.1	sp|K1QF57|K1QF57_CRAGI	4.2e-31	139.8	67.16%	73.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007897.1	sp|K1QTZ0|K1QTZ0_CRAGI	4.1e-31	141.0	89.42%	33.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016790|	GO:0006633|
GN007898.1	sp|K1R187|K1R187_CRAGI	3.8e-226	790.0	69.94%	89.18%	Protein TSPEAR;OS=Crassostrea;PE=4;SV=1
GN007899.1	sp|K1PTA3|K1PTA3_CRAGI	0.0e+00	3680.2	98.84%	74.13%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0005576|	GO:0008061|	GO:0006030|
GN007900.1	sp|K1QUX9|K1QUX9_CRAGI	0.0e+00	1958.0	93.85%	87.52%	Prolow-density lipoprotein receptor-related protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN007901.1	sp|K1QUX9|K1QUX9_CRAGI	0.0e+00	1390.9	86.56%	76.91%	Prolow-density lipoprotein receptor-related protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN007902.1	sp|A0A210PHV0|A0A210PHV0_MIZYE	2.4e-159	567.8	83.53%	61.18%	Low-density lipoprotein receptor-related protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN007903.1	sp|K1PMZ2|K1PMZ2_CRAGI	6.7e-80	302.4	99.46%	74.73%	Low-density lipoprotein receptor-related protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN007904.1	sp|K1PUI4|K1PUI4_CRAGI	1.0e-92	345.1	100.00%	74.07%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003755|
GN007905.1	sp|A0A210PJM6|A0A210PJM6_MIZYE	8.3e-32	142.9	97.35%	36.40%	Peptidylprolyl isomerase;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|GO:0003755|
GN007906.1	sp|A0A1W6EVW0|A0A1W6EVW0_AMPCP	4.2e-23	114.0	86.46%	33.49%	Peptidylprolyl isomerase;OS=Ampulex;PE=2;SV=1	GO:0005509|GO:0003755|
GN007907.1	sp|K1QI99|K1QI99_CRAGI	1.0e-35	156.0	65.16%	50.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007908.1	sp|A0A210PJM6|A0A210PJM6_MIZYE	3.1e-31	141.0	97.35%	35.96%	Peptidylprolyl isomerase;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|GO:0003755|
GN007909.1	sp|A0A1W6EVW0|A0A1W6EVW0_AMPCP	4.2e-23	114.0	86.46%	33.49%	Peptidylprolyl isomerase;OS=Ampulex;PE=2;SV=1	GO:0005509|GO:0003755|
GN006244.1	sp|K1RHM2|K1RHM2_CRAGI	3.6e-55	221.1	97.07%	34.94%	Low-density lipoprotein receptor-related protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006398.1	sp|K1R2K5|K1R2K5_CRAGI	2.2e-249	867.1	98.85%	73.31%	Monocarboxylate transporter 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN007910.1	sp|K1QI99|K1QI99_CRAGI	4.2e-37	160.6	64.90%	50.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007911.1	sp|A0A1D1UN63|A0A1D1UN63_RAMVA	1.3e-18	99.0	93.46%	33.50%	Peptidylprolyl isomerase;OS=Ramazzottius;PE=4;SV=1	GO:0005509|GO:0003755|
GN007912.1	sp|K1R400|K1R400_CRAGI	2.8e-64	250.8	100.00%	56.11%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003755|
GN007914.1	sp|K1PW75|K1PW75_CRAGI	0.0e+00	1152.1	99.54%	84.63%	Calpain-5;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN007915.1	sp|K1Q404|K1Q404_CRAGI	0.0e+00	2377.1	82.06%	89.18%	DNA topoisomerase 2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003677|GO:0003918|	GO:0006265|
GN007916.1	sp|K1QBR6|K1QBR6_CRAGI	2.3e-92	343.6	100.00%	98.18%	Ubiquitin-conjugating enzyme E2 G2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN007917.1	sp|K1QIA3|K1QIA3_CRAGI	0.0e+00	1667.9	100.00%	90.94%	Mitogen-activated protein kinase kinase kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004709|	GO:0046777|
GN007918.1	sp|A0A210QRF9|A0A210QRF9_MIZYE	1.7e-127	461.1	98.58%	80.14%	Phosphonoacetaldehyde hydrolase-like protein;OS=Mizuhopecten;PE=3;SV=1	GO:0050194|	GO:0019700|
GN007919.1	sp|K1R138|K1R138_CRAGI	3.0e-47	194.9	99.18%	72.28%	Nuclear pore glycoprotein p62;OS=Crassostrea;PE=4;SV=1	GO:0005643|	GO:0017056|
GN007920.1	sp|V4AKX4|V4AKX4_LOTGI	1.9e-25	120.9	85.38%	50.91%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN007921.1	sp|K1QHT3|K1QHT3_CRAGI	1.9e-14	85.9	73.22%	24.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007923.1	sp|V4A8A4|V4A8A4_LOTGI	1.6e-18	99.0	52.81%	39.29%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006399.1	sp|A0A2L2Z2J1|A0A2L2Z2J1_PARTP	9.9e-15	86.7	31.55%	43.00%	Uncharacterized protein;OS=Parasteatoda;PE=2;SV=1
GN007924.1	sp|K1Q406|K1Q406_CRAGI	0.0e+00	1538.5	84.17%	54.60%	Chitin synthase C;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016758|
GN007925.1	sp|K1R407|K1R407_CRAGI	0.0e+00	1423.7	98.36%	82.97%	DnaJ-like protein subfamily C member 10;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN007926.1	sp|A0A210Q4F1|A0A210Q4F1_MIZYE	6.9e-56	222.6	98.95%	83.96%	Dynactin subunit 5;OS=Mizuhopecten;PE=4;SV=1
GN007929.1	sp|K1QPN4|K1QPN4_CRAGI	0.0e+00	1592.0	93.55%	76.19%	Chitin synthase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016758|
GN007930.1	sp|K1QPN4|K1QPN4_CRAGI	2.4e-165	587.4	100.00%	76.65%	Chitin synthase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016758|
GN007931.1	sp|K1PHI3|K1PHI3_CRAGI	9.6e-86	322.4	77.19%	69.41%	Pyrazinamidase/nicotinamidase;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN007932.1	sp|K1PP62|K1PP62_CRAGI	8.3e-126	455.7	99.07%	67.81%	Retinol dehydrogenase 7;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN007933.1	sp|K1PP62|K1PP62_CRAGI	2.7e-37	160.2	90.24%	66.36%	Retinol dehydrogenase 7;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN007934.1	sp|K1Q3K7|K1Q3K7_CRAGI	9.0e-40	170.2	90.67%	40.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007935.1	sp|K1QPP1|K1QPP1_CRAGI	0.0e+00	1297.3	100.00%	89.78%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN007936.1	sp|K1PHI7|K1PHI7_CRAGI	0.0e+00	1201.8	97.26%	67.47%	CutA-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0010038|
GN007937.1	sp|K1R475|K1R475_CRAGI	6.0e-208	728.8	100.00%	86.57%	Queuine tRNA-ribosyltransferase catalytic subunit 1;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0046872|GO:0008479|	GO:0101030|
GN007938.1	sp|K1QC02|K1QC02_CRAGI	1.3e-34	151.4	78.57%	73.47%	ELAV-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN007939.1	sp|A0A0L8FPI1|A0A0L8FPI1_OCTBM	2.9e-86	324.3	100.00%	50.76%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0003723|
GN007940.1	sp|K1QC02|K1QC02_CRAGI	2.6e-161	573.5	100.00%	89.62%	ELAV-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN007941.1	sp|K1Q486|K1Q486_CRAGI	9.6e-64	249.6	60.40%	59.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007942.1	sp|W4YMP2|W4YMP2_STRPU	2.4e-22	111.3	67.80%	48.95%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN007943.1	sp|K1R0V5|K1R0V5_CRAGI	2.6e-168	597.0	82.79%	98.68%	Cell differentiation protein RCD1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0030014|	GO:0006402|
GN007944.1	sp|K1QEV1|K1QEV1_CRAGI	1.4e-64	251.9	92.62%	55.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007945.1	sp|K1RPM0|K1RPM0_CRAGI	1.4e-90	337.8	99.43%	94.22%	Ras-related protein Rab-30;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN007946.1	sp|K1QHU0|K1QHU0_CRAGI	0.0e+00	1162.5	95.56%	67.19%	Pre-mRNA cleavage complex 2 protein Pcf11;OS=Crassostrea;PE=4;SV=1
GN007947.1	sp|K1QRK0|K1QRK0_CRAGI	2.5e-127	460.3	100.00%	92.56%	Ras-related protein Rab-33B;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN007948.1	sp|A0A1S3H4N3|A0A1S3H4N3_LINUN	1.8e-203	714.5	92.44%	62.84%	malate synthase, glyoxysomal-like isoform X2;OS=Lingula;PE=4;SV=1	GO:0004474|	GO:0006097|
GN007949.1	sp|A0A2C9JLQ1|A0A2C9JLQ1_BIOGL	1.6e-29	136.3	73.63%	29.46%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN007950.1	sp|K1RPM8|K1RPM8_CRAGI	1.7e-44	183.7	100.00%	95.51%	NTF2-related export protein 2;OS=Crassostrea;PE=4;SV=1
GN007951.1	sp|K1QC38|K1QC38_CRAGI	8.5e-132	475.3	100.00%	81.62%	Putative deoxyribonuclease TATDN3;OS=Crassostrea;PE=4;SV=1	GO:0016888|
GN007952.1	sp|K1Q999|K1Q999_CRAGI	3.1e-94	352.4	31.64%	62.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007955.1	sp|K1QYD3|K1QYD3_CRAGI	9.7e-41	172.9	72.26%	46.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007956.1	sp|K1R129|K1R129_CRAGI	6.0e-106	389.8	98.86%	66.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007957.1	sp|K1R7J9|K1R7J9_CRAGI	1.4e-306	1057.4	99.87%	74.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007959.1	sp|K1RRS8|K1RRS8_CRAGI	4.0e-220	769.6	91.63%	81.70%	Phosphoglucomutase-2;OS=Crassostrea;PE=3;SV=1	GO:0016868|GO:0000287|	GO:0005975|
GN007960.1	sp|A0A210QQX9|A0A210QQX9_MIZYE	6.5e-167	592.8	99.59%	59.15%	Disrupted in renal carcinoma protein 2-like;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN007961.1	sp|K1QBF5|K1QBF5_CRAGI	1.4e-207	728.0	100.00%	75.10%	Octopamine receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN007962.1	sp|K1PWQ9|K1PWQ9_CRAGI	0.0e+00	1722.2	83.02%	80.75%	Cytoplasmic FMR1-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007963.1	sp|K1PPN2|K1PPN2_CRAGI	4.9e-24	115.5	85.90%	80.30%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007964.1	sp|K1PPN2|K1PPN2_CRAGI	7.8e-49	198.7	82.73%	83.33%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007965.1	sp|K1PPN2|K1PPN2_CRAGI	6.7e-19	98.2	100.00%	67.19%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007966.1	sp|K1PPN2|K1PPN2_CRAGI	2.2e-52	211.8	89.55%	45.82%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN007967.1	sp|K1P940|K1P940_CRAGI	3.0e-36	158.3	59.71%	46.73%	RING finger protein 44;OS=Crassostrea;PE=4;SV=1
GN007968.1	sp|K1P940|K1P940_CRAGI	3.0e-27	126.7	84.40%	58.24%	RING finger protein 44;OS=Crassostrea;PE=4;SV=1
GN007969.1	sp|K1PVG0|K1PVG0_CRAGI	0.0e+00	1173.3	95.94%	88.07%	Long-chain fatty acid transport protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004467|GO:0031957|	GO:0015908|
GN007970.1	sp|K1PN22|K1PN22_CRAGI	2.1e-118	431.0	100.00%	53.20%	Pyrimidine-specific ribonucleoside hydrolase rihA;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN007972.1	sp|K1QLK4|K1QLK4_CRAGI	9.9e-38	162.9	85.47%	41.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007973.1	sp|K1PF96|K1PF96_CRAGI	6.4e-235	818.5	99.30%	97.64%	Spliceosome RNA helicase BAT1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN007974.1	sp|K1P936|K1P936_CRAGI	1.3e-155	555.1	87.04%	73.76%	Spliceosome RNA helicase BAT1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN007975.1	sp|K1P936|K1P936_CRAGI	1.7e-15	87.0	88.73%	64.52%	Spliceosome RNA helicase BAT1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN007976.1	sp|K1QFD6|K1QFD6_CRAGI	6.2e-16	89.0	59.18%	80.70%	UPF0184 protein C9orf16-like protein;OS=Crassostrea;PE=4;SV=1
GN007977.1	sp|K1PVF5|K1PVF5_CRAGI	9.0e-94	349.4	67.53%	74.15%	Zinc finger protein 16;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007978.1	sp|K1PN18|K1PN18_CRAGI	1.0e-204	718.4	100.00%	77.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007979.1	sp|K1PF93|K1PF93_CRAGI	1.2e-129	469.5	78.25%	52.99%	Matrin-3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|
GN007980.1	sp|A0A210Q4W7|A0A210Q4W7_MIZYE	3.7e-235	820.1	97.89%	59.06%	Urea-proton symporter DUR3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0015204|
GN007981.1	sp|K1R9X2|K1R9X2_CRAGI	1.4e-45	187.6	94.59%	93.27%	Transmembrane protein 93;OS=Crassostrea;PE=4;SV=1	GO:0072546|
GN007982.1	sp|A0A210PJ10|A0A210PJ10_MIZYE	6.0e-194	682.9	97.03%	86.88%	Kelch-like protein 5;OS=Mizuhopecten;PE=4;SV=1
GN007983.1	sp|K1PHE8|K1PHE8_CRAGI	0.0e+00	2495.7	94.35%	81.01%	Tetratricopeptide repeat protein 6;OS=Crassostrea;PE=4;SV=1
GN007984.1	sp|K1P1G7|K1P1G7_CRAGI	2.6e-102	377.5	83.04%	74.06%	39S ribosomal protein L28, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|
GN007986.1	sp|K1PPD1|K1PPD1_CRAGI	1.3e-180	638.6	98.36%	77.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016607|	GO:0003713|	GO:0007219|GO:0045944|
GN007988.1	sp|A0A210QEF0|A0A210QEF0_MIZYE	6.2e-88	329.7	100.00%	75.68%	Paired mesoderm homeobox protein 2B;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN007989.1	sp|K1P3I7|K1P3I7_CRAGI	7.8e-112	409.5	100.00%	72.44%	Protein ovo;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN007990.1	sp|K1QZJ7|K1QZJ7_CRAGI	4.8e-65	255.0	65.57%	34.95%	MAP kinase kinase kinase win1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN007991.1	sp|K1PPD8|K1PPD8_CRAGI	2.3e-99	367.9	95.68%	64.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007992.1	sp|K1QA32|K1QA32_CRAGI	2.9e-200	703.7	99.63%	74.35%	Insulin-like growth factor-binding protein complex acid labile chain;OS=Crassostrea;PE=4;SV=1
GN007993.1	sp|A0A210QYU0|A0A210QYU0_MIZYE	1.7e-73	281.6	98.40%	49.39%	S-acyl fatty acid synthase thioesterase, medium chain;OS=Mizuhopecten;PE=4;SV=1	GO:0016788|	GO:0009058|
GN007994.1	sp|K1P3J5|K1P3J5_CRAGI	3.7e-161	573.9	100.00%	76.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN007995.1	sp|K1PA54|K1PA54_CRAGI	9.5e-167	591.7	100.00%	94.94%	Replication factor C subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006260|
GN006400.1	sp|K1PU64|K1PU64_CRAGI	1.5e-44	186.8	40.54%	40.15%	B-cell receptor CD22;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0098609|
GN007997.1	sp|K1PHF9|K1PHF9_CRAGI	0.0e+00	1364.0	100.00%	71.16%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN007998.1	sp|K1PDK0|K1PDK0_CRAGI	8.1e-132	477.2	92.82%	33.77%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN007999.1	sp|A0A210QVV2|A0A210QVV2_MIZYE	2.2e-54	217.2	92.25%	93.08%	V-type proton ATPase proteolipid subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|GO:0033179|GO:0005774|	GO:0015078|	GO:0015991|
GN008000.1	sp|K1Q5K6|K1Q5K6_CRAGI	0.0e+00	1424.1	93.67%	81.16%	Periodic tryptophan protein 2-like protein;OS=Crassostrea;PE=4;SV=1
GN008001.1	sp|A0A210QVZ0|A0A210QVZ0_MIZYE	3.0e-210	737.6	90.08%	50.12%	Cyclic nucleotide-binding domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1
GN008002.1	sp|K1QJX1|K1QJX1_CRAGI	0.0e+00	1194.1	58.36%	67.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008003.1	sp|K1PY65|K1PY65_CRAGI	8.9e-255	885.2	80.35%	85.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008004.1	sp|K1R5H1|K1R5H1_CRAGI	1.8e-284	983.8	95.63%	75.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006401.1	sp|A0A1S3I398|A0A1S3I398_LINUN	8.4e-18	94.7	86.30%	66.67%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN008005.1	sp|K1QJW9|K1QJW9_CRAGI	5.3e-142	509.2	97.79%	88.68%	PCTP-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN008006.1	sp|K1QDM5|K1QDM5_CRAGI	0.0e+00	1369.0	100.00%	77.93%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN008007.1	sp|K1QDM5|K1QDM5_CRAGI	4.5e-14	82.4	63.16%	85.11%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN008011.1	sp|K1Q2T0|K1Q2T0_CRAGI	1.7e-86	325.1	73.51%	58.00%	ADP-dependent glucokinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0016773|	GO:0005975|
GN008012.1	sp|C3Z1R2|C3Z1R2_BRAFL	2.2e-71	275.0	97.46%	40.79%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN008013.1	sp|K1PXB3|K1PXB3_CRAGI	3.1e-108	397.9	95.71%	55.67%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN008015.1	sp|K1Q906|K1Q906_CRAGI	9.9e-92	341.7	92.97%	95.32%	Heart-and neural crest derivatives-expressed protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN008016.1	sp|K1QG65|K1QG65_CRAGI	9.3e-130	468.8	73.75%	98.30%	rRNA 2'-O-methyltransferase fibrillarin;OS=Crassostrea;PE=3;SV=1	GO:0008168|GO:0003723|	GO:0006364|
GN008017.1	sp|K1R237|K1R237_CRAGI	2.9e-204	716.8	83.61%	81.61%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008018.1	sp|K1PU56|K1PU56_CRAGI	3.1e-31	140.2	66.15%	69.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|	GO:0007155|
GN008019.1	sp|K1Q1N3|K1Q1N3_CRAGI	5.8e-26	122.5	75.22%	64.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|	GO:0007155|
GN008021.1	sp|A0A210QZ25|A0A210QZ25_MIZYE	5.0e-43	180.3	98.74%	45.11%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0035556|
GN008022.1	sp|A0A1C9U2Y3|A0A1C9U2Y3_MIZYE	2.5e-57	228.8	88.37%	32.67%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN008024.1	sp|K1Q900|K1Q900_CRAGI	4.3e-126	456.4	94.12%	75.74%	Galectin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN008025.1	sp|C3Y0M7|C3Y0M7_BRAFL	3.1e-15	87.8	78.22%	27.47%	Galectin;OS=Branchiostoma;PE=4;SV=1	GO:0030246|
GN008027.1	sp|K1PS92|K1PS92_CRAGI	0.0e+00	1090.9	100.00%	56.07%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN008028.1	sp|K1QSC6|K1QSC6_CRAGI	4.0e-189	667.2	89.44%	57.89%	DNA damage-regulated autophagy modulator protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008029.1	sp|A0A210R5Z0|A0A210R5Z0_MIZYE	1.4e-281	974.5	86.73%	69.81%	Alpha-catulin;OS=Mizuhopecten;PE=4;SV=1	GO:0051015|GO:0045296|	GO:0007155|GO:0007266|
GN008030.1	sp|K1RED9|K1RED9_CRAGI	6.0e-127	459.9	96.15%	56.54%	General receptor for phosphoinositides 1-associated scaffold protein;OS=Crassostrea;PE=4;SV=1
GN008031.1	sp|K1RKF5|K1RKF5_CRAGI	1.8e-64	252.3	55.04%	56.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008033.1	sp|K1QYN6|K1QYN6_CRAGI	5.9e-90	336.3	99.24%	67.43%	CD63 antigen;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN008034.1	sp|K1REE0|K1REE0_CRAGI	6.7e-145	519.2	98.59%	78.45%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|GO:0004983|
GN008035.1	sp|K1QL05|K1QL05_CRAGI	9.6e-164	582.8	98.70%	49.12%	CUB and sushi domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008036.1	sp|K1QYN9|K1QYN9_CRAGI	5.8e-90	336.7	85.63%	61.22%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008037.1	sp|K1QYN9|K1QYN9_CRAGI	3.8e-104	384.0	67.99%	71.79%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008038.1	sp|K1QYN9|K1QYN9_CRAGI	3.4e-105	387.5	68.16%	71.43%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008039.1	sp|K1S3W9|K1S3W9_CRAGI	0.0e+00	1146.7	99.02%	91.91%	Guanylate cyclase soluble subunit beta-1;OS=Crassostrea;PE=3;SV=1	GO:0004383|GO:0020037|GO:0000166|	GO:0035556|
GN008040.1	sp|K1QYP4|K1QYP4_CRAGI	1.1e-54	218.0	100.00%	85.59%	Guanylate cyclase soluble subunit alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0004383|GO:0020037|GO:0000166|	GO:0035556|
GN008041.1	sp|K1REE7|K1REE7_CRAGI	0.0e+00	4340.8	82.57%	83.97%	Protein dachsous;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN006406.1	sp|A0A3M6ULE6|A0A3M6ULE6_9CNID	4.4e-16	91.3	91.64%	26.96%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN008042.1	sp|K1RKG4|K1RKG4_CRAGI	0.0e+00	1365.1	96.77%	91.18%	Putative urea active transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015204|
GN008043.1	sp|A0A1X7UEV0|A0A1X7UEV0_AMPQE	9.0e-43	179.9	93.67%	31.41%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046872|
GN008045.1	sp|K1PCK3|K1PCK3_CRAGI	2.0e-171	607.8	86.27%	69.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008046.1	sp|K1PIY1|K1PIY1_CRAGI	2.1e-244	850.5	99.65%	79.97%	Spartin;OS=Crassostrea;PE=4;SV=1
GN008047.1	sp|K1PRR7|K1PRR7_CRAGI	0.0e+00	4877.4	99.94%	81.05%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008048.1	sp|K1PRR7|K1PRR7_CRAGI	0.0e+00	2452.2	91.36%	78.57%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008049.1	sp|K1PYD2|K1PYD2_CRAGI	7.0e-127	459.5	97.22%	68.15%	Collagen alpha-1(XIV) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN008050.1	sp|A0A210QJR7|A0A210QJR7_MIZYE	5.4e-34	151.8	47.08%	32.14%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008051.1	sp|K1R044|K1R044_CRAGI	2.3e-113	413.7	100.00%	97.56%	Ras-related protein Rab-9A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN008052.1	sp|K1RAD7|K1RAD7_CRAGI	2.1e-142	510.8	99.69%	73.75%	Nocturnin;OS=Crassostrea;PE=4;SV=1
GN008053.1	sp|K1RG23|K1RG23_CRAGI	6.1e-233	812.4	100.00%	89.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008054.1	sp|A0A2T7PLY1|A0A2T7PLY1_POMCA	1.2e-81	308.5	95.08%	60.61%	ATP-dependent (S)-NAD(P)H-hydrate dehydratase;OS=Pomacea;PE=3;SV=1	GO:0052855|GO:0005524|GO:0047453|	GO:0046496|
GN008055.1	sp|K1S5R0|K1S5R0_CRAGI	0.0e+00	1874.0	98.37%	85.69%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008056.1	sp|K1R047|K1R047_CRAGI	0.0e+00	1563.9	96.69%	74.66%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008058.1	sp|K1RG26|K1RG26_CRAGI	1.3e-263	914.4	100.00%	70.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0033179|	GO:0015078|	GO:0015991|
GN008059.1	sp|K1S6T6|K1S6T6_CRAGI	2.6e-68	263.8	99.45%	82.87%	UPF0480 protein C15orf24-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN008060.1	sp|K1R1K4|K1R1K4_CRAGI	0.0e+00	1345.1	100.00%	49.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008061.1	sp|K1RBM8|K1RBM8_CRAGI	3.3e-148	530.0	99.04%	76.45%	PI-PLC X domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008081|	GO:0006629|
GN008062.1	sp|J9Q7E1|J9Q7E1_OSTED	3.4e-85	319.7	100.00%	98.69%	Nucleoside diphosphate kinase;OS=Ostrea;PE=2;SV=1	GO:0005524|GO:0004550|	GO:0006241|GO:0006183|GO:0006228|
GN008064.1	sp|K1RNG7|K1RNG7_CRAGI	6.7e-58	229.2	91.86%	72.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008066.1	sp|K1RNG7|K1RNG7_CRAGI	1.1e-34	152.1	86.02%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008067.1	sp|K1RIS2|K1RIS2_CRAGI	7.1e-120	435.6	99.23%	85.27%	3-oxoacyl-[acyl-carrier-protein] reductase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN008068.1	sp|A0A210Q999|A0A210Q999_MIZYE	3.0e-112	411.0	88.83%	56.95%	Sorting nexin-5;OS=Mizuhopecten;PE=4;SV=1	GO:0005737|	GO:0035091|
GN008069.1	sp|K1QJZ4|K1QJZ4_CRAGI	1.2e-255	887.9	100.00%	74.92%	Tripartite motif-containing protein 54;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006245.1	sp|A0A210QME0|A0A210QME0_MIZYE	5.3e-159	566.6	97.86%	58.82%	Protein FAM73B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008053|
GN008070.1	sp|K1QBG5|K1QBG5_CRAGI	5.9e-175	619.0	95.60%	89.54%	Pyrazinamidase/nicotinamidase;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003824|
GN008073.1	sp|A0A2T7PNI5|A0A2T7PNI5_POMCA	1.8e-88	332.0	87.50%	58.49%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN008076.1	sp|K1QJZ0|K1QJZ0_CRAGI	4.4e-138	496.9	97.48%	38.73%	Putative asparaginyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004812|GO:0005524|	GO:0006418|
GN008077.1	sp|K1Q3L3|K1Q3L3_CRAGI	1.9e-33	146.7	100.00%	93.33%	Anaphase-promoting complex subunit 13;OS=Crassostrea;PE=4;SV=1	GO:0005680|
GN008078.1	sp|K1PVX0|K1PVX0_CRAGI	2.1e-126	457.6	78.66%	87.80%	Protein ETHE1, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN008079.1	sp|A0A210PYZ1|A0A210PYZ1_MIZYE	2.1e-85	320.5	100.00%	91.25%	Splicing factor U2AF 26 kDa subunit;OS=Mizuhopecten;PE=4;SV=1	GO:0089701|	GO:0046872|GO:0003723|	GO:0000398|
GN008080.1	sp|K1QSE2|K1QSE2_CRAGI	8.1e-304	1048.1	99.86%	77.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008081.1	sp|K1QBA1|K1QBA1_CRAGI	0.0e+00	1110.1	98.30%	80.72%	Putative methyltransferase NSUN7;OS=Crassostrea;PE=3;SV=1	GO:0008168|GO:0003723|
GN008082.1	sp|K1QI17|K1QI17_CRAGI	8.0e-108	395.6	100.00%	77.56%	Cholecystokinin receptor type A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015054|
GN008083.1	sp|K1R0B6|K1R0B6_CRAGI	2.4e-31	142.5	62.10%	35.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008084.1	sp|B4K5I5|B4K5I5_DROMO	2.1e-13	80.9	93.60%	39.66%	Uncharacterized protein;OS=Drosophila;PE=3;SV=1
GN008087.1	sp|K1PVV7|K1PVV7_CRAGI	3.1e-42	176.4	97.06%	91.84%	Serine/threonine-protein phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005506|GO:0030145|GO:0004721|	GO:0050906|
GN008088.1	sp|K1Q3J4|K1Q3J4_CRAGI	2.4e-203	714.5	97.82%	76.96%	F-box/WD repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN008089.1	sp|K1R3M6|K1R3M6_CRAGI	2.8e-108	396.7	100.00%	97.49%	Ubiquitin-conjugating enzyme E2-22 kDa;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN008092.1	sp|A0A2B4SNB7|A0A2B4SNB7_STYPI	1.5e-44	186.0	66.25%	37.97%	Dipeptidyl peptidase 8;OS=Stylophora;PE=3;SV=1	GO:0008236|
GN006407.1	sp|K1PUR5|K1PUR5_CRAGI	1.9e-131	474.9	98.31%	50.65%	RING finger protein nhl-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008093.1	sp|J9KE05|J9KE05_ACYPI	2.4e-21	107.5	97.20%	37.68%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2	GO:0046983|
GN008094.1	sp|A0A210PZG9|A0A210PZG9_MIZYE	8.8e-159	565.8	92.60%	62.93%	Adenylate cyclase type 9;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0000166|GO:0016849|	GO:0009190|GO:0035556|
GN008095.1	sp|K1PNJ6|K1PNJ6_CRAGI	0.0e+00	1189.1	99.16%	83.99%	Adenylate cyclase type 9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0000166|GO:0016849|	GO:0009190|GO:0035556|
GN008096.1	sp|K1R087|K1R087_CRAGI	4.6e-95	352.8	98.98%	84.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008097.1	sp|K1RAJ1|K1RAJ1_CRAGI	5.5e-279	965.3	100.00%	75.54%	T-complex protein 1 subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN008098.1	sp|A0A2H4EU06|A0A2H4EU06_LOCMI	4.5e-23	115.2	74.18%	23.67%	CENP-B-like protein 2;OS=Locusta;PE=2;SV=1	GO:0000775|GO:0005634|	GO:0003682|GO:0003677|
GN006408.1	sp|K1PUR5|K1PUR5_CRAGI	4.9e-159	566.6	94.95%	60.04%	RING finger protein nhl-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008099.1	sp|K1S5V6|K1S5V6_CRAGI	0.0e+00	1911.3	100.00%	88.03%	Protein WWC2;OS=Crassostrea;PE=4;SV=1
GN008100.1	sp|K1R090|K1R090_CRAGI	1.7e-96	358.2	98.41%	63.90%	snRNA-activating protein complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0019185|	GO:0003677|	GO:0009301|
GN008101.1	sp|A0A2B4SCA1|A0A2B4SCA1_STYPI	2.2e-11	73.9	68.27%	47.14%	Coiled-coil domain-containing protein 180;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN008102.1	sp|K1R090|K1R090_CRAGI	2.6e-244	851.3	79.57%	43.64%	snRNA-activating protein complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0019185|	GO:0003677|	GO:0009301|
GN006409.1	sp|K1R2N9|K1R2N9_CRAGI	4.5e-102	376.7	85.91%	65.88%	RING finger protein nhl-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008105.1	sp|H6BD33|H6BD33_OSTED	3.1e-128	463.8	75.46%	93.06%	Kin of irre-like protein;OS=Ostrea;PE=2;SV=1
GN008106.1	sp|K1Q214|K1Q214_CRAGI	8.2e-219	765.0	97.37%	90.91%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN008107.1	sp|K1Q917|K1Q917_CRAGI	7.9e-70	270.0	50.13%	67.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008108.1	sp|K1PWB2|K1PWB2_CRAGI	1.4e-139	502.7	99.87%	47.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008109.1	sp|V4A2Z2|V4A2Z2_LOTGI	4.9e-107	394.0	69.57%	51.86%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN006410.1	sp|K1QGW9|K1QGW9_CRAGI	2.6e-155	554.3	95.05%	54.36%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008110.1	sp|K1S6A9|K1S6A9_CRAGI	4.9e-84	316.2	80.79%	88.96%	Zinc finger MYND domain-containing protein 19;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008111.1	sp|K1RGM9|K1RGM9_CRAGI	6.1e-290	1001.9	99.84%	74.06%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008112.1	sp|K1RGM9|K1RGM9_CRAGI	2.6e-50	205.3	98.61%	31.13%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008115.1	sp|K1QI08|K1QI08_CRAGI	6.8e-88	328.9	89.42%	97.62%	Ribose-phosphate pyrophosphokinase 1;OS=Crassostrea;PE=3;SV=1	GO:0016301|GO:0000287|GO:0004749|	GO:0009116|GO:0009165|GO:0009156|
GN006411.1	sp|K1Q9Q7|K1Q9Q7_CRAGI	1.4e-106	392.1	98.79%	49.75%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008122.1	sp|A0A210PW13|A0A210PW13_MIZYE	9.1e-14	82.0	62.18%	57.53%	Growth hormone secretagogue receptor type 1;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008123.1	sp|K1QIM1|K1QIM1_CRAGI	1.5e-41	175.3	75.00%	84.15%	Fibronectin type 3 and ankyrin repeat domains 1 protein;OS=Crassostrea;PE=4;SV=1
GN006412.1	sp|K1Q295|K1Q295_CRAGI	5.6e-91	339.7	75.27%	80.58%	1-acyl-sn-glycerol-3-phosphate acyltransferase beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016746|
GN008124.1	sp|K1QJV4|K1QJV4_CRAGI	3.8e-46	190.7	72.98%	85.00%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN008125.1	sp|K1QAX7|K1QAX7_CRAGI	1.7e-67	263.5	18.60%	69.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008126.1	sp|A0A210QQ72|A0A210QQ72_MIZYE	1.2e-15	87.8	89.77%	55.13%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008127.1	sp|K1QBW0|K1QBW0_CRAGI	1.6e-72	278.5	84.23%	82.91%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN008129.1	sp|A0A1X7T7W9|A0A1X7T7W9_AMPQE	1.4e-11	74.3	94.12%	47.56%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN008130.1	sp|A0A1X7TV50|A0A1X7TV50_AMPQE	2.5e-32	144.4	89.60%	41.40%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN006246.1	sp|K1P6B5|K1P6B5_CRAGI	2.4e-36	156.8	100.00%	83.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008132.1	sp|K1QZC6|K1QZC6_CRAGI	3.7e-95	354.4	92.26%	42.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008133.1	sp|K1QZC6|K1QZC6_CRAGI	2.1e-27	128.6	64.01%	34.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008134.1	sp|K1QDC3|K1QDC3_CRAGI	8.8e-198	695.3	99.13%	72.97%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008136.1	sp|K1RFD5|K1RFD5_CRAGI	1.4e-97	363.2	52.96%	48.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008137.1	sp|K1R9J9|K1R9J9_CRAGI	5.9e-162	576.2	85.96%	74.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN006413.1	sp|K1QZQ1|K1QZQ1_CRAGI	0.0e+00	1317.4	100.00%	83.53%	Protein O-mannosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0000030|	GO:0006493|
GN008138.1	sp|K1QZC2|K1QZC2_CRAGI	9.6e-66	256.1	82.61%	50.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008140.1	sp|K1S4V9|K1S4V9_CRAGI	5.5e-81	307.0	100.00%	49.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008141.1	sp|K1S4V9|K1S4V9_CRAGI	5.1e-38	162.9	96.67%	61.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008142.1	sp|K1S4V9|K1S4V9_CRAGI	1.2e-201	708.0	97.42%	84.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008143.1	sp|K1RLG0|K1RLG0_CRAGI	9.7e-104	382.5	100.00%	54.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008144.1	sp|K1RFC9|K1RFC9_CRAGI	1.1e-105	389.0	85.98%	58.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008145.1	sp|K1RFC9|K1RFC9_CRAGI	1.0e-157	562.4	93.50%	62.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008146.1	sp|K1R9J3|K1R9J3_CRAGI	0.0e+00	1312.4	98.71%	76.35%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008147.1	sp|A0A210PLF4|A0A210PLF4_MIZYE	2.7e-179	634.8	96.17%	42.84%	Protocadherin-9;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN006414.1	sp|K1QZQ1|K1QZQ1_CRAGI	1.4e-88	332.4	92.86%	56.13%	Protein O-mannosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0000030|	GO:0006493|
GN008148.1	sp|K1PPS6|K1PPS6_CRAGI	0.0e+00	1641.3	100.00%	79.30%	Protocadherin-19;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008149.1	sp|K1PX32|K1PX32_CRAGI	0.0e+00	1706.0	100.00%	78.36%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008150.1	sp|A0A1S3HZ97|A0A1S3HZ97_LINUN	9.2e-15	87.4	60.83%	28.10%	E3 ubiquitin-protein ligase TRIM56-like;OS=Lingula;PE=4;SV=1	GO:0016874|GO:0008270|
GN008151.1	sp|K1Q454|K1Q454_CRAGI	0.0e+00	1690.2	100.00%	81.86%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008152.1	sp|K1QQ70|K1QQ70_CRAGI	0.0e+00	1647.5	99.62%	81.71%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008153.1	sp|K1PLI0|K1PLI0_CRAGI	0.0e+00	1741.9	100.00%	84.20%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008154.1	sp|K1PDP2|K1PDP2_CRAGI	0.0e+00	1573.5	99.21%	83.12%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008155.1	sp|K1P7M1|K1P7M1_CRAGI	0.0e+00	1565.1	99.62%	78.02%	Protocadherin-11 Y-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008156.1	sp|K1PLH5|K1PLH5_CRAGI	0.0e+00	1748.4	97.82%	84.27%	Protocadherin-9;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008157.1	sp|K1PUQ4|K1PUQ4_CRAGI	5.6e-26	124.4	22.30%	66.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN008158.1	sp|A0A2T7PNH1|A0A2T7PNH1_POMCA	8.0e-76	289.3	95.24%	49.21%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN008159.1	sp|K1RDA4|K1RDA4_CRAGI	0.0e+00	6803.4	100.00%	80.30%	Putative E3 ubiquitin-protein ligase MYCBP2;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN008160.1	sp|K1RJ68|K1RJ68_CRAGI	8.1e-84	315.5	97.45%	80.00%	Tctex1 domain-containing protein 1-B;OS=Crassostrea;PE=4;SV=1
GN008161.1	sp|K1PT65|K1PT65_CRAGI	1.5e-28	132.9	50.65%	39.20%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN006416.1	sp|K1QKJ1|K1QKJ1_CRAGI	0.0e+00	1175.2	64.26%	77.45%	Tudor domain-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN008163.1	sp|K1R7A8|K1R7A8_CRAGI	3.6e-95	353.2	96.57%	84.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006914|
GN008164.1	sp|K1PIH9|K1PIH9_CRAGI	3.7e-22	112.5	23.47%	38.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008167.1	sp|K1RJ71|K1RJ71_CRAGI	1.8e-67	260.8	92.16%	82.14%	UPF0686 protein C11orf1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN006417.1	sp|K1QBX4|K1QBX4_CRAGI	3.5e-73	280.8	58.39%	75.56%	Tetratricopeptide repeat protein 19;OS=Crassostrea;PE=4;SV=1
GN008169.1	sp|A0A210QV32|A0A210QV32_MIZYE	2.8e-35	154.5	61.14%	55.00%	Insoluble matrix shell protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN008170.1	sp|K1RDB2|K1RDB2_CRAGI	2.6e-70	270.4	87.50%	84.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN008171.1	sp|K1RJ76|K1RJ76_CRAGI	7.4e-66	256.1	97.58%	50.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008172.1	sp|K1QZ59|K1QZ59_CRAGI	2.0e-309	1067.0	98.42%	69.25%	Dipeptidyl peptidase 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008236|
GN006418.1	sp|A0A210PJB3|A0A210PJB3_MIZYE	1.3e-91	342.8	71.67%	61.44%	Zinc transporter SLC39A7;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0046873|
GN008175.1	sp|K1QQQ9|K1QQQ9_CRAGI	5.9e-23	112.5	100.00%	60.36%	Zinc finger matrin-type protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|
GN008176.1	sp|K1QH30|K1QH30_CRAGI	2.4e-266	923.3	99.82%	84.63%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008177.1	sp|K1S0V2|K1S0V2_CRAGI	1.3e-16	93.2	32.91%	39.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008178.1	sp|A0A1X7T0L5|A0A1X7T0L5_AMPQE	8.7e-33	146.7	94.13%	28.17%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN008179.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	3.3e-11	75.1	34.65%	33.61%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN008180.1	sp|K1RNY3|K1RNY3_CRAGI	0.0e+00	1632.1	92.61%	78.18%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008183.1	sp|K1QY67|K1QY67_CRAGI	2.4e-148	530.4	100.00%	89.14%	Otopetrin-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008186.1	sp|C3ZUK9|C3ZUK9_BRAFL	1.9e-18	97.4	67.92%	64.79%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN008187.1	sp|K1PN63|K1PN63_CRAGI	2.3e-93	347.8	99.68%	56.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008188.1	sp|A0A210QRA0|A0A210QRA0_MIZYE	1.8e-40	173.3	36.55%	38.40%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008189.1	sp|K1QHB0|K1QHB0_CRAGI	2.4e-26	125.2	51.14%	45.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008191.1	sp|K1PS07|K1PS07_CRAGI	9.2e-116	422.5	97.14%	58.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008193.1	sp|K1Q6E8|K1Q6E8_CRAGI	2.5e-232	810.4	98.67%	65.33%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN008194.1	sp|K1PRF4|K1PRF4_CRAGI	4.8e-50	202.6	100.00%	80.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008195.1	sp|A0A194RV51|A0A194RV51_PAPMA	4.9e-65	253.8	65.96%	53.70%	28S ribosomal protein S2, mitochondrial;OS=Papilio;PE=3;SV=1	GO:0015935|	GO:0003735|	GO:0006412|
GN008196.1	sp|K1Q6E4|K1Q6E4_CRAGI	2.3e-106	391.3	99.74%	85.12%	Zinc finger protein Gfi-1;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0030097|GO:0051569|GO:0006355|
GN008197.1	sp|K1Q6E0|K1Q6E0_CRAGI	2.5e-58	230.3	96.45%	77.04%	von Willebrand factor C domain-containing protein 2-like protein;OS=Crassostrea;PE=4;SV=1
GN008198.1	sp|A0A210PVM6|A0A210PVM6_MIZYE	2.1e-23	113.6	97.70%	60.47%	DNA polymerase III PolC-type;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN008199.1	sp|K1RKI3|K1RKI3_CRAGI	6.8e-139	499.2	100.00%	72.24%	Glycine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005230|GO:0004888|
GN006247.1	sp|K1QCA8|K1QCA8_CRAGI	0.0e+00	1532.3	100.00%	82.55%	Regulator of G-protein signaling 3;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN008200.1	sp|K1QMY4|K1QMY4_CRAGI	7.2e-55	219.5	95.30%	48.65%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN008201.1	sp|K1RLM8|K1RLM8_CRAGI	1.0e-197	694.9	94.88%	90.75%	Chromosome-associated kinesin KIF4A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN008202.1	sp|K1R293|K1R293_CRAGI	1.5e-185	654.4	100.00%	79.59%	Ubiquitin-associated domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN008203.1	sp|A0A210QS84|A0A210QS84_MIZYE	6.8e-11	73.2	100.00%	33.18%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008206.1	sp|A0A210QS84|A0A210QS84_MIZYE	1.0e-82	312.0	99.55%	65.75%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008208.1	sp|K1Q702|K1Q702_CRAGI	2.0e-27	130.2	27.82%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008211.1	sp|K1QT97|K1QT97_CRAGI	1.2e-127	461.5	94.16%	97.93%	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN008212.1	sp|K1R2Q2|K1R2Q2_CRAGI	2.5e-70	270.4	100.00%	75.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008213.1	sp|K1R8S3|K1R8S3_CRAGI	2.5e-92	343.6	100.00%	92.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008214.1	sp|K1RYD1|K1RYD1_CRAGI	4.0e-174	616.7	78.80%	77.93%	DBH-like monooxygenase protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN008215.1	sp|K1RAM7|K1RAM7_CRAGI	4.7e-147	526.6	96.50%	58.11%	DBH-like monooxygenase protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN008216.1	sp|K1RAM7|K1RAM7_CRAGI	1.0e-308	1065.1	62.47%	69.82%	DBH-like monooxygenase protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN008217.1	sp|K1RAM7|K1RAM7_CRAGI	2.1e-279	967.6	59.06%	71.71%	DBH-like monooxygenase protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN008218.1	sp|K1RYD1|K1RYD1_CRAGI	2.2e-51	207.6	80.43%	65.33%	DBH-like monooxygenase protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN008219.1	sp|K1R891|K1R891_CRAGI	2.2e-294	1016.5	100.00%	82.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006422.1	sp|K1QGI2|K1QGI2_CRAGI	1.1e-206	725.3	90.92%	57.64%	Peroxidasin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008220.1	sp|K1RAH5|K1RAH5_CRAGI	2.9e-105	387.5	98.83%	55.29%	Toll-like receptor 6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN008221.1	sp|K1QYE0|K1QYE0_CRAGI	7.0e-118	429.5	82.54%	72.64%	N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN008222.1	sp|K1RK51|K1RK51_CRAGI	0.0e+00	1729.5	99.65%	61.66%	Vascular endothelial growth factor receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0005509|GO:0019838|GO:0004714|	GO:0048010|
GN008223.1	sp|K1QYE6|K1QYE6_CRAGI	2.0e-47	195.3	100.00%	38.24%	Chymotrypsin-like elastase family member 1;OS=Crassostrea;PE=4;SV=1	GO:0004252|
GN008224.1	sp|K1QIT4|K1QIT4_CRAGI	1.3e-130	471.5	97.94%	75.00%	Nucleoside diphosphate-linked moiety X motif 6;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN008225.1	sp|A0A210PL87|A0A210PL87_MIZYE	7.1e-15	87.4	41.18%	36.20%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN006423.1	sp|K1QGI2|K1QGI2_CRAGI	1.9e-233	814.3	96.78%	59.76%	Peroxidasin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008226.1	sp|K1Q3M9|K1Q3M9_CRAGI	1.8e-217	760.8	98.56%	83.86%	Proton-coupled amino acid transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008227.1	sp|K1RAN6|K1RAN6_CRAGI	1.3e-186	659.1	88.65%	73.24%	Fibrillin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003676|
GN008228.1	sp|A0A210QAG7|A0A210QAG7_MIZYE	4.3e-83	315.1	44.37%	42.18%	Atrial natriuretic peptide-converting enzyme;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0005044|GO:0004252|
GN008229.1	sp|K1Q7R9|K1Q7R9_CRAGI	3.6e-34	149.8	85.71%	71.84%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN008230.1	sp|K1Q7R9|K1Q7R9_CRAGI	5.7e-34	149.8	52.63%	73.27%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN008233.1	sp|K1QQH5|K1QQH5_CRAGI	0.0e+00	2560.0	100.00%	77.87%	Macrophage mannose receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN006424.1	sp|K1QGI2|K1QGI2_CRAGI	2.8e-87	327.4	98.11%	57.35%	Peroxidasin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008234.1	sp|W4YMP2|W4YMP2_STRPU	4.6e-25	120.2	86.11%	50.31%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN008235.1	sp|K1QQH5|K1QQH5_CRAGI	0.0e+00	1778.5	87.15%	93.04%	Macrophage mannose receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN008237.1	sp|K1Q3L9|K1Q3L9_CRAGI	1.1e-36	158.3	69.12%	77.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046982|
GN008238.1	sp|K1R5V4|K1R5V4_CRAGI	1.1e-86	325.1	99.53%	71.09%	GTP-binding nuclear protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0005525|GO:0003924|	GO:0006913|GO:0015031|
GN008239.1	sp|K1R9G8|K1R9G8_CRAGI	1.0e-99	369.0	72.41%	74.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN008240.1	sp|K1P7B7|K1P7B7_CRAGI	1.4e-51	207.6	98.28%	83.19%	DNA-directed RNA polymerase subunit;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0003899|GO:0003676|GO:0008270|	GO:0006379|GO:0006351|
GN008241.1	sp|K1PC83|K1PC83_CRAGI	7.0e-28	131.3	25.43%	45.12%	Down syndrome cell adhesion molecule;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008242.1	sp|K1R4C1|K1R4C1_CRAGI	2.2e-31	140.6	89.26%	60.75%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN006425.1	sp|K1R2D2|K1R2D2_CRAGI	1.2e-36	159.5	62.58%	41.38%	Peroxidasin;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008243.1	sp|K1QDT8|K1QDT8_CRAGI	1.0e-24	118.2	95.37%	50.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008244.1	sp|K1P7F0|K1P7F0_CRAGI	3.6e-16	90.9	47.49%	52.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008245.1	sp|K1PXC9|K1PXC9_CRAGI	5.4e-30	136.7	85.92%	43.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008246.1	sp|K1PQ25|K1PQ25_CRAGI	2.9e-20	103.6	83.76%	62.00%	Putative GTP-binding protein Parf;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN008247.1	sp|K1PQ25|K1PQ25_CRAGI	3.6e-239	833.6	87.44%	67.89%	Putative GTP-binding protein Parf;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN008248.1	sp|K1PIB2|K1PIB2_CRAGI	7.5e-234	815.8	65.71%	91.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008249.1	sp|K1RE33|K1RE33_CRAGI	1.9e-60	237.7	100.00%	97.06%	Protein Dr1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046982|
GN008250.1	sp|K1Q3U5|K1Q3U5_CRAGI	2.0e-10	72.0	43.87%	42.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006426.1	sp|K1PF23|K1PF23_CRAGI	8.7e-87	327.4	97.11%	46.78%	GDNF-inducible zinc finger protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008251.1	sp|K1PND2|K1PND2_CRAGI	5.0e-67	259.6	98.39%	65.93%	Amiloride-sensitive cation channel 2-A, neuronal;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN008252.1	sp|K1PND2|K1PND2_CRAGI	2.7e-153	547.4	96.42%	63.68%	Amiloride-sensitive cation channel 2-A, neuronal;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN006427.1	sp|K1PJU8|K1PJU8_CRAGI	5.3e-41	172.9	91.82%	55.86%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008253.1	sp|K1Q4G3|K1Q4G3_CRAGI	2.2e-151	540.8	98.92%	67.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008254.1	sp|K1PLP7|K1PLP7_CRAGI	2.1e-137	494.6	100.00%	61.69%	D(2) dopamine receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008255.1	sp|A0A210QUN9|A0A210QUN9_MIZYE	1.2e-53	216.9	82.83%	30.00%	G-protein coupled receptor 101;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008256.1	sp|A0A2B4SU51|A0A2B4SU51_STYPI	2.9e-68	265.4	62.09%	37.90%	Sphingomyelin synthase-related protein 1;OS=Stylophora;PE=4;SV=1	GO:0016021|
GN006428.1	sp|K1PS85|K1PS85_CRAGI	1.6e-55	221.5	99.00%	53.77%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN008257.1	sp|K1PID8|K1PID8_CRAGI	1.5e-137	494.6	96.77%	76.59%	Prostaglandin E synthase 2;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0009055|GO:0050220|GO:0015035|	GO:0045454|
GN008259.1	sp|K1PQ38|K1PQ38_CRAGI	1.2e-75	288.5	100.00%	72.94%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN008260.1	sp|K1PAB1|K1PAB1_CRAGI	1.8e-51	207.6	94.08%	66.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008261.1	sp|K1QQH4|K1QQH4_CRAGI	0.0e+00	2385.1	100.00%	72.93%	AT-hook-containing transcription factor;OS=Crassostrea;PE=4;SV=1
GN008262.1	sp|K1PIE4|K1PIE4_CRAGI	2.6e-73	280.4	100.00%	77.71%	Transmembrane protein C9orf7;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008263.1	sp|K1PQ41|K1PQ41_CRAGI	1.1e-90	338.6	86.75%	74.42%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN006248.1	sp|K1PRS8|K1PRS8_CRAGI	1.2e-264	917.5	100.00%	92.23%	Putative adenylate kinase-like protein C9orf98-like protein;OS=Crassostrea;PE=3;SV=1	GO:0004017|GO:0005524|
GN006429.1	sp|K1PS85|K1PS85_CRAGI	5.6e-56	223.0	99.00%	54.27%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN008265.1	sp|K1QQH9|K1QQH9_CRAGI	9.5e-303	1045.0	64.94%	84.37%	DNA (Cytosine-5)-methyltransferase 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003682|GO:0003886|GO:0003677|GO:0008270|
GN008266.1	sp|H6BD80|H6BD80_OSTED	1.1e-58	231.1	100.00%	100.00%	XP001642131-like protein;OS=Ostrea;PE=2;SV=1
GN008268.1	sp|V3ZSJ4|V3ZSJ4_LOTGI	8.8e-60	237.3	54.23%	38.69%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN008270.1	sp|K1PIC0|K1PIC0_CRAGI	2.6e-126	457.2	99.66%	71.96%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN008271.1	sp|K1PIC0|K1PIC0_CRAGI	4.9e-125	453.0	99.66%	71.28%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN008272.1	sp|A0A210QSS3|A0A210QSS3_MIZYE	2.3e-36	159.5	97.17%	24.50%	E3 ubiquitin-protein ligase TRIM56;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN008273.1	sp|K1PQ29|K1PQ29_CRAGI	1.3e-52	212.2	82.75%	80.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008274.1	sp|A0A126Q9D7|A0A126Q9D7_MYTGA	5.0e-222	775.8	96.87%	88.13%	DDX6;OS=Mytilus;PE=2;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN008275.1	sp|K1R6Q3|K1R6Q3_CRAGI	2.0e-193	681.4	70.42%	65.31%	Trehalase;OS=Crassostrea;PE=3;SV=1	GO:0004555|	GO:0005991|
GN008276.1	sp|A0A1B6MPV9|A0A1B6MPV9_9HEMI	1.3e-17	96.3	51.83%	32.37%	Uncharacterized protein;OS=Graphocephala;PE=4;SV=1
GN008277.1	sp|A7SKP6|A7SKP6_NEMVE	1.9e-61	242.3	58.12%	49.61%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN008278.1	sp|K1RR44|K1RR44_CRAGI	1.0e-123	448.7	81.79%	78.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008279.1	sp|K1R0B7|K1R0B7_CRAGI	2.3e-106	394.0	39.95%	32.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008279.1	sp|K1R0B7|K1R0B7_CRAGI	1.0e-40	176.0	11.07%	46.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006430.1	sp|A0A0P4WGA4|A0A0P4WGA4_9EUCA	5.8e-34	149.8	94.36%	37.23%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN008280.1	sp|K1R6R1|K1R6R1_CRAGI	8.8e-22	109.4	87.24%	37.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008281.1	sp|K1RIW4|K1RIW4_CRAGI	9.2e-86	323.6	91.42%	33.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008282.1	sp|A0A2B4S577|A0A2B4S577_STYPI	7.1e-55	220.7	92.41%	32.25%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN008283.1	sp|A0A210PU81|A0A210PU81_MIZYE	5.8e-198	696.0	90.73%	84.89%	Retinoblastoma-binding protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0048188|
GN008284.1	sp|K1RR48|K1RR48_CRAGI	2.7e-244	850.5	100.00%	79.40%	WD repeat-containing protein 42A;OS=Crassostrea;PE=4;SV=1
GN008285.1	sp|K1QJH1|K1QJH1_CRAGI	0.0e+00	1269.6	100.00%	79.03%	Hormone-sensitive lipase;OS=Crassostrea;PE=4;SV=1	GO:0016298|	GO:0008203|GO:0016042|
GN008286.1	sp|A0A210R0L7|A0A210R0L7_MIZYE	2.3e-75	288.5	100.00%	42.44%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008287.1	sp|K1R0C4|K1R0C4_CRAGI	7.6e-26	122.1	77.88%	72.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006431.1	sp|K1QG84|K1QG84_CRAGI	0.0e+00	1929.8	96.04%	78.54%	THO complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0000347|	GO:0006406|GO:0006397|
GN008293.1	sp|K1Q902|K1Q902_CRAGI	8.5e-84	316.6	97.61%	38.19%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN008294.1	sp|K1R6R9|K1R6R9_CRAGI	5.1e-85	319.7	100.00%	69.75%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN008295.1	sp|K1RKG6|K1RKG6_CRAGI	8.5e-48	197.2	34.30%	56.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006432.1	sp|K1Q808|K1Q808_CRAGI	2.0e-13	80.5	60.00%	75.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008296.1	sp|K1PMG9|K1PMG9_CRAGI	1.7e-10	70.5	66.67%	68.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008297.1	sp|K1Q5I1|K1Q5I1_CRAGI	1.8e-49	200.7	95.80%	90.27%	cAMP-dependent protein kinase regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN008299.1	sp|W4YR48|W4YR48_STRPU	4.3e-62	244.2	85.95%	43.24%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN008300.1	sp|K1PIC0|K1PIC0_CRAGI	4.6e-76	290.4	99.69%	45.57%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN006433.1	sp|K1QL21|K1QL21_CRAGI	9.1e-114	416.8	55.36%	68.77%	Nucleoporin p58/p45;OS=Crassostrea;PE=4;SV=1	GO:0005643|	GO:0006913|
GN008301.1	sp|K1RNI4|K1RNI4_CRAGI	2.9e-144	517.7	99.07%	56.01%	Three prime repair exonuclease 1;OS=Crassostrea;PE=4;SV=1	GO:0004527|GO:0003676|
GN008303.1	sp|K1RLI2|K1RLI2_CRAGI	2.2e-104	384.0	98.73%	79.83%	Quinone oxidoreductase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN008304.1	sp|K1Q5J7|K1Q5J7_CRAGI	5.9e-48	197.6	43.95%	59.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006434.1	sp|K1PF27|K1PF27_CRAGI	0.0e+00	1387.9	100.00%	83.65%	Myotubularin-related protein 8;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0052866|GO:0004725|	GO:0046856|
GN008305.1	sp|K1Q5J7|K1Q5J7_CRAGI	2.6e-91	342.0	76.69%	46.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008306.1	sp|K1QD22|K1QD22_CRAGI	2.9e-40	172.2	35.31%	56.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008307.1	sp|K1R2P7|K1R2P7_CRAGI	3.2e-188	664.1	90.19%	67.64%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN008308.1	sp|K1R8R7|K1R8R7_CRAGI	3.6e-66	256.9	98.09%	58.33%	Myeloperoxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008309.1	sp|K1R8R7|K1R8R7_CRAGI	1.6e-190	671.4	95.84%	60.19%	Myeloperoxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008310.1	sp|K1R8R7|K1R8R7_CRAGI	9.9e-72	275.4	98.09%	63.24%	Myeloperoxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008312.1	sp|K1PVU0|K1PVU0_CRAGI	2.6e-27	127.5	97.56%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008313.1	sp|K1R8R7|K1R8R7_CRAGI	9.4e-98	362.5	92.77%	58.64%	Myeloperoxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN008315.1	sp|K1QBG4|K1QBG4_CRAGI	6.7e-300	1035.0	81.91%	91.82%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN008316.1	sp|K1QX93|K1QX93_CRAGI	1.4e-208	731.9	99.86%	54.35%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN008317.1	sp|K1QX93|K1QX93_CRAGI	4.7e-85	320.1	88.21%	60.98%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN008319.1	sp|K1QX93|K1QX93_CRAGI	1.2e-222	778.5	99.29%	58.03%	Nose resistant to fluoxetine protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016747|
GN006435.1	sp|K1PV74|K1PV74_CRAGI	0.0e+00	1637.5	100.00%	70.83%	Calpain-15;OS=Crassostrea;PE=3;SV=1	GO:0004198|GO:0046872|
GN008320.1	sp|K1Q192|K1Q192_CRAGI	2.9e-129	468.0	91.72%	42.91%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN008321.1	sp|A0A210PUC7|A0A210PUC7_MIZYE	1.1e-185	655.6	99.55%	49.63%	Kin of IRRE-like protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN008322.1	sp|K1QXA0|K1QXA0_CRAGI	1.1e-111	409.5	67.70%	60.17%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1
GN008324.1	sp|K1PGX9|K1PGX9_CRAGI	6.7e-64	250.8	66.60%	39.12%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN006436.1	sp|K1PV74|K1PV74_CRAGI	3.0e-83	313.5	91.19%	86.86%	Calpain-15;OS=Crassostrea;PE=3;SV=1	GO:0004198|GO:0046872|
GN008325.1	sp|K1QQQ0|K1QQQ0_CRAGI	5.4e-78	295.8	100.00%	91.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008326.1	sp|K1PVI8|K1PVI8_CRAGI	4.3e-185	654.4	80.52%	41.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008327.1	sp|K1Q2Z3|K1Q2Z3_CRAGI	2.0e-148	530.8	100.00%	82.86%	E3 ubiquitin-protein ligase NRDP1;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0061630|
GN008328.1	sp|K1QA74|K1QA74_CRAGI	1.6e-208	731.1	100.00%	67.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008329.1	sp|A0A210QB58|A0A210QB58_MIZYE	5.6e-25	119.8	63.31%	54.21%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN008330.1	sp|K1R9G8|K1R9G8_CRAGI	1.5e-82	312.8	33.97%	75.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN008331.1	sp|A0A2G8JRA8|A0A2G8JRA8_STIJA	9.9e-113	413.7	57.90%	40.08%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN008332.1	sp|K1PKF0|K1PKF0_CRAGI	6.2e-29	133.7	58.06%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006249.1	sp|K1PJP7|K1PJP7_CRAGI	3.7e-143	513.1	100.00%	94.44%	Surfeit locus protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008334.1	sp|K1PNU8|K1PNU8_CRAGI	2.6e-94	350.1	100.00%	96.47%	Ubiquitin-fold modifier-conjugating enzyme 1;OS=Crassostrea;PE=3;SV=1
GN008335.1	sp|K1PVU0|K1PVU0_CRAGI	1.4e-28	131.7	97.56%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008336.1	sp|K1QPU0|K1QPU0_CRAGI	3.5e-09	67.0	36.03%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008338.1	sp|K1QZX5|K1QZX5_CRAGI	2.9e-221	773.5	100.00%	73.03%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008375|
GN008339.1	sp|K1RA69|K1RA69_CRAGI	1.6e-74	285.4	75.21%	59.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008340.1	sp|K1RFW1|K1RFW1_CRAGI	7.6e-239	832.0	80.24%	84.20%	Putative sulfite oxidase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0020037|GO:0030151|GO:0043546|GO:0016491|GO:0004888|	GO:0042128|
GN008341.1	sp|K1QBZ2|K1QBZ2_CRAGI	8.8e-49	199.9	78.74%	38.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008343.1	sp|K1RFW1|K1RFW1_CRAGI	2.8e-73	282.3	40.35%	51.35%	Putative sulfite oxidase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0020037|GO:0030151|GO:0043546|GO:0016491|GO:0004888|	GO:0042128|
GN008347.1	sp|K1Q8R4|K1Q8R4_CRAGI	1.1e-187	662.1	53.65%	98.79%	Kelch-like protein 20;OS=Crassostrea;PE=4;SV=1
GN008348.1	sp|K1QGU8|K1QGU8_CRAGI	1.4e-114	418.3	75.57%	93.51%	Ankyrin repeat domain-containing protein 45;OS=Crassostrea;PE=4;SV=1
GN008349.1	sp|K1PRS4|K1PRS4_CRAGI	2.5e-91	340.5	98.07%	81.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008350.1	sp|K1PYD7|K1PYD7_CRAGI	2.9e-56	223.4	100.00%	87.41%	60S ribosomal protein L28;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN008353.1	sp|K1Q9A7|K1Q9A7_CRAGI	9.4e-23	112.1	69.85%	53.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008354.1	sp|A0A210QWK6|A0A210QWK6_MIZYE	3.5e-122	444.1	98.89%	50.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN008356.1	sp|K1R383|K1R383_CRAGI	0.0e+00	5475.6	100.00%	80.12%	Protocadherin Fat 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN008357.1	sp|A0A0B7AZ66|A0A0B7AZ66_9EUPU	6.0e-114	416.0	99.25%	80.99%	Uncharacterized protein;OS=Arion;PE=3;SV=1	GO:0015935|	GO:0003723|GO:0003735|	GO:0006412|
GN008358.1	sp|A0A210QAG9|A0A210QAG9_MIZYE	5.3e-64	249.6	98.43%	60.96%	Cathepsin O;OS=Mizuhopecten;PE=3;SV=1	GO:0008234|
GN006440.1	sp|K1RH39|K1RH39_CRAGI	2.1e-56	224.9	57.79%	64.46%	TBC1 domain family member 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008361.1	sp|K1PGA0|K1PGA0_CRAGI	2.7e-258	896.7	99.68%	74.68%	RNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004386|GO:0003723|
GN008362.1	sp|K1PA43|K1PA43_CRAGI	9.5e-34	149.1	100.00%	53.19%	E3 ubiquitin-protein ligase LINCR;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN008364.1	sp|K1PP55|K1PP55_CRAGI	2.4e-188	663.7	96.89%	82.04%	GDP-fucose protein O-fucosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0008417|	GO:0006004|GO:0007219|
GN008365.1	sp|K1PG97|K1PG97_CRAGI	0.0e+00	1953.3	97.96%	85.75%	Ribonuclease 3;OS=Crassostrea;PE=3;SV=1	GO:0004525|GO:0003723|	GO:0006396|GO:0016075|
GN006441.1	sp|K1Q868|K1Q868_CRAGI	2.5e-99	368.6	99.33%	33.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008366.1	sp|K1PA39|K1PA39_CRAGI	2.4e-115	420.6	100.00%	77.39%	Crystallin J1C;OS=Crassostrea;PE=4;SV=1
GN008367.1	sp|K1QGD5|K1QGD5_CRAGI	1.0e-115	422.5	100.00%	55.61%	Zinc finger SWIM domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN008368.1	sp|K1PP53|K1PP53_CRAGI	1.2e-74	285.4	98.04%	58.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008369.1	sp|K1PG92|K1PG92_CRAGI	4.7e-111	407.1	100.00%	45.28%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1
GN008370.1	sp|V4A2Z2|V4A2Z2_LOTGI	5.0e-100	370.9	61.12%	49.33%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN008372.1	sp|K1R4E4|K1R4E4_CRAGI	1.2e-75	288.1	100.00%	97.69%	MORN repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN008373.1	sp|K1PWQ2|K1PWQ2_CRAGI	1.4e-192	679.1	100.00%	85.40%	60 kDa neurofilament protein;OS=Crassostrea;PE=3;SV=1	GO:0005882|	GO:0005198|
GN006442.1	sp|A0A1C9U302|A0A1C9U302_MIZYE	1.9e-117	428.7	97.39%	40.66%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN008374.1	sp|K1QC74|K1QC74_CRAGI	0.0e+00	1214.9	72.80%	42.12%	Uncharacterized protein C3orf63-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007140|GO:0010569|GO:0007129|
GN008375.1	sp|K1QIQ1|K1QIQ1_CRAGI	2.0e-84	317.8	100.00%	51.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008376.1	sp|K1R4E8|K1R4E8_CRAGI	2.7e-60	237.7	63.97%	73.62%	Acyl-CoA-binding domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0000062|
GN008377.1	sp|K1PWR0|K1PWR0_CRAGI	5.5e-99	366.3	84.81%	96.93%	Protein SET;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0006334|
GN008378.1	sp|K1Q4G6|K1Q4G6_CRAGI	1.0e-90	338.6	74.44%	93.94%	LIM domain transcription factor LMO4.1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008383.1	sp|K1QC78|K1QC78_CRAGI	2.8e-99	366.7	100.00%	100.00%	Ras-related protein Rab-14;OS=Crassostrea;PE=4;SV=1	GO:0005829|GO:0045335|GO:0055037|GO:0005802|	GO:0005525|GO:0003924|	GO:0042742|GO:0032456|GO:0006895|GO:0090382|
GN006443.1	sp|R7TF11|R7TF11_CAPTE	2.6e-25	120.9	99.42%	33.53%	Guanylate cyclase;OS=Capitella;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN008384.1	sp|K1QIQ6|K1QIQ6_CRAGI	1.3e-222	777.7	100.00%	94.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008385.1	sp|K1R4F2|K1R4F2_CRAGI	1.2e-251	875.2	99.54%	62.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008386.1	sp|K1R4F2|K1R4F2_CRAGI	1.8e-12	76.6	100.00%	67.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008387.1	sp|K1PWR6|K1PWR6_CRAGI	5.3e-136	489.6	99.70%	80.55%	Transcription initiation factor TFIID subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0003743|
GN008388.1	sp|K1PWR6|K1PWR6_CRAGI	0.0e+00	2042.3	99.93%	85.55%	Transcription initiation factor TFIID subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0003743|
GN008389.1	sp|K1R4F5|K1R4F5_CRAGI	9.7e-186	656.0	99.87%	57.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008390.1	sp|K1PWS2|K1PWS2_CRAGI	2.6e-104	384.4	57.87%	90.73%	Alpha-aspartyl dipeptidase;OS=Crassostrea;PE=4;SV=1	GO:0008236|
GN008391.1	sp|V4ACN4|V4ACN4_LOTGI	8.0e-98	363.6	94.90%	34.89%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN008392.1	sp|V4ACN4|V4ACN4_LOTGI	1.4e-87	329.7	91.25%	33.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN008393.1	sp|A0A2C9JNJ0|A0A2C9JNJ0_BIOGL	1.5e-306	1058.1	98.15%	43.22%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN008394.1	sp|Q869G3|Q869G3_LYMST	2.0e-269	933.7	99.51%	73.66%	Neural-specific syntaxin-binding protein 1;OS=Lymnaea;PE=2;SV=1	GO:0006904|
GN008395.1	sp|A0A210PL93|A0A210PL93_MIZYE	1.8e-66	258.8	88.58%	56.92%	Krueppel-like factor 12;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN008396.1	sp|K1RBI4|K1RBI4_CRAGI	1.1e-298	1031.2	99.23%	74.16%	Protein Jade-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008397.1	sp|K1RBI4|K1RBI4_CRAGI	0.0e+00	1088.6	99.70%	60.74%	Protein Jade-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN008398.1	sp|A0A210Q1U8|A0A210Q1U8_MIZYE	1.2e-136	492.7	98.07%	45.73%	Gamma-glutamyltranspeptidase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0036374|	GO:0006751|
GN008399.1	sp|A0A2C9JYV8|A0A2C9JYV8_BIOGL	3.9e-21	107.8	96.62%	27.62%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|
GN008400.1	sp|A0A210QEA4|A0A210QEA4_MIZYE	6.5e-64	250.4	96.49%	39.23%	RNA-binding protein 41;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN006444.1	sp|K1QN76|K1QN76_CRAGI	6.5e-60	236.9	94.02%	39.27%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN008401.1	sp|K1QJX0|K1QJX0_CRAGI	0.0e+00	2023.1	98.67%	83.78%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN008402.1	sp|A0A210Q2D9|A0A210Q2D9_MIZYE	5.3e-69	266.5	84.77%	62.80%	Ubiquitin carboxyl-terminal hydrolase;OS=Mizuhopecten;PE=3;SV=1	GO:0004843|	GO:0006511|
GN008403.1	sp|K1RBJ3|K1RBJ3_CRAGI	9.8e-53	211.8	94.77%	69.87%	DnaJ-like protein subfamily C member 13;OS=Crassostrea;PE=4;SV=1
GN008404.1	sp|K1RBJ3|K1RBJ3_CRAGI	0.0e+00	4019.2	98.48%	90.67%	DnaJ-like protein subfamily C member 13;OS=Crassostrea;PE=4;SV=1
GN008405.1	sp|K1S2C8|K1S2C8_CRAGI	2.6e-297	1026.5	77.52%	86.12%	Tyrosine-protein phosphatase Lar;OS=Crassostrea;PE=4;SV=1
GN008406.1	sp|K1QX16|K1QX16_CRAGI	3.0e-239	833.6	95.62%	65.60%	Tyrosine-protein phosphatase Lar;OS=Crassostrea;PE=4;SV=1
GN006250.1	sp|K1PCA4|K1PCA4_CRAGI	7.9e-127	459.1	84.21%	79.79%	Transcriptional adapter 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070461|
GN008407.1	sp|A0A0K2UDF0|A0A0K2UDF0_LEPSM	1.5e-29	134.4	91.23%	56.31%	Putative LOC100378177 [Saccoglossus kowalevskii];OS=Lepeophtheirus;PE=4;SV=1	GO:0003677|
GN008408.1	sp|K1R6Q4|K1R6Q4_CRAGI	1.1e-103	382.5	65.01%	96.55%	WD repeat-containing protein 86;OS=Crassostrea;PE=4;SV=1
GN008411.1	sp|K1QK97|K1QK97_CRAGI	5.2e-50	204.1	72.80%	45.26%	Alpha-2A adrenergic receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008412.1	sp|K1QBQ3|K1QBQ3_CRAGI	4.3e-48	198.0	93.97%	34.29%	Galanin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008413.1	sp|K1QSP3|K1QSP3_CRAGI	1.1e-96	358.2	95.17%	89.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008414.1	sp|K1QBQ0|K1QBQ0_CRAGI	1.2e-80	304.7	100.00%	94.55%	PRA1 family protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN008419.1	sp|K1R377|K1R377_CRAGI	1.5e-166	591.3	98.96%	78.95%	Annetocin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005000|
GN006447.1	sp|K1QK25|K1QK25_CRAGI	2.1e-153	549.3	73.21%	47.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008421.1	sp|K1RBX8|K1RBX8_CRAGI	9.0e-31	140.2	56.23%	43.64%	GTPase-activating protein and VPS9 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0043087|GO:0007165|
GN008422.1	sp|K1PX38|K1PX38_CRAGI	1.6e-157	561.6	79.47%	78.87%	Golgi-associated plant pathogenesis-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005576|
GN008423.1	sp|K1Q460|K1Q460_CRAGI	3.5e-105	386.7	100.00%	73.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN008425.1	sp|K1QQ77|K1QQ77_CRAGI	2.1e-81	308.9	60.47%	58.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008426.1	sp|K1RXT6|K1RXT6_CRAGI	6.0e-72	276.2	96.33%	60.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN006448.1	sp|K1Q9B5|K1Q9B5_CRAGI	5.6e-64	249.2	94.84%	81.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008427.1	sp|A0A210Q6K6|A0A210Q6K6_MIZYE	1.5e-58	231.5	96.81%	63.19%	COP9 signalosome complex subunit 8;OS=Mizuhopecten;PE=4;SV=1	GO:0008180|	GO:0010387|GO:0000338|
GN008428.1	sp|K1R3K8|K1R3K8_CRAGI	6.0e-195	685.6	96.23%	84.82%	Angio-associated migratory cell protein;OS=Crassostrea;PE=4;SV=1
GN008429.1	sp|A0A210Q563|A0A210Q563_MIZYE	0.0e+00	1171.0	99.88%	71.60%	Kinesin-like protein;OS=Mizuhopecten;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN008430.1	sp|K1PVT1|K1PVT1_CRAGI	9.4e-279	964.5	96.76%	92.44%	Voltage-dependent L-type calcium channel subunit beta-2;OS=Crassostrea;PE=4;SV=1	GO:0005891|	GO:0005245|
GN008431.1	sp|A0A0C5PW45|A0A0C5PW45_MYTGA	7.0e-178	629.0	98.31%	77.62%	MAP kinase kinase 7-like protein;OS=Mytilus;PE=2;SV=1	GO:0005524|GO:0004672|
GN008432.1	sp|K1PCW2|K1PCW2_CRAGI	1.6e-241	840.9	98.25%	74.02%	Folylpolyglutamate synthase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004326|	GO:0006730|
GN008433.1	sp|K1PYN7|K1PYN7_CRAGI	7.0e-198	695.3	100.00%	91.46%	Deoxyhypusine synthase;OS=Crassostrea;PE=4;SV=1	GO:0008612|
GN008434.1	sp|K1PS05|K1PS05_CRAGI	0.0e+00	1223.8	98.47%	60.41%	Calcium-activated chloride channel regulator 4;OS=Crassostrea;PE=4;SV=1
GN008435.1	sp|A0A088B1V1|A0A088B1V1_9BIVA	1.8e-151	541.2	98.75%	66.67%	Caspase-3;OS=Crassostrea;PE=2;SV=1	GO:0097200|
GN008436.1	sp|T1I8R4|T1I8R4_RHOPR	8.6e-40	170.2	89.72%	31.13%	Uncharacterized protein;OS=Rhodnius;PE=4;SV=1
GN008437.1	sp|K1Q5I7|K1Q5I7_CRAGI	1.1e-199	702.6	98.41%	42.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008439.1	sp|A0A1S3K511|A0A1S3K511_LINUN	1.0e-20	104.8	98.90%	47.19%	uncharacterized protein LOC106178750;OS=Lingula;PE=4;SV=1
GN008440.1	sp|K1QSI1|K1QSI1_CRAGI	0.0e+00	1241.1	100.00%	90.68%	Xenotropic and polytropic retrovirus receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008441.1	sp|K1QL94|K1QL94_CRAGI	0.0e+00	1219.1	99.83%	58.60%	Partitioning defective 6-like protein beta;OS=Crassostrea;PE=4;SV=1
GN008442.1	sp|K1QD37|K1QD37_CRAGI	3.0e-152	544.3	83.48%	60.00%	Serine beta-lactamase-like protein LACTB, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN008444.1	sp|K1Q5L4|K1Q5L4_CRAGI	4.2e-114	417.2	49.52%	95.59%	Pre-mRNA-splicing factor 38B;OS=Crassostrea;PE=4;SV=1
GN008445.1	sp|V4AI92|V4AI92_LOTGI	2.2e-52	211.8	91.35%	34.74%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004531|
GN008446.1	sp|A0A194ALE3|A0A194ALE3_PINFU	2.6e-219	766.5	100.00%	100.00%	Putative actin 00526;OS=Pinctada;PE=3;SV=1	GO:0005524|
GN008447.1	sp|K1QI76|K1QI76_CRAGI	1.5e-47	198.0	12.13%	52.43%	Gem-associated protein 5;OS=Crassostrea;PE=4;SV=1
GN006451.1	sp|K1P0H4|K1P0H4_CRAGI	6.1e-14	83.6	48.93%	37.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008448.1	sp|K1QD27|K1QD27_CRAGI	3.7e-271	939.5	100.00%	74.50%	NF-kappa-B-repressing factor;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN008449.1	sp|A0A0B6YCI2|A0A0B6YCI2_9EUPU	3.3e-69	266.9	91.33%	71.91%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0005509|
GN008450.1	sp|K1RCN3|K1RCN3_CRAGI	1.7e-267	927.5	72.64%	81.92%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN008451.1	sp|A0A1X7VAJ5|A0A1X7VAJ5_AMPQE	2.3e-11	74.3	55.32%	41.77%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0008270|
GN008452.1	sp|A0A210QQ78|A0A210QQ78_MIZYE	5.9e-55	220.3	93.27%	40.13%	Mu-type opioid receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008453.1	sp|A0A210QQ78|A0A210QQ78_MIZYE	8.7e-54	216.5	91.29%	40.58%	Mu-type opioid receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008454.1	sp|K1R6R9|K1R6R9_CRAGI	3.2e-111	407.1	95.75%	65.19%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN008455.1	sp|K1RR53|K1RR53_CRAGI	2.4e-209	733.8	87.78%	81.46%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN008456.1	sp|K1RR53|K1RR53_CRAGI	2.3e-212	743.8	87.78%	82.38%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN008457.1	sp|K1R6R9|K1R6R9_CRAGI	1.2e-189	668.3	97.76%	63.73%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN008458.1	sp|K1Q8H1|K1Q8H1_CRAGI	7.3e-228	795.0	100.00%	92.93%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN008459.1	sp|K1QFN4|K1QFN4_CRAGI	1.2e-225	787.7	100.00%	91.08%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN008460.1	sp|A0A210Q013|A0A210Q013_MIZYE	7.3e-84	316.6	91.86%	43.62%	Innexin;OS=Mizuhopecten;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN008461.1	sp|K1Q8H6|K1Q8H6_CRAGI	0.0e+00	1126.3	100.00%	80.36%	PP2C-like domain-containing protein C3orf48;OS=Crassostrea;PE=4;SV=1	GO:0004722|
GN008462.1	sp|K1QFN6|K1QFN6_CRAGI	0.0e+00	1127.9	100.00%	90.37%	EF-hand domain-containing family member B;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN008463.1	sp|K1R1Q8|K1R1Q8_CRAGI	1.5e-115	421.0	100.00%	98.59%	Ras-related protein Rab-5C;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN008464.1	sp|K1PTR3|K1PTR3_CRAGI	2.8e-55	219.9	99.15%	89.66%	Oxysterol-binding protein;OS=Crassostrea;PE=3;SV=1	GO:0006869|
GN008465.1	sp|K1Q8I1|K1Q8I1_CRAGI	7.7e-46	190.3	27.01%	93.20%	WW domain-containing adapter protein with coiled-coil;OS=Crassostrea;PE=4;SV=1
GN008466.1	sp|K1R1R1|K1R1R1_CRAGI	0.0e+00	4347.3	78.75%	85.45%	Bullous pemphigoid antigen 1, isoforms 6/9/10;OS=Crassostrea;PE=4;SV=1	GO:0005856|
GN008468.1	sp|K1Q8I6|K1Q8I6_CRAGI	0.0e+00	1236.1	98.20%	72.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006251.1	sp|K1P6B3|K1P6B3_CRAGI	5.8e-198	697.2	32.47%	90.67%	Endoplasmic reticulum resident protein ERp44;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN006454.1	sp|K1QVN6|K1QVN6_CRAGI	5.1e-38	163.3	80.10%	51.57%	Tetraspanin-18;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN008472.1	sp|K1Q4S4|K1Q4S4_CRAGI	1.2e-43	182.2	97.71%	45.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008473.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	8.0e-21	106.3	66.19%	46.04%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN008474.1	sp|K1QCA4|K1QCA4_CRAGI	0.0e+00	1075.5	99.86%	70.94%	Amine oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0008131|GO:0048038|	GO:0009308|
GN008475.1	sp|K1Q4U1|K1Q4U1_CRAGI	4.2e-200	703.0	98.45%	77.30%	TNF receptor-associated factor 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0042981|GO:0007165|
GN008477.1	sp|K1QKE7|K1QKE7_CRAGI	4.9e-57	226.5	69.23%	77.54%	Queuine tRNA-ribosyltransferase subunit QTRTD1;OS=Crassostrea;PE=4;SV=1	GO:0016763|	GO:0006400|
GN008478.1	sp|K1RBY3|K1RBY3_CRAGI	0.0e+00	1567.0	100.00%	76.19%	WD repeat-containing protein 47;OS=Crassostrea;PE=4;SV=1
GN008479.1	sp|K1Q456|K1Q456_CRAGI	0.0e+00	1334.7	98.42%	72.41%	Anoctamin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0046983|
GN008481.1	sp|A0A210QW02|A0A210QW02_MIZYE	0.0e+00	1157.5	99.86%	76.83%	Bardet-Biedl syndrome 7 protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0034464|	GO:1905515|
GN008482.1	sp|A0A210QVZ1|A0A210QVZ1_MIZYE	7.2e-27	128.3	61.95%	27.31%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN008483.1	sp|K1R2P9|K1R2P9_CRAGI	5.4e-206	722.2	97.56%	97.21%	Protein mab-21-like 2-B;OS=Crassostrea;PE=4;SV=1
GN008484.1	sp|K1QND2|K1QND2_CRAGI	2.7e-172	610.5	94.70%	85.37%	Septin-2;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN008485.1	sp|K1RM12|K1RM12_CRAGI	0.0e+00	2435.6	85.61%	75.23%	Histone-lysine N-methyltransferase MLL3;OS=Crassostrea;PE=4;SV=1	GO:0044666|	GO:0042800|GO:0046872|
GN008486.1	sp|A0A210QVY0|A0A210QVY0_MIZYE	6.7e-32	143.7	76.13%	35.98%	Steroid receptor RNA activator 1;OS=Mizuhopecten;PE=4;SV=1	GO:0030374|	GO:0006357|
GN008487.1	sp|K1QEV5|K1QEV5_CRAGI	2.1e-17	93.6	87.95%	56.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008488.1	sp|K1QEV5|K1QEV5_CRAGI	2.1e-17	93.6	87.95%	56.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006455.1	sp|K1QVN3|K1QVN3_CRAGI	2.6e-240	837.8	97.43%	49.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008489.1	sp|K1QEV5|K1QEV5_CRAGI	2.1e-17	93.6	87.95%	56.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008490.1	sp|K1QEV5|K1QEV5_CRAGI	2.1e-17	93.6	87.95%	56.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008491.1	sp|K1QEV5|K1QEV5_CRAGI	1.9e-33	148.3	63.68%	47.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008492.1	sp|K1R2R0|K1R2R0_CRAGI	3.9e-88	331.3	97.38%	38.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008493.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	1.1e-44	186.8	23.00%	70.18%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN008494.1	sp|K1Q471|K1Q471_CRAGI	4.8e-270	936.8	89.80%	70.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008496.1	sp|K1QQ87|K1QQ87_CRAGI	0.0e+00	1191.4	55.83%	77.01%	Gamma-aminobutyric acid receptor subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005507|GO:0005230|GO:0004890|GO:0016715|
GN008497.1	sp|K1PPU8|K1PPU8_CRAGI	5.1e-153	546.2	100.00%	83.15%	Neurogenic locus Notch protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0030154|GO:0007219|GO:0050793|
GN008498.1	sp|K1QQ89|K1QQ89_CRAGI	5.0e-209	733.0	61.16%	94.58%	AP-3 complex subunit mu-1;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0006886|GO:0016192|
GN008504.1	sp|A0A2B4R6Q7|A0A2B4R6Q7_STYPI	8.5e-53	213.4	97.42%	35.78%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|GO:0008270|
GN006457.1	sp|K1Q9V8|K1Q9V8_CRAGI	2.4e-62	243.8	100.00%	74.19%	39S ribosomal protein L41, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN008506.1	sp|K1QUP2|K1QUP2_CRAGI	2.3e-56	225.3	45.63%	61.50%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN008508.1	sp|A0A1S3I398|A0A1S3I398_LINUN	2.9e-14	84.3	55.14%	40.20%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN008509.1	sp|K1RGY5|K1RGY5_CRAGI	1.5e-18	99.4	44.10%	42.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008510.1	sp|K1QLK4|K1QLK4_CRAGI	6.5e-37	159.8	98.22%	44.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008512.1	sp|K1Q5Q6|K1Q5Q6_CRAGI	3.4e-17	95.1	52.47%	30.14%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006458.1	sp|K1Q2L3|K1Q2L3_CRAGI	6.9e-157	559.7	96.74%	59.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008513.1	sp|K1QUM3|K1QUM3_CRAGI	5.4e-61	239.2	96.53%	80.43%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN008514.1	sp|K1QUP2|K1QUP2_CRAGI	1.8e-57	228.8	53.87%	62.57%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN008515.1	sp|K1QXA0|K1QXA0_CRAGI	4.2e-44	184.1	50.00%	60.27%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1
GN008516.1	sp|K1PPP6|K1PPP6_CRAGI	3.9e-47	193.7	84.98%	54.14%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN008517.1	sp|K1RZW6|K1RZW6_CRAGI	3.4e-98	363.6	87.55%	78.13%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN008518.1	sp|K1R463|K1R463_CRAGI	3.4e-45	189.1	27.89%	49.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008520.1	sp|K1RZV9|K1RZV9_CRAGI	5.5e-61	239.6	67.37%	90.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008521.1	sp|K1RGK4|K1RGK4_CRAGI	0.0e+00	1547.3	100.00%	90.89%	Villin-1;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0007010|
GN008522.1	sp|K1RA93|K1RA93_CRAGI	0.0e+00	1282.7	100.00%	69.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0043130|GO:0008270|	GO:0016236|
GN008524.1	sp|A0A1I8J146|A0A1I8J146_9PLAT	3.3e-29	134.8	61.79%	35.35%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN008531.1	sp|K1QE85|K1QE85_CRAGI	7.2e-18	95.1	93.90%	59.21%	Protein dcd1A;OS=Crassostrea;PE=4;SV=1	GO:0005783|	GO:0016702|GO:0004656|
GN008533.1	sp|A0A059TDQ0|A0A059TDQ0_CRAHO	1.5e-47	194.5	95.86%	70.42%	Serum amyloid A;OS=Crassostrea;PE=2;SV=1	GO:0005576|
GN008534.1	sp|K1QMW7|K1QMW7_CRAGI	1.4e-187	661.8	100.00%	65.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008535.1	sp|K1QE94|K1QE94_CRAGI	2.6e-209	733.4	97.30%	84.09%	Alpha-galactosidase;OS=Crassostrea;PE=3;SV=1	GO:0004553|	GO:0005975|
GN008536.1	sp|K1RLL7|K1RLL7_CRAGI	1.6e-167	594.7	100.00%	62.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008537.1	sp|K1QEA5|K1QEA5_CRAGI	4.0e-296	1022.7	97.14%	74.03%	72 kDa inositol polyphosphate 5-phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0046856|
GN008538.1	sp|K1QMX7|K1QMX7_CRAGI	0.0e+00	1090.1	70.28%	67.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006252.1	sp|K1PJP6|K1PJP6_CRAGI	0.0e+00	2142.1	81.86%	74.86%	PR domain zinc finger protein 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005634|	GO:0003676|	GO:0071630|GO:0031144|
GN006459.1	sp|K1PJ60|K1PJ60_CRAGI	2.6e-72	277.7	98.19%	55.47%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN008539.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	4.9e-19	99.8	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN008540.1	sp|K1PEZ2|K1PEZ2_CRAGI	4.6e-108	397.1	82.82%	62.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008541.1	sp|K1R6C9|K1R6C9_CRAGI	9.6e-173	611.7	100.00%	84.30%	LIM homeobox transcription factor 1-beta;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0043565|	GO:0006355|
GN008542.1	sp|K1R014|K1R014_CRAGI	2.4e-170	604.0	75.00%	93.77%	LIM homeobox transcription factor 1-beta;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0043565|	GO:0006355|
GN008543.1	sp|K1PWG1|K1PWG1_CRAGI	0.0e+00	1555.4	95.45%	91.58%	Rab GTPase-activating protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|
GN008544.1	sp|A0A1S3KF99|A0A1S3KF99_LINUN	7.6e-266	921.4	98.26%	98.89%	Tubulin alpha chain;OS=Lingula;PE=3;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN008545.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	3.9e-19	99.8	86.36%	48.42%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN008546.1	sp|A0A0L8HTD1|A0A0L8HTD1_OCTBM	9.5e-114	415.6	99.69%	63.89%	Sideroflexin;OS=Octopus;PE=3;SV=1	GO:0016021|GO:0031966|	GO:0015075|
GN008547.1	sp|K1QUZ7|K1QUZ7_CRAGI	1.5e-308	1064.7	91.22%	66.81%	Bromodomain testis-specific protein;OS=Crassostrea;PE=4;SV=1
GN008549.1	sp|K1QWC1|K1QWC1_CRAGI	4.7e-65	253.1	96.76%	66.85%	WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008552.1	sp|K1PPD0|K1PPD0_CRAGI	4.8e-39	168.3	94.35%	25.31%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008553.1	sp|A0A210PLD0|A0A210PLD0_MIZYE	1.1e-75	289.7	90.37%	37.56%	Ankyrin-2;OS=Mizuhopecten;PE=4;SV=1
GN008554.1	sp|K1RBZ5|K1RBZ5_CRAGI	1.8e-177	628.2	90.88%	74.00%	Ran GTPase-activating protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|	GO:0007165|
GN008555.1	sp|K1RHD6|K1RHD6_CRAGI	0.0e+00	1077.0	77.66%	60.56%	Intersectin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008556.1	sp|A0A210R1P3|A0A210R1P3_MIZYE	9.3e-89	332.0	100.00%	82.11%	Vesicle-associated membrane protein 7;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0016192|
GN008557.1	sp|K1S6W6|K1S6W6_CRAGI	6.3e-140	502.7	90.43%	71.06%	Metallophosphoesterase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN008559.1	sp|K1QH64|K1QH64_CRAGI	4.0e-159	566.2	100.00%	88.78%	Inositol oxygenase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0050113|GO:0005506|	GO:0019310|
GN008561.1	sp|K1QNQ4|K1QNQ4_CRAGI	2.9e-267	926.4	100.00%	81.04%	MAGUK p55 subfamily member 7;OS=Crassostrea;PE=3;SV=1
GN008562.1	sp|K1R914|K1R914_CRAGI	0.0e+00	5275.3	95.61%	76.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008565.1	sp|K1QH69|K1QH69_CRAGI	0.0e+00	1110.9	97.43%	82.55%	Guanylate cyclase 32E;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004383|	GO:0035556|
GN008566.1	sp|K1QNR1|K1QNR1_CRAGI	5.4e-29	135.2	8.86%	98.39%	Cyclin-dependent kinases regulatory subunit;OS=Crassostrea;PE=3;SV=1	GO:0016538|GO:0016301|	GO:0007049|GO:0051301|
GN008567.1	sp|K1R921|K1R921_CRAGI	6.0e-81	305.8	98.91%	83.98%	Succinate dehydrogenase cytochrome b560 subunit, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0045281|	GO:0009055|GO:0046872|GO:0000104|	GO:0006099|
GN008568.1	sp|K1Q267|K1Q267_CRAGI	6.0e-62	245.0	56.31%	35.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008569.1	sp|K1R930|K1R930_CRAGI	2.2e-20	105.5	28.91%	52.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008570.1	sp|K1P5X1|K1P5X1_CRAGI	1.7e-42	177.9	98.19%	51.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008572.1	sp|K1QX85|K1QX85_CRAGI	0.0e+00	1191.8	99.04%	82.09%	Bestrophin homolog;OS=Crassostrea;PE=3;SV=1	GO:0034707|GO:0005886|	GO:0005254|
GN008573.1	sp|K1Q419|K1Q419_CRAGI	3.3e-156	556.6	99.36%	93.87%	Upstream stimulatory factor 2;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0006355|
GN008574.1	sp|K1QBF7|K1QBF7_CRAGI	0.0e+00	1251.5	89.83%	78.99%	Hypoxia up-regulated protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN008575.1	sp|K1QX88|K1QX88_CRAGI	0.0e+00	1092.8	69.49%	53.69%	Reticulocyte-binding protein 2-like protein a;OS=Crassostrea;PE=4;SV=1
GN008576.1	sp|K1PPN7|K1PPN7_CRAGI	7.1e-290	1001.5	100.00%	86.87%	Frizzled-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0042813|	GO:0007275|
GN008577.1	sp|K1PWR7|K1PWR7_CRAGI	3.1e-38	164.9	51.62%	50.84%	Ras-related protein Rab-5B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003896|GO:0005525|GO:0003924|
GN008578.1	sp|K1PWR7|K1PWR7_CRAGI	1.0e-36	158.3	84.55%	78.64%	Ras-related protein Rab-5B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003896|GO:0005525|GO:0003924|
GN008580.1	sp|K1PRH2|K1PRH2_CRAGI	6.0e-23	113.2	39.06%	77.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008581.1	sp|K1Q423|K1Q423_CRAGI	3.3e-102	379.0	41.21%	45.51%	ADAM family mig-17;OS=Crassostrea;PE=4;SV=1	GO:0004222|
GN008583.1	sp|K1QBG0|K1QBG0_CRAGI	2.8e-238	829.7	100.00%	89.74%	Flavin-containing monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0004499|GO:0050661|
GN008585.1	sp|K1QX90|K1QX90_CRAGI	1.3e-227	795.0	70.27%	79.42%	Sugar phosphate exchanger 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN008592.1	sp|K1PPN9|K1PPN9_CRAGI	2.0e-50	203.8	93.97%	84.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008593.1	sp|K1QS69|K1QS69_CRAGI	4.3e-28	130.2	89.77%	43.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008594.1	sp|K1RFC0|K1RFC0_CRAGI	3.3e-114	417.2	98.48%	57.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008595.1	sp|K1REJ8|K1REJ8_CRAGI	2.2e-13	83.2	31.58%	31.94%	Dual oxidase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0020037|GO:0016174|GO:0004601|	GO:0050665|GO:0006979|
GN008596.1	sp|K1RXS2|K1RXS2_CRAGI	1.5e-55	221.1	100.00%	81.43%	DNA-directed RNA polymerase III subunit RPC9;OS=Crassostrea;PE=4;SV=1	GO:0005666|	GO:0003899|GO:0000166|	GO:0006384|
GN008597.1	sp|K1R827|K1R827_CRAGI	7.5e-229	799.3	100.00%	66.18%	B-cell lymphoma 3-encoded protein;OS=Crassostrea;PE=4;SV=1
GN008598.1	sp|A0A210Q5M9|A0A210Q5M9_MIZYE	1.3e-126	458.4	100.00%	88.85%	Beclin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0006914|GO:0006897|GO:0032465|
GN008600.1	sp|K1Q3F9|K1Q3F9_CRAGI	0.0e+00	1157.9	91.49%	90.08%	Armadillo repeat-containing protein 8;OS=Crassostrea;PE=4;SV=1
GN008601.1	sp|V3ZPK4|V3ZPK4_LOTGI	2.5e-24	120.2	24.59%	29.29%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN008602.1	sp|K1QNR9|K1QNR9_CRAGI	0.0e+00	1550.8	90.76%	86.01%	Integrator complex subunit 5;OS=Crassostrea;PE=4;SV=1	GO:0032039|
GN008603.1	sp|K1Q2W1|K1Q2W1_CRAGI	0.0e+00	1349.7	100.00%	69.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003839|
GN008604.1	sp|K1PW32|K1PW32_CRAGI	7.0e-135	485.7	99.67%	79.67%	BTB and MATH domain-containing protein 38;OS=Crassostrea;PE=4;SV=1
GN008605.1	sp|K1PNF6|K1PNF6_CRAGI	9.1e-36	155.2	67.97%	75.58%	Temptin;OS=Crassostrea;PE=4;SV=1
GN008606.1	sp|K1R4V3|K1R4V3_CRAGI	3.6e-106	391.0	75.42%	63.97%	Acetylcholine receptor subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN008607.1	sp|K1Q8G8|K1Q8G8_CRAGI	2.8e-103	381.3	63.68%	67.24%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN008608.1	sp|K1PH08|K1PH08_CRAGI	3.0e-305	1052.7	99.84%	88.17%	Otopetrin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008609.1	sp|A0A210PLC9|A0A210PLC9_MIZYE	1.1e-57	228.8	74.53%	63.69%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008610.1	sp|K1QNR7|K1QNR7_CRAGI	2.0e-102	377.5	94.76%	86.18%	Protein YIPF;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN008611.1	sp|K1Q2V7|K1Q2V7_CRAGI	8.8e-09	67.8	30.66%	29.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008612.1	sp|K1RFI5|K1RFI5_CRAGI	3.6e-231	806.6	82.92%	84.65%	Sodium/myo-inositol cotransporter 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN008613.1	sp|A0A210QE76|A0A210QE76_MIZYE	7.7e-205	719.2	99.84%	61.13%	Sodium/myo-inositol cotransporter 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0022857|
GN008614.1	sp|K1PI21|K1PI21_CRAGI	2.0e-18	97.8	84.56%	44.62%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN008615.1	sp|K1PI21|K1PI21_CRAGI	6.6e-39	165.6	80.00%	82.83%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN006253.1	sp|A0A210Q0G4|A0A210Q0G4_MIZYE	3.0e-78	298.9	89.20%	43.57%	Ribosomal RNA processing protein 1-like B;OS=Mizuhopecten;PE=4;SV=1	GO:0030688|	GO:0006364|
GN008616.1	sp|K1QVA6|K1QVA6_CRAGI	1.0e-169	602.1	93.25%	67.61%	Sodium/glucose cotransporter 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN008617.1	sp|K1QP75|K1QP75_CRAGI	1.2e-35	154.5	89.69%	83.72%	Sodium/glucose cotransporter 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN008618.1	sp|K1QG67|K1QG67_CRAGI	4.0e-252	876.7	83.68%	75.93%	Sodium/glucose cotransporter 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN008619.1	sp|K1Q7Z2|K1Q7Z2_CRAGI	1.5e-131	474.9	100.00%	64.64%	UPF0594 protein C13orf38-like protein;OS=Crassostrea;PE=4;SV=1
GN008620.1	sp|K1QS20|K1QS20_CRAGI	1.1e-18	98.2	94.50%	44.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008621.1	sp|K1R1C4|K1R1C4_CRAGI	2.7e-71	275.8	56.56%	42.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008622.1	sp|A0A1C9U2Y4|A0A1C9U2Y4_MIZYE	5.5e-205	719.5	99.48%	61.39%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN008623.1	sp|A0A210QRA0|A0A210QRA0_MIZYE	1.5e-22	112.5	60.73%	36.26%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN006464.1	sp|A0A2T7PN70|A0A2T7PN70_POMCA	2.6e-18	98.2	90.12%	29.49%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN008625.1	sp|K1QIC7|K1QIC7_CRAGI	9.5e-74	282.7	68.97%	60.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008626.1	sp|K1R428|K1R428_CRAGI	4.6e-37	159.1	100.00%	73.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008627.1	sp|A0A210QRA0|A0A210QRA0_MIZYE	1.1e-47	196.4	69.19%	36.43%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008629.1	sp|K1R4P3|K1R4P3_CRAGI	8.3e-44	182.6	80.81%	58.75%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN008630.1	sp|K1RAJ4|K1RAJ4_CRAGI	2.8e-143	513.8	98.31%	74.43%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008632.1	sp|K1RED4|K1RED4_CRAGI	1.2e-39	169.1	99.61%	43.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008633.1	sp|K1QA79|K1QA79_CRAGI	6.6e-190	668.7	97.67%	95.82%	DnaJ-like protein subfamily B member 11;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0051082|	GO:0006457|
GN008634.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	8.5e-47	192.6	95.26%	48.50%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN008636.1	sp|K1QI57|K1QI57_CRAGI	3.1e-279	966.5	100.00%	68.51%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008637.1	sp|K1QPR4|K1QPR4_CRAGI	5.1e-255	885.9	99.85%	63.44%	Tripartite motif-containing protein 13;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008638.1	sp|A0A0F6V015|A0A0F6V015_CRAGI	7.5e-45	184.9	100.00%	100.00%	Thyroid hormone receptor;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0004879|GO:0043565|GO:0003707|GO:0008270|
GN008639.1	sp|A0A0F6V015|A0A0F6V015_CRAGI	1.4e-10	71.6	48.55%	51.39%	Thyroid hormone receptor;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0004879|GO:0043565|GO:0003707|GO:0008270|
GN008640.1	sp|K1QA86|K1QA86_CRAGI	4.0e-182	643.3	94.32%	79.12%	Solute carrier family 35 member F5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008641.1	sp|K1PXQ0|K1PXQ0_CRAGI	6.0e-39	167.2	96.66%	34.26%	Cannabinoid receptor type 1B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008642.1	sp|K1PXQ0|K1PXQ0_CRAGI	1.4e-40	172.6	96.65%	34.98%	Cannabinoid receptor type 1B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008644.1	sp|K1PXY8|K1PXY8_CRAGI	4.4e-190	670.2	78.89%	66.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006465.1	sp|K1PX35|K1PX35_CRAGI	2.3e-136	491.5	66.79%	71.12%	ATP-dependent DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN008645.1	sp|A0A151WPL7|A0A151WPL7_9HYME	8.3e-32	142.1	99.25%	50.36%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN008646.1	sp|X1WK50|X1WK50_ACYPI	2.0e-26	124.8	94.76%	34.97%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1	GO:0046983|
GN008647.1	sp|A0A3L5TRJ7|A0A3L5TRJ7_MYTGA	7.0e-72	276.9	57.77%	52.83%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN008650.1	sp|K1QY38|K1QY38_CRAGI	3.9e-282	976.1	92.32%	79.91%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0004553|GO:0043565|GO:0003707|GO:0008270|	GO:0005975|
GN008652.1	sp|R7TJZ6|R7TJZ6_CAPTE	3.2e-09	67.4	66.27%	31.25%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN008653.1	sp|K1QY38|K1QY38_CRAGI	0.0e+00	1139.4	97.44%	80.83%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0004553|GO:0043565|GO:0003707|GO:0008270|	GO:0005975|
GN008654.1	sp|K1S383|K1S383_CRAGI	6.6e-64	250.0	98.39%	49.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006466.1	sp|A0A2G8K3C7|A0A2G8K3C7_STIJA	2.5e-14	85.5	31.94%	43.86%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0004803|	GO:0006313|
GN008655.1	sp|K1R7X0|K1R7X0_CRAGI	1.8e-154	550.8	100.00%	88.49%	NmrA-like family domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN008656.1	sp|K1QGE1|K1QGE1_CRAGI	1.7e-26	124.8	99.41%	46.41%	E3 ubiquitin-protein ligase LRSAM1;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN008657.1	sp|K1QGE1|K1QGE1_CRAGI	3.2e-63	247.3	99.14%	58.09%	E3 ubiquitin-protein ligase LRSAM1;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN008658.1	sp|K1PWD7|K1PWD7_CRAGI	3.7e-228	796.2	98.93%	80.00%	Kynurenine--oxoglutarate transaminase 3;OS=Crassostrea;PE=4;SV=1	GO:0036137|GO:0030170|	GO:0009058|
GN008659.1	sp|K1QG71|K1QG71_CRAGI	1.1e-18	100.1	16.13%	60.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008660.1	sp|K1Q7Z6|K1Q7Z6_CRAGI	1.7e-209	734.2	99.57%	88.77%	Protein FAM47E;OS=Crassostrea;PE=4;SV=1
GN006467.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	2.0e-86	324.7	93.06%	58.46%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008663.1	sp|K1RTF1|K1RTF1_CRAGI	5.9e-16	89.4	90.98%	57.66%	Annexin;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005544|
GN008664.1	sp|K1RFK9|K1RFK9_CRAGI	1.6e-40	174.1	23.48%	35.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008668.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	4.2e-33	146.4	99.21%	54.33%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN006469.1	sp|R7T5V7|R7T5V7_CAPTE	5.2e-108	397.1	97.93%	42.60%	Uncharacterized protein;OS=Capitella;PE=4;SV=1	GO:0007276|
GN006254.1	sp|K1PC99|K1PC99_CRAGI	2.5e-80	305.4	52.23%	53.95%	Leucine-rich repeat and fibronectin type-III domain-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN006472.1	sp|K1PXN3|K1PXN3_CRAGI	2.6e-09	68.2	56.39%	34.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006476.1	sp|A0A210PKX9|A0A210PKX9_MIZYE	4.2e-41	174.9	37.37%	48.31%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN006477.1	sp|K1QI98|K1QI98_CRAGI	2.9e-19	102.4	21.67%	46.90%	Uncharacterized protein C19orf55-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006478.1	sp|A0A2G8KA18|A0A2G8KA18_STIJA	4.3e-19	100.9	84.50%	30.30%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0004190|
GN006255.1	sp|K1PZ82|K1PZ82_CRAGI	0.0e+00	2662.9	100.00%	70.43%	Collagen alpha-3(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN006479.1	sp|K1QI98|K1QI98_CRAGI	1.1e-22	113.6	24.21%	47.37%	Uncharacterized protein C19orf55-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006480.1	sp|K1PZI1|K1PZI1_CRAGI	7.0e-132	476.9	60.43%	60.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006481.1	sp|A0A210Q0N7|A0A210Q0N7_MIZYE	2.4e-50	203.8	100.00%	75.36%	Prefoldin subunit 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016272|	GO:0051082|	GO:0006457|
GN006482.1	sp|A0A210Q0R1|A0A210Q0R1_MIZYE	3.8e-43	180.3	88.46%	57.31%	Homeobox protein BarH-like 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006483.1	sp|K1PMS4|K1PMS4_CRAGI	1.1e-54	218.8	89.32%	51.35%	Laccase-18;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005507|	GO:0055114|
GN006484.1	sp|K1PC21|K1PC21_CRAGI	6.5e-271	938.7	78.71%	89.08%	Sodium/myo-inositol cotransporter 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN006485.1	sp|K1QXW4|K1QXW4_CRAGI	1.5e-142	511.5	100.00%	69.11%	Zinc finger HIT domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN006256.1	sp|K1PZ82|K1PZ82_CRAGI	0.0e+00	1810.0	89.97%	50.14%	Collagen alpha-3(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN006486.1	sp|K1R4R1|K1R4R1_CRAGI	8.1e-113	413.3	89.45%	78.76%	Coiled-coil domain-containing protein 19, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN006487.1	sp|K1RB99|K1RB99_CRAGI	1.1e-77	295.4	73.97%	73.60%	39S ribosomal protein L39, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0000166|
GN006488.1	sp|K1RUW0|K1RUW0_CRAGI	0.0e+00	1515.4	98.73%	65.00%	E3 SUMO-protein ligase RanBP2;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0016874|GO:0046872|	GO:0046907|
GN006489.1	sp|K1RUW0|K1RUW0_CRAGI	0.0e+00	1129.4	97.86%	73.75%	E3 SUMO-protein ligase RanBP2;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0016874|GO:0046872|	GO:0046907|
GN006490.1	sp|K1QNQ0|K1QNQ0_CRAGI	4.3e-116	422.9	100.00%	87.66%	Platelet-activating factor acetylhydrolase IB subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN006491.1	sp|K1RFV6|K1RFV6_CRAGI	7.3e-254	882.9	65.00%	64.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN006493.1	sp|K1R9E7|K1R9E7_CRAGI	3.4e-85	321.2	50.55%	72.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006494.1	sp|K1R3G1|K1R3G1_CRAGI	4.5e-49	199.9	100.00%	58.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006495.1	sp|K1QTX2|K1QTX2_CRAGI	1.5e-37	161.4	100.00%	53.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006496.1	sp|K1QTX2|K1QTX2_CRAGI	6.6e-46	189.1	99.33%	62.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006497.1	sp|K1RZ40|K1RZ40_CRAGI	5.6e-54	216.1	77.30%	81.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006498.1	sp|K1RFV2|K1RFV2_CRAGI	3.9e-62	243.4	100.00%	66.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006499.1	sp|K1QAT2|K1QAT2_CRAGI	0.0e+00	2079.7	97.95%	91.27%	Phospholipid-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0000287|GO:0004012|
GN006500.1	sp|A0A1S3JDX8|A0A1S3JDX8_LINUN	4.3e-125	454.5	47.87%	62.40%	exosome complex component RRP45;OS=Lingula;PE=4;SV=1	GO:0000178|	GO:0006396|
GN006501.1	sp|K1QHQ8|K1QHQ8_CRAGI	3.2e-194	683.3	95.36%	87.14%	G2/mitotic-specific cyclin-A;OS=Crassostrea;PE=3;SV=1	GO:0005634|
GN006502.1	sp|K1QAT6|K1QAT6_CRAGI	1.5e-175	620.9	99.10%	93.64%	POU domain protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0048839|GO:0007605|
GN006226.1	sp|K1RU71|K1RU71_CRAGI	1.0e-33	149.4	97.75%	35.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN006257.1	sp|K1PZ82|K1PZ82_CRAGI	2.4e-63	247.3	94.74%	72.05%	Collagen alpha-3(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN006503.1	sp|K1Q393|K1Q393_CRAGI	4.4e-291	1006.1	95.03%	66.14%	Spermatogenesis-associated protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN006504.1	sp|K1QVJ0|K1QVJ0_CRAGI	1.6e-41	174.9	94.02%	47.43%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN006505.1	sp|K1R271|K1R271_CRAGI	2.1e-26	124.0	100.00%	50.00%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN006258.1	sp|K1PZ82|K1PZ82_CRAGI	4.3e-57	226.1	100.00%	79.85%	Collagen alpha-3(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN006506.1	sp|K1Q9C8|K1Q9C8_CRAGI	3.0e-74	283.5	96.00%	84.43%	Glutamate--cysteine ligase regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0035226|GO:0016874|	GO:0006750|
GN006508.1	sp|K1R2E2|K1R2E2_CRAGI	3.1e-43	181.4	36.75%	71.90%	Putative glycerophosphodiester phosphodiesterase 5;OS=Crassostrea;PE=4;SV=1	GO:0008081|GO:2001070|	GO:0006629|
GN006509.1	sp|K1R2E2|K1R2E2_CRAGI	7.9e-288	995.0	100.00%	73.56%	Putative glycerophosphodiester phosphodiesterase 5;OS=Crassostrea;PE=4;SV=1	GO:0008081|GO:2001070|	GO:0006629|
GN006510.1	sp|K1Q3Q5|K1Q3Q5_CRAGI	5.0e-19	99.0	97.56%	63.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006511.1	sp|K1QGJ8|K1QGJ8_CRAGI	5.7e-56	224.2	73.25%	45.56%	Cell division cycle 7-related protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|	GO:0051301|
GN006514.1	sp|W4Y8Y6|W4Y8Y6_STRPU	5.8e-51	207.2	86.85%	40.31%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN006516.1	sp|K1QGJ8|K1QGJ8_CRAGI	6.3e-160	569.7	75.92%	73.74%	Cell division cycle 7-related protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|	GO:0051301|
GN006517.1	sp|K1Q1Y8|K1Q1Y8_CRAGI	1.5e-194	684.9	80.03%	70.26%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN006518.1	sp|K1Q9C0|K1Q9C0_CRAGI	1.5e-173	615.1	97.14%	52.78%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN006519.1	sp|K1QEC9|K1QEC9_CRAGI	8.4e-31	139.8	58.15%	46.84%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN006520.1	sp|K1QEC9|K1QEC9_CRAGI	2.6e-31	141.4	92.28%	38.60%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN006521.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	5.0e-23	112.8	90.16%	51.38%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN006522.1	sp|K1PXU3|K1PXU3_CRAGI	8.1e-41	172.2	89.58%	61.72%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN006523.1	sp|K1PYU9|K1PYU9_CRAGI	2.1e-134	484.2	100.00%	76.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006525.1	sp|K1PYU9|K1PYU9_CRAGI	1.8e-117	427.9	100.00%	69.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006526.1	sp|K1QPM1|K1QPM1_CRAGI	1.1e-175	621.7	96.18%	72.59%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006527.1	sp|K1PYU9|K1PYU9_CRAGI	4.2e-135	486.5	100.00%	76.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006528.1	sp|K1QK11|K1QK11_CRAGI	0.0e+00	7450.1	100.00%	92.63%	Dynein heavy chain 7, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0030286|	GO:0005524|GO:0005509|GO:0003777|	GO:0007018|
GN006529.1	sp|K1QSG4|K1QSG4_CRAGI	3.0e-64	251.5	48.66%	96.97%	Nephrocystin-3;OS=Crassostrea;PE=4;SV=1
GN006530.1	sp|K1QK10|K1QK10_CRAGI	4.6e-59	232.6	99.23%	86.72%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN006531.1	sp|K1QBI4|K1QBI4_CRAGI	3.3e-220	770.8	92.70%	67.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0008270|
GN006532.1	sp|K1QSG1|K1QSG1_CRAGI	1.2e-65	257.3	98.57%	52.90%	Zinc finger protein 91;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN006533.1	sp|K1PLY4|K1PLY4_CRAGI	2.0e-29	136.3	32.53%	34.90%	Laminin-like protein epi-1;OS=Crassostrea;PE=4;SV=1
GN006534.1	sp|K1PYK0|K1PYK0_CRAGI	1.2e-225	789.3	94.78%	63.08%	Myomegalin;OS=Crassostrea;PE=4;SV=1
GN006535.1	sp|K1Q5H5|K1Q5H5_CRAGI	3.6e-172	610.1	100.00%	70.38%	Phosphatidylinositol-4-phosphate 5-kinase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016307|
GN006536.1	sp|K1QRK6|K1QRK6_CRAGI	6.6e-125	453.0	92.70%	63.37%	UPF0486 protein C1orf59-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008171|GO:0008173|
GN006262.1	sp|K1Q975|K1Q975_CRAGI	1.4e-175	622.9	47.83%	70.91%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006537.1	sp|K1PJK2|K1PJK2_CRAGI	1.6e-128	464.9	100.00%	70.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006538.1	sp|K1PRC2|K1PRC2_CRAGI	5.8e-71	272.7	92.11%	79.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006539.1	sp|K1PYK4|K1PYK4_CRAGI	1.4e-119	434.9	100.00%	68.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006540.1	sp|K1Q5I1|K1Q5I1_CRAGI	0.0e+00	1089.7	100.00%	84.26%	cAMP-dependent protein kinase regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN006541.1	sp|V3ZWC6|V3ZWC6_LOTGI	1.3e-27	127.9	90.57%	56.84%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN006542.1	sp|A0A1S3KAA9|A0A1S3KAA9_LINUN	3.6e-55	221.1	96.20%	38.02%	uncharacterized protein LOC106180092;OS=Lingula;PE=4;SV=1	GO:0008270|
GN006543.1	sp|K1QDT8|K1QDT8_CRAGI	3.2e-34	150.6	78.02%	48.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006544.1	sp|K1RY97|K1RY97_CRAGI	1.8e-64	251.9	89.26%	59.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006545.1	sp|K1QJN2|K1QJN2_CRAGI	1.5e-24	117.1	100.00%	81.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN006264.1	sp|A0A2T7NL24|A0A2T7NL24_POMCA	2.5e-87	327.0	98.91%	91.67%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0003995|GO:0050660|
GN006550.1	sp|K1PQZ3|K1PQZ3_CRAGI	2.9e-292	1010.4	90.49%	87.42%	Armadillo repeat-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN006552.1	sp|K1PIV8|K1PIV8_CRAGI	0.0e+00	1181.8	98.20%	90.24%	Putative nuclear hormone receptor HR38;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0004879|GO:0043565|GO:0003707|GO:0008270|
GN006553.1	sp|K1RE61|K1RE61_CRAGI	0.0e+00	1508.4	95.02%	72.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006554.1	sp|K1PQZ8|K1PQZ8_CRAGI	6.4e-151	538.9	100.00%	87.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006555.1	sp|A0A210R412|A0A210R412_MIZYE	1.6e-59	235.3	79.54%	68.15%	Krueppel-like factor 7;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN006556.1	sp|K1PND9|K1PND9_CRAGI	2.2e-22	110.5	92.79%	51.96%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN006265.1	sp|K1QI40|K1QI40_CRAGI	2.2e-47	193.4	100.00%	91.40%	Selenium-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008430|
GN006557.1	sp|A0A1S3I398|A0A1S3I398_LINUN	1.0e-25	122.1	64.90%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN006558.1	sp|A0A210Q2Z4|A0A210Q2Z4_MIZYE	4.6e-35	154.1	66.09%	44.04%	ATP-dependent DNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN006561.1	sp|K1R554|K1R554_CRAGI	0.0e+00	1760.7	97.66%	84.88%	Anion exchange protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005452|
GN006562.1	sp|A0A2G8K374|A0A2G8K374_STIJA	2.4e-25	122.5	53.68%	35.77%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN006563.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	2.7e-58	231.5	90.43%	38.02%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN006564.1	sp|K1QYT8|K1QYT8_CRAGI	7.4e-149	532.3	97.08%	76.35%	Guanylate kinase;OS=Crassostrea;PE=3;SV=1	GO:0004385|
GN006565.1	sp|K1QRI1|K1QRI1_CRAGI	1.1e-47	196.1	69.80%	86.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006567.1	sp|K1QHR7|K1QHR7_CRAGI	2.0e-28	131.3	66.29%	50.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006568.1	sp|K1RPK4|K1RPK4_CRAGI	2.4e-36	157.1	76.56%	69.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006569.1	sp|A0A210QM01|A0A210QM01_MIZYE	1.8e-178	631.7	94.48%	53.81%	C2 domain-containing protein 2-like;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN006570.1	sp|A0A210PQ58|A0A210PQ58_MIZYE	5.4e-22	111.3	49.02%	33.33%	Collagen alpha-6(VI) chain;OS=Mizuhopecten;PE=4;SV=1	GO:0005581|
GN006571.1	sp|U5PYX2|U5PYX2_CRAGI	1.3e-137	495.0	99.43%	67.25%	Toll-like receptor 2;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0007165|
GN006572.1	sp|K1QG50|K1QG50_CRAGI	7.1e-107	393.7	99.83%	42.25%	Cytoskeleton-associated protein 2;OS=Crassostrea;PE=4;SV=1
GN006573.1	sp|A0A210QIC0|A0A210QIC0_MIZYE	2.9e-196	690.3	99.57%	71.55%	General transcription factor IIH subunit 4;OS=Mizuhopecten;PE=3;SV=1	GO:0000439|	GO:0001671|	GO:0006289|
GN006574.1	sp|K1QG54|K1QG54_CRAGI	9.1e-121	438.7	100.00%	74.20%	Protein transport protein sec16;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0000139|	GO:0048208|GO:0015031|
GN006575.1	sp|K1PVT8|K1PVT8_CRAGI	8.8e-95	352.1	100.00%	76.92%	Thioredoxin domain-containing protein 9;OS=Crassostrea;PE=4;SV=1
GN006576.1	sp|K1R3L8|K1R3L8_CRAGI	7.8e-240	835.1	99.20%	78.56%	Iduronate 2-sulfatase;OS=Crassostrea;PE=4;SV=1	GO:0004423|
GN006577.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	1.1e-63	248.8	98.74%	49.79%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN006267.1	sp|K1QGD7|K1QGD7_CRAGI	3.9e-141	507.3	73.38%	62.47%	Multiple epidermal growth factor-like domains 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006579.1	sp|W4ZIE5|W4ZIE5_STRPU	3.0e-93	349.0	61.90%	36.03%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN006580.1	sp|K1PJD2|K1PJD2_CRAGI	8.1e-68	262.7	81.96%	60.10%	ATP-dependent DNA helicase Q5;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0008026|GO:0003676|	GO:0006310|
GN006581.1	sp|A0A210PYU4|A0A210PYU4_MIZYE	1.5e-269	934.9	98.58%	50.92%	Non-specific serine/threonine protein kinase;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004674|
GN006583.1	sp|K1QR39|K1QR39_CRAGI	3.8e-251	873.6	86.83%	56.61%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006584.1	sp|K1QR39|K1QR39_CRAGI	1.3e-251	875.2	86.83%	56.73%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006585.1	sp|A0A2C9MA35|A0A2C9MA35_BIOGL	1.3e-26	124.8	94.44%	50.00%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0031177|GO:0016740|
GN006586.1	sp|K1QLU3|K1QLU3_CRAGI	9.1e-101	374.0	60.99%	38.29%	Putative polyketide synthase 17;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN006587.1	sp|K1R941|K1R941_CRAGI	7.3e-45	186.4	95.67%	39.51%	Erythronolide synthase, modules 3 and 4;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN006588.1	sp|C3YWQ8|C3YWQ8_BRAFL	8.1e-30	136.3	93.19%	35.84%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN006590.1	sp|A0A210PHM3|A0A210PHM3_MIZYE	4.6e-38	165.2	25.98%	44.02%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN006591.1	sp|V4ABF7|V4ABF7_LOTGI	8.2e-28	130.6	61.20%	30.40%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN006592.1	sp|A0A210QC01|A0A210QC01_MIZYE	0.0e+00	2190.2	99.77%	81.83%	WD repeat-containing protein 19;OS=Mizuhopecten;PE=4;SV=1	GO:0005929|	GO:0035721|
GN006593.1	sp|K1QLS4|K1QLS4_CRAGI	3.3e-179	633.3	99.18%	82.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006594.1	sp|K1QLS4|K1QLS4_CRAGI	9.8e-142	508.8	100.00%	63.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006597.1	sp|A0A210QUN9|A0A210QUN9_MIZYE	1.7e-26	128.3	9.81%	34.83%	G-protein coupled receptor 101;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN006269.1	sp|K1QF56|K1QF56_CRAGI	4.8e-39	166.4	94.81%	58.90%	Chlorophyllide a oxygenase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0051537|GO:0016491|
GN006598.1	sp|K1Q3A1|K1Q3A1_CRAGI	3.2e-142	510.4	87.12%	65.50%	Alpha-amylase;OS=Crassostrea;PE=3;SV=1	GO:0004556|GO:0103025|GO:0043169|	GO:0005975|
GN006599.1	sp|K1QAV5|K1QAV5_CRAGI	1.4e-94	352.1	62.50%	74.89%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN006600.1	sp|K1Q3A1|K1Q3A1_CRAGI	0.0e+00	1235.3	98.44%	81.84%	Alpha-amylase;OS=Crassostrea;PE=3;SV=1	GO:0004556|GO:0103025|GO:0043169|	GO:0005975|
GN006601.1	sp|K1PVL1|K1PVL1_CRAGI	1.2e-28	132.1	38.83%	79.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006602.1	sp|K1R3F0|K1R3F0_CRAGI	7.4e-107	393.7	93.40%	77.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006603.1	sp|K1R941|K1R941_CRAGI	1.4e-84	320.5	55.66%	33.56%	Erythronolide synthase, modules 3 and 4;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN006604.1	sp|K1R941|K1R941_CRAGI	3.0e-171	608.6	94.73%	32.06%	Erythronolide synthase, modules 3 and 4;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN006605.1	sp|K1QLU3|K1QLU3_CRAGI	4.7e-187	660.2	96.68%	49.05%	Putative polyketide synthase 17;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN006606.1	sp|K1R941|K1R941_CRAGI	0.0e+00	1355.1	95.64%	52.09%	Erythronolide synthase, modules 3 and 4;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN006608.1	sp|V4A8A4|V4A8A4_LOTGI	1.1e-11	76.6	25.72%	42.70%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006610.1	sp|K1S5H1|K1S5H1_CRAGI	5.1e-26	122.9	93.80%	46.28%	Zinc finger MYM-type protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0051607|
GN006611.1	sp|V4A8A4|V4A8A4_LOTGI	1.1e-130	473.4	71.08%	37.57%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006612.1	sp|K1QR39|K1QR39_CRAGI	9.9e-252	875.5	88.92%	55.62%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006613.1	sp|A0A2B4S577|A0A2B4S577_STYPI	1.6e-54	219.5	92.41%	31.32%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN006614.1	sp|K1RIW4|K1RIW4_CRAGI	4.0e-84	318.2	87.24%	33.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006615.1	sp|V4A8A4|V4A8A4_LOTGI	1.0e-128	466.8	71.08%	37.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006617.1	sp|A0A210QHH9|A0A210QHH9_MIZYE	2.1e-14	85.9	72.54%	24.84%	BTB/POZ domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1
GN006618.1	sp|K1QMT8|K1QMT8_CRAGI	5.6e-87	327.0	72.91%	60.68%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006619.1	sp|K1QR39|K1QR39_CRAGI	5.7e-55	219.9	93.75%	52.65%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006621.1	sp|C3YK76|C3YK76_BRAFL	2.9e-62	244.6	57.68%	60.66%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN006622.1	sp|K1QR39|K1QR39_CRAGI	3.4e-79	300.8	93.77%	52.98%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006624.1	sp|K1QR39|K1QR39_CRAGI	2.0e-79	301.6	93.77%	53.31%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN006272.1	sp|K1RMB2|K1RMB2_CRAGI	4.9e-210	735.7	100.00%	85.86%	Chlorophyllide a oxygenase;OS=Crassostrea;PE=4;SV=1	GO:0051537|GO:0016491|
GN006626.1	sp|K1QXY1|K1QXY1_CRAGI	4.4e-12	75.5	100.00%	56.67%	Glycerol kinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0016773|	GO:0005975|
GN006627.1	sp|K1PQ68|K1PQ68_CRAGI	3.1e-60	237.7	96.06%	46.84%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN006628.1	sp|K1PXZ2|K1PXZ2_CRAGI	3.4e-107	393.7	86.85%	77.60%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN006630.1	sp|K1PIH7|K1PIH7_CRAGI	0.0e+00	1126.7	88.83%	86.43%	Dual specificity tyrosine-phosphorylation-regulated kinase 1A;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004712|	GO:0046777|
GN006632.1	sp|K1PJW3|K1PJW3_CRAGI	4.2e-229	799.3	100.00%	92.39%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN006633.1	sp|K1PRW3|K1PRW3_CRAGI	1.9e-146	524.2	100.00%	77.71%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN006634.1	sp|K1QHE7|K1QHE7_CRAGI	2.8e-13	80.1	83.51%	52.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006636.1	sp|K1QPU5|K1QPU5_CRAGI	1.4e-16	90.9	100.00%	52.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006274.1	sp|K1R2Z2|K1R2Z2_CRAGI	5.9e-248	862.1	99.20%	84.01%	Methyltransferase-like protein 13;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN006637.1	sp|K1QTS7|K1QTS7_CRAGI	1.1e-29	134.4	98.77%	73.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006275.1	sp|K1QWI5|K1QWI5_CRAGI	3.0e-182	644.0	72.12%	77.05%	Target of rapamycin complex 2 subunit MAPKAP1;OS=Crassostrea;PE=4;SV=1
GN006645.1	sp|A0A210QKB1|A0A210QKB1_MIZYE	8.1e-171	606.7	92.38%	42.18%	Transient receptor potential cation channel subfamily V member 5;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005216|
GN006276.1	sp|K1QNP2|K1QNP2_CRAGI	5.1e-214	749.6	100.00%	66.39%	Cytochrome P450 2B4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0016705|
GN006647.1	sp|A0A210QKB1|A0A210QKB1_MIZYE	6.2e-171	607.1	95.92%	41.53%	Transient receptor potential cation channel subfamily V member 5;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005216|
GN006648.1	sp|K1Q606|K1Q606_CRAGI	9.2e-76	288.9	100.00%	81.08%	Sex-determining protein fem-1;OS=Crassostrea;PE=4;SV=1
GN006651.1	sp|K1RD34|K1RD34_CRAGI	1.1e-27	129.4	29.02%	91.89%	Ankyrin repeat domain-containing protein 12;OS=Crassostrea;PE=4;SV=1
GN006653.1	sp|K1Q967|K1Q967_CRAGI	2.4e-59	234.6	100.00%	47.53%	Protein TANC1;OS=Crassostrea;PE=4;SV=1
GN006654.1	sp|K1R0C7|K1R0C7_CRAGI	2.4e-227	795.0	85.85%	77.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006656.1	sp|K1P798|K1P798_CRAGI	8.4e-32	144.8	56.96%	32.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006657.1	sp|K1PDC3|K1PDC3_CRAGI	0.0e+00	1202.6	100.00%	64.32%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN006659.1	sp|K1PSX6|K1PSX6_CRAGI	2.0e-48	198.0	98.06%	48.28%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0030246|
GN006660.1	sp|K1PSX6|K1PSX6_CRAGI	1.9e-65	254.2	94.12%	69.18%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0030246|
GN006661.1	sp|K1QDD3|K1QDD3_CRAGI	1.1e-203	714.9	98.01%	81.04%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN006662.1	sp|K1PLC5|K1PLC5_CRAGI	2.0e-68	265.4	93.86%	42.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN006277.1	sp|A0A210QWH8|A0A210QWH8_MIZYE	8.8e-43	180.3	95.55%	27.72%	Degenerin-like protein asic-2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005272|
GN006663.1	sp|K1PSX6|K1PSX6_CRAGI	5.3e-150	536.2	100.00%	70.59%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0030246|
GN006664.1	sp|K1QHS8|K1QHS8_CRAGI	0.0e+00	1488.4	99.25%	92.14%	Ribonucleoside-diphosphate reductase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004748|	GO:0006260|
GN006665.1	sp|K1PVK5|K1PVK5_CRAGI	9.2e-132	475.3	100.00%	87.07%	GDT1 family protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN006667.1	sp|K1R2S0|K1R2S0_CRAGI	9.4e-27	126.3	30.68%	64.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006669.1	sp|K1PJW7|K1PJW7_CRAGI	8.9e-214	748.4	98.28%	76.32%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN006670.1	sp|K1P0H4|K1P0H4_CRAGI	1.5e-54	219.2	54.88%	55.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006278.1	sp|K1QLT0|K1QLT0_CRAGI	1.5e-71	275.4	100.00%	57.59%	Syntaxin-17;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0016021|	GO:0000149|	GO:0097352|GO:0006888|GO:0097111|
GN006671.1	sp|K1QGQ1|K1QGQ1_CRAGI	1.2e-46	193.0	99.49%	32.02%	Prolyl 4-hydroxylase subunit alpha-1;OS=Crassostrea;PE=4;SV=1	GO:0005783|	GO:0005506|GO:0031418|GO:0016702|GO:0004656|
GN006673.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	9.7e-23	112.8	51.88%	39.84%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN006674.1	sp|K1PRW5|K1PRW5_CRAGI	9.9e-161	573.2	100.00%	47.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006675.1	sp|A0A210QRH1|A0A210QRH1_MIZYE	5.6e-175	620.5	95.74%	44.42%	Trafficking kinesin-binding protein 1;OS=Mizuhopecten;PE=4;SV=1
GN006676.1	sp|K1QCE9|K1QCE9_CRAGI	7.1e-101	372.1	100.00%	92.67%	Neurobeachin-like protein 2;OS=Crassostrea;PE=4;SV=1
GN006677.1	sp|A0A3M6TQM8|A0A3M6TQM8_9CNID	1.8e-11	74.7	88.67%	35.04%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN006279.1	sp|A0A210Q788|A0A210Q788_MIZYE	1.3e-186	658.7	97.00%	51.30%	ADAM 17-like protease;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004222|
GN006680.1	sp|K1QN95|K1QN95_CRAGI	6.5e-44	181.8	96.70%	95.40%	Myosin light chain kinase, smooth muscle;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN006681.1	sp|K1QXA8|K1QXA8_CRAGI	8.6e-158	562.0	100.00%	84.07%	Homeobox protein CDX-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006682.1	sp|A0A210QJL2|A0A210QJL2_MIZYE	1.1e-76	292.0	91.71%	70.20%	Ankyrin repeat domain-containing protein 50;OS=Mizuhopecten;PE=4;SV=1
GN006683.1	sp|K1QA38|K1QA38_CRAGI	0.0e+00	1216.1	99.84%	88.47%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006684.1	sp|K1Q306|K1Q306_CRAGI	1.5e-147	527.7	100.00%	85.27%	Pirin;OS=Crassostrea;PE=3;SV=1
GN006280.1	sp|K1PR90|K1PR90_CRAGI	1.8e-301	1040.4	83.31%	81.29%	Krev interaction trapped protein 1;OS=Crassostrea;PE=4;SV=1
GN006685.1	sp|K1R9X3|K1R9X3_CRAGI	7.5e-150	535.4	96.95%	87.72%	Pirin;OS=Crassostrea;PE=3;SV=1
GN006686.1	sp|K1PXQ4|K1PXQ4_CRAGI	7.0e-68	262.7	100.00%	63.80%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0016021|
GN006690.1	sp|K1PQ87|K1PQ87_CRAGI	6.2e-66	257.3	45.06%	64.11%	Collagen alpha-1(XIV) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0016021|
GN006691.1	sp|K1QY13|K1QY13_CRAGI	3.3e-50	204.5	87.96%	44.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006281.1	sp|K1PIE1|K1PIE1_CRAGI	0.0e+00	1540.0	100.00%	68.94%	Ankyrin-2;OS=Crassostrea;PE=4;SV=1
GN006693.1	sp|K1QY06|K1QY06_CRAGI	2.8e-209	733.4	100.00%	78.91%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN006694.1	sp|K1Q539|K1Q539_CRAGI	0.0e+00	1511.1	100.00%	84.76%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0003824|	GO:0006811|
GN006695.1	sp|A0A210QTI0|A0A210QTI0_MIZYE	1.0e-30	139.8	61.16%	41.71%	Mitochondrial assembly of ribosomal large subunit protein 1;OS=Mizuhopecten;PE=3;SV=1
GN006696.1	sp|K1PXN8|K1PXN8_CRAGI	3.3e-273	947.6	34.92%	92.99%	Pre-mRNA-splicing factor CWC22-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN006697.1	sp|K1R162|K1R162_CRAGI	7.1e-66	256.9	77.26%	47.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005525|
GN006698.1	sp|K1PQ82|K1PQ82_CRAGI	3.9e-90	337.0	77.21%	77.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006699.1	sp|K1QC98|K1QC98_CRAGI	0.0e+00	1643.6	99.90%	85.70%	Serine/threonine-protein kinase SIK2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN006700.1	sp|K1QV05|K1QV05_CRAGI	7.0e-193	679.1	97.57%	70.06%	F-box/LRR-repeat protein 2;OS=Crassostrea;PE=4;SV=1
GN006701.1	sp|K1PN21|K1PN21_CRAGI	3.3e-40	169.5	86.81%	98.72%	Tubulin beta chain;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN006702.1	sp|K1PUL3|K1PUL3_CRAGI	8.5e-279	965.3	76.05%	73.42%	Ubiquitin carboxyl-terminal hydrolase 38;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN006282.1	sp|K1PBZ7|K1PBZ7_CRAGI	7.0e-50	202.6	75.42%	78.36%	Sjoegren syndrome nuclear autoantigen 1;OS=Crassostrea;PE=4;SV=1
GN006703.1	sp|K1Q226|K1Q226_CRAGI	6.7e-225	785.8	83.49%	76.92%	Caseinolytic peptidase B-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN006704.1	sp|K1Q978|K1Q978_CRAGI	0.0e+00	2348.9	100.00%	84.93%	Phospholipid-transporting ATPase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0000287|GO:0004012|
GN006705.1	sp|K1R9G8|K1R9G8_CRAGI	3.9e-99	367.1	71.08%	73.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN006706.1	sp|K1Q232|K1Q232_CRAGI	1.6e-41	175.3	62.14%	64.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006707.1	sp|K1PUL7|K1PUL7_CRAGI	1.3e-51	209.9	34.52%	60.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006708.1	sp|K1QUV1|K1QUV1_CRAGI	0.0e+00	1107.8	97.48%	68.15%	PDZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0060271|GO:0001736|
GN006709.1	sp|K1QM48|K1QM48_CRAGI	2.9e-50	203.4	90.40%	74.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN006710.1	sp|K1QM48|K1QM48_CRAGI	3.1e-53	213.8	72.28%	73.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN006283.1	sp|A0A1W6JGL9|A0A1W6JGL9_CRAGI	9.8e-229	798.1	97.42%	92.27%	RXR2 retinoid X receptor isoform 2;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN006712.1	sp|K1QM48|K1QM48_CRAGI	2.4e-141	507.3	100.00%	70.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN006713.1	sp|K1R323|K1R323_CRAGI	3.6e-87	326.6	97.51%	75.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN006714.1	sp|K1R9P5|K1R9P5_CRAGI	2.0e-255	887.1	100.00%	82.85%	Mitochondrial import receptor subunit TOM70;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006715.1	sp|K1Q963|K1Q963_CRAGI	1.1e-148	531.9	100.00%	91.60%	Endophilin-B1;OS=Crassostrea;PE=4;SV=1	GO:0005737|
GN006716.1	sp|K1RGK9|K1RGK9_CRAGI	0.0e+00	1412.1	96.65%	77.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006717.1	sp|K1QWC9|K1QWC9_CRAGI	2.5e-110	404.1	83.93%	80.34%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006718.1	sp|K1QWC9|K1QWC9_CRAGI	2.2e-121	441.0	91.10%	69.61%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006719.1	sp|K1QWC9|K1QWC9_CRAGI	8.9e-155	552.4	100.00%	63.19%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006720.1	sp|K1QQ25|K1QQ25_CRAGI	1.1e-98	365.2	98.72%	73.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006721.1	sp|K1RMM6|K1RMM6_CRAGI	9.4e-280	969.1	97.58%	61.83%	Centromere protein J;OS=Crassostrea;PE=4;SV=1
GN006722.1	sp|K1RAB5|K1RAB5_CRAGI	6.2e-66	256.1	75.60%	77.22%	Large subunit GTPase 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN006723.1	sp|K1QQ48|K1QQ48_CRAGI	0.0e+00	1583.2	100.00%	83.32%	Serine/threonine-protein kinase N2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0017049|GO:0004674|	GO:0007165|
GN006724.1	sp|V4BBR4|V4BBR4_LOTGI	1.5e-94	352.1	93.06%	50.96%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006725.1	sp|K1QIH3|K1QIH3_CRAGI	5.0e-35	152.5	95.37%	77.67%	ATP-binding cassette sub-family G member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016887|
GN006727.1	sp|K1QAN0|K1QAN0_CRAGI	1.6e-77	294.7	84.76%	74.01%	Mammalian ependymin-related protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN006285.1	sp|K1RSN8|K1RSN8_CRAGI	2.0e-44	184.5	94.51%	56.90%	Uncharacterized protein y4mH;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN006729.1	sp|K1QQ45|K1QQ45_CRAGI	8.7e-56	223.4	93.86%	35.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006732.1	sp|K1RJB9|K1RJB9_CRAGI	2.3e-18	98.2	53.39%	76.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006733.1	sp|K1PZV8|K1PZV8_CRAGI	7.3e-22	109.8	76.42%	67.08%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN006734.1	sp|K1PZV8|K1PZV8_CRAGI	3.9e-23	114.0	82.16%	62.07%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN006735.1	sp|K1Q606|K1Q606_CRAGI	1.0e-08	65.5	88.06%	49.15%	Sex-determining protein fem-1;OS=Crassostrea;PE=4;SV=1
GN006736.1	sp|K1QXA9|K1QXA9_CRAGI	1.8e-24	119.0	32.39%	55.88%	Sortilin-related receptor;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|
GN006737.1	sp|K1QXA9|K1QXA9_CRAGI	1.3e-183	648.7	96.31%	60.93%	Sortilin-related receptor;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|
GN006738.1	sp|K1QVN7|K1QVN7_CRAGI	1.6e-153	548.1	100.00%	77.75%	DNA-binding protein D-ETS-3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN006739.1	sp|A0A2T7P211|A0A2T7P211_POMCA	1.9e-43	181.8	75.19%	49.30%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN006287.1	sp|A0A210PLJ2|A0A210PLJ2_MIZYE	4.5e-69	266.5	100.00%	56.74%	Uncharacterized protein y4mH;OS=Mizuhopecten;PE=4;SV=1	GO:0016787|
GN006740.1	sp|K1QVP0|K1QVP0_CRAGI	2.1e-36	157.9	67.55%	62.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006741.1	sp|K1QVP0|K1QVP0_CRAGI	3.5e-35	153.7	75.15%	60.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006742.1	sp|K1QVP0|K1QVP0_CRAGI	3.8e-38	163.7	67.55%	65.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006743.1	sp|K1QVP0|K1QVP0_CRAGI	8.2e-41	172.6	58.73%	76.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006744.1	sp|K1QVP0|K1QVP0_CRAGI	8.3e-62	242.3	98.40%	67.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006745.1	sp|K1QVP0|K1QVP0_CRAGI	2.3e-35	154.5	98.92%	43.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006746.1	sp|K1R962|K1R962_CRAGI	2.0e-105	387.9	84.19%	81.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007186|GO:0019236|
GN006747.1	sp|K1QK83|K1QK83_CRAGI	6.1e-70	269.2	100.00%	68.89%	Cytochrome P450 4F22;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN006749.1	sp|K1PSB4|K1PSB4_CRAGI	8.7e-64	249.6	48.56%	81.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006751.1	sp|K1P8Z2|K1P8Z2_CRAGI	3.6e-264	916.0	94.84%	91.92%	Histidyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0004821|	GO:0006427|
GN006752.1	sp|K1QF98|K1QF98_CRAGI	5.7e-118	429.5	80.07%	89.22%	Spermatogenesis-associated protein 4;OS=Crassostrea;PE=4;SV=1
GN006289.1	sp|A0A210Q1P3|A0A210Q1P3_MIZYE	6.5e-138	496.9	100.00%	55.47%	Inactive protein kinase-like protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004713|
GN006755.1	sp|K1Q2W7|K1Q2W7_CRAGI	5.0e-69	266.5	85.02%	69.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006756.1	sp|A0A210PZF4|A0A210PZF4_MIZYE	1.1e-150	539.3	62.17%	65.22%	Kelch-like protein 8;OS=Mizuhopecten;PE=4;SV=1
GN006757.1	sp|V4ALX6|V4ALX6_LOTGI	2.9e-112	410.6	87.01%	73.78%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN006758.1	sp|K1PMF1|K1PMF1_CRAGI	1.4e-190	671.4	87.76%	81.10%	Krueppel-like factor 5;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN006760.1	sp|K1PXN3|K1PXN3_CRAGI	7.9e-09	66.6	52.10%	34.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006761.1	sp|A0A1S3I398|A0A1S3I398_LINUN	1.2e-26	125.2	64.90%	59.41%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN006290.1	sp|K1QVA8|K1QVA8_CRAGI	9.7e-63	245.0	100.00%	91.43%	Mediator of RNA polymerase II transcription subunit 22;OS=Crassostrea;PE=4;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN006762.1	sp|K1RD73|K1RD73_CRAGI	2.7e-93	347.4	98.56%	65.58%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN006763.1	sp|G8XSQ6|G8XSQ6_CRAAR	1.2e-86	325.1	97.91%	73.39%	Tetraspanin;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN006764.1	sp|K1QQK6|K1QQK6_CRAGI	7.0e-100	369.0	100.00%	83.33%	Calcium-dependent protein kinase isoform 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016301|
GN006765.1	sp|A0A210PIN4|A0A210PIN4_MIZYE	2.5e-12	78.2	55.02%	37.60%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN006766.1	sp|K1QZZ7|K1QZZ7_CRAGI	1.5e-105	388.3	100.00%	71.92%	Zinc finger CCCH domain-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN006769.1	sp|K1R6S7|K1R6S7_CRAGI	6.4e-186	655.6	100.00%	91.10%	Mannose-1-phosphate guanyltransferase alpha-A;OS=Crassostrea;PE=4;SV=1	GO:0016779|	GO:0009058|
GN006770.1	sp|K1RD78|K1RD78_CRAGI	3.5e-71	273.5	95.94%	68.25%	Phosphatidylethanolamine-binding protein 4;OS=Crassostrea;PE=4;SV=1
GN006230.1	sp|K1QAK7|K1QAK7_CRAGI	5.2e-167	593.2	90.93%	70.32%	High-affinity choline transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN006291.1	sp|K1QL67|K1QL67_CRAGI	1.5e-128	464.5	99.63%	90.26%	60S ribosomal protein L7a;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0042254|
GN006771.1	sp|A0A210PH84|A0A210PH84_MIZYE	7.6e-170	602.8	99.83%	61.13%	Islet cell autoantigen 1;OS=Mizuhopecten;PE=4;SV=1	GO:0019904|
GN006772.1	sp|A0A210R6S0|A0A210R6S0_MIZYE	6.6e-42	176.8	70.24%	43.69%	Uncharacterized protein F58A4.6;OS=Mizuhopecten;PE=4;SV=1
GN006773.1	sp|K1R000|K1R000_CRAGI	2.5e-43	181.0	89.32%	49.21%	GTP-binding protein 8;OS=Crassostrea;PE=4;SV=1
GN006774.1	sp|K1R6T1|K1R6T1_CRAGI	3.2e-129	468.8	22.95%	89.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN006775.1	sp|K1QQL6|K1QQL6_CRAGI	0.0e+00	2083.1	99.83%	86.18%	Leucyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0002161|GO:0005524|GO:0004823|	GO:0006429|
GN006776.1	sp|K1R006|K1R006_CRAGI	9.3e-75	285.0	99.35%	81.70%	NudC domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN006777.1	sp|K1R6T5|K1R6T5_CRAGI	8.1e-225	785.0	99.77%	83.52%	Transcriptional adapter 2-alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN006779.1	sp|K1PZL4|K1PZL4_CRAGI	8.6e-70	270.4	32.98%	94.05%	Sperm surface protein Sp17;OS=Crassostrea;PE=4;SV=1
GN006292.1	sp|A0A210QB58|A0A210QB58_MIZYE	1.1e-20	104.4	86.67%	65.63%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN006780.1	sp|K1Q750|K1Q750_CRAGI	4.0e-100	370.5	100.00%	82.07%	Protein BTG3;OS=Crassostrea;PE=4;SV=1
GN006781.1	sp|K1QE91|K1QE91_CRAGI	9.2e-81	306.2	98.37%	64.40%	Ubiquitin carboxyl-terminal hydrolase 37;OS=Crassostrea;PE=4;SV=1	GO:0036459|	GO:0016579|
GN006782.1	sp|K1RAR5|K1RAR5_CRAGI	6.5e-188	662.1	100.00%	92.27%	Cyclin-Y-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0019901|	GO:0000079|
GN006783.1	sp|K1R482|K1R482_CRAGI	6.5e-208	728.8	98.06%	93.32%	Cleavage stimulation factor 50 kDa subunit;OS=Crassostrea;PE=4;SV=1
GN006784.1	sp|K1QXA1|K1QXA1_CRAGI	2.7e-129	467.2	79.88%	88.33%	Retinol dehydrogenase 12;OS=Crassostrea;PE=4;SV=1
GN006788.1	sp|K1QXA1|K1QXA1_CRAGI	2.4e-116	424.1	99.66%	70.89%	Retinol dehydrogenase 12;OS=Crassostrea;PE=4;SV=1
GN006789.1	sp|K1QXA1|K1QXA1_CRAGI	6.9e-125	452.6	96.24%	73.20%	Retinol dehydrogenase 12;OS=Crassostrea;PE=4;SV=1
GN006293.1	sp|K1PEP3|K1PEP3_CRAGI	5.2e-34	150.2	43.81%	68.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006790.1	sp|A0A3M6TQQ8|A0A3M6TQQ8_9CNID	6.6e-23	113.2	66.04%	40.14%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN006793.1	sp|K1PQ72|K1PQ72_CRAGI	5.6e-30	136.3	64.20%	66.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006794.1	sp|K1PXL5|K1PXL5_CRAGI	6.0e-79	299.3	98.97%	69.15%	2-aminoethanethiol dioxygenase;OS=Crassostrea;PE=4;SV=1	GO:0016702|
GN006795.1	sp|K1Q514|K1Q514_CRAGI	2.4e-89	335.1	100.00%	42.71%	F-box/LRR-repeat protein 6;OS=Crassostrea;PE=4;SV=1
GN006796.1	sp|K1QC85|K1QC85_CRAGI	3.0e-111	406.8	100.00%	88.18%	Methyltransferase-like protein 11A;OS=Crassostrea;PE=4;SV=1	GO:0008168|	GO:0006480|
GN006797.1	sp|K1QXY9|K1QXY9_CRAGI	9.1e-148	528.5	100.00%	89.04%	Exosome complex exonuclease RRP4;OS=Crassostrea;PE=4;SV=1	GO:0000178|	GO:0004527|GO:0003723|
GN006294.1	sp|K1PZL3|K1PZL3_CRAGI	7.8e-156	555.4	98.78%	78.40%	Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN006798.1	sp|K1Q523|K1Q523_CRAGI	3.7e-37	160.2	97.01%	73.29%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN006799.1	sp|K1QXZ5|K1QXZ5_CRAGI	0.0e+00	1500.3	99.59%	78.39%	Tyrosine kinase receptor Cad96Ca;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0005509|GO:0004714|
GN006800.1	sp|K1PXN1|K1PXN1_CRAGI	1.1e-62	245.4	62.20%	90.00%	Leucine-rich repeat-containing protein 58;OS=Crassostrea;PE=4;SV=1
GN006801.1	sp|K1Q532|K1Q532_CRAGI	1.8e-97	361.3	99.64%	69.06%	Peroxisomal biogenesis factor 19;OS=Crassostrea;PE=4;SV=1	GO:0005777|
GN006802.1	sp|K1QW88|K1QW88_CRAGI	4.0e-95	354.0	96.88%	52.29%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006295.1	sp|K1Q1Y0|K1Q1Y0_CRAGI	5.6e-258	896.3	98.17%	50.72%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN006803.1	sp|K1QW88|K1QW88_CRAGI	1.4e-81	308.9	92.42%	46.07%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006804.1	sp|K1QW88|K1QW88_CRAGI	2.4e-100	371.3	96.33%	54.20%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN006805.1	sp|A0A1C9U2W6|A0A1C9U2W6_MIZYE	3.0e-270	936.4	96.23%	75.26%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN006806.1	sp|K1R9P9|K1R9P9_CRAGI	3.8e-227	792.7	98.84%	91.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005741|	GO:0035694|
GN006807.1	sp|K1QW83|K1QW83_CRAGI	3.1e-308	1062.8	95.08%	81.33%	Serine/threonine-protein kinase DCLK1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|	GO:0035556|
GN006808.1	sp|K1QM53|K1QM53_CRAGI	2.0e-126	458.4	87.86%	53.63%	Disrupted in renal carcinoma protein 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN006296.1	sp|K1PXB3|K1PXB3_CRAGI	1.7e-202	711.1	97.55%	87.11%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN006809.1	sp|K1PDB8|K1PDB8_CRAGI	8.0e-203	712.6	85.14%	57.74%	Kelch-like protein 26;OS=Crassostrea;PE=4;SV=1
GN006810.1	sp|K1QDC3|K1QDC3_CRAGI	3.8e-270	936.0	99.83%	76.72%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006811.1	sp|K1QDC3|K1QDC3_CRAGI	4.4e-173	613.2	99.12%	68.14%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006812.1	sp|K1QDC3|K1QDC3_CRAGI	8.7e-243	845.1	99.66%	69.55%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006813.1	sp|K1QT08|K1QT08_CRAGI	8.3e-73	278.5	96.64%	95.10%	TBC1 domain family member 19;OS=Crassostrea;PE=4;SV=1
GN006815.1	sp|K1RFA5|K1RFA5_CRAGI	1.8e-52	211.5	98.62%	52.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN006816.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	3.4e-35	153.7	96.95%	50.93%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN006817.1	sp|A0A210PJS3|A0A210PJS3_MIZYE	7.4e-15	85.9	77.86%	43.24%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN006818.1	sp|W4YR48|W4YR48_STRPU	9.0e-88	329.7	96.24%	40.10%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN006821.1	sp|K1PJ60|K1PJ60_CRAGI	2.5e-88	330.9	98.13%	65.92%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN006822.1	sp|K1PB94|K1PB94_CRAGI	0.0e+00	1177.2	99.51%	95.71%	ATP-binding cassette sub-family E member 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016887|
GN006823.1	sp|A0A210Q2M1|A0A210Q2M1_MIZYE	1.3e-11	74.7	88.68%	43.16%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|
GN006299.1	sp|K1QQE9|K1QQE9_CRAGI	5.0e-48	197.2	97.04%	44.85%	ADAM family mig-17;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|
GN006824.1	sp|A0A0K2TVC7|A0A0K2TVC7_LEPSM	5.6e-10	68.9	83.13%	47.06%	Papilinlike [Pelodiscus sinensis];OS=Lepeophtheirus;PE=4;SV=1	GO:0004867|
GN006826.1	sp|K1PGL8|K1PGL8_CRAGI	7.7e-27	126.3	58.53%	49.21%	ATP synthase subunits region ORF 7;OS=Crassostrea;PE=4;SV=1	GO:0030246|	GO:0007155|
GN006828.1	sp|K1QB06|K1QB06_CRAGI	6.4e-231	805.8	94.03%	66.00%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN006829.1	sp|K1PB88|K1PB88_CRAGI	2.9e-225	786.9	98.65%	65.70%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN006830.1	sp|A0A210QW27|A0A210QW27_MIZYE	2.9e-216	757.3	94.19%	75.07%	Kinesin-like protein;OS=Mizuhopecten;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN006833.1	sp|K1PLX3|K1PLX3_CRAGI	7.6e-195	685.3	98.96%	87.63%	Glycine receptor subunit alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005230|GO:0004888|
GN006834.1	sp|K1PSY0|K1PSY0_CRAGI	2.7e-43	182.6	88.56%	27.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006835.1	sp|A0A210PLE1|A0A210PLE1_MIZYE	5.4e-154	550.4	97.16%	48.86%	Sulfate anion transporter 1;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0008271|
GN006231.1	sp|K1QAK7|K1QAK7_CRAGI	6.2e-187	659.4	100.00%	71.02%	High-affinity choline transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN006301.1	sp|K1QST7|K1QST7_CRAGI	2.4e-177	628.2	67.40%	56.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006836.1	sp|K1PL17|K1PL17_CRAGI	3.3e-279	966.8	71.86%	67.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006837.1	sp|K1PE19|K1PE19_CRAGI	2.6e-53	214.2	96.08%	52.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006838.1	sp|A0A1S3HY27|A0A1S3HY27_LINUN	7.4e-48	197.2	68.60%	36.42%	uncharacterized protein LOC106158895;OS=Lingula;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN006840.1	sp|K1Q7V6|K1Q7V6_CRAGI	2.2e-212	744.6	96.93%	52.89%	von Willebrand factor A domain-containing protein 5A;OS=Crassostrea;PE=4;SV=1
GN006841.1	sp|K1Q136|K1Q136_CRAGI	8.6e-38	164.1	35.73%	44.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006842.1	sp|A0A2B4R9F6|A0A2B4R9F6_STYPI	8.4e-44	183.3	99.71%	32.18%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN006843.1	sp|K1PUL6|K1PUL6_CRAGI	1.7e-15	87.4	57.45%	71.70%	von Willebrand factor A domain-containing protein 5A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006844.1	sp|K1PUL6|K1PUL6_CRAGI	1.8e-25	120.9	66.13%	72.84%	von Willebrand factor A domain-containing protein 5A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006845.1	sp|K1PUL6|K1PUL6_CRAGI	1.7e-29	134.4	66.41%	77.38%	von Willebrand factor A domain-containing protein 5A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006302.1	sp|K1PXB8|K1PXB8_CRAGI	1.8e-57	227.6	95.71%	69.23%	A disintegrin and metalloproteinase with thrombospondin motifs 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN006846.1	sp|K1Q7V6|K1Q7V6_CRAGI	4.3e-24	116.3	93.16%	50.00%	von Willebrand factor A domain-containing protein 5A;OS=Crassostrea;PE=4;SV=1
GN006848.1	sp|K1Q7V6|K1Q7V6_CRAGI	4.4e-206	723.8	94.88%	47.97%	von Willebrand factor A domain-containing protein 5A;OS=Crassostrea;PE=4;SV=1
GN006849.1	sp|A0A2C9JS94|A0A2C9JS94_BIOGL	1.4e-42	179.1	41.50%	71.32%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006850.1	sp|K1Q9J9|K1Q9J9_CRAGI	1.3e-49	201.1	100.00%	80.87%	Sulfiredoxin;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0032542|
GN006851.1	sp|A0A2T7NMT0|A0A2T7NMT0_POMCA	4.9e-40	169.9	82.95%	56.55%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN006852.1	sp|K1Q255|K1Q255_CRAGI	1.6e-297	1027.3	99.32%	67.17%	FtsJ methyltransferase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN006853.1	sp|K1QG52|K1QG52_CRAGI	7.4e-217	758.4	100.00%	89.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006854.1	sp|K1Q7X3|K1Q7X3_CRAGI	0.0e+00	1604.0	99.18%	93.62%	Pre-mRNA-splicing factor SYF1;OS=Crassostrea;PE=4;SV=1	GO:0006396|
GN006857.1	sp|K1RET1|K1RET1_CRAGI	2.8e-52	210.3	96.05%	63.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006303.1	sp|K1PXB8|K1PXB8_CRAGI	4.5e-63	249.6	14.50%	55.32%	A disintegrin and metalloproteinase with thrombospondin motifs 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN006859.1	sp|K1QG49|K1QG49_CRAGI	9.4e-111	407.1	91.56%	65.14%	Golgin subfamily A member 1;OS=Crassostrea;PE=4;SV=1
GN006860.1	sp|D0PX87|D0PX87_CRAGI	7.1e-222	775.4	85.31%	83.29%	Cyclooxygenase;OS=Crassostrea;PE=2;SV=2	GO:0020037|GO:0004601|	GO:0006979|
GN006861.1	sp|K1P6P4|K1P6P4_CRAGI	0.0e+00	1256.1	98.57%	84.39%	Phospholipase A2;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0046872|GO:0004623|GO:0102567|GO:0102568|	GO:0009395|
GN006862.1	sp|K1PCQ2|K1PCQ2_CRAGI	0.0e+00	4023.4	100.00%	91.78%	E3 ubiquitin-protein ligase UBR4;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN006863.1	sp|K1PCQ2|K1PCQ2_CRAGI	0.0e+00	4679.0	99.86%	85.43%	E3 ubiquitin-protein ligase UBR4;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN006304.1	sp|K1PXB8|K1PXB8_CRAGI	1.1e-234	818.1	99.29%	69.63%	A disintegrin and metalloproteinase with thrombospondin motifs 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN006864.1	sp|K1PK79|K1PK79_CRAGI	3.5e-205	720.7	99.51%	51.99%	TNF receptor-associated factor 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006865.1	sp|K1PK79|K1PK79_CRAGI	2.7e-147	526.9	92.08%	88.85%	TNF receptor-associated factor 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN006866.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.4e-19	100.1	43.22%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN006867.1	sp|K1Q0J6|K1Q0J6_CRAGI	8.5e-195	685.6	100.00%	83.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005929|
GN006868.1	sp|A0A2C9M9K3|A0A2C9M9K3_BIOGL	2.1e-76	291.2	99.19%	60.41%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016491|
GN006869.1	sp|A0A2B4SVK7|A0A2B4SVK7_STYPI	2.6e-26	124.0	98.63%	39.46%	Testisin;OS=Stylophora;PE=4;SV=1	GO:0004252|
GN006870.1	sp|K1PM32|K1PM32_CRAGI	3.7e-15	89.0	18.66%	54.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006305.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	4.7e-36	157.1	91.94%	37.72%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN006871.1	sp|K1PEN0|K1PEN0_CRAGI	1.6e-34	150.6	100.00%	78.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006872.1	sp|K1QET0|K1QET0_CRAGI	3.2e-33	149.1	15.42%	79.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006873.1	sp|K1PMB0|K1PMB0_CRAGI	8.2e-96	355.5	99.56%	81.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006874.1	sp|K1QP63|K1QP63_CRAGI	1.2e-63	248.1	99.32%	75.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006875.1	sp|K1PTS2|K1PTS2_CRAGI	4.0e-28	129.8	96.83%	57.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN006876.1	sp|K1PTS2|K1PTS2_CRAGI	2.5e-72	276.9	98.72%	83.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN006877.1	sp|K1PTS2|K1PTS2_CRAGI	2.7e-210	736.9	99.79%	74.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN006878.1	sp|K1PTS2|K1PTS2_CRAGI	8.0e-210	735.3	99.79%	73.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN006879.1	sp|K1PTS2|K1PTS2_CRAGI	2.7e-210	736.9	99.79%	74.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN006880.1	sp|K1PTS2|K1PTS2_CRAGI	1.1e-130	472.2	74.47%	73.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN006306.1	sp|K1PXB8|K1PXB8_CRAGI	3.2e-23	116.3	9.26%	74.68%	A disintegrin and metalloproteinase with thrombospondin motifs 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN006881.1	sp|K1PEM0|K1PEM0_CRAGI	1.1e-48	198.0	100.00%	92.66%	Ubiquitin-like modifier-activating enzyme 5;OS=Crassostrea;PE=4;SV=1	GO:0008641|
GN006882.1	sp|K1P8H3|K1P8H3_CRAGI	0.0e+00	1768.4	32.27%	70.93%	Histone-lysine N-methyltransferase SETD2;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0005634|	GO:0018024|	GO:0006355|
GN006883.1	sp|A0A194AJY7|A0A194AJY7_PINFU	2.0e-45	187.2	92.50%	82.73%	Putative eukaryotic translation initiation factor 1-like protein;OS=Pinctada;PE=4;SV=1	GO:0003743|
GN006884.1	sp|K1PMA3|K1PMA3_CRAGI	5.7e-133	480.7	67.92%	70.67%	Spermatogenesis-associated serine-rich protein 2;OS=Crassostrea;PE=4;SV=1
GN006885.1	sp|K1PEL2|K1PEL2_CRAGI	0.0e+00	3174.8	98.22%	88.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006886.1	sp|K1P8H0|K1P8H0_CRAGI	1.2e-35	155.6	84.19%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN006887.1	sp|K1PUN0|K1PUN0_CRAGI	0.0e+00	1466.4	99.60%	73.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006888.1	sp|K1Q297|K1Q297_CRAGI	1.5e-19	101.7	84.62%	34.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006889.1	sp|A0A2G8KBF3|A0A2G8KBF3_STIJA	1.9e-10	71.2	97.89%	33.79%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN006307.1	sp|K1PXB8|K1PXB8_CRAGI	9.6e-90	337.4	23.21%	69.20%	A disintegrin and metalloproteinase with thrombospondin motifs 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN006891.1	sp|K1Q055|K1Q055_CRAGI	8.5e-30	136.0	52.63%	76.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006892.1	sp|K1PJI7|K1PJI7_CRAGI	4.1e-94	352.8	100.00%	29.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN006893.1	sp|A0A210PIN1|A0A210PIN1_MIZYE	4.7e-93	347.1	96.74%	47.91%	Influenza virus NS1A-binding protein-like;OS=Mizuhopecten;PE=4;SV=1
GN006895.1	sp|K1R6J1|K1R6J1_CRAGI	1.5e-34	151.8	94.68%	51.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN006896.1	sp|K1PYI4|K1PYI4_CRAGI	6.1e-18	94.7	100.00%	96.15%	Sjoegren syndrome nuclear autoantigen 1;OS=Crassostrea;PE=4;SV=1
GN006897.1	sp|K1Q5G2|K1Q5G2_CRAGI	2.3e-50	204.1	100.00%	63.64%	Fibrinolytic enzyme, isozyme C;OS=Crassostrea;PE=4;SV=1	GO:0004252|	GO:0006915|GO:0051092|GO:0042981|
GN006900.1	sp|K1PGW7|K1PGW7_CRAGI	4.9e-95	353.2	96.03%	66.30%	Transmembrane protein 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0003700|GO:0043565|
GN006901.1	sp|A0A1J0M5P7|A0A1J0M5P7_9BIVA	8.1e-29	132.5	100.00%	58.72%	Homeobox parahox xlox;OS=Nucula;PE=2;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006902.1	sp|K1PVZ4|K1PVZ4_CRAGI	7.3e-115	419.1	100.00%	78.34%	GS homeobox 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN006904.1	sp|V4A8A4|V4A8A4_LOTGI	1.8e-18	98.2	57.06%	47.00%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN006905.1	sp|K1Q2R3|K1Q2R3_CRAGI	0.0e+00	1230.7	90.05%	80.76%	Glutamate receptor, ionotropic kainate 3;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN006906.1	sp|A0A1E1X121|A0A1E1X121_9ACAR	6.9e-23	112.8	64.12%	44.44%	Uncharacterized protein;OS=Amblyomma;PE=2;SV=1	GO:0003677|
GN006907.1	sp|A0A131XQ81|A0A131XQ81_IXORI	1.5e-49	203.0	91.62%	31.15%	Putative is4eu-1 dr;OS=Ixodes;PE=2;SV=1	GO:0008270|
GN006908.1	sp|K1QNL6|K1QNL6_CRAGI	0.0e+00	1355.5	99.88%	83.81%	Glutamate receptor 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN006909.1	sp|K1PNC6|K1PNC6_CRAGI	4.2e-276	956.4	100.00%	84.88%	Armadillo repeat-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN008676.1	sp|K1QTS7|K1QTS7_CRAGI	7.7e-20	102.8	69.40%	44.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008737.1	sp|A0A210QD90|A0A210QD90_MIZYE	7.2e-68	263.8	97.23%	32.00%	UDP-glucuronosyltransferase 1-2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016758|
GN009364.1	sp|K1P6P8|K1P6P8_CRAGI	3.6e-283	979.2	100.00%	88.43%	Sphingosine-1-phosphate lyase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016831|GO:0030170|	GO:0019752|
GN009365.1	sp|K1RHG5|K1RHG5_CRAGI	0.0e+00	1107.8	95.88%	68.66%	Solute carrier organic anion transporter family member;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN009366.1	sp|W4XIE7|W4XIE7_STRPU	7.3e-35	154.8	12.95%	70.00%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0016021|	GO:0005044|
GN009367.1	sp|J9Q4M8|J9Q4M8_OSTED	1.1e-25	122.1	42.68%	88.41%	Membrane-spanning 4 domains subfamily A member 14;OS=Ostrea;PE=2;SV=1
GN009371.1	sp|K1QHN7|K1QHN7_CRAGI	0.0e+00	2330.8	99.72%	77.80%	Nuclear receptor coactivator 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0030374|GO:0046983|	GO:0006355|
GN008738.1	sp|U5HKA5|U5HKA5_OSTED	9.6e-87	325.5	67.77%	95.71%	Omega glutathione S transferase;OS=Ostrea;PE=2;SV=1	GO:0005737|	GO:0004364|
GN009372.1	sp|K1R8P1|K1R8P1_CRAGI	7.6e-93	346.7	99.12%	34.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009373.1	sp|K1PHB8|K1PHB8_CRAGI	8.7e-99	365.9	100.00%	70.12%	SAP30-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0006355|
GN009375.1	sp|K1QIG8|K1QIG8_CRAGI	4.2e-131	473.4	85.80%	71.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009376.1	sp|K1PAX1|K1PAX1_CRAGI	0.0e+00	1931.8	99.93%	84.24%	Kinesin-like protein KIF27;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN009377.1	sp|K1QH36|K1QH36_CRAGI	2.0e-297	1026.9	90.44%	88.34%	Axonemal 84 kDa protein;OS=Crassostrea;PE=4;SV=1
GN009378.1	sp|A0A2T7PJZ5|A0A2T7PJZ5_POMCA	2.9e-184	651.0	95.38%	54.99%	Kinesin-like protein;OS=Pomacea;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN009379.1	sp|K1PQ28|K1PQ28_CRAGI	3.4e-101	374.0	79.83%	67.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009380.1	sp|K1PHB2|K1PHB2_CRAGI	1.0e-174	618.2	98.55%	87.06%	Integrin-alpha FG-GAP repeat-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0007229|
GN009381.1	sp|K1PAW6|K1PAW6_CRAGI	1.0e-127	461.8	99.66%	75.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009382.1	sp|K1PAW6|K1PAW6_CRAGI	4.7e-136	489.6	99.66%	79.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009383.1	sp|K1QP17|K1QP17_CRAGI	1.0e-171	609.0	77.62%	80.78%	Caprin-1;OS=Crassostrea;PE=4;SV=1
GN009385.1	sp|K1Q357|K1Q357_CRAGI	1.8e-231	807.4	97.33%	74.02%	Putative cytochrome P450 12b2, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN009386.1	sp|K1PNP8|K1PNP8_CRAGI	6.5e-115	420.6	98.19%	61.51%	SPT2-like protein;OS=Crassostrea;PE=4;SV=1
GN009390.1	sp|A0A210PZ62|A0A210PZ62_MIZYE	5.0e-118	430.6	82.78%	45.94%	Poly [ADP-ribose] polymerase;OS=Mizuhopecten;PE=4;SV=1	GO:0003950|
GN009391.1	sp|K1QP21|K1QP21_CRAGI	2.4e-189	667.5	100.00%	61.98%	Ferredoxin-fold anticodon-binding domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN009392.1	sp|K1Q354|K1Q354_CRAGI	1.1e-219	769.6	98.74%	39.89%	Proline-rich protein 12;OS=Crassostrea;PE=4;SV=1
GN008739.1	sp|K1PYG2|K1PYG2_CRAGI	4.1e-281	972.6	97.58%	71.21%	Acyl-coenzyme A oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005777|	GO:0003997|GO:0071949|	GO:0006635|
GN009393.1	sp|K1QP17|K1QP17_CRAGI	6.9e-198	696.0	79.64%	81.80%	Caprin-1;OS=Crassostrea;PE=4;SV=1
GN009394.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN009395.1	sp|K1PW95|K1PW95_CRAGI	1.1e-229	801.6	95.95%	76.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009396.1	sp|A0A182PHG0|A0A182PHG0_9DIPT	8.3e-10	70.1	47.45%	29.01%	Uncharacterized protein;OS=Anopheles;PE=4;SV=1	GO:0003676|
GN009398.1	sp|K1Q345|K1Q345_CRAGI	2.3e-44	185.7	61.97%	38.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008740.1	sp|A0A1Y1MNG4|A0A1Y1MNG4_PHOPY	4.3e-39	166.8	90.71%	45.45%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN009399.1	sp|A0A0P4W9K7|A0A0P4W9K7_9EUCA	3.4e-60	238.8	42.19%	38.51%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN009400.1	sp|K1PXM5|K1PXM5_CRAGI	9.4e-61	240.4	92.64%	36.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009401.1	sp|K1REQ9|K1REQ9_CRAGI	7.8e-17	94.0	16.71%	60.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008741.1	sp|K1Q5Z4|K1Q5Z4_CRAGI	1.1e-105	389.0	83.01%	60.60%	G2/M phase-specific E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN009402.1	sp|K1Q434|K1Q434_CRAGI	2.1e-47	195.3	50.59%	55.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009405.1	sp|V4B1F1|V4B1F1_LOTGI	6.1e-42	176.0	96.82%	49.23%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005506|GO:0031418|GO:0016705|
GN009406.1	sp|K1S0B6|K1S0B6_CRAGI	1.4e-221	774.6	96.89%	69.31%	Low-density lipoprotein receptor-related protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009407.1	sp|K1QV29|K1QV29_CRAGI	2.9e-95	353.6	99.06%	80.86%	Ras-related protein Rab-20;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN009411.1	sp|R7VED2|R7VED2_CAPTE	4.5e-48	197.2	89.74%	42.04%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN009412.1	sp|K1PZN3|K1PZN3_CRAGI	1.3e-89	337.0	48.42%	40.43%	Protein G7c;OS=Crassostrea;PE=4;SV=1
GN009413.1	sp|A0A210PQS2|A0A210PQS2_MIZYE	4.5e-77	294.3	87.89%	43.92%	Orexin receptor type 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009415.1	sp|A0A210PVW4|A0A210PVW4_MIZYE	2.1e-178	630.9	99.16%	66.60%	Methionine--tRNA ligase, cytoplasmic;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004825|	GO:0006431|
GN009416.1	sp|K1QJP2|K1QJP2_CRAGI	6.1e-17	93.6	52.30%	37.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009417.1	sp|K1PNX0|K1PNX0_CRAGI	5.3e-104	382.9	82.40%	83.90%	Methionyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004825|	GO:0006431|
GN009418.1	sp|K1PNX0|K1PNX0_CRAGI	8.2e-98	362.5	84.64%	75.85%	Methionyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004825|	GO:0006431|
GN009419.1	sp|K1Q9T1|K1Q9T1_CRAGI	0.0e+00	1401.0	99.75%	45.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008743.1	sp|K1PYG2|K1PYG2_CRAGI	0.0e+00	1107.4	99.25%	79.19%	Acyl-coenzyme A oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005777|	GO:0003997|GO:0071949|	GO:0006635|
GN009420.1	sp|K1PZI1|K1PZI1_CRAGI	1.1e-133	482.6	63.20%	63.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009422.1	sp|A0A0G3ZAP7|A0A0G3ZAP7_MYTGA	4.8e-28	129.8	87.16%	50.00%	MgCIKSL;OS=Mytilus;PE=2;SV=1	GO:0007165|
GN009423.1	sp|A0A210QGX2|A0A210QGX2_MIZYE	3.8e-27	128.3	97.04%	33.49%	Adapter protein CIKS;OS=Mizuhopecten;PE=4;SV=1
GN009424.1	sp|K1Q3U7|K1Q3U7_CRAGI	5.2e-167	592.4	100.00%	95.96%	CCR4-NOT transcription complex subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0030014|	GO:0003676|GO:0004535|
GN009425.1	sp|K1QEU7|K1QEU7_CRAGI	1.1e-45	188.7	89.47%	57.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009426.1	sp|K1QLH3|K1QLH3_CRAGI	2.0e-150	537.7	82.25%	86.89%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008744.1	sp|K1Q0A5|K1Q0A5_CRAGI	3.7e-43	179.9	98.54%	61.94%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN009427.1	sp|K1PZI3|K1PZI3_CRAGI	0.0e+00	1505.0	100.00%	89.18%	SWI/SNF complex subunit SMARCC2;OS=Crassostrea;PE=4;SV=1	GO:0016514|	GO:0003677|	GO:0043044|
GN009428.1	sp|A0A2B4STW4|A0A2B4STW4_STYPI	4.2e-20	104.4	44.44%	44.53%	Zinc finger protein 862;OS=Stylophora;PE=4;SV=1
GN009429.1	sp|K1QFZ6|K1QFZ6_CRAGI	5.3e-25	120.2	50.00%	48.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009430.1	sp|A0A0A1UA62|A0A0A1UA62_ENTIV	1.8e-42	179.1	95.38%	34.03%	ATP-dependent DNA helicase;OS=Entamoeba;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN009432.1	sp|K1RXD0|K1RXD0_CRAGI	1.2e-121	441.4	100.00%	90.57%	Homeobox protein LOX2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN009433.1	sp|K1RHX0|K1RHX0_CRAGI	1.7e-111	407.9	73.33%	95.19%	Homeobox protein Hox-B7;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN009437.1	sp|K1QVS8|K1QVS8_CRAGI	1.4e-10	70.5	100.00%	54.24%	Poly [ADP-ribose] polymerase 14;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN009438.1	sp|K1PLC5|K1PLC5_CRAGI	9.5e-26	122.1	93.66%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009440.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	3.4e-86	324.3	99.23%	41.20%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN009441.1	sp|K1PA93|K1PA93_CRAGI	1.2e-84	318.9	99.70%	49.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|
GN009443.1	sp|A0A210PC41|A0A210PC41_MIZYE	3.8e-81	307.0	99.23%	59.35%	Homeobox protein Hox-A5;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0007275|
GN009444.1	sp|K1QFQ3|K1QFQ3_CRAGI	3.5e-100	370.2	100.00%	94.38%	Homeobox protein Hox-B4a;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0007275|
GN009445.1	sp|K1QNR4|K1QNR4_CRAGI	5.7e-137	493.0	100.00%	74.38%	Homeobox protein HOX3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0007275|
GN008746.1	sp|K1PWD8|K1PWD8_CRAGI	5.8e-32	146.0	22.74%	37.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009447.1	sp|K1QFQ0|K1QFQ0_CRAGI	1.2e-192	678.3	100.00%	73.91%	Homeobox protein Hox-A2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN009449.1	sp|A0A210PC74|A0A210PC74_MIZYE	2.1e-99	367.9	100.00%	65.26%	Homeobox protein Hox-A1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN009450.1	sp|K1QWF9|K1QWF9_CRAGI	1.1e-35	155.6	90.91%	43.58%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009451.1	sp|K1QK79|K1QK79_CRAGI	3.2e-33	147.1	84.05%	50.36%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009453.1	sp|K1QDV9|K1QDV9_CRAGI	9.4e-96	355.9	100.00%	63.56%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009454.1	sp|K1Q6E9|K1Q6E9_CRAGI	0.0e+00	1252.3	99.47%	69.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009455.1	sp|K1PZ62|K1PZ62_CRAGI	2.2e-245	853.6	100.00%	82.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009456.1	sp|K1QEG2|K1QEG2_CRAGI	0.0e+00	1464.1	100.00%	71.93%	Beta-mannosidase;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0005975|
GN009457.1	sp|K1RHV5|K1RHV5_CRAGI	1.8e-20	105.1	97.16%	29.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN009458.1	sp|K1Q6E2|K1Q6E2_CRAGI	8.0e-36	154.8	100.00%	85.88%	PDZ and LIM domain protein 1;OS=Crassostrea;PE=4;SV=1
GN008748.1	sp|K1QBY4|K1QBY4_CRAGI	3.5e-112	409.8	100.00%	94.17%	RNA-binding protein 24-A;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN009460.1	sp|K1PVC6|K1PVC6_CRAGI	0.0e+00	1191.4	100.00%	75.60%	Protein hunchback;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009462.1	sp|K1P915|K1P915_CRAGI	4.9e-131	473.0	89.91%	80.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009463.1	sp|A0A210QK78|A0A210QK78_MIZYE	3.5e-60	236.9	97.31%	63.89%	HD domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0002953|
GN009464.1	sp|J9Q544|J9Q544_OSTED	7.2e-93	345.5	100.00%	90.16%	Mitochondrial ribosomal protein S28;OS=Ostrea;PE=2;SV=1	GO:0005840|
GN009465.1	sp|K1PMZ7|K1PMZ7_CRAGI	1.4e-149	534.6	98.12%	78.59%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008107|	GO:0005975|GO:0006486|
GN009466.1	sp|K1QDT8|K1QDT8_CRAGI	1.0e-09	67.8	64.71%	60.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009467.1	sp|K1QFC1|K1QFC1_CRAGI	3.5e-270	936.0	98.70%	83.24%	Sodium-and chloride-dependent GABA transporter ine;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|GO:0005328|
GN009468.1	sp|K1QFC1|K1QFC1_CRAGI	5.5e-95	352.8	100.00%	71.79%	Sodium-and chloride-dependent GABA transporter ine;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|GO:0005328|
GN009470.1	sp|K1Q6U9|K1Q6U9_CRAGI	5.2e-307	1058.5	100.00%	83.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN009472.1	sp|V3ZTK4|V3ZTK4_LOTGI	1.2e-53	215.7	74.62%	60.51%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN009473.1	sp|K1RIZ3|K1RIZ3_CRAGI	8.2e-219	765.0	97.36%	89.90%	Bone morphogenetic protein 7;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008083|
GN009474.1	sp|K1QZE3|K1QZE3_CRAGI	5.2e-170	602.4	100.00%	89.58%	UPF0554 protein C2orf43-like protein;OS=Crassostrea;PE=4;SV=1
GN009475.1	sp|K1QSL7|K1QSL7_CRAGI	0.0e+00	1464.1	100.00%	84.11%	V-type proton ATPase subunit a;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0000220|	GO:0015078|	GO:0015991|
GN009476.1	sp|K1QK64|K1QK64_CRAGI	2.8e-118	430.6	91.93%	67.12%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN009477.1	sp|K1QP27|K1QP27_CRAGI	1.5e-185	655.2	99.85%	56.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009478.1	sp|K1R8I1|K1R8I1_CRAGI	3.1e-84	317.4	97.92%	56.54%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN009479.1	sp|K1QMM9|K1QMM9_CRAGI	1.5e-54	219.5	33.75%	65.03%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016888|
GN009481.1	sp|K1R8I4|K1R8I4_CRAGI	4.7e-33	147.9	50.24%	52.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009482.1	sp|A0A210PSN0|A0A210PSN0_MIZYE	2.9e-22	112.1	78.99%	29.30%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009483.1	sp|A0A210PLN9|A0A210PLN9_MIZYE	1.0e-53	216.1	93.62%	39.79%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009484.1	sp|V3ZEJ5|V3ZEJ5_LOTGI	1.4e-131	476.9	50.04%	42.67%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0016758|
GN009485.1	sp|K1QGQ4|K1QGQ4_CRAGI	1.1e-225	788.1	100.00%	81.03%	Uridine 5'-monophosphate synthase;OS=Crassostrea;PE=3;SV=1	GO:0004588|GO:0004590|	GO:0006207|GO:0044205|GO:0009116|
GN009486.1	sp|K1QN72|K1QN72_CRAGI	3.5e-51	206.5	92.31%	93.33%	DNA-directed RNA polymerase II subunit RPB4;OS=Crassostrea;PE=4;SV=1	GO:0030880|	GO:0003899|GO:0000166|	GO:0006352|
GN009488.1	sp|K1Q8L8|K1Q8L8_CRAGI	3.4e-16	92.4	65.78%	28.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009489.1	sp|A0A210QDU1|A0A210QDU1_MIZYE	2.5e-43	180.3	100.00%	59.84%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009490.1	sp|K1QN79|K1QN79_CRAGI	7.2e-75	285.4	96.84%	89.47%	40S ribosomal protein S11;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN009492.1	sp|V3ZW02|V3ZW02_LOTGI	1.0e-43	182.2	72.73%	56.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0015232|
GN009493.1	sp|K1QVE8|K1QVE8_CRAGI	1.2e-265	921.0	100.00%	83.42%	Phosphoacetylglucosamine mutase;OS=Crassostrea;PE=3;SV=1	GO:0000287|GO:0004610|	GO:0005975|GO:0006048|
GN009494.1	sp|K1PK84|K1PK84_CRAGI	1.4e-95	354.8	100.00%	72.96%	Oxidoreductase HTATIP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008751.1	sp|V4APF4|V4APF4_LOTGI	1.1e-60	240.0	91.87%	33.33%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN009495.1	sp|A0A1S3JFN7|A0A1S3JFN7_LINUN	6.8e-81	307.0	99.57%	39.11%	uncharacterized protein LOC106172813;OS=Lingula;PE=4;SV=1
GN009496.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	1.1e-107	396.0	84.06%	50.39%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN009497.1	sp|K1R518|K1R518_CRAGI	6.1e-104	382.9	100.00%	72.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009498.1	sp|K1QQ63|K1QQ63_CRAGI	2.2e-130	471.5	97.56%	50.52%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN008752.1	sp|V4APF4|V4APF4_LOTGI	2.8e-55	221.9	93.91%	33.49%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN009502.1	sp|K1R2J3|K1R2J3_CRAGI	7.9e-32	144.4	23.73%	49.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009503.1	sp|A0A210QT29|A0A210QT29_MIZYE	1.4e-11	76.3	85.80%	25.94%	Glucose-dependent insulinotropic receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009504.1	sp|K1QSM4|K1QSM4_CRAGI	7.6e-40	169.9	90.77%	48.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0006919|GO:0006915|
GN009505.1	sp|K1RDJ5|K1RDJ5_CRAGI	6.6e-83	312.4	99.47%	75.00%	Very long-chain acyl-CoA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN008753.1	sp|V4APF4|V4APF4_LOTGI	2.1e-64	252.3	93.13%	34.90%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN009506.1	sp|K1RDJ5|K1RDJ5_CRAGI	5.3e-270	935.6	100.00%	69.22%	Very long-chain acyl-CoA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN009509.1	sp|K1R9L5|K1R9L5_CRAGI	7.8e-157	559.3	93.04%	59.23%	Glucosylceramidase;OS=Crassostrea;PE=3;SV=1	GO:0004348|	GO:0006665|
GN009510.1	sp|K1R638|K1R638_CRAGI	2.4e-146	524.2	100.00%	69.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009511.1	sp|K1RQN4|K1RQN4_CRAGI	7.5e-136	488.8	98.19%	87.08%	Placental protein 11;OS=Crassostrea;PE=4;SV=1	GO:0004521|GO:0030247|GO:0005044|	GO:0006955|
GN009512.1	sp|K1R638|K1R638_CRAGI	3.7e-34	149.8	91.13%	46.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008754.1	sp|K1QVX2|K1QVX2_CRAGI	1.5e-57	228.4	67.11%	72.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009513.1	sp|K1Q405|K1Q405_CRAGI	6.0e-66	257.7	76.79%	35.54%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN009514.1	sp|K1QQ63|K1QQ63_CRAGI	1.3e-122	445.7	97.37%	49.38%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009515.1	sp|K1QSS5|K1QSS5_CRAGI	4.4e-154	551.6	57.82%	56.44%	PHD finger protein 20-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0071339|	GO:0046872|GO:0003676|	GO:0006355|
GN009516.1	sp|K1QSS5|K1QSS5_CRAGI	1.6e-46	191.0	85.71%	79.83%	PHD finger protein 20-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0071339|	GO:0046872|GO:0003676|	GO:0006355|
GN009517.1	sp|K1P8T7|K1P8T7_CRAGI	9.3e-170	602.1	100.00%	69.91%	Fibrillin-3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009518.1	sp|K1P8T7|K1P8T7_CRAGI	1.6e-169	601.3	100.00%	69.67%	Fibrillin-3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009520.1	sp|K1P8T7|K1P8T7_CRAGI	6.5e-96	355.9	100.00%	72.65%	Fibrillin-3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN008755.1	sp|K1Q8Q7|K1Q8Q7_CRAGI	0.0e+00	1880.5	80.43%	75.00%	Xanthine dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0051537|GO:0009055|GO:0071949|GO:0005506|
GN009521.1	sp|K1QZR7|K1QZR7_CRAGI	7.3e-28	131.0	94.05%	35.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009522.1	sp|K1P8T7|K1P8T7_CRAGI	3.2e-126	457.2	98.36%	58.55%	Fibrillin-3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009523.1	sp|K1RKI0|K1RKI0_CRAGI	8.3e-75	285.4	91.76%	75.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009524.1	sp|A0A1S3I117|A0A1S3I117_LINUN	1.9e-113	415.2	92.49%	46.15%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN009526.1	sp|K1P8T7|K1P8T7_CRAGI	7.0e-217	760.4	99.17%	71.17%	Fibrillin-3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009527.1	sp|K1Q5C4|K1Q5C4_CRAGI	4.3e-60	238.0	100.00%	32.23%	Calmodulin-like protein 12;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009528.1	sp|K1QF50|K1QF50_CRAGI	3.3e-153	547.0	96.47%	69.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008756.1	sp|D6BJL2|D6BJL2_OSTED	3.8e-257	892.5	100.00%	95.88%	Elongation factor 1-alpha;OS=Ostrea;PE=2;SV=1	GO:0005525|GO:0003924|GO:0003746|
GN009529.1	sp|K1PMQ4|K1PMQ4_CRAGI	3.6e-250	870.2	93.01%	59.98%	Microtubule-associated serine/threonine-protein kinase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016272|	GO:0005524|GO:0004674|GO:0051082|	GO:0006457|
GN009530.1	sp|K1R162|K1R162_CRAGI	3.2e-40	171.4	75.38%	39.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005525|
GN009533.1	sp|K1PMQ4|K1PMQ4_CRAGI	3.0e-68	263.5	96.89%	90.97%	Microtubule-associated serine/threonine-protein kinase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016272|	GO:0005524|GO:0004674|GO:0051082|	GO:0006457|
GN009534.1	sp|K1PEY6|K1PEY6_CRAGI	1.1e-239	835.5	98.32%	64.70%	Tax1-binding protein 1-like protein B;OS=Crassostrea;PE=4;SV=1
GN009535.1	sp|K1P8T5|K1P8T5_CRAGI	4.9e-161	572.8	94.40%	89.97%	Glycerol-3-phosphate dehydrogenase [NAD(+)];OS=Crassostrea;PE=3;SV=1	GO:0009331|	GO:0004367|GO:0051287|GO:0042803|	GO:0005975|GO:0046168|
GN009536.1	sp|K1QF46|K1QF46_CRAGI	8.0e-140	502.3	87.76%	76.79%	Isopenicillin N synthetase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN008757.1	sp|A0A2G8KA18|A0A2G8KA18_STIJA	2.8e-27	128.3	73.36%	34.38%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0004190|
GN009537.1	sp|K1P0H4|K1P0H4_CRAGI	1.9e-39	167.5	83.33%	70.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009538.1	sp|K1QU53|K1QU53_CRAGI	0.0e+00	1763.0	96.07%	91.04%	NAD(P) transhydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008746|	GO:1902600|
GN009538.1	sp|K1QU53|K1QU53_CRAGI	2.7e-117	429.1	22.73%	91.74%	NAD(P) transhydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008746|	GO:1902600|
GN009539.1	sp|K1RZE2|K1RZE2_CRAGI	2.1e-260	903.3	99.78%	95.72%	Isocitrate dehydrogenase [NADP];OS=Crassostrea;PE=3;SV=1	GO:0004450|GO:0000287|GO:0051287|	GO:0006102|GO:0006099|
GN009540.1	sp|K1RG24|K1RG24_CRAGI	1.6e-126	459.5	61.20%	45.01%	Doublecortin domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN009541.1	sp|K1RZD4|K1RZD4_CRAGI	0.0e+00	1094.3	87.00%	85.96%	ATP-dependent RNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0005524|GO:0004004|GO:0003723|
GN009542.1	sp|K1QU49|K1QU49_CRAGI	6.1e-95	353.2	97.94%	59.01%	Methyl-CpG-binding domain protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN009543.1	sp|K1QU49|K1QU49_CRAGI	6.1e-95	353.2	97.94%	59.01%	Methyl-CpG-binding domain protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN009544.1	sp|K1RZD4|K1RZD4_CRAGI	4.6e-302	1042.3	86.96%	85.62%	ATP-dependent RNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0005524|GO:0004004|GO:0003723|
GN009545.1	sp|K1PGR1|K1PGR1_CRAGI	7.8e-58	230.7	52.15%	43.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008759.1	sp|A0A1S3I398|A0A1S3I398_LINUN	5.8e-26	122.9	66.22%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN009550.1	sp|K1QTD7|K1QTD7_CRAGI	1.4e-14	85.1	45.91%	54.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009551.1	sp|K1PPG4|K1PPG4_CRAGI	4.0e-52	211.1	54.64%	58.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009552.1	sp|K1QY88|K1QY88_CRAGI	4.3e-117	427.2	90.95%	56.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN009554.1	sp|A0A1L4FR25|A0A1L4FR25_9BIVA	9.4e-69	265.8	100.00%	55.38%	GST-alpha-like protein;OS=Crassostrea;PE=2;SV=1
GN009555.1	sp|K1R6D4|K1R6D4_CRAGI	1.6e-75	288.1	99.12%	59.21%	Glutathione S-transferase A;OS=Crassostrea;PE=3;SV=1	GO:0016740|
GN008760.1	sp|K1QVX5|K1QVX5_CRAGI	0.0e+00	1159.8	100.00%	73.28%	TBC1 domain family member 5;OS=Crassostrea;PE=4;SV=1
GN009556.1	sp|K1QDQ7|K1QDQ7_CRAGI	2.9e-60	237.7	66.16%	65.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009557.1	sp|K1RB02|K1RB02_CRAGI	7.1e-68	262.3	100.00%	75.29%	Tctex1 domain-containing protein 1-B;OS=Crassostrea;PE=4;SV=1
GN009558.1	sp|K1QQT9|K1QQT9_CRAGI	0.0e+00	1216.1	89.94%	72.93%	Suppression of tumorigenicity 5;OS=Crassostrea;PE=4;SV=1
GN009559.1	sp|K1Q3X5|K1Q3X5_CRAGI	1.6e-45	188.3	96.14%	53.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009560.1	sp|K1QBC3|K1QBC3_CRAGI	1.0e-160	572.0	91.63%	79.84%	Major egg antigen;OS=Crassostrea;PE=3;SV=1
GN009561.1	sp|A0A210QPK3|A0A210QPK3_MIZYE	3.8e-158	563.1	100.00%	75.52%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009562.1	sp|K1RNF7|K1RNF7_CRAGI	1.1e-189	668.3	87.44%	89.49%	Uncharacterized protein C22orf9-like protein;OS=Crassostrea;PE=4;SV=1
GN008761.1	sp|A0A210PVV1|A0A210PVV1_MIZYE	2.1e-48	198.0	74.21%	56.00%	Transmembrane protein 169;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009564.1	sp|A0A210QIF9|A0A210QIF9_MIZYE	7.3e-40	170.2	88.82%	33.99%	ATP-dependent DNA helicase RecQ;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|
GN009565.1	sp|K1P5G4|K1P5G4_CRAGI	2.5e-22	109.8	94.44%	77.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009566.1	sp|K1S6S9|K1S6S9_CRAGI	8.5e-38	162.2	60.00%	91.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009567.1	sp|K1RKI0|K1RKI0_CRAGI	0.0e+00	3359.3	99.41%	83.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009568.1	sp|A0A210QAU4|A0A210QAU4_MIZYE	5.6e-61	240.4	96.41%	41.93%	Biotin--protein ligase;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|
GN009569.1	sp|A0A210R1Q8|A0A210R1Q8_MIZYE	6.4e-49	200.7	84.37%	36.92%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003700|GO:0046983|	GO:0007283|
GN009570.1	sp|K1PKQ4|K1PKQ4_CRAGI	1.8e-44	186.8	34.30%	25.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009571.1	sp|K1QU80|K1QU80_CRAGI	7.7e-93	347.1	85.00%	59.64%	Formin-binding protein 4;OS=Crassostrea;PE=4;SV=1
GN009572.1	sp|K1QU80|K1QU80_CRAGI	1.6e-30	137.9	57.78%	90.91%	Formin-binding protein 4;OS=Crassostrea;PE=4;SV=1
GN009574.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN009575.1	sp|A0A1Z5L4K9|A0A1Z5L4K9_ORNMO	7.6e-11	73.2	44.60%	37.23%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0008270|
GN009577.1	sp|A0A210PEM1|A0A210PEM1_MIZYE	1.6e-80	305.1	93.49%	55.51%	Solute carrier family 25 member 51;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0022857|
GN008765.1	sp|K1RX54|K1RX54_CRAGI	1.3e-121	442.2	77.78%	65.75%	Muscle M-line assembly protein unc-89;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009579.1	sp|A0A2B4S577|A0A2B4S577_STYPI	6.2e-29	133.7	79.93%	32.89%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN009580.1	sp|K1RIW4|K1RIW4_CRAGI	5.2e-51	206.5	96.37%	56.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009581.1	sp|K1PX35|K1PX35_CRAGI	2.2e-134	485.0	66.79%	70.57%	ATP-dependent DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN009582.1	sp|A0A210Q2S4|A0A210Q2S4_MIZYE	6.6e-126	456.1	99.71%	61.65%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009583.1	sp|K1RNK4|K1RNK4_CRAGI	1.5e-31	141.4	100.00%	44.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009585.1	sp|K1PAN6|K1PAN6_CRAGI	8.0e-134	482.3	96.17%	84.11%	Cholecystokinin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008767.1	sp|K1QRF8|K1QRF8_CRAGI	2.7e-130	471.1	85.03%	73.27%	Glucocorticoid modulatory element-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003713|
GN009586.1	sp|K1QPU0|K1QPU0_CRAGI	3.5e-09	67.0	36.03%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009588.1	sp|A0A2B4RZJ3|A0A2B4RZJ3_STYPI	3.4e-17	94.4	63.32%	34.90%	Collagen alpha-4(VI) chain;OS=Stylophora;PE=4;SV=1	GO:0005581|
GN009589.1	sp|K1PHP4|K1PHP4_CRAGI	1.1e-42	177.9	81.73%	98.81%	Serine/threonine-protein kinase receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0046872|GO:0004675|
GN009591.1	sp|K1PRW8|K1PRW8_CRAGI	5.9e-91	339.7	100.00%	63.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN008768.1	sp|A0A210PZ23|A0A210PZ23_MIZYE	2.5e-263	913.7	98.91%	62.86%	Exocyst complex component 3;OS=Mizuhopecten;PE=4;SV=1	GO:0000145|	GO:0006887|
GN009594.1	sp|K1QKH0|K1QKH0_CRAGI	2.9e-27	126.7	91.43%	62.50%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN009595.1	sp|A0A1Z5L4K9|A0A1Z5L4K9_ORNMO	7.6e-11	73.2	44.60%	37.23%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0008270|
GN009596.1	sp|K1RDG7|K1RDG7_CRAGI	1.2e-89	335.1	100.00%	89.74%	U1 small nuclear ribonucleoprotein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0019013|	GO:0003723|
GN009600.1	sp|K1QD04|K1QD04_CRAGI	1.7e-122	446.0	99.64%	35.86%	Repetitive proline-rich cell wall protein 2;OS=Crassostrea;PE=4;SV=1
GN009602.1	sp|K1PSJ4|K1PSJ4_CRAGI	1.7e-169	602.1	74.21%	53.82%	Metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN009606.1	sp|K1PF60|K1PF60_CRAGI	2.1e-209	733.8	95.52%	90.84%	3-ketoacyl-CoA thiolase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN009607.1	sp|K1PUR2|K1PUR2_CRAGI	4.5e-114	417.2	76.40%	80.00%	Nucleobindin-2;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009608.1	sp|K1RN92|K1RN92_CRAGI	9.2e-167	592.0	96.77%	69.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN009610.1	sp|K1QXH8|K1QXH8_CRAGI	0.0e+00	1080.9	65.71%	71.06%	A disintegrin and metalloproteinase with thrombospondin motifs 18;OS=Crassostrea;PE=4;SV=1	GO:0004222|	GO:0007229|
GN008770.1	sp|A0A210QPM3|A0A210QPM3_MIZYE	3.9e-114	417.9	99.10%	48.21%	Leucine-rich repeat-containing protein 56;OS=Mizuhopecten;PE=4;SV=1
GN009611.1	sp|K1QW33|K1QW33_CRAGI	1.6e-33	148.3	95.60%	41.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009614.1	sp|K1PMG4|K1PMG4_CRAGI	5.6e-34	149.1	99.09%	65.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN009617.1	sp|K1QHB0|K1QHB0_CRAGI	1.3e-28	132.9	47.40%	46.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009618.1	sp|A0A210PI28|A0A210PI28_MIZYE	1.0e-89	336.3	64.87%	59.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009619.1	sp|K1QPU9|K1QPU9_CRAGI	5.7e-146	523.1	89.02%	71.87%	Voltage-gated hydrogen channel 1;OS=Crassostrea;PE=4;SV=1	GO:0005887|	GO:0030171|
GN008771.1	sp|K1R5I0|K1R5I0_CRAGI	7.9e-71	272.3	99.49%	72.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009622.1	sp|K1R0N3|K1R0N3_CRAGI	8.8e-122	443.0	98.83%	44.70%	Carboxylesterase 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN009623.1	sp|K1PQQ5|K1PQQ5_CRAGI	9.2e-24	115.5	66.67%	55.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009624.1	sp|K1PRN1|K1PRN1_CRAGI	3.0e-26	124.4	47.03%	51.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009625.1	sp|K1QF65|K1QF65_CRAGI	1.2e-147	528.5	73.54%	85.07%	Secreted frizzled-related protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0007275|GO:0016055|
GN009626.1	sp|K1PA61|K1PA61_CRAGI	5.0e-216	755.7	100.00%	86.85%	Actin-like protein 6A;OS=Crassostrea;PE=3;SV=1
GN009627.1	sp|K1PGB8|K1PGB8_CRAGI	1.3e-77	295.4	100.00%	58.84%	Protein TSSC4;OS=Crassostrea;PE=4;SV=1
GN009628.1	sp|K1PP80|K1PP80_CRAGI	0.0e+00	1820.4	98.97%	82.34%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN009630.1	sp|K1PP80|K1PP80_CRAGI	8.3e-75	286.2	54.69%	80.95%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN009631.1	sp|K1PP80|K1PP80_CRAGI	2.7e-109	400.6	97.44%	73.58%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN009632.1	sp|K1QGF7|K1QGF7_CRAGI	1.4e-22	112.5	50.94%	52.90%	Ankyrin repeat domain-containing protein 49;OS=Crassostrea;PE=4;SV=1
GN009633.1	sp|K1RDN8|K1RDN8_CRAGI	2.8e-222	776.5	98.62%	83.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009634.1	sp|K1QTC8|K1QTC8_CRAGI	1.2e-110	405.2	99.01%	70.81%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN009635.1	sp|K1QTC8|K1QTC8_CRAGI	7.8e-50	201.8	96.61%	87.61%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN009637.1	sp|K1QNT6|K1QNT6_CRAGI	4.2e-34	151.4	26.96%	63.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009639.1	sp|K1RP61|K1RP61_CRAGI	3.6e-118	430.3	95.89%	72.13%	Histamine H2 receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009640.1	sp|W4Z0S9|W4Z0S9_STRPU	8.9e-22	109.0	100.00%	40.38%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN009641.1	sp|K1PCK7|K1PCK7_CRAGI	6.3e-42	177.2	43.45%	57.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009642.1	sp|K1PCK7|K1PCK7_CRAGI	6.8e-40	170.6	46.63%	47.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009643.1	sp|K1PCK7|K1PCK7_CRAGI	5.0e-45	187.6	31.41%	70.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009644.1	sp|K1PCK7|K1PCK7_CRAGI	1.7e-55	221.5	100.00%	55.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009645.1	sp|K1R0N7|K1R0N7_CRAGI	1.3e-57	228.0	96.55%	78.42%	Putative nuclease HARBI1;OS=Crassostrea;PE=4;SV=1
GN009646.1	sp|K1P6L3|K1P6L3_CRAGI	5.7e-185	653.3	100.00%	75.15%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0005886|	GO:0043236|	GO:0007213|GO:0043113|
GN009648.1	sp|A0A0L8IAP2|A0A0L8IAP2_OCTBM	0.0e+00	1167.9	98.73%	74.56%	DNA helicase;OS=Octopus;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0003678|	GO:0006270|
GN009649.1	sp|V3ZPA1|V3ZPA1_LOTGI	3.9e-83	313.5	90.28%	70.27%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0016021|
GN008775.1	sp|K1QJX6|K1QJX6_CRAGI	1.8e-63	248.1	88.11%	63.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009652.1	sp|K1PK36|K1PK36_CRAGI	0.0e+00	1103.6	98.09%	59.72%	Protein G7c;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009653.1	sp|K1PK36|K1PK36_CRAGI	3.4e-102	377.9	95.45%	42.54%	Protein G7c;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009654.1	sp|K1PK36|K1PK36_CRAGI	3.4e-176	625.2	66.64%	39.03%	Protein G7c;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009656.1	sp|A0A210QDF8|A0A210QDF8_MIZYE	8.9e-31	139.0	86.90%	48.03%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008776.1	sp|K1QDN6|K1QDN6_CRAGI	5.1e-131	473.8	87.65%	53.92%	Protein G7c;OS=Crassostrea;PE=4;SV=1
GN009657.1	sp|A0A210R0F4|A0A210R0F4_MIZYE	4.4e-183	647.1	98.77%	48.91%	Serine/threonine-protein kinase 33;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN009658.1	sp|K1P6M6|K1P6M6_CRAGI	2.2e-13	80.9	96.06%	39.20%	Cerebellin-1;OS=Crassostrea;PE=4;SV=1
GN009659.1	sp|K1RNN3|K1RNN3_CRAGI	7.7e-212	742.3	99.65%	67.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009660.1	sp|K1S705|K1S705_CRAGI	9.1e-290	1001.1	99.28%	91.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009661.1	sp|K1RM29|K1RM29_CRAGI	1.4e-89	334.7	97.27%	74.18%	N(6)-adenine-specific DNA methyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0008168|GO:0003676|
GN009662.1	sp|K1S6S4|K1S6S4_CRAGI	2.1e-167	594.0	100.00%	83.24%	Metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0004222|GO:0008270|
GN009663.1	sp|K1QBU9|K1QBU9_CRAGI	2.7e-11	76.6	24.56%	23.67%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009664.1	sp|K1Q5B7|K1Q5B7_CRAGI	7.5e-98	362.1	100.00%	89.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0015035|
GN008778.1	sp|K1Q5L2|K1Q5L2_CRAGI	0.0e+00	1159.1	87.08%	63.40%	Protein G7c;OS=Crassostrea;PE=4;SV=1
GN009666.1	sp|A0A2B4RXT6|A0A2B4RXT6_STYPI	1.8e-10	72.8	48.85%	31.82%	Protocadherin Fat 4;OS=Stylophora;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN009667.1	sp|K1RVA8|K1RVA8_CRAGI	1.6e-77	294.7	100.00%	76.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009668.1	sp|K1RBS7|K1RBS7_CRAGI	5.6e-67	259.6	100.00%	63.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009669.1	sp|K1RKT7|K1RKT7_CRAGI	2.8e-32	144.8	35.42%	73.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009670.1	sp|K1RKT7|K1RKT7_CRAGI	2.3e-32	144.8	42.86%	73.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009671.1	sp|K1S475|K1S475_CRAGI	0.0e+00	1165.6	89.26%	72.51%	Peptidase inhibitor 16;OS=Crassostrea;PE=3;SV=1	GO:0005576|GO:0016021|	GO:0005509|	GO:0007156|
GN009672.1	sp|K1REM7|K1REM7_CRAGI	5.9e-48	197.2	48.20%	55.49%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN009673.1	sp|K1QL78|K1QL78_CRAGI	1.2e-13	81.3	79.78%	50.00%	Cytochrome P450 3A9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN009674.1	sp|C3YWQ8|C3YWQ8_BRAFL	9.4e-49	199.9	95.16%	33.79%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN009676.1	sp|K1QYX5|K1QYX5_CRAGI	3.7e-154	550.4	97.29%	53.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009677.1	sp|K1S478|K1S478_CRAGI	3.0e-94	350.9	80.17%	69.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009679.1	sp|K1R589|K1R589_CRAGI	4.0e-64	250.8	86.75%	51.81%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN009680.1	sp|K1QP68|K1QP68_CRAGI	3.2e-44	185.7	23.85%	54.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009681.1	sp|A0A210PI48|A0A210PI48_MIZYE	3.2e-96	357.5	86.61%	59.79%	Harmonin;OS=Mizuhopecten;PE=4;SV=1	GO:0051015|	GO:0007605|
GN008781.1	sp|A0A210PR19|A0A210PR19_MIZYE	9.0e-27	125.6	70.47%	58.65%	ATP-dependent DNA helicase Q-like 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN009684.1	sp|K1RW87|K1RW87_CRAGI	0.0e+00	1380.5	99.24%	65.74%	Hydantoin utilization protein A;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN009685.1	sp|A0A0L8HAD8|A0A0L8HAD8_OCTBM	2.3e-24	116.7	88.75%	80.00%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0008541|	GO:0006406|GO:0043248|
GN009686.1	sp|K1PR91|K1PR91_CRAGI	8.4e-53	214.2	92.43%	27.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008782.1	sp|A0A210Q9B3|A0A210Q9B3_MIZYE	4.4e-68	264.2	100.00%	37.50%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009688.1	sp|K1QYJ3|K1QYJ3_CRAGI	7.3e-19	100.1	29.48%	62.82%	Protein disulfide-isomerase A5;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0016853|	GO:0045454|
GN009690.1	sp|K1QYJ3|K1QYJ3_CRAGI	7.3e-19	100.1	29.48%	62.82%	Protein disulfide-isomerase A5;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0016853|	GO:0045454|
GN009692.1	sp|K1QYJ3|K1QYJ3_CRAGI	7.3e-19	100.1	29.48%	62.82%	Protein disulfide-isomerase A5;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0016853|	GO:0045454|
GN009693.1	sp|K1QF40|K1QF40_CRAGI	1.9e-49	203.0	50.23%	33.95%	Protein mab-21;OS=Crassostrea;PE=4;SV=1
GN009694.1	sp|K1QQG6|K1QQG6_CRAGI	1.1e-49	203.8	92.74%	27.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009696.1	sp|A0A3L5TRT6|A0A3L5TRT6_MYTGA	2.9e-67	261.5	76.03%	40.95%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN009697.1	sp|K1S2V5|K1S2V5_CRAGI	4.6e-248	862.8	71.08%	85.19%	N-acetylglucosamine-6-sulfatase;OS=Crassostrea;PE=4;SV=1	GO:0005764|	GO:0008449|	GO:0030203|
GN009698.1	sp|K1RJ85|K1RJ85_CRAGI	0.0e+00	1253.0	96.43%	46.57%	Hermansky-Pudlak syndrome 5 protein;OS=Crassostrea;PE=4;SV=1
GN009699.1	sp|K1PXH4|K1PXH4_CRAGI	1.6e-196	691.0	92.84%	85.79%	Fuzzy-like protein;OS=Crassostrea;PE=4;SV=1
GN009700.1	sp|K1QHM3|K1QHM3_CRAGI	4.9e-208	729.9	100.00%	73.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000981|GO:0003676|	GO:0040034|
GN009704.1	sp|A0A0K8TSK4|A0A0K8TSK4_TABBR	1.7e-47	195.7	89.08%	36.89%	Putative nuclease harbi1-like protein;OS=Tabanus;PE=2;SV=1
GN009705.1	sp|K1R7B8|K1R7B8_CRAGI	9.3e-154	548.5	100.00%	84.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009706.1	sp|K1R7B8|K1R7B8_CRAGI	2.5e-151	540.4	100.00%	84.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009707.1	sp|C3YWA3|C3YWA3_BRAFL	3.8e-71	274.2	99.72%	40.11%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN009708.1	sp|K1PBZ8|K1PBZ8_CRAGI	9.8e-57	224.9	92.54%	86.18%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN009709.1	sp|A0A2G8KTM7|A0A2G8KTM7_STIJA	4.8e-12	77.0	41.03%	41.77%	Endonuclease-reverse transcriptase;OS=Stichopus;PE=4;SV=1	GO:0004519|GO:0003964|
GN009710.1	sp|K1PDW2|K1PDW2_CRAGI	6.3e-100	369.4	72.90%	92.63%	Sodium/potassium-transporting ATPase subunit beta-1-interacting protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009711.1	sp|C3S7I7|C3S7I7_CRAGI	8.3e-62	241.9	90.28%	97.67%	Serine/threonine protein kinase 38;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004674|
GN009712.1	sp|K1QE09|K1QE09_CRAGI	1.7e-46	191.4	56.25%	96.26%	Transcription initiation factor TFIID subunit 11;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046982|GO:0003743|	GO:0006367|
GN009713.1	sp|K1PTK4|K1PTK4_CRAGI	5.0e-260	902.5	97.64%	73.33%	Nuclear receptor ROR-gamma;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN009714.1	sp|K1PLP6|K1PLP6_CRAGI	1.5e-194	684.9	82.60%	70.82%	Nuclear receptor ROR-beta;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN009715.1	sp|K1PDV8|K1PDV8_CRAGI	4.4e-92	344.0	99.75%	44.55%	Nuclear receptor ROR-gamma;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN009716.1	sp|W4ZF66|W4ZF66_STRPU	1.9e-79	302.0	94.01%	40.74%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN009718.1	sp|W4ZF66|W4ZF66_STRPU	3.0e-80	304.7	94.19%	40.26%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN008786.1	sp|K1RBG4|K1RBG4_CRAGI	7.4e-41	172.2	85.61%	63.39%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009719.1	sp|K1QE03|K1QE03_CRAGI	3.0e-51	207.2	100.00%	41.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0007165|
GN009721.1	sp|K1PTJ7|K1PTJ7_CRAGI	4.7e-235	819.3	99.62%	75.00%	Nuclear receptor ROR-alpha;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN009722.1	sp|A0A210R504|A0A210R504_MIZYE	6.0e-146	522.7	78.57%	93.07%	Vacuolar protein sorting-associated protein 26B-like;OS=Mizuhopecten;PE=4;SV=1
GN009723.1	sp|K1QYZ0|K1QYZ0_CRAGI	9.5e-63	246.1	79.03%	53.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009724.1	sp|K1QYZ0|K1QYZ0_CRAGI	9.5e-63	246.1	79.03%	53.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009725.1	sp|K1QYZ0|K1QYZ0_CRAGI	9.5e-63	246.1	79.03%	53.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008787.1	sp|K1PQH4|K1PQH4_CRAGI	1.2e-115	422.5	99.39%	45.29%	Transcription intermediary factor 1-beta;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009726.1	sp|K1QYZ0|K1QYZ0_CRAGI	9.5e-63	246.1	79.03%	53.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009728.1	sp|K1PE19|K1PE19_CRAGI	5.7e-29	133.3	95.92%	39.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008788.1	sp|K1Q8V6|K1Q8V6_CRAGI	3.7e-23	116.3	22.75%	35.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009731.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	2.6e-29	134.4	96.43%	41.97%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009733.1	sp|K1R474|K1R474_CRAGI	6.1e-291	1005.0	99.44%	84.75%	Myotubularin-related protein 9;OS=Crassostrea;PE=3;SV=1
GN009736.1	sp|A0A210Q8Y1|A0A210Q8Y1_MIZYE	9.9e-126	455.7	97.16%	62.86%	Cysteinyl leukotriene receptor 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009737.1	sp|K1R336|K1R336_CRAGI	9.6e-33	145.6	77.65%	78.63%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN008789.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	2.1e-83	315.1	81.19%	43.56%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN009738.1	sp|C3ZM17|C3ZM17_BRAFL	8.7e-14	82.4	55.41%	45.68%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003677|
GN009739.1	sp|K1PR82|K1PR82_CRAGI	5.5e-248	863.6	86.99%	51.31%	Fibrillin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0004888|	GO:0007160|
GN009740.1	sp|K1QDZ9|K1QDZ9_CRAGI	9.2e-11	72.4	38.82%	51.72%	Nucleosome-remodeling factor subunit BPTF;OS=Crassostrea;PE=4;SV=1	GO:0048188|	GO:0046872|GO:0045322|
GN008790.1	sp|K1REY6|K1REY6_CRAGI	4.7e-84	317.8	81.38%	40.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009741.1	sp|K1S449|K1S449_CRAGI	1.9e-20	105.1	56.33%	38.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009742.1	sp|K1QIX0|K1QIX0_CRAGI	1.5e-119	434.9	98.41%	66.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009743.1	sp|K1PUA1|K1PUA1_CRAGI	5.9e-228	797.7	37.59%	50.06%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009744.1	sp|K1PUA1|K1PUA1_CRAGI	0.0e+00	1154.0	24.70%	70.32%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009745.1	sp|K1RN92|K1RN92_CRAGI	3.3e-126	456.8	87.06%	86.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN009746.1	sp|K1QG61|K1QG61_CRAGI	0.0e+00	1166.0	100.00%	90.91%	Acetolactate synthase-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003824|GO:0000287|GO:0030976|
GN009747.1	sp|K1QPV4|K1QPV4_CRAGI	3.4e-251	873.6	99.66%	62.90%	Sodium-dependent glucose transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008643|GO:0055085|
GN009748.1	sp|K1QXI5|K1QXI5_CRAGI	3.9e-174	616.3	95.42%	94.28%	Major egg antigen;OS=Crassostrea;PE=3;SV=1
GN009749.1	sp|K1QG66|K1QG66_CRAGI	1.6e-97	362.1	98.56%	51.08%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN009750.1	sp|K1PMG4|K1PMG4_CRAGI	8.9e-17	90.9	100.00%	81.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN008792.1	sp|K1PUC6|K1PUC6_CRAGI	4.4e-195	686.0	96.81%	95.04%	Ras-related GTP-binding protein C;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN009753.1	sp|K1PYW5|K1PYW5_CRAGI	2.2e-119	434.9	100.00%	46.39%	Membrane-associated transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN009754.1	sp|K1QJA9|K1QJA9_CRAGI	5.8e-127	460.7	96.14%	65.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009755.1	sp|K1PD24|K1PD24_CRAGI	1.3e-143	514.6	100.00%	93.43%	DnaJ-like protein subfamily C member 27;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN009756.1	sp|K1Q6H8|K1Q6H8_CRAGI	3.1e-57	227.3	99.52%	56.52%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN009757.1	sp|K1PHJ6|K1PHJ6_CRAGI	2.4e-99	369.4	62.70%	36.70%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN009758.1	sp|K1RLP8|K1RLP8_CRAGI	1.0e-27	127.9	89.02%	76.39%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN009759.1	sp|K1Q6H8|K1Q6H8_CRAGI	2.3e-24	119.8	38.83%	31.60%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN009760.1	sp|K1R5C2|K1R5C2_CRAGI	9.8e-28	127.9	96.25%	77.63%	Polyribonucleotide nucleotidyltransferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004654|GO:0003723|	GO:0006402|GO:0006396|
GN009761.1	sp|K1PS80|K1PS80_CRAGI	1.5e-263	914.1	100.00%	77.88%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN009762.1	sp|A0A210PGU4|A0A210PGU4_MIZYE	1.9e-83	314.3	100.00%	81.90%	Nascent polypeptide-associated complex subunit alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0005854|
GN009763.1	sp|K1Q865|K1Q865_CRAGI	5.8e-115	419.1	100.00%	90.37%	Trafficking protein particle complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0030008|	GO:0016192|
GN009764.1	sp|K1Q0Z4|K1Q0Z4_CRAGI	2.2e-154	551.2	94.67%	62.91%	UPF0470 protein C19orf51-like protein;OS=Crassostrea;PE=4;SV=1	GO:0070286|
GN009765.1	sp|K1R831|K1R831_CRAGI	1.6e-202	711.1	95.11%	70.26%	CWF19-like protein 1;OS=Crassostrea;PE=4;SV=1
GN009766.1	sp|K1QMP0|K1QMP0_CRAGI	5.7e-132	476.1	99.04%	79.48%	Phosphopantothenate--cysteine ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN008793.1	sp|K1QLD7|K1QLD7_CRAGI	1.3e-194	685.3	98.59%	74.84%	Kinetochore protein NDC80-like protein;OS=Crassostrea;PE=4;SV=1
GN009767.1	sp|K1Q864|K1Q864_CRAGI	4.8e-185	652.9	100.00%	78.10%	Bystin;OS=Crassostrea;PE=4;SV=1
GN009768.1	sp|K1Q0Z3|K1Q0Z3_CRAGI	1.1e-148	531.6	99.67%	85.48%	Estradiol 17-beta-dehydrogenase 11;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN009769.1	sp|A0A1S3K5K2|A0A1S3K5K2_LINUN	3.8e-89	335.1	73.56%	37.46%	uncharacterized protein LOC106179004;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0000166|GO:0016849|	GO:0009190|GO:0035556|
GN009770.1	sp|K1QDN7|K1QDN7_CRAGI	3.2e-12	77.4	69.59%	39.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009771.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.9e-76	291.2	79.60%	48.19%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN009772.1	sp|W4Z366|W4Z366_STRPU	7.5e-10	68.9	71.43%	40.24%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN009773.1	sp|W4XTM0|W4XTM0_STRPU	2.8e-16	90.5	96.92%	40.15%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN009775.1	sp|K1QUV0|K1QUV0_CRAGI	1.8e-95	354.4	97.78%	76.71%	Glutamine amidotransferase subunit pdxT;OS=Crassostrea;PE=3;SV=1	GO:0004359|GO:0016740|	GO:0006541|GO:0042823|
GN009776.1	sp|K1QMG8|K1QMG8_CRAGI	3.0e-152	543.9	71.16%	93.71%	Putative pyridoxine biosynthesis SNZERR;OS=Crassostrea;PE=3;SV=1	GO:0003824|	GO:0042823|
GN009779.1	sp|K1QY88|K1QY88_CRAGI	6.0e-76	290.4	98.35%	41.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN009780.1	sp|K1QNJ7|K1QNJ7_CRAGI	4.5e-47	193.4	89.58%	55.43%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0005975|
GN009782.1	sp|K1RE99|K1RE99_CRAGI	1.4e-37	161.0	99.07%	70.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN009783.1	sp|K1QNJ7|K1QNJ7_CRAGI	7.7e-47	192.6	89.58%	56.07%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0005975|
GN009784.1	sp|C3YWQ8|C3YWQ8_BRAFL	4.2e-49	201.1	95.16%	34.07%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN009785.1	sp|K1RLP8|K1RLP8_CRAGI	7.5e-29	132.1	84.48%	62.63%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN009786.1	sp|K1Q4W2|K1Q4W2_CRAGI	1.9e-46	191.0	94.30%	65.33%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN009787.1	sp|K1REL4|K1REL4_CRAGI	2.5e-154	550.8	100.00%	67.54%	Putative transcription factor PML;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009791.1	sp|K1RHQ2|K1RHQ2_CRAGI	7.0e-94	349.4	96.32%	67.30%	tRNA-splicing endonuclease subunit Sen34;OS=Crassostrea;PE=3;SV=1	GO:0000214|	GO:0016829|GO:0003676|GO:0000213|	GO:0000379|
GN009792.1	sp|K1QXQ8|K1QXQ8_CRAGI	0.0e+00	1239.2	100.00%	65.03%	DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0004386|	GO:0006270|
GN009793.1	sp|K1PXN3|K1PXN3_CRAGI	1.2e-09	69.3	56.39%	34.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009794.1	sp|A0A0B2V027|A0A0B2V027_TOXCA	6.8e-11	72.4	95.54%	37.74%	ATPase inhibitor mai-2, mitochondrial;OS=Toxocara;PE=4;SV=1	GO:0005739|	GO:0042030|	GO:0032780|
GN009795.1	sp|A0A173GPI5|A0A173GPI5_9BIVA	3.7e-93	346.7	95.07%	78.67%	Translocating chain-associated membrane protein;OS=Azumapecten;PE=2;SV=1	GO:0005623|GO:0016021|	GO:0006616|
GN009796.1	sp|A0A2R2MTP5|A0A2R2MTP5_LINUN	9.3e-84	316.6	89.84%	40.04%	glycosyltransferase-like domain-containing protein 1 isoform X1;OS=Lingula;PE=4;SV=1	GO:0016740|
GN009797.1	sp|K1PYM3|K1PYM3_CRAGI	1.4e-232	811.2	100.00%	78.69%	Phosphate transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005315|	GO:0006817|
GN009798.1	sp|K1QJ41|K1QJ41_CRAGI	2.0e-90	337.8	92.25%	75.95%	Mitochondrial fission factor-like protein B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009799.1	sp|A0A210QKX6|A0A210QKX6_MIZYE	2.4e-22	110.9	94.84%	40.40%	Meiotic recombination protein REC114-like;OS=Mizuhopecten;PE=4;SV=1
GN009800.1	sp|K1QJ41|K1QJ41_CRAGI	9.1e-72	276.2	54.71%	77.22%	Mitochondrial fission factor-like protein B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009801.1	sp|K1PCV3|K1PCV3_CRAGI	7.3e-64	249.2	100.00%	61.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009802.1	sp|K1PJ56|K1PJ56_CRAGI	1.5e-28	132.5	30.27%	67.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009803.1	sp|K1PS00|K1PS00_CRAGI	3.3e-201	706.8	100.00%	77.33%	Tetratricopeptide repeat protein 25;OS=Crassostrea;PE=4;SV=1
GN009804.1	sp|K1Q8B5|K1Q8B5_CRAGI	4.0e-196	690.3	79.72%	75.19%	NGFI-A-binding-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0045892|
GN008794.1	sp|K1R060|K1R060_CRAGI	2.9e-119	433.7	92.14%	85.66%	Transmembrane protein 41B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009806.1	sp|K1QVP1|K1QVP1_CRAGI	1.9e-199	700.7	98.35%	83.37%	Sorting nexin-4;OS=Crassostrea;PE=4;SV=1	GO:0035091|	GO:0015031|
GN009807.1	sp|K1RFW2|K1RFW2_CRAGI	1.9e-100	372.1	44.31%	78.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009809.1	sp|K1RFZ3|K1RFZ3_CRAGI	0.0e+00	1242.3	99.13%	76.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0051321|
GN009810.1	sp|K1Q8C0|K1Q8C0_CRAGI	0.0e+00	2657.9	99.96%	63.63%	Separin;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008233|
GN009811.1	sp|K1QGK6|K1QGK6_CRAGI	2.0e-44	183.7	89.81%	86.46%	Adenosine deaminase;OS=Crassostrea;PE=4;SV=1	GO:0019239|	GO:0009168|
GN009812.1	sp|K1PK14|K1PK14_CRAGI	1.0e-215	755.4	81.00%	63.22%	Beta-galactosidase;OS=Crassostrea;PE=3;SV=1	GO:0004565|	GO:0005975|
GN008795.1	sp|A0A210QQT5|A0A210QQT5_MIZYE	2.9e-242	843.6	98.80%	58.71%	tRNA wybutosine-synthesizing protein 1-like;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0051539|GO:0003824|GO:0010181|	GO:0055114|GO:0008033|
GN009815.1	sp|K1PZ66|K1PZ66_CRAGI	8.0e-90	335.5	100.00%	83.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009817.1	sp|K1Q632|K1Q632_CRAGI	3.3e-36	156.8	95.52%	59.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009818.1	sp|K1QS09|K1QS09_CRAGI	4.3e-113	412.9	100.00%	93.42%	Protein C20orf11;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009819.1	sp|K1PRS1|K1PRS1_CRAGI	3.3e-304	1050.0	69.22%	80.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009820.1	sp|K1Q638|K1Q638_CRAGI	8.2e-66	255.4	82.61%	93.94%	PHD finger protein 13;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN009821.1	sp|K1QS13|K1QS13_CRAGI	1.5e-94	352.8	90.14%	53.66%	Protein AATF;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN008796.1	sp|K1Q713|K1Q713_CRAGI	1.3e-224	784.3	97.85%	91.69%	Putative tubulin polyglutamylase TTLL1;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0018095|
GN009822.1	sp|K1QS22|K1QS22_CRAGI	5.0e-167	592.8	92.02%	86.42%	UPF0160 protein MYG1, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN009823.1	sp|K1PK38|K1PK38_CRAGI	3.4e-12	80.1	9.03%	42.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009824.1	sp|K1PRT6|K1PRT6_CRAGI	3.6e-56	226.1	16.73%	55.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009825.1	sp|K1PZ85|K1PZ85_CRAGI	7.5e-178	629.4	96.03%	57.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009826.1	sp|A0A210QJQ0|A0A210QJQ0_MIZYE	6.3e-17	93.6	36.99%	47.25%	THAP domain-containing protein 1 A;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN009827.1	sp|K1QLK3|K1QLK3_CRAGI	5.7e-64	250.4	99.14%	39.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009828.1	sp|M4I2A6|M4I2A6_CRAGI	9.7e-168	595.1	100.00%	79.67%	Myeloid differentiation factor 88-1;OS=Crassostrea;PE=2;SV=1	GO:0070976|	GO:0002755|GO:0043123|
GN008797.1	sp|K1PZH7|K1PZH7_CRAGI	5.7e-265	918.7	100.00%	84.92%	Synembryn-A;OS=Crassostrea;PE=4;SV=1
GN009829.1	sp|M4I2A6|M4I2A6_CRAGI	4.8e-69	266.2	85.54%	85.82%	Myeloid differentiation factor 88-1;OS=Crassostrea;PE=2;SV=1	GO:0070976|	GO:0002755|GO:0043123|
GN009830.1	sp|M4I2A6|M4I2A6_CRAGI	6.6e-92	342.4	91.43%	82.72%	Myeloid differentiation factor 88-1;OS=Crassostrea;PE=2;SV=1	GO:0070976|	GO:0002755|GO:0043123|
GN009833.1	sp|K1RYI8|K1RYI8_CRAGI	1.4e-260	904.8	91.62%	62.27%	Disks large-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0023052|
GN009834.1	sp|M4I212|M4I212_CRAGI	1.5e-173	614.8	82.71%	84.57%	Myeloid differentiation factor 88-2;OS=Crassostrea;PE=2;SV=1	GO:0070976|	GO:0002755|GO:0043123|
GN009835.1	sp|K1R8Z1|K1R8Z1_CRAGI	0.0e+00	1662.9	100.00%	66.19%	Insulin receptor substrate 1;OS=Crassostrea;PE=4;SV=1	GO:0005158|	GO:0008286|
GN008798.1	sp|K1QAK6|K1QAK6_CRAGI	2.8e-210	738.4	37.71%	71.86%	Dicer-like protein 2;OS=Crassostrea;PE=4;SV=1
GN009836.1	sp|K1R2Z3|K1R2Z3_CRAGI	4.7e-15	87.8	47.31%	39.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009837.1	sp|K1R1T5|K1R1T5_CRAGI	1.8e-150	538.1	78.11%	71.07%	mTERF domain-containing protein 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003690|	GO:0006355|
GN009840.1	sp|V4BS74|V4BS74_LOTGI	5.3e-13	79.3	86.79%	47.52%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|
GN009841.1	sp|K1QHZ1|K1QHZ1_CRAGI	5.3e-260	902.9	98.40%	59.06%	Otopetrin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009843.1	sp|K1QNL3|K1QNL3_CRAGI	3.5e-70	270.0	100.00%	78.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008799.1	sp|K1RHP7|K1RHP7_CRAGI	5.7e-18	97.1	30.92%	55.26%	Dual specificity protein phosphatase 3;OS=Crassostrea;PE=3;SV=1	GO:0004725|GO:0008138|
GN009844.1	sp|K1RW82|K1RW82_CRAGI	4.1e-46	191.0	53.14%	50.26%	Ubiquinol-cytochrome c reductase complex chaperone CBP3-like protein;OS=Crassostrea;PE=4;SV=1
GN009845.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	7.4e-85	320.1	82.17%	44.09%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN009846.1	sp|K1R6E9|K1R6E9_CRAGI	2.7e-165	587.4	87.18%	77.54%	Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex;OS=Crassostrea;PE=3;SV=1	GO:0016746|
GN009847.1	sp|K1QZL6|K1QZL6_CRAGI	1.3e-150	538.1	91.67%	86.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009848.1	sp|K1RCI7|K1RCI7_CRAGI	0.0e+00	1375.5	98.79%	87.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009850.1	sp|K1PAK1|K1PAK1_CRAGI	7.5e-12	75.9	75.74%	36.54%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN009852.1	sp|K4TZS3|K4TZS3_9BIVA	0.0e+00	1250.0	96.70%	93.03%	Glycogen [starch] synthase;OS=Crassostrea;PE=2;SV=1	GO:0004373|	GO:0005978|
GN008800.1	sp|K1RHP7|K1RHP7_CRAGI	3.1e-75	287.0	84.62%	84.76%	Dual specificity protein phosphatase 3;OS=Crassostrea;PE=3;SV=1	GO:0004725|GO:0008138|
GN009853.1	sp|K1QBD3|K1QBD3_CRAGI	3.8e-68	264.6	95.80%	39.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009855.1	sp|A0A210PUA2|A0A210PUA2_MIZYE	1.6e-09	68.6	73.03%	34.11%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009856.1	sp|K1QX65|K1QX65_CRAGI	8.1e-60	236.9	28.01%	95.00%	F-box/LRR-repeat protein 20;OS=Crassostrea;PE=4;SV=1
GN008801.1	sp|K1QRC8|K1QRC8_CRAGI	1.5e-214	751.1	100.00%	77.22%	Muscarinic acetylcholine receptor M3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009857.1	sp|K1PPM3|K1PPM3_CRAGI	1.0e-295	1021.1	100.00%	78.48%	Cytoplasmic dynein 1 intermediate chain 2;OS=Crassostrea;PE=4;SV=1	GO:0005868|	GO:0007018|
GN009858.1	sp|A0A210PWB1|A0A210PWB1_MIZYE	8.1e-14	83.2	26.07%	65.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009859.1	sp|K1PPM4|K1PPM4_CRAGI	2.6e-185	653.7	100.00%	73.35%	JmjC domain-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN009860.1	sp|K1PWP2|K1PWP2_CRAGI	6.5e-238	828.6	100.00%	86.35%	1-alkyl-2-acetylglycerophosphocholine esterase;OS=Crassostrea;PE=4;SV=1	GO:0003847|	GO:0016042|
GN009861.1	sp|K1QWN3|K1QWN3_CRAGI	5.1e-30	136.3	64.86%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN009862.1	sp|K1QWN3|K1QWN3_CRAGI	9.1e-20	102.1	70.87%	60.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN009863.1	sp|K1Q9E7|K1Q9E7_CRAGI	4.2e-240	835.9	99.79%	84.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN008802.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	2.3e-12	78.2	84.73%	34.10%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN009864.1	sp|K1Q9E7|K1Q9E7_CRAGI	2.8e-218	763.5	87.25%	83.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN009865.1	sp|K1RGV0|K1RGV0_CRAGI	1.2e-45	190.3	83.66%	47.96%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009867.1	sp|K1Q9T5|K1Q9T5_CRAGI	0.0e+00	2102.8	100.00%	75.49%	Sodium/hydrogen exchanger 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015299|
GN009868.1	sp|V4B342|V4B342_LOTGI	1.2e-121	442.2	95.95%	52.97%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0019867|
GN009869.1	sp|K1P9U7|K1P9U7_CRAGI	6.9e-168	595.9	100.00%	74.14%	Forkhead box protein N4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN008803.1	sp|A0A0L8HY01|A0A0L8HY01_OCTBM	1.0e-165	589.3	90.62%	51.32%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0016021|
GN009870.1	sp|K1QNQ9|K1QNQ9_CRAGI	7.8e-14	84.0	39.43%	37.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009871.1	sp|K1Q7H2|K1Q7H2_CRAGI	7.8e-75	287.0	89.07%	36.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009872.1	sp|K1QN90|K1QN90_CRAGI	7.6e-35	152.1	98.40%	52.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047961|
GN009873.1	sp|K1QUT0|K1QUT0_CRAGI	0.0e+00	1419.4	98.16%	52.57%	F-box/LRR-repeat protein 20;OS=Crassostrea;PE=4;SV=1
GN009874.1	sp|K1Q7H0|K1Q7H0_CRAGI	0.0e+00	1187.9	28.10%	85.26%	ATP-dependent DNA helicase II subunit 2;OS=Crassostrea;PE=3;SV=1	GO:0043564|	GO:0005524|GO:0004003|GO:0003684|GO:0042162|	GO:0006310|GO:0006303|GO:0000723|
GN009875.1	sp|K1RF24|K1RF24_CRAGI	3.4e-37	160.6	76.85%	50.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009876.1	sp|K1QNQ2|K1QNQ2_CRAGI	4.3e-123	446.4	97.45%	80.90%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN009877.1	sp|K1QNQ2|K1QNQ2_CRAGI	3.4e-221	773.1	99.79%	78.97%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN009878.1	sp|K1QNQ2|K1QNQ2_CRAGI	1.7e-228	797.3	99.79%	81.68%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN009879.1	sp|K1QUS5|K1QUS5_CRAGI	2.0e-36	157.1	100.00%	72.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009880.1	sp|K1QNP7|K1QNP7_CRAGI	4.7e-106	390.6	100.00%	84.11%	LIM and SH3 domain protein Lasp;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN009881.1	sp|K1QFN1|K1QFN1_CRAGI	5.3e-69	265.8	96.45%	100.00%	60S ribosomal protein L23;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN009882.1	sp|A0A2C9KC42|A0A2C9KC42_BIOGL	2.4e-40	171.0	87.89%	50.90%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN009883.1	sp|K1RF16|K1RF16_CRAGI	4.1e-256	889.4	100.00%	74.24%	Rho-related protein racA;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN009884.1	sp|A0A210QCN9|A0A210QCN9_MIZYE	9.4e-42	176.0	76.67%	46.74%	SPRY domain-containing SOCS box protein 2;OS=Mizuhopecten;PE=4;SV=1
GN009885.1	sp|K1QNP4|K1QNP4_CRAGI	5.2e-130	469.5	99.67%	73.51%	Rho-related protein racA;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN009886.1	sp|K1RGW1|K1RGW1_CRAGI	1.8e-30	137.9	100.00%	73.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009888.1	sp|K1RN55|K1RN55_CRAGI	9.8e-181	638.6	97.82%	67.54%	Low-density lipoprotein receptor-related protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009891.1	sp|A0A210Q7E8|A0A210Q7E8_MIZYE	7.2e-282	975.3	88.64%	80.92%	Potassium voltage-gated channel protein Shaw;OS=Mizuhopecten;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN009892.1	sp|K1RN59|K1RN59_CRAGI	1.1e-151	542.0	99.00%	77.89%	Laminin-like protein epi-1;OS=Crassostrea;PE=4;SV=1
GN009893.1	sp|K1RJ70|K1RJ70_CRAGI	2.5e-229	800.0	96.00%	84.03%	Cytosolic non-specific dipeptidase;OS=Crassostrea;PE=4;SV=1	GO:0016805|GO:0046872|GO:0008237|
GN009894.1	sp|K1QSV0|K1QSV0_CRAGI	5.2e-228	797.7	46.35%	64.87%	PHD and RING finger domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN009895.1	sp|A0A2G8KX79|A0A2G8KX79_STIJA	1.7e-10	72.0	20.85%	79.07%	Putative nuclease HARBI1;OS=Stichopus;PE=4;SV=1
GN009896.1	sp|A0A210R1C3|A0A210R1C3_MIZYE	3.0e-86	323.6	98.98%	77.32%	Protein pitchfork;OS=Mizuhopecten;PE=4;SV=1
GN009897.1	sp|K1RJ65|K1RJ65_CRAGI	2.9e-275	953.0	97.23%	85.61%	General transcription factor IIH subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0000439|	GO:0006289|GO:0006351|
GN009898.1	sp|K1QZJ9|K1QZJ9_CRAGI	4.2e-263	912.5	99.63%	77.12%	Temptin;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN009899.1	sp|K1QSU4|K1QSU4_CRAGI	9.1e-159	565.5	83.17%	73.94%	Wall-associated receptor kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016301|
GN009900.1	sp|K1QKE4|K1QKE4_CRAGI	6.8e-253	878.6	98.37%	79.74%	Vesicular glutamate transporter 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN009901.1	sp|K1QBT8|K1QBT8_CRAGI	1.3e-43	182.6	97.09%	38.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009902.1	sp|K1RJ60|K1RJ60_CRAGI	0.0e+00	1744.9	92.27%	49.08%	NFX1-type zinc finger-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN009904.1	sp|K1QEP6|K1QEP6_CRAGI	2.6e-91	342.4	58.64%	37.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009905.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	4.2e-42	177.2	98.73%	40.42%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN009908.1	sp|A0A2T7PY20|A0A2T7PY20_POMCA	5.7e-63	247.3	77.59%	37.95%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN009909.1	sp|K1QI43|K1QI43_CRAGI	1.4e-16	90.9	64.71%	75.93%	Sequestosome-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009910.1	sp|K1QI43|K1QI43_CRAGI	1.0e-93	348.6	100.00%	70.40%	Sequestosome-1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009911.1	sp|W4XQ99|W4XQ99_STRPU	5.2e-17	93.2	73.08%	38.60%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN009912.1	sp|K1S066|K1S066_CRAGI	7.9e-25	120.2	38.71%	55.00%	ATP-binding cassette sub-family A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN009913.1	sp|K1PIH9|K1PIH9_CRAGI	2.3e-24	117.9	87.91%	45.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009914.1	sp|K1S066|K1S066_CRAGI	5.9e-22	109.4	63.64%	72.29%	ATP-binding cassette sub-family A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN008805.1	sp|K1PEC7|K1PEC7_CRAGI	0.0e+00	1189.1	98.35%	67.97%	Patched domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009916.1	sp|K1PC63|K1PC63_CRAGI	8.5e-91	339.3	99.06%	51.74%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009917.1	sp|K1QES2|K1QES2_CRAGI	7.6e-21	104.8	85.51%	84.48%	Gamma-glutamyltranspeptidase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0036374|	GO:0006751|
GN009919.1	sp|K1R6K3|K1R6K3_CRAGI	0.0e+00	1161.7	100.00%	73.48%	Glutamate receptor, ionotropic kainate 3;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN009920.1	sp|A0A210QZH0|A0A210QZH0_MIZYE	1.9e-96	358.2	96.56%	54.17%	Glutamate receptor ionotropic, kainate 3;OS=Mizuhopecten;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN009921.1	sp|K1QET2|K1QET2_CRAGI	0.0e+00	1884.8	97.49%	94.65%	Coatomer subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0030126|GO:0000139|	GO:0005198|	GO:0006886|GO:0016192|
GN009922.1	sp|K1R4H6|K1R4H6_CRAGI	3.6e-163	580.1	97.74%	68.46%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0003824|GO:0005230|GO:0004888|
GN009923.1	sp|K1R4H6|K1R4H6_CRAGI	3.2e-172	610.1	99.25%	70.45%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0003824|GO:0005230|GO:0004888|
GN009924.1	sp|A0A210PQW3|A0A210PQW3_MIZYE	7.4e-11	73.6	25.83%	46.38%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009925.1	sp|K1QEU2|K1QEU2_CRAGI	2.7e-54	217.6	66.52%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009926.1	sp|K1QLG8|K1QLG8_CRAGI	6.9e-238	828.6	98.75%	80.72%	UPF0748 protein yngK;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN009927.1	sp|K1R6M2|K1R6M2_CRAGI	1.1e-96	360.1	94.65%	38.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009929.1	sp|K1PZH8|K1PZH8_CRAGI	1.8e-43	181.4	74.23%	64.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009930.1	sp|K1Q6T3|K1Q6T3_CRAGI	4.6e-164	585.5	30.12%	53.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008806.1	sp|K1PW88|K1PW88_CRAGI	4.0e-83	313.2	83.51%	89.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009932.1	sp|K1QLH1|K1QLH1_CRAGI	0.0e+00	2017.7	100.00%	72.23%	Gamma-tubulin complex component 6;OS=Crassostrea;PE=4;SV=1	GO:0005815|GO:0000922|	GO:0043015|	GO:0007020|
GN009933.1	sp|K1P9U5|K1P9U5_CRAGI	1.5e-182	644.8	100.00%	62.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009935.1	sp|K1PH31|K1PH31_CRAGI	8.7e-193	678.3	100.00%	91.69%	Protein arginine N-methyltransferase 1;OS=Crassostrea;PE=3;SV=1	GO:0008168|	GO:0006479|
GN009936.1	sp|K1R1V6|K1R1V6_CRAGI	5.2e-189	666.0	99.76%	82.08%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0008168|	GO:0006479|
GN008807.1	sp|K1QAK0|K1QAK0_CRAGI	3.1e-120	438.0	42.48%	79.92%	Fibronectin type III domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN009938.1	sp|K1QMF3|K1QMF3_CRAGI	6.3e-251	872.8	55.57%	76.36%	Chromodomain-helicase-DNA-binding protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004003|GO:0003677|	GO:0006338|GO:0006281|
GN009939.1	sp|K1QUS8|K1QUS8_CRAGI	0.0e+00	1594.3	95.50%	88.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005829|GO:1990745|	GO:0032456|GO:0042147|
GN009940.1	sp|K1R1J7|K1R1J7_CRAGI	5.6e-247	858.6	99.54%	94.39%	SPRY domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN009941.1	sp|K1QUT4|K1QUT4_CRAGI	2.0e-69	267.7	96.10%	68.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009942.1	sp|K1R1K5|K1R1K5_CRAGI	8.0e-82	308.9	100.00%	74.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009943.1	sp|K1RMK3|K1RMK3_CRAGI	3.0e-148	530.4	99.72%	69.86%	Archaemetzincin-2;OS=Crassostrea;PE=4;SV=1	GO:0008237|GO:0008270|
GN009944.1	sp|A0A210QWM6|A0A210QWM6_MIZYE	1.8e-156	557.8	99.74%	74.61%	Kinesin-like protein KIF6;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN009945.1	sp|K1PEY4|K1PEY4_CRAGI	0.0e+00	1364.4	99.55%	86.42%	26S proteasome non-ATPase regulatory subunit 2;OS=Crassostrea;PE=3;SV=1	GO:0008540|	GO:0030234|	GO:0042176|
GN008808.1	sp|K1QIV2|K1QIV2_CRAGI	2.9e-134	485.3	56.85%	48.59%	Cubilin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009946.1	sp|K1QL73|K1QL73_CRAGI	0.0e+00	1392.5	100.00%	83.35%	Kinesin-like protein KIF17;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN009947.1	sp|K1PWN3|K1PWN3_CRAGI	7.7e-156	556.6	92.42%	44.62%	Chorion peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN009948.1	sp|K1Q3B4|K1Q3B4_CRAGI	1.1e-184	651.4	100.00%	90.57%	DNA topoisomerase;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0003917|	GO:0006265|
GN009949.1	sp|A0A210R559|A0A210R559_MIZYE	1.9e-43	181.4	98.08%	42.38%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009950.1	sp|K1QAL8|K1QAL8_CRAGI	2.9e-157	560.1	100.00%	88.49%	Uridine phosphorylase 2;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0004850|	GO:0009116|GO:0009166|
GN009951.1	sp|K1QMZ4|K1QMZ4_CRAGI	2.2e-239	834.3	95.30%	67.89%	Cyclin-T2;OS=Crassostrea;PE=4;SV=1	GO:0019901|	GO:0006355|
GN009952.1	sp|K1QE97|K1QE97_CRAGI	7.4e-188	662.5	75.37%	84.03%	Uncharacterized protein C12orf41-like protein;OS=Crassostrea;PE=4;SV=1	GO:0000123|
GN009953.1	sp|K1Q660|K1Q660_CRAGI	9.4e-74	281.6	100.00%	97.18%	Protein roadkill;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN009954.1	sp|K1Q660|K1Q660_CRAGI	3.4e-115	419.9	96.82%	96.70%	Protein roadkill;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN009955.1	sp|K1Q9K5|K1Q9K5_CRAGI	2.8e-54	217.6	92.89%	54.05%	Protein XRP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005096|	GO:0000902|
GN009956.1	sp|K1Q9K5|K1Q9K5_CRAGI	4.6e-162	576.2	97.75%	88.44%	Protein XRP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005096|	GO:0000902|
GN009957.1	sp|K1QHL6|K1QHL6_CRAGI	5.5e-80	304.3	99.65%	87.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009958.1	sp|A0A210QW63|A0A210QW63_MIZYE	2.0e-295	1021.1	99.63%	51.69%	Kinesin-like protein KIF21A;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN009960.1	sp|K1Q9K9|K1Q9K9_CRAGI	1.3e-308	1064.3	100.00%	65.31%	Ankyrin repeat domain-containing protein 53;OS=Crassostrea;PE=4;SV=1
GN009961.1	sp|K1R9I7|K1R9I7_CRAGI	1.7e-61	243.4	91.07%	31.72%	NIPA-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008270|
GN009962.1	sp|K1Q9L0|K1Q9L0_CRAGI	1.0e-198	698.4	99.56%	69.09%	Four-jointed box protein 1;OS=Crassostrea;PE=4;SV=1
GN009963.1	sp|A0A2T7NIF8|A0A2T7NIF8_POMCA	9.3e-13	79.7	52.05%	37.80%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN009964.1	sp|A0A2T7NIF8|A0A2T7NIF8_POMCA	1.7e-13	81.3	89.68%	40.18%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN009965.1	sp|K1QHM2|K1QHM2_CRAGI	5.9e-311	1071.6	98.58%	83.09%	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0008250|	GO:0016740|	GO:0006487|
GN009966.1	sp|K1QS87|K1QS87_CRAGI	3.3e-59	233.0	93.55%	97.39%	Pre-mRNA branch site p14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN009967.1	sp|K1Q2M5|K1Q2M5_CRAGI	4.7e-48	197.2	97.93%	71.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009968.1	sp|A0A210PPT0|A0A210PPT0_MIZYE	2.3e-106	391.0	97.67%	65.53%	Kelch-like protein 3;OS=Mizuhopecten;PE=4;SV=1
GN009969.1	sp|K1RQ92|K1RQ92_CRAGI	8.5e-277	958.7	71.23%	82.31%	Coiled-coil domain-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN009970.1	sp|A0A210PPW4|A0A210PPW4_MIZYE	2.9e-48	197.6	82.89%	52.36%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009971.1	sp|K1QS78|K1QS78_CRAGI	4.1e-99	366.7	100.00%	72.90%	Coiled-coil domain-containing protein 75;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009973.1	sp|A0A210QEC2|A0A210QEC2_MIZYE	1.8e-27	129.8	40.35%	33.20%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0035694|
GN008809.1	sp|K1RHP1|K1RHP1_CRAGI	3.3e-43	180.3	100.00%	85.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009974.1	sp|K1QR35|K1QR35_CRAGI	9.0e-20	102.8	59.53%	36.92%	C-type lectin domain family 10 member A;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN009976.1	sp|K1QBR0|K1QBR0_CRAGI	4.9e-43	179.5	99.28%	58.39%	Low-density lipoprotein receptor-related protein 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009977.1	sp|K1QYR2|K1QYR2_CRAGI	7.2e-135	486.5	83.27%	54.52%	Astacin-like metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009978.1	sp|K1R5L7|K1R5L7_CRAGI	2.6e-53	213.4	90.60%	98.10%	Titin;OS=Crassostrea;PE=4;SV=1
GN009979.1	sp|K1RC59|K1RC59_CRAGI	2.8e-77	295.0	40.54%	70.10%	Caspase-8;OS=Crassostrea;PE=3;SV=1	GO:0004197|	GO:0006915|
GN009995.1	sp|K1RVJ9|K1RVJ9_CRAGI	1.4e-163	581.6	94.12%	74.22%	Cephalotocin receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008812.1	sp|A0A210PHR4|A0A210PHR4_MIZYE	2.6e-46	191.0	82.43%	47.15%	Chromatin modification-related protein YNG2;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN009996.1	sp|A0A210PFT1|A0A210PFT1_MIZYE	1.9e-56	225.3	57.52%	62.44%	Motor neuron and pancreas homeobox protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN009997.1	sp|A0A210Q3N6|A0A210Q3N6_MIZYE	6.5e-174	616.3	87.76%	59.50%	RNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004386|GO:0003723|
GN010001.1	sp|K1QLQ6|K1QLQ6_CRAGI	5.6e-96	355.9	100.00%	88.18%	Thioredoxin domain-containing protein C2F3.12c;OS=Crassostrea;PE=4;SV=1
GN010002.1	sp|K1QD40|K1QD40_CRAGI	0.0e+00	1621.3	100.00%	78.16%	Importin-7;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008536|	GO:0006886|
GN008813.1	sp|K1QPY5|K1QPY5_CRAGI	1.7e-32	144.8	97.22%	45.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN010004.1	sp|A0A210Q9B3|A0A210Q9B3_MIZYE	4.4e-68	264.2	100.00%	37.50%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010005.1	sp|K1QEX0|K1QEX0_CRAGI	9.2e-40	169.1	96.88%	46.24%	Werner syndrome ATP-dependent helicase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN010006.1	sp|A0A2R2MIM6|A0A2R2MIM6_LINUN	3.7e-13	79.7	69.39%	46.27%	perlucin-like;OS=Lingula;PE=4;SV=1	GO:0030246|
GN010007.1	sp|D8VNA2|D8VNA2_9BIVA	2.8e-21	107.8	60.85%	41.09%	C-type lectin 5;OS=Azumapecten;PE=2;SV=1	GO:0030246|
GN008684.1	sp|K1QTD3|K1QTD3_CRAGI	4.5e-83	313.5	77.35%	72.40%	DNA damage-regulated autophagy modulator protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0010506|
GN008814.1	sp|K1QHK2|K1QHK2_CRAGI	1.1e-42	179.1	98.74%	42.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010008.1	sp|K1R744|K1R744_CRAGI	0.0e+00	1196.4	100.00%	80.36%	Low-density lipoprotein receptor-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0048513|GO:0030509|GO:0060828|
GN010009.1	sp|K1PLL1|K1PLL1_CRAGI	0.0e+00	1292.7	88.66%	67.64%	Chitobiase;OS=Crassostrea;PE=4;SV=1	GO:0004563|GO:0030247|	GO:0005975|
GN010010.1	sp|K1Q151|K1Q151_CRAGI	1.9e-68	263.8	100.00%	99.25%	60S ribosomal protein L32;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN010011.1	sp|A0A210QH60|A0A210QH60_MIZYE	2.3e-59	235.0	73.48%	53.06%	Syntaxin-12;OS=Mizuhopecten;PE=3;SV=1	GO:0005623|GO:0016021|	GO:0005484|	GO:0006886|GO:0016192|
GN010012.1	sp|A0A0L8GKX5|A0A0L8GKX5_OCTBM	7.3e-29	132.5	88.44%	49.61%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN010013.1	sp|K1RA71|K1RA71_CRAGI	4.6e-82	309.7	100.00%	72.91%	Glutathione-requiring prostaglandin D synthase;OS=Crassostrea;PE=4;SV=1
GN010014.1	sp|K1R3S2|K1R3S2_CRAGI	8.4e-118	430.3	90.71%	51.46%	Transcription factor TFIIIB component B''-like protein;OS=Crassostrea;PE=4;SV=1	GO:0000126|	GO:0003677|GO:0000995|
GN010015.1	sp|K1PLZ0|K1PLZ0_CRAGI	1.2e-16	92.8	29.86%	45.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010016.1	sp|K1QHW7|K1QHW7_CRAGI	4.0e-94	350.9	97.55%	88.58%	Microfibrillar-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010017.1	sp|K1QEU6|K1QEU6_CRAGI	1.8e-118	432.2	75.46%	62.94%	Zinc finger protein 41;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010018.1	sp|K1PEP6|K1PEP6_CRAGI	0.0e+00	1525.0	96.10%	80.04%	Gamma-tubulin complex component;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|GO:0005815|GO:0000922|	GO:0043015|	GO:0007020|
GN010019.1	sp|K1PMD6|K1PMD6_CRAGI	2.5e-31	143.3	22.97%	48.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010021.1	sp|K1PUS2|K1PUS2_CRAGI	7.2e-230	802.0	100.00%	83.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010022.1	sp|K1QEV3|K1QEV3_CRAGI	1.0e-186	658.3	96.44%	85.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010023.1	sp|K1P8J3|K1P8J3_CRAGI	1.3e-183	648.3	100.00%	78.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN010024.1	sp|K1PEQ4|K1PEQ4_CRAGI	7.0e-181	639.0	99.30%	80.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0070513|GO:0002020|	GO:0042981|
GN010025.1	sp|K1PEQ4|K1PEQ4_CRAGI	4.2e-45	186.8	56.84%	85.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0070513|GO:0002020|	GO:0042981|
GN010026.1	sp|K1PME4|K1PME4_CRAGI	6.9e-112	409.5	100.00%	71.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010027.1	sp|K1QS48|K1QS48_CRAGI	2.1e-10	72.4	22.94%	49.35%	Putative ATP-dependent DNA helicase HFM1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN010030.1	sp|K1QI81|K1QI81_CRAGI	8.0e-86	323.6	88.38%	50.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010032.1	sp|K1RQ52|K1RQ52_CRAGI	4.7e-124	449.9	92.58%	78.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010033.1	sp|K1R5K3|K1R5K3_CRAGI	5.6e-128	463.0	100.00%	67.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN010034.1	sp|C3YZB0|C3YZB0_BRAFL	4.8e-13	80.5	78.14%	29.94%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN010035.1	sp|K1QZ88|K1QZ88_CRAGI	1.1e-247	861.3	87.92%	85.11%	Serine/threonine-protein kinase RIO3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004674|
GN010036.1	sp|H9LSX1|H9LSX1_CRAAR	3.5e-191	672.9	100.00%	88.56%	Cathepsin B;OS=Crassostrea;PE=2;SV=1	GO:0004197|	GO:0050790|
GN010037.1	sp|K1R9C3|K1R9C3_CRAGI	1.5e-64	251.1	99.37%	74.21%	Spore cortex-lytic enzyme;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN010038.1	sp|K1RAH9|K1RAH9_CRAGI	2.0e-61	241.1	75.62%	79.47%	Putative calcium-binding protein CML14;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010039.1	sp|K1PSE0|K1PSE0_CRAGI	8.7e-43	179.5	98.38%	65.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010040.1	sp|K1QIM3|K1QIM3_CRAGI	6.8e-261	905.2	90.84%	86.19%	ETS translocation variant 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN010042.1	sp|K1RYJ3|K1RYJ3_CRAGI	2.8e-30	137.1	97.08%	46.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010043.1	sp|K1R306|K1R306_CRAGI	2.9e-47	194.5	61.40%	63.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010044.1	sp|K1RQP2|K1RQP2_CRAGI	5.1e-129	466.5	100.00%	68.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010048.1	sp|K1QZ34|K1QZ34_CRAGI	0.0e+00	1255.0	95.97%	70.85%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0050660|GO:0016614|
GN010049.1	sp|K1S4G8|K1S4G8_CRAGI	1.6e-83	314.3	96.55%	82.04%	Substrate-specific endoprotease Tex31;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008233|
GN010050.1	sp|A0A0C5DGQ6|A0A0C5DGQ6_CRAHO	1.7e-92	344.4	98.50%	86.80%	Bax protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0043065|
GN010051.1	sp|K1REY9|K1REY9_CRAGI	5.1e-68	263.5	97.82%	51.12%	C-type lectin isoform 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN010052.1	sp|K1REY9|K1REY9_CRAGI	7.3e-78	296.2	67.86%	78.65%	C-type lectin isoform 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN010053.1	sp|K1Q0E3|K1Q0E3_CRAGI	1.2e-148	531.6	100.00%	81.52%	Homeobox protein DBX1-A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN010054.1	sp|K1PR66|K1PR66_CRAGI	5.4e-217	759.2	99.80%	73.20%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010055.1	sp|K1PJF3|K1PJF3_CRAGI	2.3e-46	192.2	49.43%	69.20%	FMRFamide neuropeptide;OS=Crassostrea;PE=4;SV=1	GO:0007218|
GN010056.1	sp|K1QDC7|K1QDC7_CRAGI	1.1e-38	166.0	49.62%	58.14%	Jumonji-C domain-containing protein KDM4B;OS=Crassostrea;PE=2;SV=1	GO:0016021|GO:0005634|	GO:0046872|GO:0008168|
GN010057.1	sp|K1PYF3|K1PYF3_CRAGI	0.0e+00	1182.9	98.74%	74.20%	Lysine-specific histone demethylase 1B;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008168|GO:0016491|GO:0008270|
GN010059.1	sp|K1PR69|K1PR69_CRAGI	0.0e+00	2215.7	95.36%	59.48%	Zinc finger protein 40;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN010060.1	sp|W4YX27|W4YX27_STRPU	4.0e-13	79.7	67.31%	52.17%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004190|
GN010061.1	sp|W4ZG06|W4ZG06_STRPU	6.4e-11	73.2	69.44%	33.59%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0004190|GO:0003676|GO:0008270|	GO:0015074|
GN010063.1	sp|K1PYF5|K1PYF5_CRAGI	2.8e-295	1019.6	99.20%	78.62%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN010064.1	sp|A0A1S3KFN7|A0A1S3KFN7_LINUN	2.1e-36	157.9	78.95%	49.33%	uncharacterized protein LOC106181466;OS=Lingula;PE=4;SV=1
GN010066.1	sp|K1RM61|K1RM61_CRAGI	3.9e-30	137.1	100.00%	34.87%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN008815.1	sp|K1PY74|K1PY74_CRAGI	4.3e-63	248.1	37.15%	61.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010067.1	sp|K1QJJ0|K1QJJ0_CRAGI	6.0e-22	109.0	92.16%	62.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010068.1	sp|A0A1X7UEV0|A0A1X7UEV0_AMPQE	4.1e-46	192.2	47.90%	30.50%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046872|
GN010070.1	sp|A0A210QI48|A0A210QI48_MIZYE	6.2e-16	88.6	86.67%	60.94%	M-phase inducer phosphatase;OS=Mizuhopecten;PE=4;SV=1	GO:0004725|	GO:1902751|
GN010071.1	sp|K1QI66|K1QI66_CRAGI	5.0e-19	101.7	28.44%	33.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010072.1	sp|A0A210PX26|A0A210PX26_MIZYE	3.2e-30	136.7	85.25%	61.17%	M-phase inducer phosphatase 2;OS=Mizuhopecten;PE=4;SV=1	GO:0004725|	GO:1902751|
GN008816.1	sp|K1PY74|K1PY74_CRAGI	8.0e-46	188.7	76.64%	81.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010073.1	sp|A0A210QI48|A0A210QI48_MIZYE	1.2e-16	90.9	86.67%	62.50%	M-phase inducer phosphatase;OS=Mizuhopecten;PE=4;SV=1	GO:0004725|	GO:1902751|
GN010074.1	sp|A0A210QI48|A0A210QI48_MIZYE	9.5e-17	91.3	86.67%	62.50%	M-phase inducer phosphatase;OS=Mizuhopecten;PE=4;SV=1	GO:0004725|	GO:1902751|
GN010076.1	sp|K1PSN8|K1PSN8_CRAGI	0.0e+00	1080.5	94.01%	72.22%	GDH/6PGL endoplasmic bifunctional protein;OS=Crassostrea;PE=4;SV=1	GO:0017057|GO:0004345|GO:0050661|	GO:0006006|GO:0006098|
GN010077.1	sp|K1PDD7|K1PDD7_CRAGI	0.0e+00	1159.1	71.48%	89.40%	Acyl-CoA synthetase short-chain family member 3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN010078.1	sp|K1Q6F7|K1Q6F7_CRAGI	1.3e-207	727.6	99.48%	93.96%	V-type proton ATPase subunit C;OS=Crassostrea;PE=3;SV=1	GO:0033180|	GO:0015078|	GO:0015991|
GN010079.1	sp|K1QEC8|K1QEC8_CRAGI	8.0e-50	202.6	88.78%	58.76%	Dynein assembly factor 1, axonemal homolog;OS=Crassostrea;PE=3;SV=1	GO:0005929|	GO:0044458|
GN008817.1	sp|K1PIS0|K1PIS0_CRAGI	4.1e-231	806.2	89.96%	78.67%	Adenosine deaminase CECR1;OS=Crassostrea;PE=4;SV=1	GO:0005615|	GO:0004000|	GO:0006154|
GN010080.1	sp|K1QMG4|K1QMG4_CRAGI	3.1e-28	130.2	99.20%	51.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010081.1	sp|K1QTH8|K1QTH8_CRAGI	1.5e-175	621.7	91.42%	73.71%	Cadherin EGF LAG seven-pass G-type receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN010082.1	sp|K1RTH5|K1RTH5_CRAGI	0.0e+00	1761.9	99.85%	70.74%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN010083.1	sp|K1RDM4|K1RDM4_CRAGI	4.0e-39	167.5	35.40%	78.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010085.1	sp|K1R2Y6|K1R2Y6_CRAGI	0.0e+00	1312.0	98.81%	96.71%	RNA polymerase-associated protein CTR9-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016570|GO:0006355|
GN008818.1	sp|K1PCD8|K1PCD8_CRAGI	1.2e-142	511.9	76.00%	81.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010086.1	sp|A0A210QIW5|A0A210QIW5_MIZYE	1.1e-37	163.3	58.88%	41.83%	Homeobox protein ceh-40;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|
GN010087.1	sp|K1PG94|K1PG94_CRAGI	7.2e-11	74.3	22.00%	36.73%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN010088.1	sp|K1QM21|K1QM21_CRAGI	0.0e+00	1413.3	95.37%	89.91%	Oxysterol-binding protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0006869|
GN010089.1	sp|K1RTH2|K1RTH2_CRAGI	3.3e-162	577.0	100.00%	75.63%	Zinc transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN010090.1	sp|K1QKA1|K1QKA1_CRAGI	1.6e-139	501.1	100.00%	88.67%	Hairy/enhancer-of-split related with YRPW motif protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046983|	GO:0006355|
GN010091.1	sp|K1QSQ2|K1QSQ2_CRAGI	2.4e-88	331.3	72.11%	64.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010092.1	sp|K1QSQ2|K1QSQ2_CRAGI	9.1e-96	355.9	99.09%	53.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010093.1	sp|K1QZG9|K1QZG9_CRAGI	1.5e-132	478.4	84.80%	62.03%	Alpha-(1,3)-fucosyltransferase C;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN008819.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	1.8e-81	308.9	96.23%	35.47%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN010094.1	sp|K1PPZ8|K1PPZ8_CRAGI	5.3e-204	716.5	94.08%	59.52%	Solute carrier organic anion transporter family member 1A5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0055085|
GN010095.1	sp|K1QK40|K1QK40_CRAGI	7.9e-68	263.8	95.32%	28.91%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010098.1	sp|A0A2T7PUU4|A0A2T7PUU4_POMCA	6.4e-56	223.4	97.65%	55.82%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN010099.1	sp|A0A210QLE5|A0A210QLE5_MIZYE	2.7e-128	464.5	93.60%	49.36%	6-hydroxy-D-nicotine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0071949|GO:0016491|
GN010100.1	sp|A0A210QLE5|A0A210QLE5_MIZYE	4.1e-116	424.1	93.61%	45.63%	6-hydroxy-D-nicotine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0071949|GO:0016491|
GN010101.1	sp|K1Q7X5|K1Q7X5_CRAGI	4.7e-123	446.4	92.38%	77.70%	Carnitinyl-CoA dehydratase;OS=Crassostrea;PE=3;SV=1	GO:0003824|
GN010102.1	sp|K1QTM9|K1QTM9_CRAGI	1.4e-20	103.6	98.25%	83.64%	Dual oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0020037|GO:0016174|GO:0004601|	GO:0050665|GO:0006979|
GN010103.1	sp|K1R0B6|K1R0B6_CRAGI	9.1e-29	133.3	46.33%	47.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010104.1	sp|K1PEJ7|K1PEJ7_CRAGI	7.6e-18	96.7	19.52%	79.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010105.1	sp|A0A210QLE5|A0A210QLE5_MIZYE	3.6e-91	340.9	92.19%	39.53%	6-hydroxy-D-nicotine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0071949|GO:0016491|
GN010106.1	sp|A0A210QLE5|A0A210QLE5_MIZYE	1.3e-136	492.3	94.81%	48.34%	6-hydroxy-D-nicotine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0071949|GO:0016491|
GN010107.1	sp|A0A210QLE5|A0A210QLE5_MIZYE	1.6e-115	422.2	93.61%	45.42%	6-hydroxy-D-nicotine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0071949|GO:0016491|
GN010108.1	sp|K1Q0S3|K1Q0S3_CRAGI	0.0e+00	1388.2	100.00%	70.57%	PAS domain-containing serine/threonine-protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN010109.1	sp|K1PLP5|K1PLP5_CRAGI	5.1e-190	669.5	96.26%	76.66%	Dual oxidase maturation factor 1;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|	GO:0015031|
GN010110.1	sp|K1QU13|K1QU13_CRAGI	0.0e+00	1275.0	82.87%	71.76%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010111.1	sp|K1PM00|K1PM00_CRAGI	8.7e-40	168.3	99.07%	87.62%	Coiled-coil domain-containing protein 12;OS=Crassostrea;PE=4;SV=1
GN010112.1	sp|K1PPG7|K1PPG7_CRAGI	4.0e-176	622.9	100.00%	89.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010113.1	sp|K1QWX2|K1QWX2_CRAGI	4.1e-138	496.5	87.66%	89.86%	60S acidic ribosomal protein P0;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0042254|
GN010114.1	sp|K1QB38|K1QB38_CRAGI	0.0e+00	1086.2	91.42%	79.46%	Solute carrier organic anion transporter family member;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN010115.1	sp|K1Q9Q9|K1Q9Q9_CRAGI	1.5e-186	658.3	92.80%	68.08%	Carbonyl reductase [NADPH] 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010116.1	sp|K1Q9Q9|K1Q9Q9_CRAGI	3.3e-142	510.0	100.00%	84.15%	Carbonyl reductase [NADPH] 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010117.1	sp|A0A210PQR4|A0A210PQR4_MIZYE	2.7e-36	158.3	76.51%	32.79%	BTB/POZ domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1
GN010118.1	sp|K1Q2S1|K1Q2S1_CRAGI	1.1e-302	1044.3	88.96%	87.60%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN010119.1	sp|K1R9M7|K1R9M7_CRAGI	7.7e-213	745.7	100.00%	78.82%	Ras association domain-containing protein 8;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN010120.1	sp|K1QPD5|K1QPD5_CRAGI	6.6e-109	399.1	100.00%	76.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010121.1	sp|K1QKB9|K1QKB9_CRAGI	0.0e+00	1409.4	100.00%	70.73%	Intermediate filament tail domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005882|	GO:0005198|
GN010122.1	sp|K1R8D7|K1R8D7_CRAGI	5.8e-52	209.9	99.16%	46.75%	Complement C1q tumor necrosis factor-related protein 4;OS=Crassostrea;PE=4;SV=1
GN010123.1	sp|K1R8D7|K1R8D7_CRAGI	1.3e-42	179.1	99.29%	37.24%	Complement C1q tumor necrosis factor-related protein 4;OS=Crassostrea;PE=4;SV=1
GN010124.1	sp|K1R8D7|K1R8D7_CRAGI	6.8e-40	169.1	97.89%	57.04%	Complement C1q tumor necrosis factor-related protein 4;OS=Crassostrea;PE=4;SV=1
GN010125.1	sp|K1QPQ5|K1QPQ5_CRAGI	3.2e-68	265.8	92.84%	28.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010127.1	sp|A0A1S3JUQ1|A0A1S3JUQ1_LINUN	7.4e-58	228.8	98.63%	76.22%	peroxisomal membrane protein 4-like;OS=Lingula;PE=4;SV=1
GN010129.1	sp|K1R669|K1R669_CRAGI	2.3e-69	267.3	94.89%	81.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010130.1	sp|K1QSR8|K1QSR8_CRAGI	1.3e-131	474.6	100.00%	87.40%	Histone-lysine N-methyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0042799|	GO:0034773|
GN010131.1	sp|K1RY14|K1RY14_CRAGI	3.2e-88	330.9	100.00%	56.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010132.1	sp|K1RSD9|K1RSD9_CRAGI	3.7e-50	203.8	61.43%	77.52%	Secreted frizzled-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0007275|GO:0016055|
GN010133.1	sp|K1QJL0|K1QJL0_CRAGI	0.0e+00	1165.6	100.00%	59.30%	Putative ATP-dependent RNA helicase DDX58;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0003677|GO:0004386|	GO:0042981|
GN010134.1	sp|K1QJL0|K1QJL0_CRAGI	5.6e-184	650.2	84.85%	49.71%	Putative ATP-dependent RNA helicase DDX58;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0003677|GO:0004386|	GO:0042981|
GN010135.1	sp|K1PSM9|K1PSM9_CRAGI	0.0e+00	1640.9	99.30%	72.32%	Putative ATP-dependent RNA helicase DDX58;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0004386|
GN010137.1	sp|K1QZ79|K1QZ79_CRAGI	5.7e-291	1005.4	100.00%	79.22%	Putative muscarinic acetylcholine receptor gar-2;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0016907|
GN008820.1	sp|K1PK84|K1PK84_CRAGI	9.3e-66	255.4	91.30%	73.81%	Oxidoreductase HTATIP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010140.1	sp|K1S180|K1S180_CRAGI	2.9e-267	926.4	99.13%	79.33%	Differentially expressed in FDCP 8-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0035556|
GN010141.1	sp|K1PZK2|K1PZK2_CRAGI	1.8e-96	357.5	98.42%	91.40%	Putative myosin regulatory light chain;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010142.1	sp|K1PM37|K1PM37_CRAGI	9.0e-284	981.5	98.96%	86.45%	THO complex subunit 5-like protein;OS=Crassostrea;PE=4;SV=1
GN010143.1	sp|A0A210QNX9|A0A210QNX9_MIZYE	7.4e-118	429.5	95.51%	62.60%	Protein LMBR1L;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN010144.1	sp|K1QLJ6|K1QLJ6_CRAGI	0.0e+00	1211.8	100.00%	87.87%	Solute carrier family 12 member 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN010145.1	sp|A0A210R293|A0A210R293_MIZYE	2.4e-53	213.8	93.57%	70.00%	Centromere protein V;OS=Mizuhopecten;PE=4;SV=1	GO:0016846|
GN010146.1	sp|K1QG83|K1QG83_CRAGI	3.0e-191	674.1	64.09%	67.76%	Bile acid receptor;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN010147.1	sp|K1PWG0|K1PWG0_CRAGI	4.6e-25	120.6	68.09%	39.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010148.1	sp|K1QVQ7|K1QVQ7_CRAGI	6.2e-98	364.0	48.12%	64.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010149.1	sp|K1QWN3|K1QWN3_CRAGI	4.5e-10	70.1	75.17%	35.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN010151.1	sp|K1QLK1|K1QLK1_CRAGI	7.3e-203	713.0	68.44%	61.27%	Metabotropic glutamate receptor 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010152.1	sp|K1RT03|K1RT03_CRAGI	1.2e-134	485.0	100.00%	68.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010153.1	sp|K1QG39|K1QG39_CRAGI	2.6e-26	125.6	60.65%	34.71%	Ceramide kinase;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN010154.1	sp|K1R2E8|K1R2E8_CRAGI	0.0e+00	1338.9	100.00%	87.41%	Prolyl endopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0004252|GO:0070008|
GN010155.1	sp|K1QVQ2|K1QVQ2_CRAGI	6.2e-112	409.1	88.94%	94.00%	Mps one binder kinase activator-like 2B;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN010156.1	sp|K1RB50|K1RB50_CRAGI	2.4e-217	760.0	100.00%	94.74%	Actin-1;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN008821.1	sp|K1PLQ6|K1PLQ6_CRAGI	8.5e-09	65.9	30.67%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010158.1	sp|K1RBA9|K1RBA9_CRAGI	1.4e-20	104.0	97.26%	71.43%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010159.1	sp|K1R133|K1R133_CRAGI	1.7e-31	141.4	88.27%	59.86%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010160.1	sp|K1R5U8|K1R5U8_CRAGI	3.4e-126	457.2	98.69%	81.27%	UBX domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003676|
GN010162.1	sp|K1RCG7|K1RCG7_CRAGI	6.6e-59	232.6	96.30%	61.88%	Carbohydrate sulfotransferase 4;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010163.1	sp|K1RFD8|K1RFD8_CRAGI	3.0e-51	206.8	100.00%	67.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN010164.1	sp|T2MDY9|T2MDY9_HYDVU	5.2e-13	81.3	55.16%	25.33%	Kelch-like ECH-associated protein 1;OS=Hydra;PE=2;SV=1
GN010165.1	sp|K1RVT1|K1RVT1_CRAGI	1.5e-69	268.5	98.84%	66.54%	Complement C1q tumor necrosis factor-related protein 6;OS=Crassostrea;PE=4;SV=1
GN008822.1	sp|K1PLQ6|K1PLQ6_CRAGI	4.6e-16	90.5	38.32%	60.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010166.1	sp|A0A210QQ94|A0A210QQ94_MIZYE	3.0e-98	365.2	97.87%	32.77%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN010168.1	sp|M4VR96|M4VR96_MYTGA	1.5e-31	141.7	98.92%	36.07%	Toll-like receptor W;OS=Mytilus;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN010169.1	sp|A0A210R699|A0A210R699_MIZYE	1.0e-27	129.8	55.80%	34.46%	Toll-like receptor 6;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN010171.1	sp|K1RCH3|K1RCH3_CRAGI	4.1e-197	693.0	94.93%	79.61%	[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004672|
GN010172.1	sp|K1RVT4|K1RVT4_CRAGI	4.8e-120	438.0	32.56%	77.94%	Halomucin;OS=Crassostrea;PE=4;SV=1
GN010174.1	sp|K1R6T4|K1R6T4_CRAGI	4.1e-172	609.8	97.17%	82.49%	ETS-related transcription factor Elf-5;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0003700|GO:0004930|GO:0043565|
GN010175.1	sp|K1R6T4|K1R6T4_CRAGI	2.0e-234	817.8	76.90%	67.79%	ETS-related transcription factor Elf-5;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0003700|GO:0004930|GO:0043565|
GN010176.1	sp|K1QPU0|K1QPU0_CRAGI	1.0e-09	68.2	53.85%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010178.1	sp|K1R0D7|K1R0D7_CRAGI	3.0e-160	570.1	99.07%	91.17%	Eukaryotic translation initiation factor 3 subunit M;OS=Crassostrea;PE=3;SV=1	GO:0005852|	GO:0003743|
GN010179.1	sp|K1R9R3|K1R9R3_CRAGI	4.0e-82	311.2	99.81%	39.21%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010180.1	sp|K1PMG4|K1PMG4_CRAGI	8.9e-17	90.9	100.00%	81.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN008823.1	sp|K1PFT1|K1PFT1_CRAGI	4.3e-181	639.4	100.00%	90.03%	Tribbles-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN010181.1	sp|K1RAG1|K1RAG1_CRAGI	3.8e-72	277.7	100.00%	44.61%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN010182.1	sp|K1PMC5|K1PMC5_CRAGI	2.0e-38	164.1	97.73%	64.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010184.1	sp|K1PLC5|K1PLC5_CRAGI	8.8e-40	170.2	92.93%	30.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010185.1	sp|K1R190|K1R190_CRAGI	4.1e-14	83.6	87.10%	49.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010186.1	sp|A0A210QUH5|A0A210QUH5_MIZYE	1.6e-45	188.0	96.25%	59.48%	Low molecular weight phosphotyrosine protein phosphatase;OS=Mizuhopecten;PE=4;SV=1	GO:0005737|	GO:0003993|GO:0004726|
GN010187.1	sp|K1PYE6|K1PYE6_CRAGI	1.3e-134	485.3	66.36%	85.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010189.1	sp|A0A210QRZ3|A0A210QRZ3_MIZYE	1.7e-31	141.7	81.86%	42.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004842|
GN010190.1	sp|A0A210QRZ3|A0A210QRZ3_MIZYE	7.2e-74	283.5	99.52%	39.76%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004842|
GN010191.1	sp|K1R5P4|K1R5P4_CRAGI	3.9e-154	550.1	85.42%	80.78%	E3 ubiquitin-protein ligase RSP5;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN010192.1	sp|K1QK91|K1QK91_CRAGI	0.0e+00	1403.3	100.00%	88.49%	Prestin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008271|
GN010193.1	sp|K1QK91|K1QK91_CRAGI	4.9e-44	182.6	88.14%	84.47%	Prestin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008271|
GN010194.1	sp|K1QK91|K1QK91_CRAGI	5.3e-214	749.2	100.00%	83.16%	Prestin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008271|
GN008824.1	sp|K1QD00|K1QD00_CRAGI	1.1e-23	114.4	78.48%	95.08%	Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0046872|
GN010195.1	sp|K1QDW9|K1QDW9_CRAGI	3.2e-212	743.8	90.79%	68.75%	Prestin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008271|
GN010196.1	sp|K1Q5T3|K1Q5T3_CRAGI	8.7e-64	248.8	99.45%	66.30%	DNA damage-regulated autophagy modulator protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0010506|
GN010197.1	sp|A0A210QUF7|A0A210QUF7_MIZYE	5.6e-74	283.5	99.38%	51.66%	Homeobox protein aristaless-like 4;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN010198.1	sp|H9LIF3|H9LIF3_CRAAR	1.3e-72	278.5	95.26%	76.02%	Mediator complex subunit 30-like protein;OS=Crassostrea;PE=2;SV=1
GN010199.1	sp|K1QMD3|K1QMD3_CRAGI	3.4e-190	669.8	90.03%	92.59%	Glycerol-3-phosphate dehydrogenase [NAD(+)];OS=Crassostrea;PE=3;SV=1	GO:0009331|	GO:0004367|GO:0051287|GO:0042803|	GO:0005975|GO:0046168|
GN010200.1	sp|A0A210Q2R2|A0A210Q2R2_MIZYE	2.1e-82	311.6	95.38%	53.55%	Immunoglobulin-binding protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0009966|
GN010201.1	sp|K1PCY0|K1PCY0_CRAGI	1.8e-11	73.2	86.27%	79.07%	UPF0562 protein C7orf55;OS=Crassostrea;PE=4;SV=1
GN010202.1	sp|K1P6W8|K1P6W8_CRAGI	1.9e-131	474.2	100.00%	86.23%	GATA zinc finger domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0043565|GO:0008270|	GO:0006355|
GN010203.1	sp|K1QCY0|K1QCY0_CRAGI	9.5e-253	878.2	80.17%	89.50%	Serine hydroxymethyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004372|GO:0008168|GO:0030170|	GO:0019264|GO:0035999|
GN010206.1	sp|K1Q907|K1Q907_CRAGI	2.2e-31	142.9	82.57%	23.33%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010207.1	sp|A0A210QM04|A0A210QM04_MIZYE	2.1e-13	82.8	46.67%	25.23%	Tripartite motif-containing protein 2;OS=Mizuhopecten;PE=4;SV=1
GN010208.1	sp|K1PSG6|K1PSG6_CRAGI	2.9e-276	956.4	88.99%	79.01%	Neutral and basic amino acid transport protein rBAT;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|	GO:0005975|
GN010210.1	sp|A0A210Q444|A0A210Q444_MIZYE	2.5e-97	360.9	100.00%	60.90%	C-5 sterol desaturase erg32;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005506|GO:0016491|	GO:0008610|
GN010211.1	sp|K1QCX0|K1QCX0_CRAGI	1.4e-119	436.4	97.59%	36.15%	V-type proton ATPase subunit F;OS=Crassostrea;PE=4;SV=1	GO:0033180|	GO:0046961|	GO:0015991|GO:0042981|
GN010212.1	sp|A0A210QWY1|A0A210QWY1_MIZYE	1.1e-57	228.0	100.00%	89.34%	V-type proton ATPase subunit F;OS=Mizuhopecten;PE=3;SV=1	GO:0033180|	GO:0046961|	GO:0015991|
GN008825.1	sp|K1Q6H8|K1Q6H8_CRAGI	3.3e-22	112.5	41.09%	30.86%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN010213.1	sp|K1P6V6|K1P6V6_CRAGI	1.2e-105	389.0	100.00%	60.97%	Transmembrane and ubiquitin-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030433|
GN010214.1	sp|K1PCW8|K1PCW8_CRAGI	0.0e+00	2084.3	99.77%	73.54%	Bromodomain adjacent to zinc finger domain protein 2B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046872|
GN010215.1	sp|A0A210QWZ3|A0A210QWZ3_MIZYE	7.9e-107	393.3	97.83%	62.12%	WD repeat, SAM and U-box domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004842|
GN010216.1	sp|K1PKF8|K1PKF8_CRAGI	1.7e-201	708.0	95.34%	71.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010217.1	sp|K1QCX5|K1QCX5_CRAGI	2.2e-143	515.0	82.52%	62.40%	Cyclic AMP-dependent transcription factor ATF-2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0003676|	GO:0006357|
GN010218.1	sp|K1P6W2|K1P6W2_CRAGI	8.9e-127	459.1	98.19%	62.01%	Thyrotropin-releasing hormone receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010219.1	sp|K1PUA9|K1PUA9_CRAGI	7.0e-202	709.5	86.47%	53.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008826.1	sp|K1Q6H8|K1Q6H8_CRAGI	2.9e-21	109.4	40.43%	30.11%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN010220.1	sp|K1PPJ8|K1PPJ8_CRAGI	7.4e-30	135.6	92.91%	49.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN010222.1	sp|K1PAC6|K1PAC6_CRAGI	6.8e-120	436.0	90.40%	90.38%	Homeobox even-skipped-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN010223.1	sp|K1QA73|K1QA73_CRAGI	1.2e-78	298.5	75.54%	89.14%	Homeobox protein XHOX-3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN010224.1	sp|K1QA73|K1QA73_CRAGI	1.7e-24	117.9	52.55%	87.32%	Homeobox protein XHOX-3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN010225.1	sp|K1PAB7|K1PAB7_CRAGI	2.9e-98	364.0	98.23%	78.70%	Protein HEXIM1;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0004861|GO:0017069|	GO:0000122|
GN010226.1	sp|K1P3Q5|K1P3Q5_CRAGI	0.0e+00	1296.2	92.96%	87.57%	Programmed cell death 6-interacting protein;OS=Crassostrea;PE=4;SV=1
GN010227.1	sp|K1QA67|K1QA67_CRAGI	2.3e-184	650.2	100.00%	94.86%	Cell division protein kinase 6;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0051301|
GN010228.1	sp|K1PH92|K1PH92_CRAGI	1.8e-39	169.1	32.54%	80.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010229.1	sp|K1QP56|K1QP56_CRAGI	1.9e-118	431.0	100.00%	77.26%	Proteasome inhibitor PI31 subunit;OS=Crassostrea;PE=4;SV=1	GO:0000502|
GN010230.1	sp|K1Q375|K1Q375_CRAGI	1.6e-183	647.9	99.33%	72.69%	tRNA guanosine-2'-O-methyltransferase TRM11-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008168|GO:0003676|
GN010231.1	sp|K1PWC3|K1PWC3_CRAGI	4.5e-147	526.2	97.94%	92.25%	Tetratricopeptide repeat protein 35;OS=Crassostrea;PE=4;SV=1
GN010232.1	sp|B6RB89|B6RB89_HALDI	2.4e-107	394.0	98.84%	95.28%	Axonemal dynein light chain p33;OS=Haliotis;PE=2;SV=1
GN010233.1	sp|K1PH89|K1PH89_CRAGI	1.7e-145	521.2	100.00%	68.75%	Calumenin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010234.1	sp|K1PH87|K1PH87_CRAGI	0.0e+00	1087.4	97.84%	89.85%	Soluble guanylate cyclase 88E;OS=Crassostrea;PE=4;SV=1	GO:0004383|GO:0020037|	GO:0035556|
GN010235.1	sp|A0A0L8HMN5|A0A0L8HMN5_OCTBM	1.8e-89	335.1	88.80%	49.05%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN010236.1	sp|K1QHC8|K1QHC8_CRAGI	6.4e-124	449.5	99.71%	70.20%	DNA repair protein XRCC4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006310|GO:0006302|
GN010237.1	sp|K1QTA3|K1QTA3_CRAGI	1.9e-93	350.1	21.04%	67.44%	Latrophilin-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN010238.1	sp|K1QKU8|K1QKU8_CRAGI	1.7e-109	401.4	100.00%	62.09%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN010239.1	sp|K1PD08|K1PD08_CRAGI	9.7e-38	162.2	88.02%	56.16%	Plexin-B1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0017154|
GN010240.1	sp|K1QPE0|K1QPE0_CRAGI	8.5e-282	974.5	100.00%	94.19%	Lin-9-like protein;OS=Crassostrea;PE=4;SV=1	GO:0017053|	GO:0006351|
GN010244.1	sp|K1QH43|K1QH43_CRAGI	1.4e-161	575.9	46.91%	70.26%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0004197|
GN010244.1	sp|K1QH43|K1QH43_CRAGI	7.1e-09	68.6	13.99%	37.50%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0004197|
GN010245.1	sp|K1QH43|K1QH43_CRAGI	1.4e-38	164.9	98.68%	59.06%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0004197|
GN010247.1	sp|A0A210QZQ0|A0A210QZQ0_MIZYE	2.0e-15	88.6	83.26%	26.77%	Neuropeptide Y receptor type 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010248.1	sp|W4Y8Y6|W4Y8Y6_STRPU	1.2e-51	209.5	86.85%	40.63%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN010250.1	sp|K1QYM7|K1QYM7_CRAGI	0.0e+00	1214.1	98.12%	88.32%	1,4-alpha-glucan-branching enzyme;OS=Crassostrea;PE=4;SV=1	GO:0003844|GO:0043169|GO:0004553|	GO:0005978|
GN008832.1	sp|A0A210QSP0|A0A210QSP0_MIZYE	7.4e-30	135.6	92.06%	50.43%	Iodothyronine deiodinase;OS=Mizuhopecten;PE=3;SV=1	GO:0004800|	GO:0042446|
GN010252.1	sp|K1RKF3|K1RKF3_CRAGI	5.8e-58	229.6	90.72%	57.71%	Latrophilin-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010253.1	sp|K1P1K2|K1P1K2_CRAGI	3.8e-41	173.7	59.09%	72.41%	Glucosamine 6-phosphate N-acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004343|	GO:0006048|
GN010254.1	sp|A0A210QH91|A0A210QH91_MIZYE	5.9e-46	192.2	51.12%	25.23%	Ankyrin-2;OS=Mizuhopecten;PE=4;SV=1
GN010256.1	sp|C3YY23|C3YY23_BRAFL	9.1e-23	113.2	73.38%	34.11%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN008833.1	sp|K1PTW4|K1PTW4_CRAGI	8.1e-74	282.0	91.87%	97.95%	Protein lin-7 homolog;OS=Crassostrea;PE=3;SV=1	GO:0016323|GO:0097025|GO:0098793|	GO:0097016|	GO:0006887|GO:0007269|GO:0015031|
GN010257.1	sp|K1QAZ2|K1QAZ2_CRAGI	1.5e-64	253.1	40.43%	53.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010258.1	sp|A0A0X3Q2S1|A0A0X3Q2S1_SCHSO	2.2e-32	144.4	98.88%	80.23%	Ras suppressor protein 1;OS=Schistocephalus;PE=4;SV=1
GN010259.1	sp|K1PEC3|K1PEC3_CRAGI	8.7e-70	269.6	100.00%	91.92%	Probable cytosolic iron-sulfur protein assembly protein CIAO1 homolog;OS=Crassostrea;PE=3;SV=1	GO:0097361|	GO:0016226|
GN010260.1	sp|A0A1S3HHJ7|A0A1S3HHJ7_LINUN	6.1e-18	95.9	83.90%	53.47%	uncharacterized protein LOC106155332;OS=Lingula;PE=4;SV=1
GN010261.1	sp|K1RR10|K1RR10_CRAGI	6.5e-118	429.1	87.06%	87.78%	Peptide methionine sulfoxide reductase msrA 2;OS=Crassostrea;PE=3;SV=1	GO:0008113|
GN008834.1	sp|K1PM78|K1PM78_CRAGI	4.4e-65	254.2	46.55%	72.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010263.1	sp|K1P493|K1P493_CRAGI	4.3e-53	214.2	42.73%	79.43%	Protein odd-skipped-related 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010264.1	sp|K1PAR4|K1PAR4_CRAGI	0.0e+00	1604.7	100.00%	86.61%	Unc-45-like protein A;OS=Crassostrea;PE=4;SV=1
GN010265.1	sp|C4TJC8|C4TJC8_CRAGI	3.4e-171	606.7	99.21%	71.12%	Peptidoglycan recognition protein L;OS=Crassostrea;PE=2;SV=1	GO:0003796|GO:0008745|GO:0008270|	GO:0016998|GO:0009253|
GN010266.1	sp|K1RQ40|K1RQ40_CRAGI	3.0e-77	294.7	75.00%	47.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010268.1	sp|K1RQ40|K1RQ40_CRAGI	4.5e-76	290.8	71.53%	47.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010270.1	sp|A0A2G8JSW5|A0A2G8JSW5_STIJA	4.8e-91	340.9	63.01%	49.85%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN010273.1	sp|W4ZKT7|W4ZKT7_STRPU	9.7e-09	66.6	48.28%	39.72%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN010275.1	sp|K1QQ13|K1QQ13_CRAGI	1.9e-12	77.8	28.79%	75.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010277.1	sp|A0A2B4RXP4|A0A2B4RXP4_STYPI	3.3e-140	503.8	97.06%	59.09%	Protein MB21D2;OS=Stylophora;PE=4;SV=1
GN010278.1	sp|A0A210PG43|A0A210PG43_MIZYE	2.0e-69	268.1	91.15%	55.06%	Palmitoyltransferase ZDHHC17;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0015095|GO:0016409|
GN010279.1	sp|K1R3S4|K1R3S4_CRAGI	8.7e-151	538.9	88.36%	86.79%	Palmitoyltransferase ZDHHC17;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015095|GO:0016409|
GN010282.1	sp|K1QRH2|K1QRH2_CRAGI	7.9e-163	578.9	99.24%	72.11%	SAM pointed domain-containing Ets transcription factor;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN010283.1	sp|K1Q5D1|K1Q5D1_CRAGI	2.9e-169	600.5	90.85%	73.22%	DNA-binding protein D-ETS-4;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN010284.1	sp|Unreviewed|A0A087TEV3_9ARAC	3.3e-15	86.7	100.00%	47.12%	Transposable element Tcb2 transposase;OS=Stegodyphus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006355|GO:0006313|
GN010285.1	sp|K1PYF9|K1PYF9_CRAGI	3.1e-300	1036.2	97.61%	82.28%	ATP-binding cassette sub-family B member 8, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN010286.1	sp|K1PR74|K1PR74_CRAGI	1.7e-111	408.3	68.65%	74.70%	Opioid growth factor receptor-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0004985|
GN010293.1	sp|K1QW74|K1QW74_CRAGI	3.5e-48	196.8	65.85%	85.98%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN010294.1	sp|A0A210PYS2|A0A210PYS2_MIZYE	1.6e-22	112.1	59.21%	46.43%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010295.1	sp|K1QS31|K1QS31_CRAGI	2.4e-11	75.1	45.28%	34.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010296.1	sp|K1PRC8|K1PRC8_CRAGI	3.0e-246	856.7	99.67%	85.19%	TNF receptor-associated factor 3;OS=Crassostrea;PE=4;SV=1	GO:0004842|GO:0008270|	GO:0042981|GO:0007165|
GN010298.1	sp|K1QBH6|K1QBH6_CRAGI	5.6e-46	190.7	36.24%	69.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010299.1	sp|K1RG79|K1RG79_CRAGI	2.8e-93	347.8	61.07%	67.54%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN010300.1	sp|K1RZL5|K1RZL5_CRAGI	3.7e-43	181.0	98.68%	55.22%	Uncharacterized protein CXorf39-like protein;OS=Crassostrea;PE=4;SV=1
GN010303.1	sp|K1PCA9|K1PCA9_CRAGI	1.5e-13	80.5	98.53%	56.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008838.1	sp|K1PUC1|K1PUC1_CRAGI	9.2e-232	809.7	80.35%	52.76%	Zinc finger protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003676|
GN010304.1	sp|A0A2B4S577|A0A2B4S577_STYPI	7.5e-47	193.7	91.30%	33.73%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN010305.1	sp|K1R9W1|K1R9W1_CRAGI	3.8e-51	206.8	89.25%	62.42%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN010306.1	sp|K1QUD2|K1QUD2_CRAGI	1.0e-76	291.6	99.37%	89.17%	Selenoprotein O;OS=Crassostrea;PE=3;SV=1
GN010307.1	sp|K1R3W1|K1R3W1_CRAGI	4.3e-106	390.2	71.83%	74.03%	Arrestin domain-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN010308.1	sp|K1QT86|K1QT86_CRAGI	3.8e-21	105.5	100.00%	86.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010309.1	sp|K1R9W6|K1R9W6_CRAGI	2.2e-65	254.6	98.46%	65.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN010310.1	sp|K1RG89|K1RG89_CRAGI	0.0e+00	2242.2	100.00%	70.77%	Calmodulin-regulated spectrin-associated protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005874|	GO:0005516|GO:0008017|GO:0030507|	GO:0031175|
GN010311.1	sp|K1RZM3|K1RZM3_CRAGI	1.2e-160	571.6	100.00%	76.63%	Cartilage acidic protein 1;OS=Crassostrea;PE=4;SV=1
GN008839.1	sp|K1PEG1|K1PEG1_CRAGI	8.5e-216	755.0	100.00%	85.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN010313.1	sp|K1QUD6|K1QUD6_CRAGI	4.5e-77	293.1	100.00%	82.78%	Clathrin light chain;OS=Crassostrea;PE=3;SV=1	GO:0030132|GO:0030130|	GO:0005198|	GO:0006886|GO:0016192|
GN010314.1	sp|A0A210PUH0|A0A210PUH0_MIZYE	1.8e-109	402.1	95.92%	37.66%	Tubulin-specific chaperone cofactor E-like protein;OS=Mizuhopecten;PE=4;SV=1
GN010315.1	sp|K1S2Y8|K1S2Y8_CRAGI	8.1e-43	178.7	99.26%	75.56%	U11/U12 small nuclear ribonucleoprotein 25 kDa protein;OS=Crassostrea;PE=4;SV=1	GO:0005689|GO:0019013|	GO:0000398|
GN010316.1	sp|K1R7H7|K1R7H7_CRAGI	5.2e-161	572.8	100.00%	79.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010317.1	sp|K1RDH0|K1RDH0_CRAGI	7.1e-54	215.3	100.00%	77.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008840.1	sp|K1QYL7|K1QYL7_CRAGI	2.3e-161	575.1	97.54%	42.75%	Bardet-Biedl syndrome 12-like protein;OS=Crassostrea;PE=4;SV=1
GN010319.1	sp|K1QXT8|K1QXT8_CRAGI	1.7e-67	261.2	99.44%	70.06%	Receptor-interacting serine/threonine-protein kinase 4;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN010320.1	sp|K1QS32|K1QS32_CRAGI	1.2e-41	176.4	46.58%	43.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010321.1	sp|K1QRS9|K1QRS9_CRAGI	4.0e-10	69.7	43.56%	72.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010322.1	sp|K1QRS9|K1QRS9_CRAGI	1.9e-38	165.2	55.27%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010324.1	sp|K1R7I1|K1R7I1_CRAGI	3.3e-93	347.4	87.43%	56.70%	Histone-lysine N-methyltransferase PRDM9;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN010325.1	sp|K1RDH5|K1RDH5_CRAGI	2.6e-149	533.5	95.20%	97.67%	E3 ubiquitin-protein ligase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0016874|GO:0008270|	GO:0007275|GO:0016567|GO:0006511|
GN008841.1	sp|K1R4X9|K1R4X9_CRAGI	7.3e-270	934.9	100.00%	87.45%	UDP-N-acetylhexosamine pyrophosphorylase;OS=Crassostrea;PE=4;SV=1	GO:0070569|
GN010326.1	sp|K1QD13|K1QD13_CRAGI	4.4e-59	235.3	47.64%	67.36%	Niemann-Pick C1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN010327.1	sp|K1Q2J0|K1Q2J0_CRAGI	1.2e-93	350.1	52.57%	41.74%	Fibrillin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007160|
GN010328.1	sp|A0A2C9JYC7|A0A2C9JYC7_BIOGL	1.8e-68	264.6	78.44%	71.18%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005509|
GN010329.1	sp|K1QD13|K1QD13_CRAGI	0.0e+00	1392.9	96.92%	73.52%	Niemann-Pick C1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN010330.1	sp|A0A210Q408|A0A210Q408_MIZYE	4.5e-81	306.6	89.41%	77.14%	Niemann-Pick C1 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005319|
GN010333.1	sp|W4YHJ9|W4YHJ9_STRPU	1.4e-43	183.7	61.30%	30.19%	Uncharacterized protein;OS=Strongylocentrotus;PE=3;SV=1	GO:0016021|	GO:0022857|
GN010334.1	sp|K1PF48|K1PF48_CRAGI	0.0e+00	1841.6	100.00%	75.00%	Niemann-Pick C1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005319|
GN008842.1	sp|K1RPE1|K1RPE1_CRAGI	4.8e-31	139.8	87.10%	53.73%	Telomeric repeat-binding factor 1;OS=Crassostrea;PE=4;SV=1	GO:0042803|GO:0042162|
GN010335.1	sp|K1QDQ3|K1QDQ3_CRAGI	2.7e-32	145.2	28.97%	64.08%	Cytochrome b-c1 complex subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0005750|	GO:0006122|
GN010337.1	sp|K1QF94|K1QF94_CRAGI	2.4e-142	510.8	93.56%	75.82%	Putative G-protein coupled receptor 83;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010338.1	sp|K1PMW1|K1PMW1_CRAGI	1.3e-214	751.1	100.00%	80.94%	F-box only protein 47;OS=Crassostrea;PE=4;SV=1
GN010339.1	sp|K1QF92|K1QF92_CRAGI	2.5e-217	760.8	87.70%	70.27%	Zinc finger and BTB domain-containing protein 10;OS=Crassostrea;PE=4;SV=1
GN010340.1	sp|K1QTG7|K1QTG7_CRAGI	3.1e-103	380.6	100.00%	61.13%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010341.1	sp|K1QTG7|K1QTG7_CRAGI	4.7e-107	393.3	99.34%	63.33%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN008843.1	sp|K1RPE1|K1RPE1_CRAGI	1.0e-12	78.6	66.95%	47.44%	Telomeric repeat-binding factor 1;OS=Crassostrea;PE=4;SV=1	GO:0042803|GO:0042162|
GN010342.1	sp|K1QTG7|K1QTG7_CRAGI	1.2e-88	332.4	67.86%	64.78%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010343.1	sp|K1PFK6|K1PFK6_CRAGI	2.2e-23	114.8	92.34%	36.68%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN010344.1	sp|K1QTG7|K1QTG7_CRAGI	4.5e-110	403.3	100.00%	63.58%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010345.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	9.7e-60	235.7	98.72%	48.51%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN010347.1	sp|K1PU61|K1PU61_CRAGI	3.8e-156	556.6	100.00%	80.85%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN008844.1	sp|K1QHI1|K1QHI1_CRAGI	1.5e-305	1053.9	100.00%	72.09%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN010350.1	sp|K1QUH9|K1QUH9_CRAGI	3.9e-223	780.0	91.92%	65.45%	UNC5C-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005042|
GN010355.1	sp|K1PU14|K1PU14_CRAGI	3.7e-211	740.0	100.00%	75.96%	Ras association domain-containing protein 9;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN010356.1	sp|K1QWZ3|K1QWZ3_CRAGI	7.0e-128	462.2	100.00%	83.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010357.1	sp|K1S2B0|K1S2B0_CRAGI	4.4e-173	613.2	99.35%	63.48%	Bifunctional protein birA;OS=Crassostrea;PE=4;SV=1	GO:0004077|	GO:0006464|
GN010358.1	sp|K1S2B0|K1S2B0_CRAGI	1.9e-168	597.8	92.67%	63.83%	Bifunctional protein birA;OS=Crassostrea;PE=4;SV=1	GO:0004077|	GO:0006464|
GN010359.1	sp|K1RIL5|K1RIL5_CRAGI	1.2e-94	352.1	100.00%	63.51%	Mdm2-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0031396|
GN008845.1	sp|K1R8S4|K1R8S4_CRAGI	6.2e-86	322.4	100.00%	71.98%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010361.1	sp|K1RIL5|K1RIL5_CRAGI	1.4e-119	435.6	95.83%	48.94%	Mdm2-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0031396|
GN010362.1	sp|K1RCP3|K1RCP3_CRAGI	1.1e-152	545.0	99.71%	75.37%	Teneurin-2;OS=Crassostrea;PE=4;SV=1
GN010363.1	sp|K1R6J8|K1R6J8_CRAGI	1.9e-179	634.0	100.00%	81.59%	Wnt inhibitory factor 1;OS=Crassostrea;PE=4;SV=1
GN010364.1	sp|A0A210PIS3|A0A210PIS3_MIZYE	7.4e-76	290.0	83.59%	43.84%	Galactosylceramide sulfotransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0001733|	GO:0009247|
GN010365.1	sp|A0A2G8JF55|A0A2G8JF55_STIJA	1.9e-16	91.7	60.91%	40.48%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|GO:0008270|
GN008846.1	sp|K1QYU0|K1QYU0_CRAGI	1.5e-84	317.8	100.00%	71.58%	Collectin-12;OS=Crassostrea;PE=4;SV=1
GN010367.1	sp|K1R6I6|K1R6I6_CRAGI	5.3e-63	245.7	100.00%	89.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010368.1	sp|K1QWX7|K1QWX7_CRAGI	3.5e-228	796.2	98.42%	88.81%	Phosphonopyruvate decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0000287|GO:0033980|GO:0030976|	GO:0032923|
GN010369.1	sp|A0A210QF52|A0A210QF52_MIZYE	1.5e-96	358.6	100.00%	68.33%	Rhabdoid tumor deletion region protein 1;OS=Mizuhopecten;PE=4;SV=1
GN010370.1	sp|K1S294|K1S294_CRAGI	3.9e-109	401.4	98.40%	39.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010371.1	sp|K1RIK3|K1RIK3_CRAGI	8.4e-87	326.2	100.00%	51.78%	Sodium channel modifier 1;OS=Crassostrea;PE=4;SV=1	GO:0008380|
GN010372.1	sp|K1RCM9|K1RCM9_CRAGI	4.2e-240	835.9	100.00%	87.42%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0005528|GO:0031072|GO:0003755|
GN008847.1	sp|K1R8S4|K1R8S4_CRAGI	6.2e-86	322.4	100.00%	71.98%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010377.1	sp|K1Q450|K1Q450_CRAGI	1.1e-45	188.0	100.00%	84.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010378.1	sp|K1PX30|K1PX30_CRAGI	2.7e-118	430.6	100.00%	79.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010379.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	3751.4	55.52%	64.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN010380.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	3755.3	56.68%	64.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN010381.1	sp|K1PQD9|K1PQD9_CRAGI	1.2e-208	731.9	69.01%	86.23%	Branched-chain-amino-acid aminotransferase;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0004084|GO:0003677|	GO:0009081|
GN010383.1	sp|K1QCL6|K1QCL6_CRAGI	1.4e-151	541.6	100.00%	86.96%	Proteasomal ubiquitin receptor ADRM1;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|
GN010384.1	sp|K1Q583|K1Q583_CRAGI	4.4e-102	376.7	94.81%	70.36%	Dorsal root ganglia homeobox protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN010385.1	sp|K1R4Z1|K1R4Z1_CRAGI	4.1e-29	132.5	90.36%	74.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010387.1	sp|K1Q2T8|K1Q2T8_CRAGI	5.3e-10	69.7	60.00%	64.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010388.1	sp|A0A2B4R1B6|A0A2B4R1B6_STYPI	3.5e-15	87.0	100.00%	32.43%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0046872|
GN010389.1	sp|K1QDB3|K1QDB3_CRAGI	7.2e-39	165.2	83.65%	94.19%	Cleavage and polyadenylation specificity factor subunit 3;OS=Crassostrea;PE=4;SV=1
GN010390.1	sp|K1QDB3|K1QDB3_CRAGI	0.0e+00	1128.2	99.48%	95.97%	Cleavage and polyadenylation specificity factor subunit 3;OS=Crassostrea;PE=4;SV=1
GN008849.1	sp|K1R8S4|K1R8S4_CRAGI	6.0e-85	319.3	87.14%	71.43%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010391.1	sp|K1QJK5|K1QJK5_CRAGI	1.3e-134	485.3	77.96%	71.95%	Peptide chain release factor 1-like, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003747|
GN010392.1	sp|K1R558|K1R558_CRAGI	5.3e-40	170.6	96.88%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003690|GO:0003723|GO:0003697|	GO:0006281|
GN010393.1	sp|K1PP88|K1PP88_CRAGI	2.1e-53	216.1	43.98%	41.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010394.1	sp|K1QVL9|K1QVL9_CRAGI	4.0e-61	240.4	98.74%	50.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010395.1	sp|K1PPN5|K1PPN5_CRAGI	1.4e-63	248.1	88.70%	70.51%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN010396.1	sp|K1RJN9|K1RJN9_CRAGI	2.0e-44	184.5	71.67%	70.31%	Myeloid differentiation primary response protein MyD88;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN010397.1	sp|C4TJC8|C4TJC8_CRAGI	7.3e-206	722.2	97.79%	66.87%	Peptidoglycan recognition protein L;OS=Crassostrea;PE=2;SV=1	GO:0003796|GO:0008745|GO:0008270|	GO:0016998|GO:0009253|
GN010398.1	sp|K1RJQ4|K1RJQ4_CRAGI	1.6e-41	174.9	99.47%	81.58%	Protein phosphatase inhibitor 2;OS=Crassostrea;PE=4;SV=1	GO:0004864|	GO:0009966|
GN010399.1	sp|K1R023|K1R023_CRAGI	1.9e-156	558.5	47.94%	80.56%	SET and MYND domain-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN008850.1	sp|K1QYU0|K1QYU0_CRAGI	1.7e-24	117.1	88.61%	71.01%	Collectin-12;OS=Crassostrea;PE=4;SV=1
GN010400.1	sp|K1QWV5|K1QWV5_CRAGI	2.5e-192	677.2	100.00%	75.38%	Putative metal tolerance protein C3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN010401.1	sp|K1QKU5|K1QKU5_CRAGI	1.3e-182	644.8	95.36%	69.35%	Di-N-acetylchitobiase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005975|
GN010402.1	sp|A0A210QLV4|A0A210QLV4_MIZYE	0.0e+00	1105.5	84.00%	34.13%	Calcineurin-binding protein cabin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0006336|
GN010403.1	sp|K1QT91|K1QT91_CRAGI	0.0e+00	1249.2	61.54%	73.16%	LIM domain and actin-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN010404.1	sp|A0A210QZW9|A0A210QZW9_MIZYE	1.5e-79	300.8	100.00%	97.18%	Thioredoxin-like protein 4A;OS=Mizuhopecten;PE=4;SV=1	GO:0046540|	GO:0000398|
GN008686.1	sp|A0A210QTD7|A0A210QTD7_MIZYE	3.1e-65	255.0	50.95%	52.65%	DNA damage-regulated autophagy modulator protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN010406.1	sp|K9JAB2|K9JAB2_OSTED	3.7e-94	349.7	100.00%	94.59%	Myeloid differentiation primary response protein 88;OS=Ostrea;PE=2;SV=1	GO:0007165|
GN010407.1	sp|K1QC47|K1QC47_CRAGI	6.0e-48	196.8	79.21%	48.42%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN010408.1	sp|K1QE29|K1QE29_CRAGI	3.1e-220	770.4	100.00%	70.85%	Myeloid differentiation primary response protein MyD88;OS=Crassostrea;PE=4;SV=1	GO:0070976|	GO:0002755|GO:0043123|
GN010409.1	sp|K1QMB0|K1QMB0_CRAGI	5.9e-168	597.0	88.84%	45.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010410.1	sp|K1QTC5|K1QTC5_CRAGI	5.6e-134	483.4	71.78%	68.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008851.1	sp|K1QYU0|K1QYU0_CRAGI	8.4e-83	312.0	100.00%	72.68%	Collectin-12;OS=Crassostrea;PE=4;SV=1
GN010413.1	sp|K1RDN4|K1RDN4_CRAGI	3.3e-164	583.9	56.90%	94.08%	Kelch-like protein 18;OS=Crassostrea;PE=4;SV=1
GN010414.1	sp|K1QUR2|K1QUR2_CRAGI	0.0e+00	1283.5	100.00%	78.99%	Tetratricopeptide repeat protein 25;OS=Crassostrea;PE=4;SV=1
GN010415.1	sp|K1PZI7|K1PZI7_CRAGI	0.0e+00	1333.2	100.00%	68.32%	DNA replication licensing factor MCM9;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003677|	GO:0006270|
GN010416.1	sp|A0A210QV24|A0A210QV24_MIZYE	2.7e-261	906.7	94.74%	74.14%	78 kDa glucose-regulated protein;OS=Mizuhopecten;PE=2;SV=1	GO:0005524|
GN010417.1	sp|K1QEV6|K1QEV6_CRAGI	2.0e-104	384.0	100.00%	90.05%	Ras-related and estrogen-regulated growth inhibitor;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN010418.1	sp|K1Q6V1|K1Q6V1_CRAGI	2.9e-112	410.6	99.02%	63.12%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010419.1	sp|K1PVU0|K1PVU0_CRAGI	9.6e-30	135.6	97.56%	41.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008852.1	sp|K1QYU0|K1QYU0_CRAGI	1.8e-89	334.3	88.89%	77.05%	Collectin-12;OS=Crassostrea;PE=4;SV=1
GN010420.1	sp|K1Q6V1|K1Q6V1_CRAGI	1.7e-82	311.2	97.70%	64.45%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010421.1	sp|K1Q6V1|K1Q6V1_CRAGI	3.8e-63	246.9	90.52%	59.47%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010422.1	sp|K1QKD8|K1QKD8_CRAGI	3.8e-34	149.8	72.66%	87.10%	Cytosolic carboxypeptidase 2;OS=Crassostrea;PE=4;SV=1	GO:0004181|GO:0008270|
GN010423.1	sp|A0A2C9K6P4|A0A2C9K6P4_BIOGL	4.1e-56	223.4	92.63%	60.57%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|	GO:0043085|GO:0016485|
GN010424.1	sp|K1R6P1|K1R6P1_CRAGI	0.0e+00	1169.5	92.02%	71.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010427.1	sp|K1PZJ2|K1PZJ2_CRAGI	0.0e+00	1513.4	100.00%	88.53%	Transcription elongation factor SPT5;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003746|	GO:0032784|GO:0006357|
GN008853.1	sp|K1R8S4|K1R8S4_CRAGI	2.0e-84	317.4	100.00%	71.98%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010429.1	sp|K1PJS4|K1PJS4_CRAGI	4.0e-106	392.9	15.46%	76.64%	Zonadhesin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010430.1	sp|K1QKD8|K1QKD8_CRAGI	0.0e+00	2238.4	100.00%	73.51%	Cytosolic carboxypeptidase 2;OS=Crassostrea;PE=4;SV=1	GO:0004181|GO:0008270|
GN010431.1	sp|A0A210QPU8|A0A210QPU8_MIZYE	2.1e-148	530.8	99.40%	74.70%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010432.1	sp|K1PZJ0|K1PZJ0_CRAGI	0.0e+00	1195.6	76.03%	68.55%	Metabotropic glutamate receptor 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010434.1	sp|C8BLQ8|C8BLQ8_9BIVA	1.2e-78	298.1	100.00%	73.03%	Uncharacterized protein;OS=Crassostrea;PE=2;SV=1
GN010435.1	sp|K1Q4U8|K1Q4U8_CRAGI	7.6e-146	523.9	39.17%	59.54%	Beta-1,3-glucan-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0005975|
GN010436.1	sp|K1QV53|K1QV53_CRAGI	4.5e-245	852.4	98.11%	83.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016715|
GN010437.1	sp|K1QMM4|K1QMM4_CRAGI	4.7e-127	459.5	100.00%	93.21%	Leucine zipper transcription factor-like protein 1;OS=Crassostrea;PE=4;SV=1
GN010438.1	sp|K1RLC8|K1RLC8_CRAGI	2.8e-89	334.3	96.58%	57.23%	DTW domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN010441.1	sp|K1QMM2|K1QMM2_CRAGI	6.8e-133	479.6	100.00%	76.46%	Microtubule-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0015631|
GN008854.1	sp|K1QYT6|K1QYT6_CRAGI	9.7e-141	505.4	100.00%	78.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010442.1	sp|K1QDY2|K1QDY2_CRAGI	2.1e-50	205.7	32.11%	73.65%	Microtubule-associated protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005874|	GO:0015631|
GN010443.1	sp|K1RLC5|K1RLC5_CRAGI	1.4e-17	94.7	100.00%	44.96%	T-complex protein 1 subunit epsilon;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN010444.1	sp|K1RLC5|K1RLC5_CRAGI	9.3e-237	824.7	99.33%	93.44%	T-complex protein 1 subunit epsilon;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN010445.1	sp|K1R1W7|K1R1W7_CRAGI	1.5e-63	247.7	100.00%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010446.1	sp|K1QV46|K1QV46_CRAGI	0.0e+00	2132.1	98.78%	84.87%	Tetratricopeptide repeat protein 21B;OS=Crassostrea;PE=4;SV=1
GN010447.1	sp|A0A1S3HZQ8|A0A1S3HZQ8_LINUN	1.3e-26	127.5	74.29%	24.29%	uncharacterized protein LOC106159339 isoform X1;OS=Lingula;PE=4;SV=1	GO:0005813|GO:0005874|GO:0000922|	GO:0032467|
GN010448.1	sp|K1QDX8|K1QDX8_CRAGI	5.0e-16	90.5	93.07%	31.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010449.1	sp|A0A210QPF9|A0A210QPF9_MIZYE	1.2e-96	359.0	59.18%	88.84%	U1 small nuclear ribonucleoprotein 70 kDa;OS=Mizuhopecten;PE=4;SV=1	GO:0005685|GO:0019013|	GO:0030619|	GO:0000398|
GN010450.1	sp|K1RLC2|K1RLC2_CRAGI	2.9e-258	896.3	93.97%	98.76%	Potassium voltage-gated channel protein Shaker;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN010451.1	sp|K1Q4X4|K1Q4X4_CRAGI	4.8e-125	452.6	99.11%	97.29%	Ropporin-1-like protein;OS=Crassostrea;PE=4;SV=1
GN010452.1	sp|A0A210PYS5|A0A210PYS5_MIZYE	8.2e-24	115.9	63.53%	54.63%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN010453.1	sp|K1RC20|K1RC20_CRAGI	6.5e-129	465.7	98.11%	83.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010454.1	sp|K1RC20|K1RC20_CRAGI	6.8e-126	455.7	98.11%	81.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010455.1	sp|K1QCF7|K1QCF7_CRAGI	3.4e-192	676.4	95.89%	95.99%	Myosin light chain kinase, smooth muscle;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN010456.1	sp|K1Q136|K1Q136_CRAGI	7.3e-37	159.8	55.56%	51.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010459.1	sp|K1RC23|K1RC23_CRAGI	3.7e-269	932.6	95.37%	90.06%	Fatty acyl-CoA reductase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102965|GO:0080019|	GO:0006629|
GN008855.1	sp|K1PTJ8|K1PTJ8_CRAGI	1.1e-11	74.7	88.37%	46.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010462.1	sp|K1RJT8|K1RJT8_CRAGI	6.0e-133	479.6	99.72%	65.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010466.1	sp|K1QMK9|K1QMK9_CRAGI	0.0e+00	1427.5	99.32%	73.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0006801|
GN010467.1	sp|K1Q136|K1Q136_CRAGI	2.3e-09	68.2	37.93%	41.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010468.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	5.5e-29	134.4	27.21%	56.64%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010469.1	sp|K1QMK9|K1QMK9_CRAGI	2.1e-125	454.1	98.56%	73.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0006801|
GN010470.1	sp|K1QMK9|K1QMK9_CRAGI	4.4e-86	323.2	96.85%	66.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0006801|
GN010471.1	sp|A0A210R1F5|A0A210R1F5_MIZYE	8.4e-49	199.1	86.67%	57.89%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010472.1	sp|K1R8N7|K1R8N7_CRAGI	1.5e-25	120.9	93.14%	71.28%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010473.1	sp|K1REF4|K1REF4_CRAGI	3.9e-109	400.6	99.50%	63.61%	Gametocyte-specific factor 1;OS=Crassostrea;PE=4;SV=1
GN010474.1	sp|K1RRD7|K1RRD7_CRAGI	4.6e-144	516.5	89.87%	69.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010477.1	sp|K1R8N4|K1R8N4_CRAGI	1.8e-132	478.0	99.73%	65.53%	Zinc transporter ZIP10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN010478.1	sp|A0A2R2MTC6|A0A2R2MTC6_LINUN	1.5e-33	151.0	46.34%	26.02%	C4b-binding protein alpha chain-like;OS=Lingula;PE=4;SV=1
GN010479.1	sp|K1PXQ6|K1PXQ6_CRAGI	4.6e-141	508.4	38.53%	46.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010480.1	sp|A0A210QLA0|A0A210QLA0_MIZYE	1.7e-104	385.2	81.12%	59.75%	Sodium-coupled monocarboxylate transporter 1;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0022857|
GN010482.1	sp|K1QHX0|K1QHX0_CRAGI	2.0e-90	337.8	100.00%	67.55%	Double-stranded RNA-specific editase 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0007283|
GN010483.1	sp|A0A210PHI6|A0A210PHI6_MIZYE	6.2e-172	612.1	34.30%	49.42%	PHD finger protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016817|GO:0046872|	GO:0006351|
GN010483.1	sp|A0A210PHI6|A0A210PHI6_MIZYE	6.7e-17	97.1	10.21%	39.30%	PHD finger protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016817|GO:0046872|	GO:0006351|
GN010487.1	sp|K1R7H3|K1R7H3_CRAGI	7.3e-173	612.1	100.00%	87.13%	NAD-dependent alcohol dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN008857.1	sp|K1PFR4|K1PFR4_CRAGI	1.5e-29	135.2	78.22%	43.67%	Alpha-tectorin;OS=Crassostrea;PE=4;SV=1	GO:0007160|
GN010491.1	sp|K1Q369|K1Q369_CRAGI	8.0e-48	195.7	92.81%	54.55%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010492.1	sp|K1Q369|K1Q369_CRAGI	6.3e-47	192.6	99.35%	58.71%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010493.1	sp|K1Q369|K1Q369_CRAGI	4.8e-47	193.0	99.35%	58.71%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1
GN010494.1	sp|K1RH94|K1RH94_CRAGI	1.5e-149	535.0	98.91%	57.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010495.1	sp|A0A0L8GGK3|A0A0L8GGK3_OCTBM	1.2e-34	151.8	45.75%	100.00%	U1 small nuclear ribonucleoprotein C;OS=Octopus;PE=3;SV=1	GO:0000243|GO:0005685|GO:0071004|	GO:0003729|GO:0030619|GO:0008270|	GO:0000395|GO:0000387|
GN010497.1	sp|K1PWE1|K1PWE1_CRAGI	5.7e-106	389.8	99.70%	53.64%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN010498.1	sp|K1PWE1|K1PWE1_CRAGI	5.9e-162	577.0	61.73%	54.70%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN010499.1	sp|K1PWE1|K1PWE1_CRAGI	2.0e-168	598.6	57.30%	56.37%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN010501.1	sp|A0A210PST3|A0A210PST3_MIZYE	2.3e-105	388.3	94.09%	56.56%	Oxysterol-binding protein-related protein 1;OS=Mizuhopecten;PE=4;SV=1
GN010502.1	sp|A0A1S3KCW4|A0A1S3KCW4_LINUN	4.1e-11	72.4	73.13%	77.08%	oxysterol-binding protein-related protein 1;OS=Lingula;PE=4;SV=1
GN010503.1	sp|K1RWJ1|K1RWJ1_CRAGI	2.5e-09	67.4	58.14%	48.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010504.1	sp|A0A210PSS7|A0A210PSS7_MIZYE	9.4e-162	575.5	92.94%	72.34%	Oxysterol-binding protein;OS=Mizuhopecten;PE=3;SV=1	GO:0006869|
GN010505.1	sp|K1QGL1|K1QGL1_CRAGI	3.2e-149	533.5	99.70%	79.33%	Kelch domain-containing protein 9;OS=Crassostrea;PE=4;SV=1
GN010507.1	sp|K1PPG1|K1PPG1_CRAGI	3.8e-42	177.6	45.94%	72.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010509.1	sp|K1Q3T6|K1Q3T6_CRAGI	4.7e-77	293.1	96.30%	73.56%	Tetraspanin-31;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN010510.1	sp|K1PQ43|K1PQ43_CRAGI	3.0e-49	200.7	95.10%	61.11%	Sorting nexin-11;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN010511.1	sp|K1P4A1|K1P4A1_CRAGI	1.4e-139	502.3	68.28%	86.11%	F-box/LRR-repeat protein 7;OS=Crassostrea;PE=4;SV=1
GN010512.1	sp|K1PUB2|K1PUB2_CRAGI	2.4e-14	84.7	36.68%	62.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010514.1	sp|K1QIN0|K1QIN0_CRAGI	2.3e-99	367.1	99.49%	91.79%	Uncharacterized protein C11orf73-like protein;OS=Crassostrea;PE=4;SV=1
GN010516.1	sp|K1QUX3|K1QUX3_CRAGI	5.1e-14	82.0	98.48%	51.56%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN010517.1	sp|K1QWK6|K1QWK6_CRAGI	3.0e-10	69.3	82.76%	63.83%	Metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005509|GO:0004222|GO:0008270|
GN010518.1	sp|K1QMP8|K1QMP8_CRAGI	6.6e-47	192.2	94.40%	74.36%	Activator of basal transcription 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN010519.1	sp|E9JS89|E9JS89_OSTED	1.5e-186	657.5	100.00%	97.01%	Galectin;OS=Ostrea;PE=2;SV=1	GO:0030246|
GN010520.1	sp|K1Q866|K1Q866_CRAGI	6.7e-296	1021.9	95.76%	86.98%	RAS and EF-hand domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0005525|GO:0003924|
GN010521.1	sp|K1Q0Z8|K1Q0Z8_CRAGI	6.1e-52	208.8	100.00%	89.29%	RAS and EF-hand domain-containing-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010523.1	sp|K1RF80|K1RF80_CRAGI	2.8e-159	567.4	97.83%	60.79%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN010524.1	sp|K1R8M2|K1R8M2_CRAGI	8.3e-59	232.3	83.43%	71.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010525.1	sp|A0A3M6UFK7|A0A3M6UFK7_9CNID	6.2e-41	173.3	84.55%	41.23%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN010527.1	sp|K1Q2R1|K1Q2R1_CRAGI	2.2e-88	332.8	99.33%	29.19%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit C;OS=Crassostrea;PE=4;SV=1
GN010529.1	sp|V4CK76|V4CK76_LOTGI	4.9e-39	166.0	96.67%	68.10%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004045|
GN010530.1	sp|K1QR51|K1QR51_CRAGI	4.0e-135	488.0	97.79%	63.70%	Transcription elongation factor B polypeptide 3;OS=Crassostrea;PE=4;SV=1	GO:0070449|	GO:0003746|	GO:0006357|
GN010531.1	sp|K1Q519|K1Q519_CRAGI	1.9e-82	311.2	84.43%	69.52%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN010532.1	sp|K1QXP0|K1QXP0_CRAGI	1.4e-61	241.5	91.21%	68.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN010533.1	sp|K1PW38|K1PW38_CRAGI	6.7e-92	342.4	100.00%	81.13%	Homeobox protein engrailed-like;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN010534.1	sp|K1PNG1|K1PNG1_CRAGI	5.0e-109	399.4	100.00%	86.46%	Segmentation polarity homeobox protein engrailed;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN008687.1	sp|K1R8V5|K1R8V5_CRAGI	4.4e-96	356.3	83.17%	98.26%	NEDD8-conjugating enzyme Ubc12;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN010535.1	sp|K1PW35|K1PW35_CRAGI	2.4e-115	421.0	97.34%	68.37%	Homeobox protein GBX-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN010536.1	sp|K1R608|K1R608_CRAGI	7.2e-54	216.1	96.21%	53.96%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN010537.1	sp|K1QG66|K1QG66_CRAGI	2.0e-68	265.4	100.00%	54.95%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN010538.1	sp|K1RZT4|K1RZT4_CRAGI	0.0e+00	1946.8	90.68%	80.04%	Contactin;OS=Crassostrea;PE=4;SV=1
GN010539.1	sp|K1PLV8|K1PLV8_CRAGI	1.3e-147	528.9	69.20%	85.42%	NK-tumor recognition protein;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN010540.1	sp|K1PTW2|K1PTW2_CRAGI	2.8e-38	165.2	76.60%	62.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010543.1	sp|K1QE77|K1QE77_CRAGI	1.3e-106	392.1	61.54%	86.55%	Solute carrier family 25 member 40;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN010545.1	sp|K1QE79|K1QE79_CRAGI	7.3e-152	543.1	63.59%	65.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010546.1	sp|K1PE28|K1PE28_CRAGI	7.3e-45	185.7	75.17%	79.28%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN010547.1	sp|K1PE28|K1PE28_CRAGI	3.0e-57	226.9	99.36%	73.38%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN010548.1	sp|A0A210Q1H5|A0A210Q1H5_MIZYE	4.9e-265	919.1	99.33%	77.33%	Bifunctional purine biosynthesis protein PURH;OS=Mizuhopecten;PE=3;SV=1	GO:0003937|GO:0004643|	GO:0006164|
GN010549.1	sp|K1PXK0|K1PXK0_CRAGI	2.8e-96	357.5	97.31%	65.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010550.1	sp|K1PXK0|K1PXK0_CRAGI	1.7e-216	757.7	98.55%	68.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010551.1	sp|K1QXX5|K1QXX5_CRAGI	2.9e-132	477.6	86.59%	71.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010552.1	sp|K1QX19|K1QX19_CRAGI	1.2e-92	345.1	100.00%	66.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016790|	GO:0006633|
GN010553.1	sp|K1QX19|K1QX19_CRAGI	9.5e-74	282.7	80.06%	55.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016790|	GO:0006633|
GN010554.1	sp|K1QX19|K1QX19_CRAGI	4.6e-72	276.9	91.13%	53.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016790|	GO:0006633|
GN010555.1	sp|K1QS85|K1QS85_CRAGI	1.2e-124	451.8	99.69%	75.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010556.1	sp|K1RXP2|K1RXP2_CRAGI	2.5e-154	550.8	100.00%	62.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010557.1	sp|K1R7Z5|K1R7Z5_CRAGI	2.2e-41	174.5	67.37%	68.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016192|
GN008859.1	sp|V3ZY80|V3ZY80_LOTGI	1.2e-71	275.8	97.93%	50.00%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010559.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-35	156.0	58.22%	47.37%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN010561.1	sp|K1QXH5|K1QXH5_CRAGI	0.0e+00	1084.3	100.00%	78.78%	Leucine-rich repeat-containing G-protein coupled receptor 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|GO:0016500|
GN010562.1	sp|K1PPW3|K1PPW3_CRAGI	0.0e+00	1169.5	100.00%	65.09%	E3 ubiquitin-protein ligase TRIM33;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0008270|
GN010563.1	sp|K1R7F7|K1R7F7_CRAGI	1.6e-72	278.1	100.00%	63.64%	C-C chemokine receptor type 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010565.1	sp|K1R1Z6|K1R1Z6_CRAGI	2.7e-25	122.1	38.24%	39.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010566.1	sp|K1PQK0|K1PQK0_CRAGI	2.2e-296	1023.5	99.31%	71.85%	alpha-1,2-Mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0005509|GO:0004571|	GO:0008152|
GN010567.1	sp|K1PQ75|K1PQ75_CRAGI	7.0e-124	450.3	97.25%	57.52%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN010568.1	sp|K1PB09|K1PB09_CRAGI	5.9e-80	302.8	83.64%	84.27%	Ras-related and estrogen-regulated growth inhibitor-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN010569.1	sp|K1PX73|K1PX73_CRAGI	2.2e-29	134.8	92.31%	39.51%	Complement component 1 Q subcomponent-binding protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005759|
GN010570.1	sp|V4AKX4|V4AKX4_LOTGI	9.6e-35	152.9	56.99%	47.77%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN010571.1	sp|K1R2S3|K1R2S3_CRAGI	1.1e-303	1047.3	100.00%	95.28%	Sec1 family domain-containing protein 1;OS=Crassostrea;PE=3;SV=1	GO:0006904|
GN010572.1	sp|K1QTB9|K1QTB9_CRAGI	6.3e-260	901.7	100.00%	97.22%	Tektin-3;OS=Crassostrea;PE=4;SV=1
GN010573.1	sp|K1RFD8|K1RFD8_CRAGI	9.3e-44	181.8	95.42%	68.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN010575.1	sp|K1R2R5|K1R2R5_CRAGI	2.4e-72	277.7	95.55%	55.51%	Tolloid-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010576.1	sp|K1R2R5|K1R2R5_CRAGI	2.2e-28	131.3	74.62%	53.06%	Tolloid-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010577.1	sp|K1R8T1|K1R8T1_CRAGI	2.4e-196	690.6	72.48%	93.97%	Translation initiation factor eIF-2B subunit delta;OS=Crassostrea;PE=3;SV=1	GO:0003743|
GN010579.1	sp|A0A2G8KA18|A0A2G8KA18_STIJA	3.2e-25	121.3	96.40%	30.90%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0004190|
GN010580.1	sp|K1QF17|K1QF17_CRAGI	2.8e-15	88.2	87.55%	31.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010581.1	sp|K1PSE0|K1PSE0_CRAGI	2.9e-68	264.2	65.06%	77.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010582.1	sp|K1R086|K1R086_CRAGI	1.3e-218	764.6	100.00%	81.29%	Amino acid transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015293|
GN010583.1	sp|V3ZT05|V3ZT05_LOTGI	4.1e-111	406.8	99.33%	67.56%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN010584.1	sp|K1Q5T4|K1Q5T4_CRAGI	4.8e-148	529.6	91.07%	80.48%	Protein quiver;OS=Crassostrea;PE=3;SV=1	GO:0031225|GO:0005886|	GO:0003860|GO:0034235|	GO:1903818|GO:0045187|GO:0032222|GO:0048511|GO:0030431|
GN010585.1	sp|K1RJT3|K1RJT3_CRAGI	8.9e-52	208.8	100.00%	43.68%	Myosin-I heavy chain;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0003779|GO:0005524|GO:0003774|	GO:0006355|
GN010586.1	sp|K1RJT3|K1RJT3_CRAGI	0.0e+00	1527.7	100.00%	64.16%	Myosin-I heavy chain;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0003779|GO:0005524|GO:0003774|	GO:0006355|
GN010587.1	sp|K1QC77|K1QC77_CRAGI	3.3e-265	921.0	99.87%	55.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010589.1	sp|K1RDG2|K1RDG2_CRAGI	1.2e-78	298.9	69.38%	71.56%	Na(+)/H(+) exchange regulatory cofactor NHE-RF1;OS=Crassostrea;PE=4;SV=1
GN010591.1	sp|A0A2B4S577|A0A2B4S577_STYPI	3.0e-52	211.5	86.76%	36.91%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN010592.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	3.5e-11	75.1	33.24%	33.61%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN010593.1	sp|K1PJH3|K1PJH3_CRAGI	8.1e-111	406.0	99.72%	58.29%	B2 bradykinin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010594.1	sp|K1PPB4|K1PPB4_CRAGI	0.0e+00	1424.8	98.09%	93.64%	Protein fat-free;OS=Crassostrea;PE=4;SV=1
GN010595.1	sp|A0A0A1UA62|A0A0A1UA62_ENTIV	2.5e-37	163.3	34.30%	34.50%	ATP-dependent DNA helicase;OS=Entamoeba;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN008688.1	sp|K1RFF7|K1RFF7_CRAGI	1.0e-56	225.3	99.45%	68.89%	Protein lethal(2)essential for life;OS=Crassostrea;PE=3;SV=1
GN010596.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	3.1e-99	368.2	79.04%	42.42%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN010597.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	3.1e-99	368.2	79.04%	42.42%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN010598.1	sp|A0A0A1UA62|A0A0A1UA62_ENTIV	2.5e-37	163.3	34.30%	34.50%	ATP-dependent DNA helicase;OS=Entamoeba;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN010601.1	sp|K1RAG1|K1RAG1_CRAGI	2.9e-29	133.7	71.76%	73.12%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN010602.1	sp|K1PN41|K1PN41_CRAGI	0.0e+00	1100.1	100.00%	63.33%	Cyclin-H;OS=Crassostrea;PE=3;SV=1	GO:0070985|	GO:0016538|GO:0003700|GO:0043565|	GO:0006351|
GN010603.1	sp|K1QEW8|K1QEW8_CRAGI	4.2e-69	266.5	90.63%	73.99%	Cysteine proteinase 3;OS=Crassostrea;PE=3;SV=1	GO:0008234|
GN010604.1	sp|K1Q6V7|K1Q6V7_CRAGI	1.0e-20	104.8	69.23%	88.71%	Liprin-beta-2;OS=Crassostrea;PE=4;SV=1
GN010606.1	sp|K1PZJ9|K1PZJ9_CRAGI	0.0e+00	1304.7	94.17%	82.38%	Liprin-beta-1;OS=Crassostrea;PE=4;SV=1
GN010607.1	sp|K1QLJ0|K1QLJ0_CRAGI	1.5e-79	303.1	48.33%	47.90%	Toll-like receptor 2 type-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN010608.1	sp|K1QLJ0|K1QLJ0_CRAGI	4.7e-118	431.0	44.51%	65.92%	Toll-like receptor 2 type-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN008867.1	sp|K1QCU8|K1QCU8_CRAGI	2.5e-55	221.9	48.24%	64.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010609.1	sp|A0A210Q4W4|A0A210Q4W4_MIZYE	3.4e-171	607.4	78.35%	58.49%	Lipase maturation factor;OS=Mizuhopecten;PE=3;SV=1	GO:0005789|GO:0016021|
GN010610.1	sp|K1PZJ4|K1PZJ4_CRAGI	4.7e-277	959.1	99.39%	77.36%	Methylcytosine dioxygenase TET1;OS=Crassostrea;PE=4;SV=1	GO:0051213|GO:0003677|GO:0008270|
GN010611.1	sp|K1QLI8|K1QLI8_CRAGI	1.4e-144	518.5	89.02%	65.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010613.1	sp|A0A210QPP6|A0A210QPP6_MIZYE	3.9e-33	147.1	75.00%	49.66%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010614.1	sp|K1RA35|K1RA35_CRAGI	3.3e-27	127.5	31.22%	93.65%	Splicing factor, arginine/serine-rich 7;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN010615.1	sp|K1Q373|K1Q373_CRAGI	1.6e-59	235.3	38.36%	94.59%	Splicing factor, arginine/serine-rich 7;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008270|
GN010616.1	sp|K1QAD1|K1QAD1_CRAGI	1.3e-70	271.6	84.49%	80.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008868.1	sp|K1QJ94|K1QJ94_CRAGI	6.9e-216	755.7	93.39%	66.29%	Cubilin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010619.1	sp|K1QI92|K1QI92_CRAGI	6.2e-273	945.3	100.00%	88.26%	RUN domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN010621.1	sp|K1QPW6|K1QPW6_CRAGI	8.7e-294	1014.6	99.01%	83.00%	Patatin-like phospholipase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0016042|
GN010622.1	sp|K1QW73|K1QW73_CRAGI	0.0e+00	1277.3	100.00%	71.61%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN008869.1	sp|K1R4S4|K1R4S4_CRAGI	6.5e-57	226.9	94.36%	40.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010627.1	sp|K1R307|K1R307_CRAGI	4.0e-43	180.6	62.75%	64.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008870.1	sp|K1Q4X2|K1Q4X2_CRAGI	8.3e-36	156.8	29.12%	69.00%	Hepatocyte growth factor;OS=Crassostrea;PE=4;SV=1
GN010629.1	sp|W4XTE2|W4XTE2_STRPU	1.8e-19	102.8	85.88%	25.58%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0046872|
GN010630.1	sp|W4YHJ9|W4YHJ9_STRPU	1.1e-35	156.4	72.05%	35.97%	Uncharacterized protein;OS=Strongylocentrotus;PE=3;SV=1	GO:0016021|	GO:0022857|
GN010632.1	sp|K1R429|K1R429_CRAGI	1.8e-198	697.6	100.00%	79.91%	PTB domain-containing engulfment adapter protein 1;OS=Crassostrea;PE=4;SV=1
GN010633.1	sp|K1QUM9|K1QUM9_CRAGI	1.6e-92	345.1	97.88%	48.76%	Cytochrome P450 2B4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0016705|
GN010635.1	sp|K1PTG7|K1PTG7_CRAGI	1.8e-44	185.3	77.50%	44.44%	Nucleosome-remodeling factor subunit BPTF;OS=Crassostrea;PE=4;SV=1	GO:0048188|	GO:0046872|GO:0045322|
GN010636.1	sp|K1QK55|K1QK55_CRAGI	2.7e-128	464.5	81.47%	51.00%	Cytochrome P450 2B5;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN008871.1	sp|K1P3H0|K1P3H0_CRAGI	6.7e-196	689.5	92.21%	69.89%	Protein OS-9;OS=Crassostrea;PE=4;SV=1
GN010638.1	sp|K1QK55|K1QK55_CRAGI	2.2e-135	488.0	79.06%	56.86%	Cytochrome P450 2B5;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN010639.1	sp|K1R1F0|K1R1F0_CRAGI	5.6e-283	978.8	88.00%	85.64%	ATP-dependent DNA helicase 2 subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0043564|	GO:0004003|GO:0003684|GO:0042162|	GO:0006303|GO:0000723|
GN010642.1	sp|W4Y8Y6|W4Y8Y6_STRPU	3.8e-53	214.9	90.38%	33.19%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN010644.1	sp|K1QUN3|K1QUN3_CRAGI	6.7e-30	135.6	95.61%	84.26%	Zinc transporter 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN010645.1	sp|K1QUN3|K1QUN3_CRAGI	1.9e-69	268.1	82.28%	66.07%	Zinc transporter 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN010646.1	sp|K1R1F5|K1R1F5_CRAGI	1.9e-205	721.1	94.84%	72.20%	Zinc transporter ZIP10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN010647.1	sp|K1QTZ5|K1QTZ5_CRAGI	0.0e+00	1824.7	99.68%	57.19%	Transient receptor potential cation channel subfamily M member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN008872.1	sp|K1QP72|K1QP72_CRAGI	3.2e-37	161.8	70.12%	39.09%	UPF0544 protein C5orf45-like protein;OS=Crassostrea;PE=4;SV=1
GN010648.1	sp|K1Q2X6|K1Q2X6_CRAGI	6.6e-97	359.0	100.00%	84.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010649.1	sp|K1PW42|K1PW42_CRAGI	1.2e-106	391.3	99.00%	95.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010651.1	sp|K1PH16|K1PH16_CRAGI	5.7e-84	315.8	91.21%	93.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010653.1	sp|K1QNS9|K1QNS9_CRAGI	0.0e+00	1409.0	99.09%	56.50%	Protocadherin Fat 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN010655.1	sp|K1QGN6|K1QGN6_CRAGI	5.6e-174	616.3	71.20%	83.43%	NmrA-like family domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN010657.1	sp|K1R015|K1R015_CRAGI	2.5e-50	203.4	99.09%	92.66%	Two pore potassium channel protein sup-9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN008670.1	sp|K1QJ73|K1QJ73_CRAGI	2.3e-72	278.5	43.45%	78.65%	Neuropeptide Y receptor type 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008689.1	sp|K1Q171|K1Q171_CRAGI	5.9e-84	317.4	93.55%	33.91%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0019013|	GO:0003723|
GN010659.1	sp|A0A210PPW6|A0A210PPW6_MIZYE	9.1e-104	382.1	100.00%	78.17%	Potassium channel subfamily K member 9;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005267|
GN010660.1	sp|A0A3L5TTH4|A0A3L5TTH4_MYTGA	8.5e-30	136.7	70.46%	32.31%	Putative titin protein;OS=Mytilus;PE=4;SV=1
GN010662.1	sp|K1R2H6|K1R2H6_CRAGI	2.6e-48	198.7	88.72%	41.67%	DnaJ-like protein subfamily B member 5;OS=Crassostrea;PE=4;SV=1
GN010664.1	sp|K1QAT1|K1QAT1_CRAGI	1.4e-45	188.3	99.44%	50.50%	Protein sym-1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN010665.1	sp|K1QIL3|K1QIL3_CRAGI	0.0e+00	1520.0	98.05%	76.44%	Protein lap4;OS=Crassostrea;PE=4;SV=1
GN010667.1	sp|K1QQA7|K1QQA7_CRAGI	8.0e-37	160.6	91.26%	64.57%	Nucleoporin-like 2;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN010668.1	sp|K1RAG3|K1RAG3_CRAGI	2.1e-228	797.0	100.00%	84.34%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN010669.1	sp|K1Q3I2|K1Q3I2_CRAGI	1.2e-73	282.0	100.00%	63.29%	Survival of motor neuron-related-splicing factor 30;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0003723|	GO:0006397|
GN010670.1	sp|K1QAU4|K1QAU4_CRAGI	6.0e-228	795.4	100.00%	87.53%	Sorting nexin-17;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0035091|	GO:0006886|GO:0007165|
GN010671.1	sp|K1QIL8|K1QIL8_CRAGI	4.2e-78	296.2	100.00%	85.62%	Aldehyde dehydrogenase family 8 member A1;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN010673.1	sp|K1PKU7|K1PKU7_CRAGI	5.9e-64	250.4	82.78%	44.78%	Neuromedin-U receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN008873.1	sp|K1QJ88|K1QJ88_CRAGI	3.1e-41	173.3	82.64%	83.84%	Signal transducing adapter molecule 2;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0006886|
GN010674.1	sp|A0A1S3H413|A0A1S3H413_LINUN	9.8e-40	169.5	63.57%	47.65%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN010676.1	sp|K1QS65|K1QS65_CRAGI	4.5e-17	94.4	32.55%	47.92%	Histone-lysine N-methyltransferase MLL3;OS=Crassostrea;PE=3;SV=1	GO:0044666|	GO:0042800|GO:0004553|GO:0046872|GO:0016491|	GO:0005975|
GN010677.1	sp|R7V5U4|R7V5U4_CAPTE	1.3e-21	109.8	46.58%	35.36%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN008874.1	sp|K1QCP5|K1QCP5_CRAGI	4.9e-162	576.2	94.93%	75.84%	Glycosyltransferase 8 domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016757|
GN010679.1	sp|K1QS65|K1QS65_CRAGI	6.8e-18	95.9	81.95%	46.30%	Histone-lysine N-methyltransferase MLL3;OS=Crassostrea;PE=3;SV=1	GO:0044666|	GO:0042800|GO:0004553|GO:0046872|GO:0016491|	GO:0005975|
GN010681.1	sp|K1R587|K1R587_CRAGI	3.0e-176	623.6	87.14%	83.88%	Ankyrin repeat and MYND domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN010682.1	sp|K1RBS1|K1RBS1_CRAGI	1.1e-99	368.2	97.54%	87.31%	Abhydrolase domain-containing protein 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN010683.1	sp|C3S7I9|C3S7I9_CRAGI	0.0e+00	1083.9	62.23%	91.28%	Predicted phosphoinositide 4-kinase beta;OS=Crassostrea;PE=2;SV=1	GO:0016301|	GO:0046854|GO:0048015|
GN010684.1	sp|K1Q8T8|K1Q8T8_CRAGI	0.0e+00	1667.5	100.00%	69.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008875.1	sp|K1QDW1|K1QDW1_CRAGI	1.5e-49	203.0	100.00%	76.06%	Integrator complex subunit 12;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0016180|
GN010685.1	sp|K1RU09|K1RU09_CRAGI	1.5e-234	817.8	99.48%	73.14%	Prestin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008271|
GN010686.1	sp|K1PYY5|K1PYY5_CRAGI	2.0e-38	164.1	99.22%	60.63%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN010687.1	sp|K1QY17|K1QY17_CRAGI	4.5e-33	146.4	77.78%	59.62%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN010688.1	sp|K1QY17|K1QY17_CRAGI	2.3e-119	434.5	94.41%	59.60%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN010689.1	sp|K1Q7B8|K1Q7B8_CRAGI	8.3e-135	485.7	93.31%	73.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010690.1	sp|K1QQV4|K1QQV4_CRAGI	3.0e-119	433.3	97.30%	92.09%	Phosphatidylcholine transfer protein;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN010691.1	sp|K1QLP0|K1QLP0_CRAGI	0.0e+00	1649.4	99.59%	68.57%	Transient receptor potential cation channel subfamily M member 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN010693.1	sp|A0A1S3HE30|A0A1S3HE30_LINUN	8.3e-19	98.6	61.90%	67.19%	zinc finger protein 862-like;OS=Lingula;PE=4;SV=1	GO:0046983|
GN008876.1	sp|K1PS30|K1PS30_CRAGI	1.6e-74	284.3	99.35%	81.05%	Rieske domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0051537|GO:0008942|
GN010699.1	sp|A0A0P4W9K7|A0A0P4W9K7_9EUCA	9.2e-32	142.5	97.92%	33.33%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN008877.1	sp|K1R053|K1R053_CRAGI	2.0e-269	934.1	84.57%	74.03%	NAD-dependent deacetylase sirtuin-3, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN010700.1	sp|K1PK89|K1PK89_CRAGI	3.1e-23	115.5	15.79%	68.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010701.1	sp|A0A2C9KD41|A0A2C9KD41_BIOGL	2.5e-17	94.4	97.65%	31.82%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016020|
GN010702.1	sp|K1Q6C7|K1Q6C7_CRAGI	0.0e+00	1874.0	92.65%	56.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|GO:0004252|
GN010703.1	sp|K1Q8P7|K1Q8P7_CRAGI	7.8e-234	815.1	93.45%	89.26%	Aspartyl aminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0004177|GO:0008237|GO:0008270|
GN010704.1	sp|K1RRZ9|K1RRZ9_CRAGI	5.4e-84	317.4	85.45%	56.79%	MKI67 FHA domain-interacting nucleolar phosphoprotein-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN010705.1	sp|K1QKI3|K1QKI3_CRAGI	1.9e-242	844.0	88.70%	84.42%	Putative malate dehydrogenase 1B;OS=Crassostrea;PE=4;SV=1	GO:0016615|GO:0016616|	GO:0005975|GO:0006108|
GN010706.1	sp|K1QUC1|K1QUC1_CRAGI	2.2e-44	184.9	100.00%	72.86%	CDV3-like protein;OS=Crassostrea;PE=4;SV=1
GN010707.1	sp|K1PT65|K1PT65_CRAGI	5.9e-110	403.3	100.00%	57.32%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN010708.1	sp|K1R7T2|K1R7T2_CRAGI	2.7e-222	776.5	100.00%	94.63%	Isocitrate dehydrogenase [NADP];OS=Crassostrea;PE=3;SV=1	GO:0004450|GO:0000287|GO:0051287|	GO:0006102|GO:0006099|
GN010709.1	sp|K1RS04|K1RS04_CRAGI	4.9e-246	856.3	99.47%	70.64%	Mediator of RNA polymerase II transcription subunit 25;OS=Crassostrea;PE=4;SV=1
GN010710.1	sp|A0A210PFV9|A0A210PFV9_MIZYE	6.3e-175	619.4	98.73%	60.68%	Aldehyde dehydrogenase;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0016620|	GO:0006081|
GN010711.1	sp|K1QWG6|K1QWG6_CRAGI	1.2e-82	311.2	100.00%	90.13%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN008878.1	sp|K1QUQ3|K1QUQ3_CRAGI	3.1e-82	310.5	100.00%	79.83%	FGFR1 oncogene partner 2-like protein;OS=Crassostrea;PE=4;SV=1
GN010718.1	sp|K1QTH4|K1QTH4_CRAGI	4.6e-37	160.6	47.62%	52.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008690.1	sp|K1Q171|K1Q171_CRAGI	6.2e-108	397.1	93.87%	41.79%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0019013|	GO:0003723|
GN008879.1	sp|K1QYX7|K1QYX7_CRAGI	1.6e-44	184.9	77.37%	60.81%	Integrin beta-like protein D;OS=Crassostrea;PE=4;SV=1	GO:0007229|
GN010724.1	sp|K1P5Y5|K1P5Y5_CRAGI	3.8e-38	163.7	57.45%	68.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010725.1	sp|K1R903|K1R903_CRAGI	1.2e-88	332.0	94.12%	61.96%	Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016757|
GN010726.1	sp|K1R906|K1R906_CRAGI	4.6e-303	1045.4	100.00%	84.11%	Phosphoinositide phospholipase C;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0004435|	GO:0035556|GO:0016042|
GN010727.1	sp|A0A210Q3C9|A0A210Q3C9_MIZYE	1.2e-54	218.4	79.21%	70.71%	Phosphoinositide phospholipase C;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|GO:0004435|	GO:0035556|GO:0016042|
GN010728.1	sp|K1Q729|K1Q729_CRAGI	1.7e-274	950.7	88.31%	80.90%	ABC transporter G family member 22;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016887|
GN010729.1	sp|K1QLQ7|K1QLQ7_CRAGI	9.0e-240	835.5	100.00%	81.76%	Coiled-coil domain-containing protein 13;OS=Crassostrea;PE=4;SV=1
GN010730.1	sp|K1R6X3|K1R6X3_CRAGI	6.9e-105	385.6	100.00%	92.49%	Golgi SNAP receptor complex member 2;OS=Crassostrea;PE=3;SV=1	GO:0005794|GO:0016021|	GO:0005484|	GO:0015031|GO:0016192|
GN010732.1	sp|K1PZS1|K1PZS1_CRAGI	2.0e-125	456.4	28.45%	63.07%	Schlafen-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN010733.1	sp|K1QMV3|K1QMV3_CRAGI	3.8e-105	386.7	98.86%	62.46%	Metallophosphoesterase MPPED2;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN010734.1	sp|K1QGF2|K1QGF2_CRAGI	1.8e-254	883.6	100.00%	93.12%	Gamma-1-syntrophin;OS=Crassostrea;PE=4;SV=1	GO:0005198|
GN010735.1	sp|K1Q894|K1Q894_CRAGI	0.0e+00	1253.8	100.00%	93.14%	EF-hand domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010736.1	sp|K1Q141|K1Q141_CRAGI	1.7e-37	161.0	82.03%	75.96%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN010737.1	sp|V3ZEC4|V3ZEC4_LOTGI	8.7e-109	399.1	99.03%	61.51%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016491|
GN010738.1	sp|K1P6S9|K1P6S9_CRAGI	4.3e-55	220.7	98.08%	43.20%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN010739.1	sp|K1R877|K1R877_CRAGI	5.4e-78	296.2	96.65%	74.63%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN010740.1	sp|K1R877|K1R877_CRAGI	3.2e-181	639.8	98.82%	91.29%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN010741.1	sp|A0A210QPP7|A0A210QPP7_MIZYE	4.6e-94	350.5	93.70%	46.54%	Atrial natriuretic peptide receptor 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN010742.1	sp|K1QAX9|K1QAX9_CRAGI	1.2e-40	172.9	30.94%	64.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010743.1	sp|K1QCR2|K1QCR2_CRAGI	2.0e-234	817.8	97.42%	56.01%	Chorion peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN010744.1	sp|K1QTV0|K1QTV0_CRAGI	5.5e-51	206.8	50.37%	73.88%	Latent-transforming growth factor beta-binding protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010745.1	sp|K1QLA5|K1QLA5_CRAGI	4.8e-44	183.3	78.28%	64.29%	DNA damage-regulated autophagy modulator protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010747.1	sp|W4Z9W9|W4Z9W9_STRPU	6.8e-20	103.2	69.34%	39.73%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN010748.1	sp|K1QDR7|K1QDR7_CRAGI	8.8e-57	226.9	38.55%	59.20%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN010749.1	sp|K1R0N8|K1R0N8_CRAGI	1.3e-254	885.2	100.00%	52.51%	Flap endonuclease GEN-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004519|	GO:0006281|
GN010750.1	sp|K1RK83|K1RK83_CRAGI	0.0e+00	1511.9	99.49%	77.50%	Tyrosine-protein kinase BAZ1B;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0046872|
GN010751.1	sp|A0A3M6U363|A0A3M6U363_9CNID	5.8e-26	125.2	25.27%	35.64%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN010753.1	sp|A0A210Q9C0|A0A210Q9C0_MIZYE	1.1e-09	68.6	53.13%	45.59%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010755.1	sp|K1QHA3|K1QHA3_CRAGI	0.0e+00	1147.9	99.40%	84.59%	Glutamate--cysteine ligase catalytic subunit;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004357|	GO:0006750|
GN010756.1	sp|K1QA77|K1QA77_CRAGI	1.6e-95	355.1	98.83%	57.89%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN010757.1	sp|K1QA77|K1QA77_CRAGI	1.5e-128	464.9	98.57%	72.97%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN010758.1	sp|K1QA77|K1QA77_CRAGI	2.4e-86	324.7	87.85%	62.38%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN010759.1	sp|K1Q2M3|K1Q2M3_CRAGI	8.1e-149	532.3	89.45%	79.29%	Neuropeptide Y receptor type 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010760.1	sp|K1PV22|K1PV22_CRAGI	5.8e-146	523.1	95.96%	62.41%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN010761.1	sp|K1R2Y3|K1R2Y3_CRAGI	2.8e-79	300.1	100.00%	87.90%	Uncharacterized protein C2orf50;OS=Crassostrea;PE=4;SV=1
GN010762.1	sp|K1QH99|K1QH99_CRAGI	2.8e-208	729.9	100.00%	87.59%	Abhydrolase domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN010763.1	sp|K1QA72|K1QA72_CRAGI	8.9e-125	451.8	96.25%	98.26%	Double-strand-break repair protein rad21-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008278|	GO:0007062|
GN010764.1	sp|K1QA72|K1QA72_CRAGI	6.0e-141	506.1	100.00%	89.75%	Double-strand-break repair protein rad21-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008278|	GO:0007062|
GN010766.1	sp|K1Q2L9|K1Q2L9_CRAGI	8.9e-68	262.3	95.81%	60.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010767.1	sp|K1PV20|K1PV20_CRAGI	0.0e+00	1187.2	100.00%	93.23%	Suppressor of hairless-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0001228|GO:0000978|
GN010768.1	sp|K1QA68|K1QA68_CRAGI	1.2e-43	183.7	27.06%	56.15%	F-box only protein 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010770.1	sp|K1QBP0|K1QBP0_CRAGI	3.8e-108	397.5	70.17%	63.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010772.1	sp|K1RTR7|K1RTR7_CRAGI	8.5e-64	250.0	56.00%	55.16%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010773.1	sp|A0A226DV20|A0A226DV20_FOLCA	4.4e-44	184.1	99.02%	34.54%	Zinc finger BED domain-containing protein DAYSLEEPER;OS=Folsomia;PE=4;SV=1
GN010774.1	sp|J9M3G5|J9M3G5_ACYPI	4.2e-17	93.2	93.70%	42.02%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2	GO:0046983|
GN010777.1	sp|K1Q5Q0|K1Q5Q0_CRAGI	4.9e-244	850.1	89.83%	47.81%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010778.1	sp|K1PIQ0|K1PIQ0_CRAGI	2.7e-80	304.3	84.04%	64.83%	Estrogen sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010779.1	sp|K1PCB5|K1PCB5_CRAGI	5.5e-111	406.4	100.00%	63.29%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010780.1	sp|V4ATH7|V4ATH7_LOTGI	2.4e-09	69.7	43.65%	21.35%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN010783.1	sp|A0A210PJF2|A0A210PJF2_MIZYE	9.5e-12	76.3	27.43%	52.46%	Zinc finger and SCAN domain-containing protein 29;OS=Mizuhopecten;PE=4;SV=1
GN008691.1	sp|K1QLK4|K1QLK4_CRAGI	1.6e-92	345.9	93.12%	39.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008880.1	sp|K1PDF0|K1PDF0_CRAGI	2.2e-186	657.1	98.92%	89.67%	Protein disulfide-isomerase A6;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0016853|	GO:0045454|
GN008881.1	sp|K1PEG3|K1PEG3_CRAGI	9.3e-153	545.4	99.74%	69.21%	Lipoyltransferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016740|	GO:0009249|
GN008882.1	sp|K1PL77|K1PL77_CRAGI	1.1e-155	555.4	99.59%	74.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008886.1	sp|K1Q6T1|K1Q6T1_CRAGI	2.1e-168	597.4	88.61%	86.53%	Decaprenyl-diphosphate synthase subunit 1;OS=Crassostrea;PE=3;SV=1	GO:0016740|	GO:0008299|
GN008887.1	sp|K1P0G7|K1P0G7_CRAGI	2.0e-92	344.0	98.90%	85.96%	Putative hydrolase RBBP9;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN008692.1	sp|K1QTE0|K1QTE0_CRAGI	5.0e-35	152.5	100.00%	67.57%	Epidermal retinal dehydrogenase 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN008888.1	sp|K1QDG5|K1QDG5_CRAGI	0.0e+00	1484.9	98.02%	80.60%	Homeobox protein TGIF2LX;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN008889.1	sp|K1P7D7|K1P7D7_CRAGI	0.0e+00	1528.5	99.71%	61.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008890.1	sp|A0A183N3F1|A0A183N3F1_9TREM	6.5e-15	85.9	83.74%	40.20%	Uncharacterized protein;OS=Schistosoma;PE=4;SV=1
GN008893.1	sp|K1PT16|K1PT16_CRAGI	1.1e-95	354.8	100.00%	91.11%	Fas apoptotic inhibitory molecule;OS=Crassostrea;PE=4;SV=1	GO:0043066|
GN008894.1	sp|K1QDH4|K1QDH4_CRAGI	1.3e-25	121.3	62.07%	83.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008898.1	sp|B6EY04|B6EY04_CRAGI	9.8e-226	788.1	100.00%	78.57%	Beta-glucan recognition protein 2;OS=Crassostrea;PE=2;SV=1	GO:0030246|GO:0004553|	GO:0005975|
GN008899.1	sp|K1S3T7|K1S3T7_CRAGI	1.7e-33	148.7	77.13%	39.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008900.1	sp|K1QDD5|K1QDD5_CRAGI	1.3e-42	178.3	80.86%	66.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008901.1	sp|A0A210PPQ9|A0A210PPQ9_MIZYE	4.5e-71	275.0	82.64%	29.70%	CD109;OS=Mizuhopecten;PE=4;SV=1	GO:0005615|	GO:0004866|
GN008902.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	5.3e-31	140.2	85.97%	42.63%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008903.1	sp|K1QAH8|K1QAH8_CRAGI	4.5e-87	327.0	90.27%	51.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|	GO:0004866|GO:0003723|
GN008904.1	sp|K1QAH8|K1QAH8_CRAGI	5.7e-47	195.7	20.74%	38.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|	GO:0004866|GO:0003723|
GN008694.1	sp|K1RYG2|K1RYG2_CRAGI	0.0e+00	1508.0	32.18%	71.44%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008905.1	sp|A0A210QNZ5|A0A210QNZ5_MIZYE	1.8e-198	698.0	99.66%	58.81%	IQ calmodulin-binding motif-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005516|	GO:0060271|
GN008906.1	sp|A0JPS3|A0JPS3_STRPU	8.9e-15	87.4	36.49%	30.85%	Transposase domain-containing protein; Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN008912.1	sp|A0A210PUF4|A0A210PUF4_MIZYE	5.6e-14	84.7	77.75%	24.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008913.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	1.5e-35	155.6	74.91%	42.57%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008914.1	sp|A7SKZ0|A7SKZ0_NEMVE	2.4e-148	532.3	82.89%	35.01%	ATP-dependent DNA helicase;OS=Nematostella;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN008695.1	sp|K1QR52|K1QR52_CRAGI	0.0e+00	1441.0	97.55%	62.55%	YEATS domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006355|
GN008915.1	sp|K1QAB1|K1QAB1_CRAGI	0.0e+00	1544.3	99.34%	84.95%	AP-2 complex subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0030122|	GO:0035615|	GO:0072583|GO:0006886|
GN008916.1	sp|K1Q4J0|K1Q4J0_CRAGI	0.0e+00	2696.8	81.14%	85.50%	Doublecortin domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN008917.1	sp|A0A210QPQ1|A0A210QPQ1_MIZYE	2.0e-10	72.4	45.71%	33.78%	Resistance to inhibitors of cholinesterase protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN008918.1	sp|A0A210QPQ3|A0A210QPQ3_MIZYE	1.4e-195	688.0	97.80%	81.76%	CCR4-NOT transcription complex subunit 11;OS=Mizuhopecten;PE=4;SV=1	GO:0030014|
GN008919.1	sp|K1S5Q9|K1S5Q9_CRAGI	2.1e-90	339.7	28.78%	53.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008920.1	sp|K1QSV1|K1QSV1_CRAGI	0.0e+00	1365.9	100.00%	74.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008921.1	sp|K1QKK7|K1QKK7_CRAGI	3.1e-83	313.9	97.69%	63.64%	Otolin-1;OS=Crassostrea;PE=4;SV=1
GN008923.1	sp|K1QHD1|K1QHD1_CRAGI	2.3e-185	654.4	96.71%	57.41%	C1q-related factor;OS=Crassostrea;PE=4;SV=1
GN008924.1	sp|K1QHD1|K1QHD1_CRAGI	4.5e-32	143.3	76.25%	59.50%	C1q-related factor;OS=Crassostrea;PE=4;SV=1
GN008696.1	sp|K1QAD2|K1QAD2_CRAGI	4.2e-74	283.1	84.86%	91.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN008925.1	sp|K1QMG0|K1QMG0_CRAGI	2.6e-41	175.6	61.13%	41.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN008926.1	sp|A0A210Q445|A0A210Q445_MIZYE	1.4e-194	684.9	92.87%	63.57%	Arylsulfatase I;OS=Mizuhopecten;PE=4;SV=1	GO:0008484|
GN008927.1	sp|A0A210R559|A0A210R559_MIZYE	5.1e-44	183.3	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008928.1	sp|K1RL41|K1RL41_CRAGI	8.4e-253	878.2	100.00%	84.41%	Protein Malvolio;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0046873|
GN008929.1	sp|K1PW94|K1PW94_CRAGI	8.8e-136	488.8	100.00%	70.40%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN008930.1	sp|K1RQK7|K1RQK7_CRAGI	6.8e-73	279.3	96.14%	68.69%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN008931.1	sp|K1R424|K1R424_CRAGI	0.0e+00	2014.2	71.23%	87.35%	Protein TANC2;OS=Crassostrea;PE=4;SV=1
GN008697.1	sp|K1RHI8|K1RHI8_CRAGI	0.0e+00	1133.6	93.87%	67.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008933.1	sp|A0A210PLJ4|A0A210PLJ4_MIZYE	2.7e-147	527.3	97.46%	62.17%	SCY1-like protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN008934.1	sp|K1PA71|K1PA71_CRAGI	2.5e-250	870.5	85.54%	67.39%	Tectonic-3;OS=Crassostrea;PE=4;SV=1
GN008935.1	sp|K1PN01|K1PN01_CRAGI	1.0e-41	176.0	86.05%	47.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008936.1	sp|K1S2Z7|K1S2Z7_CRAGI	2.0e-217	760.8	95.50%	71.12%	6-hydroxy-D-nicotine oxidase;OS=Crassostrea;PE=3;SV=1	GO:0071949|GO:0016491|
GN008937.1	sp|K1PR82|K1PR82_CRAGI	1.8e-243	849.4	67.06%	43.19%	Fibrillin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0004888|	GO:0007160|
GN008938.1	sp|A0A1S3J244|A0A1S3J244_LINUN	2.0e-42	179.1	78.35%	25.42%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN008939.1	sp|K1PM74|K1PM74_CRAGI	2.2e-111	408.3	92.02%	71.62%	DNA mismatch repair protein Msh6;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0030983|	GO:0006298|
GN008940.1	sp|A0A210PES3|A0A210PES3_MIZYE	1.2e-145	521.5	100.00%	76.00%	Hydroxyacid-oxoacid transhydrogenase, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|GO:0016491|
GN008698.1	sp|K1PT52|K1PT52_CRAGI	1.1e-67	262.7	54.15%	69.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008941.1	sp|A0A210PES8|A0A210PES8_MIZYE	3.2e-66	258.1	59.55%	53.01%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN008942.1	sp|Q7Z0P7|Q7Z0P7_CRAGI	9.1e-117	425.2	97.56%	87.87%	Ribosomal protein L7;OS=Crassostrea;PE=2;SV=1	GO:0005840|
GN008943.1	sp|K1Q171|K1Q171_CRAGI	5.6e-141	506.5	99.78%	57.53%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0019013|	GO:0003723|
GN008944.1	sp|V4AMN4|V4AMN4_LOTGI	1.9e-86	324.7	98.93%	56.32%	Elongation of very long chain fatty acids protein;OS=Lottia;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN008945.1	sp|K1QU72|K1QU72_CRAGI	3.7e-149	533.1	100.00%	86.25%	Elongation of very long chain fatty acids protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN008946.1	sp|K1QU76|K1QU76_CRAGI	1.6e-89	334.7	73.28%	89.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0031418|GO:0016705|
GN008699.1	sp|A0A2G8L4X1|A0A2G8L4X1_STIJA	8.0e-69	266.5	99.18%	40.65%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN008948.1	sp|K1QZP7|K1QZP7_CRAGI	6.0e-09	67.0	25.53%	54.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008950.1	sp|A0A0K8TLX5|A0A0K8TLX5_TABBR	2.4e-28	131.3	87.04%	35.93%	Putative harbinger-4 pst;OS=Tabanus;PE=2;SV=1
GN008951.1	sp|K1PAQ8|K1PAQ8_CRAGI	7.6e-14	82.4	58.91%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN008953.1	sp|W4YR48|W4YR48_STRPU	3.8e-18	97.4	70.89%	40.12%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN008700.1	sp|K1Q2I1|K1Q2I1_CRAGI	3.3e-39	166.4	89.81%	87.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008957.1	sp|K1RZF9|K1RZF9_CRAGI	5.9e-91	339.7	98.95%	67.96%	DNA damage-regulated autophagy modulator protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008701.1	sp|K1QKF7|K1QKF7_CRAGI	1.1e-68	265.4	84.89%	63.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN008960.1	sp|A0A1S3I398|A0A1S3I398_LINUN	6.2e-15	87.0	38.61%	43.27%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN008962.1	sp|K1Q137|K1Q137_CRAGI	2.2e-42	177.6	98.20%	58.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008963.1	sp|K1QEP5|K1QEP5_CRAGI	2.6e-81	307.4	100.00%	63.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN008964.1	sp|K1QEP5|K1QEP5_CRAGI	2.3e-61	240.7	100.00%	64.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN008965.1	sp|K1QEP5|K1QEP5_CRAGI	2.0e-167	594.3	100.00%	64.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN008966.1	sp|K1PEK1|K1PEK1_CRAGI	7.8e-31	138.7	85.84%	71.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008968.1	sp|K1QL92|K1QL92_CRAGI	1.1e-36	158.7	86.67%	52.82%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN008969.1	sp|K1Q137|K1Q137_CRAGI	1.7e-37	161.4	100.00%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008970.1	sp|K1Q1R1|K1Q1R1_CRAGI	5.5e-114	416.4	88.82%	73.72%	Exostosin-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016491|GO:0016757|	GO:0006486|
GN008971.1	sp|K1QN93|K1QN93_CRAGI	1.3e-23	114.4	97.92%	58.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008972.1	sp|K1QBH6|K1QBH6_CRAGI	6.7e-34	150.2	33.56%	70.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008973.1	sp|K1Q181|K1Q181_CRAGI	1.3e-31	143.7	32.52%	38.50%	BTB/POZ domain-containing protein KCTD6;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0051260|
GN008974.1	sp|T1JNK2|T1JNK2_STRMM	5.0e-11	75.1	16.20%	46.07%	Uncharacterized protein;OS=Strigamia;PE=4;SV=1
GN008976.1	sp|A0A210QSP0|A0A210QSP0_MIZYE	5.8e-32	142.5	95.87%	52.17%	Iodothyronine deiodinase;OS=Mizuhopecten;PE=3;SV=1	GO:0004800|	GO:0042446|
GN008977.1	sp|K1QRN9|K1QRN9_CRAGI	4.3e-09	68.6	6.80%	93.75%	Zinc finger protein 91;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008979.1	sp|K1QPT3|K1QPT3_CRAGI	4.3e-24	116.3	89.74%	56.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008702.1	sp|A0A210QU73|A0A210QU73_MIZYE	4.8e-13	79.7	88.98%	35.83%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008982.1	sp|A0A210QPB3|A0A210QPB3_MIZYE	0.0e+00	1394.0	99.46%	65.25%	Ankyrin-2;OS=Mizuhopecten;PE=4;SV=1
GN008983.1	sp|A0A210QPB3|A0A210QPB3_MIZYE	4.9e-106	389.8	98.58%	62.99%	Ankyrin-2;OS=Mizuhopecten;PE=4;SV=1
GN008986.1	sp|K1QST7|K1QST7_CRAGI	1.4e-85	322.0	95.98%	52.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008987.1	sp|K1R7K2|K1R7K2_CRAGI	5.0e-311	1072.0	99.85%	75.79%	Acyl-coenzyme A oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005777|	GO:0003997|GO:0071949|	GO:0006635|
GN008988.1	sp|A0A210PES0|A0A210PES0_MIZYE	3.3e-97	360.5	98.32%	58.76%	Beta-lactamase-like protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN008989.1	sp|A0A2B4S664|A0A2B4S664_STYPI	1.9e-13	82.4	89.57%	26.38%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN008990.1	sp|K1R7K5|K1R7K5_CRAGI	5.8e-143	512.7	86.54%	86.52%	Kynurenine--oxoglutarate transaminase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|GO:0030170|	GO:0009058|
GN008991.1	sp|K1PKQ4|K1PKQ4_CRAGI	3.7e-19	101.3	35.64%	42.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008992.1	sp|A0A210PG90|A0A210PG90_MIZYE	5.7e-87	327.0	92.29%	42.64%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0035556|
GN008993.1	sp|K1P0H4|K1P0H4_CRAGI	5.0e-40	169.5	81.16%	72.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008994.1	sp|K1RKT7|K1RKT7_CRAGI	5.6e-31	140.6	33.33%	72.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008704.1	sp|K1PIS2|K1PIS2_CRAGI	1.9e-40	172.6	76.85%	36.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008995.1	sp|K1RD63|K1RD63_CRAGI	7.4e-10	68.9	64.55%	41.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008996.1	sp|R7T5V7|R7T5V7_CAPTE	1.2e-39	168.7	91.41%	44.81%	Uncharacterized protein;OS=Capitella;PE=4;SV=1	GO:0007276|
GN008997.1	sp|A0A210Q2U7|A0A210Q2U7_MIZYE	5.5e-48	197.2	97.93%	42.59%	Protein TANC2;OS=Mizuhopecten;PE=4;SV=1
GN008998.1	sp|K1PJW7|K1PJW7_CRAGI	1.4e-127	461.8	91.86%	58.95%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN008999.1	sp|K1PR65|K1PR65_CRAGI	1.4e-36	158.3	79.64%	62.12%	Calmodulin-like protein 12;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009001.1	sp|A0A1S3HXZ7|A0A1S3HXZ7_LINUN	6.3e-75	287.7	50.65%	44.04%	uncharacterized protein LOC106158870;OS=Lingula;PE=4;SV=1	GO:0004842|	GO:0015031|
GN009002.1	sp|W4YZM0|W4YZM0_STRPU	7.2e-42	176.0	97.84%	45.86%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|	GO:0015074|
GN009004.1	sp|K1R7G0|K1R7G0_CRAGI	9.3e-64	248.8	83.67%	98.16%	Chromobox-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005719|	GO:0045892|
GN009005.1	sp|K1RJA7|K1RJA7_CRAGI	4.0e-36	156.4	96.00%	67.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008706.1	sp|A0A210Q7G4|A0A210Q7G4_MIZYE	3.2e-265	919.5	100.00%	83.43%	Transmembrane 9 superfamily member;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN009006.1	sp|A0A1S3I288|A0A1S3I288_LINUN	2.4e-25	121.3	79.72%	38.60%	uncharacterized protein LOC106160347;OS=Lingula;PE=4;SV=1
GN009007.1	sp|A0A210QC61|A0A210QC61_MIZYE	9.0e-19	100.5	68.68%	28.43%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009008.1	sp|K1Q4V2|K1Q4V2_CRAGI	6.9e-34	151.0	80.23%	25.41%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009009.1	sp|K1Q128|K1Q128_CRAGI	1.1e-126	459.5	98.17%	63.39%	Vacuolar protein 8;OS=Crassostrea;PE=4;SV=1
GN009011.1	sp|K1PTR4|K1PTR4_CRAGI	1.5e-40	173.7	11.92%	91.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009012.1	sp|K1PM34|K1PM34_CRAGI	1.4e-190	671.4	100.00%	86.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008707.1	sp|K1RYX0|K1RYX0_CRAGI	0.0e+00	1219.5	99.25%	82.31%	DNA-binding protein SATB2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006338|
GN009013.1	sp|K1RJB4|K1RJB4_CRAGI	9.0e-307	1058.1	97.26%	74.08%	Ubiquitin carboxyl-terminal hydrolase 1;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN009014.1	sp|K1QRI4|K1QRI4_CRAGI	9.0e-154	549.3	99.44%	65.97%	SH3 domain-binding protein 5-like protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN009016.1	sp|K1PYH3|K1PYH3_CRAGI	0.0e+00	3104.3	98.65%	73.41%	Thrombospondin type-1 domain-containing protein 7B;OS=Crassostrea;PE=4;SV=1
GN009017.1	sp|K1PJH5|K1PJH5_CRAGI	2.8e-168	597.8	55.80%	79.21%	GATA-binding factor A;OS=Crassostrea;PE=4;SV=1	GO:0003700|GO:0043565|GO:0008270|
GN009019.1	sp|K1PR89|K1PR89_CRAGI	4.5e-134	483.0	100.00%	80.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009020.1	sp|K1PJH1|K1PJH1_CRAGI	3.6e-86	323.6	95.40%	66.52%	Androgen-induced protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009021.1	sp|K1QRH8|K1QRH8_CRAGI	0.0e+00	2623.2	99.69%	70.07%	1-phosphatidylinositol-3-phosphate 5-kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0046872|GO:0016307|
GN009022.1	sp|K1Q705|K1Q705_CRAGI	1.3e-39	170.2	22.79%	60.87%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN009023.1	sp|K1Q705|K1Q705_CRAGI	4.3e-85	320.5	83.53%	55.63%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN009024.1	sp|K1PGR1|K1PGR1_CRAGI	4.1e-56	223.8	99.21%	46.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009028.1	sp|K1QWT8|K1QWT8_CRAGI	7.9e-36	157.1	51.90%	40.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009029.1	sp|K1QWT8|K1QWT8_CRAGI	2.2e-32	145.6	52.76%	40.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009030.1	sp|K1QWT8|K1QWT8_CRAGI	7.9e-36	157.1	51.90%	40.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009032.1	sp|K1QWT8|K1QWT8_CRAGI	6.0e-36	157.5	51.90%	41.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009033.1	sp|K1QWT8|K1QWT8_CRAGI	4.1e-40	171.0	97.85%	35.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008709.1	sp|K1QTB8|K1QTB8_CRAGI	5.3e-209	732.3	93.33%	98.28%	WD repeat-containing protein 68;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009038.1	sp|K1PSN4|K1PSN4_CRAGI	4.2e-248	862.4	98.06%	94.26%	Tetratricopeptide repeat protein 39C;OS=Crassostrea;PE=4;SV=1
GN009039.1	sp|K1Q709|K1Q709_CRAGI	6.9e-14	82.4	73.50%	62.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|	GO:0006366|GO:0006384|
GN009040.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	4.6e-84	317.4	80.37%	45.95%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN009041.1	sp|A0A0F6P9D4|A0A0F6P9D4_CRAHO	6.4e-41	172.2	85.09%	82.29%	Aquaporin 1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0015267|
GN009042.1	sp|K1QAW0|K1QAW0_CRAGI	7.2e-124	450.3	93.58%	42.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009043.1	sp|K1QAW0|K1QAW0_CRAGI	3.0e-95	355.1	89.69%	39.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009044.1	sp|K1QAW0|K1QAW0_CRAGI	3.4e-82	311.6	57.37%	49.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009045.1	sp|K1RNN9|K1RNN9_CRAGI	0.0e+00	2574.7	100.00%	73.15%	Cytoskeleton-associated protein 5;OS=Crassostrea;PE=4;SV=1
GN009046.1	sp|K1R3Q6|K1R3Q6_CRAGI	2.8e-179	634.4	96.30%	45.32%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009048.1	sp|A0A3M6UX53|A0A3M6UX53_9CNID	1.8e-26	125.9	31.38%	43.65%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN009049.1	sp|K1QHK4|K1QHK4_CRAGI	2.1e-12	79.0	13.98%	82.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009053.1	sp|W4XMZ2|W4XMZ2_STRPU	4.6e-134	484.6	98.08%	33.26%	ATP-dependent DNA helicase;OS=Strongylocentrotus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN009054.1	sp|A0A2B4S7H1|A0A2B4S7H1_STYPI	4.8e-19	100.9	70.20%	31.51%	E3 ubiquitin-protein ligase DTX3L;OS=Stylophora;PE=4;SV=1	GO:0016874|GO:0046872|
GN009055.1	sp|A0A0L8GEW0|A0A0L8GEW0_OCTBM	1.0e-19	101.7	87.39%	51.52%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0003677|
GN009056.1	sp|A0A210QYM3|A0A210QYM3_MIZYE	1.4e-28	132.1	64.76%	51.85%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009057.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	4.3e-74	283.9	71.83%	57.14%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN008710.1	sp|K1QIF6|K1QIF6_CRAGI	1.4e-72	278.5	89.92%	83.33%	Myomodulin neuropeptide 2;OS=Crassostrea;PE=4;SV=1	GO:0007218|
GN009061.1	sp|K1PSE0|K1PSE0_CRAGI	1.1e-41	175.6	71.83%	58.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009064.1	sp|K1RIW4|K1RIW4_CRAGI	1.9e-122	444.5	100.00%	63.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009065.1	sp|V4AKX4|V4AKX4_LOTGI	1.2e-45	188.3	96.84%	55.56%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN009066.1	sp|K1Q3P2|K1Q3P2_CRAGI	2.6e-109	401.0	91.50%	59.01%	Vitamin D(3) 25-hydroxylase;OS=Crassostrea;PE=3;SV=1	GO:0005901|GO:0000139|GO:0016021|	GO:0020037|GO:0005506|GO:0016705|	GO:0070836|
GN009067.1	sp|K1R912|K1R912_CRAGI	9.1e-27	125.6	76.00%	58.41%	Uncharacterized protein C2orf65;OS=Crassostrea;PE=4;SV=1	GO:0007127|GO:0007283|
GN009068.1	sp|K1R912|K1R912_CRAGI	3.6e-16	89.7	83.84%	54.76%	Uncharacterized protein C2orf65;OS=Crassostrea;PE=4;SV=1	GO:0007127|GO:0007283|
GN009069.1	sp|K1R912|K1R912_CRAGI	4.6e-57	226.5	91.76%	64.46%	Uncharacterized protein C2orf65;OS=Crassostrea;PE=4;SV=1	GO:0007127|GO:0007283|
GN009071.1	sp|K1R311|K1R311_CRAGI	6.1e-26	124.4	32.22%	52.41%	FMRF-amide neuropeptide;OS=Crassostrea;PE=4;SV=1	GO:0007218|
GN009074.1	sp|K1RYJ8|K1RYJ8_CRAGI	8.7e-101	372.1	100.00%	90.17%	Synaptonemal complex protein 3;OS=Crassostrea;PE=4;SV=1
GN009075.1	sp|K1RFK1|K1RFK1_CRAGI	1.4e-196	691.0	99.75%	86.80%	Corticosteroid 11-beta-dehydrogenase isozyme 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN009077.1	sp|K1QLQ4|K1QLQ4_CRAGI	1.1e-64	253.8	98.91%	47.95%	Pin2-interacting protein X1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008711.1	sp|K1QL83|K1QL83_CRAGI	8.6e-40	168.3	98.11%	77.67%	Solute carrier family 35 member F3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009078.1	sp|K1QF31|K1QF31_CRAGI	4.8e-277	958.7	95.92%	93.71%	Serine/threonine-protein kinase PLK;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN009079.1	sp|K1Q725|K1Q725_CRAGI	1.2e-150	538.5	86.45%	80.53%	5-hydroxytryptamine receptor 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN009080.1	sp|K1QC26|K1QC26_CRAGI	3.7e-74	283.1	99.39%	73.91%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|	GO:0006004|
GN009081.1	sp|K1QF27|K1QF27_CRAGI	8.8e-50	201.8	99.24%	73.08%	Deoxyribonuclease-1;OS=Crassostrea;PE=4;SV=1	GO:0004536|	GO:0006308|
GN009082.1	sp|K1QAX0|K1QAX0_CRAGI	3.3e-150	537.0	96.09%	69.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0016787|
GN009083.1	sp|A0A210QKV1|A0A210QKV1_MIZYE	1.2e-108	399.1	99.51%	47.38%	STE20-related kinase adapter protein alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN009084.1	sp|K1QEM5|K1QEM5_CRAGI	5.5e-118	429.5	98.57%	81.75%	Transcription initiation factor TFIID subunit 8;OS=Crassostrea;PE=4;SV=1	GO:0005669|	GO:0046982|GO:0003743|
GN009085.1	sp|K1QL90|K1QL90_CRAGI	0.0e+00	1718.0	100.00%	87.89%	Protein FAM65C;OS=Crassostrea;PE=4;SV=1
GN009086.1	sp|K1QEN0|K1QEN0_CRAGI	1.2e-29	134.4	98.89%	71.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009087.1	sp|K1QL97|K1QL97_CRAGI	5.1e-204	716.1	90.35%	79.17%	Ammonium transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008519|
GN009088.1	sp|K1R6F2|K1R6F2_CRAGI	1.3e-163	581.3	100.00%	93.64%	Homeodomain-interacting protein kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0004672|
GN009089.1	sp|W4ZIE5|W4ZIE5_STRPU	2.0e-96	359.8	51.12%	37.15%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN009090.1	sp|K1R6F2|K1R6F2_CRAGI	1.9e-28	130.2	81.01%	96.83%	Homeodomain-interacting protein kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0004672|
GN009091.1	sp|A0A151XDL9|A0A151XDL9_9HYME	2.1e-14	84.0	97.06%	40.82%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN009092.1	sp|K1QCD2|K1QCD2_CRAGI	0.0e+00	1320.8	100.00%	50.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009093.1	sp|K1P0H4|K1P0H4_CRAGI	1.7e-33	148.3	84.02%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009094.1	sp|K1QKG1|K1QKG1_CRAGI	5.5e-68	263.5	94.58%	49.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009095.1	sp|K1QS32|K1QS32_CRAGI	1.5e-34	151.4	97.18%	47.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009098.1	sp|K1QCD5|K1QCD5_CRAGI	5.2e-225	785.8	99.16%	95.37%	Paired box protein Pax-6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN009101.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	4.5e-20	104.0	64.29%	38.82%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009102.1	sp|K1QKG5|K1QKG5_CRAGI	4.0e-114	417.2	83.54%	61.13%	Melanocortin receptor 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN009103.1	sp|K1Q4V5|K1Q4V5_CRAGI	7.5e-92	342.0	98.90%	93.26%	Transmembrane protein 86A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009105.1	sp|K1P0H0|K1P0H0_CRAGI	4.6e-211	740.3	47.13%	82.54%	Aspartyl/asparaginyl beta-hydroxylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004597|	GO:0042264|
GN009106.1	sp|K1P6K5|K1P6K5_CRAGI	1.6e-131	475.3	50.99%	91.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009107.1	sp|K1PHH2|K1PHH2_CRAGI	4.0e-95	354.8	93.73%	30.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009108.1	sp|K1PTJ8|K1PTJ8_CRAGI	2.0e-11	73.9	94.90%	39.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009110.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	1.7e-20	105.5	59.16%	38.96%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN009111.1	sp|K1QSN8|K1QSN8_CRAGI	9.5e-157	558.5	98.53%	82.69%	Substance-K receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009112.1	sp|K1Q6D7|K1Q6D7_CRAGI	1.9e-25	120.6	75.76%	72.97%	Centrin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN009114.1	sp|K1PKN7|K1PKN7_CRAGI	0.0e+00	1746.9	100.00%	85.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008714.1	sp|K1PTC0|K1PTC0_CRAGI	1.1e-111	409.5	55.34%	60.29%	Major facilitator superfamily domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009116.1	sp|K1PJG8|K1PJG8_CRAGI	4.6e-167	594.0	99.48%	63.68%	Timeless-like protein;OS=Crassostrea;PE=4;SV=1
GN009117.1	sp|A0A2C9JEF4|A0A2C9JEF4_BIOGL	3.6e-13	82.4	52.83%	45.02%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|
GN009118.1	sp|K1PJG8|K1PJG8_CRAGI	1.6e-269	934.1	99.69%	77.08%	Timeless-like protein;OS=Crassostrea;PE=4;SV=1
GN009119.1	sp|K1QRH6|K1QRH6_CRAGI	2.7e-127	461.1	95.01%	64.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0008154|
GN009121.1	sp|K1PYG5|K1PYG5_CRAGI	2.4e-130	470.7	100.00%	80.90%	Homeotic protein distal-less;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN009122.1	sp|C3ZM17|C3ZM17_BRAFL	8.7e-14	82.4	55.41%	45.68%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003677|
GN009123.1	sp|K1PFP3|K1PFP3_CRAGI	1.1e-78	298.5	99.50%	77.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008715.1	sp|A0A210PGU7|A0A210PGU7_MIZYE	6.1e-41	172.9	94.05%	45.76%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009129.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	1.2e-30	139.0	95.63%	36.68%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN009130.1	sp|A0A3L5TSJ7|A0A3L5TSJ7_MYTGA	1.8e-21	107.1	98.80%	62.96%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN009131.1	sp|A0A210QDI0|A0A210QDI0_MIZYE	6.9e-116	422.9	98.67%	55.38%	WD repeat-containing protein 76;OS=Mizuhopecten;PE=4;SV=1	GO:0006974|
GN009132.1	sp|K1Q650|K1Q650_CRAGI	1.7e-122	444.5	99.32%	74.23%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN009133.1	sp|K1RDX1|K1RDX1_CRAGI	1.4e-136	491.9	91.30%	62.19%	Putative S-adenosyl-L-methionine-dependent methyltransferase METT5D1;OS=Crassostrea;PE=3;SV=1	GO:0008168|
GN009134.1	sp|A0A2G8KZM8|A0A2G8KZM8_STIJA	7.6e-88	331.3	57.76%	33.61%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN008716.1	sp|A0A210PGW1|A0A210PGW1_MIZYE	3.7e-217	760.8	98.79%	47.09%	PHD finger protein 14;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN009135.1	sp|K1Q6T9|K1Q6T9_CRAGI	1.6e-36	158.7	100.00%	37.65%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN009137.1	sp|K1R333|K1R333_CRAGI	2.2e-176	624.0	100.00%	78.08%	Cholecystokinin receptor type A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN009139.1	sp|K1RL61|K1RL61_CRAGI	9.2e-59	232.3	100.00%	55.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009140.1	sp|K1PPC8|K1PPC8_CRAGI	1.1e-111	408.7	94.95%	75.44%	Protein FAM8A1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008717.1	sp|K1RR98|K1RR98_CRAGI	4.8e-46	189.1	92.52%	80.61%	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2;OS=Crassostrea;PE=4;SV=1
GN009141.1	sp|K1QAY5|K1QAY5_CRAGI	1.3e-118	431.4	100.00%	79.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009144.1	sp|K1QCW3|K1QCW3_CRAGI	4.1e-92	343.6	74.06%	75.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009145.1	sp|K1QEJ1|K1QEJ1_CRAGI	1.0e-69	268.9	99.14%	61.47%	E3 SUMO-protein ligase NSE2;OS=Crassostrea;PE=4;SV=1	GO:0030915|	GO:0016874|GO:0019789|GO:0008270|	GO:0000724|
GN009146.1	sp|W4Y8Y6|W4Y8Y6_STRPU	1.2e-51	209.5	86.85%	40.63%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN009148.1	sp|K1QTD7|K1QTD7_CRAGI	9.6e-16	89.4	36.68%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009150.1	sp|K1R0I7|K1R0I7_CRAGI	5.0e-195	686.0	100.00%	80.09%	Serine incorporator 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN008718.1	sp|Q8ITC5|Q8ITC5_ARGIR	4.4e-53	212.6	97.41%	91.96%	Ribosomal protein L30;OS=Argopecten;PE=2;SV=1	GO:0005840|	GO:0003723|GO:0003735|	GO:0006412|
GN009153.1	sp|K1RHP3|K1RHP3_CRAGI	1.4e-28	131.0	98.98%	82.29%	Proliferation-associated protein 2G4;OS=Crassostrea;PE=4;SV=1
GN009154.1	sp|K1QAK5|K1QAK5_CRAGI	4.4e-210	736.1	100.00%	78.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009157.1	sp|A0A2T7PGW7|A0A2T7PGW7_POMCA	2.5e-92	344.0	85.90%	78.35%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016020|
GN009158.1	sp|K1QWR5|K1QWR5_CRAGI	2.2e-179	634.0	99.76%	79.57%	Alanyl-tRNA synthetase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0004812|GO:0005524|	GO:0043039|
GN009159.1	sp|W4YX27|W4YX27_STRPU	3.6e-31	140.6	98.98%	40.69%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004190|
GN008719.1	sp|K1QVS2|K1QVS2_CRAGI	1.1e-196	691.4	100.00%	81.52%	Thioredoxin domain-containing protein 5;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0016853|	GO:0045454|
GN009161.1	sp|K1PA29|K1PA29_CRAGI	2.3e-91	341.7	100.00%	49.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009162.1	sp|K1R0F9|K1R0F9_CRAGI	1.5e-181	641.3	97.54%	71.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0051536|
GN009163.1	sp|K1R781|K1R781_CRAGI	2.2e-107	393.7	100.00%	96.17%	Muscle LIM protein Mlp84B;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN009164.1	sp|K1R9G8|K1R9G8_CRAGI	3.3e-78	297.4	82.21%	58.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN009165.1	sp|A0A2B4REN1|A0A2B4REN1_STYPI	6.1e-35	153.3	76.79%	49.13%	Uncharacterized protein KIAA1958-like;OS=Stylophora;PE=4;SV=1
GN009166.1	sp|K1QGX5|K1QGX5_CRAGI	8.0e-105	386.3	65.32%	68.04%	Octopamine receptor beta-1R;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN008720.1	sp|J9Q550|J9Q550_OSTED	2.8e-27	127.1	51.47%	95.65%	Ribosomal protein P1;OS=Ostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006414|
GN009168.1	sp|K1QW17|K1QW17_CRAGI	6.7e-182	642.1	100.00%	90.54%	Adenosine monophosphate-protein transferase FICD;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN009169.1	sp|K1RGC7|K1RGC7_CRAGI	3.6e-228	796.6	90.88%	76.72%	ATP-dependent RNA helicase DDX51;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0005524|GO:0004386|GO:0004879|GO:0043565|GO:0003707|GO:0008270|
GN009170.1	sp|K1RGC7|K1RGC7_CRAGI	7.5e-17	92.0	90.10%	65.22%	ATP-dependent RNA helicase DDX51;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0005524|GO:0004386|GO:0004879|GO:0043565|GO:0003707|GO:0008270|
GN009171.1	sp|K1PHH2|K1PHH2_CRAGI	1.4e-83	316.2	96.70%	30.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009172.1	sp|K1QAI0|K1QAI0_CRAGI	6.6e-48	196.4	92.34%	54.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009173.1	sp|A0A210QGS3|A0A210QGS3_MIZYE	3.2e-38	163.3	98.35%	71.31%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN008721.1	sp|K1Q3H6|K1Q3H6_CRAGI	0.0e+00	1258.0	100.00%	85.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009175.1	sp|K1QAI0|K1QAI0_CRAGI	1.5e-139	503.1	68.93%	55.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009176.1	sp|A0A210PK78|A0A210PK78_MIZYE	8.4e-83	313.2	76.34%	49.04%	Neuronal acetylcholine receptor subunit alpha-6;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN009177.1	sp|A0A210PK78|A0A210PK78_MIZYE	1.1e-82	312.8	96.35%	42.07%	Neuronal acetylcholine receptor subunit alpha-6;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN009178.1	sp|A0A210PK78|A0A210PK78_MIZYE	1.1e-87	329.3	98.49%	42.47%	Neuronal acetylcholine receptor subunit alpha-6;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN009179.1	sp|A0A210QPD3|A0A210QPD3_MIZYE	3.1e-88	330.5	98.42%	61.57%	Adapter molecule Crk;OS=Mizuhopecten;PE=4;SV=1
GN009180.1	sp|A0A210QSP0|A0A210QSP0_MIZYE	4.9e-31	139.4	95.87%	52.17%	Iodothyronine deiodinase;OS=Mizuhopecten;PE=3;SV=1	GO:0004800|	GO:0042446|
GN009181.1	sp|H6U5U5|H6U5U5_9BIVA	7.0e-10	69.3	77.04%	34.91%	Iodothyronine deiodinase;OS=Azumapecten;PE=2;SV=1	GO:0016021|	GO:0004800|	GO:0042446|
GN009182.1	sp|A0A210QSP0|A0A210QSP0_MIZYE	1.3e-31	141.4	95.20%	50.85%	Iodothyronine deiodinase;OS=Mizuhopecten;PE=3;SV=1	GO:0004800|	GO:0042446|
GN009183.1	sp|A0A210QP33|A0A210QP33_MIZYE	1.7e-27	129.4	96.39%	26.24%	Cholecystokinin receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN009184.1	sp|A0A210QLG4|A0A210QLG4_MIZYE	4.3e-33	146.7	98.25%	45.56%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009185.1	sp|K1QHB0|K1QHB0_CRAGI	1.3e-26	125.9	55.67%	45.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009186.1	sp|R7VES8|R7VES8_CAPTE	1.2e-26	125.2	88.16%	47.79%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN009188.1	sp|K1PAQ6|K1PAQ6_CRAGI	0.0e+00	1477.2	100.00%	63.16%	Gastrula zinc finger protein XlCGF9.1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009189.1	sp|K1PHX3|K1PHX3_CRAGI	1.0e-166	592.4	75.66%	79.12%	Calpain-9;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004198|GO:0004672|
GN009190.1	sp|K1PHX3|K1PHX3_CRAGI	4.1e-53	213.4	63.64%	76.27%	Calpain-9;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004198|GO:0004672|
GN009192.1	sp|K1PNR0|K1PNR0_CRAGI	2.4e-237	827.8	59.96%	70.61%	WD repeat-containing protein 60;OS=Crassostrea;PE=4;SV=1
GN009193.1	sp|K1P2Y9|K1P2Y9_CRAGI	1.7e-166	591.7	83.42%	64.50%	Polyamine oxidase 3;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN009195.1	sp|K1Q9P4|K1Q9P4_CRAGI	6.7e-122	443.4	97.27%	82.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009196.1	sp|K1PNQ8|K1PNQ8_CRAGI	1.1e-155	555.8	100.00%	91.21%	Sperm-associated antigen 16 protein;OS=Crassostrea;PE=4;SV=1
GN008723.1	sp|K1RAF6|K1RAF6_CRAGI	2.2e-214	751.1	75.24%	69.05%	Pleckstrin-like protein domain-containing family A member 6;OS=Crassostrea;PE=4;SV=1
GN009197.1	sp|K1Q9N9|K1Q9N9_CRAGI	0.0e+00	1494.9	100.00%	79.27%	BCL9-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008013|GO:0003713|	GO:0060070|
GN009198.1	sp|W4XW52|W4XW52_STRPU	4.2e-17	93.2	84.13%	40.00%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|
GN009200.1	sp|K1Q9N8|K1Q9N8_CRAGI	2.0e-199	700.7	100.00%	78.42%	Guanine nucleotide-binding protein G(S) subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0031683|GO:0005525|GO:0003924|	GO:0007186|
GN009201.1	sp|K1PGX5|K1PGX5_CRAGI	0.0e+00	1380.9	100.00%	82.91%	Guanine nucleotide-binding protein G(S) subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0031683|GO:0005525|GO:0003924|	GO:0007186|
GN009204.1	sp|K1P2Y0|K1P2Y0_CRAGI	2.7e-138	496.9	98.12%	90.38%	Guanine nucleotide-binding protein G(S) subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0031683|GO:0005525|GO:0003924|	GO:0007186|
GN009205.1	sp|K1P828|K1P828_CRAGI	5.2e-121	439.9	91.64%	64.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009206.1	sp|A0A210QMH7|A0A210QMH7_MIZYE	4.3e-106	390.2	72.12%	77.64%	RING finger protein 113A;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN009207.1	sp|K1PGX1|K1PGX1_CRAGI	1.0e-264	917.9	99.83%	83.36%	Major facilitator superfamily domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009208.1	sp|K1PGX1|K1PGX1_CRAGI	1.2e-97	361.7	97.85%	82.82%	Major facilitator superfamily domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009209.1	sp|K1P9N7|K1P9N7_CRAGI	1.8e-96	357.8	100.00%	66.45%	14-3-3 protein zeta;OS=Crassostrea;PE=3;SV=1	GO:0019904|
GN008724.1	sp|K1Q109|K1Q109_CRAGI	0.0e+00	2449.9	97.86%	83.44%	Neurexin-4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009211.1	sp|K1RF87|K1RF87_CRAGI	4.3e-302	1042.3	95.43%	82.03%	Double-stranded RNA-binding protein Staufen-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN009212.1	sp|A0A210PSQ1|A0A210PSQ1_MIZYE	5.7e-96	356.7	93.75%	56.64%	F-box only protein 16;OS=Mizuhopecten;PE=4;SV=1
GN009213.1	sp|K1R8M9|K1R8M9_CRAGI	1.9e-69	267.7	85.86%	77.58%	Calcium-dependent protein kinase 31;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016301|
GN009214.1	sp|K1R833|K1R833_CRAGI	2.2e-171	607.4	98.79%	72.90%	Tachykinin-like peptide receptor 86C;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN009215.1	sp|K1PZZ7|K1PZZ7_CRAGI	1.3e-74	285.8	98.64%	50.25%	HCLS1-binding protein 3;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN008725.1	sp|K1Q879|K1Q879_CRAGI	2.3e-238	832.0	40.29%	63.38%	Zinc finger protein 91;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008725.1	sp|K1Q879|K1Q879_CRAGI	4.2e-30	140.2	7.15%	96.83%	Zinc finger protein 91;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN008726.1	sp|A0A210PGQ8|A0A210PGQ8_MIZYE	2.7e-220	770.4	84.51%	77.50%	Aspartate--tRNA ligase, cytoplasmic;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0004815|GO:0005524|	GO:0006422|
GN009238.1	sp|K1Q2J0|K1Q2J0_CRAGI	0.0e+00	2028.8	31.76%	65.12%	Fibrillin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007160|
GN009239.1	sp|K1QH75|K1QH75_CRAGI	7.4e-72	276.2	99.25%	61.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009240.1	sp|K1R2W8|K1R2W8_CRAGI	8.8e-196	689.5	94.73%	66.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009242.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	3.8e-69	267.3	87.50%	52.12%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN009248.1	sp|K1QA55|K1QA55_CRAGI	7.2e-157	559.3	98.86%	62.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009249.1	sp|K1PV11|K1PV11_CRAGI	1.2e-55	223.0	77.64%	42.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009250.1	sp|K1PRZ5|K1PRZ5_CRAGI	0.0e+00	1154.0	87.76%	71.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009251.1	sp|K1PYM1|K1PYM1_CRAGI	4.1e-61	240.0	100.00%	69.95%	COX assembly mitochondrial protein;OS=Crassostrea;PE=3;SV=1	GO:0005739|
GN009252.1	sp|K1QJ39|K1QJ39_CRAGI	7.4e-140	502.3	92.23%	90.49%	Pyrroline-5-carboxylate reductase;OS=Crassostrea;PE=3;SV=1	GO:0004735|	GO:0055129|
GN009253.1	sp|K1Q0U0|K1Q0U0_CRAGI	6.8e-110	402.5	90.15%	86.50%	Pyrroline-5-carboxylate reductase 1, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0004735|	GO:0006561|
GN009254.1	sp|K1QTQ1|K1QTQ1_CRAGI	9.4e-90	335.1	97.85%	88.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009255.1	sp|K1RMS2|K1RMS2_CRAGI	3.5e-101	373.2	100.00%	81.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009256.1	sp|K1Q0T7|K1Q0T7_CRAGI	1.4e-111	407.9	100.00%	84.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009257.1	sp|K1PTF5|K1PTF5_CRAGI	1.7e-92	344.4	99.02%	85.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009258.1	sp|K1Q0T7|K1Q0T7_CRAGI	5.5e-47	192.2	87.62%	89.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009259.1	sp|K1Q0T7|K1Q0T7_CRAGI	2.2e-50	203.8	100.00%	80.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009260.1	sp|K1PTF5|K1PTF5_CRAGI	1.8e-70	270.8	98.70%	67.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009261.1	sp|K1QTP3|K1QTP3_CRAGI	2.2e-102	377.5	100.00%	88.10%	Neuronal acetylcholine receptor subunit alpha-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN009262.1	sp|K1R4B5|K1R4B5_CRAGI	0.0e+00	1244.2	99.46%	70.68%	Poly(A) RNA polymerase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003730|GO:0050265|	GO:0006378|
GN009263.1	sp|A0A210PQQ9|A0A210PQQ9_MIZYE	9.6e-175	619.0	98.37%	59.00%	Solute carrier family 13 member 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN009264.1	sp|A0A210PQT5|A0A210PQT5_MIZYE	2.8e-26	123.6	81.15%	64.29%	Solute carrier family 13 member 5;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0006814|GO:0055085|
GN008728.1	sp|K1R523|K1R523_CRAGI	1.0e-69	269.6	73.66%	46.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009266.1	sp|K1RA89|K1RA89_CRAGI	7.3e-83	313.5	97.42%	63.68%	BAG family molecular chaperone regulator 4;OS=Crassostrea;PE=4;SV=1	GO:0051087|
GN009267.1	sp|A0A210PX11|A0A210PX11_MIZYE	0.0e+00	1228.8	99.87%	79.23%	ATP-dependent 6-phosphofructokinase;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0003872|GO:0005524|GO:0046872|	GO:0006002|
GN009269.1	sp|Q70MM2|Q70MM2_CRAGI	1.7e-84	317.8	100.00%	99.49%	Ribosomal protein L19;OS=Crassostrea;PE=2;SV=1	GO:0022625|	GO:0003723|GO:0003735|	GO:0006412|
GN009270.1	sp|A0A210PII8|A0A210PII8_MIZYE	1.1e-220	771.5	99.80%	73.90%	60S ribosomal export protein NMD3;OS=Mizuhopecten;PE=4;SV=1	GO:0043023|
GN009271.1	sp|K1PLF3|K1PLF3_CRAGI	4.7e-276	956.4	99.21%	71.25%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009272.1	sp|K1P7K0|K1P7K0_CRAGI	1.2e-75	288.1	100.00%	78.79%	Gamma-interferon-inducible lysosomal thiol reductase;OS=Crassostrea;PE=4;SV=1
GN009274.1	sp|K1PDL5|K1PDL5_CRAGI	1.8e-234	817.8	94.40%	73.98%	Nuclear factor erythroid 2-related factor 2;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0003677|GO:0003700|	GO:0034599|
GN009275.1	sp|K1QZV6|K1QZV6_CRAGI	1.3e-185	655.2	81.90%	72.04%	Serine/threonine-protein phosphatase BSU1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055114|
GN009276.1	sp|K1QF97|K1QF97_CRAGI	0.0e+00	1094.0	99.20%	57.47%	Leucine-rich repeat and IQ domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN009279.1	sp|A0A210R3Y7|A0A210R3Y7_MIZYE	3.7e-34	151.0	36.26%	69.39%	ETS-related transcription factor Elf-4;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN009280.1	sp|K1QQ05|K1QQ05_CRAGI	1.5e-189	669.1	92.32%	87.34%	Insulin-like growth factor-binding protein complex acid labile chain;OS=Crassostrea;PE=4;SV=1
GN009281.1	sp|K1QFT8|K1QFT8_CRAGI	8.0e-64	248.8	89.29%	75.84%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN009282.1	sp|K1PNF4|K1PNF4_CRAGI	1.7e-122	446.0	65.10%	51.39%	Src kinase-associated phosphoprotein 2-A;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN009283.1	sp|K1PVT7|K1PVT7_CRAGI	4.4e-260	902.5	98.03%	82.63%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN009284.1	sp|K1QFU1|K1QFU1_CRAGI	7.8e-83	313.2	85.56%	48.62%	GDP-fucose protein O-fucosyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0006004|
GN009285.1	sp|K1P9F9|K1P9F9_CRAGI	1.2e-223	781.2	100.00%	84.79%	GDP-fucose protein O-fucosyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0006004|
GN009286.1	sp|K1QX72|K1QX72_CRAGI	1.2e-237	828.2	94.18%	70.22%	Rho GTPase-activating protein 18;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN009287.1	sp|K1Q3Z9|K1Q3Z9_CRAGI	1.7e-13	80.9	59.41%	64.41%	Angiotensin-converting enzyme;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0004180|GO:0046872|GO:0008237|GO:0008241|
GN009288.1	sp|A0A210Q9D8|A0A210Q9D8_MIZYE	1.2e-253	881.3	96.53%	65.05%	Angiotensin-converting enzyme;OS=Mizuhopecten;PE=3;SV=1	GO:0016020|	GO:0004180|GO:0046872|GO:0008237|GO:0008241|
GN009289.1	sp|K1QHQ1|K1QHQ1_CRAGI	1.2e-209	734.9	78.22%	96.38%	YTH domain family protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN009290.1	sp|K1R9L3|K1R9L3_CRAGI	0.0e+00	1266.9	99.52%	59.27%	Zinc finger protein 91;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009291.1	sp|K1S606|K1S606_CRAGI	2.5e-52	210.7	83.24%	91.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009292.1	sp|K1R0F7|K1R0F7_CRAGI	2.1e-29	134.4	96.23%	63.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009293.1	sp|K1RAQ7|K1RAQ7_CRAGI	2.1e-92	344.4	84.82%	79.26%	Exosome complex exonuclease MTR3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004527|
GN009294.1	sp|K1RGB7|K1RGB7_CRAGI	7.6e-153	545.4	100.00%	86.36%	Epidermal retinal dehydrogenase 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN009296.1	sp|A0A210QRW3|A0A210QRW3_MIZYE	2.8e-108	397.5	63.61%	96.73%	Splicing factor 3A subunit 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003676|GO:0008270|
GN009297.1	sp|K1PVU0|K1PVU0_CRAGI	1.4e-28	131.7	97.56%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008729.1	sp|K1RKU0|K1RKU0_CRAGI	3.1e-309	1065.8	98.95%	91.33%	2-hydroxyacyl-CoA lyase 1;OS=Crassostrea;PE=3;SV=1	GO:0016829|GO:0000287|GO:0030976|
GN009298.1	sp|K1QXB6|K1QXB6_CRAGI	1.6e-263	914.4	91.19%	69.23%	Otopetrin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009299.1	sp|K1RHH1|K1RHH1_CRAGI	1.1e-53	215.3	75.26%	76.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009300.1	sp|K1PWW0|K1PWW0_CRAGI	1.7e-16	92.4	68.08%	25.84%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN009301.1	sp|A0A210PGT2|A0A210PGT2_MIZYE	6.1e-32	143.3	87.50%	39.38%	RING-H2 finger protein ATL30;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009303.1	sp|K1Q136|K1Q136_CRAGI	1.1e-38	166.0	66.79%	47.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN008730.1	sp|K1REP8|K1REP8_CRAGI	2.1e-172	610.9	99.56%	65.35%	GTP-binding protein 10-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN009305.1	sp|K1Q8W2|K1Q8W2_CRAGI	5.3e-151	541.6	98.26%	32.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009306.1	sp|A0A2R2MJE1|A0A2R2MJE1_LINUN	3.5e-78	297.4	93.96%	48.94%	uncharacterized protein LOC112041353;OS=Lingula;PE=4;SV=1
GN009308.1	sp|A0A2S2QV27|A0A2S2QV27_9HEMI	3.2e-13	81.6	48.14%	33.33%	Putative RNA-directed DNA polymerase;OS=Sipha;PE=4;SV=1	GO:0003676|GO:0003964|GO:0004523|
GN009309.1	sp|A0A1S3IJU7|A0A1S3IJU7_LINUN	7.4e-52	209.5	75.86%	60.00%	E3 SUMO-protein ligase KIAA1586-like;OS=Lingula;PE=4;SV=1	GO:0016874|
GN009310.1	sp|K1Q0E2|K1Q0E2_CRAGI	9.6e-86	323.6	63.88%	39.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009311.1	sp|A0A2B4S577|A0A2B4S577_STYPI	9.9e-21	105.5	66.67%	46.53%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN008731.1	sp|K1R8W3|K1R8W3_CRAGI	2.0e-55	220.7	90.34%	100.00%	S-phase kinase-associated protein 1;OS=Crassostrea;PE=3;SV=1	GO:0016301|	GO:0006511|
GN009312.1	sp|K1QL89|K1QL89_CRAGI	1.3e-13	80.9	86.67%	69.23%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN009313.1	sp|K1QL89|K1QL89_CRAGI	7.1e-54	215.3	93.50%	91.23%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN009315.1	sp|K1Q3Q1|K1Q3Q1_CRAGI	7.2e-40	169.9	80.16%	41.95%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN009316.1	sp|K1Q7A3|K1Q7A3_CRAGI	2.6e-72	276.9	98.12%	77.56%	Beta,beta-carotene 15,15'-monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004497|GO:0016702|
GN009317.1	sp|K1Q7A3|K1Q7A3_CRAGI	4.0e-106	389.8	95.69%	81.00%	Beta,beta-carotene 15,15'-monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004497|GO:0016702|
GN009321.1	sp|K1Q7A3|K1Q7A3_CRAGI	1.4e-158	564.7	93.30%	78.08%	Beta,beta-carotene 15,15'-monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004497|GO:0016702|
GN009323.1	sp|A0A2G8K194|A0A2G8K194_STIJA	3.2e-25	120.2	97.60%	49.18%	Endonuclease-reverse transcriptase;OS=Stichopus;PE=4;SV=1	GO:0004519|GO:0003964|
GN009324.1	sp|K1P3I0|K1P3I0_CRAGI	0.0e+00	2855.9	99.94%	71.43%	Structural maintenance of chromosomes flexible hinge domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005694|	GO:0005524|	GO:0051276|GO:0006302|
GN009325.1	sp|K1QA22|K1QA22_CRAGI	5.2e-169	599.4	100.00%	80.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009326.1	sp|K1PPC5|K1PPC5_CRAGI	3.8e-131	474.2	58.98%	73.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN009327.1	sp|X1WW30|X1WW30_ACYPI	4.3e-16	90.5	75.38%	34.87%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1	GO:0003677|
GN009328.1	sp|K1P0H4|K1P0H4_CRAGI	7.0e-65	253.4	92.82%	36.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009329.1	sp|W4YR48|W4YR48_STRPU	4.2e-45	186.8	91.05%	55.37%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN009330.1	sp|K1QZK2|K1QZK2_CRAGI	1.7e-45	188.3	83.56%	53.93%	Tax1-binding protein 1-like protein B;OS=Crassostrea;PE=4;SV=1
GN009331.1	sp|K1QZK2|K1QZK2_CRAGI	1.9e-31	140.6	99.07%	57.89%	Tax1-binding protein 1-like protein B;OS=Crassostrea;PE=4;SV=1
GN009332.1	sp|K1RQI2|K1RQI2_CRAGI	1.5e-252	877.9	92.98%	76.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009335.1	sp|K1PYN8|K1PYN8_CRAGI	1.2e-189	668.3	99.79%	65.63%	Cytochrome P450 2B19;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN009336.1	sp|W4XAN4|W4XAN4_STRPU	1.6e-61	241.5	77.67%	67.92%	Uncharacterized protein;OS=Strongylocentrotus;PE=3;SV=1	GO:0005634|	GO:0005524|GO:0061631|	GO:0006974|
GN009337.1	sp|A0A210QDD5|A0A210QDD5_MIZYE	1.3e-19	102.8	64.67%	37.50%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN009338.1	sp|K1QZJ8|K1QZJ8_CRAGI	2.3e-148	531.6	94.17%	53.16%	Ring canal kelch-like protein;OS=Crassostrea;PE=4;SV=1
GN009339.1	sp|K1QSJ8|K1QSJ8_CRAGI	1.4e-226	792.3	39.15%	74.75%	Peroxidasin;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN009340.1	sp|K1QX66|K1QX66_CRAGI	4.5e-80	303.1	99.53%	65.09%	Carbonic anhydrase 2;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|
GN009341.1	sp|K1R3K9|K1R3K9_CRAGI	5.0e-76	289.7	97.57%	61.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009343.1	sp|K1QJY0|K1QJY0_CRAGI	2.3e-36	158.3	50.00%	55.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009344.1	sp|K1QJY0|K1QJY0_CRAGI	2.1e-48	198.7	99.45%	40.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009346.1	sp|K1Q5W7|K1Q5W7_CRAGI	1.1e-18	98.6	87.59%	42.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN009348.1	sp|K1Q5W7|K1Q5W7_CRAGI	1.5e-18	98.2	87.50%	41.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN009350.1	sp|K1Q136|K1Q136_CRAGI	2.9e-33	148.3	54.79%	41.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN009353.1	sp|A0A1Y1JT91|A0A1Y1JT91_PHOPY	7.1e-65	253.4	88.68%	42.18%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN009355.1	sp|K1QCR8|K1QCR8_CRAGI	9.0e-179	633.3	60.97%	53.83%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009356.1	sp|K1QCR8|K1QCR8_CRAGI	8.6e-201	706.4	59.75%	59.94%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN009357.1	sp|K1RV76|K1RV76_CRAGI	1.4e-61	242.3	91.88%	41.34%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN009358.1	sp|K1RV76|K1RV76_CRAGI	4.6e-60	237.3	92.92%	40.07%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN009359.1	sp|A0A2T7PLM1|A0A2T7PLM1_POMCA	2.5e-31	142.5	65.25%	27.25%	Uncharacterized protein;OS=Pomacea;PE=3;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN009361.1	sp|K1PK85|K1PK85_CRAGI	0.0e+00	1795.0	100.00%	96.13%	Cullin-associated NEDD8-dissociated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0010265|
GN009362.1	sp|K1PK85|K1PK85_CRAGI	5.3e-45	186.4	81.62%	68.07%	Cullin-associated NEDD8-dissociated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0010265|
GN009363.1	sp|K1PCQ5|K1PCQ5_CRAGI	0.0e+00	1362.4	89.02%	89.64%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016874|GO:0046872|GO:0004842|
GN010785.1	sp|K1QJW8|K1QJW8_CRAGI	6.2e-17	93.6	70.08%	33.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010791.1	sp|K1Q1M0|K1Q1M0_CRAGI	5.6e-47	193.4	91.18%	45.83%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN010850.1	sp|A0A2G8KZE9|A0A2G8KZE9_STIJA	4.5e-74	285.0	54.82%	39.13%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN011493.1	sp|K1QJA7|K1QJA7_CRAGI	1.8e-105	387.5	100.00%	93.63%	Histone chaperone asf1-B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006333|
GN011494.1	sp|K1QAU3|K1QAU3_CRAGI	0.0e+00	1644.0	100.00%	88.70%	WD repeat-containing protein 63;OS=Crassostrea;PE=4;SV=1
GN011495.1	sp|K1PBF8|K1PBF8_CRAGI	5.3e-238	829.3	99.52%	71.80%	Tether containing UBX domain for GLUT4;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN011496.1	sp|K1QHP9|K1QHP9_CRAGI	0.0e+00	1978.4	97.87%	76.99%	DNA excision repair protein ERCC-6;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN011497.1	sp|K1PXJ1|K1PXJ1_CRAGI	8.4e-227	791.6	100.00%	85.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011498.1	sp|K1PQJ9|K1PQJ9_CRAGI	3.5e-75	286.6	100.00%	88.30%	ATP synthase subunit delta, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0045261|	GO:0046933|	GO:0015986|
GN011499.1	sp|K1PHU1|K1PHU1_CRAGI	0.0e+00	1606.7	100.00%	80.46%	Rapamycin-insensitive companion of mTOR;OS=Crassostrea;PE=4;SV=1	GO:0031932|	GO:0031929|
GN011500.1	sp|A0A210PEI0|A0A210PEI0_MIZYE	2.3e-133	480.7	99.35%	68.30%	Diisopropyl-fluorophosphatase;OS=Mizuhopecten;PE=4;SV=1
GN011501.1	sp|K1PHU1|K1PHU1_CRAGI	0.0e+00	2529.2	99.20%	39.40%	Rapamycin-insensitive companion of mTOR;OS=Crassostrea;PE=4;SV=1	GO:0031932|	GO:0031929|
GN011502.1	sp|K1QA91|K1QA91_CRAGI	4.9e-202	710.7	60.04%	63.17%	26S proteasome non-ATPase regulatory subunit 10;OS=Crassostrea;PE=4;SV=1	GO:0000502|	GO:0007165|
GN011503.1	sp|K1PNQ7|K1PNQ7_CRAGI	1.1e-120	438.7	100.00%	69.02%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011504.1	sp|K1PRQ9|K1PRQ9_CRAGI	5.1e-118	429.9	100.00%	60.70%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN011505.1	sp|K1PRQ9|K1PRQ9_CRAGI	2.3e-233	813.9	100.00%	62.76%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN011506.1	sp|K1PYC7|K1PYC7_CRAGI	2.8e-249	866.7	100.00%	70.22%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN011507.1	sp|K1Q637|K1Q637_CRAGI	3.5e-33	147.9	97.05%	32.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011508.1	sp|K1PTD8|K1PTD8_CRAGI	1.1e-12	79.0	87.95%	31.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011513.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	4.7e-31	140.2	96.45%	41.88%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN011517.1	sp|K1RRD7|K1RRD7_CRAGI	1.1e-31	143.3	27.62%	49.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011518.1	sp|K1Q6N5|K1Q6N5_CRAGI	3.1e-141	507.7	70.59%	65.28%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN011519.1	sp|K1QST7|K1QST7_CRAGI	9.2e-150	535.8	98.32%	54.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011521.1	sp|K1PHU1|K1PHU1_CRAGI	0.0e+00	1441.0	99.15%	54.55%	Rapamycin-insensitive companion of mTOR;OS=Crassostrea;PE=4;SV=1	GO:0031932|	GO:0031929|
GN011522.1	sp|K1QST7|K1QST7_CRAGI	8.3e-170	602.8	85.92%	53.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011524.1	sp|K1RJH1|K1RJH1_CRAGI	4.4e-73	279.6	98.29%	77.19%	28S ribosomal protein S34, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|GO:0005840|	GO:0003735|
GN011525.1	sp|K1QMR8|K1QMR8_CRAGI	2.5e-41	175.3	91.58%	30.68%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010852.1	sp|K1QF17|K1QF17_CRAGI	5.0e-13	80.9	90.51%	28.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011529.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	1.6e-20	105.5	63.79%	38.96%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN011531.1	sp|K1QWT8|K1QWT8_CRAGI	4.6e-36	157.9	50.95%	40.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011534.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	1.6e-20	105.5	63.79%	38.96%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010853.1	sp|K1PSE0|K1PSE0_CRAGI	1.2e-48	199.5	100.00%	35.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011537.1	sp|K1QWT8|K1QWT8_CRAGI	5.7e-33	147.5	52.76%	40.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011538.1	sp|K1QWT8|K1QWT8_CRAGI	4.6e-36	157.9	50.95%	40.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011539.1	sp|K1RBU3|K1RBU3_CRAGI	6.4e-193	679.5	84.97%	82.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011540.1	sp|K1QC76|K1QC76_CRAGI	0.0e+00	1469.1	97.23%	68.86%	Transmembrane protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011541.1	sp|K1RFW2|K1RFW2_CRAGI	9.2e-68	262.3	71.62%	77.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010854.1	sp|V4CS71|V4CS71_LOTGI	5.2e-48	196.8	93.83%	45.53%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN011543.1	sp|K1QKA4|K1QKA4_CRAGI	5.7e-205	719.5	73.55%	71.85%	Polypeptide N-acetylgalactosaminyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN011544.1	sp|A0A210PUJ3|A0A210PUJ3_MIZYE	4.0e-49	200.7	95.56%	41.70%	NUAK family SNF1-like kinase 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN011547.1	sp|K1RDM4|K1RDM4_CRAGI	2.3e-14	84.0	47.41%	70.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010855.1	sp|K1RQK0|K1RQK0_CRAGI	8.5e-53	213.8	31.81%	68.75%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011550.1	sp|K1R3A9|K1R3A9_CRAGI	7.4e-38	163.7	67.85%	36.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011553.1	sp|K1QUS9|K1QUS9_CRAGI	3.5e-94	350.5	99.35%	57.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011554.1	sp|K1QLK4|K1QLK4_CRAGI	3.6e-40	171.0	80.56%	40.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011556.1	sp|K1QFV0|K1QFV0_CRAGI	3.8e-40	170.2	91.53%	53.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011557.1	sp|K1QG13|K1QG13_CRAGI	1.7e-124	451.1	94.42%	84.98%	Serine/threonine-protein kinase 19;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN011558.1	sp|K1PFY0|K1PFY0_CRAGI	7.3e-213	745.3	100.00%	80.57%	ZZ-type zinc finger-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN011559.1	sp|K1QV23|K1QV23_CRAGI	5.2e-18	96.3	51.13%	67.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011560.1	sp|K1RMN9|K1RMN9_CRAGI	2.1e-258	897.1	99.69%	67.66%	Fem-1-like protein A;OS=Crassostrea;PE=4;SV=1
GN011561.1	sp|K1R3D0|K1R3D0_CRAGI	1.4e-129	468.8	73.28%	67.74%	Polymerase delta-interacting protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0003723|	GO:0006406|
GN011562.1	sp|K1QWX5|K1QWX5_CRAGI	5.3e-95	352.8	88.55%	89.00%	Mitochondrial uncoupling protein 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN011563.1	sp|K1QP30|K1QP30_CRAGI	1.9e-48	197.2	97.48%	76.52%	Growth factor receptor-bound protein 2;OS=Crassostrea;PE=4;SV=1
GN011564.1	sp|K1QAV1|K1QAV1_CRAGI	0.0e+00	1211.4	100.00%	90.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN010792.1	sp|K1Q1M0|K1Q1M0_CRAGI	1.7e-89	335.1	98.17%	47.31%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN011565.1	sp|K1RI46|K1RI46_CRAGI	8.6e-152	542.7	100.00%	66.49%	DnaJ-like protein subfamily C member 21;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN011568.1	sp|K1QRS6|K1QRS6_CRAGI	0.0e+00	1589.7	96.41%	90.60%	Phosphatidylinositol 3-kinase regulatory subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0005942|	GO:0016301|GO:0046872|GO:0035014|	GO:0035556|
GN011569.1	sp|K1QYA2|K1QYA2_CRAGI	3.8e-190	669.5	100.00%	94.13%	UDP-glucose 4-epimerase;OS=Crassostrea;PE=3;SV=1	GO:0003978|	GO:0006012|
GN011570.1	sp|K1RI53|K1RI53_CRAGI	5.5e-118	429.5	100.00%	79.79%	UPF0549 protein C20orf43-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:1902979|
GN011571.1	sp|K1QAW2|K1QAW2_CRAGI	1.8e-120	437.6	100.00%	84.55%	Lysosomal-associated transmembrane protein 4A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011573.1	sp|W4YG93|W4YG93_STRPU	1.3e-47	194.9	90.30%	58.78%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000175|GO:0003676|	GO:0000738|GO:0000467|
GN011574.1	sp|K1RA09|K1RA09_CRAGI	4.8e-78	298.1	27.75%	71.94%	Zinc finger FYVE domain-containing protein 9;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN011575.1	sp|K1R852|K1R852_CRAGI	7.9e-120	435.3	100.00%	98.63%	Ras-related protein Rab-3;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN011576.1	sp|K1Q114|K1Q114_CRAGI	7.5e-301	1038.5	96.20%	73.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011577.1	sp|A0A210Q059|A0A210Q059_MIZYE	0.0e+00	1495.7	100.00%	87.93%	Transportin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0008536|	GO:0006606|
GN011578.1	sp|K1QMS0|K1QMS0_CRAGI	0.0e+00	1391.7	100.00%	74.16%	Transient receptor potential cation channel subfamily A member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005216|
GN011579.1	sp|A0A0P5USD3|A0A0P5USD3_9CRUS	1.3e-32	145.2	96.49%	87.20%	Calmodulin;OS=Daphnia;PE=4;SV=1	GO:0005509|
GN011580.1	sp|K1QFK6|K1QFK6_CRAGI	1.2e-40	171.8	57.86%	92.31%	Troponin C;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011581.1	sp|Q8IFX2|Q8IFX2_CRAGI	0.0e+00	1625.5	99.89%	79.30%	Metalloendopeptidase;OS=Crassostrea;PE=2;SV=1	GO:0005509|GO:0004222|GO:0008270|
GN011582.1	sp|K1QWX8|K1QWX8_CRAGI	8.0e-138	495.4	100.00%	89.82%	IQ domain-containing protein K;OS=Crassostrea;PE=4;SV=1
GN011583.1	sp|K1QYG6|K1QYG6_CRAGI	0.0e+00	1236.1	40.85%	70.24%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011584.1	sp|K1QHC7|K1QHC7_CRAGI	3.4e-258	896.0	100.00%	95.23%	G protein-activated inward rectifier potassium channel 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN011585.1	sp|K1RRD7|K1RRD7_CRAGI	3.1e-34	150.2	63.91%	78.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011586.1	sp|K1QYG9|K1QYG9_CRAGI	1.2e-232	811.2	99.60%	83.03%	Caskin-1;OS=Crassostrea;PE=4;SV=1
GN011587.1	sp|K1R4T1|K1R4T1_CRAGI	1.2e-216	758.1	100.00%	76.61%	2-(3-amino-3-carboxypropyl)histidine synthase subunit 2;OS=Crassostrea;PE=3;SV=1	GO:0016740|	GO:0017183|
GN011588.1	sp|A0A0L8FG32|A0A0L8FG32_OCTBM	5.9e-90	336.3	87.31%	69.60%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN011589.1	sp|K1QHD2|K1QHD2_CRAGI	6.1e-220	769.2	98.97%	67.89%	Exonuclease domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0004527|GO:0003676|GO:0008270|
GN011590.1	sp|K1QYH3|K1QYH3_CRAGI	3.4e-227	793.5	93.59%	68.81%	Monocarboxylate transporter 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN011597.1	sp|A0A1C9U307|A0A1C9U307_MIZYE	2.3e-14	85.1	80.62%	27.06%	Heat shock 70 kDa protein;OS=Mizuhopecten;PE=2;SV=1
GN011599.1	sp|K1QYH3|K1QYH3_CRAGI	7.5e-294	1015.0	100.00%	80.75%	Monocarboxylate transporter 14;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN011600.1	sp|K1R4T4|K1R4T4_CRAGI	1.9e-52	210.7	99.24%	78.46%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1
GN011601.1	sp|K1R5Q6|K1R5Q6_CRAGI	2.3e-73	280.4	100.00%	85.53%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN011602.1	sp|K1RCB3|K1RCB3_CRAGI	2.8e-82	310.5	83.10%	87.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0004842|
GN011603.1	sp|V4A067|V4A067_LOTGI	5.5e-120	436.8	99.10%	54.01%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003755|	GO:0006457|
GN011604.1	sp|K1Q084|K1Q084_CRAGI	5.9e-143	513.8	83.62%	44.67%	Peptidyl-prolyl cis-trans isomerase SDCCAG10;OS=Crassostrea;PE=4;SV=1	GO:0016853|
GN011605.1	sp|K1QKI0|K1QKI0_CRAGI	4.4e-196	690.3	98.44%	56.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN011606.1	sp|K1PEA8|K1PEA8_CRAGI	5.5e-91	341.3	51.72%	51.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011607.1	sp|K1Q0R5|K1Q0R5_CRAGI	1.7e-146	524.2	100.00%	82.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011608.1	sp|A0A210PEN9|A0A210PEN9_MIZYE	3.7e-23	113.6	92.99%	37.93%	RecQ-mediated genome instability protein 2;OS=Mizuhopecten;PE=4;SV=1
GN011609.1	sp|K1Q884|K1Q884_CRAGI	4.3e-234	815.8	97.72%	92.76%	Serine/threonine-protein kinase Nek8;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN011610.1	sp|K1Q122|K1Q122_CRAGI	6.2e-88	328.9	99.42%	95.86%	Myosin regulatory light chain sqh;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011611.1	sp|K1R860|K1R860_CRAGI	6.2e-267	925.6	96.35%	72.05%	Phosphodiesterase;OS=Crassostrea;PE=3;SV=1	GO:0004114|GO:0046872|	GO:0007165|
GN010859.1	sp|K1QDT8|K1QDT8_CRAGI	2.6e-28	131.0	76.84%	44.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011612.1	sp|K1QMS4|K1QMS4_CRAGI	0.0e+00	1410.2	94.88%	81.11%	Alpha-N-acetylglucosaminidase;OS=Crassostrea;PE=4;SV=1
GN011613.1	sp|K1Q881|K1Q881_CRAGI	0.0e+00	1356.3	82.81%	79.24%	Glutamate [NMDA] receptor subunit 3A;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN011614.1	sp|K1Q117|K1Q117_CRAGI	0.0e+00	1498.0	99.90%	73.78%	Glutamate [NMDA] receptor subunit 3A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004970|
GN011615.1	sp|K1R855|K1R855_CRAGI	5.5e-57	226.1	98.20%	69.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010860.1	sp|K1RDL0|K1RDL0_CRAGI	1.8e-185	655.6	46.22%	63.60%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN011622.1	sp|K1RBW0|K1RBW0_CRAGI	2.0e-36	157.5	80.14%	66.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011623.1	sp|K1QPA4|K1QPA4_CRAGI	2.7e-175	620.2	100.00%	84.00%	DNA polymerase beta;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003887|	GO:0006281|
GN011624.1	sp|K1QVV0|K1QVV0_CRAGI	2.5e-26	123.6	89.81%	63.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011625.1	sp|K1R5C6|K1R5C6_CRAGI	1.1e-236	824.7	88.76%	76.92%	Alanine--glyoxylate aminotransferase 2-like 1;OS=Crassostrea;PE=3;SV=1	GO:0030170|GO:0008483|
GN011626.1	sp|K1Q0W8|K1Q0W8_CRAGI	6.5e-44	182.2	98.32%	69.83%	Follistatin-related protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008378|	GO:0006486|
GN011627.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.2e-59	234.6	98.31%	49.36%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN011628.1	sp|K1RBW4|K1RBW4_CRAGI	1.1e-71	275.0	82.95%	93.79%	Guanine nucleotide-binding protein subunit alpha-12;OS=Crassostrea;PE=4;SV=1	GO:0001664|GO:0031683|GO:0005525|GO:0003924|	GO:0007186|GO:0007266|
GN011629.1	sp|K1RBX0|K1RBX0_CRAGI	7.0e-95	352.4	97.82%	78.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011630.1	sp|K1RVE6|K1RVE6_CRAGI	8.9e-226	788.5	93.30%	77.20%	AP complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030117|	GO:0030276|	GO:0006886|GO:0016192|
GN011631.1	sp|K1QPB0|K1QPB0_CRAGI	1.5e-84	318.5	71.29%	72.97%	U3 small nucleolar RNA-associated protein 6-like protein;OS=Crassostrea;PE=4;SV=1	GO:0030515|	GO:0000462|
GN011632.1	sp|K1QYH4|K1QYH4_CRAGI	1.8e-129	467.6	100.00%	86.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011633.1	sp|K1RBX5|K1RBX5_CRAGI	1.2e-218	765.4	54.22%	88.89%	Kelch-like protein 20;OS=Crassostrea;PE=4;SV=1
GN011634.1	sp|A0A2B4S9J1|A0A2B4S9J1_STYPI	1.7e-16	90.9	92.23%	47.87%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN011635.1	sp|A0A210R1U6|A0A210R1U6_MIZYE	9.5e-183	645.6	98.90%	59.05%	Cytochrome P450 10;OS=Mizuhopecten;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN011636.1	sp|A0A210R1U6|A0A210R1U6_MIZYE	5.1e-161	573.5	83.17%	54.65%	Cytochrome P450 10;OS=Mizuhopecten;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN011637.1	sp|A0A210R1U6|A0A210R1U6_MIZYE	5.0e-184	649.8	99.27%	56.91%	Cytochrome P450 10;OS=Mizuhopecten;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN011638.1	sp|K1RN17|K1RN17_CRAGI	1.1e-61	241.9	91.10%	66.47%	Calcium-binding protein NCS-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011639.1	sp|K1RN17|K1RN17_CRAGI	3.1e-80	303.5	90.58%	86.63%	Calcium-binding protein NCS-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010793.1	sp|K1Q136|K1Q136_CRAGI	1.9e-32	145.6	54.30%	40.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011640.1	sp|K1S6E0|K1S6E0_CRAGI	4.6e-92	342.8	100.00%	87.23%	Neurocalcin-delta;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011641.1	sp|K1R0X1|K1R0X1_CRAGI	3.1e-212	743.8	99.85%	52.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011642.1	sp|K1R0X1|K1R0X1_CRAGI	1.8e-14	83.6	83.82%	66.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011643.1	sp|K1QE93|K1QE93_CRAGI	1.2e-92	345.1	92.18%	69.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011646.1	sp|K1QS31|K1QS31_CRAGI	1.3e-51	209.5	70.00%	45.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010861.1	sp|K1RDL0|K1RDL0_CRAGI	2.1e-188	665.2	50.00%	64.43%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN011648.1	sp|K1RWJ1|K1RWJ1_CRAGI	2.5e-09	67.4	58.14%	48.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011649.1	sp|K1QL27|K1QL27_CRAGI	1.7e-177	627.9	100.00%	78.46%	Glutamate-rich WD repeat-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN011650.1	sp|A0A210QGB7|A0A210QGB7_MIZYE	4.0e-201	706.4	100.00%	71.64%	Cytosolic Fe-S cluster assembly factor NARFL;OS=Mizuhopecten;PE=3;SV=1
GN011651.1	sp|K1QE38|K1QE38_CRAGI	3.9e-158	563.1	99.12%	85.71%	Target of rapamycin complex subunit lst8;OS=Crassostrea;PE=4;SV=1	GO:0031931|GO:0031932|	GO:0032008|GO:0031929|
GN011652.1	sp|A0A210QSQ7|A0A210QSQ7_MIZYE	7.6e-36	155.6	94.96%	56.69%	Brain protein I3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN011653.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	2.4e-42	178.7	27.92%	69.72%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN011654.1	sp|K1PYK1|K1PYK1_CRAGI	4.4e-35	152.5	100.00%	78.72%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0008168|	GO:0001510|
GN011659.1	sp|A0A1S3JB50|A0A1S3JB50_LINUN	1.5e-26	125.6	92.56%	34.84%	uncharacterized protein LOC106171724;OS=Lingula;PE=4;SV=1
GN011660.1	sp|K1QKG3|K1QKG3_CRAGI	5.2e-25	119.0	97.80%	60.23%	Nucleoredoxin;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN011661.1	sp|K1QLK4|K1QLK4_CRAGI	1.1e-38	165.6	60.00%	62.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011662.1	sp|K1RF74|K1RF74_CRAGI	2.0e-19	102.1	33.93%	55.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011663.1	sp|A0A1S3H205|A0A1S3H205_LINUN	1.0e-46	192.2	91.58%	54.29%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN011664.1	sp|A0A0J7KAV3|A0A0J7KAV3_LASNI	4.7e-32	143.3	87.95%	41.56%	Nuclease harbi1;OS=Lasius;PE=4;SV=1
GN011665.1	sp|A0A0L8IDJ6|A0A0L8IDJ6_OCTBM	3.4e-17	94.7	43.00%	41.98%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN011667.1	sp|A0A210PH76|A0A210PH76_MIZYE	1.7e-22	113.2	33.76%	34.04%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN011668.1	sp|K1PKX6|K1PKX6_CRAGI	1.4e-29	135.6	32.79%	86.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN011671.1	sp|K1S047|K1S047_CRAGI	7.1e-131	472.6	100.00%	70.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011672.1	sp|K1RH86|K1RH86_CRAGI	2.5e-13	80.5	77.48%	60.47%	Membrane progestin receptor gamma-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003676|
GN011673.1	sp|K1RH86|K1RH86_CRAGI	2.5e-13	80.5	77.48%	60.47%	Membrane progestin receptor gamma-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003676|
GN011677.1	sp|D8VNA2|D8VNA2_9BIVA	1.8e-10	70.5	90.00%	40.85%	C-type lectin 5;OS=Azumapecten;PE=2;SV=1	GO:0030246|
GN011678.1	sp|K1R0N3|K1R0N3_CRAGI	1.1e-234	818.1	95.53%	68.83%	Carboxylesterase 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN010863.1	sp|K1P1T5|K1P1T5_CRAGI	5.0e-52	211.5	24.58%	69.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011679.1	sp|K1R0N3|K1R0N3_CRAGI	4.3e-234	816.2	95.53%	68.83%	Carboxylesterase 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN011680.1	sp|K1QED4|K1QED4_CRAGI	1.9e-249	867.1	99.81%	77.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011681.1	sp|A0A210QWB3|A0A210QWB3_MIZYE	2.7e-70	270.8	96.96%	63.96%	UPF0193 protein EVG1-like;OS=Mizuhopecten;PE=4;SV=1
GN011682.1	sp|K1PWU3|K1PWU3_CRAGI	2.1e-136	491.5	74.60%	61.29%	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN011683.1	sp|K1PWU3|K1PWU3_CRAGI	7.3e-131	473.0	79.74%	58.71%	Peroxisomal N(1)-acetyl-spermine/spermidine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN011684.1	sp|K1PPC4|K1PPC4_CRAGI	2.0e-148	530.8	99.69%	79.31%	Acyl-CoA desaturase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016717|	GO:0006633|
GN011685.1	sp|K1PPC4|K1PPC4_CRAGI	2.1e-153	547.4	98.80%	79.27%	Acyl-CoA desaturase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016717|	GO:0006633|
GN011686.1	sp|K1PWS8|K1PWS8_CRAGI	5.8e-66	255.8	99.33%	87.66%	Mitotic spindle assembly checkpoint protein MAD2A;OS=Crassostrea;PE=4;SV=1	GO:0007094|
GN011687.1	sp|K1Q3Q2|K1Q3Q2_CRAGI	1.2e-71	275.0	100.00%	71.21%	Neurogenic differentiation factor 1;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN011688.1	sp|K1QPV3|K1QPV3_CRAGI	1.1e-92	345.5	99.67%	67.45%	Neurogenin-1;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0022008|GO:0006355|
GN011691.1	sp|K1RBY9|K1RBY9_CRAGI	4.2e-48	199.5	21.14%	40.81%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011692.1	sp|K1Q5Y6|K1Q5Y6_CRAGI	2.1e-124	451.1	100.00%	66.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011693.1	sp|K1PJY7|K1PJY7_CRAGI	1.2e-87	328.2	100.00%	82.54%	ADP-ribosylation factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN011694.1	sp|K1RG92|K1RG92_CRAGI	1.3e-74	284.6	97.60%	84.57%	ADP-ribosylation factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN011695.1	sp|K1R0D0|K1R0D0_CRAGI	5.1e-83	312.8	98.42%	82.80%	ADP-ribosylation factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN011696.1	sp|K1RG92|K1RG92_CRAGI	1.8e-88	330.9	100.00%	85.71%	ADP-ribosylation factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN011697.1	sp|K1RG92|K1RG92_CRAGI	3.1e-88	330.1	100.00%	85.71%	ADP-ribosylation factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN011698.1	sp|K1R0C6|K1R0C6_CRAGI	8.2e-95	352.4	99.63%	80.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011702.1	sp|K1QF00|K1QF00_CRAGI	2.6e-202	710.7	97.09%	87.99%	Actin-binding protein IPP;OS=Crassostrea;PE=4;SV=1
GN011704.1	sp|K1Q7X1|K1Q7X1_CRAGI	1.3e-174	618.6	97.92%	89.81%	Hydrocephalus-inducing protein;OS=Crassostrea;PE=4;SV=1
GN011705.1	sp|K1RSW2|K1RSW2_CRAGI	6.3e-85	320.1	66.13%	67.21%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN011706.1	sp|K1Q0H7|K1Q0H7_CRAGI	1.3e-36	157.5	86.96%	89.87%	Ankyrin repeat domain-containing protein 13C-B;OS=Crassostrea;PE=4;SV=1
GN011707.1	sp|K1R104|K1R104_CRAGI	5.2e-165	586.3	99.28%	85.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN011708.1	sp|A0A210Q3X4|A0A210Q3X4_MIZYE	0.0e+00	1185.6	93.90%	29.18%	Delta-like protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007275|GO:0007219|
GN011709.1	sp|K1PLY9|K1PLY9_CRAGI	6.2e-135	486.1	93.79%	72.67%	Receptor-type tyrosine-protein phosphatase eta;OS=Crassostrea;PE=4;SV=1	GO:0005001|
GN011710.1	sp|K1PLY9|K1PLY9_CRAGI	6.2e-135	486.1	93.79%	72.67%	Receptor-type tyrosine-protein phosphatase eta;OS=Crassostrea;PE=4;SV=1	GO:0005001|
GN011711.1	sp|K1PKH9|K1PKH9_CRAGI	1.7e-41	174.9	100.00%	68.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011712.1	sp|K1QCZ3|K1QCZ3_CRAGI	1.6e-33	147.5	98.18%	71.96%	Melanopsin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|GO:0009881|	GO:0007602|GO:0018298|GO:0007601|
GN011713.1	sp|K1P6Y0|K1P6Y0_CRAGI	3.3e-86	323.6	99.08%	73.83%	Melanopsin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|GO:0009881|	GO:0018298|
GN011714.1	sp|V4AI04|V4AI04_LOTGI	4.1e-28	131.7	49.69%	33.99%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN011715.1	sp|K1PCZ2|K1PCZ2_CRAGI	0.0e+00	2275.7	98.35%	89.48%	Regulatory-associated protein of mTOR;OS=Crassostrea;PE=4;SV=1	GO:0031931|	GO:0031929|
GN010864.1	sp|K1R0N7|K1R0N7_CRAGI	1.7e-54	217.6	96.55%	75.54%	Putative nuclease HARBI1;OS=Crassostrea;PE=4;SV=1
GN011716.1	sp|K1R211|K1R211_CRAGI	6.2e-87	327.0	100.00%	47.83%	Baculoviral IAP repeat-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011717.1	sp|K1PFP3|K1PFP3_CRAGI	1.7e-78	298.1	75.69%	81.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011718.1	sp|A0A210QWB6|A0A210QWB6_MIZYE	3.3e-114	417.2	90.03%	65.10%	Hexosyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN011719.1	sp|K1PS85|K1PS85_CRAGI	1.2e-50	204.9	100.00%	63.69%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN011723.1	sp|A0A131XQ81|A0A131XQ81_IXORI	5.7e-49	201.1	94.20%	31.08%	Putative is4eu-1 dr;OS=Ixodes;PE=2;SV=1	GO:0008270|
GN011724.1	sp|W4Y1J4|W4Y1J4_STRPU	1.0e-09	70.1	91.02%	22.16%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0004190|GO:0003700|GO:0003676|GO:0008270|	GO:0015074|
GN010865.1	sp|K1RDL0|K1RDL0_CRAGI	7.4e-186	656.4	66.89%	63.60%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN011725.1	sp|K1QHD3|K1QHD3_CRAGI	2.8e-54	216.5	100.00%	99.05%	Dynein light chain;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0030286|GO:0005874|	GO:0003774|	GO:0007017|
GN011726.1	sp|A0A0B6ZP62|A0A0B6ZP62_9EUPU	2.8e-16	91.3	27.56%	65.57%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN011727.1	sp|K1QNX6|K1QNX6_CRAGI	6.0e-148	530.8	97.17%	44.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011728.1	sp|K1PW19|K1PW19_CRAGI	5.1e-109	399.4	100.00%	80.93%	C3a anaphylatoxin chemotactic receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011729.1	sp|K1PNQ7|K1PNQ7_CRAGI	7.4e-144	515.8	98.88%	74.22%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011730.1	sp|K1R4H0|K1R4H0_CRAGI	1.1e-80	305.4	76.56%	76.92%	Aquaporin-8;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN011731.1	sp|K1QUZ8|K1QUZ8_CRAGI	4.4e-10	68.9	100.00%	50.00%	Aquaporin-8;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN011733.1	sp|K1PIV5|K1PIV5_CRAGI	1.0e-95	356.7	44.66%	59.44%	Estrogen sulfotransferase;OS=Crassostrea;PE=3;SV=1	GO:0008305|	GO:0008146|	GO:0007155|GO:0007229|
GN011734.1	sp|K1QWT1|K1QWT1_CRAGI	1.7e-82	312.0	94.07%	45.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010867.1	sp|K1QAY6|K1QAY6_CRAGI	1.7e-157	561.2	90.70%	82.29%	UPF0661 TPR repeat-containing protein C16D10.01c;OS=Crassostrea;PE=4;SV=1
GN011736.1	sp|A0A1S3IHK7|A0A1S3IHK7_LINUN	5.0e-22	109.4	97.32%	48.21%	uncharacterized protein LOC106164102;OS=Lingula;PE=4;SV=1	GO:0008270|
GN011740.1	sp|K1R4G8|K1R4G8_CRAGI	7.4e-46	189.5	100.00%	41.63%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011741.1	sp|K1R4G8|K1R4G8_CRAGI	5.0e-73	280.8	99.77%	35.21%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011742.1	sp|K1R4G8|K1R4G8_CRAGI	7.4e-158	563.1	99.85%	39.87%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011743.1	sp|K1QN93|K1QN93_CRAGI	9.6e-10	69.3	78.61%	34.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011744.1	sp|K1QRB1|K1QRB1_CRAGI	2.2e-189	667.2	89.39%	94.63%	Dual specificity mitogen-activated protein kinase kinase 4;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN011745.1	sp|A0A210PHV4|A0A210PHV4_MIZYE	4.6e-95	352.8	96.43%	89.42%	Ras-related protein Rab-40B;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0035556|
GN010868.1	sp|K1P4W2|K1P4W2_CRAGI	3.9e-92	343.2	96.67%	82.18%	PRELI domain-containing protein 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005758|
GN011746.1	sp|K1Q574|K1Q574_CRAGI	1.1e-174	619.4	97.78%	48.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011747.1	sp|A0A210PHU2|A0A210PHU2_MIZYE	2.4e-158	563.9	100.00%	78.61%	Phosphoribosyl pyrophosphate synthase-associated protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0000287|GO:0004749|	GO:0009116|GO:0009165|
GN011748.1	sp|K1PY85|K1PY85_CRAGI	2.2e-123	447.6	80.77%	82.07%	Endonuclease III homolog;OS=Crassostrea;PE=3;SV=1	GO:0005739|GO:0005634|	GO:0051539|GO:0140078|GO:0003677|GO:0004519|GO:0046872|GO:0000703|	GO:0006285|
GN011749.1	sp|K1PJ85|K1PJ85_CRAGI	1.3e-219	767.7	100.00%	100.00%	26S protease regulatory subunit 6A;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0008233|GO:0036402|	GO:0030163|
GN011751.1	sp|K1Q568|K1Q568_CRAGI	1.8e-122	444.9	99.00%	57.07%	Monocarboxylate transporter 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN011754.1	sp|K1PJ78|K1PJ78_CRAGI	8.4e-157	559.3	97.66%	61.86%	Pro-neuregulin-2, membrane-bound isoform;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005102|	GO:0007399|
GN011755.1	sp|A0A210QGU3|A0A210QGU3_MIZYE	1.1e-22	112.1	91.36%	43.87%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN011756.1	sp|K1R9S5|K1R9S5_CRAGI	1.5e-149	534.3	100.00%	92.31%	Cytosolic Fe-S cluster assembly factor NUBP2 homolog;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0051539|GO:0005524|GO:0046872|	GO:0016226|
GN011757.1	sp|K1Q2W5|K1Q2W5_CRAGI	3.3e-64	250.0	89.61%	86.13%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN011758.1	sp|K1Q2W5|K1Q2W5_CRAGI	3.7e-108	396.7	90.80%	84.81%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN011760.1	sp|K1QLD6|K1QLD6_CRAGI	4.7e-35	154.1	38.44%	70.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011761.1	sp|K1Q2W5|K1Q2W5_CRAGI	0.0e+00	3003.8	90.60%	86.05%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN011762.1	sp|K1Q9W3|K1Q9W3_CRAGI	1.8e-152	544.3	97.04%	82.73%	SPRY domain-containing SOCS box protein 3;OS=Crassostrea;PE=4;SV=1
GN010869.1	sp|K1QAZ1|K1QAZ1_CRAGI	1.9e-96	357.8	99.63%	64.81%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|GO:0030246|	GO:0007156|
GN011763.1	sp|A0A077GZK0|A0A077GZK0_MYTTR	3.6e-117	426.8	81.69%	91.34%	Ribosomal protein S2;OS=Mytilus;PE=2;SV=1	GO:0015935|	GO:0003723|GO:0003735|	GO:0006412|
GN011764.1	sp|K1QHY0|K1QHY0_CRAGI	1.9e-214	750.4	100.00%	96.02%	Actin-3;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN011765.1	sp|W4YMP2|W4YMP2_STRPU	2.3e-20	104.4	86.79%	47.89%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0015074|GO:0006310|
GN011766.1	sp|K1QPJ1|K1QPJ1_CRAGI	2.4e-217	760.0	100.00%	99.73%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN011767.1	sp|K1R9T2|K1R9T2_CRAGI	0.0e+00	1349.7	100.00%	92.87%	Eukaryotic translation initiation factor 3 subunit B;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0005852|	GO:0003743|GO:0031369|	GO:0001732|
GN011768.1	sp|K1Q2X2|K1Q2X2_CRAGI	2.2e-149	534.3	93.35%	78.54%	RNA-binding protein 9;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN011769.1	sp|K1QRB9|K1QRB9_CRAGI	5.7e-20	103.6	85.84%	32.35%	DnaJ-like protein subfamily C member 5;OS=Crassostrea;PE=4;SV=1
GN011770.1	sp|K1QHY6|K1QHY6_CRAGI	8.4e-287	991.5	98.77%	83.26%	Rap1 GTPase-GDP dissociation stimulator 1-A;OS=Crassostrea;PE=4;SV=1	GO:0005096|
GN011771.1	sp|K1QPJ4|K1QPJ4_CRAGI	0.0e+00	2560.4	93.34%	70.08%	Sorbin and SH3 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0007015|
GN010870.1	sp|A0A2C9L2R1|A0A2C9L2R1_BIOGL	5.0e-38	163.7	88.76%	41.41%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN011772.1	sp|K1Q2X5|K1Q2X5_CRAGI	0.0e+00	1129.8	99.52%	77.26%	Synaptopodin-2;OS=Crassostrea;PE=4;SV=1
GN011774.1	sp|K1QHZ0|K1QHZ0_CRAGI	7.0e-32	141.7	98.84%	84.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011777.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	3.3e-22	111.7	46.28%	35.93%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN011778.1	sp|K1P578|K1P578_CRAGI	0.0e+00	1147.5	99.90%	62.58%	Formin-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN011779.1	sp|K1QB73|K1QB73_CRAGI	9.8e-131	472.2	100.00%	61.73%	Neuronal acetylcholine receptor subunit alpha-5;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN011780.1	sp|K1PBD9|K1PBD9_CRAGI	4.2e-56	223.4	98.48%	60.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011782.1	sp|K1PBD9|K1PBD9_CRAGI	1.8e-207	728.4	100.00%	55.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010795.1	sp|K1Q1M0|K1Q1M0_CRAGI	1.5e-101	375.9	97.89%	33.61%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN011785.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-35	156.0	58.22%	47.37%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN011786.1	sp|K1RGS9|K1RGS9_CRAGI	7.2e-59	233.4	98.85%	38.04%	5-hydroxytryptamine receptor 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011787.1	sp|K1RI39|K1RI39_CRAGI	1.0e-87	328.6	100.00%	83.18%	Tctex1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN011788.1	sp|K1S1Q4|K1S1Q4_CRAGI	0.0e+00	1453.7	82.63%	64.86%	Terminal uridylyltransferase 4;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0016779|GO:0008270|
GN011789.1	sp|K1QWF6|K1QWF6_CRAGI	0.0e+00	1259.6	97.11%	79.03%	RNA exonuclease 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0004527|GO:0003676|
GN011790.1	sp|K1RUP2|K1RUP2_CRAGI	3.9e-182	645.2	94.39%	38.05%	Mediator of DNA damage checkpoint protein 1;OS=Crassostrea;PE=4;SV=1
GN011791.1	sp|K1R4G2|K1R4G2_CRAGI	1.8e-10	72.0	40.72%	47.87%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN011792.1	sp|K1RIZ6|K1RIZ6_CRAGI	1.9e-31	142.1	64.26%	49.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011793.1	sp|K1PUT5|K1PUT5_CRAGI	8.6e-21	105.5	55.64%	65.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011795.1	sp|K1RUN5|K1RUN5_CRAGI	0.0e+00	1083.9	86.61%	61.79%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011796.1	sp|K1RB09|K1RB09_CRAGI	0.0e+00	1119.0	100.00%	82.35%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011798.1	sp|K1R4F9|K1R4F9_CRAGI	1.5e-170	604.7	100.00%	79.03%	Vasculin-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|	GO:0045893|GO:0006351|
GN011799.1	sp|K1QXJ1|K1QXJ1_CRAGI	5.4e-210	735.7	100.00%	86.21%	UPF0465 protein C5orf33;OS=Crassostrea;PE=4;SV=1	GO:0003951|	GO:0019674|GO:0006741|
GN011800.1	sp|V4A9D4|V4A9D4_LOTGI	5.9e-67	260.0	92.98%	42.59%	rRNA adenine N(6)-methyltransferase;OS=Lottia;PE=3;SV=1	GO:0003723|GO:0000179|
GN011801.1	sp|K1QCH3|K1QCH3_CRAGI	4.1e-176	624.0	100.00%	52.95%	XK-related protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN011802.1	sp|K1QIZ4|K1QIZ4_CRAGI	1.1e-128	465.7	99.14%	73.38%	BSD domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN011803.1	sp|K1Q4P5|K1Q4P5_CRAGI	1.2e-155	555.8	98.64%	48.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011805.1	sp|K1R4L1|K1R4L1_CRAGI	6.6e-25	119.0	100.00%	52.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011806.1	sp|K1Q1J4|K1Q1J4_CRAGI	6.8e-159	567.0	93.75%	58.71%	Protein disabled;OS=Crassostrea;PE=4;SV=1	GO:0032502|
GN011807.1	sp|A0A2H4PXF8|A0A2H4PXF8_CRAVI	1.8e-138	498.0	89.65%	92.68%	Calreticulin;OS=Crassostrea;PE=2;SV=1	GO:0005783|	GO:0005509|GO:0051082|	GO:0006457|
GN011808.1	sp|K1PQE5|K1PQE5_CRAGI	1.1e-117	428.3	96.43%	87.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005319|
GN011809.1	sp|A0A210Q2E1|A0A210Q2E1_MIZYE	0.0e+00	1411.4	99.15%	65.97%	DIS3-like exonuclease 1;OS=Mizuhopecten;PE=3;SV=1	GO:0000175|GO:0003723|	GO:0016075|
GN011810.1	sp|A0A210QGI7|A0A210QGI7_MIZYE	3.6e-172	610.5	99.13%	53.40%	Glucokinase regulatory protein;OS=Mizuhopecten;PE=4;SV=1	GO:0097367|GO:0016301|	GO:1901135|
GN011811.1	sp|K1QQW4|K1QQW4_CRAGI	2.5e-119	434.5	90.78%	88.77%	Protein phosphatase 1 regulatory subunit 7;OS=Crassostrea;PE=4;SV=1
GN011812.1	sp|K1PXS5|K1PXS5_CRAGI	7.7e-24	115.9	95.00%	68.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011813.1	sp|K1RM61|K1RM61_CRAGI	1.6e-29	135.2	98.09%	37.68%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN011814.1	sp|K1PXS5|K1PXS5_CRAGI	7.8e-19	99.4	61.68%	52.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011815.1	sp|K1RWC3|K1RWC3_CRAGI	1.8e-106	391.0	100.00%	80.09%	RNA 3'-terminal phosphate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003963|	GO:0006396|
GN011816.1	sp|K1PXS5|K1PXS5_CRAGI	1.7e-22	112.1	79.25%	51.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010872.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	6.6e-26	122.9	97.63%	44.71%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN011817.1	sp|K1QZS4|K1QZS4_CRAGI	1.6e-11	74.7	50.00%	54.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011819.1	sp|K1QZS4|K1QZS4_CRAGI	8.6e-35	152.9	99.17%	60.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011820.1	sp|K1QNT6|K1QNT6_CRAGI	4.0e-21	106.7	40.58%	83.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011821.1	sp|K1R6J5|K1R6J5_CRAGI	1.5e-220	772.7	44.14%	56.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011822.1	sp|K1RCZ9|K1RCZ9_CRAGI	6.5e-09	67.8	40.84%	26.37%	Delta-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0016592|	GO:0005509|GO:0003712|	GO:0007154|GO:0007275|GO:0042981|GO:0006357|
GN011823.1	sp|K1RCZ9|K1RCZ9_CRAGI	3.8e-102	377.5	97.41%	52.03%	Delta-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0016592|	GO:0005509|GO:0003712|	GO:0007154|GO:0007275|GO:0042981|GO:0006357|
GN011824.1	sp|K1QWN3|K1QWN3_CRAGI	9.6e-25	119.8	80.97%	31.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN011825.1	sp|K1QYS2|K1QYS2_CRAGI	9.8e-94	349.4	100.00%	62.73%	Nuclear transcription factor Y subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0016602|	GO:0003677|GO:0003700|GO:0046982|
GN011826.1	sp|K1R5N1|K1R5N1_CRAGI	0.0e+00	1083.2	98.34%	98.87%	Elongator complex protein 3;OS=Crassostrea;PE=3;SV=1	GO:0004402|GO:0051536|GO:0046872|
GN011827.1	sp|K1RWC7|K1RWC7_CRAGI	1.0e-48	198.7	62.36%	80.91%	MRG-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0043189|	GO:0006355|
GN011828.1	sp|A0A210QBT1|A0A210QBT1_MIZYE	0.0e+00	1886.3	100.00%	79.67%	WASH complex subunit strumpellin;OS=Mizuhopecten;PE=4;SV=1	GO:0071203|
GN011829.1	sp|K1PNM8|K1PNM8_CRAGI	1.2e-154	552.0	94.47%	77.16%	Peroxisomal membrane protein PEX13;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005777|	GO:0016560|
GN011830.1	sp|K1PNM8|K1PNM8_CRAGI	2.1e-167	594.3	100.00%	76.74%	Peroxisomal membrane protein PEX13;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005777|	GO:0016560|
GN011831.1	sp|A0A210PHH4|A0A210PHH4_MIZYE	3.9e-87	327.8	47.94%	65.09%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016787|GO:0046872|GO:0003676|
GN011832.1	sp|K1P2W3|K1P2W3_CRAGI	0.0e+00	1186.4	59.56%	66.48%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 3;OS=Crassostrea;PE=4;SV=1	GO:0016787|GO:0046872|GO:0003676|
GN011833.1	sp|K1P2W3|K1P2W3_CRAGI	2.8e-29	132.9	100.00%	60.58%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 3;OS=Crassostrea;PE=4;SV=1	GO:0016787|GO:0046872|GO:0003676|
GN011834.1	sp|R7TWC7|R7TWC7_CAPTE	1.1e-39	169.9	79.40%	34.28%	Uncharacterized protein;OS=Capitella;PE=4;SV=1	GO:0016021|	GO:0008528|
GN011835.1	sp|K1QNF8|K1QNF8_CRAGI	4.2e-14	85.1	34.13%	33.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011836.1	sp|K1PGV8|K1PGV8_CRAGI	0.0e+00	1532.7	92.05%	71.24%	Nucleoprotein TPR;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0019013|	GO:0006606|
GN011837.1	sp|K1PNN3|K1PNN3_CRAGI	2.4e-218	763.5	100.00%	94.79%	Tektin-2;OS=Crassostrea;PE=4;SV=1
GN010873.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	2.1e-76	292.0	98.84%	38.04%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN011838.1	sp|K1P2V7|K1P2V7_CRAGI	1.1e-226	791.2	97.31%	92.61%	Transcription factor AP-2 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|
GN011840.1	sp|K1P9M6|K1P9M6_CRAGI	6.0e-56	222.2	92.86%	88.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011841.1	sp|A0A210QC55|A0A210QC55_MIZYE	1.0e-67	262.7	98.75%	40.85%	ATP synthase mitochondrial F1 complex assembly factor 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005739|	GO:0065003|
GN011843.1	sp|K1PNN7|K1PNN7_CRAGI	5.7e-78	295.8	99.40%	84.85%	Substance-K receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011844.1	sp|K1RGY5|K1RGY5_CRAGI	9.0e-19	100.5	33.56%	43.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011846.1	sp|K1PSE0|K1PSE0_CRAGI	1.6e-12	78.6	90.67%	29.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011848.1	sp|A0A210R2K0|A0A210R2K0_MIZYE	1.4e-45	191.0	56.77%	25.78%	Tyrosine-protein kinase FRK;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN011849.1	sp|A0A210R2K0|A0A210R2K0_MIZYE	8.0e-45	188.0	84.32%	25.85%	Tyrosine-protein kinase FRK;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN011850.1	sp|K1RFI4|K1RFI4_CRAGI	3.4e-82	309.7	100.00%	94.67%	RING finger protein 11;OS=Crassostrea;PE=4;SV=1
GN011851.1	sp|A0A210PHL3|A0A210PHL3_MIZYE	3.7e-120	438.3	92.53%	36.43%	F-box/LRR-repeat protein 20;OS=Mizuhopecten;PE=4;SV=1
GN011852.1	sp|K1R8Y7|K1R8Y7_CRAGI	7.4e-94	349.7	100.00%	67.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010875.1	sp|K1R0N3|K1R0N3_CRAGI	1.0e-194	684.9	100.00%	82.78%	Carboxylesterase 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN011853.1	sp|K1R2Y9|K1R2Y9_CRAGI	5.2e-217	760.8	33.93%	77.82%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN011854.1	sp|K1PGW6|K1PGW6_CRAGI	2.6e-197	693.7	90.65%	76.20%	Alpha-(1,3)-fucosyltransferase 10;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN011855.1	sp|K1PNP0|K1PNP0_CRAGI	2.4e-229	800.0	96.16%	86.35%	Alpha-(1,3)-fucosyltransferase 10;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN011856.1	sp|K1PNP0|K1PNP0_CRAGI	7.5e-159	565.8	95.54%	64.37%	Alpha-(1,3)-fucosyltransferase 10;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN011857.1	sp|K1R102|K1R102_CRAGI	1.6e-106	392.1	81.22%	50.78%	Carbohydrate sulfotransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008146|	GO:0016051|
GN011858.1	sp|K1RA15|K1RA15_CRAGI	1.1e-217	761.9	73.17%	75.96%	Germ cell-less protein-like 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011859.1	sp|K1PGW9|K1PGW9_CRAGI	2.7e-87	327.4	83.21%	69.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011860.1	sp|K1Q9N6|K1Q9N6_CRAGI	0.0e+00	1404.8	99.32%	93.81%	Rhomboid family member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004252|
GN010876.1	sp|K1R0N3|K1R0N3_CRAGI	3.3e-231	806.6	90.39%	76.41%	Carboxylesterase 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN011863.1	sp|A0A210QYA4|A0A210QYA4_MIZYE	0.0e+00	1111.3	99.67%	88.65%	Tetratricopeptide repeat protein 30A;OS=Mizuhopecten;PE=4;SV=1
GN011864.1	sp|K1PIR5|K1PIR5_CRAGI	1.7e-91	342.0	53.13%	62.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011865.1	sp|K1QWJ5|K1QWJ5_CRAGI	1.8e-157	562.8	36.74%	63.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011866.1	sp|K1Q347|K1Q347_CRAGI	1.3e-12	78.2	83.33%	43.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011867.1	sp|K1Q379|K1Q379_CRAGI	9.6e-83	312.8	55.83%	78.00%	Neuropeptide Y receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011868.1	sp|K1PN63|K1PN63_CRAGI	1.2e-128	464.9	97.89%	80.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011869.1	sp|C3ZUK9|C3ZUK9_BRAFL	1.2e-56	226.1	85.75%	42.90%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN010877.1	sp|K1R0N3|K1R0N3_CRAGI	5.7e-233	813.5	88.54%	39.96%	Carboxylesterase 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN011870.1	sp|K1R0G2|K1R0G2_CRAGI	1.2e-72	278.5	85.45%	69.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011872.1	sp|K1Q110|K1Q110_CRAGI	3.5e-22	110.9	46.67%	56.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011873.1	sp|K1QCE0|K1QCE0_CRAGI	0.0e+00	2161.0	54.50%	92.66%	von Willebrand factor A domain-containing protein 3A;OS=Crassostrea;PE=4;SV=1
GN011874.1	sp|K1PCE5|K1PCE5_CRAGI	4.6e-169	599.7	88.49%	82.04%	Pyroglutamylated RFamide peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN011875.1	sp|K1PJV8|K1PJV8_CRAGI	2.7e-117	427.6	98.61%	57.79%	UPF0489 protein C5orf22;OS=Crassostrea;PE=4;SV=1
GN011876.1	sp|K1PRW0|K1PRW0_CRAGI	1.4e-44	186.0	99.74%	32.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010878.1	sp|K1RGI1|K1RGI1_CRAGI	5.8e-210	736.1	95.60%	63.54%	Fatty acyl-CoA hydrolase, medium chain;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN011877.1	sp|K1QCE2|K1QCE2_CRAGI	2.3e-43	181.0	67.72%	71.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011878.1	sp|K1Q4D4|K1Q4D4_CRAGI	2.1e-125	455.3	52.06%	65.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010879.1	sp|K1RMS5|K1RMS5_CRAGI	1.4e-99	367.9	92.65%	93.62%	Uncharacterized protein C6orf62-like protein;OS=Crassostrea;PE=4;SV=1
GN011882.1	sp|A0A1S3J244|A0A1S3J244_LINUN	1.7e-25	121.7	95.77%	34.80%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN011883.1	sp|A0A2H1W609|A0A2H1W609_SPOFR	1.5e-29	134.8	98.03%	44.51%	SFRICE_037012;OS=Spodoptera;PE=4;SV=1
GN011884.1	sp|K1QYB7|K1QYB7_CRAGI	1.0e-36	158.3	100.00%	97.52%	Transcription factor MafK;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN011885.1	sp|K1R4N2|K1R4N2_CRAGI	8.9e-226	788.9	100.00%	56.08%	Fem-1-like protein C;OS=Crassostrea;PE=4;SV=1
GN011886.1	sp|K1QYC0|K1QYC0_CRAGI	4.6e-119	433.3	96.14%	61.08%	Transmembrane protein 26;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011888.1	sp|K1RP20|K1RP20_CRAGI	4.0e-147	527.3	100.00%	51.89%	Fibroblast growth factor receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN011889.1	sp|K1RP20|K1RP20_CRAGI	5.8e-78	295.8	100.00%	75.44%	Fibroblast growth factor receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN011890.1	sp|A0A1S3JP28|A0A1S3JP28_LINUN	4.8e-32	144.4	83.29%	32.22%	transcobalamin-2;OS=Lingula;PE=4;SV=1	GO:0031419|	GO:0015889|
GN011891.1	sp|K1QH70|K1QH70_CRAGI	1.1e-125	456.1	96.36%	84.12%	Leucine-rich repeat-containing protein 40;OS=Crassostrea;PE=4;SV=1
GN011893.1	sp|A0A210QKS7|A0A210QKS7_MIZYE	1.5e-26	125.9	77.06%	32.18%	Protocadherin Fat 4;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN011894.1	sp|K1R4M8|K1R4M8_CRAGI	4.1e-108	398.7	27.50%	69.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011895.1	sp|K1RP20|K1RP20_CRAGI	0.0e+00	1560.8	99.68%	62.79%	Fibroblast growth factor receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN011896.1	sp|K1QQU6|K1QQU6_CRAGI	1.4e-106	392.5	93.75%	73.85%	Phosphatase and actin regulator 1;OS=Crassostrea;PE=4;SV=1
GN011897.1	sp|K1QH68|K1QH68_CRAGI	1.2e-134	485.0	94.17%	83.10%	Syntenin-1;OS=Crassostrea;PE=4;SV=1	GO:0030036|GO:0007268|GO:0035556|
GN011898.1	sp|K1QSJ6|K1QSJ6_CRAGI	1.0e-258	897.9	85.33%	96.83%	Tyrosine-protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004715|
GN011899.1	sp|K1R4M3|K1R4M3_CRAGI	0.0e+00	2458.3	99.78%	89.73%	RIC1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0034066|	GO:0006886|
GN011900.1	sp|K1QYA4|K1QYA4_CRAGI	1.8e-90	337.4	100.00%	95.38%	Tctex1 domain-containing protein 1-B;OS=Crassostrea;PE=4;SV=1
GN011901.1	sp|K1QQU5|K1QQU5_CRAGI	2.9e-210	736.9	85.69%	86.74%	Sorting nexin-30;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN011902.1	sp|K1RP14|K1RP14_CRAGI	1.0e-243	848.6	84.11%	73.61%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055114|
GN011903.1	sp|K1R4M1|K1R4M1_CRAGI	6.6e-235	818.5	99.10%	92.94%	Intraflagellar transport protein 52-like protein;OS=Crassostrea;PE=4;SV=1	GO:0031514|	GO:0060271|
GN010881.1	sp|K1QZI0|K1QZI0_CRAGI	2.0e-81	308.1	87.04%	64.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011904.1	sp|K1QQU0|K1QQU0_CRAGI	4.5e-87	326.6	74.30%	84.24%	Dehydrogenase/reductase SDR family member 11;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN011905.1	sp|K1QH61|K1QH61_CRAGI	0.0e+00	1571.6	95.89%	74.87%	Zinc finger protein PLAG1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011906.1	sp|A0A0M8ZXZ0|A0A0M8ZXZ0_9HYME	3.9e-11	73.2	61.82%	43.28%	Coiled-coil-helix-coiled-coil-helix domain-containing protein 7;OS=Melipona;PE=4;SV=1
GN011908.1	sp|K1RP09|K1RP09_CRAGI	3.6e-177	626.3	100.00%	87.65%	F-box only protein 25;OS=Crassostrea;PE=4;SV=1
GN011910.1	sp|K1R3B2|K1R3B2_CRAGI	6.5e-13	78.6	55.26%	82.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011911.1	sp|K1QY99|K1QY99_CRAGI	1.8e-96	357.8	79.35%	89.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010882.1	sp|K1P606|K1P606_CRAGI	3.7e-181	639.8	91.73%	90.11%	D-beta-hydroxybutyrate dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1
GN011915.1	sp|K1QQT6|K1QQT6_CRAGI	2.5e-195	687.6	100.00%	59.54%	N-acetyltransferase ESCO1;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN011916.1	sp|I7HP94|I7HP94_CRAGI	3.3e-212	743.0	100.00%	84.03%	Alanopine dehydrogenase 1;OS=Crassostrea;PE=2;SV=1	GO:0047636|GO:0050662|
GN011917.1	sp|B5D5P3|B5D5P3_OSTED	2.2e-232	810.1	100.00%	98.02%	Strombine dehydrogenase;OS=Ostrea;PE=2;SV=1	GO:0050662|GO:0050305|
GN011918.1	sp|K1RP03|K1RP03_CRAGI	3.3e-32	144.1	100.00%	47.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011920.1	sp|K1QQS8|K1QQS8_CRAGI	9.4e-48	195.7	99.49%	60.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010883.1	sp|K1PC20|K1PC20_CRAGI	0.0e+00	1345.1	78.87%	81.92%	Lysosomal alpha-glucosidase;OS=Crassostrea;PE=3;SV=1	GO:0030246|GO:0004553|	GO:0005975|
GN011921.1	sp|V4B0R1|V4B0R1_LOTGI	4.6e-29	132.5	100.00%	63.04%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN011922.1	sp|K1QY89|K1QY89_CRAGI	2.5e-107	394.0	78.44%	91.90%	NFU1 iron-sulfur cluster scaffold-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0051536|	GO:0016226|
GN011924.1	sp|A0A2B4R8T7|A0A2B4R8T7_STYPI	3.3e-108	398.7	45.23%	52.14%	Zinc finger MYM-type protein 1;OS=Stylophora;PE=4;SV=1
GN011925.1	sp|K1R4K7|K1R4K7_CRAGI	1.4e-64	251.9	64.98%	77.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011926.1	sp|K1RNZ6|K1RNZ6_CRAGI	0.0e+00	1862.4	98.98%	93.42%	Eukaryotic translation initiation factor 3 subunit D;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0005852|	GO:0098808|GO:0003743|	GO:0002191|GO:0001732|
GN011928.1	sp|K1R4X9|K1R4X9_CRAGI	3.0e-117	426.8	99.16%	84.81%	UDP-N-acetylhexosamine pyrophosphorylase;OS=Crassostrea;PE=4;SV=1	GO:0070569|
GN011929.1	sp|K1PN75|K1PN75_CRAGI	9.5e-233	812.0	96.01%	61.26%	Chitotriosidase-1;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008061|GO:0004553|	GO:0005975|GO:0006030|
GN011931.1	sp|K1P987|K1P987_CRAGI	2.0e-198	697.6	100.00%	91.26%	Leucine-rich repeat-containing protein 48;OS=Crassostrea;PE=4;SV=1
GN011932.1	sp|K1PFE8|K1PFE8_CRAGI	1.0e-126	458.4	100.00%	85.27%	ATP synthase mitochondrial F1 complex assembly factor 2;OS=Crassostrea;PE=4;SV=1	GO:0043461|
GN011933.1	sp|K1PN79|K1PN79_CRAGI	1.7e-104	384.0	100.00%	97.79%	Uncharacterized protein C17orf39;OS=Crassostrea;PE=4;SV=1
GN011934.1	sp|K1PVM8|K1PVM8_CRAGI	1.0e-130	472.6	71.73%	70.92%	Zinc finger protein ubi-d4;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003676|
GN011935.1	sp|A0A210PTB0|A0A210PTB0_MIZYE	2.9e-161	574.3	99.66%	46.89%	Sn1-specific diacylglycerol lipase beta;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016787|	GO:0006629|
GN011936.1	sp|K1QDX6|K1QDX6_CRAGI	7.9e-36	156.4	91.94%	43.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011937.1	sp|A7REN5|A7REN5_NEMVE	6.3e-34	151.0	61.06%	31.76%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN011938.1	sp|A7SPH6|A7SPH6_NEMVE	6.3e-19	99.4	58.09%	58.97%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN011941.1	sp|K1RCP9|K1RCP9_CRAGI	2.6e-40	171.8	38.90%	61.19%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0004402|	GO:0006355|
GN010884.1	sp|K1P612|K1P612_CRAGI	5.7e-90	335.9	98.44%	84.57%	Neurocalcin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011943.1	sp|K1PLM3|K1PLM3_CRAGI	6.9e-154	548.9	100.00%	88.06%	Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003857|GO:0070403|	GO:0006631|
GN011944.1	sp|K1PTH1|K1PTH1_CRAGI	2.4e-125	454.5	89.98%	57.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011946.1	sp|K1PFE6|K1PFE6_CRAGI	2.3e-206	725.3	100.00%	45.59%	Uncharacterized protein C3orf63;OS=Crassostrea;PE=4;SV=1	GO:0007140|GO:0010569|GO:0007129|
GN011947.1	sp|K1REY6|K1REY6_CRAGI	1.4e-54	218.8	91.54%	50.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011948.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	2.4e-109	401.4	88.92%	54.33%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN011949.1	sp|K1P983|K1P983_CRAGI	1.9e-115	422.2	100.00%	43.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011950.1	sp|A0A210QX99|A0A210QX99_MIZYE	2.3e-57	227.6	99.51%	53.92%	UPF0585 protein C16orf13-like A;OS=Mizuhopecten;PE=4;SV=1
GN011951.1	sp|K1R3W8|K1R3W8_CRAGI	0.0e+00	1719.5	100.00%	69.73%	Ubiquitin carboxyl-terminal hydrolase 31;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN011952.1	sp|K1RE67|K1RE67_CRAGI	3.2e-86	323.6	87.38%	81.72%	Methylated-DNA--protein-cysteine methyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0003908|	GO:0006281|
GN011953.1	sp|A0A2T7PY59|A0A2T7PY59_POMCA	2.6e-150	537.0	98.31%	84.14%	Serine/threonine-protein phosphatase;OS=Pomacea;PE=3;SV=1	GO:0046872|GO:0004721|
GN011955.1	sp|K1Q1N1|K1Q1N1_CRAGI	0.0e+00	1729.1	100.00%	77.65%	Alpha-mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0004559|GO:0030246|GO:0046872|	GO:0006013|
GN011956.1	sp|K1QMX5|K1QMX5_CRAGI	0.0e+00	1798.9	93.92%	96.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN010886.1	sp|K1PC25|K1PC25_CRAGI	1.4e-75	290.0	45.22%	50.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011957.1	sp|K1QWY4|K1QWY4_CRAGI	1.6e-68	265.0	96.00%	61.92%	Transmembrane protein 26;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011958.1	sp|K1R795|K1R795_CRAGI	3.2e-182	643.7	97.53%	66.02%	Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6-B;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN011959.1	sp|K1RD93|K1RD93_CRAGI	0.0e+00	4217.5	100.00%	82.70%	Myosin-XV;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0003779|GO:0005524|GO:0003774|	GO:0007605|
GN011960.1	sp|K1S2T4|K1S2T4_CRAGI	6.4e-99	366.3	62.54%	85.20%	5'(3')-deoxyribonucleotidase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008253|	GO:0009264|
GN011961.1	sp|K1RED4|K1RED4_CRAGI	2.3e-13	80.5	99.02%	48.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011962.1	sp|K1P980|K1P980_CRAGI	1.9e-23	115.9	79.65%	33.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010887.1	sp|K1PJE4|K1PJE4_CRAGI	4.1e-218	762.7	98.57%	92.72%	Serine/threonine-protein kinase NIM1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004674|
GN011963.1	sp|K1Q642|K1Q642_CRAGI	1.2e-60	238.0	95.17%	81.02%	Hepatocyte growth factor-regulated tyrosine kinase substrate;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0016301|GO:0046872|	GO:0006886|
GN011964.1	sp|K1RD97|K1RD97_CRAGI	0.0e+00	1865.1	100.00%	77.44%	Ras-associating and dilute domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN011965.1	sp|K1QT25|K1QT25_CRAGI	2.6e-97	361.3	50.39%	89.74%	Thioredoxin domain-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016021|	GO:0045454|
GN010888.1	sp|K1PRK2|K1PRK2_CRAGI	2.4e-62	245.0	95.21%	66.17%	Small glutamine-rich tetratricopeptide repeat-containing protein beta;OS=Crassostrea;PE=4;SV=1
GN010889.1	sp|K1RF49|K1RF49_CRAGI	2.5e-17	95.1	36.07%	77.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010890.1	sp|K1P618|K1P618_CRAGI	5.7e-67	258.8	97.58%	100.00%	Neuronal calcium sensor 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011995.1	sp|K1QM05|K1QM05_CRAGI	8.7e-105	385.6	75.66%	91.04%	Elongation of very long chain fatty acids protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN011996.1	sp|K1QDP2|K1QDP2_CRAGI	3.1e-124	450.3	98.96%	74.65%	Testis-specific serine/threonine-protein kinase 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN011997.1	sp|K1Q635|K1Q635_CRAGI	3.5e-150	537.0	91.23%	86.23%	Clusterin-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN011998.1	sp|K1RD83|K1RD83_CRAGI	7.1e-251	871.7	100.00%	87.32%	Serine hydroxymethyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004372|GO:0008168|GO:0030170|	GO:0019264|GO:0035999|
GN011999.1	sp|K1RB32|K1RB32_CRAGI	1.3e-34	152.5	58.33%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010891.1	sp|K1RMM2|K1RMM2_CRAGI	1.6e-257	894.8	63.32%	76.39%	Solute carrier family 2, facilitated glucose transporter member 12;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|	GO:0008643|
GN012000.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN012001.1	sp|K1PJ18|K1PJ18_CRAGI	2.0e-311	1073.9	95.32%	63.66%	Protein FAM13B;OS=Crassostrea;PE=4;SV=1	GO:0016491|GO:0008270|	GO:0007165|
GN012002.1	sp|K1PQQ4|K1PQQ4_CRAGI	8.7e-248	861.3	100.00%	93.75%	L-rhamnonate dehydratase;OS=Crassostrea;PE=4;SV=1
GN012003.1	sp|A0A1S3HHJ7|A0A1S3HHJ7_LINUN	1.3e-47	195.3	91.75%	53.44%	uncharacterized protein LOC106155332;OS=Lingula;PE=4;SV=1
GN012004.1	sp|K1PY10|K1PY10_CRAGI	7.1e-187	658.7	100.00%	88.17%	Putative L-threonine 3-dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016491|GO:0008270|
GN012005.1	sp|K1Q505|K1Q505_CRAGI	0.0e+00	1140.9	98.83%	82.02%	Calpain-9;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN012006.1	sp|K1QDN3|K1QDN3_CRAGI	1.6e-219	767.7	99.61%	74.41%	Cytochrome P450 4V2;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN012007.1	sp|K1QT21|K1QT21_CRAGI	2.0e-270	937.2	77.55%	94.47%	Putative ATP-dependent RNA helicase DDX5;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN012008.1	sp|K1Q4Z9|K1Q4Z9_CRAGI	0.0e+00	2298.9	98.04%	86.73%	Ankyrin repeat domain-containing protein 17;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN010892.1	sp|K1R3C1|K1R3C1_CRAGI	2.9e-253	880.2	99.86%	66.95%	UPF0419 protein C12orf48-like protein;OS=Crassostrea;PE=4;SV=1	GO:2000042|
GN012009.1	sp|F5A8D3|F5A8D3_CRAGI	1.5e-81	308.1	100.00%	65.84%	FAS-associating death domain-containing protein;OS=Crassostrea;PE=2;SV=1	GO:0042981|GO:0007165|
GN012010.1	sp|K1PY34|K1PY34_CRAGI	0.0e+00	1114.8	98.62%	86.42%	Sodium-coupled monocarboxylate transporter 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN012011.1	sp|K1PIM4|K1PIM4_CRAGI	4.2e-70	270.0	99.53%	62.09%	ADP-ribosylation factor;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN012012.1	sp|K1PIM4|K1PIM4_CRAGI	8.1e-43	179.5	100.00%	43.53%	ADP-ribosylation factor;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN012013.1	sp|K1PIM4|K1PIM4_CRAGI	8.8e-76	288.9	99.53%	65.88%	ADP-ribosylation factor;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN012014.1	sp|K1PC79|K1PC79_CRAGI	0.0e+00	1515.4	100.00%	93.65%	Polycystin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012015.1	sp|K1RBS2|K1RBS2_CRAGI	2.7e-87	327.0	100.00%	79.90%	Transmembrane protease, serine 5;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004252|
GN012017.1	sp|K1RNK0|K1RNK0_CRAGI	0.0e+00	6369.3	100.00%	87.52%	WD repeat and FYVE domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN012018.1	sp|K1S6X7|K1S6X7_CRAGI	0.0e+00	1107.0	99.53%	90.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN012019.1	sp|A0A210R4N5|A0A210R4N5_MIZYE	9.4e-80	303.1	98.20%	53.93%	Cerebellar degeneration-related protein 2;OS=Mizuhopecten;PE=4;SV=1
GN012021.1	sp|K1PBE6|K1PBE6_CRAGI	3.2e-129	467.6	100.00%	76.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010893.1	sp|K1QP14|K1QP14_CRAGI	1.8e-187	661.0	92.39%	76.43%	Adenine DNA glycosylase;OS=Crassostrea;PE=3;SV=1	GO:0051539|GO:0003677|GO:0016787|	GO:0006284|
GN012022.1	sp|K1QHN5|K1QHN5_CRAGI	9.7e-195	685.3	100.00%	80.53%	Zinc finger protein Noc;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012024.1	sp|K1QPU0|K1QPU0_CRAGI	2.6e-09	67.0	49.00%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012025.1	sp|K1QQF9|K1QQF9_CRAGI	2.7e-271	940.6	98.94%	59.78%	Tetratricopeptide repeat protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012026.1	sp|K1QQF9|K1QQF9_CRAGI	3.8e-94	350.1	92.06%	74.25%	Tetratricopeptide repeat protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012027.1	sp|K1QQF9|K1QQF9_CRAGI	3.2e-44	183.3	100.00%	75.78%	Tetratricopeptide repeat protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012028.1	sp|K1QQF9|K1QQF9_CRAGI	0.0e+00	1089.3	100.00%	94.05%	Tetratricopeptide repeat protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012029.1	sp|K1R6J1|K1R6J1_CRAGI	8.3e-11	71.2	95.08%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012030.1	sp|W4Y8Y6|W4Y8Y6_STRPU	4.5e-12	75.9	67.90%	64.81%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN012031.1	sp|A0A2T7PWN6|A0A2T7PWN6_POMCA	1.8e-72	278.9	99.29%	38.61%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN012032.1	sp|K1QHV6|K1QHV6_CRAGI	3.5e-69	266.5	92.50%	90.54%	Whirlin;OS=Crassostrea;PE=4;SV=1
GN012034.1	sp|A0A210Q060|A0A210Q060_MIZYE	6.5e-106	390.6	51.86%	63.46%	YTH domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN010895.1	sp|K1QFI5|K1QFI5_CRAGI	2.2e-92	345.1	80.09%	63.51%	Putative kinetochore protein NUF2;OS=Crassostrea;PE=4;SV=1	GO:0031262|
GN012035.1	sp|K1QIB0|K1QIB0_CRAGI	9.4e-55	219.5	89.22%	47.10%	Transcription factor SOX-7;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN012036.1	sp|K1PC40|K1PC40_CRAGI	9.5e-188	661.8	100.00%	76.85%	Uncharacterized protein y4xO;OS=Crassostrea;PE=4;SV=1	GO:0050662|GO:0016491|
GN012037.1	sp|A0A210Q7R7|A0A210Q7R7_MIZYE	6.4e-66	256.1	82.71%	67.61%	Transmembrane protein 68;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016746|
GN012038.1	sp|K1PMV3|K1PMV3_CRAGI	4.7e-223	780.0	100.00%	52.93%	Aminopeptidase O;OS=Crassostrea;PE=4;SV=1	GO:0005730|	GO:0070006|GO:0008270|
GN012039.1	sp|A0A210Q7V2|A0A210Q7V2_MIZYE	9.7e-98	362.8	93.01%	42.11%	Cell division cycle protein 20-like;OS=Mizuhopecten;PE=4;SV=1	GO:0010997|GO:0097027|	GO:0051301|GO:1904668|
GN012040.1	sp|K1QFB1|K1QFB1_CRAGI	4.9e-43	180.6	98.07%	96.05%	Ankyrin repeat domain-containing protein 29;OS=Crassostrea;PE=4;SV=1
GN012041.1	sp|K1QLV8|K1QLV8_CRAGI	5.1e-119	433.3	93.55%	62.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN010896.1	sp|K1RML9|K1RML9_CRAGI	4.4e-101	373.2	100.00%	70.61%	UPF0405 protein C3orf75-like protein;OS=Crassostrea;PE=4;SV=1	GO:0033588|	GO:0002098|
GN012042.1	sp|K1R733|K1R733_CRAGI	7.0e-77	293.1	85.27%	55.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012043.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	2.2e-52	211.1	100.00%	51.46%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN012044.1	sp|K1Q017|K1Q017_CRAGI	5.0e-197	693.3	63.19%	78.39%	EF-hand calcium-binding domain-containing protein 7;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012046.1	sp|A0A210QAU6|A0A210QAU6_MIZYE	2.0e-26	125.9	24.77%	59.05%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012047.1	sp|K1QXV2|K1QXV2_CRAGI	3.9e-19	101.3	33.23%	46.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012049.1	sp|A0A2R2MRQ2|A0A2R2MRQ2_LINUN	9.6e-69	266.2	100.00%	42.78%	zinc finger protein 862-like;OS=Lingula;PE=4;SV=1	GO:0046983|
GN012050.1	sp|K1P828|K1P828_CRAGI	3.1e-121	440.7	91.64%	64.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012052.1	sp|K1RWJ1|K1RWJ1_CRAGI	1.0e-17	96.3	82.69%	30.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012053.1	sp|A0A2R2MP35|A0A2R2MP35_LINUN	2.1e-28	132.5	97.16%	25.84%	zinc finger protein 862-like;OS=Lingula;PE=4;SV=1	GO:0046983|
GN010898.1	sp|K1R3B7|K1R3B7_CRAGI	3.4e-55	220.3	99.47%	61.83%	Neurocalcin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012056.1	sp|K1Q626|K1Q626_CRAGI	2.2e-13	82.0	68.60%	28.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012057.1	sp|V4A8A4|V4A8A4_LOTGI	2.8e-90	338.6	67.22%	45.28%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN012058.1	sp|K1PG51|K1PG51_CRAGI	2.9e-22	109.4	96.92%	85.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012059.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	8.4e-09	66.6	55.34%	29.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012060.1	sp|K1QAS5|K1QAS5_CRAGI	4.6e-237	825.9	100.00%	89.27%	MAP kinase-interacting serine/threonine-protein kinase 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN012061.1	sp|K1R0N7|K1R0N7_CRAGI	1.1e-39	167.9	99.01%	77.78%	Putative nuclease HARBI1;OS=Crassostrea;PE=4;SV=1
GN012062.1	sp|K1PS34|K1PS34_CRAGI	0.0e+00	1126.7	97.90%	58.28%	Disks large-associated protein 5;OS=Crassostrea;PE=4;SV=1	GO:0023052|
GN012063.1	sp|K1PJE5|K1PJE5_CRAGI	1.4e-196	691.4	75.30%	81.96%	Pancreatic triacylglycerol lipase;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0004806|	GO:0006629|
GN012064.1	sp|K1PYZ9|K1PYZ9_CRAGI	0.0e+00	2882.4	99.87%	76.58%	SCO-spondin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012067.1	sp|K1PNV5|K1PNV5_CRAGI	3.7e-94	349.7	100.00%	96.22%	Vacuolar protein sorting-associated protein 28 homolog;OS=Crassostrea;PE=3;SV=1	GO:0000813|	GO:0043328|
GN012068.1	sp|A0A194AKA6|A0A194AKA6_PINFU	7.5e-84	315.5	100.00%	81.67%	Putative UPF0573 protein C2orf70-like A-like protein;OS=Pinctada;PE=4;SV=1
GN012069.1	sp|K1PNU9|K1PNU9_CRAGI	3.0e-116	423.7	88.89%	78.23%	Methylmalonic aciduria and homocystinuria type C-like protein;OS=Crassostrea;PE=4;SV=1
GN012070.1	sp|K1PH10|K1PH10_CRAGI	6.7e-174	615.9	91.25%	78.76%	Polyadenylate-binding protein-interacting protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN012071.1	sp|K1P321|K1P321_CRAGI	0.0e+00	1385.9	89.77%	83.14%	Putative global transcription activator SNF2L4;OS=Crassostrea;PE=4;SV=1	GO:0016514|	GO:0005524|GO:0016887|GO:0042393|	GO:0006338|GO:0006355|
GN010899.1	sp|A0A210PNQ8|A0A210PNQ8_MIZYE	2.0e-167	594.7	99.82%	57.45%	P3 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN012072.1	sp|K1Q9R8|K1Q9R8_CRAGI	1.5e-293	1014.2	92.33%	77.09%	Coiled-coil domain-containing protein 52;OS=Crassostrea;PE=4;SV=1	GO:0090307|
GN012073.1	sp|K1PNU2|K1PNU2_CRAGI	3.7e-310	1068.9	100.00%	90.50%	Histone-arginine methyltransferase CARM1;OS=Crassostrea;PE=3;SV=1	GO:0008168|	GO:0006479|
GN012074.1	sp|K1PH06|K1PH06_CRAGI	6.3e-80	302.4	98.86%	81.40%	Exosome complex exonuclease RRP40;OS=Crassostrea;PE=4;SV=1	GO:0000178|	GO:0004527|GO:0003723|
GN012075.1	sp|K1P9S4|K1P9S4_CRAGI	6.6e-58	228.8	100.00%	89.06%	Iron-sulfur cluster assembly 1-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0051536|GO:0005198|	GO:0097428|
GN012076.1	sp|K1P317|K1P317_CRAGI	2.4e-287	993.8	69.54%	78.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012077.1	sp|K1Q9R5|K1Q9R5_CRAGI	0.0e+00	1626.7	99.31%	77.37%	Mitogen-activated protein kinase kinase kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|GO:0008270|
GN012078.1	sp|K1Q9R5|K1Q9R5_CRAGI	5.4e-98	362.5	100.00%	96.17%	Mitogen-activated protein kinase kinase kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|GO:0008270|
GN012079.1	sp|K1PNU0|K1PNU0_CRAGI	1.0e-162	578.6	89.29%	85.39%	Major facilitator superfamily domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015293|	GO:0008643|
GN010796.1	sp|A0A210QBT3|A0A210QBT3_MIZYE	1.1e-62	245.0	76.43%	98.32%	Transcription elongation factor B polypeptide 1;OS=Mizuhopecten;PE=3;SV=1	GO:0003746|	GO:0006511|
GN010900.1	sp|K1QP09|K1QP09_CRAGI	3.3e-76	290.4	87.23%	64.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012080.1	sp|K1P9S0|K1P9S0_CRAGI	3.6e-260	903.3	70.17%	81.64%	Dystrophin, isoform D;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012081.1	sp|K1P313|K1P313_CRAGI	6.5e-25	118.2	98.51%	81.54%	Protein sine oculis;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN012082.1	sp|K1PNT5|K1PNT5_CRAGI	9.3e-219	765.0	97.02%	86.06%	Threonine dehydratase catabolic;OS=Crassostrea;PE=4;SV=1	GO:0004794|	GO:0006567|
GN012083.1	sp|K1PH00|K1PH00_CRAGI	1.8e-77	295.0	99.68%	56.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012084.1	sp|K1QLV1|K1QLV1_CRAGI	3.0e-154	550.1	94.63%	92.55%	L-threonine 3-dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0050662|
GN012085.1	sp|A0A2T7NS08|A0A2T7NS08_POMCA	7.5e-24	115.9	100.00%	41.38%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN010901.1	sp|K1QFI0|K1QFI0_CRAGI	0.0e+00	1780.8	100.00%	97.30%	WD repeat-containing protein 65;OS=Crassostrea;PE=4;SV=1
GN012087.1	sp|K1QVE9|K1QVE9_CRAGI	9.1e-56	221.9	99.32%	82.64%	V-type proton ATPase 21 kDa proteolipid subunit;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0033179|	GO:0015078|	GO:0015991|
GN012088.1	sp|K1PCW5|K1PCW5_CRAGI	1.6e-214	750.7	100.00%	84.98%	Alpha-1,3-mannosyltransferase ALG2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004378|	GO:0006486|
GN012089.1	sp|K1QJ53|K1QJ53_CRAGI	2.5e-280	969.9	100.00%	83.17%	WD repeat-containing protein 70;OS=Crassostrea;PE=4;SV=1
GN012090.1	sp|Q962A3|Q962A3_CRAGI	7.4e-94	349.0	100.00%	77.27%	Transcription factor Tal;OS=Crassostrea;PE=2;SV=1	GO:0046983|
GN012091.1	sp|K1PS08|K1PS08_CRAGI	5.5e-163	578.9	99.64%	100.00%	Fizzy-related-like protein;OS=Crassostrea;PE=4;SV=1	GO:0010997|GO:0097027|	GO:1904668|
GN012092.1	sp|K1Q9N5|K1Q9N5_CRAGI	0.0e+00	1445.3	100.00%	84.33%	Kinesin-like protein KIF16B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN012093.1	sp|K1Q2E0|K1Q2E0_CRAGI	3.0e-224	783.1	93.85%	98.23%	AP-1 complex subunit mu-1;OS=Crassostrea;PE=3;SV=1	GO:0030131|	GO:0006886|GO:0016192|
GN010902.1	sp|K1RML5|K1RML5_CRAGI	1.6e-36	158.7	86.45%	53.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN012094.1	sp|K1PNF7|K1PNF7_CRAGI	3.2e-92	343.6	100.00%	76.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012095.1	sp|K1QVE5|K1QVE5_CRAGI	4.0e-230	802.7	99.57%	78.11%	Ornithine decarboxylase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003824|	GO:0006596|
GN012097.1	sp|K1P6Q5|K1P6Q5_CRAGI	8.9e-37	158.3	92.38%	85.42%	Prefoldin subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0016272|	GO:0051082|	GO:0006457|
GN012098.1	sp|K1Q150|K1Q150_CRAGI	9.0e-26	122.1	67.41%	70.33%	Origin recognition complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003682|
GN012099.1	sp|A0A210Q089|A0A210Q089_MIZYE	2.2e-41	174.9	50.20%	70.77%	Pre-mRNA-splicing factor 38A;OS=Mizuhopecten;PE=4;SV=1
GN010903.1	sp|W4Y8Y6|W4Y8Y6_STRPU	3.6e-36	157.9	85.23%	35.00%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN012100.1	sp|A0A210Q066|A0A210Q066_MIZYE	5.6e-299	1032.3	96.00%	64.41%	Ubiquitin-conjugating enzyme E2;OS=Mizuhopecten;PE=4;SV=1
GN012101.1	sp|K1QGG1|K1QGG1_CRAGI	3.3e-309	1065.8	98.87%	85.95%	Tetratricopeptide repeat protein 39B;OS=Crassostrea;PE=4;SV=1
GN012102.1	sp|A0A0B6ZVJ6|A0A0B6ZVJ6_9EUPU	1.4e-132	478.4	97.64%	64.12%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0016021|	GO:0055085|
GN012103.1	sp|K1Q8A4|K1Q8A4_CRAGI	4.6e-196	689.9	87.17%	66.14%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN012104.1	sp|K1QGG5|K1QGG5_CRAGI	1.2e-172	611.7	99.76%	77.54%	Histone acetyltransferase MYST4;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016740|
GN012105.1	sp|K1QAP2|K1QAP2_CRAGI	9.2e-245	851.3	99.77%	97.95%	Cyclic nucleotide-gated olfactory channel;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN012106.1	sp|K1R2J7|K1R2J7_CRAGI	2.2e-45	188.7	98.43%	79.26%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN012107.1	sp|K1R2J7|K1R2J7_CRAGI	2.6e-54	218.4	100.00%	88.77%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN012108.1	sp|K1QMX2|K1QMX2_CRAGI	1.4e-64	251.5	79.58%	86.75%	Serine/threonine-protein kinase RIO1;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0005524|GO:0004674|	GO:0007031|
GN012109.1	sp|K1QMX2|K1QMX2_CRAGI	3.1e-185	653.7	69.61%	92.90%	Serine/threonine-protein kinase RIO1;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0005524|GO:0004674|	GO:0007031|
GN012110.1	sp|V4A4D8|V4A4D8_LOTGI	0.0e+00	1415.2	96.19%	65.92%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN012111.1	sp|K1Q158|K1Q158_CRAGI	3.9e-142	510.0	95.91%	77.74%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004957|
GN010905.1	sp|K1R3B4|K1R3B4_CRAGI	7.0e-78	295.8	78.37%	89.51%	Alkylated DNA repair protein alkB-like protein 7;OS=Crassostrea;PE=4;SV=1	GO:0005759|	GO:0006974|GO:1902445|
GN012112.1	sp|K1RHF5|K1RHF5_CRAGI	1.9e-102	377.5	98.60%	88.15%	Exosome complex exonuclease RRP46;OS=Crassostrea;PE=4;SV=1	GO:0004527|
GN012113.1	sp|K1RBS9|K1RBS9_CRAGI	4.3e-121	441.0	100.00%	41.15%	HEAT repeat-containing protein C7orf27-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008283|GO:0006974|
GN012114.1	sp|K1QGH9|K1QGH9_CRAGI	0.0e+00	3955.2	98.96%	81.55%	Fatty acid synthase;OS=Crassostrea;PE=4;SV=1	GO:0004312|GO:0016788|GO:0016491|GO:0031177|	GO:0009058|
GN012115.1	sp|K1QMY3|K1QMY3_CRAGI	0.0e+00	1538.9	88.00%	89.15%	Myosin-XV;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0003779|GO:0005524|GO:0003774|
GN012116.1	sp|K1R8B2|K1R8B2_CRAGI	2.7e-217	760.0	100.00%	81.53%	Isovaleryl-CoA dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003995|GO:0050660|
GN012117.1	sp|K1Q173|K1Q173_CRAGI	1.9e-100	370.9	84.26%	86.29%	UPF0563 protein C17orf95-like protein;OS=Crassostrea;PE=4;SV=1
GN012118.1	sp|V4BKI0|V4BKI0_LOTGI	1.1e-34	151.4	96.40%	67.92%	Uncharacterized protein;OS=Lottia;PE=3;SV=1
GN012119.1	sp|K1Q8C5|K1Q8C5_CRAGI	2.7e-311	1072.8	96.38%	72.21%	Putative ATP-dependent RNA helicase DDX47;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0004222|GO:0003676|
GN012120.1	sp|K1Q8C5|K1Q8C5_CRAGI	1.1e-208	731.5	90.18%	95.69%	Putative ATP-dependent RNA helicase DDX47;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0004222|GO:0003676|
GN010906.1	sp|K1QWV6|K1QWV6_CRAGI	0.0e+00	2159.4	97.85%	86.75%	Protein neuralized;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN012121.1	sp|K1Q3E1|K1Q3E1_CRAGI	4.5e-12	75.5	100.00%	56.45%	Hyaluronan mediated motility receptor;OS=Crassostrea;PE=4;SV=1	GO:0005540|
GN012123.1	sp|K1RNL1|K1RNL1_CRAGI	7.4e-73	278.9	100.00%	77.19%	DnaJ-like protein subfamily C member 12;OS=Crassostrea;PE=4;SV=1
GN012124.1	sp|K1RHF7|K1RHF7_CRAGI	2.0e-228	797.7	100.00%	62.65%	NAD-dependent deacetylase sirtuin-1;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN012125.1	sp|K1QGH9|K1QGH9_CRAGI	7.2e-61	238.8	98.63%	79.72%	Fatty acid synthase;OS=Crassostrea;PE=4;SV=1	GO:0004312|GO:0016788|GO:0016491|GO:0031177|	GO:0009058|
GN012126.1	sp|K1Q8C1|K1Q8C1_CRAGI	1.0e-102	379.0	97.63%	76.60%	Putative RNA-binding protein Luc7-like 2;OS=Crassostrea;PE=4;SV=1	GO:0005685|	GO:0003729|	GO:0006376|
GN012127.1	sp|A0A210PTB4|A0A210PTB4_MIZYE	1.5e-10	73.2	44.79%	29.63%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0042981|
GN012128.1	sp|A0A210QSX9|A0A210QSX9_MIZYE	2.0e-57	227.6	94.38%	61.08%	Gem-associated protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0000245|
GN010907.1	sp|A0A210PRG8|A0A210PRG8_MIZYE	1.4e-263	914.4	100.00%	63.91%	LMBR1 domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN012129.1	sp|K1R8A9|K1R8A9_CRAGI	2.3e-160	570.5	97.81%	89.39%	UPF0505 protein C16orf62-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN012130.1	sp|K1QMY1|K1QMY1_CRAGI	0.0e+00	1473.4	99.74%	91.47%	Aconitate hydratase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0051539|GO:0003994|GO:0046872|	GO:0006099|
GN012131.1	sp|K1Q8B8|K1Q8B8_CRAGI	3.3e-49	201.1	93.20%	42.86%	Putative arylformamidase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN012132.1	sp|A0A2H4FUP5|A0A2H4FUP5_CRAHO	6.3e-219	765.4	93.29%	96.65%	Mitogen-activated protein kinase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004707|
GN012133.1	sp|K1R8A5|K1R8A5_CRAGI	2.0e-247	860.5	100.00%	75.47%	Rho GTPase-activating protein 24;OS=Crassostrea;PE=4;SV=1	GO:0005096|	GO:0007165|
GN012134.1	sp|A0A210Q772|A0A210Q772_MIZYE	6.4e-204	716.5	94.49%	51.17%	PH and SEC7 domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005086|GO:0005543|	GO:0032012|
GN012135.1	sp|K1Q3G1|K1Q3G1_CRAGI	1.9e-111	408.7	91.87%	46.00%	Activating transcription factor 7-interacting protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012136.1	sp|A0A1S3I786|A0A1S3I786_LINUN	2.7e-152	544.7	96.49%	55.31%	RUN and FYVE domain-containing protein 2 isoform X1;OS=Lingula;PE=4;SV=1	GO:0046872|
GN010908.1	sp|K1PJF0|K1PJF0_CRAGI	0.0e+00	3027.7	96.07%	84.12%	Cadherin-23;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN012137.1	sp|K1RAD3|K1RAD3_CRAGI	1.8e-60	237.7	98.14%	71.52%	Cysteine-rich secretory protein LCCL domain-containing 2;OS=Crassostrea;PE=4;SV=1
GN012139.1	sp|K1S066|K1S066_CRAGI	4.6e-35	154.1	48.63%	57.75%	ATP-binding cassette sub-family A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN012140.1	sp|K1QQ73|K1QQ73_CRAGI	3.1e-140	503.4	100.00%	86.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012141.1	sp|A0A210QCQ6|A0A210QCQ6_MIZYE	2.9e-103	380.6	98.19%	64.07%	Nuclear pore complex protein Nup85;OS=Mizuhopecten;PE=3;SV=1	GO:0031965|GO:0031080|	GO:0017056|	GO:0051028|GO:0015031|
GN012142.1	sp|K1QAQ4|K1QAQ4_CRAGI	6.8e-131	472.6	89.05%	81.00%	Mu-crystallin-like protein;OS=Crassostrea;PE=4;SV=1
GN012143.1	sp|K1Q3F5|K1Q3F5_CRAGI	0.0e+00	2674.8	96.77%	83.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012144.1	sp|K1QQ68|K1QQ68_CRAGI	2.3e-267	926.4	100.00%	99.78%	Tubulin alpha chain;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN012145.1	sp|K1QQ68|K1QQ68_CRAGI	3.2e-258	896.0	100.00%	99.54%	Tubulin alpha chain;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN010909.1	sp|K1PC32|K1PC32_CRAGI	0.0e+00	1133.2	100.00%	93.48%	CAP-Gly domain-containing linker protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012146.1	sp|K1QAQ0|K1QAQ0_CRAGI	0.0e+00	1343.6	100.00%	88.41%	G2/mitotic-specific cyclin-F;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0051726|
GN012147.1	sp|K1Q3F2|K1Q3F2_CRAGI	0.0e+00	1129.4	88.32%	90.78%	Coiled-coil domain-containing protein 40;OS=Crassostrea;PE=4;SV=1	GO:0035082|
GN012148.1	sp|K1RAC4|K1RAC4_CRAGI	0.0e+00	1718.7	99.79%	90.82%	TBC1 domain family member 16;OS=Crassostrea;PE=4;SV=1
GN012149.1	sp|K1QAP0|K1QAP0_CRAGI	0.0e+00	1776.1	99.42%	82.45%	Alpha-mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0004559|GO:0030246|GO:0046872|	GO:0006013|
GN012150.1	sp|K1PKI0|K1PKI0_CRAGI	8.3e-152	542.3	97.76%	68.66%	Malcavernin;OS=Crassostrea;PE=4;SV=1
GN012151.1	sp|K1QSG8|K1QSG8_CRAGI	6.6e-125	452.2	100.00%	89.66%	SPRY domain-containing SOCS box protein 3;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN012152.1	sp|K1PKH6|K1PKH6_CRAGI	0.0e+00	1444.5	64.87%	75.81%	Regulator of G-protein signaling 22;OS=Crassostrea;PE=4;SV=1
GN012153.1	sp|K1Q6R8|K1Q6R8_CRAGI	7.3e-299	1031.6	98.46%	87.03%	Eyes absent homolog;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004725|	GO:0007275|
GN010797.1	sp|K1QHN8|K1QHN8_CRAGI	1.8e-56	225.3	88.82%	37.79%	Inhibin beta B chain;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008083|
GN010910.1	sp|V4CRM4|V4CRM4_LOTGI	3.0e-99	366.7	99.48%	92.63%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005509|
GN012154.1	sp|K1QSF7|K1QSF7_CRAGI	7.6e-121	438.7	95.34%	87.05%	Zinc finger CCHC domain-containing protein 24;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN012155.1	sp|K1PY02|K1PY02_CRAGI	0.0e+00	1265.4	82.93%	81.69%	Microsomal triglyceride transfer protein large subunit;OS=Crassostrea;PE=4;SV=1	GO:0005548|
GN012156.1	sp|K1PZP8|K1PZP8_CRAGI	3.9e-90	337.0	84.56%	66.54%	RNA (Guanine-9-)-methyltransferase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN012157.1	sp|K1PSE4|K1PSE4_CRAGI	1.0e-82	311.6	100.00%	88.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012158.1	sp|K1PKG6|K1PKG6_CRAGI	4.4e-159	566.6	81.46%	82.00%	ATPase family AAA domain-containing protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012159.1	sp|K1R8A0|K1R8A0_CRAGI	0.0e+00	3416.3	95.88%	88.97%	WD repeat-containing protein 90;OS=Crassostrea;PE=4;SV=1
GN012160.1	sp|K1Q3G1|K1Q3G1_CRAGI	3.2e-45	189.5	19.25%	65.00%	Activating transcription factor 7-interacting protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012162.1	sp|A0A210QET2|A0A210QET2_MIZYE	2.4e-116	424.5	87.24%	64.67%	Solute carrier family 35 member D3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN012163.1	sp|K1QIK2|K1QIK2_CRAGI	1.9e-248	864.0	100.00%	86.86%	AN1-type zinc finger and ubiquitin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012164.1	sp|K1QQ93|K1QQ93_CRAGI	2.0e-189	667.2	97.53%	89.55%	Adenosine kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0004001|	GO:0006166|
GN012165.1	sp|K1QFT0|K1QFT0_CRAGI	1.1e-14	84.3	98.53%	60.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012166.1	sp|K1R3R4|K1R3R4_CRAGI	1.3e-171	607.8	97.44%	95.07%	Cytosolic Fe-S cluster assembly factor NUBP1 homolog;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0051539|GO:0005524|GO:0046872|	GO:0016226|
GN012167.1	sp|K1QM52|K1QM52_CRAGI	1.1e-170	605.5	68.56%	87.53%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012168.1	sp|K1QEQ6|K1QEQ6_CRAGI	1.1e-244	851.3	98.23%	84.77%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN012170.1	sp|A0A210PFH3|A0A210PFH3_MIZYE	9.2e-158	562.8	95.46%	48.69%	Cytosolic endo-beta-N-acetylglucosaminidase;OS=Mizuhopecten;PE=4;SV=1	GO:0005737|	GO:0033925|
GN012172.1	sp|K1RAE7|K1RAE7_CRAGI	0.0e+00	2797.3	100.00%	80.26%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000786|GO:0005634|	GO:0003677|GO:0003700|GO:0004402|GO:0008270|	GO:0006334|
GN012173.1	sp|K1QLY5|K1QLY5_CRAGI	1.6e-155	554.7	100.00%	76.08%	Doublesex-and mab-3-related transcription factor A2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0046872|GO:0043565|
GN012174.1	sp|K1S132|K1S132_CRAGI	3.4e-78	296.6	100.00%	79.76%	Sulfhydryl oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016971|
GN012177.1	sp|K1PIB9|K1PIB9_CRAGI	0.0e+00	2187.5	94.79%	77.64%	Inactive ubiquitin carboxyl-terminal hydrolase 54;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN012179.1	sp|K1PQE0|K1PQE0_CRAGI	2.4e-265	920.2	85.91%	84.30%	Sodium-dependent multivitamin transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN012180.1	sp|K1QAT3|K1QAT3_CRAGI	1.6e-118	431.0	100.00%	93.28%	Voltage-dependent calcium channel gamma-5 subunit;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0006816|
GN012181.1	sp|K1QM45|K1QM45_CRAGI	1.6e-139	501.1	99.66%	79.52%	Sulfurtransferase;OS=Crassostrea;PE=4;SV=1	GO:0004792|
GN012182.1	sp|K1R7D0|K1R7D0_CRAGI	4.4e-72	276.9	99.63%	58.99%	NAD-dependent deacetylase sirtuin-7;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN012183.1	sp|A0A210QEM2|A0A210QEM2_MIZYE	8.3e-62	245.0	47.23%	35.78%	PDZ and LIM domain protein 3;OS=Mizuhopecten;PE=4;SV=1
GN012188.1	sp|K1QLC6|K1QLC6_CRAGI	9.3e-39	167.5	28.51%	40.00%	JmjC domain-containing protein 8;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN010912.1	sp|K1QP23|K1QP23_CRAGI	0.0e+00	2883.6	100.00%	94.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012189.1	sp|A0A210QSY7|A0A210QSY7_MIZYE	0.0e+00	1187.6	86.00%	73.71%	Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0015016|GO:0016787|
GN012190.1	sp|K1PES6|K1PES6_CRAGI	1.2e-10	72.0	80.00%	34.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012191.1	sp|K1Q6Y6|K1Q6Y6_CRAGI	7.0e-130	469.5	91.95%	61.54%	Short chain dehydrogenase/reductase family 42E member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003854|	GO:0006694|
GN012192.1	sp|K1R6T3|K1R6T3_CRAGI	8.0e-162	575.9	99.36%	60.34%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012193.1	sp|K1QG19|K1QG19_CRAGI	1.2e-35	156.0	88.54%	34.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012195.1	sp|A0A210QV46|A0A210QV46_MIZYE	7.9e-53	211.8	100.00%	84.43%	Proliferating cell nuclear antigen;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0030337|	GO:0006260|GO:0006275|
GN012196.1	sp|A0A2T7PZL1|A0A2T7PZL1_POMCA	3.5e-42	176.4	93.97%	75.00%	Proliferating cell nuclear antigen;OS=Pomacea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0030337|	GO:0006260|GO:0006275|
GN012197.1	sp|K1PZM6|K1PZM6_CRAGI	2.0e-206	724.2	100.00%	74.72%	Calcium-binding atopy-related autoantigen 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0006851|
GN012198.1	sp|K1R6S5|K1R6S5_CRAGI	2.0e-95	354.0	100.00%	95.21%	40S ribosomal protein S9;OS=Crassostrea;PE=4;SV=1	GO:0015935|	GO:0019843|GO:0003735|	GO:0006412|
GN012199.1	sp|K1QGA8|K1QGA8_CRAGI	8.0e-61	240.4	53.05%	49.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010786.1	sp|K1Q1M0|K1Q1M0_CRAGI	3.0e-17	94.0	69.48%	44.34%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN010914.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	3.7e-11	75.1	30.83%	33.61%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN012200.1	sp|K1QLK8|K1QLK8_CRAGI	2.6e-100	370.2	97.81%	98.88%	GTP-binding protein SAR1b;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0005794|	GO:0005525|	GO:0006886|GO:0016192|
GN012201.1	sp|K1QEZ2|K1QEZ2_CRAGI	1.5e-241	840.9	98.11%	82.79%	Uncharacterized protein C12orf4-like protein;OS=Crassostrea;PE=4;SV=1
GN012202.1	sp|K1R6S3|K1R6S3_CRAGI	0.0e+00	1268.4	77.80%	91.67%	Putative nuclear hormone receptor HR3;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN012203.1	sp|K1PMC5|K1PMC5_CRAGI	2.1e-44	184.5	76.96%	62.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012204.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	3.2e-16	89.7	97.73%	50.59%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN012205.1	sp|K1QEY5|K1QEY5_CRAGI	7.2e-40	168.3	90.91%	98.73%	E3 ubiquitin-protein ligase MIB1;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN012206.1	sp|K1QDJ5|K1QDJ5_CRAGI	3.7e-26	124.4	52.94%	44.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012207.1	sp|A0A1W5B362|A0A1W5B362_CIOIN	8.5e-37	159.8	71.67%	41.98%	uncharacterized protein LOC108949340;OS=Ciona;PE=4;SV=1
GN012208.1	sp|A0A1W5B325|A0A1W5B325_CIOIN	4.4e-29	134.4	64.48%	35.59%	uncharacterized protein LOC108949341;OS=Ciona;PE=4;SV=1	GO:0003677|
GN012209.1	sp|K1Q6X0|K1Q6X0_CRAGI	5.6e-174	615.9	100.00%	99.73%	E3 ubiquitin-protein ligase MIB1;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN012211.1	sp|K1RD30|K1RD30_CRAGI	1.9e-112	412.1	96.08%	44.26%	Forkhead box protein H1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN012212.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	5.3e-20	103.2	42.42%	59.42%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN012213.1	sp|K1QU57|K1QU57_CRAGI	2.9e-17	94.0	73.51%	52.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012215.1	sp|K1R913|K1R913_CRAGI	7.9e-147	526.2	100.00%	58.22%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012216.1	sp|K1R913|K1R913_CRAGI	1.5e-51	208.0	88.12%	75.00%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010916.1	sp|K1R3C4|K1R3C4_CRAGI	2.1e-210	737.6	73.08%	89.67%	E3 ubiquitin-protein ligase TRAF7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0016829|GO:0008270|	GO:0006520|
GN012217.1	sp|K1RSV8|K1RSV8_CRAGI	9.7e-209	731.9	99.81%	63.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012219.1	sp|K1QN93|K1QN93_CRAGI	2.5e-17	93.6	97.94%	52.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010917.1	sp|K1R3C4|K1R3C4_CRAGI	1.6e-94	351.3	85.17%	79.81%	E3 ubiquitin-protein ligase TRAF7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0016829|GO:0008270|	GO:0006520|
GN012222.1	sp|A0A1S3J188|A0A1S3J188_LINUN	6.0e-54	216.1	98.29%	59.06%	uncharacterized protein K02A2.6;OS=Lingula;PE=4;SV=1
GN012225.1	sp|A0A2G8JBW6|A0A2G8JBW6_STIJA	6.6e-38	162.9	95.85%	40.00%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN012226.1	sp|A0A2G8JD28|A0A2G8JD28_STIJA	1.8e-26	126.3	35.51%	34.36%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN012228.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	3.1e-11	73.6	79.46%	40.45%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN012231.1	sp|K1PE45|K1PE45_CRAGI	6.3e-13	79.7	97.59%	31.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN012232.1	sp|K1PE45|K1PE45_CRAGI	4.5e-23	113.6	75.13%	40.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN012234.1	sp|K1P7I3|K1P7I3_CRAGI	2.6e-22	111.3	90.87%	31.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012235.1	sp|K1R4W0|K1R4W0_CRAGI	2.9e-60	238.4	97.79%	33.33%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012236.1	sp|A0A2B4RZW9|A0A2B4RZW9_STYPI	3.9e-16	90.5	63.19%	33.33%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0008270|
GN012237.1	sp|A0A2B4QY92|A0A2B4QY92_STYPI	5.2e-26	124.4	31.70%	48.36%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN012239.1	sp|K1R4W0|K1R4W0_CRAGI	2.6e-173	613.6	100.00%	84.36%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012241.1	sp|K1QJC4|K1QJC4_CRAGI	1.7e-174	617.8	100.00%	71.30%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN010918.1	sp|K1QWW7|K1QWW7_CRAGI	2.9e-139	500.4	99.37%	75.23%	Kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|	GO:0032958|
GN012242.1	sp|K1QCZ7|K1QCZ7_CRAGI	1.5e-209	734.2	100.00%	87.02%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012243.1	sp|K1Q503|K1Q503_CRAGI	3.3e-160	570.5	95.22%	64.25%	Neuronal acetylcholine receptor subunit alpha-9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012244.1	sp|K1Q503|K1Q503_CRAGI	1.4e-163	581.3	100.00%	82.15%	Neuronal acetylcholine receptor subunit alpha-9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012245.1	sp|K1R4V3|K1R4V3_CRAGI	6.8e-154	549.3	98.26%	78.99%	Acetylcholine receptor subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012246.1	sp|K1QCY8|K1QCY8_CRAGI	7.0e-141	506.1	84.40%	80.62%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012247.1	sp|A0A1S3KAA9|A0A1S3KAA9_LINUN	1.3e-95	356.3	98.99%	36.75%	uncharacterized protein LOC106180092;OS=Lingula;PE=4;SV=1	GO:0008270|
GN010919.1	sp|K1Q7Y6|K1Q7Y6_CRAGI	0.0e+00	1172.5	100.00%	93.53%	Heat shock protein 70 B2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012249.1	sp|K1RWJ1|K1RWJ1_CRAGI	2.5e-09	67.4	58.14%	48.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010920.1	sp|K1Q7Y6|K1Q7Y6_CRAGI	0.0e+00	1177.9	100.00%	94.16%	Heat shock protein 70 B2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012250.1	sp|K1PXI2|K1PXI2_CRAGI	2.7e-147	527.3	93.54%	81.72%	Forkhead box protein D3-B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN012251.1	sp|R7URM3|R7URM3_CAPTE	9.5e-21	105.5	99.32%	38.10%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN012252.1	sp|K1R0U3|K1R0U3_CRAGI	1.3e-82	311.6	100.00%	67.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012253.1	sp|A0A2B4S9E0|A0A2B4S9E0_STYPI	1.9e-26	125.2	88.33%	36.84%	THAP domain-containing protein 1;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN012254.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	5.8e-100	370.2	99.27%	45.41%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN012255.1	sp|K1QYZ9|K1QYZ9_CRAGI	1.4e-15	89.0	32.27%	54.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010798.1	sp|K1PQJ1|K1PQJ1_CRAGI	1.4e-238	831.2	99.84%	71.97%	HAUS augmin-like complex subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0070652|	GO:0051225|
GN010921.1	sp|K1Q7Y6|K1Q7Y6_CRAGI	0.0e+00	1157.1	100.00%	92.27%	Heat shock protein 70 B2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012256.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	1.3e-95	355.9	96.54%	41.03%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN012257.1	sp|K1RCB6|K1RCB6_CRAGI	1.4e-147	528.9	74.83%	68.22%	Cholesterol 25-hydroxylase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005506|GO:0016491|	GO:0008610|
GN012258.1	sp|K1QS68|K1QS68_CRAGI	1.4e-34	152.9	45.48%	42.67%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0097200|
GN012259.1	sp|K1PNT0|K1PNT0_CRAGI	3.5e-10	70.1	61.74%	48.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012260.1	sp|A0A3M6TI11|A0A3M6TI11_9CNID	3.6e-28	131.3	68.48%	39.74%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN012261.1	sp|A0A210PFL5|A0A210PFL5_MIZYE	1.3e-19	101.3	90.29%	51.52%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005739|	GO:0051607|
GN012262.1	sp|K1QCP2|K1QCP2_CRAGI	1.6e-70	270.8	100.00%	89.93%	Regucalcin;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0030234|
GN012263.1	sp|K1QNI2|K1QNI2_CRAGI	1.6e-11	74.7	78.91%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012264.1	sp|K1RCB1|K1RCB1_CRAGI	7.4e-148	528.9	99.68%	78.90%	Regucalcin;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0030234|
GN012265.1	sp|K1QCN7|K1QCN7_CRAGI	8.4e-31	137.9	100.00%	92.86%	Guanine nucleotide-binding protein subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0005834|	GO:0003924|	GO:0007186|
GN012266.1	sp|K1R1N0|K1R1N0_CRAGI	8.0e-225	786.6	42.37%	87.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012267.1	sp|K1RGP8|K1RGP8_CRAGI	7.4e-168	596.3	59.57%	78.02%	Serine/threonine-protein kinase CTR1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN010922.1	sp|K1Q637|K1Q637_CRAGI	3.5e-11	73.2	61.86%	61.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012268.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	1.1e-37	162.2	87.18%	47.06%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN012269.1	sp|K1PQX7|K1PQX7_CRAGI	9.7e-160	568.5	92.20%	79.39%	Protein Wnt;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0005102|	GO:0007275|GO:0016055|
GN012270.1	sp|K1QBA5|K1QBA5_CRAGI	2.2e-197	693.7	100.00%	89.03%	Neuropeptide FF receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004983|
GN012271.1	sp|K1PIU5|K1PIU5_CRAGI	3.6e-64	249.6	95.31%	90.08%	Protein quiver;OS=Crassostrea;PE=3;SV=1	GO:0031225|GO:0016021|GO:0005886|	GO:0034235|	GO:1903818|GO:0045187|GO:0032222|GO:0048511|GO:0030431|
GN012272.1	sp|K1P5B4|K1P5B4_CRAGI	2.2e-142	510.8	100.00%	77.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012273.1	sp|A0A210PYS2|A0A210PYS2_MIZYE	2.9e-20	104.8	59.16%	39.61%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012274.1	sp|K1PQY6|K1PQY6_CRAGI	4.6e-151	539.7	90.29%	83.44%	PDZ domain-containing RING finger protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005164|GO:0004842|GO:0008270|
GN012275.1	sp|W4YR48|W4YR48_STRPU	3.9e-16	90.5	57.46%	49.07%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN012276.1	sp|K1Q5I7|K1Q5I7_CRAGI	2.7e-17	96.3	32.35%	29.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012277.1	sp|V3ZLT0|V3ZLT0_LOTGI	3.7e-26	124.0	79.90%	41.92%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN012278.1	sp|A0A0B6VI55|A0A0B6VI55_LOTGI	5.8e-93	346.7	100.00%	51.68%	Anti-dorsalizing morphogenetic protein;OS=Lottia;PE=3;SV=1	GO:0005576|	GO:0008083|
GN012279.1	sp|A0A2B4SGV1|A0A2B4SGV1_STYPI	5.1e-31	140.2	92.13%	42.29%	Zinc finger BED domain-containing protein 1;OS=Stylophora;PE=4;SV=1	GO:0008234|GO:0003677|GO:0046983|
GN010923.1	sp|K1R2T4|K1R2T4_CRAGI	4.2e-12	76.6	80.15%	40.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012281.1	sp|K1S4U2|K1S4U2_CRAGI	2.1e-103	383.3	100.00%	56.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012282.1	sp|K1RLE8|K1RLE8_CRAGI	0.0e+00	1669.4	100.00%	83.49%	Uncharacterized protein C17orf66;OS=Crassostrea;PE=4;SV=1
GN012283.1	sp|K1R9Q7|K1R9Q7_CRAGI	6.6e-82	309.3	95.52%	66.51%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016757|	GO:0005975|
GN012284.1	sp|K1R0P3|K1R0P3_CRAGI	4.6e-53	213.8	59.56%	74.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012285.1	sp|K1RGC9|K1RGC9_CRAGI	0.0e+00	1458.0	99.77%	86.92%	Sodium/calcium exchanger 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005432|	GO:0007154|
GN012286.1	sp|K1Q8V8|K1Q8V8_CRAGI	1.1e-196	691.8	98.64%	68.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN012287.1	sp|K1QGY3|K1QGY3_CRAGI	2.1e-26	124.8	69.76%	50.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010924.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	2.8e-35	154.1	93.26%	48.02%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN012288.1	sp|K1QW22|K1QW22_CRAGI	1.3e-32	144.8	94.70%	53.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012289.1	sp|K1Q609|K1Q609_CRAGI	1.1e-54	218.0	98.44%	85.60%	Lipid phosphate phosphatase-related protein type 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012290.1	sp|K1QDK2|K1QDK2_CRAGI	1.5e-31	141.7	60.22%	62.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012291.1	sp|K1QLW8|K1QLW8_CRAGI	9.8e-98	362.8	100.00%	67.63%	Stromal membrane-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0046872|
GN012292.1	sp|K1QSZ8|K1QSZ8_CRAGI	0.0e+00	2560.4	99.94%	83.46%	DNA-directed RNA polymerase subunit;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003899|GO:0008270|	GO:0006351|
GN010925.1	sp|K1QCK5|K1QCK5_CRAGI	0.0e+00	1514.2	33.02%	56.25%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN010925.1	sp|K1QCK5|K1QCK5_CRAGI	2.4e-76	295.0	9.26%	43.99%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN010925.1	sp|K1QCK5|K1QCK5_CRAGI	4.3e-54	221.1	6.25%	47.51%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN012293.1	sp|K1RD49|K1RD49_CRAGI	8.8e-149	532.3	77.91%	76.01%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN012294.1	sp|K1RD58|K1RD58_CRAGI	0.0e+00	3321.6	48.87%	74.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN012295.1	sp|K1PSK2|K1PSK2_CRAGI	1.2e-276	957.6	100.00%	79.35%	Transcription factor glial cells missing;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0001228|
GN012296.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	5.4e-87	326.6	98.67%	51.85%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN010926.1	sp|K1QCK5|K1QCK5_CRAGI	0.0e+00	1577.4	34.45%	56.72%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN010926.1	sp|K1QCK5|K1QCK5_CRAGI	2.2e-82	315.1	8.68%	48.40%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN012298.1	sp|K1PZT2|K1PZT2_CRAGI	2.4e-23	114.4	63.79%	44.64%	Cytochrome c oxidase subunit 5B, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005740|	GO:0004129|
GN012299.1	sp|K1Q6T7|K1Q6T7_CRAGI	1.3e-231	808.1	70.63%	79.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012300.1	sp|K1PZR9|K1PZR9_CRAGI	5.2e-114	416.4	97.04%	71.10%	Transcription elongation factor A protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003746|GO:0008270|	GO:0006351|
GN012301.1	sp|K1QFP3|K1QFP3_CRAGI	1.8e-162	578.2	97.89%	58.15%	Nucleolar protein 11-like protein;OS=Crassostrea;PE=4;SV=1
GN010927.1	sp|K1QKQ5|K1QKQ5_CRAGI	0.0e+00	1265.8	100.00%	71.99%	N-terminal acetyltransferase B complex subunit MDM20;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN012302.1	sp|K1QIH6|K1QIH6_CRAGI	2.1e-29	134.8	97.09%	41.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012303.1	sp|K1RAB8|K1RAB8_CRAGI	3.3e-76	290.4	66.09%	85.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012304.1	sp|K1QQ53|K1QQ53_CRAGI	5.6e-140	502.7	100.00%	85.57%	Serine/threonine-protein kinase SMG1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0000184|
GN012305.1	sp|K1QQ53|K1QQ53_CRAGI	0.0e+00	5624.3	99.57%	87.56%	Serine/threonine-protein kinase SMG1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|	GO:0000184|
GN012306.1	sp|K1QIH6|K1QIH6_CRAGI	2.1e-29	134.8	97.09%	41.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012307.1	sp|K1QIH6|K1QIH6_CRAGI	2.1e-29	134.8	97.09%	41.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012308.1	sp|K1QFP3|K1QFP3_CRAGI	1.8e-162	578.2	97.89%	58.15%	Nucleolar protein 11-like protein;OS=Crassostrea;PE=4;SV=1
GN010928.1	sp|K1QKQ5|K1QKQ5_CRAGI	2.3e-38	163.3	96.51%	98.78%	N-terminal acetyltransferase B complex subunit MDM20;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN012310.1	sp|K1QX08|K1QX08_CRAGI	0.0e+00	2061.6	100.00%	78.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005777|
GN010929.1	sp|K1QS38|K1QS38_CRAGI	3.1e-58	229.9	100.00%	86.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012314.1	sp|K1RMT1|K1RMT1_CRAGI	3.4e-52	210.3	89.07%	72.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012315.1	sp|K1R3G4|K1R3G4_CRAGI	0.0e+00	2865.9	100.00%	80.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012317.1	sp|K1QPU1|K1QPU1_CRAGI	2.7e-44	183.7	76.22%	85.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012318.1	sp|K1QG42|K1QG42_CRAGI	9.1e-110	403.7	94.19%	34.01%	NADH-cytochrome b5 reductase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016491|
GN012319.1	sp|K1QG42|K1QG42_CRAGI	4.8e-97	360.1	91.84%	59.34%	NADH-cytochrome b5 reductase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016491|
GN010930.1	sp|K1R9G8|K1R9G8_CRAGI	1.5e-99	368.6	64.17%	74.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN012321.1	sp|K1R3T7|K1R3T7_CRAGI	0.0e+00	1197.6	100.00%	69.58%	Ribonucleases P/MRP protein subunit POP1;OS=Crassostrea;PE=4;SV=1	GO:0005655|GO:0000172|	GO:0001682|
GN012322.1	sp|K1QXF9|K1QXF9_CRAGI	2.0e-107	395.2	47.76%	81.62%	Acyl-protein thioesterase 2;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN012323.1	sp|K1QPT7|K1QPT7_CRAGI	3.2e-94	350.1	94.86%	90.10%	NIPA-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015095|
GN012324.1	sp|K1QG40|K1QG40_CRAGI	0.0e+00	1771.5	100.00%	80.87%	Cytosolic carboxypeptidase-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0004180|
GN012325.1	sp|K1RN77|K1RN77_CRAGI	7.2e-104	383.6	94.68%	51.92%	Nuclear autoantigenic sperm protein;OS=Crassostrea;PE=4;SV=1
GN012326.1	sp|K1R3T3|K1R3T3_CRAGI	1.4e-73	281.2	98.73%	97.42%	Transcription factor BTF3;OS=Crassostrea;PE=3;SV=1
GN012328.1	sp|K1QXF5|K1QXF5_CRAGI	4.0e-105	386.3	100.00%	86.12%	Calcyphosin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012329.1	sp|K1QPT0|K1QPT0_CRAGI	1.2e-48	198.7	56.31%	87.07%	DNA-binding protein inhibitor ID-2;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0003677|GO:0046983|	GO:0045892|
GN012330.1	sp|K1QG31|K1QG31_CRAGI	0.0e+00	1412.9	96.00%	79.08%	Niemann-Pick C1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012331.1	sp|K1QXF0|K1QXF0_CRAGI	7.4e-272	941.8	100.00%	77.50%	Dual specificity testis-specific protein kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN012332.1	sp|K1QPS5|K1QPS5_CRAGI	0.0e+00	1114.0	97.28%	74.85%	Ribonucleoprotein PTB-binding 2;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN012333.1	sp|A0A164R9F5|A0A164R9F5_9CRUS	2.6e-46	193.4	44.38%	29.71%	Uncharacterized protein;OS=Daphnia;PE=4;SV=1
GN010932.1	sp|A0A2T7PW72|A0A2T7PW72_POMCA	3.2e-37	161.8	51.19%	59.07%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN012335.1	sp|K1RHG9|K1RHG9_CRAGI	9.3e-48	194.9	100.00%	81.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012336.1	sp|K1S139|K1S139_CRAGI	5.3e-54	215.7	99.15%	85.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012337.1	sp|K1QVR5|K1QVR5_CRAGI	0.0e+00	1300.8	99.78%	89.04%	Zinc finger MIZ domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012338.1	sp|K1RBC4|K1RBC4_CRAGI	0.0e+00	1629.8	96.81%	66.59%	Cyclin G-associated kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN012339.1	sp|K1R5G8|K1R5G8_CRAGI	4.2e-87	326.6	76.69%	90.00%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016192|
GN012340.1	sp|A0A2T7PVF9|A0A2T7PVF9_POMCA	9.0e-208	729.6	80.85%	51.17%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003723|
GN010933.1	sp|K1QCK9|K1QCK9_CRAGI	2.0e-269	934.9	92.22%	56.59%	TATA element modulatory factor;OS=Crassostrea;PE=4;SV=1
GN012341.1	sp|K1PH53|K1PH53_CRAGI	4.9e-158	563.9	100.00%	49.79%	Mitotic spindle assembly checkpoint protein MAD1;OS=Crassostrea;PE=4;SV=1	GO:0007094|
GN012342.1	sp|K1R487|K1R487_CRAGI	8.2e-171	605.5	95.39%	69.90%	Carbohydrate sulfotransferase 15;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN012343.1	sp|K1PNF3|K1PNF3_CRAGI	2.3e-207	728.4	97.49%	46.89%	LIM domain-binding protein 3;OS=Crassostrea;PE=4;SV=1
GN012344.1	sp|K1Q5X2|K1Q5X2_CRAGI	7.1e-92	342.8	78.98%	75.21%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012345.1	sp|K1P345|K1P345_CRAGI	0.0e+00	1872.8	91.55%	76.68%	KN motif and ankyrin repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN012346.1	sp|A0A210PWF5|A0A210PWF5_MIZYE	1.4e-35	155.2	95.57%	41.06%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0000350|
GN012347.1	sp|A0A210PWH8|A0A210PWH8_MIZYE	6.6e-93	347.1	100.00%	63.18%	General transcription factor IIF subunit 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0032968|GO:0006367|
GN012348.1	sp|K1PH44|K1PH44_CRAGI	1.8e-135	488.0	88.64%	65.71%	F-box only protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|	GO:0031146|
GN010934.1	sp|K1RC83|K1RC83_CRAGI	5.8e-45	186.0	92.86%	66.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012349.1	sp|A0A210R027|A0A210R027_MIZYE	8.8e-40	169.9	95.25%	42.90%	Protein trunk;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN012351.1	sp|K1P348|K1P348_CRAGI	7.6e-159	566.6	73.12%	54.23%	Pentatricopeptide repeat-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN012352.1	sp|K1Q9U7|K1Q9U7_CRAGI	2.9e-169	600.1	97.69%	80.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012353.1	sp|A0A1B0CJY0|A0A1B0CJY0_LUTLO	2.3e-31	140.6	98.41%	51.22%	Uncharacterized protein;OS=Lutzomyia;PE=3;SV=1
GN012354.1	sp|K1R9G8|K1R9G8_CRAGI	7.9e-53	211.8	98.37%	78.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN012355.1	sp|K1QS32|K1QS32_CRAGI	2.8e-42	177.9	63.81%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012356.1	sp|A0A210R6G9|A0A210R6G9_MIZYE	1.2e-127	461.8	91.57%	72.94%	Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial;OS=Mizuhopecten;PE=3;SV=1	GO:0016787|GO:0004488|
GN010935.1	sp|K1QS38|K1QS38_CRAGI	3.1e-58	229.9	100.00%	86.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012357.1	sp|A0A210PJB5|A0A210PJB5_MIZYE	4.3e-281	972.6	99.27%	70.76%	Choline O-acetyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0016746|
GN012358.1	sp|K1PH05|K1PH05_CRAGI	2.1e-270	936.8	100.00%	86.75%	Vesicular acetylcholine transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015238|
GN012359.1	sp|K1QDU1|K1QDU1_CRAGI	2.4e-48	196.8	100.00%	89.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012360.1	sp|K1QM44|K1QM44_CRAGI	4.1e-104	386.0	45.83%	38.48%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016888|
GN012361.1	sp|K1QZP3|K1QZP3_CRAGI	6.4e-27	127.1	43.65%	45.26%	BTB/POZ domain-containing protein KCTD21;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN012362.1	sp|K1QM44|K1QM44_CRAGI	1.8e-58	231.1	68.21%	90.60%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016888|
GN012363.1	sp|K1QT65|K1QT65_CRAGI	1.1e-261	907.9	100.00%	74.84%	Collagen alpha-3(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0016021|
GN012364.1	sp|K1RBU8|K1RBU8_CRAGI	9.5e-124	449.1	74.12%	94.56%	Leucine-rich repeat-containing protein 67;OS=Crassostrea;PE=4;SV=1
GN010936.1	sp|K1QKQ5|K1QKQ5_CRAGI	0.0e+00	1427.5	100.00%	74.28%	N-terminal acetyltransferase B complex subunit MDM20;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN012365.1	sp|K1QHK8|K1QHK8_CRAGI	2.1e-226	792.3	56.61%	59.80%	Centrosome and spindle pole-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005813|GO:0005874|GO:0000922|	GO:0032467|
GN012366.1	sp|K1QP76|K1QP76_CRAGI	1.0e-133	483.0	98.41%	44.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012367.1	sp|K1R9H9|K1R9H9_CRAGI	2.6e-96	357.1	98.13%	81.34%	Nucleoredoxin-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|GO:0045494|GO:0007600|
GN012368.1	sp|A0A210R0K5|A0A210R0K5_MIZYE	0.0e+00	1653.6	90.12%	76.51%	Zinc finger SWIM domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0008270|
GN012369.1	sp|K1Q9T7|K1Q9T7_CRAGI	8.1e-138	496.5	100.00%	64.63%	Afadin-and alpha-actinin-binding protein;OS=Crassostrea;PE=4;SV=1
GN012370.1	sp|K1P341|K1P341_CRAGI	9.9e-155	553.9	86.85%	36.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012371.1	sp|A0A0P4WGA4|A0A0P4WGA4_9EUCA	8.2e-89	333.6	81.85%	37.55%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN010937.1	sp|A0A210PIF8|A0A210PIF8_MIZYE	0.0e+00	1651.7	92.62%	29.47%	Sacsin;OS=Mizuhopecten;PE=4;SV=1
GN012372.1	sp|K1P9V1|K1P9V1_CRAGI	0.0e+00	1500.0	100.00%	87.14%	DNA repair endonuclease XPF;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004519|
GN012373.1	sp|K1PNZ4|K1PNZ4_CRAGI	2.7e-173	614.4	81.32%	88.29%	Something about silencing protein 10;OS=Crassostrea;PE=4;SV=1
GN012374.1	sp|A0A210PIR3|A0A210PIR3_MIZYE	1.2e-125	456.4	95.46%	37.71%	Latrophilin-3;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN012375.1	sp|K1QT60|K1QT60_CRAGI	1.1e-305	1054.7	98.03%	89.72%	Radial spoke head 10-like protein B2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012376.1	sp|K1QM39|K1QM39_CRAGI	1.2e-137	494.6	100.00%	95.53%	Receptor protein-tyrosine kinase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN012377.1	sp|K1QDT5|K1QDT5_CRAGI	5.5e-120	436.4	70.29%	82.77%	Pancreatic lipase-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0004806|	GO:0006629|
GN012378.1	sp|K1QCA6|K1QCA6_CRAGI	1.4e-123	448.4	82.81%	75.52%	Pancreatic lipase-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0004806|	GO:0006629|
GN010938.1	sp|K1RC85|K1RC85_CRAGI	1.8e-74	284.3	100.00%	79.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012380.1	sp|K1QTF3|K1QTF3_CRAGI	1.9e-144	517.7	80.34%	87.19%	Pancreatic lipase-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0052689|	GO:0006629|
GN012381.1	sp|K1RJW1|K1RJW1_CRAGI	6.5e-57	225.7	99.34%	76.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012382.1	sp|A0A1S3H413|A0A1S3H413_LINUN	1.9e-33	148.3	84.04%	41.11%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN012383.1	sp|A0A2C9JH48|A0A2C9JH48_BIOGL	1.7e-11	75.5	34.85%	54.22%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003700|
GN010799.1	sp|D6WXW8|D6WXW8_TRICA	3.3e-27	126.7	95.12%	50.86%	Uncharacterized protein;OS=Tribolium;PE=4;SV=1
GN012384.1	sp|K1PU46|K1PU46_CRAGI	0.0e+00	1543.1	99.23%	84.61%	Lethal(2) giant larvae-like protein 1;OS=Crassostrea;PE=4;SV=1
GN012387.1	sp|K1PE69|K1PE69_CRAGI	6.1e-281	971.8	95.85%	83.91%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0016614|
GN012388.1	sp|K1P835|K1P835_CRAGI	2.7e-70	271.6	60.26%	64.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012389.1	sp|K1QCN8|K1QCN8_CRAGI	1.1e-86	325.5	100.00%	72.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012390.1	sp|K1P6N5|K1P6N5_CRAGI	3.3e-231	806.6	98.05%	75.58%	Solute carrier family 15 member 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|	GO:0006857|
GN012391.1	sp|K1PK68|K1PK68_CRAGI	2.9e-183	647.1	100.00%	74.90%	Usher syndrome type-1G-like protein;OS=Crassostrea;PE=4;SV=1
GN012393.1	sp|K1QCP4|K1QCP4_CRAGI	4.6e-114	416.4	100.00%	91.42%	UPF0472 protein C16orf72-like protein;OS=Crassostrea;PE=4;SV=1
GN012394.1	sp|K1P6N8|K1P6N8_CRAGI	0.0e+00	2065.4	100.00%	93.35%	Ubiquitin carboxyl-terminal hydrolase 7;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN012395.1	sp|K1PCP3|K1PCP3_CRAGI	1.7e-160	570.9	100.00%	80.90%	UPF0602 protein C4orf47-like protein;OS=Crassostrea;PE=4;SV=1
GN012396.1	sp|K1PK70|K1PK70_CRAGI	1.1e-281	974.5	74.04%	93.98%	Double-strand break repair protein;OS=Crassostrea;PE=3;SV=1	GO:0030870|	GO:0008408|GO:0004519|GO:0030145|	GO:0006302|GO:0051321|
GN012397.1	sp|K1PS71|K1PS71_CRAGI	0.0e+00	1205.7	98.93%	83.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000139|	GO:0008565|	GO:0006886|GO:0048280|
GN012398.1	sp|K1R0U6|K1R0U6_CRAGI	4.2e-251	872.8	77.71%	86.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012399.1	sp|K1PVE1|K1PVE1_CRAGI	3.0e-170	604.0	100.00%	75.38%	ADP-ribosylation factor GTPase-activating protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0046872|
GN010939.1	sp|K1QZP3|K1QZP3_CRAGI	1.7e-25	122.1	49.03%	46.83%	BTB/POZ domain-containing protein KCTD21;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN012401.1	sp|K1PF85|K1PF85_CRAGI	1.3e-77	295.0	94.98%	75.36%	Class E basic helix-loop-helix protein 22;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN012402.1	sp|K1PN10|K1PN10_CRAGI	0.0e+00	2552.7	99.43%	88.75%	Intron-binding protein aquarius;OS=Crassostrea;PE=3;SV=1	GO:0005681|	GO:0000398|
GN012403.1	sp|K1QFD1|K1QFD1_CRAGI	3.7e-244	849.7	95.57%	76.46%	Ligatin;OS=Crassostrea;PE=4;SV=1	GO:0003743|	GO:0001731|
GN012404.1	sp|K1P929|K1P929_CRAGI	0.0e+00	2166.3	100.00%	82.21%	Sperm flagellar protein 2;OS=Crassostrea;PE=4;SV=1	GO:0031514|	GO:0005524|GO:0019205|	GO:0006139|
GN012405.1	sp|K1PF88|K1PF88_CRAGI	0.0e+00	1472.6	91.54%	77.31%	Nardilysin;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004222|
GN012406.1	sp|K1R0A2|K1R0A2_CRAGI	1.7e-100	371.7	100.00%	52.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012408.1	sp|K1PS84|K1PS84_CRAGI	1.0e-64	251.9	94.02%	77.46%	Alpha-crystallin B chain;OS=Crassostrea;PE=3;SV=1	GO:0046872|
GN012409.1	sp|K1PS84|K1PS84_CRAGI	1.0e-64	251.9	94.02%	77.46%	Alpha-crystallin B chain;OS=Crassostrea;PE=3;SV=1	GO:0046872|
GN012410.1	sp|K1PZL2|K1PZL2_CRAGI	0.0e+00	4340.8	99.92%	77.77%	Maltase-glucoamylase, intestinal;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|GO:0004553|	GO:0005975|
GN010940.1	sp|A0A210QP64|A0A210QP64_MIZYE	5.5e-30	137.5	64.61%	34.85%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012411.1	sp|A0A210PNN5|A0A210PNN5_MIZYE	2.0e-176	624.8	84.07%	57.93%	Cell cycle checkpoint protein RAD17;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0006281|
GN012412.1	sp|A0A210PNQ5|A0A210PNQ5_MIZYE	9.4e-27	126.3	62.64%	43.03%	Transmembrane protein 69;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN012413.1	sp|K1QII9|K1QII9_CRAGI	9.7e-223	778.1	100.00%	92.31%	Non-specific lipid-transfer protein;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN012414.1	sp|K1QC27|K1QC27_CRAGI	1.7e-208	730.7	98.57%	86.65%	Hydroxysteroid dehydrogenase-like protein 2;OS=Crassostrea;PE=4;SV=1
GN012415.1	sp|A0A1S3JA43|A0A1S3JA43_LINUN	2.7e-38	164.1	84.39%	57.93%	required for excision 1-B domain-containing protein;OS=Lingula;PE=4;SV=1
GN012416.1	sp|A0A210Q8I6|A0A210Q8I6_MIZYE	1.8e-214	750.7	83.55%	92.99%	Histone deacetylase;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0046872|GO:0032041|
GN012417.1	sp|K1PY78|K1PY78_CRAGI	4.2e-127	459.9	100.00%	86.69%	Deoxyhypusine hydroxylase;OS=Crassostrea;PE=3;SV=1	GO:0019135|GO:0046872|	GO:0008612|
GN012418.1	sp|K1Q5M3|K1Q5M3_CRAGI	1.5e-150	538.5	100.00%	60.29%	Uncharacterized protein C9orf72;OS=Crassostrea;PE=4;SV=1	GO:0005085|
GN012419.1	sp|K1PIT3|K1PIT3_CRAGI	3.9e-75	288.9	31.26%	38.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012420.1	sp|K1P5A5|K1P5A5_CRAGI	2.3e-276	956.8	99.24%	76.99%	Uncharacterized protein C18orf8-like protein;OS=Crassostrea;PE=4;SV=1	GO:0035658|	GO:0010506|
GN012422.1	sp|K1PIT8|K1PIT8_CRAGI	3.7e-86	324.3	54.07%	72.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012425.1	sp|K1PZ93|K1PZ93_CRAGI	0.0e+00	1677.5	87.69%	92.11%	Dihydropyrimidine dehydrogenase [NADP(+)];OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0051539|GO:0017113|	GO:0019483|
GN010942.1	sp|K1QKR5|K1QKR5_CRAGI	1.1e-88	332.0	100.00%	69.48%	WW domain-binding protein 2;OS=Crassostrea;PE=4;SV=1
GN012426.1	sp|V4BHM1|V4BHM1_LOTGI	2.2e-183	647.9	89.03%	56.59%	Mannosyltransferase;OS=Lottia;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0000030|	GO:0006506|
GN012427.1	sp|K1PSM2|K1PSM2_CRAGI	1.6e-222	777.3	100.00%	91.11%	DNA excision repair protein ERCC-8;OS=Crassostrea;PE=4;SV=1
GN012428.1	sp|K1PJR1|K1PJR1_CRAGI	1.0e-131	474.9	98.84%	89.80%	RNA 3'-terminal phosphate cyclase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005730|	GO:0003824|	GO:0042254|GO:0006396|
GN012429.1	sp|K1QJL6|K1QJL6_CRAGI	1.5e-120	438.0	100.00%	79.09%	Microtubule-associated protein RP/EB family member 3;OS=Crassostrea;PE=4;SV=1	GO:0005874|	GO:0051010|	GO:0070507|
GN012432.1	sp|K1QDP6|K1QDP6_CRAGI	3.7e-31	139.8	89.92%	68.87%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN010943.1	sp|K1QS45|K1QS45_CRAGI	6.3e-207	726.1	72.29%	76.40%	Tyrosine--tRNA ligase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0003723|GO:0004831|	GO:0006437|
GN012433.1	sp|A0A210R3L2|A0A210R3L2_MIZYE	8.4e-189	665.6	96.15%	71.23%	Nuclear receptor-binding protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN012435.1	sp|A0A210R3W6|A0A210R3W6_MIZYE	5.2e-237	825.9	96.76%	74.35%	Dual specificity protein phosphatase CDC14A;OS=Mizuhopecten;PE=4;SV=1	GO:0004725|GO:0008138|
GN012436.1	sp|A0A210PQ26|A0A210PQ26_MIZYE	1.7e-72	278.1	96.98%	58.04%	Thioredoxin-like protein AAED1;OS=Mizuhopecten;PE=4;SV=1	GO:0055114|
GN012437.1	sp|K1RC51|K1RC51_CRAGI	4.6e-112	409.5	94.55%	94.69%	Serine/threonine-protein kinase PLK1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN012438.1	sp|A0A1X7V777|A0A1X7V777_AMPQE	2.8e-10	70.5	95.83%	34.75%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN010944.1	sp|K1RC89|K1RC89_CRAGI	3.0e-41	174.1	90.55%	80.11%	DNA-directed RNA polymerase III subunit RPC4;OS=Crassostrea;PE=4;SV=1	GO:0005666|	GO:0003677|GO:0003899|	GO:0006383|
GN012440.1	sp|A0A210PIJ7|A0A210PIJ7_MIZYE	1.6e-266	924.1	99.20%	76.01%	Transmembrane 9 superfamily member;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN012441.1	sp|A0A210PQ40|A0A210PQ40_MIZYE	7.6e-283	978.4	100.00%	71.73%	Serine/threonine-protein kinase PLK;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004674|
GN012442.1	sp|A0A210PIJ9|A0A210PIJ9_MIZYE	2.5e-34	151.8	64.69%	48.11%	Vacuolar protein sorting-associated protein 72-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043486|GO:0006355|
GN012443.1	sp|K1P0H4|K1P0H4_CRAGI	4.6e-41	172.9	81.16%	73.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012444.1	sp|K1QS14|K1QS14_CRAGI	4.8e-173	612.8	100.00%	84.25%	Neuromedin-U receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008528|
GN012445.1	sp|K1RZ99|K1RZ99_CRAGI	0.0e+00	1656.3	100.00%	94.58%	Filamin-A;OS=Crassostrea;PE=4;SV=1
GN012447.1	sp|K1RFY1|K1RFY1_CRAGI	1.4e-82	311.2	100.00%	81.08%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN012448.1	sp|K1RFY1|K1RFY1_CRAGI	1.1e-248	864.8	96.42%	79.15%	Chloride channel protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005247|
GN012449.1	sp|K1R9H8|K1R9H8_CRAGI	0.0e+00	1170.6	100.00%	82.92%	DNA-directed RNA polymerase III subunit RPC5;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003899|	GO:0006351|
GN012450.1	sp|K1Q5B1|K1Q5B1_CRAGI	1.7e-146	524.6	100.00%	67.84%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012451.1	sp|K1QSA3|K1QSA3_CRAGI	7.4e-98	362.5	92.89%	76.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016021|	GO:0015035|	GO:0045454|GO:0006662|
GN012452.1	sp|A0A210QQ69|A0A210QQ69_MIZYE	1.4e-70	272.7	80.62%	42.15%	Testis-expressed sequence 33 protein;OS=Mizuhopecten;PE=4;SV=1
GN012453.1	sp|K1QSA3|K1QSA3_CRAGI	2.5e-35	154.1	56.69%	82.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016021|	GO:0015035|	GO:0045454|GO:0006662|
GN012454.1	sp|K1QKZ8|K1QKZ8_CRAGI	0.0e+00	1102.0	97.76%	91.79%	Kinesin-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN012455.1	sp|K1Q5A1|K1Q5A1_CRAGI	1.0e-62	246.5	37.85%	66.46%	Serine/threonine-protein kinase Nek4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004713|
GN012457.1	sp|K1QS99|K1QS99_CRAGI	9.0e-249	864.8	100.00%	83.47%	Neuroligin-4, X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN012458.1	sp|K1Q7Y6|K1Q7Y6_CRAGI	0.0e+00	1177.9	100.00%	94.01%	Heat shock protein 70 B2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012459.1	sp|K1Q7Y6|K1Q7Y6_CRAGI	0.0e+00	1176.8	100.00%	93.85%	Heat shock protein 70 B2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012460.1	sp|K1Q7Y6|K1Q7Y6_CRAGI	0.0e+00	1178.7	100.00%	94.01%	Heat shock protein 70 B2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN012461.1	sp|K1QKZ3|K1QKZ3_CRAGI	6.0e-65	252.3	100.00%	86.33%	Heat shock protein beta-11;OS=Crassostrea;PE=4;SV=1	GO:0005929|GO:0030992|	GO:0042073|
GN012463.1	sp|A0A210R5J4|A0A210R5J4_MIZYE	2.3e-54	218.0	46.64%	85.59%	Zinc finger Ran-binding domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN010800.1	sp|A0A0L8ICQ2|A0A0L8ICQ2_OCTBM	2.2e-11	74.3	62.86%	45.98%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005634|	GO:0006915|
GN010946.1	sp|K1PYY8|K1PYY8_CRAGI	1.6e-77	295.8	56.55%	52.57%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN012464.1	sp|C7ENG9|C7ENG9_ACRMI	3.2e-11	74.3	52.79%	36.19%	Transposase;OS=Acropora;PE=4;SV=1
GN012467.1	sp|R7V5U4|R7V5U4_CAPTE	1.3e-21	109.8	46.58%	35.36%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN010947.1	sp|K1R620|K1R620_CRAGI	3.0e-26	123.6	98.47%	49.61%	Rhodopsin, G0-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012468.1	sp|K1RAD5|K1RAD5_CRAGI	0.0e+00	1115.5	100.00%	84.39%	Eukaryotic elongation factor 2 kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0005509|GO:0005516|GO:0004686|GO:0003746|
GN012469.1	sp|B3XZN5|B3XZN5_9BIVA	1.1e-122	445.3	100.00%	68.71%	Actin-related protein 2/3 complex subunit;OS=Saccostrea;PE=2;SV=1	GO:0005885|GO:0005737|	GO:0003779|	GO:0034314|
GN012470.1	sp|K1QUP8|K1QUP8_CRAGI	8.3e-91	339.0	84.03%	83.42%	Canopy-like protein 3;OS=Crassostrea;PE=4;SV=1
GN012471.1	sp|K1RZX4|K1RZX4_CRAGI	0.0e+00	1290.0	99.78%	76.25%	Testis-expressed sequence 2 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008289|	GO:0006869|
GN012473.1	sp|K1RGL5|K1RGL5_CRAGI	0.0e+00	1402.5	93.76%	90.20%	Serine/threonine-protein kinase/endoribonuclease ire-1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|GO:0004540|	GO:0006397|
GN012474.1	sp|K1RAB1|K1RAB1_CRAGI	7.9e-142	508.8	89.32%	90.91%	Histone-lysine N-methyltransferase, H3 lysine-9 specific 5;OS=Crassostrea;PE=4;SV=1	GO:0008168|	GO:0035556|
GN012475.1	sp|O61565|O61565_CRAGI	0.0e+00	1165.2	100.00%	75.66%	I-kappa-B kinase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004672|
GN012476.1	sp|K1QZ46|K1QZ46_CRAGI	0.0e+00	1262.3	100.00%	84.11%	Inhibitor of nuclear factor kappa-B kinase subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN012477.1	sp|K1PYT6|K1PYT6_CRAGI	2.8e-165	587.0	97.65%	76.27%	Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016263|	GO:0016266|
GN012478.1	sp|K1RGP6|K1RGP6_CRAGI	6.9e-200	702.2	99.54%	76.71%	Kelch-like protein 6;OS=Crassostrea;PE=4;SV=1
GN012479.1	sp|C3S7J2|C3S7J2_CRAGI	7.5e-70	269.2	100.00%	92.31%	Charged multivesicular body protein 5;OS=Crassostrea;PE=2;SV=1	GO:0007034|
GN012480.1	sp|K1QUT5|K1QUT5_CRAGI	2.1e-109	400.6	94.06%	96.10%	Amine oxidase;OS=Crassostrea;PE=3;SV=1	GO:0016491|GO:0016740|
GN012481.1	sp|K1RAE8|K1RAE8_CRAGI	2.9e-36	157.1	66.45%	78.00%	Acyl carrier protein;OS=Crassostrea;PE=3;SV=1	GO:0006633|
GN012482.1	sp|K1R4D5|K1R4D5_CRAGI	1.0e-278	965.3	95.41%	59.82%	Serine/threonine-protein kinase LMTK1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN012483.1	sp|K1QND6|K1QND6_CRAGI	0.0e+00	1303.1	84.81%	80.09%	Ubiquitin carboxyl-terminal hydrolase 36;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN010948.1	sp|K1QKU3|K1QKU3_CRAGI	1.9e-48	198.0	86.67%	56.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN012484.1	sp|K1RUL0|K1RUL0_CRAGI	2.1e-23	114.4	46.05%	76.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012486.1	sp|K1R4D2|K1R4D2_CRAGI	0.0e+00	3250.3	83.73%	73.42%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012487.1	sp|K1QXF7|K1QXF7_CRAGI	0.0e+00	1174.1	100.00%	74.22%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012488.1	sp|K1QXF7|K1QXF7_CRAGI	0.0e+00	1335.1	42.70%	84.66%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012490.1	sp|K1RUK6|K1RUK6_CRAGI	5.1e-59	232.6	97.92%	80.00%	Calcium-regulated heat stable protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010949.1	sp|K1QKU3|K1QKU3_CRAGI	9.6e-58	228.8	91.53%	62.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN012491.1	sp|K1RG57|K1RG57_CRAGI	9.5e-62	243.4	98.11%	36.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012492.1	sp|K1RMC0|K1RMC0_CRAGI	1.4e-250	870.5	100.00%	94.70%	Histone deacetylase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0046872|GO:0032041|
GN012493.1	sp|A0A210QF72|A0A210QF72_MIZYE	8.1e-84	316.2	62.16%	71.83%	Superoxide dismutase [Cu-Zn];OS=Mizuhopecten;PE=4;SV=1	GO:0046872|GO:0004784|
GN012495.1	sp|K1RG52|K1RG52_CRAGI	2.8e-168	596.7	100.00%	96.32%	Glycine dehydrogenase [decarboxylating], mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0004375|GO:0016829|	GO:0006546|
GN012496.1	sp|K1RG52|K1RG52_CRAGI	9.0e-265	917.9	99.80%	68.70%	Glycine dehydrogenase [decarboxylating], mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0004375|GO:0016829|	GO:0006546|
GN010950.1	sp|K1QE93|K1QE93_CRAGI	2.0e-89	334.3	93.22%	68.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012497.1	sp|A0A210PQ25|A0A210PQ25_MIZYE	1.2e-15	89.4	29.07%	57.65%	Superoxide dismutase [Cu-Zn];OS=Mizuhopecten;PE=4;SV=1	GO:0046872|GO:0004784|
GN012498.1	sp|A0A210PQ33|A0A210PQ33_MIZYE	2.5e-204	716.8	100.00%	86.57%	Sialin;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN012499.1	sp|A0A210QH80|A0A210QH80_MIZYE	7.8e-88	330.5	93.77%	42.60%	Crossover junction endonuclease EME1;OS=Mizuhopecten;PE=4;SV=1	GO:0048476|GO:0005634|	GO:0003677|GO:0004519|	GO:0006281|
GN012500.1	sp|A0A0L8GF04|A0A0L8GF04_OCTBM	7.5e-26	122.5	82.19%	50.42%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN012501.1	sp|K1QWE2|K1QWE2_CRAGI	2.8e-57	226.9	100.00%	72.92%	28S ribosomal protein S7, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0006412|
GN012502.1	sp|K1S1P1|K1S1P1_CRAGI	3.9e-89	333.2	90.73%	85.95%	Leucine-rich repeat-containing protein 14;OS=Crassostrea;PE=4;SV=1
GN012503.1	sp|K1RC25|K1RC25_CRAGI	0.0e+00	2244.2	100.00%	63.95%	BAH and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003682|	GO:0030154|
GN012504.1	sp|K1R617|K1R617_CRAGI	0.0e+00	1443.3	98.30%	83.93%	Kinesin-like protein KIF19;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN012504.1	sp|K1R617|K1R617_CRAGI	1.0e-22	114.8	6.39%	89.83%	Kinesin-like protein KIF19;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN012505.1	sp|A0A210PH24|A0A210PH24_MIZYE	6.8e-22	110.9	100.00%	29.85%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012506.1	sp|K1QWD9|K1QWD9_CRAGI	2.1e-275	954.9	95.71%	60.35%	Retinoblastoma-binding protein 6;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0061630|GO:0008270|	GO:0006397|
GN012508.1	sp|K1S1N8|K1S1N8_CRAGI	0.0e+00	1310.0	89.21%	76.28%	Coiled-coil and C2 domain-containing protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0001227|
GN012509.1	sp|A0A1S3JS61|A0A1S3JS61_LINUN	1.6e-24	118.6	56.07%	43.31%	uncharacterized protein LOC106175667;OS=Lingula;PE=4;SV=1
GN012510.1	sp|K1PQD2|K1PQD2_CRAGI	6.4e-207	725.7	92.95%	81.64%	Major facilitator superfamily domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN012511.1	sp|K1PAZ8|K1PAZ8_CRAGI	1.7e-81	308.1	68.50%	89.02%	Phosphoglucomutase;OS=Crassostrea;PE=4;SV=1	GO:0016868|GO:0000287|	GO:0005975|
GN012514.1	sp|K1Q1M0|K1Q1M0_CRAGI	6.9e-97	360.1	94.88%	38.49%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN012515.1	sp|K1QAS7|K1QAS7_CRAGI	3.7e-274	949.9	79.83%	71.30%	Glutamate receptor, ionotropic kainate 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN012516.1	sp|K1PQD5|K1PQD5_CRAGI	1.3e-264	917.5	99.25%	94.69%	Mitogen-activated protein kinase kinase kinase 7-interacting protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0004722|
GN012517.1	sp|K1PB00|K1PB00_CRAGI	3.2e-80	305.1	76.80%	70.02%	Calcium homeostasis endoplasmic reticulum protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0003676|	GO:0006874|
GN012518.1	sp|K1RWJ1|K1RWJ1_CRAGI	2.5e-09	67.4	58.14%	48.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010951.1	sp|K1QS52|K1QS52_CRAGI	1.2e-174	619.4	89.85%	43.86%	Unc-84-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0005639|GO:0034993|
GN012519.1	sp|A0A2B4R8K9|A0A2B4R8K9_STYPI	6.4e-12	76.6	55.78%	32.73%	Uncharacterized protein F54H12.2;OS=Stylophora;PE=4;SV=1	GO:0003676|	GO:0015074|GO:0055114|
GN012520.1	sp|K1QH16|K1QH16_CRAGI	4.7e-159	566.6	65.58%	90.73%	F-box/LRR-repeat protein 16;OS=Crassostrea;PE=4;SV=1
GN012521.1	sp|K1PX08|K1PX08_CRAGI	1.7e-51	208.0	76.88%	69.01%	Transmembrane protein 11;OS=Crassostrea;PE=4;SV=1	GO:0031305|	GO:0007005|
GN012522.1	sp|A0A2P6KQB9|A0A2P6KQB9_NEPCL	2.5e-58	231.1	87.85%	54.17%	Dehydrogenase/reductase SDR family protein 7-like;OS=Nephila;PE=3;SV=1	GO:0016021|
GN012523.1	sp|K1PH84|K1PH84_CRAGI	1.0e-251	874.8	74.19%	94.27%	Ubiquitinyl hydrolase 1;OS=Crassostrea;PE=3;SV=1	GO:0036459|GO:0008270|	GO:0016579|GO:0006511|
GN012524.1	sp|K1PLN2|K1PLN2_CRAGI	0.0e+00	1556.2	72.26%	90.33%	WD repeat-containing protein 49;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012525.1	sp|K1S2J7|K1S2J7_CRAGI	0.0e+00	1278.8	100.00%	72.41%	Glutamine-rich protein 2;OS=Crassostrea;PE=4;SV=1
GN010801.1	sp|K1QJN2|K1QJN2_CRAGI	3.7e-55	220.7	52.42%	79.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN012526.1	sp|A0A210QQ94|A0A210QQ94_MIZYE	3.4e-150	538.1	96.64%	36.79%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN012527.1	sp|A0A2R3ZQC1|A0A2R3ZQC1_HYRCU	2.2e-37	162.2	97.56%	30.00%	Toll5;OS=Hyriopsis;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN012528.1	sp|K1Q8G4|K1Q8G4_CRAGI	2.8e-50	203.8	98.15%	56.79%	Toll-like receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN012529.1	sp|K1QN93|K1QN93_CRAGI	5.8e-27	125.9	76.19%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012536.1	sp|K1Q1B2|K1Q1B2_CRAGI	1.6e-57	229.6	99.82%	35.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010954.1	sp|K1Q545|K1Q545_CRAGI	3.8e-38	164.9	21.10%	85.06%	Splicing factor, arginine/serine-rich 7;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN012537.1	sp|K1Q8D4|K1Q8D4_CRAGI	1.5e-235	820.8	100.00%	75.90%	Fringe glycosyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0016757|GO:0008270|	GO:0042981|
GN012539.1	sp|A0A131Y4N2|A0A131Y4N2_IXORI	1.8e-25	121.7	92.54%	39.58%	Putative tick transposon;OS=Ixodes;PE=2;SV=1	GO:0003676|	GO:0015074|
GN012540.1	sp|A7SKZ0|A7SKZ0_NEMVE	2.6e-17	93.6	86.27%	44.83%	ATP-dependent DNA helicase;OS=Nematostella;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN012541.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN010955.1	sp|K1QCM0|K1QCM0_CRAGI	7.2e-96	355.5	100.00%	87.38%	Rho GDP-dissociation inhibitor 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005094|
GN012542.1	sp|A0A2C9JN85|A0A2C9JN85_BIOGL	9.1e-28	129.0	97.59%	43.56%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005509|
GN012543.1	sp|A0A210QAI3|A0A210QAI3_MIZYE	4.3e-280	969.1	100.00%	77.24%	Heat shock protein 70 B2;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|
GN012544.1	sp|A0A210QAE9|A0A210QAE9_MIZYE	2.8e-40	172.2	34.35%	49.40%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN012545.1	sp|A0A210QAI3|A0A210QAI3_MIZYE	4.3e-280	969.1	100.00%	77.24%	Heat shock protein 70 B2;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|
GN012546.1	sp|K1REX3|K1REX3_CRAGI	1.9e-39	167.9	53.30%	81.25%	Uncharacterized protein CXorf41;OS=Crassostrea;PE=4;SV=1
GN012547.1	sp|A0A210QNI9|A0A210QNI9_MIZYE	1.0e-12	79.0	90.63%	40.69%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003700|
GN012548.1	sp|A0A1D8GZE2|A0A1D8GZE2_PINFU	3.0e-133	480.7	98.76%	60.58%	BMP10;OS=Pinctada;PE=2;SV=1	GO:0005576|	GO:0008083|
GN012549.1	sp|C3YWQ8|C3YWQ8_BRAFL	1.5e-49	202.6	95.16%	34.34%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN012550.1	sp|K1Q2P2|K1Q2P2_CRAGI	1.5e-155	554.3	100.00%	91.78%	Defective in cullin neddylation protein;OS=Crassostrea;PE=4;SV=1
GN010956.1	sp|K1QKS3|K1QKS3_CRAGI	2.5e-195	687.2	91.74%	74.45%	NADPH:adrenodoxin oxidoreductase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0015039|
GN012551.1	sp|A0A210QA63|A0A210QA63_MIZYE	0.0e+00	1670.6	98.99%	55.16%	Helicase with zinc finger domain;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|GO:0046872|GO:0003676|
GN012552.1	sp|K1QHB3|K1QHB3_CRAGI	6.7e-40	169.9	94.61%	42.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012553.1	sp|K1RF80|K1RF80_CRAGI	2.0e-35	156.0	71.31%	28.77%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN012554.1	sp|K1PV30|K1PV30_CRAGI	2.9e-122	443.7	83.22%	97.11%	Homeobox protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0007275|
GN012555.1	sp|K1R2Z0|K1R2Z0_CRAGI	2.7e-307	1059.7	99.58%	73.14%	Tripartite motif-containing protein 47;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012557.1	sp|K1RRD7|K1RRD7_CRAGI	8.1e-80	302.8	64.26%	70.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012558.1	sp|A0A0U2Q0U2|A0A0U2Q0U2_CRAGI	6.3e-156	555.8	98.55%	76.68%	Viperin;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0003824|GO:0051536|
GN012559.1	sp|K1PU07|K1PU07_CRAGI	3.6e-207	726.5	80.65%	93.58%	Glutaryl-CoA dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003995|GO:0050660|
GN012560.1	sp|K1QFR5|K1QFR5_CRAGI	5.0e-35	152.5	99.07%	72.64%	Solute carrier organic anion transporter family member;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN010957.1	sp|K1RC94|K1RC94_CRAGI	1.3e-298	1031.2	100.00%	70.51%	Storkhead-box protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006357|
GN012561.1	sp|K1R2J0|K1R2J0_CRAGI	5.2e-47	195.3	48.13%	29.09%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN012562.1	sp|K1QFV0|K1QFV0_CRAGI	1.6e-81	308.9	89.47%	41.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012564.1	sp|K1QQS0|K1QQS0_CRAGI	1.9e-13	81.3	76.92%	50.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012566.1	sp|A0A210QVG8|A0A210QVG8_MIZYE	2.1e-76	291.6	98.49%	45.92%	NudC domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1
GN012567.1	sp|K1RC42|K1RC42_CRAGI	4.1e-26	122.5	98.75%	64.10%	Plasminogen;OS=Crassostrea;PE=4;SV=1
GN012568.1	sp|K1QK14|K1QK14_CRAGI	1.2e-177	628.2	100.00%	74.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012569.1	sp|K1R971|K1R971_CRAGI	2.0e-166	590.9	92.84%	76.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012570.1	sp|K1R2E4|K1R2E4_CRAGI	5.8e-310	1068.9	100.00%	61.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012571.1	sp|K1QLJ3|K1QLJ3_CRAGI	5.0e-50	203.0	93.98%	71.34%	Tenascin-X;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN012572.1	sp|A0A210QK51|A0A210QK51_MIZYE	8.8e-109	399.8	93.41%	43.48%	XK-related protein;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN012573.1	sp|K1QLJ3|K1QLJ3_CRAGI	1.7e-177	629.0	95.70%	67.19%	Tenascin-X;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN012574.1	sp|K1RSZ8|K1RSZ8_CRAGI	0.0e+00	1137.5	98.92%	89.84%	Choline transporter-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN012575.1	sp|K1R969|K1R969_CRAGI	6.0e-200	702.2	100.00%	91.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012576.1	sp|K1R2E0|K1R2E0_CRAGI	1.4e-174	618.2	95.27%	70.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012577.1	sp|K1RH39|K1RH39_CRAGI	0.0e+00	1211.4	98.88%	67.04%	TBC1 domain family member 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012578.1	sp|K1RAV2|K1RAV2_CRAGI	5.9e-109	399.4	98.15%	72.35%	UPF0600 protein C5orf51-like protein;OS=Crassostrea;PE=4;SV=1
GN012579.1	sp|K1R4T7|K1R4T7_CRAGI	9.9e-265	917.9	100.00%	82.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012580.1	sp|K1QQD1|K1QQD1_CRAGI	0.0e+00	1816.6	99.33%	72.52%	Heparan-alpha-glucosaminide N-acetyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN012584.1	sp|K1PX93|K1PX93_CRAGI	1.9e-190	671.0	86.13%	80.96%	Putative ZDHHC-type palmitoyltransferase 6;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN012585.1	sp|K1PPZ4|K1PPZ4_CRAGI	4.6e-121	440.3	96.14%	59.60%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|GO:0009881|	GO:0007602|GO:0018298|GO:0007601|
GN012586.1	sp|K1PI76|K1PI76_CRAGI	4.3e-223	779.6	96.44%	65.75%	Neurotrypsin;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0005044|GO:0004252|
GN010802.1	sp|K1PM99|K1PM99_CRAGI	2.5e-51	208.8	76.87%	35.33%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN012587.1	sp|K1QQC8|K1QQC8_CRAGI	1.7e-276	957.6	79.37%	66.15%	Tolloid-like protein 2;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN012588.1	sp|K1R5J5|K1R5J5_CRAGI	2.3e-71	273.9	89.41%	88.08%	Nucleolar protein 4;OS=Crassostrea;PE=4;SV=1
GN012590.1	sp|K1PY88|K1PY88_CRAGI	1.6e-302	1043.9	97.75%	75.79%	Protein THEMIS;OS=Crassostrea;PE=4;SV=1
GN012592.1	sp|K1Q5N2|K1Q5N2_CRAGI	1.1e-59	235.0	100.00%	73.83%	Protein rolling stone;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012593.1	sp|K1QDQ9|K1QDQ9_CRAGI	1.1e-49	201.8	76.19%	89.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012594.1	sp|K1QK17|K1QK17_CRAGI	3.3e-72	276.9	100.00%	72.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012595.1	sp|K1Q5N4|K1Q5N4_CRAGI	1.1e-247	861.7	93.75%	90.22%	Hook-like protein 3;OS=Crassostrea;PE=4;SV=1
GN012596.1	sp|K1QDR4|K1QDR4_CRAGI	1.6e-124	451.1	98.04%	87.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0061630|
GN010961.1	sp|K1P6X3|K1P6X3_CRAGI	2.2e-40	172.2	62.37%	39.02%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005001|
GN012598.1	sp|K1Q5N8|K1Q5N8_CRAGI	0.0e+00	2051.6	97.87%	64.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030374|GO:0004540|GO:0003723|
GN012599.1	sp|K1Q5N8|K1Q5N8_CRAGI	0.0e+00	1769.6	87.60%	52.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030374|GO:0004540|GO:0003723|
GN012600.1	sp|A0A210QEW8|A0A210QEW8_MIZYE	0.0e+00	1527.3	97.38%	41.97%	Helicase with zinc finger domain 2;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|GO:0030374|GO:0004540|GO:0003723|
GN012601.1	sp|A0A210QEW8|A0A210QEW8_MIZYE	0.0e+00	1558.9	97.30%	41.83%	Helicase with zinc finger domain 2;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|GO:0030374|GO:0004540|GO:0003723|
GN012602.1	sp|A0A210QEW8|A0A210QEW8_MIZYE	0.0e+00	1328.9	82.17%	43.68%	Helicase with zinc finger domain 2;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|GO:0030374|GO:0004540|GO:0003723|
GN010962.1	sp|K1PSH4|K1PSH4_CRAGI	1.2e-114	420.2	29.20%	70.53%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN012603.1	sp|A0A210PPZ5|A0A210PPZ5_MIZYE	4.6e-18	95.1	100.00%	73.08%	Intraflagellar transport protein 172;OS=Mizuhopecten;PE=4;SV=1	GO:0031514|
GN012604.1	sp|K1R5K5|K1R5K5_CRAGI	3.3e-60	237.7	53.77%	69.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030374|
GN012605.1	sp|A0A210QEW8|A0A210QEW8_MIZYE	0.0e+00	1264.6	98.62%	42.33%	Helicase with zinc finger domain 2;OS=Mizuhopecten;PE=4;SV=1	GO:0004386|GO:0030374|GO:0004540|GO:0003723|
GN012606.1	sp|K1R8D4|K1R8D4_CRAGI	4.6e-254	882.5	99.44%	86.73%	Uridine kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004849|	GO:0044211|GO:0009116|GO:0044206|
GN012607.1	sp|K1S3M7|K1S3M7_CRAGI	8.8e-169	598.6	99.72%	80.61%	Heparan sulfate glucosamine 3-O-sulfotransferase 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008146|
GN012608.1	sp|K1RK68|K1RK68_CRAGI	0.0e+00	2395.2	96.14%	81.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005643|	GO:0017056|
GN012609.1	sp|K1S3L6|K1S3L6_CRAGI	1.0e-108	400.6	39.35%	55.74%	Trimethylguanosine synthase;OS=Crassostrea;PE=4;SV=1	GO:0008168|	GO:0009452|GO:0001510|
GN012610.1	sp|K1R8B8|K1R8B8_CRAGI	3.3e-74	283.1	100.00%	93.06%	Profilin;OS=Crassostrea;PE=3;SV=1	GO:0003779|
GN012611.1	sp|K1QZP7|K1QZP7_CRAGI	3.4e-09	66.6	63.73%	56.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012613.1	sp|A0A210PHV3|A0A210PHV3_MIZYE	5.7e-41	172.2	79.21%	100.00%	U6 snRNA-associated Sm-like protein LSm4;OS=Mizuhopecten;PE=3;SV=1	GO:0005681|	GO:0003723|	GO:0000398|GO:0000956|
GN010964.1	sp|K1PSH4|K1PSH4_CRAGI	2.4e-81	308.9	43.91%	53.62%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN012614.1	sp|K1RK73|K1RK73_CRAGI	8.1e-62	242.3	100.00%	67.55%	Calcyphosin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012615.1	sp|K1PT97|K1PT97_CRAGI	3.5e-20	103.6	74.83%	51.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012616.1	sp|K1S3M0|K1S3M0_CRAGI	0.0e+00	1523.5	100.00%	88.37%	Tubulin polyglutamylase TTLL7;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0006464|
GN012617.1	sp|K1QYG5|K1QYG5_CRAGI	4.5e-214	749.6	100.00%	78.52%	XK-related protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN012618.1	sp|K1R8C6|K1R8C6_CRAGI	1.1e-71	274.6	100.00%	97.08%	40S ribosomal protein S12;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN012619.1	sp|K1RK80|K1RK80_CRAGI	1.7e-158	564.3	100.00%	81.96%	Heparan sulfate glucosamine 3-O-sulfotransferase 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008146|
GN012620.1	sp|K1QYF9|K1QYF9_CRAGI	2.3e-65	253.8	91.56%	85.71%	Protein aveugle;OS=Crassostrea;PE=4;SV=1
GN012621.1	sp|K1R8B8|K1R8B8_CRAGI	3.3e-74	283.1	100.00%	93.06%	Profilin;OS=Crassostrea;PE=3;SV=1	GO:0003779|
GN012622.1	sp|K1PAQ8|K1PAQ8_CRAGI	3.0e-30	137.9	67.05%	41.53%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN012623.1	sp|A0A1Y1KDD6|A0A1Y1KDD6_PHOPY	4.6e-42	177.2	83.33%	37.90%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN012625.1	sp|K1RK73|K1RK73_CRAGI	8.1e-62	242.3	100.00%	67.55%	Calcyphosin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012629.1	sp|C8BLQ6|C8BLQ6_9BIVA	1.9e-14	84.3	57.60%	49.30%	Low-density lipoprotein receptor;OS=Crassostrea;PE=2;SV=1
GN012630.1	sp|K1PTP4|K1PTP4_CRAGI	2.1e-94	351.3	95.24%	72.91%	Dorsal root ganglia homeobox protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN012631.1	sp|K1PTP4|K1PTP4_CRAGI	1.5e-95	355.1	95.24%	67.56%	Dorsal root ganglia homeobox protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN012633.1	sp|R4LAY2|R4LAY2_9BIVA	1.6e-141	507.7	100.00%	88.19%	DMC1/LIM15-like protein;OS=Nodipecten;PE=2;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0008094|GO:0000150|	GO:0006281|GO:0007131|
GN012634.1	sp|D1M848|D1M848_CHRTR	1.3e-32	144.1	100.00%	87.34%	Non-histone chromosome protein 2;OS=Chrysomela;PE=2;SV=1	GO:0005730|GO:1990904|	GO:0003723|	GO:0042254|
GN012635.1	sp|A0A210R4M0|A0A210R4M0_MIZYE	1.1e-267	928.3	100.00%	59.20%	Sodium/calcium exchanger 3;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005432|	GO:0007154|
GN012636.1	sp|K1R516|K1R516_CRAGI	0.0e+00	1427.5	100.00%	86.92%	Sodium/calcium exchanger 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005432|	GO:0007154|
GN010966.1	sp|K1QG06|K1QG06_CRAGI	3.1e-89	333.2	99.38%	95.00%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|	GO:0006457|
GN012637.1	sp|V3ZX17|V3ZX17_LOTGI	4.4e-97	360.1	84.39%	64.82%	Rhomboid-like protein;OS=Lottia;PE=3;SV=1	GO:0016021|	GO:0004252|
GN012638.1	sp|K1QJ81|K1QJ81_CRAGI	3.4e-70	270.0	98.84%	77.91%	Uncharacterized protein C16orf89-like protein;OS=Crassostrea;PE=4;SV=1
GN012639.1	sp|K1QD81|K1QD81_CRAGI	0.0e+00	1622.8	100.00%	79.42%	Ubiquitin conjugation factor E4 A;OS=Crassostrea;PE=4;SV=1	GO:0000151|	GO:0034450|	GO:0006511|
GN012640.1	sp|A0A1S3ILI3|A0A1S3ILI3_LINUN	2.5e-40	171.0	92.93%	43.69%	HAUS augmin-like complex subunit 2;OS=Lingula;PE=4;SV=1	GO:0070652|	GO:0007098|GO:0051225|
GN012641.1	sp|A0A2C9JG55|A0A2C9JG55_BIOGL	0.0e+00	1489.9	100.00%	72.12%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0051015|	GO:0030036|GO:0051014|
GN012642.1	sp|K1PJ96|K1PJ96_CRAGI	0.0e+00	3235.7	100.00%	90.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN012643.1	sp|K1PCZ5|K1PCZ5_CRAGI	5.9e-76	288.9	100.00%	94.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012644.1	sp|K1PIR3|K1PIR3_CRAGI	5.4e-76	291.2	53.70%	48.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012646.1	sp|A0A191Z434|A0A191Z434_PINFU	1.9e-163	581.3	98.71%	65.21%	Bone morphogenetic protein 3;OS=Pinctada;PE=2;SV=1	GO:0005576|	GO:0008083|
GN010967.1	sp|A0A210PRF0|A0A210PRF0_MIZYE	0.0e+00	2127.1	100.00%	63.68%	Glycogen debranching enzyme;OS=Mizuhopecten;PE=4;SV=1	GO:0004134|GO:0004135|	GO:0005978|GO:0005980|
GN012647.1	sp|K1PTQ1|K1PTQ1_CRAGI	9.3e-127	458.4	100.00%	99.15%	Uncharacterized protein C4orf22-like protein;OS=Crassostrea;PE=4;SV=1
GN012648.1	sp|A0A210R4T5|A0A210R4T5_MIZYE	1.3e-253	881.3	98.98%	62.68%	Long-chain-fatty-acid--CoA ligase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016874|
GN012649.1	sp|A0A210PV52|A0A210PV52_MIZYE	3.6e-95	354.8	32.25%	91.49%	Epsin-2;OS=Mizuhopecten;PE=4;SV=1
GN012650.1	sp|K1PZV0|K1PZV0_CRAGI	6.2e-146	523.1	63.52%	87.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012651.1	sp|K1Q7F8|K1Q7F8_CRAGI	9.7e-26	122.9	80.16%	42.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012652.1	sp|K1PK06|K1PK06_CRAGI	1.1e-16	92.8	52.87%	40.31%	Myb-related transcription factor, partner of profilin;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN012653.1	sp|K1QEJ0|K1QEJ0_CRAGI	1.0e-145	522.3	89.17%	93.32%	Ras GTPase-activating protein-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0034063|
GN010968.1	sp|A0A210QAH6|A0A210QAH6_MIZYE	2.1e-35	154.1	96.27%	60.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012655.1	sp|K1QEJ0|K1QEJ0_CRAGI	8.8e-101	372.9	87.44%	87.85%	Ras GTPase-activating protein-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0034063|
GN012656.1	sp|A0A1S3KBR4|A0A1S3KBR4_LINUN	2.1e-37	161.8	84.53%	39.60%	uncharacterized protein LOC106180601;OS=Lingula;PE=4;SV=1
GN012657.1	sp|K1P442|K1P442_CRAGI	1.8e-156	558.1	97.22%	58.57%	Cytochrome P450 4d2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0016705|
GN012658.1	sp|K1PNI5|K1PNI5_CRAGI	2.4e-137	494.6	90.36%	71.16%	Putative ankyrin repeat protein L93;OS=Crassostrea;PE=4;SV=1
GN012659.1	sp|K1PVW5|K1PVW5_CRAGI	3.2e-164	583.6	99.75%	69.37%	Forkhead box protein E1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN012660.1	sp|K1RKD6|K1RKD6_CRAGI	1.6e-103	380.9	100.00%	91.13%	ADP-ribosylation factor-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN012661.1	sp|A0A210R077|A0A210R077_MIZYE	3.0e-62	243.4	100.00%	76.16%	Diphosphoinositol polyphosphate phosphohydrolase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016787|
GN010969.1	sp|K1QGX2|K1QGX2_CRAGI	3.4e-54	218.0	70.57%	79.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN012662.1	sp|A0A210Q9B3|A0A210Q9B3_MIZYE	9.8e-14	82.0	81.10%	44.12%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012663.1	sp|K1RE30|K1RE30_CRAGI	7.6e-168	595.5	86.18%	95.58%	Minor histocompatibility antigen H13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004190|
GN012664.1	sp|K1QWV5|K1QWV5_CRAGI	2.7e-178	630.6	100.00%	75.05%	Putative metal tolerance protein C3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN012667.1	sp|A0A210QM29|A0A210QM29_MIZYE	4.8e-104	382.9	99.56%	81.70%	Ras-related protein Rab-26;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|GO:0003924|
GN012668.1	sp|K1PFR1|K1PFR1_CRAGI	1.7e-272	943.7	100.00%	85.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0051539|GO:0016740|	GO:0006400|
GN012669.1	sp|J9M9Z7|J9M9Z7_ACYPI	4.4e-23	113.6	87.03%	37.27%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2
GN010970.1	sp|K1P6L0|K1P6L0_CRAGI	1.6e-110	405.2	69.10%	76.79%	THUMP domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006400|
GN012671.1	sp|K1P9J0|K1P9J0_CRAGI	2.2e-11	74.7	27.07%	79.17%	ATP-dependent RNA helicase DBP2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN012672.1	sp|K1P9J0|K1P9J0_CRAGI	6.5e-111	406.4	83.65%	68.30%	ATP-dependent RNA helicase DBP2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN012673.1	sp|K1PVW0|K1PVW0_CRAGI	7.5e-233	811.6	100.00%	96.59%	S-adenosylmethionine synthase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004478|	GO:0006730|GO:0006556|
GN012674.1	sp|K1PNI0|K1PNI0_CRAGI	1.5e-45	187.6	100.00%	79.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012675.1	sp|K1P9I2|K1P9I2_CRAGI	1.2e-54	219.2	44.19%	81.82%	F-box only protein 37;OS=Crassostrea;PE=4;SV=1
GN012676.1	sp|K1REB6|K1REB6_CRAGI	1.6e-129	468.4	92.38%	64.19%	Beta-1 adrenergic receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010971.1	sp|K1PEH3|K1PEH3_CRAGI	4.0e-149	533.5	98.08%	64.15%	Neuropeptide FF receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN012677.1	sp|K1QS25|K1QS25_CRAGI	3.4e-128	463.4	98.22%	76.73%	TNF receptor-associated factor 6;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012678.1	sp|K1R1G6|K1R1G6_CRAGI	4.5e-218	762.7	100.00%	79.87%	Synaptotagmin-15;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012679.1	sp|K1REB9|K1REB9_CRAGI	1.6e-15	86.7	98.04%	83.67%	TD and POZ domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN012680.1	sp|A0A2T7PVW5|A0A2T7PVW5_POMCA	6.1e-11	72.4	68.32%	48.53%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003908|	GO:0006281|
GN010972.1	sp|K1Q6U2|K1Q6U2_CRAGI	4.7e-143	513.5	69.52%	83.23%	Peroxisomal membrane protein PMP34;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN012682.1	sp|A0A267DCN9|A0A267DCN9_9PLAT	2.3e-23	114.8	73.02%	45.51%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN012683.1	sp|K1QDY1|K1QDY1_CRAGI	5.8e-54	215.7	100.00%	81.40%	UPF0561 protein C2orf68-like protein;OS=Crassostrea;PE=4;SV=1
GN012684.1	sp|K1Q5U2|K1Q5U2_CRAGI	2.8e-287	993.0	100.00%	80.12%	U4/U6.U5 tri-snRNP-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0036459|GO:0008270|	GO:0016579|GO:0000245|
GN012685.1	sp|K1PYF0|K1PYF0_CRAGI	0.0e+00	1765.4	100.00%	90.82%	EF-hand calcium-binding domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012686.1	sp|A0A210QHU1|A0A210QHU1_MIZYE	1.6e-28	132.9	50.00%	36.89%	Vertnin;OS=Mizuhopecten;PE=4;SV=1
GN010973.1	sp|K1QGD6|K1QGD6_CRAGI	1.9e-119	434.9	81.66%	76.99%	Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex;OS=Crassostrea;PE=3;SV=1	GO:0016746|
GN012688.1	sp|W4XHT1|W4XHT1_STRPU	2.1e-46	191.4	94.81%	42.99%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN012689.1	sp|K1Q037|K1Q037_CRAGI	3.5e-123	446.8	92.52%	81.62%	Neuromedin-K receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN012690.1	sp|K1PSQ3|K1PSQ3_CRAGI	1.2e-186	658.3	86.30%	81.19%	Methyltransferase-like protein 14;OS=Crassostrea;PE=3;SV=1	GO:0008168|
GN012691.1	sp|K1R0P0|K1R0P0_CRAGI	3.5e-136	490.0	99.65%	87.28%	Uncharacterized protein C7orf62;OS=Crassostrea;PE=4;SV=1	GO:0009882|GO:0071949|
GN012692.1	sp|A0A210QVH9|A0A210QVH9_MIZYE	2.8e-60	238.0	98.79%	39.78%	G patch domain and ankyrin repeat-containing protein 1-like;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN012695.1	sp|K1P5G4|K1P5G4_CRAGI	1.1e-47	194.9	97.81%	72.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012696.1	sp|K1P324|K1P324_CRAGI	7.6e-97	359.0	98.72%	76.96%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|GO:0009881|	GO:0018298|
GN012697.1	sp|K1PSP8|K1PSP8_CRAGI	1.6e-129	468.0	87.03%	81.39%	Pyroglutamylated RFamide peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN012698.1	sp|A0A210QJQ0|A0A210QJQ0_MIZYE	6.3e-17	93.6	36.55%	47.25%	THAP domain-containing protein 1 A;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN012699.1	sp|J7HDW1|J7HDW1_CRAGI	6.0e-308	1061.6	100.00%	90.85%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN012700.1	sp|K1PTW6|K1PTW6_CRAGI	1.3e-81	308.1	87.18%	91.12%	Armadillo repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN012701.1	sp|K1RZ93|K1RZ93_CRAGI	2.5e-126	458.4	74.65%	51.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012702.1	sp|K1RZ93|K1RZ93_CRAGI	2.9e-112	412.1	33.90%	64.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012703.1	sp|K1R9H3|K1R9H3_CRAGI	4.9e-152	543.9	46.78%	76.80%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 5;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN012704.1	sp|K1R3I1|K1R3I1_CRAGI	3.1e-193	679.9	97.08%	82.74%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN012705.1	sp|A0A210QSX2|A0A210QSX2_MIZYE	2.6e-66	259.2	23.89%	62.71%	E3 ubiquitin-protein ligase PDZRN3;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN012706.1	sp|K1PWN6|K1PWN6_CRAGI	3.0e-135	487.3	92.29%	71.39%	Pyroglutamylated RFamide peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN012707.1	sp|K1PJF5|K1PJF5_CRAGI	0.0e+00	1095.1	99.20%	59.86%	Transmembrane protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012708.1	sp|K1QEX7|K1QEX7_CRAGI	0.0e+00	2179.1	100.00%	82.57%	Limkain-b1;OS=Crassostrea;PE=4;SV=1	GO:0005777|	GO:0003676|	GO:0010468|
GN012709.1	sp|K1P8K1|K1P8K1_CRAGI	1.6e-111	408.3	69.14%	79.25%	Meteorin-like protein;OS=Crassostrea;PE=4;SV=1
GN012711.1	sp|K1PUT4|K1PUT4_CRAGI	1.5e-278	963.8	95.40%	88.73%	Diacylglycerol kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004143|GO:0003951|	GO:0035556|GO:0007205|
GN012712.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	5.8e-20	103.6	96.62%	31.47%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN012713.1	sp|A0A210QWX3|A0A210QWX3_MIZYE	2.8e-24	118.2	91.10%	32.37%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN012715.1	sp|K1Q6E7|K1Q6E7_CRAGI	2.9e-71	273.5	100.00%	81.33%	Glutathione S-transferase P 1;OS=Crassostrea;PE=4;SV=1	GO:0004364|
GN012717.1	sp|A0A131Y5K4|A0A131Y5K4_IXORI	1.8e-11	75.5	30.80%	46.84%	Putative tick transposon;OS=Ixodes;PE=2;SV=1
GN012718.1	sp|K1R7X1|K1R7X1_CRAGI	1.7e-302	1044.3	75.60%	87.40%	Transducin beta-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0032040|	GO:0006364|
GN012719.1	sp|K1R1C1|K1R1C1_CRAGI	6.4e-204	715.7	100.00%	78.38%	PPPDE peptidase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN012720.1	sp|K1QUG2|K1QUG2_CRAGI	2.9e-240	836.6	85.95%	86.17%	tRNA-dihydrouridine synthase 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0050660|GO:0017150|
GN012721.1	sp|K1QKL8|K1QKL8_CRAGI	0.0e+00	1560.0	100.00%	85.93%	V-type proton ATPase subunit a;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0000220|	GO:0015078|	GO:0015991|
GN012722.1	sp|K1RS36|K1RS36_CRAGI	4.8e-263	912.1	96.70%	98.93%	COP9 signalosome complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0008180|	GO:0000338|
GN012723.1	sp|K1PZF5|K1PZF5_CRAGI	4.0e-156	557.0	100.00%	63.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012724.1	sp|K1PSW1|K1PSW1_CRAGI	6.5e-248	862.4	99.86%	71.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012726.1	sp|K1R1J0|K1R1J0_CRAGI	3.1e-108	397.9	96.48%	43.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010804.1	sp|K1RHJ3|K1RHJ3_CRAGI	3.5e-19	101.7	23.86%	57.30%	Multiple epidermal growth factor-like domains 11;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|GO:0005044|
GN010975.1	sp|K1Q130|K1Q130_CRAGI	1.5e-139	503.4	98.12%	38.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012729.1	sp|K1R1I9|K1R1I9_CRAGI	1.0e-67	262.3	99.19%	47.76%	Neuroligin-4, Y-linked;OS=Crassostrea;PE=3;SV=1	GO:0016787|	GO:0007165|
GN012730.1	sp|K1R1I9|K1R1I9_CRAGI	1.4e-220	771.2	97.47%	71.73%	Neuroligin-4, Y-linked;OS=Crassostrea;PE=3;SV=1	GO:0016787|	GO:0007165|
GN012731.1	sp|K1S6R7|K1S6R7_CRAGI	4.6e-77	293.1	79.52%	80.72%	Cysteine-rich secretory protein LCCL domain-containing 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012732.1	sp|K1RNE9|K1RNE9_CRAGI	0.0e+00	1137.5	100.00%	51.62%	Neurogenic locus notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010976.1	sp|K1Q886|K1Q886_CRAGI	1.4e-144	518.1	100.00%	67.82%	Programmed cell death protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0046872|
GN012734.1	sp|K1RH81|K1RH81_CRAGI	6.3e-139	499.2	86.82%	91.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN012735.1	sp|A0A210PTV8|A0A210PTV8_MIZYE	1.7e-120	439.5	87.71%	54.80%	Transcription factor E4F1;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN012736.1	sp|A0A3L8D9X5|A0A3L8D9X5_OOCBI	6.5e-78	295.8	77.72%	88.59%	Uncharacterized protein;OS=Ooceraea;PE=4;SV=1
GN012737.1	sp|A0A210QQ86|A0A210QQ86_MIZYE	2.2e-198	698.0	97.87%	47.88%	RAD50-interacting protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005783|	GO:0048193|
GN012738.1	sp|K1RLT0|K1RLT0_CRAGI	2.6e-116	423.7	100.00%	86.48%	D-erythrulose reductase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN012739.1	sp|K1S595|K1S595_CRAGI	7.7e-117	426.0	89.08%	67.27%	Uncharacterized protein C17orf56-like protein;OS=Crassostrea;PE=4;SV=1
GN010977.1	sp|K1QGE0|K1QGE0_CRAGI	2.7e-101	373.6	100.00%	83.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012740.1	sp|K1QZP0|K1QZP0_CRAGI	2.7e-46	190.7	72.88%	71.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012741.1	sp|K1RA06|K1RA06_CRAGI	5.3e-36	156.8	40.37%	87.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012742.1	sp|K1RFQ6|K1RFQ6_CRAGI	0.0e+00	5860.0	100.00%	76.29%	Putative helicase with zinc finger domain;OS=Crassostrea;PE=4;SV=1	GO:0004386|GO:0046872|GO:0030374|GO:0004540|GO:0003723|
GN012743.1	sp|K1RLT4|K1RLT4_CRAGI	2.4e-242	843.6	84.44%	88.54%	Signal recognition particle subunit SRP68;OS=Crassostrea;PE=3;SV=1	GO:0005786|	GO:0008312|GO:0030942|GO:0005047|	GO:0006614|
GN012744.1	sp|K1P202|K1P202_CRAGI	4.5e-73	279.6	100.00%	80.79%	Tubulin polymerization-promoting protein family member 3;OS=Crassostrea;PE=4;SV=1
GN012745.1	sp|K1QUW5|K1QUW5_CRAGI	5.0e-198	696.0	100.00%	81.47%	U2 snRNP auxiliary factor large subunit;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003723|	GO:0006397|GO:0008380|
GN012746.1	sp|K1R4D4|K1R4D4_CRAGI	5.5e-146	522.7	95.65%	90.55%	40S ribosomal protein SA;OS=Crassostrea;PE=3;SV=1	GO:0022627|	GO:0003735|	GO:0000028|GO:0006412|
GN012747.1	sp|K1RGS7|K1RGS7_CRAGI	1.7e-13	81.6	53.01%	88.51%	cGMP-dependent protein kinase 1, alpha isozyme;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN012749.1	sp|K1QUW8|K1QUW8_CRAGI	0.0e+00	1225.7	100.00%	95.61%	cGMP-dependent protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0030553|GO:0004692|
GN012751.1	sp|K1RAI1|K1RAI1_CRAGI	1.0e-65	255.4	79.23%	72.39%	Uncharacterized protein C4orf45-like protein;OS=Crassostrea;PE=4;SV=1
GN012752.1	sp|K1PM54|K1PM54_CRAGI	3.5e-39	166.4	81.58%	90.22%	Transmembrane protein 14C;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012753.1	sp|K1P8L1|K1P8L1_CRAGI	1.7e-103	380.9	90.87%	94.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012754.1	sp|K1PYW8|K1PYW8_CRAGI	8.4e-200	703.0	73.71%	54.61%	Annexin;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005544|
GN012756.1	sp|K1Q145|K1Q145_CRAGI	6.0e-10	69.7	60.53%	38.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012757.1	sp|K1RGS9|K1RGS9_CRAGI	1.5e-129	468.4	99.48%	64.62%	5-hydroxytryptamine receptor 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012758.1	sp|K1QJ33|K1QJ33_CRAGI	3.1e-113	413.7	93.91%	77.78%	Aminoacyl tRNA synthetase complex-interacting multifunctional protein 2;OS=Crassostrea;PE=4;SV=1	GO:0004812|
GN012759.1	sp|K1PYL1|K1PYL1_CRAGI	8.5e-87	327.0	39.94%	58.06%	Matrilin-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004930|	GO:0007166|
GN012760.1	sp|K1PJ44|K1PJ44_CRAGI	0.0e+00	1756.9	100.00%	81.21%	Putative E3 ubiquitin-protein ligase HERC4;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN012761.1	sp|K1PCT9|K1PCT9_CRAGI	1.2e-146	525.4	89.82%	61.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010978.1	sp|K1QZ11|K1QZ11_CRAGI	2.2e-275	953.4	98.43%	83.99%	Geranylgeranyl transferase type-2 subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0005968|	GO:0004663|GO:0008270|	GO:0018344|
GN012762.1	sp|K1QE95|K1QE95_CRAGI	0.0e+00	3242.2	100.00%	76.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016589|	GO:0046872|GO:0035064|
GN012763.1	sp|K1Q6E3|K1Q6E3_CRAGI	1.6e-35	154.8	67.06%	65.79%	Phosphatidylinositol-glycan biosynthesis class X protein;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|	GO:0006506|
GN012764.1	sp|A0A1S3ILT4|A0A1S3ILT4_LINUN	1.1e-59	235.3	80.19%	74.55%	charged multivesicular body protein 6-B;OS=Lingula;PE=3;SV=1	GO:0007034|
GN012765.1	sp|A0A210QCJ8|A0A210QCJ8_MIZYE	1.3e-39	167.9	94.12%	67.50%	Ubiquitin-like protein ATG12;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0000045|
GN012766.1	sp|K1RDT2|K1RDT2_CRAGI	0.0e+00	1257.7	99.85%	91.96%	WD repeat-containing protein 16;OS=Crassostrea;PE=4;SV=1
GN012767.1	sp|K1QTG0|K1QTG0_CRAGI	0.0e+00	1114.4	92.67%	93.20%	Forkhead box protein K1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN012768.1	sp|K1QME7|K1QME7_CRAGI	2.4e-224	783.5	100.00%	89.38%	Tektin-4;OS=Crassostrea;PE=4;SV=1
GN012769.1	sp|K1QE89|K1QE89_CRAGI	5.1e-52	211.5	40.23%	47.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012770.1	sp|K1QE82|K1QE82_CRAGI	4.7e-106	392.1	32.29%	66.82%	Reticulocyte-binding protein 2-like protein a;OS=Crassostrea;PE=4;SV=1
GN010979.1	sp|K1R8Z9|K1R8Z9_CRAGI	2.7e-219	766.9	98.06%	83.69%	Amino acid transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015293|
GN012771.1	sp|K1Q6D8|K1Q6D8_CRAGI	4.2e-153	547.7	60.09%	57.83%	Sorting nexin-19;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN012772.1	sp|K1RDS1|K1RDS1_CRAGI	1.9e-51	208.0	48.80%	98.02%	Splicing factor, arginine/serine-rich 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN012773.1	sp|K1RDS1|K1RDS1_CRAGI	2.2e-55	221.5	40.66%	95.45%	Splicing factor, arginine/serine-rich 2;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN012774.1	sp|K1QMD9|K1QMD9_CRAGI	4.8e-228	795.8	91.11%	94.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012775.1	sp|A0A0L8I0M5|A0A0L8I0M5_OCTBM	1.0e-41	176.0	49.80%	60.32%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN012776.1	sp|A0A210PFJ6|A0A210PFJ6_MIZYE	0.0e+00	1089.3	86.47%	81.41%	DNA ligase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0003677|GO:0003910|	GO:0071897|GO:0051103|GO:0006310|GO:0006260|
GN012777.1	sp|A0A2T7PYK4|A0A2T7PYK4_POMCA	6.6e-98	363.2	95.55%	56.05%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN012778.1	sp|K1QB60|K1QB60_CRAGI	3.0e-174	616.7	100.00%	83.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010980.1	sp|K1RET5|K1RET5_CRAGI	1.0e-75	288.1	100.00%	93.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012779.1	sp|K1Q3S2|K1Q3S2_CRAGI	0.0e+00	1184.9	99.85%	89.78%	Mitochondrial Rho GTPase;OS=Crassostrea;PE=3;SV=1	GO:0031307|	GO:0005509|GO:0005525|GO:0003924|	GO:0007005|
GN012780.1	sp|K1QQM2|K1QQM2_CRAGI	3.3e-40	169.9	89.83%	75.24%	Tubulin-specific chaperone D;OS=Crassostrea;PE=4;SV=1	GO:0048487|GO:0005096|	GO:0007023|GO:0007021|
GN012781.1	sp|K1QIY5|K1QIY5_CRAGI	1.8e-46	191.0	88.82%	67.16%	Dentin matrix protein 4;OS=Crassostrea;PE=4;SV=1
GN012782.1	sp|K1PXP3|K1PXP3_CRAGI	6.4e-63	245.7	99.37%	76.88%	Ankyrin repeat domain-containing protein 40;OS=Crassostrea;PE=4;SV=1
GN012783.1	sp|K1R4Z7|K1R4Z7_CRAGI	4.9e-255	885.6	92.67%	93.63%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0072487|	GO:0004402|	GO:0006355|
GN012784.1	sp|K1Q3R6|K1Q3R6_CRAGI	3.9e-79	300.1	96.28%	66.67%	Testican-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012785.1	sp|K1QB55|K1QB55_CRAGI	3.7e-100	370.2	95.37%	75.61%	Leucine-rich repeat-containing protein C10orf11-like protein;OS=Crassostrea;PE=4;SV=1
GN012786.1	sp|A0A290WN60|A0A290WN60_CRAHO	6.1e-147	526.9	65.44%	72.75%	Heterochromatin protein 1 binding protein 3;OS=Crassostrea;PE=2;SV=1	GO:0000786|GO:0005634|	GO:0003682|GO:0003677|	GO:0070828|GO:0006334|GO:0006355|
GN012787.1	sp|K1Q3R9|K1Q3R9_CRAGI	1.1e-36	157.9	100.00%	76.77%	3,2-trans-enoyl-CoA isomerase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016853|
GN012791.1	sp|K1PUS8|K1PUS8_CRAGI	9.4e-307	1057.7	98.91%	77.86%	Location of vulva defective 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012792.1	sp|K1PUS8|K1PUS8_CRAGI	1.8e-31	140.6	92.00%	68.04%	Location of vulva defective 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012793.1	sp|K1P8J8|K1P8J8_CRAGI	5.5e-19	98.6	100.00%	71.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004602|	GO:0006979|
GN012794.1	sp|K1PUS8|K1PUS8_CRAGI	0.0e+00	5601.9	99.14%	79.14%	Location of vulva defective 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012795.1	sp|A0A2T7PXI2|A0A2T7PXI2_POMCA	3.3e-76	291.6	81.91%	36.58%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN012796.1	sp|K1RWA9|K1RWA9_CRAGI	0.0e+00	1454.9	98.55%	86.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012797.1	sp|K1RWA9|K1RWA9_CRAGI	0.0e+00	1671.0	86.27%	92.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012798.1	sp|K1QQB6|K1QQB6_CRAGI	1.4e-75	287.7	100.00%	98.00%	40S ribosomal protein S14;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN010805.1	sp|K1RDL0|K1RDL0_CRAGI	1.7e-153	548.1	93.14%	64.76%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN012799.1	sp|K1R6H5|K1R6H5_CRAGI	4.0e-260	902.5	94.32%	86.98%	N-sulfoglucosamine sulfohydrolase;OS=Crassostrea;PE=4;SV=1	GO:0008484|
GN012800.1	sp|K1RCY5|K1RCY5_CRAGI	3.6e-224	783.5	99.70%	76.08%	Leucine-rich repeat-containing protein 45;OS=Crassostrea;PE=4;SV=1
GN012801.1	sp|K1RWB1|K1RWB1_CRAGI	2.3e-50	204.1	100.00%	82.46%	Leucine-rich repeat-containing protein 20;OS=Crassostrea;PE=4;SV=1
GN012802.1	sp|K1QQC0|K1QQC0_CRAGI	1.0e-100	373.6	46.48%	57.41%	Poly [ADP-ribose] polymerase 14;OS=Crassostrea;PE=4;SV=1
GN012803.1	sp|K1QZQ8|K1QZQ8_CRAGI	9.6e-219	765.8	93.66%	72.33%	Low-density lipoprotein receptor-related protein 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN012804.1	sp|A0A210PJG3|A0A210PJG3_MIZYE	1.3e-198	698.4	97.28%	58.93%	Acyl-coenzyme A synthetase ACSM3, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0003824|
GN012805.1	sp|K1PKX6|K1PKX6_CRAGI	4.8e-30	137.1	33.33%	87.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN012807.1	sp|K1Q5Z4|K1Q5Z4_CRAGI	5.0e-106	389.8	99.31%	61.77%	G2/M phase-specific E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN012808.1	sp|K1RCY7|K1RCY7_CRAGI	1.8e-248	864.0	100.00%	75.25%	Eukaryotic peptide chain release factor GTP-binding subunit ERF3B;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN012809.1	sp|K1RWB4|K1RWB4_CRAGI	2.7e-124	451.1	54.82%	96.12%	Cisplatin resistance-associated overexpressed protein;OS=Crassostrea;PE=4;SV=1	GO:0005685|	GO:0003729|	GO:0006376|
GN012810.1	sp|K1QQ63|K1QQ63_CRAGI	3.8e-69	268.1	97.02%	32.45%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN012811.1	sp|K1QQC4|K1QQC4_CRAGI	7.6e-72	278.1	24.81%	61.07%	Halomucin;OS=Crassostrea;PE=4;SV=1
GN012813.1	sp|C3YWQ8|C3YWQ8_BRAFL	2.2e-48	198.7	89.37%	33.88%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN012814.1	sp|K1R6I1|K1R6I1_CRAGI	7.4e-54	216.1	72.94%	60.49%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN012815.1	sp|A0A0E3M1V7|A0A0E3M1V7_CRAGI	2.0e-72	277.7	90.91%	70.90%	SOCS2;OS=Crassostrea;PE=2;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN012817.1	sp|K1RD25|K1RD25_CRAGI	1.4e-71	274.6	93.45%	85.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012818.1	sp|K1PND9|K1PND9_CRAGI	8.5e-25	118.6	91.30%	56.19%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN012819.1	sp|K1R6I1|K1R6I1_CRAGI	3.5e-54	216.9	90.75%	61.25%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN012820.1	sp|A0A0E3M1V7|A0A0E3M1V7_CRAGI	2.4e-66	257.3	100.00%	69.44%	SOCS2;OS=Crassostrea;PE=2;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN012821.1	sp|A0A0E3M1V7|A0A0E3M1V7_CRAGI	7.6e-72	275.8	91.39%	70.00%	SOCS2;OS=Crassostrea;PE=2;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN010985.1	sp|K1QGP4|K1QGP4_CRAGI	1.1e-168	599.7	86.58%	54.64%	Peptidase inhibitor 16;OS=Crassostrea;PE=4;SV=1
GN012822.1	sp|A0A0E3M1V7|A0A0E3M1V7_CRAGI	7.6e-72	275.8	91.39%	70.00%	SOCS2;OS=Crassostrea;PE=2;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN012823.1	sp|A0A0E3M1V7|A0A0E3M1V7_CRAGI	7.7e-72	275.8	89.67%	70.00%	SOCS2;OS=Crassostrea;PE=2;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN012824.1	sp|K1R6I1|K1R6I1_CRAGI	1.0e-53	215.3	90.75%	61.25%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN012825.1	sp|A0A0E3M1V7|A0A0E3M1V7_CRAGI	5.8e-72	276.2	91.39%	70.00%	SOCS2;OS=Crassostrea;PE=2;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN012828.1	sp|A0A2B4RYI2|A0A2B4RYI2_STYPI	5.0e-23	113.6	77.03%	36.70%	THAP domain-containing protein 11;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN012829.1	sp|A0A0P4W9K7|A0A0P4W9K7_9EUCA	5.6e-72	276.9	97.95%	41.84%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN012830.1	sp|K1R1J0|K1R1J0_CRAGI	1.1e-103	382.9	100.00%	41.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010986.1	sp|K1QGP4|K1QGP4_CRAGI	1.1e-40	171.4	87.93%	78.64%	Peptidase inhibitor 16;OS=Crassostrea;PE=4;SV=1
GN012831.1	sp|K1QZW2|K1QZW2_CRAGI	1.5e-192	678.3	61.79%	91.44%	Splicing factor 1;OS=Crassostrea;PE=4;SV=1	GO:0045131|GO:0008270|	GO:0000398|
GN012832.1	sp|K1QQG7|K1QQG7_CRAGI	0.0e+00	2450.6	97.84%	92.31%	DNA-directed RNA polymerase subunit;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0003899|	GO:0006351|
GN012835.1	sp|K1RWG2|K1RWG2_CRAGI	1.1e-195	688.7	83.03%	73.08%	Proton-coupled amino acid transporter 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012836.1	sp|A0A210R4H3|A0A210R4H3_MIZYE	2.1e-23	114.8	33.33%	69.70%	Kinetochore protein Spc24;OS=Mizuhopecten;PE=4;SV=1
GN012837.1	sp|K1QQG7|K1QQG7_CRAGI	1.0e-33	147.9	96.67%	86.05%	DNA-directed RNA polymerase subunit;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0003899|	GO:0006351|
GN012839.1	sp|K1QQG7|K1QQG7_CRAGI	0.0e+00	1251.5	98.02%	92.75%	DNA-directed RNA polymerase subunit;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0003899|	GO:0006351|
GN012840.1	sp|K1QZW2|K1QZW2_CRAGI	4.2e-192	676.8	61.79%	91.18%	Splicing factor 1;OS=Crassostrea;PE=4;SV=1	GO:0045131|GO:0008270|	GO:0000398|
GN012841.1	sp|K1R1J0|K1R1J0_CRAGI	7.3e-113	413.3	96.61%	44.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012842.1	sp|K1R1J0|K1R1J0_CRAGI	7.4e-105	386.7	100.00%	41.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012843.1	sp|A0A3M6TI11|A0A3M6TI11_9CNID	6.6e-45	187.6	84.65%	31.66%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN010987.1	sp|K1QPM7|K1QPM7_CRAGI	0.0e+00	1190.3	100.00%	77.37%	Protein FAM59A;OS=Crassostrea;PE=4;SV=1
GN012844.1	sp|K1R358|K1R358_CRAGI	3.6e-111	407.1	90.91%	68.28%	Uncharacterized protein C16orf73;OS=Crassostrea;PE=4;SV=1
GN012845.1	sp|K1QHH9|K1QHH9_CRAGI	7.3e-200	701.8	100.00%	86.05%	Methionine aminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0070006|	GO:0070084|
GN012846.1	sp|K1QAH4|K1QAH4_CRAGI	1.2e-174	618.2	89.40%	81.13%	Cystinosin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012848.1	sp|K1PM39|K1PM39_CRAGI	2.0e-132	477.2	100.00%	95.40%	E3 ubiquitin-protein ligase MARCH1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0008270|
GN012849.1	sp|K1Q8P4|K1Q8P4_CRAGI	0.0e+00	1255.0	100.00%	94.68%	ATP-binding cassette sub-family D member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005777|	GO:0005524|GO:0042626|GO:0005324|GO:0042803|	GO:0015910|
GN012850.1	sp|K1QW40|K1QW40_CRAGI	1.5e-10	73.6	63.83%	24.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010988.1	sp|K1R3Z5|K1R3Z5_CRAGI	2.7e-114	417.5	83.94%	72.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012856.1	sp|K1QM14|K1QM14_CRAGI	0.0e+00	1588.9	70.22%	75.67%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN012857.1	sp|K1QQ20|K1QQ20_CRAGI	1.2e-102	379.4	51.72%	81.48%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN012858.1	sp|K1QQ20|K1QQ20_CRAGI	1.0e-305	1054.3	99.53%	76.88%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN012859.1	sp|K1QQ20|K1QQ20_CRAGI	0.0e+00	1689.1	80.46%	79.51%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN010989.1	sp|K1RZP9|K1RZP9_CRAGI	4.1e-49	199.9	96.32%	70.51%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN012860.1	sp|K1QQ26|K1QQ26_CRAGI	1.8e-126	458.0	100.00%	70.14%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012864.1	sp|K1PEU8|K1PEU8_CRAGI	2.6e-14	86.3	21.00%	54.48%	Tenascin-X;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005044|
GN012865.1	sp|K1Q7F7|K1Q7F7_CRAGI	2.0e-11	74.3	95.08%	41.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012866.1	sp|K1P0S8|K1P0S8_CRAGI	3.0e-75	287.0	99.47%	69.52%	GTP-binding protein SAR1;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0005794|	GO:0005525|	GO:0006886|GO:0016192|
GN012869.1	sp|K1PEU8|K1PEU8_CRAGI	3.6e-14	85.9	20.09%	54.48%	Tenascin-X;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005044|
GN012870.1	sp|K1Q7F7|K1Q7F7_CRAGI	6.1e-16	89.4	98.41%	44.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012871.1	sp|K1R3R8|K1R3R8_CRAGI	1.5e-93	349.4	100.00%	31.97%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN012872.1	sp|K1QDZ0|K1QDZ0_CRAGI	2.4e-43	182.6	50.87%	36.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012873.1	sp|K1RGA9|K1RGA9_CRAGI	1.5e-16	92.0	100.00%	35.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012874.1	sp|K1RAP5|K1RAP5_CRAGI	9.4e-179	631.7	100.00%	89.17%	Doublesex-and mab-3-related transcription factor A2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0046872|GO:0043565|
GN012875.1	sp|K1S5Z7|K1S5Z7_CRAGI	3.6e-74	283.5	100.00%	65.37%	Calcyphosin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012876.1	sp|K1RGA5|K1RGA5_CRAGI	3.6e-46	191.0	95.16%	38.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012877.1	sp|A0A210PF92|A0A210PF92_MIZYE	7.4e-15	87.0	98.06%	26.58%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN012878.1	sp|V4B996|V4B996_LOTGI	4.2e-256	889.4	96.03%	79.17%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN012879.1	sp|K1QWW1|K1QWW1_CRAGI	0.0e+00	1297.3	97.95%	83.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0044599|
GN012880.1	sp|K1RU43|K1RU43_CRAGI	0.0e+00	1753.0	65.51%	70.56%	WD repeat-containing protein on Y chromosome;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN012881.1	sp|K1QMV6|K1QMV6_CRAGI	0.0e+00	2098.2	98.09%	72.09%	Transient receptor potential cation channel subfamily M member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN012882.1	sp|K1QWW4|K1QWW4_CRAGI	3.4e-287	993.0	99.48%	75.10%	Lin-54-like protein;OS=Crassostrea;PE=4;SV=1
GN012883.1	sp|K1R3V8|K1R3V8_CRAGI	7.0e-198	695.3	100.00%	97.28%	COP9 signalosome complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0008180|GO:0005737|
GN012884.1	sp|K1PPZ9|K1PPZ9_CRAGI	8.8e-99	365.9	100.00%	54.76%	Nodal-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008083|
GN012885.1	sp|K1PI78|K1PI78_CRAGI	0.0e+00	2973.3	95.45%	84.63%	Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1;OS=Crassostrea;PE=4;SV=1	GO:0005086|GO:0005524|GO:0004672|	GO:0032012|
GN012886.1	sp|K1R182|K1R182_CRAGI	1.9e-240	837.4	100.00%	77.15%	Sorting nexin-29;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN010991.1	sp|K1RGC2|K1RGC2_CRAGI	4.5e-81	306.2	100.00%	81.67%	Calcineurin subunit B type 1;OS=Crassostrea;PE=4;SV=1
GN012887.1	sp|G8XSN4|G8XSN4_CRAAR	3.9e-66	256.1	100.00%	93.80%	Qm-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN012888.1	sp|K1QKG7|K1QKG7_CRAGI	2.4e-20	103.6	100.00%	77.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012890.1	sp|K1R185|K1R185_CRAGI	0.0e+00	1195.6	99.84%	93.10%	Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase;OS=Crassostrea;PE=3;SV=1	GO:0004020|GO:0005524|GO:0004781|	GO:0000103|
GN012891.1	sp|K1R7R4|K1R7R4_CRAGI	1.2e-213	748.0	96.99%	78.00%	Multiple inositol polyphosphate phosphatase 1;OS=Crassostrea;PE=3;SV=1	GO:0016791|
GN012892.1	sp|K1R7R4|K1R7R4_CRAGI	8.4e-57	225.3	100.00%	71.62%	Multiple inositol polyphosphate phosphatase 1;OS=Crassostrea;PE=3;SV=1	GO:0016791|
GN012893.1	sp|K1RRZ2|K1RRZ2_CRAGI	1.4e-36	159.8	28.93%	53.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010992.1	sp|K1RA02|K1RA02_CRAGI	2.5e-102	377.1	90.74%	89.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012895.1	sp|K1PH56|K1PH56_CRAGI	1.2e-65	255.0	100.00%	73.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN012896.1	sp|K1PXW5|K1PXW5_CRAGI	5.0e-42	176.8	97.26%	42.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012897.1	sp|K1QS32|K1QS32_CRAGI	3.3e-34	150.2	97.18%	46.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012898.1	sp|K1PV26|K1PV26_CRAGI	1.4e-17	95.5	76.70%	38.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012899.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	5.9e-79	300.4	64.57%	50.90%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN010993.1	sp|K1R0Q6|K1R0Q6_CRAGI	0.0e+00	5434.4	100.00%	82.67%	Laminin subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0007155|
GN012900.1	sp|H9LIY6|H9LIY6_CRAAR	4.0e-119	433.3	85.14%	83.14%	Chromobox 8-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005634|
GN012901.1	sp|K1QL78|K1QL78_CRAGI	1.2e-213	748.0	98.78%	77.00%	Cytochrome P450 3A9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN012904.1	sp|A0A1I8G553|A0A1I8G553_9PLAT	9.6e-29	133.7	61.40%	30.71%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN012905.1	sp|K1P0S8|K1P0S8_CRAGI	5.3e-19	98.6	79.10%	82.69%	GTP-binding protein SAR1;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0005794|	GO:0005525|	GO:0006886|GO:0016192|
GN012906.1	sp|K1Q7F7|K1Q7F7_CRAGI	3.9e-15	86.7	98.41%	44.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010994.1	sp|K1QTW5|K1QTW5_CRAGI	1.5e-184	651.4	96.44%	70.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012907.1	sp|K1PI60|K1PI60_CRAGI	6.3e-208	729.2	95.99%	68.53%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012908.1	sp|K1PI60|K1PI60_CRAGI	3.0e-117	427.6	87.15%	54.81%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012909.1	sp|K1PQZ0|K1PQZ0_CRAGI	3.2e-109	400.2	100.00%	79.13%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN012910.1	sp|K1PI60|K1PI60_CRAGI	2.1e-182	644.4	100.00%	58.68%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012911.1	sp|K1PI60|K1PI60_CRAGI	4.4e-63	246.5	95.24%	65.92%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN010995.1	sp|A0A210PEJ2|A0A210PEJ2_MIZYE	8.3e-173	612.8	98.95%	50.53%	Choline transporter-like protein 1;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN012912.1	sp|A0A1I8G553|A0A1I8G553_9PLAT	8.1e-28	130.6	61.40%	29.96%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN012913.1	sp|K1QIG7|K1QIG7_CRAGI	8.7e-229	798.1	99.76%	91.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN012914.1	sp|K1QX84|K1QX84_CRAGI	7.7e-159	565.5	95.83%	86.36%	Ethanolamine-phosphate cytidylyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0016779|	GO:0009058|
GN010996.1	sp|K1QLC4|K1QLC4_CRAGI	0.0e+00	1085.1	98.70%	68.51%	Transmembrane protein 8A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012915.1	sp|K1RHE8|K1RHE8_CRAGI	0.0e+00	4018.0	95.87%	53.72%	Polycystic kidney disease and receptor for egg jelly-related protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005044|
GN012917.1	sp|K1QB29|K1QB29_CRAGI	3.2e-35	154.1	47.03%	80.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012918.1	sp|K1QHX9|K1QHX9_CRAGI	1.3e-195	688.0	100.00%	85.48%	Somatostatin receptor type 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN012920.1	sp|A0A210PEK6|A0A210PEK6_MIZYE	7.0e-111	406.8	76.71%	52.54%	Prostaglandin E2 receptor EP4 subtype;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004960|
GN012921.1	sp|A0A1S3HHJ7|A0A1S3HHJ7_LINUN	2.7e-38	163.7	88.89%	66.39%	uncharacterized protein LOC106155332;OS=Lingula;PE=4;SV=1
GN012923.1	sp|K1R222|K1R222_CRAGI	7.6e-63	245.4	88.89%	93.70%	Mitochondrial dicarboxylate carrier;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN012924.1	sp|K1QHX7|K1QHX7_CRAGI	5.6e-127	460.3	98.33%	42.75%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN012925.1	sp|K1QHX7|K1QHX7_CRAGI	0.0e+00	1209.5	99.91%	56.56%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN012926.1	sp|K1QB43|K1QB43_CRAGI	4.6e-219	766.1	80.00%	90.48%	Protein pangolin, isoforms A/H/I;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0016055|
GN012927.1	sp|K1Q3F4|K1Q3F4_CRAGI	9.9e-138	495.4	75.81%	88.67%	Inorganic pyrophosphatase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0004427|GO:0000287|	GO:0006796|
GN012928.1	sp|K1Q6H8|K1Q6H8_CRAGI	8.1e-41	175.3	48.40%	24.04%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN012929.1	sp|H6BD26|H6BD26_OSTED	3.5e-55	219.9	72.00%	96.26%	Endonuclease/reverse transcriptase;OS=Ostrea;PE=2;SV=1	GO:0004519|GO:0003964|
GN012930.1	sp|A0A2B4R728|A0A2B4R728_STYPI	6.4e-41	173.7	94.21%	35.37%	Zinc finger protein 862;OS=Stylophora;PE=4;SV=1	GO:0046983|
GN010998.1	sp|K1R0Q1|K1R0Q1_CRAGI	1.9e-144	518.1	100.00%	69.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012933.1	sp|A0A210R385|A0A210R385_MIZYE	1.5e-95	355.1	94.04%	60.67%	FMRFamide receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008528|
GN012934.1	sp|K1RSG4|K1RSG4_CRAGI	2.4e-19	102.1	97.34%	28.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012935.1	sp|K1RVG3|K1RVG3_CRAGI	3.4e-125	453.4	100.00%	80.38%	Neuropeptide FF receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN012937.1	sp|K1PHT5|K1PHT5_CRAGI	8.7e-226	788.5	99.62%	78.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN012938.1	sp|A0A210QGF7|A0A210QGF7_MIZYE	1.3e-49	202.6	74.02%	66.40%	Cleavage and polyadenylation specificity factor subunit 4;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|GO:0008270|
GN012939.1	sp|K1PAM3|K1PAM3_CRAGI	2.9e-159	567.8	60.89%	72.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010999.1	sp|K1QTW2|K1QTW2_CRAGI	1.1e-181	641.7	85.65%	86.46%	Serine/threonine-protein kinase 11;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0030295|GO:0004674|	GO:0030010|GO:0042593|GO:0001558|
GN012940.1	sp|V4A8A4|V4A8A4_LOTGI	3.6e-28	131.3	58.84%	38.46%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN012941.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	3.6e-74	284.3	97.44%	41.98%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN011000.1	sp|K1QLB9|K1QLB9_CRAGI	5.4e-262	909.1	96.06%	72.86%	Asparagine synthetase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0004066|	GO:0006529|
GN012942.1	sp|A0A210Q3C0|A0A210Q3C0_MIZYE	1.8e-22	111.3	68.67%	55.88%	Mitochondrial import receptor subunit TOM22-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005741|	GO:0006886|
GN012943.1	sp|K1RVH7|K1RVH7_CRAGI	3.4e-107	393.7	86.57%	77.46%	Exportin-6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008565|GO:0008536|	GO:0006611|
GN012944.1	sp|K1RC21|K1RC21_CRAGI	1.4e-127	461.5	83.06%	84.71%	Probable ribosome biogenesis protein CGI_10026589;OS=Crassostrea;PE=3;SV=1	GO:0006364|
GN012945.1	sp|K1R5H2|K1R5H2_CRAGI	1.3e-272	944.5	92.99%	68.51%	Vitamin K-dependent gamma-carboxylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008488|	GO:0017187|
GN012946.1	sp|K1QRU8|K1QRU8_CRAGI	0.0e+00	1593.6	45.73%	86.48%	Myosin heavy chain, striated muscle;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0051015|GO:0005524|GO:0003774|
GN012947.1	sp|K1RE81|K1RE81_CRAGI	0.0e+00	1677.9	100.00%	74.25%	Transport protein Sec24B;OS=Crassostrea;PE=4;SV=1	GO:0030127|	GO:0008270|	GO:0006888|GO:0006886|
GN012948.1	sp|A0A1S3IU22|A0A1S3IU22_LINUN	1.8e-31	141.4	96.41%	41.53%	uncharacterized protein LOC106167464;OS=Lingula;PE=4;SV=1
GN012951.1	sp|K1Q136|K1Q136_CRAGI	1.7e-41	175.6	57.54%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012952.1	sp|K1QYL9|K1QYL9_CRAGI	0.0e+00	1479.5	97.80%	59.69%	Putative chitinase 3;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008061|GO:0004553|	GO:0005975|GO:0006030|
GN012953.1	sp|Q1RQ16|Q1RQ16_CRAGI	4.1e-240	835.9	100.00%	86.80%	Clp1 protein;OS=Crassostrea;PE=3;SV=1	GO:0008061|GO:0004568|	GO:0005975|
GN012954.1	sp|K1RC30|K1RC30_CRAGI	1.9e-229	800.4	100.00%	80.97%	Chitotriosidase-1;OS=Crassostrea;PE=3;SV=1	GO:0008061|	GO:0005975|
GN012955.1	sp|Q1RQ21|Q1RQ21_CRAGI	9.1e-201	704.9	100.00%	87.47%	Clp3 protein;OS=Crassostrea;PE=2;SV=1	GO:0008061|GO:0004568|	GO:0005975|
GN012957.1	sp|K1QPE5|K1QPE5_CRAGI	0.0e+00	3641.3	100.00%	85.29%	FRAS1-related extracellular matrix protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005604|GO:0016021|	GO:0030246|GO:0003677|GO:0015667|	GO:0007154|GO:0007160|
GN012958.1	sp|K1RC27|K1RC27_CRAGI	6.4e-99	365.5	100.00%	95.65%	Trafficking protein particle complex subunit 5;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0005794|GO:0030008|	GO:0048193|
GN012959.1	sp|K1R5H7|K1R5H7_CRAGI	5.0e-255	885.6	100.00%	88.41%	Cell division cycle protein 20-like protein;OS=Crassostrea;PE=4;SV=1	GO:0010997|GO:0097027|	GO:0031145|GO:0051301|GO:1904668|
GN012960.1	sp|K1QYK9|K1QYK9_CRAGI	6.9e-109	399.8	77.46%	59.33%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN012961.1	sp|K1Q136|K1Q136_CRAGI	3.3e-43	181.4	52.82%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012962.1	sp|K1QYL9|K1QYL9_CRAGI	1.2e-116	425.6	97.71%	57.14%	Putative chitinase 3;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008061|GO:0004553|	GO:0005975|GO:0006030|
GN012963.1	sp|K1QYL9|K1QYL9_CRAGI	4.8e-57	226.5	85.42%	65.06%	Putative chitinase 3;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008061|GO:0004553|	GO:0005975|GO:0006030|
GN012964.1	sp|K1PJA3|K1PJA3_CRAGI	1.9e-101	374.4	100.00%	71.83%	Noggin-2;OS=Crassostrea;PE=4;SV=1	GO:0030514|GO:0045596|
GN012965.1	sp|K1PD01|K1PD01_CRAGI	7.2e-57	225.7	97.62%	56.83%	Temptin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012968.1	sp|K1PW44|K1PW44_CRAGI	4.7e-31	139.8	92.76%	52.08%	Temptin;OS=Crassostrea;PE=4;SV=1
GN012969.1	sp|K1RKT7|K1RKT7_CRAGI	2.6e-32	144.4	49.51%	73.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012970.1	sp|K1PP90|K1PP90_CRAGI	1.1e-127	462.2	100.00%	72.98%	Homeobox protein unc-4-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN012971.1	sp|K1QWK5|K1QWK5_CRAGI	3.5e-131	473.4	88.22%	86.21%	UPF0363 protein C7orf20;OS=Crassostrea;PE=4;SV=1
GN012972.1	sp|K1QAS2|K1QAS2_CRAGI	3.1e-140	503.8	92.02%	67.54%	WD repeat-containing protein 85;OS=Crassostrea;PE=4;SV=1
GN011004.1	sp|K1RK91|K1RK91_CRAGI	1.1e-193	681.4	98.21%	86.20%	Kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|	GO:0032958|
GN012973.1	sp|K1QY42|K1QY42_CRAGI	1.5e-86	325.9	94.00%	55.81%	SH2 domain-containing protein 4B;OS=Crassostrea;PE=4;SV=1
GN012974.1	sp|K1R502|K1R502_CRAGI	1.4e-204	718.4	97.06%	72.92%	Cyclin-dependent kinase-like 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN012975.1	sp|V4B6P9|V4B6P9_LOTGI	5.4e-152	543.5	59.48%	75.29%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN012976.1	sp|K1QNY2|K1QNY2_CRAGI	1.0e-47	194.9	100.00%	69.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012977.1	sp|K1R506|K1R506_CRAGI	3.2e-15	86.3	91.14%	60.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012978.1	sp|K1R506|K1R506_CRAGI	4.6e-29	132.9	88.52%	59.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012979.1	sp|K1RBH8|K1RBH8_CRAGI	4.8e-222	777.3	97.20%	58.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012980.1	sp|K1RV30|K1RV30_CRAGI	4.3e-51	208.0	22.17%	90.20%	Collagen alpha-1(IV) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN012981.1	sp|K1QNY4|K1QNY4_CRAGI	3.5e-144	518.5	99.08%	33.80%	Salivary glue protein Sgs-4;OS=Crassostrea;PE=4;SV=1
GN012982.1	sp|K1QNY4|K1QNY4_CRAGI	3.4e-23	114.8	88.20%	36.00%	Salivary glue protein Sgs-4;OS=Crassostrea;PE=4;SV=1
GN012983.1	sp|K1QY47|K1QY47_CRAGI	1.7e-243	847.8	85.95%	63.04%	Metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN012984.1	sp|K1R509|K1R509_CRAGI	2.7e-52	211.5	92.57%	44.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012985.1	sp|K1R509|K1R509_CRAGI	3.0e-64	251.5	98.80%	41.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN012986.1	sp|A0A210QA65|A0A210QA65_MIZYE	0.0e+00	1306.6	64.42%	80.43%	Protein transport protein Sec24C;OS=Mizuhopecten;PE=4;SV=1	GO:0030127|	GO:0008270|	GO:0006888|GO:0006886|
GN012987.1	sp|K1QY49|K1QY49_CRAGI	9.2e-35	152.5	44.44%	89.66%	ATPase family AAA domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0032006|
GN012988.1	sp|K1R511|K1R511_CRAGI	1.6e-179	634.8	100.00%	60.66%	Fibronectin type-III domain-containing protein C4orf31-like protein;OS=Crassostrea;PE=4;SV=1
GN011006.1	sp|K1QCS6|K1QCS6_CRAGI	0.0e+00	1836.2	99.68%	92.71%	Ankyrin-1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN012989.1	sp|K1QNZ1|K1QNZ1_CRAGI	8.4e-41	173.7	27.48%	67.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012990.1	sp|K1QY52|K1QY52_CRAGI	1.7e-86	324.3	98.97%	81.15%	Kelch-like protein 29;OS=Crassostrea;PE=4;SV=1
GN012991.1	sp|K1QY52|K1QY52_CRAGI	4.2e-156	556.2	99.67%	83.88%	Kelch-like protein 29;OS=Crassostrea;PE=4;SV=1
GN012992.1	sp|J9Q7S3|J9Q7S3_OSTED	3.2e-162	576.6	100.00%	99.68%	Receptor of activated kinase C;OS=Ostrea;PE=2;SV=1	GO:0016301|
GN012993.1	sp|K1QY52|K1QY52_CRAGI	8.1e-286	988.0	99.47%	83.24%	Kelch-like protein 29;OS=Crassostrea;PE=4;SV=1
GN012994.1	sp|K1QNZ1|K1QNZ1_CRAGI	2.9e-40	172.2	23.20%	67.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012995.1	sp|K1R511|K1R511_CRAGI	1.6e-179	634.8	100.00%	60.66%	Fibronectin type-III domain-containing protein C4orf31-like protein;OS=Crassostrea;PE=4;SV=1
GN012996.1	sp|K1RDM4|K1RDM4_CRAGI	3.3e-35	154.5	35.27%	75.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN012999.1	sp|A0A1S3J244|A0A1S3J244_LINUN	1.2e-17	95.5	56.98%	45.10%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN013000.1	sp|K1P0H4|K1P0H4_CRAGI	9.2e-42	175.3	83.33%	74.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013001.1	sp|K1PQQ9|K1PQQ9_CRAGI	9.9e-185	651.7	100.00%	81.13%	Pyroglutamylated RFamide peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN013002.1	sp|K1S066|K1S066_CRAGI	4.6e-24	117.1	55.81%	55.37%	ATP-binding cassette sub-family A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN013005.1	sp|K1PI60|K1PI60_CRAGI	0.0e+00	1112.1	99.79%	58.16%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013006.1	sp|K1PI60|K1PI60_CRAGI	0.0e+00	1364.0	99.64%	61.19%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013007.1	sp|K1PI60|K1PI60_CRAGI	0.0e+00	1171.4	98.75%	53.67%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011010.1	sp|K1RK91|K1RK91_CRAGI	1.3e-32	144.1	88.89%	88.73%	Kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|	GO:0032958|
GN013008.1	sp|A0A210PQE5|A0A210PQE5_MIZYE	1.7e-17	95.9	44.81%	34.15%	E3 ubiquitin-protein ligase;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0046872|GO:0061630|	GO:0000209|
GN013009.1	sp|K1QB23|K1QB23_CRAGI	2.2e-230	804.7	94.28%	47.13%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1
GN013010.1	sp|K1QLK4|K1QLK4_CRAGI	4.2e-61	241.5	86.80%	32.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013011.1	sp|K1QB23|K1QB23_CRAGI	4.9e-222	776.9	95.53%	48.30%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1
GN013012.1	sp|K1PVQ5|K1PVQ5_CRAGI	0.0e+00	2130.1	87.51%	83.90%	Rap guanine nucleotide exchange factor 2;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0017034|	GO:0042127|GO:0007264|
GN013013.1	sp|K1R3I7|K1R3I7_CRAGI	1.4e-186	658.3	94.10%	78.92%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN013014.1	sp|K1QHX2|K1QHX2_CRAGI	2.5e-117	428.3	95.33%	59.50%	La-related protein 7;OS=Crassostrea;PE=4;SV=1	GO:0005634|GO:1990904|	GO:0003723|	GO:0006396|
GN013015.1	sp|K1QB16|K1QB16_CRAGI	7.3e-48	197.6	90.22%	28.10%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013016.1	sp|K1QB16|K1QB16_CRAGI	1.6e-113	415.6	100.00%	44.90%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013017.1	sp|K1Q3D4|K1Q3D4_CRAGI	0.0e+00	3573.9	61.27%	80.54%	Extracellular matrix protein FRAS1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007154|
GN013018.1	sp|K1R0K2|K1R0K2_CRAGI	2.2e-20	104.0	62.07%	70.42%	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7;OS=Crassostrea;PE=4;SV=1	GO:0005743|	GO:0008137|	GO:0042773|
GN013020.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.3e-88	331.6	87.19%	47.98%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN013021.1	sp|K1PI60|K1PI60_CRAGI	9.3e-291	1005.0	97.69%	60.37%	Metabotropic glutamate receptor 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011012.1	sp|K1QCS6|K1QCS6_CRAGI	0.0e+00	1659.8	99.93%	92.96%	Ankyrin-1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN013022.1	sp|K1PND9|K1PND9_CRAGI	2.6e-23	113.6	92.79%	52.94%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN013024.1	sp|K1QX49|K1QX49_CRAGI	1.1e-48	200.7	44.93%	36.20%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN013025.1	sp|K1PQ35|K1PQ35_CRAGI	4.3e-41	176.0	25.34%	36.77%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN011013.1	sp|K1RB67|K1RB67_CRAGI	5.2e-162	577.0	99.56%	49.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013026.1	sp|K1PXW4|K1PXW4_CRAGI	1.2e-61	243.0	94.95%	34.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016787|	GO:0016042|
GN013027.1	sp|K1PXW4|K1PXW4_CRAGI	4.4e-68	264.6	95.66%	33.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016787|	GO:0016042|
GN013028.1	sp|K1QY26|K1QY26_CRAGI	3.1e-134	483.4	98.89%	83.15%	Soluble calcium-activated nucleotidase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0017110|
GN013029.1	sp|K1R4E3|K1R4E3_CRAGI	1.1e-130	471.9	100.00%	76.90%	DnaJ-like protein subfamily B member 12;OS=Crassostrea;PE=4;SV=1
GN013030.1	sp|A0A210PID3|A0A210PID3_MIZYE	1.2e-159	568.2	99.71%	79.18%	WD repeat domain phosphoinositide-interacting protein 4;OS=Mizuhopecten;PE=4;SV=1	GO:0006914|
GN013031.1	sp|K1RNU5|K1RNU5_CRAGI	7.7e-220	768.5	100.00%	97.70%	Pre-mRNA-splicing factor RBM22;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003723|	GO:0000398|
GN013032.1	sp|K1RID2|K1RID2_CRAGI	7.3e-23	112.5	98.54%	42.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006353|
GN013033.1	sp|K1PWN0|K1PWN0_CRAGI	2.3e-39	167.2	99.22%	63.49%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN011014.1	sp|A0A210Q071|A0A210Q071_MIZYE	2.8e-137	493.8	92.68%	82.18%	Eukaryotic translation initiation factor 2 subunit 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003743|
GN013034.1	sp|K1RNV1|K1RNV1_CRAGI	1.6e-51	208.0	85.71%	64.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011015.1	sp|K1QBJ8|K1QBJ8_CRAGI	4.9e-86	323.2	100.00%	67.87%	Centromere protein K;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051382|
GN013041.1	sp|K1Q697|K1Q697_CRAGI	2.8e-21	108.2	93.64%	28.37%	NAD(P)(+)--arginine ADP-ribosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0003956|	GO:0006471|
GN013044.1	sp|K1QGX1|K1QGX1_CRAGI	2.8e-79	300.4	98.51%	76.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013046.1	sp|K1QQJ8|K1QQJ8_CRAGI	3.8e-102	376.7	98.02%	74.80%	Ribosomal L1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN013047.1	sp|K1QTQ8|K1QTQ8_CRAGI	2.7e-113	416.8	28.45%	38.33%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN013048.1	sp|R7VJR0|R7VJR0_CAPTE	3.0e-63	248.1	44.54%	71.60%	GTP:AMP phosphotransferase, mitochondrial;OS=Capitella;PE=3;SV=1	GO:0005759|	GO:0004017|GO:0005524|GO:0005525|GO:0046899|	GO:0006172|GO:0046033|GO:0046039|GO:0046041|
GN013050.1	sp|K1RC37|K1RC37_CRAGI	2.0e-154	551.2	90.00%	63.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000276|	GO:0003824|GO:0015078|	GO:0015986|
GN013051.1	sp|W0G8X4|W0G8X4_CRAHO	5.2e-124	449.5	100.00%	84.35%	AP-1 transcription factor;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0006357|
GN011016.1	sp|K1QR14|K1QR14_CRAGI	2.9e-208	730.3	77.08%	82.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013053.1	sp|K1RA64|K1RA64_CRAGI	6.1e-88	330.1	78.40%	52.38%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN013055.1	sp|K1RA64|K1RA64_CRAGI	4.3e-153	546.6	82.56%	78.19%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN013056.1	sp|K1QZA5|K1QZA5_CRAGI	1.6e-66	257.7	87.50%	83.45%	Glutathione peroxidase;OS=Crassostrea;PE=3;SV=1	GO:0004602|	GO:0006979|
GN013057.1	sp|K1QAH9|K1QAH9_CRAGI	2.6e-39	167.5	47.09%	91.01%	H/ACA ribonucleoprotein complex subunit;OS=Crassostrea;PE=3;SV=1	GO:0031429|GO:0019013|	GO:0003723|	GO:0001522|GO:0006364|
GN013058.1	sp|A0A1S3I117|A0A1S3I117_LINUN	1.3e-67	262.3	90.99%	46.94%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN013060.1	sp|K1QHI2|K1QHI2_CRAGI	3.8e-248	862.8	100.00%	80.94%	Heterogeneous nuclear ribonucleoprotein L;OS=Crassostrea;PE=4;SV=1	GO:0005634|GO:0019013|	GO:0003723|	GO:0006397|
GN013061.1	sp|K1R362|K1R362_CRAGI	7.7e-70	269.6	86.49%	85.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN011018.1	sp|K1Q3M6|K1Q3M6_CRAGI	2.6e-71	273.9	97.86%	68.13%	Cytochrome P450 3A9;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN013062.1	sp|K1QHI8|K1QHI8_CRAGI	7.0e-144	516.2	76.08%	78.44%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013063.1	sp|K1QAI9|K1QAI9_CRAGI	1.7e-35	154.1	100.00%	71.56%	Thioredoxin;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0015035|	GO:0045454|GO:0006662|
GN013064.1	sp|K1PVC5|K1PVC5_CRAGI	3.5e-61	240.7	93.41%	50.96%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013065.1	sp|A0A1Y1NKF5|A0A1Y1NKF5_PHOPY	1.7e-12	77.8	82.35%	40.40%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN013066.1	sp|K1PQ12|K1PQ12_CRAGI	2.0e-12	77.8	36.23%	78.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013067.1	sp|K1PVC5|K1PVC5_CRAGI	3.7e-68	263.8	94.96%	53.41%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013068.1	sp|K1PVB8|K1PVB8_CRAGI	6.5e-118	429.5	97.87%	71.03%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013071.1	sp|K1R183|K1R183_CRAGI	4.5e-29	133.3	96.79%	57.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013072.1	sp|K1S5R4|K1S5R4_CRAGI	2.2e-118	430.6	100.00%	88.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013073.1	sp|A0A210QYA1|A0A210QYA1_MIZYE	6.9e-13	78.2	98.39%	56.67%	Leukocyte receptor cluster member 8-like;OS=Mizuhopecten;PE=4;SV=1
GN013074.1	sp|K1PTB7|K1PTB7_CRAGI	0.0e+00	1736.5	100.00%	72.58%	Protein SpAN;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN013075.1	sp|K1PLI3|K1PLI3_CRAGI	8.1e-160	568.9	88.27%	80.92%	G protein-activated inward rectifier potassium channel 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN013076.1	sp|K1PDP6|K1PDP6_CRAGI	2.2e-177	627.1	99.71%	85.10%	ATP-sensitive inward rectifier potassium channel 11;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN013077.1	sp|K1P7M3|K1P7M3_CRAGI	4.4e-193	679.5	99.51%	85.64%	ATP-sensitive inward rectifier potassium channel 12;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004000|GO:0005242|GO:0003723|	GO:0034765|GO:0006396|
GN013078.1	sp|K1PVC5|K1PVC5_CRAGI	4.7e-93	346.7	95.77%	57.49%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013079.1	sp|K1P7M3|K1P7M3_CRAGI	1.2e-193	681.4	99.51%	85.89%	ATP-sensitive inward rectifier potassium channel 12;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004000|GO:0005242|GO:0003723|	GO:0034765|GO:0006396|
GN013080.1	sp|K1PDP6|K1PDP6_CRAGI	1.1e-179	634.8	99.71%	85.96%	ATP-sensitive inward rectifier potassium channel 11;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN013081.1	sp|K1PLI3|K1PLI3_CRAGI	6.6e-162	575.9	88.27%	81.50%	G protein-activated inward rectifier potassium channel 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005242|	GO:0034765|
GN013082.1	sp|K1PTB7|K1PTB7_CRAGI	0.0e+00	1649.4	100.00%	73.27%	Protein SpAN;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN013083.1	sp|K1P7M5|K1P7M5_CRAGI	5.6e-13	80.5	43.03%	50.47%	Reticulocyte-binding protein 2-like protein a;OS=Crassostrea;PE=4;SV=1
GN013084.1	sp|K1PVU0|K1PVU0_CRAGI	2.1e-29	134.4	97.56%	41.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013086.1	sp|W4XQI2|W4XQI2_STRPU	9.7e-31	139.0	80.87%	46.94%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN013087.1	sp|K1PVU0|K1PVU0_CRAGI	8.1e-29	132.5	97.56%	41.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013088.1	sp|K1Q316|K1Q316_CRAGI	0.0e+00	1328.5	87.26%	89.04%	WD repeat-containing protein 78;OS=Crassostrea;PE=4;SV=1
GN013089.1	sp|C3YY23|C3YY23_BRAFL	1.1e-27	129.4	73.26%	36.18%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN013090.1	sp|K1QDJ5|K1QDJ5_CRAGI	1.4e-26	126.3	32.24%	49.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013091.1	sp|A0A210QJB9|A0A210QJB9_MIZYE	5.9e-134	483.4	99.61%	57.31%	Mesoderm induction early response protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|
GN013092.1	sp|K1PSR9|K1PSR9_CRAGI	4.5e-18	99.4	13.78%	44.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013093.1	sp|K1QQL8|K1QQL8_CRAGI	2.2e-104	384.0	100.00%	86.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN013094.1	sp|K1QIX9|K1QIX9_CRAGI	1.4e-108	397.9	100.00%	89.91%	Ras-related protein Rap-1b;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN011020.1	sp|K1PV94|K1PV94_CRAGI	1.1e-255	887.9	100.00%	88.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013095.1	sp|K1QIX9|K1QIX9_CRAGI	1.0e-98	365.2	100.00%	82.30%	Ras-related protein Rap-1b;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN013096.1	sp|K1R7M8|K1R7M8_CRAGI	1.6e-17	94.7	89.05%	46.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013097.1	sp|K1R7M8|K1R7M8_CRAGI	6.6e-216	756.1	73.00%	67.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013100.1	sp|K1RE51|K1RE51_CRAGI	7.0e-83	312.4	83.08%	93.37%	Neuropeptide Y receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008188|
GN013101.1	sp|K1R160|K1R160_CRAGI	9.6e-63	245.0	95.00%	85.82%	Neuropeptide Y receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN013102.1	sp|K1R160|K1R160_CRAGI	2.2e-121	440.7	96.55%	88.84%	Neuropeptide Y receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN013103.1	sp|K1R7N2|K1R7N2_CRAGI	2.2e-31	140.6	94.17%	51.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013104.1	sp|K1R7M8|K1R7M8_CRAGI	8.2e-59	231.9	99.27%	77.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013107.1	sp|K1QRQ2|K1QRQ2_CRAGI	4.0e-290	1002.3	100.00%	90.59%	Glutamate dehydrogenase 1, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016639|	GO:0006520|
GN013108.1	sp|A0A2C9LAH9|A0A2C9LAH9_BIOGL	1.2e-26	126.3	99.13%	26.55%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN013109.1	sp|K1RXC0|K1RXC0_CRAGI	1.7e-30	137.9	46.15%	98.46%	CCR4-NOT transcription complex subunit 6-like protein;OS=Crassostrea;PE=4;SV=1
GN013110.1	sp|K1RE48|K1RE48_CRAGI	0.0e+00	1303.5	100.00%	80.64%	CCR4-NOT transcription complex subunit 6-like protein;OS=Crassostrea;PE=4;SV=1
GN013111.1	sp|K1RC80|K1RC80_CRAGI	5.3e-48	199.5	8.41%	69.40%	Tyrosine-protein kinase transforming protein Fps;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013111.1	sp|K1RC80|K1RC80_CRAGI	1.1e-21	112.1	7.17%	53.45%	Tyrosine-protein kinase transforming protein Fps;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013112.1	sp|K1RIW4|K1RIW4_CRAGI	1.9e-60	238.4	98.29%	41.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013113.1	sp|A0A2B4S577|A0A2B4S577_STYPI	1.1e-40	173.3	83.83%	33.41%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN013114.1	sp|K1PAQ8|K1PAQ8_CRAGI	2.3e-30	138.3	67.32%	41.53%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN013115.1	sp|A0A0K8TSK4|A0A0K8TSK4_TABBR	2.5e-57	228.4	89.71%	38.62%	Putative nuclease harbi1-like protein;OS=Tabanus;PE=2;SV=1
GN011021.1	sp|K1QVR4|K1QVR4_CRAGI	5.7e-130	469.2	100.00%	90.20%	Trimeric intracellular cation channel type B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005261|	GO:0015672|
GN013117.1	sp|A0A210PXG1|A0A210PXG1_MIZYE	2.1e-83	315.1	80.96%	48.43%	Hexosyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN013118.1	sp|K1PAS1|K1PAS1_CRAGI	1.5e-186	658.3	94.67%	63.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013122.1	sp|K1QGY5|K1QGY5_CRAGI	1.4e-129	468.4	95.25%	67.65%	Indoleamine 2,3-dioxygenase 1;OS=Crassostrea;PE=4;SV=1	GO:0051213|GO:0020037|GO:0046872|	GO:0019441|
GN013124.1	sp|K1RC43|K1RC43_CRAGI	1.4e-218	764.2	99.07%	92.96%	U4/U6 small nuclear ribonucleoprotein Prp31;OS=Crassostrea;PE=4;SV=1	GO:0046540|GO:0019013|	GO:0000244|
GN013126.1	sp|K1RVJ4|K1RVJ4_CRAGI	1.2e-245	854.7	97.05%	70.03%	Choline transporter-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN011022.1	sp|K1PNN4|K1PNN4_CRAGI	2.4e-103	380.9	97.01%	66.10%	Tetratricopeptide repeat protein 33;OS=Crassostrea;PE=4;SV=1
GN013127.1	sp|A0A1S3I398|A0A1S3I398_LINUN	5.8e-26	122.9	66.22%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN013128.1	sp|A0A2R2MJZ2|A0A2R2MJZ2_LINUN	9.6e-15	86.7	45.13%	37.41%	uncharacterized protein LOC106174167;OS=Lingula;PE=4;SV=1	GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|
GN013129.1	sp|K1RYZ3|K1RYZ3_CRAGI	5.1e-43	181.0	95.47%	35.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013130.1	sp|K1QTU1|K1QTU1_CRAGI	1.4e-83	314.7	97.49%	84.46%	Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008410|
GN013131.1	sp|K1S0L1|K1S0L1_CRAGI	2.9e-88	330.9	90.26%	74.55%	Syntaxin-1A;OS=Crassostrea;PE=3;SV=1	GO:0005623|GO:0016021|	GO:0005484|	GO:0006886|GO:0016192|
GN013132.1	sp|K1R9C2|K1R9C2_CRAGI	5.3e-117	426.0	93.90%	90.87%	Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008410|
GN013133.1	sp|K1RFT2|K1RFT2_CRAGI	6.2e-111	406.8	97.81%	49.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011023.1	sp|K1PV98|K1PV98_CRAGI	2.2e-308	1063.1	100.00%	84.59%	ATP-dependent DNA helicase PIF1;OS=Crassostrea;PE=3;SV=1	GO:0005739|GO:0005634|	GO:0005524|GO:0043141|GO:0003677|	GO:0006310|GO:0006281|GO:0000002|GO:0000723|
GN013134.1	sp|K1RZ00|K1RZ00_CRAGI	1.2e-57	228.0	100.00%	81.06%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1
GN013135.1	sp|K1QTU3|K1QTU3_CRAGI	5.4e-201	705.7	100.00%	92.67%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN013136.1	sp|A0A210PNU3|A0A210PNU3_MIZYE	6.8e-135	486.1	99.48%	61.98%	COBW domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1
GN013137.1	sp|K1R9B9|K1R9B9_CRAGI	5.1e-30	137.1	81.25%	48.34%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013138.1	sp|K1RYY5|K1RYY5_CRAGI	3.1e-187	660.2	100.00%	75.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013139.1	sp|K1RM28|K1RM28_CRAGI	1.2e-168	598.6	100.00%	74.21%	Receptor-interacting serine/threonine-protein kinase 4;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013140.1	sp|K1QY60|K1QY60_CRAGI	2.5e-156	557.8	97.28%	73.40%	Spermatogenesis-associated protein 6;OS=Crassostrea;PE=4;SV=1
GN013142.1	sp|K1R521|K1R521_CRAGI	7.8e-110	402.5	91.72%	59.41%	Uncharacterized protein C8orf74-like protein;OS=Crassostrea;PE=4;SV=1
GN011024.1	sp|K1Q2Q1|K1Q2Q1_CRAGI	1.4e-126	458.4	99.72%	63.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004888|	GO:0007166|
GN013143.1	sp|K1QY58|K1QY58_CRAGI	4.8e-182	642.5	99.69%	94.39%	Eukaryotic translation initiation factor 3 subunit I;OS=Crassostrea;PE=3;SV=1	GO:0005852|	GO:0003743|
GN013144.1	sp|A0A2C9LYX4|A0A2C9LYX4_BIOGL	1.8e-23	114.4	100.00%	48.06%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN013145.1	sp|A0A3M6TI11|A0A3M6TI11_9CNID	1.6e-28	132.1	80.00%	36.27%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN013146.1	sp|K1QFL5|K1QFL5_CRAGI	1.7e-49	203.4	45.72%	34.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013147.1	sp|K1RM61|K1RM61_CRAGI	3.0e-31	141.4	67.51%	42.78%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN013149.1	sp|K1QNB3|K1QNB3_CRAGI	0.0e+00	2161.0	95.58%	67.09%	Neurotrypsin;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0005044|GO:0004252|
GN013150.1	sp|K1R8N3|K1R8N3_CRAGI	2.6e-30	136.3	100.00%	89.19%	Exocyst complex component 7;OS=Crassostrea;PE=3;SV=1	GO:0000145|	GO:0006887|GO:0015031|
GN013151.1	sp|K1Q1Q0|K1Q1Q0_CRAGI	2.2e-89	335.5	100.00%	60.42%	WW domain-binding protein 11;OS=Crassostrea;PE=4;SV=1	GO:0006396|
GN013152.1	sp|K1Q8Q9|K1Q8Q9_CRAGI	1.5e-159	568.2	68.76%	92.20%	Forkhead box protein J1-A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN013153.1	sp|K1QGU3|K1QGU3_CRAGI	8.6e-87	325.5	97.69%	88.57%	Pyridoxal-dependent decarboxylase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016831|GO:0030170|	GO:0019752|
GN013155.1	sp|K1QGU3|K1QGU3_CRAGI	5.5e-18	95.5	80.49%	78.46%	Pyridoxal-dependent decarboxylase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016831|GO:0030170|	GO:0019752|
GN013156.1	sp|A0A210QG62|A0A210QG62_MIZYE	2.1e-123	448.4	89.78%	48.94%	Major facilitator superfamily domain-containing protein 6-like protein B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN013157.1	sp|K1Q0E8|K1Q0E8_CRAGI	8.0e-65	252.3	99.47%	71.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013158.1	sp|K1R7E9|K1R7E9_CRAGI	2.9e-250	870.2	92.97%	72.07%	Receptor-type tyrosine-protein phosphatase S;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN013159.1	sp|K1R7E9|K1R7E9_CRAGI	1.4e-117	429.1	77.36%	57.52%	Receptor-type tyrosine-protein phosphatase S;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN013161.1	sp|K1R8L1|K1R8L1_CRAGI	0.0e+00	1776.5	100.00%	91.63%	Exportin-2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008536|	GO:0006886|
GN013162.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	1.3e-32	146.0	96.71%	30.72%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN013163.1	sp|K1Q1L7|K1Q1L7_CRAGI	4.4e-126	457.2	73.60%	61.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013165.1	sp|K1QGS2|K1QGS2_CRAGI	2.1e-177	627.1	100.00%	93.67%	Putative transcription factor SOX-14;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN013166.1	sp|A0A161I6R2|A0A161I6R2_9BIVA	0.0e+00	2719.5	100.00%	63.03%	Vitellogenin;OS=Saccostrea;PE=2;SV=1	GO:0005319|
GN013167.1	sp|K1R8M3|K1R8M3_CRAGI	4.6e-226	789.6	100.00%	76.91%	Mediator of RNA polymerase II transcription subunit 26;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN011025.1	sp|K1QLM4|K1QLM4_CRAGI	5.4e-95	353.6	92.11%	48.77%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0005230|GO:0043565|GO:0004888|	GO:0006355|
GN013168.1	sp|K1Q1N2|K1Q1N2_CRAGI	0.0e+00	1586.6	97.99%	65.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013169.1	sp|K1Q8P5|K1Q8P5_CRAGI	1.6e-129	468.0	99.09%	73.03%	Poly [ADP-ribose] polymerase 1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN013170.1	sp|V4BH79|V4BH79_LOTGI	1.2e-59	235.7	61.51%	67.06%	UMP-CMP kinase;OS=Lottia;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0005524|GO:0004127|GO:0009041|	GO:0006207|GO:0006221|
GN013171.1	sp|K1QGT2|K1QGT2_CRAGI	1.2e-30	139.8	27.97%	65.71%	Uncharacterized protein C7orf50;OS=Crassostrea;PE=4;SV=1
GN013172.1	sp|K1QNA8|K1QNA8_CRAGI	3.8e-248	863.6	99.89%	70.97%	Uncharacterized protein C18orf34;OS=Crassostrea;PE=4;SV=1
GN013173.1	sp|K1R8M7|K1R8M7_CRAGI	3.4e-296	1023.5	85.43%	70.78%	Polycomb protein Asx;OS=Crassostrea;PE=4;SV=1
GN013174.1	sp|V4A8A4|V4A8A4_LOTGI	1.5e-70	272.7	70.89%	44.41%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN013175.1	sp|K1Q1L7|K1Q1L7_CRAGI	4.4e-126	457.2	73.60%	61.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013176.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	1.3e-32	146.0	96.71%	30.72%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN013177.1	sp|K1Q1L7|K1Q1L7_CRAGI	7.8e-96	355.9	99.65%	62.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013178.1	sp|K1R7F6|K1R7F6_CRAGI	2.2e-17	93.2	74.24%	83.33%	Cystathionine gamma-lyase;OS=Crassostrea;PE=3;SV=1	GO:0016829|GO:0030170|
GN013179.1	sp|K1QHE7|K1QHE7_CRAGI	2.1e-13	80.5	85.87%	53.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013180.1	sp|K1QM65|K1QM65_CRAGI	1.1e-168	598.2	100.00%	84.89%	Ubiquitin-conjugating enzyme E2 U;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN013181.1	sp|K1QFR3|K1QFR3_CRAGI	2.4e-211	740.7	98.48%	62.24%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013182.1	sp|A0A210PMH6|A0A210PMH6_MIZYE	1.4e-57	227.6	100.00%	80.95%	Adrenodoxin-like protein, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0051537|GO:0009055|
GN013183.1	sp|K1Q7N4|K1Q7N4_CRAGI	0.0e+00	2438.7	96.21%	83.67%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013184.1	sp|A0A1S3HQ90|A0A1S3HQ90_LINUN	1.7e-24	118.6	97.85%	36.67%	uncharacterized protein LOC106156822;OS=Lingula;PE=4;SV=1	GO:0003677|
GN013185.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	2.0e-83	315.1	97.84%	43.25%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN013186.1	sp|K1Q7P1|K1Q7P1_CRAGI	6.4e-117	426.0	99.66%	73.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011026.1	sp|K1RCA3|K1RCA3_CRAGI	1.1e-200	704.9	100.00%	86.46%	Regulator of chromosome condensation;OS=Crassostrea;PE=4;SV=1
GN013187.1	sp|A0A210QQ78|A0A210QQ78_MIZYE	2.3e-60	238.4	80.17%	43.25%	Mu-type opioid receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013188.1	sp|K1Q8S1|K1Q8S1_CRAGI	3.3e-137	493.4	97.34%	74.15%	Serine palmitoyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030170|GO:0016740|	GO:0009058|
GN013189.1	sp|K1PTY5|K1PTY5_CRAGI	0.0e+00	5674.0	98.04%	83.28%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN013190.1	sp|K1Q4U7|K1Q4U7_CRAGI	0.0e+00	1665.2	93.84%	88.08%	AP-3 complex subunit delta-1;OS=Crassostrea;PE=4;SV=1	GO:0030123|	GO:0006886|GO:0016192|
GN011027.1	sp|K1QWJ4|K1QWJ4_CRAGI	1.2e-42	177.6	100.00%	94.12%	Splicing factor 3B subunit 5;OS=Crassostrea;PE=3;SV=1	GO:0071011|GO:0005689|	GO:0000398|
GN013192.1	sp|K1QC33|K1QC33_CRAGI	1.1e-295	1021.1	91.33%	88.26%	Nuclear factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0006260|
GN013193.1	sp|K1QN47|K1QN47_CRAGI	2.9e-91	340.9	94.87%	90.24%	Nuclear distribution protein nudE-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:2000574|
GN013194.1	sp|K1RQ33|K1RQ33_CRAGI	2.0e-84	318.2	100.00%	55.89%	Programmed cell death protein 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|
GN013197.1	sp|K1PFG5|K1PFG5_CRAGI	1.5e-92	345.9	44.71%	64.58%	Glutamate receptor, ionotropic kainate 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN013198.1	sp|K1PFG5|K1PFG5_CRAGI	4.8e-34	149.8	90.06%	50.34%	Glutamate receptor, ionotropic kainate 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN013199.1	sp|K1QI71|K1QI71_CRAGI	2.0e-34	151.4	64.43%	59.20%	Glutamate receptor delta-1 subunit;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN010808.1	sp|K1QI91|K1QI91_CRAGI	8.0e-157	558.9	99.46%	67.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011028.1	sp|K1P0R0|K1P0R0_CRAGI	2.2e-31	142.1	94.35%	36.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007131|
GN013202.1	sp|A0A210QSW9|A0A210QSW9_MIZYE	3.2e-117	427.2	97.87%	65.63%	L-threonine dehydratase catabolic TdcB;OS=Mizuhopecten;PE=4;SV=1
GN013203.1	sp|K1QI71|K1QI71_CRAGI	9.6e-41	173.7	19.11%	87.23%	Glutamate receptor delta-1 subunit;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN013204.1	sp|V4AI10|V4AI10_LOTGI	4.7e-94	349.7	96.62%	70.18%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0046872|	GO:0006511|
GN013205.1	sp|K1QS29|K1QS29_CRAGI	1.4e-48	198.0	85.33%	77.10%	Neuropeptide FF receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013206.1	sp|A0A210PR84|A0A210PR84_MIZYE	5.5e-65	253.4	74.31%	60.63%	Neuropeptide Y receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004983|
GN013207.1	sp|K1QJW8|K1QJW8_CRAGI	4.2e-33	147.1	64.95%	55.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011029.1	sp|K1PN15|K1PN15_CRAGI	1.4e-187	662.1	78.33%	70.38%	Epidermal growth factor receptor substrate 15-like 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007165|
GN013210.1	sp|K1PQ32|K1PQ32_CRAGI	5.8e-45	187.2	100.00%	41.98%	Cell adhesion molecule 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013211.1	sp|K1Q4T9|K1Q4T9_CRAGI	1.6e-41	175.3	68.80%	51.53%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN013212.1	sp|K1Q4T9|K1Q4T9_CRAGI	4.9e-136	490.0	72.68%	80.28%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN011030.1	sp|K1PN15|K1PN15_CRAGI	4.2e-206	723.4	78.62%	74.90%	Epidermal growth factor receptor substrate 15-like 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007165|
GN013213.1	sp|K1PQ36|K1PQ36_CRAGI	5.2e-124	449.5	100.00%	86.32%	Transcription initiation factor IIE subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0005673|	GO:0003677|GO:0003743|	GO:0006367|
GN013214.1	sp|K1QXS3|K1QXS3_CRAGI	6.6e-151	538.9	96.53%	89.17%	4-aminobutyrate aminotransferase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003867|GO:0030170|	GO:0009448|
GN013215.1	sp|K1PQ23|K1PQ23_CRAGI	2.8e-228	797.0	98.15%	70.10%	PDZ and LIM domain protein 5;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN013216.1	sp|K1PXC3|K1PXC3_CRAGI	8.4e-162	575.5	100.00%	76.52%	PDZ and LIM domain protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN013218.1	sp|K1QC16|K1QC16_CRAGI	1.2e-80	304.7	100.00%	86.62%	Ovochymase-1;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN013219.1	sp|K1QC16|K1QC16_CRAGI	2.9e-260	902.9	97.70%	86.08%	Ovochymase-1;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN013220.1	sp|K1QXT1|K1QXT1_CRAGI	2.1e-117	427.9	75.62%	80.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013221.1	sp|K1PXD2|K1PXD2_CRAGI	1.0e-75	288.9	96.73%	58.05%	Putative thiopurine S-methyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0008119|
GN013222.1	sp|K1QC10|K1QC10_CRAGI	8.3e-305	1051.2	100.00%	93.90%	GTP-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013223.1	sp|K1QC10|K1QC10_CRAGI	1.0e-33	148.3	100.00%	91.53%	GTP-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013224.1	sp|K1QC10|K1QC10_CRAGI	5.9e-253	878.6	99.16%	94.11%	GTP-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013225.1	sp|A0A210QAK5|A0A210QAK5_MIZYE	1.1e-46	192.6	99.30%	37.94%	Uncharacterized protein C8orf76;OS=Mizuhopecten;PE=4;SV=1
GN011031.1	sp|A0A2C9JQY0|A0A2C9JQY0_BIOGL	1.9e-225	787.7	94.72%	63.03%	Oxysterol-binding protein;OS=Biomphalaria;PE=3;SV=1	GO:0006869|
GN013226.1	sp|K1PZM5|K1PZM5_CRAGI	0.0e+00	1148.3	100.00%	74.26%	Tetratricopeptide repeat protein 15;OS=Crassostrea;PE=4;SV=1
GN013227.1	sp|K1R3T0|K1R3T0_CRAGI	1.4e-160	572.0	61.13%	72.86%	Protein-L-isoaspartate O-methyltransferase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0004719|
GN013228.1	sp|A0A210R5Y7|A0A210R5Y7_MIZYE	2.8e-27	128.3	97.64%	29.95%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN013229.1	sp|K1RF09|K1RF09_CRAGI	0.0e+00	2442.5	99.94%	82.45%	Coiled-coil and C2 domain-containing protein 2A;OS=Crassostrea;PE=4;SV=1
GN013230.1	sp|K1RY35|K1RY35_CRAGI	1.5e-134	484.6	93.49%	81.25%	Bone morphogenetic protein 7;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0008083|
GN013231.1	sp|Q869H8|Q869H8_CRAGI	1.2e-35	154.8	83.58%	71.55%	GDF2;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0008083|
GN011032.1	sp|K1PVE9|K1PVE9_CRAGI	0.0e+00	1404.0	99.34%	80.73%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN013232.1	sp|K1R2E7|K1R2E7_CRAGI	1.8e-250	870.9	93.10%	69.62%	XK-related protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013233.1	sp|K1RF15|K1RF15_CRAGI	2.3e-163	580.5	92.45%	92.46%	Nuclear inhibitor of protein phosphatase 1;OS=Crassostrea;PE=4;SV=1
GN013234.1	sp|A0A2C9JH48|A0A2C9JH48_BIOGL	6.5e-12	76.6	34.65%	59.42%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003700|
GN013236.1	sp|K1RY40|K1RY40_CRAGI	4.1e-66	256.5	94.97%	79.29%	Transcription factor 23;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN013237.1	sp|K1QSW7|K1QSW7_CRAGI	1.6e-36	157.5	73.21%	96.30%	Transcription factor 21;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN011033.1	sp|A0A1S3JH76|A0A1S3JH76_LINUN	1.4e-83	315.5	96.25%	44.15%	D-aspartate oxidase isoform X1;OS=Lingula;PE=4;SV=1	GO:0003884|GO:0071949|	GO:0046416|
GN013239.1	sp|K1R8G8|K1R8G8_CRAGI	0.0e+00	1264.2	99.46%	53.34%	Unhealthy ribosome biogenesis protein 2-like protein;OS=Crassostrea;PE=4;SV=1
GN013240.1	sp|K1RF22|K1RF22_CRAGI	1.9e-209	734.6	100.00%	60.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013243.1	sp|K1R1I7|K1R1I7_CRAGI	1.4e-21	108.6	47.83%	57.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013244.1	sp|A0A2T7NPL4|A0A2T7NPL4_POMCA	2.7e-75	287.7	95.88%	74.82%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN013245.1	sp|K1QJ36|K1QJ36_CRAGI	4.6e-68	263.5	97.96%	57.08%	Muscle, skeletal receptor tyrosine protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN013246.1	sp|K1QPU0|K1QPU0_CRAGI	3.5e-09	67.0	36.03%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013247.1	sp|K1QJ36|K1QJ36_CRAGI	7.2e-240	835.1	99.79%	89.46%	Muscle, skeletal receptor tyrosine protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN013248.1	sp|K1QB91|K1QB91_CRAGI	5.0e-24	116.3	46.67%	91.94%	p21-activated protein kinase-interacting protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013249.1	sp|K1QB91|K1QB91_CRAGI	2.8e-112	411.0	81.63%	62.58%	p21-activated protein kinase-interacting protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013250.1	sp|A0A210QBE3|A0A210QBE3_MIZYE	8.0e-79	299.3	75.19%	72.08%	tRNA selenocysteine 1-associated protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN013251.1	sp|K1QSY9|K1QSY9_CRAGI	2.4e-46	190.3	100.00%	91.45%	Huntingtin-interacting protein K;OS=Crassostrea;PE=4;SV=1
GN013252.1	sp|K1QBD7|K1QBD7_CRAGI	0.0e+00	2333.1	99.93%	78.82%	Nephrocystin-4;OS=Crassostrea;PE=4;SV=1	GO:0005856|GO:0097730|	GO:0090090|
GN013253.1	sp|K1RF28|K1RF28_CRAGI	6.9e-19	99.0	61.06%	63.24%	Amiloride-sensitive sodium channel subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN013255.1	sp|K1RF28|K1RF28_CRAGI	1.6e-65	255.0	87.35%	64.68%	Amiloride-sensitive sodium channel subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN013256.1	sp|K1QJ46|K1QJ46_CRAGI	2.5e-255	886.7	98.22%	78.78%	Putative methylcrotonoyl-CoA carboxylase beta chain, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN013257.1	sp|K1QB93|K1QB93_CRAGI	2.1e-250	870.2	100.00%	89.50%	DNA methyltransferase 1-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035267|	GO:0003677|GO:0008168|	GO:0006338|GO:0006281|GO:0043968|GO:0043967|GO:0045892|
GN013258.1	sp|K1R6K1|K1R6K1_CRAGI	1.6e-70	271.6	100.00%	59.73%	Tctex1 domain-containing protein 1-B;OS=Crassostrea;PE=4;SV=1
GN013259.1	sp|K1RD04|K1RD04_CRAGI	1.9e-45	188.0	59.38%	78.26%	Tctex1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN013260.1	sp|K1RWD4|K1RWD4_CRAGI	2.2e-218	763.5	100.00%	99.47%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013261.1	sp|K1QQE6|K1QQE6_CRAGI	4.0e-163	579.7	89.41%	90.10%	Trans-2,3-enoyl-CoA reductase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016627|	GO:0006629|
GN013262.1	sp|K1R6K6|K1R6K6_CRAGI	2.7e-28	130.6	77.08%	66.36%	Transmembrane protein C20orf46;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013264.1	sp|K1RD06|K1RD06_CRAGI	1.3e-62	247.3	18.28%	68.21%	Collagen alpha-1(IX) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013265.1	sp|K1QZT6|K1QZT6_CRAGI	5.4e-132	476.1	98.98%	77.59%	Transmembrane protein 53;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010809.1	sp|K1PXY2|K1PXY2_CRAGI	1.7e-166	591.3	100.00%	69.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN011036.1	sp|A0A210QYL7|A0A210QYL7_MIZYE	1.6e-59	235.0	92.76%	55.77%	Counting factor associated protein D;OS=Mizuhopecten;PE=3;SV=1	GO:0008234|
GN013268.1	sp|K1R6K9|K1R6K9_CRAGI	3.0e-213	746.5	100.00%	83.73%	Bifunctional polynucleotide phosphatase/kinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013269.1	sp|K1Q3V3|K1Q3V3_CRAGI	4.3e-163	579.7	89.73%	90.66%	Myc protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|GO:0046983|
GN013270.1	sp|K1RAY2|K1RAY2_CRAGI	2.2e-199	700.7	95.47%	74.09%	tRNA isopentenyltransferase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003676|GO:0016740|	GO:0008033|
GN013271.1	sp|K1R235|K1R235_CRAGI	2.8e-49	200.3	84.03%	80.33%	Growth arrest and DNA-damage-inducible protein GADD45 gamma;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN013272.1	sp|K1RTZ8|K1RTZ8_CRAGI	1.9e-69	267.3	100.00%	90.48%	Growth arrest and DNA-damage-inducible protein GADD45 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN013273.1	sp|K1QWP8|K1QWP8_CRAGI	1.4e-217	760.8	100.00%	99.20%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013274.1	sp|C4NY62|C4NY62_CRAGI	6.3e-218	761.9	100.00%	99.47%	Actin;OS=Crassostrea;PE=2;SV=1	GO:0005524|
GN013275.1	sp|K1QWP8|K1QWP8_CRAGI	6.3e-218	761.9	100.00%	99.47%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013276.1	sp|K1Q821|K1Q821_CRAGI	6.3e-218	761.9	100.00%	99.47%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013277.1	sp|K1RWD4|K1RWD4_CRAGI	8.0e-177	625.2	100.00%	93.01%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013278.1	sp|A0A2B4RV85|A0A2B4RV85_STYPI	2.9e-16	89.7	78.21%	68.33%	Putative nuclease HARBI1;OS=Stylophora;PE=4;SV=1
GN013281.1	sp|K1QWP8|K1QWP8_CRAGI	2.0e-216	756.9	100.00%	98.14%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013282.1	sp|K1Q821|K1Q821_CRAGI	9.2e-177	625.2	100.00%	82.80%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013283.1	sp|C4NY61|C4NY61_CRAGI	1.0e-144	518.5	96.87%	81.82%	Actin;OS=Crassostrea;PE=2;SV=1	GO:0005524|
GN011037.1	sp|K1QVX1|K1QVX1_CRAGI	8.8e-42	176.0	53.98%	68.60%	RWD domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0032088|GO:1902073|GO:0033235|
GN013284.1	sp|K1QCT6|K1QCT6_CRAGI	3.6e-132	478.4	85.64%	32.27%	Tankyrase-1;OS=Crassostrea;PE=4;SV=1	GO:0008380|
GN013285.1	sp|K1R6J7|K1R6J7_CRAGI	3.7e-218	762.7	100.00%	98.94%	Actin;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013286.1	sp|K1RWD1|K1RWD1_CRAGI	4.4e-155	553.1	100.00%	85.11%	Krueppel-like factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN013287.1	sp|K1QQE2|K1QQE2_CRAGI	4.0e-105	386.3	100.00%	89.10%	Tctex1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN013288.1	sp|K1QZS9|K1QZS9_CRAGI	1.3e-103	381.3	100.00%	91.43%	Tctex1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN013289.1	sp|K1QEM9|K1QEM9_CRAGI	3.0e-94	350.1	100.00%	85.57%	Tctex1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN013290.1	sp|V3ZZ47|V3ZZ47_LOTGI	2.3e-33	147.1	82.50%	63.37%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005623|	GO:0045454|
GN013292.1	sp|A0A1S3IHK7|A0A1S3IHK7_LINUN	1.5e-20	104.4	88.57%	52.08%	uncharacterized protein LOC106164102;OS=Lingula;PE=4;SV=1	GO:0008270|
GN013293.1	sp|K1QNE3|K1QNE3_CRAGI	1.7e-225	787.7	69.12%	88.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005615|
GN011039.1	sp|K1RBI7|K1RBI7_CRAGI	0.0e+00	1371.3	100.00%	84.51%	Amyloid protein-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN013294.1	sp|K1PUS3|K1PUS3_CRAGI	1.4e-65	254.6	92.17%	82.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013295.1	sp|K1PUS3|K1PUS3_CRAGI	1.5e-13	80.9	86.05%	65.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013296.1	sp|K1PUS3|K1PUS3_CRAGI	3.2e-159	567.4	99.25%	64.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013297.1	sp|K1Q1M3|K1Q1M3_CRAGI	3.7e-28	131.0	27.24%	85.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013298.1	sp|V3ZID4|V3ZID4_LOTGI	1.7e-94	352.4	95.99%	38.96%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN013299.1	sp|K1QJM2|K1QJM2_CRAGI	1.1e-116	425.2	90.79%	76.73%	Protein YIPF;OS=Crassostrea;PE=3;SV=1	GO:0005794|GO:0016021|	GO:0016192|
GN013301.1	sp|K1PDD4|K1PDD4_CRAGI	7.2e-74	282.7	100.00%	74.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013303.1	sp|K1PJS3|K1PJS3_CRAGI	5.2e-163	579.7	72.81%	84.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011040.1	sp|A0A067RHF4|A0A067RHF4_ZOONE	9.7e-73	278.9	92.48%	64.15%	ATP-dependent Clp protease proteolytic subunit;OS=Zootermopsis;PE=3;SV=1	GO:0004252|
GN013304.1	sp|K1PZA0|K1PZA0_CRAGI	7.1e-276	956.1	99.83%	55.91%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN013305.1	sp|A0A210PKX9|A0A210PKX9_MIZYE	1.0e-24	118.2	96.19%	55.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN011041.1	sp|K1RBI7|K1RBI7_CRAGI	1.3e-157	563.1	93.69%	38.37%	Amyloid protein-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN013311.1	sp|K1Q678|K1Q678_CRAGI	2.3e-57	227.6	97.06%	61.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN013312.1	sp|K1QYM4|K1QYM4_CRAGI	1.8e-129	468.0	71.35%	83.64%	D-beta-hydroxybutyrate dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN013313.1	sp|K1QPF2|K1QPF2_CRAGI	0.0e+00	1176.8	94.97%	77.99%	5-azacytidine-induced protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005929|	GO:0035735|
GN013314.1	sp|A0A126Q9B1|A0A126Q9B1_MYTGA	2.5e-205	721.1	100.00%	59.97%	MG_CNOT3;OS=Mytilus;PE=2;SV=1	GO:0030015|GO:0005634|	GO:0006355|
GN013315.1	sp|K1QPF2|K1QPF2_CRAGI	7.4e-98	363.6	55.26%	55.34%	5-azacytidine-induced protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005929|	GO:0035735|
GN013318.1	sp|K1RVI8|K1RVI8_CRAGI	7.3e-102	376.3	100.00%	81.73%	Chromobox-like protein 8;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN013319.1	sp|K1PWQ7|K1PWQ7_CRAGI	4.5e-27	127.5	25.18%	87.32%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013320.1	sp|K1PHJ9|K1PHJ9_CRAGI	6.7e-21	107.1	25.75%	68.42%	Collagen-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN011043.1	sp|K1RHN5|K1RHN5_CRAGI	9.9e-105	385.2	91.03%	97.17%	GTP-binding protein Di-Ras2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN013322.1	sp|K1RFX2|K1RFX2_CRAGI	4.5e-119	433.7	94.48%	56.49%	Transcription elongation factor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003746|
GN013323.1	sp|K1Q077|K1Q077_CRAGI	1.2e-67	261.5	97.01%	70.81%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013324.1	sp|K1QSL2|K1QSL2_CRAGI	4.0e-39	166.8	87.43%	53.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013326.1	sp|K1Q077|K1Q077_CRAGI	9.0e-68	261.9	97.01%	71.43%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013327.1	sp|A6YRK7|A6YRK7_CRAGI	3.6e-229	799.7	99.80%	73.84%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN013328.1	sp|A6YRK7|A6YRK7_CRAGI	6.6e-90	335.9	99.56%	67.71%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN013329.1	sp|K1QNX0|K1QNX0_CRAGI	2.4e-88	330.9	96.46%	61.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011044.1	sp|A0A210PEH4|A0A210PEH4_MIZYE	7.5e-37	159.8	96.53%	41.03%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN013330.1	sp|A0A210PNT7|A0A210PNT7_MIZYE	3.8e-30	136.7	81.94%	59.83%	Cholecystokinin receptor type A;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004983|
GN013333.1	sp|K1Q3Z0|K1Q3Z0_CRAGI	6.9e-221	772.3	87.43%	80.33%	FAS-associated factor 1;OS=Crassostrea;PE=4;SV=1
GN013334.1	sp|K1Q3Z0|K1Q3Z0_CRAGI	6.9e-221	772.3	87.43%	80.33%	FAS-associated factor 1;OS=Crassostrea;PE=4;SV=1
GN013335.1	sp|K1QT03|K1QT03_CRAGI	2.3e-100	372.1	75.97%	44.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013336.1	sp|F0V455|F0V455_MYTGA	9.2e-32	142.5	98.96%	39.90%	Putative C1q domain containing protein MgC1q18;OS=Mytilus;PE=2;SV=1
GN013337.1	sp|A0A210R559|A0A210R559_MIZYE	5.1e-44	183.3	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010810.1	sp|K1QLS3|K1QLS3_CRAGI	7.3e-195	685.6	99.16%	69.62%	Cytochrome b-c1 complex subunit 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0046872|
GN011045.1	sp|F5A8D7|F5A8D7_CRAGI	1.3e-149	534.6	100.00%	84.97%	Caspase-1;OS=Crassostrea;PE=2;SV=1	GO:0004197|
GN013338.1	sp|K1QZ04|K1QZ04_CRAGI	1.6e-32	144.8	99.40%	44.31%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN013339.1	sp|K1QBE1|K1QBE1_CRAGI	3.3e-274	949.5	96.79%	80.74%	Telomerase protein component 1;OS=Crassostrea;PE=4;SV=1
GN013340.1	sp|K1QBE1|K1QBE1_CRAGI	3.8e-100	370.5	100.00%	63.82%	Telomerase protein component 1;OS=Crassostrea;PE=4;SV=1
GN013341.1	sp|K1QJC3|K1QJC3_CRAGI	4.1e-83	313.2	99.49%	74.49%	Methyltransferase-like protein 12, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN013342.1	sp|K1R4L5|K1R4L5_CRAGI	2.1e-29	134.0	92.62%	61.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011046.1	sp|K1QZM6|K1QZM6_CRAGI	9.7e-266	921.4	98.98%	78.39%	RNA polymerase I-specific transcription initiation factor RRN3;OS=Crassostrea;PE=4;SV=1	GO:0003743|
GN013344.1	sp|K1QTW0|K1QTW0_CRAGI	7.0e-13	78.6	75.61%	52.46%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013345.1	sp|K1PMG4|K1PMG4_CRAGI	1.8e-31	141.4	79.41%	47.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN011047.1	sp|K1RJ96|K1RJ96_CRAGI	1.2e-109	402.5	99.15%	56.73%	Sphere organelles protein SPH-1;OS=Crassostrea;PE=4;SV=1
GN013354.1	sp|K1PRN6|K1PRN6_CRAGI	1.9e-272	943.7	100.00%	71.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN013355.1	sp|K1QZN6|K1QZN6_CRAGI	2.6e-94	352.1	62.21%	50.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN013356.1	sp|K1QDP0|K1QDP0_CRAGI	2.9e-132	478.0	72.56%	64.04%	Cadherin-89D;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007156|
GN013357.1	sp|K1Q6N1|K1Q6N1_CRAGI	5.4e-32	144.4	43.29%	44.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013358.1	sp|K1Q6N1|K1Q6N1_CRAGI	4.9e-265	919.1	90.56%	77.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013359.1	sp|H6BD39|H6BD39_OSTED	7.0e-44	181.8	87.76%	96.47%	NADH dehydrogenase (Ubiquinona) Fe-S protein 6;OS=Ostrea;PE=2;SV=1
GN013362.1	sp|K1QGZ9|K1QGZ9_CRAGI	4.8e-23	112.5	96.67%	69.32%	Synaptogyrin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013363.1	sp|K1QGZ9|K1QGZ9_CRAGI	6.2e-47	192.6	71.90%	87.16%	Synaptogyrin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013364.1	sp|K1Q2C0|K1Q2C0_CRAGI	3.6e-169	601.3	74.20%	55.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013365.1	sp|K1R2R1|K1R2R1_CRAGI	1.2e-143	515.8	59.76%	69.86%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN013366.1	sp|K1QGZ0|K1QGZ0_CRAGI	1.5e-168	597.8	89.17%	92.50%	Guanine nucleotide-binding protein G(O) subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0031683|GO:0005525|GO:0003924|	GO:0007186|
GN013367.1	sp|K1QK67|K1QK67_CRAGI	7.9e-54	215.7	60.45%	94.34%	Thymidine kinase 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0019206|
GN013369.1	sp|K1QBQ6|K1QBQ6_CRAGI	7.4e-283	978.8	100.00%	65.85%	ATP-dependent RNA helicase DDX24;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|GO:0008146|
GN013370.1	sp|K1PMC5|K1PMC5_CRAGI	2.7e-25	120.2	98.11%	58.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011049.1	sp|K1QBW1|K1QBW1_CRAGI	4.2e-271	939.5	98.88%	70.51%	Fidgetin-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN013371.1	sp|K1PBS8|K1PBS8_CRAGI	2.2e-94	350.9	100.00%	67.47%	Methyltransferase-like protein 7A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008168|
GN013372.1	sp|K1QBP8|K1QBP8_CRAGI	2.3e-60	238.0	53.85%	77.48%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN013373.1	sp|K1PJ37|K1PJ37_CRAGI	0.0e+00	1206.0	92.16%	90.87%	ATP-binding cassette sub-family A member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN013374.1	sp|K1PJ37|K1PJ37_CRAGI	0.0e+00	2197.2	90.44%	83.22%	ATP-binding cassette sub-family A member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN013375.1	sp|K1QV59|K1QV59_CRAGI	1.5e-17	96.3	12.73%	95.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013376.1	sp|A0A210Q3X6|A0A210Q3X6_MIZYE	1.9e-37	162.2	95.58%	37.89%	Oxidative stress-responsive serine-rich protein 1;OS=Mizuhopecten;PE=4;SV=1
GN013377.1	sp|K1R4P6|K1R4P6_CRAGI	1.7e-249	867.5	97.06%	76.81%	HBS1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013378.1	sp|K1R4P6|K1R4P6_CRAGI	1.0e-60	240.4	22.82%	85.00%	HBS1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013379.1	sp|K1RAR4|K1RAR4_CRAGI	2.8e-97	360.1	93.26%	90.50%	Inosine triphosphate pyrophosphatase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0046872|GO:0035529|GO:0047429|GO:0000166|	GO:0009204|GO:0009117|
GN013380.1	sp|K1RH12|K1RH12_CRAGI	4.6e-137	493.0	93.79%	79.73%	Annexin;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005544|
GN011050.1	sp|A0A210QP52|A0A210QP52_MIZYE	5.9e-43	179.1	96.09%	68.85%	Deoxynucleotidyltransferase terminal-interacting protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016740|
GN013381.1	sp|K1S0E2|K1S0E2_CRAGI	4.8e-71	272.7	100.00%	83.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013383.1	sp|K1S0E7|K1S0E7_CRAGI	7.5e-214	749.6	73.18%	67.98%	DnaJ-like protein subfamily C member 14;OS=Crassostrea;PE=4;SV=1
GN013384.1	sp|K1S0E7|K1S0E7_CRAGI	1.7e-46	191.8	54.72%	73.38%	DnaJ-like protein subfamily C member 14;OS=Crassostrea;PE=4;SV=1
GN013385.1	sp|A0A2T7NQ24|A0A2T7NQ24_POMCA	6.3e-54	216.9	75.24%	54.84%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005634|	GO:0003684|	GO:0006289|GO:0043161|
GN013386.1	sp|K1QV67|K1QV67_CRAGI	5.6e-128	462.6	100.00%	80.00%	Putative hydroxypyruvate isomerase;OS=Crassostrea;PE=4;SV=1	GO:0016853|GO:0008168|	GO:0008033|
GN013388.1	sp|K1R4S7|K1R4S7_CRAGI	2.5e-104	383.6	98.00%	97.44%	Ras-related protein Rab-10;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013390.1	sp|K1RZG8|K1RZG8_CRAGI	1.3e-09	68.2	29.91%	88.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013391.1	sp|A0A2G8JE59|A0A2G8JE59_STIJA	7.9e-60	236.9	68.94%	42.67%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN013392.1	sp|K1RAU8|K1RAU8_CRAGI	3.0e-213	746.5	98.55%	92.63%	Eukaryotic translation initiation factor 3 subunit E;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0071540|	GO:0003743|	GO:0001732|
GN013393.1	sp|K1RH35|K1RH35_CRAGI	2.3e-112	410.6	85.77%	85.78%	R-spondin-3;OS=Crassostrea;PE=4;SV=1
GN013394.1	sp|K1QV94|K1QV94_CRAGI	4.3e-31	139.8	97.86%	52.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011051.1	sp|K1QZN2|K1QZN2_CRAGI	1.2e-178	631.7	82.48%	84.99%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013395.1	sp|K1QUA2|K1QUA2_CRAGI	1.8e-97	360.9	100.00%	79.53%	Josephin-2;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN013396.1	sp|K1RAS9|K1RAS9_CRAGI	9.4e-38	161.8	98.37%	71.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013397.1	sp|K1RRY6|K1RRY6_CRAGI	3.8e-30	136.0	100.00%	73.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN013398.1	sp|K1R178|K1R178_CRAGI	2.8e-10	69.7	81.43%	51.79%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN013399.1	sp|K1QU95|K1QU95_CRAGI	1.9e-134	484.6	97.02%	70.59%	Galanin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013400.1	sp|K1QU95|K1QU95_CRAGI	5.9e-136	489.6	97.02%	71.15%	Galanin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013401.1	sp|K1P6W1|K1P6W1_CRAGI	3.2e-11	74.7	28.74%	53.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013402.1	sp|K1R507|K1R507_CRAGI	9.1e-127	458.8	86.42%	81.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013403.1	sp|K1R507|K1R507_CRAGI	3.8e-69	266.9	100.00%	58.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013404.1	sp|K1QKF8|K1QKF8_CRAGI	5.0e-168	595.9	96.23%	91.80%	S-(hydroxymethyl)glutathione dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051903|GO:0008270|	GO:0006069|
GN013405.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	1.0e-23	115.2	96.77%	48.33%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN013406.1	sp|K1RRY2|K1RRY2_CRAGI	3.8e-256	891.3	65.77%	40.52%	NFX1-type zinc finger-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN013407.1	sp|A0A2R2MIQ9|A0A2R2MIQ9_LINUN	9.3e-195	687.2	92.52%	30.68%	NFX1-type zinc finger-containing protein 1-like;OS=Lingula;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN013409.1	sp|V9HWZ5|V9HWZ5_OSTED	1.4e-155	554.7	100.00%	92.59%	cAMP-responsive element binding protein;OS=Ostrea;PE=2;SV=1	GO:0003700|
GN013411.1	sp|K1QKF4|K1QKF4_CRAGI	5.8e-15	87.4	20.38%	64.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013412.1	sp|K1QKF4|K1QKF4_CRAGI	3.8e-164	583.6	91.75%	69.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013414.1	sp|V9HWZ5|V9HWZ5_OSTED	1.4e-155	554.7	100.00%	92.59%	cAMP-responsive element binding protein;OS=Ostrea;PE=2;SV=1	GO:0003700|
GN013417.1	sp|K1R7P6|K1R7P6_CRAGI	8.0e-28	128.3	68.60%	100.00%	Leucine-rich repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN013419.1	sp|K1QNA9|K1QNA9_CRAGI	5.0e-25	120.9	93.79%	29.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013422.1	sp|K1QMT1|K1QMT1_CRAGI	8.0e-153	545.4	100.00%	84.15%	DnaJ-like protein subfamily B member 4;OS=Crassostrea;PE=4;SV=1	GO:0051082|	GO:0006457|
GN013423.1	sp|K1QNZ8|K1QNZ8_CRAGI	1.9e-139	500.7	94.78%	93.28%	Elongation of very long chain fatty acids protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN013426.1	sp|K1PZX8|K1PZX8_CRAGI	1.0e-110	405.6	94.31%	65.62%	Adenosine receptor A2b;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013427.1	sp|K1PZX8|K1PZX8_CRAGI	7.4e-61	240.0	50.60%	71.43%	Adenosine receptor A2b;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013428.1	sp|A0A210PGU4|A0A210PGU4_MIZYE	1.0e-55	221.9	98.78%	71.27%	Nascent polypeptide-associated complex subunit alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0005854|
GN013429.1	sp|K1PKP7|K1PKP7_CRAGI	4.7e-71	273.9	91.01%	56.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013430.1	sp|K1Q8I4|K1Q8I4_CRAGI	0.0e+00	1970.7	99.20%	87.80%	F-box/WD repeat-containing protein 10;OS=Crassostrea;PE=4;SV=1
GN013431.1	sp|K1Q1F4|K1Q1F4_CRAGI	5.5e-220	768.8	99.50%	91.75%	60S ribosomal protein L3;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN013432.1	sp|K1QVC0|K1QVC0_CRAGI	1.3e-26	126.3	77.05%	70.48%	Transient receptor potential cation channel subfamily A member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005216|
GN011053.1	sp|A0A0L8ICQ2|A0A0L8ICQ2_OCTBM	1.3e-11	75.1	62.86%	45.98%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005634|	GO:0006915|
GN013434.1	sp|K1R4Q8|K1R4Q8_CRAGI	5.4e-159	565.8	98.39%	86.51%	24-dehydrocholesterol reductase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0016491|
GN013435.1	sp|A0A2T7PA07|A0A2T7PA07_POMCA	2.2e-11	73.6	49.38%	82.05%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005634|	GO:0046872|
GN011054.1	sp|A0A0L8HI95|A0A0L8HI95_OCTBM	1.9e-64	250.8	98.72%	75.48%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN013437.1	sp|A0A2T7PA07|A0A2T7PA07_POMCA	2.2e-11	73.6	49.38%	82.05%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005634|	GO:0046872|
GN013438.1	sp|K1RAS4|K1RAS4_CRAGI	7.0e-98	362.1	96.17%	97.14%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013439.1	sp|K1RAS4|K1RAS4_CRAGI	6.8e-102	375.6	99.50%	83.00%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013440.1	sp|K1RAS4|K1RAS4_CRAGI	5.3e-37	159.5	60.28%	92.86%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013441.1	sp|K1QV71|K1QV71_CRAGI	8.2e-122	442.2	100.00%	81.56%	TATA box-binding-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006352|
GN013442.1	sp|K1R4Q8|K1R4Q8_CRAGI	3.6e-255	885.9	98.94%	89.08%	24-dehydrocholesterol reductase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0016491|
GN013443.1	sp|K1RAS4|K1RAS4_CRAGI	0.0e+00	1309.3	99.87%	87.61%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013445.1	sp|K1R4Q8|K1R4Q8_CRAGI	1.3e-190	671.4	84.87%	87.43%	24-dehydrocholesterol reductase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0016491|
GN013446.1	sp|K1RAS4|K1RAS4_CRAGI	1.0e-39	167.9	98.97%	78.95%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013447.1	sp|K1RAS4|K1RAS4_CRAGI	3.6e-90	336.7	77.25%	96.91%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013448.1	sp|A0A2T7PA07|A0A2T7PA07_POMCA	2.2e-11	73.6	49.38%	82.05%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005634|	GO:0046872|
GN013449.1	sp|A0A2T7NNI2|A0A2T7NNI2_POMCA	1.4e-62	244.6	98.73%	78.57%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003723|
GN011055.1	sp|K1R4A5|K1R4A5_CRAGI	0.0e+00	1147.9	96.10%	66.59%	GPI ethanolamine phosphate transferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0051377|	GO:0006506|
GN013452.1	sp|K1RAS9|K1RAS9_CRAGI	3.8e-39	166.4	98.37%	72.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013454.1	sp|K1RXV8|K1RXV8_CRAGI	7.4e-28	128.6	97.09%	64.65%	PAT1-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000290|
GN013455.1	sp|K1R4R4|K1R4R4_CRAGI	8.2e-154	549.3	80.75%	70.00%	Methylthioribose kinase;OS=Crassostrea;PE=4;SV=1	GO:0046522|	GO:0009086|
GN013456.1	sp|K1RAT4|K1RAT4_CRAGI	3.9e-55	219.5	100.00%	93.60%	Mitogen-activated protein-binding protein-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0005085|GO:0032947|	GO:0032008|
GN013457.1	sp|K1RH25|K1RH25_CRAGI	2.7e-72	277.3	99.54%	66.36%	Phosphatidylinositol-glycan-specific phospholipase D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0004621|
GN013458.1	sp|K1RAT8|K1RAT8_CRAGI	1.8e-72	278.1	88.10%	67.54%	Ribonuclease H1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0000287|GO:0003676|GO:0004523|
GN013459.1	sp|A0A210PEH3|A0A210PEH3_MIZYE	9.6e-19	99.8	69.89%	36.65%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN013460.1	sp|A0A210PEH6|A0A210PEH6_MIZYE	3.0e-26	125.2	96.55%	29.08%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN011056.1	sp|K1QIJ6|K1QIJ6_CRAGI	5.3e-111	406.0	100.00%	90.87%	Homeobox protein TGIF2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN013461.1	sp|K1S0H7|K1S0H7_CRAGI	0.0e+00	1192.2	98.07%	71.06%	Phosphatidylinositol-glycan-specific phospholipase D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0004621|
GN013462.1	sp|K1RAT4|K1RAT4_CRAGI	3.9e-55	219.5	100.00%	93.60%	Mitogen-activated protein-binding protein-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0005085|GO:0032947|	GO:0032008|
GN013463.1	sp|K1R4R8|K1R4R8_CRAGI	1.5e-42	178.3	68.37%	81.20%	SGT1-like protein;OS=Crassostrea;PE=4;SV=1
GN013464.1	sp|K1R4R4|K1R4R4_CRAGI	1.1e-144	518.5	99.71%	70.00%	Methylthioribose kinase;OS=Crassostrea;PE=4;SV=1	GO:0046522|	GO:0009086|
GN013465.1	sp|K1RXV8|K1RXV8_CRAGI	2.1e-27	127.1	97.09%	63.64%	PAT1-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000290|
GN013466.1	sp|K1PN63|K1PN63_CRAGI	2.4e-84	319.7	41.74%	37.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013467.1	sp|K1RAS9|K1RAS9_CRAGI	1.0e-36	158.3	98.37%	69.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013468.1	sp|K1QV76|K1QV76_CRAGI	1.0e-24	117.5	98.36%	88.14%	Neutral ceramidase B;OS=Crassostrea;PE=4;SV=1
GN013469.1	sp|K1QV76|K1QV76_CRAGI	2.7e-211	740.0	99.24%	90.26%	Neutral ceramidase B;OS=Crassostrea;PE=4;SV=1
GN011057.1	sp|A0A210Q041|A0A210Q041_MIZYE	3.3e-154	550.1	97.58%	82.92%	ATPase ASNA1 homolog;OS=Mizuhopecten;PE=3;SV=1	GO:0005783|	GO:0005524|GO:0016887|GO:0046872|	GO:0045048|
GN013470.1	sp|K1QV76|K1QV76_CRAGI	1.2e-130	471.5	100.00%	84.98%	Neutral ceramidase B;OS=Crassostrea;PE=4;SV=1
GN013471.1	sp|K1RC00|K1RC00_CRAGI	2.1e-37	160.6	95.93%	69.23%	Phosphorylase b kinase regulatory subunit;OS=Crassostrea;PE=3;SV=1	GO:0005886|	GO:0005516|GO:0016301|	GO:0005977|
GN013472.1	sp|K1RAS9|K1RAS9_CRAGI	6.5e-39	165.6	98.37%	73.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013473.1	sp|K1PTD5|K1PTD5_CRAGI	1.1e-288	998.0	100.00%	67.37%	RING finger protein unkempt;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN013474.1	sp|K1QMX0|K1QMX0_CRAGI	6.2e-97	359.0	98.95%	89.36%	DNA topoisomerase 3-alpha;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0003677|GO:0003917|GO:0008270|	GO:0006265|
GN013475.1	sp|A0A3M6UP19|A0A3M6UP19_9CNID	1.9e-21	109.0	70.28%	33.91%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN013476.1	sp|K1QMX0|K1QMX0_CRAGI	9.1e-28	128.6	78.74%	67.00%	DNA topoisomerase 3-alpha;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0003677|GO:0003917|GO:0008270|	GO:0006265|
GN013477.1	sp|A0A210QNX3|A0A210QNX3_MIZYE	3.5e-51	206.5	100.00%	77.95%	Protein chibby-like 1;OS=Mizuhopecten;PE=4;SV=1
GN010812.1	sp|K1PIG4|K1PIG4_CRAGI	5.5e-118	429.5	99.64%	72.56%	Renalase;OS=Crassostrea;PE=4;SV=1	GO:0016651|
GN011058.1	sp|K1Q4C1|K1Q4C1_CRAGI	1.1e-134	485.3	81.48%	74.59%	NAD-dependent deacetylase sirtuin-6;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN013478.1	sp|K1QMX0|K1QMX0_CRAGI	0.0e+00	1119.4	95.45%	78.70%	DNA topoisomerase 3-alpha;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0003677|GO:0003917|GO:0008270|	GO:0006265|
GN013479.1	sp|K1Q6P1|K1Q6P1_CRAGI	0.0e+00	1184.1	100.00%	95.14%	Small G protein signaling modulator 3-like protein;OS=Crassostrea;PE=4;SV=1
GN013480.1	sp|K1Q6P1|K1Q6P1_CRAGI	8.6e-84	315.1	98.12%	93.59%	Small G protein signaling modulator 3-like protein;OS=Crassostrea;PE=4;SV=1
GN013482.1	sp|K1REA2|K1REA2_CRAGI	1.9e-44	184.1	98.50%	70.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013483.1	sp|K1REA2|K1REA2_CRAGI	1.1e-85	322.0	87.60%	68.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013484.1	sp|A0A210PIT4|A0A210PIT4_MIZYE	2.4e-97	361.3	96.46%	57.38%	FMRFamide receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013485.1	sp|A0A210QNN8|A0A210QNN8_MIZYE	1.7e-50	204.1	93.60%	79.31%	Set1/Ash2 histone methyltransferase complex subunit ASH2;OS=Mizuhopecten;PE=4;SV=1	GO:0048188|	GO:0046872|GO:0008168|	GO:0051568|
GN013486.1	sp|K1P7N3|K1P7N3_CRAGI	5.9e-83	314.3	91.39%	64.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013487.1	sp|H9LJ37|H9LJ37_CRAAR	1.4e-103	381.3	97.82%	76.68%	Mitochondrial ATP synthase-like protein;OS=Crassostrea;PE=2;SV=1	GO:0000276|	GO:0015078|	GO:0015986|
GN013488.1	sp|K1PLJ9|K1PLJ9_CRAGI	7.4e-167	592.0	97.55%	88.33%	Progestin and adipoQ receptor family member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013489.1	sp|K1PDR2|K1PDR2_CRAGI	4.6e-221	773.1	85.51%	75.77%	AP2-associated protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013490.1	sp|K1PDR2|K1PDR2_CRAGI	1.3e-212	745.0	97.50%	65.54%	AP2-associated protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013492.1	sp|K1PLK1|K1PLK1_CRAGI	1.7e-163	581.3	98.82%	60.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035658|	GO:0004649|	GO:0005975|GO:0016192|
GN013493.1	sp|K1QB48|K1QB48_CRAGI	3.2e-53	214.5	39.94%	78.91%	Putative G-protein coupled receptor No18;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013494.1	sp|K1Q3R1|K1Q3R1_CRAGI	1.3e-27	128.3	81.16%	52.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013495.1	sp|K1RAS6|K1RAS6_CRAGI	6.1e-53	212.2	100.00%	80.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013496.1	sp|K1QQL3|K1QQL3_CRAGI	1.2e-118	431.8	93.42%	80.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013497.1	sp|K1QIX1|K1QIX1_CRAGI	5.7e-124	449.5	100.00%	74.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013498.1	sp|K1QB46|K1QB46_CRAGI	2.3e-150	538.5	93.99%	55.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN013500.1	sp|K1Q3R0|K1Q3R0_CRAGI	1.3e-238	830.9	100.00%	92.04%	Dynactin subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005869|
GN013501.1	sp|A0A210QAC1|A0A210QAC1_MIZYE	1.5e-88	331.6	99.26%	57.04%	4,5-DOPA dioxygenase extradiol-like protein;OS=Mizuhopecten;PE=4;SV=1	GO:0051213|GO:0008198|GO:0016701|GO:0008270|	GO:0006725|
GN011060.1	sp|K1R284|K1R284_CRAGI	4.2e-16	90.5	66.32%	40.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013502.1	sp|K1RAS3|K1RAS3_CRAGI	0.0e+00	1458.4	99.82%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0003677|GO:0003700|	GO:0007165|
GN013503.1	sp|A0A210QA97|A0A210QA97_MIZYE	4.1e-169	600.1	99.80%	56.94%	Hexosyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0032580|	GO:0008376|
GN013504.1	sp|E5CXX6|E5CXX6_OSTED	1.1e-61	241.9	66.48%	97.50%	Glyceraldehyde-3-phosphate dehydrogenase;OS=Ostrea;PE=2;SV=1	GO:0004365|GO:0051287|GO:0050661|	GO:0006006|GO:0006096|
GN013506.1	sp|K1PN36|K1PN36_CRAGI	1.1e-67	262.3	86.92%	60.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013508.1	sp|K1Q3Q7|K1Q3Q7_CRAGI	3.7e-183	646.4	100.00%	87.67%	Dual specificity mitogen-activated protein kinase kinase 3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013509.1	sp|K1QB44|K1QB44_CRAGI	4.4e-59	233.4	68.37%	77.40%	Fanconi anemia-associated protein of 24 kDa;OS=Crassostrea;PE=4;SV=1	GO:0043240|	GO:0036297|
GN013510.1	sp|K1QQL0|K1QQL0_CRAGI	2.5e-25	121.7	99.65%	32.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013514.1	sp|K1R6J1|K1R6J1_CRAGI	3.6e-73	281.2	87.47%	44.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013518.1	sp|K1R6J1|K1R6J1_CRAGI	7.2e-74	283.5	87.47%	44.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013522.1	sp|K1R6J1|K1R6J1_CRAGI	2.1e-73	282.0	87.11%	44.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013525.1	sp|K1R6J1|K1R6J1_CRAGI	6.7e-72	276.9	87.47%	44.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013528.1	sp|K1R6J1|K1R6J1_CRAGI	3.7e-69	267.7	73.67%	52.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013529.1	sp|K1PLK1|K1PLK1_CRAGI	1.4e-31	141.7	50.88%	75.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035658|	GO:0004649|	GO:0005975|GO:0016192|
GN013530.1	sp|A0A1S3J244|A0A1S3J244_LINUN	3.2e-25	120.6	82.72%	39.85%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN011063.1	sp|K1QI50|K1QI50_CRAGI	0.0e+00	1392.9	99.88%	80.70%	Putative E3 ubiquitin-protein ligase HECTD3;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN013532.1	sp|A0A210QNK0|A0A210QNK0_MIZYE	3.5e-95	354.4	47.50%	81.73%	BTB/POZ domain-containing protein KCTD5;OS=Mizuhopecten;PE=4;SV=1	GO:0051260|
GN013534.1	sp|K1QXV2|K1QXV2_CRAGI	3.9e-19	101.7	24.40%	46.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013535.1	sp|K1RC37|K1RC37_CRAGI	6.7e-44	181.8	100.00%	81.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000276|	GO:0003824|GO:0015078|	GO:0015986|
GN013536.1	sp|K1PLJ9|K1PLJ9_CRAGI	2.2e-166	590.5	97.55%	88.33%	Progestin and adipoQ receptor family member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013537.1	sp|K1PDR2|K1PDR2_CRAGI	0.0e+00	1803.5	100.00%	71.59%	AP2-associated protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013538.1	sp|K1PTD5|K1PTD5_CRAGI	1.1e-288	998.0	100.00%	67.37%	RING finger protein unkempt;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN013539.1	sp|K1QMX0|K1QMX0_CRAGI	0.0e+00	1494.2	94.26%	68.55%	DNA topoisomerase 3-alpha;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0003677|GO:0003917|GO:0008270|	GO:0006265|
GN013540.1	sp|A0A210QNX3|A0A210QNX3_MIZYE	3.5e-51	206.5	100.00%	77.95%	Protein chibby-like 1;OS=Mizuhopecten;PE=4;SV=1
GN013541.1	sp|K1QMX0|K1QMX0_CRAGI	0.0e+00	1119.4	95.45%	78.70%	DNA topoisomerase 3-alpha;OS=Crassostrea;PE=4;SV=1	GO:0005694|GO:0016021|	GO:0003677|GO:0003917|GO:0008270|	GO:0006265|
GN013542.1	sp|K1QEU0|K1QEU0_CRAGI	5.9e-278	962.6	100.00%	73.02%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1	GO:0004096|GO:0020037|
GN013543.1	sp|K1Q6P1|K1Q6P1_CRAGI	0.0e+00	1556.2	100.00%	94.77%	Small G protein signaling modulator 3-like protein;OS=Crassostrea;PE=4;SV=1
GN013545.1	sp|K1REA2|K1REA2_CRAGI	1.9e-44	184.1	98.50%	70.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013546.1	sp|K1REA2|K1REA2_CRAGI	1.1e-85	322.0	87.60%	68.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013547.1	sp|A0A210PIT4|A0A210PIT4_MIZYE	2.4e-97	361.3	96.46%	57.38%	FMRFamide receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013548.1	sp|K1QMW1|K1QMW1_CRAGI	2.0e-284	984.6	49.54%	78.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013552.1	sp|K1QRQ2|K1QRQ2_CRAGI	2.3e-290	1003.0	100.00%	90.77%	Glutamate dehydrogenase 1, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016639|	GO:0006520|
GN013553.1	sp|K1RXC0|K1RXC0_CRAGI	8.0e-36	156.0	89.58%	90.64%	CCR4-NOT transcription complex subunit 6-like protein;OS=Crassostrea;PE=4;SV=1
GN013554.1	sp|W4XHT1|W4XHT1_STRPU	2.3e-48	198.0	97.47%	42.06%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN013555.1	sp|K1RE48|K1RE48_CRAGI	0.0e+00	1303.5	100.00%	80.64%	CCR4-NOT transcription complex subunit 6-like protein;OS=Crassostrea;PE=4;SV=1
GN013556.1	sp|A0A1Y1KDD6|A0A1Y1KDD6_PHOPY	2.1e-42	178.3	83.33%	38.36%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN011065.1	sp|X1WW30|X1WW30_ACYPI	1.4e-83	316.2	97.91%	33.73%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1	GO:0003677|
GN013557.1	sp|K1QGY5|K1QGY5_CRAGI	1.4e-129	468.4	95.25%	67.65%	Indoleamine 2,3-dioxygenase 1;OS=Crassostrea;PE=4;SV=1	GO:0051213|GO:0020037|GO:0046872|	GO:0019441|
GN013559.1	sp|K1RC43|K1RC43_CRAGI	1.4e-218	764.2	99.07%	92.96%	U4/U6 small nuclear ribonucleoprotein Prp31;OS=Crassostrea;PE=4;SV=1	GO:0046540|GO:0019013|	GO:0000244|
GN013560.1	sp|K1RVJ4|K1RVJ4_CRAGI	1.2e-245	854.7	97.05%	70.03%	Choline transporter-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013561.1	sp|A0A210PNU3|A0A210PNU3_MIZYE	1.5e-138	498.4	98.58%	59.52%	COBW domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1
GN011066.1	sp|K1QZ25|K1QZ25_CRAGI	2.2e-290	1003.0	100.00%	94.85%	Tyrosine-protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004715|
GN013562.1	sp|K1QTU3|K1QTU3_CRAGI	5.4e-201	705.7	100.00%	92.67%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN013563.1	sp|K1RZ00|K1RZ00_CRAGI	1.2e-57	228.0	100.00%	81.06%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1
GN013564.1	sp|K1RFT2|K1RFT2_CRAGI	6.2e-111	406.8	97.81%	49.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013565.1	sp|A0A2T7NR33|A0A2T7NR33_POMCA	3.4e-190	670.2	92.93%	70.04%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0008410|
GN013566.1	sp|K1RYZ3|K1RYZ3_CRAGI	5.1e-43	181.0	95.47%	35.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013567.1	sp|A0A2R2MJZ2|A0A2R2MJZ2_LINUN	9.6e-15	86.7	45.13%	37.41%	uncharacterized protein LOC106174167;OS=Lingula;PE=4;SV=1	GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|
GN013568.1	sp|A0A1S3I398|A0A1S3I398_LINUN	5.8e-26	122.9	66.22%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN013569.1	sp|K1R3C3|K1R3C3_CRAGI	8.7e-32	142.9	72.46%	47.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013570.1	sp|K1RYY5|K1RYY5_CRAGI	3.1e-187	660.2	100.00%	75.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013571.1	sp|K1RM28|K1RM28_CRAGI	1.2e-168	598.6	100.00%	74.21%	Receptor-interacting serine/threonine-protein kinase 4;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013572.1	sp|K1QY60|K1QY60_CRAGI	2.5e-156	557.8	97.28%	73.40%	Spermatogenesis-associated protein 6;OS=Crassostrea;PE=4;SV=1
GN013573.1	sp|K1R521|K1R521_CRAGI	7.8e-110	402.5	91.72%	59.41%	Uncharacterized protein C8orf74-like protein;OS=Crassostrea;PE=4;SV=1
GN013574.1	sp|A0A3M6TI11|A0A3M6TI11_9CNID	1.6e-28	132.1	80.00%	36.27%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN011067.1	sp|K1S4F0|K1S4F0_CRAGI	2.3e-62	246.9	20.19%	49.24%	DBF4-like protein B;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN011067.1	sp|K1S4F0|K1S4F0_CRAGI	1.6e-58	234.2	24.84%	48.09%	DBF4-like protein B;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN013575.1	sp|K1QFL5|K1QFL5_CRAGI	2.0e-16	92.4	38.42%	36.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013576.1	sp|K1RM61|K1RM61_CRAGI	3.0e-31	141.4	67.51%	42.78%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN013578.1	sp|K1QWM8|K1QWM8_CRAGI	0.0e+00	2207.9	60.79%	78.76%	Protein sidekick-2;OS=Crassostrea;PE=4;SV=1
GN013579.1	sp|K1QNB6|K1QNB6_CRAGI	0.0e+00	1168.3	96.77%	61.33%	Proactivator polypeptide;OS=Crassostrea;PE=4;SV=1	GO:0005764|	GO:0006665|
GN011068.1	sp|K1PMB4|K1PMB4_CRAGI	3.4e-30	137.5	93.61%	33.33%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013580.1	sp|A0A210QG62|A0A210QG62_MIZYE	7.0e-158	563.1	99.02%	48.17%	Major facilitator superfamily domain-containing protein 6-like protein B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN013581.1	sp|K1Q8Q9|K1Q8Q9_CRAGI	1.5e-159	568.2	68.76%	92.20%	Forkhead box protein J1-A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN013582.1	sp|K1Q1Q0|K1Q1Q0_CRAGI	2.2e-89	335.5	100.00%	60.42%	WW domain-binding protein 11;OS=Crassostrea;PE=4;SV=1	GO:0006396|
GN013583.1	sp|K1R8N3|K1R8N3_CRAGI	3.7e-292	1009.2	100.00%	83.74%	Exocyst complex component 7;OS=Crassostrea;PE=3;SV=1	GO:0000145|	GO:0006887|GO:0015031|
GN013584.1	sp|K1QGT7|K1QGT7_CRAGI	1.4e-170	604.4	100.00%	95.44%	Caspase-3;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN013585.1	sp|K1R8M7|K1R8M7_CRAGI	3.4e-296	1023.5	85.43%	70.78%	Polycomb protein Asx;OS=Crassostrea;PE=4;SV=1
GN013586.1	sp|K1QNA8|K1QNA8_CRAGI	1.1e-247	862.1	99.89%	70.86%	Uncharacterized protein C18orf34;OS=Crassostrea;PE=4;SV=1
GN013587.1	sp|K1QGT2|K1QGT2_CRAGI	1.2e-30	139.8	28.19%	65.71%	Uncharacterized protein C7orf50;OS=Crassostrea;PE=4;SV=1
GN013588.1	sp|V4BH79|V4BH79_LOTGI	1.0e-59	235.7	69.23%	67.06%	UMP-CMP kinase;OS=Lottia;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0005524|GO:0004127|GO:0009041|	GO:0006207|GO:0006221|
GN013589.1	sp|K1Q8P5|K1Q8P5_CRAGI	1.6e-129	468.0	99.09%	73.03%	Poly [ADP-ribose] polymerase 1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN013590.1	sp|K1Q1N2|K1Q1N2_CRAGI	0.0e+00	1586.6	97.99%	65.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013591.1	sp|K1R8M3|K1R8M3_CRAGI	7.6e-240	835.5	100.00%	77.62%	Mediator of RNA polymerase II transcription subunit 26;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN013592.1	sp|K1QGS6|K1QGS6_CRAGI	0.0e+00	1423.7	94.78%	71.64%	Protein kinase kin1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013593.1	sp|K1QGS2|K1QGS2_CRAGI	1.9e-181	640.6	100.00%	93.81%	Putative transcription factor SOX-14;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN013594.1	sp|K1Q1L7|K1Q1L7_CRAGI	4.4e-126	457.2	73.60%	61.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013595.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	1.3e-32	146.0	96.71%	30.72%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN013596.1	sp|K1Q0E8|K1Q0E8_CRAGI	8.0e-65	252.3	99.47%	71.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013597.1	sp|A0A210QQ78|A0A210QQ78_MIZYE	5.8e-40	170.2	80.00%	40.37%	Mu-type opioid receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011070.1	sp|K1QDP6|K1QDP6_CRAGI	7.4e-22	108.6	92.78%	56.18%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013598.1	sp|K1Q7P1|K1Q7P1_CRAGI	6.4e-117	426.0	99.66%	73.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013599.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	2.0e-45	188.3	94.25%	39.59%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN013600.1	sp|K1R0N7|K1R0N7_CRAGI	1.6e-57	227.6	96.55%	76.98%	Putative nuclease HARBI1;OS=Crassostrea;PE=4;SV=1
GN013601.1	sp|A0A210PR84|A0A210PR84_MIZYE	1.0e-99	369.4	80.83%	55.74%	Neuropeptide Y receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004983|
GN013602.1	sp|K1QI71|K1QI71_CRAGI	5.5e-15	87.8	12.94%	82.00%	Glutamate receptor delta-1 subunit;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN013603.1	sp|A0A210QSW9|A0A210QSW9_MIZYE	3.2e-117	427.2	97.87%	65.63%	L-threonine dehydratase catabolic TdcB;OS=Mizuhopecten;PE=4;SV=1
GN013607.1	sp|K1QC33|K1QC33_CRAGI	1.8e-301	1040.4	100.00%	88.52%	Nuclear factor 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0006260|
GN013608.1	sp|K1Q4U7|K1Q4U7_CRAGI	0.0e+00	1785.4	95.90%	88.66%	AP-3 complex subunit delta-1;OS=Crassostrea;PE=4;SV=1	GO:0030123|	GO:0006886|GO:0016192|
GN013609.1	sp|K1PQ36|K1PQ36_CRAGI	5.2e-124	449.5	100.00%	86.32%	Transcription initiation factor IIE subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0005673|	GO:0003677|GO:0003743|	GO:0006367|
GN011071.1	sp|K1REV9|K1REV9_CRAGI	1.9e-187	661.4	100.00%	62.84%	Mucolipin-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005261|
GN013611.1	sp|K1PXD2|K1PXD2_CRAGI	1.0e-75	288.9	96.73%	58.05%	Putative thiopurine S-methyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0008119|
GN013612.1	sp|K1QXT1|K1QXT1_CRAGI	2.0e-117	427.9	80.47%	80.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011072.1	sp|K1R916|K1R916_CRAGI	7.7e-49	198.7	91.24%	72.58%	Structural maintenance of chromosomes protein;OS=Crassostrea;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0005524|	GO:0051276|
GN013613.1	sp|K1QC16|K1QC16_CRAGI	0.0e+00	1505.7	99.89%	78.60%	Ovochymase-1;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN013615.1	sp|K1QC10|K1QC10_CRAGI	3.5e-303	1045.8	100.00%	93.74%	GTP-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013616.1	sp|K1RA78|K1RA78_CRAGI	3.5e-44	184.1	65.45%	57.23%	Laminin subunit alpha-2;OS=Crassostrea;PE=4;SV=1
GN013617.1	sp|K1PZM5|K1PZM5_CRAGI	0.0e+00	1148.3	100.00%	74.26%	Tetratricopeptide repeat protein 15;OS=Crassostrea;PE=4;SV=1
GN011073.1	sp|A0A210PRK7|A0A210PRK7_MIZYE	5.2e-44	182.6	93.60%	84.48%	Structural maintenance of chromosomes protein;OS=Mizuhopecten;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0005524|	GO:0051276|
GN013618.1	sp|A0A210QAI9|A0A210QAI9_MIZYE	5.6e-112	411.0	99.74%	47.66%	Suppression of tumorigenicity 18 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN013619.1	sp|K1R3T0|K1R3T0_CRAGI	1.4e-160	572.0	61.13%	72.86%	Protein-L-isoaspartate O-methyltransferase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0004719|
GN013620.1	sp|K1R8F5|K1R8F5_CRAGI	0.0e+00	1648.3	84.83%	69.90%	Lethal(3)malignant brain tumor-like 4 protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN013621.1	sp|A0A210R5Y7|A0A210R5Y7_MIZYE	2.8e-27	128.3	97.64%	29.95%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN013622.1	sp|K1RF09|K1RF09_CRAGI	0.0e+00	1281.5	100.00%	78.04%	Coiled-coil and C2 domain-containing protein 2A;OS=Crassostrea;PE=4;SV=1
GN011074.1	sp|A0A210PRK7|A0A210PRK7_MIZYE	6.4e-288	996.1	88.36%	78.14%	Structural maintenance of chromosomes protein;OS=Mizuhopecten;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0005524|	GO:0051276|
GN013624.1	sp|K1R2E7|K1R2E7_CRAGI	1.8e-250	870.9	93.10%	69.62%	XK-related protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013625.1	sp|K1RF15|K1RF15_CRAGI	2.3e-163	580.5	92.45%	92.46%	Nuclear inhibitor of protein phosphatase 1;OS=Crassostrea;PE=4;SV=1
GN013626.1	sp|A0A2C9JH48|A0A2C9JH48_BIOGL	6.5e-12	76.6	34.65%	59.42%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003700|
GN013628.1	sp|K1RY40|K1RY40_CRAGI	4.1e-66	256.5	94.97%	79.29%	Transcription factor 23;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN013629.1	sp|K1RRD7|K1RRD7_CRAGI	4.7e-101	373.2	90.71%	66.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013631.1	sp|K1R2F3|K1R2F3_CRAGI	3.8e-68	263.8	86.84%	54.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011075.1	sp|K1RJA7|K1RJA7_CRAGI	0.0e+00	1129.0	98.34%	60.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013632.1	sp|K1R2G0|K1R2G0_CRAGI	9.1e-17	91.7	85.11%	64.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013633.1	sp|K1RF28|K1RF28_CRAGI	9.2e-257	891.7	99.70%	67.37%	Amiloride-sensitive sodium channel subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN013635.1	sp|K1QBD7|K1QBD7_CRAGI	0.0e+00	2333.1	99.93%	78.82%	Nephrocystin-4;OS=Crassostrea;PE=4;SV=1	GO:0005856|GO:0097730|	GO:0090090|
GN013636.1	sp|K1QSY9|K1QSY9_CRAGI	2.4e-46	190.3	100.00%	91.45%	Huntingtin-interacting protein K;OS=Crassostrea;PE=4;SV=1
GN011076.1	sp|K1QZN9|K1QZN9_CRAGI	3.7e-158	563.1	94.55%	82.96%	Tartrate-resistant acid phosphatase type 5;OS=Crassostrea;PE=4;SV=1	GO:0003993|GO:0046872|
GN013637.1	sp|K1R2G7|K1R2G7_CRAGI	4.0e-151	540.4	92.01%	72.86%	Ran-binding protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0046907|
GN013638.1	sp|K1R8I0|K1R8I0_CRAGI	7.8e-69	265.8	65.87%	94.12%	tRNA selenocysteine 1-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN013639.1	sp|K1QB91|K1QB91_CRAGI	1.6e-24	117.9	54.76%	85.29%	p21-activated protein kinase-interacting protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013640.1	sp|K1QJ36|K1QJ36_CRAGI	7.2e-240	835.1	99.79%	89.46%	Muscle, skeletal receptor tyrosine protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN013641.1	sp|K1QPU0|K1QPU0_CRAGI	3.5e-09	67.0	36.03%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013642.1	sp|K1QJ36|K1QJ36_CRAGI	3.6e-58	230.3	95.59%	58.97%	Muscle, skeletal receptor tyrosine protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN013643.1	sp|K1Q3U9|K1Q3U9_CRAGI	0.0e+00	1712.2	66.64%	82.27%	Coiled-coil domain-containing protein 17;OS=Crassostrea;PE=4;SV=1
GN011077.1	sp|K1QSX8|K1QSX8_CRAGI	0.0e+00	1298.5	96.32%	86.43%	ATPase family AAA domain-containing protein 2B;OS=Crassostrea;PE=4;SV=1	GO:0016507|	GO:0003857|GO:0005524|GO:0016887|GO:0004300|	GO:0006325|GO:0006635|GO:0006355|
GN013644.1	sp|K1QB93|K1QB93_CRAGI	2.1e-250	870.2	100.00%	89.50%	DNA methyltransferase 1-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035267|	GO:0003677|GO:0008168|	GO:0006338|GO:0006281|GO:0043968|GO:0043967|GO:0045892|
GN013645.1	sp|K1QJ46|K1QJ46_CRAGI	2.5e-255	886.7	98.22%	78.78%	Putative methylcrotonoyl-CoA carboxylase beta chain, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN013646.1	sp|K1QQR0|K1QQR0_CRAGI	5.8e-89	332.8	98.70%	69.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013647.1	sp|K1RAY2|K1RAY2_CRAGI	2.2e-199	700.7	95.47%	74.09%	tRNA isopentenyltransferase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003676|GO:0016740|	GO:0008033|
GN013648.1	sp|K1Q3V3|K1Q3V3_CRAGI	4.3e-163	579.7	89.73%	90.66%	Myc protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|GO:0046983|
GN013649.1	sp|K1R6K9|K1R6K9_CRAGI	4.5e-130	469.5	99.24%	85.77%	Bifunctional polynucleotide phosphatase/kinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN013651.1	sp|K1QZT6|K1QZT6_CRAGI	5.4e-132	476.1	98.98%	77.59%	Transmembrane protein 53;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013652.1	sp|K1QQE8|K1QQE8_CRAGI	3.3e-145	520.0	93.36%	96.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013653.1	sp|K1RD06|K1RD06_CRAGI	6.0e-82	311.6	21.68%	68.52%	Collagen alpha-1(IX) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN011078.1	sp|A0A210QTH7|A0A210QTH7_MIZYE	1.3e-183	648.3	95.31%	70.80%	Trifunctional enzyme subunit beta, mitochondrial;OS=Mizuhopecten;PE=3;SV=1	GO:0016747|
GN013654.1	sp|K1R6K6|K1R6K6_CRAGI	2.7e-28	130.6	77.08%	66.36%	Transmembrane protein C20orf46;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013655.1	sp|K1QZT3|K1QZT3_CRAGI	0.0e+00	1140.2	100.00%	83.93%	Serrate RNA effector molecule-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0006397|
GN013656.1	sp|K1QQE6|K1QQE6_CRAGI	4.0e-163	579.7	89.41%	90.10%	Trans-2,3-enoyl-CoA reductase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016627|	GO:0006629|
GN013657.1	sp|K1RWD4|K1RWD4_CRAGI	2.2e-218	763.5	100.00%	99.47%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013658.1	sp|K1RD04|K1RD04_CRAGI	1.9e-45	188.0	59.38%	78.26%	Tctex1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN013659.1	sp|K1R6K1|K1R6K1_CRAGI	1.6e-70	271.6	100.00%	59.73%	Tctex1 domain-containing protein 1-B;OS=Crassostrea;PE=4;SV=1
GN013660.1	sp|K1QZS9|K1QZS9_CRAGI	1.3e-103	381.3	100.00%	91.43%	Tctex1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN013661.1	sp|K1QQE2|K1QQE2_CRAGI	4.0e-105	386.3	100.00%	89.10%	Tctex1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN013662.1	sp|K1RWD1|K1RWD1_CRAGI	2.3e-176	624.0	100.00%	85.10%	Krueppel-like factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN013663.1	sp|K1R6J7|K1R6J7_CRAGI	3.7e-218	762.7	100.00%	98.94%	Actin;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013664.1	sp|K1QCT6|K1QCT6_CRAGI	3.6e-132	478.4	85.64%	32.27%	Tankyrase-1;OS=Crassostrea;PE=4;SV=1	GO:0008380|
GN013665.1	sp|C4NY61|C4NY61_CRAGI	2.8e-128	463.8	91.86%	83.70%	Actin;OS=Crassostrea;PE=2;SV=1	GO:0005524|
GN013666.1	sp|K1Q821|K1Q821_CRAGI	9.2e-177	625.2	100.00%	82.80%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013668.1	sp|K1QWP8|K1QWP8_CRAGI	2.0e-216	756.9	100.00%	98.14%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013670.1	sp|A0A2B4RV85|A0A2B4RV85_STYPI	2.9e-16	89.7	78.21%	68.33%	Putative nuclease HARBI1;OS=Stylophora;PE=4;SV=1
GN013671.1	sp|K1RWD4|K1RWD4_CRAGI	8.0e-177	625.2	100.00%	93.01%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN010815.1	sp|K1QLK4|K1QLK4_CRAGI	2.7e-14	83.6	73.79%	46.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011079.1	sp|A0A210Q076|A0A210Q076_MIZYE	2.2e-248	863.6	99.81%	76.52%	Non-specific lipid-transfer protein;OS=Mizuhopecten;PE=3;SV=1	GO:0016747|
GN013672.1	sp|K1PH78|K1PH78_CRAGI	3.0e-37	161.4	84.31%	36.15%	Werner syndrome ATP-dependent helicase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN013673.1	sp|K1Q821|K1Q821_CRAGI	6.3e-218	761.9	100.00%	99.47%	Actin, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013674.1	sp|K1QWP8|K1QWP8_CRAGI	6.3e-218	761.9	100.00%	99.47%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013675.1	sp|C4NY62|C4NY62_CRAGI	6.3e-218	761.9	100.00%	99.47%	Actin;OS=Crassostrea;PE=2;SV=1	GO:0005524|
GN013676.1	sp|K1QWP8|K1QWP8_CRAGI	1.4e-217	760.8	100.00%	99.20%	Actin-2;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN013677.1	sp|K1QMN1|K1QMN1_CRAGI	9.6e-37	159.1	58.25%	73.21%	Growth arrest and DNA-damage-inducible protein GADD45 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN013678.1	sp|K1RTZ8|K1RTZ8_CRAGI	1.9e-69	267.3	100.00%	90.48%	Growth arrest and DNA-damage-inducible protein GADD45 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN013679.1	sp|K1R235|K1R235_CRAGI	2.6e-49	200.3	90.30%	80.33%	Growth arrest and DNA-damage-inducible protein GADD45 gamma;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN013680.1	sp|K1RXW6|K1RXW6_CRAGI	4.3e-249	865.9	100.00%	77.06%	Atrial gland-specific antigen;OS=Crassostrea;PE=4;SV=1	GO:0005615|	GO:0019239|
GN013681.1	sp|A0A1S3IHK7|A0A1S3IHK7_LINUN	1.5e-20	104.4	88.57%	52.08%	uncharacterized protein LOC106164102;OS=Lingula;PE=4;SV=1	GO:0008270|
GN013682.1	sp|K1QJM2|K1QJM2_CRAGI	1.1e-116	425.2	90.79%	76.73%	Protein YIPF;OS=Crassostrea;PE=3;SV=1	GO:0005794|GO:0016021|	GO:0016192|
GN013684.1	sp|K1PDD4|K1PDD4_CRAGI	7.2e-74	282.7	100.00%	74.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013685.1	sp|K1PJS3|K1PJS3_CRAGI	5.2e-163	579.7	72.81%	84.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013686.1	sp|K1PZA0|K1PZA0_CRAGI	7.1e-276	956.1	99.83%	55.91%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN013687.1	sp|K1QM60|K1QM60_CRAGI	0.0e+00	1409.4	100.00%	88.53%	Pantothenate kinase 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004594|	GO:0015937|
GN013692.1	sp|K1Q678|K1Q678_CRAGI	2.3e-57	227.6	97.06%	61.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN011081.1	sp|K1QH27|K1QH27_CRAGI	5.2e-237	825.5	100.00%	93.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013693.1	sp|K1R5J3|K1R5J3_CRAGI	5.0e-121	439.5	90.46%	82.63%	Leucine-rich repeat serine/threonine-protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013694.1	sp|A0A2C9JFZ0|A0A2C9JFZ0_BIOGL	2.8e-43	180.3	99.27%	61.48%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005524|GO:0004672|
GN013695.1	sp|K1R5J3|K1R5J3_CRAGI	7.6e-247	858.6	99.83%	79.52%	Leucine-rich repeat serine/threonine-protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN013696.1	sp|K1QYM4|K1QYM4_CRAGI	1.8e-129	468.0	71.35%	83.64%	D-beta-hydroxybutyrate dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN013698.1	sp|K1QPF2|K1QPF2_CRAGI	0.0e+00	1177.5	98.67%	78.06%	5-azacytidine-induced protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005929|	GO:0035735|
GN013699.1	sp|K1QPF2|K1QPF2_CRAGI	1.3e-107	396.0	62.97%	55.99%	5-azacytidine-induced protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005929|	GO:0035735|
GN013701.1	sp|K1RVI8|K1RVI8_CRAGI	4.9e-120	436.8	100.00%	87.06%	Chromobox-like protein 8;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN013702.1	sp|K1QPS0|K1QPS0_CRAGI	5.5e-139	499.2	97.82%	84.70%	Plasminogen;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0004252|	GO:0007596|
GN013703.1	sp|K1PWQ7|K1PWQ7_CRAGI	4.5e-27	127.5	25.18%	87.32%	Collagen alpha-5(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013704.1	sp|K1PHJ9|K1PHJ9_CRAGI	6.7e-21	107.1	25.75%	68.42%	Collagen-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013705.1	sp|K1QPR3|K1QPR3_CRAGI	1.7e-135	487.6	98.55%	86.67%	Suppressor of SWI4 1-like protein;OS=Crassostrea;PE=4;SV=1
GN013706.1	sp|K1RA87|K1RA87_CRAGI	0.0e+00	1287.3	100.00%	62.94%	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013707.1	sp|K1RFX2|K1RFX2_CRAGI	4.5e-119	433.7	94.48%	56.49%	Transcription elongation factor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003746|
GN013708.1	sp|K1Q077|K1Q077_CRAGI	6.0e-63	246.1	97.42%	60.64%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN011082.1	sp|K1Q220|K1Q220_CRAGI	6.0e-115	419.5	100.00%	73.72%	DEP domain-containing mTOR-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN013710.1	sp|K1Q077|K1Q077_CRAGI	9.0e-68	261.9	97.01%	71.43%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN013711.1	sp|A6YRK7|A6YRK7_CRAGI	3.6e-229	799.7	99.80%	73.84%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN013712.1	sp|A6YRK7|A6YRK7_CRAGI	6.6e-90	335.9	99.56%	67.71%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN013713.1	sp|K1QNX0|K1QNX0_CRAGI	7.1e-97	359.4	97.88%	59.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013714.1	sp|A0A210PNT7|A0A210PNT7_MIZYE	3.8e-30	136.7	81.94%	59.83%	Cholecystokinin receptor type A;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004983|
GN011083.1	sp|K1R8X6|K1R8X6_CRAGI	0.0e+00	2912.5	100.00%	72.62%	HEAT repeat-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN013717.1	sp|K1QJC3|K1QJC3_CRAGI	4.1e-83	313.2	99.49%	74.49%	Methyltransferase-like protein 12, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN013721.1	sp|K1QJC3|K1QJC3_CRAGI	6.6e-34	149.8	95.89%	48.89%	Methyltransferase-like protein 12, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN013722.1	sp|K1QJC3|K1QJC3_CRAGI	1.8e-11	73.6	93.94%	55.74%	Methyltransferase-like protein 12, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN013723.1	sp|K1R4L5|K1R4L5_CRAGI	2.1e-29	134.0	92.62%	61.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011084.1	sp|A0A210PNP9|A0A210PNP9_MIZYE	1.1e-207	729.2	98.67%	47.91%	Histone H2A deubiquitinase MYSM1;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|GO:0004843|	GO:0035522|
GN013724.1	sp|K1QNG0|K1QNG0_CRAGI	1.1e-186	658.3	98.79%	78.57%	Polycystin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN013725.1	sp|A0A210PS86|A0A210PS86_MIZYE	3.9e-248	863.6	99.59%	47.92%	Location of vulva defective 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN013726.1	sp|A0A210PSA7|A0A210PSA7_MIZYE	3.6e-300	1036.9	97.36%	41.69%	Polycystic kidney disease protein 1-like 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN013727.1	sp|K1R913|K1R913_CRAGI	3.3e-14	84.0	58.18%	42.86%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013728.1	sp|K1QTW0|K1QTW0_CRAGI	2.9e-13	80.1	63.37%	52.38%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013729.1	sp|K1QTW0|K1QTW0_CRAGI	1.2e-149	537.0	79.82%	31.45%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013730.1	sp|K1PMG4|K1PMG4_CRAGI	1.8e-31	141.4	79.41%	47.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN011085.1	sp|K1QYH8|K1QYH8_CRAGI	0.0e+00	1550.8	100.00%	70.36%	Latrophilin-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0030246|GO:0004930|	GO:0007166|
GN013740.1	sp|K1PZ75|K1PZ75_CRAGI	3.3e-47	193.4	100.00%	73.57%	Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase PTEN;OS=Crassostrea;PE=4;SV=1	GO:0004725|GO:0008138|
GN013741.1	sp|K1PRN6|K1PRN6_CRAGI	1.9e-272	943.7	100.00%	71.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN013742.1	sp|K1QZN6|K1QZN6_CRAGI	1.0e-80	306.6	64.01%	52.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN013743.1	sp|K1QDP0|K1QDP0_CRAGI	2.3e-132	478.0	91.08%	64.04%	Cadherin-89D;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007156|
GN013744.1	sp|K1Q6N1|K1Q6N1_CRAGI	4.9e-265	919.1	90.56%	77.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013747.1	sp|K1QGZ9|K1QGZ9_CRAGI	4.8e-23	112.5	96.67%	69.32%	Synaptogyrin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013748.1	sp|K1Q2C0|K1Q2C0_CRAGI	4.6e-136	490.7	100.00%	52.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013749.1	sp|K1PUU1|K1PUU1_CRAGI	0.0e+00	1937.2	95.89%	95.42%	Short transient receptor potential channel 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005262|
GN013750.1	sp|K1R2R1|K1R2R1_CRAGI	1.2e-143	515.8	59.76%	69.86%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN013751.1	sp|K1QK67|K1QK67_CRAGI	7.9e-54	215.7	60.45%	94.34%	Thymidine kinase 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0019206|
GN013752.1	sp|K1PRA6|K1PRA6_CRAGI	7.5e-289	998.8	97.84%	58.67%	Tyrosine-protein phosphatase Lar;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013753.1	sp|K1PJ47|K1PJ47_CRAGI	3.4e-93	346.7	99.51%	80.60%	Uncharacterized protein C19orf52;OS=Crassostrea;PE=4;SV=1	GO:0042721|
GN013755.1	sp|K1QBQ6|K1QBQ6_CRAGI	7.4e-283	978.8	100.00%	65.85%	ATP-dependent RNA helicase DDX24;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|GO:0008146|
GN013756.1	sp|A0A210PVW9|A0A210PVW9_MIZYE	2.5e-218	763.8	98.80%	63.26%	A disintegrin and metalloproteinase with thrombospondin motifs 7;OS=Mizuhopecten;PE=4;SV=1	GO:0004222|	GO:0007229|
GN013757.1	sp|K1PMC5|K1PMC5_CRAGI	2.7e-25	120.2	98.11%	58.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013758.1	sp|K1PBS8|K1PBS8_CRAGI	4.6e-57	226.5	94.48%	66.47%	Methyltransferase-like protein 7A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008168|
GN013759.1	sp|K1QBP8|K1QBP8_CRAGI	2.3e-60	238.0	53.85%	77.48%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN013760.1	sp|K1PJ37|K1PJ37_CRAGI	0.0e+00	2147.1	95.90%	82.52%	ATP-binding cassette sub-family A member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN013761.1	sp|K1PJ37|K1PJ37_CRAGI	0.0e+00	1663.3	95.94%	81.40%	ATP-binding cassette sub-family A member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN011086.1	sp|A0A2B4S577|A0A2B4S577_STYPI	3.0e-53	215.3	92.41%	30.94%	ATP-dependent helicase SGS1;OS=Stylophora;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN013762.1	sp|K1PBS3|K1PBS3_CRAGI	1.6e-52	211.5	85.71%	62.28%	Mpv17-like protein 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN013763.1	sp|K1QV59|K1QV59_CRAGI	1.5e-17	96.3	12.73%	95.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013764.1	sp|K1R4P6|K1R4P6_CRAGI	8.8e-296	1021.5	98.27%	61.75%	HBS1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN013765.1	sp|K1RAR4|K1RAR4_CRAGI	2.8e-97	360.1	93.26%	90.50%	Inosine triphosphate pyrophosphatase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0046872|GO:0035529|GO:0047429|GO:0000166|	GO:0009204|GO:0009117|
GN013766.1	sp|K1RH12|K1RH12_CRAGI	4.6e-137	493.0	93.79%	79.73%	Annexin;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005544|
GN013767.1	sp|K1S0E2|K1S0E2_CRAGI	4.8e-71	272.7	100.00%	83.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011087.1	sp|K1RIW4|K1RIW4_CRAGI	2.4e-84	318.9	87.24%	33.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013769.1	sp|K1S0E7|K1S0E7_CRAGI	0.0e+00	1594.3	82.71%	67.66%	DnaJ-like protein subfamily C member 14;OS=Crassostrea;PE=4;SV=1
GN013770.1	sp|K1S0E7|K1S0E7_CRAGI	4.5e-120	436.8	66.39%	90.83%	DnaJ-like protein subfamily C member 14;OS=Crassostrea;PE=4;SV=1
GN013772.1	sp|K1Q189|K1Q189_CRAGI	7.6e-31	138.7	87.27%	68.75%	F-box/WD repeat-containing protein 9;OS=Crassostrea;PE=4;SV=1
GN013775.1	sp|K1RH19|K1RH19_CRAGI	1.4e-35	155.6	98.02%	39.68%	Nanos-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0008270|	GO:0006417|
GN013776.1	sp|K1S0F4|K1S0F4_CRAGI	1.6e-98	365.2	97.75%	54.91%	Phosphatidylinositol-glycan-specific phospholipase D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0004621|
GN013777.1	sp|K1Q1L2|K1Q1L2_CRAGI	2.1e-23	114.8	42.35%	68.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013778.1	sp|K1RAS4|K1RAS4_CRAGI	9.9e-225	784.6	98.05%	90.55%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013779.1	sp|A0A2T7PA07|A0A2T7PA07_POMCA	2.2e-11	73.6	49.38%	82.05%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005634|	GO:0046872|
GN011088.1	sp|K1PUS1|K1PUS1_CRAGI	1.1e-78	298.5	96.79%	70.48%	Cytochrome P450 3A11;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN013781.1	sp|K1Q6H7|K1Q6H7_CRAGI	3.1e-24	117.1	99.31%	62.33%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|
GN013782.1	sp|K1RAS4|K1RAS4_CRAGI	9.9e-225	784.6	98.05%	90.55%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013784.1	sp|K1R4Q8|K1R4Q8_CRAGI	1.3e-190	671.4	84.87%	87.43%	24-dehydrocholesterol reductase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0016491|
GN013785.1	sp|K1RAS4|K1RAS4_CRAGI	7.9e-64	249.2	100.00%	77.42%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN013786.1	sp|K1RAS4|K1RAS4_CRAGI	7.4e-182	642.1	95.09%	89.70%	E3 ubiquitin-protein ligase UHRF1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0016874|GO:0046872|
GN011089.1	sp|K1PIH9|K1PIH9_CRAGI	2.8e-09	67.4	71.53%	37.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013790.1	sp|K1RAU8|K1RAU8_CRAGI	3.6e-35	153.7	42.53%	100.00%	Eukaryotic translation initiation factor 3 subunit E;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0071540|	GO:0003743|	GO:0001732|
GN013791.1	sp|K1R4T2|K1R4T2_CRAGI	9.4e-109	399.1	100.00%	70.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0072572|GO:0061630|GO:0008270|	GO:0016055|
GN013792.1	sp|K1QV91|K1QV91_CRAGI	1.3e-133	481.5	99.00%	75.93%	1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon;OS=Crassostrea;PE=4;SV=1	GO:0016746|
GN013793.1	sp|K1S0I9|K1S0I9_CRAGI	6.4e-54	216.5	77.96%	56.25%	Troponin C, skeletal muscle;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN013794.1	sp|K1RH32|K1RH32_CRAGI	7.6e-181	639.0	100.00%	68.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013795.1	sp|K1S0I9|K1S0I9_CRAGI	4.8e-92	344.0	99.77%	40.40%	Troponin C, skeletal muscle;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN013796.1	sp|K1R4T2|K1R4T2_CRAGI	9.4e-109	399.1	100.00%	70.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0072572|GO:0061630|GO:0008270|	GO:0016055|
GN013797.1	sp|K1RAU8|K1RAU8_CRAGI	2.4e-218	763.5	100.00%	92.98%	Eukaryotic translation initiation factor 3 subunit E;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0071540|	GO:0003743|	GO:0001732|
GN013799.1	sp|K1S0J4|K1S0J4_CRAGI	4.7e-179	633.3	87.48%	87.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013800.1	sp|K1QV94|K1QV94_CRAGI	4.3e-31	139.8	97.86%	52.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013801.1	sp|K1QUA2|K1QUA2_CRAGI	1.5e-97	361.3	95.54%	79.53%	Josephin-2;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN013802.1	sp|K1QKG2|K1QKG2_CRAGI	1.1e-41	175.3	81.40%	51.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN013803.1	sp|K1RAS9|K1RAS9_CRAGI	9.4e-38	161.8	98.37%	71.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013804.1	sp|K1RRY6|K1RRY6_CRAGI	7.6e-80	302.4	100.00%	70.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN013805.1	sp|K1R178|K1R178_CRAGI	1.4e-79	301.6	99.56%	63.39%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN013806.1	sp|K1R178|K1R178_CRAGI	8.6e-158	562.4	100.00%	58.43%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN013807.1	sp|K1QU95|K1QU95_CRAGI	1.7e-135	488.0	97.02%	70.87%	Galanin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013808.1	sp|K1QU95|K1QU95_CRAGI	5.9e-136	489.6	97.02%	71.15%	Galanin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013809.1	sp|K1P6W1|K1P6W1_CRAGI	3.2e-11	74.7	29.18%	53.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013810.1	sp|K1R507|K1R507_CRAGI	5.3e-149	532.7	98.76%	78.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013811.1	sp|K1R507|K1R507_CRAGI	3.8e-69	266.9	100.00%	58.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013812.1	sp|K1QKF8|K1QKF8_CRAGI	5.0e-168	595.9	96.23%	91.80%	S-(hydroxymethyl)glutathione dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051903|GO:0008270|	GO:0006069|
GN013813.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	1.0e-23	115.2	96.77%	48.33%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN013814.1	sp|K1RRY2|K1RRY2_CRAGI	3.8e-256	891.3	65.12%	40.52%	NFX1-type zinc finger-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN013815.1	sp|A0A2R2MIQ9|A0A2R2MIQ9_LINUN	9.3e-195	687.2	92.52%	30.68%	NFX1-type zinc finger-containing protein 1-like;OS=Lingula;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN013818.1	sp|K1R7P6|K1R7P6_CRAGI	8.0e-28	128.3	68.60%	100.00%	Leucine-rich repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN013822.1	sp|K1QNA9|K1QNA9_CRAGI	6.9e-20	103.6	91.49%	28.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011093.1	sp|A0A210R699|A0A210R699_MIZYE	1.4e-115	422.9	82.30%	35.18%	Toll-like receptor 6;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN013824.1	sp|K1QMT1|K1QMT1_CRAGI	2.1e-167	594.0	100.00%	84.75%	DnaJ-like protein subfamily B member 4;OS=Crassostrea;PE=4;SV=1	GO:0051082|	GO:0006457|
GN013826.1	sp|K1QVC0|K1QVC0_CRAGI	4.1e-100	370.2	99.31%	65.63%	Transient receptor potential cation channel subfamily A member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005216|
GN013828.1	sp|K1QVC0|K1QVC0_CRAGI	5.3e-69	268.1	91.67%	62.10%	Transient receptor potential cation channel subfamily A member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005216|
GN013830.1	sp|A0A0L8GVY8|A0A0L8GVY8_OCTBM	1.5e-25	121.7	83.63%	40.54%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN013831.1	sp|K1Q1F4|K1Q1F4_CRAGI	5.5e-220	768.8	99.50%	91.75%	60S ribosomal protein L3;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN013832.1	sp|K1Q8I4|K1Q8I4_CRAGI	0.0e+00	1970.7	99.20%	87.80%	F-box/WD repeat-containing protein 10;OS=Crassostrea;PE=4;SV=1
GN013833.1	sp|K1QUG1|K1QUG1_CRAGI	2.6e-162	577.0	100.00%	82.20%	Alanine--glyoxylate aminotransferase 2-like 1;OS=Crassostrea;PE=3;SV=1	GO:0030170|GO:0008483|
GN013834.1	sp|K1QSQ3|K1QSQ3_CRAGI	2.9e-120	438.3	77.47%	48.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013835.1	sp|K1PKP7|K1PKP7_CRAGI	4.7e-71	273.9	91.01%	56.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013837.1	sp|A0A210PGU4|A0A210PGU4_MIZYE	1.1e-30	138.3	86.44%	77.23%	Nascent polypeptide-associated complex subunit alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0005854|
GN013838.1	sp|A0A210PGU4|A0A210PGU4_MIZYE	4.8e-13	78.6	96.43%	77.36%	Nascent polypeptide-associated complex subunit alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0005854|
GN013839.1	sp|K1PZX8|K1PZX8_CRAGI	7.4e-61	240.0	50.60%	71.43%	Adenosine receptor A2b;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013840.1	sp|K1PZX8|K1PZX8_CRAGI	1.0e-110	405.6	94.31%	65.62%	Adenosine receptor A2b;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN011095.1	sp|A0A1S3I117|A0A1S3I117_LINUN	2.6e-59	234.6	96.13%	45.99%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN013843.1	sp|K1QNZ8|K1QNZ8_CRAGI	1.9e-139	500.7	94.78%	93.28%	Elongation of very long chain fatty acids protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN013844.1	sp|K1RV42|K1RV42_CRAGI	0.0e+00	1239.9	88.50%	77.34%	FCH domain only protein 2;OS=Crassostrea;PE=4;SV=1
GN013847.1	sp|K1R517|K1R517_CRAGI	4.7e-166	590.1	64.35%	91.81%	Superkiller viralicidic activity 2-like 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003723|GO:0003724|	GO:0006401|
GN013848.1	sp|W4YMY5|W4YMY5_STRPU	1.6e-28	130.6	93.02%	72.15%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005783|	GO:0045454|GO:0060548|
GN013849.1	sp|K1QEM9|K1QEM9_CRAGI	3.0e-94	350.1	100.00%	85.57%	Tctex1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN011096.1	sp|A0A210PUS9|A0A210PUS9_MIZYE	4.2e-255	886.3	99.16%	61.75%	BTB/POZ domain-containing protein 16;OS=Mizuhopecten;PE=4;SV=1
GN013850.1	sp|K1QFL5|K1QFL5_CRAGI	1.9e-28	132.5	61.34%	34.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011097.1	sp|K1Q099|K1Q099_CRAGI	1.0e-134	485.7	82.96%	59.84%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN011098.1	sp|K1Q099|K1Q099_CRAGI	6.0e-139	499.6	95.91%	60.10%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN010816.1	sp|K1QKK9|K1QKK9_CRAGI	1.1e-36	158.3	77.04%	74.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN011099.1	sp|K1Q099|K1Q099_CRAGI	7.0e-110	402.9	98.59%	54.34%	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008375|
GN011100.1	sp|K1QVS3|K1QVS3_CRAGI	0.0e+00	1139.8	100.00%	84.77%	Thimet oligopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004222|
GN011101.1	sp|K1QVS3|K1QVS3_CRAGI	1.3e-254	884.4	99.83%	68.58%	Thimet oligopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004222|
GN011102.1	sp|K1Q2Q4|K1Q2Q4_CRAGI	0.0e+00	1999.2	85.29%	86.41%	Patched-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011105.1	sp|K1PVA1|K1PVA1_CRAGI	0.0e+00	1529.2	100.00%	97.62%	Transitional endoplasmic reticulum ATPase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016787|
GN011106.1	sp|K1PNN8|K1PNN8_CRAGI	4.5e-107	393.3	100.00%	70.45%	BRCA1-A complex subunit MERIT40;OS=Crassostrea;PE=4;SV=1	GO:0070531|GO:0070552|	GO:0045739|
GN010817.1	sp|K1QFZ6|K1QFZ6_CRAGI	7.3e-25	119.8	47.49%	48.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011107.1	sp|K1QVR9|K1QVR9_CRAGI	1.4e-225	788.5	62.92%	83.49%	Membralin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011108.1	sp|K1QG39|K1QG39_CRAGI	1.9e-131	474.9	89.55%	54.65%	Ceramide kinase;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN011109.1	sp|A0A210PEJ7|A0A210PEJ7_MIZYE	2.3e-88	331.3	94.64%	51.35%	Serine/threonine-protein kinase mos;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004674|
GN011110.1	sp|K1R5N9|K1R5N9_CRAGI	3.6e-61	240.7	53.55%	83.33%	Syntaxin-7;OS=Crassostrea;PE=3;SV=1	GO:0005623|GO:0016021|	GO:0005484|	GO:0006886|GO:0016192|
GN011111.1	sp|K1RBJ7|K1RBJ7_CRAGI	4.1e-85	320.5	100.00%	79.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0031110|
GN011112.1	sp|K1QYB0|K1QYB0_CRAGI	1.3e-30	140.6	100.00%	34.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011113.1	sp|V4AE92|V4AE92_LOTGI	7.1e-37	159.1	93.75%	53.73%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN010818.1	sp|K1QS04|K1QS04_CRAGI	2.4e-76	290.4	100.00%	83.13%	Growth arrest and DNA-damage-inducible protein GADD45 alpha;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0051726|
GN011114.1	sp|A0A2B4R6Q7|A0A2B4R6Q7_STYPI	2.1e-59	235.3	96.92%	34.03%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|GO:0008270|
GN011115.1	sp|K1PI93|K1PI93_CRAGI	8.5e-142	508.8	100.00%	73.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011116.1	sp|K1PBV7|K1PBV7_CRAGI	1.3e-111	408.3	97.91%	80.00%	Cytochrome c heme lyase;OS=Crassostrea;PE=3;SV=1	GO:0005743|	GO:0004408|GO:0046872|
GN011117.1	sp|K1QS32|K1QS32_CRAGI	1.6e-39	169.9	34.43%	28.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011118.1	sp|A0A210PNZ5|A0A210PNZ5_MIZYE	1.4e-93	348.6	99.07%	53.92%	S-phase kinase-associated protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN011119.1	sp|K1QS03|K1QS03_CRAGI	5.7e-48	196.1	94.87%	62.84%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN011120.1	sp|K1QI31|K1QI31_CRAGI	2.2e-43	180.3	100.00%	85.98%	S-phase kinase-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN011121.1	sp|K1QI31|K1QI31_CRAGI	1.3e-43	181.0	100.00%	85.98%	S-phase kinase-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN011122.1	sp|K1QRT1|K1QRT1_CRAGI	5.0e-157	560.1	97.89%	55.56%	Protein toll;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN010819.1	sp|K1PJF5|K1PJF5_CRAGI	2.6e-293	1013.8	98.14%	47.69%	Transmembrane protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011125.1	sp|K1R340|K1R340_CRAGI	1.6e-132	479.6	33.03%	79.01%	Zinc transporter ZIP12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN011126.1	sp|B3MEH7|B3MEH7_DROAN	3.6e-10	71.6	49.86%	25.26%	Uncharacterized protein;OS=Drosophila;PE=4;SV=1	GO:0044295|GO:0030425|GO:0016021|GO:0043025|GO:0005886|GO:0071666|GO:0031982|	GO:0008201|	GO:0016199|GO:0070983|GO:0035050|GO:0009649|GO:0008406|GO:0008045|GO:0046716|GO:0003151|GO:0072499|GO:0030335|GO:0022409|GO:0050773|GO:2000274|GO:0035385|GO:0007432|
GN011127.1	sp|A0A210PQ57|A0A210PQ57_MIZYE	0.0e+00	1372.5	99.93%	62.70%	Rho-associated protein kinase 2;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0017049|GO:0046872|GO:0004674|	GO:2000114|GO:0051492|GO:0007266|
GN011128.1	sp|K1QLI2|K1QLI2_CRAGI	2.7e-43	182.6	76.45%	29.25%	Toll-like receptor 6;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN010820.1	sp|K1QS20|K1QS20_CRAGI	2.2e-27	129.4	25.56%	43.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011130.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	9.2e-36	155.6	93.49%	50.31%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN011133.1	sp|A0A210QX71|A0A210QX71_MIZYE	6.4e-29	132.1	88.89%	78.16%	Vesicle transport through interaction with t-SNAREs-like 1A;OS=Mizuhopecten;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0005484|	GO:0006886|GO:0016192|
GN011134.1	sp|K1R0Y9|K1R0Y9_CRAGI	2.3e-162	577.0	99.34%	94.37%	ADP,ATP carrier protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005743|	GO:0022857|
GN011135.1	sp|K1PT27|K1PT27_CRAGI	3.2e-104	383.6	97.68%	74.21%	DNA-3-methyladenine glycosylase;OS=Crassostrea;PE=3;SV=1	GO:0003905|GO:0003677|	GO:0006284|
GN011136.1	sp|K1Q0G7|K1Q0G7_CRAGI	8.3e-199	698.4	99.18%	95.57%	Developmentally-regulated GTP-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN011137.1	sp|K1Q7W0|K1Q7W0_CRAGI	9.8e-83	313.2	36.48%	81.05%	Cytochrome c oxidase assembly protein COX11, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005507|
GN010821.1	sp|A0A210R4W3|A0A210R4W3_MIZYE	8.2e-15	85.1	76.67%	55.71%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN011138.1	sp|K1QEZ0|K1QEZ0_CRAGI	3.6e-14	85.9	13.33%	52.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011139.1	sp|K1R0Z4|K1R0Z4_CRAGI	1.8e-57	229.2	45.05%	53.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011140.1	sp|K1R0Z4|K1R0Z4_CRAGI	4.8e-42	177.2	65.69%	52.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011141.1	sp|K1R0Z4|K1R0Z4_CRAGI	1.1e-54	220.7	23.35%	55.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011143.1	sp|K1QWT8|K1QWT8_CRAGI	5.3e-31	140.6	72.32%	39.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011145.1	sp|K1Q7W5|K1Q7W5_CRAGI	9.1e-122	443.0	85.82%	53.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011146.1	sp|K1QEZ3|K1QEZ3_CRAGI	4.5e-264	915.6	100.00%	87.98%	Fascin;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005856|	GO:0051015|GO:0030674|	GO:0007015|
GN011149.1	sp|K1PT36|K1PT36_CRAGI	4.2e-91	339.7	94.12%	79.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011150.1	sp|K1RHA8|K1RHA8_CRAGI	4.6e-234	816.2	76.76%	82.88%	Sphingosine kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN011151.1	sp|K1RBN1|K1RBN1_CRAGI	2.4e-259	901.4	96.01%	64.38%	Fas-binding factor 1;OS=Crassostrea;PE=4;SV=1	GO:0097539|	GO:0060271|GO:0090162|
GN011152.1	sp|K1R1K7|K1R1K7_CRAGI	6.1e-114	415.6	100.00%	97.58%	Nucleoside diphosphate kinase-like protein 5;OS=Crassostrea;PE=3;SV=1	GO:0004550|	GO:0006241|GO:0006183|GO:0048515|GO:0006228|
GN011153.1	sp|K1PRJ3|K1PRJ3_CRAGI	1.7e-255	887.1	100.00%	85.89%	Metalloreductase STEAP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011155.1	sp|K1RNH1|K1RNH1_CRAGI	3.9e-91	339.7	99.47%	93.05%	60S ribosomal protein L18;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN010822.1	sp|K1PXJ3|K1PXJ3_CRAGI	3.3e-11	73.9	47.13%	45.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011156.1	sp|K1S6U3|K1S6U3_CRAGI	2.8e-48	197.2	94.15%	67.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011157.1	sp|K1RBN6|K1RBN6_CRAGI	4.7e-62	243.4	97.87%	64.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011158.1	sp|K1RHB2|K1RHB2_CRAGI	5.6e-250	869.4	67.20%	86.28%	Nucleolar RNA helicase 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0004386|GO:0003723|
GN011159.1	sp|E9JS90|E9JS90_OSTED	2.0e-115	420.6	98.66%	94.12%	Regulator of interferon;OS=Ostrea;PE=2;SV=1	GO:0003700|GO:0044212|	GO:0006915|GO:0008285|GO:0050776|
GN011161.1	sp|K1RJC8|K1RJC8_CRAGI	1.1e-181	642.1	100.00%	60.50%	Nuclear receptor coactivator 4;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0003713|	GO:0006879|
GN011162.1	sp|K1QBY5|K1QBY5_CRAGI	1.8e-125	454.5	100.00%	72.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN011163.1	sp|K1Q4E4|K1Q4E4_CRAGI	9.2e-125	451.8	93.60%	90.13%	Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide;OS=Crassostrea;PE=4;SV=1
GN011164.1	sp|K1PXC1|K1PXC1_CRAGI	5.7e-34	149.1	88.39%	76.24%	Uncharacterized protein C17orf62;OS=Crassostrea;PE=4;SV=1
GN011165.1	sp|A0A210Q7V1|A0A210Q7V1_MIZYE	2.5e-171	607.4	97.87%	59.61%	Hexosaminidase D;OS=Mizuhopecten;PE=4;SV=1	GO:0015929|	GO:0005975|
GN011167.1	sp|K1PWP0|K1PWP0_CRAGI	1.2e-229	801.2	94.00%	81.49%	CDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008444|	GO:0032049|
GN011168.1	sp|K1PAG1|K1PAG1_CRAGI	0.0e+00	8386.6	99.98%	92.83%	Dynein beta chain, ciliary;OS=Crassostrea;PE=4;SV=1	GO:0030286|	GO:0005524|GO:0003777|	GO:0007018|
GN011169.1	sp|A0A0L8HM03|A0A0L8HM03_OCTBM	4.9e-15	86.7	86.08%	35.71%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0003676|
GN011170.1	sp|K1QGP7|K1QGP7_CRAGI	2.7e-84	317.0	95.77%	84.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005739|	GO:0051560|
GN011171.1	sp|K1PWP4|K1PWP4_CRAGI	5.2e-177	625.9	90.36%	91.74%	Phenylalanyl-tRNA synthetase alpha chain;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0004826|GO:0000049|	GO:0006432|
GN011172.1	sp|K1RJJ0|K1RJJ0_CRAGI	0.0e+00	1208.4	87.96%	69.10%	Transmembrane channel-like protein 7;OS=Crassostrea;PE=4;SV=1	GO:0005887|
GN011173.1	sp|K1Q9D8|K1Q9D8_CRAGI	5.4e-80	303.1	85.88%	63.30%	Latrophilin-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN010823.1	sp|K1QCG8|K1QCG8_CRAGI	2.4e-103	381.7	93.11%	58.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011174.1	sp|K1QT32|K1QT32_CRAGI	6.0e-215	753.1	55.66%	89.51%	Putative sodium-coupled neutral amino acid transporter 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011175.1	sp|K1QC19|K1QC19_CRAGI	4.6e-194	682.6	96.37%	88.95%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|	GO:0006004|
GN011176.1	sp|K1QKP8|K1QKP8_CRAGI	5.4e-246	855.5	97.33%	84.36%	Phospholipase B-like;OS=Crassostrea;PE=3;SV=1	GO:0016787|	GO:0016042|
GN011177.1	sp|K1QC15|K1QC15_CRAGI	0.0e+00	1123.2	99.82%	92.54%	Plasma kallikrein;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN011179.1	sp|K1QT24|K1QT24_CRAGI	1.4e-67	261.5	100.00%	64.50%	Interleukin-17D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN011180.1	sp|K1QT24|K1QT24_CRAGI	1.2e-53	214.9	100.00%	66.24%	Interleukin-17D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN010824.1	sp|K1Q4Z0|K1Q4Z0_CRAGI	3.7e-40	169.9	77.44%	78.43%	Uncharacterized protein C17orf90;OS=Crassostrea;PE=4;SV=1
GN011182.1	sp|K1QT24|K1QT24_CRAGI	1.4e-54	218.0	100.00%	67.52%	Interleukin-17D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN011183.1	sp|K1QT24|K1QT24_CRAGI	8.6e-66	255.8	93.67%	61.54%	Interleukin-17D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN011184.1	sp|K1QT24|K1QT24_CRAGI	4.2e-54	216.5	97.50%	66.24%	Interleukin-17D;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN010825.1	sp|K1RC36|K1RC36_CRAGI	2.9e-71	274.2	86.59%	66.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011185.1	sp|K1R8A3|K1R8A3_CRAGI	1.7e-57	229.6	62.02%	39.66%	Neural cell adhesion molecule L1-like protein;OS=Crassostrea;PE=4;SV=1
GN011187.1	sp|K1R8A3|K1R8A3_CRAGI	1.4e-56	226.5	62.02%	39.39%	Neural cell adhesion molecule L1-like protein;OS=Crassostrea;PE=4;SV=1
GN011188.1	sp|K1PZG0|K1PZG0_CRAGI	7.9e-16	89.7	97.66%	35.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN011189.1	sp|K1R9G8|K1R9G8_CRAGI	5.7e-78	296.2	85.52%	72.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN011190.1	sp|V4BIY2|V4BIY2_LOTGI	1.1e-11	75.5	73.12%	29.94%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004190|
GN011191.1	sp|K1R4F6|K1R4F6_CRAGI	6.4e-11	72.0	82.72%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN010787.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	5.3e-79	300.4	79.95%	47.44%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN011192.1	sp|W4XLN5|W4XLN5_STRPU	4.2e-16	92.8	13.53%	39.29%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN011193.1	sp|A0A210QHL4|A0A210QHL4_MIZYE	3.9e-55	221.1	57.92%	51.39%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN011197.1	sp|K1QYU6|K1QYU6_CRAGI	7.7e-53	213.0	54.48%	71.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011198.1	sp|K1R8T0|K1R8T0_CRAGI	9.4e-154	548.5	100.00%	91.08%	Ribosome production factor 1;OS=Crassostrea;PE=4;SV=1
GN011199.1	sp|K1REK0|K1REK0_CRAGI	3.5e-144	517.3	64.31%	79.62%	Target of EGR1 protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011200.1	sp|K1PLK6|K1PLK6_CRAGI	4.0e-156	556.2	97.94%	96.48%	BTB/POZ domain-containing protein 9;OS=Crassostrea;PE=4;SV=1
GN011201.1	sp|K1R8T3|K1R8T3_CRAGI	0.0e+00	1717.6	100.00%	86.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN011203.1	sp|K1RKP1|K1RKP1_CRAGI	8.8e-100	370.2	81.16%	47.84%	TNF receptor-associated factor 6;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0007165|
GN010828.1	sp|K1PWN0|K1PWN0_CRAGI	2.9e-21	107.8	59.73%	43.51%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN011204.1	sp|K1QUY3|K1QUY3_CRAGI	8.7e-283	978.0	94.05%	90.94%	Potassium voltage-gated channel subfamily C member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|	GO:0051260|GO:0034765|
GN011208.1	sp|K1S440|K1S440_CRAGI	7.9e-63	245.7	100.00%	64.50%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN011209.1	sp|K1QYU1|K1QYU1_CRAGI	3.9e-145	521.2	100.00%	60.43%	HMG domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN011210.1	sp|K1R8S7|K1R8S7_CRAGI	2.8e-276	956.8	99.75%	84.35%	Phospholipase A-2-activating protein;OS=Crassostrea;PE=4;SV=1	GO:0043130|	GO:0043161|
GN011211.1	sp|K1REJ6|K1REJ6_CRAGI	3.7e-11	73.2	52.88%	62.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011213.1	sp|K1PV71|K1PV71_CRAGI	9.5e-122	442.2	97.22%	73.57%	Calumenin-B;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011214.1	sp|K1QVG2|K1QVG2_CRAGI	3.5e-267	926.4	98.99%	75.80%	Nucleolar GTP-binding protein 2;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0005525|
GN011215.1	sp|K1S0U1|K1S0U1_CRAGI	1.3e-198	699.1	94.87%	52.73%	Neurogenic locus Notch protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN011216.1	sp|K1S0U1|K1S0U1_CRAGI	8.7e-26	122.5	82.94%	40.70%	Neurogenic locus Notch protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN011217.1	sp|K1RH90|K1RH90_CRAGI	2.3e-191	674.1	100.00%	65.61%	2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016706|GO:0005506|GO:0031418|
GN011218.1	sp|A0A210PHS5|A0A210PHS5_MIZYE	1.6e-118	431.8	89.98%	55.43%	Transmembrane prolyl 4-hydroxylase;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0005506|GO:0031418|GO:0016705|
GN011219.1	sp|K1RB28|K1RB28_CRAGI	1.0e-89	335.9	83.38%	61.49%	Krueppel-like factor 11;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010830.1	sp|A0A2B4RYI2|A0A2B4RYI2_STYPI	6.9e-25	119.8	91.30%	34.72%	THAP domain-containing protein 11;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN011221.1	sp|K1RB28|K1RB28_CRAGI	1.8e-61	242.3	78.80%	44.38%	Krueppel-like factor 11;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011222.1	sp|K1R524|K1R524_CRAGI	2.0e-51	208.4	97.90%	88.53%	Malignant fibrous histiocytoma-amplified sequence 1-like protein;OS=Crassostrea;PE=4;SV=1
GN011223.1	sp|K1S440|K1S440_CRAGI	0.0e+00	1387.1	100.00%	81.01%	Receptor-type tyrosine-protein phosphatase kappa;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN011224.1	sp|K1RFM7|K1RFM7_CRAGI	8.5e-71	272.7	92.78%	55.08%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010831.1	sp|T1F6Y3|T1F6Y3_HELRO	5.4e-15	87.0	58.67%	33.99%	Uncharacterized protein;OS=Helobdella;PE=4;SV=1	GO:0004843|	GO:0016579|
GN011225.1	sp|A0A0D3MML9|A0A0D3MML9_CRAHO	6.4e-135	486.1	96.68%	73.94%	Prostaglandin E receptor 4;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0004930|
GN011226.1	sp|K1RYP1|K1RYP1_CRAGI	3.6e-144	516.9	94.81%	69.78%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011227.1	sp|K1RYP1|K1RYP1_CRAGI	1.6e-130	471.5	98.58%	66.18%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011228.1	sp|K1RYP1|K1RYP1_CRAGI	8.2e-135	485.7	96.61%	69.50%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011229.1	sp|K1R349|K1R349_CRAGI	1.4e-22	112.1	91.13%	39.52%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011230.1	sp|K1RYP1|K1RYP1_CRAGI	3.3e-104	383.6	99.26%	67.04%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011232.1	sp|K1RYP1|K1RYP1_CRAGI	2.6e-131	474.2	94.04%	66.18%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011233.1	sp|K1RYP1|K1RYP1_CRAGI	8.2e-135	485.7	96.61%	69.50%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN010832.1	sp|K1Q4Y8|K1Q4Y8_CRAGI	1.1e-27	129.0	50.49%	67.65%	Histone H1oo;OS=Crassostrea;PE=3;SV=1	GO:0000786|GO:0005634|	GO:0003677|	GO:0006334|
GN011234.1	sp|K1R349|K1R349_CRAGI	1.4e-22	112.1	91.13%	39.52%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011235.1	sp|K1RYP1|K1RYP1_CRAGI	2.6e-104	384.0	99.26%	67.04%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011237.1	sp|K1RYP1|K1RYP1_CRAGI	2.6e-131	474.2	94.04%	66.18%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011238.1	sp|K1RYP1|K1RYP1_CRAGI	8.2e-135	485.7	96.61%	69.50%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011239.1	sp|K1R349|K1R349_CRAGI	1.4e-22	112.1	91.13%	39.52%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011240.1	sp|K1RYP1|K1RYP1_CRAGI	8.8e-105	385.6	99.26%	67.04%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011242.1	sp|K1RYP1|K1RYP1_CRAGI	2.6e-131	474.2	94.04%	66.18%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011243.1	sp|K1RYP1|K1RYP1_CRAGI	3.8e-135	486.9	92.74%	69.19%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011244.1	sp|K1R349|K1R349_CRAGI	4.2e-24	117.9	70.87%	34.35%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011245.1	sp|K1RYP1|K1RYP1_CRAGI	2.6e-104	384.0	99.26%	67.04%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011247.1	sp|K1RYP1|K1RYP1_CRAGI	1.6e-128	464.9	94.27%	63.43%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011248.1	sp|K1RYP1|K1RYP1_CRAGI	3.8e-135	486.9	91.94%	69.50%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011249.1	sp|K1R349|K1R349_CRAGI	8.0e-26	123.6	67.62%	35.11%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011250.1	sp|K1R349|K1R349_CRAGI	8.5e-131	473.4	66.34%	73.25%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011252.1	sp|K1QIC4|K1QIC4_CRAGI	5.5e-288	995.7	100.00%	71.05%	Putative DNA repair and recombination protein RAD26-like protein;OS=Crassostrea;PE=4;SV=1
GN011253.1	sp|K1R426|K1R426_CRAGI	6.3e-25	118.2	96.92%	90.32%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN011254.1	sp|K1R426|K1R426_CRAGI	4.2e-22	109.8	98.35%	51.69%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN011256.1	sp|K1PCK0|K1PCK0_CRAGI	4.0e-44	183.0	98.39%	67.77%	Spore cortex-lytic enzyme;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN011257.1	sp|K1QLK4|K1QLK4_CRAGI	1.5e-19	102.8	96.92%	24.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011258.1	sp|K1RS19|K1RS19_CRAGI	4.0e-116	423.7	91.71%	61.70%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011259.1	sp|K1PG28|K1PG28_CRAGI	0.0e+00	3356.2	96.96%	74.23%	ATP-binding cassette sub-family A member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN011262.1	sp|K1PNW3|K1PNW3_CRAGI	5.1e-293	1012.3	100.00%	74.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011263.1	sp|K1QG59|K1QG59_CRAGI	5.7e-78	295.8	92.31%	92.26%	DNA primase large subunit;OS=Crassostrea;PE=3;SV=1	GO:0051539|GO:0003677|GO:0003896|GO:0046872|
GN010833.1	sp|K1PJI1|K1PJI1_CRAGI	1.2e-45	189.1	77.95%	43.17%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1
GN011264.1	sp|K1PG28|K1PG28_CRAGI	7.2e-169	599.4	68.12%	82.08%	ATP-binding cassette sub-family A member 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN011267.1	sp|K1PNW3|K1PNW3_CRAGI	5.7e-292	1008.8	100.00%	74.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011268.1	sp|K1PW60|K1PW60_CRAGI	0.0e+00	1188.3	99.91%	64.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011269.1	sp|K1P9W7|K1P9W7_CRAGI	1.1e-218	765.0	99.44%	82.36%	Putative lysosomal cobalamin transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011270.1	sp|K1PG33|K1PG33_CRAGI	2.0e-108	397.5	94.29%	85.22%	Peroxidasin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011271.1	sp|K1RDY2|K1RDY2_CRAGI	2.8e-144	516.9	100.00%	85.33%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004842|GO:0008270|
GN011272.1	sp|K1RJW8|K1RJW8_CRAGI	6.2e-73	280.4	78.76%	85.71%	Protein DEK;OS=Crassostrea;PE=4;SV=1
GN011273.1	sp|K1RF40|K1RF40_CRAGI	1.3e-61	241.5	99.41%	64.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011274.1	sp|K1R811|K1R811_CRAGI	4.2e-186	656.4	83.72%	90.53%	Ribonucleoside-diphosphate reductase small chain;OS=Crassostrea;PE=4;SV=1	GO:0016491|	GO:0009263|
GN011275.1	sp|K1RDY2|K1RDY2_CRAGI	2.8e-144	516.9	100.00%	85.33%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004842|GO:0008270|
GN011276.1	sp|K1QFX0|K1QFX0_CRAGI	2.9e-32	143.3	98.10%	65.83%	Eukaryotic translation elongation factor 1 epsilon-1;OS=Crassostrea;PE=4;SV=1	GO:0003746|
GN011277.1	sp|K1R1W6|K1R1W6_CRAGI	7.9e-83	312.4	99.56%	73.21%	Peroxisome biogenesis factor 10;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0008270|	GO:0016558|
GN011278.1	sp|K1R0N9|K1R0N9_CRAGI	0.0e+00	1696.0	100.00%	89.51%	DNA ligase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003677|GO:0003910|	GO:0071897|GO:0051103|GO:0006310|GO:0006260|
GN011279.1	sp|K1RGI6|K1RGI6_CRAGI	1.9e-74	285.0	50.97%	85.99%	MMS19 nucleotide excision repair-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0097428|
GN011280.1	sp|K1RLX6|K1RLX6_CRAGI	5.1e-65	253.1	100.00%	61.50%	Ras-like GTP-binding protein RYL1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN011281.1	sp|K1PXK2|K1PXK2_CRAGI	2.0e-94	351.3	84.38%	75.70%	Microcephalin;OS=Crassostrea;PE=4;SV=1
GN011282.1	sp|K1PXK2|K1PXK2_CRAGI	9.7e-178	629.0	99.83%	62.61%	Microcephalin;OS=Crassostrea;PE=4;SV=1
GN011283.1	sp|K1PHV3|K1PHV3_CRAGI	2.3e-231	807.0	100.00%	75.62%	Leucine-rich repeat-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN011284.1	sp|K1PHV3|K1PHV3_CRAGI	1.1e-44	184.5	97.12%	84.00%	Leucine-rich repeat-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN011285.1	sp|K1PHV3|K1PHV3_CRAGI	5.4e-150	536.6	99.36%	79.18%	Leucine-rich repeat-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN011286.1	sp|A0A0L8IEP1|A0A0L8IEP1_OCTBM	5.7e-154	550.1	99.30%	47.90%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN011287.1	sp|K1QUZ4|K1QUZ4_CRAGI	0.0e+00	1405.2	85.03%	75.90%	Delphilin;OS=Crassostrea;PE=4;SV=1
GN011288.1	sp|K1QJA5|K1QJA5_CRAGI	7.9e-48	196.4	72.34%	56.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011289.1	sp|K1S058|K1S058_CRAGI	0.0e+00	1283.1	98.82%	89.66%	Transcription factor RFX3;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|
GN011290.1	sp|K1S058|K1S058_CRAGI	1.9e-28	130.6	66.34%	93.94%	Transcription factor RFX3;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|
GN011291.1	sp|K1QJA5|K1QJA5_CRAGI	7.9e-48	196.4	72.34%	56.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011292.1	sp|A0A2C9L8Y5|A0A2C9L8Y5_BIOGL	1.8e-17	95.5	97.77%	40.13%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0042981|
GN011293.1	sp|A0A210QCT5|A0A210QCT5_MIZYE	6.7e-240	836.6	99.84%	42.64%	Zinc finger and BTB domain-containing protein 40;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|
GN011294.1	sp|K1Q7Y1|K1Q7Y1_CRAGI	1.0e-161	575.5	87.14%	67.93%	Carbohydrate sulfotransferase 15;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN010834.1	sp|K1RQK0|K1RQK0_CRAGI	2.8e-53	214.5	57.55%	68.13%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011295.1	sp|K1RWF3|K1RWF3_CRAGI	1.1e-29	135.6	88.17%	41.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011296.1	sp|A0A210PVX2|A0A210PVX2_MIZYE	8.4e-165	585.5	98.98%	79.29%	ELAV-like protein 4;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN011297.1	sp|K1Q7Y4|K1Q7Y4_CRAGI	3.5e-74	283.9	97.35%	51.35%	Signal peptide, CUB and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011301.1	sp|K1R0M7|K1R0M7_CRAGI	2.4e-207	727.2	97.38%	70.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN011302.1	sp|K1RAY9|K1RAY9_CRAGI	4.0e-55	221.1	54.79%	88.89%	Plasminogen activator inhibitor 1 RNA-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN011303.1	sp|K1RGH7|K1RGH7_CRAGI	2.0e-144	517.7	100.00%	83.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN010836.1	sp|K1QM93|K1QM93_CRAGI	2.4e-09	67.0	50.00%	57.78%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011304.1	sp|K1RMS0|K1RMS0_CRAGI	3.2e-122	443.4	99.18%	93.33%	Translation initiation factor eIF-2B subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0003743|
GN011305.1	sp|K1RMS0|K1RMS0_CRAGI	2.0e-36	157.1	87.04%	88.17%	Translation initiation factor eIF-2B subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0003743|
GN011306.1	sp|K1RP96|K1RP96_CRAGI	0.0e+00	1899.4	99.70%	72.26%	Histone-lysine N-methyltransferase, H3 lysine-79 specific;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0031151|	GO:0051726|
GN011308.1	sp|K1QHD5|K1QHD5_CRAGI	8.2e-67	258.8	100.00%	74.16%	BAG family molecular chaperone regulator 2;OS=Crassostrea;PE=4;SV=1	GO:0000774|GO:0051087|
GN011309.1	sp|K1RRY0|K1RRY0_CRAGI	9.7e-33	146.0	93.72%	40.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011310.1	sp|K1QR50|K1QR50_CRAGI	7.5e-106	389.0	100.00%	82.88%	Ras-related protein Rab-23;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN011311.1	sp|K1QYH5|K1QYH5_CRAGI	4.3e-259	899.0	99.38%	89.86%	Ubiquitin carboxyl-terminal hydrolase 14;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN011313.1	sp|K1RBA5|K1RBA5_CRAGI	2.9e-86	325.1	99.27%	34.65%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN011314.1	sp|K1RPA0|K1RPA0_CRAGI	2.9e-165	587.0	98.23%	80.36%	Neuropeptide FF receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN011316.1	sp|K1QYI0|K1QYI0_CRAGI	2.8e-191	673.3	100.00%	91.85%	Serine/threonine-protein kinase SBK1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN011317.1	sp|K1PIH9|K1PIH9_CRAGI	1.1e-22	112.8	55.71%	40.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011319.1	sp|A0A1S3I8D9|A0A1S3I8D9_LINUN	6.3e-43	179.5	73.18%	65.38%	pre-mRNA-splicing factor ISY1 homolog;OS=Lingula;PE=4;SV=1	GO:0000350|
GN010838.1	sp|K1QM93|K1QM93_CRAGI	3.8e-09	67.0	30.67%	57.78%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011321.1	sp|A5XEK1|A5XEK1_9BIVA	9.4e-30	135.6	98.12%	66.03%	LPS-induced TNF-alpha factor;OS=Azumapecten;PE=2;SV=1
GN011322.1	sp|K1PL14|K1PL14_CRAGI	6.9e-94	349.4	100.00%	68.13%	Suppressor of cytokine signaling 2;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005159|GO:0008269|	GO:0035556|GO:0046426|GO:0001558|
GN011323.1	sp|K1QHE9|K1QHE9_CRAGI	2.0e-93	347.4	98.02%	85.79%	Thymidine kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004797|	GO:0071897|
GN011324.1	sp|K1RPB0|K1RPB0_CRAGI	3.3e-168	597.4	63.70%	91.05%	Coiled-coil domain-containing protein 96;OS=Crassostrea;PE=4;SV=1
GN011325.1	sp|K1R4V1|K1R4V1_CRAGI	1.4e-83	314.7	100.00%	77.66%	N-acetyltransferase 9;OS=Crassostrea;PE=4;SV=1	GO:0016747|
GN011326.1	sp|K1QYI7|K1QYI7_CRAGI	9.0e-243	845.1	87.06%	90.84%	Paired box protein Pax-2-A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN011327.1	sp|K1R4U6|K1R4U6_CRAGI	2.2e-34	150.6	73.98%	75.56%	Lipopolysaccharide-induced tumor necrosis factor-alpha factor-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011328.1	sp|K1QYI4|K1QYI4_CRAGI	7.7e-111	406.0	90.96%	63.25%	ADP,ATP carrier protein 1, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005743|	GO:0022857|
GN011330.1	sp|K1PSY6|K1PSY6_CRAGI	4.0e-52	211.1	98.62%	69.64%	Death-associated protein kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|	GO:0035556|
GN011334.1	sp|K1PL35|K1PL35_CRAGI	2.4e-26	122.9	100.00%	91.67%	2-oxoglutarate dehydrogenase E1 component, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004591|GO:0030976|	GO:0006099|
GN011335.1	sp|K1QTH6|K1QTH6_CRAGI	6.9e-26	123.2	57.02%	55.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN011336.1	sp|A0A1S3H205|A0A1S3H205_LINUN	1.2e-31	142.1	99.49%	37.84%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN011338.1	sp|K1Q7G8|K1Q7G8_CRAGI	0.0e+00	3419.4	99.92%	67.28%	Fatty acid synthase;OS=Crassostrea;PE=4;SV=1	GO:0004312|GO:0016491|GO:0031177|
GN011339.1	sp|A0A210QSU7|A0A210QSU7_MIZYE	3.4e-183	646.7	87.70%	86.24%	PRKCA-binding protein;OS=Mizuhopecten;PE=4;SV=1	GO:0019904|
GN011340.1	sp|K1Q7G8|K1Q7G8_CRAGI	4.5e-115	419.5	100.00%	86.49%	Fatty acid synthase;OS=Crassostrea;PE=4;SV=1	GO:0004312|GO:0016491|GO:0031177|
GN011341.1	sp|K1PT00|K1PT00_CRAGI	4.1e-129	468.4	99.91%	63.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011342.1	sp|V4A2P9|V4A2P9_LOTGI	9.1e-37	158.7	91.49%	54.69%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN011343.1	sp|K1QT62|K1QT62_CRAGI	9.9e-293	1011.9	97.58%	65.59%	Coiled-coil domain-containing protein 57;OS=Crassostrea;PE=4;SV=1
GN011344.1	sp|K1Q7G4|K1Q7G4_CRAGI	4.1e-34	150.2	46.33%	80.25%	Protein LAP2;OS=Crassostrea;PE=4;SV=1
GN011345.1	sp|K1Q098|K1Q098_CRAGI	0.0e+00	1189.1	93.54%	71.31%	DNA (Cytosine-5)-methyltransferase 3A;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0008168|
GN011346.1	sp|K1PSZ6|K1PSZ6_CRAGI	1.8e-168	597.8	95.50%	72.70%	Vesicular inhibitory amino acid transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007009|
GN011348.1	sp|K1Q0W8|K1Q0W8_CRAGI	5.1e-56	223.8	86.22%	39.48%	Follistatin-related protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008378|	GO:0006486|
GN011349.1	sp|K1PSZ6|K1PSZ6_CRAGI	1.0e-118	432.6	100.00%	65.39%	Vesicular inhibitory amino acid transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007009|
GN011350.1	sp|K1PSZ6|K1PSZ6_CRAGI	3.7e-49	199.9	77.93%	88.39%	Vesicular inhibitory amino acid transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007009|
GN011351.1	sp|K1QT58|K1QT58_CRAGI	1.1e-56	226.1	62.93%	59.20%	Programmed cell death protein 6;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011353.1	sp|K1Q7F9|K1Q7F9_CRAGI	0.0e+00	1338.9	98.68%	87.43%	Axin-1;OS=Crassostrea;PE=4;SV=1	GO:0030877|	GO:0009982|GO:0030159|GO:0003723|	GO:0001522|GO:0016055|
GN011354.1	sp|A0A210QSW4|A0A210QSW4_MIZYE	1.6e-90	338.6	97.14%	48.09%	TD and POZ domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1
GN011356.1	sp|K1QT52|K1QT52_CRAGI	5.2e-33	146.0	76.67%	69.23%	F-box/LRR-repeat protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011357.1	sp|K1Q7F4|K1Q7F4_CRAGI	5.0e-96	360.1	39.77%	29.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011357.1	sp|K1Q7F4|K1Q7F4_CRAGI	3.3e-15	91.7	7.00%	35.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010839.1	sp|K1RQK0|K1RQK0_CRAGI	1.3e-51	208.8	69.26%	60.00%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011358.1	sp|K1PL53|K1PL53_CRAGI	1.2e-93	348.6	100.00%	72.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011361.1	sp|R7VES8|R7VES8_CAPTE	7.0e-102	377.5	88.83%	35.62%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN011362.1	sp|K1PQZ5|K1PQZ5_CRAGI	1.6e-31	143.3	29.95%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008191|
GN011363.1	sp|K1Q0B1|K1Q0B1_CRAGI	1.7e-182	644.8	85.64%	61.48%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011364.1	sp|K1Q0B1|K1Q0B1_CRAGI	8.3e-178	629.0	97.56%	61.67%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011365.1	sp|K1Q0B1|K1Q0B1_CRAGI	9.2e-152	542.7	88.62%	51.36%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011366.1	sp|K1Q0B1|K1Q0B1_CRAGI	9.1e-192	675.6	88.64%	63.69%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011367.1	sp|K1QLJ9|K1QLJ9_CRAGI	2.6e-46	190.7	99.41%	61.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011368.1	sp|K1QU31|K1QU31_CRAGI	0.0e+00	2289.6	97.98%	77.79%	Protein Dok-7;OS=Crassostrea;PE=4;SV=1	GO:0019901|	GO:0061098|
GN011369.1	sp|K1R0T2|K1R0T2_CRAGI	2.7e-41	176.8	16.29%	62.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011370.1	sp|K1Q7Q7|K1Q7Q7_CRAGI	0.0e+00	1117.8	100.00%	85.14%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN011372.1	sp|K1Q083|K1Q083_CRAGI	2.7e-195	687.6	94.39%	64.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011374.1	sp|K1Q7Q1|K1Q7Q1_CRAGI	1.9e-52	213.0	38.90%	49.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011374.1	sp|K1Q7Q1|K1Q7Q1_CRAGI	1.1e-10	74.3	7.45%	69.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011376.1	sp|K1Q7Q1|K1Q7Q1_CRAGI	1.2e-56	226.9	35.32%	51.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011377.1	sp|A0A2C9K8F5|A0A2C9K8F5_BIOGL	1.3e-34	151.8	54.49%	76.67%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003713|
GN011378.1	sp|K1Q7H4|K1Q7H4_CRAGI	0.0e+00	1110.9	98.73%	73.56%	Sterile alpha motif domain-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN011379.1	sp|K1Q0B1|K1Q0B1_CRAGI	4.1e-160	570.5	86.60%	54.83%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011380.1	sp|K1Q0B1|K1Q0B1_CRAGI	5.0e-190	669.8	88.02%	62.72%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011381.1	sp|K1Q0B1|K1Q0B1_CRAGI	2.4e-182	644.0	99.79%	65.17%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011382.1	sp|K1Q0B1|K1Q0B1_CRAGI	1.5e-154	552.0	85.36%	55.58%	Cholinesterase;OS=Crassostrea;PE=4;SV=1
GN011383.1	sp|K1QLJ9|K1QLJ9_CRAGI	5.8e-46	189.5	99.41%	61.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011384.1	sp|K1PNH1|K1PNH1_CRAGI	5.1e-90	336.7	100.00%	58.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011385.1	sp|K1PNH1|K1PNH1_CRAGI	9.0e-78	296.2	91.38%	52.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011386.1	sp|K1PH23|K1PH23_CRAGI	6.1e-57	226.9	71.11%	55.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011387.1	sp|K1PW48|K1PW48_CRAGI	2.5e-35	154.8	96.69%	42.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN011388.1	sp|K1PNI3|K1PNI3_CRAGI	1.9e-13	80.1	69.23%	90.91%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN011389.1	sp|K1PNI3|K1PNI3_CRAGI	1.9e-13	80.1	69.23%	90.91%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN011390.1	sp|K1PNI3|K1PNI3_CRAGI	1.9e-13	80.1	69.23%	90.91%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN011391.1	sp|K1PNI3|K1PNI3_CRAGI	1.9e-13	80.1	69.23%	90.91%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN011392.1	sp|K1PNI3|K1PNI3_CRAGI	1.9e-13	80.1	69.23%	90.91%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN011393.1	sp|A0JPR6|A0JPR6_CIOIN	5.5e-09	66.6	42.17%	47.83%	Transposase domain-containing protein;OS=Ciona;PE=4;SV=1
GN011394.1	sp|K1RFU3|K1RFU3_CRAGI	4.1e-19	100.5	81.73%	42.60%	DnaJ-like protein 1, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN011395.1	sp|K1Q2Y6|K1Q2Y6_CRAGI	3.0e-243	846.3	100.00%	94.65%	Synaptotagmin-17;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0006887|
GN011396.1	sp|K1QNT9|K1QNT9_CRAGI	1.9e-47	194.5	94.41%	63.95%	Transmembrane protein 26;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011397.1	sp|K1PH24|K1PH24_CRAGI	1.0e-81	308.5	98.01%	72.77%	Uncharacterized protein C11D3.13;OS=Crassostrea;PE=4;SV=1
GN011398.1	sp|K1PH30|K1PH30_CRAGI	5.3e-100	369.4	98.18%	80.47%	Mitochondrial import inner membrane translocase subunit Tim23;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011401.1	sp|A0A0B6ZWU8|A0A0B6ZWU8_9EUPU	1.7e-50	204.9	98.64%	52.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN011402.1	sp|K1PNH9|K1PNH9_CRAGI	5.8e-184	650.2	84.29%	80.92%	IQ domain-containing protein E;OS=Crassostrea;PE=4;SV=1
GN011403.1	sp|K1PH26|K1PH26_CRAGI	3.8e-277	959.1	99.81%	91.65%	Sorting nexin-8;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0035091|	GO:0042147|
GN011404.1	sp|K1QNU3|K1QNU3_CRAGI	7.2e-184	649.0	100.00%	88.38%	Uncharacterized protein C2orf81-like protein;OS=Crassostrea;PE=4;SV=1
GN011405.1	sp|K1Q2Z0|K1Q2Z0_CRAGI	1.8e-137	494.2	100.00%	88.89%	Uncharacterized protein C16orf48;OS=Crassostrea;PE=4;SV=1
GN011406.1	sp|K1PW50|K1PW50_CRAGI	1.2e-171	608.2	98.98%	74.94%	NAD-dependent deacetylase sirtuin-6;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN011407.1	sp|K1PNH5|K1PNH5_CRAGI	1.2e-174	618.2	100.00%	76.61%	NAD-dependent deacetylase sirtuin-6;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN011408.1	sp|K1PH24|K1PH24_CRAGI	1.9e-79	301.2	100.00%	45.99%	Uncharacterized protein C11D3.13;OS=Crassostrea;PE=4;SV=1
GN011409.1	sp|K1PNI3|K1PNI3_CRAGI	5.5e-32	142.5	85.96%	64.95%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN011410.1	sp|K1PNI3|K1PNI3_CRAGI	7.2e-32	141.7	89.77%	86.08%	BAI1-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN010790.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	2.6e-11	73.9	50.00%	57.38%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN010842.1	sp|K1PLJ1|K1PLJ1_CRAGI	1.3e-16	91.7	62.69%	47.62%	Protein D7;OS=Crassostrea;PE=4;SV=1	GO:0007283|
GN011411.1	sp|A0A1S3J244|A0A1S3J244_LINUN	3.2e-25	120.6	82.72%	39.85%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN011413.1	sp|K1PW59|K1PW59_CRAGI	0.0e+00	1723.8	100.00%	90.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN011414.1	sp|K1PNI6|K1PNI6_CRAGI	1.6e-89	335.1	62.69%	89.62%	Heterogeneous nuclear ribonucleoprotein A/B;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN011415.1	sp|A0A0B6ZPK1|A0A0B6ZPK1_9EUPU	4.9e-63	246.1	100.00%	71.34%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN011416.1	sp|K1PNI6|K1PNI6_CRAGI	3.3e-52	209.9	85.82%	91.23%	Heterogeneous nuclear ribonucleoprotein A/B;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN011417.1	sp|K1PH33|K1PH33_CRAGI	3.5e-168	596.7	100.00%	86.84%	Core histone macro-H2A.1;OS=Crassostrea;PE=3;SV=1	GO:0000786|GO:0005634|	GO:0003677|GO:0046982|
GN011418.1	sp|K1Q305|K1Q305_CRAGI	3.3e-227	793.1	98.58%	82.72%	High-affinity choline transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN011421.1	sp|W4XMZ2|W4XMZ2_STRPU	8.5e-21	106.7	89.42%	30.60%	ATP-dependent DNA helicase;OS=Strongylocentrotus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN011422.1	sp|K1QJN2|K1QJN2_CRAGI	9.8e-56	222.6	52.42%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN011424.1	sp|A0A2B4QXI7|A0A2B4QXI7_STYPI	1.3e-24	117.9	90.57%	51.58%	PiggyBac transposable element-derived protein 1;OS=Stylophora;PE=4;SV=1	GO:0016021|
GN011425.1	sp|A0A3L5TT68|A0A3L5TT68_MYTGA	1.0e-25	121.7	64.71%	69.74%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN011426.1	sp|A0A1S3J244|A0A1S3J244_LINUN	5.7e-16	89.4	94.92%	38.66%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN011427.1	sp|K1Q305|K1Q305_CRAGI	1.3e-39	168.3	57.76%	91.30%	High-affinity choline transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN011428.1	sp|K1Q305|K1Q305_CRAGI	3.3e-210	736.5	99.08%	86.11%	High-affinity choline transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN011430.1	sp|K1RL12|K1RL12_CRAGI	1.3e-84	318.2	81.34%	92.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011431.1	sp|V3ZWC6|V3ZWC6_LOTGI	7.6e-28	128.6	90.57%	56.84%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN011432.1	sp|K1QPU5|K1QPU5_CRAGI	2.0e-48	198.7	45.92%	57.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011433.1	sp|K1RCP9|K1RCP9_CRAGI	2.5e-40	171.8	39.02%	61.19%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0004402|	GO:0006355|
GN011435.1	sp|K1QYH6|K1QYH6_CRAGI	6.8e-229	798.5	100.00%	92.71%	COP9 signalosome complex subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0008180|GO:0005737|
GN011436.1	sp|K1S3A6|K1S3A6_CRAGI	1.4e-61	241.1	89.51%	87.40%	Glyoxalase domain-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN011437.1	sp|A0A210QBT8|A0A210QBT8_MIZYE	7.9e-253	879.0	99.76%	55.92%	tRNA threonylcarbamoyladenosine biosynthesis protein YwlC;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0003725|
GN011438.1	sp|A0A210QBT4|A0A210QBT4_MIZYE	9.6e-166	589.7	99.41%	40.14%	tRNA threonylcarbamoyladenosine biosynthesis protein YwlC;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0003725|
GN011439.1	sp|K1RJW3|K1RJW3_CRAGI	1.6e-216	757.7	95.19%	77.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016829|
GN011440.1	sp|K1RDX6|K1RDX6_CRAGI	5.4e-64	249.2	97.99%	75.17%	Phytanoyl-CoA dioxygenase, peroxisomal;OS=Crassostrea;PE=4;SV=1	GO:0051213|
GN011441.1	sp|A0A210QNX1|A0A210QNX1_MIZYE	1.2e-140	505.0	98.48%	69.97%	Hypoxia-inducible factor 1-alpha inhibitor;OS=Mizuhopecten;PE=4;SV=1
GN011442.1	sp|A0A210PLZ9|A0A210PLZ9_MIZYE	9.9e-126	455.7	97.16%	56.46%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN011443.1	sp|K1QUY9|K1QUY9_CRAGI	3.2e-77	294.7	98.09%	88.51%	Coiled-coil domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN011444.1	sp|A0A210PM21|A0A210PM21_MIZYE	8.2e-114	415.6	100.00%	68.71%	STIP1 homology and U box-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004842|
GN011446.1	sp|A0A210QTM7|A0A210QTM7_MIZYE	4.9e-201	708.0	68.35%	35.99%	Sterile alpha motif domain-containing protein 9-like;OS=Mizuhopecten;PE=4;SV=1
GN011447.1	sp|K1PVB6|K1PVB6_CRAGI	3.0e-14	84.0	56.08%	50.00%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN011448.1	sp|K1R9U9|K1R9U9_CRAGI	3.8e-14	83.6	78.32%	34.75%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN011449.1	sp|A0A3M6UGW1|A0A3M6UGW1_9CNID	3.3e-15	88.2	94.48%	29.37%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN011450.1	sp|K1RK99|K1RK99_CRAGI	2.0e-50	203.8	100.00%	86.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011451.1	sp|K1RK99|K1RK99_CRAGI	2.0e-50	203.8	100.00%	86.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN010846.1	sp|K1PSE0|K1PSE0_CRAGI	1.2e-34	152.9	100.00%	34.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011452.1	sp|V3ZWC6|V3ZWC6_LOTGI	7.6e-28	128.6	90.57%	56.84%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN011453.1	sp|K1RCP9|K1RCP9_CRAGI	2.5e-40	171.8	39.02%	61.19%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0004402|	GO:0006355|
GN011454.1	sp|K1QYH6|K1QYH6_CRAGI	6.8e-229	798.5	100.00%	92.71%	COP9 signalosome complex subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0008180|GO:0005737|
GN011455.1	sp|K1S3N6|K1S3N6_CRAGI	1.8e-27	127.9	100.00%	53.10%	Active regulator of SIRT1;OS=Crassostrea;PE=4;SV=1
GN011456.1	sp|K1S3A6|K1S3A6_CRAGI	1.1e-61	241.5	89.51%	87.40%	Glyoxalase domain-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN011457.1	sp|A0A210QBT8|A0A210QBT8_MIZYE	1.6e-223	781.6	98.37%	53.82%	tRNA threonylcarbamoyladenosine biosynthesis protein YwlC;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0003725|
GN011458.1	sp|A0A210QBT4|A0A210QBT4_MIZYE	1.1e-166	592.8	99.14%	41.50%	tRNA threonylcarbamoyladenosine biosynthesis protein YwlC;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0003725|
GN011459.1	sp|K1RJW3|K1RJW3_CRAGI	4.1e-217	759.6	95.19%	77.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016829|
GN011460.1	sp|K1RJW3|K1RJW3_CRAGI	9.2e-217	758.4	95.19%	77.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016829|
GN011461.1	sp|K1RDX6|K1RDX6_CRAGI	2.1e-111	407.5	97.31%	73.02%	Phytanoyl-CoA dioxygenase, peroxisomal;OS=Crassostrea;PE=4;SV=1	GO:0051213|
GN010847.1	sp|K1RQK0|K1RQK0_CRAGI	3.3e-48	198.7	27.21%	57.50%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011464.1	sp|K1PND3|K1PND3_CRAGI	5.7e-99	366.3	90.75%	66.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011465.1	sp|K1R8F9|K1R8F9_CRAGI	5.0e-60	235.7	100.00%	98.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011466.1	sp|K1QYH9|K1QYH9_CRAGI	6.8e-273	945.3	100.00%	81.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011467.1	sp|K1S3P1|K1S3P1_CRAGI	2.6e-48	197.2	97.52%	62.18%	Phosphoinositide 3-kinase adapter protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN011468.1	sp|N6TYP6|N6TYP6_DENPD	4.8e-15	86.3	74.79%	46.59%	Uncharacterized protein;OS=Dendroctonus;PE=4;SV=1
GN011469.1	sp|K1QFL5|K1QFL5_CRAGI	4.5e-42	179.5	25.18%	33.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011471.1	sp|K1Q2C5|K1Q2C5_CRAGI	1.0e-81	308.9	93.63%	59.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011472.1	sp|K1PKD6|K1PKD6_CRAGI	4.2e-119	433.0	100.00%	88.51%	Alkylated DNA repair protein alkB-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0035515|	GO:0006397|GO:0035553|
GN011473.1	sp|K1RE95|K1RE95_CRAGI	1.3e-43	181.4	77.86%	86.11%	Uncharacterized protein C10orf35-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011474.1	sp|K1PSA1|K1PSA1_CRAGI	4.2e-237	825.9	96.21%	95.13%	Transmembrane 9 superfamily member;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004725|
GN011475.1	sp|K1PSA1|K1PSA1_CRAGI	5.5e-95	352.4	97.80%	90.96%	Transmembrane 9 superfamily member;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004725|
GN011476.1	sp|K1PSA1|K1PSA1_CRAGI	3.1e-40	169.5	100.00%	98.80%	Transmembrane 9 superfamily member;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004725|
GN010848.1	sp|K1RQK0|K1RQK0_CRAGI	3.5e-46	190.7	54.35%	67.20%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011477.1	sp|K1PSA1|K1PSA1_CRAGI	1.1e-110	406.4	54.28%	57.76%	Transmembrane 9 superfamily member;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004725|
GN011482.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	4.7e-31	140.2	96.45%	41.88%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN011483.1	sp|K1QJN2|K1QJN2_CRAGI	1.6e-55	221.5	73.06%	79.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN010849.1	sp|K1RQK0|K1RQK0_CRAGI	1.2e-51	209.1	56.14%	68.13%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN011488.1	sp|K1QRS9|K1QRS9_CRAGI	4.0e-36	157.5	57.14%	52.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN011489.1	sp|K1PMC5|K1PMC5_CRAGI	1.2e-44	185.7	78.01%	54.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN011490.1	sp|K1PTD8|K1PTD8_CRAGI	1.2e-16	92.0	89.03%	35.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN011491.1	sp|K1QY62|K1QY62_CRAGI	8.3e-118	429.1	80.06%	86.92%	Solute carrier family 35 member E1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013852.1	sp|A0A1S3H0I4|A0A1S3H0I4_LINUN	3.9e-23	113.2	76.19%	57.89%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN013926.1	sp|K1QA60|K1QA60_CRAGI	2.5e-59	233.8	100.00%	75.64%	DNA polymerase theta;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0003887|	GO:0006261|
GN014485.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	4.2e-86	324.3	99.37%	35.06%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN014487.1	sp|K1QAE3|K1QAE3_CRAGI	1.8e-79	301.6	99.30%	54.90%	Leucine-rich repeat-containing protein 8D;OS=Crassostrea;PE=4;SV=1
GN014488.1	sp|K1QHG2|K1QHG2_CRAGI	8.3e-98	363.2	95.85%	50.54%	Leucine-rich repeats and immunoglobulin-like domains protein 3;OS=Crassostrea;PE=4;SV=1
GN014489.1	sp|K1REK9|K1REK9_CRAGI	1.5e-57	229.2	96.42%	54.74%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN013927.1	sp|K1QA60|K1QA60_CRAGI	0.0e+00	2228.8	99.20%	56.41%	DNA polymerase theta;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0003887|	GO:0006261|
GN014492.1	sp|K1QUS6|K1QUS6_CRAGI	1.8e-34	152.1	90.16%	32.85%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN014494.1	sp|K1QUS6|K1QUS6_CRAGI	9.1e-34	149.8	90.82%	32.27%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN014495.1	sp|K1QHH0|K1QHH0_CRAGI	1.4e-248	864.0	100.00%	89.59%	Protein henna;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0004505|	GO:0006559|
GN014496.1	sp|K1Q2X0|K1Q2X0_CRAGI	2.6e-107	393.7	99.55%	91.82%	Ras-related and estrogen-regulated growth inhibitor-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN014497.1	sp|A0A210QB10|A0A210QB10_MIZYE	2.5e-113	414.5	88.45%	62.79%	Hsp90 co-chaperone Cdc37;OS=Mizuhopecten;PE=4;SV=1	GO:0019901|
GN014498.1	sp|S4SCW4|S4SCW4_CRAGI	5.7e-248	862.1	97.70%	89.29%	Serine palmitoyltransferase-1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0030170|GO:0016740|	GO:0009058|
GN014499.1	sp|K1PLM9|K1PLM9_CRAGI	7.6e-146	522.3	98.54%	74.48%	Phosphoglycolate phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0016791|
GN014500.1	sp|K1R5Q5|K1R5Q5_CRAGI	5.7e-26	124.8	43.43%	38.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014501.1	sp|A0A2T7P3N5|A0A2T7P3N5_POMCA	4.4e-22	111.3	48.26%	35.20%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0046983|
GN014502.1	sp|K1QAE9|K1QAE9_CRAGI	2.8e-296	1023.8	83.22%	64.63%	Nuclear receptor interaction protein;OS=Crassostrea;PE=4;SV=1
GN014504.1	sp|A0A1S3I398|A0A1S3I398_LINUN	6.5e-16	89.7	58.52%	42.72%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN014505.1	sp|K1QSU1|K1QSU1_CRAGI	4.3e-148	531.2	70.41%	44.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014506.1	sp|A0A2T7P3X0|A0A2T7P3X0_POMCA	1.0e-25	123.2	98.81%	28.78%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN014508.1	sp|K1QVV2|K1QVV2_CRAGI	1.6e-37	161.0	77.69%	76.60%	Kinesin-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN014509.1	sp|A0A210QAZ8|A0A210QAZ8_MIZYE	5.3e-41	172.6	95.08%	66.09%	Cornifelin;OS=Mizuhopecten;PE=4;SV=1
GN014511.1	sp|A0A0K2V0D6|A0A0K2V0D6_LEPSM	6.9e-102	377.5	98.08%	34.06%	Uncharacterized protein;OS=Lepeophtheirus;PE=4;SV=1	GO:0016021|
GN014512.1	sp|K1RGD8|K1RGD8_CRAGI	9.5e-36	156.0	67.98%	46.63%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN014513.1	sp|K1RGD8|K1RGD8_CRAGI	3.3e-22	110.5	97.59%	40.96%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN014514.1	sp|K1RGD8|K1RGD8_CRAGI	3.7e-110	404.1	98.81%	49.16%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN014517.1	sp|K1QY36|K1QY36_CRAGI	8.5e-29	132.1	71.76%	69.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014521.1	sp|A0A210QZE3|A0A210QZE3_MIZYE	2.7e-84	318.9	95.40%	27.96%	Slit-like 1 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN014522.1	sp|A0A210QZE3|A0A210QZE3_MIZYE	7.3e-74	284.3	93.32%	26.82%	Slit-like 1 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN014523.1	sp|K1PEX2|K1PEX2_CRAGI	0.0e+00	1399.0	99.77%	78.97%	Glutamate receptor, ionotropic kainate 2;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN014525.1	sp|O97375|O97375_STRPU	4.7e-228	797.0	84.25%	46.70%	Scavenger receptor cysteine-rich protein type 12;OS=Strongylocentrotus;PE=2;SV=1	GO:0016020|	GO:0005044|
GN014526.1	sp|K1RW99|K1RW99_CRAGI	5.5e-165	585.9	100.00%	83.88%	Alkyl transferase;OS=Crassostrea;PE=3;SV=1	GO:0016765|
GN014527.1	sp|K1RCW7|K1RCW7_CRAGI	0.0e+00	2354.7	100.00%	81.04%	Bromodomain and WD repeat-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN014528.1	sp|K1R6G3|K1R6G3_CRAGI	2.9e-154	550.4	81.91%	85.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014529.1	sp|K1QZN4|K1QZN4_CRAGI	3.3e-106	390.2	100.00%	80.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014530.1	sp|K1QQ98|K1QQ98_CRAGI	6.0e-15	85.1	90.91%	62.71%	cAMP-dependent protein kinase regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN014531.1	sp|K1QQ98|K1QQ98_CRAGI	1.6e-114	418.3	90.78%	63.49%	cAMP-dependent protein kinase regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN014532.1	sp|K1RW95|K1RW95_CRAGI	7.1e-95	352.4	91.45%	78.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014533.1	sp|K1PFP3|K1PFP3_CRAGI	1.1e-27	128.6	84.81%	51.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014534.1	sp|K1QR21|K1QR21_CRAGI	6.7e-23	112.1	81.44%	71.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014535.1	sp|K1QZ04|K1QZ04_CRAGI	2.9e-25	119.8	98.86%	61.63%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN014536.1	sp|K1RW95|K1RW95_CRAGI	8.7e-93	345.5	92.74%	77.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014537.1	sp|A0A210QK60|A0A210QK60_MIZYE	3.6e-23	114.0	89.74%	34.07%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005892|
GN014538.1	sp|K1Q2D8|K1Q2D8_CRAGI	8.2e-53	213.0	99.65%	61.03%	Epithelial-stromal interaction protein 1;OS=Crassostrea;PE=4;SV=1
GN014539.1	sp|K1QHH8|K1QHH8_CRAGI	3.4e-33	147.1	76.14%	63.43%	Putative 10-formyltetrahydrofolate dehydrogenase ALDH1L2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0016155|GO:0016742|GO:0016620|	GO:0009258|GO:0009058|GO:0006730|GO:0016567|
GN014540.1	sp|K1PSP9|K1PSP9_CRAGI	2.7e-256	890.2	99.85%	66.87%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014541.1	sp|K1QQ72|K1QQ72_CRAGI	1.2e-149	535.8	100.00%	61.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014543.1	sp|V4AGB0|V4AGB0_LOTGI	2.1e-49	201.8	98.74%	37.11%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003824|GO:0030151|GO:0030170|
GN014544.1	sp|A0A1X7T0L5|A0A1X7T0L5_AMPQE	8.7e-33	146.7	94.13%	28.17%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN014545.1	sp|K1S0V2|K1S0V2_CRAGI	1.3e-16	93.2	32.91%	39.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014546.1	sp|A0A2C9KXQ9|A0A2C9KXQ9_BIOGL	2.3e-19	100.9	95.83%	40.88%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005840|	GO:0019843|GO:0003735|	GO:0006412|
GN014548.1	sp|K1QDT8|K1QDT8_CRAGI	8.7e-20	101.7	96.77%	53.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014550.1	sp|K1QFL5|K1QFL5_CRAGI	1.5e-21	109.4	43.11%	39.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014553.1	sp|K1RZC1|K1RZC1_CRAGI	3.4e-89	336.3	70.52%	27.24%	Latrophilin-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|GO:0005044|	GO:0007166|GO:0016525|
GN013932.1	sp|A0A210Q129|A0A210Q129_MIZYE	4.7e-22	111.3	92.66%	22.76%	Serine/threonine-protein kinase pats1;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN014555.1	sp|K1QG70|K1QG70_CRAGI	1.4e-271	940.6	98.35%	89.93%	Katanin p60 ATPase-containing subunit A1;OS=Crassostrea;PE=3;SV=1	GO:0005813|GO:0005737|GO:0005874|GO:0000922|	GO:0005524|GO:0016853|GO:0008017|GO:0008568|	GO:0007049|GO:0051301|
GN014556.1	sp|K1QG70|K1QG70_CRAGI	1.6e-227	795.4	99.92%	78.86%	Katanin p60 ATPase-containing subunit A1;OS=Crassostrea;PE=3;SV=1	GO:0005813|GO:0005737|GO:0005874|GO:0000922|	GO:0005524|GO:0016853|GO:0008017|GO:0008568|	GO:0007049|GO:0051301|
GN014557.1	sp|K1QPW3|K1QPW3_CRAGI	2.7e-54	218.0	51.84%	72.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014558.1	sp|K1QXJ7|K1QXJ7_CRAGI	3.0e-144	517.3	100.00%	65.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014559.1	sp|K1R3W7|K1R3W7_CRAGI	7.8e-267	925.2	100.00%	71.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014560.1	sp|K1RN98|K1RN98_CRAGI	7.7e-91	339.7	61.54%	71.00%	Putative arylformamidase;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN014561.1	sp|K1QGN7|K1QGN7_CRAGI	5.2e-52	210.7	58.06%	51.66%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN014564.1	sp|A0A210Q2Z4|A0A210Q2Z4_MIZYE	5.3e-35	154.1	57.01%	44.04%	ATP-dependent DNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN014565.1	sp|K1PCX5|K1PCX5_CRAGI	2.1e-93	348.6	90.93%	45.05%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN014566.1	sp|K1PCX5|K1PCX5_CRAGI	1.1e-20	106.3	86.15%	28.20%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN014569.1	sp|K1QDC3|K1QDC3_CRAGI	2.2e-14	84.7	96.83%	28.34%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014570.1	sp|K1P486|K1P486_CRAGI	4.2e-27	128.3	84.41%	25.64%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN014571.1	sp|A0A1S3H5B5|A0A1S3H5B5_LINUN	1.5e-31	141.4	91.91%	55.65%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN014572.1	sp|A0A2B4S0L8|A0A2B4S0L8_STYPI	1.4e-13	82.0	54.35%	43.43%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0005634|	GO:0006915|
GN014573.1	sp|K1PCX5|K1PCX5_CRAGI	4.0e-31	140.6	100.00%	41.28%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN014574.1	sp|K1PCX5|K1PCX5_CRAGI	7.0e-41	174.1	79.19%	30.59%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN014575.1	sp|K1QJ62|K1QJ62_CRAGI	2.5e-184	651.0	99.51%	88.47%	SWI/SNF-related matrix-associated actin-dependent regulator chromatin subfamily E member 1;OS=Crassostrea;PE=4;SV=1	GO:0016514|	GO:0003677|	GO:0043044|
GN014576.1	sp|K1PYQ7|K1PYQ7_CRAGI	9.7e-151	538.9	80.66%	75.57%	T-box transcription factor TBX15;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN014577.1	sp|K1RRN9|K1RRN9_CRAGI	8.9e-48	196.8	41.87%	53.89%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN014578.1	sp|K1PIH9|K1PIH9_CRAGI	5.0e-22	110.2	83.07%	38.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014580.1	sp|K1R215|K1R215_CRAGI	4.4e-131	473.8	75.10%	76.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014581.1	sp|K1Q8Y2|K1Q8Y2_CRAGI	8.5e-224	781.6	98.56%	88.51%	Monomeric sarcosine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016491|
GN014582.1	sp|K1PU32|K1PU32_CRAGI	5.0e-188	662.9	94.26%	70.16%	Glutathione gamma-glutamylcysteinyltransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016756|GO:0046872|	GO:0046938|GO:0010038|
GN014583.1	sp|A0A0U1XZW2|A0A0U1XZW2_9BIVA	2.4e-48	198.4	82.01%	36.27%	Inhibitor of apoptosis proteins 2;OS=Azumapecten;PE=2;SV=1
GN014584.1	sp|K1Q1K6|K1Q1K6_CRAGI	8.8e-61	238.8	89.39%	68.55%	Pancreatic triacylglycerol lipase;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0052689|
GN014585.1	sp|K1RGU4|K1RGU4_CRAGI	1.3e-213	748.8	99.89%	54.90%	WD repeat-containing protein C2orf44-like protein;OS=Crassostrea;PE=4;SV=1
GN014586.1	sp|K1S049|K1S049_CRAGI	7.4e-244	849.7	78.58%	69.11%	Putative RNA-binding protein 16;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN014587.1	sp|K1PG30|K1PG30_CRAGI	3.2e-185	653.3	92.11%	84.24%	Glycoprotein endo-alpha-1,2-mannosidase;OS=Crassostrea;PE=4;SV=1	GO:0016798|
GN014588.1	sp|K1R4G0|K1R4G0_CRAGI	1.2e-110	404.8	100.00%	91.23%	Zinc finger C4H2 domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN014589.1	sp|K1R920|K1R920_CRAGI	1.1e-56	224.9	91.67%	93.66%	Eukaryotic translation initiation factor 1A, X-chromosomal;OS=Crassostrea;PE=3;SV=1	GO:0003743|
GN014590.1	sp|K1R320|K1R320_CRAGI	2.3e-22	111.3	36.22%	70.42%	Tripartite motif-containing protein 59;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN014591.1	sp|K1R0X8|K1R0X8_CRAGI	1.8e-75	288.1	71.71%	71.20%	E3 ubiquitin-protein ligase SHPRH;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016874|GO:0046872|
GN014592.1	sp|K1QEN5|K1QEN5_CRAGI	3.5e-16	92.0	97.69%	21.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014593.1	sp|K1PK94|K1PK94_CRAGI	3.4e-50	203.0	96.49%	90.83%	Lambda-crystallin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003857|GO:0070403|	GO:0006631|
GN014594.1	sp|K1PK94|K1PK94_CRAGI	1.3e-87	328.2	92.23%	81.48%	Lambda-crystallin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003857|GO:0070403|	GO:0006631|
GN014595.1	sp|K1PS96|K1PS96_CRAGI	2.7e-158	564.3	98.86%	65.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN014596.1	sp|A0A0C5DYM0|A0A0C5DYM0_CRAHO	7.8e-110	402.1	100.00%	89.70%	Bak protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0043065|
GN014597.1	sp|A0A210Q000|A0A210Q000_MIZYE	3.6e-82	311.6	82.92%	34.50%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014598.1	sp|K1PR91|K1PR91_CRAGI	5.1e-255	885.9	99.70%	67.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014599.1	sp|K1PSP9|K1PSP9_CRAGI	9.6e-254	881.7	99.85%	67.22%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014600.1	sp|K1R2C7|K1R2C7_CRAGI	4.6e-248	862.8	99.85%	64.95%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014601.1	sp|K1PSP9|K1PSP9_CRAGI	2.4e-252	877.1	99.85%	66.77%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014602.1	sp|K1PKA2|K1PKA2_CRAGI	1.5e-270	937.2	100.00%	95.62%	Splicing factor 3A subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0005681|	GO:0003723|GO:0008270|	GO:0000398|
GN014603.1	sp|K1PS99|K1PS99_CRAGI	5.5e-227	793.1	100.00%	76.01%	M-phase phosphoprotein 8;OS=Crassostrea;PE=4;SV=1
GN014604.1	sp|K1QCS9|K1QCS9_CRAGI	2.7e-112	411.0	100.00%	62.30%	BTB/POZ domain-containing protein KCTD10;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN014605.1	sp|K1PCS4|K1PCS4_CRAGI	1.9e-259	900.2	100.00%	98.31%	Eukaryotic translation initiation factor 2 subunit 3, Y-linked;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0003743|
GN014606.1	sp|K1PKA9|K1PKA9_CRAGI	3.9e-146	523.1	99.67%	85.57%	Membrane-bound transcription factor site-2 protease;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|
GN014607.1	sp|K1R2C7|K1R2C7_CRAGI	3.1e-252	876.7	99.85%	66.16%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014608.1	sp|K1PSA6|K1PSA6_CRAGI	0.0e+00	2213.3	100.00%	78.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0030036|
GN014609.1	sp|K1QCT5|K1QCT5_CRAGI	4.4e-150	536.2	99.67%	84.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014610.1	sp|K1QSC5|K1QSC5_CRAGI	4.0e-53	213.0	85.71%	78.99%	Tyrosine-protein phosphatase 10D;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN014612.1	sp|K1QBB8|K1QBB8_CRAGI	0.0e+00	1334.3	96.76%	88.11%	Kielin/chordin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|GO:0004867|
GN013859.1	sp|K1R645|K1R645_CRAGI	2.9e-14	84.0	79.31%	43.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014613.1	sp|K1RIN0|K1RIN0_CRAGI	0.0e+00	1355.9	100.00%	66.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005544|
GN014614.1	sp|K1RAQ9|K1RAQ9_CRAGI	2.7e-129	467.2	99.68%	63.49%	Phosphoglycolate phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0016791|
GN014615.1	sp|K1R4P0|K1R4P0_CRAGI	1.5e-63	249.6	99.27%	31.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014616.1	sp|A0A210PJM2|A0A210PJM2_MIZYE	3.2e-54	218.0	88.83%	36.99%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014618.1	sp|K1QV54|K1QV54_CRAGI	1.6e-48	199.5	83.53%	52.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014622.1	sp|K1PKM0|K1PKM0_CRAGI	3.1e-262	910.2	100.00%	74.15%	RalBP1-associated Eps domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN014624.1	sp|A0A210PT87|A0A210PT87_MIZYE	7.9e-185	652.1	100.00%	84.58%	Histone-binding protein RBBP7;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|
GN014625.1	sp|K1P710|K1P710_CRAGI	1.1e-240	838.2	93.07%	81.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014626.1	sp|K1Q9D3|K1Q9D3_CRAGI	1.5e-65	255.4	80.14%	53.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014627.1	sp|K1QD23|K1QD23_CRAGI	1.3e-113	414.8	94.42%	88.98%	Acetyl-CoA acetyltransferase B, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN014628.1	sp|K1PK04|K1PK04_CRAGI	1.5e-262	911.0	99.85%	67.68%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014629.1	sp|K1QD23|K1QD23_CRAGI	3.0e-18	97.1	39.06%	91.84%	Acetyl-CoA acetyltransferase B, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN014630.1	sp|K1QD23|K1QD23_CRAGI	1.0e-17	94.0	98.04%	87.76%	Acetyl-CoA acetyltransferase B, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN014631.1	sp|K1R2C7|K1R2C7_CRAGI	6.9e-252	875.5	99.85%	65.71%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN013935.1	sp|A0A210Q129|A0A210Q129_MIZYE	5.9e-15	87.4	94.10%	23.29%	Serine/threonine-protein kinase pats1;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN014632.1	sp|K1PK04|K1PK04_CRAGI	2.2e-258	897.1	99.85%	66.77%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014633.1	sp|W4Z415|W4Z415_STRPU	1.4e-23	115.5	96.83%	36.07%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN014634.1	sp|K1PK04|K1PK04_CRAGI	3.5e-259	899.8	97.94%	66.92%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014635.1	sp|K1PSM7|K1PSM7_CRAGI	9.7e-46	188.7	91.57%	63.82%	Ankyrin repeat domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN014636.1	sp|K1PR91|K1PR91_CRAGI	2.7e-248	863.6	99.70%	64.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014637.1	sp|K1PSM7|K1PSM7_CRAGI	0.0e+00	1250.3	80.52%	65.96%	Ankyrin repeat domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN014638.1	sp|K1P704|K1P704_CRAGI	5.8e-285	986.1	99.25%	55.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014639.1	sp|K1QD20|K1QD20_CRAGI	9.7e-16	88.6	75.42%	56.82%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014640.1	sp|K1P704|K1P704_CRAGI	9.1e-28	130.2	62.26%	38.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014641.1	sp|K1P704|K1P704_CRAGI	3.8e-130	471.9	87.23%	26.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014643.1	sp|K1P704|K1P704_CRAGI	4.1e-28	131.3	62.26%	38.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014644.1	sp|K1QD20|K1QD20_CRAGI	1.2e-47	195.7	84.77%	49.77%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014645.1	sp|K1PSL8|K1PSL8_CRAGI	5.7e-76	289.7	100.00%	74.79%	RWD domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN014646.1	sp|K1PNM0|K1PNM0_CRAGI	2.0e-50	204.1	86.84%	74.81%	Coiled-coil domain-containing protein 58;OS=Crassostrea;PE=4;SV=1
GN014647.1	sp|K1PV79|K1PV79_CRAGI	6.5e-192	676.0	98.90%	95.90%	Importin subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0061608|GO:0008565|	GO:0006606|
GN014648.1	sp|K1Q2M8|K1Q2M8_CRAGI	7.8e-32	142.1	99.19%	60.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014649.1	sp|K1QHD7|K1QHD7_CRAGI	4.5e-69	267.3	99.43%	39.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014650.1	sp|K1PV83|K1PV83_CRAGI	1.2e-35	155.6	42.67%	83.51%	Two pore calcium channel protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005765|	GO:0072345|GO:0005245|
GN013937.1	sp|A7SV06|A7SV06_NEMVE	4.6e-18	97.1	82.41%	33.54%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN014651.1	sp|K1R8S8|K1R8S8_CRAGI	3.9e-89	333.6	98.86%	67.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014652.1	sp|K1QJ59|K1QJ59_CRAGI	2.0e-79	301.2	88.57%	64.68%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014653.1	sp|K1Q2N1|K1Q2N1_CRAGI	2.4e-70	271.2	80.08%	67.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0070513|GO:0002020|	GO:0042981|GO:0007165|
GN014654.1	sp|A0A2G8JSW5|A0A2G8JSW5_STIJA	1.2e-90	339.7	55.61%	50.15%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN014655.1	sp|K1Q2N1|K1Q2N1_CRAGI	1.6e-59	236.1	60.56%	47.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0070513|GO:0002020|	GO:0042981|GO:0007165|
GN014656.1	sp|A0A210QFP4|A0A210QFP4_MIZYE	2.0e-48	198.0	100.00%	50.94%	Achaete-scute-like 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006357|
GN014657.1	sp|K1RT99|K1RT99_CRAGI	2.1e-18	97.1	84.44%	67.53%	Achaete-scute-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006357|
GN014658.1	sp|K1R9F4|K1R9F4_CRAGI	8.5e-97	358.6	100.00%	89.95%	Achaete-scute-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006357|
GN014659.1	sp|K1QLU7|K1QLU7_CRAGI	7.8e-83	312.4	100.00%	74.21%	Achaete-scute-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006357|
GN014660.1	sp|K1RT93|K1RT93_CRAGI	1.2e-95	356.7	78.83%	53.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014661.1	sp|V4AIH2|V4AIH2_LOTGI	4.8e-60	236.1	97.33%	73.79%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005664|	GO:0003677|	GO:0006260|
GN014662.1	sp|K1Q8M6|K1Q8M6_CRAGI	1.2e-11	75.1	42.40%	63.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014663.1	sp|K1R9E5|K1R9E5_CRAGI	3.4e-59	234.6	64.38%	52.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014664.1	sp|K1QGF8|K1QGF8_CRAGI	7.8e-247	858.2	100.00%	88.91%	Uncharacterized protein C11orf66-like protein;OS=Crassostrea;PE=4;SV=1
GN014665.1	sp|V4AIF9|V4AIF9_LOTGI	4.8e-268	929.1	99.84%	72.39%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005524|GO:0003676|
GN014666.1	sp|A0A0L8I304|A0A0L8I304_OCTBM	9.7e-96	356.3	97.82%	40.96%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0016021|
GN014668.1	sp|K1PEH4|K1PEH4_CRAGI	2.7e-15	89.4	19.53%	33.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014669.1	sp|K1PR64|K1PR64_CRAGI	8.8e-163	578.6	98.51%	84.24%	N-acylethanolamine-hydrolyzing acid amidase;OS=Crassostrea;PE=4;SV=1	GO:0005764|	GO:0006629|
GN014670.1	sp|A0A210Q246|A0A210Q246_MIZYE	1.9e-222	778.1	59.44%	74.51%	RNA helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004386|GO:0003723|
GN014671.1	sp|K1Q5B9|K1Q5B9_CRAGI	3.3e-199	699.9	94.58%	83.25%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN014672.1	sp|K1QY36|K1QY36_CRAGI	4.0e-38	164.1	42.21%	71.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014673.1	sp|K1RG59|K1RG59_CRAGI	3.4e-195	686.8	97.78%	71.34%	Putative disease resistance protein RGA3;OS=Crassostrea;PE=4;SV=1	GO:0043531|
GN014674.1	sp|K1PWH8|K1PWH8_CRAGI	1.4e-18	98.2	90.30%	45.00%	Major facilitator superfamily domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0043531|GO:0005215|	GO:0055085|
GN014675.1	sp|K1RMC7|K1RMC7_CRAGI	2.2e-285	987.3	93.33%	62.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0043531|
GN014676.1	sp|K1PNY5|K1PNY5_CRAGI	1.8e-130	471.9	49.71%	90.31%	Splicing factor, proline-and glutamine-rich;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN014677.1	sp|K1RDK2|K1RDK2_CRAGI	3.0e-24	117.1	95.74%	52.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013940.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	2.6e-74	285.0	99.77%	35.93%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN014678.1	sp|C3XVZ0|C3XVZ0_BRAFL	2.4e-109	400.6	90.61%	87.78%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005829|GO:0043005|GO:0031982|	GO:0051087|GO:0030544|GO:0051879|	GO:0060548|
GN014679.1	sp|K1QI16|K1QI16_CRAGI	1.4e-243	847.8	100.00%	73.98%	Growth factor receptor-bound protein 2;OS=Crassostrea;PE=4;SV=1
GN014680.1	sp|K1RPW4|K1RPW4_CRAGI	2.2e-43	182.2	96.81%	36.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014681.1	sp|K1R5E0|K1R5E0_CRAGI	2.3e-242	843.6	94.56%	81.31%	Synaptic vesicle glycoprotein 2C;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN014682.1	sp|V3ZX45|V3ZX45_LOTGI	2.5e-99	368.2	93.97%	48.20%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN014683.1	sp|K1QZJ5|K1QZJ5_CRAGI	9.2e-201	705.3	98.79%	66.93%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0050660|GO:0016614|
GN014684.1	sp|K1R9W4|K1R9W4_CRAGI	2.8e-67	260.4	97.71%	79.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014687.1	sp|K1S548|K1S548_CRAGI	1.0e-97	363.2	93.14%	42.05%	Paired box protein Pax-6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN014688.1	sp|K1QZK0|K1QZK0_CRAGI	1.6e-212	744.6	100.00%	80.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014690.1	sp|A0A1S3J026|A0A1S3J026_LINUN	3.9e-118	430.3	99.41%	63.31%	quinone oxidoreductase PIG3-like;OS=Lingula;PE=4;SV=1	GO:0016491|
GN014691.1	sp|K1RFN0|K1RFN0_CRAGI	0.0e+00	1388.6	89.39%	59.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014692.1	sp|K1PRR3|K1PRR3_CRAGI	3.5e-226	789.6	100.00%	82.17%	BTB/POZ domain-containing protein 17;OS=Crassostrea;PE=4;SV=1
GN014693.1	sp|K1QC96|K1QC96_CRAGI	1.5e-119	435.3	93.87%	59.69%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN014694.1	sp|K1PC90|K1PC90_CRAGI	1.9e-214	751.1	99.85%	60.30%	Low-density lipoprotein receptor-related protein 1B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014695.1	sp|K1QD19|K1QD19_CRAGI	1.7e-105	388.7	99.55%	53.88%	Interferon-induced, double-stranded RNA-activated protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN014697.1	sp|K1RNK4|K1RNK4_CRAGI	2.0e-23	114.4	94.44%	39.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013941.1	sp|A0A0L8HFK6|A0A0L8HFK6_OCTBM	2.8e-40	170.6	93.64%	53.42%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005739|	GO:0051607|
GN014700.1	sp|A0A2S2P439|A0A2S2P439_SCHGA	8.5e-16	90.1	57.43%	30.86%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN014701.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	4.9e-19	99.8	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN014703.1	sp|W4Z9W9|W4Z9W9_STRPU	5.4e-44	184.1	66.84%	40.64%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN014704.1	sp|K1QDR7|K1QDR7_CRAGI	1.4e-57	229.6	41.76%	54.04%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN014706.1	sp|A0A210QB18|A0A210QB18_MIZYE	7.4e-186	655.6	100.00%	74.50%	Tyrosine--tRNA ligase;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0000049|GO:0004831|	GO:0006437|
GN014707.1	sp|A0A210PM68|A0A210PM68_MIZYE	0.0e+00	3435.6	95.09%	75.28%	Acetyl-CoA carboxylase;OS=Mizuhopecten;PE=4;SV=1	GO:0003989|GO:0005524|GO:0046872|	GO:0006633|
GN014708.1	sp|K1QKA0|K1QKA0_CRAGI	8.9e-35	155.2	38.29%	33.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014709.1	sp|A0A210Q720|A0A210Q720_MIZYE	1.7e-221	774.2	99.06%	74.14%	Transmembrane protein 181;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0015643|
GN014710.1	sp|K1QS77|K1QS77_CRAGI	0.0e+00	1482.2	98.91%	71.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005813|GO:0097546|	GO:0031122|GO:0007052|GO:1905515|
GN014711.1	sp|V4A2Z2|V4A2Z2_LOTGI	3.8e-110	404.1	96.99%	50.00%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN014712.1	sp|K1Q973|K1Q973_CRAGI	4.2e-254	883.6	76.28%	55.28%	Vacuolar protein sorting-associated protein 13D;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN014713.1	sp|A0A3M6UFK7|A0A3M6UFK7_9CNID	2.5e-20	104.0	92.48%	40.48%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN014714.1	sp|K1RYP8|K1RYP8_CRAGI	5.7e-85	319.7	96.18%	60.87%	Mannan polymerase complex subunit mnn9;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014715.1	sp|K1QTM5|K1QTM5_CRAGI	1.2e-132	478.4	99.39%	70.61%	Lactadherin;OS=Crassostrea;PE=4;SV=1
GN013942.1	sp|K1QY88|K1QY88_CRAGI	2.8e-85	322.4	55.21%	40.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN014716.1	sp|K1R355|K1R355_CRAGI	0.0e+00	1326.2	99.52%	88.65%	Transmembrane and TPR repeat-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014717.1	sp|K1RFU7|K1RFU7_CRAGI	1.7e-79	301.6	86.55%	66.53%	Achaete-scute-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046983|	GO:0006357|
GN014718.1	sp|A0A0B6ZAJ3|A0A0B6ZAJ3_9EUPU	2.5e-13	80.5	82.88%	44.33%	Mitochondrial pyruvate carrier;OS=Arion;PE=3;SV=1	GO:0005743|	GO:0006850|
GN014719.1	sp|K1QI06|K1QI06_CRAGI	1.3e-139	501.9	94.52%	85.58%	Cleavage stimulation factor 64 kDa subunit;OS=Crassostrea;PE=4;SV=1	GO:0005847|	GO:0003723|	GO:0006378|
GN013943.1	sp|K1Q5B6|K1Q5B6_CRAGI	2.0e-49	201.1	92.70%	58.54%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN014720.1	sp|K1PR03|K1PR03_CRAGI	1.7e-90	337.4	100.00%	96.97%	Sorting nexin-12;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN014721.1	sp|K1QI11|K1QI11_CRAGI	1.2e-179	634.8	99.74%	71.52%	Pyruvate dehydrogenase E1 component subunit alpha type II, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016624|
GN014723.1	sp|K1PXH5|K1PXH5_CRAGI	3.9e-32	143.3	89.93%	58.82%	Putative saccharopine dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN013944.1	sp|K1RJ89|K1RJ89_CRAGI	2.3e-64	251.9	77.11%	44.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014724.1	sp|K1PFL5|K1PFL5_CRAGI	0.0e+00	1266.5	88.76%	85.57%	Putative beta-D-xylosidase 2;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0005975|
GN014725.1	sp|A0A210PMA0|A0A210PMA0_MIZYE	1.8e-145	521.5	93.62%	53.96%	Organic cation transporter protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0022857|
GN014727.1	sp|K1QLY9|K1QLY9_CRAGI	3.4e-218	763.1	95.15%	90.26%	Small conductance calcium-activated potassium channel protein;OS=Crassostrea;PE=4;SV=1	GO:0008076|	GO:0005516|GO:0016286|GO:0005249|
GN014728.1	sp|K1RLU0|K1RLU0_CRAGI	3.7e-24	117.1	100.00%	48.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014729.1	sp|K1QNG6|K1QNG6_CRAGI	1.3e-185	654.8	90.69%	82.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014730.1	sp|A0A210PMD6|A0A210PMD6_MIZYE	4.4e-35	154.8	84.91%	33.41%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014731.1	sp|A0A210PRQ3|A0A210PRQ3_MIZYE	9.8e-100	369.4	100.00%	53.61%	General transcription factor IIE subunit 1;OS=Mizuhopecten;PE=4;SV=1	GO:0043565|	GO:0006367|
GN014735.1	sp|K1QNK9|K1QNK9_CRAGI	2.0e-48	197.2	78.40%	86.60%	Temptin;OS=Crassostrea;PE=4;SV=1
GN014736.1	sp|K1RR05|K1RR05_CRAGI	6.0e-50	202.2	94.87%	85.45%	Temptin;OS=Crassostrea;PE=4;SV=1
GN014737.1	sp|K1RB62|K1RB62_CRAGI	0.0e+00	1221.5	100.00%	80.06%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN014738.1	sp|K1QXR1|K1QXR1_CRAGI	0.0e+00	1362.8	99.16%	79.88%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN014739.1	sp|K1QAF5|K1QAF5_CRAGI	1.1e-116	425.2	100.00%	78.05%	Neuropeptide capa receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN014740.1	sp|K1QCU2|K1QCU2_CRAGI	0.0e+00	1484.9	100.00%	79.77%	Cubilin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014742.1	sp|K1QN93|K1QN93_CRAGI	5.3e-20	102.4	92.78%	53.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014743.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	1.7e-20	105.5	59.16%	38.96%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014744.1	sp|K1R1H6|K1R1H6_CRAGI	2.1e-175	620.9	100.00%	83.01%	Golgi-associated PDZ and coiled-coil motif-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0005794|	GO:0043004|
GN014745.1	sp|K1RCC8|K1RCC8_CRAGI	8.6e-30	135.6	93.88%	53.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0051607|
GN014748.1	sp|K1QBD1|K1QBD1_CRAGI	6.0e-44	183.0	99.47%	52.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014749.1	sp|K1PVP0|K1PVP0_CRAGI	6.6e-54	216.1	80.93%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014750.1	sp|K1QCD8|K1QCD8_CRAGI	0.0e+00	1134.0	97.97%	84.29%	USP6 N-terminal-like protein;OS=Crassostrea;PE=4;SV=1
GN014752.1	sp|K1RK03|K1RK03_CRAGI	1.0e-62	245.4	100.00%	67.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014753.1	sp|K1QCF3|K1QCF3_CRAGI	4.2e-29	134.0	62.65%	50.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014754.1	sp|K1QL32|K1QL32_CRAGI	3.8e-49	200.7	85.94%	54.55%	Ashwin;OS=Crassostrea;PE=4;SV=1	GO:0072669|	GO:0048598|
GN014756.1	sp|K1PK24|K1PK24_CRAGI	3.5e-127	460.7	65.10%	79.45%	snRNA-activating protein complex subunit 1;OS=Crassostrea;PE=4;SV=1
GN014758.1	sp|K1QVJ0|K1QVJ0_CRAGI	1.4e-17	94.7	99.19%	40.50%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN014759.1	sp|K1QZD5|K1QZD5_CRAGI	1.9e-172	611.3	92.52%	62.42%	LAS1-like protein;OS=Crassostrea;PE=4;SV=1
GN014760.1	sp|K1PRG0|K1PRG0_CRAGI	1.1e-140	505.0	100.00%	84.49%	Adenosine receptor A2a;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013945.1	sp|K1QFL5|K1QFL5_CRAGI	2.0e-17	95.9	51.76%	31.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014761.1	sp|K1PCB3|K1PCB3_CRAGI	6.0e-136	491.1	63.61%	39.50%	Apolipoprotein L3;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0008289|	GO:0006869|GO:0042157|
GN014763.1	sp|K1RIW4|K1RIW4_CRAGI	1.3e-80	304.7	100.00%	85.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014764.1	sp|K1RIW4|K1RIW4_CRAGI	5.6e-138	496.5	74.94%	63.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013946.1	sp|K1S0T7|K1S0T7_CRAGI	4.7e-57	227.3	53.33%	63.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014765.1	sp|K1S5H7|K1S5H7_CRAGI	0.0e+00	1358.2	100.00%	90.83%	Cell division cycle 5-related protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0051301|
GN014766.1	sp|K1QZV9|K1QZV9_CRAGI	4.7e-246	856.7	99.79%	58.31%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B;OS=Crassostrea;PE=4;SV=1
GN014767.1	sp|K1RA54|K1RA54_CRAGI	8.9e-177	627.1	47.14%	47.26%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN014771.1	sp|A0A182ZAQ3|A0A182ZAQ3_BIOGL	2.4e-11	75.5	59.33%	31.63%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN014772.1	sp|K1RM01|K1RM01_CRAGI	0.0e+00	2726.0	99.82%	86.76%	Dystrophin;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN014774.1	sp|K1Q935|K1Q935_CRAGI	6.1e-36	156.0	82.07%	71.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016887|GO:0004842|
GN014775.1	sp|K1R495|K1R495_CRAGI	1.3e-28	132.1	87.13%	44.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN013947.1	sp|K1PPI2|K1PPI2_CRAGI	1.6e-149	534.3	100.00%	90.61%	alpha-1,2-Mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004571|	GO:0008152|
GN014776.1	sp|A0A1X7UEV0|A0A1X7UEV0_AMPQE	4.3e-59	235.0	61.41%	33.78%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046872|
GN014777.1	sp|K1R149|K1R149_CRAGI	2.0e-143	514.2	96.59%	80.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016887|GO:0004842|
GN014778.1	sp|K1QF30|K1QF30_CRAGI	0.0e+00	1169.8	97.65%	76.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016887|GO:0004842|
GN014779.1	sp|K1QF30|K1QF30_CRAGI	0.0e+00	1978.4	90.76%	79.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016887|GO:0004842|
GN014780.1	sp|K1QF30|K1QF30_CRAGI	0.0e+00	2180.2	98.70%	80.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016887|GO:0004842|
GN014781.1	sp|K1QJJ1|K1QJJ1_CRAGI	0.0e+00	1356.3	100.00%	71.29%	Anoctamin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0046983|
GN014783.1	sp|K1PXR5|K1PXR5_CRAGI	4.2e-145	519.6	100.00%	81.85%	Transmembrane protein 45B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013949.1	sp|K1QF88|K1QF88_CRAGI	5.0e-53	213.0	91.28%	62.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014787.1	sp|K1PMC5|K1PMC5_CRAGI	6.0e-25	119.0	98.11%	57.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014788.1	sp|A0A210PQY4|A0A210PQY4_MIZYE	5.9e-132	476.1	100.00%	68.92%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014789.1	sp|K1QI38|K1QI38_CRAGI	1.2e-242	845.5	93.81%	70.12%	Protein SON;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0051726|GO:0043484|
GN014790.1	sp|K1QBD2|K1QBD2_CRAGI	2.3e-243	847.0	100.00%	73.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014794.1	sp|A0A1S3JPV4|A0A1S3JPV4_LINUN	1.4e-63	248.4	100.00%	81.78%	charged multivesicular body protein 2a;OS=Lingula;PE=3;SV=1	GO:0007034|
GN014795.1	sp|K1PVZ3|K1PVZ3_CRAGI	0.0e+00	1486.9	97.79%	90.84%	Cold shock domain-containing protein E1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014796.1	sp|K1R3Q5|K1R3Q5_CRAGI	6.1e-198	696.0	83.33%	77.06%	Protein arginine N-methyltransferase 3;OS=Crassostrea;PE=3;SV=1	GO:0008168|GO:0003676|	GO:0006479|
GN014798.1	sp|K1QI32|K1QI32_CRAGI	0.0e+00	1805.4	100.00%	64.54%	Synaptotagmin-like protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016020|	GO:0017137|	GO:0006886|
GN014799.1	sp|K1QYL2|K1QYL2_CRAGI	2.2e-240	837.4	86.63%	64.72%	Laccase-24;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN014800.1	sp|K1QYL2|K1QYL2_CRAGI	3.1e-225	786.9	89.86%	64.89%	Laccase-24;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN014801.1	sp|K1PBC1|K1PBC1_CRAGI	3.9e-19	100.5	57.22%	46.23%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014803.1	sp|K1P8U6|K1P8U6_CRAGI	0.0e+00	1241.9	96.31%	76.42%	Outer dense fiber protein 3;OS=Crassostrea;PE=4;SV=1
GN014804.1	sp|K1PV42|K1PV42_CRAGI	3.5e-15	87.0	70.95%	52.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014805.1	sp|A0A210PME2|A0A210PME2_MIZYE	5.5e-223	780.0	93.77%	46.64%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014806.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	4.5e-33	146.7	93.26%	47.46%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN014807.1	sp|K1PB73|K1PB73_CRAGI	0.0e+00	1860.1	87.33%	79.77%	Ubiquitin carboxyl-terminal hydrolase 47;OS=Crassostrea;PE=3;SV=1	GO:0036459|	GO:0006511|
GN014808.1	sp|K1PTC2|K1PTC2_CRAGI	4.9e-32	142.5	70.87%	97.22%	c-Myc-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0003713|	GO:0006355|
GN014809.1	sp|K1Q9Y4|K1Q9Y4_CRAGI	2.4e-56	225.7	29.42%	64.20%	Cytoplasmic phosphatidylinositol transfer protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005548|
GN014810.1	sp|K1QI87|K1QI87_CRAGI	3.3e-09	67.0	65.12%	45.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014811.1	sp|Q70MN8|Q70MN8_CRAGI	5.4e-27	125.9	58.62%	97.01%	Ribosomal protein L24;OS=Crassostrea;PE=2;SV=1	GO:0005840|
GN014813.1	sp|K1R525|K1R525_CRAGI	6.6e-105	386.0	100.00%	66.54%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN014814.1	sp|K1Q7T3|K1Q7T3_CRAGI	5.1e-66	256.5	97.35%	56.76%	Beta-1,3-galactosyltransferase 5;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0008378|	GO:0006486|
GN014815.1	sp|K1PEP3|K1PEP3_CRAGI	1.1e-19	102.1	100.00%	37.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014816.1	sp|A0A1S3I398|A0A1S3I398_LINUN	1.2e-14	85.5	58.29%	41.18%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN014817.1	sp|K1RD15|K1RD15_CRAGI	4.6e-111	406.8	97.93%	58.61%	Beta-1,3-galactosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0008378|	GO:0006486|
GN014819.1	sp|K1RRD7|K1RRD7_CRAGI	2.1e-134	485.0	60.78%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014820.1	sp|A7RGD7|A7RGD7_NEMVE	3.8e-12	77.4	50.25%	43.14%	Predicted protein;OS=Nematostella;PE=4;SV=1	GO:0030246|GO:0004888|
GN014824.1	sp|K1PLC9|K1PLC9_CRAGI	4.5e-22	109.8	98.48%	46.15%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN014826.1	sp|A0A1S3H1P8|A0A1S3H1P8_LINUN	3.0e-134	483.8	98.85%	62.43%	cytochrome b-245 heavy chain;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0016491|
GN014827.1	sp|K1QMC7|K1QMC7_CRAGI	2.1e-44	184.1	81.76%	77.50%	U7 snRNA-associated Sm-like protein LSm10;OS=Crassostrea;PE=4;SV=1
GN014828.1	sp|K1QCJ2|K1QCJ2_CRAGI	2.8e-204	716.8	99.78%	81.25%	UPF0638 protein B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014829.1	sp|K1PCJ3|K1PCJ3_CRAGI	2.3e-255	886.7	100.00%	88.48%	Frizzled-4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0042813|	GO:0007275|
GN013953.1	sp|A0A1S3J9Z2|A0A1S3J9Z2_LINUN	1.8e-18	99.4	57.29%	29.84%	uncharacterized protein LOC106171421;OS=Lingula;PE=3;SV=1	GO:0004197|	GO:0006915|GO:0042981|
GN014830.1	sp|K1PCJ1|K1PCJ1_CRAGI	2.8e-48	197.2	100.00%	88.30%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN014831.1	sp|K1PBC1|K1PBC1_CRAGI	1.1e-18	99.0	61.83%	44.35%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014832.1	sp|K1PBC1|K1PBC1_CRAGI	3.5e-20	104.0	62.03%	43.48%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014834.1	sp|K1QYF4|K1QYF4_CRAGI	1.2e-87	328.6	100.00%	69.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014835.1	sp|A0A1S3H413|A0A1S3H413_LINUN	3.5e-34	150.6	96.00%	41.06%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN014836.1	sp|K1R451|K1R451_CRAGI	1.2e-11	75.9	26.94%	58.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014837.1	sp|K1Q453|K1Q453_CRAGI	2.1e-185	654.4	93.93%	69.71%	JNK-interacting protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014840.1	sp|K1PMC5|K1PMC5_CRAGI	2.0e-38	164.1	97.73%	64.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014841.1	sp|K1Q1H6|K1Q1H6_CRAGI	4.2e-18	97.1	32.60%	79.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014843.1	sp|A0A1S3JFN7|A0A1S3JFN7_LINUN	3.3e-121	441.0	99.80%	45.72%	uncharacterized protein LOC106172813;OS=Lingula;PE=4;SV=1
GN013954.1	sp|K1QFL5|K1QFL5_CRAGI	2.7e-46	193.0	38.65%	33.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014846.1	sp|K1RLB5|K1RLB5_CRAGI	1.4e-105	388.7	90.70%	54.60%	Protein phosphatase 1K, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004722|
GN014847.1	sp|K1QMR7|K1QMR7_CRAGI	4.9e-23	112.8	85.12%	52.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014848.1	sp|A0A210QNY4|A0A210QNY4_MIZYE	5.9e-09	65.5	80.00%	46.03%	Hemicentin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014850.1	sp|A0A210PZA1|A0A210PZA1_MIZYE	1.7e-137	495.4	97.38%	44.21%	Solute carrier organic anion transporter family member;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN014851.1	sp|A0A210PZ30|A0A210PZ30_MIZYE	6.0e-150	537.0	94.01%	43.01%	Solute carrier organic anion transporter family member;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN014852.1	sp|R7V392|R7V392_CAPTE	9.1e-28	130.6	38.17%	42.47%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN014853.1	sp|K1Q235|K1Q235_CRAGI	7.7e-63	246.9	95.32%	39.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014854.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	4.4e-36	156.8	95.03%	47.37%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014855.1	sp|K1PZQ8|K1PZQ8_CRAGI	1.0e-28	133.7	52.41%	30.71%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014857.1	sp|K1QN50|K1QN50_CRAGI	2.9e-12	78.2	60.84%	30.12%	Complement C1q subcomponent subunit B;OS=Crassostrea;PE=4;SV=1
GN014859.1	sp|K1RKS8|K1RKS8_CRAGI	4.8e-289	999.2	91.91%	72.87%	Circularly permutated Ras protein 1;OS=Crassostrea;PE=4;SV=1	GO:0030127|	GO:0008270|	GO:0006888|GO:0006886|
GN014860.1	sp|K1R192|K1R192_CRAGI	8.7e-173	612.1	100.00%	75.12%	Thymidine phosphorylase;OS=Crassostrea;PE=3;SV=1	GO:0004645|GO:0016154|GO:0009032|	GO:0006206|GO:0006213|
GN014861.1	sp|K1QUG6|K1QUG6_CRAGI	1.9e-53	214.2	100.00%	66.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014862.1	sp|K1PP23|K1PP23_CRAGI	4.3e-72	276.9	98.85%	51.31%	Chymotrypsin-like serine proteinase;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN014863.1	sp|K1R192|K1R192_CRAGI	3.7e-27	125.9	93.75%	81.08%	Thymidine phosphorylase;OS=Crassostrea;PE=3;SV=1	GO:0004645|GO:0016154|GO:0009032|	GO:0006206|GO:0006213|
GN013956.1	sp|K1RRD7|K1RRD7_CRAGI	6.2e-24	116.7	29.86%	81.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014866.1	sp|K1PYS7|K1PYS7_CRAGI	4.3e-41	173.3	100.00%	47.95%	TATA-box-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006352|
GN014867.1	sp|K1QJ76|K1QJ76_CRAGI	6.0e-18	95.9	73.50%	58.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014868.1	sp|A0A2G8JBW6|A0A2G8JBW6_STIJA	2.2e-27	127.9	97.78%	35.26%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN014869.1	sp|A0A210Q454|A0A210Q454_MIZYE	7.2e-45	186.4	77.91%	50.25%	Fibrinolytic enzyme, isozyme C;OS=Mizuhopecten;PE=3;SV=1	GO:0004252|
GN014870.1	sp|K1PP23|K1PP23_CRAGI	6.4e-49	199.5	84.97%	56.36%	Chymotrypsin-like serine proteinase;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN014871.1	sp|A0A194AKH3|A0A194AKH3_PINFU	1.8e-18	97.8	92.54%	50.79%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1
GN014874.1	sp|K1QLZ8|K1QLZ8_CRAGI	8.9e-20	102.4	41.98%	67.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014876.1	sp|K1PNT0|K1PNT0_CRAGI	3.2e-24	117.5	42.19%	67.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014877.1	sp|K1R189|K1R189_CRAGI	1.5e-110	405.2	86.54%	81.71%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN014878.1	sp|K1QLZ3|K1QLZ3_CRAGI	7.6e-309	1064.7	99.53%	85.69%	ATP-binding cassette sub-family B member 7, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN014879.1	sp|V3ZGE8|V3ZGE8_LOTGI	2.8e-88	330.5	92.89%	75.96%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0009116|
GN014880.1	sp|K1RKR9|K1RKR9_CRAGI	3.8e-258	896.7	84.65%	65.26%	PR domain zinc finger protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014881.1	sp|K1R184|K1R184_CRAGI	2.9e-83	313.9	100.00%	68.46%	Serine-enriched protein;OS=Crassostrea;PE=4;SV=1
GN014882.1	sp|K1QLY8|K1QLY8_CRAGI	0.0e+00	1642.1	99.45%	83.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014883.1	sp|A0A210Q1Y3|A0A210Q1Y3_MIZYE	6.9e-30	137.1	93.91%	32.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014885.1	sp|A0A1S3I398|A0A1S3I398_LINUN	5.8e-26	122.9	66.22%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN014888.1	sp|K1P9B4|K1P9B4_CRAGI	3.9e-49	200.7	95.11%	49.06%	Oligodendrocyte transcription factor 2;OS=Crassostrea;PE=4;SV=1	GO:0000981|GO:0046983|	GO:0022008|
GN014889.1	sp|K1PNG8|K1PNG8_CRAGI	0.0e+00	1424.5	99.80%	67.80%	Tumor necrosis factor, alpha-induced protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN014890.1	sp|K1QTC0|K1QTC0_CRAGI	6.3e-135	485.7	97.06%	82.51%	Sialate O-acetylesterase;OS=Crassostrea;PE=4;SV=1	GO:0001681|
GN014891.1	sp|K1Q9T0|K1Q9T0_CRAGI	2.7e-220	770.8	58.90%	82.63%	Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0030956|GO:0005739|	GO:0004040|GO:0005524|GO:0050567|GO:0016740|	GO:0070681|GO:0032543|
GN014892.1	sp|K1QVK0|K1QVK0_CRAGI	7.7e-148	528.9	98.76%	85.05%	Transaldolase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004801|	GO:0005975|GO:0006098|
GN014893.1	sp|K1Q096|K1Q096_CRAGI	1.9e-27	127.5	100.00%	50.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013960.1	sp|V4AGJ7|V4AGJ7_LOTGI	9.6e-28	129.4	78.07%	42.46%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN014895.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	8.1e-18	95.9	95.57%	37.82%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014896.1	sp|A7SPC6|A7SPC6_NEMVE	4.7e-35	154.1	97.95%	33.33%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN014899.1	sp|K1QA85|K1QA85_CRAGI	1.0e-29	134.8	100.00%	67.00%	Decaprenyl-diphosphate synthase subunit 2;OS=Crassostrea;PE=3;SV=1	GO:0016740|	GO:0008299|
GN013961.1	sp|A0A131XQ81|A0A131XQ81_IXORI	3.5e-30	138.3	86.67%	30.99%	Putative is4eu-1 dr;OS=Ixodes;PE=2;SV=1	GO:0008270|
GN014900.1	sp|A4KAD9|A4KAD9_HELZE	7.8e-26	122.5	94.77%	44.44%	Putative DNA-mediated transposase;OS=Helicoverpa;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006313|
GN014901.1	sp|K1P3R7|K1P3R7_CRAGI	1.3e-76	292.0	68.50%	74.19%	39S ribosomal protein L9, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN014902.1	sp|A0A1X7URD4|A0A1X7URD4_AMPQE	6.8e-26	122.9	95.95%	40.70%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN014903.1	sp|E9J352|E9J352_SOLIN	7.0e-52	210.3	73.67%	37.99%	Uncharacterized protein;OS=Solenopsis;PE=4;SV=1
GN014904.1	sp|K1PPK9|K1PPK9_CRAGI	5.0e-192	676.0	100.00%	83.65%	LanC-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN014905.1	sp|K1PV87|K1PV87_CRAGI	1.0e-59	235.0	98.59%	82.14%	Uncharacterized protein C11orf65-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014906.1	sp|K1PV87|K1PV87_CRAGI	1.7e-228	797.3	96.27%	84.91%	Uncharacterized protein C11orf65-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014907.1	sp|K1Q3V0|K1Q3V0_CRAGI	4.7e-273	946.8	100.00%	59.23%	Zinc finger C3H1 domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0004867|	GO:0006396|
GN014908.1	sp|K1RMV6|K1RMV6_CRAGI	7.0e-13	79.7	29.89%	62.96%	Ficolin-2;OS=Crassostrea;PE=4;SV=1
GN014909.1	sp|K1PPI3|K1PPI3_CRAGI	0.0e+00	2405.2	98.59%	56.69%	Nucleolar pre-ribosomal-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN014910.1	sp|K1PWW0|K1PWW0_CRAGI	1.6e-214	751.1	98.30%	70.19%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014911.1	sp|A0A0N5DQE1|A0A0N5DQE1_TRIMR	7.5e-31	138.7	100.00%	70.37%	Uncharacterized protein;OS=Trichuris;PE=3;SV=1	GO:0007034|
GN014912.1	sp|A0A1S3JJM8|A0A1S3JJM8_LINUN	4.8e-18	97.4	28.52%	63.16%	sperm-specific protein PHI-2B-like;OS=Lingula;PE=3;SV=1	GO:0000786|GO:0005634|	GO:0003677|	GO:0006334|
GN014913.1	sp|K1Q3V6|K1Q3V6_CRAGI	0.0e+00	1438.3	96.28%	79.48%	Glutamine-dependent NAD(+) synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003952|	GO:0009435|
GN014914.1	sp|K1QQ06|K1QQ06_CRAGI	0.0e+00	1207.6	100.00%	68.96%	Ubiquitinyl hydrolase 1;OS=Crassostrea;PE=3;SV=1	GO:0036459|GO:0008270|	GO:0016579|GO:0006511|
GN014915.1	sp|K1PHQ4|K1PHQ4_CRAGI	1.8e-96	358.2	59.09%	86.73%	Smad nuclear-interacting protein 1;OS=Crassostrea;PE=4;SV=1
GN014916.1	sp|K1PPJ0|K1PPJ0_CRAGI	0.0e+00	1147.1	100.00%	84.18%	Monocarboxylate transporter 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN013963.1	sp|A0A0L8H8R1|A0A0L8H8R1_OCTBM	2.6e-64	251.1	97.83%	45.07%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005739|	GO:0003735|	GO:0032543|
GN014919.1	sp|K1PP60|K1PP60_CRAGI	4.4e-137	493.4	96.73%	61.10%	Acetylcholine receptor subunit delta;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN014921.1	sp|K1QYL0|K1QYL0_CRAGI	9.1e-114	416.0	93.07%	53.24%	Cephalotocin receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN014922.1	sp|K1RIC2|K1RIC2_CRAGI	2.9e-167	593.6	96.16%	82.88%	Protor-2-like protein;OS=Crassostrea;PE=4;SV=1
GN014923.1	sp|A0A194QFH1|A0A194QFH1_PAPXU	2.2e-12	80.5	16.79%	34.91%	Ankyrin-2;OS=Papilio;PE=4;SV=1
GN014926.1	sp|K1QB08|K1QB08_CRAGI	4.7e-170	602.8	97.80%	80.23%	Aminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0004177|GO:0008237|GO:0008270|
GN014927.1	sp|A7T5N5|A7T5N5_NEMVE	8.7e-15	86.7	48.56%	34.04%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN014928.1	sp|K1QB08|K1QB08_CRAGI	2.6e-198	697.6	63.18%	79.02%	Aminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0004177|GO:0008237|GO:0008270|
GN014929.1	sp|K1QS00|K1QS00_CRAGI	0.0e+00	2073.9	93.19%	77.68%	Serine/threonine-protein kinase Nek8;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN014930.1	sp|K1RIJ9|K1RIJ9_CRAGI	7.2e-40	169.5	74.24%	54.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0032981|
GN014931.1	sp|A0A210PW77|A0A210PW77_MIZYE	5.4e-164	582.8	91.86%	82.37%	Transcriptional enhancer factor TEF-1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0035329|
GN014932.1	sp|V4A1Y9|V4A1Y9_LOTGI	6.8e-40	168.7	93.58%	72.28%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN014933.1	sp|A0A3M6UNS5|A0A3M6UNS5_9CNID	2.1e-14	85.5	42.11%	35.66%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN014934.1	sp|K1RK50|K1RK50_CRAGI	6.7e-55	220.7	96.47%	27.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014935.1	sp|K1PYD6|K1PYD6_CRAGI	1.1e-36	159.8	85.93%	26.79%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014937.1	sp|K1Q7U0|K1Q7U0_CRAGI	2.9e-33	147.5	47.94%	70.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0097196|	GO:0016887|GO:0003697|	GO:0000725|
GN014939.1	sp|K1QJ92|K1QJ92_CRAGI	1.0e-135	488.4	94.29%	91.29%	WD and tetratricopeptide repeats protein 1;OS=Crassostrea;PE=4;SV=1
GN014940.1	sp|K1QJ92|K1QJ92_CRAGI	5.3e-175	619.4	81.61%	88.54%	WD and tetratricopeptide repeats protein 1;OS=Crassostrea;PE=4;SV=1
GN014941.1	sp|K1PHT6|K1PHT6_CRAGI	1.9e-89	334.7	65.61%	92.51%	Mitochondrial glutamate carrier 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN014942.1	sp|K1PQJ6|K1PQJ6_CRAGI	4.8e-104	382.9	95.63%	84.47%	Rab-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN014943.1	sp|A0A210Q8D6|A0A210Q8D6_MIZYE	0.0e+00	2217.2	99.76%	56.00%	Brefeldin A-inhibited guanine nucleotide-exchange protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005086|	GO:0032012|
GN014944.1	sp|K1RAI5|K1RAI5_CRAGI	1.3e-86	325.5	99.08%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014945.1	sp|K1RAI5|K1RAI5_CRAGI	2.4e-138	498.0	97.35%	50.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014948.1	sp|K1QIF0|K1QIF0_CRAGI	4.3e-37	160.2	67.53%	56.92%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN014949.1	sp|K1RGT6|K1RGT6_CRAGI	3.3e-10	70.9	42.47%	46.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014950.1	sp|K1RAI5|K1RAI5_CRAGI	8.8e-32	142.5	98.91%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014951.1	sp|K1QIF0|K1QIF0_CRAGI	3.2e-38	164.5	48.18%	57.25%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN013966.1	sp|K1Q8X1|K1Q8X1_CRAGI	2.9e-69	266.5	100.00%	94.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014952.1	sp|K1QNN3|K1QNN3_CRAGI	2.6e-21	106.7	100.00%	56.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014954.1	sp|K1RAI5|K1RAI5_CRAGI	1.6e-37	161.8	90.05%	44.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014956.1	sp|K1PHJ6|K1PHJ6_CRAGI	6.3e-153	547.7	67.45%	36.47%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN014959.1	sp|K1Q6H8|K1Q6H8_CRAGI	4.6e-53	213.4	97.61%	52.68%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN013967.1	sp|K1Q1S3|K1Q1S3_CRAGI	0.0e+00	2050.8	100.00%	90.77%	Myosin-VI;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0051015|GO:0005524|GO:0003774|
GN014960.1	sp|K1Q6H8|K1Q6H8_CRAGI	3.8e-29	136.7	17.83%	36.15%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN014961.1	sp|K1QU85|K1QU85_CRAGI	8.4e-77	292.4	93.78%	62.38%	Ficolin-2;OS=Crassostrea;PE=4;SV=1
GN014962.1	sp|K1QKV9|K1QKV9_CRAGI	3.0e-79	300.8	99.65%	54.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014963.1	sp|V4A2Z2|V4A2Z2_LOTGI	1.5e-109	402.5	72.14%	49.41%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN014964.1	sp|A0A210PJW9|A0A210PJW9_MIZYE	1.8e-14	84.0	85.56%	50.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014965.1	sp|K1QKY4|K1QKY4_CRAGI	7.7e-68	263.5	96.88%	37.47%	DNA-directed RNA polymerases I and III subunit RPAC2;OS=Crassostrea;PE=3;SV=1	GO:0004197|GO:0003677|GO:0003899|GO:0046983|	GO:0006351|
GN014966.1	sp|K1PVQ6|K1PVQ6_CRAGI	2.9e-18	98.6	52.62%	40.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014968.1	sp|K1PNZ5|K1PNZ5_CRAGI	2.8e-293	1012.7	97.68%	94.25%	Catalase;OS=Crassostrea;PE=3;SV=1	GO:0004096|GO:0020037|GO:0046872|	GO:0042744|GO:0006979|
GN014969.1	sp|A7L9T8|A7L9T8_CRAGI	3.8e-231	806.2	99.59%	78.78%	Catalase;OS=Crassostrea;PE=2;SV=1	GO:0004096|GO:0020037|GO:0046872|	GO:0042744|GO:0006979|
GN014970.1	sp|K1R072|K1R072_CRAGI	1.8e-265	920.2	96.50%	95.31%	Tryptophan 5-hydroxylase 1;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0004510|	GO:0009072|GO:0042427|
GN014971.1	sp|K1RJU9|K1RJU9_CRAGI	3.4e-35	153.7	76.97%	59.84%	Putative 39S ribosomal protein L23, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN014972.1	sp|K1QKY4|K1QKY4_CRAGI	6.0e-93	347.1	97.65%	43.38%	DNA-directed RNA polymerases I and III subunit RPAC2;OS=Crassostrea;PE=3;SV=1	GO:0004197|GO:0003677|GO:0003899|GO:0046983|	GO:0006351|
GN014973.1	sp|K1PIC7|K1PIC7_CRAGI	3.1e-128	465.3	94.51%	38.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014974.1	sp|K1PBY4|K1PBY4_CRAGI	9.1e-220	768.1	100.00%	95.63%	Protein FAM46A;OS=Crassostrea;PE=4;SV=1	GO:1990817|
GN014977.1	sp|K1QL54|K1QL54_CRAGI	1.2e-192	677.9	100.00%	84.05%	2-oxoisovalerate dehydrogenase subunit beta, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN014978.1	sp|K1QCZ5|K1QCZ5_CRAGI	1.5e-165	588.2	100.00%	63.73%	Arginyl-tRNA--protein transferase 1;OS=Crassostrea;PE=3;SV=1	GO:0004057|
GN014980.1	sp|H6BDA1|H6BDA1_OSTED	2.1e-45	186.8	100.00%	98.91%	TIMM13 Translocase of inner mitochondrial membrane;OS=Ostrea;PE=2;SV=1	GO:0005758|	GO:0046872|	GO:0072321|
GN014981.1	sp|K1Q5H2|K1Q5H2_CRAGI	0.0e+00	2083.5	97.85%	76.24%	Protein dopey-2;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0006895|
GN014982.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	1.2e-86	325.9	96.37%	44.50%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN014983.1	sp|A0A2B4SLU3|A0A2B4SLU3_STYPI	8.5e-19	99.0	65.00%	51.06%	THAP domain-containing protein 6;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN014984.1	sp|K1R4F3|K1R4F3_CRAGI	8.3e-161	572.4	97.74%	64.40%	Carbohydrate sulfotransferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN014985.1	sp|K1QBE6|K1QBE6_CRAGI	1.7e-34	151.0	92.25%	61.02%	Putative sodium-coupled neutral amino acid transporter 11;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014986.1	sp|K1QUY0|K1QUY0_CRAGI	4.3e-185	653.7	71.96%	70.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN014987.1	sp|A0A210Q714|A0A210Q714_MIZYE	3.5e-37	160.6	94.69%	45.69%	Tctex1 domain-containing protein 1-A;OS=Mizuhopecten;PE=4;SV=1
GN014988.1	sp|K1RAI9|K1RAI9_CRAGI	7.8e-139	499.6	99.21%	61.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN014989.1	sp|Q6A330|Q6A330_CRAGI	5.5e-185	652.5	98.71%	77.43%	Flavin-containing monooxygenase;OS=Crassostrea;PE=2;SV=1	GO:0050660|GO:0004499|GO:0050661|
GN014990.1	sp|Q6A330|Q6A330_CRAGI	5.7e-182	642.5	98.70%	78.63%	Flavin-containing monooxygenase;OS=Crassostrea;PE=2;SV=1	GO:0050660|GO:0004499|GO:0050661|
GN013969.1	sp|K1PMS6|K1PMS6_CRAGI	2.4e-193	681.0	92.48%	57.02%	Protein still life, isoform SIF type 1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035556|GO:0035023|
GN014991.1	sp|Q6A330|Q6A330_CRAGI	3.9e-138	496.5	96.33%	79.51%	Flavin-containing monooxygenase;OS=Crassostrea;PE=2;SV=1	GO:0050660|GO:0004499|GO:0050661|
GN014992.1	sp|Q6A330|Q6A330_CRAGI	1.7e-230	803.9	99.56%	81.96%	Flavin-containing monooxygenase;OS=Crassostrea;PE=2;SV=1	GO:0050660|GO:0004499|GO:0050661|
GN014993.1	sp|K1R4F0|K1R4F0_CRAGI	1.3e-76	291.2	100.00%	91.03%	Iron-sulfur cluster assembly enzyme ISCU, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005506|GO:0051536|	GO:0016226|
GN014994.1	sp|K1QUX7|K1QUX7_CRAGI	4.5e-108	397.1	100.00%	49.40%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0005829|GO:0005739|	GO:0016874|GO:0046872|GO:0004842|
GN014995.1	sp|K1RAI5|K1RAI5_CRAGI	2.9e-80	305.1	95.71%	37.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014996.1	sp|K1R338|K1R338_CRAGI	8.9e-41	172.2	92.99%	56.55%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN013970.1	sp|K1PZ41|K1PZ41_CRAGI	1.1e-41	174.9	91.80%	77.12%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN014999.1	sp|K1QB12|K1QB12_CRAGI	4.2e-181	639.8	98.42%	73.17%	Stomatin-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015000.1	sp|K1QS15|K1QS15_CRAGI	1.4e-222	777.7	98.72%	81.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015001.1	sp|K1PWE2|K1PWE2_CRAGI	1.4e-52	212.2	56.58%	68.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013971.1	sp|K1QJH0|K1QJH0_CRAGI	3.1e-242	843.2	95.80%	76.94%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015002.1	sp|K1PP66|K1PP66_CRAGI	6.6e-176	623.2	99.44%	50.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN015003.1	sp|K1PA49|K1PA49_CRAGI	2.6e-207	727.6	99.33%	54.33%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055114|
GN015004.1	sp|K1PP63|K1PP63_CRAGI	1.1e-167	595.5	87.70%	56.08%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN015005.1	sp|K1R0R4|K1R0R4_CRAGI	1.2e-212	745.0	89.17%	69.46%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN015006.1	sp|K1RU68|K1RU68_CRAGI	6.5e-22	109.4	65.28%	53.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015007.1	sp|K1R0R4|K1R0R4_CRAGI	2.9e-213	746.9	96.92%	68.99%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN015008.1	sp|A0A210Q583|A0A210Q583_MIZYE	0.0e+00	1764.2	99.88%	65.12%	Intersectin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|GO:0005089|	GO:0006897|GO:0035023|
GN013972.1	sp|K1QJH0|K1QJH0_CRAGI	8.3e-219	765.4	96.17%	70.24%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015010.1	sp|K1PEP3|K1PEP3_CRAGI	1.6e-22	111.3	74.07%	51.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015011.1	sp|K1R0S4|K1R0S4_CRAGI	6.4e-49	199.1	95.95%	65.25%	Fibrinogen-like protein A;OS=Crassostrea;PE=4;SV=1
GN015012.1	sp|K1QSS8|K1QSS8_CRAGI	1.2e-16	90.9	97.26%	55.71%	Angiopoietin-4;OS=Crassostrea;PE=4;SV=1
GN015013.1	sp|K1PXQ2|K1PXQ2_CRAGI	1.2e-119	435.3	78.04%	76.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015014.1	sp|K1RGK7|K1RGK7_CRAGI	1.3e-26	124.4	86.73%	63.10%	Ficolin-1;OS=Crassostrea;PE=4;SV=1
GN013973.1	sp|K1PD83|K1PD83_CRAGI	2.5e-41	173.7	100.00%	69.29%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015016.1	sp|J9Q387|J9Q387_OSTED	1.4e-42	177.6	84.76%	89.77%	Farnesoic acid-o-methyltransferase;OS=Ostrea;PE=2;SV=1	GO:0008168|
GN015017.1	sp|J9Q387|J9Q387_OSTED	2.3e-75	287.0	100.00%	90.21%	Farnesoic acid-o-methyltransferase;OS=Ostrea;PE=2;SV=1	GO:0008168|
GN015018.1	sp|K1QUG6|K1QUG6_CRAGI	1.0e-59	235.0	100.00%	71.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015019.1	sp|K1QF52|K1QF52_CRAGI	5.2e-233	812.8	98.90%	64.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015020.1	sp|K1QLK4|K1QLK4_CRAGI	7.5e-23	113.6	87.34%	28.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015022.1	sp|K1QQI6|K1QQI6_CRAGI	2.2e-29	134.8	96.83%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013974.1	sp|K1PJJ4|K1PJJ4_CRAGI	2.4e-229	800.4	100.00%	70.68%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015023.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	3.6e-35	154.5	58.22%	46.78%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN013975.1	sp|K1PJJ4|K1PJJ4_CRAGI	3.8e-261	906.0	100.00%	85.50%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015024.1	sp|K1RXE8|K1RXE8_CRAGI	4.7e-21	109.4	10.92%	42.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015027.1	sp|K1QSQ8|K1QSQ8_CRAGI	1.0e-09	70.1	59.52%	32.11%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015028.1	sp|K1QZQ7|K1QZQ7_CRAGI	8.0e-46	189.1	93.33%	52.69%	Collagen alpha-2(VIII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN015029.1	sp|K1QZQ7|K1QZQ7_CRAGI	1.5e-63	248.1	100.00%	70.00%	Collagen alpha-2(VIII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN015030.1	sp|K1R627|K1R627_CRAGI	3.4e-116	423.3	98.74%	89.36%	Acetyl-CoA acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN015031.1	sp|K1R627|K1R627_CRAGI	5.0e-77	292.7	93.10%	88.20%	Acetyl-CoA acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN013976.1	sp|R7VES8|R7VES8_CAPTE	1.6e-88	332.4	74.63%	45.39%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN015032.1	sp|J9Q552|J9Q552_OSTED	1.2e-50	204.9	64.15%	99.01%	Ribosomal protein L44;OS=Ostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN015033.1	sp|K1PN02|K1PN02_CRAGI	0.0e+00	2268.8	99.96%	48.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016887|GO:0004842|
GN015034.1	sp|K1RKF6|K1RKF6_CRAGI	1.2e-26	127.9	11.75%	57.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015035.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	7.0e-23	112.8	97.09%	37.02%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN015036.1	sp|K1QLM6|K1QLM6_CRAGI	0.0e+00	1104.0	100.00%	90.72%	Pre-mRNA-processing factor 17;OS=Crassostrea;PE=4;SV=1	GO:0071013|	GO:0000398|
GN015038.1	sp|K1QU51|K1QU51_CRAGI	5.5e-159	566.6	100.00%	80.19%	Wiskott-Aldrich syndrome protein family member 3;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0003779|	GO:0030036|
GN015039.1	sp|K1QD11|K1QD11_CRAGI	1.1e-202	712.6	85.99%	56.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015040.1	sp|K1QU56|K1QU56_CRAGI	0.0e+00	1095.1	100.00%	91.90%	Malic enzyme;OS=Crassostrea;PE=3;SV=1	GO:0004471|GO:0046872|GO:0051287|
GN015041.1	sp|K1R0Z6|K1R0Z6_CRAGI	4.4e-115	419.5	100.00%	93.93%	Ras-related protein Rab-39B;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN015043.1	sp|K1RKG5|K1RKG5_CRAGI	0.0e+00	1256.9	93.30%	78.84%	SH3 and multiple ankyrin repeat domains protein 3;OS=Crassostrea;PE=4;SV=1
GN015044.1	sp|K1RKG5|K1RKG5_CRAGI	0.0e+00	1842.8	99.89%	71.26%	SH3 and multiple ankyrin repeat domains protein 3;OS=Crassostrea;PE=4;SV=1
GN015045.1	sp|A0A210PZA1|A0A210PZA1_MIZYE	7.9e-155	553.1	99.40%	42.27%	Solute carrier organic anion transporter family member;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN015046.1	sp|A7SGB3|A7SGB3_NEMVE	6.7e-40	171.4	78.21%	25.27%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN015048.1	sp|K1QFW5|K1QFW5_CRAGI	7.7e-37	158.7	100.00%	62.18%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015049.1	sp|K1QFW5|K1QFW5_CRAGI	1.9e-24	117.1	98.85%	62.35%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015050.1	sp|J9Q5L2|J9Q5L2_OSTED	1.2e-15	89.0	30.96%	80.00%	GA180707-like protein;OS=Ostrea;PE=2;SV=1
GN013978.1	sp|K1QTF9|K1QTF9_CRAGI	8.1e-37	159.1	92.68%	58.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015051.1	sp|K1QFW5|K1QFW5_CRAGI	1.9e-24	117.1	98.85%	62.35%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015052.1	sp|K1QBX6|K1QBX6_CRAGI	0.0e+00	1422.1	98.69%	80.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN015053.1	sp|K1PHZ1|K1PHZ1_CRAGI	1.3e-56	226.1	80.30%	40.13%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015054.1	sp|K1PHZ1|K1PHZ1_CRAGI	4.5e-57	227.6	73.23%	42.27%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015055.1	sp|K1Q458|K1Q458_CRAGI	1.4e-47	194.9	90.70%	65.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015056.1	sp|K1QIE8|K1QIE8_CRAGI	2.0e-304	1050.8	75.95%	68.47%	EF-hand calcium-binding domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN015057.1	sp|K1PXU3|K1PXU3_CRAGI	1.4e-43	181.8	90.10%	51.12%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN015058.1	sp|K1PUL7|K1PUL7_CRAGI	6.9e-34	149.1	90.30%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015059.1	sp|K1QIE8|K1QIE8_CRAGI	1.8e-79	301.6	99.32%	69.30%	EF-hand calcium-binding domain-containing protein 6;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN015060.1	sp|K1PXU3|K1PXU3_CRAGI	2.3e-43	181.0	90.10%	50.56%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN015061.1	sp|K1PUL7|K1PUL7_CRAGI	1.5e-228	798.9	99.75%	38.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015062.1	sp|K1QU85|K1QU85_CRAGI	1.7e-69	268.5	71.85%	56.94%	Ficolin-2;OS=Crassostrea;PE=4;SV=1
GN015064.1	sp|A0A1S3I117|A0A1S3I117_LINUN	7.6e-41	173.3	85.71%	31.82%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN015065.1	sp|K1R627|K1R627_CRAGI	4.4e-64	249.6	96.23%	82.89%	Acetyl-CoA acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016747|
GN015066.1	sp|K1QG66|K1QG66_CRAGI	7.2e-74	283.5	98.80%	53.37%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN015067.1	sp|K1R3V7|K1R3V7_CRAGI	2.2e-48	197.6	100.00%	56.40%	Complement C1q-like protein 2;OS=Crassostrea;PE=4;SV=1
GN015068.1	sp|K1R0B6|K1R0B6_CRAGI	4.3e-35	154.5	86.86%	36.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015077.1	sp|K1Q188|K1Q188_CRAGI	1.6e-33	147.5	93.33%	71.13%	BEN domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN015078.1	sp|K1PMC5|K1PMC5_CRAGI	1.4e-40	171.4	98.58%	63.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015079.1	sp|K1QJT2|K1QJT2_CRAGI	1.5e-39	168.3	96.77%	49.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015080.1	sp|K1QS32|K1QS32_CRAGI	1.1e-39	169.5	59.25%	44.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015081.1	sp|K1RLP8|K1RLP8_CRAGI	9.0e-43	178.3	99.12%	70.54%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN015082.1	sp|K1QVV9|K1QVV9_CRAGI	8.0e-287	991.5	98.87%	81.24%	Neuron navigator 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0022008|GO:0006744|
GN015083.1	sp|K1QT37|K1QT37_CRAGI	4.1e-151	540.8	98.81%	44.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015084.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	1.4e-22	112.5	85.98%	34.71%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015086.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	9.4e-33	145.2	99.21%	53.54%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN015087.1	sp|K1R0B6|K1R0B6_CRAGI	2.2e-28	132.1	43.15%	47.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015088.1	sp|A0A1W4XKH3|A0A1W4XKH3_AGRPL	3.4e-20	103.2	84.76%	58.43%	uncharacterized protein LOC108742291 isoform X1;OS=Agrilus;PE=4;SV=1
GN015094.1	sp|K1QPY5|K1QPY5_CRAGI	8.0e-222	776.2	86.91%	49.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN015095.1	sp|A0A0L8HFK6|A0A0L8HFK6_OCTBM	2.2e-09	67.0	73.26%	54.84%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005739|	GO:0051607|
GN015104.1	sp|K1QHE7|K1QHE7_CRAGI	2.4e-12	77.0	81.82%	49.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015105.1	sp|K1PW66|K1PW66_CRAGI	1.3e-85	321.6	95.56%	73.36%	Transient receptor potential cation channel subfamily M member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN015106.1	sp|A0A1S3H205|A0A1S3H205_LINUN	1.7e-19	100.9	93.52%	45.19%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN015108.1	sp|C3YZ71|C3YZ71_BRAFL	3.6e-41	174.1	96.33%	38.65%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN015109.1	sp|K1PLC5|K1PLC5_CRAGI	2.3e-67	261.5	77.19%	53.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015110.1	sp|V4A8A4|V4A8A4_LOTGI	8.6e-104	384.0	85.15%	30.31%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN015111.1	sp|K1PYR8|K1PYR8_CRAGI	5.5e-91	340.1	90.86%	49.24%	Lachesin;OS=Crassostrea;PE=4;SV=1
GN015112.1	sp|K1QB33|K1QB33_CRAGI	6.3e-58	230.3	88.89%	39.81%	Vacuolar protein sorting-associated protein 4B;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN015113.1	sp|A0A2G8JPM0|A0A2G8JPM0_STIJA	3.5e-16	90.1	73.98%	43.33%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0030246|
GN015116.1	sp|A0A2B4RIG1|A0A2B4RIG1_STYPI	9.2e-126	456.8	86.38%	37.90%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN015117.1	sp|K1Q7K6|K1Q7K6_CRAGI	4.7e-53	213.0	96.93%	71.88%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|
GN015119.1	sp|D3BA25|D3BA25_POLPP	4.7e-43	181.0	92.31%	36.56%	ATP-dependent DNA helicase;OS=Polysphondylium;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN015121.1	sp|K1QFV0|K1QFV0_CRAGI	9.1e-104	382.9	86.57%	50.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015122.1	sp|A0A2G8K3C7|A0A2G8K3C7_STIJA	9.2e-17	93.2	49.28%	38.24%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0004803|	GO:0006313|
GN015125.1	sp|K1Q637|K1Q637_CRAGI	1.3e-16	91.7	81.02%	47.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015127.1	sp|A0A3M6TKY5|A0A3M6TKY5_9CNID	3.5e-11	74.7	49.65%	27.21%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN015130.1	sp|A0A2G8K856|A0A2G8K856_STIJA	3.1e-85	322.8	59.57%	28.83%	RHS repeat-associated core domain protein;OS=Stichopus;PE=4;SV=1
GN015131.1	sp|A0A2G8JZU3|A0A2G8JZU3_STIJA	4.5e-56	224.9	83.06%	27.69%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN013865.1	sp|K1QFL5|K1QFL5_CRAGI	1.2e-41	177.2	47.72%	33.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015132.1	sp|K1QQH7|K1QQH7_CRAGI	1.1e-39	168.3	78.36%	80.77%	3-oxoacyl-[acyl-carrier-protein] reductase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN015133.1	sp|K1QQH7|K1QQH7_CRAGI	1.6e-53	214.5	74.70%	82.03%	3-oxoacyl-[acyl-carrier-protein] reductase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN015135.1	sp|K1RMW8|K1RMW8_CRAGI	3.3e-214	749.6	100.00%	95.53%	Nuclear receptor subfamily 2 group E member 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN015136.1	sp|K1S6A1|K1S6A1_CRAGI	3.5e-76	290.0	96.26%	81.01%	Nuclear receptor subfamily 2 group E member 1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN015137.1	sp|K1RGM3|K1RGM3_CRAGI	8.5e-88	330.1	65.84%	49.71%	Toll-like receptor 4;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN013979.1	sp|A0A3M6UL89|A0A3M6UL89_9CNID	3.9e-47	194.1	100.00%	35.90%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN015138.1	sp|K1RB29|K1RB29_CRAGI	7.5e-47	192.2	98.59%	62.59%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN015139.1	sp|K1RGM3|K1RGM3_CRAGI	1.6e-114	419.5	62.14%	46.79%	Toll-like receptor 4;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN015141.1	sp|K1RB29|K1RB29_CRAGI	1.5e-39	167.9	98.59%	55.40%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN015142.1	sp|K1PEP3|K1PEP3_CRAGI	1.4e-46	191.8	92.04%	54.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015144.1	sp|K1QFZ6|K1QFZ6_CRAGI	1.8e-23	115.2	47.49%	47.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013980.1	sp|A0A3M6UL89|A0A3M6UL89_9CNID	2.5e-19	100.5	81.51%	47.92%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN015146.1	sp|A0A210R107|A0A210R107_MIZYE	4.5e-10	69.7	89.38%	40.95%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015148.1	sp|K1PCW3|K1PCW3_CRAGI	6.2e-276	955.7	94.01%	77.72%	Sine oculis-binding-like protein;OS=Crassostrea;PE=4;SV=1
GN015149.1	sp|K1Q3M6|K1Q3M6_CRAGI	7.2e-105	386.7	92.35%	42.95%	Cytochrome P450 3A9;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN015152.1	sp|K1PR91|K1PR91_CRAGI	4.2e-257	892.9	99.70%	67.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015154.1	sp|K1R946|K1R946_CRAGI	3.0e-117	427.6	93.80%	82.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN015157.1	sp|K1RSY1|K1RSY1_CRAGI	4.9e-127	462.2	24.93%	55.98%	Sentrin-specific protease 6;OS=Crassostrea;PE=4;SV=1	GO:0008234|
GN015158.1	sp|K1QYN9|K1QYN9_CRAGI	3.4e-43	179.9	100.00%	71.77%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015159.1	sp|K1PHF9|K1PHF9_CRAGI	2.6e-98	364.4	94.63%	61.44%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN015160.1	sp|K1QYN9|K1QYN9_CRAGI	1.2e-97	362.5	72.61%	65.52%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015161.1	sp|K1QYN9|K1QYN9_CRAGI	1.5e-100	372.1	74.50%	67.22%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015162.1	sp|K1QYN9|K1QYN9_CRAGI	1.6e-31	141.7	71.29%	55.94%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013983.1	sp|K1QFL5|K1QFL5_CRAGI	2.3e-22	112.5	59.35%	28.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015163.1	sp|K1QYN9|K1QYN9_CRAGI	7.1e-95	353.2	72.75%	65.75%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015164.1	sp|K1QYN9|K1QYN9_CRAGI	2.0e-22	111.3	69.94%	54.17%	Prolactin-releasing peptide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015165.1	sp|K1QLH0|K1QLH0_CRAGI	1.5e-135	487.6	99.60%	93.95%	Peroxiredoxin-4;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0051920|	GO:0045454|
GN015166.1	sp|K1QVM4|K1QVM4_CRAGI	2.0e-72	279.3	64.72%	71.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015167.1	sp|K1R2C3|K1R2C3_CRAGI	7.1e-74	283.1	98.07%	54.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015168.1	sp|W4Y3E1|W4Y3E1_STRPU	3.0e-194	684.5	91.63%	43.49%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0009897|	GO:0005044|
GN015171.1	sp|K1PSI9|K1PSI9_CRAGI	3.0e-93	347.8	97.97%	45.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015172.1	sp|K1RDT1|K1RDT1_CRAGI	3.9e-15	86.3	79.17%	61.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015173.1	sp|W4YPT5|W4YPT5_STRPU	1.8e-12	77.4	98.96%	39.22%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN015174.1	sp|K1PDD5|K1PDD5_CRAGI	1.1e-30	139.8	90.99%	50.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015175.1	sp|K1PDD5|K1PDD5_CRAGI	5.1e-132	476.1	100.00%	81.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013984.1	sp|K1RQH9|K1RQH9_CRAGI	1.9e-56	224.6	82.47%	62.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015176.1	sp|K1PL40|K1PL40_CRAGI	1.9e-19	100.9	57.50%	58.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015178.1	sp|K1QDE7|K1QDE7_CRAGI	8.6e-121	438.7	100.00%	76.16%	Glutathione peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0004602|	GO:0006979|
GN015179.1	sp|K1P7B9|K1P7B9_CRAGI	2.7e-61	241.1	95.64%	50.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015180.1	sp|K1PL52|K1PL52_CRAGI	2.1e-91	340.9	99.12%	69.06%	Williams-Beuren syndrome chromosomal region 27 protein;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN015181.1	sp|K1QUE1|K1QUE1_CRAGI	5.1e-45	186.0	96.30%	68.99%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0050660|GO:0016614|
GN015182.1	sp|K1PDE3|K1PDE3_CRAGI	1.4e-94	351.3	100.00%	83.65%	Ras-related protein Rab-21;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN015183.1	sp|K1PL63|K1PL63_CRAGI	0.0e+00	1229.5	100.00%	91.54%	TBC1 domain family member 15;OS=Crassostrea;PE=4;SV=1
GN015184.1	sp|K1PT02|K1PT02_CRAGI	5.7e-97	359.8	64.65%	87.43%	Calcipressin-1;OS=Crassostrea;PE=4;SV=1	GO:0003676|	GO:0019722|
GN015185.1	sp|A0A210Q8G3|A0A210Q8G3_MIZYE	1.1e-113	415.6	98.10%	54.92%	Methylosome protein 50;OS=Mizuhopecten;PE=4;SV=1
GN013985.1	sp|K1QTV3|K1QTV3_CRAGI	2.1e-19	101.7	63.68%	42.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015186.1	sp|A0A210QF09|A0A210QF09_MIZYE	8.2e-17	95.1	32.16%	29.23%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015187.1	sp|K1QUE1|K1QUE1_CRAGI	3.7e-35	153.7	68.89%	59.35%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0050660|GO:0016614|
GN015189.1	sp|K1QQF5|K1QQF5_CRAGI	2.1e-13	81.6	66.36%	38.73%	Collagen alpha-2(VIII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN015190.1	sp|K1QUE1|K1QUE1_CRAGI	5.1e-32	143.7	55.08%	55.04%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0050660|GO:0016614|
GN015191.1	sp|A0A1S3I117|A0A1S3I117_LINUN	7.9e-112	409.8	98.58%	42.21%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN015192.1	sp|K1QT37|K1QT37_CRAGI	1.5e-91	342.0	96.79%	49.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015193.1	sp|K1QUE1|K1QUE1_CRAGI	1.0e-34	152.1	76.05%	57.94%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0050660|GO:0016614|
GN015194.1	sp|A0A210QW24|A0A210QW24_MIZYE	1.4e-79	301.2	98.29%	87.72%	Ras-related protein R-Ras2;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN015195.1	sp|K1QVE4|K1QVE4_CRAGI	1.9e-58	233.8	12.77%	80.00%	Inner centromere protein;OS=Crassostrea;PE=4;SV=1	GO:0000070|GO:1902412|
GN015199.1	sp|K1QVE4|K1QVE4_CRAGI	4.0e-56	223.0	98.59%	83.45%	Inner centromere protein;OS=Crassostrea;PE=4;SV=1	GO:0000070|GO:1902412|
GN013987.1	sp|K1Q815|K1Q815_CRAGI	2.8e-52	213.0	44.35%	51.06%	Laminin subunit beta-4;OS=Crassostrea;PE=4;SV=1
GN015201.1	sp|K1S0S7|K1S0S7_CRAGI	3.5e-123	446.4	100.00%	91.96%	F-box only protein 21;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN015203.1	sp|K1Q5S2|K1Q5S2_CRAGI	7.9e-21	105.9	36.48%	82.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015204.1	sp|K1QJW4|K1QJW4_CRAGI	1.0e-53	216.1	49.83%	67.33%	Osteopetrosis-associated transmembrane protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015205.1	sp|A0A1B6C052|A0A1B6C052_9HEMI	2.2e-13	81.3	93.37%	35.48%	Uncharacterized protein;OS=Clastoptera;PE=4;SV=1	GO:0003676|
GN015207.1	sp|K1Q3X7|K1Q3X7_CRAGI	1.4e-33	149.4	72.78%	34.39%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015208.1	sp|K1PF00|K1PF00_CRAGI	8.2e-67	260.0	68.25%	46.69%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN015209.1	sp|K1QBX5|K1QBX5_CRAGI	4.5e-232	811.2	99.63%	35.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013988.1	sp|K1QY88|K1QY88_CRAGI	9.7e-74	283.1	98.36%	41.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN015210.1	sp|K1RBH2|K1RBH2_CRAGI	1.9e-119	434.1	100.00%	90.68%	Ras-related and estrogen-regulated growth inhibitor;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN015211.1	sp|K1S562|K1S562_CRAGI	1.7e-125	454.9	71.39%	74.73%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN015212.1	sp|A0A210PHP0|A0A210PHP0_MIZYE	5.1e-110	403.7	99.33%	43.76%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015213.1	sp|A0A210PHP8|A0A210PHP8_MIZYE	1.6e-282	977.6	100.00%	85.49%	Intraflagellar transport protein 88-like;OS=Mizuhopecten;PE=4;SV=1	GO:0031514|
GN015215.1	sp|K1P698|K1P698_CRAGI	3.4e-28	129.8	76.19%	72.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015216.1	sp|V4AM91|V4AM91_LOTGI	3.0e-48	198.0	94.30%	33.04%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN015218.1	sp|K1PRR1|K1PRR1_CRAGI	1.9e-254	884.0	99.37%	71.61%	Monocarboxylate transporter 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN015219.1	sp|K1PJM5|K1PJM5_CRAGI	1.8e-105	388.7	56.02%	80.37%	Protein TFG;OS=Crassostrea;PE=4;SV=1	GO:0000139|	GO:0042802|	GO:0048208|
GN015220.1	sp|K1PSD4|K1PSD4_CRAGI	3.7e-60	238.0	54.50%	48.98%	Tenascin;OS=Crassostrea;PE=4;SV=1
GN015221.1	sp|K1QVI2|K1QVI2_CRAGI	3.4e-32	144.1	77.07%	45.57%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN015222.1	sp|A0A2R3ZQC1|A0A2R3ZQC1_HYRCU	1.4e-90	340.1	94.07%	27.28%	Toll5;OS=Hyriopsis;PE=2;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN015223.1	sp|K1PKX3|K1PKX3_CRAGI	6.0e-118	429.1	100.00%	89.36%	Ras-like protein family member 11B;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN015224.1	sp|A0A210QDG4|A0A210QDG4_MIZYE	1.6e-28	131.0	97.22%	60.58%	Uncharacterized protein K02A2.6;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|	GO:0015074|
GN015225.1	sp|K1R5B3|K1R5B3_CRAGI	7.4e-89	333.2	100.00%	45.31%	Baculoviral IAP repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN015226.1	sp|A0A1S3I398|A0A1S3I398_LINUN	2.1e-12	77.0	82.76%	45.83%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN015228.1	sp|K1PKF0|K1PKF0_CRAGI	3.5e-29	134.4	60.45%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015229.1	sp|K1QJC5|K1QJC5_CRAGI	5.7e-41	172.9	93.06%	53.75%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015230.1	sp|K1Q239|K1Q239_CRAGI	1.2e-185	654.8	80.97%	89.94%	Transmembrane protein 39A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015231.1	sp|K1Q9I0|K1Q9I0_CRAGI	1.5e-150	537.7	99.67%	87.33%	PIH1 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN015234.1	sp|K1PUJ1|K1PUJ1_CRAGI	1.9e-202	711.1	100.00%	91.07%	Radixin;OS=Crassostrea;PE=4;SV=1	GO:0005856|	GO:0003779|
GN015235.1	sp|K1R2I1|K1R2I1_CRAGI	2.7e-158	563.9	87.96%	84.92%	Pre-mRNA-splicing regulator female-lethal(2)D;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0080009|GO:0000381|
GN015236.1	sp|E7CHR2|E7CHR2_CRAHO	3.1e-102	376.7	100.00%	85.71%	Superoxide dismutase;OS=Crassostrea;PE=2;SV=1	GO:0046872|GO:0004784|
GN015237.1	sp|K1Q9H4|K1Q9H4_CRAGI	1.4e-104	385.2	92.52%	64.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015240.1	sp|K1PZ52|K1PZ52_CRAGI	1.5e-27	127.9	100.00%	54.92%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015241.1	sp|K1QFK7|K1QFK7_CRAGI	2.3e-121	441.0	98.87%	58.45%	Betaine--homocysteine S-methyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN015242.1	sp|K1PZ52|K1PZ52_CRAGI	7.2e-36	156.0	98.84%	48.82%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015243.1	sp|K1QJC5|K1QJC5_CRAGI	2.2e-40	171.0	93.06%	54.37%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015244.1	sp|K1QFK7|K1QFK7_CRAGI	1.2e-48	198.4	98.80%	54.80%	Betaine--homocysteine S-methyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN015245.1	sp|K1RFL2|K1RFL2_CRAGI	2.5e-154	551.2	91.58%	54.78%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN015246.1	sp|K1QJC5|K1QJC5_CRAGI	5.4e-39	166.4	100.00%	50.58%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015247.1	sp|A0A210PM27|A0A210PM27_MIZYE	3.0e-121	440.7	97.45%	61.05%	Betaine--homocysteine S-methyltransferase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN015248.1	sp|K1QJC5|K1QJC5_CRAGI	4.8e-26	122.9	100.00%	52.46%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015249.1	sp|K1QJC5|K1QJC5_CRAGI	2.4e-39	167.5	93.06%	54.37%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015250.1	sp|K1RFL2|K1RFL2_CRAGI	9.2e-141	506.1	91.37%	52.75%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN015251.1	sp|K1Q814|K1Q814_CRAGI	1.8e-19	101.7	37.17%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015252.1	sp|K1QG87|K1QG87_CRAGI	0.0e+00	1419.4	97.61%	89.63%	Armadillo repeat-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016614|
GN015253.1	sp|K1QT93|K1QT93_CRAGI	3.3e-122	443.7	100.00%	63.64%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0016614|
GN015255.1	sp|K1QT93|K1QT93_CRAGI	1.1e-229	801.6	94.98%	65.87%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0016614|
GN015256.1	sp|K1QG87|K1QG87_CRAGI	1.2e-77	295.0	85.99%	77.40%	Armadillo repeat-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016614|
GN015257.1	sp|K1QT93|K1QT93_CRAGI	1.9e-247	861.3	64.08%	68.90%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0016614|
GN015258.1	sp|A0A3L5TU25|A0A3L5TU25_MYTGA	7.9e-62	243.4	59.30%	50.64%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN015259.1	sp|K1QVD2|K1QVD2_CRAGI	3.7e-71	275.4	70.00%	34.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015260.1	sp|K1RFL9|K1RFL9_CRAGI	2.0e-54	217.6	94.12%	66.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015261.1	sp|K1QG92|K1QG92_CRAGI	3.3e-104	384.8	82.61%	41.82%	Protocadherin-11 X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN015262.1	sp|K1QPA9|K1QPA9_CRAGI	3.8e-41	174.5	83.03%	34.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015263.1	sp|K1QBA7|K1QBA7_CRAGI	1.4e-37	161.8	96.72%	46.59%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN015264.1	sp|K1Q828|K1Q828_CRAGI	4.0e-19	99.8	90.27%	52.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN013992.1	sp|K1Q0W5|K1Q0W5_CRAGI	3.6e-175	620.5	63.50%	78.68%	Choline dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0050660|GO:0016614|
GN015266.1	sp|K1Q828|K1Q828_CRAGI	4.0e-48	198.0	45.78%	53.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN015269.1	sp|K1RD17|K1RD17_CRAGI	4.8e-38	165.6	23.41%	47.66%	Fibropellin-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0004930|
GN015270.1	sp|K1QWS8|K1QWS8_CRAGI	1.2e-172	611.7	94.00%	80.59%	Metal transporter CNNM2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015271.1	sp|W4YR48|W4YR48_STRPU	8.4e-52	210.7	50.00%	41.64%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN015272.1	sp|K1PWA3|K1PWA3_CRAGI	5.6e-52	211.1	39.02%	53.03%	Toll-like receptor 4;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN015273.1	sp|K1PPE2|K1PPE2_CRAGI	5.3e-202	709.1	98.80%	85.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015274.1	sp|K1QWS1|K1QWS1_CRAGI	0.0e+00	3465.6	99.74%	87.12%	Sperm-associated antigen 17;OS=Crassostrea;PE=4;SV=1
GN015275.1	sp|K1Q3M7|K1Q3M7_CRAGI	1.8e-166	590.9	94.89%	84.68%	Trans-2-enoyl-CoA reductase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN015276.1	sp|K1PW99|K1PW99_CRAGI	1.1e-193	681.4	100.00%	92.39%	Protein OSCP1;OS=Crassostrea;PE=4;SV=1
GN015277.1	sp|K1PPD7|K1PPD7_CRAGI	2.7e-101	374.0	81.29%	79.56%	24-hydroxycholesterol 7-alpha-hydroxylase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN015278.1	sp|K1Q3M3|K1Q3M3_CRAGI	1.0e-265	921.8	82.65%	66.91%	Kinesin light chain 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015279.1	sp|K1Q3M3|K1Q3M3_CRAGI	1.5e-261	907.9	82.65%	66.47%	Kinesin light chain 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015280.1	sp|K1Q3M3|K1Q3M3_CRAGI	8.5e-84	315.8	100.00%	58.74%	Kinesin light chain 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015281.1	sp|K1Q3M3|K1Q3M3_CRAGI	3.3e-133	481.5	83.47%	38.73%	Kinesin light chain 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015282.1	sp|K1QAY9|K1QAY9_CRAGI	2.8e-61	240.7	99.54%	65.89%	Protein FAM60A;OS=Crassostrea;PE=4;SV=1
GN015283.1	sp|K1PVA0|K1PVA0_CRAGI	0.0e+00	1495.3	100.00%	99.21%	Cullin-5;OS=Crassostrea;PE=3;SV=1	GO:0031461|	GO:0031625|	GO:0006511|
GN015284.1	sp|K1Q211|K1Q211_CRAGI	7.5e-66	256.1	62.15%	83.33%	Peroxisomal NADH pyrophosphatase NUDT12;OS=Crassostrea;PE=4;SV=1	GO:0016787|GO:0046872|
GN015286.1	sp|A0A2G8K856|A0A2G8K856_STIJA	1.2e-49	203.8	67.51%	27.14%	RHS repeat-associated core domain protein;OS=Stichopus;PE=4;SV=1
GN015292.1	sp|K1Q7K6|K1Q7K6_CRAGI	1.5e-103	382.1	60.85%	76.54%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008502|
GN015293.1	sp|K1QFH8|K1QFH8_CRAGI	1.2e-59	235.0	98.86%	64.16%	Discoidin-2;OS=Crassostrea;PE=4;SV=1	GO:0030246|	GO:0007155|
GN013995.1	sp|K1Q0V7|K1Q0V7_CRAGI	5.9e-79	299.7	85.32%	80.37%	Orexin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015295.1	sp|K1REW7|K1REW7_CRAGI	1.2e-242	845.1	100.00%	55.00%	Baculoviral IAP repeat-containing protein 7-A;OS=Crassostrea;PE=4;SV=1
GN015296.1	sp|A0A210QI99|A0A210QI99_MIZYE	1.2e-37	161.4	98.31%	66.38%	Adenylate kinase isoenzyme 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0019205|	GO:0006139|
GN013996.1	sp|K1R873|K1R873_CRAGI	4.3e-81	307.4	94.72%	48.36%	Orexin receptor type 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015297.1	sp|K1QFH4|K1QFH4_CRAGI	4.5e-221	772.7	97.27%	84.05%	GTP-binding protein YPT7;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN015298.1	sp|A0A210PR05|A0A210PR05_MIZYE	1.2e-79	303.5	94.26%	30.50%	Fimbrial assembly protein FimD, serogroup H1;OS=Mizuhopecten;PE=4;SV=1
GN015299.1	sp|K1Q7A0|K1Q7A0_CRAGI	1.0e-124	453.4	60.05%	51.38%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015301.1	sp|K1Q7A0|K1Q7A0_CRAGI	2.1e-33	148.7	93.49%	34.69%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015302.1	sp|K1QW81|K1QW81_CRAGI	0.0e+00	2580.1	98.67%	75.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:1990112|	GO:0061630|	GO:1990116|
GN015303.1	sp|K1QAE7|K1QAE7_CRAGI	2.1e-19	101.3	61.49%	53.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015304.1	sp|A0A1S3JER1|A0A1S3JER1_LINUN	8.1e-38	162.9	99.58%	37.37%	uncharacterized protein LOC106172655;OS=Lingula;PE=4;SV=1	GO:0003677|
GN013997.1	sp|K1Q7I2|K1Q7I2_CRAGI	8.5e-107	392.5	88.44%	71.48%	COMM domain-containing protein 10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015305.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	8.1e-29	132.1	92.00%	56.03%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN015307.1	sp|K1PP31|K1PP31_CRAGI	5.5e-86	323.9	68.34%	53.03%	Putative inhibitor of apoptosis;OS=Crassostrea;PE=4;SV=1
GN015308.1	sp|K1PP31|K1PP31_CRAGI	1.1e-84	319.7	50.10%	57.60%	Putative inhibitor of apoptosis;OS=Crassostrea;PE=4;SV=1
GN015309.1	sp|K1R1I7|K1R1I7_CRAGI	1.3e-13	82.4	33.92%	55.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013998.1	sp|K1QEK8|K1QEK8_CRAGI	1.3e-155	554.7	99.70%	86.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015310.1	sp|R4J1W5|R4J1W5_CRAVI	5.0e-24	117.9	18.05%	73.24%	Inhibitor of apoptosis protein-1;OS=Crassostrea;PE=2;SV=1
GN015312.1	sp|A0A210R559|A0A210R559_MIZYE	1.1e-43	182.2	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015313.1	sp|K1RKT7|K1RKT7_CRAGI	1.6e-26	124.4	70.59%	75.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015315.1	sp|R7V392|R7V392_CAPTE	4.0e-27	128.3	41.86%	42.31%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN015316.1	sp|K1QUQ0|K1QUQ0_CRAGI	8.3e-296	1021.9	100.00%	87.42%	WD repeat-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN015317.1	sp|K1QAJ2|K1QAJ2_CRAGI	2.2e-65	255.0	87.84%	46.53%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015318.1	sp|K1PP35|K1PP35_CRAGI	6.9e-67	259.2	96.97%	64.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015319.1	sp|K1PP35|K1PP35_CRAGI	4.5e-10	69.7	84.96%	46.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015321.1	sp|W4ZF66|W4ZF66_STRPU	1.9e-88	332.4	75.13%	37.98%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN015322.1	sp|K1PP35|K1PP35_CRAGI	7.3e-22	108.2	100.00%	79.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015324.1	sp|K1R3R8|K1R3R8_CRAGI	3.4e-230	803.1	98.65%	74.02%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN015325.1	sp|A0A210Q9Y0|A0A210Q9Y0_MIZYE	7.9e-84	316.2	93.25%	51.32%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN015326.1	sp|N6TYP6|N6TYP6_DENPD	9.0e-17	92.0	76.03%	47.25%	Uncharacterized protein;OS=Dendroctonus;PE=4;SV=1
GN015328.1	sp|A0A210QV12|A0A210QV12_MIZYE	4.0e-46	191.0	95.07%	34.23%	Orexin receptor type 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN013867.1	sp|K1R2B0|K1R2B0_CRAGI	0.0e+00	1147.1	99.87%	79.66%	Hormonally up-regulated neu tumor-associated kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN015329.1	sp|K1QI55|K1QI55_CRAGI	1.6e-56	224.2	96.92%	80.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015330.1	sp|K1R3S8|K1R3S8_CRAGI	6.7e-230	802.4	88.85%	70.54%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015332.1	sp|K1QJZ8|K1QJZ8_CRAGI	4.6e-21	106.7	48.41%	66.23%	Small acidic protein;OS=Crassostrea;PE=4;SV=1
GN015333.1	sp|A0A210QUN6|A0A210QUN6_MIZYE	0.0e+00	1189.5	99.28%	68.16%	Elongation factor 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|GO:0003924|GO:0003746|
GN015334.1	sp|K1QXV1|K1QXV1_CRAGI	2.0e-51	207.6	91.36%	61.22%	Potassium voltage-gated channel protein Shal;OS=Crassostrea;PE=4;SV=1	GO:0008076|	GO:0005249|	GO:0051260|
GN015335.1	sp|K1QXV1|K1QXV1_CRAGI	5.3e-47	193.0	86.71%	60.40%	Potassium voltage-gated channel protein Shal;OS=Crassostrea;PE=4;SV=1	GO:0008076|	GO:0005249|	GO:0051260|
GN015337.1	sp|K1QXU4|K1QXU4_CRAGI	3.9e-49	200.3	94.58%	57.07%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN015338.1	sp|K1QNM7|K1QNM7_CRAGI	7.5e-172	609.0	100.00%	83.76%	Serine/threonine-protein kinase 33;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN015340.1	sp|K1R667|K1R667_CRAGI	4.6e-42	178.3	99.15%	25.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015342.1	sp|K1PCK7|K1PCK7_CRAGI	2.9e-22	112.1	28.61%	50.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015343.1	sp|K1S1U8|K1S1U8_CRAGI	3.6e-257	893.6	99.49%	70.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013999.1	sp|K1QVG6|K1QVG6_CRAGI	3.3e-96	359.0	45.55%	41.90%	Mediator of RNA polymerase II transcription subunit 14;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN015344.1	sp|K1S2G2|K1S2G2_CRAGI	7.9e-184	648.7	100.00%	83.12%	Molybdenum cofactor biosynthesis protein 1;OS=Crassostrea;PE=3;SV=1	GO:0019008|	GO:0051539|GO:0003824|GO:0046872|	GO:0006777|
GN015346.1	sp|K1Q3N9|K1Q3N9_CRAGI	2.7e-76	290.8	87.30%	69.77%	CUE domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN015347.1	sp|K1RAP8|K1RAP8_CRAGI	0.0e+00	1123.6	99.34%	90.73%	Malic enzyme;OS=Crassostrea;PE=3;SV=1	GO:0004471|GO:0046872|GO:0051287|
GN015349.1	sp|A0A2B4RIG1|A0A2B4RIG1_STYPI	1.9e-40	172.2	80.47%	37.15%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN015350.1	sp|K1R7N7|K1R7N7_CRAGI	4.1e-30	136.3	94.17%	65.22%	Cystatin-A2;OS=Crassostrea;PE=4;SV=1	GO:0004869|
GN014000.1	sp|K1Q3I0|K1Q3I0_CRAGI	3.7e-29	132.9	98.97%	69.47%	Reticulon-4-interacting protein 1-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0016491|GO:0008270|
GN015351.1	sp|K1Q9C2|K1Q9C2_CRAGI	1.3e-84	320.1	62.00%	39.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015352.1	sp|C7ENG9|C7ENG9_ACRMI	1.4e-12	79.0	57.62%	34.43%	Transposase;OS=Acropora;PE=4;SV=1
GN015353.1	sp|K1Q5B6|K1Q5B6_CRAGI	5.5e-96	357.1	69.44%	54.87%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN015354.1	sp|K1Q5B6|K1Q5B6_CRAGI	8.8e-119	433.3	75.00%	46.22%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN015355.1	sp|K1R0S3|K1R0S3_CRAGI	2.3e-282	976.5	100.00%	88.97%	T-complex protein 1 subunit theta;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN015356.1	sp|V3ZDV8|V3ZDV8_LOTGI	0.0e+00	1394.4	96.29%	62.50%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN015357.1	sp|B3Y024|B3Y024_9BIVA	1.8e-234	817.0	100.00%	94.05%	Brachyury;OS=Saccostrea;PE=2;SV=1	GO:0005634|	GO:0003677|GO:0003700|
GN015364.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.1e-101	375.2	77.29%	49.87%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN015365.1	sp|A0A1S3I398|A0A1S3I398_LINUN	4.5e-26	123.2	64.90%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN015367.1	sp|K1RWJ1|K1RWJ1_CRAGI	8.3e-18	97.8	50.98%	24.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015369.1	sp|K1QG64|K1QG64_CRAGI	1.2e-175	622.5	54.03%	67.22%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0036459|GO:0004842|	GO:0016579|
GN015370.1	sp|K1RLP8|K1RLP8_CRAGI	2.0e-47	195.3	56.83%	55.91%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN014002.1	sp|K1QC91|K1QC91_CRAGI	4.3e-44	183.3	74.58%	59.54%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN015371.1	sp|K1QG64|K1QG64_CRAGI	1.1e-41	176.0	78.32%	39.91%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0036459|GO:0004842|	GO:0016579|
GN015372.1	sp|A0A158RF25|A0A158RF25_HYDTA	1.8e-12	80.1	24.19%	31.13%	Uncharacterized protein;OS=Hydatigena;PE=3;SV=1	GO:0036459|	GO:0016579|GO:0006511|
GN015373.1	sp|K1Q136|K1Q136_CRAGI	1.5e-27	128.6	60.39%	50.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015374.1	sp|K1RB32|K1RB32_CRAGI	2.2e-34	151.8	59.79%	45.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014003.1	sp|K1PP36|K1PP36_CRAGI	8.9e-71	273.5	45.97%	55.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015378.1	sp|K1QY64|K1QY64_CRAGI	7.6e-196	690.6	53.37%	44.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015379.1	sp|J9Q660|J9Q660_OSTED	5.7e-85	318.9	100.00%	99.34%	Histone deacetylase complex subunit SAP18;OS=Ostrea;PE=2;SV=1
GN015380.1	sp|K1PSX6|K1PSX6_CRAGI	2.8e-32	143.3	88.78%	66.28%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0030246|
GN015381.1	sp|A0A210PRH6|A0A210PRH6_MIZYE	3.9e-25	121.7	40.09%	36.87%	Kelch-like protein 40;OS=Mizuhopecten;PE=4;SV=1
GN015382.1	sp|K1QQN4|K1QQN4_CRAGI	2.6e-289	1000.0	87.90%	79.69%	Paladin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN015383.1	sp|A0A1S3HM35|A0A1S3HM35_LINUN	7.9e-54	217.2	67.57%	35.69%	Metalloendopeptidase;OS=Lingula;PE=4;SV=1	GO:0004222|GO:0008270|	GO:0018996|
GN014004.1	sp|K1QPK7|K1QPK7_CRAGI	2.2e-200	704.1	92.79%	91.41%	Centrosomal protein of 57 kDa;OS=Crassostrea;PE=4;SV=1	GO:0043015|GO:0042802|GO:0008017|	GO:0034453|
GN015384.1	sp|A0A0B2UWH6|A0A0B2UWH6_TOXCA	8.5e-25	120.2	35.93%	51.64%	Zinc metalloproteinase;OS=Toxocara;PE=4;SV=1	GO:0005576|	GO:0004222|GO:0008270|	GO:0018996|
GN015386.1	sp|A0A3P7SBP9|A0A3P7SBP9_DRAME	1.6e-37	162.2	71.91%	42.78%	Uncharacterized protein;OS=Dracunculus;PE=4;SV=1
GN015387.1	sp|K1Q1T5|K1Q1T5_CRAGI	9.4e-310	1068.9	73.00%	64.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015391.1	sp|K1Q1U1|K1Q1U1_CRAGI	1.3e-132	478.4	99.72%	64.71%	Phthiotriol/phenolphthiotriol dimycocerosates methyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN015392.1	sp|K1QH11|K1QH11_CRAGI	9.8e-28	129.4	61.54%	44.76%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015393.1	sp|K1P770|K1P770_CRAGI	2.9e-10	69.3	100.00%	63.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015394.1	sp|K1PQH1|K1PQH1_CRAGI	3.0e-36	157.1	90.63%	43.15%	Collectin-12;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN015395.1	sp|K1Q1U1|K1Q1U1_CRAGI	5.2e-110	403.3	99.71%	53.78%	Phthiotriol/phenolphthiotriol dimycocerosates methyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN014006.1	sp|K7JLS9|K7JLS9_NASVI	2.0e-22	111.7	88.94%	29.17%	Uncharacterized protein;OS=Nasonia;PE=3;SV=1	GO:0033897|GO:0003723|
GN015396.1	sp|K1QGN7|K1QGN7_CRAGI	2.2e-27	128.3	56.41%	46.56%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015397.1	sp|K1REY6|K1REY6_CRAGI	8.4e-75	286.6	96.82%	40.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015398.1	sp|K1QSU1|K1QSU1_CRAGI	4.7e-33	147.5	95.57%	29.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015399.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	8.1e-109	399.4	99.73%	54.64%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN015400.1	sp|K1QSU1|K1QSU1_CRAGI	4.0e-32	144.4	95.57%	29.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015401.1	sp|A0A0P6F9Y3|A0A0P6F9Y3_9CRUS	3.4e-13	80.9	74.62%	28.95%	Uncharacterized protein;OS=Daphnia;PE=3;SV=1	GO:0005525|
GN015402.1	sp|K1QSU1|K1QSU1_CRAGI	4.8e-29	134.4	96.99%	25.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015403.1	sp|K1QSU1|K1QSU1_CRAGI	2.5e-30	138.7	96.99%	25.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015404.1	sp|K1PQH1|K1PQH1_CRAGI	1.6e-45	188.0	84.81%	57.89%	Collectin-12;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN015405.1	sp|K1S1R2|K1S1R2_CRAGI	5.4e-19	99.8	46.41%	71.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015407.1	sp|K1QT54|K1QT54_CRAGI	1.7e-12	77.8	81.20%	55.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015408.1	sp|K1S1R2|K1S1R2_CRAGI	5.4e-24	116.7	50.52%	63.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015413.1	sp|K1PT52|K1PT52_CRAGI	7.2e-27	125.6	91.60%	58.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015415.1	sp|A0A2B4R6R6|A0A2B4R6R6_STYPI	2.4e-17	94.4	96.23%	33.55%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0055114|
GN015416.1	sp|A0A2G8L4X1|A0A2G8L4X1_STIJA	6.7e-42	176.4	97.78%	39.19%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN015417.1	sp|K1Q2I1|K1Q2I1_CRAGI	4.6e-42	176.4	99.35%	83.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015418.1	sp|K1QKF7|K1QKF7_CRAGI	1.7e-64	251.1	100.00%	62.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN015419.1	sp|K1QAU5|K1QAU5_CRAGI	3.5e-42	177.6	55.34%	54.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015422.1	sp|K1RQM8|K1RQM8_CRAGI	8.9e-53	213.0	97.10%	41.25%	Cholecystokinin receptor type A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN015424.1	sp|K1RQM8|K1RQM8_CRAGI	2.8e-54	218.0	97.10%	41.33%	Cholecystokinin receptor type A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN015425.1	sp|A0A210PXZ1|A0A210PXZ1_MIZYE	2.4e-107	394.4	89.68%	56.87%	Carboxylic ester hydrolase;OS=Mizuhopecten;PE=3;SV=1	GO:0016787|
GN015426.1	sp|K1PIG0|K1PIG0_CRAGI	2.4e-220	770.4	92.83%	74.84%	Sialate O-acetylesterase;OS=Crassostrea;PE=4;SV=1	GO:0001681|
GN015427.1	sp|K1PFP3|K1PFP3_CRAGI	1.2e-70	271.9	87.50%	71.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015428.1	sp|K1PGL3|K1PGL3_CRAGI	4.8e-34	150.2	97.63%	38.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015429.1	sp|K1Q5B6|K1Q5B6_CRAGI	3.2e-145	520.4	98.15%	66.31%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN015431.1	sp|K1QIT2|K1QIT2_CRAGI	1.8e-31	141.7	74.77%	48.77%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN015432.1	sp|K1R0B6|K1R0B6_CRAGI	1.2e-09	68.9	37.50%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015433.1	sp|K9LHI5|K9LHI5_OSTED	7.0e-50	202.6	67.22%	73.33%	Dermatopontin;OS=Ostrea;PE=2;SV=1
GN015434.1	sp|K1PB46|K1PB46_CRAGI	7.7e-162	575.5	100.00%	75.43%	Alpha-galactosidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004553|	GO:0005975|
GN015435.1	sp|K9LHI5|K9LHI5_OSTED	3.8e-60	236.5	78.06%	90.00%	Dermatopontin;OS=Ostrea;PE=2;SV=1
GN015437.1	sp|A0A210Q8G1|A0A210Q8G1_MIZYE	9.6e-291	1005.0	99.65%	60.38%	Major vault protein;OS=Mizuhopecten;PE=4;SV=1
GN015438.1	sp|K1QJ02|K1QJ02_CRAGI	3.8e-137	493.8	83.30%	60.44%	Putative amidohydrolase ytcJ;OS=Crassostrea;PE=4;SV=1	GO:0016810|
GN015440.1	sp|K1QJ02|K1QJ02_CRAGI	6.7e-156	556.6	64.93%	66.26%	Putative amidohydrolase ytcJ;OS=Crassostrea;PE=4;SV=1	GO:0016810|
GN015441.1	sp|K1QDR7|K1QDR7_CRAGI	2.6e-56	225.3	41.76%	53.54%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN015442.1	sp|K1PZ52|K1PZ52_CRAGI	5.0e-19	99.8	98.57%	36.69%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015443.1	sp|K1PZ52|K1PZ52_CRAGI	9.7e-39	165.6	93.44%	50.00%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN013869.1	sp|A0A1X7TH61|A0A1X7TH61_AMPQE	7.9e-14	84.0	24.36%	40.00%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN014007.1	sp|B3S2E1|B3S2E1_TRIAD	1.2e-09	68.2	66.02%	47.76%	Uncharacterized protein;OS=Trichoplax;PE=4;SV=1	GO:0005509|GO:0016787|	GO:0016042|
GN015445.1	sp|K1QBA7|K1QBA7_CRAGI	1.1e-36	158.7	98.84%	48.82%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN015446.1	sp|K1PZ52|K1PZ52_CRAGI	9.1e-23	112.1	84.09%	50.91%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015447.1	sp|K1QJC5|K1QJC5_CRAGI	1.5e-39	168.3	94.54%	52.91%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015448.1	sp|K1RLP8|K1RLP8_CRAGI	3.7e-29	134.4	32.14%	72.34%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN015449.1	sp|K1QJC5|K1QJC5_CRAGI	3.2e-42	177.2	87.98%	55.00%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015450.1	sp|K1QJC5|K1QJC5_CRAGI	2.3e-40	171.0	94.54%	51.74%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015452.1	sp|K1PZ52|K1PZ52_CRAGI	2.2e-38	164.5	90.16%	52.44%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015453.1	sp|K1QBA7|K1QBA7_CRAGI	2.1e-35	154.5	99.42%	48.54%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN014008.1	sp|K1Q053|K1Q053_CRAGI	1.8e-129	468.0	95.15%	66.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015454.1	sp|K1RQG6|K1RQG6_CRAGI	1.7e-36	157.9	95.39%	54.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015456.1	sp|K1PPK2|K1PPK2_CRAGI	1.2e-201	709.1	96.89%	48.22%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN015457.1	sp|K1Q5F6|K1Q5F6_CRAGI	8.1e-17	92.4	71.13%	47.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015458.1	sp|K1Q5F6|K1Q5F6_CRAGI	4.9e-117	426.8	90.86%	58.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014009.1	sp|K1PKW6|K1PKW6_CRAGI	1.3e-41	175.6	59.52%	60.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015459.1	sp|K1R140|K1R140_CRAGI	6.5e-24	115.5	99.03%	52.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015460.1	sp|K1Q560|K1Q560_CRAGI	4.5e-53	213.4	99.02%	57.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015462.1	sp|K1PV69|K1PV69_CRAGI	6.5e-39	166.4	68.72%	50.00%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN015463.1	sp|K1PV69|K1PV69_CRAGI	1.2e-21	109.4	31.77%	51.72%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN015464.1	sp|K1PNG2|K1PNG2_CRAGI	5.8e-16	90.1	81.46%	35.71%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1
GN015466.1	sp|K1PAU5|K1PAU5_CRAGI	2.2e-68	265.0	82.18%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015467.1	sp|A0A2B4R6D5|A0A2B4R6D5_STYPI	7.4e-18	95.9	94.44%	29.90%	Pro-Pol polyprotein;OS=Stylophora;PE=4;SV=1	GO:0003676|	GO:0015074|
GN015468.1	sp|K1PAU5|K1PAU5_CRAGI	5.9e-35	153.7	34.40%	77.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015470.1	sp|K1QUN0|K1QUN0_CRAGI	2.1e-67	261.9	90.55%	44.67%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN015471.1	sp|K1RIW4|K1RIW4_CRAGI	1.5e-62	245.4	98.29%	42.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015472.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	3.1e-36	158.3	73.99%	35.79%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN015474.1	sp|K1RDM4|K1RDM4_CRAGI	6.8e-14	82.4	46.96%	69.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015476.1	sp|K1QC73|K1QC73_CRAGI	1.5e-13	82.0	23.12%	75.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008083|
GN015477.1	sp|K1QKW4|K1QKW4_CRAGI	9.6e-126	455.3	100.00%	80.68%	Toll-interacting protein;OS=Crassostrea;PE=4;SV=1
GN015478.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	1.8e-27	127.9	89.93%	43.61%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN015479.1	sp|K1PAE2|K1PAE2_CRAGI	4.2e-91	340.1	76.32%	78.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005892|
GN014011.1	sp|K1P7V6|K1P7V6_CRAGI	1.9e-168	597.8	98.04%	64.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015480.1	sp|K1R9M5|K1R9M5_CRAGI	4.3e-71	274.2	88.11%	44.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015481.1	sp|K1PHL1|K1PHL1_CRAGI	5.6e-238	828.9	92.90%	88.94%	Feline leukemia virus subgroup C receptor-related protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN015484.1	sp|K1PM84|K1PM84_CRAGI	1.8e-161	574.7	79.58%	74.93%	Monocarboxylate transporter 10;OS=Crassostrea;PE=4;SV=1	GO:0005887|	GO:0015349|
GN014012.1	sp|K1PTR8|K1PTR8_CRAGI	3.2e-205	719.9	99.32%	79.86%	Leukotriene-B(4) omega-hydroxylase 1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN015486.1	sp|A0A1X7VAJ5|A0A1X7VAJ5_AMPQE	6.8e-12	75.5	60.64%	51.79%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0008270|
GN015487.1	sp|A0A1X7U990|A0A1X7U990_AMPQE	3.0e-17	94.4	63.24%	40.00%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|
GN015488.1	sp|K1Q041|K1Q041_CRAGI	1.6e-30	137.9	98.48%	51.94%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN014013.1	sp|K1QE47|K1QE47_CRAGI	1.3e-147	528.1	95.09%	77.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015490.1	sp|K1QJT2|K1QJT2_CRAGI	4.0e-15	87.4	85.52%	35.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015491.1	sp|K1QPL9|K1QPL9_CRAGI	2.2e-110	404.8	66.59%	67.14%	Telomerase protein component 1;OS=Crassostrea;PE=4;SV=1
GN015492.1	sp|W4ZIR1|W4ZIR1_STRPU	4.1e-78	298.5	66.28%	32.97%	ATP-dependent DNA helicase;OS=Strongylocentrotus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN015493.1	sp|W4ZFJ0|W4ZFJ0_STRPU	3.8e-67	261.5	95.56%	32.21%	ATP-dependent DNA helicase;OS=Strongylocentrotus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN015494.1	sp|K1RN48|K1RN48_CRAGI	6.0e-222	776.2	98.58%	54.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015496.1	sp|K1RXL3|K1RXL3_CRAGI	7.9e-50	203.8	58.50%	40.07%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN015497.1	sp|K1R4P3|K1R4P3_CRAGI	5.1e-28	130.6	52.96%	50.68%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015499.1	sp|K1QKH0|K1QKH0_CRAGI	1.7e-51	209.1	43.81%	56.52%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN015500.1	sp|K1QQ13|K1QQ13_CRAGI	1.1e-81	310.1	29.88%	73.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015501.1	sp|K1QME8|K1QME8_CRAGI	5.7e-117	426.0	84.35%	93.64%	Tubby-related protein 4;OS=Crassostrea;PE=3;SV=1
GN015502.1	sp|K1S583|K1S583_CRAGI	1.5e-36	159.8	21.74%	56.52%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN015503.1	sp|K1PWD3|K1PWD3_CRAGI	4.1e-73	280.8	62.22%	65.79%	[Phe13]-bombesin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN013870.1	sp|K1R4N1|K1R4N1_CRAGI	2.9e-61	240.4	100.00%	68.02%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015505.1	sp|K1PWD3|K1PWD3_CRAGI	3.6e-71	274.2	61.45%	68.06%	[Phe13]-bombesin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015506.1	sp|A0A210Q1Y7|A0A210Q1Y7_MIZYE	7.9e-179	632.1	100.00%	72.04%	Actin-related protein 6;OS=Mizuhopecten;PE=3;SV=1	GO:0005634|	GO:0006338|
GN015507.1	sp|K1QN09|K1QN09_CRAGI	6.6e-31	138.7	77.08%	93.15%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|GO:0003723|
GN015508.1	sp|K1QN09|K1QN09_CRAGI	7.2e-36	154.8	100.00%	92.11%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|GO:0003723|
GN014015.1	sp|K1PAJ7|K1PAJ7_CRAGI	0.0e+00	2048.1	100.00%	90.17%	DNA-directed RNA polymerase subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0003899|GO:0032549|	GO:0006351|
GN015510.1	sp|K1Q1A5|K1Q1A5_CRAGI	4.0e-183	646.4	97.44%	74.70%	Alpha-1,4 glucan phosphorylase;OS=Crassostrea;PE=3;SV=1	GO:0008184|GO:0102250|GO:0030170|GO:0102499|	GO:0005975|
GN015511.1	sp|K1Q1A5|K1Q1A5_CRAGI	7.3e-204	715.3	99.02%	85.82%	Alpha-1,4 glucan phosphorylase;OS=Crassostrea;PE=3;SV=1	GO:0008184|GO:0102250|GO:0030170|GO:0102499|	GO:0005975|
GN015512.1	sp|K1R8D5|K1R8D5_CRAGI	3.4e-226	790.0	82.71%	76.42%	Carnitine O-palmitoyltransferase 1, liver isoform;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016746|
GN015513.1	sp|K1QGK2|K1QGK2_CRAGI	3.3e-195	686.4	100.00%	93.99%	Coatomer subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0030126|GO:0000139|	GO:0005198|	GO:0006886|GO:0016192|
GN015514.1	sp|C3ZC99|C3ZC99_BRAFL	1.4e-09	70.1	9.83%	63.04%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0016021|
GN015516.1	sp|A0A210Q318|A0A210Q318_MIZYE	2.3e-45	188.3	75.00%	42.86%	Outer dense fiber protein 3;OS=Mizuhopecten;PE=4;SV=1
GN014016.1	sp|K1QGS4|K1QGS4_CRAGI	2.6e-199	701.0	95.81%	72.42%	Putative tubulin polyglutamylase TTLL2;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0006464|
GN015517.1	sp|K1QYF0|K1QYF0_CRAGI	0.0e+00	1337.4	99.46%	86.22%	Putative beta-D-xylosidase 5;OS=Crassostrea;PE=4;SV=1	GO:0004553|	GO:0005975|
GN015518.1	sp|K1QU44|K1QU44_CRAGI	1.7e-73	282.0	58.98%	72.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005890|	GO:0006813|GO:0006814|
GN015519.1	sp|K1QF01|K1QF01_CRAGI	9.1e-131	471.9	92.78%	94.24%	40S ribosomal protein S4;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0019843|GO:0003735|	GO:0006412|
GN015520.1	sp|K1REE2|K1REE2_CRAGI	5.0e-91	340.9	100.00%	37.66%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015521.1	sp|K1PEP3|K1PEP3_CRAGI	3.5e-30	137.1	49.42%	73.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015522.1	sp|K1QS32|K1QS32_CRAGI	4.0e-60	238.4	39.97%	36.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015523.1	sp|K1Q6S4|K1Q6S4_CRAGI	1.5e-95	355.5	98.55%	42.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014017.1	sp|K1QGS4|K1QGS4_CRAGI	0.0e+00	1248.4	97.97%	77.64%	Putative tubulin polyglutamylase TTLL2;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0006464|
GN015524.1	sp|K1QUN2|K1QUN2_CRAGI	6.4e-79	301.2	41.38%	53.92%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN015526.1	sp|K1RK96|K1RK96_CRAGI	3.1e-17	94.7	70.04%	32.99%	Neural cell adhesion molecule 1;OS=Crassostrea;PE=4;SV=1
GN015528.1	sp|K1QFI4|K1QFI4_CRAGI	3.3e-271	939.5	99.65%	92.36%	Notum-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN015529.1	sp|K1QZ41|K1QZ41_CRAGI	1.6e-20	105.1	65.28%	43.08%	Phosphotidylinositol phosphatase PTPRQ;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN014018.1	sp|K1PWS3|K1PWS3_CRAGI	4.2e-167	593.6	67.91%	79.40%	UBX domain-containing protein 11;OS=Crassostrea;PE=4;SV=1
GN015532.1	sp|K1R4P3|K1R4P3_CRAGI	3.0e-40	171.4	58.65%	50.53%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN014019.1	sp|A0A210PRW7|A0A210PRW7_MIZYE	4.9e-31	140.2	60.00%	47.54%	Pancreatic secretory granule membrane major glycoprotein GP2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014020.1	sp|K1PD19|K1PD19_CRAGI	4.8e-104	383.6	74.29%	58.68%	Uromodulin;OS=Crassostrea;PE=4;SV=1
GN013871.1	sp|K1PVQ2|K1PVQ2_CRAGI	1.6e-75	287.7	100.00%	78.61%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013872.1	sp|A0A2B4R9F6|A0A2B4R9F6_STYPI	4.8e-33	147.5	93.83%	31.43%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN014024.1	sp|K1PD19|K1PD19_CRAGI	4.0e-98	364.0	75.38%	55.18%	Uromodulin;OS=Crassostrea;PE=4;SV=1
GN014025.1	sp|K1PK61|K1PK61_CRAGI	1.8e-38	165.2	77.74%	49.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014026.1	sp|K1QRS9|K1QRS9_CRAGI	9.2e-74	283.5	78.07%	29.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014029.1	sp|C3XT18|C3XT18_BRAFL	7.9e-25	119.0	99.28%	48.55%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN013873.1	sp|A0A210Q3V0|A0A210Q3V0_MIZYE	2.0e-22	112.5	93.12%	26.42%	Orexin receptor type 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN014030.1	sp|K1PE45|K1PE45_CRAGI	3.4e-10	70.5	60.54%	40.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN014034.1	sp|K1R1B7|K1R1B7_CRAGI	1.9e-192	677.9	95.56%	59.79%	Mannosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0016757|
GN013874.1	sp|A0A210Q3R4|A0A210Q3R4_MIZYE	2.2e-21	109.0	93.39%	26.91%	Vasopressin V1a receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN014035.1	sp|K1QKL3|K1QKL3_CRAGI	2.6e-98	364.4	97.63%	61.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014038.1	sp|K1PZV7|K1PZV7_CRAGI	2.2e-131	474.2	89.74%	79.21%	Peptidyl-prolyl cis-trans isomerase-like 6;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003755|
GN014039.1	sp|K1QKU7|K1QKU7_CRAGI	2.7e-72	277.3	83.56%	76.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014040.1	sp|K1PKU3|K1PKU3_CRAGI	1.7e-128	464.5	98.03%	72.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014041.1	sp|K1PTV0|K1PTV0_CRAGI	1.6e-127	461.1	96.28%	82.17%	Beta-1,4-N-acetylgalactosaminyltransferase bre-4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016757|	GO:0005975|
GN013875.1	sp|K1RLP8|K1RLP8_CRAGI	5.5e-15	87.0	35.06%	42.22%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN014044.1	sp|A0A210QUU1|A0A210QUU1_MIZYE	9.7e-26	122.5	85.79%	39.51%	Blood vessel epicardial substance;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014046.1	sp|K1PCW7|K1PCW7_CRAGI	4.2e-119	434.5	82.02%	49.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013876.1	sp|T1JFN6|T1JFN6_STRMM	6.4e-17	92.8	85.62%	42.86%	Uncharacterized protein;OS=Strigamia;PE=4;SV=1
GN014047.1	sp|A0A210QD07|A0A210QD07_MIZYE	3.5e-300	1036.9	78.81%	51.33%	Inhibitor of Bruton tyrosine kinase;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN014048.1	sp|K1QJG6|K1QJG6_CRAGI	1.5e-21	108.6	77.72%	36.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013877.1	sp|A0A210QAV0|A0A210QAV0_MIZYE	9.1e-103	379.0	99.34%	57.37%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014049.1	sp|K1RFL5|K1RFL5_CRAGI	1.0e-75	289.3	96.27%	36.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014051.1	sp|K1QB79|K1QB79_CRAGI	5.5e-119	434.9	52.49%	45.25%	Apoptosis 1 inhibitor;OS=Crassostrea;PE=4;SV=1
GN014053.1	sp|K1QCV0|K1QCV0_CRAGI	1.7e-101	377.1	40.99%	40.61%	Apoptosis 1 inhibitor;OS=Crassostrea;PE=4;SV=1
GN014054.1	sp|K1QS73|K1QS73_CRAGI	1.5e-86	325.5	53.26%	82.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013878.1	sp|A0A210QAW0|A0A210QAW0_MIZYE	1.3e-73	282.7	74.77%	70.53%	Nuclear migration protein nudC;OS=Mizuhopecten;PE=4;SV=1
GN014055.1	sp|K1R1K6|K1R1K6_CRAGI	1.5e-40	171.4	71.43%	74.78%	Heat shock protein beta-1;OS=Crassostrea;PE=3;SV=1
GN014056.1	sp|K1PTM0|K1PTM0_CRAGI	1.3e-176	624.8	100.00%	78.33%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN014057.1	sp|K1PTM3|K1PTM3_CRAGI	1.1e-116	425.2	93.81%	87.50%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|	GO:0006355|
GN014058.1	sp|K1RQR1|K1RQR1_CRAGI	4.8e-38	163.3	97.28%	46.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014060.1	sp|K1QJR6|K1QJR6_CRAGI	0.0e+00	3404.8	99.95%	83.67%	Glutamate synthase [NADH], amyloplastic;OS=Crassostrea;PE=4;SV=1	GO:0051538|GO:0050660|GO:0010181|GO:0016040|GO:0005506|	GO:0006537|
GN013879.1	sp|K1PZP7|K1PZP7_CRAGI	3.5e-113	413.7	90.88%	71.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014061.1	sp|K1QT37|K1QT37_CRAGI	1.5e-153	548.9	98.81%	45.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014062.1	sp|K1QT37|K1QT37_CRAGI	1.2e-109	402.9	88.91%	41.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014063.1	sp|K1QFH3|K1QFH3_CRAGI	8.5e-148	529.6	86.91%	60.61%	Protein still life, isoform SIF type 1;OS=Crassostrea;PE=4;SV=1
GN014064.1	sp|K1RPV4|K1RPV4_CRAGI	7.0e-261	905.2	100.00%	81.19%	Potassium voltage-gated channel subfamily KQT member 1;OS=Crassostrea;PE=3;SV=1	GO:0008076|	GO:0005249|
GN014065.1	sp|K1PTL4|K1PTL4_CRAGI	5.8e-178	629.4	99.56%	70.07%	Odr-4-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014066.1	sp|K1R1J9|K1R1J9_CRAGI	1.6e-64	253.8	11.44%	97.60%	Serine/arginine repetitive matrix protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006397|
GN014066.1	sp|K1R1J9|K1R1J9_CRAGI	3.8e-21	109.8	6.54%	77.46%	Serine/arginine repetitive matrix protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006397|
GN014067.1	sp|A0A1S3JER1|A0A1S3JER1_LINUN	5.3e-71	273.9	100.00%	32.73%	uncharacterized protein LOC106172655;OS=Lingula;PE=4;SV=1	GO:0003677|
GN013880.1	sp|K1R9K5|K1R9K5_CRAGI	1.7e-33	147.5	93.16%	61.95%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014068.1	sp|K1QFL5|K1QFL5_CRAGI	3.8e-50	205.7	44.00%	35.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014069.1	sp|A0A210QW54|A0A210QW54_MIZYE	7.2e-213	745.3	99.78%	74.94%	Homogentisate 1,2-dioxygenase;OS=Mizuhopecten;PE=4;SV=1	GO:0004411|	GO:0006559|GO:0006570|
GN014070.1	sp|K1QFL5|K1QFL5_CRAGI	2.6e-17	95.1	42.62%	36.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014072.1	sp|K1P4V4|K1P4V4_CRAGI	9.4e-21	106.7	100.00%	38.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014073.1	sp|K1QAY1|K1QAY1_CRAGI	1.8e-87	328.9	99.61%	42.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014074.1	sp|K1PQH9|K1PQH9_CRAGI	3.7e-135	487.3	100.00%	76.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008017|
GN014076.1	sp|K1PFY6|K1PFY6_CRAGI	3.3e-18	97.1	78.01%	39.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014077.1	sp|K1PB60|K1PB60_CRAGI	1.9e-67	261.9	86.52%	47.06%	Bcl-2-like protein 13;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN014078.1	sp|K1RA48|K1RA48_CRAGI	1.7e-31	141.7	99.03%	42.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014079.1	sp|Unreviewed|A0A087U1V2_9ARAC	1.5e-23	115.5	72.57%	38.60%	Uncharacterized protein;OS=Stegodyphus;PE=4;SV=1
GN014081.1	sp|A0A2G8L4X1|A0A2G8L4X1_STIJA	5.7e-18	96.3	100.00%	33.79%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN014082.1	sp|K1QWY5|K1QWY5_CRAGI	7.3e-36	156.0	90.29%	44.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN014085.1	sp|A0A1S3I398|A0A1S3I398_LINUN	5.8e-26	122.9	66.22%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN014088.1	sp|A0A1S3I398|A0A1S3I398_LINUN	7.6e-26	122.5	66.22%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN014093.1	sp|K1QJ64|K1QJ64_CRAGI	2.5e-105	387.1	100.00%	88.69%	Protein DGCR6L;OS=Crassostrea;PE=4;SV=1
GN014094.1	sp|K1QWA9|K1QWA9_CRAGI	3.4e-101	374.0	92.84%	59.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013881.1	sp|K1R2B0|K1R2B0_CRAGI	5.3e-16	89.0	87.06%	65.75%	Hormonally up-regulated neu tumor-associated kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN014096.1	sp|A0A0B6ZNV7|A0A0B6ZNV7_9EUPU	5.4e-131	473.0	99.71%	64.54%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN014099.1	sp|A0A2B4S0M7|A0A2B4S0M7_STYPI	1.5e-10	72.4	53.75%	33.33%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN013882.1	sp|K1RBW3|K1RBW3_CRAGI	8.7e-191	672.2	98.40%	65.80%	Ectonucleotide pyrophosphatase/phosphodiesterase family member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|
GN014100.1	sp|K1PBD9|K1PBD9_CRAGI	4.6e-57	226.5	100.00%	64.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014102.1	sp|K1RA23|K1RA23_CRAGI	2.9e-46	192.2	98.36%	28.04%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014104.1	sp|K1PMG1|K1PMG1_CRAGI	5.0e-46	191.4	98.37%	25.75%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014106.1	sp|K1PMG1|K1PMG1_CRAGI	1.5e-47	196.4	98.37%	26.02%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN013883.1	sp|K1R5W3|K1R5W3_CRAGI	0.0e+00	2810.4	91.59%	86.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005643|
GN014109.1	sp|K1QZH0|K1QZH0_CRAGI	1.6e-268	930.6	100.00%	76.86%	Single-minded-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|GO:0005667|	GO:0003677|GO:0003700|GO:0046983|
GN014110.1	sp|K1RLN2|K1RLN2_CRAGI	3.6e-304	1049.3	100.00%	75.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014111.1	sp|K1PGN7|K1PGN7_CRAGI	6.9e-22	109.8	98.50%	38.14%	Baculoviral IAP repeat-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN014112.1	sp|K1PPI1|K1PPI1_CRAGI	6.1e-50	203.4	85.02%	46.52%	Inhibitor of apoptosis protein;OS=Crassostrea;PE=4;SV=1
GN013884.1	sp|K1R5W1|K1R5W1_CRAGI	2.0e-16	93.6	11.48%	44.32%	Apoptosis inhibitor IAP;OS=Crassostrea;PE=4;SV=1
GN014114.1	sp|A0A1Y1JT91|A0A1Y1JT91_PHOPY	1.2e-65	256.1	83.50%	42.48%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN014115.1	sp|K1QD80|K1QD80_CRAGI	6.5e-167	592.4	93.51%	80.56%	Protein quaking-B;OS=Crassostrea;PE=4;SV=1	GO:0003727|	GO:0006417|
GN013885.1	sp|F5A8D5|F5A8D5_CRAGI	4.4e-36	157.1	87.98%	32.94%	Inhibitor of apoptosis protein;OS=Crassostrea;PE=2;SV=1
GN014121.1	sp|A0A2G8JZY7|A0A2G8JZY7_STIJA	3.0e-15	88.2	76.34%	27.44%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0016021|
GN014123.1	sp|K1QAW7|K1QAW7_CRAGI	1.1e-16	92.0	55.10%	58.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014124.1	sp|K1QFL5|K1QFL5_CRAGI	7.0e-51	208.4	35.10%	36.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014125.1	sp|K1QQR2|K1QQR2_CRAGI	1.7e-19	100.5	98.78%	62.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013886.1	sp|A0A210Q8J5|A0A210Q8J5_MIZYE	3.8e-78	297.0	93.52%	66.52%	Loss of heterozygosity 12 chromosomal region 1 protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0032418|
GN014126.1	sp|K1QLE4|K1QLE4_CRAGI	1.1e-60	238.0	99.23%	92.19%	Synaptotagmin-7;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005544|	GO:0006887|
GN014127.1	sp|K1QFL5|K1QFL5_CRAGI	1.0e-51	211.5	25.69%	36.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014129.1	sp|K1QFL5|K1QFL5_CRAGI	2.1e-22	112.8	41.81%	31.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014130.1	sp|K1QQA0|K1QQA0_CRAGI	1.4e-292	1010.7	100.00%	78.26%	Forkhead box protein O;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN014133.1	sp|K1PPR7|K1PPR7_CRAGI	8.3e-255	885.6	92.80%	60.02%	Type II inositol-1,4,5-trisphosphate 5-phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0046856|GO:0007165|
GN014135.1	sp|K1QFL5|K1QFL5_CRAGI	2.8e-15	89.0	53.93%	26.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014136.1	sp|K1Q7B8|K1Q7B8_CRAGI	9.2e-38	162.2	79.11%	63.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014144.1	sp|K1QFL5|K1QFL5_CRAGI	8.1e-20	103.6	44.55%	39.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014146.1	sp|K1QFL5|K1QFL5_CRAGI	5.4e-46	191.8	42.77%	33.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014150.1	sp|A0A1X7TVL2|A0A1X7TVL2_AMPQE	1.2e-67	263.8	64.85%	30.24%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN014151.1	sp|A7RPZ5|A7RPZ5_NEMVE	2.3e-22	111.7	48.05%	44.26%	Predicted protein;OS=Nematostella;PE=4;SV=1	GO:0005694|GO:0005737|GO:0005634|	GO:0005524|GO:0043140|GO:0003677|GO:0009378|	GO:0032508|GO:0006310|GO:0006281|GO:0000724|
GN014152.1	sp|K1QV96|K1QV96_CRAGI	4.3e-17	93.6	38.92%	65.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014153.1	sp|K1PNA1|K1PNA1_CRAGI	1.9e-102	377.5	100.00%	86.19%	Ras-related and estrogen-regulated growth inhibitor;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN014154.1	sp|K1PUT6|K1PUT6_CRAGI	9.3e-57	225.7	76.50%	64.24%	Baculoviral IAP repeat-containing protein 7-B;OS=Crassostrea;PE=4;SV=1
GN013889.1	sp|K1R548|K1R548_CRAGI	2.6e-19	102.4	17.16%	58.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014155.1	sp|K1QFL5|K1QFL5_CRAGI	6.4e-13	80.5	48.61%	29.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014156.1	sp|K1QWY5|K1QWY5_CRAGI	8.6e-37	159.1	97.13%	45.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN014157.1	sp|Unreviewed|A0A087TX31_9ARAC	3.9e-28	130.6	96.10%	35.86%	Uncharacterized protein;OS=Stegodyphus;PE=4;SV=1	GO:0055114|
GN014158.1	sp|A0A1I7SFX9|A0A1I7SFX9_BURXY	3.3e-10	71.2	87.35%	31.84%	Uncharacterized protein;OS=Bursaphelenchus;PE=4;SV=1	GO:0003676|	GO:0015074|
GN014163.1	sp|K1QVB4|K1QVB4_CRAGI	3.6e-84	316.6	99.49%	71.65%	Vitelline membrane outer layer protein 1;OS=Crassostrea;PE=4;SV=1
GN014167.1	sp|K1PY69|K1PY69_CRAGI	1.6e-14	84.3	55.45%	70.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN013890.1	sp|K1R543|K1R543_CRAGI	7.1e-126	456.8	100.00%	46.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014168.1	sp|K1QMM9|K1QMM9_CRAGI	4.2e-23	113.6	61.14%	50.47%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016888|
GN014169.1	sp|K1R5H6|K1R5H6_CRAGI	3.1e-22	111.7	52.51%	41.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014170.1	sp|K1Q5K0|K1Q5K0_CRAGI	5.7e-194	682.9	99.31%	56.65%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN014171.1	sp|V9HX09|V9HX09_OSTED	1.3e-100	371.3	98.53%	93.50%	Inhibitor of apoptosis protein 1;OS=Ostrea;PE=2;SV=1
GN014172.1	sp|K1QP13|K1QP13_CRAGI	3.2e-19	99.8	78.02%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014173.1	sp|J9Q4I7|J9Q4I7_OSTED	1.2e-65	255.4	53.56%	95.28%	Uncharacterized protein;OS=Ostrea;PE=2;SV=1
GN014176.1	sp|K1R2G2|K1R2G2_CRAGI	2.0e-14	85.5	34.28%	41.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014177.1	sp|C3YJW0|C3YJW0_BRAFL	1.0e-80	307.4	59.73%	33.12%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN013892.1	sp|K1QVH2|K1QVH2_CRAGI	5.8e-103	379.8	87.96%	69.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014180.1	sp|A0A210R3E8|A0A210R3E8_MIZYE	0.0e+00	1130.2	93.66%	81.87%	TFIIH basal transcription factor complex helicase XPB subunit;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004003|GO:0003677|	GO:0006289|GO:0006367|
GN013893.1	sp|K1R858|K1R858_CRAGI	8.1e-142	508.8	99.69%	80.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014181.1	sp|V4CH05|V4CH05_LOTGI	2.6e-13	80.9	84.97%	38.76%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN014183.1	sp|K1QRQ0|K1QRQ0_CRAGI	8.9e-18	95.1	86.14%	50.00%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN014184.1	sp|F1KY01|F1KY01_ASCSU	8.6e-18	95.9	89.88%	35.76%	60 kDa SS-A/Ro ribonucleoprotein;OS=Ascaris;PE=2;SV=1	GO:0019013|	GO:0003723|
GN013894.1	sp|K1REP2|K1REP2_CRAGI	1.6e-56	224.2	100.00%	83.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN014186.1	sp|A0A2C9M7I4|A0A2C9M7I4_BIOGL	3.5e-11	73.6	80.62%	35.58%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN014187.1	sp|K1PVU0|K1PVU0_CRAGI	2.4e-28	131.0	97.56%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN013895.1	sp|K1Q829|K1Q829_CRAGI	6.4e-60	237.3	87.95%	33.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014188.1	sp|A0A210Q4D7|A0A210Q4D7_MIZYE	3.9e-09	66.6	85.47%	40.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014189.1	sp|K1QRQ0|K1QRQ0_CRAGI	1.9e-136	491.9	98.64%	43.20%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN014190.1	sp|K1S3C0|K1S3C0_CRAGI	2.2e-09	68.6	28.16%	44.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014191.1	sp|K1QRQ0|K1QRQ0_CRAGI	2.5e-136	491.5	98.64%	43.28%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN014192.1	sp|K1QZD4|K1QZD4_CRAGI	2.9e-71	275.4	54.89%	42.82%	Apoptosis 2 inhibitor;OS=Crassostrea;PE=4;SV=1
GN013855.1	sp|A0A131XQ81|A0A131XQ81_IXORI	1.9e-46	192.6	90.99%	31.14%	Putative is4eu-1 dr;OS=Ixodes;PE=2;SV=1	GO:0008270|
GN013896.1	sp|K1Q829|K1Q829_CRAGI	4.4e-53	214.5	88.31%	32.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014193.1	sp|K1S4Y1|K1S4Y1_CRAGI	1.5e-45	188.7	75.29%	46.70%	Baculoviral IAP repeat-containing protein 7-B;OS=Crassostrea;PE=4;SV=1
GN014194.1	sp|K1P7K4|K1P7K4_CRAGI	1.6e-151	541.6	100.00%	70.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014195.1	sp|A0A210QLR8|A0A210QLR8_MIZYE	3.7e-09	67.0	46.53%	40.91%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014196.1	sp|K1PLF5|K1PLF5_CRAGI	2.3e-43	181.8	95.28%	40.33%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN014197.1	sp|K1PLF5|K1PLF5_CRAGI	4.2e-15	87.4	93.51%	33.49%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN014198.1	sp|K1PLF5|K1PLF5_CRAGI	1.3e-21	109.4	90.36%	31.49%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN014199.1	sp|K1QMZ9|K1QMZ9_CRAGI	1.4e-42	178.3	84.92%	58.28%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN014201.1	sp|K1PLF5|K1PLF5_CRAGI	3.1e-40	171.4	88.89%	40.63%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN014202.1	sp|K1QMZ9|K1QMZ9_CRAGI	5.2e-40	170.6	47.96%	60.53%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN014203.1	sp|K1Q8E5|K1Q8E5_CRAGI	2.3e-225	787.3	99.01%	67.77%	Copine-4;OS=Crassostrea;PE=4;SV=1
GN014204.1	sp|A0A2B4RV85|A0A2B4RV85_STYPI	9.3e-31	138.7	68.66%	68.13%	Putative nuclease HARBI1;OS=Stylophora;PE=4;SV=1
GN014205.1	sp|K1QGJ7|K1QGJ7_CRAGI	1.7e-130	471.9	100.00%	67.32%	Ubiquitin-conjugating enzyme E2 J1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014206.1	sp|K1PR91|K1PR91_CRAGI	1.9e-257	894.0	99.70%	67.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014207.1	sp|K1R2C7|K1R2C7_CRAGI	5.1e-252	875.9	99.69%	67.29%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN013898.1	sp|K1R523|K1R523_CRAGI	4.4e-73	280.8	75.95%	50.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014208.1	sp|K1PK04|K1PK04_CRAGI	3.9e-258	896.3	97.94%	67.17%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014209.1	sp|K1PV89|K1PV89_CRAGI	1.1e-101	375.6	77.61%	72.33%	WW domain-containing oxidoreductase;OS=Crassostrea;PE=4;SV=1
GN014210.1	sp|K1PV89|K1PV89_CRAGI	9.7e-103	379.0	76.80%	73.81%	WW domain-containing oxidoreductase;OS=Crassostrea;PE=4;SV=1
GN014211.1	sp|K1PV89|K1PV89_CRAGI	4.9e-106	391.0	41.85%	73.31%	WW domain-containing oxidoreductase;OS=Crassostrea;PE=4;SV=1
GN014212.1	sp|K1R0P8|K1R0P8_CRAGI	0.0e+00	1161.7	99.84%	92.93%	CTP synthase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0003883|	GO:0044210|GO:0006541|
GN014213.1	sp|K1QQ92|K1QQ92_CRAGI	3.5e-78	297.0	94.42%	68.49%	Alstrom syndrome protein 1;OS=Crassostrea;PE=4;SV=1
GN014214.1	sp|K1PSP9|K1PSP9_CRAGI	2.1e-234	817.4	100.00%	63.85%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014215.1	sp|K1QY62|K1QY62_CRAGI	3.1e-38	163.7	94.23%	56.85%	Solute carrier family 35 member E1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014216.1	sp|K1QTV7|K1QTV7_CRAGI	0.0e+00	1526.9	95.09%	93.69%	Aldehyde dehydrogenase family 16 member A1;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN014217.1	sp|K1QZ98|K1QZ98_CRAGI	5.0e-158	563.9	91.54%	57.88%	Beta-taxilin;OS=Crassostrea;PE=4;SV=1	GO:0019905|
GN014218.1	sp|A0A210QFT7|A0A210QFT7_MIZYE	5.1e-151	540.0	100.00%	54.42%	Headcase protein-like;OS=Mizuhopecten;PE=4;SV=1
GN014219.1	sp|A0A3M6TSR0|A0A3M6TSR0_9CNID	1.3e-59	236.5	84.43%	32.62%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN014220.1	sp|K1RF91|K1RF91_CRAGI	1.7e-127	461.1	100.00%	78.75%	Proteasome assembly chaperone 1;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0000502|	GO:0043248|
GN013899.1	sp|K1QSH8|K1QSH8_CRAGI	1.4e-163	581.3	97.61%	90.52%	Deformed epidermal autoregulatory factor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN014223.1	sp|K1RJ49|K1RJ49_CRAGI	4.0e-49	200.3	90.87%	61.38%	Oligodendrocyte transcription factor 3;OS=Crassostrea;PE=4;SV=1	GO:0003700|GO:0046983|	GO:0042552|GO:0030182|GO:0021778|
GN014224.1	sp|K1RGD8|K1RGD8_CRAGI	2.4e-109	401.4	98.81%	48.69%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN014225.1	sp|K1RGD8|K1RGD8_CRAGI	3.0e-112	411.0	98.10%	51.33%	Innexin;OS=Crassostrea;PE=3;SV=1	GO:0005921|GO:0016021|GO:0005886|	GO:0006811|
GN013900.1	sp|K1PA93|K1PA93_CRAGI	1.3e-102	379.0	84.83%	55.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|
GN014226.1	sp|K1QXH3|K1QXH3_CRAGI	6.3e-13	79.3	96.03%	43.09%	Translational activator GCN1;OS=Crassostrea;PE=4;SV=1	GO:0019901|GO:0019887|GO:0043022|	GO:0033674|GO:0006417|
GN014227.1	sp|K1RDR7|K1RDR7_CRAGI	1.8e-57	227.6	100.00%	70.25%	Tctex1 domain-containing protein 1-A;OS=Crassostrea;PE=4;SV=1
GN014228.1	sp|K1QPA6|K1QPA6_CRAGI	2.6e-29	133.7	96.52%	56.36%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0016614|
GN014229.1	sp|K1QT93|K1QT93_CRAGI	1.5e-245	854.4	94.93%	70.38%	Glucose dehydrogenase [acceptor];OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0016614|
GN014230.1	sp|K1R7T3|K1R7T3_CRAGI	0.0e+00	1370.9	100.00%	71.39%	Amine oxidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0008131|GO:0048038|	GO:0009308|
GN014231.1	sp|K1QY04|K1QY04_CRAGI	1.3e-152	545.0	82.54%	96.97%	Radial spoke head protein 3-like protein;OS=Crassostrea;PE=4;SV=1
GN014232.1	sp|K1S350|K1S350_CRAGI	2.7e-180	637.1	96.34%	70.78%	PR domain zinc finger protein 13;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014233.1	sp|K1S347|K1S347_CRAGI	1.4e-250	871.3	100.00%	63.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014234.1	sp|K1RJM8|K1RJM8_CRAGI	3.3e-82	310.5	63.16%	95.48%	SAGA-associated factor 11 homolog;OS=Crassostrea;PE=3;SV=1	GO:0005858|GO:0071819|GO:0000124|	GO:0005524|GO:0016887|GO:0003777|GO:0003713|GO:0008270|	GO:0003341|GO:0016578|GO:0045893|
GN013901.1	sp|K1QSH8|K1QSH8_CRAGI	4.1e-25	120.2	40.74%	92.31%	Deformed epidermal autoregulatory factor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN014236.1	sp|K1RDQ7|K1RDQ7_CRAGI	1.6e-191	674.9	93.88%	73.65%	Cyclic AMP-responsive element-binding protein 3-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0035497|GO:0003700|	GO:0030968|GO:0045944|
GN014237.1	sp|K1PKF0|K1PKF0_CRAGI	3.6e-29	134.4	58.06%	46.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014238.1	sp|K1RC63|K1RC63_CRAGI	2.2e-18	97.8	85.09%	37.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014239.1	sp|K1R8J7|K1R8J7_CRAGI	3.6e-13	80.1	57.26%	54.29%	BTB and MATH domain-containing protein 38;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014240.1	sp|A0A1S3J188|A0A1S3J188_LINUN	9.3e-63	246.5	94.15%	37.75%	uncharacterized protein K02A2.6;OS=Lingula;PE=4;SV=1
GN014241.1	sp|A0A210QDG4|A0A210QDG4_MIZYE	7.0e-24	116.3	53.40%	59.80%	Uncharacterized protein K02A2.6;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|	GO:0015074|
GN014242.1	sp|K1R7S5|K1R7S5_CRAGI	4.3e-198	696.4	98.02%	74.44%	Rho GTPase-activating protein 8;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN014243.1	sp|K1QXZ6|K1QXZ6_CRAGI	9.3e-181	640.2	45.63%	65.98%	Dual specificity protein kinase TTK;OS=Crassostrea;PE=4;SV=1	GO:0004712|	GO:0051304|GO:0007093|
GN013902.1	sp|K1Q5B6|K1Q5B6_CRAGI	1.0e-190	672.9	63.39%	54.76%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN014245.1	sp|K1QL46|K1QL46_CRAGI	9.3e-28	128.6	88.46%	57.89%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014246.1	sp|K1QQ92|K1QQ92_CRAGI	7.9e-85	319.3	95.31%	61.98%	Alstrom syndrome protein 1;OS=Crassostrea;PE=4;SV=1
GN014247.1	sp|K1S583|K1S583_CRAGI	1.9e-105	388.3	80.84%	64.82%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014249.1	sp|K1PHK7|K1PHK7_CRAGI	6.9e-62	243.0	58.65%	73.58%	Excitatory amino acid transporter 2;OS=Crassostrea;PE=3;SV=1	GO:0005576|GO:0016021|	GO:0004623|GO:0015293|	GO:0050482|GO:0006644|
GN014250.1	sp|K1PK04|K1PK04_CRAGI	1.4e-244	851.3	99.69%	66.36%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014251.1	sp|K1Q3N8|K1Q3N8_CRAGI	2.6e-36	159.1	100.00%	82.84%	Src substrate cortactin;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN013903.1	sp|K1QSH8|K1QSH8_CRAGI	1.6e-56	226.5	28.48%	58.66%	Deformed epidermal autoregulatory factor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN014252.1	sp|K1RAL8|K1RAL8_CRAGI	5.0e-163	580.1	99.82%	54.81%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN014253.1	sp|K1QV09|K1QV09_CRAGI	1.9e-82	311.2	78.31%	68.27%	Ufm1-specific protease 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0071567|
GN014254.1	sp|A0A210QFR7|A0A210QFR7_MIZYE	1.2e-116	425.2	98.49%	63.24%	Lactadherin;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0005509|
GN014255.1	sp|K1QV09|K1QV09_CRAGI	1.6e-154	551.2	86.67%	78.50%	Ufm1-specific protease 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0071567|
GN014256.1	sp|K1S079|K1S079_CRAGI	1.1e-152	545.0	100.00%	73.46%	Contactin-associated protein like 5-2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005509|
GN014257.1	sp|K1RGX0|K1RGX0_CRAGI	8.0e-154	548.9	100.00%	75.62%	EGF-like repeat and discoidin I-like domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005509|
GN014258.1	sp|K1RAL4|K1RAL4_CRAGI	1.2e-146	525.0	92.01%	74.17%	EGF-like repeat and discoidin I-like domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN014259.1	sp|K1R4I1|K1R4I1_CRAGI	6.6e-35	153.3	94.69%	43.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014261.1	sp|K1R4I1|K1R4I1_CRAGI	5.3e-122	443.0	96.79%	79.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014262.1	sp|K1QWF3|K1QWF3_CRAGI	1.6e-37	161.4	75.62%	55.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004623|	GO:0050482|GO:0006644|
GN014263.1	sp|K1R3C8|K1R3C8_CRAGI	5.4e-67	259.6	100.00%	68.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014264.1	sp|K1R9W4|K1R9W4_CRAGI	2.2e-16	91.3	97.16%	37.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014265.1	sp|K1QWF3|K1QWF3_CRAGI	1.2e-59	234.6	99.25%	79.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004623|	GO:0050482|GO:0006644|
GN014267.1	sp|K1QMC8|K1QMC8_CRAGI	5.5e-69	266.2	98.96%	75.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014268.1	sp|A0A1X7VAJ5|A0A1X7VAJ5_AMPQE	4.0e-12	76.3	60.64%	51.79%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0008270|
GN014269.1	sp|C3ZIM2|C3ZIM2_BRAFL	3.8e-22	110.9	100.00%	31.60%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003677|
GN013856.1	sp|V4AGJ7|V4AGJ7_LOTGI	9.2e-41	172.9	80.94%	40.89%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN013904.1	sp|K1QX39|K1QX39_CRAGI	1.7e-11	75.9	22.40%	45.71%	Metal transporter CNNM2;OS=Crassostrea;PE=4;SV=1
GN014270.1	sp|K1RTR1|K1RTR1_CRAGI	0.0e+00	2079.3	100.00%	92.11%	ATP-citrate synthase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0003878|GO:0048037|GO:0046872|	GO:0006085|GO:0006101|GO:0006629|
GN014271.1	sp|K1R9W5|K1R9W5_CRAGI	2.3e-67	260.8	89.89%	79.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014272.1	sp|K1QBJ1|K1QBJ1_CRAGI	2.7e-68	263.8	100.00%	77.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014273.1	sp|A0A210QQ94|A0A210QQ94_MIZYE	2.2e-72	278.9	99.61%	31.43%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN014275.1	sp|A0A210QS10|A0A210QS10_MIZYE	1.9e-71	275.8	99.62%	31.46%	Toll-like receptor 13;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN014276.1	sp|K1Q730|K1Q730_CRAGI	1.8e-106	392.9	38.40%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN014277.1	sp|A0A1S3J1V0|A0A1S3J1V0_LINUN	2.1e-20	105.5	83.60%	29.43%	uncharacterized protein LOC106169495;OS=Lingula;PE=4;SV=1	GO:0003676|
GN014278.1	sp|K1RMM6|K1RMM6_CRAGI	1.4e-30	138.3	60.26%	67.78%	Centromere protein J;OS=Crassostrea;PE=4;SV=1
GN014279.1	sp|K1QRA0|K1QRA0_CRAGI	1.1e-196	691.4	99.49%	88.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014280.1	sp|K1QHH1|K1QHH1_CRAGI	2.8e-73	280.8	62.45%	86.16%	Runt-related transcription factor 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0003700|
GN014281.1	sp|A0A210QFG8|A0A210QFG8_MIZYE	3.4e-122	444.1	99.08%	48.05%	Protein notum-like;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016787|
GN014282.1	sp|A0A210QQ94|A0A210QQ94_MIZYE	2.7e-79	302.0	99.29%	33.10%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN014283.1	sp|A0A210QQ94|A0A210QQ94_MIZYE	1.2e-74	286.6	96.89%	32.22%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN014284.1	sp|K1S0M8|K1S0M8_CRAGI	1.3e-41	176.4	39.95%	47.65%	Toll-like receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN013906.1	sp|K1PTB0|K1PTB0_CRAGI	1.9e-35	154.1	89.17%	67.92%	Leucine-rich repeat-containing protein 24;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014289.1	sp|K1RE99|K1RE99_CRAGI	5.2e-18	97.1	26.99%	68.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN014291.1	sp|W4XLM4|W4XLM4_STRPU	8.2e-23	112.5	90.97%	36.43%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005829|	GO:0003676|GO:0004748|	GO:0009263|GO:0015074|
GN014292.1	sp|Unreviewed|A0A087TB85_9ARAC	9.0e-20	101.7	97.92%	52.69%	Protein NYNRIN;OS=Stegodyphus;PE=4;SV=1	GO:0003676|	GO:0015074|
GN013907.1	sp|K1QX39|K1QX39_CRAGI	1.5e-11	76.6	13.62%	50.79%	Metal transporter CNNM2;OS=Crassostrea;PE=4;SV=1
GN014293.1	sp|A0A1S3I398|A0A1S3I398_LINUN	3.5e-26	123.6	64.90%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN014296.1	sp|K1QMF0|K1QMF0_CRAGI	3.1e-292	1009.6	95.84%	77.24%	Xaa-Pro aminopeptidase 1;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0070006|
GN014297.1	sp|K1PPM2|K1PPM2_CRAGI	1.0e-114	419.1	100.00%	58.72%	Protein Mis18-alpha;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN014299.1	sp|K1QS33|K1QS33_CRAGI	7.1e-43	178.3	100.00%	96.63%	POU domain protein;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN014301.1	sp|K1Q051|K1Q051_CRAGI	8.7e-42	177.2	55.24%	42.41%	Transcription factor E3;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0006959|GO:0045893|
GN014302.1	sp|K1QF22|K1QF22_CRAGI	1.6e-116	424.5	100.00%	86.61%	U3 small nucleolar RNA-associated protein 11;OS=Crassostrea;PE=3;SV=1	GO:0005730|GO:0032040|	GO:0006364|
GN014303.1	sp|K1RBU7|K1RBU7_CRAGI	1.2e-13	81.6	90.08%	39.64%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN014305.1	sp|K1RBU7|K1RBU7_CRAGI	2.7e-13	80.5	90.08%	39.64%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN014306.1	sp|K1QLG9|K1QLG9_CRAGI	4.3e-34	153.7	27.26%	42.39%	Serine protease inhibitor dipetalogastin;OS=Crassostrea;PE=4;SV=1	GO:0008233|
GN014307.1	sp|K1RKC6|K1RKC6_CRAGI	1.1e-89	335.9	92.43%	45.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN013908.1	sp|A0A0C5Q4G7|A0A0C5Q4G7_MYTGA	2.2e-121	441.8	96.33%	40.39%	MACPF domain-containing protein 4;OS=Mytilus;PE=2;SV=1
GN014309.1	sp|A0A2G8KZM8|A0A2G8KZM8_STIJA	1.3e-54	220.3	72.02%	28.82%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN014310.1	sp|K1QDT6|K1QDT6_CRAGI	1.0e-22	113.2	32.64%	47.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014312.1	sp|K1QCW4|K1QCW4_CRAGI	6.0e-47	192.2	97.35%	88.99%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN014314.1	sp|A0A210QJW5|A0A210QJW5_MIZYE	2.3e-74	284.3	98.19%	62.50%	YrdC domain-containing protein, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0003725|
GN014315.1	sp|K1QLH4|K1QLH4_CRAGI	1.1e-251	874.8	84.50%	79.58%	CDK5 regulatory subunit-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0051539|GO:0016740|	GO:0006400|
GN014316.1	sp|K1R0U7|K1R0U7_CRAGI	1.1e-99	368.6	95.11%	70.36%	Biliverdin reductase A;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN014317.1	sp|K1RA29|K1RA29_CRAGI	0.0e+00	5050.7	84.49%	75.70%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN014318.1	sp|K1RKC8|K1RKC8_CRAGI	1.4e-145	522.3	99.19%	60.69%	Protein Mdm4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043066|GO:0071157|GO:0000122|GO:0016567|
GN014319.1	sp|K1QCW7|K1QCW7_CRAGI	1.4e-287	993.8	100.00%	89.50%	Exostosin-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015020|	GO:0006024|GO:0015012|GO:0006486|
GN014320.1	sp|K1R284|K1R284_CRAGI	2.9e-17	94.4	60.10%	44.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014321.1	sp|K1QLH8|K1QLH8_CRAGI	0.0e+00	1186.0	88.86%	76.33%	Peroxidasin;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN014322.1	sp|K1QK19|K1QK19_CRAGI	6.0e-84	316.6	50.93%	84.66%	Chorion peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN014323.1	sp|K1R0V0|K1R0V0_CRAGI	1.7e-203	716.5	70.90%	40.93%	Glucose-repressible alcohol dehydrogenase transcriptional effector;OS=Crassostrea;PE=4;SV=1
GN014323.1	sp|K1R0V0|K1R0V0_CRAGI	4.1e-24	120.6	8.31%	41.95%	Glucose-repressible alcohol dehydrogenase transcriptional effector;OS=Crassostrea;PE=4;SV=1
GN014324.1	sp|K1R0V0|K1R0V0_CRAGI	1.2e-109	402.1	95.52%	57.06%	Glucose-repressible alcohol dehydrogenase transcriptional effector;OS=Crassostrea;PE=4;SV=1
GN014325.1	sp|K1QWQ1|K1QWQ1_CRAGI	1.7e-121	441.4	98.52%	66.87%	Methyltransferase-like protein;OS=Crassostrea;PE=3;SV=1	GO:0008168|
GN014326.1	sp|A0A1S3JJM8|A0A1S3JJM8_LINUN	2.7e-21	108.2	32.33%	68.60%	sperm-specific protein PHI-2B-like;OS=Lingula;PE=3;SV=1	GO:0000786|GO:0005634|	GO:0003677|	GO:0006334|
GN014327.1	sp|A0A210PM42|A0A210PM42_MIZYE	1.4e-34	151.4	92.09%	58.14%	Peptidase M20 domain-containing protein 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016787|
GN014328.1	sp|A0A210PM42|A0A210PM42_MIZYE	2.0e-63	247.7	97.86%	62.09%	Peptidase M20 domain-containing protein 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016787|
GN013910.1	sp|A0A0C5PRK6|A0A0C5PRK6_MYTGA	1.5e-17	94.4	84.85%	51.81%	MACPF domain-containing protein 2;OS=Mytilus;PE=2;SV=1
GN014329.1	sp|K1RU05|K1RU05_CRAGI	2.5e-200	704.1	100.00%	64.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN014330.1	sp|K1QMP9|K1QMP9_CRAGI	2.0e-137	494.6	99.75%	64.62%	SH3 domain-containing kinase-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN014331.1	sp|K1RU07|K1RU07_CRAGI	4.3e-162	577.8	50.36%	71.57%	Glucose-repressible alcohol dehydrogenase transcriptional effector;OS=Crassostrea;PE=4;SV=1
GN013911.1	sp|K1Q730|K1Q730_CRAGI	8.9e-91	340.9	73.92%	40.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN014333.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	6.4e-120	436.8	91.40%	45.04%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN014334.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	9.1e-124	449.5	97.78%	45.92%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN014335.1	sp|A0A2G8KA18|A0A2G8KA18_STIJA	1.1e-26	126.3	73.36%	33.48%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0004190|
GN014336.1	sp|A0A2T7P639|A0A2T7P639_POMCA	2.1e-21	107.8	90.12%	45.39%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003677|
GN013912.1	sp|A0A210QDR0|A0A210QDR0_MIZYE	1.6e-22	112.5	73.31%	32.74%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014337.1	sp|A0A1S3IHK7|A0A1S3IHK7_LINUN	4.5e-22	110.2	91.28%	40.88%	uncharacterized protein LOC106164102;OS=Lingula;PE=4;SV=1	GO:0008270|
GN014338.1	sp|K1QEX9|K1QEX9_CRAGI	1.1e-145	522.3	80.90%	63.54%	Fibronectin type III domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN014339.1	sp|K1Q0Q0|K1Q0Q0_CRAGI	1.3e-15	87.4	86.11%	78.69%	Rab-like protein 2A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN014341.1	sp|K1QPL6|K1QPL6_CRAGI	8.0e-24	117.5	94.00%	27.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014342.1	sp|K1QFY0|K1QFY0_CRAGI	1.6e-66	258.5	77.24%	61.17%	Gastric triacylglycerol lipase;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN014343.1	sp|K1QFY0|K1QFY0_CRAGI	7.5e-138	495.7	77.51%	90.04%	Gastric triacylglycerol lipase;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN014344.1	sp|K1RN13|K1RN13_CRAGI	4.3e-285	985.7	100.00%	85.86%	Kinesin-like protein KIF25;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN014345.1	sp|K1R3M7|K1R3M7_CRAGI	9.5e-279	964.5	94.11%	84.41%	Tubulin--tyrosine ligase-like protein 12;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016874|	GO:0006464|
GN014346.1	sp|K1R3M7|K1R3M7_CRAGI	2.4e-44	184.1	56.10%	90.11%	Tubulin--tyrosine ligase-like protein 12;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016874|	GO:0006464|
GN013913.1	sp|A0A210QAY3|A0A210QAY3_MIZYE	7.5e-193	679.1	100.00%	62.76%	Ankyrin repeat and protein kinase domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN014347.1	sp|K1PNG6|K1PNG6_CRAGI	2.8e-135	487.3	100.00%	70.09%	Melatonin receptor type 1A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008502|
GN014348.1	sp|K1RN05|K1RN05_CRAGI	0.0e+00	1521.9	100.00%	90.99%	Transportin-3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008536|	GO:0006886|
GN014349.1	sp|K1QX87|K1QX87_CRAGI	4.9e-222	775.8	100.00%	88.26%	BTB/POZ domain-containing protein 10;OS=Crassostrea;PE=4;SV=1
GN014351.1	sp|K1QN54|K1QN54_CRAGI	1.8e-172	610.9	100.00%	78.59%	Brain protein 16;OS=Crassostrea;PE=4;SV=1
GN014352.1	sp|K1QUN6|K1QUN6_CRAGI	1.6e-60	237.3	100.00%	98.23%	Dynein light chain Tctex-type 1;OS=Crassostrea;PE=4;SV=1
GN014353.1	sp|K1QKS5|K1QKS5_CRAGI	6.1e-69	266.9	96.43%	49.45%	Uncharacterized protein C3orf19-like protein;OS=Crassostrea;PE=4;SV=1
GN014354.1	sp|K1QKS5|K1QKS5_CRAGI	1.0e-13	80.9	84.75%	77.55%	Uncharacterized protein C3orf19-like protein;OS=Crassostrea;PE=4;SV=1
GN014355.1	sp|K1RS92|K1RS92_CRAGI	9.1e-68	261.9	88.76%	89.26%	Transcription initiation factor TFIID subunit 12;OS=Crassostrea;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0003743|	GO:0006352|
GN013914.1	sp|A0A210QAY8|A0A210QAY8_MIZYE	4.4e-33	146.7	96.53%	42.51%	Dual specificity protein phosphatase 14;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004725|GO:0008138|
GN014356.1	sp|A0A210QFF4|A0A210QFF4_MIZYE	2.6e-111	407.9	93.24%	55.69%	Coiled-coil domain-containing protein 83;OS=Mizuhopecten;PE=4;SV=1
GN014357.1	sp|K1PHW9|K1PHW9_CRAGI	5.4e-76	289.3	100.00%	89.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014358.1	sp|K1RAX8|K1RAX8_CRAGI	1.5e-223	781.2	98.74%	70.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014359.1	sp|A0A2C9K5G7|A0A2C9K5G7_BIOGL	3.8e-69	266.9	95.11%	62.91%	Ubiquinone biosynthesis O-methyltransferase, mitochondrial;OS=Biomphalaria;PE=3;SV=1	GO:0031314|	GO:0008425|GO:1990886|GO:0008689|GO:0004395|	GO:0006744|
GN014360.1	sp|K1R4X6|K1R4X6_CRAGI	4.6e-115	421.4	56.56%	77.27%	Splicing factor, arginine/serine-rich 18;OS=Crassostrea;PE=4;SV=1
GN014361.1	sp|A0A1X7VBE6|A0A1X7VBE6_AMPQE	2.0e-44	184.5	97.21%	49.71%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN014362.1	sp|K1QVB8|K1QVB8_CRAGI	7.3e-122	442.6	98.77%	66.15%	High mobility group protein B2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN014363.1	sp|K1QVB8|K1QVB8_CRAGI	6.7e-48	196.8	90.10%	44.10%	High mobility group protein B2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN014364.1	sp|K1S0M8|K1S0M8_CRAGI	2.8e-53	213.4	97.67%	80.80%	Toll-like receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN014365.1	sp|K1RPF1|K1RPF1_CRAGI	2.3e-50	203.8	98.48%	74.42%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN014366.1	sp|K1RMZ0|K1RMZ0_CRAGI	8.9e-10	69.7	23.45%	67.31%	Methionyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004825|	GO:0006431|
GN014367.1	sp|K1RN94|K1RN94_CRAGI	7.5e-12	76.3	52.25%	41.30%	Complement C1q-like protein 2;OS=Crassostrea;PE=4;SV=1
GN014368.1	sp|K1QJZ2|K1QJZ2_CRAGI	2.4e-47	193.7	95.42%	75.20%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN013916.1	sp|K1PA90|K1PA90_CRAGI	1.1e-93	348.2	99.48%	87.50%	Dual specificity protein phosphatase 14;OS=Crassostrea;PE=4;SV=1	GO:0017017|GO:0004725|
GN014369.1	sp|K1RMZ0|K1RMZ0_CRAGI	8.9e-10	69.7	23.45%	67.31%	Methionyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004825|	GO:0006431|
GN014370.1	sp|K1QRB3|K1QRB3_CRAGI	2.9e-49	200.3	95.97%	72.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014371.1	sp|K1QYM3|K1QYM3_CRAGI	2.5e-191	674.5	100.00%	53.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014372.1	sp|K1RIW4|K1RIW4_CRAGI	2.8e-74	284.3	99.64%	52.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014373.1	sp|A0A2T7P3E5|A0A2T7P3E5_POMCA	2.3e-39	167.2	100.00%	64.52%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN014374.1	sp|K1RYK8|K1RYK8_CRAGI	3.2e-18	95.9	100.00%	70.97%	Peptidase M20 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN014375.1	sp|K1RYK8|K1RYK8_CRAGI	6.0e-30	135.2	100.00%	80.52%	Peptidase M20 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN014376.1	sp|K1PEU5|K1PEU5_CRAGI	1.2e-150	538.5	100.00%	69.02%	Peptidase M20 domain-containing protein 2;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN014377.1	sp|A0A2T7P3E5|A0A2T7P3E5_POMCA	1.9e-55	221.1	94.89%	65.09%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN014378.1	sp|K1RYK8|K1RYK8_CRAGI	2.5e-66	257.3	100.00%	65.59%	Peptidase M20 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN014379.1	sp|A0A1Q1NMJ7|A0A1Q1NMJ7_CRAGI	3.0e-309	1065.8	97.69%	91.62%	Cryptochrome 2;OS=Crassostrea;PE=2;SV=1
GN014381.1	sp|K1PMJ9|K1PMJ9_CRAGI	5.6e-124	449.5	99.35%	47.93%	Cleavage stimulation factor 77 kDa subunit;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006397|
GN014382.1	sp|K1PUX6|K1PUX6_CRAGI	8.4e-55	218.4	95.90%	93.97%	Transcription initiation factor TFIID subunit 13;OS=Crassostrea;PE=4;SV=1	GO:0046982|GO:0003743|	GO:0006366|
GN014383.1	sp|W4ZFN2|W4ZFN2_STRPU	4.2e-11	72.8	78.02%	52.11%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN014384.1	sp|K1RN94|K1RN94_CRAGI	1.0e-54	219.5	98.81%	51.38%	Complement C1q-like protein 2;OS=Crassostrea;PE=4;SV=1
GN014386.1	sp|K1RV97|K1RV97_CRAGI	3.2e-50	203.8	74.05%	70.59%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN013918.1	sp|A0A210PZW4|A0A210PZW4_MIZYE	5.9e-72	275.8	100.00%	83.23%	Transmembrane protein 138;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014387.1	sp|K1RPF1|K1RPF1_CRAGI	2.0e-49	200.7	94.20%	74.62%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN014388.1	sp|K1R608|K1R608_CRAGI	2.4e-42	177.2	94.12%	70.54%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014390.1	sp|K1QFW5|K1QFW5_CRAGI	1.0e-36	158.3	98.33%	63.25%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN014391.1	sp|K1R608|K1R608_CRAGI	1.4e-44	184.5	97.66%	73.44%	Multimerin-1;OS=Crassostrea;PE=4;SV=1
GN014392.1	sp|K1QF03|K1QF03_CRAGI	2.1e-182	643.7	100.00%	97.48%	DnaJ-like protein subfamily B member 13;OS=Crassostrea;PE=4;SV=1	GO:0051082|	GO:0006457|
GN014393.1	sp|K1P8P3|K1P8P3_CRAGI	0.0e+00	5885.1	100.00%	91.04%	Uncharacterized protein CXorf22;OS=Crassostrea;PE=4;SV=1
GN013919.1	sp|A0A210PZW5|A0A210PZW5_MIZYE	3.9e-66	256.9	82.22%	70.81%	Gamma-tubulin complex component;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|GO:0005874|GO:0005815|GO:0000922|	GO:0043015|	GO:0007020|
GN014394.1	sp|K1PEV3|K1PEV3_CRAGI	1.3e-37	164.5	10.78%	68.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005730|
GN014394.1	sp|K1PEV3|K1PEV3_CRAGI	2.7e-27	130.2	6.61%	84.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005730|
GN014396.1	sp|A0A2B4R8T7|A0A2B4R8T7_STYPI	2.1e-101	375.6	51.26%	56.00%	Zinc finger MYM-type protein 1;OS=Stylophora;PE=4;SV=1
GN014397.1	sp|K1PS26|K1PS26_CRAGI	1.8e-85	321.2	99.58%	69.58%	Arrestin domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN014398.1	sp|K1QRU1|K1QRU1_CRAGI	0.0e+00	1209.9	94.93%	53.83%	DNA helicase B;OS=Crassostrea;PE=4;SV=1	GO:0004003|	GO:0006269|
GN014399.1	sp|K1QZZ5|K1QZZ5_CRAGI	7.7e-105	385.6	100.00%	79.08%	Stress-induced protein 1;OS=Crassostrea;PE=3;SV=1
GN014400.1	sp|K1QDY8|K1QDY8_CRAGI	2.7e-120	437.2	100.00%	77.33%	Uncharacterized protein C21orf59-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003352|
GN014401.1	sp|K1Q6W1|K1Q6W1_CRAGI	1.7e-169	600.9	99.72%	87.32%	Uncharacterized protein C21orf63-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN013920.1	sp|K1PPH0|K1PPH0_CRAGI	3.0e-230	803.1	92.75%	96.44%	Gamma-tubulin complex component;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|GO:0005815|GO:0000922|	GO:0043015|	GO:0007020|
GN014403.1	sp|K1QXU5|K1QXU5_CRAGI	8.7e-27	125.2	99.09%	61.47%	Serine/threonine-protein kinase 40;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN014404.1	sp|K1QXU5|K1QXU5_CRAGI	2.0e-249	867.5	95.42%	68.38%	Serine/threonine-protein kinase 40;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN014405.1	sp|K1R4A2|K1R4A2_CRAGI	2.1e-14	83.6	100.00%	62.35%	Pericentriolar material 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0005813|	GO:0060271|GO:0034454|GO:0071539|
GN014407.1	sp|K1PI23|K1PI23_CRAGI	1.3e-276	958.4	95.84%	49.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0008289|	GO:0006869|GO:0042157|
GN014408.1	sp|A0A210R1E9|A0A210R1E9_MIZYE	4.2e-42	176.8	100.00%	48.07%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014411.1	sp|K1R348|K1R348_CRAGI	4.6e-09	65.5	87.10%	52.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014412.1	sp|K1RQM8|K1RQM8_CRAGI	2.8e-20	104.8	100.00%	30.04%	Cholecystokinin receptor type A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN014413.1	sp|K1Q2X7|K1Q2X7_CRAGI	7.5e-247	858.6	88.21%	79.84%	5'-nucleotidase;OS=Crassostrea;PE=3;SV=1	GO:0016788|GO:0046872|GO:0000166|	GO:0009166|
GN014414.1	sp|A0A194AJW9|A0A194AJW9_PINFU	2.8e-29	134.4	97.64%	41.63%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1
GN014416.1	sp|K7STV1|K7STV1_9BIVA	5.8e-10	68.6	96.97%	42.86%	Igf-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005576|
GN014417.1	sp|K1QHH3|K1QHH3_CRAGI	7.2e-50	203.8	82.97%	41.76%	CASP8-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0097190|
GN014418.1	sp|K1QHH3|K1QHH3_CRAGI	4.1e-49	202.6	79.04%	30.06%	CASP8-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0097190|
GN014419.1	sp|K1PYA4|K1PYA4_CRAGI	3.9e-39	167.2	94.42%	37.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014420.1	sp|A0A2B4S9E0|A0A2B4S9E0_STYPI	1.1e-20	105.9	87.56%	32.89%	THAP domain-containing protein 1;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN014421.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	1.7e-91	342.0	93.40%	43.03%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN014422.1	sp|K1R350|K1R350_CRAGI	3.1e-154	550.8	100.00%	67.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014423.1	sp|J9Q709|J9Q709_OSTED	1.1e-89	334.7	100.00%	97.66%	Ferritin;OS=Ostrea;PE=2;SV=1	GO:0005623|	GO:0008199|GO:0004322|	GO:0006879|GO:0006826|
GN014424.1	sp|A0A210QUY5|A0A210QUY5_MIZYE	3.7e-68	264.6	67.58%	44.26%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014425.1	sp|A0A210QUY5|A0A210QUY5_MIZYE	1.4e-46	192.2	88.89%	41.56%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014426.1	sp|K1RT88|K1RT88_CRAGI	4.1e-176	623.2	96.83%	71.85%	Lysine histidine transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014427.1	sp|K1R4I7|K1R4I7_CRAGI	3.2e-47	195.7	92.22%	25.49%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN013922.1	sp|K1P3P0|K1P3P0_CRAGI	0.0e+00	1790.8	100.00%	72.02%	QN1-like protein;OS=Crassostrea;PE=4;SV=1
GN014428.1	sp|K1QEC7|K1QEC7_CRAGI	1.3e-144	518.5	100.00%	65.86%	43 kDa receptor-associated protein of the synapse;OS=Crassostrea;PE=4;SV=1	GO:0033130|GO:0043495|	GO:0007268|
GN013923.1	sp|K1PHP1|K1PHP1_CRAGI	1.8e-74	284.3	96.61%	74.59%	Spermatogenesis-associated serine-rich protein 1;OS=Crassostrea;PE=4;SV=1
GN014432.1	sp|A0A210QNA2|A0A210QNA2_MIZYE	6.0e-105	386.3	99.05%	64.97%	Pyridoxal kinase;OS=Mizuhopecten;PE=4;SV=1	GO:0008478|	GO:0009443|
GN014433.1	sp|A0A210QND3|A0A210QND3_MIZYE	1.2e-81	308.5	99.19%	63.11%	3-hydroxybutyrate dehydrogenase type 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN014434.1	sp|K1P106|K1P106_CRAGI	6.4e-65	255.0	91.05%	46.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014435.1	sp|K1QUM5|K1QUM5_CRAGI	4.4e-41	176.0	12.56%	55.71%	Titin;OS=Crassostrea;PE=4;SV=1
GN014436.1	sp|K1PAH9|K1PAH9_CRAGI	8.0e-75	288.1	26.99%	47.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014438.1	sp|A0A210R0Z2|A0A210R0Z2_MIZYE	1.7e-22	112.1	61.13%	39.33%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN014439.1	sp|K1PGQ2|K1PGQ2_CRAGI	1.9e-30	139.0	57.22%	37.41%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1
GN014440.1	sp|K1RME4|K1RME4_CRAGI	3.9e-255	886.3	99.85%	65.61%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014442.1	sp|K1RGI5|K1RGI5_CRAGI	3.7e-67	259.6	92.81%	92.19%	S-adenosylmethionine decarboxylase proenzyme;OS=Crassostrea;PE=4;SV=1	GO:0004014|	GO:0008295|GO:0006597|
GN014443.1	sp|K1RGI5|K1RGI5_CRAGI	8.6e-61	238.8	78.98%	87.14%	S-adenosylmethionine decarboxylase proenzyme;OS=Crassostrea;PE=4;SV=1	GO:0004014|	GO:0008295|GO:0006597|
GN014444.1	sp|K1QWA1|K1QWA1_CRAGI	4.2e-205	720.3	49.93%	89.68%	Zinc finger with UFM1-specific peptidase domain protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014445.1	sp|K1QH85|K1QH85_CRAGI	5.0e-96	355.9	100.00%	96.67%	Trafficking protein particle complex subunit;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0005794|GO:0030008|	GO:0048193|
GN014446.1	sp|K1PK04|K1PK04_CRAGI	1.5e-82	311.6	99.61%	63.60%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN014447.1	sp|E7D8A8|E7D8A8_CRAGI	8.8e-239	832.8	99.83%	72.80%	Toll-like receptor 1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0007165|
GN014448.1	sp|K1PFQ7|K1PFQ7_CRAGI	9.0e-40	169.5	43.90%	67.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014449.1	sp|K1RME4|K1RME4_CRAGI	1.6e-226	791.2	99.84%	61.05%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN014450.1	sp|K1PJN7|K1PJN7_CRAGI	0.0e+00	1218.8	99.62%	77.08%	PC3-like endoprotease variant A;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN014451.1	sp|A0A210PMH3|A0A210PMH3_MIZYE	2.1e-166	591.3	92.04%	54.17%	Metalloendopeptidase;OS=Mizuhopecten;PE=4;SV=1	GO:0004222|GO:0008270|
GN014454.1	sp|K1QN57|K1QN57_CRAGI	1.1e-41	176.8	67.01%	36.25%	Toll-like receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN014455.1	sp|K1QUM5|K1QUM5_CRAGI	1.2e-21	109.4	82.12%	35.17%	Titin;OS=Crassostrea;PE=4;SV=1
GN014456.1	sp|A0A210R5Q0|A0A210R5Q0_MIZYE	3.2e-23	114.4	94.27%	38.03%	Titin;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN014458.1	sp|K1R420|K1R420_CRAGI	0.0e+00	1156.0	98.17%	96.27%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0000287|GO:0004674|	GO:0035556|
GN014460.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	1.4e-85	322.4	87.53%	45.89%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN014461.1	sp|A0A210Q7Y0|A0A210Q7Y0_MIZYE	1.1e-134	485.7	99.35%	50.10%	Major facilitator superfamily domain-containing protein 8;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0055085|
GN014462.1	sp|K1QF17|K1QF17_CRAGI	1.0e-13	83.2	90.51%	28.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014463.1	sp|K1QBJ7|K1QBJ7_CRAGI	0.0e+00	1176.4	100.00%	76.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014464.1	sp|K1QBJ7|K1QBJ7_CRAGI	1.2e-18	97.4	81.43%	80.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014465.1	sp|K1PR44|K1PR44_CRAGI	2.3e-122	444.5	100.00%	59.69%	Phospholipase A2 inhibitor subunit B;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN014466.1	sp|K1PJ01|K1PJ01_CRAGI	2.4e-247	861.7	94.40%	51.66%	Transcriptional repressor CTCF;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN014467.1	sp|K1Q9Y8|K1Q9Y8_CRAGI	3.3e-25	120.2	90.63%	54.31%	Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0008375|	GO:0006486|
GN014468.1	sp|K1PBN1|K1PBN1_CRAGI	0.0e+00	2110.1	100.00%	76.87%	Phospholipase;OS=Crassostrea;PE=3;SV=1	GO:0070290|GO:0035091|GO:0004630|	GO:0048017|GO:0016042|GO:0006654|
GN014469.1	sp|A0A210Q1V7|A0A210Q1V7_MIZYE	5.2e-75	287.0	97.90%	46.67%	Protein downstream neighbor of son-like;OS=Mizuhopecten;PE=4;SV=1
GN014470.1	sp|A0A1L4FR35|A0A1L4FR35_9BIVA	3.4e-63	246.5	100.00%	81.69%	GST-microsomal-like protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN014471.1	sp|K1PMB9|K1PMB9_CRAGI	5.2e-48	196.1	97.20%	65.22%	Microsomal glutathione S-transferase 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN014473.1	sp|K1QE86|K1QE86_CRAGI	1.4e-43	182.2	40.38%	77.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014474.1	sp|K1PR34|K1PR34_CRAGI	1.9e-35	153.7	91.21%	74.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014475.1	sp|K1PIZ4|K1PIZ4_CRAGI	7.6e-188	662.1	87.71%	87.30%	Wee1-like protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0005524|GO:0000287|GO:0004715|	GO:0000278|
GN014476.1	sp|K1PIZ4|K1PIZ4_CRAGI	1.2e-55	221.5	91.95%	79.41%	Wee1-like protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0005524|GO:0000287|GO:0004715|	GO:0000278|
GN014477.1	sp|K1RHG8|K1RHG8_CRAGI	4.0e-21	105.5	100.00%	81.97%	Uncharacterized protein C1orf93-like protein;OS=Crassostrea;PE=4;SV=1
GN013925.1	sp|K1PHI0|K1PHI0_CRAGI	2.1e-159	567.4	100.00%	83.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN014479.1	sp|A0A0B7B1J4|A0A0B7B1J4_9EUPU	9.9e-240	835.1	94.24%	62.25%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0008270|
GN014480.1	sp|K1R183|K1R183_CRAGI	4.5e-29	133.3	96.79%	57.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014481.1	sp|K1R162|K1R162_CRAGI	1.3e-52	211.5	93.42%	72.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005525|
GN014482.1	sp|K1R162|K1R162_CRAGI	1.6e-126	458.4	100.00%	61.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005525|
GN014483.1	sp|K1RBV0|K1RBV0_CRAGI	9.1e-58	229.6	89.90%	45.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN014484.1	sp|K1RNL5|K1RNL5_CRAGI	7.0e-160	568.9	100.00%	81.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN015604.1	sp|K1Q5B6|K1Q5B6_CRAGI	3.2e-162	577.4	98.17%	54.29%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN016242.1	sp|K1QS69|K1QS69_CRAGI	1.1e-28	132.1	89.77%	43.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016247.1	sp|K1Q5I4|K1Q5I4_CRAGI	4.2e-24	117.5	25.68%	87.69%	COP9 signalosome complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0008180|
GN016249.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	4.9e-19	99.8	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN016250.1	sp|A0A2S2P439|A0A2S2P439_SCHGA	1.5e-16	92.8	53.62%	30.11%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN016251.1	sp|K1R190|K1R190_CRAGI	2.9e-12	77.4	87.01%	47.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016253.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-15	87.8	96.51%	51.19%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN015606.1	sp|K1QEP4|K1QEP4_CRAGI	3.8e-37	161.4	54.03%	44.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016255.1	sp|K1RVM2|K1RVM2_CRAGI	1.4e-180	637.9	91.86%	87.39%	Photoreceptor-specific nuclear receptor;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN016256.1	sp|K1QEH5|K1QEH5_CRAGI	1.1e-305	1054.3	100.00%	76.37%	Smaug-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0030371|	GO:0043488|
GN016257.1	sp|K1R0H3|K1R0H3_CRAGI	4.9e-160	569.3	100.00%	88.24%	Mitochondrial 2-oxodicarboxylate carrier;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN016258.1	sp|K1PSH2|K1PSH2_CRAGI	1.7e-61	240.7	100.00%	92.19%	28S ribosomal protein S12, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0015935|	GO:0003735|	GO:0006412|
GN016259.1	sp|K1PZU2|K1PZU2_CRAGI	6.0e-45	185.7	95.04%	94.74%	RNA-binding protein 25;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006397|
GN015607.1	sp|A0A210Q9P6|A0A210Q9P6_MIZYE	6.3e-68	263.1	89.19%	54.11%	Ribonuclease Oy;OS=Mizuhopecten;PE=3;SV=1	GO:0033897|GO:0003723|
GN016262.1	sp|K1PZU2|K1PZU2_CRAGI	1.0e-132	479.6	55.52%	83.04%	RNA-binding protein 25;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006397|
GN016263.1	sp|K1Q7F0|K1Q7F0_CRAGI	8.4e-35	152.9	98.74%	46.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016265.1	sp|K1QEI1|K1QEI1_CRAGI	5.0e-31	141.7	42.93%	92.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016271.1	sp|K1PSH7|K1PSH7_CRAGI	2.3e-17	96.3	10.23%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016273.1	sp|K1PZU4|K1PZU4_CRAGI	1.3e-93	348.2	100.00%	78.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016274.1	sp|K1Q7F3|K1Q7F3_CRAGI	3.8e-129	467.6	100.00%	51.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016276.1	sp|K1QEI5|K1QEI5_CRAGI	2.8e-104	383.6	100.00%	84.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015608.1	sp|K1S4Q2|K1S4Q2_CRAGI	2.7e-262	909.8	92.55%	96.18%	T-complex protein 1 subunit delta;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0051082|	GO:0006457|
GN016280.1	sp|K1PCC7|K1PCC7_CRAGI	2.2e-235	820.1	98.34%	94.92%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN015609.1	sp|K1QZ87|K1QZ87_CRAGI	3.2e-96	356.7	100.00%	83.59%	Sphingosine-1-phosphate phosphatase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016281.1	sp|A0A210PU56|A0A210PU56_MIZYE	2.1e-97	361.3	100.00%	51.10%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016285.1	sp|K1QLP7|K1QLP7_CRAGI	8.9e-143	511.9	100.00%	77.70%	Sulfotransferase family cytosolic 1B member 1;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN016286.1	sp|A0A0L8HWS9|A0A0L8HWS9_OCTBM	2.7e-143	515.0	96.57%	40.48%	Poly [ADP-ribose] polymerase;OS=Octopus;PE=4;SV=1	GO:0003950|
GN016289.1	sp|V4AYR3|V4AYR3_LOTGI	2.0e-104	384.8	93.78%	57.46%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0008502|
GN016290.1	sp|K1PQH5|K1PQH5_CRAGI	1.2e-121	443.0	98.74%	36.95%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN015610.1	sp|A7TDB1|A7TDB1_NEMVE	3.9e-19	100.5	97.86%	34.41%	Predicted protein;OS=Nematostella;PE=4;SV=1	GO:0016021|
GN016291.1	sp|K1PQH5|K1PQH5_CRAGI	8.5e-115	420.2	98.32%	36.78%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN016292.1	sp|A0A210QPN8|A0A210QPN8_MIZYE	7.5e-31	139.8	63.07%	50.32%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016293.1	sp|K1PYG9|K1PYG9_CRAGI	2.5e-117	427.6	100.00%	88.82%	FAM50-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN016294.1	sp|A0A1S3DFF2|A0A1S3DFF2_DIACI	2.1e-11	75.1	44.54%	40.57%	dnaJ-like protein 60;OS=Diaphorina;PE=4;SV=1	GO:0016021|
GN016295.1	sp|K1PVP8|K1PVP8_CRAGI	2.3e-185	653.7	100.00%	89.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016296.1	sp|K1QS20|K1QS20_CRAGI	4.4e-22	111.3	26.81%	50.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016298.1	sp|K1PG51|K1PG51_CRAGI	4.6e-18	95.5	82.61%	85.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016299.1	sp|K1QSF5|K1QSF5_CRAGI	5.6e-142	509.2	100.00%	80.14%	Structure-specific endonuclease subunit SLX1 homolog;OS=Crassostrea;PE=3;SV=1	GO:0033557|	GO:0017108|GO:0046872|	GO:0006310|GO:0006281|
GN016300.1	sp|K1PV26|K1PV26_CRAGI	9.0e-17	92.8	76.70%	40.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016301.1	sp|K1QLX5|K1QLX5_CRAGI	7.5e-191	672.5	100.00%	69.04%	TNF receptor-associated factor 3;OS=Crassostrea;PE=4;SV=1	GO:0005164|GO:0008270|	GO:0045087|GO:0032088|GO:0042981|GO:0001817|GO:0050688|GO:0008063|GO:0033209|
GN016302.1	sp|K1QW11|K1QW11_CRAGI	1.1e-179	636.0	83.29%	72.41%	U3 small nucleolar ribonucleoprotein protein MPP10;OS=Crassostrea;PE=3;SV=1	GO:0034457|GO:0005732|	GO:0006364|
GN016304.1	sp|K1RED4|K1RED4_CRAGI	5.2e-24	118.6	24.89%	44.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015612.1	sp|K1R9D2|K1R9D2_CRAGI	1.7e-226	790.8	100.00%	74.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016307.1	sp|K1RED4|K1RED4_CRAGI	1.0e-24	119.0	94.59%	44.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016309.1	sp|K1R8J8|K1R8J8_CRAGI	4.8e-113	412.9	86.22%	85.78%	BTB/POZ domain-containing protein KCTD7;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN016310.1	sp|K1QT13|K1QT13_CRAGI	0.0e+00	1122.8	99.89%	64.42%	Alanyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004813|GO:0005524|GO:0000049|GO:0008270|	GO:0006419|
GN016311.1	sp|K1PQH5|K1PQH5_CRAGI	1.3e-78	299.7	95.83%	31.17%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN015613.1	sp|A0A210QVV1|A0A210QVV1_MIZYE	6.4e-114	417.5	85.63%	33.05%	Kyphoscoliosis peptidase;OS=Mizuhopecten;PE=4;SV=1
GN016313.1	sp|K1QT20|K1QT20_CRAGI	5.2e-39	166.8	49.08%	79.25%	C16orf88-like protein;OS=Crassostrea;PE=4;SV=1
GN016314.1	sp|A0A210QFZ9|A0A210QFZ9_MIZYE	4.7e-114	417.2	97.00%	51.39%	Exocyst complex component 2;OS=Mizuhopecten;PE=4;SV=1
GN016315.1	sp|K1R8K3|K1R8K3_CRAGI	5.5e-172	609.4	94.25%	76.06%	Ubiquitin-conjugating enzyme E2 Q2;OS=Crassostrea;PE=4;SV=1
GN016316.1	sp|H9LJ92|H9LJ92_CRAAR	8.7e-65	251.9	96.13%	79.05%	USP-like protein isoform 2;OS=Crassostrea;PE=2;SV=1
GN015614.1	sp|A0A210QZ72|A0A210QZ72_MIZYE	5.0e-141	507.3	94.78%	43.92%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0007165|
GN016318.1	sp|H9LJ92|H9LJ92_CRAAR	8.9e-46	188.7	96.71%	58.90%	USP-like protein isoform 2;OS=Crassostrea;PE=2;SV=1
GN016319.1	sp|K1RF68|K1RF68_CRAGI	2.8e-29	133.3	100.00%	63.54%	Bile acyl-CoA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0004197|
GN016320.1	sp|A0A210QYZ8|A0A210QYZ8_MIZYE	3.4e-25	120.2	91.73%	42.98%	Very long-chain acyl-CoA synthetase;OS=Mizuhopecten;PE=4;SV=1	GO:0003824|
GN016321.1	sp|K1RF68|K1RF68_CRAGI	1.1e-30	137.9	100.00%	63.54%	Bile acyl-CoA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0004197|
GN016322.1	sp|K1RF68|K1RF68_CRAGI	1.4e-63	248.8	84.08%	50.20%	Bile acyl-CoA synthetase;OS=Crassostrea;PE=4;SV=1	GO:0004197|
GN016323.1	sp|K1RY94|K1RY94_CRAGI	9.2e-227	791.6	99.57%	83.15%	N-acetylgalactosamine kinase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0004335|GO:0005534|	GO:0006012|
GN016324.1	sp|K1QT41|K1QT41_CRAGI	2.8e-227	793.5	99.63%	69.06%	28S ribosomal protein S30, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005739|GO:0005840|	GO:0003735|	GO:0006412|
GN016325.1	sp|K1R9V2|K1R9V2_CRAGI	4.8e-59	233.0	94.94%	65.05%	28S ribosomal protein S16, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN015615.1	sp|A0A0U5LCN0|A0A0U5LCN0_MIMNO	1.6e-163	582.0	91.20%	44.23%	Toll like receptor-1;OS=Mimachlamys;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN016328.1	sp|K1RLP3|K1RLP3_CRAGI	1.8e-144	518.5	100.00%	48.23%	TNF receptor-associated factor 3;OS=Crassostrea;PE=4;SV=1	GO:0005164|GO:0008270|	GO:0045087|GO:0032088|GO:0042981|GO:0001817|GO:0050688|GO:0008063|GO:0033209|
GN016329.1	sp|K1Q734|K1Q734_CRAGI	5.8e-99	367.1	74.17%	49.38%	Flap endonuclease GEN-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004519|	GO:0006281|
GN016330.1	sp|K1PXF9|K1PXF9_CRAGI	1.3e-109	401.4	100.00%	86.30%	Cyclin-O;OS=Crassostrea;PE=3;SV=1	GO:0005634|
GN015616.1	sp|A0A0U5LCN0|A0A0U5LCN0_MIMNO	1.5e-164	585.5	91.20%	44.39%	Toll like receptor-1;OS=Mimachlamys;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN016332.1	sp|K1RCU7|K1RCU7_CRAGI	1.5e-99	368.6	88.76%	52.35%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN016333.1	sp|A0A210QGN7|A0A210QGN7_MIZYE	2.5e-54	218.0	87.50%	47.37%	Iron-sulfur cluster co-chaperone protein HscB, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0001671|GO:0051087|	GO:0051259|GO:0097428|
GN016334.1	sp|A0A210QGP9|A0A210QGP9_MIZYE	2.4e-64	252.3	80.43%	41.70%	Cyclic AMP-responsive element-binding protein 3-like protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0035497|GO:0003700|	GO:0030968|GO:0045944|
GN016335.1	sp|K1RGY3|K1RGY3_CRAGI	0.0e+00	1582.4	95.82%	72.05%	Nucleolar protein 6;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0003723|
GN016337.1	sp|K1QC39|K1QC39_CRAGI	0.0e+00	1431.4	100.00%	79.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016338.1	sp|K1QXU9|K1QXU9_CRAGI	1.6e-183	647.9	80.00%	85.64%	Casein kinase I isoform gamma-3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN016340.1	sp|A0A210QVQ7|A0A210QVQ7_MIZYE	4.9e-28	129.8	96.73%	43.60%	Polypeptide N-acetylgalactosaminyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN016341.1	sp|K1P503|K1P503_CRAGI	1.7e-305	1053.5	89.69%	85.97%	Polypeptide N-acetylgalactosaminyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN016342.1	sp|K1PLB0|K1PLB0_CRAGI	1.3e-13	81.6	33.58%	84.09%	Mitochondrial import inner membrane translocase subunit TIM44;OS=Crassostrea;PE=4;SV=1
GN016343.1	sp|K1R4C9|K1R4C9_CRAGI	9.5e-25	119.0	100.00%	46.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016344.1	sp|K1QXF3|K1QXF3_CRAGI	1.4e-38	164.5	94.02%	79.28%	Homeobox protein orthopedia;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN015618.1	sp|A0A0U5LCN0|A0A0U5LCN0_MIMNO	1.2e-161	575.9	91.06%	44.14%	Toll like receptor-1;OS=Mimachlamys;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN016346.1	sp|K1QXF3|K1QXF3_CRAGI	4.1e-72	276.2	100.00%	93.79%	Homeobox protein orthopedia;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN016347.1	sp|K1RAX0|K1RAX0_CRAGI	9.9e-242	841.6	86.24%	76.22%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016349.1	sp|K1R8S8|K1R8S8_CRAGI	8.6e-83	312.4	96.76%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015619.1	sp|K1PVD7|K1PVD7_CRAGI	3.6e-78	296.6	89.07%	85.80%	Cytochrome c oxidase subunit 5A, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005743|	GO:0004129|
GN016353.1	sp|K1RI69|K1RI69_CRAGI	4.8e-111	407.1	86.90%	60.34%	Protein SPEC3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016354.1	sp|K1S1T4|K1S1T4_CRAGI	3.0e-124	450.3	94.98%	78.03%	Elongation of very long chain fatty acids protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN016355.1	sp|K1QHH5|K1QHH5_CRAGI	5.9e-87	325.9	100.00%	82.99%	Bcl-2-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN016356.1	sp|K1QP26|K1QP26_CRAGI	6.5e-51	205.7	97.89%	76.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016357.1	sp|K1R2F2|K1R2F2_CRAGI	3.2e-13	80.9	79.57%	33.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016358.1	sp|K1Q199|K1Q199_CRAGI	4.9e-26	122.9	80.80%	54.00%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016361.1	sp|K1RBI5|K1RBI5_CRAGI	6.9e-12	74.7	92.86%	60.78%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016362.1	sp|A0A210Q532|A0A210Q532_MIZYE	1.3e-19	102.8	52.66%	35.93%	Caspase-6;OS=Mizuhopecten;PE=3;SV=1	GO:0097200|
GN016363.1	sp|K1R7L6|K1R7L6_CRAGI	2.3e-172	610.5	90.76%	66.15%	Galactose-1-phosphate uridylyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0008108|GO:0008270|	GO:0033499|
GN016364.1	sp|V4BCB5|V4BCB5_LOTGI	2.7e-64	250.8	75.59%	73.12%	Receptor expression-enhancing protein;OS=Lottia;PE=3;SV=1	GO:0016021|
GN016365.1	sp|K1QWR4|K1QWR4_CRAGI	2.8e-311	1073.2	99.60%	76.67%	Mitogen-activated protein kinase 6;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004707|
GN016366.1	sp|K1QWN9|K1QWN9_CRAGI	0.0e+00	1766.1	35.39%	60.34%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016368.1	sp|K1QFA0|K1QFA0_CRAGI	5.7e-265	918.7	99.06%	85.26%	Neuronal acetylcholine receptor subunit alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN016373.1	sp|K1QZZ3|K1QZZ3_CRAGI	2.5e-74	284.3	89.02%	62.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007050|
GN016375.1	sp|K1QY88|K1QY88_CRAGI	7.4e-86	324.3	55.26%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN016376.1	sp|K1RHQ0|K1RHQ0_CRAGI	5.6e-114	416.4	99.39%	67.28%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN016377.1	sp|K1RFW9|K1RFW9_CRAGI	1.7e-50	205.7	92.12%	34.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015622.1	sp|K1PXR6|K1PXR6_CRAGI	1.4e-66	258.5	98.68%	59.82%	5-formyltetrahydrofolate cyclo-ligase;OS=Crassostrea;PE=3;SV=1	GO:0030272|GO:0005524|GO:0046872|
GN016378.1	sp|K1RFW9|K1RFW9_CRAGI	3.4e-120	437.2	98.08%	58.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016379.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	5.6e-65	253.4	87.29%	49.42%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN016380.1	sp|V4ARM3|V4ARM3_LOTGI	2.9e-12	77.4	59.48%	45.56%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN016381.1	sp|N6TYP6|N6TYP6_DENPD	4.0e-17	93.2	77.31%	48.35%	Uncharacterized protein;OS=Dendroctonus;PE=4;SV=1
GN016383.1	sp|K1RA80|K1RA80_CRAGI	5.4e-169	599.4	99.73%	79.79%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN016385.1	sp|K1RM18|K1RM18_CRAGI	4.7e-12	75.9	68.60%	55.56%	Dual oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0020037|GO:0016174|GO:0004601|	GO:0050665|GO:0006979|
GN015623.1	sp|V4A2Z2|V4A2Z2_LOTGI	1.6e-101	375.9	61.12%	49.87%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN016386.1	sp|K1RM18|K1RM18_CRAGI	2.2e-121	440.7	99.62%	82.24%	Dual oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0020037|GO:0016174|GO:0004601|	GO:0050665|GO:0006979|
GN016387.1	sp|K1RM18|K1RM18_CRAGI	3.0e-66	256.5	97.74%	89.15%	Dual oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0020037|GO:0016174|GO:0004601|	GO:0050665|GO:0006979|
GN016388.1	sp|A0A1X7T7W9|A0A1X7T7W9_AMPQE	2.8e-44	184.5	76.45%	47.60%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN016389.1	sp|K1QH93|K1QH93_CRAGI	1.1e-43	182.2	72.14%	57.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015624.1	sp|K1PFG3|K1PFG3_CRAGI	4.9e-222	776.2	100.00%	69.34%	McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0051082|	GO:0060271|GO:0006457|
GN016390.1	sp|K1S5J6|K1S5J6_CRAGI	1.2e-141	508.4	96.42%	66.76%	Apical endosomal glycoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN016391.1	sp|K1RFW3|K1RFW3_CRAGI	4.7e-55	219.2	100.00%	82.91%	Methionine aminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0004177|GO:0046872|GO:0008235|
GN016392.1	sp|K1RA73|K1RA73_CRAGI	1.5e-81	308.1	81.90%	84.44%	Canopy-like protein 2;OS=Crassostrea;PE=4;SV=1
GN016393.1	sp|K1Q2T1|K1Q2T1_CRAGI	9.0e-223	778.5	100.00%	77.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016394.1	sp|K1QNP3|K1QNP3_CRAGI	5.0e-127	459.5	100.00%	76.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016395.1	sp|A0A1S3H413|A0A1S3H413_LINUN	1.8e-36	157.9	96.36%	52.80%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN016396.1	sp|A0A210PYG0|A0A210PYG0_MIZYE	1.7e-18	98.2	56.36%	47.83%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015625.1	sp|K1PNB0|K1PNB0_CRAGI	6.3e-64	251.5	87.37%	31.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016399.1	sp|K1PGZ0|K1PGZ0_CRAGI	2.5e-17	93.6	60.82%	79.31%	Thyroid adenoma-associated protein;OS=Crassostrea;PE=4;SV=1
GN016400.1	sp|K1PGZ0|K1PGZ0_CRAGI	1.9e-194	684.5	92.22%	67.38%	Thyroid adenoma-associated protein;OS=Crassostrea;PE=4;SV=1
GN016401.1	sp|A0A194ALR6|A0A194ALR6_PINFU	7.5e-42	175.3	94.69%	71.70%	Putative iron-sulfur cluster assembly 2-like, mitochondrial-like protein;OS=Pinctada;PE=4;SV=1	GO:0051536|GO:0005198|	GO:0097428|
GN016402.1	sp|K1QNP9|K1QNP9_CRAGI	9.9e-172	608.2	100.00%	92.48%	Putative deoxyribose-phosphate aldolase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0004139|	GO:0009264|
GN016403.1	sp|K1R6Q6|K1R6Q6_CRAGI	9.9e-218	761.5	100.00%	82.96%	Calcium-independent protein kinase C;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004697|
GN016404.1	sp|K1RD54|K1RD54_CRAGI	7.0e-136	489.2	84.48%	85.82%	Kelch-like protein 2;OS=Crassostrea;PE=4;SV=1
GN015626.1	sp|K1P9B8|K1P9B8_CRAGI	1.6e-16	91.3	51.22%	75.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016405.1	sp|K1PNE2|K1PNE2_CRAGI	0.0e+00	1335.1	99.37%	75.10%	FERM domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005856|
GN016406.1	sp|K1PGZ0|K1PGZ0_CRAGI	1.0e-113	415.2	98.88%	75.67%	Thyroid adenoma-associated protein;OS=Crassostrea;PE=4;SV=1
GN016407.1	sp|A0A2C9LKR7|A0A2C9LKR7_BIOGL	1.6e-27	128.6	52.40%	55.46%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN015627.1	sp|C3Y2X9|C3Y2X9_BRAFL	2.4e-40	171.8	89.70%	32.59%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN016411.1	sp|K1R737|K1R737_CRAGI	4.6e-144	516.5	98.13%	62.32%	Cytochrome P450 2C8;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN016412.1	sp|K1QLW1|K1QLW1_CRAGI	2.1e-152	544.7	97.59%	58.01%	Nuclear receptor ROR-beta;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN016413.1	sp|K1RE44|K1RE44_CRAGI	2.3e-292	1010.0	99.70%	72.85%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN016414.1	sp|K1RE44|K1RE44_CRAGI	2.6e-291	1006.5	99.70%	72.55%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN015628.1	sp|K1P9B8|K1P9B8_CRAGI	7.0e-17	92.4	51.22%	77.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016415.1	sp|A0A210QGM0|A0A210QGM0_MIZYE	3.9e-84	318.2	92.14%	31.07%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003824|
GN016416.1	sp|K1P828|K1P828_CRAGI	3.4e-120	437.2	91.64%	64.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016417.1	sp|K1R9F6|K1R9F6_CRAGI	5.2e-73	279.6	99.52%	93.20%	Dead ringer-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN016418.1	sp|K1R9F6|K1R9F6_CRAGI	1.2e-80	304.7	99.38%	94.34%	Dead ringer-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN016419.1	sp|K1R9F6|K1R9F6_CRAGI	5.3e-30	136.0	83.19%	90.82%	Dead ringer-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN016420.1	sp|A0A210Q712|A0A210Q712_MIZYE	1.7e-41	176.0	92.74%	30.74%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016422.1	sp|A0A210Q712|A0A210Q712_MIZYE	5.9e-56	223.0	100.00%	60.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016424.1	sp|K1R737|K1R737_CRAGI	6.5e-146	522.7	98.96%	61.64%	Cytochrome P450 2C8;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN016425.1	sp|K1R737|K1R737_CRAGI	3.0e-188	663.7	99.58%	61.34%	Cytochrome P450 2C8;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN016426.1	sp|W4Z5F3|W4Z5F3_STRPU	3.8e-29	133.7	86.63%	43.92%	ATP-dependent DNA helicase;OS=Strongylocentrotus;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN016427.1	sp|K1QP46|K1QP46_CRAGI	2.8e-99	367.1	100.00%	84.35%	U3 small nucleolar RNA-associated protein 15-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005730|	GO:0006364|
GN016428.1	sp|K1QHI5|K1QHI5_CRAGI	0.0e+00	2222.6	100.00%	91.34%	Pyruvate carboxylase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0009374|GO:0046872|GO:0004736|	GO:0006094|GO:0006090|
GN016429.1	sp|A0A1S3J8P1|A0A1S3J8P1_LINUN	7.4e-115	420.6	62.42%	43.43%	TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L;OS=Lingula;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|	GO:0006357|GO:0006367|
GN015630.1	sp|A0A210QE28|A0A210QE28_MIZYE	5.4e-45	186.0	99.30%	62.14%	Calmodulin;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|	GO:0019722|
GN016432.1	sp|K1Q9H5|K1Q9H5_CRAGI	0.0e+00	1242.6	100.00%	85.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016433.1	sp|K1RKT7|K1RKT7_CRAGI	6.2e-31	139.4	67.11%	71.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016434.1	sp|K1R9F2|K1R9F2_CRAGI	4.9e-18	97.4	74.91%	54.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016435.1	sp|K1R677|K1R677_CRAGI	6.2e-54	216.1	96.13%	64.16%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN016436.1	sp|K1R9F2|K1R9F2_CRAGI	1.4e-39	168.3	85.96%	61.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015631.1	sp|K1PNB5|K1PNB5_CRAGI	1.6e-271	941.4	98.45%	88.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016439.1	sp|K1Q6V0|K1Q6V0_CRAGI	4.2e-65	252.7	98.45%	88.89%	Beta-hexosaminidase subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0004563|	GO:0005975|
GN016440.1	sp|A0A210QDW8|A0A210QDW8_MIZYE	4.3e-243	847.4	98.40%	35.25%	RNA-dependent RNA polymerase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003968|
GN016441.1	sp|K1QZ50|K1QZ50_CRAGI	8.3e-176	622.5	95.98%	60.32%	RNA-dependent RNA polymerase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003723|GO:0003968|
GN016442.1	sp|A0A210QDP4|A0A210QDP4_MIZYE	1.0e-245	855.9	100.00%	40.55%	RNA-dependent RNA polymerase;OS=Mizuhopecten;PE=3;SV=1	GO:0003723|GO:0003968|
GN016443.1	sp|A0A210QDP4|A0A210QDP4_MIZYE	5.0e-237	827.0	100.00%	39.26%	RNA-dependent RNA polymerase;OS=Mizuhopecten;PE=3;SV=1	GO:0003723|GO:0003968|
GN016444.1	sp|K1QZ50|K1QZ50_CRAGI	3.3e-169	600.5	97.25%	58.57%	RNA-dependent RNA polymerase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003723|GO:0003968|
GN015632.1	sp|A0A210QNT1|A0A210QNT1_MIZYE	1.1e-42	179.1	79.22%	47.54%	Tetratricopeptide repeat protein 9C;OS=Mizuhopecten;PE=4;SV=1
GN016448.1	sp|A0A210QWK6|A0A210QWK6_MIZYE	2.5e-117	427.6	100.00%	60.29%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN016449.1	sp|K1QZ44|K1QZ44_CRAGI	2.4e-136	490.7	99.70%	83.89%	Muscarinic acetylcholine receptor M3;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0016907|
GN015633.1	sp|K1PVQ8|K1PVQ8_CRAGI	1.3e-117	427.9	98.19%	94.91%	Eukaryotic translation initiation factor 3 subunit K;OS=Crassostrea;PE=3;SV=1	GO:0016282|GO:0033290|GO:0005852|	GO:0043022|GO:0003743|	GO:0001732|GO:0006446|
GN016450.1	sp|K1RVU7|K1RVU7_CRAGI	1.3e-153	548.9	100.00%	72.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016451.1	sp|K1RCJ3|K1RCJ3_CRAGI	1.6e-101	375.2	87.39%	62.38%	D-beta-hydroxybutyrate dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN016452.1	sp|A0A210QB58|A0A210QB58_MIZYE	1.5e-31	141.4	74.64%	60.78%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN016453.1	sp|A0A1W2W194|A0A1W2W194_CIOIN	1.5e-26	125.9	47.71%	42.41%	uncharacterized protein LOC100184639;OS=Ciona;PE=4;SV=1
GN016455.1	sp|K1PVU0|K1PVU0_CRAGI	5.8e-27	126.3	97.56%	41.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016456.1	sp|K1QK59|K1QK59_CRAGI	1.1e-77	295.0	93.94%	75.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016457.1	sp|K1QSL4|K1QSL4_CRAGI	1.9e-276	956.8	100.00%	83.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016458.1	sp|K1QZD9|K1QZD9_CRAGI	8.9e-172	609.0	94.93%	64.23%	Ladybird homeobox corepressor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046332|
GN016459.1	sp|K1RIZ0|K1RIZ0_CRAGI	2.0e-110	404.1	95.52%	83.96%	Angiopoietin-related protein 1;OS=Crassostrea;PE=4;SV=1
GN016460.1	sp|K1QS20|K1QS20_CRAGI	2.5e-31	142.1	34.90%	47.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016461.1	sp|A0A210R316|A0A210R316_MIZYE	1.8e-28	131.3	88.12%	45.45%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016463.1	sp|K1PHP0|K1PHP0_CRAGI	3.4e-206	723.4	99.62%	79.73%	RNA-binding protein MEX3C;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN016466.1	sp|K1QBM9|K1QBM9_CRAGI	2.6e-14	84.0	61.07%	48.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016468.1	sp|K1PZ48|K1PZ48_CRAGI	4.0e-172	609.8	100.00%	78.78%	Type-1B angiotensin II receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN016469.1	sp|K1QJ27|K1QJ27_CRAGI	1.8e-89	334.7	81.04%	70.05%	Cathepsin L;OS=Crassostrea;PE=3;SV=1	GO:0008234|
GN016470.1	sp|K1R662|K1R662_CRAGI	1.3e-145	521.5	100.00%	75.53%	Membrane progestin receptor beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016471.1	sp|K1PFP0|K1PFP0_CRAGI	7.3e-142	509.6	100.00%	90.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015635.1	sp|K1RKB9|K1RKB9_CRAGI	7.5e-38	162.5	63.69%	77.36%	Multiple coagulation factor deficiency protein 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003676|
GN016472.1	sp|K1PNH0|K1PNH0_CRAGI	2.7e-155	553.5	99.33%	85.37%	Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0006516|
GN016473.1	sp|K1PNH0|K1PNH0_CRAGI	3.5e-82	310.1	99.00%	72.14%	Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0006516|
GN016474.1	sp|K1PVU9|K1PVU9_CRAGI	1.2e-84	318.5	99.21%	65.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016475.1	sp|K1QHS0|K1QHS0_CRAGI	1.2e-60	238.0	100.00%	77.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016476.1	sp|K1P9H6|K1P9H6_CRAGI	1.9e-270	937.2	73.68%	92.84%	DNA polymerase epsilon subunit;OS=Crassostrea;PE=3;SV=1	GO:0008622|	GO:0003677|GO:0003887|	GO:0006261|
GN016477.1	sp|C8BLQ8|C8BLQ8_9BIVA	3.5e-74	283.9	66.92%	72.32%	Uncharacterized protein;OS=Crassostrea;PE=2;SV=1
GN016478.1	sp|K1Q8W0|K1Q8W0_CRAGI	1.4e-43	181.8	95.96%	48.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN016479.1	sp|V4ARM3|V4ARM3_LOTGI	2.4e-12	77.0	92.86%	44.44%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN016480.1	sp|A0A2R2MN13|A0A2R2MN13_LINUN	3.3e-32	143.7	98.71%	43.95%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN015636.1	sp|A0A1S3GZA4|A0A1S3GZA4_LINUN	3.2e-33	146.7	89.68%	67.24%	retinal homeobox protein Rx1-like;OS=Lingula;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN016481.1	sp|K1RFP0|K1RFP0_CRAGI	2.9e-31	140.6	87.34%	53.62%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016482.1	sp|K1PNE6|K1PNE6_CRAGI	4.5e-160	570.1	84.66%	66.27%	Protein flp;OS=Crassostrea;PE=4;SV=1
GN016483.1	sp|K1PP77|K1PP77_CRAGI	0.0e+00	2729.1	100.00%	68.62%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003723|GO:0005044|
GN016485.1	sp|A0A210PTC9|A0A210PTC9_MIZYE	6.0e-78	297.4	59.81%	48.06%	Folate gamma-glutamyl hydrolase;OS=Mizuhopecten;PE=4;SV=1	GO:0034722|
GN016486.1	sp|K1R7J5|K1R7J5_CRAGI	1.6e-28	132.1	47.64%	88.33%	Cell death specification protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN016488.1	sp|K1QKF7|K1QKF7_CRAGI	5.6e-64	249.2	99.35%	73.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN016490.1	sp|K1QY88|K1QY88_CRAGI	7.9e-76	290.0	98.36%	41.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN016491.1	sp|K1Q199|K1Q199_CRAGI	7.0e-40	168.7	81.25%	82.22%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016492.1	sp|K1QSJ1|K1QSJ1_CRAGI	1.9e-101	374.8	83.63%	60.71%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN016494.1	sp|K1QY88|K1QY88_CRAGI	7.9e-38	163.3	94.33%	37.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN016495.1	sp|V3ZX45|V3ZX45_LOTGI	6.0e-80	303.9	90.00%	40.32%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN015638.1	sp|K1PPF4|K1PPF4_CRAGI	7.4e-73	278.9	100.00%	76.61%	NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016651|	GO:0022900|
GN016496.1	sp|K1PY81|K1PY81_CRAGI	9.3e-35	152.5	86.63%	46.86%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016497.1	sp|K1Q1Z1|K1Q1Z1_CRAGI	9.6e-161	572.4	97.65%	61.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN016498.1	sp|K1Q939|K1Q939_CRAGI	1.5e-46	192.6	50.40%	50.52%	F-box only protein 18;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004003|GO:0003677|
GN016499.1	sp|A0A210QVC5|A0A210QVC5_MIZYE	0.0e+00	1337.0	99.71%	63.30%	Ubiquitin-like modifier-activating enzyme 6;OS=Mizuhopecten;PE=4;SV=1	GO:0008641|	GO:0006464|
GN016501.1	sp|K1RFP5|K1RFP5_CRAGI	7.5e-48	195.3	89.26%	82.24%	Neural cell adhesion molecule 1;OS=Crassostrea;PE=4;SV=1
GN015639.1	sp|K1QIJ1|K1QIJ1_CRAGI	1.4e-34	153.7	15.12%	71.00%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN016502.1	sp|A0A210QJQ5|A0A210QJQ5_MIZYE	3.0e-37	162.5	73.89%	24.28%	E3 ubiquitin-protein ligase TRIM71;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0008270|
GN016503.1	sp|K1PRQ0|K1PRQ0_CRAGI	4.4e-311	1072.4	92.51%	68.96%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN016504.1	sp|K1R466|K1R466_CRAGI	7.4e-81	305.4	97.70%	92.90%	T-complex protein 1 subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN016505.1	sp|K1R466|K1R466_CRAGI	3.1e-137	493.4	94.72%	86.01%	T-complex protein 1 subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN016506.1	sp|K1QBY8|K1QBY8_CRAGI	6.5e-297	1025.0	100.00%	83.50%	Vacuolar protein sorting-associated protein 33B;OS=Crassostrea;PE=3;SV=1	GO:0006904|
GN016507.1	sp|K1R1H7|K1R1H7_CRAGI	2.1e-162	578.2	98.72%	46.78%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016508.1	sp|K1QS36|K1QS36_CRAGI	1.8e-42	178.3	99.57%	42.98%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016509.1	sp|K1PQH5|K1PQH5_CRAGI	1.4e-79	302.0	99.67%	50.17%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN016510.1	sp|K1R462|K1R462_CRAGI	1.1e-171	609.0	99.68%	48.67%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016511.1	sp|K1PLB7|K1PLB7_CRAGI	1.9e-39	167.5	100.00%	61.94%	Toll-like receptor 2 type-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN016512.1	sp|K1PQH5|K1PQH5_CRAGI	1.7e-105	388.7	99.77%	46.76%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN016513.1	sp|A0A210QBZ8|A0A210QBZ8_MIZYE	3.8e-217	760.4	98.10%	54.59%	Small conductance calcium-activated potassium channel protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005516|GO:0016286|
GN016514.1	sp|S4S9Y8|S4S9Y8_9BIVA	4.8e-96	356.7	84.51%	80.48%	Estrogen receptor;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN015640.1	sp|K1QK49|K1QK49_CRAGI	1.6e-95	355.9	60.85%	54.36%	Down syndrome cell adhesion molecule;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016515.1	sp|K1PB87|K1PB87_CRAGI	3.8e-82	310.1	95.39%	58.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008168|
GN016516.1	sp|K1PIA5|K1PIA5_CRAGI	5.3e-37	160.2	96.25%	43.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016517.1	sp|K1PIS8|K1PIS8_CRAGI	1.1e-290	1005.0	100.00%	67.52%	CWF19-like protein 2;OS=Crassostrea;PE=4;SV=1
GN015641.1	sp|K1QTX5|K1QTX5_CRAGI	1.9e-128	464.9	90.42%	68.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016518.1	sp|A0A210R3Y9|A0A210R3Y9_MIZYE	2.6e-197	693.7	97.68%	67.74%	Cytochrome P450 4F12;OS=Mizuhopecten;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN016519.1	sp|K1Q4R1|K1Q4R1_CRAGI	2.7e-278	963.0	100.00%	80.33%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN016520.1	sp|K1PXR1|K1PXR1_CRAGI	3.8e-248	862.8	98.53%	74.77%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN016521.1	sp|K1Q473|K1Q473_CRAGI	1.1e-53	215.7	90.61%	48.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016522.1	sp|K1QMN2|K1QMN2_CRAGI	1.1e-169	602.4	97.19%	47.93%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016524.1	sp|K1PQH5|K1PQH5_CRAGI	8.5e-102	376.3	99.77%	46.30%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN015642.1	sp|K1R0Y6|K1R0Y6_CRAGI	8.6e-77	293.1	100.00%	50.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016526.1	sp|K1RDY5|K1RDY5_CRAGI	0.0e+00	2580.8	99.87%	78.43%	Linear gramicidin synthetase subunit D;OS=Crassostrea;PE=4;SV=1	GO:0016742|	GO:0009058|
GN016529.1	sp|A0A2B4S856|A0A2B4S856_STYPI	1.0e-10	72.4	97.56%	38.27%	Uncharacterized protein K02A2.6;OS=Stylophora;PE=4;SV=1
GN016530.1	sp|K1RDY5|K1RDY5_CRAGI	0.0e+00	2595.5	99.25%	78.56%	Linear gramicidin synthetase subunit D;OS=Crassostrea;PE=4;SV=1	GO:0016742|	GO:0009058|
GN016533.1	sp|A0A2L1K0V6|A0A2L1K0V6_CRAGI	1.5e-81	308.1	98.22%	66.52%	HIF-alpha prolyl 4-hydroxylases PHD2B isoform 2;OS=Crassostrea;PE=2;SV=1	GO:0046872|
GN016534.1	sp|A0A024D9V7|A0A024D9V7_MYTGA	1.3e-150	538.9	97.69%	50.90%	TNF receptor-associated factor 3;OS=Mytilus;PE=2;SV=1	GO:0005164|GO:0008270|	GO:0045087|GO:0032088|GO:0042981|GO:0001817|GO:0050688|GO:0008063|GO:0033209|
GN016535.1	sp|K1Q1V7|K1Q1V7_CRAGI	1.6e-62	245.0	94.54%	56.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016209|GO:0016491|
GN016536.1	sp|K1Q8W0|K1Q8W0_CRAGI	2.3e-83	314.7	99.10%	48.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN016539.1	sp|C8BLQ8|C8BLQ8_9BIVA	1.4e-78	298.5	67.04%	73.03%	Uncharacterized protein;OS=Crassostrea;PE=2;SV=1
GN016540.1	sp|K1R117|K1R117_CRAGI	6.4e-43	178.7	99.06%	71.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016541.1	sp|A0A3L5TRR6|A0A3L5TRR6_MYTGA	5.1e-50	203.8	70.21%	47.55%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN016542.1	sp|K1P0Y5|K1P0Y5_CRAGI	6.2e-54	216.9	54.37%	61.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016545.1	sp|K1P0Y5|K1P0Y5_CRAGI	2.2e-57	228.8	97.03%	38.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016546.1	sp|K1QTL5|K1QTL5_CRAGI	2.1e-52	211.1	100.00%	63.13%	Sjoegren syndrome/scleroderma autoantigen 1;OS=Crassostrea;PE=4;SV=1
GN015645.1	sp|A0A210QZ46|A0A210QZ46_MIZYE	6.4e-126	456.1	100.00%	64.52%	Tubulin polyglutamylase complex subunit 2;OS=Mizuhopecten;PE=4;SV=1	GO:0018095|
GN016548.1	sp|K1Q8W0|K1Q8W0_CRAGI	2.3e-83	314.7	99.10%	48.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN016550.1	sp|C8BLQ8|C8BLQ8_9BIVA	1.2e-78	298.1	100.00%	73.03%	Uncharacterized protein;OS=Crassostrea;PE=2;SV=1
GN016552.1	sp|K1PFK5|K1PFK5_CRAGI	2.0e-93	349.7	23.47%	71.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN016553.1	sp|K1PP25|K1PP25_CRAGI	9.6e-12	75.1	69.61%	49.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016554.1	sp|K1PP25|K1PP25_CRAGI	1.7e-12	77.4	83.52%	51.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016555.1	sp|K1PP25|K1PP25_CRAGI	2.6e-25	120.6	69.85%	62.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016556.1	sp|K1QIB4|K1QIB4_CRAGI	1.5e-96	358.6	90.36%	63.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016557.1	sp|K1QS96|K1QS96_CRAGI	4.3e-22	110.2	97.56%	69.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016558.1	sp|K1QZD3|K1QZD3_CRAGI	1.3e-117	429.9	44.38%	54.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016559.1	sp|K1R5P7|K1R5P7_CRAGI	1.3e-60	240.0	72.41%	68.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016560.1	sp|K1RQA8|K1RQA8_CRAGI	3.8e-112	410.2	99.67%	75.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016563.1	sp|K1QP68|K1QP68_CRAGI	3.2e-44	185.7	24.19%	54.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016564.1	sp|K1QPK0|K1QPK0_CRAGI	7.7e-260	901.7	97.74%	90.91%	RNA-binding protein Nova-1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN016566.1	sp|K1PWL3|K1PWL3_CRAGI	5.8e-108	396.7	79.32%	63.08%	Beta-2 adrenergic receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN016568.1	sp|K1QPJ5|K1QPJ5_CRAGI	2.8e-63	246.9	86.71%	80.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN016569.1	sp|K1RDU6|K1RDU6_CRAGI	3.8e-222	776.2	89.33%	95.51%	Regulator of G-protein signaling 7;OS=Crassostrea;PE=4;SV=1	GO:0007186|GO:0035556|GO:0008277|
GN016570.1	sp|A0A2C9KWY2|A0A2C9KWY2_BIOGL	4.0e-46	191.4	99.77%	39.37%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN015648.1	sp|K1R7E6|K1R7E6_CRAGI	9.4e-178	628.6	86.25%	84.01%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016573.1	sp|K1PIM0|K1PIM0_CRAGI	0.0e+00	1099.7	100.00%	67.24%	Circularly permutated Ras protein 1;OS=Crassostrea;PE=4;SV=1	GO:0030127|	GO:0005525|GO:0003924|GO:0008270|	GO:0006888|GO:0006886|GO:0007165|
GN016574.1	sp|K1PK04|K1PK04_CRAGI	1.0e-258	898.3	99.55%	67.47%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN016578.1	sp|K1QGB1|K1QGB1_CRAGI	5.0e-41	172.6	100.00%	84.48%	DNA polymerase epsilon subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0046982|
GN016579.1	sp|K1PA20|K1PA20_CRAGI	0.0e+00	1242.3	98.39%	71.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016580.1	sp|A0A210QYK8|A0A210QYK8_MIZYE	6.0e-67	260.0	94.50%	43.35%	Monoacylglycerol lipase ABHD12;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016581.1	sp|K1PP30|K1PP30_CRAGI	4.1e-132	476.9	99.74%	84.33%	F-box only protein 28;OS=Crassostrea;PE=4;SV=1
GN016582.1	sp|K1QGB4|K1QGB4_CRAGI	3.7e-67	259.6	100.00%	97.04%	40S ribosomal protein S17;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN016583.1	sp|K1PA22|K1PA22_CRAGI	1.1e-60	238.8	100.00%	88.84%	Osteoclast-stimulating factor 1;OS=Crassostrea;PE=4;SV=1
GN016584.1	sp|K1PWB9|K1PWB9_CRAGI	1.3e-109	401.4	100.00%	86.30%	EH domain-containing protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0005509|GO:0005525|	GO:0032456|
GN016585.1	sp|K1QGC0|K1QGC0_CRAGI	2.2e-63	246.9	99.17%	99.16%	Protein yippee-like;OS=Crassostrea;PE=3;SV=1	GO:0046872|
GN016586.1	sp|K1QC86|K1QC86_CRAGI	1.1e-64	251.9	81.09%	75.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016587.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	2590.5	54.12%	61.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN016588.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	2600.5	54.12%	61.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN016589.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	1270.4	62.71%	80.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN016590.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	3817.7	56.68%	64.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN016591.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	3829.6	56.68%	65.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN016592.1	sp|K1QBR5|K1QBR5_CRAGI	0.0e+00	3822.3	56.68%	64.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN016594.1	sp|K1QMF9|K1QMF9_CRAGI	5.1e-23	112.8	90.48%	45.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN016595.1	sp|K1QR68|K1QR68_CRAGI	5.6e-74	282.7	93.16%	71.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016596.1	sp|K1RDS3|K1RDS3_CRAGI	5.3e-46	189.1	100.00%	68.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016597.1	sp|K1P7T1|K1P7T1_CRAGI	1.4e-19	101.3	97.35%	54.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003676|
GN016598.1	sp|K1QLT5|K1QLT5_CRAGI	9.8e-226	788.1	89.33%	99.50%	26S protease regulatory subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0016788|GO:0008233|GO:0036402|	GO:0030163|
GN016599.1	sp|K1QF80|K1QF80_CRAGI	7.5e-65	255.8	28.42%	36.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016599.1	sp|K1QF80|K1QF80_CRAGI	7.3e-12	79.7	7.88%	39.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015652.1	sp|K1Q7U4|K1Q7U4_CRAGI	3.0e-21	107.1	50.00%	65.15%	F-box/WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN016604.1	sp|K1QQR2|K1QQR2_CRAGI	1.0e-19	101.3	100.00%	61.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016605.1	sp|K1Q764|K1Q764_CRAGI	1.4e-49	201.4	98.10%	69.48%	Protein SPEC3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016606.1	sp|K1PK61|K1PK61_CRAGI	3.1e-12	77.0	54.40%	51.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016607.1	sp|K1QLT1|K1QLT1_CRAGI	7.9e-100	369.0	98.81%	69.35%	15-hydroxyprostaglandin dehydrogenase [NAD+];OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN016608.1	sp|K1Q759|K1Q759_CRAGI	3.5e-136	490.7	57.35%	77.50%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN015653.1	sp|K1PUJ3|K1PUJ3_CRAGI	2.1e-135	488.0	91.54%	55.61%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016609.1	sp|A0A1X7UYM0|A0A1X7UYM0_AMPQE	5.6e-27	126.3	96.18%	47.06%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN016610.1	sp|K1QJ67|K1QJ67_CRAGI	1.5e-51	210.3	52.91%	44.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016611.1	sp|K1Q9D7|K1Q9D7_CRAGI	8.4e-197	692.2	100.00%	71.81%	Sorting nexin-2;OS=Crassostrea;PE=4;SV=1	GO:0005829|GO:0030904|	GO:0035091|	GO:0006886|GO:0042147|
GN016612.1	sp|K1QHF3|K1QHF3_CRAGI	1.7e-48	197.6	89.47%	85.71%	Alpha-endosulfine;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004864|	GO:0007049|GO:0051301|
GN016613.1	sp|K1QNZ7|K1QNZ7_CRAGI	8.5e-118	429.9	100.00%	79.34%	Ubiquilin-1;OS=Crassostrea;PE=4;SV=1
GN016615.1	sp|K1PY25|K1PY25_CRAGI	1.9e-174	618.2	97.02%	49.44%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN016616.1	sp|K1R6J1|K1R6J1_CRAGI	4.9e-11	73.9	49.36%	35.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016617.1	sp|K1R6J1|K1R6J1_CRAGI	2.7e-36	157.5	94.68%	52.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016619.1	sp|A0A210PQ49|A0A210PQ49_MIZYE	5.4e-76	290.4	85.34%	49.70%	FMRFamide receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008528|
GN016620.1	sp|K1PR91|K1PR91_CRAGI	4.5e-78	296.6	96.89%	69.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016622.1	sp|K1QF44|K1QF44_CRAGI	1.2e-198	698.0	100.00%	82.93%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016623.1	sp|K1PV21|K1PV21_CRAGI	1.1e-110	405.6	90.81%	69.44%	Ileal sodium/bile acid cotransporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016624.1	sp|K1PMP7|K1PMP7_CRAGI	2.3e-40	170.6	85.21%	70.00%	Ileal sodium/bile acid cotransporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016625.1	sp|A0A210PSA8|A0A210PSA8_MIZYE	2.8e-58	232.6	85.43%	26.91%	Polycystic kidney disease protein 1-like 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN016626.1	sp|A0A210PS86|A0A210PS86_MIZYE	3.8e-269	934.1	88.89%	38.72%	Location of vulva defective 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN016627.1	sp|K1RA27|K1RA27_CRAGI	6.4e-58	229.6	99.53%	58.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016628.1	sp|A0A2B4RG89|A0A2B4RG89_STYPI	2.8e-27	127.5	77.71%	42.22%	Gypsy retrotransposon integrase-like protein 1;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0004803|	GO:0015074|GO:0006313|
GN015654.1	sp|K1P8F1|K1P8F1_CRAGI	1.2e-188	665.2	99.28%	63.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016629.1	sp|K1R8S8|K1R8S8_CRAGI	2.2e-95	354.4	95.62%	71.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016630.1	sp|K1PK04|K1PK04_CRAGI	1.4e-252	877.9	99.85%	66.52%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN016631.1	sp|K1RI31|K1RI31_CRAGI	1.2e-253	881.7	97.04%	55.60%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN016632.1	sp|K1PSP9|K1PSP9_CRAGI	2.4e-252	877.1	99.85%	66.87%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN016633.1	sp|K1RA27|K1RA27_CRAGI	1.5e-59	235.0	99.53%	60.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016634.1	sp|V4A343|V4A343_LOTGI	2.1e-09	68.6	74.47%	31.22%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005525|
GN016635.1	sp|K1RIW4|K1RIW4_CRAGI	1.1e-86	326.6	91.42%	34.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016636.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	8.2e-27	126.7	67.66%	37.85%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN016637.1	sp|K1RXL3|K1RXL3_CRAGI	1.7e-108	397.9	96.68%	73.95%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN016638.1	sp|K1RXL3|K1RXL3_CRAGI	2.7e-107	394.0	90.03%	73.18%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN015655.1	sp|K1PEI7|K1PEI7_CRAGI	0.0e+00	1096.3	68.60%	76.90%	OTU domain-containing protein 7B;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN016639.1	sp|A0A2C9M7I4|A0A2C9M7I4_BIOGL	5.1e-13	80.1	77.59%	31.39%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN016640.1	sp|K1QS39|K1QS39_CRAGI	6.9e-32	141.7	96.47%	83.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016641.1	sp|K1RXK6|K1RXK6_CRAGI	3.9e-98	364.4	78.77%	48.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016644.1	sp|K1R1H2|K1R1H2_CRAGI	0.0e+00	1449.5	58.47%	79.60%	Leucine-rich repeat serine/threonine-protein kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|
GN015656.1	sp|K1PUK3|K1PUK3_CRAGI	5.5e-122	443.0	89.34%	79.23%	Armadillo repeat-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN016645.1	sp|K1R7L8|K1R7L8_CRAGI	1.4e-145	521.2	99.63%	94.16%	Paired box protein Pax-9;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0007275|
GN016646.1	sp|K1RXL3|K1RXL3_CRAGI	1.7e-108	397.9	96.68%	73.95%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN016647.1	sp|K1RXM1|K1RXM1_CRAGI	1.4e-206	724.5	100.00%	78.38%	Repulsive guidance molecule A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016649.1	sp|K1R6F9|K1R6F9_CRAGI	1.1e-127	462.6	96.87%	79.35%	DNA polymerase kappa;OS=Crassostrea;PE=3;SV=1	GO:0003684|GO:0003887|	GO:0006281|
GN015657.1	sp|K1P486|K1P486_CRAGI	8.9e-118	429.9	97.97%	41.10%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN016650.1	sp|K1QZM9|K1QZM9_CRAGI	3.8e-79	300.4	92.39%	68.87%	Spindle and kinetochore-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008017|	GO:0051301|GO:0007059|
GN016653.1	sp|K1QZM9|K1QZM9_CRAGI	2.2e-79	301.2	92.39%	63.04%	Spindle and kinetochore-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008017|	GO:0051301|GO:0007059|
GN016654.1	sp|K1R6F9|K1R6F9_CRAGI	1.1e-127	462.6	96.87%	79.35%	DNA polymerase kappa;OS=Crassostrea;PE=3;SV=1	GO:0003684|GO:0003887|	GO:0006281|
GN015658.1	sp|K1PFP3|K1PFP3_CRAGI	2.4e-16	90.5	91.74%	51.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016655.1	sp|K1RI78|K1RI78_CRAGI	1.0e-86	325.1	99.49%	76.65%	Pyroglutamyl-peptidase 1;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0016920|
GN016656.1	sp|K1RW88|K1RW88_CRAGI	1.6e-181	642.5	99.91%	55.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016657.1	sp|K1RW88|K1RW88_CRAGI	2.5e-103	382.1	99.86%	45.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016658.1	sp|K1RCV9|K1RCV9_CRAGI	1.8e-98	364.0	100.00%	93.89%	Adenylate kinase isoenzyme 6 homolog;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0004017|GO:0005524|GO:0016887|
GN016659.1	sp|K1R6F7|K1R6F7_CRAGI	1.4e-144	518.1	100.00%	80.92%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003950|
GN016660.1	sp|K1QZM5|K1QZM5_CRAGI	0.0e+00	1143.6	98.60%	79.44%	Rho guanine nucleotide exchange factor 10;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN016661.1	sp|K1R6F7|K1R6F7_CRAGI	1.4e-144	518.1	100.00%	80.92%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003950|
GN016662.1	sp|K1QZM5|K1QZM5_CRAGI	0.0e+00	1695.6	99.82%	78.24%	Rho guanine nucleotide exchange factor 10;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN016663.1	sp|K1Q8H3|K1Q8H3_CRAGI	2.7e-256	890.2	68.75%	89.59%	Tyrosyl-DNA phosphodiesterase 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008081|	GO:0006281|
GN016664.1	sp|K1Q1C8|K1Q1C8_CRAGI	3.3e-105	386.3	100.00%	96.00%	B9 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN015659.1	sp|K1QEQ4|K1QEQ4_CRAGI	2.3e-26	126.7	20.44%	43.26%	Zinc finger and BTB domain-containing protein 24;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016665.1	sp|K1R8E9|K1R8E9_CRAGI	7.5e-128	462.6	98.34%	51.23%	Protein arginine methyltransferase NDUFAF7;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0008168|
GN016666.1	sp|K1QN22|K1QN22_CRAGI	7.6e-218	761.9	92.81%	85.92%	ERO1-like protein beta;OS=Crassostrea;PE=4;SV=1	GO:0005783|	GO:0016671|GO:0003756|
GN016667.1	sp|K1QGL6|K1QGL6_CRAGI	2.8e-120	437.2	89.83%	75.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0031418|GO:0016705|
GN016668.1	sp|K1Q8G9|K1Q8G9_CRAGI	2.9e-221	773.9	74.45%	80.12%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016669.1	sp|K1R8E7|K1R8E7_CRAGI	5.7e-126	457.2	52.76%	70.11%	Coiled-coil domain-containing protein 85C;OS=Crassostrea;PE=4;SV=1
GN016673.1	sp|K1QVR6|K1QVR6_CRAGI	3.6e-68	263.8	83.00%	55.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015660.1	sp|K1QD02|K1QD02_CRAGI	8.8e-192	675.6	84.62%	71.82%	tRNA modification GTPase GTPBP3, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0003924|	GO:0006400|
GN016677.1	sp|V4AGJ7|V4AGJ7_LOTGI	3.1e-32	144.4	76.64%	42.25%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN016678.1	sp|K1RG19|K1RG19_CRAGI	8.0e-144	516.2	65.00%	80.62%	Protein FAM98A;OS=Crassostrea;PE=4;SV=1
GN016679.1	sp|K1QVR0|K1QVR0_CRAGI	1.0e-147	528.5	80.61%	98.49%	26S proteasome non-ATPase regulatory subunit 8;OS=Crassostrea;PE=4;SV=1	GO:0005838|	GO:0006508|
GN015661.1	sp|K1PUT5|K1PUT5_CRAGI	2.2e-28	130.6	72.65%	65.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016681.1	sp|K1R987|K1R987_CRAGI	8.5e-246	855.1	100.00%	76.49%	Enhanced at puberty protein 1-like protein B;OS=Crassostrea;PE=4;SV=1
GN016682.1	sp|K1QLL1|K1QLL1_CRAGI	2.4e-301	1039.6	98.12%	87.94%	Acetyl-coenzyme A synthetase;OS=Crassostrea;PE=3;SV=1	GO:0003987|GO:0016208|GO:0005524|	GO:0019427|
GN016683.1	sp|K1RT10|K1RT10_CRAGI	1.2e-135	488.8	75.34%	72.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016684.1	sp|K1R2F6|K1R2F6_CRAGI	5.0e-94	349.4	94.79%	88.72%	DNA replication complex GINS protein PSF1;OS=Crassostrea;PE=4;SV=1	GO:0000811|	GO:0006260|
GN016685.1	sp|K1QVQ8|K1QVQ8_CRAGI	9.2e-113	412.5	97.83%	68.29%	NF-kappa-B inhibitor cactus;OS=Crassostrea;PE=4;SV=1
GN016688.1	sp|A0A2B4S7J7|A0A2B4S7J7_STYPI	5.5e-14	82.4	98.92%	42.86%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN016689.1	sp|K1PYH4|K1PYH4_CRAGI	0.0e+00	1176.0	96.15%	64.02%	Thioredoxin domain-containing protein 16;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN016691.1	sp|K1S4M2|K1S4M2_CRAGI	0.0e+00	1307.0	100.00%	71.64%	X-linked retinitis pigmentosa GTPase regulator;OS=Crassostrea;PE=4;SV=1
GN016693.1	sp|K1RL83|K1RL83_CRAGI	5.8e-194	682.6	87.80%	70.54%	Protein flp;OS=Crassostrea;PE=4;SV=1
GN016694.1	sp|K1S4M9|K1S4M9_CRAGI	8.2e-240	835.1	98.86%	76.86%	Penicillin-binding protein 4;OS=Crassostrea;PE=4;SV=1
GN015664.1	sp|K1QKR4|K1QKR4_CRAGI	8.2e-59	233.4	83.21%	39.82%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN016695.1	sp|K1QNS2|K1QNS2_CRAGI	1.5e-42	177.6	98.26%	73.04%	Transient receptor potential cation channel subfamily M member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN016696.1	sp|A0A1X7UEV0|A0A1X7UEV0_AMPQE	8.7e-46	190.7	58.38%	32.73%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046872|
GN016697.1	sp|A0A210PZ53|A0A210PZ53_MIZYE	3.8e-49	200.7	99.61%	38.28%	Sulfotransferase 1C4;OS=Mizuhopecten;PE=4;SV=1	GO:0008146|
GN016699.1	sp|K1QZY0|K1QZY0_CRAGI	1.2e-78	298.5	90.83%	65.55%	DBH-like monooxygenase protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005507|GO:0016715|
GN015541.1	sp|K1QV93|K1QV93_CRAGI	2.3e-75	288.9	88.17%	33.00%	Low-density lipoprotein receptor-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015665.1	sp|K1QLT1|K1QLT1_CRAGI	6.2e-52	209.9	95.69%	40.87%	15-hydroxyprostaglandin dehydrogenase [NAD+];OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN016700.1	sp|A0A183LX04|A0A183LX04_9TREM	1.5e-15	87.8	87.62%	44.57%	Uncharacterized protein;OS=Schistosoma;PE=4;SV=1
GN016701.1	sp|K1PUT5|K1PUT5_CRAGI	3.8e-30	136.3	75.89%	69.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016702.1	sp|A0A210QZ56|A0A210QZ56_MIZYE	8.8e-33	148.7	30.24%	27.67%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016704.1	sp|K1R507|K1R507_CRAGI	2.9e-74	283.9	89.35%	65.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016705.1	sp|K1QS72|K1QS72_CRAGI	1.8e-229	800.8	72.18%	96.09%	BTB/POZ domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN015666.1	sp|K1RCM3|K1RCM3_CRAGI	3.2e-29	133.7	68.53%	61.86%	Carbonic anhydrase 2;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|
GN016706.1	sp|K1QI94|K1QI94_CRAGI	0.0e+00	1405.6	95.63%	84.15%	3-hydroxy-3-methylglutaryl coenzyme A reductase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0004420|GO:0050661|	GO:0015936|GO:0008299|
GN016707.1	sp|K1RQ81|K1RQ81_CRAGI	3.4e-155	553.1	100.00%	92.98%	Uncharacterized protein C15orf26-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN016710.1	sp|A0A194AL83|A0A194AL83_PINFU	1.3e-58	231.9	94.26%	54.31%	Putative ganglioside GM2 activator-like protein;OS=Pinctada;PE=4;SV=1	GO:0008047|	GO:0006689|
GN016711.1	sp|V4BHI4|V4BHI4_LOTGI	1.8e-59	236.1	97.50%	32.62%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN016712.1	sp|K1PIL4|K1PIL4_CRAGI	1.8e-12	79.0	52.38%	34.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016713.1	sp|K1QLK4|K1QLK4_CRAGI	1.4e-72	279.6	79.81%	39.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015667.1	sp|K1QSG0|K1QSG0_CRAGI	4.8e-125	453.0	98.97%	69.97%	Carbonic anhydrase 2;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|
GN016715.1	sp|K1QQL7|K1QQL7_CRAGI	2.1e-304	1050.0	86.87%	81.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016810|	GO:0005975|
GN016716.1	sp|K1PKG5|K1PKG5_CRAGI	2.6e-269	933.3	100.00%	96.78%	Fem-1-like protein C;OS=Crassostrea;PE=4;SV=1
GN016717.1	sp|K1PTD4|K1PTD4_CRAGI	1.1e-262	911.4	99.84%	66.51%	SITS-binding protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004553|	GO:0005975|
GN016718.1	sp|A0A1S3IPL5|A0A1S3IPL5_LINUN	4.5e-26	123.2	89.93%	48.15%	E3 ubiquitin-protein ligase TRAF7-like;OS=Lingula;PE=4;SV=1	GO:0016874|GO:0046872|
GN016720.1	sp|A0A0P4WGA4|A0A0P4WGA4_9EUCA	2.9e-100	371.3	98.70%	40.00%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN016722.1	sp|K1RDG8|K1RDG8_CRAGI	1.1e-85	322.0	100.00%	67.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015669.1	sp|K1QS69|K1QS69_CRAGI	1.1e-28	132.1	89.77%	43.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016725.1	sp|K1QDU8|K1QDU8_CRAGI	0.0e+00	1518.4	91.41%	82.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004842|
GN016726.1	sp|A0A210Q0C9|A0A210Q0C9_MIZYE	8.8e-173	612.5	99.81%	55.89%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016727.1	sp|K1RDG4|K1RDG4_CRAGI	0.0e+00	1276.2	98.65%	96.04%	DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003688|GO:0004386|	GO:0006270|
GN016728.1	sp|A0A210PQ73|A0A210PQ73_MIZYE	8.8e-255	885.6	92.99%	50.23%	Tankyrase-1;OS=Mizuhopecten;PE=4;SV=1
GN016729.1	sp|A0A194APN9|A0A194APN9_PINFU	1.4e-51	208.0	98.63%	67.13%	Glutaredoxin;OS=Pinctada;PE=3;SV=1	GO:0005623|	GO:0051537|GO:0009055|GO:0046872|GO:0015035|	GO:0045454|
GN016730.1	sp|A0A210PQ56|A0A210PQ56_MIZYE	8.9e-178	629.8	84.84%	49.48%	Cyclic nucleotide-gated channel rod photoreceptor subunit alpha;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005216|
GN016731.1	sp|A0A1W3JFX7|A0A1W3JFX7_CIOIN	2.9e-14	84.3	61.05%	40.83%	complement C1q tumor necrosis factor-related protein 4-like;OS=Ciona;PE=4;SV=1
GN016732.1	sp|A0A210QI37|A0A210QI37_MIZYE	2.6e-35	154.1	100.00%	52.87%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016733.1	sp|K1QC81|K1QC81_CRAGI	0.0e+00	1267.3	100.00%	84.17%	Dynein intermediate chain 2, ciliary;OS=Crassostrea;PE=4;SV=1
GN016734.1	sp|K1PRP6|K1PRP6_CRAGI	5.2e-45	185.7	100.00%	87.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016735.1	sp|A0A0C9S0G1|A0A0C9S0G1_AMBAM	2.5e-15	88.2	41.53%	44.90%	Putative ubiquinone oxidoreductase b16.6 subunit/cell death-regulatory protein;OS=Amblyomma;PE=2;SV=1	GO:0016021|
GN016736.1	sp|A0A2C9L0J7|A0A2C9L0J7_BIOGL	1.7e-67	261.9	85.94%	47.10%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN016737.1	sp|K1P643|K1P643_CRAGI	1.3e-155	555.4	77.11%	74.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN016738.1	sp|K1QJN2|K1QJN2_CRAGI	9.9e-24	114.4	100.00%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN016739.1	sp|K1QC61|K1QC61_CRAGI	8.6e-267	924.9	99.48%	76.27%	Steryl-sulfatase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008484|
GN016740.1	sp|K1PRM6|K1PRM6_CRAGI	0.0e+00	1122.5	100.00%	89.70%	Ankyrin repeat-containing protein C20orf12-like protein;OS=Crassostrea;PE=4;SV=1
GN016741.1	sp|A0A210Q5L1|A0A210Q5L1_MIZYE	4.3e-77	293.9	93.07%	43.69%	Membrane progestin receptor alpha-B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016742.1	sp|K1PWN0|K1PWN0_CRAGI	1.7e-28	132.1	50.00%	47.69%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN016743.1	sp|K1PJH4|K1PJH4_CRAGI	2.2e-165	587.0	100.00%	95.59%	Homeobox protein SIX1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0048513|GO:0006915|GO:0008283|
GN016745.1	sp|K1PF67|K1PF67_CRAGI	3.6e-39	166.4	97.41%	75.00%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN016746.1	sp|K1QJJ7|K1QJJ7_CRAGI	8.2e-69	266.5	51.60%	61.46%	Fumarylacetoacetate hydrolase domain-containing protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN016747.1	sp|K1PF67|K1PF67_CRAGI	6.5e-81	305.8	100.00%	75.38%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN016748.1	sp|K1PMY9|K1PMY9_CRAGI	1.2e-61	241.9	83.08%	72.78%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN016749.1	sp|K1QFB5|K1QFB5_CRAGI	3.5e-236	823.5	97.33%	59.60%	DNA polymerase iota;OS=Crassostrea;PE=4;SV=1	GO:0003684|	GO:0006281|
GN016750.1	sp|K1Q852|K1Q852_CRAGI	3.7e-139	500.7	90.89%	51.80%	Ubiquitin-conjugating enzyme E2 R2;OS=Crassostrea;PE=3;SV=1	GO:0004518|GO:0016740|	GO:0006281|
GN015673.1	sp|K1Q5I4|K1Q5I4_CRAGI	1.4e-245	854.0	100.00%	98.42%	COP9 signalosome complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0008180|
GN016752.1	sp|A0A1S3K4X7|A0A1S3K4X7_LINUN	6.3e-124	450.7	99.74%	38.59%	uncharacterized protein LOC106178715;OS=Lingula;PE=4;SV=1	GO:0005509|
GN016754.1	sp|A0A1S3K4X7|A0A1S3K4X7_LINUN	7.0e-123	447.2	99.74%	38.59%	uncharacterized protein LOC106178715;OS=Lingula;PE=4;SV=1	GO:0005509|
GN016755.1	sp|K1RMG0|K1RMG0_CRAGI	1.4e-238	831.6	93.61%	63.35%	Snurportin-1;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0004484|	GO:0006370|GO:0061015|
GN016756.1	sp|K1Q8J1|K1Q8J1_CRAGI	2.0e-33	147.1	75.96%	98.72%	DnaJ-like protein subfamily C member 17;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016757.1	sp|K1RC00|K1RC00_CRAGI	4.4e-19	99.8	96.77%	47.06%	Phosphorylase b kinase regulatory subunit;OS=Crassostrea;PE=3;SV=1	GO:0005886|	GO:0005516|GO:0016301|	GO:0005977|
GN016758.1	sp|K1RFW1|K1RFW1_CRAGI	1.3e-47	195.3	78.97%	53.57%	Putative sulfite oxidase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0020037|GO:0030151|GO:0043546|GO:0016491|GO:0004888|	GO:0042128|
GN016759.1	sp|K1S5J4|K1S5J4_CRAGI	7.5e-18	97.8	15.95%	52.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016760.1	sp|K1QUG5|K1QUG5_CRAGI	7.9e-228	795.0	100.00%	87.98%	PDF receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN016761.1	sp|K1PMG6|K1PMG6_CRAGI	5.5e-105	386.3	100.00%	74.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016762.1	sp|K1PU50|K1PU50_CRAGI	2.8e-54	218.4	45.64%	58.92%	Leucine-rich repeat-containing protein 28;OS=Crassostrea;PE=4;SV=1
GN016763.1	sp|K1Q8J5|K1Q8J5_CRAGI	6.3e-67	258.8	98.55%	91.11%	Uncharacterized protein C5orf48-like protein;OS=Crassostrea;PE=4;SV=1
GN016764.1	sp|K1QUG9|K1QUG9_CRAGI	6.6e-155	552.7	99.77%	69.68%	G patch domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016765.1	sp|K1PMH0|K1PMH0_CRAGI	1.6e-125	454.9	98.61%	64.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015542.1	sp|K1QJN2|K1QJN2_CRAGI	1.1e-54	219.2	52.42%	79.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN015674.1	sp|K1R190|K1R190_CRAGI	2.9e-12	77.4	87.01%	47.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016767.1	sp|K1Q8J9|K1Q8J9_CRAGI	1.3e-236	825.1	94.06%	83.69%	Coiled-coil domain-containing protein C6orf97;OS=Crassostrea;PE=4;SV=1
GN016769.1	sp|K1QUH5|K1QUH5_CRAGI	9.6e-125	451.8	97.69%	81.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0051998|
GN016772.1	sp|A0A3L5TTL7|A0A3L5TTL7_MYTGA	4.5e-10	69.7	53.10%	47.46%	N-acetyltransferase 6-like;OS=Mytilus;PE=4;SV=1
GN016773.1	sp|K1PMH4|K1PMH4_CRAGI	3.5e-86	323.2	100.00%	82.39%	Gamma-glutamylcyclotransferase;OS=Crassostrea;PE=3;SV=1	GO:0003839|GO:0061928|	GO:0006751|
GN016774.1	sp|K1PU58|K1PU58_CRAGI	4.2e-105	386.7	100.00%	77.82%	Palmitoyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0019706|
GN016775.1	sp|K1Q1H1|K1Q1H1_CRAGI	6.6e-83	313.2	96.28%	63.41%	Splicing factor, arginine/serine-rich 7;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN016777.1	sp|A0A210QAD6|A0A210QAD6_MIZYE	4.0e-119	433.3	100.00%	77.13%	Potassium channel subfamily K member 12;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005267|
GN016778.1	sp|K1RB07|K1RB07_CRAGI	5.9e-49	198.7	96.15%	92.93%	60S ribosomal protein L27a;OS=Crassostrea;PE=3;SV=1	GO:0015934|	GO:0003735|	GO:0006412|
GN016779.1	sp|K1P912|K1P912_CRAGI	2.6e-31	140.2	95.41%	60.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015675.1	sp|K1PT38|K1PT38_CRAGI	6.5e-129	466.8	90.75%	45.07%	Carnitine O-palmitoyltransferase 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0016746|
GN016782.1	sp|A0A210QAD6|A0A210QAD6_MIZYE	4.0e-119	433.3	100.00%	77.13%	Potassium channel subfamily K member 12;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005267|
GN016783.1	sp|A0A1S3H413|A0A1S3H413_LINUN	5.0e-34	149.8	91.07%	47.40%	unconventional myosin-Vb;OS=Lingula;PE=4;SV=1
GN016784.1	sp|K1RAM2|K1RAM2_CRAGI	3.3e-53	214.9	94.94%	82.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016785.1	sp|K1PK42|K1PK42_CRAGI	1.1e-168	599.0	98.76%	57.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016786.1	sp|K1RNC0|K1RNC0_CRAGI	1.2e-309	1067.4	99.84%	76.80%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015676.1	sp|A0A2S2P439|A0A2S2P439_SCHGA	1.5e-16	92.8	53.62%	30.11%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN016787.1	sp|K1RH48|K1RH48_CRAGI	0.0e+00	1900.9	98.71%	46.28%	Breast cancer type 2 susceptibility-like protein;OS=Crassostrea;PE=4;SV=1	GO:0000724|
GN016788.1	sp|K1RBG0|K1RBG0_CRAGI	3.9e-61	240.7	90.97%	45.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016789.1	sp|K1Q0L6|K1Q0L6_CRAGI	9.9e-266	921.8	98.23%	55.98%	Serine/threonine-protein kinase Nek10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0005507|GO:0008131|GO:0004672|GO:0048038|	GO:0009308|
GN016790.1	sp|K1Q0L6|K1Q0L6_CRAGI	8.4e-265	918.7	98.23%	55.80%	Serine/threonine-protein kinase Nek10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0005507|GO:0008131|GO:0004672|GO:0048038|	GO:0009308|
GN016792.1	sp|K1Q0L6|K1Q0L6_CRAGI	4.0e-40	170.6	95.85%	38.26%	Serine/threonine-protein kinase Nek10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0005507|GO:0008131|GO:0004672|GO:0048038|	GO:0009308|
GN016793.1	sp|K1Q0L6|K1Q0L6_CRAGI	1.2e-201	708.4	99.81%	61.79%	Serine/threonine-protein kinase Nek10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0005507|GO:0008131|GO:0004672|GO:0048038|	GO:0009308|
GN016794.1	sp|K1RNB6|K1RNB6_CRAGI	3.7e-280	969.1	94.99%	91.19%	Alpha-aminoadipic semialdehyde dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN015677.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	4.9e-19	99.8	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN016795.1	sp|K1Q2W4|K1Q2W4_CRAGI	3.7e-283	979.2	100.00%	84.21%	Transcription intermediary factor 1-alpha;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016797.1	sp|K1RRD7|K1RRD7_CRAGI	1.1e-67	261.5	100.00%	71.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016798.1	sp|K1R1D1|K1R1D1_CRAGI	1.8e-200	704.1	100.00%	83.49%	Myosin-10;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0008061|	GO:0006030|
GN016799.1	sp|K1RKW5|K1RKW5_CRAGI	2.4e-124	451.1	97.42%	63.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016800.1	sp|K1PBV0|K1PBV0_CRAGI	6.8e-193	678.7	100.00%	90.16%	UDP-glucose 6-dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0003979|
GN016801.1	sp|K1RDM4|K1RDM4_CRAGI	6.8e-14	82.4	46.96%	69.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016802.1	sp|A0A210PRH0|A0A210PRH0_MIZYE	0.0e+00	1171.8	99.57%	57.37%	Kinesin-like calmodulin-binding protein-like;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN016803.1	sp|K1Q8T2|K1Q8T2_CRAGI	0.0e+00	1434.1	94.85%	70.69%	A disintegrin and metalloproteinase with thrombospondin motifs 16;OS=Crassostrea;PE=4;SV=1	GO:0008233|	GO:0007229|
GN016804.1	sp|A0A1X7T0L5|A0A1X7T0L5_AMPQE	8.6e-21	106.3	88.00%	29.27%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN016805.1	sp|K1S0V2|K1S0V2_CRAGI	5.9e-17	93.2	72.47%	39.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016806.1	sp|A0A210PFJ3|A0A210PFJ3_MIZYE	3.5e-31	142.5	37.99%	30.47%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|GO:0004842|
GN016807.1	sp|K1PMP9|K1PMP9_CRAGI	1.5e-200	704.1	100.00%	94.44%	Cyclin-dependent kinase-like 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN016808.1	sp|A0A210QP31|A0A210QP31_MIZYE	2.9e-187	660.2	100.00%	75.36%	BRO1 domain-containing protein BROX;OS=Mizuhopecten;PE=4;SV=1
GN016809.1	sp|K1QWT1|K1QWT1_CRAGI	8.4e-102	377.1	57.50%	45.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016810.1	sp|K1QWT1|K1QWT1_CRAGI	9.9e-103	380.2	55.98%	46.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016811.1	sp|K1QB32|K1QB32_CRAGI	8.8e-194	682.2	85.63%	75.55%	Legumain;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008233|
GN016812.1	sp|K1QWW2|K1QWW2_CRAGI	1.3e-17	95.9	43.31%	47.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015679.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-15	87.8	96.51%	51.19%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN016813.1	sp|C3Z4A7|C3Z4A7_BRAFL	1.9e-58	231.5	93.25%	47.62%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN016815.1	sp|K1PFP3|K1PFP3_CRAGI	7.6e-38	162.9	82.43%	53.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016816.1	sp|K1PHY5|K1PHY5_CRAGI	3.4e-49	199.9	100.00%	76.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016817.1	sp|K1RGV7|K1RGV7_CRAGI	3.5e-148	530.8	96.82%	49.37%	Diphosphomevalonate decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0005524|GO:0004163|	GO:0019287|
GN016820.1	sp|K1Q5N1|K1Q5N1_CRAGI	1.7e-108	397.5	100.00%	92.65%	Sperm-associated antigen 8;OS=Crassostrea;PE=4;SV=1	GO:0008017|
GN016821.1	sp|K1PRH0|K1PRH0_CRAGI	1.1e-145	521.5	100.00%	87.67%	Solute carrier family 25 member 44;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN016822.1	sp|K1PJQ3|K1PJQ3_CRAGI	1.3e-58	232.6	64.43%	58.95%	U11/U12 small nuclear ribonucleoprotein 48 kDa protein;OS=Crassostrea;PE=4;SV=1	GO:0019013|
GN016824.1	sp|K1PV26|K1PV26_CRAGI	1.4e-17	95.5	76.70%	38.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016825.1	sp|K1PYS4|K1PYS4_CRAGI	1.2e-191	674.9	84.70%	84.44%	Elongation factor Tu, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0003746|
GN016826.1	sp|K1Q036|K1Q036_CRAGI	6.6e-17	93.2	96.48%	38.81%	Solute carrier family 22 member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|	GO:0055085|
GN016827.1	sp|A0A210QW99|A0A210QW99_MIZYE	1.2e-30	139.0	72.37%	42.42%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016828.1	sp|K1Q5N5|K1Q5N5_CRAGI	3.5e-276	956.4	95.18%	69.19%	Uncharacterized protein C18H10.09;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016829.1	sp|K1QRQ3|K1QRQ3_CRAGI	3.9e-180	637.1	94.41%	61.76%	Ubiquitin-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000813|	GO:0043130|	GO:0043162|
GN016830.1	sp|K1PJQ9|K1PJQ9_CRAGI	2.1e-130	471.1	99.16%	84.18%	Ataxin-3;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN016831.1	sp|A7UQZ6|A7UQZ6_ANOGA	5.7e-40	168.7	93.48%	96.47%	AGAP012844-PA;OS=Anopheles;PE=4;SV=1	GO:0005509|	GO:0019722|
GN016832.1	sp|K1PRH3|K1PRH3_CRAGI	4.1e-15	85.9	58.97%	95.56%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN016833.1	sp|A0A2H1VY24|A0A2H1VY24_SPOFR	1.4e-24	117.5	90.24%	82.19%	SFRICE_024547;OS=Spodoptera;PE=4;SV=1	GO:0005509|
GN016834.1	sp|K1PYT1|K1PYT1_CRAGI	2.9e-30	137.1	52.82%	93.24%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN015543.1	sp|K1QL13|K1QL13_CRAGI	3.2e-38	163.3	100.00%	69.35%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN016836.1	sp|K1QFE1|K1QFE1_CRAGI	5.9e-172	609.4	97.91%	82.62%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN016837.1	sp|K1QNG8|K1QNG8_CRAGI	1.6e-10	70.5	94.37%	56.06%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN016838.1	sp|Q3BDI8|Q3BDI8_PINFU	1.2e-48	198.4	86.39%	63.45%	Calmodulin-like protein;OS=Pinctada;PE=2;SV=1	GO:0005509|
GN016839.1	sp|K1QUI0|K1QUI0_CRAGI	5.7e-69	265.8	97.35%	84.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016840.1	sp|K1RXR0|K1RXR0_CRAGI	1.2e-166	591.7	94.85%	79.40%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016841.1	sp|K1R810|K1R810_CRAGI	1.1e-107	395.6	100.00%	69.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005856|
GN016842.1	sp|K1Q9R1|K1Q9R1_CRAGI	2.4e-60	236.9	100.00%	90.40%	Neuroglobin;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN016843.1	sp|K1S3L1|K1S3L1_CRAGI	5.9e-197	692.6	96.82%	73.22%	Glutamate receptor, ionotropic kainate 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN016844.1	sp|K1RK62|K1RK62_CRAGI	3.2e-95	353.6	98.71%	72.93%	HHIP-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN016846.1	sp|K1QWW9|K1QWW9_CRAGI	1.6e-169	601.3	89.59%	81.57%	Tubulin--tyrosine ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|	GO:0006464|
GN016847.1	sp|K1QQN9|K1QQN9_CRAGI	0.0e+00	2154.8	93.92%	82.64%	Putative ATP-dependent RNA helicase DHX57;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0046872|GO:0003676|
GN016848.1	sp|K1QI47|K1QI47_CRAGI	0.0e+00	1156.7	95.85%	75.64%	N-terminal kinase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN016849.1	sp|A0A210PQ89|A0A210PQ89_MIZYE	1.8e-127	461.5	79.75%	70.38%	3'(2'),5'-bisphosphate nucleotidase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0046854|
GN016850.1	sp|K1Q9Q4|K1Q9Q4_CRAGI	0.0e+00	1218.8	99.25%	78.28%	Protein stoned-B;OS=Crassostrea;PE=4;SV=1	GO:0006897|
GN016851.1	sp|A0A2T7NY68|A0A2T7NY68_POMCA	4.0e-171	606.3	99.12%	90.75%	DNA repair protein RAD51 homolog;OS=Pomacea;PE=3;SV=1	GO:0005634|	GO:0005524|GO:0008094|GO:0003690|GO:0000150|GO:0003697|	GO:0000724|GO:1990426|
GN016852.1	sp|K1RH50|K1RH50_CRAGI	4.6e-103	380.2	100.00%	55.23%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN016853.1	sp|K1QJZ6|K1QJZ6_CRAGI	2.5e-72	277.7	73.21%	66.32%	Neuronal acetylcholine receptor subunit beta-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN016855.1	sp|K1RI30|K1RI30_CRAGI	9.1e-59	233.8	95.68%	28.42%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016856.1	sp|K1REI6|K1REI6_CRAGI	7.1e-137	492.3	98.96%	76.14%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016857.1	sp|K1QSB7|K1QSB7_CRAGI	2.8e-118	430.6	88.99%	71.83%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016858.1	sp|K1QSB7|K1QSB7_CRAGI	5.3e-170	602.8	84.91%	84.20%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016859.1	sp|K1QSB7|K1QSB7_CRAGI	2.0e-146	524.2	99.41%	75.67%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016860.1	sp|K1QSE0|K1QSE0_CRAGI	5.0e-19	100.9	53.97%	36.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016861.1	sp|K1QSB7|K1QSB7_CRAGI	6.8e-303	1045.0	95.36%	80.45%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN016862.1	sp|K1R1U6|K1R1U6_CRAGI	9.1e-184	648.7	100.00%	72.97%	Seryl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004828|	GO:0006434|
GN016863.1	sp|K1R817|K1R817_CRAGI	4.6e-274	948.7	100.00%	95.82%	BTB/POZ domain-containing protein 17;OS=Crassostrea;PE=4;SV=1
GN016864.1	sp|K1REJ2|K1REJ2_CRAGI	0.0e+00	1526.9	100.00%	78.35%	Lon protease homolog, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005759|	GO:0005524|GO:0004176|GO:0043565|GO:0004252|	GO:0034599|GO:0051131|GO:0070407|GO:0006515|
GN016865.1	sp|K1RXR9|K1RXR9_CRAGI	1.7e-227	793.9	100.00%	91.27%	Synaptotagmin-4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0006887|
GN015682.1	sp|K1QYS7|K1QYS7_CRAGI	8.5e-94	349.0	97.62%	73.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016866.1	sp|K1QSC2|K1QSC2_CRAGI	5.6e-134	482.6	100.00%	84.27%	LysM and putative peptidoglycan-binding domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016867.1	sp|A0A210Q1X1|A0A210Q1X1_MIZYE	1.4e-191	676.4	79.16%	35.18%	NFX1-type zinc finger-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN016868.1	sp|K1QR41|K1QR41_CRAGI	8.7e-212	741.9	100.00%	81.29%	Serine/threonine-protein kinase RIO2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN016869.1	sp|A0A210QZ51|A0A210QZ51_MIZYE	1.3e-162	578.6	93.40%	58.74%	Serine incorporator 5;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016870.1	sp|A0A210Q1X1|A0A210Q1X1_MIZYE	4.7e-192	677.9	79.16%	35.26%	NFX1-type zinc finger-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN016871.1	sp|V4AI91|V4AI91_LOTGI	1.4e-85	322.0	99.36%	54.49%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0004252|
GN016872.1	sp|K1QR41|K1QR41_CRAGI	2.2e-44	184.5	100.00%	64.15%	Serine/threonine-protein kinase RIO2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN016873.1	sp|K1R822|K1R822_CRAGI	2.9e-41	172.9	96.59%	98.81%	Serine/threonine-protein kinase RIO2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004674|GO:0004252|
GN015683.1	sp|K1RVM2|K1RVM2_CRAGI	1.4e-180	637.9	91.86%	87.39%	Photoreceptor-specific nuclear receptor;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN016874.1	sp|K1RAZ3|K1RAZ3_CRAGI	2.8e-221	773.9	93.97%	57.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016875.1	sp|K1Q3W1|K1Q3W1_CRAGI	6.8e-49	199.5	95.63%	48.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016876.1	sp|K1RGP1|K1RGP1_CRAGI	1.3e-266	924.5	95.06%	65.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006915|
GN016877.1	sp|K1QSJ7|K1QSJ7_CRAGI	0.0e+00	1258.0	100.00%	69.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016879.1	sp|K1QGF4|K1QGF4_CRAGI	7.1e-62	243.4	98.03%	64.84%	Serum response factor-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN016880.1	sp|A0A210PEI2|A0A210PEI2_MIZYE	9.6e-95	353.6	46.92%	52.29%	Ankyrin repeat and LEM domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004519|
GN016880.1	sp|A0A210PEI2|A0A210PEI2_MIZYE	1.4e-08	67.4	10.87%	48.00%	Ankyrin repeat and LEM domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004519|
GN016881.1	sp|K1RJE3|K1RJE3_CRAGI	0.0e+00	1508.4	87.97%	48.45%	Protein jagged-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN016882.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	2725.3	99.48%	67.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016883.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	1628.2	99.93%	53.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016884.1	sp|K1PY19|K1PY19_CRAGI	7.5e-62	242.7	89.09%	55.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016885.1	sp|K1PY19|K1PY19_CRAGI	9.4e-61	239.2	78.31%	52.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016886.1	sp|K1PY19|K1PY19_CRAGI	7.6e-135	486.1	96.54%	54.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016887.1	sp|K1PY19|K1PY19_CRAGI	6.2e-46	189.1	85.61%	66.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016888.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	1347.4	97.21%	67.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016889.1	sp|K1RJE3|K1RJE3_CRAGI	0.0e+00	1733.0	97.98%	53.24%	Protein jagged-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN016891.1	sp|K1QSJ7|K1QSJ7_CRAGI	0.0e+00	1274.6	99.30%	59.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016892.1	sp|K1RGP1|K1RGP1_CRAGI	3.8e-202	709.9	99.40%	66.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006915|
GN016893.1	sp|K1RAZ3|K1RAZ3_CRAGI	6.2e-221	772.7	94.25%	57.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016894.1	sp|K1Q5F6|K1Q5F6_CRAGI	2.4e-231	807.4	100.00%	57.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016895.1	sp|K1Q428|K1Q428_CRAGI	4.8e-76	289.7	87.94%	83.91%	CCAAT/enhancer-binding protein zeta;OS=Crassostrea;PE=4;SV=1
GN016896.1	sp|K1PY19|K1PY19_CRAGI	1.7e-307	1060.8	99.47%	50.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016897.1	sp|K1PY19|K1PY19_CRAGI	7.4e-106	389.4	99.69%	53.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016898.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	1627.8	99.93%	53.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016899.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	2294.6	98.33%	68.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016900.1	sp|K1PY19|K1PY19_CRAGI	1.1e-45	188.3	91.37%	73.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016901.1	sp|K1PY19|K1PY19_CRAGI	1.5e-64	251.5	94.71%	64.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016902.1	sp|K1PY19|K1PY19_CRAGI	1.8e-54	217.6	97.35%	65.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016903.1	sp|A0A210QB56|A0A210QB56_MIZYE	4.0e-278	963.0	98.15%	58.53%	Amine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0008131|GO:0048038|	GO:0009308|
GN016904.1	sp|V4B523|V4B523_LOTGI	2.4e-09	67.8	36.25%	54.39%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN015534.1	sp|A0A210PUP6|A0A210PUP6_MIZYE	8.5e-143	512.3	99.19%	64.21%	1-deoxypentalenic acid 11-beta-hydroxylase;OS=Mizuhopecten;PE=4;SV=1
GN015684.1	sp|K1R0H3|K1R0H3_CRAGI	4.9e-160	569.3	100.00%	88.24%	Mitochondrial 2-oxodicarboxylate carrier;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN016905.1	sp|K1Q5P7|K1Q5P7_CRAGI	2.8e-109	400.2	100.00%	87.44%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|
GN016906.1	sp|K1QDT4|K1QDT4_CRAGI	1.4e-256	891.3	100.00%	64.66%	GON-4-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN016907.1	sp|K1QK43|K1QK43_CRAGI	4.9e-184	649.4	98.04%	83.00%	FMRFamide receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008528|
GN016908.1	sp|K1R5L5|K1R5L5_CRAGI	3.2e-259	901.4	40.69%	67.34%	GON-4-like protein;OS=Crassostrea;PE=4;SV=1
GN016909.1	sp|K1PP76|K1PP76_CRAGI	1.1e-105	388.7	97.12%	71.69%	Metaxin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0001401|
GN016910.1	sp|K1PWF1|K1PWF1_CRAGI	2.5e-106	390.6	99.60%	78.31%	Major facilitator superfamily domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN016911.1	sp|K1QGF4|K1QGF4_CRAGI	2.4e-62	245.0	98.03%	64.27%	Serum response factor-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN016912.1	sp|A0A2J7PCU9|A0A2J7PCU9_9NEOP	7.1e-11	72.4	82.91%	39.22%	Uncharacterized protein;OS=Cryptotermes;PE=4;SV=1	GO:0004519|
GN016913.1	sp|A0A210PEI2|A0A210PEI2_MIZYE	7.5e-95	353.6	59.53%	52.29%	Ankyrin repeat and LEM domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0004519|
GN015685.1	sp|K1PSH2|K1PSH2_CRAGI	1.7e-61	240.7	100.00%	92.19%	28S ribosomal protein S12, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0015935|	GO:0003735|	GO:0006412|
GN016915.1	sp|A0A210PEQ9|A0A210PEQ9_MIZYE	1.4e-09	67.8	59.38%	48.21%	Nuclease HARBI1;OS=Mizuhopecten;PE=4;SV=1
GN016916.1	sp|K1P689|K1P689_CRAGI	5.4e-174	615.9	98.90%	85.24%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN016917.1	sp|K1PC78|K1PC78_CRAGI	8.4e-40	171.4	16.40%	59.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016918.1	sp|K1PWY2|K1PWY2_CRAGI	6.6e-251	872.1	100.00%	73.82%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN015686.1	sp|K1PZU2|K1PZU2_CRAGI	7.4e-242	842.4	100.00%	86.16%	RNA-binding protein 25;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006397|
GN016919.1	sp|K1PPK0|K1PPK0_CRAGI	7.0e-103	379.4	65.67%	95.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003341|
GN016920.1	sp|A0A2B4RG89|A0A2B4RG89_STYPI	4.3e-30	137.1	82.33%	35.85%	Gypsy retrotransposon integrase-like protein 1;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0004803|	GO:0015074|GO:0006313|
GN016921.1	sp|K1PHR6|K1PHR6_CRAGI	6.5e-157	558.9	100.00%	88.82%	Protein rolling stone;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016922.1	sp|A0A1S3IMH1|A0A1S3IMH1_LINUN	1.0e-25	122.1	92.72%	46.15%	uncharacterized protein LOC106165683 isoform X1;OS=Lingula;PE=4;SV=1	GO:0005768|GO:0005794|GO:0016021|	GO:0019904|	GO:0006622|
GN016923.1	sp|A0A210QTV5|A0A210QTV5_MIZYE	2.2e-123	448.0	99.03%	53.49%	Monomeric sarcosine oxidase;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN016924.1	sp|A0A210Q1X1|A0A210Q1X1_MIZYE	1.8e-254	885.9	50.25%	41.18%	NFX1-type zinc finger-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN015687.1	sp|K1Q7F0|K1Q7F0_CRAGI	8.4e-35	152.9	98.74%	46.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016925.1	sp|A0A210Q1X1|A0A210Q1X1_MIZYE	2.0e-261	909.1	89.34%	44.52%	NFX1-type zinc finger-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0008270|
GN016926.1	sp|K1QDT0|K1QDT0_CRAGI	6.0e-159	566.2	99.78%	66.67%	NAD-dependent deacetylase sirtuin-6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0070403|GO:0004725|
GN016927.1	sp|K1QDT0|K1QDT0_CRAGI	6.2e-18	95.5	66.67%	78.69%	NAD-dependent deacetylase sirtuin-6;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0070403|GO:0004725|
GN016929.1	sp|K1QU27|K1QU27_CRAGI	1.8e-111	409.1	46.70%	58.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016931.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	6.2e-85	320.5	99.38%	34.92%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN016932.1	sp|K1R3J8|K1R3J8_CRAGI	1.6e-19	102.8	49.19%	32.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016934.1	sp|K1QLA0|K1QLA0_CRAGI	0.0e+00	3227.2	74.48%	51.76%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016935.1	sp|K1QQF7|K1QQF7_CRAGI	1.3e-27	128.6	88.64%	41.40%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016936.1	sp|K1QLA0|K1QLA0_CRAGI	0.0e+00	3498.0	74.11%	55.79%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN015689.1	sp|K1QEI1|K1QEI1_CRAGI	5.0e-31	141.7	42.93%	92.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016938.1	sp|V3ZYW0|V3ZYW0_LOTGI	7.5e-10	68.9	89.29%	39.42%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN016939.1	sp|K1QLA0|K1QLA0_CRAGI	4.8e-149	535.0	39.39%	44.71%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016940.1	sp|K1QLA0|K1QLA0_CRAGI	0.0e+00	2592.4	100.00%	53.12%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016941.1	sp|K1R0V3|K1R0V3_CRAGI	1.3e-204	718.0	99.79%	70.86%	Cytochrome P450 2J1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0016705|
GN016942.1	sp|K1QRE6|K1QRE6_CRAGI	5.6e-19	99.4	99.17%	37.70%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN016943.1	sp|K1QRE6|K1QRE6_CRAGI	4.9e-30	135.6	96.43%	77.78%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN016944.1	sp|K1RX47|K1RX47_CRAGI	2.3e-76	291.2	75.36%	71.30%	MAP3K12-binding inhibitory protein 1;OS=Crassostrea;PE=4;SV=1
GN016945.1	sp|K1RDX7|K1RDX7_CRAGI	5.4e-97	360.9	95.71%	73.40%	E3 ubiquitin-protein ligase RNF8;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0003676|GO:0008270|
GN016947.1	sp|K1R7F8|K1R7F8_CRAGI	4.4e-72	276.2	100.00%	82.80%	Peroxiredoxin-5, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0016491|	GO:0045454|
GN016948.1	sp|K1QRE2|K1QRE2_CRAGI	0.0e+00	2132.8	100.00%	91.12%	Son of sevenless-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0000786|GO:0005634|	GO:0003677|GO:0046982|GO:0005089|	GO:0035023|GO:0007264|
GN016949.1	sp|K1R0U5|K1R0U5_CRAGI	1.8e-114	417.9	76.59%	90.35%	Axin interactor, dorsalization-associated protein;OS=Crassostrea;PE=4;SV=1
GN016950.1	sp|K1RX43|K1RX43_CRAGI	5.4e-129	466.5	100.00%	67.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016951.1	sp|K1RDX3|K1RDX3_CRAGI	0.0e+00	1247.3	89.88%	66.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0031047|
GN016952.1	sp|K1QLA0|K1QLA0_CRAGI	0.0e+00	2944.5	70.45%	55.99%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016953.1	sp|A0A3L5TVF9|A0A3L5TVF9_MYTGA	1.9e-79	303.1	99.77%	28.04%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN016954.1	sp|K1QLA0|K1QLA0_CRAGI	0.0e+00	3040.0	97.55%	56.96%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016955.1	sp|K1R1L5|K1R1L5_CRAGI	8.4e-143	512.3	95.91%	71.51%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN016956.1	sp|K1RDY1|K1RDY1_CRAGI	9.5e-88	328.6	100.00%	83.08%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN016957.1	sp|K1Q1X8|K1Q1X8_CRAGI	1.1e-228	798.5	87.25%	61.40%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016958.1	sp|K1Q1X8|K1Q1X8_CRAGI	3.5e-166	590.5	88.70%	58.77%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016961.1	sp|K1QGH7|K1QGH7_CRAGI	0.0e+00	2076.2	99.02%	61.47%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN016962.1	sp|K1PTS5|K1PTS5_CRAGI	4.3e-54	216.5	100.00%	63.80%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN016963.1	sp|K1PTS5|K1PTS5_CRAGI	1.4e-132	478.4	97.36%	61.46%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN016964.1	sp|K1RD55|K1RD55_CRAGI	1.9e-51	208.8	85.88%	35.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016966.1	sp|K1QGC3|K1QGC3_CRAGI	1.7e-299	1033.5	100.00%	87.50%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016968.1	sp|K1QGC3|K1QGC3_CRAGI	2.6e-300	1036.2	100.00%	87.67%	Tripartite motif-containing protein 71;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016969.1	sp|K1PG80|K1PG80_CRAGI	0.0e+00	2126.3	100.00%	76.79%	Kinesin-like protein KIF26A;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN016970.1	sp|K1RD19|K1RD19_CRAGI	1.6e-57	228.4	46.38%	96.30%	RNA-binding protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008270|
GN015694.1	sp|K1PSH7|K1PSH7_CRAGI	1.5e-14	86.3	36.78%	36.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016971.1	sp|K1QPG4|K1QPG4_CRAGI	1.2e-90	339.0	92.69%	52.05%	Cytochrome P450 2U1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN016972.1	sp|A0A3M6TYK9|A0A3M6TYK9_9CNID	5.2e-23	114.0	41.61%	45.83%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN016973.1	sp|K1QPG4|K1QPG4_CRAGI	2.3e-48	198.0	94.63%	40.35%	Cytochrome P450 2U1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN016974.1	sp|K1PXG1|K1PXG1_CRAGI	2.8e-44	184.1	77.08%	60.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016975.1	sp|K1PMM1|K1PMM1_CRAGI	4.3e-172	610.9	99.78%	70.02%	Laminin subunit alpha-2;OS=Crassostrea;PE=4;SV=1
GN016976.1	sp|K1PEW1|K1PEW1_CRAGI	7.8e-198	695.3	100.00%	89.90%	Sorting nexin;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0035091|	GO:0006886|
GN015695.1	sp|K1PSH7|K1PSH7_CRAGI	2.3e-17	96.3	10.23%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016979.1	sp|A0A210QX77|A0A210QX77_MIZYE	2.0e-76	291.6	71.56%	64.11%	N-alpha-acetyltransferase 30;OS=Mizuhopecten;PE=4;SV=1	GO:0016740|
GN016980.1	sp|K1QZU9|K1QZU9_CRAGI	1.8e-122	446.4	19.78%	84.65%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN016980.1	sp|K1QZU9|K1QZU9_CRAGI	7.3e-15	89.0	7.94%	54.95%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN016984.1	sp|K1QDX5|K1QDX5_CRAGI	6.6e-123	446.0	100.00%	66.67%	Uncharacterized protein yqjG;OS=Crassostrea;PE=4;SV=1	GO:0004364|
GN016985.1	sp|A0A0L8FVN3|A0A0L8FVN3_OCTBM	2.1e-216	757.7	95.45%	55.66%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN016986.1	sp|A0A210QW59|A0A210QW59_MIZYE	4.4e-125	453.8	92.00%	48.43%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN016987.1	sp|K1QBZ4|K1QBZ4_CRAGI	0.0e+00	1660.6	50.14%	55.58%	Sushi repeat-containing protein SRPX2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN016988.1	sp|A0A210QW59|A0A210QW59_MIZYE	1.2e-117	428.7	95.90%	52.00%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN015697.1	sp|K1PZU4|K1PZU4_CRAGI	1.2e-94	351.7	100.00%	78.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016989.1	sp|K1PY08|K1PY08_CRAGI	2.6e-241	840.1	99.44%	80.63%	Protein numb;OS=Crassostrea;PE=4;SV=1	GO:0005929|GO:0005868|	GO:0035721|GO:0035735|
GN016990.1	sp|K1PRE5|K1PRE5_CRAGI	6.9e-264	915.2	100.00%	79.35%	KIF1-binding-like protein;OS=Crassostrea;PE=4;SV=1
GN016991.1	sp|A0A210Q9P6|A0A210Q9P6_MIZYE	5.0e-51	206.8	86.01%	44.86%	Ribonuclease Oy;OS=Mizuhopecten;PE=3;SV=1	GO:0033897|GO:0003723|
GN015698.1	sp|K1Q7F3|K1Q7F3_CRAGI	3.8e-129	467.6	100.00%	51.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016992.1	sp|K1QNW6|K1QNW6_CRAGI	5.5e-226	789.6	96.90%	61.72%	Kanadaptin;OS=Crassostrea;PE=4;SV=1	GO:0016891|
GN016993.1	sp|K1QFW9|K1QFW9_CRAGI	0.0e+00	1357.8	99.58%	91.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN016994.1	sp|V4AU73|V4AU73_LOTGI	3.2e-29	134.0	83.60%	40.76%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0004842|
GN016995.1	sp|K1RF96|K1RF96_CRAGI	2.4e-53	214.2	100.00%	60.96%	WD repeat-containing protein C2orf86;OS=Crassostrea;PE=4;SV=1	GO:0007283|
GN016996.1	sp|Q9VQ35|Q9VQ35_DROME	1.8e-19	101.7	73.44%	37.06%	Mitochondrial ribosomal protein L48, isoform A;OS=Drosophila;PE=1;SV=1	GO:0005762|GO:0005761|	GO:0003735|	GO:0032543|
GN016998.1	sp|K1QNW9|K1QNW9_CRAGI	0.0e+00	2681.0	100.00%	81.44%	Bifunctional aminoacyl-tRNA synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004818|GO:0004827|	GO:0006424|GO:0006433|
GN016999.1	sp|K1QV07|K1QV07_CRAGI	0.0e+00	1136.3	100.00%	86.49%	BTB/POZ domain-containing protein 9;OS=Crassostrea;PE=4;SV=1
GN017000.1	sp|K1RFA1|K1RFA1_CRAGI	8.8e-50	203.4	89.56%	60.92%	Dr1-associated corepressor;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046982|
GN017001.1	sp|K1Q7Q2|K1Q7Q2_CRAGI	0.0e+00	1270.8	100.00%	74.62%	CCAAT/enhancer-binding protein zeta;OS=Crassostrea;PE=4;SV=1	GO:0042254|
GN017002.1	sp|K1QV12|K1QV12_CRAGI	4.6e-110	402.9	99.58%	82.05%	Transmembrane protein 86A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017003.1	sp|A0A210PWF1|A0A210PWF1_MIZYE	5.1e-166	589.3	99.14%	81.34%	Sorbitol dehydrogenase;OS=Mizuhopecten;PE=4;SV=1	GO:0016491|
GN017004.1	sp|K1RFA3|K1RFA3_CRAGI	1.3e-162	578.6	99.61%	81.48%	Lamin Dm0;OS=Crassostrea;PE=3;SV=1	GO:0005882|	GO:0005198|
GN017005.1	sp|K1Q7Q6|K1Q7Q6_CRAGI	2.3e-175	620.5	84.83%	90.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015699.1	sp|K1QEI5|K1QEI5_CRAGI	2.8e-104	383.6	100.00%	84.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017006.1	sp|A0A210Q2Z1|A0A210Q2Z1_MIZYE	4.4e-91	341.3	63.45%	61.08%	Ubiquitin-associated protein 2;OS=Mizuhopecten;PE=4;SV=1
GN017007.1	sp|K1RFA8|K1RFA8_CRAGI	1.2e-226	791.2	100.00%	80.89%	Aryl hydrocarbon receptor nuclear translocator-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005737|GO:0005634|GO:0005667|	GO:0003677|GO:0003700|GO:0046983|
GN017008.1	sp|K1QFY1|K1QFY1_CRAGI	5.1e-210	736.1	79.54%	86.37%	Ammonium transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008519|
GN017009.1	sp|K1RFB1|K1RFB1_CRAGI	1.5e-133	481.5	93.88%	89.26%	Stomatin-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN017010.1	sp|K1Q7R7|K1Q7R7_CRAGI	2.9e-145	520.4	100.00%	76.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017011.1	sp|K1QFY8|K1QFY8_CRAGI	1.2e-172	611.7	91.97%	73.88%	Lysosomal protein NCU-G1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017012.1	sp|K1QNY6|K1QNY6_CRAGI	6.6e-49	201.1	43.62%	56.12%	Lines-like protein 1;OS=Crassostrea;PE=4;SV=1
GN017013.1	sp|A0A210QZ02|A0A210QZ02_MIZYE	8.2e-136	488.8	99.33%	77.78%	GPN-loop GTPase 2;OS=Mizuhopecten;PE=3;SV=1	GO:0005525|GO:0016787|
GN017014.1	sp|K1RFB5|K1RFB5_CRAGI	6.7e-248	862.1	87.77%	82.39%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN017015.1	sp|A0A210QVY5|A0A210QVY5_MIZYE	2.0e-109	401.0	89.22%	84.52%	Proteasome subunit alpha type;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|GO:0005634|GO:0019773|	GO:0004298|	GO:0006511|
GN017016.1	sp|K1QNZ0|K1QNZ0_CRAGI	0.0e+00	1095.1	91.69%	93.49%	Ras GTPase-activating protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|	GO:0046580|GO:0007165|
GN017017.1	sp|K1PWQ0|K1PWQ0_CRAGI	2.6e-26	123.6	75.65%	73.56%	Sorting nexin-24;OS=Crassostrea;PE=4;SV=1	GO:0035091|
GN017018.1	sp|K1PPM8|K1PPM8_CRAGI	0.0e+00	1129.8	77.62%	79.83%	Fanconi-associated nuclease;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0046872|GO:0004528|	GO:0036297|
GN017019.1	sp|K1QX77|K1QX77_CRAGI	0.0e+00	3006.9	98.90%	83.51%	G-protein coupled receptor 98;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007194|
GN017020.1	sp|K1PHA6|K1PHA6_CRAGI	3.3e-41	173.7	77.65%	62.32%	Putative gluconokinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|	GO:0005975|
GN017022.1	sp|K1PAW2|K1PAW2_CRAGI	4.6e-245	852.8	100.00%	71.74%	FERM domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005856|GO:0016021|	GO:0008092|
GN017023.1	sp|K1QUJ6|K1QUJ6_CRAGI	1.2e-266	924.5	100.00%	78.13%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1
GN017025.1	sp|A0A2T7NU69|A0A2T7NU69_POMCA	7.8e-16	90.5	32.13%	35.65%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN017026.1	sp|V4A8A4|V4A8A4_LOTGI	1.3e-25	122.1	61.46%	50.43%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN017027.1	sp|V4A8A4|V4A8A4_LOTGI	8.5e-68	263.5	77.41%	41.50%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN017029.1	sp|A0A210PHH9|A0A210PHH9_MIZYE	7.4e-51	206.8	87.71%	39.63%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN017031.1	sp|K1PW34|K1PW34_CRAGI	5.6e-30	136.3	57.06%	72.83%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1
GN017032.1	sp|A0A210PHH9|A0A210PHH9_MIZYE	2.2e-49	201.8	90.18%	39.43%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN017034.1	sp|K1PW34|K1PW34_CRAGI	1.4e-236	824.7	81.61%	80.37%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1
GN017035.1	sp|K1PNS9|K1PNS9_CRAGI	6.7e-145	520.0	67.21%	63.57%	Cartilage matrix protein;OS=Crassostrea;PE=4;SV=1
GN017036.1	sp|K1PG00|K1PG00_CRAGI	4.9e-52	209.5	80.52%	81.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017037.1	sp|K1PG00|K1PG00_CRAGI	1.8e-41	174.5	81.82%	66.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017038.1	sp|K1QG28|K1QG28_CRAGI	1.3e-21	107.1	98.28%	85.71%	Stress response protein nhaX;OS=Crassostrea;PE=4;SV=1
GN017039.1	sp|K1PW28|K1PW28_CRAGI	7.5e-136	489.2	100.00%	71.11%	mRNA-decapping enzyme 2;OS=Crassostrea;PE=4;SV=1	GO:0016787|GO:0030145|GO:0003723|
GN017040.1	sp|K1PNS1|K1PNS1_CRAGI	5.5e-37	160.6	47.04%	57.42%	Glucosylceramidase;OS=Crassostrea;PE=3;SV=1	GO:0004348|	GO:0006665|
GN017041.1	sp|K1Q627|K1Q627_CRAGI	2.2e-37	160.6	98.46%	66.14%	Retinol dehydrogenase 14;OS=Crassostrea;PE=4;SV=1
GN017042.1	sp|K1Q627|K1Q627_CRAGI	2.4e-113	414.1	99.65%	72.18%	Retinol dehydrogenase 14;OS=Crassostrea;PE=4;SV=1
GN017043.1	sp|A0A210QP57|A0A210QP57_MIZYE	5.3e-113	412.9	99.29%	71.12%	Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0016853|
GN017045.1	sp|K1Q627|K1Q627_CRAGI	2.4e-113	414.1	99.65%	72.18%	Retinol dehydrogenase 14;OS=Crassostrea;PE=4;SV=1
GN017048.1	sp|K1PYS1|K1PYS1_CRAGI	5.6e-140	503.8	46.32%	91.08%	Splicing factor, arginine/serine-rich 16;OS=Crassostrea;PE=4;SV=1
GN017051.1	sp|K1Q627|K1Q627_CRAGI	1.2e-121	441.8	94.34%	72.00%	Retinol dehydrogenase 14;OS=Crassostrea;PE=4;SV=1
GN017055.1	sp|K1RRX6|K1RRX6_CRAGI	1.7e-58	231.9	94.31%	46.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017057.1	sp|K1QD74|K1QD74_CRAGI	5.6e-233	812.4	100.00%	76.15%	Solute carrier organic anion transporter family member;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN015703.1	sp|V4AYR3|V4AYR3_LOTGI	2.0e-104	384.8	93.78%	57.46%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0008502|
GN017058.1	sp|R7V392|R7V392_CAPTE	2.2e-45	188.7	62.47%	42.92%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN017065.1	sp|K1RV66|K1RV66_CRAGI	2.4e-151	541.2	96.55%	59.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008061|	GO:0006030|
GN017066.1	sp|K1RBM4|K1RBM4_CRAGI	0.0e+00	1901.3	99.91%	81.55%	DNA polymerase subunit gamma-1;OS=Crassostrea;PE=4;SV=1	GO:0005760|	GO:0003677|GO:0003887|	GO:0006260|
GN017067.1	sp|K1R1A3|K1R1A3_CRAGI	3.6e-34	150.2	56.33%	80.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017068.1	sp|K1PE19|K1PE19_CRAGI	9.4e-51	205.7	96.08%	52.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017069.1	sp|K1Q136|K1Q136_CRAGI	5.5e-44	183.7	53.74%	52.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017070.1	sp|C3YZ71|C3YZ71_BRAFL	5.1e-45	187.6	58.93%	40.17%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN017071.1	sp|K1RGC1|K1RGC1_CRAGI	1.2e-39	168.3	100.00%	55.70%	ATP-dependent DNA helicase hus2/rqh1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN017073.1	sp|K1QBY1|K1QBY1_CRAGI	2.6e-42	176.8	100.00%	84.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017075.1	sp|K1Q4P4|K1Q4P4_CRAGI	5.5e-53	213.0	69.47%	68.70%	GLIPR1-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005576|
GN017077.1	sp|K1PX90|K1PX90_CRAGI	1.9e-55	222.2	84.36%	57.53%	Nucleolar and spindle-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005874|GO:0005819|	GO:0040001|GO:0000281|
GN017078.1	sp|K1PQ05|K1PQ05_CRAGI	0.0e+00	1510.7	87.94%	74.55%	Extended synaptotagmin-2-A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008289|	GO:0006869|
GN017079.1	sp|K1QXP5|K1QXP5_CRAGI	0.0e+00	1414.1	99.25%	89.22%	BTB/POZ domain-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN017081.1	sp|K1PX94|K1PX94_CRAGI	5.5e-103	380.9	32.85%	80.36%	Uncharacterized protein C12orf26;OS=Crassostrea;PE=4;SV=1
GN017082.1	sp|K1Q4Q6|K1Q4Q6_CRAGI	2.8e-131	473.8	98.04%	71.19%	Guanine nucleotide-binding protein subunit beta-like protein 1;OS=Crassostrea;PE=4;SV=1
GN017083.1	sp|K1QBZ1|K1QBZ1_CRAGI	0.0e+00	2339.3	100.00%	80.23%	Pleckstrin-like protein domain-containing family H member 2;OS=Crassostrea;PE=4;SV=1	GO:0005856|
GN017084.1	sp|K1PQ11|K1PQ11_CRAGI	4.1e-159	566.6	100.00%	93.25%	Butyrate response factor 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN017085.1	sp|K1Q4R2|K1Q4R2_CRAGI	2.3e-36	157.5	90.51%	54.23%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017086.1	sp|K1Q4R2|K1Q4R2_CRAGI	0.0e+00	1895.2	97.05%	67.02%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017093.1	sp|K1Q4S0|K1Q4S0_CRAGI	5.3e-133	479.6	95.05%	74.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN017094.1	sp|K1Q537|K1Q537_CRAGI	8.3e-105	386.0	98.80%	58.46%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN017095.1	sp|K1Q537|K1Q537_CRAGI	3.5e-108	397.1	100.00%	60.90%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN017096.1	sp|A0A210PW13|A0A210PW13_MIZYE	2.0e-86	325.1	89.79%	52.16%	Growth hormone secretagogue receptor type 1;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN017097.1	sp|K1QCH9|K1QCH9_CRAGI	1.6e-114	417.9	99.64%	77.29%	Growth hormone secretagogue receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN017098.1	sp|K1P6I6|K1P6I6_CRAGI	2.4e-103	380.9	100.00%	72.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017099.1	sp|K1PCI2|K1PCI2_CRAGI	5.6e-61	240.0	69.53%	69.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017100.1	sp|K1Q5B5|K1Q5B5_CRAGI	2.5e-212	744.2	100.00%	66.90%	Periaxin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017101.1	sp|A0A210PXH2|A0A210PXH2_MIZYE	4.9e-20	103.6	60.80%	40.98%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017102.1	sp|K1QR22|K1QR22_CRAGI	2.1e-50	206.1	97.19%	73.13%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1
GN017104.1	sp|K1Q1X1|K1Q1X1_CRAGI	4.4e-25	120.6	71.81%	42.77%	Putative potassium channel regulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN017105.1	sp|K1PPF9|K1PPF9_CRAGI	3.8e-48	197.2	87.88%	51.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017106.1	sp|K1QWV1|K1QWV1_CRAGI	6.4e-50	202.2	98.40%	81.97%	tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6;OS=Crassostrea;PE=3;SV=1	GO:0005634|GO:0031515|	GO:0008168|	GO:0030488|
GN017107.1	sp|A0A224YYR1|A0A224YYR1_9ACAR	6.8e-09	65.5	80.22%	41.67%	Protein containing Myb5 and GT1 domain;OS=Rhipicephalus;PE=4;SV=1	GO:0005634|	GO:0006915|
GN017108.1	sp|K1QWV1|K1QWV1_CRAGI	3.6e-101	373.6	100.00%	69.64%	tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6;OS=Crassostrea;PE=3;SV=1	GO:0005634|GO:0031515|	GO:0008168|	GO:0030488|
GN017109.1	sp|K1PWC5|K1PWC5_CRAGI	3.2e-27	126.3	87.78%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015708.1	sp|A0A210PU56|A0A210PU56_MIZYE	2.1e-97	361.3	100.00%	51.10%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017110.1	sp|K1PPF6|K1PPF6_CRAGI	0.0e+00	1483.4	99.56%	69.09%	DNA mismatch repair protein Msh3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0030983|	GO:0006298|
GN017111.1	sp|K1QWU4|K1QWU4_CRAGI	9.7e-198	695.7	74.13%	72.95%	StAR-related lipid transfer protein 9;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN017112.1	sp|K1QH05|K1QH05_CRAGI	4.5e-156	556.2	100.00%	79.88%	MOSC domain-containing protein 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0030151|GO:0030170|
GN017113.1	sp|A0A0S2GL00|A0A0S2GL00_CRAHO	4.7e-250	869.0	95.91%	89.64%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004674|
GN017114.1	sp|V4AH97|V4AH97_LOTGI	9.1e-26	123.6	47.61%	41.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017115.1	sp|V4AH97|V4AH97_LOTGI	3.5e-25	121.7	47.61%	40.53%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN015709.1	sp|V4AE92|V4AE92_LOTGI	3.8e-67	260.4	99.17%	51.65%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN017116.1	sp|V4AH97|V4AH97_LOTGI	1.9e-26	125.9	46.32%	41.58%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017117.1	sp|V4AH97|V4AH97_LOTGI	1.2e-25	123.2	46.32%	41.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017120.1	sp|V4AH97|V4AH97_LOTGI	1.5e-21	108.2	90.54%	46.62%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017121.1	sp|V4AH97|V4AH97_LOTGI	2.5e-26	125.6	46.32%	41.58%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017122.1	sp|V4AH97|V4AH97_LOTGI	5.5e-26	124.4	46.32%	41.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017123.1	sp|V4AH97|V4AH97_LOTGI	5.0e-27	127.9	47.06%	41.97%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017124.1	sp|V4AH97|V4AH97_LOTGI	1.2e-25	123.2	46.32%	41.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017125.1	sp|V4AH97|V4AH97_LOTGI	1.4e-26	126.3	47.06%	41.45%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN015710.1	sp|W4XVM5|W4XVM5_STRPU	3.8e-57	227.3	100.00%	45.98%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005739|	GO:0000175|
GN017126.1	sp|V4AH97|V4AH97_LOTGI	4.2e-26	124.8	46.32%	41.58%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017127.1	sp|V4AH97|V4AH97_LOTGI	5.5e-26	124.4	46.32%	41.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017128.1	sp|V4AH97|V4AH97_LOTGI	1.6e-25	122.9	47.61%	41.05%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017129.1	sp|V4AH97|V4AH97_LOTGI	7.2e-26	124.0	47.06%	40.41%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017130.1	sp|K1Q8Y4|K1Q8Y4_CRAGI	2.0e-159	568.5	44.97%	86.15%	Kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|	GO:0032958|
GN017131.1	sp|K1RY07|K1RY07_CRAGI	6.9e-110	403.7	92.11%	86.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017132.1	sp|A0A210PQD3|A0A210PQD3_MIZYE	3.2e-52	212.2	98.28%	61.10%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN017134.1	sp|K1QZF2|K1QZF2_CRAGI	1.0e-162	579.3	92.19%	55.84%	Endoglucanase;OS=Crassostrea;PE=3;SV=1	GO:0008810|	GO:0030245|
GN017135.1	sp|K1QQ10|K1QQ10_CRAGI	4.4e-122	443.7	77.90%	63.45%	Opioid-binding protein/cell adhesion molecule;OS=Crassostrea;PE=4;SV=1
GN017136.1	sp|A0A210PMX4|A0A210PMX4_MIZYE	2.6e-90	338.6	96.21%	38.57%	Major facilitator superfamily domain-containing protein 12;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0015293|	GO:0008643|
GN017137.1	sp|A0A2B4RG89|A0A2B4RG89_STYPI	8.1e-29	132.5	92.07%	40.67%	Gypsy retrotransposon integrase-like protein 1;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0004803|	GO:0015074|GO:0006313|
GN017138.1	sp|K1P486|K1P486_CRAGI	7.2e-112	410.2	99.83%	39.35%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN017139.1	sp|K1Q7M8|K1Q7M8_CRAGI	4.3e-306	1055.8	91.94%	71.27%	Acid trehalase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN017140.1	sp|K1QJ28|K1QJ28_CRAGI	2.6e-23	112.8	100.00%	80.65%	Mammalian ependymin-related protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007160|
GN017141.1	sp|A0A210R4Y5|A0A210R4Y5_MIZYE	1.4e-57	229.2	99.15%	37.64%	Carbohydrate sulfotransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008146|	GO:0016051|
GN017142.1	sp|K1REY6|K1REY6_CRAGI	1.2e-30	138.7	95.35%	43.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017144.1	sp|K1QNT7|K1QNT7_CRAGI	9.7e-278	961.1	100.00%	89.40%	Aldehyde dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN017145.1	sp|K1QH93|K1QH93_CRAGI	2.7e-98	363.6	99.51%	81.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017147.1	sp|K1Q283|K1Q283_CRAGI	1.0e-109	402.5	73.23%	69.90%	Tolloid-like protein 2;OS=Crassostrea;PE=4;SV=1
GN017148.1	sp|K1R944|K1R944_CRAGI	7.3e-27	125.2	88.04%	72.50%	Tetratricopeptide repeat protein 37;OS=Crassostrea;PE=4;SV=1	GO:0055087|	GO:0006401|GO:0006396|
GN017149.1	sp|K1R944|K1R944_CRAGI	0.0e+00	1638.6	100.00%	62.32%	Tetratricopeptide repeat protein 37;OS=Crassostrea;PE=4;SV=1	GO:0055087|	GO:0006401|GO:0006396|
GN017150.1	sp|K1QNT1|K1QNT1_CRAGI	0.0e+00	1489.9	100.00%	78.73%	Advillin;OS=Crassostrea;PE=4;SV=1	GO:0051015|	GO:0007010|
GN017152.1	sp|K1P6Q8|K1P6Q8_CRAGI	0.0e+00	1453.3	85.36%	79.48%	Tau-tubulin kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN017153.1	sp|A0A210QVD4|A0A210QVD4_MIZYE	1.9e-96	357.8	79.38%	78.33%	SprT-like domain-containing protein Spartan;OS=Mizuhopecten;PE=4;SV=1
GN017154.1	sp|K1PZU3|K1PZU3_CRAGI	3.8e-204	716.1	98.90%	95.26%	Protein pellino;OS=Crassostrea;PE=4;SV=1	GO:0008063|
GN017155.1	sp|K1QSK9|K1QSK9_CRAGI	6.6e-218	761.9	100.00%	90.45%	Leucine-rich repeat-containing protein 8E;OS=Crassostrea;PE=4;SV=1
GN017156.1	sp|K1PZT9|K1PZT9_CRAGI	8.3e-49	198.7	100.00%	66.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017157.1	sp|V4ATN2|V4ATN2_LOTGI	2.5e-54	217.6	81.13%	60.23%	Nucleoside diphosphate kinase;OS=Lottia;PE=3;SV=1	GO:0005524|GO:0004550|	GO:0006241|GO:0006183|GO:0006228|
GN017159.1	sp|K1QE52|K1QE52_CRAGI	1.5e-138	500.0	31.19%	60.96%	Neurogenic locus notch-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN017160.1	sp|K1PIY2|K1PIY2_CRAGI	6.5e-38	162.9	94.71%	53.89%	Fibropellin-1;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0030247|GO:0005044|	GO:0006955|
GN017161.1	sp|K1QE52|K1QE52_CRAGI	5.2e-84	318.9	28.42%	40.60%	Neurogenic locus notch-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN017162.1	sp|K1P5F1|K1P5F1_CRAGI	3.8e-156	556.6	99.72%	85.96%	Visual system homeobox 2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN017163.1	sp|K1QBF2|K1QBF2_CRAGI	8.2e-62	241.9	99.30%	80.14%	Visual system homeobox 2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN017164.1	sp|K1QBF2|K1QBF2_CRAGI	6.9e-111	405.6	96.05%	92.66%	Visual system homeobox 2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN017165.1	sp|K1PR20|K1PR20_CRAGI	6.1e-268	928.7	99.83%	79.76%	Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (Cyclizing);OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004371|GO:0016829|	GO:0006071|
GN017166.1	sp|K1PIX8|K1PIX8_CRAGI	8.7e-283	978.0	99.66%	85.98%	Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (Cyclizing);OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004371|GO:0016829|	GO:0006071|
GN017167.1	sp|K1P5D4|K1P5D4_CRAGI	4.9e-194	682.6	95.26%	90.38%	Cysteine synthase;OS=Crassostrea;PE=4;SV=1
GN017168.1	sp|K1PR04|K1PR04_CRAGI	0.0e+00	1418.7	100.00%	85.94%	Neuronal PAS domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046983|
GN017169.1	sp|K1R7W3|K1R7W3_CRAGI	0.0e+00	1163.7	94.06%	87.87%	Kelch domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN017170.1	sp|K1QY30|K1QY30_CRAGI	5.2e-299	1032.3	93.83%	80.81%	U4/U6.U5 tri-snRNP-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0000398|
GN017171.1	sp|K1S373|K1S373_CRAGI	1.6e-24	117.9	67.20%	73.49%	Nuclear RNA export factor 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0003723|	GO:0006406|
GN017173.1	sp|K1RJS6|K1RJS6_CRAGI	1.5e-209	734.6	99.81%	66.79%	Transmembrane protein 62;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017174.1	sp|A0A210PMP0|A0A210PMP0_MIZYE	2.1e-33	148.7	40.13%	60.74%	Protein phosphatase 1 regulatory subunit 14C;OS=Mizuhopecten;PE=4;SV=1	GO:0005737|	GO:0042325|
GN017175.1	sp|K1RDU0|K1RDU0_CRAGI	1.3e-207	729.2	96.86%	52.84%	Low-density lipoprotein receptor-related protein 11;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017176.1	sp|A0A210QCU1|A0A210QCU1_MIZYE	1.8e-10	71.2	48.15%	45.45%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN017177.1	sp|K1Q6Z6|K1Q6Z6_CRAGI	1.5e-17	94.4	100.00%	56.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|	GO:0006357|
GN017178.1	sp|K1PKM5|K1PKM5_CRAGI	9.8e-90	335.5	82.35%	78.47%	Copper chaperone for superoxide dismutase;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0030001|GO:0006801|
GN017179.1	sp|K1Q6Z2|K1Q6Z2_CRAGI	8.4e-92	342.0	100.00%	82.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017180.1	sp|K1PZU9|K1PZU9_CRAGI	5.7e-184	649.4	90.11%	74.47%	Kinesin-like protein KIF6;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN017181.1	sp|A0A210PXF7|A0A210PXF7_MIZYE	4.2e-125	454.1	73.32%	52.38%	Selenoprotein N;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN017182.1	sp|A0A210Q480|A0A210Q480_MIZYE	6.9e-226	789.6	57.24%	75.67%	GTP-binding protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|GO:0003924|
GN017183.1	sp|K1PSL7|K1PSL7_CRAGI	0.0e+00	1688.3	88.58%	88.91%	Disheveled-associated activator of morphogenesis 2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN017184.1	sp|K1PKM4|K1PKM4_CRAGI	2.5e-151	540.8	100.00%	76.16%	Ribosome biogenesis protein NOP53;OS=Crassostrea;PE=3;SV=1	GO:0005730|GO:0005654|	GO:0000027|
GN017185.1	sp|A0A1S3HU86|A0A1S3HU86_LINUN	2.0e-102	377.9	99.67%	61.41%	prostaglandin reductase 2-like;OS=Lingula;PE=4;SV=1	GO:0047522|	GO:0006693|
GN017186.1	sp|K1PKM8|K1PKM8_CRAGI	1.4e-72	278.1	94.12%	75.43%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN017187.1	sp|K1PM79|K1PM79_CRAGI	1.4e-267	927.9	79.77%	73.44%	Ribosome-releasing factor 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005525|GO:0003924|
GN017188.1	sp|X1WW30|X1WW30_ACYPI	2.1e-22	111.3	83.33%	40.28%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1	GO:0003677|
GN017189.1	sp|K1QSN4|K1QSN4_CRAGI	1.9e-160	571.2	94.41%	85.38%	Sprouty-related, EVH1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0007275|GO:0009966|
GN017190.1	sp|K1PZW1|K1PZW1_CRAGI	5.6e-78	296.2	89.81%	76.17%	Cyclin-dependent kinase 2-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN017191.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	1.1e-94	352.8	96.54%	40.36%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN017193.1	sp|K1PIS2|K1PIS2_CRAGI	8.7e-26	123.2	51.72%	44.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017195.1	sp|K1Q589|K1Q589_CRAGI	2.2e-18	98.6	74.20%	31.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017198.1	sp|K1RB98|K1RB98_CRAGI	4.2e-93	346.3	100.00%	80.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017199.1	sp|K1QBN7|K1QBN7_CRAGI	8.0e-150	535.8	100.00%	75.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017200.1	sp|K1QJM8|K1QJM8_CRAGI	3.7e-266	922.9	99.09%	77.44%	Collagen alpha-1(XII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN017201.1	sp|A0A0L8HGX9|A0A0L8HGX9_OCTBM	6.9e-74	283.1	93.79%	49.48%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN017202.1	sp|K1QR49|K1QR49_CRAGI	7.3e-258	895.6	86.28%	89.52%	Uncharacterized protein C19orf29;OS=Crassostrea;PE=4;SV=1
GN017203.1	sp|K1RBA3|K1RBA3_CRAGI	3.9e-27	129.0	26.60%	68.39%	Zinc finger protein 7;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017204.1	sp|K1QR54|K1QR54_CRAGI	0.0e+00	1220.3	95.45%	91.64%	Zinc finger RNA-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN015713.1	sp|K1PZ40|K1PZ40_CRAGI	5.2e-54	217.2	96.46%	34.97%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017205.1	sp|K1RBA8|K1RBA8_CRAGI	0.0e+00	3422.9	100.00%	71.77%	Chondroitin sulfate proteoglycan 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017206.1	sp|K1Q496|K1Q496_CRAGI	4.6e-297	1025.8	91.46%	74.60%	Spermatogenesis-associated protein 5-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN017207.1	sp|K1QJN8|K1QJN8_CRAGI	0.0e+00	1570.8	100.00%	90.02%	AP-3 complex subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0030123|	GO:0006886|GO:0016192|
GN017208.1	sp|K1QR61|K1QR61_CRAGI	4.6e-149	533.1	100.00%	78.92%	Secretory carrier-associated membrane protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015031|
GN017209.1	sp|K1RBB1|K1RBB1_CRAGI	5.2e-229	799.3	92.63%	80.78%	High-affinity choline transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN017210.1	sp|A0A2P6KJJ4|A0A2P6KJJ4_NEPCL	2.2e-67	261.5	96.54%	44.90%	Trmo;OS=Nephila;PE=4;SV=1
GN017212.1	sp|A0A210Q364|A0A210Q364_MIZYE	3.0e-81	307.8	99.43%	42.65%	Dolichol kinase;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN017213.1	sp|K1Q4A0|K1Q4A0_CRAGI	0.0e+00	1807.0	97.83%	90.30%	Coiled-coil domain-containing protein 87;OS=Crassostrea;PE=4;SV=1
GN017214.1	sp|K1QBQ1|K1QBQ1_CRAGI	3.6e-156	556.6	84.80%	87.54%	Aquaporin-9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015267|
GN015714.1	sp|K1PVE4|K1PVE4_CRAGI	3.5e-56	224.6	91.23%	35.99%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017215.1	sp|A0A210R0B1|A0A210R0B1_MIZYE	3.4e-88	330.5	97.83%	57.25%	Poly [ADP-ribose] polymerase;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0003950|GO:0004842|GO:0008270|
GN017216.1	sp|R7VED2|R7VED2_CAPTE	7.9e-41	172.9	90.83%	42.20%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN017217.1	sp|K1QZN1|K1QZN1_CRAGI	4.4e-106	389.4	100.00%	97.94%	Ribosome biogenesis protein NSA2-like protein;OS=Crassostrea;PE=4;SV=1
GN017218.1	sp|K1QQ96|K1QQ96_CRAGI	0.0e+00	2217.6	100.00%	82.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017220.1	sp|A0A210QDT8|A0A210QDT8_MIZYE	5.7e-54	218.0	88.92%	29.36%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|GO:0004842|
GN017221.1	sp|K1RW92|K1RW92_CRAGI	2.6e-285	986.9	87.47%	69.85%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017222.1	sp|K1RBC2|K1RBC2_CRAGI	6.1e-116	422.9	92.84%	66.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017223.1	sp|K1S6J0|K1S6J0_CRAGI	3.6e-199	700.7	57.27%	88.38%	Tetratricopeptide repeat protein 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017224.1	sp|A0A1S3K2C9|A0A1S3K2C9_LINUN	4.9e-40	171.0	78.24%	32.27%	photoreceptor outer segment membrane glycoprotein 2-like;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0007601|
GN017225.1	sp|A0A210PQ54|A0A210PQ54_MIZYE	2.6e-75	288.1	96.16%	39.89%	N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016757|
GN017226.1	sp|K1RN78|K1RN78_CRAGI	4.2e-265	919.1	94.39%	90.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN017227.1	sp|A0A1S3IKI1|A0A1S3IKI1_LINUN	1.3e-189	668.3	100.00%	73.77%	SNW domain-containing protein 1;OS=Lingula;PE=4;SV=1	GO:0005681|	GO:0000398|
GN017228.1	sp|K1RGZ4|K1RGZ4_CRAGI	3.0e-66	257.7	99.66%	51.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017229.1	sp|K1RBB8|K1RBB8_CRAGI	3.1e-78	297.0	100.00%	74.13%	Ras-related protein Rab-1A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN017231.1	sp|K1R157|K1R157_CRAGI	2.5e-72	276.9	94.19%	82.76%	Countin-1;OS=Crassostrea;PE=4;SV=1
GN017232.1	sp|K1S6I3|K1S6I3_CRAGI	3.0e-117	427.2	100.00%	65.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015547.1	sp|A0A210QDU7|A0A210QDU7_MIZYE	0.0e+00	1602.0	98.31%	32.85%	D-galactoside-specific lectin;OS=Mizuhopecten;PE=4;SV=1	GO:0030246|
GN015715.1	sp|K1QW11|K1QW11_CRAGI	3.4e-192	677.6	84.22%	72.35%	U3 small nucleolar ribonucleoprotein protein MPP10;OS=Crassostrea;PE=3;SV=1	GO:0034457|GO:0005732|	GO:0006364|
GN017233.1	sp|K1R6F9|K1R6F9_CRAGI	2.5e-305	1053.5	100.00%	62.82%	DNA polymerase kappa;OS=Crassostrea;PE=3;SV=1	GO:0003684|GO:0003887|	GO:0006281|
GN017234.1	sp|K1RCW2|K1RCW2_CRAGI	0.0e+00	1094.7	100.00%	92.49%	Collagen type IV alpha-3-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0008289|
GN017236.1	sp|K1RA34|K1RA34_CRAGI	3.4e-75	287.7	82.42%	57.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017237.1	sp|K1QKC6|K1QKC6_CRAGI	4.1e-13	79.3	100.00%	66.67%	Potassium channel subfamily K member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN017238.1	sp|K1Q034|K1Q034_CRAGI	5.5e-81	306.6	97.22%	66.31%	CDK-activating kinase assembly factor MAT1;OS=Crassostrea;PE=4;SV=1	GO:0005675|	GO:0061575|GO:0016301|	GO:0006289|
GN015716.1	sp|K1QLX5|K1QLX5_CRAGI	7.5e-191	672.5	100.00%	69.04%	TNF receptor-associated factor 3;OS=Crassostrea;PE=4;SV=1	GO:0005164|GO:0008270|	GO:0045087|GO:0032088|GO:0042981|GO:0001817|GO:0050688|GO:0008063|GO:0033209|
GN017239.1	sp|K1RGF5|K1RGF5_CRAGI	6.9e-185	652.1	92.68%	89.44%	E3 ubiquitin-protein ligase UBR2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|GO:0008270|	GO:0071596|
GN017240.1	sp|K1RZS7|K1RZS7_CRAGI	5.7e-138	495.7	100.00%	93.75%	Homeobox protein SIX4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017241.1	sp|K1PM99|K1PM99_CRAGI	9.0e-140	502.3	100.00%	68.95%	IMPACT-like protein;OS=Crassostrea;PE=4;SV=1
GN017242.1	sp|K1PY83|K1PY83_CRAGI	2.4e-125	453.8	97.58%	90.50%	Rho-related GTP-binding protein RhoU;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN017243.1	sp|K1PCF3|K1PCF3_CRAGI	0.0e+00	1107.8	96.32%	75.63%	28S ribosomal protein S5, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0008017|GO:0003723|GO:0003735|	GO:0000226|GO:0006412|
GN015717.1	sp|K1QSF5|K1QSF5_CRAGI	5.6e-142	509.2	100.00%	80.14%	Structure-specific endonuclease subunit SLX1 homolog;OS=Crassostrea;PE=3;SV=1	GO:0033557|	GO:0017108|GO:0046872|	GO:0006310|GO:0006281|
GN017244.1	sp|K1PIT6|K1PIT6_CRAGI	1.9e-138	497.7	93.15%	84.23%	Ribokinase;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0005524|GO:0046872|GO:0004747|	GO:0019303|
GN017245.1	sp|K1QVE0|K1QVE0_CRAGI	1.9e-123	448.0	100.00%	70.74%	Coiled-coil domain-containing protein 42-like protein;OS=Crassostrea;PE=4;SV=1
GN017246.1	sp|A0A210QJ88|A0A210QJ88_MIZYE	9.5e-22	109.4	97.64%	42.15%	SERTA domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1
GN017247.1	sp|A0A210QJ88|A0A210QJ88_MIZYE	3.3e-38	164.1	63.72%	66.44%	SERTA domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1
GN015718.1	sp|K1RCL8|K1RCL8_CRAGI	3.1e-213	746.5	90.74%	90.82%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN017250.1	sp|K1QAR9|K1QAR9_CRAGI	3.1e-304	1049.7	71.23%	93.47%	Fermitin family-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0007229|
GN017251.1	sp|K1QAR9|K1QAR9_CRAGI	2.6e-19	99.4	92.86%	94.12%	Fermitin family-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0007229|
GN017253.1	sp|A0A210QCY9|A0A210QCY9_MIZYE	4.2e-242	842.8	99.82%	67.38%	Dihydroxyacetone phosphate acyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0008374|	GO:0044255|
GN017254.1	sp|K1PY87|K1PY87_CRAGI	6.9e-53	212.6	78.80%	70.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN017255.1	sp|K1Q5H2|K1Q5H2_CRAGI	3.1e-32	143.7	81.94%	62.50%	Protein dopey-2;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0006895|
GN017256.1	sp|K1QL80|K1QL80_CRAGI	1.2e-150	539.3	77.43%	61.27%	Salvador-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0032947|	GO:0006915|GO:0035329|GO:0042127|
GN015719.1	sp|K1PG51|K1PG51_CRAGI	8.6e-29	131.3	97.44%	86.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017257.1	sp|K1RSP5|K1RSP5_CRAGI	7.7e-230	802.0	96.02%	92.13%	Radial spoke head protein 4-like protein A;OS=Crassostrea;PE=4;SV=1
GN017259.1	sp|K1R8T5|K1R8T5_CRAGI	0.0e+00	1348.6	100.00%	89.41%	Tripartite motif-containing protein 9;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017260.1	sp|K1R224|K1R224_CRAGI	4.4e-173	612.8	93.48%	89.67%	L-2-hydroxyglutarate dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN017261.1	sp|A0A221J378|A0A221J378_CRAGI	2.9e-191	673.3	100.00%	83.06%	Cysteine sulfinate decarboxylase 2;OS=Crassostrea;PE=2;SV=1	GO:0030170|GO:0004782|	GO:0019752|
GN017262.1	sp|K1QL77|K1QL77_CRAGI	3.9e-79	300.1	98.17%	70.23%	Autophagy-related protein 2-like protein B;OS=Crassostrea;PE=4;SV=1	GO:0006914|
GN017263.1	sp|K1QL77|K1QL77_CRAGI	3.5e-26	122.9	92.13%	75.31%	Autophagy-related protein 2-like protein B;OS=Crassostrea;PE=4;SV=1	GO:0006914|
GN017264.1	sp|K1R8S5|K1R8S5_CRAGI	4.7e-171	607.4	79.10%	50.14%	Platelet glycoprotein V;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017265.1	sp|K1PU09|K1PU09_CRAGI	2.6e-146	525.4	98.77%	33.87%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN017267.1	sp|K1QLA3|K1QLA3_CRAGI	1.4e-44	184.9	80.84%	68.61%	Kaptin;OS=Crassostrea;PE=4;SV=1	GO:0015629|	GO:0003779|	GO:0007015|
GN017268.1	sp|K1QDV0|K1QDV0_CRAGI	9.0e-65	251.9	85.71%	87.59%	RNA-binding protein PNO1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN017269.1	sp|K1Q5R0|K1Q5R0_CRAGI	1.3e-61	241.5	90.64%	74.84%	Apoptosis regulatory protein Siva;OS=Crassostrea;PE=4;SV=1
GN017270.1	sp|A0A210QAA8|A0A210QAA8_MIZYE	1.1e-197	695.7	91.64%	61.74%	Serologically defined colon cancer antigen 8-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005813|	GO:0007098|
GN017271.1	sp|K1QNF8|K1QNF8_CRAGI	4.2e-14	85.1	34.13%	33.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017273.1	sp|A0A210QZL0|A0A210QZL0_MIZYE	7.5e-197	693.3	99.12%	37.47%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016810|	GO:0005975|
GN015721.1	sp|K1QS20|K1QS20_CRAGI	4.4e-22	111.3	26.81%	50.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017274.1	sp|K1PYB7|K1PYB7_CRAGI	1.1e-219	768.5	72.27%	78.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016810|	GO:0005975|
GN017275.1	sp|R7UCN5|R7UCN5_CAPTE	2.9e-10	70.5	85.04%	33.33%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN017276.1	sp|K1QT76|K1QT76_CRAGI	2.8e-11	76.6	38.11%	21.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017277.1	sp|K1PGB5|K1PGB5_CRAGI	7.0e-102	375.6	100.00%	90.82%	Vacuolar protein sorting-associated protein 45;OS=Crassostrea;PE=3;SV=1	GO:0006904|
GN017278.1	sp|K1PYB0|K1PYB0_CRAGI	9.8e-43	178.7	98.77%	57.50%	Cofilin;OS=Crassostrea;PE=3;SV=1	GO:0015629|	GO:0003779|	GO:0030042|
GN015722.1	sp|A0A210PW07|A0A210PW07_MIZYE	0.0e+00	1482.6	75.90%	70.30%	Symplekin;OS=Mizuhopecten;PE=4;SV=1
GN017280.1	sp|A0A210QGQ4|A0A210QGQ4_MIZYE	1.8e-18	99.4	99.21%	28.78%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017281.1	sp|K1R5M3|K1R5M3_CRAGI	4.8e-186	656.0	99.73%	83.11%	Peptidyl-glycine alpha-amidating monooxygenase A;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0004497|	GO:0006518|
GN017282.1	sp|K1PA58|K1PA58_CRAGI	6.2e-162	575.9	94.25%	79.01%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN017283.1	sp|K1PWE8|K1PWE8_CRAGI	1.5e-88	331.3	99.50%	83.50%	39S ribosomal protein L11, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN017284.1	sp|K1PGB2|K1PGB2_CRAGI	0.0e+00	4180.2	91.65%	74.83%	Zinc finger FYVE domain-containing protein 26;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0032266|	GO:0000724|GO:0000281|
GN017285.1	sp|A0A210R3A5|A0A210R3A5_MIZYE	1.2e-89	335.5	100.00%	57.32%	Hydrolethalus syndrome protein 1-like;OS=Mizuhopecten;PE=4;SV=1
GN017286.1	sp|Q4H448|Q4H448_CRAGI	6.4e-56	222.2	94.81%	88.19%	40S ribosomal protein S30;OS=Crassostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN017288.1	sp|K1PMM0|K1PMM0_CRAGI	1.5e-70	271.9	54.42%	79.87%	39S ribosomal protein L4, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN017289.1	sp|K1PHA7|K1PHA7_CRAGI	6.0e-28	130.2	54.07%	55.71%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN017290.1	sp|K1R895|K1R895_CRAGI	7.4e-79	299.3	69.96%	83.72%	U11/U12 small nuclear ribonucleoprotein 35 kDa protein;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0003723|
GN017291.1	sp|K1P3D7|K1P3D7_CRAGI	3.3e-225	786.6	99.81%	71.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017292.1	sp|K1PA00|K1PA00_CRAGI	2.0e-131	474.9	90.30%	69.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017293.1	sp|K1PP83|K1PP83_CRAGI	3.0e-188	664.1	64.94%	79.76%	Vesicular glutamate transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017294.1	sp|K1Q9Z5|K1Q9Z5_CRAGI	3.3e-91	340.1	88.10%	89.67%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|	GO:0006457|
GN017296.1	sp|K1P3E8|K1P3E8_CRAGI	1.4e-83	315.1	67.66%	84.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017297.1	sp|C3YZ71|C3YZ71_BRAFL	6.8e-44	183.7	64.29%	41.60%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN015548.1	sp|K1QDE0|K1QDE0_CRAGI	7.0e-99	367.1	42.20%	67.68%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007160|
GN017298.1	sp|K1QSQ1|K1QSQ1_CRAGI	9.5e-149	531.9	94.08%	87.42%	Forkhead box protein B1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN017299.1	sp|A0A226D9P1|A0A226D9P1_FOLCA	1.5e-15	88.6	73.18%	38.64%	Myb/SANT-like DNA-binding domain-containing protein 3;OS=Folsomia;PE=4;SV=1	GO:0003677|
GN017300.1	sp|K1QZP9|K1QZP9_CRAGI	5.1e-47	193.7	99.29%	45.26%	Cell death regulator Aven;OS=Crassostrea;PE=4;SV=1
GN017301.1	sp|K1R616|K1R616_CRAGI	7.7e-193	679.1	91.50%	69.82%	Synaptotagmin-1;OS=Crassostrea;PE=4;SV=1	GO:0005544|	GO:0006887|
GN017303.1	sp|A0A1S3JB50|A0A1S3JB50_LINUN	1.1e-21	109.4	93.39%	34.15%	uncharacterized protein LOC106171724;OS=Lingula;PE=4;SV=1
GN015725.1	sp|K1PYG9|K1PYG9_CRAGI	2.5e-117	427.6	100.00%	88.82%	FAM50-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN015726.1	sp|A0A210QPN8|A0A210QPN8_MIZYE	7.5e-31	139.8	63.07%	50.32%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017320.1	sp|K1Q8M5|K1Q8M5_CRAGI	0.0e+00	1467.6	95.89%	70.87%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN017321.1	sp|A0A210QXD5|A0A210QXD5_MIZYE	4.8e-181	639.8	94.27%	63.94%	Histone-lysine N-methyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0046975|GO:0003713|	GO:0018027|GO:0018026|GO:0018023|
GN017322.1	sp|K1PU31|K1PU31_CRAGI	3.8e-92	344.4	100.00%	69.63%	Cyclin-K;OS=Crassostrea;PE=3;SV=1
GN015727.1	sp|K1PQH5|K1PQH5_CRAGI	8.5e-115	420.2	98.32%	36.78%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN017323.1	sp|K1Q1D8|K1Q1D8_CRAGI	6.5e-53	212.6	88.44%	66.67%	ADP-ribosylation factor-like protein 11;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN017324.1	sp|K1QTK0|K1QTK0_CRAGI	4.2e-59	234.2	82.56%	43.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017325.1	sp|K1QP07|K1QP07_CRAGI	3.5e-196	689.9	97.92%	85.48%	Mediator of RNA polymerase II transcription subunit 17;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN017326.1	sp|K1RV50|K1RV50_CRAGI	0.0e+00	1979.9	100.00%	79.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017327.1	sp|K1QP03|K1QP03_CRAGI	1.3e-123	448.4	89.75%	75.35%	Retinol dehydrogenase 13;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN017328.1	sp|K1P624|K1P624_CRAGI	4.7e-68	263.5	58.80%	89.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017329.1	sp|K1QUR5|K1QUR5_CRAGI	4.1e-91	340.9	62.39%	69.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0034993|	GO:0051015|	GO:0090286|
GN017330.1	sp|K1QUR5|K1QUR5_CRAGI	9.9e-34	148.3	92.92%	73.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0034993|	GO:0051015|	GO:0090286|
GN017331.1	sp|K1RF08|K1RF08_CRAGI	0.0e+00	5380.5	98.91%	81.03%	Nesprin-1;OS=Crassostrea;PE=4;SV=1	GO:0034993|	GO:0051015|	GO:0090286|
GN017334.1	sp|K1R9P2|K1R9P2_CRAGI	1.1e-255	889.0	54.56%	70.80%	Dispatched-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007224|
GN017335.1	sp|A0A2G8JSV9|A0A2G8JSV9_STIJA	4.7e-37	161.8	47.01%	38.18%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN017337.1	sp|K1PTW9|K1PTW9_CRAGI	4.8e-12	77.0	53.61%	37.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015728.1	sp|K1R2I6|K1R2I6_CRAGI	6.4e-16	89.4	77.44%	54.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017340.1	sp|K1PC63|K1PC63_CRAGI	3.4e-41	173.7	97.69%	46.15%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017341.1	sp|K1PC63|K1PC63_CRAGI	1.3e-38	164.9	100.00%	58.04%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017343.1	sp|K1QXL1|K1QXL1_CRAGI	1.7e-135	488.4	82.21%	66.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017344.1	sp|K1QXL4|K1QXL4_CRAGI	1.3e-146	525.0	99.46%	65.76%	Disintegrin and metalloproteinase domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN017345.1	sp|A0A210QNS9|A0A210QNS9_MIZYE	4.8e-48	197.2	82.09%	42.51%	Disintegrin and metalloproteinase domain-containing protein 10;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN017346.1	sp|K1S2S5|K1S2S5_CRAGI	2.2e-27	127.1	74.04%	78.95%	Retinol dehydrogenase 12;OS=Crassostrea;PE=4;SV=1
GN017347.1	sp|K1R790|K1R790_CRAGI	5.6e-112	409.5	97.37%	78.38%	Retinol dehydrogenase 13;OS=Crassostrea;PE=3;SV=1
GN017348.1	sp|K1RJ48|K1RJ48_CRAGI	5.0e-154	549.7	95.57%	91.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0045252|	GO:0004149|	GO:0006099|
GN017349.1	sp|A0A210QNR6|A0A210QNR6_MIZYE	2.1e-83	315.8	89.59%	41.59%	Homeobox protein prospero;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|	GO:0006355|
GN017350.1	sp|K1RD84|K1RD84_CRAGI	3.2e-83	313.2	100.00%	95.48%	Homeobox protein prospero;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN017351.1	sp|K1RD88|K1RD88_CRAGI	2.0e-66	258.1	95.72%	51.81%	Disintegrin and metalloproteinase domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0007229|
GN017352.1	sp|K1RD88|K1RD88_CRAGI	6.3e-209	732.6	93.33%	62.20%	Disintegrin and metalloproteinase domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0008270|	GO:0007229|
GN015729.1	sp|K1R8J8|K1R8J8_CRAGI	3.2e-113	413.3	100.00%	85.78%	BTB/POZ domain-containing protein KCTD7;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN017353.1	sp|K1RJ53|K1RJ53_CRAGI	0.0e+00	1223.4	100.00%	84.06%	Tetratricopeptide repeat protein 12;OS=Crassostrea;PE=4;SV=1
GN017354.1	sp|K1S2S8|K1S2S8_CRAGI	2.3e-240	836.6	100.00%	98.86%	Signal recognition particle 54 kDa protein;OS=Crassostrea;PE=3;SV=1	GO:0005786|	GO:0008312|GO:0005525|GO:0003924|	GO:0006614|
GN017355.1	sp|K1QXL7|K1QXL7_CRAGI	0.0e+00	1156.7	100.00%	87.12%	BTB/POZ domain-containing protein KCTD3;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN017356.1	sp|V4AA55|V4AA55_LOTGI	2.1e-98	364.8	89.75%	55.73%	Phosphatidate cytidylyltransferase, mitochondrial;OS=Lottia;PE=3;SV=1	GO:0005743|	GO:0004605|	GO:0032049|GO:0016024|
GN017357.1	sp|A0A210QI09|A0A210QI09_MIZYE	3.3e-46	189.9	97.60%	71.07%	Actin-binding Rho-activating protein;OS=Mizuhopecten;PE=4;SV=1
GN017358.1	sp|K1RD89|K1RD89_CRAGI	5.0e-18	96.3	63.78%	57.50%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN017359.1	sp|K1PVQ2|K1PVQ2_CRAGI	2.2e-55	220.7	91.77%	76.39%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017360.1	sp|K1QE52|K1QE52_CRAGI	8.4e-139	501.1	25.06%	60.71%	Neurogenic locus notch-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN017361.1	sp|K1Q4X9|K1Q4X9_CRAGI	2.0e-162	577.4	100.00%	83.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017362.1	sp|K1QG34|K1QG34_CRAGI	3.7e-15	88.2	29.65%	41.12%	Titin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017364.1	sp|K1QLA4|K1QLA4_CRAGI	1.2e-27	128.6	77.71%	58.91%	DNA repair protein REV1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003684|GO:0016779|	GO:0042276|
GN017365.1	sp|K1QLA4|K1QLA4_CRAGI	0.0e+00	1269.2	99.57%	75.45%	DNA repair protein REV1;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003684|GO:0016779|	GO:0042276|
GN017366.1	sp|K1QSB0|K1QSB0_CRAGI	4.2e-181	639.4	98.82%	92.54%	Fructose-1,6-bisphosphatase 1;OS=Crassostrea;PE=3;SV=1	GO:0042132|	GO:0005975|
GN017367.1	sp|K1RCH0|K1RCH0_CRAGI	0.0e+00	2847.4	100.00%	72.18%	Putative histone-lysine N-methyltransferase ASH1L;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003682|GO:0003677|GO:0018024|GO:0046872|
GN017368.1	sp|A0A059XSR0|A0A059XSR0_9VEST	1.4e-48	198.7	94.40%	40.00%	Mitochondrial 28S ribosomal protein S29 isoform 1;OS=Haliotis;PE=2;SV=1	GO:0005761|GO:0015935|	GO:0006915|
GN017369.1	sp|K1PF20|K1PF20_CRAGI	0.0e+00	1157.9	91.81%	91.73%	Gamma-tubulin complex component;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|GO:0005815|GO:0000922|	GO:0043015|	GO:0007020|
GN015731.1	sp|A0A210QFL3|A0A210QFL3_MIZYE	3.8e-13	79.7	81.19%	50.62%	Regulator of G-protein signaling 9-binding protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN017370.1	sp|K1RWV4|K1RWV4_CRAGI	7.0e-272	941.8	96.63%	80.35%	Alpha-(1,6)-fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008424|	GO:0033578|
GN017371.1	sp|K1R753|K1R753_CRAGI	1.3e-142	511.9	92.38%	65.81%	Arrestin domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN017372.1	sp|K1QR05|K1QR05_CRAGI	1.5e-126	458.4	94.76%	59.02%	Mitochondrial genome maintenance exonuclease 1;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0008297|	GO:0043504|
GN017373.1	sp|K1RWU9|K1RWU9_CRAGI	4.4e-95	353.6	100.00%	74.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005681|	GO:0003676|GO:0008270|
GN017375.1	sp|A0A210QE04|A0A210QE04_MIZYE	4.0e-17	93.6	94.19%	35.86%	Sugar transporter SWEET1;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0008643|
GN017376.1	sp|K1RDL1|K1RDL1_CRAGI	3.4e-75	287.3	100.00%	75.99%	Survival motor neuron protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0003723|	GO:0006397|
GN017377.1	sp|K1PE62|K1PE62_CRAGI	1.8e-98	364.8	100.00%	78.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017378.1	sp|K1QKB1|K1QKB1_CRAGI	2.3e-219	766.9	90.11%	94.63%	Tryptophanyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004830|	GO:0006436|
GN017379.1	sp|K1Q018|K1Q018_CRAGI	7.5e-137	493.0	53.95%	79.57%	WD repeat-containing protein 25;OS=Crassostrea;PE=4;SV=1
GN017380.1	sp|K1PTF8|K1PTF8_CRAGI	3.4e-223	779.6	99.55%	84.05%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN017381.1	sp|A0A210QIW6|A0A210QIW6_MIZYE	1.5e-75	288.9	89.36%	41.83%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|	GO:0035556|
GN017382.1	sp|K1QKX9|K1QKX9_CRAGI	3.0e-21	107.1	99.26%	40.50%	Ryanodine receptor 44F;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0016021|	GO:0005509|GO:0005219|
GN017383.1	sp|K1R1N3|K1R1N3_CRAGI	1.5e-79	301.6	78.99%	85.56%	HAUS augmin-like complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0070652|	GO:0051225|
GN017384.1	sp|K1Q7T5|K1Q7T5_CRAGI	8.1e-236	821.6	98.03%	88.14%	Protein disulfide-isomerase;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0003756|	GO:0045454|
GN017385.1	sp|K1RFC5|K1RFC5_CRAGI	1.5e-135	487.6	100.00%	97.18%	Methyl-CpG-binding domain protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN017386.1	sp|K1QV41|K1QV41_CRAGI	0.0e+00	1983.8	99.82%	88.16%	Tetratricopeptide repeat protein 28;OS=Crassostrea;PE=4;SV=1
GN017387.1	sp|K1QV41|K1QV41_CRAGI	1.5e-150	540.0	99.79%	32.38%	Tetratricopeptide repeat protein 28;OS=Crassostrea;PE=4;SV=1
GN017388.1	sp|K1R9V5|K1R9V5_CRAGI	3.6e-116	423.3	98.04%	80.72%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN017389.1	sp|K1QI00|K1QI00_CRAGI	1.4e-136	491.5	100.00%	84.30%	Myocyte-specific enhancer factor 2A;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0046983|GO:0000977|	GO:0045944|
GN017390.1	sp|K1QA05|K1QA05_CRAGI	0.0e+00	1113.2	99.82%	96.42%	DET1-like protein;OS=Crassostrea;PE=4;SV=1
GN017391.1	sp|K1Q2Y5|K1Q2Y5_CRAGI	0.0e+00	1522.3	75.81%	71.23%	Formin-2;OS=Crassostrea;PE=4;SV=1
GN017392.1	sp|A0A210R4Y8|A0A210R4Y8_MIZYE	2.0e-144	518.1	93.79%	65.93%	Myocyte-specific enhancer factor 2A;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0046983|GO:0000977|	GO:0045944|
GN015735.1	sp|K1RY80|K1RY80_CRAGI	9.1e-188	662.1	90.30%	72.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|	GO:0007165|
GN017393.1	sp|R7V4A1|R7V4A1_CAPTE	5.3e-86	323.2	87.41%	68.64%	Uncharacterized protein;OS=Capitella;PE=3;SV=1	GO:0051539|GO:0046872|GO:0008137|GO:0048038|
GN017394.1	sp|K1Q2Y1|K1Q2Y1_CRAGI	2.6e-58	229.9	100.00%	100.00%	40S ribosomal protein S15;OS=Crassostrea;PE=3;SV=1	GO:0015935|	GO:0003723|GO:0003735|	GO:0006412|
GN017395.1	sp|K1R165|K1R165_CRAGI	2.0e-15	88.6	35.77%	48.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017396.1	sp|K1S039|K1S039_CRAGI	5.8e-73	279.3	87.64%	75.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017398.1	sp|K1QVG5|K1QVG5_CRAGI	6.0e-177	625.9	97.87%	71.26%	Retinal dehydrogenase 1;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN017402.1	sp|K1QL96|K1QL96_CRAGI	0.0e+00	1676.0	100.00%	85.44%	Alpha-mannosidase;OS=Crassostrea;PE=3;SV=1	GO:0004559|GO:0030246|GO:0046872|	GO:0006013|
GN015736.1	sp|K1QT20|K1QT20_CRAGI	5.2e-39	166.8	49.08%	79.25%	C16orf88-like protein;OS=Crassostrea;PE=4;SV=1
GN017404.1	sp|K1PWP8|K1PWP8_CRAGI	0.0e+00	1313.9	100.00%	77.14%	Echinoderm microtubule-associated protein-like 1;OS=Crassostrea;PE=4;SV=1
GN017405.1	sp|K1PPI7|K1PPI7_CRAGI	9.1e-309	1064.7	97.75%	82.50%	Dynein heavy chain 1, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0005858|	GO:0005524|GO:0016887|GO:0003777|	GO:0060285|GO:0007018|
GN017406.1	sp|K1PPI7|K1PPI7_CRAGI	0.0e+00	7477.5	99.79%	90.38%	Dynein heavy chain 1, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0005858|	GO:0005524|GO:0016887|GO:0003777|	GO:0060285|GO:0007018|
GN017407.1	sp|K1QRK5|K1QRK5_CRAGI	0.0e+00	1226.5	97.14%	83.36%	Myotubularin-related protein 10-A;OS=Crassostrea;PE=3;SV=1
GN017408.1	sp|K1PRX5|K1PRX5_CRAGI	7.7e-111	406.4	63.11%	66.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015737.1	sp|K1R2J2|K1R2J2_CRAGI	2.0e-71	274.6	87.24%	60.38%	C-type lectin domain family 5 member A;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN017410.1	sp|K1QJ15|K1QJ15_CRAGI	2.0e-181	641.0	98.07%	70.65%	Forkhead box protein B1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN017412.1	sp|K1R8Y9|K1R8Y9_CRAGI	1.9e-104	384.4	94.78%	77.91%	Translin-associated protein X;OS=Crassostrea;PE=4;SV=1	GO:0043565|
GN017413.1	sp|K1Q233|K1Q233_CRAGI	2.6e-227	794.3	99.31%	62.28%	Kinesin-like protein KIF16B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|GO:0035091|	GO:0007018|
GN017414.1	sp|K1Q233|K1Q233_CRAGI	8.9e-207	724.9	98.48%	93.30%	Kinesin-like protein KIF16B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|GO:0035091|	GO:0007018|
GN017415.1	sp|K1Q942|K1Q942_CRAGI	2.1e-174	617.8	99.81%	59.49%	Angel-like protein 2;OS=Crassostrea;PE=4;SV=1
GN017416.1	sp|K1QH50|K1QH50_CRAGI	5.6e-155	552.7	100.00%	74.87%	Vasohibin-1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0045765|
GN017417.1	sp|K1QNP0|K1QNP0_CRAGI	0.0e+00	1625.9	82.28%	84.59%	Multidrug resistance-associated protein 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN017419.1	sp|K1R902|K1R902_CRAGI	0.0e+00	1442.2	100.00%	85.76%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0000287|GO:0004674|	GO:0035556|
GN017420.1	sp|K1Q247|K1Q247_CRAGI	3.2e-76	290.0	100.00%	84.02%	UPF0566 protein;OS=Crassostrea;PE=4;SV=1	GO:0002161|
GN017421.1	sp|K1QNP6|K1QNP6_CRAGI	1.8e-160	571.2	76.16%	84.36%	RNA polymerase II-associated factor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016593|	GO:0016570|GO:0006368|
GN017422.1	sp|K1Q253|K1Q253_CRAGI	2.8e-263	913.3	100.00%	70.52%	Neutral and basic amino acid transport protein rBAT;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003824|	GO:0005975|
GN017423.1	sp|K1P534|K1P534_CRAGI	9.9e-89	332.4	86.75%	64.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017424.1	sp|K1PBB1|K1PBB1_CRAGI	9.1e-88	329.3	100.00%	77.68%	Stress-induced-phosphoprotein 1;OS=Crassostrea;PE=4;SV=1
GN017425.1	sp|K1PBB1|K1PBB1_CRAGI	2.8e-214	750.4	100.00%	82.86%	Stress-induced-phosphoprotein 1;OS=Crassostrea;PE=4;SV=1
GN017426.1	sp|K1PIN3|K1PIN3_CRAGI	1.6e-74	285.4	93.16%	50.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017427.1	sp|K1P541|K1P541_CRAGI	4.6e-152	542.7	100.00%	94.86%	Alpha-soluble NSF attachment protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0006886|
GN017428.1	sp|K1QB39|K1QB39_CRAGI	6.2e-176	623.2	96.71%	88.07%	Golgin subfamily A member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007030|
GN017429.1	sp|K1PIM9|K1PIM9_CRAGI	3.5e-253	879.4	100.00%	89.32%	Forkhead box protein N3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN017430.1	sp|K1QIC7|K1QIC7_CRAGI	2.7e-38	165.2	74.55%	37.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017431.1	sp|K1QB42|K1QB42_CRAGI	0.0e+00	1451.0	94.79%	81.87%	F-box/WD repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN017432.1	sp|K1P547|K1P547_CRAGI	3.3e-97	360.1	100.00%	77.19%	Cyclin-dependent kinase inhibitor 3;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0004725|
GN017435.1	sp|K1RH58|K1RH58_CRAGI	0.0e+00	1728.4	100.00%	97.07%	Alpha-actinin, sarcomeric;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0005509|
GN017437.1	sp|K1QKX8|K1QKX8_CRAGI	0.0e+00	1250.7	100.00%	69.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017438.1	sp|K1PTX2|K1PTX2_CRAGI	1.2e-58	232.6	69.94%	55.36%	D-galactoside-specific lectin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN017439.1	sp|K1PTX2|K1PTX2_CRAGI	4.3e-18	97.8	35.44%	41.60%	D-galactoside-specific lectin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN017442.1	sp|A7RQS6|A7RQS6_NEMVE	1.6e-27	129.0	100.00%	31.00%	Predicted protein;OS=Nematostella;PE=4;SV=1
GN017443.1	sp|A0A2G8LMM1|A0A2G8LMM1_STIJA	1.7e-33	149.1	78.72%	34.36%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN017445.1	sp|K1QRN4|K1QRN4_CRAGI	1.7e-294	1017.7	95.41%	52.28%	Zonadhesin;OS=Crassostrea;PE=4;SV=1
GN017447.1	sp|K1QQA6|K1QQA6_CRAGI	0.0e+00	2268.0	98.21%	91.37%	Serine/threonine-protein kinase ULK4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN015549.1	sp|K1PKN9|K1PKN9_CRAGI	2.3e-74	285.4	68.88%	44.85%	Calcitonin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN015739.1	sp|A0A210QJQ0|A0A210QJQ0_MIZYE	4.4e-16	90.5	45.05%	46.15%	THAP domain-containing protein 1 A;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN017448.1	sp|K1RQC1|K1RQC1_CRAGI	0.0e+00	2167.9	96.43%	83.46%	Xanthine dehydrogenase/oxidase;OS=Crassostrea;PE=4;SV=1	GO:0051537|GO:0009055|GO:0071949|GO:0005506|GO:0004854|GO:0004855|
GN017449.1	sp|K1QID5|K1QID5_CRAGI	4.5e-115	420.2	93.07%	75.64%	Thyrotroph embryonic factor;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN017450.1	sp|K1QSC0|K1QSC0_CRAGI	1.3e-25	120.9	96.55%	84.34%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0000469|
GN017451.1	sp|K1QZF1|K1QZF1_CRAGI	4.4e-205	719.2	100.00%	94.93%	WD repeat-containing protein 92;OS=Crassostrea;PE=4;SV=1
GN017452.1	sp|A0A210R0B9|A0A210R0B9_MIZYE	3.7e-56	223.4	100.00%	60.69%	EF-hand calcium-binding domain-containing protein 11;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN017453.1	sp|K1QL91|K1QL91_CRAGI	6.1e-157	560.5	94.00%	95.29%	F-box only protein 11;OS=Crassostrea;PE=4;SV=1	GO:0000151|	GO:0008270|	GO:0016567|
GN017454.1	sp|K1Q0W8|K1Q0W8_CRAGI	1.5e-73	281.6	69.96%	81.94%	Follistatin-related protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0008378|	GO:0006486|
GN017455.1	sp|K1QDV2|K1QDV2_CRAGI	1.1e-23	115.9	82.19%	34.75%	Neuroendocrine convertase 1;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN017456.1	sp|A0A131XQ81|A0A131XQ81_IXORI	4.5e-49	201.4	91.63%	31.29%	Putative is4eu-1 dr;OS=Ixodes;PE=2;SV=1	GO:0008270|
GN017457.1	sp|V4AGJ7|V4AGJ7_LOTGI	1.4e-32	145.6	77.87%	41.58%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN017459.1	sp|A0A1X7T0L5|A0A1X7T0L5_AMPQE	1.5e-32	146.0	94.13%	28.17%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN017460.1	sp|K1S0V2|K1S0V2_CRAGI	2.9e-16	90.9	72.47%	39.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017461.1	sp|K1QCU1|K1QCU1_CRAGI	6.6e-92	343.2	100.00%	73.74%	Homeobox protein Nkx-2.2a;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017462.1	sp|K1PVH5|K1PVH5_CRAGI	0.0e+00	1225.3	94.06%	84.39%	Centromere/kinetochore protein zw10-like protein;OS=Crassostrea;PE=4;SV=1	GO:0000775|GO:0005634|	GO:0000278|
GN017463.1	sp|K1PPX3|K1PPX3_CRAGI	1.2e-79	302.8	89.36%	71.29%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017466.1	sp|A0A1X7U207|A0A1X7U207_AMPQE	1.5e-32	146.0	96.77%	26.59%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN017467.1	sp|K1S0V2|K1S0V2_CRAGI	5.9e-17	93.2	72.47%	39.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017468.1	sp|C3ZC42|C3ZC42_BRAFL	5.2e-09	67.8	65.71%	25.31%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN017470.1	sp|K1PK06|K1PK06_CRAGI	3.6e-17	94.4	52.87%	40.31%	Myb-related transcription factor, partner of profilin;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN017471.1	sp|K1R5Q8|K1R5Q8_CRAGI	7.8e-37	158.3	98.91%	70.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN017472.1	sp|C3ZG36|C3ZG36_BRAFL	3.5e-30	137.9	64.85%	37.17%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0015074|GO:0006310|GO:0009299|
GN017473.1	sp|K1QSB4|K1QSB4_CRAGI	4.3e-188	663.3	100.00%	74.58%	Uncharacterized protein C14orf45-like protein;OS=Crassostrea;PE=4;SV=1	GO:0036064|
GN017475.1	sp|K1QDR7|K1QDR7_CRAGI	2.0e-56	225.7	37.47%	58.62%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN017476.1	sp|W4Z9W9|W4Z9W9_STRPU	1.5e-41	176.0	66.93%	41.47%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN017478.1	sp|K1PGR1|K1PGR1_CRAGI	2.8e-65	255.4	48.18%	48.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017479.1	sp|I6LKQ5|I6LKQ5_9BIVA	3.7e-29	133.7	69.28%	57.89%	Glutathione S-transferase zeta;OS=Azumapecten;PE=2;SV=1	GO:0005737|	GO:0016740|	GO:0009072|
GN017480.1	sp|A0A210R5U8|A0A210R5U8_MIZYE	1.0e-38	165.2	79.87%	63.87%	Protein O-mannosyl-transferase 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0000030|	GO:0006493|
GN017481.1	sp|A0A210QXN2|A0A210QXN2_MIZYE	5.0e-66	257.3	90.59%	42.27%	Beta-N-acetyl-D-glucosaminide beta-1,4-N-acetylglucosaminyl-transferase;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016757|	GO:0005975|
GN017482.1	sp|A0A210QDZ8|A0A210QDZ8_MIZYE	5.6e-38	162.9	100.00%	52.33%	Neudesin;OS=Mizuhopecten;PE=3;SV=1
GN017485.1	sp|K1Q8L9|K1Q8L9_CRAGI	1.1e-176	625.2	95.58%	86.54%	Eukaryotic translation initiation factor 5;OS=Crassostrea;PE=4;SV=1	GO:0003743|
GN017486.1	sp|K1PTU0|K1PTU0_CRAGI	2.1e-198	698.0	98.29%	90.42%	Kinesin light chain;OS=Crassostrea;PE=4;SV=1	GO:0005871|	GO:0003777|
GN015743.1	sp|K1R9V2|K1R9V2_CRAGI	4.6e-59	233.0	100.00%	65.05%	28S ribosomal protein S16, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN017487.1	sp|K1QFR9|K1QFR9_CRAGI	0.0e+00	4243.3	100.00%	91.50%	Spectrin beta chain;OS=Crassostrea;PE=3;SV=1	GO:0008091|	GO:0003779|GO:0005543|GO:0005200|	GO:0051693|
GN017488.1	sp|A0A210QC21|A0A210QC21_MIZYE	8.4e-133	479.9	80.96%	47.67%	DDB1-and CUL4-associated factor 5;OS=Mizuhopecten;PE=4;SV=1
GN017489.1	sp|K1PLJ1|K1PLJ1_CRAGI	5.6e-09	66.6	63.47%	32.08%	Protein D7;OS=Crassostrea;PE=4;SV=1	GO:0007283|
GN017490.1	sp|K1QFR5|K1QFR5_CRAGI	7.1e-100	369.0	99.56%	80.80%	Solute carrier organic anion transporter family member;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005215|	GO:0006811|GO:0055085|
GN017491.1	sp|K1PXN3|K1PXN3_CRAGI	9.2e-10	69.7	51.28%	36.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017492.1	sp|K1QSF1|K1QSF1_CRAGI	7.8e-29	131.7	89.13%	82.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0030234|	GO:0019348|
GN017493.1	sp|K1QSF1|K1QSF1_CRAGI	1.3e-23	113.6	98.15%	100.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030176|	GO:0030234|	GO:0019348|
GN017494.1	sp|A0A210QJF8|A0A210QJF8_MIZYE	2.7e-132	478.0	87.72%	64.74%	Coiled-coil domain-containing protein 61;OS=Mizuhopecten;PE=4;SV=1
GN017495.1	sp|K1RXU3|K1RXU3_CRAGI	2.6e-203	713.8	91.43%	73.80%	F-box/WD repeat-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN017496.1	sp|K1PUB3|K1PUB3_CRAGI	7.6e-30	135.2	89.90%	74.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN017497.1	sp|K1R202|K1R202_CRAGI	9.8e-169	599.0	100.00%	94.05%	T-complex-associated testis-expressed protein 1;OS=Crassostrea;PE=4;SV=1
GN017498.1	sp|K1QSG6|K1QSG6_CRAGI	4.7e-65	252.7	97.18%	87.68%	D-aminoacyl-tRNA deacylase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0051500|GO:0000049|
GN017500.1	sp|K1RXU8|K1RXU8_CRAGI	2.0e-33	147.9	75.58%	56.94%	Cell growth regulator with RING finger domain protein 1;OS=Crassostrea;PE=4;SV=1
GN015550.1	sp|K1R9N6|K1R9N6_CRAGI	3.5e-53	214.9	56.01%	43.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015744.1	sp|K1PXF9|K1PXF9_CRAGI	1.3e-109	401.4	100.00%	86.30%	Cyclin-O;OS=Crassostrea;PE=3;SV=1	GO:0005634|
GN017501.1	sp|K1REN0|K1REN0_CRAGI	0.0e+00	1622.8	97.79%	86.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017502.1	sp|K1R846|K1R846_CRAGI	0.0e+00	1911.3	99.71%	73.05%	RNA polymerase II-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006366|
GN017503.1	sp|K1PBL7|K1PBL7_CRAGI	0.0e+00	3528.0	100.00%	90.65%	HEAT repeat-containing protein 5B;OS=Crassostrea;PE=4;SV=1
GN017504.1	sp|K1QHV5|K1QHV5_CRAGI	4.5e-152	543.9	96.82%	48.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004531|
GN017505.1	sp|K1PBM7|K1PBM7_CRAGI	8.3e-164	582.0	100.00%	81.82%	tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A;OS=Crassostrea;PE=3;SV=1	GO:0005634|GO:0031515|	GO:0016429|
GN017506.1	sp|K1PI13|K1PI13_CRAGI	9.8e-39	166.8	39.28%	56.79%	Leucine-rich repeat protein soc-2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017507.1	sp|K1PQT5|K1PQT5_CRAGI	9.0e-137	492.7	100.00%	54.30%	Isthmin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017509.1	sp|A0A0P4VQ93|A0A0P4VQ93_9EUCA	1.4e-94	352.4	96.54%	40.58%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN017510.1	sp|K1QHW0|K1QHW0_CRAGI	3.3e-146	523.9	98.85%	66.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017513.1	sp|K1PQU1|K1PQU1_CRAGI	0.0e+00	1939.9	100.00%	70.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017514.1	sp|K1QHW4|K1QHW4_CRAGI	4.8e-33	146.4	55.86%	81.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0032299|	GO:0006401|
GN017515.1	sp|A0A210PPK2|A0A210PPK2_MIZYE	1.6e-35	154.8	68.24%	74.78%	Protein FAM89B;OS=Mizuhopecten;PE=4;SV=1
GN015746.1	sp|K1QAU5|K1QAU5_CRAGI	2.1e-13	81.3	29.56%	76.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017517.1	sp|K1QUU2|K1QUU2_CRAGI	1.0e-170	605.1	100.00%	77.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017518.1	sp|K1PR28|K1PR28_CRAGI	1.9e-47	193.7	100.00%	88.46%	Cytoglobin-1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN017519.1	sp|K1PR28|K1PR28_CRAGI	1.9e-47	193.7	100.00%	88.46%	Cytoglobin-1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN017520.1	sp|K1PBL2|K1PBL2_CRAGI	0.0e+00	2121.3	99.93%	82.19%	Eukaryotic initiation factor 4A-III;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003743|
GN017521.1	sp|K1QWT7|K1QWT7_CRAGI	1.0e-143	515.0	98.64%	82.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017522.1	sp|K1QNF8|K1QNF8_CRAGI	4.2e-14	85.1	33.69%	33.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015747.1	sp|K1PXF9|K1PXF9_CRAGI	6.7e-111	405.6	100.00%	87.21%	Cyclin-O;OS=Crassostrea;PE=3;SV=1	GO:0005634|
GN017523.1	sp|K1Q157|K1Q157_CRAGI	1.0e-127	462.2	81.43%	82.08%	Protein PRRC1-A;OS=Crassostrea;PE=4;SV=1
GN017524.1	sp|K1Q4E2|K1Q4E2_CRAGI	1.0e-228	798.5	95.67%	61.63%	Protein toll;OS=Crassostrea;PE=3;SV=1	GO:0005576|GO:0016021|	GO:0030414|	GO:0045087|GO:0007165|
GN015748.1	sp|A0A210R559|A0A210R559_MIZYE	8.7e-44	182.6	98.08%	42.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017526.1	sp|K1QC56|K1QC56_CRAGI	6.0e-37	158.7	94.62%	81.61%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017527.1	sp|K1QIM0|K1QIM0_CRAGI	0.0e+00	1330.9	99.44%	70.06%	Protein flp;OS=Crassostrea;PE=4;SV=1
GN017528.1	sp|K1QC56|K1QC56_CRAGI	1.5e-17	94.4	63.73%	73.44%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017529.1	sp|K1QC56|K1QC56_CRAGI	3.5e-163	580.1	99.74%	69.41%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017530.1	sp|K1QC56|K1QC56_CRAGI	3.6e-19	99.8	63.73%	76.56%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017531.1	sp|K1QC56|K1QC56_CRAGI	7.8e-163	578.9	99.74%	69.15%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017532.1	sp|K1QC56|K1QC56_CRAGI	3.9e-19	99.8	59.09%	78.13%	Protein flp;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017533.1	sp|K1QLT3|K1QLT3_CRAGI	1.1e-10	72.0	49.26%	54.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017534.1	sp|K1Q4E9|K1Q4E9_CRAGI	1.1e-71	275.4	95.54%	62.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017535.1	sp|K1QMU1|K1QMU1_CRAGI	9.1e-35	152.5	76.02%	54.05%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN015749.1	sp|K1PQ45|K1PQ45_CRAGI	2.7e-35	153.7	93.02%	67.23%	Thrombospondin-3;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|	GO:0007155|
GN017536.1	sp|K1PWN1|K1PWN1_CRAGI	1.6e-212	744.6	91.71%	67.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017537.1	sp|K1Q4E7|K1Q4E7_CRAGI	1.2e-165	588.6	98.75%	65.62%	Beta-lactamase;OS=Crassostrea;PE=4;SV=1
GN017538.1	sp|K1PWN1|K1PWN1_CRAGI	1.9e-218	764.2	99.28%	69.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017539.1	sp|K1QLK4|K1QLK4_CRAGI	2.8e-68	265.4	93.68%	34.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017540.1	sp|K1R4C7|K1R4C7_CRAGI	4.5e-198	696.4	92.41%	68.03%	Protein fmtA;OS=Crassostrea;PE=4;SV=1
GN017541.1	sp|A0A2G8JMV7|A0A2G8JMV7_STIJA	9.1e-26	123.2	52.48%	42.14%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|GO:0008270|
GN017542.1	sp|K1QFZ6|K1QFZ6_CRAGI	3.4e-22	110.9	47.49%	42.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017544.1	sp|K1QC65|K1QC65_CRAGI	4.2e-270	937.2	39.86%	80.69%	DNA polymerase alpha subunit B;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003887|	GO:0006260|
GN017545.1	sp|K1R0M5|K1R0M5_CRAGI	1.2e-19	102.8	92.06%	49.44%	MACRO domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017546.1	sp|K1PGC1|K1PGC1_CRAGI	0.0e+00	1691.0	100.00%	81.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015750.1	sp|K1QXU9|K1QXU9_CRAGI	6.6e-185	652.5	79.78%	82.72%	Casein kinase I isoform gamma-3;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN015751.1	sp|K1QC39|K1QC39_CRAGI	0.0e+00	1431.4	100.00%	79.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017561.1	sp|A0A210QDU9|A0A210QDU9_MIZYE	0.0e+00	2323.9	92.21%	38.15%	Delta-like protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005509|
GN017562.1	sp|K1PV26|K1PV26_CRAGI	4.8e-18	97.1	76.70%	38.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017563.1	sp|A0A1S3HJ12|A0A1S3HJ12_LINUN	0.0e+00	2655.6	93.40%	34.82%	uncharacterized protein LOC106155695;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0005319|
GN015752.1	sp|K1Q9G8|K1Q9G8_CRAGI	3.1e-55	219.9	91.67%	83.33%	Cytosolic Fe-S cluster assembly factor NBP35;OS=Crassostrea;PE=3;SV=1
GN017564.1	sp|K1QCP0|K1QCP0_CRAGI	0.0e+00	1354.3	90.05%	52.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007267|
GN015535.1	sp|K1PQE9|K1PQE9_CRAGI	1.1e-107	394.8	99.50%	89.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017573.1	sp|K1R4N9|K1R4N9_CRAGI	1.7e-108	400.2	61.60%	36.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017575.1	sp|K1PX52|K1PX52_CRAGI	1.1e-76	291.6	91.86%	85.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017576.1	sp|K1PX52|K1PX52_CRAGI	3.5e-30	136.0	88.46%	91.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015753.1	sp|A0A210QGP9|A0A210QGP9_MIZYE	2.4e-64	252.3	80.43%	41.70%	Cyclic AMP-responsive element-binding protein 3-like protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0035497|GO:0003700|	GO:0030968|GO:0045944|
GN017578.1	sp|K1PIF8|K1PIF8_CRAGI	6.4e-95	352.8	98.91%	60.37%	O-methyltransferase mdmC;OS=Crassostrea;PE=4;SV=1	GO:0008171|
GN017580.1	sp|K1PND9|K1PND9_CRAGI	1.5e-23	114.4	92.79%	52.94%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN017583.1	sp|K1Q4R7|K1Q4R7_CRAGI	2.4e-48	197.2	75.17%	75.00%	Papilin;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN015754.1	sp|A0A210QGN7|A0A210QGN7_MIZYE	2.5e-54	218.0	87.50%	47.37%	Iron-sulfur cluster co-chaperone protein HscB, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0001671|GO:0051087|	GO:0051259|GO:0097428|
GN017584.1	sp|K1RBB4|K1RBB4_CRAGI	1.0e-134	486.5	74.46%	46.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017586.1	sp|K1PX42|K1PX42_CRAGI	2.4e-100	371.7	42.20%	77.73%	Carboxypeptidase inhibitor SmCI;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN017588.1	sp|A0A210QWJ5|A0A210QWJ5_MIZYE	1.9e-99	368.2	84.72%	67.11%	Kelch-like protein 10;OS=Mizuhopecten;PE=4;SV=1
GN017589.1	sp|K1QDR1|K1QDR1_CRAGI	1.5e-260	904.0	100.00%	79.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017590.1	sp|K1QDT9|K1QDT9_CRAGI	2.0e-16	92.4	100.00%	26.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015755.1	sp|K1RCU7|K1RCU7_CRAGI	1.5e-99	368.6	88.76%	52.35%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN017592.1	sp|K1PX28|K1PX28_CRAGI	2.1e-169	600.9	100.00%	72.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017593.1	sp|K1PG62|K1PG62_CRAGI	2.3e-91	342.0	98.92%	35.75%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017594.1	sp|K1QAU5|K1QAU5_CRAGI	4.1e-13	80.5	32.97%	63.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017595.1	sp|K1QHE7|K1QHE7_CRAGI	5.9e-22	109.4	75.76%	58.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017596.1	sp|K1QHE7|K1QHE7_CRAGI	5.9e-22	109.4	75.76%	58.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017597.1	sp|K1RLP8|K1RLP8_CRAGI	4.4e-41	172.9	97.73%	65.38%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN017598.1	sp|K1QHE7|K1QHE7_CRAGI	5.9e-22	109.4	75.76%	58.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017599.1	sp|A0A210QBY0|A0A210QBY0_MIZYE	3.0e-157	560.5	100.00%	78.52%	Insulin gene enhancer protein isl-1;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0046872|
GN017600.1	sp|K1QFV5|K1QFV5_CRAGI	5.5e-34	151.0	21.57%	82.22%	Tropomyosin;OS=Crassostrea;PE=4;SV=1
GN017602.1	sp|K1QQ56|K1QQ56_CRAGI	3.0e-105	387.5	65.82%	80.60%	Adenosine deaminase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0019239|
GN017604.1	sp|I3UIB5|I3UIB5_PINMT	3.0e-29	135.2	37.59%	44.23%	Toll-like receptor 3;OS=Pinctada;PE=2;SV=1	GO:0007165|
GN017605.1	sp|K1QG36|K1QG36_CRAGI	1.9e-235	820.5	99.79%	83.20%	Neuronal acetylcholine receptor subunit alpha-7;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN017607.1	sp|K1PU15|K1PU15_CRAGI	3.0e-106	391.7	45.93%	65.13%	Serine/threonine-protein kinase 32B;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|GO:0003697|
GN017608.1	sp|K1QG33|K1QG33_CRAGI	6.2e-245	852.0	100.00%	82.31%	Acetylcholine receptor subunit alpha-like protein;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN017609.1	sp|K1R208|K1R208_CRAGI	4.5e-194	682.9	84.87%	80.05%	Acetylcholine receptor subunit alpha-like protein;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0022848|GO:0004888|
GN017610.1	sp|K1PU20|K1PU20_CRAGI	5.1e-200	703.0	73.19%	88.12%	Acetylcholine receptor subunit beta-like 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN017611.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	1.2e-35	156.0	58.22%	47.37%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN017612.1	sp|A0A210PYA6|A0A210PYA6_MIZYE	8.6e-35	154.1	30.81%	47.13%	Toll-like receptor 4;OS=Mizuhopecten;PE=4;SV=1	GO:0046696|	GO:0001875|GO:0004888|	GO:0050829|GO:0045087|GO:0042116|GO:0002755|GO:0050707|GO:0034142|
GN015758.1	sp|K1Q9G3|K1Q9G3_CRAGI	5.7e-135	487.3	98.07%	44.15%	Isocitrate dehydrogenase [NAD] subunit, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0004449|GO:0000287|GO:0051287|	GO:0006099|
GN017615.1	sp|K1RTF1|K1RTF1_CRAGI	2.2e-15	89.7	17.93%	59.09%	Annexin;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005544|
GN017616.1	sp|K1QDR7|K1QDR7_CRAGI	1.4e-57	229.6	41.76%	54.04%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN017617.1	sp|W4Z9W9|W4Z9W9_STRPU	9.3e-45	187.2	36.13%	47.72%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN015759.1	sp|K1QWR4|K1QWR4_CRAGI	2.8e-311	1073.2	99.60%	76.67%	Mitogen-activated protein kinase 6;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004707|
GN015760.1	sp|V4BCB5|V4BCB5_LOTGI	2.7e-64	250.8	75.59%	73.12%	Receptor expression-enhancing protein;OS=Lottia;PE=3;SV=1	GO:0016021|
GN017624.1	sp|K1RNM3|K1RNM3_CRAGI	9.5e-130	470.3	98.52%	61.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017626.1	sp|K1QTP1|K1QTP1_CRAGI	7.6e-198	695.3	97.72%	82.60%	Dipeptidyl peptidase family member 6;OS=Crassostrea;PE=4;SV=1	GO:0008236|
GN017628.1	sp|A0A210PKC8|A0A210PKC8_MIZYE	1.2e-32	145.2	94.67%	47.88%	Hexosyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN017629.1	sp|K1RK33|K1RK33_CRAGI	0.0e+00	2088.5	100.00%	98.41%	Exportin-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005049|GO:0008536|	GO:0006886|
GN017630.1	sp|K1QCK2|K1QCK2_CRAGI	1.1e-271	941.4	100.00%	72.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015551.1	sp|A0A210Q6Z1|A0A210Q6Z1_MIZYE	4.4e-61	240.7	84.91%	41.96%	MFS-type transporter SLC18B1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN015761.1	sp|K1PQ40|K1PQ40_CRAGI	5.4e-198	697.2	58.22%	78.00%	Leucine-rich repeat-containing protein 49;OS=Crassostrea;PE=4;SV=1
GN017631.1	sp|K1QL60|K1QL60_CRAGI	3.7e-215	753.1	87.92%	87.68%	Ubiquinone biosynthesis monooxygenase COQ6, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0031314|	GO:0071949|GO:0016709|GO:0016712|	GO:0006744|
GN017632.1	sp|A0A210PHW3|A0A210PHW3_MIZYE	6.6e-255	885.6	99.70%	68.07%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005623|	GO:0006606|
GN017633.1	sp|K1R0H9|K1R0H9_CRAGI	1.3e-175	621.3	100.00%	88.04%	Homeobox protein Nkx-2.1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017635.1	sp|K1RBV9|K1RBV9_CRAGI	9.3e-76	288.5	96.51%	83.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017636.1	sp|K1QDR7|K1QDR7_CRAGI	2.2e-55	222.2	37.47%	58.62%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN017637.1	sp|K1R1R2|K1R1R2_CRAGI	3.1e-133	480.3	95.03%	75.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017638.1	sp|K1QHX6|K1QHX6_CRAGI	1.9e-35	154.5	70.39%	69.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017639.1	sp|K1QCJ3|K1QCJ3_CRAGI	4.3e-127	460.3	99.52%	64.16%	Nuclear valosin-containing-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN017640.1	sp|K1R0G9|K1R0G9_CRAGI	1.5e-38	164.5	100.00%	66.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017641.1	sp|K1R0G9|K1R0G9_CRAGI	4.6e-35	152.9	96.95%	63.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017642.1	sp|K1R0G9|K1R0G9_CRAGI	1.7e-45	187.6	100.00%	72.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017643.1	sp|K1QTN1|K1QTN1_CRAGI	3.6e-225	786.6	98.96%	72.42%	Nuclear valosin-containing-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN017644.1	sp|K1RK16|K1RK16_CRAGI	4.2e-107	394.0	58.86%	80.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN015762.1	sp|A0A210Q532|A0A210Q532_MIZYE	1.3e-19	102.8	54.90%	35.93%	Caspase-6;OS=Mizuhopecten;PE=3;SV=1	GO:0097200|
GN017646.1	sp|K1R0E5|K1R0E5_CRAGI	3.3e-200	703.4	100.00%	79.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017647.1	sp|A0A210QWK6|A0A210QWK6_MIZYE	4.4e-114	416.8	100.00%	59.12%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN017648.1	sp|K1QCJ3|K1QCJ3_CRAGI	1.9e-25	121.3	60.74%	63.37%	Nuclear valosin-containing-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN017649.1	sp|K1QCJ3|K1QCJ3_CRAGI	3.3e-32	142.9	83.33%	90.54%	Nuclear valosin-containing-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN017650.1	sp|K1R0G9|K1R0G9_CRAGI	9.0e-39	165.2	100.00%	67.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017651.1	sp|K1PVC4|K1PVC4_CRAGI	5.2e-91	339.3	100.00%	83.51%	Peroxiredoxin-5, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0016491|	GO:0045454|
GN017652.1	sp|K1PNQ2|K1PNQ2_CRAGI	3.1e-103	380.9	97.71%	60.88%	UPF0667 protein C1orf55-like protein;OS=Crassostrea;PE=4;SV=1
GN017653.1	sp|H9LHX3|H9LHX3_CRAAR	6.4e-41	172.9	56.48%	81.65%	Synaptojanin-2-binding protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN017654.1	sp|K1PVB9|K1PVB9_CRAGI	4.3e-74	282.7	100.00%	89.51%	Glutathione peroxidase;OS=Crassostrea;PE=3;SV=1	GO:0004602|	GO:0006979|
GN017655.1	sp|K1PNQ1|K1PNQ1_CRAGI	4.3e-261	906.4	100.00%	86.96%	Ankyrin repeat domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN017656.1	sp|K1Q9K3|K1Q9K3_CRAGI	6.7e-147	525.8	99.10%	83.03%	Hepatic leukemia factor;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN017657.1	sp|K1PNK1|K1PNK1_CRAGI	3.0e-204	717.6	88.27%	60.64%	PHD finger protein 10;OS=Crassostrea;PE=4;SV=1	GO:0071564|	GO:0046872|
GN017658.1	sp|K1PGT0|K1PGT0_CRAGI	1.5e-160	571.6	100.00%	72.65%	Homeobox protein ceh-37;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN017659.1	sp|K1P2N5|K1P2N5_CRAGI	1.2e-164	585.1	100.00%	65.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017660.1	sp|K1QVU6|K1QVU6_CRAGI	1.3e-64	251.9	99.16%	56.25%	SET and MYND domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN017661.1	sp|K1QA20|K1QA20_CRAGI	5.5e-282	975.3	97.05%	82.87%	WD repeat-containing protein 20;OS=Crassostrea;PE=4;SV=1
GN017663.1	sp|K1PVC8|K1PVC8_CRAGI	4.0e-63	247.3	100.00%	79.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017664.1	sp|K1PNQ5|K1PNQ5_CRAGI	4.5e-290	1002.3	100.00%	95.57%	Heat shock protein HSP 90-alpha 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0051082|	GO:0006457|
GN017665.1	sp|A0A1Y1JT91|A0A1Y1JT91_PHOPY	4.1e-63	247.7	84.40%	41.62%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN017666.1	sp|K1R5Y2|K1R5Y2_CRAGI	1.2e-84	318.5	85.65%	82.84%	Homeobox protein goosecoid;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017667.1	sp|A0A210PJS3|A0A210PJS3_MIZYE	9.2e-11	73.6	26.04%	44.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015765.1	sp|K1QWN9|K1QWN9_CRAGI	0.0e+00	1786.2	35.29%	60.64%	Sacsin;OS=Crassostrea;PE=4;SV=1
GN017668.1	sp|A0A3G1HB14|A0A3G1HB14_CRAGI	1.1e-175	621.7	100.00%	92.08%	Voltage-gated sodium channel alpha subunit protein variant C;OS=Crassostrea;PE=2;SV=1
GN017672.1	sp|A0A2C9LC31|A0A2C9LC31_BIOGL	2.7e-22	111.7	92.86%	28.76%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0003677|
GN015766.1	sp|K1RBI5|K1RBI5_CRAGI	6.9e-12	74.7	92.86%	60.78%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017675.1	sp|K1P8L0|K1P8L0_CRAGI	1.0e-170	605.1	84.60%	81.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017676.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN017677.1	sp|K1P8L0|K1P8L0_CRAGI	2.8e-189	666.8	89.24%	89.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017678.1	sp|A0A1Z5L4K9|A0A1Z5L4K9_ORNMO	7.6e-11	73.2	44.60%	37.23%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0008270|
GN015767.1	sp|K1RBI5|K1RBI5_CRAGI	1.9e-141	508.4	95.73%	47.60%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017679.1	sp|K1PUL4|K1PUL4_CRAGI	1.2e-35	154.8	100.00%	53.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017680.1	sp|K1QUX2|K1QUX2_CRAGI	5.9e-17	93.6	75.65%	33.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017681.1	sp|K1QUX2|K1QUX2_CRAGI	3.9e-87	326.6	91.20%	79.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017682.1	sp|K1QZ21|K1QZ21_CRAGI	1.1e-187	661.8	99.58%	75.57%	Acyl-CoA-binding domain-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN017684.1	sp|K1QHN9|K1QHN9_CRAGI	2.9e-154	550.1	100.00%	97.22%	Golgi phosphoprotein 3;OS=Crassostrea;PE=4;SV=1	GO:0070273|
GN017686.1	sp|K1Q1A3|K1Q1A3_CRAGI	9.0e-150	535.4	100.00%	71.59%	UPF0124 protein C13orf31;OS=Crassostrea;PE=4;SV=1
GN017688.1	sp|K1PNQ9|K1PNQ9_CRAGI	9.7e-46	188.3	88.28%	81.25%	Solute carrier family 22 member 16;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN017690.1	sp|A0A210PRY2|A0A210PRY2_MIZYE	4.9e-11	73.2	81.75%	37.30%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|GO:0008270|
GN017691.1	sp|K1RA79|K1RA79_CRAGI	0.0e+00	3580.4	98.13%	87.82%	E3 ubiquitin-protein ligase HECTD1;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017693.1	sp|R7TCN7|R7TCN7_CAPTE	4.1e-10	70.1	94.16%	35.88%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN015552.1	sp|K1PJF5|K1PJF5_CRAGI	4.8e-39	167.2	86.31%	39.06%	Transmembrane protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015768.1	sp|K1RBI5|K1RBI5_CRAGI	8.3e-59	233.0	95.13%	41.47%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017699.1	sp|A0A2G8JQS3|A0A2G8JQS3_STIJA	3.4e-34	151.8	53.72%	39.13%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN017700.1	sp|K1QTQ5|K1QTQ5_CRAGI	5.2e-149	532.7	100.00%	79.88%	Putative methyltransferase C20orf7-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN017701.1	sp|K1R771|K1R771_CRAGI	2.9e-17	95.1	19.76%	67.69%	Kinetochore-associated protein KNL-2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN017702.1	sp|K1PCA9|K1PCA9_CRAGI	1.8e-13	81.3	70.92%	41.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017704.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	9.5e-40	169.5	94.98%	40.24%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017706.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	2.7e-90	338.2	82.75%	45.03%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN017708.1	sp|K1R625|K1R625_CRAGI	2.6e-20	104.8	32.77%	55.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017709.1	sp|K1RZI1|K1RZI1_CRAGI	1.2e-92	345.1	79.08%	82.45%	Violaxanthin de-epoxidase;OS=Crassostrea;PE=4;SV=1	GO:0046422|
GN017710.1	sp|V4AE92|V4AE92_LOTGI	3.4e-98	364.8	75.88%	43.29%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN017711.1	sp|K1Q3Q1|K1Q3Q1_CRAGI	9.5e-46	189.5	78.49%	43.58%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN017713.1	sp|K1PJF7|K1PJF7_CRAGI	3.5e-170	604.4	100.00%	82.00%	Delta-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007275|GO:0007219|
GN017714.1	sp|K1QDT8|K1QDT8_CRAGI	1.0e-24	118.2	95.37%	50.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017715.1	sp|K1QKY5|K1QKY5_CRAGI	2.1e-84	317.4	100.00%	83.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017716.1	sp|K1RSF4|K1RSF4_CRAGI	1.3e-304	1051.2	72.13%	74.48%	Isoleucyl-tRNA synthetase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0002161|GO:0005524|GO:0004822|	GO:0006428|
GN017717.1	sp|K1R1N9|K1R1N9_CRAGI	1.4e-128	464.9	98.78%	73.91%	DNA repair protein XRCC3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0008094|	GO:0006281|
GN017718.1	sp|K1PND9|K1PND9_CRAGI	2.2e-22	110.5	92.79%	51.96%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN017720.1	sp|K1RIW4|K1RIW4_CRAGI	1.7e-97	362.5	85.86%	37.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017721.1	sp|A0A210PP32|A0A210PP32_MIZYE	2.0e-50	205.3	92.75%	39.35%	Adrenocorticotropic hormone receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004930|
GN017722.1	sp|K1R8D3|K1R8D3_CRAGI	1.9e-132	478.0	88.25%	78.75%	Uncharacterized protein C14orf50;OS=Crassostrea;PE=4;SV=1	GO:0019902|	GO:0010923|
GN017723.1	sp|A0A210PEG6|A0A210PEG6_MIZYE	2.1e-184	651.0	96.68%	63.03%	Glucosylceramidase;OS=Mizuhopecten;PE=3;SV=1	GO:0004348|	GO:0006665|
GN017724.1	sp|A0A210QG67|A0A210QG67_MIZYE	6.6e-108	396.4	99.44%	60.94%	Sodium/potassium/calcium exchanger 2;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0055085|
GN017725.1	sp|A0A210QG53|A0A210QG53_MIZYE	3.4e-206	723.4	99.61%	67.77%	von Willebrand factor A domain-containing protein 9;OS=Mizuhopecten;PE=4;SV=1	GO:0032039|
GN017727.1	sp|V4BHI4|V4BHI4_LOTGI	1.8e-148	531.9	91.13%	50.34%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN017728.1	sp|K1RCI5|K1RCI5_CRAGI	1.1e-114	419.1	81.28%	65.05%	Vesicular glutamate transporter 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017729.1	sp|K1PE45|K1PE45_CRAGI	1.4e-42	179.1	79.40%	39.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN017732.1	sp|A0A210PUZ8|A0A210PUZ8_MIZYE	7.4e-37	158.7	84.35%	82.29%	Protein MEF2BNB;OS=Mizuhopecten;PE=4;SV=1
GN017733.1	sp|K1R6Z7|K1R6Z7_CRAGI	1.7e-285	986.9	99.45%	95.20%	ATP synthase subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0045261|	GO:0005524|GO:0046933|	GO:0015986|
GN017734.1	sp|D6WXW8|D6WXW8_TRICA	4.5e-22	109.8	81.54%	48.57%	Uncharacterized protein;OS=Tribolium;PE=4;SV=1
GN017736.1	sp|K1R681|K1R681_CRAGI	3.1e-35	153.7	84.77%	69.12%	Reticulon-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|
GN017737.1	sp|K1QM10|K1QM10_CRAGI	8.9e-54	216.1	48.66%	77.78%	Ceramide kinase;OS=Crassostrea;PE=4;SV=1	GO:0003951|
GN017738.1	sp|K1R8T8|K1R8T8_CRAGI	9.1e-91	340.1	51.03%	73.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017740.1	sp|K1QGY4|K1QGY4_CRAGI	7.9e-186	655.6	91.04%	74.65%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN017741.1	sp|K1QNG5|K1QNG5_CRAGI	6.4e-69	265.8	96.47%	77.91%	Cholecystokinin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN017742.1	sp|K1R8U3|K1R8U3_CRAGI	1.4e-145	521.5	98.61%	72.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017743.1	sp|K1Q1X5|K1Q1X5_CRAGI	4.8e-131	472.6	100.00%	96.61%	Mitogen-activated protein kinase kinase kinase 9;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN017744.1	sp|A0A3M7PIT2|A0A3M7PIT2_BRAPC	3.4e-18	96.7	100.00%	39.50%	39S ribosomal mitochondrial;OS=Brachionus;PE=4;SV=1
GN017745.1	sp|K1QXN8|K1QXN8_CRAGI	1.9e-28	131.3	86.63%	56.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017746.1	sp|K1PQ00|K1PQ00_CRAGI	1.9e-168	597.4	99.43%	81.50%	Adenosine kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0004001|	GO:0006166|
GN017747.1	sp|K1R7K4|K1R7K4_CRAGI	1.1e-180	638.3	100.00%	83.21%	N-acetylserotonin O-methyltransferase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008171|
GN017748.1	sp|K1QBC8|K1QBC8_CRAGI	2.0e-95	354.0	100.00%	86.39%	Prohormone-4;OS=Crassostrea;PE=4;SV=1
GN017749.1	sp|A0A210QAC0|A0A210QAC0_MIZYE	2.3e-155	554.3	98.83%	61.45%	Purple acid phosphatase;OS=Mizuhopecten;PE=3;SV=1	GO:0003993|GO:0046872|
GN017751.1	sp|K1RG51|K1RG51_CRAGI	2.8e-15	86.3	70.00%	91.67%	Adenosine 3'-phospho 5'-phosphosulfate transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017752.1	sp|K1RG51|K1RG51_CRAGI	1.1e-12	77.4	80.70%	77.78%	Adenosine 3'-phospho 5'-phosphosulfate transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017753.1	sp|A0A210PJ89|A0A210PJ89_MIZYE	9.4e-122	441.8	100.00%	88.21%	Proteasome subunit alpha type;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|GO:0005634|GO:0019773|	GO:0004298|	GO:0006511|
GN017756.1	sp|A0A210QXA2|A0A210QXA2_MIZYE	3.9e-13	80.5	62.50%	46.79%	ADP-ribosylation factor;OS=Mizuhopecten;PE=4;SV=1	GO:0042754|GO:0045892|
GN017759.1	sp|K1PUP1|K1PUP1_CRAGI	0.0e+00	1303.5	100.00%	82.12%	N-acetylated-alpha-linked acidic dipeptidase 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017760.1	sp|K1Q1I5|K1Q1I5_CRAGI	4.2e-121	439.9	100.00%	77.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017761.1	sp|A0A210QXB4|A0A210QXB4_MIZYE	1.8e-91	341.7	92.15%	52.13%	Usherin;OS=Mizuhopecten;PE=4;SV=1	GO:0007165|
GN017763.1	sp|K1RQL8|K1RQL8_CRAGI	4.7e-83	313.2	98.68%	66.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017764.1	sp|K1QXV9|K1QXV9_CRAGI	0.0e+00	1076.6	58.40%	66.46%	Putative helicase Mov10l1;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN017765.1	sp|K1S313|K1S313_CRAGI	1.0e-11	76.3	22.04%	81.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015772.1	sp|K1QP26|K1QP26_CRAGI	6.5e-51	205.7	97.89%	76.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017767.1	sp|A0A2G8KYT8|A0A2G8KYT8_STIJA	1.1e-17	95.1	94.21%	42.48%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN015773.1	sp|K1QHH5|K1QHH5_CRAGI	4.9e-109	399.4	100.00%	86.34%	Bcl-2-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN017768.1	sp|K1PFS5|K1PFS5_CRAGI	2.8e-114	417.2	82.67%	86.84%	Elongation factor 1-gamma;OS=Crassostrea;PE=3;SV=1	GO:0003746|
GN017769.1	sp|K1RBE4|K1RBE4_CRAGI	0.0e+00	1631.7	70.16%	75.30%	Chitin synthase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016758|
GN017769.1	sp|K1RBE4|K1RBE4_CRAGI	7.5e-23	115.9	8.88%	66.20%	Chitin synthase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016758|
GN017770.1	sp|K1QHS9|K1QHS9_CRAGI	0.0e+00	1109.0	70.63%	88.51%	Tubulin polyglutamylase TTLL13;OS=Crassostrea;PE=4;SV=1	GO:0005524|	GO:0006464|
GN017771.1	sp|K1PHX7|K1PHX7_CRAGI	4.4e-150	536.6	100.00%	67.53%	snRNA-activating protein complex subunit 3;OS=Crassostrea;PE=4;SV=1
GN017772.1	sp|K1PDA4|K1PDA4_CRAGI	8.8e-44	182.6	76.89%	69.14%	Collagen alpha-4(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|GO:0062023|	GO:0005201|
GN015774.1	sp|K1S1T4|K1S1T4_CRAGI	3.0e-124	450.3	94.98%	78.03%	Elongation of very long chain fatty acids protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0102336|GO:0102337|GO:0102338|GO:0102756|	GO:0006633|
GN017773.1	sp|A0A210PE83|A0A210PE83_MIZYE	3.6e-306	1056.6	95.14%	47.22%	Collagen alpha-3(VI) chain;OS=Mizuhopecten;PE=4;SV=1	GO:0005581|
GN017774.1	sp|K1PKW5|K1PKW5_CRAGI	7.6e-16	88.2	100.00%	50.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017775.1	sp|K1RY73|K1RY73_CRAGI	0.0e+00	2280.0	91.72%	80.21%	Chromodomain-helicase-DNA-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0003677|GO:0004386|
GN017776.1	sp|A0A2C9JZ92|A0A2C9JZ92_BIOGL	4.2e-80	304.3	64.77%	52.56%	Mitochondrial import inner membrane translocase subunit TIM50;OS=Biomphalaria;PE=3;SV=1	GO:0016021|GO:0005744|	GO:0015031|
GN017777.1	sp|K1QBV1|K1QBV1_CRAGI	1.7e-113	414.5	96.51%	85.89%	Mitochondrial import inner membrane translocase subunit TIM50;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005744|	GO:0015031|
GN015775.1	sp|K1RI69|K1RI69_CRAGI	4.8e-111	407.1	86.90%	60.34%	Protein SPEC3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017778.1	sp|K1Q3Q1|K1Q3Q1_CRAGI	3.9e-82	310.1	99.55%	64.91%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN017779.1	sp|K1PND9|K1PND9_CRAGI	2.6e-23	113.6	92.79%	52.94%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN017780.1	sp|A0A210R197|A0A210R197_MIZYE	1.4e-38	165.2	96.10%	45.75%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017782.1	sp|K1RTF1|K1RTF1_CRAGI	6.7e-14	83.6	49.80%	51.97%	Annexin;OS=Crassostrea;PE=3;SV=1	GO:0005509|GO:0005544|
GN017783.1	sp|K1PWA7|K1PWA7_CRAGI	9.5e-61	238.8	94.33%	62.09%	Gamma-glutamylcyclotransferase;OS=Crassostrea;PE=3;SV=1	GO:0003839|GO:0061928|	GO:0006751|
GN017785.1	sp|K1R4W2|K1R4W2_CRAGI	0.0e+00	1129.8	80.74%	85.31%	Tetratricopeptide repeat protein 7B;OS=Crassostrea;PE=4;SV=1
GN017786.1	sp|K1RUZ0|K1RUZ0_CRAGI	2.9e-193	680.2	100.00%	76.04%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0035267|	GO:0004402|	GO:0006355|
GN017787.1	sp|K1RBD0|K1RBD0_CRAGI	1.0e-154	551.6	100.00%	89.10%	DNA-directed RNA polymerase III subunit RPC6;OS=Crassostrea;PE=3;SV=1	GO:0005666|	GO:0003899|	GO:0006383|
GN017788.1	sp|K1R4V6|K1R4V6_CRAGI	3.3e-145	520.0	93.65%	89.96%	Solute carrier family 25 member 45;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN017789.1	sp|K1QY05|K1QY05_CRAGI	0.0e+00	1385.2	99.42%	73.70%	AT-rich interactive domain-containing protein 4B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN017790.1	sp|K1QNU0|K1QNU0_CRAGI	6.3e-90	337.0	48.73%	79.48%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|GO:0003723|
GN017791.1	sp|K1QNU0|K1QNU0_CRAGI	2.2e-247	860.5	99.05%	88.08%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|GO:0003723|
GN017794.1	sp|V4ABF4|V4ABF4_LOTGI	1.2e-30	138.7	55.62%	61.22%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN017795.1	sp|K1RDQ4|K1RDQ4_CRAGI	6.5e-114	416.4	64.83%	78.05%	Small conductance calcium-activated potassium channel protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005516|GO:0016286|
GN017796.1	sp|K1RUY4|K1RUY4_CRAGI	4.5e-100	369.4	100.00%	97.28%	ADP-ribosylation factor-like protein 2;OS=Crassostrea;PE=3;SV=1	GO:0005525|
GN017797.1	sp|A0A210QCZ4|A0A210QCZ4_MIZYE	1.8e-52	211.8	54.01%	71.15%	Homeobox protein goosecoid;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017798.1	sp|A0A210PEV5|A0A210PEV5_MIZYE	2.3e-124	451.1	91.64%	62.24%	Sorbitol dehydrogenase;OS=Mizuhopecten;PE=3;SV=1	GO:0016491|GO:0008270|
GN017799.1	sp|K1PDR9|K1PDR9_CRAGI	9.3e-99	367.9	15.74%	77.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017802.1	sp|K1PND6|K1PND6_CRAGI	2.4e-149	534.6	99.08%	48.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN015779.1	sp|K1R8S8|K1R8S8_CRAGI	8.6e-83	312.4	96.76%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017806.1	sp|K1PUT5|K1PUT5_CRAGI	2.6e-29	134.0	56.67%	67.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017807.1	sp|K1QDS4|K1QDS4_CRAGI	5.4e-104	383.3	100.00%	66.57%	Zinc transporter ZIP1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN017808.1	sp|A0A2B4RMH3|A0A2B4RMH3_STYPI	1.9e-35	155.6	91.18%	31.33%	Angiopoietin-related protein 3;OS=Stylophora;PE=4;SV=1
GN017809.1	sp|K1PTE7|K1PTE7_CRAGI	1.1e-195	688.3	97.93%	69.70%	UNC5C-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005042|
GN017810.1	sp|K1QDV3|K1QDV3_CRAGI	2.6e-48	196.8	99.17%	76.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0097193|
GN017811.1	sp|K1PSW5|K1PSW5_CRAGI	4.3e-154	549.7	100.00%	78.53%	Putative proline racemase;OS=Crassostrea;PE=4;SV=1
GN015780.1	sp|K1QNC5|K1QNC5_CRAGI	4.8e-19	98.6	86.67%	84.31%	Structural maintenance of chromosomes protein 5;OS=Crassostrea;PE=4;SV=1	GO:0030915|	GO:0000724|GO:0007062|
GN017812.1	sp|A0A210QCZ4|A0A210QCZ4_MIZYE	1.8e-52	211.8	54.01%	71.15%	Homeobox protein goosecoid;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN017813.1	sp|A0A210PEV5|A0A210PEV5_MIZYE	8.3e-124	449.1	97.69%	62.31%	Sorbitol dehydrogenase;OS=Mizuhopecten;PE=3;SV=1	GO:0016491|GO:0008270|
GN017815.1	sp|K1PY81|K1PY81_CRAGI	5.9e-132	477.2	84.87%	41.67%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017816.1	sp|K1PY81|K1PY81_CRAGI	9.7e-79	299.7	99.27%	40.14%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015781.1	sp|K1QNC5|K1QNC5_CRAGI	5.5e-25	119.0	77.32%	82.43%	Structural maintenance of chromosomes protein 5;OS=Crassostrea;PE=4;SV=1	GO:0030915|	GO:0000724|GO:0007062|
GN017817.1	sp|K1PY81|K1PY81_CRAGI	2.1e-75	288.5	95.06%	39.45%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN017820.1	sp|K1QEJ9|K1QEJ9_CRAGI	7.7e-58	229.2	95.98%	62.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017821.1	sp|K1QL47|K1QL47_CRAGI	4.8e-158	563.1	95.26%	91.77%	Hepatocyte nuclear factor 3-beta;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0019904|GO:0043565|GO:0008134|
GN017822.1	sp|K1R6B0|K1R6B0_CRAGI	8.9e-226	788.9	95.11%	68.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017823.1	sp|K1PZ83|K1PZ83_CRAGI	0.0e+00	1157.5	91.72%	75.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017824.1	sp|K1Q6H3|K1Q6H3_CRAGI	1.1e-76	292.0	100.00%	62.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017825.1	sp|A0A336MFM0|A0A336MFM0_CULSO	5.5e-38	165.2	43.36%	28.69%	CSON002321 protein;OS=Culicoides;PE=4;SV=1	GO:0003677|
GN017826.1	sp|A0A0L7KXS8|A0A0L7KXS8_9NEOP	1.7e-29	136.3	41.87%	36.92%	Uncharacterized protein;OS=Operophtera;PE=4;SV=1
GN017827.1	sp|K1QUS4|K1QUS4_CRAGI	7.2e-290	1001.9	94.55%	82.68%	Digestive organ expansion factor-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN017828.1	sp|A0A2T7NZY1|A0A2T7NZY1_POMCA	1.5e-22	112.5	27.37%	70.27%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003723|
GN015783.1	sp|K1RAX0|K1RAX0_CRAGI	9.9e-242	841.6	86.24%	76.22%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN017829.1	sp|K1Q1U3|K1Q1U3_CRAGI	1.2e-161	574.7	99.38%	85.49%	MOSC domain-containing protein 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0030151|GO:0030170|
GN017830.1	sp|F0V453|F0V453_MYTGA	4.5e-39	167.2	56.91%	57.55%	Putative C1q domain containing protein MgC1q16;OS=Mytilus;PE=2;SV=1
GN017831.1	sp|A0A1S3KD68|A0A1S3KD68_LINUN	3.6e-156	557.8	94.03%	46.30%	DNA polymerase eta;OS=Lingula;PE=4;SV=1	GO:0003684|	GO:0006281|
GN017832.1	sp|A0A210QU25|A0A210QU25_MIZYE	2.4e-18	98.2	91.63%	35.59%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017833.1	sp|K1Q6F8|K1Q6F8_CRAGI	3.8e-40	170.2	100.00%	58.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017834.1	sp|K1Q6H0|K1Q6H0_CRAGI	3.9e-62	243.4	100.00%	64.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017835.1	sp|K1QEJ2|K1QEJ2_CRAGI	6.7e-13	80.1	88.70%	38.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017836.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	6.6e-83	313.9	64.47%	45.20%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN017837.1	sp|K1Q8X9|K1Q8X9_CRAGI	7.6e-40	169.9	82.78%	84.00%	Leucine-rich repeat-containing protein 57;OS=Crassostrea;PE=4;SV=1
GN017838.1	sp|K1P202|K1P202_CRAGI	9.0e-74	282.0	98.32%	78.86%	Tubulin polymerization-promoting protein family member 3;OS=Crassostrea;PE=4;SV=1
GN017839.1	sp|K1PMU0|K1PMU0_CRAGI	9.5e-87	325.9	90.97%	56.58%	Synaptosomal-associated protein;OS=Crassostrea;PE=3;SV=1	GO:0004222|
GN017840.1	sp|K1QYP7|K1QYP7_CRAGI	3.5e-249	866.7	100.00%	77.11%	Cathepsin F;OS=Crassostrea;PE=3;SV=1	GO:0004869|GO:0008234|
GN017842.1	sp|K1PSE0|K1PSE0_CRAGI	4.0e-12	78.6	69.62%	24.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015784.1	sp|A0A210QJW0|A0A210QJW0_MIZYE	6.0e-31	139.4	89.12%	50.00%	UPF0515 protein C19orf66;OS=Mizuhopecten;PE=4;SV=1
GN017843.1	sp|K1QYP7|K1QYP7_CRAGI	6.3e-73	279.3	97.40%	69.89%	Cathepsin F;OS=Crassostrea;PE=3;SV=1	GO:0004869|GO:0008234|
GN017844.1	sp|K1P9Y1|K1P9Y1_CRAGI	0.0e+00	2001.9	97.93%	62.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017845.1	sp|K1QG68|K1QG68_CRAGI	2.4e-211	740.3	89.11%	79.37%	Protein farnesyltransferase subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0005965|	GO:0004660|GO:0008270|	GO:0018343|
GN017846.1	sp|K1PW70|K1PW70_CRAGI	3.7e-74	283.1	100.00%	90.70%	Protein max;OS=Crassostrea;PE=4;SV=1	GO:0071339|GO:0090575|	GO:0046983|
GN017850.1	sp|K1Q782|K1Q782_CRAGI	2.4e-28	132.1	70.92%	39.77%	Protein GRINL1A;OS=Crassostrea;PE=4;SV=1	GO:0016591|
GN017851.1	sp|K1QE04|K1QE04_CRAGI	1.5e-210	737.6	99.54%	71.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN017852.1	sp|K1QTB3|K1QTB3_CRAGI	1.4e-121	441.4	83.03%	95.09%	Roundabout-like protein 1;OS=Crassostrea;PE=4;SV=1
GN015785.1	sp|K1QXF3|K1QXF3_CRAGI	4.1e-72	276.2	100.00%	93.79%	Homeobox protein orthopedia;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN017853.1	sp|K1Q6A6|K1Q6A6_CRAGI	2.3e-49	202.6	60.67%	50.68%	Programmed cell death protein 7;OS=Crassostrea;PE=4;SV=1
GN017854.1	sp|K1QE12|K1QE12_CRAGI	1.0e-166	592.4	80.80%	61.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017855.1	sp|K1QTB3|K1QTB3_CRAGI	1.4e-121	441.4	83.03%	95.09%	Roundabout-like protein 1;OS=Crassostrea;PE=4;SV=1
GN017856.1	sp|K1Q6A6|K1Q6A6_CRAGI	5.6e-26	124.8	42.17%	49.14%	Programmed cell death protein 7;OS=Crassostrea;PE=4;SV=1
GN017857.1	sp|K1QE12|K1QE12_CRAGI	1.5e-66	258.5	89.80%	56.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017858.1	sp|K1QE12|K1QE12_CRAGI	1.1e-30	137.9	95.70%	70.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017859.1	sp|A0A210QDU3|A0A210QDU3_MIZYE	1.3e-55	223.4	41.95%	41.54%	Collagen-like protein 7;OS=Mizuhopecten;PE=4;SV=1	GO:0005581|GO:0016021|
GN017860.1	sp|K1QTB7|K1QTB7_CRAGI	1.1e-103	381.7	98.23%	83.78%	Cell division control protein 42-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0051301|GO:0007264|
GN017862.1	sp|K1QE17|K1QE17_CRAGI	2.9e-21	107.8	75.57%	41.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN017863.1	sp|K1Q6A8|K1Q6A8_CRAGI	2.8e-99	367.1	98.74%	82.05%	Mediator of RNA polymerase II transcription subunit 6;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN017864.1	sp|A0A210QNW8|A0A210QNW8_MIZYE	9.7e-191	672.5	99.59%	48.80%	Methionine synthase reductase;OS=Mizuhopecten;PE=4;SV=1	GO:0010181|GO:0016491|
GN017865.1	sp|A0A2B4RRW3|A0A2B4RRW3_STYPI	1.1e-20	105.9	62.67%	36.05%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN017866.1	sp|A0A210PW63|A0A210PW63_MIZYE	3.2e-19	100.5	67.55%	48.54%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN017867.1	sp|K1QM18|K1QM18_CRAGI	3.7e-124	450.7	98.66%	53.62%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017868.1	sp|K1QM18|K1QM18_CRAGI	9.3e-114	416.0	99.52%	53.66%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017871.1	sp|W4YR48|W4YR48_STRPU	1.6e-52	213.0	53.19%	41.40%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN017872.1	sp|K1QM18|K1QM18_CRAGI	4.1e-123	447.2	98.66%	52.94%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017873.1	sp|K1QM18|K1QM18_CRAGI	5.8e-116	423.3	99.52%	54.39%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017874.1	sp|A0A3M6U9G3|A0A3M6U9G3_9CNID	6.8e-09	65.9	98.32%	31.40%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN017875.1	sp|K1RDA8|K1RDA8_CRAGI	0.0e+00	1723.4	100.00%	71.79%	Helicase-like transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|GO:0008270|
GN017876.1	sp|K1RDA8|K1RDA8_CRAGI	3.3e-102	379.0	86.98%	26.48%	Helicase-like transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|GO:0008270|
GN017877.1	sp|K1Q649|K1Q649_CRAGI	9.9e-234	814.7	100.00%	89.72%	Solute carrier family 46 member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN017878.1	sp|A0A0J7K1X7|A0A0J7K1X7_LASNI	1.9e-29	135.6	84.23%	28.57%	Tigger transposable element-derived protein 6-like protein;OS=Lasius;PE=4;SV=1	GO:0003676|
GN017879.1	sp|A0A0E3XHH5|A0A0E3XHH5_CRAHO	5.8e-122	443.0	100.00%	80.71%	Fos-like protein;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003677|GO:0003700|	GO:0006357|
GN017880.1	sp|K1RDA5|K1RDA5_CRAGI	8.7e-162	575.5	99.75%	73.72%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN017881.1	sp|K1PS35|K1PS35_CRAGI	4.9e-92	342.8	88.18%	93.82%	Cell division control protein 42;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0051301|GO:0007264|
GN017882.1	sp|K1R0B6|K1R0B6_CRAGI	4.5e-28	131.0	46.01%	48.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017883.1	sp|K1Q6H5|K1Q6H5_CRAGI	8.3e-223	778.9	99.36%	66.30%	Fem-1-like protein A;OS=Crassostrea;PE=4;SV=1
GN015789.1	sp|K1R4C9|K1R4C9_CRAGI	1.3e-164	585.1	85.62%	72.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017886.1	sp|K1PKC1|K1PKC1_CRAGI	1.1e-15	87.8	77.50%	63.93%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0007165|
GN017887.1	sp|K1PKC1|K1PKC1_CRAGI	6.1e-227	793.1	79.71%	58.19%	Collagen alpha-6(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0007165|
GN017888.1	sp|K1QSB2|K1QSB2_CRAGI	2.2e-216	756.9	100.00%	98.57%	26S protease regulatory subunit 6B;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0008233|GO:0036402|	GO:0030163|
GN017889.1	sp|K1Q6I7|K1Q6I7_CRAGI	1.8e-294	1016.9	99.05%	86.94%	Uncharacterized protein C2orf63-like protein;OS=Crassostrea;PE=4;SV=1
GN017890.1	sp|K1PZH3|K1PZH3_CRAGI	1.2e-102	378.3	100.00%	81.66%	Rho-related GTP-binding protein RhoJ;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN015790.1	sp|K1RAX4|K1RAX4_CRAGI	1.1e-51	208.8	59.71%	86.07%	Uncharacterized protein C9orf85-like protein;OS=Crassostrea;PE=4;SV=1
GN017891.1	sp|K1Q6H8|K1Q6H8_CRAGI	4.3e-306	1056.2	83.89%	63.73%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN017892.1	sp|K1PS42|K1PS42_CRAGI	1.1e-37	161.0	100.00%	91.57%	Nucleolar protein 66;OS=Crassostrea;PE=4;SV=1
GN017893.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.5e-306	1057.7	83.89%	63.85%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN017894.1	sp|K1PZG6|K1PZG6_CRAGI	4.9e-73	280.0	100.00%	56.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017896.1	sp|K1PS42|K1PS42_CRAGI	3.5e-139	500.0	92.57%	88.64%	Nucleolar protein 66;OS=Crassostrea;PE=4;SV=1
GN017897.1	sp|K1Q6J3|K1Q6J3_CRAGI	5.3e-50	203.4	56.28%	75.76%	Eukaryotic translation initiation factor 2-alpha kinase 4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003913|GO:0004672|GO:0003743|	GO:0006281|
GN015791.1	sp|A0A2C9JCK8|A0A2C9JCK8_BIOGL	1.6e-71	275.8	58.30%	49.42%	Mitochondrial import inner membrane translocase subunit TIM44;OS=Biomphalaria;PE=3;SV=1	GO:0005743|	GO:0051087|	GO:0030150|
GN017898.1	sp|A0A210QXA1|A0A210QXA1_MIZYE	3.1e-201	706.8	100.00%	79.28%	Homeobox protein Meis2;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN017901.1	sp|A0A210PQ40|A0A210PQ40_MIZYE	4.3e-275	952.6	100.00%	72.07%	Serine/threonine-protein kinase PLK;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004674|
GN017906.1	sp|K1RHD1|K1RHD1_CRAGI	8.0e-259	898.7	99.71%	77.68%	Chromosome-associated kinesin KIF4B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN015792.1	sp|A0A210QFR6|A0A210QFR6_MIZYE	1.9e-65	254.2	99.40%	71.08%	Methylmalonyl-CoA epimerase, mitochondrial;OS=Mizuhopecten;PE=4;SV=1
GN017908.1	sp|K1QYL2|K1QYL2_CRAGI	4.2e-190	670.2	96.24%	54.31%	Laccase-24;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN015793.1	sp|A0A210QYJ5|A0A210QYJ5_MIZYE	5.6e-40	169.5	97.40%	57.05%	Heme-binding protein 2;OS=Mizuhopecten;PE=4;SV=1
GN017909.1	sp|K1R592|K1R592_CRAGI	5.3e-80	302.8	97.89%	80.00%	Rho-related GTP-binding protein RhoQ;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN017910.1	sp|K1RB78|K1RB78_CRAGI	2.7e-81	307.0	100.00%	78.92%	Ras-related protein Rac1;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN017911.1	sp|K1RHD5|K1RHD5_CRAGI	2.2e-75	287.3	100.00%	76.76%	Rac-like GTP-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN017912.1	sp|K1QVL5|K1QVL5_CRAGI	2.0e-71	274.2	100.00%	69.19%	Cdc42-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN017913.1	sp|K1RHD5|K1RHD5_CRAGI	2.7e-60	237.3	100.00%	60.54%	Rac-like GTP-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN017914.1	sp|K1RB82|K1RB82_CRAGI	6.5e-86	322.4	100.00%	81.25%	Rho-related GTP-binding protein RhoU;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN017915.1	sp|K1S100|K1S100_CRAGI	3.5e-60	236.9	91.98%	64.91%	Cdc42-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN017916.1	sp|K1QVM2|K1QVM2_CRAGI	3.8e-89	333.2	100.00%	87.37%	Rho-related GTP-binding protein RhoJ;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN017917.1	sp|K1RHE3|K1RHE3_CRAGI	3.9e-89	333.2	100.00%	78.43%	Rac-like GTP-binding protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN017918.1	sp|K1S105|K1S105_CRAGI	3.6e-222	777.3	50.16%	77.61%	Acid trehalase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN017919.1	sp|K1QVM6|K1QVM6_CRAGI	2.9e-43	180.3	72.86%	83.17%	Acid trehalase-like protein 1;OS=Crassostrea;PE=3;SV=1	GO:0003998|
GN017920.1	sp|K1R5B4|K1R5B4_CRAGI	0.0e+00	2441.4	100.00%	85.67%	Proteasome activator complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0000502|	GO:0070577|GO:0016504|GO:0070628|
GN017921.1	sp|K1RB91|K1RB91_CRAGI	0.0e+00	1713.4	100.00%	89.09%	Neutral alpha-glucosidase AB;OS=Crassostrea;PE=3;SV=1	GO:0030246|GO:0004553|	GO:0005975|
GN017922.1	sp|V4ARX7|V4ARX7_LOTGI	6.6e-131	473.0	95.77%	56.27%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0016779|GO:0003723|	GO:0006396|
GN017923.1	sp|K1S109|K1S109_CRAGI	6.4e-160	569.3	100.00%	78.77%	Fork head domain transcription factor slp2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN017924.1	sp|K1QVN1|K1QVN1_CRAGI	9.7e-80	302.4	100.00%	83.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015794.1	sp|A0A210QVQ7|A0A210QVQ7_MIZYE	4.9e-28	129.8	96.73%	43.60%	Polypeptide N-acetylgalactosaminyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0030246|GO:0016757|	GO:0006486|
GN017925.1	sp|K1QLK4|K1QLK4_CRAGI	3.3e-31	141.0	89.79%	38.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017926.1	sp|K1QJ48|K1QJ48_CRAGI	3.3e-38	163.7	95.06%	44.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017927.1	sp|K1PVG7|K1PVG7_CRAGI	1.5e-25	122.5	60.14%	31.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN017928.1	sp|K1R5C2|K1R5C2_CRAGI	4.9e-275	952.6	96.46%	68.79%	Polyribonucleotide nucleotidyltransferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004654|GO:0003723|	GO:0006402|GO:0006396|
GN017930.1	sp|K1RHF0|K1RHF0_CRAGI	1.2e-34	152.5	42.25%	73.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017931.1	sp|K1S112|K1S112_CRAGI	7.4e-76	290.0	88.89%	73.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017932.1	sp|A0A210QDG4|A0A210QDG4_MIZYE	8.2e-26	123.2	41.39%	55.36%	Uncharacterized protein K02A2.6;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|	GO:0015074|
GN017933.1	sp|K1QVN8|K1QVN8_CRAGI	0.0e+00	1115.1	100.00%	85.50%	ATP-binding cassette sub-family G member 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016887|
GN015553.1	sp|K1RAB9|K1RAB9_CRAGI	2.1e-90	337.4	97.54%	75.63%	Epoxide hydrolase 4;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN017934.1	sp|K1R5C9|K1R5C9_CRAGI	0.0e+00	1232.2	100.00%	93.67%	ATP-binding cassette sub-family G member 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0016887|
GN017935.1	sp|K1RBA2|K1RBA2_CRAGI	1.7e-136	491.1	98.72%	76.22%	Testis-specific serine/threonine-protein kinase 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN017936.1	sp|K1RHF4|K1RHF4_CRAGI	6.7e-168	595.5	99.38%	88.75%	Testis-specific serine/threonine-protein kinase 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN017937.1	sp|K1S115|K1S115_CRAGI	0.0e+00	2102.0	99.92%	86.27%	WD repeat-containing protein 64;OS=Crassostrea;PE=4;SV=1
GN017938.1	sp|K1QVP2|K1QVP2_CRAGI	4.9e-96	356.7	81.06%	69.14%	Retinal homeobox protein Rx2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|	GO:0007275|GO:0006366|
GN017939.1	sp|K1R5D7|K1R5D7_CRAGI	7.6e-108	396.4	100.00%	62.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017940.1	sp|K1RBA7|K1RBA7_CRAGI	5.1e-127	460.3	100.00%	63.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017941.1	sp|K1RHF9|K1RHF9_CRAGI	7.2e-110	402.5	100.00%	80.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN017942.1	sp|K1RX14|K1RX14_CRAGI	1.2e-62	245.4	89.29%	60.30%	Exoskeleton protein RP43;OS=Crassostrea;PE=4;SV=1
GN017943.1	sp|K1R0P1|K1R0P1_CRAGI	0.0e+00	1174.8	63.69%	72.98%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN017945.1	sp|K1RDU1|K1RDU1_CRAGI	4.9e-238	829.3	98.79%	70.86%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN017946.1	sp|K1RX17|K1RX17_CRAGI	0.0e+00	1116.7	99.05%	77.30%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN017947.1	sp|K1RX17|K1RX17_CRAGI	2.9e-291	1006.5	94.17%	67.88%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN017948.1	sp|A0A210PTE8|A0A210PTE8_MIZYE	4.0e-102	378.3	96.07%	32.39%	Kyphoscoliosis peptidase;OS=Mizuhopecten;PE=4;SV=1
GN017949.1	sp|K1RX17|K1RX17_CRAGI	1.7e-54	219.9	89.53%	28.72%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN017951.1	sp|A0A2G8K3P7|A0A2G8K3P7_STIJA	1.4e-93	349.4	73.81%	43.24%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0046872|
GN017952.1	sp|K1RFW2|K1RFW2_CRAGI	1.6e-63	249.2	37.61%	58.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017953.1	sp|K1Q396|K1Q396_CRAGI	1.4e-19	102.1	35.20%	63.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017954.1	sp|K1RBG6|K1RBG6_CRAGI	3.0e-20	103.6	70.83%	52.38%	Actin-1/3;OS=Crassostrea;PE=3;SV=1	GO:0005524|
GN017955.1	sp|K1R0P9|K1R0P9_CRAGI	0.0e+00	1145.2	99.42%	88.58%	Zinc transporter 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN017956.1	sp|K1RDU5|K1RDU5_CRAGI	2.8e-193	680.2	100.00%	71.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017957.1	sp|K1QRB0|K1QRB0_CRAGI	1.0e-40	172.6	94.92%	45.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017958.1	sp|K1R0Q5|K1R0Q5_CRAGI	1.4e-60	239.2	98.62%	39.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017959.1	sp|K1RDM4|K1RDM4_CRAGI	1.3e-40	172.6	35.27%	79.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017960.1	sp|K1RVU3|K1RVU3_CRAGI	0.0e+00	1078.5	100.00%	77.68%	Allene oxide synthase-lipoxygenase protein;OS=Crassostrea;PE=4;SV=1	GO:0004096|GO:0020037|GO:0046872|GO:0016702|
GN017961.1	sp|K1RDM4|K1RDM4_CRAGI	1.3e-40	172.6	35.27%	79.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017962.1	sp|K1RDV6|K1RDV6_CRAGI	3.1e-95	354.0	97.61%	59.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017963.1	sp|A0A210QVN1|A0A210QVN1_MIZYE	1.2e-86	325.1	95.95%	76.42%	Ras-like protein family member 12;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0005525|GO:0003924|	GO:0007165|
GN017964.1	sp|K1R0R2|K1R0R2_CRAGI	4.1e-264	916.0	98.99%	83.62%	Sodium/glucose cotransporter 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN017965.1	sp|K1QRB8|K1QRB8_CRAGI	8.4e-94	349.4	87.35%	82.69%	G kinase-anchoring protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005794|	GO:0016301|	GO:0007165|
GN017967.1	sp|K1RX27|K1RX27_CRAGI	2.0e-138	497.3	100.00%	87.64%	Mitochondrial substrate carrier family protein ucpB;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN015798.1	sp|K1QY88|K1QY88_CRAGI	7.4e-86	324.3	55.26%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN017975.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	4.6e-90	337.0	95.13%	44.99%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN017976.1	sp|A0A1S3JFN7|A0A1S3JFN7_LINUN	8.6e-119	433.0	98.35%	47.29%	uncharacterized protein LOC106172813;OS=Lingula;PE=4;SV=1
GN017978.1	sp|K1QS20|K1QS20_CRAGI	1.5e-30	139.8	26.38%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017979.1	sp|K1PPT8|K1PPT8_CRAGI	1.2e-175	621.7	98.13%	69.45%	Acyl-coenzyme A amino acid N-acyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016790|GO:0016746|	GO:0006637|
GN017980.1	sp|K1PWY5|K1PWY5_CRAGI	0.0e+00	1196.8	95.41%	96.42%	Guanylate cyclase 32E;OS=Crassostrea;PE=4;SV=1	GO:0004383|	GO:0035556|
GN017981.1	sp|V4ARM3|V4ARM3_LOTGI	1.7e-11	75.5	39.39%	45.56%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN017982.1	sp|K1Q4D0|K1Q4D0_CRAGI	3.3e-302	1042.7	95.24%	87.25%	Guanylate cyclase 32E;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004383|	GO:0035556|
GN017983.1	sp|K1QBN5|K1QBN5_CRAGI	1.2e-54	219.9	98.83%	73.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017989.1	sp|K1RY19|K1RY19_CRAGI	1.3e-22	110.9	95.06%	77.22%	Uncharacterized protein CXorf65-like protein;OS=Crassostrea;PE=4;SV=1
GN017990.1	sp|A0A1S3J188|A0A1S3J188_LINUN	2.4e-14	83.6	69.57%	63.49%	uncharacterized protein K02A2.6;OS=Lingula;PE=4;SV=1
GN017991.1	sp|A0A210QDG4|A0A210QDG4_MIZYE	2.0e-16	90.9	65.29%	59.49%	Uncharacterized protein K02A2.6;OS=Mizuhopecten;PE=4;SV=1	GO:0003676|	GO:0015074|
GN017992.1	sp|K1QAG4|K1QAG4_CRAGI	5.0e-18	96.7	31.33%	76.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN017993.1	sp|K1QAG4|K1QAG4_CRAGI	1.2e-109	402.5	56.26%	65.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN017995.1	sp|A0A2B4RG89|A0A2B4RG89_STYPI	3.0e-31	140.6	92.07%	42.00%	Gypsy retrotransposon integrase-like protein 1;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0004803|	GO:0015074|GO:0006313|
GN017996.1	sp|A0A210PTP2|A0A210PTP2_MIZYE	4.7e-12	77.4	51.42%	29.69%	Complement C1q tumor necrosis factor-related protein 5;OS=Mizuhopecten;PE=4;SV=1
GN017997.1	sp|K1Q374|K1Q374_CRAGI	1.2e-30	140.6	15.57%	63.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN017998.1	sp|K1Q374|K1Q374_CRAGI	4.6e-27	126.7	86.90%	51.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018000.1	sp|K1S1H5|K1S1H5_CRAGI	1.8e-66	258.1	100.00%	78.02%	Helix-loop-helix protein delilah;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN018003.1	sp|K1RBU2|K1RBU2_CRAGI	1.1e-187	662.1	87.83%	73.91%	E3 ubiquitin-protein ligase synoviolin-A;OS=Crassostrea;PE=4;SV=1	GO:0000836|GO:0016021|	GO:0016874|GO:0061630|	GO:0030433|
GN015800.1	sp|K1RFW9|K1RFW9_CRAGI	1.7e-50	205.7	92.12%	34.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018004.1	sp|K1Q7A5|K1Q7A5_CRAGI	5.4e-97	359.8	78.87%	66.42%	Speedy protein 1-B;OS=Crassostrea;PE=4;SV=1
GN018005.1	sp|K1R0S9|K1R0S9_CRAGI	9.2e-186	655.2	93.56%	80.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018006.1	sp|K1R0S9|K1R0S9_CRAGI	1.2e-185	654.8	93.56%	80.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018007.1	sp|K1R0S9|K1R0S9_CRAGI	1.2e-185	654.8	93.56%	80.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018008.1	sp|K1R0S9|K1R0S9_CRAGI	5.2e-134	483.0	99.71%	69.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018009.1	sp|K1R7E8|K1R7E8_CRAGI	4.6e-142	510.0	99.75%	66.75%	Cholecystokinin receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN018010.1	sp|K1Q1U7|K1Q1U7_CRAGI	0.0e+00	4379.3	98.11%	64.55%	Kinesin-like protein KIF16B;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN015801.1	sp|K1RFW9|K1RFW9_CRAGI	6.9e-115	419.5	100.00%	57.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018012.1	sp|W4XI13|W4XI13_STRPU	2.2e-20	104.4	99.33%	37.75%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN018014.1	sp|K1S308|K1S308_CRAGI	3.1e-10	70.1	62.14%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018016.1	sp|K1PVT5|K1PVT5_CRAGI	1.9e-20	104.0	90.10%	63.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018018.1	sp|K1PVT5|K1PVT5_CRAGI	1.8e-25	120.6	100.00%	70.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015802.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	5.6e-65	253.4	87.29%	49.42%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN018022.1	sp|K1R5U7|K1R5U7_CRAGI	1.8e-75	287.7	91.58%	77.01%	Activating signal cointegrator 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008270|	GO:0006355|
GN018026.1	sp|K1PQP7|K1PQP7_CRAGI	2.7e-265	919.8	99.29%	79.36%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN018027.1	sp|K1PHY1|K1PHY1_CRAGI	7.3e-211	738.8	99.79%	73.14%	Calcium and integrin-binding family member 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007229|
GN015803.1	sp|V4ARM3|V4ARM3_LOTGI	2.9e-12	77.4	59.48%	45.56%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN018032.1	sp|A0A210Q468|A0A210Q468_MIZYE	1.0e-27	128.6	75.89%	52.83%	Multiple coagulation factor deficiency protein 2-like;OS=Mizuhopecten;PE=4;SV=1
GN018033.1	sp|K1RFQ4|K1RFQ4_CRAGI	5.1e-305	1052.4	99.40%	73.13%	Tetratricopeptide repeat protein 27;OS=Crassostrea;PE=4;SV=1
GN018035.1	sp|K1Q5S7|K1Q5S7_CRAGI	2.4e-32	145.6	78.69%	29.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018036.1	sp|K1QH06|K1QH06_CRAGI	7.2e-163	579.7	88.33%	54.40%	Neural cell adhesion molecule 2;OS=Crassostrea;PE=4;SV=1
GN018037.1	sp|K1Q0W4|K1Q0W4_CRAGI	0.0e+00	1498.0	98.27%	80.11%	Calpain-7;OS=Crassostrea;PE=3;SV=1	GO:0004198|GO:0008270|
GN018038.1	sp|C3YZ35|C3YZ35_BRAFL	4.6e-10	70.5	81.31%	29.45%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0030176|	GO:0005524|GO:0005262|GO:0008270|	GO:0032469|
GN018039.1	sp|K1RPB6|K1RPB6_CRAGI	5.9e-158	563.5	73.82%	56.26%	Transmembrane protein C6orf70-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018040.1	sp|K1QYJ4|K1QYJ4_CRAGI	9.4e-175	618.6	100.00%	78.45%	Octopamine receptor beta-1R;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN018042.1	sp|K1QR78|K1QR78_CRAGI	1.1e-160	571.6	100.00%	88.62%	Potassium channel subfamily K member 16;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN018043.1	sp|K1QHF5|K1QHF5_CRAGI	1.6e-94	353.2	99.89%	42.83%	Aftiphilin;OS=Crassostrea;PE=4;SV=1
GN018044.1	sp|K1QPU0|K1QPU0_CRAGI	3.5e-09	67.0	36.03%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018045.1	sp|K1RPB4|K1RPB4_CRAGI	6.7e-270	935.6	85.70%	72.66%	WD repeat-containing protein 91;OS=Crassostrea;PE=4;SV=1	GO:0005829|GO:0016021|	GO:0045022|GO:0043551|
GN018046.1	sp|K1R4V4|K1R4V4_CRAGI	6.3e-58	229.2	99.38%	65.63%	CB1 cannabinoid receptor-interacting protein 1;OS=Crassostrea;PE=4;SV=1
GN018047.1	sp|K1QYJ0|K1QYJ0_CRAGI	7.3e-205	718.8	100.00%	71.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018050.1	sp|K1PPT8|K1PPT8_CRAGI	1.4e-40	171.0	100.00%	72.07%	Acyl-coenzyme A amino acid N-acyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016790|GO:0016746|	GO:0006637|
GN018051.1	sp|K1QE86|K1QE86_CRAGI	7.2e-20	102.1	92.00%	48.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018052.1	sp|K1PQP2|K1PQP2_CRAGI	7.8e-35	154.1	28.46%	75.34%	Nucleolin;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN018053.1	sp|A0A0P4VRI8|A0A0P4VRI8_9EUCA	2.3e-102	378.6	84.89%	40.90%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN018054.1	sp|K1PXM3|K1PXM3_CRAGI	5.3e-227	793.5	100.00%	63.32%	Chromatin assembly factor 1 subunit A;OS=Crassostrea;PE=4;SV=1
GN018055.1	sp|K1QHT3|K1QHT3_CRAGI	2.0e-223	780.8	99.83%	65.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015805.1	sp|K1RA80|K1RA80_CRAGI	5.4e-169	599.4	99.73%	79.79%	Rhodopsin, GQ-coupled;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN018056.1	sp|K1PHY1|K1PHY1_CRAGI	2.1e-89	334.0	100.00%	85.79%	Calcium and integrin-binding family member 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007229|
GN018057.1	sp|A0A2B4R2M8|A0A2B4R2M8_STYPI	2.0e-10	70.9	74.11%	42.68%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN018058.1	sp|K1PHY1|K1PHY1_CRAGI	4.4e-89	333.2	92.24%	73.71%	Calcium and integrin-binding family member 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007229|
GN018059.1	sp|K1PQP7|K1PQP7_CRAGI	3.8e-46	189.9	81.38%	76.92%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN018060.1	sp|K1PQP7|K1PQP7_CRAGI	5.4e-247	859.0	99.26%	75.44%	Mesenchyme-specific cell surface glycoprotein;OS=Crassostrea;PE=4;SV=1
GN018062.1	sp|K1RI62|K1RI62_CRAGI	2.3e-45	187.6	74.30%	82.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018065.1	sp|K1RMF6|K1RMF6_CRAGI	3.0e-85	320.1	100.00%	84.32%	Cytoglobin-1;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN018067.1	sp|K1RAL6|K1RAL6_CRAGI	7.0e-104	382.9	100.00%	63.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018068.1	sp|K1R2B6|K1R2B6_CRAGI	9.0e-60	236.1	56.38%	67.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016747|
GN018069.1	sp|K1PXX7|K1PXX7_CRAGI	2.6e-83	313.9	98.60%	74.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018070.1	sp|K1QCK3|K1QCK3_CRAGI	8.2e-125	452.2	98.28%	78.60%	3-hydroxybutyryl-CoA dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0003857|	GO:0006631|
GN018071.1	sp|K1PQD3|K1PQD3_CRAGI	1.6e-211	741.1	100.00%	69.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018073.1	sp|K1QJH8|K1QJH8_CRAGI	7.4e-64	249.2	86.76%	71.02%	Amiloride-sensitive cation channel 2, neuronal;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN018074.1	sp|W4YW53|W4YW53_STRPU	2.0e-15	87.8	77.30%	37.96%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|
GN018075.1	sp|K1QRX0|K1QRX0_CRAGI	4.7e-40	169.5	100.00%	68.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015806.1	sp|K1RM18|K1RM18_CRAGI	0.0e+00	1967.2	99.17%	80.61%	Dual oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0020037|GO:0016174|GO:0004601|	GO:0050665|GO:0006979|
GN018076.1	sp|K1QAZ4|K1QAZ4_CRAGI	8.0e-25	119.4	83.78%	44.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018077.1	sp|K1QAZ0|K1QAZ0_CRAGI	1.8e-75	288.1	69.44%	80.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018078.1	sp|K1PG52|K1PG52_CRAGI	7.8e-56	224.6	57.88%	32.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018079.1	sp|K1RI95|K1RI95_CRAGI	1.0e-16	91.3	72.84%	77.59%	Two pore calcium channel protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN018080.1	sp|K1RI95|K1RI95_CRAGI	7.5e-120	435.6	93.82%	86.77%	Two pore calcium channel protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN015555.1	sp|A0A1S3IVT1|A0A1S3IVT1_LINUN	0.0e+00	1275.4	99.83%	27.00%	LOW QUALITY PROTEIN: sacsin;OS=Lingula;PE=4;SV=2
GN018081.1	sp|K1RI95|K1RI95_CRAGI	4.4e-75	286.2	93.87%	90.79%	Two pore calcium channel protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN018084.1	sp|K1PK91|K1PK91_CRAGI	1.1e-47	195.3	99.42%	55.29%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018085.1	sp|K1PZ77|K1PZ77_CRAGI	4.1e-38	163.3	98.08%	53.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047961|
GN018086.1	sp|K1PZ77|K1PZ77_CRAGI	2.1e-38	164.5	78.41%	57.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0047961|
GN018087.1	sp|K1QS74|K1QS74_CRAGI	9.1e-165	585.9	100.00%	50.99%	Galectin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN018088.1	sp|A0A210R7I9|A0A210R7I9_MIZYE	6.4e-95	353.6	90.97%	45.02%	Tachykinin-like peptides receptor 99D;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0004930|
GN015808.1	sp|K1R183|K1R183_CRAGI	4.5e-29	133.3	96.79%	57.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018089.1	sp|A0A210R7D6|A0A210R7D6_MIZYE	1.3e-56	225.3	84.07%	55.03%	Transmembrane emp24 domain-containing protein 7;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|
GN018090.1	sp|K1R6I4|K1R6I4_CRAGI	4.2e-81	306.2	100.00%	84.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018091.1	sp|K1RWC0|K1RWC0_CRAGI	4.5e-47	193.0	95.89%	73.38%	Basic leucine zipper transcriptional factor ATF-like 3;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|	GO:0006357|
GN018092.1	sp|K1RI90|K1RI90_CRAGI	1.8e-128	465.7	50.27%	81.92%	GRIP and coiled-coil domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN018093.1	sp|K1QAY7|K1QAY7_CRAGI	2.1e-117	429.1	68.53%	71.81%	ESF1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006364|
GN018094.1	sp|K1QRW5|K1QRW5_CRAGI	1.6e-172	610.9	94.01%	92.65%	Arginase;OS=Crassostrea;PE=3;SV=1	GO:0004053|GO:0046872|	GO:0006525|GO:0000050|
GN018095.1	sp|K1PYX6|K1PYX6_CRAGI	2.7e-38	164.9	72.13%	44.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018096.1	sp|A0A210QIZ4|A0A210QIZ4_MIZYE	1.0e-208	733.0	97.72%	52.94%	Nidogen-1;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0005509|	GO:0007160|
GN015809.1	sp|K1R8Z3|K1R8Z3_CRAGI	2.0e-256	890.6	97.93%	69.69%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN018101.1	sp|K1R6G6|K1R6G6_CRAGI	1.4e-47	196.1	69.15%	38.89%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018102.1	sp|K1PXH9|K1PXH9_CRAGI	0.0e+00	3294.2	99.91%	79.65%	Pecanex-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018103.1	sp|K1PQI4|K1PQI4_CRAGI	8.0e-126	455.7	85.35%	86.52%	Enolase-phosphatase E1;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0043715|GO:0043716|GO:0043874|GO:0000287|	GO:0019509|GO:0019284|
GN018104.1	sp|K1PBE0|K1PBE0_CRAGI	8.9e-26	124.4	99.39%	27.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018105.1	sp|K1QHM9|K1QHM9_CRAGI	1.2e-46	191.0	86.27%	96.55%	DNA-directed RNA polymerase subunit;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0003899|GO:0003676|GO:0008270|	GO:0006379|GO:0006351|
GN015810.1	sp|A0A1X7T7W9|A0A1X7T7W9_AMPQE	6.2e-40	169.5	94.12%	50.92%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN018106.1	sp|K1PXH5|K1PXH5_CRAGI	1.3e-53	214.5	94.53%	87.50%	Putative saccharopine dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN018107.1	sp|K1PXH5|K1PXH5_CRAGI	3.5e-63	246.5	95.24%	82.73%	Putative saccharopine dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN018108.1	sp|A0A1E1X121|A0A1E1X121_9ACAR	1.2e-23	115.2	71.71%	45.37%	Uncharacterized protein;OS=Amblyomma;PE=2;SV=1	GO:0003677|
GN018109.1	sp|K1R8P0|K1R8P0_CRAGI	1.3e-143	515.8	97.73%	58.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018110.1	sp|K1R1Z1|K1R1Z1_CRAGI	1.3e-231	808.1	100.00%	68.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018111.1	sp|K1R1Z1|K1R1Z1_CRAGI	1.3e-158	565.5	91.55%	60.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018112.1	sp|K1QV88|K1QV88_CRAGI	3.7e-172	609.8	99.44%	79.77%	Aldose 1-epimerase;OS=Crassostrea;PE=3;SV=1	GO:0004034|GO:0030246|	GO:0019318|
GN018113.1	sp|K1QL49|K1QL49_CRAGI	1.2e-181	641.3	100.00%	83.33%	Aldose 1-epimerase;OS=Crassostrea;PE=3;SV=1	GO:0004034|GO:0030246|	GO:0019318|
GN018114.1	sp|K1QN25|K1QN25_CRAGI	2.1e-30	138.7	27.01%	75.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018115.1	sp|K1RSM0|K1RSM0_CRAGI	5.4e-122	443.0	89.78%	79.64%	H2.0-like homeobox protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN018116.1	sp|K1R8N0|K1R8N0_CRAGI	1.7e-215	754.6	87.12%	69.41%	Inter-alpha-trypsin inhibitor heavy chain H4;OS=Crassostrea;PE=4;SV=1
GN018117.1	sp|A0A1X7SZ30|A0A1X7SZ30_AMPQE	1.6e-60	238.8	88.44%	42.86%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046983|
GN018119.1	sp|K1RDT1|K1RDT1_CRAGI	1.8e-12	78.2	76.97%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018120.1	sp|K1RCQ5|K1RCQ5_CRAGI	0.0e+00	1189.9	96.37%	71.18%	Dispatched-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007224|
GN018122.1	sp|K1RCQ5|K1RCQ5_CRAGI	1.1e-240	838.2	99.66%	72.74%	Dispatched-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007224|
GN018123.1	sp|K1QWN3|K1QWN3_CRAGI	5.4e-65	253.4	96.82%	53.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN018124.1	sp|K1RLP8|K1RLP8_CRAGI	3.7e-40	169.9	97.73%	63.85%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN018125.1	sp|A0A210R3C1|A0A210R3C1_MIZYE	2.3e-129	467.6	97.43%	63.82%	Aldose 1-epimerase;OS=Mizuhopecten;PE=3;SV=1	GO:0004034|GO:0030246|	GO:0019318|
GN018127.1	sp|J9Q3Z4|J9Q3Z4_OSTED	1.6e-38	165.2	46.64%	96.36%	Eukaryotic translation initiation factor 3 subunit J;OS=Ostrea;PE=2;SV=1	GO:0005852|	GO:0003743|
GN018128.1	sp|K1PAJ3|K1PAJ3_CRAGI	5.0e-147	526.2	98.77%	80.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018130.1	sp|K1PAJ3|K1PAJ3_CRAGI	2.3e-41	176.4	80.13%	29.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018131.1	sp|K1PAJ3|K1PAJ3_CRAGI	9.6e-71	272.3	92.47%	61.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018133.1	sp|A0A210PKX9|A0A210PKX9_MIZYE	9.9e-25	118.2	99.02%	55.00%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN018135.1	sp|K1QBD1|K1QBD1_CRAGI	6.4e-13	79.3	85.94%	42.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015811.1	sp|K1QH93|K1QH93_CRAGI	1.0e-43	182.2	75.52%	57.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018136.1	sp|K1PVP0|K1PVP0_CRAGI	2.1e-79	301.6	58.79%	71.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018138.1	sp|K1QGR8|K1QGR8_CRAGI	6.9e-273	944.9	99.20%	91.11%	Asparaginyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=4;SV=1	GO:0004816|GO:0005524|GO:0003676|	GO:0006421|
GN018139.1	sp|K1PWS0|K1PWS0_CRAGI	0.0e+00	1854.0	100.00%	93.81%	Integrator complex subunit 3;OS=Crassostrea;PE=4;SV=1
GN018140.1	sp|K1PPL3|K1PPL3_CRAGI	0.0e+00	1421.0	87.02%	91.73%	Striatin-3;OS=Crassostrea;PE=4;SV=1
GN018142.1	sp|K1Q988|K1Q988_CRAGI	4.4e-219	766.5	66.31%	89.79%	Band 4.1-like protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005911|GO:0005856|GO:0005886|	GO:0008092|	GO:0007016|GO:0001558|
GN018143.1	sp|A0A210QE17|A0A210QE17_MIZYE	1.1e-102	379.0	97.14%	50.72%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015812.1	sp|A0A1S3H2W8|A0A1S3H2W8_LINUN	3.8e-33	146.7	83.44%	58.59%	uncharacterized protein LOC106151235 isoform X1;OS=Lingula;PE=4;SV=1
GN018145.1	sp|K1RNH8|K1RNH8_CRAGI	7.8e-142	508.8	100.00%	79.41%	Solute carrier family 22 member 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN018148.1	sp|K1S6U9|K1S6U9_CRAGI	8.5e-57	226.1	70.04%	64.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018149.1	sp|K1R1L8|K1R1L8_CRAGI	9.7e-159	565.8	93.30%	65.77%	SH2 domain-containing adapter protein F;OS=Crassostrea;PE=4;SV=1
GN018150.1	sp|A0A210QJC1|A0A210QJC1_MIZYE	4.4e-46	191.0	66.85%	41.96%	Exonuclease 3'-5' domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0008408|GO:0003676|
GN015813.1	sp|K1S5J6|K1S5J6_CRAGI	1.2e-141	508.4	96.42%	66.76%	Apical endosomal glycoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN018151.1	sp|K1QMW5|K1QMW5_CRAGI	9.7e-14	81.6	74.23%	66.20%	Nicotinamide riboside kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0046872|GO:0004842|
GN018152.1	sp|K1QWX3|K1QWX3_CRAGI	1.9e-21	107.5	90.00%	78.57%	Protein CEPU-1;OS=Crassostrea;PE=4;SV=1
GN018153.1	sp|K1QWX3|K1QWX3_CRAGI	4.8e-91	340.1	72.73%	72.77%	Protein CEPU-1;OS=Crassostrea;PE=4;SV=1
GN018154.1	sp|K1RAC5|K1RAC5_CRAGI	5.4e-261	906.0	100.00%	64.40%	Crossover junction endonuclease MUS81;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004519|
GN018155.1	sp|K1RU52|K1RU52_CRAGI	0.0e+00	1096.3	100.00%	90.30%	Bardet-Biedl syndrome 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0034464|	GO:1905515|
GN018156.1	sp|K1QMW8|K1QMW8_CRAGI	5.9e-222	775.4	100.00%	97.53%	Potassium channel subfamily K member 18;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN015556.1	sp|A0A2T7NGI6|A0A2T7NGI6_POMCA	0.0e+00	1403.7	99.83%	26.85%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN018158.1	sp|K1RAC8|K1RAC8_CRAGI	2.9e-273	946.8	91.33%	57.48%	Peptidyl-glycine alpha-amidating monooxygenase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005507|GO:0016715|	GO:0006518|
GN018159.1	sp|A0A210PFP1|A0A210PFP1_MIZYE	1.2e-69	268.9	91.51%	54.90%	N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase;OS=Mizuhopecten;PE=4;SV=1	GO:0016787|
GN018160.1	sp|K1RXI6|K1RXI6_CRAGI	7.7e-216	755.7	85.71%	74.06%	Uncharacterized protein C15orf33;OS=Crassostrea;PE=4;SV=1
GN018161.1	sp|A0A1S3H2W2|A0A1S3H2W2_LINUN	2.4e-108	397.9	99.74%	51.85%	archaemetzincin-2;OS=Lingula;PE=4;SV=1	GO:0008237|GO:0008270|
GN018162.1	sp|Q962A5|Q962A5_CRAGI	5.4e-280	968.8	99.17%	80.43%	Transcription factor Rel 1;OS=Crassostrea;PE=2;SV=1	GO:0005737|GO:0005634|	GO:0003677|GO:0003700|	GO:0006357|
GN018164.1	sp|K1RIW4|K1RIW4_CRAGI	4.9e-68	263.5	95.42%	53.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018166.1	sp|A0A210QXC5|A0A210QXC5_MIZYE	0.0e+00	1921.4	97.62%	65.56%	Ral GTPase-activating protein subunit beta;OS=Mizuhopecten;PE=4;SV=1	GO:0005096|	GO:0051056|
GN015814.1	sp|K1RA73|K1RA73_CRAGI	1.5e-81	308.1	81.90%	84.44%	Canopy-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018170.1	sp|V4B2E6|V4B2E6_LOTGI	4.5e-126	456.4	100.00%	74.09%	Coatomer subunit epsilon;OS=Lottia;PE=3;SV=1	GO:0031410|GO:0000139|	GO:0005198|	GO:0015031|GO:0006890|
GN018171.1	sp|K1S5K7|K1S5K7_CRAGI	5.9e-147	525.8	97.61%	87.37%	Junction-mediating and-regulatory protein;OS=Crassostrea;PE=4;SV=1
GN018172.1	sp|K1S5K7|K1S5K7_CRAGI	8.3e-99	366.3	100.00%	68.30%	Junction-mediating and-regulatory protein;OS=Crassostrea;PE=4;SV=1
GN018173.1	sp|A0A210Q3K2|A0A210Q3K2_MIZYE	1.9e-76	292.4	47.30%	75.88%	Myelin expression factor 2;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN018174.1	sp|K1RFX1|K1RFX1_CRAGI	1.8e-114	419.1	32.68%	94.42%	CREB-regulated transcription coactivator 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0008140|	GO:0032793|GO:0051289|
GN018177.1	sp|K1QBH3|K1QBH3_CRAGI	7.8e-184	648.7	100.00%	81.53%	Alpha-methylacyl-CoA racemase;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN015815.1	sp|K1Q2T1|K1Q2T1_CRAGI	9.0e-223	778.5	100.00%	77.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018180.1	sp|K1RD83|K1RD83_CRAGI	1.4e-97	361.3	92.92%	86.22%	Serine hydroxymethyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004372|GO:0008168|GO:0030170|	GO:0019264|GO:0035999|
GN018181.1	sp|K1QEN5|K1QEN5_CRAGI	7.4e-129	466.5	99.61%	47.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018182.1	sp|K1QG17|K1QG17_CRAGI	7.1e-25	120.6	18.85%	82.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018183.1	sp|K1QV55|K1QV55_CRAGI	2.3e-63	246.9	100.00%	86.72%	Ubiquitin thioesterase OTUB1;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN015816.1	sp|A0A210QWI2|A0A210QWI2_MIZYE	8.2e-29	131.7	88.66%	72.94%	Signal recognition particle 14 kDa protein;OS=Mizuhopecten;PE=4;SV=1	GO:0005786|	GO:0008312|GO:0030942|	GO:0006614|
GN018184.1	sp|K1RFD4|K1RFD4_CRAGI	3.0e-275	953.0	98.97%	81.57%	4-coumarate--CoA ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN018185.1	sp|K1PYE2|K1PYE2_CRAGI	7.3e-261	905.6	74.58%	80.96%	KLRAQ motif-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN018186.1	sp|K1Q3B0|K1Q3B0_CRAGI	4.6e-270	935.6	99.82%	85.03%	ATP-binding cassette sub-family D member 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN018187.1	sp|K1PKE2|K1PKE2_CRAGI	2.1e-139	500.7	89.32%	84.73%	Solute carrier family 25 member 45;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN018188.1	sp|K1PTA8|K1PTA8_CRAGI	9.6e-108	395.2	99.57%	81.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018189.1	sp|K1PAJ0|K1PAJ0_CRAGI	1.3e-09	68.2	64.60%	47.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018190.1	sp|K1PZV5|K1PZV5_CRAGI	2.7e-54	218.8	23.52%	81.15%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN018192.1	sp|K1PF14|K1PF14_CRAGI	1.7e-167	596.7	57.61%	50.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN018193.1	sp|A0A210PVJ5|A0A210PVJ5_MIZYE	5.9e-101	373.2	97.16%	51.75%	Tigger transposable element-derived protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018195.1	sp|K1RDI0|K1RDI0_CRAGI	0.0e+00	3479.5	100.00%	83.09%	Myosin-I heavy chain;OS=Crassostrea;PE=3;SV=1	GO:0016459|	GO:0003779|GO:0005524|GO:0003774|
GN018197.1	sp|K1R1F4|K1R1F4_CRAGI	1.0e-236	825.1	77.16%	86.75%	Serine/threonine-protein phosphatase 5;OS=Crassostrea;PE=4;SV=1	GO:0004721|
GN018198.1	sp|K1R1Z8|K1R1Z8_CRAGI	4.4e-75	286.2	100.00%	84.15%	Putative D-tyrosyl-tRNA(Tyr) deacylase 2;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0051499|
GN018199.1	sp|K1QL55|K1QL55_CRAGI	0.0e+00	1323.1	100.00%	87.37%	Protein phosphatase 1B;OS=Crassostrea;PE=3;SV=1	GO:0005856|	GO:0000287|GO:0030145|GO:0004722|
GN018200.1	sp|A0A2B4RUK4|A0A2B4RUK4_STYPI	4.7e-18	98.2	41.78%	29.74%	Pro-Pol polyprotein;OS=Stylophora;PE=4;SV=1
GN018201.1	sp|K1RSM4|K1RSM4_CRAGI	0.0e+00	1420.6	99.13%	85.73%	S-adenosyl-L-methionine-dependent methyltransferase ftsjd2;OS=Crassostrea;PE=4;SV=1	GO:0004483|GO:0003676|	GO:0006370|
GN018204.1	sp|K1PXL1|K1PXL1_CRAGI	1.3e-75	288.1	99.48%	68.42%	Lysophospholipase-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN018205.1	sp|V4AKX4|V4AKX4_LOTGI	2.1e-29	134.0	81.60%	60.40%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN018206.1	sp|K1R861|K1R861_CRAGI	1.4e-39	168.7	86.21%	45.28%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN018207.1	sp|A0A210R544|A0A210R544_MIZYE	3.4e-97	360.1	92.37%	81.57%	Electron transfer flavoprotein subunit alpha, mitochondrial;OS=Mizuhopecten;PE=4;SV=1	GO:0009055|GO:0050660|
GN018208.1	sp|K1PW87|K1PW87_CRAGI	0.0e+00	1513.4	96.16%	80.11%	Proprotein convertase subtilisin/kexin type 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004252|GO:0004714|	GO:0007169|
GN018209.1	sp|K1PNM3|K1PNM3_CRAGI	1.3e-17	94.4	72.09%	68.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018210.1	sp|K1PW84|K1PW84_CRAGI	3.5e-173	614.0	99.68%	47.93%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018211.1	sp|K1PNL7|K1PNL7_CRAGI	1.1e-65	255.8	99.65%	51.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018212.1	sp|K1PNL7|K1PNL7_CRAGI	1.2e-58	232.3	87.70%	53.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018213.1	sp|K1PW84|K1PW84_CRAGI	1.1e-129	469.2	99.21%	46.76%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018215.1	sp|K1PPP6|K1PPP6_CRAGI	9.5e-35	151.4	100.00%	78.02%	Cell adhesion molecule 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008270|
GN015818.1	sp|K1RD54|K1RD54_CRAGI	1.2e-287	994.2	96.30%	79.43%	Kelch-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018217.1	sp|K1Q332|K1Q332_CRAGI	1.3e-53	215.3	71.18%	68.52%	Vesicle transport protein USE1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018218.1	sp|K1QNZ4|K1QNZ4_CRAGI	4.3e-259	899.0	100.00%	87.50%	Uncharacterized protein C19orf45;OS=Crassostrea;PE=4;SV=1
GN018219.1	sp|K1PH58|K1PH58_CRAGI	5.3e-103	379.4	92.48%	87.08%	Protein Wnt;OS=Crassostrea;PE=3;SV=1	GO:0005576|GO:0016021|	GO:0005102|	GO:0007275|GO:0016055|
GN018220.1	sp|K1PNL7|K1PNL7_CRAGI	8.5e-169	599.4	99.33%	54.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018221.1	sp|K1QUJ8|K1QUJ8_CRAGI	6.5e-78	295.8	90.16%	76.88%	F-box/WD repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN018222.1	sp|K1PID0|K1PID0_CRAGI	1.5e-114	417.9	100.00%	82.95%	Tight junction-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN018223.1	sp|K1PB16|K1PB16_CRAGI	3.5e-153	546.6	99.38%	74.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007186|GO:0019236|
GN015819.1	sp|A0A210QE45|A0A210QE45_MIZYE	0.0e+00	1089.7	100.00%	71.96%	Protein kinase C;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0046872|GO:0004697|	GO:0035556|
GN018224.1	sp|K1PSW5|K1PSW5_CRAGI	7.7e-56	222.2	84.66%	75.91%	Putative proline racemase;OS=Crassostrea;PE=4;SV=1
GN018225.1	sp|K1PKY4|K1PKY4_CRAGI	1.3e-294	1017.3	100.00%	88.47%	Sodium/calcium exchanger 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005432|	GO:0007154|
GN018226.1	sp|K1QJ18|K1QJ18_CRAGI	0.0e+00	1146.7	100.00%	81.75%	Phospholipase DDHD1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN018227.1	sp|A0A210Q9M6|A0A210Q9M6_MIZYE	6.7e-228	795.4	100.00%	76.91%	BTB/POZ domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1
GN018228.1	sp|K1PRX8|K1PRX8_CRAGI	5.1e-73	279.3	90.32%	96.40%	Transcription factor IIIB 90 kDa subunit;OS=Crassostrea;PE=4;SV=1	GO:0000126|	GO:0046872|GO:0000995|GO:0017025|	GO:0006355|GO:0070897|
GN018229.1	sp|K1RT25|K1RT25_CRAGI	3.1e-78	297.0	86.76%	76.14%	NAD-dependent deacetylase sirtuin-2;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN018230.1	sp|K1RT25|K1RT25_CRAGI	3.8e-36	156.0	95.65%	87.36%	NAD-dependent deacetylase sirtuin-2;OS=Crassostrea;PE=4;SV=1	GO:0070403|
GN018231.1	sp|A0A2B4RV68|A0A2B4RV68_STYPI	7.5e-12	76.3	72.88%	32.03%	Retrovirus-related Pol polyprotein;OS=Stylophora;PE=4;SV=1	GO:0003676|GO:0008270|
GN015536.1	sp|K1PXZ3|K1PXZ3_CRAGI	7.5e-219	765.0	99.74%	91.91%	Phytanoyl-CoA dioxygenase domain-containing protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0051213|
GN015820.1	sp|K1QNP9|K1QNP9_CRAGI	2.4e-170	603.6	100.00%	92.16%	Putative deoxyribose-phosphate aldolase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0004139|	GO:0009264|
GN018232.1	sp|K1QVT2|K1QVT2_CRAGI	0.0e+00	1218.0	78.01%	87.24%	Zinc finger FYVE domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0046872|
GN018233.1	sp|K1R2H8|K1R2H8_CRAGI	3.8e-152	544.3	51.80%	77.51%	RNA polymerase-associated protein RTF1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016593|	GO:0003677|	GO:0016570|GO:0006368|
GN018234.1	sp|K1PLQ9|K1PLQ9_CRAGI	1.2e-59	235.3	100.00%	57.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018235.1	sp|K1PDX1|K1PDX1_CRAGI	1.3e-11	75.5	23.50%	85.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018236.1	sp|K1PDX1|K1PDX1_CRAGI	6.4e-196	689.9	69.46%	64.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018237.1	sp|K1PZ82|K1PZ82_CRAGI	1.1e-25	124.4	12.52%	57.58%	Collagen alpha-3(VI) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005509|
GN015821.1	sp|A0A194ALR6|A0A194ALR6_PINFU	7.5e-42	175.3	94.69%	71.70%	Putative iron-sulfur cluster assembly 2-like, mitochondrial-like protein;OS=Pinctada;PE=4;SV=1	GO:0051536|GO:0005198|	GO:0097428|
GN018238.1	sp|A0A210PQ83|A0A210PQ83_MIZYE	2.9e-30	137.1	100.00%	56.55%	Pleckstrin homology domain-containing family D member 1;OS=Mizuhopecten;PE=4;SV=1
GN018241.1	sp|K1QNX9|K1QNX9_CRAGI	4.0e-167	593.2	100.00%	80.20%	Protein FAM81A;OS=Crassostrea;PE=4;SV=1
GN018242.1	sp|K1QNY8|K1QNY8_CRAGI	4.2e-46	189.5	76.42%	100.00%	Ras-specific guanine nucleotide-releasing factor 1;OS=Crassostrea;PE=4;SV=1
GN015822.1	sp|K1PGZ0|K1PGZ0_CRAGI	2.8e-225	787.3	97.75%	51.85%	Thyroid adenoma-associated protein;OS=Crassostrea;PE=4;SV=1
GN018245.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.7e-101	375.2	61.12%	49.87%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN018246.1	sp|A0A1S3I398|A0A1S3I398_LINUN	4.5e-26	123.2	64.90%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN018247.1	sp|A0A210QI67|A0A210QI67_MIZYE	1.4e-30	137.9	100.00%	61.98%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018248.1	sp|K1PNL0|K1PNL0_CRAGI	0.0e+00	1416.7	99.73%	65.79%	Microtubule-associated protein futsch;OS=Crassostrea;PE=4;SV=1	GO:0005874|	GO:0008017|	GO:0000226|
GN018249.1	sp|K1PW78|K1PW78_CRAGI	0.0e+00	1604.3	97.34%	75.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018250.1	sp|A0A210PGT6|A0A210PGT6_MIZYE	6.5e-133	479.9	81.25%	53.94%	Protein kinase domain-containing protein, cytoplasmic;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN018251.1	sp|K1QAU1|K1QAU1_CRAGI	1.0e-190	672.9	65.35%	60.82%	Angiogenic factor with G patch and FHA domains 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005507|GO:0003676|GO:0008131|GO:0046983|GO:0048038|	GO:0009308|
GN018252.1	sp|K1R5D3|K1R5D3_CRAGI	1.0e-35	155.6	94.76%	44.81%	Origin recognition complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0005634|GO:0000808|	GO:0006260|
GN018253.1	sp|A0A210QB47|A0A210QB47_MIZYE	1.7e-159	568.5	97.68%	45.76%	Amine oxidase;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0008131|GO:0048038|	GO:0009308|
GN018254.1	sp|K1P4Q0|K1P4Q0_CRAGI	1.2e-166	591.7	95.91%	84.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008017|
GN018257.1	sp|K1PB18|K1PB18_CRAGI	1.6e-175	621.3	100.00%	64.77%	Putative serine/threonine-protein kinase pats1;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016301|	GO:0007165|
GN018259.1	sp|K1PQE8|K1PQE8_CRAGI	2.4e-53	214.2	96.77%	56.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018261.1	sp|K1Q8M9|K1Q8M9_CRAGI	1.6e-121	441.4	97.81%	84.29%	Homeobox protein ARX;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0043565|	GO:0007275|GO:0006355|
GN018262.1	sp|K1QI66|K1QI66_CRAGI	5.6e-31	139.0	99.05%	64.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018263.1	sp|K1QI66|K1QI66_CRAGI	1.5e-77	295.4	87.84%	55.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018264.1	sp|K1PMC5|K1PMC5_CRAGI	1.8e-37	161.0	98.58%	59.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018266.1	sp|K1RA29|K1RA29_CRAGI	0.0e+00	1185.2	99.59%	78.46%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN018267.1	sp|K1RA29|K1RA29_CRAGI	0.0e+00	1077.4	100.00%	70.94%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN018269.1	sp|K1RA29|K1RA29_CRAGI	4.8e-117	426.4	98.96%	69.69%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN018270.1	sp|K1RA29|K1RA29_CRAGI	0.0e+00	1525.0	69.56%	66.82%	Polycystic kidney disease protein 1-like 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN018271.1	sp|K1PIL7|K1PIL7_CRAGI	2.1e-131	474.2	99.67%	77.41%	Forkhead box protein B1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN018272.1	sp|K1P514|K1P514_CRAGI	0.0e+00	1187.6	100.00%	76.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016810|	GO:0005975|
GN018273.1	sp|K1PQM5|K1PQM5_CRAGI	5.0e-80	303.5	87.66%	58.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0043066|
GN018274.1	sp|A0A1S3JNJ7|A0A1S3JNJ7_LINUN	8.5e-53	213.0	80.07%	43.57%	jmjC domain-containing protein 5;OS=Lingula;PE=4;SV=1
GN018275.1	sp|K1QBH6|K1QBH6_CRAGI	8.8e-10	68.6	80.00%	48.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018277.1	sp|K1PIL3|K1PIL3_CRAGI	4.7e-210	735.7	100.00%	98.92%	cAMP-dependent protein kinase type II regulatory subunit;OS=Crassostrea;PE=4;SV=1	GO:0005952|	GO:0030552|GO:0008603|GO:0016301|
GN018278.1	sp|K1QN82|K1QN82_CRAGI	4.8e-71	272.7	96.15%	87.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018279.1	sp|K1QN82|K1QN82_CRAGI	2.2e-99	367.5	100.00%	75.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018280.1	sp|A0A210QRK1|A0A210QRK1_MIZYE	3.5e-104	384.4	90.38%	47.47%	Lysine-specific demethylase 8;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN018281.1	sp|K1R329|K1R329_CRAGI	5.3e-171	608.2	25.88%	67.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018282.1	sp|A0A210PMQ5|A0A210PMQ5_MIZYE	9.9e-282	975.7	77.90%	50.55%	Bloom syndrome protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0043140|GO:0003676|	GO:0006310|GO:0006281|GO:0006260|
GN018283.1	sp|K1R928|K1R928_CRAGI	7.6e-46	188.7	82.44%	92.52%	60S ribosomal protein L36;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN015823.1	sp|K1Q2T9|K1Q2T9_CRAGI	0.0e+00	1316.6	98.88%	92.35%	Exocyst complex component 5;OS=Crassostrea;PE=4;SV=1	GO:0000145|	GO:0006887|GO:0048278|
GN018284.1	sp|A0A2T7PFV2|A0A2T7PFV2_POMCA	1.1e-16	93.2	34.16%	44.55%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003677|GO:0008170|	GO:0006306|
GN015824.1	sp|A0A2C9LKR7|A0A2C9LKR7_BIOGL	1.6e-27	128.6	52.40%	55.46%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1
GN018286.1	sp|K1Q055|K1Q055_CRAGI	3.1e-36	156.4	96.88%	89.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018288.1	sp|V4AE92|V4AE92_LOTGI	4.9e-91	340.5	99.27%	43.03%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN018289.1	sp|K1QY88|K1QY88_CRAGI	6.1e-76	290.4	98.36%	41.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN018290.1	sp|W4XY62|W4XY62_STRPU	8.0e-40	171.0	29.00%	40.76%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0016788|GO:0003676|GO:0008270|	GO:0015074|
GN015557.1	sp|K1QXY3|K1QXY3_CRAGI	4.7e-142	510.8	64.71%	79.20%	Transcriptional repressor p66-alpha;OS=Crassostrea;PE=4;SV=1	GO:0000122|
GN018292.1	sp|K1QYJ8|K1QYJ8_CRAGI	6.0e-43	179.9	99.55%	47.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018293.1	sp|K1R4W1|K1R4W1_CRAGI	8.8e-71	273.1	99.73%	46.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018294.1	sp|K1RPC1|K1RPC1_CRAGI	3.1e-114	417.5	99.25%	62.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018295.1	sp|K1QHG1|K1QHG1_CRAGI	7.7e-97	359.4	95.50%	66.01%	MAD2L1-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0007096|
GN018296.1	sp|K1R4W5|K1R4W5_CRAGI	0.0e+00	1454.9	100.00%	86.69%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008376|
GN018297.1	sp|K1RPC5|K1RPC5_CRAGI	4.9e-260	902.9	99.39%	66.22%	Regulation of nuclear pre-mRNA domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN018298.1	sp|K1R4W8|K1R4W8_CRAGI	1.6e-146	525.0	84.47%	66.67%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN018299.1	sp|K1R4W8|K1R4W8_CRAGI	4.6e-190	669.8	88.83%	73.29%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN018300.1	sp|K1PE41|K1PE41_CRAGI	9.4e-129	465.3	100.00%	77.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0061630|
GN018301.1	sp|K1PKG9|K1PKG9_CRAGI	1.0e-202	711.8	99.80%	71.54%	Uncharacterized protein C8orf41;OS=Crassostrea;PE=4;SV=1
GN018302.1	sp|K1Q5Z4|K1Q5Z4_CRAGI	4.2e-102	376.7	99.28%	60.41%	G2/M phase-specific E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN018303.1	sp|A0A139W9K6|A0A139W9K6_TRICA	5.2e-22	111.7	37.91%	32.42%	Uncharacterized protein;OS=Tribolium;PE=4;SV=1	GO:0005634|	GO:0006915|
GN018304.1	sp|K1QJZ5|K1QJZ5_CRAGI	0.0e+00	1442.2	91.53%	76.39%	Uncharacterized protein C9orf93;OS=Crassostrea;PE=4;SV=1
GN015827.1	sp|K1Q0I7|K1Q0I7_CRAGI	3.9e-91	339.7	91.71%	86.93%	DmX-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018305.1	sp|A0A210R728|A0A210R728_MIZYE	1.2e-42	178.3	100.00%	53.90%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018306.1	sp|K1RG40|K1RG40_CRAGI	0.0e+00	2124.0	100.00%	67.23%	Pleckstrin-like protein domain-containing family G member 1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN018307.1	sp|K1QVS9|K1QVS9_CRAGI	2.3e-71	274.6	88.54%	59.45%	Potassium channel subfamily K member 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN018308.1	sp|K1QPM1|K1QPM1_CRAGI	2.1e-64	251.1	68.95%	78.00%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018309.1	sp|K1QPM1|K1QPM1_CRAGI	4.3e-59	232.6	100.00%	85.00%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018310.1	sp|K1QPM1|K1QPM1_CRAGI	2.3e-19	100.1	75.90%	65.63%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015828.1	sp|K1Q0I7|K1Q0I7_CRAGI	0.0e+00	3002.2	99.91%	72.62%	DmX-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018311.1	sp|K1QPM1|K1QPM1_CRAGI	1.7e-83	314.3	94.48%	86.47%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018312.1	sp|K1QPM1|K1QPM1_CRAGI	4.3e-59	232.6	100.00%	85.00%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018313.1	sp|K1QPM1|K1QPM1_CRAGI	2.3e-19	100.1	75.90%	65.63%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018314.1	sp|K1QPM1|K1QPM1_CRAGI	1.7e-83	314.3	94.48%	86.47%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018315.1	sp|K1QPM1|K1QPM1_CRAGI	1.9e-197	694.1	99.54%	74.08%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018316.1	sp|K1QPM1|K1QPM1_CRAGI	1.1e-148	531.6	100.00%	85.08%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018317.1	sp|K1PT65|K1PT65_CRAGI	9.5e-108	396.0	99.49%	57.51%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018318.1	sp|K1PT65|K1PT65_CRAGI	9.3e-97	359.4	100.00%	53.85%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018319.1	sp|K1RAG1|K1RAG1_CRAGI	9.2e-88	329.7	100.00%	46.58%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018320.1	sp|K1PT65|K1PT65_CRAGI	1.7e-101	375.2	100.00%	54.14%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN015829.1	sp|K1Q0I7|K1Q0I7_CRAGI	1.1e-44	184.9	90.30%	76.67%	DmX-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018321.1	sp|K1QPM1|K1QPM1_CRAGI	7.7e-57	225.3	99.27%	78.52%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018322.1	sp|K1QPM1|K1QPM1_CRAGI	2.4e-59	234.6	88.63%	58.22%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018323.1	sp|K1RG40|K1RG40_CRAGI	7.9e-302	1042.0	100.00%	64.68%	Pleckstrin-like protein domain-containing family G member 1;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN018324.1	sp|K1RAG1|K1RAG1_CRAGI	1.6e-49	201.4	98.88%	61.93%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN015830.1	sp|K1Q0I7|K1Q0I7_CRAGI	1.8e-58	230.7	88.32%	92.50%	DmX-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018326.1	sp|A0A1S3I398|A0A1S3I398_LINUN	1.9e-25	120.6	94.95%	52.07%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN018328.1	sp|A0A2B4S3I1|A0A2B4S3I1_STYPI	1.5e-60	239.6	73.75%	33.59%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN018329.1	sp|K1QY88|K1QY88_CRAGI	5.8e-13	80.9	45.16%	33.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN018331.1	sp|K1PT65|K1PT65_CRAGI	7.5e-119	432.6	100.00%	69.25%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018332.1	sp|K1QPM1|K1QPM1_CRAGI	4.8e-188	662.9	97.59%	72.52%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018333.1	sp|K1PT65|K1PT65_CRAGI	2.0e-119	434.5	100.00%	69.57%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018334.1	sp|K1QPM1|K1QPM1_CRAGI	1.7e-112	411.0	100.00%	83.84%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018335.1	sp|K1QPM1|K1QPM1_CRAGI	0.0e+00	1127.5	99.86%	71.50%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015831.1	sp|K1Q0I7|K1Q0I7_CRAGI	3.8e-81	306.2	94.70%	98.59%	DmX-like protein 2;OS=Crassostrea;PE=4;SV=1
GN018336.1	sp|K1PT65|K1PT65_CRAGI	2.0e-119	434.5	100.00%	69.57%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018337.1	sp|K1QPM1|K1QPM1_CRAGI	2.4e-248	863.6	100.00%	71.58%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018338.1	sp|K1PT65|K1PT65_CRAGI	3.3e-114	417.2	100.00%	66.77%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018339.1	sp|K1QPM1|K1QPM1_CRAGI	4.8e-188	662.9	97.59%	72.52%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018340.1	sp|K1PT65|K1PT65_CRAGI	2.0e-119	434.5	100.00%	69.57%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018341.1	sp|K1PT65|K1PT65_CRAGI	3.3e-114	417.2	100.00%	66.77%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018342.1	sp|K1QPM1|K1QPM1_CRAGI	0.0e+00	1148.7	99.87%	70.53%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018343.1	sp|K1RAG1|K1RAG1_CRAGI	3.8e-72	277.7	100.00%	44.61%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018344.1	sp|K1PMC5|K1PMC5_CRAGI	2.0e-38	164.1	97.73%	64.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018347.1	sp|K1PT65|K1PT65_CRAGI	7.5e-119	432.6	100.00%	69.25%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018348.1	sp|K1QPM1|K1QPM1_CRAGI	2.8e-139	500.4	100.00%	79.28%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018349.1	sp|K1PT65|K1PT65_CRAGI	6.1e-107	392.9	100.00%	67.11%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018350.1	sp|K1QPM1|K1QPM1_CRAGI	1.2e-137	495.0	100.00%	78.62%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018351.1	sp|K1PT65|K1PT65_CRAGI	2.0e-119	434.5	100.00%	69.57%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018352.1	sp|K1QPM1|K1QPM1_CRAGI	2.8e-139	500.4	100.00%	79.28%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015833.1	sp|K1P828|K1P828_CRAGI	3.4e-120	437.2	91.64%	64.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018353.1	sp|K1PT65|K1PT65_CRAGI	3.3e-114	417.2	100.00%	66.77%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018354.1	sp|K1QPM1|K1QPM1_CRAGI	1.3e-141	508.1	100.00%	81.69%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018355.1	sp|K1PT65|K1PT65_CRAGI	3.3e-114	417.2	100.00%	66.77%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018356.1	sp|K1QPM1|K1QPM1_CRAGI	2.8e-139	500.4	100.00%	79.28%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018357.1	sp|K1PT65|K1PT65_CRAGI	2.0e-119	434.5	100.00%	69.57%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018358.1	sp|K1PT65|K1PT65_CRAGI	3.3e-114	417.2	100.00%	66.77%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018359.1	sp|K1QPM1|K1QPM1_CRAGI	4.8e-188	662.9	97.59%	72.52%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018360.1	sp|K1PT65|K1PT65_CRAGI	2.0e-119	434.5	100.00%	69.57%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018361.1	sp|K1QPM1|K1QPM1_CRAGI	1.3e-34	151.8	92.55%	57.33%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018362.1	sp|K1QPM1|K1QPM1_CRAGI	1.1e-95	355.1	96.51%	69.05%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018363.1	sp|K1QPM1|K1QPM1_CRAGI	8.5e-281	971.5	99.03%	77.54%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018364.1	sp|K1QPM1|K1QPM1_CRAGI	3.2e-134	483.8	84.53%	75.74%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018365.1	sp|K1QPM1|K1QPM1_CRAGI	5.6e-134	483.0	97.62%	63.32%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018366.1	sp|K1RAG1|K1RAG1_CRAGI	5.5e-80	303.9	54.21%	67.08%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018367.1	sp|K1PT65|K1PT65_CRAGI	3.0e-106	391.0	100.00%	57.92%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018368.1	sp|K1PT65|K1PT65_CRAGI	3.3e-58	231.1	73.98%	55.51%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018369.1	sp|K1RAG1|K1RAG1_CRAGI	8.5e-19	97.8	98.41%	72.13%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018370.1	sp|K1RAG1|K1RAG1_CRAGI	3.4e-34	149.8	99.12%	67.86%	Pre-B-cell leukemia transcription factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN018371.1	sp|K1QPM1|K1QPM1_CRAGI	2.4e-107	394.8	96.05%	59.73%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018372.1	sp|K1QPM1|K1QPM1_CRAGI	1.4e-47	194.5	100.00%	79.41%	Usherin;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018373.1	sp|K1QSM8|K1QSM8_CRAGI	3.1e-75	287.3	100.00%	63.08%	RRP15-like protein;OS=Crassostrea;PE=4;SV=1	GO:0006364|
GN018374.1	sp|K1R275|K1R275_CRAGI	4.1e-193	679.9	86.32%	77.35%	Putative ATP-dependent RNA helicase DDX52;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN018375.1	sp|A0A0E3JRW3|A0A0E3JRW3_CRAGI	3.2e-218	763.1	99.76%	90.12%	SOCS5;OS=Crassostrea;PE=2;SV=1	GO:0035556|
GN018376.1	sp|K1RXZ2|K1RXZ2_CRAGI	2.3e-54	218.0	88.33%	59.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018377.1	sp|K1QSN5|K1QSN5_CRAGI	6.3e-56	222.2	96.21%	87.30%	39S ribosomal protein L14, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN018378.1	sp|K1R283|K1R283_CRAGI	3.6e-116	424.5	100.00%	52.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018379.1	sp|K1R8B4|K1R8B4_CRAGI	2.8e-86	324.7	100.00%	43.94%	Blastula protease 10;OS=Crassostrea;PE=4;SV=1	GO:0004222|
GN018380.1	sp|K1R8B4|K1R8B4_CRAGI	9.5e-134	482.6	96.93%	53.39%	Blastula protease 10;OS=Crassostrea;PE=4;SV=1	GO:0004222|
GN018381.1	sp|K1REV3|K1REV3_CRAGI	4.5e-234	815.8	100.00%	83.77%	DNA polymerase delta subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003887|	GO:0006260|
GN018382.1	sp|K1RXZ8|K1RXZ8_CRAGI	1.6e-44	186.8	22.58%	61.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018383.1	sp|K1R295|K1R295_CRAGI	1.5e-186	658.7	53.55%	73.38%	Putative fumarate hydratase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0045239|	GO:0004333|	GO:0006106|GO:0006099|
GN018384.1	sp|K1REW1|K1REW1_CRAGI	2.1e-130	471.9	99.83%	88.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN018385.1	sp|A0A1X7SZ30|A0A1X7SZ30_AMPQE	3.1e-57	227.6	98.19%	43.12%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0003677|GO:0046983|
GN018386.1	sp|K1R1I0|K1R1I0_CRAGI	1.4e-69	267.7	100.00%	88.97%	Peptidylprolyl isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN018387.1	sp|K1S6Q8|K1S6Q8_CRAGI	1.5e-178	631.3	99.77%	68.26%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B;OS=Crassostrea;PE=4;SV=1
GN018388.1	sp|K1S6R2|K1S6R2_CRAGI	4.5e-60	236.1	100.00%	82.98%	N-acetyltransferase 11;OS=Crassostrea;PE=4;SV=1	GO:0043998|GO:0010485|
GN018389.1	sp|K1R1I4|K1R1I4_CRAGI	0.0e+00	2315.0	99.16%	72.16%	Mitogen-activated protein kinase-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN015834.1	sp|K1RE44|K1RE44_CRAGI	2.6e-291	1006.5	99.70%	72.55%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN018390.1	sp|K1RH75|K1RH75_CRAGI	6.3e-144	515.8	99.67%	85.15%	Egl nine-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN018391.1	sp|A0A2L1K0X8|A0A2L1K0X8_CRAGI	8.9e-58	229.9	27.81%	95.37%	HIF-alpha prolyl 4-hydroxylases PHD2A;OS=Crassostrea;PE=2;SV=1	GO:0005506|GO:0031418|GO:0016705|
GN018392.1	sp|K1Q1D1|K1Q1D1_CRAGI	1.1e-233	814.7	100.00%	82.51%	UTP--glucose-1-phosphate uridylyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0003983|	GO:0006011|
GN018393.1	sp|K1QUD9|K1QUD9_CRAGI	4.3e-234	815.8	100.00%	92.48%	Transcriptional adapter;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003713|GO:0008270|	GO:0035065|GO:0006357|
GN018394.1	sp|K1PU26|K1PU26_CRAGI	1.2e-167	594.7	99.40%	89.43%	Malate dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0030060|	GO:0005975|GO:0006108|GO:0006099|
GN018395.1	sp|A0A210QAA2|A0A210QAA2_MIZYE	1.6e-76	292.0	89.78%	45.39%	Nucleoside diphosphate-linked moiety X motif 22;OS=Mizuhopecten;PE=4;SV=1	GO:0016787|
GN018396.1	sp|K1Q8G0|K1Q8G0_CRAGI	3.7e-143	513.1	100.00%	92.00%	Radial spoke head protein 9-like protein;OS=Crassostrea;PE=4;SV=1
GN015835.1	sp|K1RE44|K1RE44_CRAGI	2.3e-292	1010.0	99.70%	72.85%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|GO:0016491|
GN018397.1	sp|K1Q861|K1Q861_CRAGI	1.3e-19	102.1	69.89%	43.18%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018399.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	8.2e-25	119.4	91.53%	38.51%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018400.1	sp|A0A210PLM5|A0A210PLM5_MIZYE	1.7e-70	273.1	84.22%	28.36%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN018401.1	sp|A0A210PLI9|A0A210PLI9_MIZYE	7.7e-49	200.7	97.13%	25.10%	Protein toll;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007165|
GN018402.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	3.1e-30	137.5	96.48%	41.45%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018403.1	sp|K1QJN2|K1QJN2_CRAGI	4.4e-24	115.5	100.00%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN018404.1	sp|A0A210PFH2|A0A210PFH2_MIZYE	8.8e-27	125.9	91.53%	39.66%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015836.1	sp|K1Q7A7|K1Q7A7_CRAGI	0.0e+00	1186.8	100.00%	85.74%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN018406.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	1.1e-104	386.0	84.42%	48.97%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN018407.1	sp|K1QK08|K1QK08_CRAGI	3.2e-51	208.0	66.76%	48.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018408.1	sp|K1QS20|K1QS20_CRAGI	1.5e-31	141.7	76.63%	47.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018411.1	sp|K1PV03|K1PV03_CRAGI	6.4e-13	79.7	41.42%	53.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018412.1	sp|K1QF29|K1QF29_CRAGI	8.0e-199	698.7	92.21%	72.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018413.1	sp|K1QF29|K1QF29_CRAGI	3.4e-210	736.5	100.00%	70.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018414.1	sp|K1PGI9|K1PGI9_CRAGI	1.6e-204	718.4	89.07%	55.91%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN018415.1	sp|K1PGI9|K1PGI9_CRAGI	8.1e-148	528.9	98.82%	77.91%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN018416.1	sp|K1PGI9|K1PGI9_CRAGI	8.3e-130	469.2	98.93%	63.32%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN015838.1	sp|K1QLW1|K1QLW1_CRAGI	2.1e-152	544.7	97.59%	58.01%	Nuclear receptor ROR-beta;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN018417.1	sp|K1PMN0|K1PMN0_CRAGI	1.5e-167	594.7	100.00%	70.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN018419.1	sp|K1R5G2|K1R5G2_CRAGI	5.4e-56	222.6	100.00%	72.30%	Endonuclease VIII-like 1;OS=Crassostrea;PE=4;SV=1	GO:0003684|GO:0003906|GO:0004519|GO:0016799|GO:0008270|	GO:0006284|GO:0006289|
GN018420.1	sp|V4A2Z2|V4A2Z2_LOTGI	2.0e-101	375.6	61.12%	49.87%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN018421.1	sp|K1PY54|K1PY54_CRAGI	5.8e-47	194.9	49.93%	39.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018422.1	sp|K1Q5J3|K1Q5J3_CRAGI	1.4e-260	904.8	98.49%	53.64%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018423.1	sp|K1Q5J3|K1Q5J3_CRAGI	7.5e-142	509.6	98.21%	49.45%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018425.1	sp|K1Q5J3|K1Q5J3_CRAGI	4.6e-264	916.4	98.49%	53.99%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018426.1	sp|K1Q5J3|K1Q5J3_CRAGI	7.5e-142	509.6	98.21%	49.45%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018428.1	sp|K1Q5J3|K1Q5J3_CRAGI	4.9e-285	986.1	99.33%	55.42%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018429.1	sp|K1Q5J3|K1Q5J3_CRAGI	6.6e-126	456.4	98.42%	51.14%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018430.1	sp|K1Q5J3|K1Q5J3_CRAGI	4.1e-100	370.5	92.53%	57.31%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN018431.1	sp|K1R128|K1R128_CRAGI	0.0e+00	1609.0	99.88%	94.00%	Vegetative incompatibility protein HET-E-1;OS=Crassostrea;PE=4;SV=1
GN018433.1	sp|A0A1I8H270|A0A1I8H270_9PLAT	1.0e-22	112.8	90.80%	34.78%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1	GO:0031419|GO:0003677|GO:0008705|GO:0008270|	GO:0015074|GO:0006310|GO:0042558|
GN018434.1	sp|K1QF19|K1QF19_CRAGI	2.4e-31	140.2	84.16%	78.57%	Solute carrier family 12 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015377|
GN018436.1	sp|K1PSE0|K1PSE0_CRAGI	4.9e-33	147.9	93.49%	33.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018438.1	sp|K1QF32|K1QF32_CRAGI	5.0e-62	245.4	36.74%	42.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018439.1	sp|K1PV06|K1PV06_CRAGI	6.5e-152	543.1	100.00%	73.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015839.1	sp|K1R737|K1R737_CRAGI	6.9e-108	396.0	99.65%	62.72%	Cytochrome P450 2C8;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN018444.1	sp|K1R008|K1R008_CRAGI	4.7e-132	476.1	100.00%	92.16%	Proteasome subunit alpha type;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|GO:0019773|	GO:0004298|	GO:0006511|
GN018445.1	sp|K1RQV0|K1RQV0_CRAGI	1.0e-227	795.0	91.13%	75.23%	Sodium-dependent phosphate transport protein 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015321|
GN018446.1	sp|K1RQV0|K1RQV0_CRAGI	1.5e-227	794.7	91.02%	68.91%	Sodium-dependent phosphate transport protein 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015321|
GN018447.1	sp|K1R6C4|K1R6C4_CRAGI	6.9e-256	888.6	98.98%	78.49%	Sodium-dependent phosphate transport protein 2B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015321|
GN018448.1	sp|K1R003|K1R003_CRAGI	1.9e-75	287.3	94.87%	93.92%	Trafficking protein particle complex subunit 6B;OS=Crassostrea;PE=4;SV=1	GO:0048193|GO:0043087|
GN018449.1	sp|K1Q063|K1Q063_CRAGI	4.1e-121	440.7	100.00%	77.28%	Pinin;OS=Crassostrea;PE=4;SV=1
GN018450.1	sp|K1QSZ1|K1QSZ1_CRAGI	3.9e-96	356.7	87.30%	82.08%	DNA repair protein RAD51-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0033063|	GO:0005524|GO:0003677|GO:0008094|	GO:0000724|
GN018451.1	sp|K1RQU8|K1RQU8_CRAGI	0.0e+00	1620.1	100.00%	79.73%	Kinesin-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN018452.1	sp|K1R6C1|K1R6C1_CRAGI	1.1e-135	489.2	100.00%	58.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018453.1	sp|K1QZZ8|K1QZZ8_CRAGI	3.7e-35	154.1	96.55%	46.93%	CREB/ATF bZIP transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN018454.1	sp|K1QSY8|K1QSY8_CRAGI	1.7e-15	87.8	81.36%	54.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018455.1	sp|K1R6B3|K1R6B3_CRAGI	5.9e-206	722.2	100.00%	87.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN018456.1	sp|K1QHD8|K1QHD8_CRAGI	1.4e-25	121.3	98.40%	55.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018457.1	sp|K1QHD8|K1QHD8_CRAGI	3.5e-16	90.1	66.13%	53.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015841.1	sp|A0A210R2T9|A0A210R2T9_MIZYE	0.0e+00	1092.0	98.09%	77.96%	E3 ubiquitin-protein ligase HERC1;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0004842|
GN018458.1	sp|K1PKX6|K1PKX6_CRAGI	5.2e-28	130.6	27.44%	86.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN018459.1	sp|K1QHD8|K1QHD8_CRAGI	5.0e-15	86.3	66.13%	52.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018460.1	sp|K1QZZ4|K1QZZ4_CRAGI	1.2e-14	85.5	96.39%	38.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018461.1	sp|W4YDL6|W4YDL6_STRPU	6.0e-18	97.1	95.42%	28.69%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0004190|GO:0003676|	GO:0015074|
GN018464.1	sp|K1QS20|K1QS20_CRAGI	3.7e-31	140.6	70.15%	47.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018471.1	sp|A0A2S2Q4N7|A0A2S2Q4N7_9HEMI	1.5e-47	195.3	91.10%	45.62%	Tigger transposable element-derived protein 4;OS=Sipha;PE=4;SV=1	GO:0003677|
GN018472.1	sp|K1QMP2|K1QMP2_CRAGI	4.9e-124	451.1	82.73%	35.28%	Acetylcholine receptor subunit alpha-like 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN018473.1	sp|A0A210QRV1|A0A210QRV1_MIZYE	3.4e-248	863.2	94.15%	70.07%	Cleft lip and palate transmembrane protein 1-like;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN015842.1	sp|A0A210Q712|A0A210Q712_MIZYE	4.5e-53	213.4	96.53%	61.42%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018474.1	sp|K1P0F7|K1P0F7_CRAGI	0.0e+00	1174.1	100.00%	90.26%	Menin;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN018475.1	sp|K1Q6R6|K1Q6R6_CRAGI	1.4e-42	178.7	65.40%	67.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018476.1	sp|K1PL64|K1PL64_CRAGI	0.0e+00	1167.9	99.59%	88.23%	Poly(A) polymerase gamma;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0004652|GO:0003723|	GO:0031123|GO:0043631|
GN018477.1	sp|K1QJ23|K1QJ23_CRAGI	3.6e-80	303.5	96.80%	73.46%	Glutaminyl-peptide cyclotransferase;OS=Crassostrea;PE=4;SV=1	GO:0016603|
GN018478.1	sp|W0GA09|W0GA09_CRAHO	6.3e-171	605.9	100.00%	78.10%	Serum response factor;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0000981|GO:0046983|GO:0000987|	GO:0045944|
GN018480.1	sp|K1S5Q2|K1S5Q2_CRAGI	1.1e-28	131.7	98.46%	51.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018483.1	sp|A0A210QZK9|A0A210QZK9_MIZYE	1.9e-37	161.8	54.72%	60.26%	Ankyrin repeat family A protein 2;OS=Mizuhopecten;PE=4;SV=1
GN018484.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.4e-19	100.1	43.22%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN018485.1	sp|K1RAC2|K1RAC2_CRAGI	0.0e+00	1686.4	100.00%	75.63%	Rho GTPase-activating protein 11A;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN018486.1	sp|A0A3M6V2X2|A0A3M6V2X2_9CNID	7.8e-46	189.5	92.07%	41.51%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN018487.1	sp|A0A210QWK6|A0A210QWK6_MIZYE	1.1e-152	545.4	98.44%	59.73%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0015074|
GN015844.1	sp|A0A210Q712|A0A210Q712_MIZYE	1.7e-41	176.0	92.74%	30.74%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018488.1	sp|K1RM65|K1RM65_CRAGI	4.4e-83	312.8	100.00%	96.32%	EF-hand calcium-binding domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN018489.1	sp|K1RG06|K1RG06_CRAGI	3.6e-59	233.4	100.00%	71.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006303|
GN018490.1	sp|K1RAC0|K1RAC0_CRAGI	9.5e-127	458.8	90.82%	75.61%	Mitochondrial uncoupling protein 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0031966|	GO:0022857|	GO:0006839|
GN018491.1	sp|G0YVG2|G0YVG2_PENVA	4.4e-10	70.1	97.24%	75.00%	Calmodulin B;OS=Penaeus;PE=2;SV=1	GO:0005509|
GN018492.1	sp|K1S5P3|K1S5P3_CRAGI	8.8e-277	959.1	90.86%	92.70%	Delta-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0005112|	GO:0007275|GO:0007219|
GN018493.1	sp|K1QFA1|K1QFA1_CRAGI	4.3e-51	206.5	83.65%	79.55%	Ribonuclease P protein subunit p20;OS=Crassostrea;PE=3;SV=1	GO:0005730|	GO:0003676|GO:0004526|	GO:0008033|
GN018494.1	sp|A0A210PP53|A0A210PP53_MIZYE	5.5e-281	972.6	99.78%	54.45%	WD repeat-containing protein 27;OS=Mizuhopecten;PE=4;SV=1
GN018495.1	sp|V4B537|V4B537_LOTGI	3.7e-15	86.3	89.01%	56.79%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN018496.1	sp|K1P8Z6|K1P8Z6_CRAGI	5.4e-96	355.9	97.46%	86.91%	WD repeat-containing protein 27;OS=Crassostrea;PE=4;SV=1	GO:0030141|	GO:0007218|
GN018497.1	sp|K1PV26|K1PV26_CRAGI	1.4e-17	95.5	76.70%	38.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018499.1	sp|K1QHE7|K1QHE7_CRAGI	2.0e-16	91.3	66.67%	42.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018500.1	sp|A0A0L8GT52|A0A0L8GT52_OCTBM	1.1e-17	94.7	81.44%	53.85%	Uncharacterized protein;OS=Octopus;PE=4;SV=1
GN018501.1	sp|K1QFA4|K1QFA4_CRAGI	9.1e-75	285.4	94.97%	74.74%	Phosphomevalonate kinase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0004631|	GO:0006695|
GN018502.1	sp|K1P8Z8|K1P8Z8_CRAGI	1.1e-234	818.1	90.34%	79.37%	tRNA (guanine(26)-N(2))-dimethyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0004809|GO:0000049|
GN018503.1	sp|K1PVU0|K1PVU0_CRAGI	4.1e-21	106.7	91.55%	38.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018504.1	sp|K1PMX9|K1PMX9_CRAGI	1.4e-103	382.1	86.98%	69.37%	Alpha-and gamma-adaptin-binding protein p34;OS=Crassostrea;PE=4;SV=1
GN018505.1	sp|K1PVA6|K1PVA6_CRAGI	2.1e-140	504.6	95.12%	66.14%	TIMELESS-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006974|GO:0000076|GO:0048478|
GN018506.1	sp|K1PCN9|K1PCN9_CRAGI	3.6e-164	584.7	81.75%	66.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003723|
GN018507.1	sp|K1R1W9|K1R1W9_CRAGI	1.9e-243	847.0	97.93%	89.83%	Nicalin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0009966|
GN018508.1	sp|K1R8K4|K1R8K4_CRAGI	2.5e-110	404.1	93.55%	76.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018509.1	sp|K1RSK7|K1RSK7_CRAGI	1.1e-136	491.9	99.72%	70.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018510.1	sp|K1R1X4|K1R1X4_CRAGI	5.0e-54	215.7	100.00%	93.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018511.1	sp|K1R8L2|K1R8L2_CRAGI	4.9e-125	453.0	100.00%	75.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018512.1	sp|K1RSL2|K1RSL2_CRAGI	8.6e-209	731.9	99.35%	79.27%	Ammonium transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008519|
GN015845.1	sp|A0A1S3J8P1|A0A1S3J8P1_LINUN	7.4e-115	420.6	62.42%	43.43%	TAF6-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 6L;OS=Lingula;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|	GO:0006357|GO:0006367|
GN018513.1	sp|K1QL44|K1QL44_CRAGI	6.9e-183	646.0	100.00%	68.01%	Organic cation transporter-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN018514.1	sp|K1QV73|K1QV73_CRAGI	5.8e-223	779.2	81.88%	84.18%	ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0008233|GO:0051082|	GO:0006457|
GN018515.1	sp|K1R1Y0|K1R1Y0_CRAGI	2.8e-48	197.6	52.49%	87.83%	DNA-directed RNA polymerase III subunit RPC7-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003899|	GO:0006383|
GN018516.1	sp|K1R8M0|K1R8M0_CRAGI	5.1e-41	172.6	100.00%	82.35%	Ubiquitin-like protein 7;OS=Crassostrea;PE=4;SV=1
GN018517.1	sp|K1PYF7|K1PYF7_CRAGI	0.0e+00	2797.7	100.00%	86.60%	Sodium channel protein;OS=Crassostrea;PE=3;SV=1	GO:0001518|	GO:0005244|GO:0005248|	GO:0034765|GO:0019233|
GN018518.1	sp|K1PNA0|K1PNA0_CRAGI	5.0e-70	269.2	100.00%	90.34%	Molybdopterin synthase catalytic subunit;OS=Crassostrea;PE=3;SV=1	GO:0005829|GO:0019008|	GO:0030366|	GO:0006777|
GN018519.1	sp|K1P784|K1P784_CRAGI	3.5e-146	523.5	100.00%	63.89%	DNA-directed RNA polymerase III subunit RPC3;OS=Crassostrea;PE=4;SV=1	GO:0005666|	GO:0003899|GO:0003697|	GO:0006351|
GN018520.1	sp|K1P0W8|K1P0W8_CRAGI	1.3e-67	263.5	56.10%	48.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015559.1	sp|K1Q8S5|K1Q8S5_CRAGI	1.7e-240	837.4	100.00%	78.23%	Enhancer of mRNA-decapping protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003729|	GO:0031087|
GN018526.1	sp|K1QF90|K1QF90_CRAGI	6.3e-123	446.4	69.21%	77.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN018527.1	sp|K1QYE7|K1QYE7_CRAGI	4.9e-85	320.1	75.17%	67.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018528.1	sp|A0A210R5H6|A0A210R5H6_MIZYE	6.7e-200	703.0	70.03%	70.57%	Transporter;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005328|
GN018530.1	sp|K1R4Q5|K1R4Q5_CRAGI	1.3e-109	401.7	96.63%	87.41%	Zinc transporter ZIP9-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN018531.1	sp|K1QYE5|K1QYE5_CRAGI	2.8e-97	361.3	95.28%	70.52%	Cysteine-rich PDZ-binding protein;OS=Crassostrea;PE=4;SV=1
GN015848.1	sp|K1Q9H5|K1Q9H5_CRAGI	0.0e+00	1242.6	100.00%	85.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018533.1	sp|K1QQZ6|K1QQZ6_CRAGI	1.6e-35	154.1	100.00%	72.00%	Putative L-asparaginase periplasmic;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004067|
GN018535.1	sp|K1RLJ9|K1RLJ9_CRAGI	2.3e-304	1050.4	99.18%	64.09%	Protein kintoun;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0070286|GO:0060285|
GN018536.1	sp|K1R252|K1R252_CRAGI	1.3e-39	167.9	89.34%	80.56%	Putative methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004491|
GN018537.1	sp|K1R252|K1R252_CRAGI	9.9e-214	748.0	100.00%	95.45%	Putative methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004491|
GN018539.1	sp|K1QVD7|K1QVD7_CRAGI	1.1e-67	263.5	95.03%	70.92%	Neuronal acetylcholine receptor subunit non-alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008408|GO:0003906|GO:0005230|GO:0004888|	GO:0006302|
GN018541.1	sp|K1QVD7|K1QVD7_CRAGI	1.4e-128	465.3	84.29%	64.43%	Neuronal acetylcholine receptor subunit non-alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008408|GO:0003906|GO:0005230|GO:0004888|	GO:0006302|
GN018542.1	sp|K1QVD7|K1QVD7_CRAGI	3.3e-94	350.9	90.88%	50.28%	Neuronal acetylcholine receptor subunit non-alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008408|GO:0003906|GO:0005230|GO:0004888|	GO:0006302|
GN018543.1	sp|K1QVD7|K1QVD7_CRAGI	1.2e-95	355.9	81.28%	51.13%	Neuronal acetylcholine receptor subunit non-alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008408|GO:0003906|GO:0005230|GO:0004888|	GO:0006302|
GN018545.1	sp|K1QE68|K1QE68_CRAGI	2.1e-76	290.8	98.44%	65.63%	Lipopolysaccharide cholinephosphotransferase licD;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016740|
GN015849.1	sp|K1R677|K1R677_CRAGI	6.2e-54	216.1	96.13%	64.16%	Uncharacterized protein C3orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN018546.1	sp|K1QNP4|K1QNP4_CRAGI	1.3e-68	265.0	100.00%	67.98%	Rho-related protein racA;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN018547.1	sp|K1QMW0|K1QMW0_CRAGI	3.8e-145	520.0	96.55%	79.10%	PDZ domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN018548.1	sp|K1QMW0|K1QMW0_CRAGI	0.0e+00	1639.4	99.65%	53.06%	PDZ domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN018549.1	sp|V4BH84|V4BH84_LOTGI	8.3e-193	678.7	99.78%	74.78%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005623|	GO:0032266|	GO:0006886|GO:0007165|
GN018550.1	sp|K1QCZ8|K1QCZ8_CRAGI	3.1e-12	77.4	76.36%	40.85%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN018551.1	sp|V4BNP4|V4BNP4_LOTGI	1.6e-85	323.6	40.70%	43.75%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN018552.1	sp|K1R256|K1R256_CRAGI	5.8e-297	1025.4	87.08%	73.75%	Long-chain-fatty-acid--CoA ligase ACSBG2;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN015850.1	sp|K1R9F2|K1R9F2_CRAGI	1.4e-39	168.3	85.96%	61.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018553.1	sp|K1QMV7|K1QMV7_CRAGI	1.6e-102	377.9	99.57%	86.07%	V-type proton ATPase subunit D;OS=Crassostrea;PE=4;SV=1	GO:0042626|
GN018554.1	sp|K1QE75|K1QE75_CRAGI	1.1e-123	448.7	86.98%	69.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018557.1	sp|A0A2B4RJ66|A0A2B4RJ66_STYPI	7.7e-43	180.3	86.36%	34.65%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN018558.1	sp|A0A210PKW1|A0A210PKW1_MIZYE	1.0e-18	97.8	96.00%	66.20%	Calmodulin;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN015851.1	sp|K1Q6V0|K1Q6V0_CRAGI	4.2e-65	252.7	98.45%	88.89%	Beta-hexosaminidase subunit beta;OS=Crassostrea;PE=4;SV=1	GO:0004563|	GO:0005975|
GN015852.1	sp|K1PEH8|K1PEH8_CRAGI	9.3e-184	648.7	94.67%	72.71%	WD repeat-containing protein 41;OS=Crassostrea;PE=4;SV=1	GO:0010506|
GN018573.1	sp|K1PUZ6|K1PUZ6_CRAGI	1.5e-168	597.8	88.74%	86.02%	Lysocardiolipin acyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016746|
GN018574.1	sp|K1QF24|K1QF24_CRAGI	8.1e-72	275.4	100.00%	78.95%	UPF0580 protein C15orf58-like protein;OS=Crassostrea;PE=4;SV=1	GO:0080048|
GN018575.1	sp|K1PTQ4|K1PTQ4_CRAGI	1.8e-154	550.8	100.00%	84.92%	BRCA1-A complex subunit BRE;OS=Crassostrea;PE=4;SV=1	GO:0070531|GO:0070552|
GN018576.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	3.1e-108	398.7	84.04%	33.80%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN018577.1	sp|K1PEW0|K1PEW0_CRAGI	7.2e-81	305.8	85.39%	78.49%	TATA-box-binding protein;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0008138|	GO:0006352|
GN018578.1	sp|K1PEW0|K1PEW0_CRAGI	1.6e-92	344.7	92.46%	93.97%	TATA-box-binding protein;OS=Crassostrea;PE=3;SV=1	GO:0003677|GO:0008138|	GO:0006352|
GN018579.1	sp|K1PML7|K1PML7_CRAGI	2.0e-278	963.8	96.46%	66.47%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018580.1	sp|K1PML7|K1PML7_CRAGI	6.6e-27	125.2	97.59%	78.75%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018581.1	sp|K1PML4|K1PML4_CRAGI	0.0e+00	1078.5	87.59%	88.98%	Pre-mRNA-processing factor 39;OS=Crassostrea;PE=4;SV=1	GO:0006396|
GN018582.1	sp|K1PEV7|K1PEV7_CRAGI	1.1e-71	275.8	86.15%	54.33%	ATP synthase subunit s-like protein;OS=Crassostrea;PE=4;SV=1
GN018583.1	sp|K1P8Q1|K1P8Q1_CRAGI	0.0e+00	2093.9	99.61%	67.44%	Putative methyltransferase TARBP1;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008173|	GO:0006396|
GN018585.1	sp|K1Q4B1|K1Q4B1_CRAGI	1.0e-82	313.2	78.73%	48.40%	Exonuclease 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0035312|GO:0003677|	GO:0006281|
GN018586.1	sp|K1Q4B1|K1Q4B1_CRAGI	1.5e-95	354.4	97.41%	91.44%	Exonuclease 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0035312|GO:0003677|	GO:0006281|
GN018587.1	sp|K1RBB7|K1RBB7_CRAGI	3.0e-35	153.3	100.00%	72.48%	Protein YIPF;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN018588.1	sp|V4BYS4|V4BYS4_LOTGI	6.0e-192	676.4	94.74%	51.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN018589.1	sp|K1QR72|K1QR72_CRAGI	1.0e-197	694.9	96.36%	86.36%	Dipeptidyl peptidase 3;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0008239|GO:0046872|GO:0008237|
GN018590.1	sp|K1QR72|K1QR72_CRAGI	5.4e-66	255.8	100.00%	88.49%	Dipeptidyl peptidase 3;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0008239|GO:0046872|GO:0008237|
GN015560.1	sp|K1Q1N4|K1Q1N4_CRAGI	3.3e-54	217.6	69.58%	63.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018591.1	sp|K1PVR0|K1PVR0_CRAGI	0.0e+00	1332.4	84.84%	83.28%	Zinc finger protein basonuclin-2;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018594.1	sp|V3ZW78|V3ZW78_LOTGI	8.5e-45	186.0	93.75%	40.95%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN018595.1	sp|K1QUS7|K1QUS7_CRAGI	1.3e-60	238.0	98.09%	78.71%	Optic atrophy 3-like protein;OS=Crassostrea;PE=4;SV=1
GN015856.1	sp|A0A210QDW8|A0A210QDW8_MIZYE	0.0e+00	1131.3	96.16%	36.67%	RNA-dependent RNA polymerase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003968|
GN018597.1	sp|K1R885|K1R885_CRAGI	2.9e-55	219.9	96.75%	87.29%	Leucine-rich repeat-containing protein 68;OS=Crassostrea;PE=3;SV=1
GN018598.1	sp|K1R885|K1R885_CRAGI	3.7e-91	341.3	56.08%	61.51%	Leucine-rich repeat-containing protein 68;OS=Crassostrea;PE=3;SV=1
GN018599.1	sp|K1R885|K1R885_CRAGI	3.0e-23	113.2	96.84%	63.04%	Leucine-rich repeat-containing protein 68;OS=Crassostrea;PE=3;SV=1
GN018600.1	sp|K1R1J8|K1R1J8_CRAGI	2.8e-227	793.1	100.00%	89.52%	Mitochondrial chaperone BCS1;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0005524|	GO:0034551|
GN018601.1	sp|K1QUS1|K1QUS1_CRAGI	1.3e-31	141.4	74.40%	67.39%	Protein AMBP;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN018602.1	sp|K1PMG4|K1PMG4_CRAGI	3.0e-18	96.7	85.00%	53.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN018603.1	sp|A0A210QAQ0|A0A210QAQ0_MIZYE	5.5e-47	193.7	87.13%	40.00%	Lipid phosphate phosphohydrolase 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016787|
GN018605.1	sp|K1QU05|K1QU05_CRAGI	8.3e-103	379.4	99.72%	54.34%	Hibernation-associated plasma protein HP-27;OS=Crassostrea;PE=4;SV=1
GN018606.1	sp|K1QU05|K1QU05_CRAGI	1.3e-126	459.1	89.60%	50.85%	Hibernation-associated plasma protein HP-27;OS=Crassostrea;PE=4;SV=1
GN018607.1	sp|K1QU05|K1QU05_CRAGI	2.8e-188	664.1	98.81%	55.31%	Hibernation-associated plasma protein HP-27;OS=Crassostrea;PE=4;SV=1
GN015858.1	sp|K1QZ50|K1QZ50_CRAGI	3.3e-169	600.5	97.25%	58.57%	RNA-dependent RNA polymerase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003723|GO:0003968|
GN018608.1	sp|K1QU05|K1QU05_CRAGI	2.8e-125	454.1	100.00%	62.11%	Hibernation-associated plasma protein HP-27;OS=Crassostrea;PE=4;SV=1
GN018610.1	sp|A0A2B4R8V5|A0A2B4R8V5_STYPI	1.4e-27	130.6	60.16%	24.76%	Retrovirus-related Pol polyprotein from transposon 17.6;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN018611.1	sp|A0A0L8GIT1|A0A0L8GIT1_OCTBM	2.0e-29	134.0	93.91%	58.18%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005509|	GO:0019722|
GN018612.1	sp|K1R711|K1R711_CRAGI	8.7e-114	416.0	61.50%	78.90%	3-oxo-5-alpha-steroid 4-dehydrogenase 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003865|	GO:0008202|
GN018613.1	sp|K1R0M6|K1R0M6_CRAGI	1.2e-33	147.9	97.22%	75.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015859.1	sp|A0A210QDP4|A0A210QDP4_MIZYE	5.0e-237	827.0	100.00%	39.26%	RNA-dependent RNA polymerase;OS=Mizuhopecten;PE=3;SV=1	GO:0003723|GO:0003968|
GN018615.1	sp|K1Q9J8|K1Q9J8_CRAGI	1.3e-126	458.8	97.30%	54.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018617.1	sp|K1QVM2|K1QVM2_CRAGI	4.7e-27	127.1	76.99%	33.15%	Rho-related GTP-binding protein RhoJ;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN018619.1	sp|K1QRB9|K1QRB9_CRAGI	1.8e-20	105.1	94.79%	31.19%	DnaJ-like protein subfamily C member 5;OS=Crassostrea;PE=4;SV=1
GN018620.1	sp|A0A1X7TF02|A0A1X7TF02_AMPQE	1.4e-13	81.6	99.28%	34.31%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0005524|GO:0003676|
GN018621.1	sp|W4Z0Q4|W4Z0Q4_STRPU	1.9e-35	155.2	98.53%	31.97%	Uncharacterized protein;OS=Strongylocentrotus;PE=3;SV=1	GO:0003676|	GO:0044237|
GN018624.1	sp|K1Q222|K1Q222_CRAGI	2.0e-47	194.9	97.20%	42.29%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN018626.1	sp|K1Q222|K1Q222_CRAGI	1.1e-49	202.6	94.10%	42.86%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN018629.1	sp|K1Q313|K1Q313_CRAGI	4.0e-141	506.5	97.15%	66.93%	Serine/threonine-protein kinase ULK3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN018630.1	sp|K1R9Y1|K1R9Y1_CRAGI	2.5e-310	1069.7	100.00%	75.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018631.1	sp|A0A0F6T4H0|A0A0F6T4H0_PINMT	2.4e-14	85.5	28.61%	41.58%	Nacreserine protease inhibitor 2;OS=Pinctada;PE=2;SV=1	GO:0008233|GO:0004867|
GN018632.1	sp|A0A0F6T4H0|A0A0F6T4H0_PINMT	2.5e-14	85.1	35.14%	41.58%	Nacreserine protease inhibitor 2;OS=Pinctada;PE=2;SV=1	GO:0008233|GO:0004867|
GN018633.1	sp|A0A224X4N3|A0A224X4N3_9HEMI	4.7e-14	85.1	19.96%	40.00%	Putative serine proteinase inhibitor ku family with thrombospondin repeat;OS=Panstrongylus;PE=4;SV=1	GO:0005576|	GO:0008233|GO:0004867|
GN018634.1	sp|A0A224X4N3|A0A224X4N3_9HEMI	5.8e-14	85.1	16.15%	40.00%	Putative serine proteinase inhibitor ku family with thrombospondin repeat;OS=Panstrongylus;PE=4;SV=1	GO:0005576|	GO:0008233|GO:0004867|
GN018635.1	sp|K1PFH3|K1PFH3_CRAGI	7.8e-117	425.6	100.00%	77.54%	Forkhead box protein I1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN018636.1	sp|A0A210PP34|A0A210PP34_MIZYE	7.4e-29	133.7	93.41%	35.44%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018637.1	sp|A0A1S3HS91|A0A1S3HS91_LINUN	3.0e-38	163.3	98.23%	72.73%	protein lin-52 homolog isoform X2;OS=Lingula;PE=4;SV=1	GO:0070176|	GO:0006351|
GN018638.1	sp|K1Q050|K1Q050_CRAGI	1.4e-82	311.2	87.10%	100.00%	Centrin-3;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN018639.1	sp|A0A210PZ63|A0A210PZ63_MIZYE	9.1e-39	167.2	72.56%	33.69%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0006915|
GN015860.1	sp|A0A210QDQ5|A0A210QDQ5_MIZYE	7.2e-247	860.1	96.28%	32.88%	RNA-dependent RNA polymerase 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003968|
GN018640.1	sp|A0A210QHL5|A0A210QHL5_MIZYE	4.2e-94	350.1	93.19%	64.86%	Dehydrogenase/reductase SDR family member 4;OS=Mizuhopecten;PE=4;SV=1
GN018641.1	sp|K1QHT3|K1QHT3_CRAGI	1.2e-31	142.5	70.59%	40.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018643.1	sp|V3ZKL9|V3ZKL9_LOTGI	1.0e-15	89.0	44.10%	47.14%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN018644.1	sp|A0A210PYX8|A0A210PYX8_MIZYE	1.0e-184	652.1	92.78%	58.96%	Tubulin polyglutamylase ttll-4;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005524|	GO:0006464|
GN018645.1	sp|K1QLY7|K1QLY7_CRAGI	3.2e-154	550.1	100.00%	78.62%	Dual specificity protein phosphatase 12;OS=Crassostrea;PE=4;SV=1	GO:0004725|GO:0008138|
GN018646.1	sp|A0A210R0T5|A0A210R0T5_MIZYE	3.5e-158	563.9	99.62%	49.72%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Mizuhopecten;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN018647.1	sp|K1QMC6|K1QMC6_CRAGI	6.0e-48	197.2	54.92%	49.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018648.1	sp|A0A210R376|A0A210R376_MIZYE	5.4e-39	166.8	90.35%	39.91%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018649.1	sp|K1RMU1|K1RMU1_CRAGI	2.8e-31	140.6	93.46%	45.14%	C-type lectin domain family 4 member G;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN018650.1	sp|K1QFD8|K1QFD8_CRAGI	6.8e-17	92.4	56.67%	67.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN018651.1	sp|K1PRN1|K1PRN1_CRAGI	4.1e-25	121.3	28.73%	51.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018652.1	sp|K1QLK4|K1QLK4_CRAGI	2.9e-28	131.0	75.74%	44.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018653.1	sp|K1PK19|K1PK19_CRAGI	3.4e-29	133.7	88.24%	44.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018654.1	sp|K1Q047|K1Q047_CRAGI	0.0e+00	1753.8	92.46%	69.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN018661.1	sp|K1QL29|K1QL29_CRAGI	9.9e-09	64.3	70.00%	78.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018663.1	sp|A0A069DM33|A0A069DM33_9CNID	2.7e-42	178.3	96.18%	33.43%	Integrase / Recombinase;OS=Clytia;PE=2;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN015862.1	sp|K1QZ44|K1QZ44_CRAGI	2.4e-136	490.7	99.70%	83.89%	Muscarinic acetylcholine receptor M3;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0016907|
GN018667.1	sp|A0A210Q5L1|A0A210Q5L1_MIZYE	6.0e-92	343.2	96.92%	47.13%	Membrane progestin receptor alpha-B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN018668.1	sp|K1QLZ0|K1QLZ0_CRAGI	2.7e-48	196.8	100.00%	80.95%	Uncharacterized protein C3orf30;OS=Crassostrea;PE=4;SV=1
GN018669.1	sp|K1R767|K1R767_CRAGI	4.0e-69	267.3	52.58%	82.82%	Coiled-coil domain-containing protein 97;OS=Crassostrea;PE=4;SV=1
GN018670.1	sp|K1R773|K1R773_CRAGI	1.4e-13	81.6	90.14%	43.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN018671.1	sp|K1Q060|K1Q060_CRAGI	4.7e-13	79.7	40.65%	77.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|	GO:0006357|
GN018672.1	sp|K1Q060|K1Q060_CRAGI	2.4e-25	120.9	96.23%	47.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|	GO:0006357|
GN018673.1	sp|K1Q7F6|K1Q7F6_CRAGI	1.1e-35	155.6	100.00%	78.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003700|
GN018674.1	sp|K1PKB1|K1PKB1_CRAGI	1.1e-73	283.1	100.00%	40.89%	Spermatogenesis-associated protein 7;OS=Crassostrea;PE=4;SV=1
GN018675.1	sp|K1R2J7|K1R2J7_CRAGI	3.9e-50	204.5	98.18%	86.21%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN018676.1	sp|K1Q6G6|K1Q6G6_CRAGI	1.6e-196	691.8	98.50%	63.21%	Fibrous sheath-interacting protein 1;OS=Crassostrea;PE=4;SV=1
GN018678.1	sp|K1PKA8|K1PKA8_CRAGI	0.0e+00	1094.3	79.44%	62.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018679.1	sp|K1PS28|K1PS28_CRAGI	2.4e-149	533.9	99.09%	78.93%	L-asparaginase;OS=Crassostrea;PE=4;SV=1	GO:0004067|
GN015863.1	sp|K1RVU7|K1RVU7_CRAGI	1.3e-153	548.9	100.00%	72.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018680.1	sp|K1Q5F6|K1Q5F6_CRAGI	1.1e-108	399.4	64.94%	48.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018682.1	sp|K1Q5F6|K1Q5F6_CRAGI	2.5e-80	303.9	99.50%	68.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018683.1	sp|K1Q5F6|K1Q5F6_CRAGI	1.7e-108	398.7	72.59%	48.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018685.1	sp|K1PY19|K1PY19_CRAGI	1.5e-64	251.5	94.71%	64.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018686.1	sp|K1PY19|K1PY19_CRAGI	1.8e-54	217.6	97.35%	65.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018687.1	sp|K1PY19|K1PY19_CRAGI	7.4e-188	662.9	68.62%	65.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015864.1	sp|K1RCJ3|K1RCJ3_CRAGI	1.6e-101	375.2	87.39%	62.38%	D-beta-hydroxybutyrate dehydrogenase, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN018688.1	sp|K1PY19|K1PY19_CRAGI	1.8e-54	217.6	97.35%	65.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018689.1	sp|K1PY19|K1PY19_CRAGI	0.0e+00	1693.3	97.78%	67.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018690.1	sp|K1PY19|K1PY19_CRAGI	1.1e-45	188.3	91.37%	73.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015865.1	sp|A0A210QB58|A0A210QB58_MIZYE	1.5e-31	141.4	74.64%	60.78%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN015866.1	sp|A0A1W2W194|A0A1W2W194_CIOIN	1.5e-26	125.9	47.71%	42.41%	uncharacterized protein LOC100184639;OS=Ciona;PE=4;SV=1
GN015561.1	sp|A0A210QVT5|A0A210QVT5_MIZYE	4.8e-28	132.5	49.79%	55.44%	Ankycorbin;OS=Mizuhopecten;PE=4;SV=1
GN015868.1	sp|K1PVU0|K1PVU0_CRAGI	5.8e-27	126.3	97.56%	41.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015870.1	sp|K1PHP0|K1PHP0_CRAGI	3.4e-206	723.4	99.62%	79.73%	RNA-binding protein MEX3C;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN015872.1	sp|A0A210R316|A0A210R316_MIZYE	4.9e-55	220.3	95.17%	43.35%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN015873.1	sp|K1QS20|K1QS20_CRAGI	2.5e-31	142.1	34.90%	47.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015874.1	sp|K1QZD9|K1QZD9_CRAGI	1.6e-171	608.2	88.47%	64.23%	Ladybird homeobox corepressor 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0046332|
GN015562.1	sp|K1PMN5|K1PMN5_CRAGI	0.0e+00	1275.0	96.09%	71.06%	Furin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004252|
GN015876.1	sp|A0A210QVC5|A0A210QVC5_MIZYE	0.0e+00	1337.0	99.71%	63.30%	Ubiquitin-like modifier-activating enzyme 6;OS=Mizuhopecten;PE=4;SV=1	GO:0008641|	GO:0006464|
GN015877.1	sp|K1Q939|K1Q939_CRAGI	1.5e-46	192.6	52.78%	50.52%	F-box only protein 18;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004003|GO:0003677|
GN015878.1	sp|K1Q1Z1|K1Q1Z1_CRAGI	9.6e-161	572.4	97.65%	61.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN015563.1	sp|K1Q1M9|K1Q1M9_CRAGI	1.1e-92	345.1	96.93%	78.13%	Peroxisomal membrane protein 11B;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0016559|
GN015879.1	sp|K1Q7R9|K1Q7R9_CRAGI	3.6e-34	149.8	85.71%	71.84%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN015880.1	sp|K1QJ48|K1QJ48_CRAGI	3.2e-99	367.5	91.93%	53.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015537.1	sp|K1QYA6|K1QYA6_CRAGI	0.0e+00	1117.4	96.26%	87.38%	Uncharacterized protein C20orf26;OS=Crassostrea;PE=4;SV=1
GN015564.1	sp|K1Q1M9|K1Q1M9_CRAGI	2.1e-105	387.5	99.60%	78.00%	Peroxisomal membrane protein 11B;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0016559|
GN015881.1	sp|K1QY88|K1QY88_CRAGI	7.9e-38	163.3	94.33%	37.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN015883.1	sp|K1QSJ1|K1QSJ1_CRAGI	1.9e-101	374.8	83.63%	60.71%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN015884.1	sp|K1Q199|K1Q199_CRAGI	1.8e-10	70.1	63.93%	78.95%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015885.1	sp|K1QY88|K1QY88_CRAGI	1.4e-75	289.3	98.36%	41.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN015886.1	sp|K1QKF7|K1QKF7_CRAGI	5.6e-64	249.2	99.35%	73.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN015565.1	sp|K1PU98|K1PU98_CRAGI	0.0e+00	1079.3	86.72%	81.31%	WD repeat-containing protein 93;OS=Crassostrea;PE=4;SV=1	GO:0016651|	GO:0022900|
GN015887.1	sp|K1PS76|K1PS76_CRAGI	0.0e+00	1114.0	97.80%	84.34%	Tyrosine-protein kinase receptor;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005524|GO:0004714|	GO:0071469|GO:0007169|
GN015889.1	sp|Q7YT64|Q7YT64_CRAGI	1.0e-27	128.3	96.26%	65.69%	Tyrosine-protein kinase receptor;OS=Crassostrea;PE=2;SV=1	GO:0005887|	GO:0005524|GO:0004714|	GO:0071469|GO:0007169|
GN015890.1	sp|K1R7J5|K1R7J5_CRAGI	1.6e-28	132.1	47.64%	88.33%	Cell death specification protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN015891.1	sp|K1QM96|K1QM96_CRAGI	2.6e-69	268.9	25.51%	80.13%	Chymotrypsin B;OS=Crassostrea;PE=3;SV=1	GO:0004252|
GN015566.1	sp|K1PMM8|K1PMM8_CRAGI	2.3e-148	531.6	80.13%	62.67%	Kelch-like protein 13;OS=Crassostrea;PE=4;SV=1
GN015892.1	sp|K1PW18|K1PW18_CRAGI	0.0e+00	2688.3	100.00%	71.14%	C-myc promoter-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015893.1	sp|A0A210PTC9|A0A210PTC9_MIZYE	1.3e-38	167.2	22.50%	51.95%	Folate gamma-glutamyl hydrolase;OS=Mizuhopecten;PE=4;SV=1	GO:0034722|
GN015895.1	sp|K1PP77|K1PP77_CRAGI	0.0e+00	2908.2	98.91%	67.86%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003723|GO:0005044|
GN015896.1	sp|K1PNE6|K1PNE6_CRAGI	4.5e-160	570.1	84.66%	66.27%	Protein flp;OS=Crassostrea;PE=4;SV=1
GN015898.1	sp|K1RIW4|K1RIW4_CRAGI	3.0e-101	375.2	74.78%	37.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015899.1	sp|K1RFP0|K1RFP0_CRAGI	2.9e-31	140.6	87.34%	53.62%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015900.1	sp|A0A2R2MN13|A0A2R2MN13_LINUN	3.3e-32	143.7	98.71%	43.95%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN015901.1	sp|V4ARM3|V4ARM3_LOTGI	2.4e-12	77.0	92.86%	44.44%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN015902.1	sp|K1Q8W0|K1Q8W0_CRAGI	1.4e-43	181.8	95.96%	48.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008527|
GN015904.1	sp|K1QHS0|K1QHS0_CRAGI	1.2e-60	238.0	100.00%	77.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015905.1	sp|K1QFV8|K1QFV8_CRAGI	0.0e+00	1855.9	91.84%	86.13%	Putative ATP-dependent RNA helicase DHX34;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|
GN015906.1	sp|K1PVU9|K1PVU9_CRAGI	9.5e-90	336.3	67.22%	60.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015907.1	sp|K1PNH0|K1PNH0_CRAGI	3.0e-79	300.4	99.07%	67.44%	Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0006516|
GN015908.1	sp|K1PNH0|K1PNH0_CRAGI	2.7e-155	553.5	99.33%	85.37%	Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0006516|
GN015909.1	sp|K1PFP0|K1PFP0_CRAGI	7.3e-142	509.6	100.00%	90.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015910.1	sp|K1R466|K1R466_CRAGI	1.3e-283	980.7	97.30%	89.54%	T-complex protein 1 subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN015911.1	sp|K1QBY8|K1QBY8_CRAGI	8.7e-283	978.0	100.00%	83.53%	Vacuolar protein sorting-associated protein 33B;OS=Crassostrea;PE=3;SV=1	GO:0006904|
GN015912.1	sp|K1R1H7|K1R1H7_CRAGI	6.1e-162	576.6	99.67%	47.00%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015913.1	sp|K1QS36|K1QS36_CRAGI	1.8e-42	178.3	99.57%	42.98%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015568.1	sp|K1R2T4|K1R2T4_CRAGI	3.3e-20	104.4	55.02%	42.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015914.1	sp|K1PQH5|K1PQH5_CRAGI	1.4e-79	302.0	99.67%	50.17%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN015915.1	sp|K1R462|K1R462_CRAGI	1.1e-171	609.0	99.68%	48.67%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015916.1	sp|K1PLB7|K1PLB7_CRAGI	1.9e-39	167.5	97.81%	61.94%	Toll-like receptor 2 type-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN015917.1	sp|K1PQH5|K1PQH5_CRAGI	4.4e-106	390.6	99.77%	46.99%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN015918.1	sp|A0A210QB79|A0A210QB79_MIZYE	3.3e-88	331.6	83.72%	36.51%	Kinase suppressor of Ras 2;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004672|
GN015919.1	sp|K1PIS8|K1PIS8_CRAGI	5.6e-45	185.7	92.98%	82.86%	CWF19-like protein 2;OS=Crassostrea;PE=4;SV=1
GN015920.1	sp|K1PJS7|K1PJS7_CRAGI	0.0e+00	2836.6	87.49%	70.84%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0005840|	GO:0003950|GO:0003735|	GO:0006471|GO:0006412|
GN015921.1	sp|K1PIS8|K1PIS8_CRAGI	8.7e-286	988.8	100.00%	61.95%	CWF19-like protein 2;OS=Crassostrea;PE=4;SV=1
GN015922.1	sp|A0A210R3Y9|A0A210R3Y9_MIZYE	9.4e-164	582.0	97.98%	66.75%	Cytochrome P450 4F12;OS=Mizuhopecten;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN015923.1	sp|K1Q4R1|K1Q4R1_CRAGI	2.7e-278	963.0	100.00%	80.33%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN015924.1	sp|K1PXR1|K1PXR1_CRAGI	3.1e-248	863.2	92.89%	74.77%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN015925.1	sp|K1PS76|K1PS76_CRAGI	6.1e-101	372.5	100.00%	88.32%	Tyrosine-protein kinase receptor;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005524|GO:0004714|	GO:0071469|GO:0007169|
GN015926.1	sp|K1PS76|K1PS76_CRAGI	5.1e-30	136.0	99.12%	66.37%	Tyrosine-protein kinase receptor;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005524|GO:0004714|	GO:0071469|GO:0007169|
GN015927.1	sp|W4YPX2|W4YPX2_STRPU	5.8e-18	97.4	89.97%	27.65%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004190|GO:0003676|GO:0008270|
GN015929.1	sp|K1PHD2|K1PHD2_CRAGI	5.3e-102	377.1	94.60%	46.59%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015930.1	sp|K1QKF7|K1QKF7_CRAGI	5.2e-82	309.7	93.86%	67.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN015931.1	sp|K1RBI5|K1RBI5_CRAGI	2.5e-139	501.5	91.82%	47.52%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015932.1	sp|K1RBI5|K1RBI5_CRAGI	5.8e-34	149.1	95.61%	59.26%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015933.1	sp|K1PHD2|K1PHD2_CRAGI	5.5e-110	403.7	92.45%	47.07%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015934.1	sp|A0A1S3I8P3|A0A1S3I8P3_LINUN	1.0e-59	236.1	82.87%	40.06%	zinc finger protein 862-like;OS=Lingula;PE=4;SV=1	GO:0046983|
GN015935.1	sp|K1RBI5|K1RBI5_CRAGI	1.0e-148	532.7	91.46%	50.44%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN015936.1	sp|K1QI67|K1QI67_CRAGI	2.3e-156	557.8	68.72%	82.75%	SHC-transforming protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN015937.1	sp|K1QI67|K1QI67_CRAGI	1.6e-18	96.7	96.15%	85.71%	SHC-transforming protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN015938.1	sp|K1PBZ4|K1PBZ4_CRAGI	0.0e+00	2110.5	100.00%	97.02%	Regulator of nonsense transcripts 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0005524|GO:0003677|GO:0004386|GO:0008270|	GO:0000184|
GN015939.1	sp|K1S211|K1S211_CRAGI	1.0e-148	532.3	63.03%	85.28%	Poly(A) RNA polymerase gld-2-like protein A;OS=Crassostrea;PE=4;SV=1
GN015940.1	sp|K1R6A9|K1R6A9_CRAGI	3.6e-310	1070.5	58.36%	66.14%	Tumor suppressor p53-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN015941.1	sp|J9Q405|J9Q405_OSTED	4.7e-126	456.1	100.00%	97.93%	40S ribosomal protein S6;OS=Ostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN015942.1	sp|A0A2G8JF98|A0A2G8JF98_STIJA	3.5e-25	120.6	94.41%	36.63%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN015944.1	sp|K1PG84|K1PG84_CRAGI	7.3e-15	85.1	97.53%	48.08%	Glutaredoxin-C6;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0009055|GO:0015035|	GO:0045454|
GN015570.1	sp|K1QAJ4|K1QAJ4_CRAGI	4.8e-81	306.6	85.08%	72.65%	Transmembrane protein C2orf18-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015946.1	sp|K1QDL6|K1QDL6_CRAGI	1.5e-191	674.9	98.75%	61.94%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015947.1	sp|H9LTE0|H9LTE0_CRAAR	1.7e-108	397.9	80.53%	87.14%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=2;SV=1	GO:0003755|	GO:0006457|
GN015948.1	sp|K1QJU9|K1QJU9_CRAGI	2.8e-92	344.0	97.32%	69.96%	Uncharacterized protein C1orf43;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015949.1	sp|K1QDL1|K1QDL1_CRAGI	9.5e-66	255.8	100.00%	79.76%	Krueppel-like factor 13;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015950.1	sp|K1P141|K1P141_CRAGI	7.7e-35	151.8	84.69%	91.46%	Keratinocyte-associated protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015951.1	sp|K1RF39|K1RF39_CRAGI	4.5e-190	669.5	96.53%	82.05%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN015952.1	sp|K1R988|K1R988_CRAGI	7.3e-10	68.9	94.50%	47.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015538.1	sp|K1QYA6|K1QYA6_CRAGI	1.3e-64	251.1	100.00%	88.46%	Uncharacterized protein C20orf26;OS=Crassostrea;PE=4;SV=1
GN015571.1	sp|T1GJB8|T1GJB8_MEGSC	3.8e-41	175.3	35.98%	44.95%	Uncharacterized protein;OS=Megaselia;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN015953.1	sp|A0A210QI16|A0A210QI16_MIZYE	1.8e-58	232.3	76.02%	35.91%	Neuronal acetylcholine receptor subunit alpha-7;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN015957.1	sp|K1QSJ1|K1QSJ1_CRAGI	1.9e-88	331.3	100.00%	58.37%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN015958.1	sp|K1S4K7|K1S4K7_CRAGI	4.2e-106	390.2	99.37%	74.29%	Nitrile-specifier protein 5;OS=Crassostrea;PE=4;SV=1
GN015959.1	sp|K1RL62|K1RL62_CRAGI	2.5e-272	943.3	95.43%	83.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015960.1	sp|K1R980|K1R980_CRAGI	7.4e-27	124.8	90.28%	85.94%	UPF0556 protein C19orf10-like protein;OS=Crassostrea;PE=4;SV=1
GN015961.1	sp|K1RF25|K1RF25_CRAGI	3.2e-249	866.3	93.41%	90.23%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN015962.1	sp|K1R974|K1R974_CRAGI	9.1e-50	202.6	89.74%	58.30%	Fimbrin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN015963.1	sp|K1QZ49|K1QZ49_CRAGI	3.2e-81	306.6	98.81%	87.27%	Adipocyte plasma membrane-associated protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016844|	GO:0009058|
GN015964.1	sp|K1S4J4|K1S4J4_CRAGI	1.7e-31	140.6	84.78%	88.31%	2-oxoisovalerate dehydrogenase subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0003863|GO:0003826|	GO:0009083|
GN015965.1	sp|K1RL48|K1RL48_CRAGI	1.2e-94	351.3	96.69%	92.53%	PPPDE peptidase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN015966.1	sp|K1RF19|K1RF19_CRAGI	3.5e-121	440.3	75.72%	84.75%	Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|	GO:0015018|GO:0046872|	GO:0006486|
GN015572.1	sp|K1RUX3|K1RUX3_CRAGI	6.5e-23	112.8	42.77%	77.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN015967.1	sp|K1R968|K1R968_CRAGI	0.0e+00	1630.5	100.00%	88.08%	Non-lysosomal glucosylceramidase;OS=Crassostrea;PE=4;SV=1	GO:0004553|
GN015968.1	sp|K1QCX3|K1QCX3_CRAGI	1.6e-108	398.3	100.00%	80.12%	Zinc transporter ZIP1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN015969.1	sp|K1QCX3|K1QCX3_CRAGI	1.1e-90	339.0	100.00%	70.90%	Zinc transporter ZIP1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN015970.1	sp|K1Q436|K1Q436_CRAGI	9.8e-15	85.9	73.37%	37.91%	Multiple epidermal growth factor-like domains 6;OS=Crassostrea;PE=4;SV=1
GN015971.1	sp|K1QCX3|K1QCX3_CRAGI	8.2e-86	322.8	100.00%	69.09%	Zinc transporter ZIP1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046873|
GN015972.1	sp|K1R968|K1R968_CRAGI	5.0e-50	203.0	88.17%	66.22%	Non-lysosomal glucosylceramidase;OS=Crassostrea;PE=4;SV=1	GO:0004553|
GN015973.1	sp|K1R968|K1R968_CRAGI	2.9e-186	656.8	99.74%	77.60%	Non-lysosomal glucosylceramidase;OS=Crassostrea;PE=4;SV=1	GO:0004553|
GN015974.1	sp|K1R974|K1R974_CRAGI	5.9e-23	112.1	71.76%	93.33%	Fimbrin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN015975.1	sp|K1RF19|K1RF19_CRAGI	4.2e-136	490.0	78.36%	85.02%	Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|	GO:0015018|GO:0046872|	GO:0006486|
GN015976.1	sp|K1Q5I7|K1Q5I7_CRAGI	1.8e-190	671.8	92.10%	46.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015977.1	sp|K1PY48|K1PY48_CRAGI	2.8e-38	162.9	100.00%	90.12%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|	GO:0006457|
GN015978.1	sp|K1QJU9|K1QJU9_CRAGI	2.8e-92	344.0	97.32%	69.96%	Uncharacterized protein C1orf43;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015979.1	sp|K1QDL1|K1QDL1_CRAGI	9.5e-66	255.8	100.00%	79.76%	Krueppel-like factor 13;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN015980.1	sp|K1RF39|K1RF39_CRAGI	4.5e-190	669.5	96.53%	82.05%	Arrestin domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN015981.1	sp|K1R988|K1R988_CRAGI	7.3e-10	68.9	94.50%	47.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN015982.1	sp|A0A210QI16|A0A210QI16_MIZYE	1.8e-58	232.3	76.02%	35.91%	Neuronal acetylcholine receptor subunit alpha-7;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN015574.1	sp|K1RBB9|K1RBB9_CRAGI	2.2e-60	238.0	100.00%	60.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015986.1	sp|K1QSJ1|K1QSJ1_CRAGI	1.9e-88	331.3	100.00%	58.37%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|	GO:0008107|	GO:0005975|GO:0006486|
GN015987.1	sp|K1S4K7|K1S4K7_CRAGI	4.2e-106	390.2	99.37%	74.29%	Nitrile-specifier protein 5;OS=Crassostrea;PE=4;SV=1
GN015988.1	sp|K1RL62|K1RL62_CRAGI	2.5e-272	943.3	95.43%	83.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015989.1	sp|K1RF31|K1RF31_CRAGI	5.2e-215	753.4	99.32%	51.32%	Peroxisomal multifunctional enzyme type 2;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN015990.1	sp|K1QJV2|K1QJV2_CRAGI	1.4e-169	601.3	99.48%	73.09%	Peroxisomal sarcosine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN015992.1	sp|K1PG84|K1PG84_CRAGI	2.3e-32	143.7	98.13%	63.46%	Glutaredoxin-C6;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0009055|GO:0015035|	GO:0045454|
GN015993.1	sp|K1QJV7|K1QJV7_CRAGI	1.1e-21	107.5	90.91%	93.22%	Organic cation transporter-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN015994.1	sp|J9Q405|J9Q405_OSTED	2.0e-26	123.6	87.36%	96.00%	40S ribosomal protein S6;OS=Ostrea;PE=2;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN015995.1	sp|K1R6A9|K1R6A9_CRAGI	3.6e-310	1070.5	58.36%	66.14%	Tumor suppressor p53-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN015996.1	sp|K1S211|K1S211_CRAGI	1.4e-148	532.3	44.78%	85.28%	Poly(A) RNA polymerase gld-2-like protein A;OS=Crassostrea;PE=4;SV=1
GN015997.1	sp|K1QI67|K1QI67_CRAGI	4.1e-22	109.0	80.00%	87.27%	SHC-transforming protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN015998.1	sp|K1QI67|K1QI67_CRAGI	6.8e-172	609.0	95.21%	84.15%	SHC-transforming protein 1;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN016000.1	sp|K1PXW9|K1PXW9_CRAGI	8.9e-24	116.3	55.14%	50.34%	Zinc finger CCHC domain-containing protein 9;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN016001.1	sp|K1RBI5|K1RBI5_CRAGI	1.0e-148	532.7	91.46%	50.44%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016003.1	sp|K1RU68|K1RU68_CRAGI	3.5e-21	106.3	93.41%	60.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016004.1	sp|K1RBI5|K1RBI5_CRAGI	2.8e-140	504.6	95.73%	47.86%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016005.1	sp|A0A1Y1KRS2|A0A1Y1KRS2_PHOPY	2.3e-29	134.4	98.27%	38.24%	Uncharacterized protein;OS=Photinus;PE=4;SV=1	GO:0055114|
GN016006.1	sp|K1QKF7|K1QKF7_CRAGI	4.8e-82	309.7	97.64%	68.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN015577.1	sp|K1PEP3|K1PEP3_CRAGI	2.1e-53	214.5	90.05%	56.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016007.1	sp|K1Q199|K1Q199_CRAGI	3.1e-40	169.9	87.50%	78.35%	Putative E3 ubiquitin-protein ligase HERC2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN016009.1	sp|W4YPX2|W4YPX2_STRPU	5.8e-18	97.4	89.97%	27.65%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0004190|GO:0003676|GO:0008270|
GN016010.1	sp|K1PS76|K1PS76_CRAGI	5.1e-30	136.0	99.12%	66.37%	Tyrosine-protein kinase receptor;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0005524|GO:0004714|	GO:0071469|GO:0007169|
GN015578.1	sp|A0A3Q0JTB6|A0A3Q0JTB6_CIOIN	1.6e-29	136.7	66.02%	26.47%	uncharacterized protein LOC113474284;OS=Ciona;PE=4;SV=1
GN016013.1	sp|A0A210QYP1|A0A210QYP1_MIZYE	2.0e-35	156.4	95.99%	23.55%	Transmembrane protein ORF68;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016018.1	sp|A0A210QYP1|A0A210QYP1_MIZYE	2.0e-35	156.4	95.99%	23.55%	Transmembrane protein ORF68;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016019.1	sp|K1PSP9|K1PSP9_CRAGI	1.2e-204	718.4	93.95%	67.23%	Uncharacterized protein C3orf59;OS=Crassostrea;PE=4;SV=1
GN016020.1	sp|K1PS26|K1PS26_CRAGI	8.5e-38	161.8	99.11%	71.82%	Arrestin domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN016021.1	sp|K1R955|K1R955_CRAGI	1.3e-185	655.6	98.22%	60.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016022.1	sp|K1R1U3|K1R1U3_CRAGI	2.5e-240	836.6	99.78%	91.74%	Putative ATP-dependent RNA helicase DDX49;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN016023.1	sp|K1S4I2|K1S4I2_CRAGI	7.3e-258	895.2	100.00%	82.30%	ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0008233|GO:0051082|	GO:0006457|
GN016024.1	sp|K1QZ42|K1QZ42_CRAGI	2.4e-58	231.1	99.16%	72.88%	Ankyrin repeat domain-containing protein 50;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN016025.1	sp|K1R960|K1R960_CRAGI	3.4e-262	909.8	100.00%	64.95%	Inositol 1,4,5-triphosphate receptor-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016026.1	sp|K1RF13|K1RF13_CRAGI	1.1e-229	802.0	100.00%	55.45%	Amiloride-sensitive cation channel 4-B;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN016027.1	sp|K1Q5L8|K1Q5L8_CRAGI	7.7e-201	705.3	99.04%	83.98%	Synaptic vesicle 2-related protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN016028.1	sp|K1RL42|K1RL42_CRAGI	7.9e-41	171.8	89.72%	76.84%	Nuclear receptor 2C2-associated protein;OS=Crassostrea;PE=4;SV=1
GN016029.1	sp|K1S4I7|K1S4I7_CRAGI	4.8e-71	273.9	95.16%	45.83%	Zinc transporter ZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0000776|	GO:0046873|	GO:0051382|
GN016030.1	sp|K1PU09|K1PU09_CRAGI	1.8e-152	545.8	98.94%	35.37%	Putative histone-lysine N-methyltransferase set-1;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN016033.1	sp|A0A210QYP1|A0A210QYP1_MIZYE	5.6e-32	144.8	96.73%	22.45%	Transmembrane protein ORF68;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016034.1	sp|A0A210QYP1|A0A210QYP1_MIZYE	3.6e-34	152.1	95.02%	24.07%	Transmembrane protein ORF68;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN016036.1	sp|K1S4H9|K1S4H9_CRAGI	1.2e-128	465.7	86.14%	61.23%	Dynactin subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004168|	GO:0043048|
GN016037.1	sp|K1QVG5|K1QVG5_CRAGI	3.8e-169	599.7	100.00%	82.56%	Retinal dehydrogenase 1;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN016038.1	sp|K1QVG5|K1QVG5_CRAGI	6.9e-167	592.4	88.86%	80.00%	Retinal dehydrogenase 1;OS=Crassostrea;PE=3;SV=1	GO:0016620|
GN016039.1	sp|K1RST0|K1RST0_CRAGI	8.8e-68	263.1	77.35%	47.30%	Dopamine D2-like receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN016044.1	sp|K1RZS2|K1RZS2_CRAGI	1.1e-10	74.3	9.05%	57.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015580.1	sp|A0A1Y1MQ96|A0A1Y1MQ96_PHOPY	4.9e-28	129.8	81.17%	50.00%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN016045.1	sp|K1RST0|K1RST0_CRAGI	1.3e-136	491.9	100.00%	64.16%	Dopamine D2-like receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN016046.1	sp|K1RST0|K1RST0_CRAGI	1.1e-87	329.3	82.78%	52.42%	Dopamine D2-like receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN015581.1	sp|K1PAQ8|K1PAQ8_CRAGI	4.2e-23	114.0	70.26%	44.44%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN016048.1	sp|A0A3Q0JPU2|A0A3Q0JPU2_CIOIN	1.0e-47	197.2	87.87%	27.34%	uncharacterized protein LOC113474251;OS=Ciona;PE=4;SV=1
GN016050.1	sp|K1RBB9|K1RBB9_CRAGI	2.2e-60	238.0	100.00%	60.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016052.1	sp|T1GJB8|T1GJB8_MEGSC	3.8e-41	175.3	35.98%	44.95%	Uncharacterized protein;OS=Megaselia;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN016053.1	sp|K1Q1M9|K1Q1M9_CRAGI	2.1e-105	387.5	99.60%	78.00%	Peroxisomal membrane protein 11B;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0016559|
GN016054.1	sp|K1PT27|K1PT27_CRAGI	8.8e-52	208.4	92.74%	85.09%	DNA-3-methyladenine glycosylase;OS=Crassostrea;PE=3;SV=1	GO:0003905|GO:0003677|	GO:0006284|
GN016056.1	sp|K1R0Y9|K1R0Y9_CRAGI	2.3e-162	577.0	99.34%	94.37%	ADP,ATP carrier protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005743|	GO:0022857|
GN016058.1	sp|K1Q1M9|K1Q1M9_CRAGI	3.2e-75	287.0	96.02%	73.47%	Peroxisomal membrane protein 11B;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0016559|
GN016059.1	sp|K1PMN5|K1PMN5_CRAGI	0.0e+00	1275.0	96.09%	71.06%	Furin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004252|
GN016060.1	sp|A0A210QVT5|A0A210QVT5_MIZYE	6.3e-28	130.6	25.22%	73.81%	Ankycorbin;OS=Mizuhopecten;PE=4;SV=1
GN015582.1	sp|K1R3T5|K1R3T5_CRAGI	1.4e-11	77.4	15.27%	38.14%	Histone-lysine N-methyltransferase SETD8;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN016061.1	sp|A0A210QVT5|A0A210QVT5_MIZYE	6.5e-23	114.8	12.32%	71.62%	Ankycorbin;OS=Mizuhopecten;PE=4;SV=1
GN016062.1	sp|K1PUA2|K1PUA2_CRAGI	2.0e-161	574.7	97.69%	64.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016063.1	sp|K1Q1N4|K1Q1N4_CRAGI	3.1e-54	217.6	75.95%	63.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016064.1	sp|K1Q8S5|K1Q8S5_CRAGI	1.7e-240	837.4	100.00%	78.23%	Enhancer of mRNA-decapping protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003729|	GO:0031087|
GN016066.1	sp|K1QXY3|K1QXY3_CRAGI	4.7e-142	510.8	64.71%	79.20%	Transcriptional repressor p66-alpha;OS=Crassostrea;PE=4;SV=1	GO:0000122|
GN016067.1	sp|K1S329|K1S329_CRAGI	7.2e-184	648.7	94.84%	93.64%	E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|	GO:0006511|
GN016068.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	6.0e-39	166.0	96.62%	56.34%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN016069.1	sp|K1R7Q3|K1R7Q3_CRAGI	5.6e-232	808.9	100.00%	77.01%	Cohesin loading complex subunit SCC4-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007064|
GN016070.1	sp|A0A2T7NGI6|A0A2T7NGI6_POMCA	0.0e+00	1403.7	99.83%	26.85%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1
GN016071.1	sp|A0A1S3IVT1|A0A1S3IVT1_LINUN	0.0e+00	1275.4	99.83%	27.00%	LOW QUALITY PROTEIN: sacsin;OS=Lingula;PE=4;SV=2
GN016072.1	sp|K1QDE0|K1QDE0_CRAGI	7.0e-99	367.1	42.20%	67.68%	Sushi, nidogen and EGF-like domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007160|
GN016073.1	sp|K1PHW0|K1PHW0_CRAGI	1.8e-226	790.4	93.95%	93.80%	Calpain-2 catalytic subunit;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN016074.1	sp|K1PKN9|K1PKN9_CRAGI	2.5e-74	285.4	63.05%	44.85%	Calcitonin receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN016075.1	sp|K1R9N6|K1R9N6_CRAGI	1.4e-51	209.1	74.77%	43.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015584.1	sp|K1PXC8|K1PXC8_CRAGI	2.2e-39	167.2	100.00%	53.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016076.1	sp|K1RAB9|K1RAB9_CRAGI	4.9e-56	222.6	99.26%	72.18%	Epoxide hydrolase 4;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN016078.1	sp|A0A1S3I117|A0A1S3I117_LINUN	4.4e-68	263.8	96.74%	46.64%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN016079.1	sp|K1PBH4|K1PBH4_CRAGI	3.5e-42	177.2	73.60%	59.72%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN016082.1	sp|K1QL13|K1QL13_CRAGI	3.2e-38	163.3	100.00%	69.35%	ATP-dependent DNA helicase recQ;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN016084.1	sp|J9M904|J9M904_ACYPI	2.2e-22	112.1	59.25%	35.86%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2	GO:0003676|	GO:0015074|
GN016085.1	sp|A0A1S3HJ12|A0A1S3HJ12_LINUN	0.0e+00	1701.8	94.58%	35.49%	uncharacterized protein LOC106155695;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0005319|
GN016086.1	sp|K1RRD7|K1RRD7_CRAGI	1.7e-156	558.5	56.83%	75.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015586.1	sp|K1R9I3|K1R9I3_CRAGI	9.1e-57	225.7	99.06%	58.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016088.1	sp|K1RIA6|K1RIA6_CRAGI	1.6e-207	729.2	98.88%	32.61%	Protein hedgehog;OS=Crassostrea;PE=4;SV=1	GO:0007267|
GN016089.1	sp|K1RGV7|K1RGV7_CRAGI	6.5e-70	270.0	96.01%	40.34%	Diphosphomevalonate decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0005524|GO:0004163|	GO:0019287|
GN016090.1	sp|K1R4X9|K1R4X9_CRAGI	2.0e-235	820.5	100.00%	78.35%	UDP-N-acetylhexosamine pyrophosphorylase;OS=Crassostrea;PE=4;SV=1	GO:0070569|
GN016091.1	sp|K1QV93|K1QV93_CRAGI	1.5e-76	293.5	53.83%	32.86%	Low-density lipoprotein receptor-related protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016094.1	sp|K1RGV7|K1RGV7_CRAGI	5.8e-40	169.9	94.17%	44.04%	Diphosphomevalonate decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0005829|	GO:0005524|GO:0004163|	GO:0019287|
GN016095.1	sp|K1R4X9|K1R4X9_CRAGI	6.9e-252	875.2	100.00%	81.69%	UDP-N-acetylhexosamine pyrophosphorylase;OS=Crassostrea;PE=4;SV=1	GO:0070569|
GN016096.1	sp|K1PZP3|K1PZP3_CRAGI	0.0e+00	1301.6	96.71%	88.03%	Conserved oligomeric Golgi complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0007030|GO:0015031|
GN016097.1	sp|K1QJY9|K1QJY9_CRAGI	7.2e-29	131.7	92.94%	80.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN015588.1	sp|K1P0H4|K1P0H4_CRAGI	1.0e-85	322.8	94.12%	41.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016100.1	sp|K1PD20|K1PD20_CRAGI	6.4e-141	505.8	98.32%	81.48%	Di-N-acetylchitobiase;OS=Crassostrea;PE=3;SV=1	GO:0008061|GO:0004553|	GO:0005975|
GN016101.1	sp|K1RKT7|K1RKT7_CRAGI	3.0e-32	144.4	42.15%	73.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016102.1	sp|K1Q4Q0|K1Q4Q0_CRAGI	1.5e-91	341.3	100.00%	83.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016103.1	sp|K1QV57|K1QV57_CRAGI	2.0e-186	657.5	98.19%	79.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003723|
GN016104.1	sp|K1PXP5|K1PXP5_CRAGI	9.7e-21	105.5	36.67%	92.59%	Uncharacterized protein C6orf64;OS=Crassostrea;PE=4;SV=1
GN015589.1	sp|K1R183|K1R183_CRAGI	3.1e-30	137.1	96.75%	54.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016105.1	sp|K1PQG0|K1PQG0_CRAGI	3.2e-102	376.7	92.52%	96.45%	Rap guanine nucleotide exchange factor 4;OS=Crassostrea;PE=4;SV=1	GO:0005085|	GO:0007264|
GN016106.1	sp|A0A2T7PBG6|A0A2T7PBG6_POMCA	3.1e-104	383.6	99.60%	73.28%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005525|GO:0003924|GO:0005085|	GO:0007264|
GN016107.1	sp|K1QYA6|K1QYA6_CRAGI	1.0e-54	218.0	100.00%	95.50%	Uncharacterized protein C20orf26;OS=Crassostrea;PE=4;SV=1
GN016108.1	sp|A0A1S3HZA4|A0A1S3HZA4_LINUN	4.9e-46	190.3	84.62%	51.90%	adenosine receptor A1;OS=Lingula;PE=4;SV=1	GO:0016021|	GO:0001609|
GN016109.1	sp|K1QYA6|K1QYA6_CRAGI	5.8e-41	172.2	91.26%	86.02%	Uncharacterized protein C20orf26;OS=Crassostrea;PE=4;SV=1
GN016110.1	sp|K1QYA6|K1QYA6_CRAGI	0.0e+00	1451.0	99.03%	88.34%	Uncharacterized protein C20orf26;OS=Crassostrea;PE=4;SV=1
GN016111.1	sp|K1QCP3|K1QCP3_CRAGI	6.9e-213	745.7	83.18%	75.55%	Crooked neck-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006396|
GN015590.1	sp|K1R183|K1R183_CRAGI	3.1e-30	137.1	96.75%	54.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016112.1	sp|K1PQF4|K1PQF4_CRAGI	4.8e-91	339.3	95.53%	97.08%	Coiled-coil domain-containing protein 46;OS=Crassostrea;PE=4;SV=1
GN016113.1	sp|A0A210QNW5|A0A210QNW5_MIZYE	4.4e-93	347.1	84.75%	64.48%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016114.1	sp|K1PQF4|K1PQF4_CRAGI	1.0e-23	114.8	71.58%	94.03%	Coiled-coil domain-containing protein 46;OS=Crassostrea;PE=4;SV=1
GN016115.1	sp|A0A210QNW5|A0A210QNW5_MIZYE	1.9e-53	214.5	94.30%	61.88%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016116.1	sp|K1PQF4|K1PQF4_CRAGI	2.6e-110	403.7	90.27%	96.57%	Coiled-coil domain-containing protein 46;OS=Crassostrea;PE=4;SV=1
GN016117.1	sp|A0A210QNW5|A0A210QNW5_MIZYE	4.4e-93	347.1	84.75%	64.48%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN016118.1	sp|K1PQF4|K1PQF4_CRAGI	2.7e-65	255.0	75.12%	68.40%	Coiled-coil domain-containing protein 46;OS=Crassostrea;PE=4;SV=1
GN015591.1	sp|K1RTD0|K1RTD0_CRAGI	7.8e-54	215.7	72.73%	81.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016119.1	sp|K1QCN0|K1QCN0_CRAGI	1.5e-24	117.5	65.93%	93.44%	Signal recognition particle 9 kDa protein;OS=Crassostrea;PE=3;SV=1	GO:0005786|	GO:0008312|	GO:0045900|GO:0006614|
GN016120.1	sp|K1PQE9|K1PQE9_CRAGI	1.2e-17	94.0	80.00%	89.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016121.1	sp|K1PQE9|K1PQE9_CRAGI	5.1e-64	249.2	83.69%	91.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016122.1	sp|K1PQE9|K1PQE9_CRAGI	5.7e-15	85.1	68.25%	90.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015592.1	sp|K1QLX8|K1QLX8_CRAGI	1.2e-165	588.6	100.00%	67.70%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN016125.1	sp|K1Q720|K1Q720_CRAGI	7.3e-11	71.2	87.04%	65.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016130.1	sp|W4XST4|W4XST4_STRPU	3.4e-38	164.1	87.33%	38.61%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN016131.1	sp|A0A1S3I398|A0A1S3I398_LINUN	3.5e-14	84.0	54.86%	42.71%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN016132.1	sp|K1REY6|K1REY6_CRAGI	8.6e-54	216.1	94.07%	49.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015593.1	sp|J9M2S7|J9M2S7_ACYPI	2.1e-35	154.8	83.64%	46.52%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2
GN016133.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	5.6e-80	303.1	100.00%	58.24%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN016135.1	sp|A0A1Y1JRG9|A0A1Y1JRG9_PHOPY	3.4e-42	177.6	92.80%	37.04%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN016136.1	sp|K1REY6|K1REY6_CRAGI	3.5e-55	220.7	94.07%	50.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016137.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	5.6e-80	303.1	100.00%	58.24%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN016139.1	sp|C3ZVM2|C3ZVM2_BRAFL	3.9e-20	103.2	97.52%	44.09%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN015594.1	sp|K1QCZ8|K1QCZ8_CRAGI	2.7e-11	74.3	76.51%	41.26%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN016141.1	sp|A0A1Y1MQ96|A0A1Y1MQ96_PHOPY	4.9e-28	129.8	81.17%	50.00%	Uncharacterized protein;OS=Photinus;PE=4;SV=1
GN016142.1	sp|K1RI47|K1RI47_CRAGI	3.6e-64	250.8	87.06%	51.17%	Fibrinogen-like protein A;OS=Crassostrea;PE=4;SV=1
GN016145.1	sp|K1QFV0|K1QFV0_CRAGI	2.6e-12	77.0	77.88%	46.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016146.1	sp|K1R3T5|K1R3T5_CRAGI	1.4e-11	77.4	15.16%	38.14%	Histone-lysine N-methyltransferase SETD8;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN016147.1	sp|K1P6U2|K1P6U2_CRAGI	1.0e-33	147.9	100.00%	78.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016149.1	sp|K1R9I3|K1R9I3_CRAGI	9.1e-57	225.7	99.06%	58.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016151.1	sp|K1P0H4|K1P0H4_CRAGI	1.0e-85	322.8	94.12%	41.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016152.1	sp|K1R183|K1R183_CRAGI	3.1e-30	137.1	96.75%	54.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016153.1	sp|K1R183|K1R183_CRAGI	3.1e-30	137.1	96.75%	54.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016154.1	sp|K1RTD0|K1RTD0_CRAGI	7.8e-54	215.7	72.73%	81.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016155.1	sp|K1QLX8|K1QLX8_CRAGI	1.2e-165	588.6	100.00%	67.70%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN016156.1	sp|K1R2S9|K1R2S9_CRAGI	4.5e-16	89.0	76.39%	68.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016157.1	sp|K1QW16|K1QW16_CRAGI	4.0e-56	224.2	95.90%	38.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0030246|
GN016159.1	sp|K1QCZ8|K1QCZ8_CRAGI	2.7e-11	74.3	76.51%	41.26%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN016160.1	sp|J9M2S7|J9M2S7_ACYPI	2.1e-35	154.8	83.64%	46.52%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2
GN016162.1	sp|C3ZK91|C3ZK91_BRAFL	8.0e-58	229.9	94.03%	39.71%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN016163.1	sp|K1R2S9|K1R2S9_CRAGI	4.5e-16	89.0	76.39%	68.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016164.1	sp|K1QKG0|K1QKG0_CRAGI	6.3e-24	115.9	98.48%	48.94%	Dipeptidase;OS=Crassostrea;PE=3;SV=1	GO:0031225|GO:0016021|	GO:0016805|GO:0008239|GO:0046872|GO:0008235|
GN016165.1	sp|K1QKG0|K1QKG0_CRAGI	3.0e-22	110.5	87.42%	47.89%	Dipeptidase;OS=Crassostrea;PE=3;SV=1	GO:0031225|GO:0016021|	GO:0016805|GO:0008239|GO:0046872|GO:0008235|
GN015539.1	sp|K1QYA6|K1QYA6_CRAGI	1.0e-54	218.0	100.00%	95.50%	Uncharacterized protein C20orf26;OS=Crassostrea;PE=4;SV=1
GN015596.1	sp|K1RAF8|K1RAF8_CRAGI	5.1e-170	603.2	94.76%	60.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016166.1	sp|A0A210Q0S2|A0A210Q0S2_MIZYE	4.1e-248	863.2	98.30%	58.06%	Autophagy-related protein 9;OS=Mizuhopecten;PE=3;SV=1	GO:0030659|GO:0005794|GO:0016021|	GO:0006914|GO:0015031|
GN016167.1	sp|K1RAF8|K1RAF8_CRAGI	6.9e-21	105.5	60.75%	75.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016168.1	sp|K1R065|K1R065_CRAGI	2.1e-37	160.6	94.31%	71.30%	Golgi membrane protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016169.1	sp|A0A1S3HPG7|A0A1S3HPG7_LINUN	1.1e-09	68.6	97.52%	36.80%	uncharacterized protein LOC106156643;OS=Lingula;PE=4;SV=1
GN016170.1	sp|K1P842|K1P842_CRAGI	3.1e-108	397.9	85.83%	49.88%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN016171.1	sp|K1P842|K1P842_CRAGI	7.8e-106	389.8	89.89%	49.75%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN016172.1	sp|A0A2R2MJE1|A0A2R2MJE1_LINUN	2.9e-33	147.5	99.48%	41.15%	uncharacterized protein LOC112041353;OS=Lingula;PE=4;SV=1
GN016174.1	sp|K1QF07|K1QF07_CRAGI	2.5e-75	287.0	100.00%	82.39%	Neuroglobin;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN016175.1	sp|K1Q5B6|K1Q5B6_CRAGI	4.2e-35	153.7	89.60%	44.02%	28S ribosomal protein S29, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005840|
GN016178.1	sp|K1QEP4|K1QEP4_CRAGI	1.5e-19	101.3	99.21%	44.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN015597.1	sp|K1R065|K1R065_CRAGI	2.1e-37	160.6	94.31%	71.30%	Golgi membrane protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016179.1	sp|K1S4Q2|K1S4Q2_CRAGI	2.7e-262	909.8	92.55%	96.18%	T-complex protein 1 subunit delta;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0051082|	GO:0006457|
GN016181.1	sp|A7TDB1|A7TDB1_NEMVE	3.9e-19	100.5	97.86%	34.41%	Predicted protein;OS=Nematostella;PE=4;SV=1	GO:0016021|
GN016183.1	sp|K1R9D2|K1R9D2_CRAGI	5.1e-19	98.6	90.63%	75.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016184.1	sp|K1R9D2|K1R9D2_CRAGI	2.9e-198	696.8	100.00%	74.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016185.1	sp|A0A210QVV1|A0A210QVV1_MIZYE	6.4e-114	417.5	85.63%	33.05%	Kyphoscoliosis peptidase;OS=Mizuhopecten;PE=4;SV=1
GN015598.1	sp|A0A1S3HPG7|A0A1S3HPG7_LINUN	1.1e-09	68.6	97.52%	36.80%	uncharacterized protein LOC106156643;OS=Lingula;PE=4;SV=1
GN016189.1	sp|A0A210QZ72|A0A210QZ72_MIZYE	1.3e-106	392.5	92.45%	45.15%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0007165|
GN016190.1	sp|A0A0U5LCN0|A0A0U5LCN0_MIMNO	1.6e-163	582.0	91.20%	44.23%	Toll like receptor-1;OS=Mimachlamys;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN016191.1	sp|A0A0U5LCN0|A0A0U5LCN0_MIMNO	1.5e-164	585.5	91.20%	44.39%	Toll like receptor-1;OS=Mimachlamys;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN016193.1	sp|A0A0U5LCN0|A0A0U5LCN0_MIMNO	1.2e-161	575.9	91.06%	44.14%	Toll like receptor-1;OS=Mimachlamys;PE=2;SV=1	GO:0016021|	GO:0045087|GO:0007165|
GN016194.1	sp|K1PVD7|K1PVD7_CRAGI	8.6e-32	142.1	57.97%	82.28%	Cytochrome c oxidase subunit 5A, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005743|	GO:0004129|
GN016195.1	sp|J9Q5I1|J9Q5I1_OSTED	8.2e-42	174.9	89.36%	97.59%	Mitochondrial cytochrome C oxidase polypeptide Va;OS=Ostrea;PE=2;SV=1	GO:0005743|	GO:0004129|
GN015599.1	sp|K1P842|K1P842_CRAGI	3.1e-108	397.9	85.83%	49.88%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN016198.1	sp|K1PXR6|K1PXR6_CRAGI	1.4e-66	258.5	98.68%	59.82%	5-formyltetrahydrofolate cyclo-ligase;OS=Crassostrea;PE=3;SV=1	GO:0030272|GO:0005524|GO:0046872|
GN016199.1	sp|V4A2Z2|V4A2Z2_LOTGI	1.6e-101	375.9	61.12%	49.87%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN016200.1	sp|K1PFG3|K1PFG3_CRAGI	4.9e-222	776.2	100.00%	69.34%	McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0051082|	GO:0060271|GO:0006457|
GN016201.1	sp|K1PNB0|K1PNB0_CRAGI	6.1e-64	251.5	89.14%	31.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016202.1	sp|K1P9B8|K1P9B8_CRAGI	1.6e-16	91.3	51.22%	75.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016203.1	sp|C3Y2X9|C3Y2X9_BRAFL	1.1e-40	172.9	89.73%	32.91%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN016204.1	sp|K1P9B8|K1P9B8_CRAGI	7.0e-17	92.4	51.22%	77.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016206.1	sp|K1PNB5|K1PNB5_CRAGI	1.6e-271	941.4	98.45%	88.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016207.1	sp|A0A210QNT1|A0A210QNT1_MIZYE	7.4e-18	95.9	64.58%	45.65%	Tetratricopeptide repeat protein 9C;OS=Mizuhopecten;PE=4;SV=1
GN015600.1	sp|K1P842|K1P842_CRAGI	7.8e-106	389.8	89.89%	49.75%	Proton-coupled folate transporter;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN016208.1	sp|J9Q559|J9Q559_OSTED	1.8e-56	223.8	95.54%	100.00%	Eukaryotic translation initiation factor 3 subunit 12;OS=Ostrea;PE=2;SV=1	GO:0005852|	GO:0043022|GO:0003743|	GO:0006446|
GN016209.1	sp|K1RKB9|K1RKB9_CRAGI	7.5e-38	162.5	63.69%	77.36%	Multiple coagulation factor deficiency protein 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003676|
GN016210.1	sp|K1Q3S7|K1Q3S7_CRAGI	0.0e+00	1523.5	88.42%	78.09%	Cytosolic carboxypeptidase 1;OS=Crassostrea;PE=4;SV=1	GO:0004181|GO:0008270|
GN016211.1	sp|K1QIJ1|K1QIJ1_CRAGI	1.4e-34	153.7	15.12%	71.00%	Deleted in malignant brain tumors 1 protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005044|
GN016212.1	sp|K1R7E1|K1R7E1_CRAGI	1.4e-130	471.5	99.68%	73.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016213.1	sp|K1QK49|K1QK49_CRAGI	9.5e-10	69.7	18.75%	72.73%	Down syndrome cell adhesion molecule;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN016214.1	sp|K1QTX5|K1QTX5_CRAGI	1.9e-128	464.9	90.42%	68.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016215.1	sp|K1R0Y6|K1R0Y6_CRAGI	8.6e-77	293.1	100.00%	50.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016218.1	sp|K1R7E4|K1R7E4_CRAGI	7.2e-72	275.8	67.00%	91.73%	Tubulin polyglutamylase complex subunit 2;OS=Crassostrea;PE=4;SV=1	GO:0018095|
GN016219.1	sp|K1R0Y7|K1R0Y7_CRAGI	1.4e-149	535.0	90.70%	74.81%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN015602.1	sp|A0A2R2MJE1|A0A2R2MJE1_LINUN	3.4e-117	427.9	79.90%	44.05%	uncharacterized protein LOC112041353;OS=Lingula;PE=4;SV=1
GN016221.1	sp|K1PUJ3|K1PUJ3_CRAGI	2.7e-127	461.1	91.91%	53.30%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN016222.1	sp|K1R9H7|K1R9H7_CRAGI	2.7e-86	325.5	32.46%	67.87%	F-box/WD repeat-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN016223.1	sp|K1P8E6|K1P8E6_CRAGI	0.0e+00	1755.0	99.93%	69.79%	Kinesin-like protein KIF24;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN016224.1	sp|B1GVI7|B1GVI7_CRAGI	8.3e-63	245.4	99.37%	74.68%	G protein coupled receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005000|
GN016225.1	sp|K1QTY2|K1QTY2_CRAGI	1.3e-100	371.7	92.54%	69.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016226.1	sp|K1RCM3|K1RCM3_CRAGI	7.1e-30	136.0	62.89%	61.62%	Carbonic anhydrase 2;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|
GN015603.1	sp|K1QF07|K1QF07_CRAGI	2.5e-75	287.0	100.00%	82.39%	Neuroglobin;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN016227.1	sp|K1Q7L5|K1Q7L5_CRAGI	1.5e-55	221.9	69.46%	67.07%	Protein IMPACT;OS=Crassostrea;PE=4;SV=1
GN016228.1	sp|K1R7P1|K1R7P1_CRAGI	3.4e-38	163.7	74.71%	62.50%	15-hydroxyprostaglandin dehydrogenase [NAD+];OS=Crassostrea;PE=4;SV=1
GN016232.1	sp|K1PUT5|K1PUT5_CRAGI	2.2e-28	130.6	72.65%	65.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016233.1	sp|K1QD02|K1QD02_CRAGI	5.7e-178	629.4	99.32%	72.25%	tRNA modification GTPase GTPBP3, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0003924|	GO:0006400|
GN016234.1	sp|K1QEQ4|K1QEQ4_CRAGI	2.3e-26	126.7	20.63%	43.26%	Zinc finger and BTB domain-containing protein 24;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN016235.1	sp|K1PFP3|K1PFP3_CRAGI	2.4e-16	90.5	91.74%	51.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016236.1	sp|K1P486|K1P486_CRAGI	8.9e-118	429.9	97.97%	41.10%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN016237.1	sp|K1PUK3|K1PUK3_CRAGI	5.5e-131	473.4	100.00%	82.58%	Armadillo repeat-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN016238.1	sp|K1PEI7|K1PEI7_CRAGI	0.0e+00	1096.3	67.16%	76.90%	OTU domain-containing protein 7B;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0008270|
GN016239.1	sp|K1P8F1|K1P8F1_CRAGI	3.1e-189	667.2	99.28%	63.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN016240.1	sp|K1QSG0|K1QSG0_CRAGI	4.8e-125	453.0	98.97%	69.97%	Carbonic anhydrase 2;OS=Crassostrea;PE=4;SV=1	GO:0004089|GO:0008270|
GN018691.1	sp|K1Q6H8|K1Q6H8_CRAGI	3.1e-31	140.2	100.00%	54.69%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018722.1	sp|A0A194ALH2|A0A194ALH2_PINFU	1.4e-71	275.0	93.69%	61.35%	Uncharacterized protein;OS=Pinctada;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019055.1	sp|K1RMI7|K1RMI7_CRAGI	0.0e+00	1082.4	98.44%	79.22%	Ubiquitin carboxyl-terminal hydrolase 8;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0036459|	GO:0016579|GO:0006511|
GN019056.1	sp|K1R391|K1R391_CRAGI	0.0e+00	1092.8	100.00%	92.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019057.1	sp|K1RJ32|K1RJ32_CRAGI	1.1e-98	367.5	52.79%	37.22%	Putative ubiquitin thioesterase L96;OS=Crassostrea;PE=4;SV=1
GN019058.1	sp|A0A210QUY8|A0A210QUY8_MIZYE	1.7e-161	575.5	84.47%	49.38%	Cyclic nucleotide-binding domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1
GN018723.1	sp|A0A210R4A8|A0A210R4A8_MIZYE	9.3e-91	339.0	90.98%	66.80%	Tetraspan membrane protein of hair cell stereocilia-like;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN019059.1	sp|K1R7M3|K1R7M3_CRAGI	8.5e-43	178.3	99.07%	78.50%	Tumor suppressor candidate 2;OS=Crassostrea;PE=4;SV=1
GN019060.1	sp|K1PNK7|K1PNK7_CRAGI	9.5e-199	698.4	100.00%	81.86%	Nephrocystin-3;OS=Crassostrea;PE=4;SV=1
GN019061.1	sp|K1R604|K1R604_CRAGI	0.0e+00	1137.1	100.00%	80.56%	DCC-interacting protein 13-alpha;OS=Crassostrea;PE=4;SV=1
GN018724.1	sp|K1RRN9|K1RRN9_CRAGI	5.0e-58	230.3	73.87%	55.14%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN019063.1	sp|K1RH78|K1RH78_CRAGI	1.4e-74	287.3	27.52%	50.00%	Neurogenic locus Notch protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0004930|
GN018725.1	sp|K1S326|K1S326_CRAGI	3.5e-13	79.3	97.14%	62.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019066.1	sp|A0A210Q162|A0A210Q162_MIZYE	1.8e-105	388.7	83.40%	68.92%	U3 small nucleolar RNA-interacting protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0034511|	GO:0006364|
GN019067.1	sp|K1QKY2|K1QKY2_CRAGI	2.2e-62	244.2	97.38%	60.43%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN019068.1	sp|K1RWJ1|K1RWJ1_CRAGI	7.8e-18	96.7	82.69%	29.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019070.1	sp|K1PYT4|K1PYT4_CRAGI	2.0e-155	554.3	100.00%	90.50%	RIB43A-like with coiled-coils protein 2;OS=Crassostrea;PE=4;SV=1
GN019071.1	sp|K1Q630|K1Q630_CRAGI	0.0e+00	1381.7	100.00%	80.58%	Structural maintenance of chromosomes protein;OS=Crassostrea;PE=3;SV=1	GO:0008278|GO:0005634|	GO:0005524|GO:0003682|	GO:0006281|GO:0007064|
GN019072.1	sp|K1QE72|K1QE72_CRAGI	0.0e+00	1247.6	72.85%	94.37%	IQ and ubiquitin-like domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN019073.1	sp|K1QKQ4|K1QKQ4_CRAGI	7.4e-45	185.3	97.39%	80.18%	Malate dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN019074.1	sp|A0A1S3I6I2|A0A1S3I6I2_LINUN	8.8e-208	730.3	95.65%	33.09%	plexin-B;OS=Lingula;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0017154|GO:0004714|
GN019076.1	sp|K1QU96|K1QU96_CRAGI	0.0e+00	1201.0	96.70%	82.75%	Pre-rRNA-processing protein TSR1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0042254|
GN019077.1	sp|K1PDG2|K1PDG2_CRAGI	2.3e-58	231.5	87.54%	50.00%	3-hydroxyacyl-CoA dehydrogenase type-2;OS=Crassostrea;PE=4;SV=1
GN019079.1	sp|K1PR68|K1PR68_CRAGI	1.5e-103	382.5	98.71%	47.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019080.1	sp|K1PYP9|K1PYP9_CRAGI	9.6e-10	68.2	58.33%	72.92%	Homeobox expressed in ES cells 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN019081.1	sp|K1Q679|K1Q679_CRAGI	6.7e-41	172.6	91.67%	53.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019082.1	sp|K1QDB9|K1QDB9_CRAGI	4.6e-266	922.2	100.00%	98.32%	Transport protein Sec61 subunit alpha isoform 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015031|
GN019083.1	sp|A0A210PMW5|A0A210PMW5_MIZYE	9.6e-237	824.7	100.00%	92.98%	RuvB-like helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0031011|GO:0035267|GO:0097255|	GO:0005524|GO:0043141|
GN019084.1	sp|K1QZ24|K1QZ24_CRAGI	0.0e+00	1232.2	100.00%	84.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019085.1	sp|K1QRM0|K1QRM0_CRAGI	1.1e-196	691.4	95.23%	91.01%	Major facilitator superfamily domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015098|
GN019086.1	sp|K1RPP1|K1RPP1_CRAGI	0.0e+00	1134.0	97.06%	63.83%	Synaptophysin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0008021|
GN018727.1	sp|K1QN84|K1QN84_CRAGI	2.6e-115	420.6	89.72%	77.87%	Monoglyceride lipase;OS=Crassostrea;PE=4;SV=1
GN019088.1	sp|K1QWK9|K1QWK9_CRAGI	5.0e-96	357.1	53.10%	73.24%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN019089.1	sp|A0A210Q949|A0A210Q949_MIZYE	8.4e-77	292.7	77.74%	60.66%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019090.1	sp|A0A3L5TU00|A0A3L5TU00_MYTGA	1.7e-97	362.1	93.36%	57.01%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN019091.1	sp|K1R2Y2|K1R2Y2_CRAGI	7.2e-118	429.1	98.23%	62.40%	Deoxyribonuclease-1;OS=Crassostrea;PE=4;SV=1	GO:0004536|	GO:0006308|
GN018728.1	sp|A0A210Q993|A0A210Q993_MIZYE	1.9e-109	401.4	99.09%	64.62%	Phenylserine dehydratase;OS=Mizuhopecten;PE=4;SV=1	GO:0030170|	GO:0006520|
GN019092.1	sp|K1QN76|K1QN76_CRAGI	6.6e-156	556.2	91.37%	62.90%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN019094.1	sp|K1QLU9|K1QLU9_CRAGI	1.5e-82	312.4	57.31%	65.70%	Tetratricopeptide repeat protein 38;OS=Crassostrea;PE=4;SV=1
GN019096.1	sp|K1QKL2|K1QKL2_CRAGI	2.3e-274	950.3	84.03%	76.84%	Autophagy-related protein 7;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0008641|	GO:0006914|
GN019097.1	sp|K1QTA7|K1QTA7_CRAGI	3.1e-11	74.7	34.25%	46.32%	Transposable element Tcb2 transposase;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019098.1	sp|K1PE97|K1PE97_CRAGI	9.1e-65	254.2	54.26%	56.19%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN019099.1	sp|K1P874|K1P874_CRAGI	0.0e+00	1096.3	79.76%	86.76%	F-box/LRR-repeat protein 13;OS=Crassostrea;PE=4;SV=1
GN019100.1	sp|K1QXZ9|K1QXZ9_CRAGI	2.8e-196	690.3	84.51%	90.79%	DNA-binding protein P3A2;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|	GO:0006357|
GN019101.1	sp|K1RCE7|K1RCE7_CRAGI	2.5e-89	334.0	100.00%	61.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019102.1	sp|K1Q596|K1Q596_CRAGI	7.3e-105	385.6	99.12%	82.51%	Phosphoserine phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0004647|	GO:0006564|
GN019103.1	sp|K1QCT3|K1QCT3_CRAGI	1.1e-89	334.7	100.00%	91.72%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|	GO:0006457|
GN019104.1	sp|K1P878|K1P878_CRAGI	3.1e-18	97.8	28.38%	73.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019105.1	sp|K1PU96|K1PU96_CRAGI	1.2e-49	201.4	88.57%	72.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019106.1	sp|A0A210QAR3|A0A210QAR3_MIZYE	1.9e-133	481.5	86.07%	58.81%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019108.1	sp|K1PX91|K1PX91_CRAGI	5.3e-46	189.5	98.05%	57.33%	Cytochrome P450 2D4;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN019110.1	sp|A0A2B4RK55|A0A2B4RK55_STYPI	3.5e-86	324.7	89.96%	40.59%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN019113.1	sp|K1Q853|K1Q853_CRAGI	0.0e+00	1245.7	99.46%	84.92%	G-protein coupled receptor 64;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN019114.1	sp|K1QG86|K1QG86_CRAGI	5.2e-128	462.6	100.00%	87.95%	JmjC domain-containing protein C2orf60-like protein;OS=Crassostrea;PE=2;SV=1	GO:0016706|GO:0000049|	GO:0031591|
GN019115.1	sp|K1PIT9|K1PIT9_CRAGI	1.5e-246	859.8	69.83%	32.76%	Lupus brain antigen 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN019116.1	sp|K1QWK9|K1QWK9_CRAGI	1.7e-83	315.1	69.90%	63.89%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN019117.1	sp|A0A210QSF3|A0A210QSF3_MIZYE	1.6e-24	119.0	98.63%	29.02%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019119.1	sp|K1RML1|K1RML1_CRAGI	1.5e-197	694.1	100.00%	97.67%	Cell cycle-related kinase;OS=Crassostrea;PE=3;SV=1	GO:0070985|	GO:0005524|GO:0008353|
GN019121.1	sp|K1R3B1|K1R3B1_CRAGI	0.0e+00	1899.8	100.00%	84.32%	Ubiquitin carboxyl-terminal hydrolase 48;OS=Crassostrea;PE=3;SV=1	GO:0004843|	GO:0016579|GO:0006511|
GN019122.1	sp|K1QFG9|K1QFG9_CRAGI	4.4e-50	203.0	76.51%	85.84%	Translocon-associated protein subunit delta;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0016021|
GN019123.1	sp|K1PPD2|K1PPD2_CRAGI	2.7e-220	770.8	100.00%	86.94%	NACHT, LRR and PYD domains-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN019124.1	sp|K1Q6I0|K1Q6I0_CRAGI	9.3e-53	212.6	73.28%	59.34%	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019125.1	sp|K1QEK3|K1QEK3_CRAGI	4.8e-78	296.6	95.85%	70.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019126.1	sp|K1QEK3|K1QEK3_CRAGI	7.8e-76	289.3	98.37%	68.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019127.1	sp|A0A1J0I8W7|A0A1J0I8W7_CRAHO	9.5e-200	701.4	100.00%	95.75%	Mitogen-activated protein kinase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004707|
GN019128.1	sp|K1QJ83|K1QJ83_CRAGI	8.5e-171	605.5	82.12%	83.43%	Glycine receptor subunit alpha-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005230|GO:0004888|
GN018731.1	sp|K1QXW9|K1QXW9_CRAGI	8.8e-114	415.2	100.00%	86.52%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN019129.1	sp|K1PRV2|K1PRV2_CRAGI	0.0e+00	1214.1	93.50%	85.94%	Threonine synthase-like 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN019131.1	sp|A0A210QSC3|A0A210QSC3_MIZYE	5.8e-34	149.4	81.63%	53.28%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019132.1	sp|K1Q7T7|K1Q7T7_CRAGI	1.9e-61	241.9	84.38%	47.45%	BTB and MATH domain-containing protein 42;OS=Crassostrea;PE=4;SV=1
GN019133.1	sp|K1RA44|K1RA44_CRAGI	1.0e-106	392.1	100.00%	54.77%	Phosducin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN019134.1	sp|K1QZU5|K1QZU5_CRAGI	0.0e+00	1140.2	97.90%	60.07%	Nuclear protein MDM1;OS=Crassostrea;PE=4;SV=1	GO:0008017|	GO:0046600|
GN019135.1	sp|K1RLY5|K1RLY5_CRAGI	1.0e-125	454.9	93.22%	97.72%	Dual serine/threonine and tyrosine protein kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019136.1	sp|K1Q763|K1Q763_CRAGI	2.5e-48	197.6	98.98%	48.76%	Ficolin-1;OS=Crassostrea;PE=4;SV=1
GN019137.1	sp|K1PUN1|K1PUN1_CRAGI	2.4e-72	276.9	100.00%	86.58%	Thioredoxin-like protein 4B;OS=Crassostrea;PE=4;SV=1	GO:0046540|	GO:0000398|
GN019138.1	sp|K1PFL2|K1PFL2_CRAGI	4.6e-51	207.2	84.93%	46.96%	Mitochondrial ribonuclease P protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0008033|
GN019139.1	sp|K1R9R8|K1R9R8_CRAGI	9.1e-184	648.3	98.53%	90.99%	Transmembrane protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019141.1	sp|K1Q3W0|K1Q3W0_CRAGI	7.9e-11	72.8	36.47%	58.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019142.1	sp|K1RCU4|K1RCU4_CRAGI	3.6e-113	413.3	99.20%	78.95%	Mitochondrial inner membrane protease ATP23;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004222|
GN018733.1	sp|K1Q1K3|K1Q1K3_CRAGI	5.7e-11	72.8	85.37%	39.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019143.1	sp|K1PLD8|K1PLD8_CRAGI	8.2e-200	702.6	63.07%	77.56%	F-box/WD repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN018734.1	sp|K1Q8P2|K1Q8P2_CRAGI	3.1e-53	215.7	20.06%	73.97%	Round spermatid basic protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN019144.1	sp|K1PLD8|K1PLD8_CRAGI	1.1e-183	648.3	98.81%	74.88%	F-box/WD repeat-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN019145.1	sp|A0A0P5I8N8|A0A0P5I8N8_9CRUS	3.3e-222	776.9	84.02%	75.46%	ATP-binding cassette sub-family F member;OS=Daphnia;PE=4;SV=1	GO:0005524|GO:0016887|
GN019146.1	sp|K1Q7P7|K1Q7P7_CRAGI	2.6e-32	143.7	63.11%	86.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019147.1	sp|A0A210PZI4|A0A210PZI4_MIZYE	2.7e-225	787.3	80.11%	75.51%	ATP-binding cassette sub-family F member 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0016887|
GN019148.1	sp|K1QTE8|K1QTE8_CRAGI	2.0e-258	897.5	100.00%	65.62%	Nuclear respiratory factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019149.1	sp|K1Q7Q5|K1Q7Q5_CRAGI	4.7e-269	932.9	99.77%	63.64%	Nuclear respiratory factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019152.1	sp|K1PHY0|K1PHY0_CRAGI	2.2e-274	950.3	99.85%	74.92%	G/T mismatch-specific thymine DNA glycosylase;OS=Crassostrea;PE=4;SV=1	GO:0019104|	GO:0006281|
GN019153.1	sp|K1R7C1|K1R7C1_CRAGI	1.4e-96	357.8	100.00%	89.30%	Neurocalcin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019154.1	sp|K1QR82|K1QR82_CRAGI	1.4e-295	1020.8	93.68%	74.96%	Acyl-coenzyme A oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005777|	GO:0003997|GO:0071949|	GO:0006635|
GN019156.1	sp|K1QR87|K1QR87_CRAGI	2.3e-96	357.5	98.76%	77.22%	Solute carrier family 35 member E3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019157.1	sp|K1R0N0|K1R0N0_CRAGI	5.4e-65	253.1	59.81%	95.28%	Zinc finger CCHC-type and RNA-binding motif-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|GO:0008270|
GN019158.1	sp|K1Q0J3|K1Q0J3_CRAGI	0.0e+00	1610.1	93.70%	80.86%	SLIT-ROBO Rho GTPase-activating protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005096|	GO:0007165|
GN019159.1	sp|K1Q7Q5|K1Q7Q5_CRAGI	4.2e-278	963.0	99.77%	64.65%	Nuclear respiratory factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019160.1	sp|K1QTE8|K1QTE8_CRAGI	1.4e-26	124.4	74.04%	72.37%	Nuclear respiratory factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019161.1	sp|K1QTE8|K1QTE8_CRAGI	2.9e-210	737.3	91.40%	68.53%	Nuclear respiratory factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019162.1	sp|K1QTE8|K1QTE8_CRAGI	9.4e-209	732.3	91.10%	68.59%	Nuclear respiratory factor 1;OS=Crassostrea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019164.1	sp|K1PLF4|K1PLF4_CRAGI	6.2e-180	636.3	61.36%	83.10%	Kelch-like protein 10;OS=Crassostrea;PE=4;SV=1
GN019165.1	sp|K1Q7R2|K1Q7R2_CRAGI	1.9e-55	221.9	43.67%	86.26%	Leucine-rich repeat and guanylate kinase domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN019166.1	sp|K1Q7R2|K1Q7R2_CRAGI	1.3e-41	174.9	99.35%	85.06%	Leucine-rich repeat and guanylate kinase domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN019168.1	sp|A0A210QSE1|A0A210QSE1_MIZYE	2.0e-204	717.6	80.18%	83.33%	Cyclin-dependent kinase 16;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004674|
GN018737.1	sp|K1QSK4|K1QSK4_CRAGI	1.1e-72	278.1	92.05%	89.86%	Calcium-binding mitochondrial carrier protein Aralar1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0003824|GO:0030170|GO:0022857|	GO:0009058|
GN019169.1	sp|V4CBN7|V4CBN7_LOTGI	4.2e-141	507.3	62.06%	69.63%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN019170.1	sp|K1Q101|K1Q101_CRAGI	5.2e-64	249.2	100.00%	87.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019171.1	sp|K1QW14|K1QW14_CRAGI	1.9e-155	554.7	94.46%	58.82%	Interferon-induced protein 44;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN018738.1	sp|A0A210PHA4|A0A210PHA4_MIZYE	4.5e-147	526.6	97.40%	65.68%	Histone acetyltransferase type B catalytic subunit;OS=Mizuhopecten;PE=3;SV=1	GO:0000781|GO:0005634|	GO:0004402|GO:0042393|	GO:0006348|
GN019173.1	sp|K1RB26|K1RB26_CRAGI	6.7e-143	513.1	99.60%	54.25%	Interferon-induced protein 44;OS=Crassostrea;PE=4;SV=1
GN019174.1	sp|K1Q3Y8|K1Q3Y8_CRAGI	4.0e-56	223.4	94.62%	60.57%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019175.1	sp|K1Q3Y8|K1Q3Y8_CRAGI	8.1e-45	185.7	92.68%	58.28%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019176.1	sp|K1PF35|K1PF35_CRAGI	9.3e-190	668.3	86.56%	96.88%	Protein Wnt;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0005102|	GO:0007275|GO:0016055|
GN019177.1	sp|K1R5Z7|K1R5Z7_CRAGI	1.0e-201	708.4	100.00%	73.28%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019178.1	sp|K1QKH0|K1QKH0_CRAGI	3.3e-26	123.2	88.07%	61.46%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN019179.1	sp|K1QKH0|K1QKH0_CRAGI	3.3e-26	123.2	88.07%	61.46%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN019180.1	sp|K1PNG2|K1PNG2_CRAGI	3.6e-45	187.6	95.37%	40.07%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1
GN019181.1	sp|A0A3L5TRT1|A0A3L5TRT1_MYTGA	5.1e-39	167.5	69.59%	38.87%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN019182.1	sp|K1QUK0|K1QUK0_CRAGI	2.8e-236	823.2	96.46%	86.80%	NEDD8-activating enzyme E1 catalytic subunit;OS=Crassostrea;PE=4;SV=1	GO:0019781|	GO:0045116|
GN019183.1	sp|K1Q8N8|K1Q8N8_CRAGI	5.7e-76	289.3	100.00%	88.20%	PRA1 family protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN019184.1	sp|K1Q405|K1Q405_CRAGI	1.4e-80	305.8	99.77%	38.25%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN019187.1	sp|K1PFU6|K1PFU6_CRAGI	2.2e-44	184.5	86.43%	57.47%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN019188.1	sp|K1QW46|K1QW46_CRAGI	2.7e-68	265.0	95.22%	37.18%	Serine/threonine-protein kinase Nek4;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN019189.1	sp|K1Q329|K1Q329_CRAGI	1.5e-192	677.6	99.72%	92.20%	Pyruvate dehydrogenase E1 component subunit beta, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018741.1	sp|K1QF83|K1QF83_CRAGI	2.7e-154	550.4	100.00%	71.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019190.1	sp|K1QYT5|K1QYT5_CRAGI	4.0e-188	662.9	93.42%	89.83%	Phosphate carrier protein, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN019191.1	sp|K1QUL5|K1QUL5_CRAGI	8.2e-183	646.7	80.57%	56.54%	ATR-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0000077|
GN019192.1	sp|K1PU95|K1PU95_CRAGI	3.0e-116	424.1	71.87%	84.82%	UDP-galactose translocator;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|	GO:0015165|
GN019193.1	sp|K1P7Y3|K1P7Y3_CRAGI	2.8e-156	557.0	95.38%	87.23%	UDP-galactose translocator;OS=Crassostrea;PE=4;SV=1	GO:0000139|GO:0016021|	GO:0015165|
GN019194.1	sp|K1PLV6|K1PLV6_CRAGI	6.1e-146	524.6	20.27%	93.07%	F-actin-capping protein subunit alpha;OS=Crassostrea;PE=3;SV=1	GO:0008290|	GO:0003779|	GO:0051016|
GN019195.1	sp|A0A210PDZ7|A0A210PDZ7_MIZYE	3.8e-60	237.3	92.19%	47.62%	Nicolin-1;OS=Mizuhopecten;PE=4;SV=1
GN019196.1	sp|K1PE13|K1PE13_CRAGI	0.0e+00	1766.5	91.16%	82.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006914|
GN019197.1	sp|K1S5S4|K1S5S4_CRAGI	0.0e+00	2768.0	90.41%	67.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019199.1	sp|K1QAY3|K1QAY3_CRAGI	1.1e-85	322.0	73.71%	78.26%	Dipeptidyl-peptidase 1;OS=Crassostrea;PE=3;SV=1	GO:0008234|
GN019200.1	sp|K1QJG4|K1QJG4_CRAGI	3.2e-149	533.5	99.39%	88.69%	Pleckstrin;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN019201.1	sp|K1QYY7|K1QYY7_CRAGI	2.3e-69	268.1	61.24%	69.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019202.1	sp|K1QHY1|K1QHY1_CRAGI	5.1e-238	829.3	98.99%	65.88%	Eosinophil peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0020037|GO:0004601|	GO:0006979|
GN019203.1	sp|K1QA69|K1QA69_CRAGI	0.0e+00	1095.9	100.00%	55.99%	Interleukin-1 receptor-associated kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|	GO:0007165|
GN019204.1	sp|K1Q330|K1Q330_CRAGI	1.4e-228	797.7	100.00%	81.49%	Dihydrolipoyl dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0005623|GO:0016021|	GO:0004148|GO:0050660|GO:0004930|	GO:0045454|GO:0007166|
GN019205.1	sp|A0A210PF36|A0A210PF36_MIZYE	2.5e-130	471.1	88.65%	59.89%	Ankyrin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN019206.1	sp|A0A210PZZ3|A0A210PZZ3_MIZYE	0.0e+00	1569.7	98.11%	45.97%	Plexin-B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0017154|
GN019207.1	sp|K1QVV5|K1QVV5_CRAGI	6.1e-131	472.6	95.38%	86.11%	Periostin;OS=Crassostrea;PE=4;SV=1
GN018742.1	sp|K1PLB3|K1PLB3_CRAGI	0.0e+00	1252.7	100.00%	82.21%	Muskelin;OS=Crassostrea;PE=4;SV=1
GN019208.1	sp|K1QS92|K1QS92_CRAGI	3.4e-122	443.4	100.00%	84.71%	Lipoma HMGIC fusion partner-like 3 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019209.1	sp|K1R639|K1R639_CRAGI	3.5e-104	383.6	100.00%	81.75%	Polyglutamine-binding protein 1;OS=Crassostrea;PE=4;SV=1
GN019210.1	sp|K1QCR6|K1QCR6_CRAGI	4.3e-95	352.8	100.00%	95.05%	Ubiquitin-conjugating enzyme E2 H;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0016740|
GN019211.1	sp|K1QS76|K1QS76_CRAGI	0.0e+00	1088.2	31.32%	92.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0017112|
GN019212.1	sp|K1Q577|K1Q577_CRAGI	2.1e-123	447.6	88.14%	84.17%	S-adenosylmethionine mitochondrial carrier protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN019214.1	sp|K1QCR1|K1QCR1_CRAGI	0.0e+00	1203.0	100.00%	68.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019215.1	sp|K1PSK3|K1PSK3_CRAGI	1.0e-66	258.5	100.00%	75.90%	Globin;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0046872|GO:0019825|GO:0005344|
GN019219.1	sp|K1RE19|K1RE19_CRAGI	1.9e-127	461.5	98.52%	59.62%	V-type proton ATPase subunit S1;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0033180|	GO:0046933|GO:0046961|	GO:0015991|
GN019220.1	sp|K1S3G6|K1S3G6_CRAGI	1.2e-174	619.0	86.35%	56.62%	Alpha-latrocrustotoxin;OS=Crassostrea;PE=4;SV=1
GN019223.1	sp|K1PBT2|K1PBT2_CRAGI	2.0e-41	174.9	100.00%	74.78%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019224.1	sp|K1QI01|K1QI01_CRAGI	7.0e-46	189.1	65.82%	88.35%	Uncharacterized protein yxiE;OS=Crassostrea;PE=4;SV=1
GN019225.1	sp|K1QYA0|K1QYA0_CRAGI	5.9e-17	92.8	61.48%	55.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005779|	GO:0044877|	GO:0045046|
GN019226.1	sp|K1R849|K1R849_CRAGI	2.8e-309	1066.2	100.00%	93.22%	Kinesin-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN019228.1	sp|K1PQG3|K1PQG3_CRAGI	2.5e-95	354.8	92.89%	54.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019229.1	sp|K1RDK2|K1RDK2_CRAGI	9.7e-23	112.8	72.69%	42.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019230.1	sp|K1R6R0|K1R6R0_CRAGI	7.3e-16	89.4	36.42%	70.37%	Multiple epidermal growth factor-like domains 11;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019231.1	sp|K1R9K3|K1R9K3_CRAGI	9.4e-233	812.4	99.66%	53.67%	Vezatin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0017022|	GO:0098609|
GN019232.1	sp|K1QY94|K1QY94_CRAGI	1.1e-39	168.7	92.90%	55.06%	Heavy metal-binding protein HIP;OS=Crassostrea;PE=4;SV=1
GN019233.1	sp|K1Q4I7|K1Q4I7_CRAGI	8.8e-169	598.6	98.89%	77.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019234.1	sp|K1Q2P6|K1Q2P6_CRAGI	6.3e-62	243.4	66.88%	56.81%	Caspase-7;OS=Crassostrea;PE=4;SV=1	GO:0004197|
GN019235.1	sp|K1R9K3|K1R9K3_CRAGI	4.7e-244	849.7	99.61%	60.74%	Vezatin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0017022|	GO:0098609|
GN019236.1	sp|K1QPA8|K1QPA8_CRAGI	4.7e-252	876.3	98.97%	81.19%	Coiled-coil domain-containing protein 41;OS=Crassostrea;PE=4;SV=1	GO:0005814|	GO:0060271|GO:0048278|
GN019237.1	sp|K1QEF6|K1QEF6_CRAGI	7.3e-166	589.3	89.27%	78.56%	E3 ubiquitin-protein ligase Hakai;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|
GN019239.1	sp|K1Q3I4|K1Q3I4_CRAGI	0.0e+00	2971.4	89.15%	66.20%	Leucine-rich repeat serine/threonine-protein kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0005525|GO:0004672|
GN019240.1	sp|K1S2C3|K1S2C3_CRAGI	2.6e-182	644.0	83.99%	75.71%	Putative carboxypeptidase PM20D1;OS=Crassostrea;PE=4;SV=1	GO:0004180|
GN019241.1	sp|A0A210PYH8|A0A210PYH8_MIZYE	5.0e-132	476.5	98.61%	67.32%	Transmembrane protein 115;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0006890|
GN019242.1	sp|A0A210Q931|A0A210Q931_MIZYE	7.8e-169	600.5	97.94%	34.48%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019243.1	sp|K1QGC5|K1QGC5_CRAGI	2.5e-116	424.1	80.39%	87.76%	Methylglutaconyl-CoA hydratase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003824|
GN019244.1	sp|K1Q850|K1Q850_CRAGI	1.2e-146	525.0	100.00%	75.98%	Whirlin;OS=Crassostrea;PE=4;SV=1
GN019245.1	sp|K1RXH3|K1RXH3_CRAGI	3.5e-77	293.1	100.00%	89.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019246.1	sp|K1QST0|K1QST0_CRAGI	2.2e-74	283.9	97.62%	80.37%	Stress response protein nhaX;OS=Crassostrea;PE=4;SV=1
GN019247.1	sp|K1PPF3|K1PPF3_CRAGI	1.6e-215	754.6	87.65%	71.90%	JmjC domain-containing protein 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019248.1	sp|K1R306|K1R306_CRAGI	3.3e-43	181.0	62.27%	59.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019249.1	sp|K1PZN4|K1PZN4_CRAGI	1.6e-30	139.0	92.90%	29.80%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN018745.1	sp|K1RB95|K1RB95_CRAGI	3.9e-73	280.0	100.00%	65.00%	S-crystallin SL11;OS=Crassostrea;PE=3;SV=1
GN019252.1	sp|K1Q3W0|K1Q3W0_CRAGI	7.7e-11	73.9	19.57%	52.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019253.1	sp|K1QKH0|K1QKH0_CRAGI	2.8e-51	207.6	82.61%	55.26%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN018746.1	sp|K1R107|K1R107_CRAGI	1.7e-32	144.1	90.38%	73.12%	S-crystallin SL11;OS=Crassostrea;PE=3;SV=1
GN019254.1	sp|A0A3M6UAZ4|A0A3M6UAZ4_9CNID	5.3e-17	93.6	44.02%	47.42%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN018747.1	sp|K1RB95|K1RB95_CRAGI	4.9e-68	263.1	100.00%	62.00%	S-crystallin SL11;OS=Crassostrea;PE=3;SV=1
GN019255.1	sp|K1RHH9|K1RHH9_CRAGI	3.5e-164	583.6	96.94%	84.29%	Transcription cofactor vestigial-like protein 4;OS=Crassostrea;PE=4;SV=1	GO:0006355|
GN019256.1	sp|K1QVS6|K1QVS6_CRAGI	2.7e-213	747.3	88.94%	64.90%	Single-strand selective monofunctional uracil DNA glycosylase;OS=Crassostrea;PE=4;SV=1	GO:0017065|	GO:0006284|
GN019257.1	sp|K1R5I9|K1R5I9_CRAGI	6.8e-126	455.7	97.74%	79.07%	Tafazzin family protein;OS=Crassostrea;PE=3;SV=1	GO:0016746|	GO:0006644|
GN019258.1	sp|K1PUT5|K1PUT5_CRAGI	3.3e-29	133.7	56.67%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019259.1	sp|K1RBD3|K1RBD3_CRAGI	2.0e-101	374.4	83.76%	82.74%	Melanoma-associated antigen G1;OS=Crassostrea;PE=4;SV=1
GN019260.1	sp|A0A0N4UVB7|A0A0N4UVB7_ENTVE	2.5e-27	128.6	87.93%	28.34%	Uncharacterized protein;OS=Enterobius;PE=4;SV=1	GO:0016021|
GN019261.1	sp|A0A210PFS7|A0A210PFS7_MIZYE	0.0e+00	1368.6	99.08%	57.43%	E3 ubiquitin-protein ligase;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|GO:0046872|GO:0004647|	GO:0006564|
GN019262.1	sp|K1RBC9|K1RBC9_CRAGI	0.0e+00	1124.4	100.00%	81.29%	Transketolase-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN019263.1	sp|K1R5H8|K1R5H8_CRAGI	3.2e-40	169.9	92.98%	78.10%	UXT-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016272|	GO:0003714|GO:0051082|	GO:0000122|GO:0006457|
GN019264.1	sp|A0A088B1V1|A0A088B1V1_9BIVA	3.3e-50	204.9	56.01%	44.35%	Caspase-3;OS=Crassostrea;PE=2;SV=1	GO:0097200|
GN018748.1	sp|A0A2T7NTG1|A0A2T7NTG1_POMCA	6.5e-127	459.9	93.33%	59.61%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN018749.1	sp|Q8T6A4|Q8T6A4_APLCA	1.1e-84	318.2	100.00%	89.22%	Tubulin alpha chain;OS=Aplysia;PE=2;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0007017|
GN018750.1	sp|K1QD54|K1QD54_CRAGI	0.0e+00	1168.3	100.00%	87.87%	Nuclear receptor subfamily 2 group C member 2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN019265.1	sp|K1QY12|K1QY12_CRAGI	0.0e+00	1271.9	100.00%	93.31%	Dynamin-1-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0003924|	GO:0000266|GO:0016559|
GN019266.1	sp|K1QRK9|K1QRK9_CRAGI	2.1e-131	474.2	83.82%	92.64%	Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016874|	GO:0006099|
GN018751.1	sp|K1RL30|K1RL30_CRAGI	0.0e+00	1315.4	100.00%	76.30%	Hepatocyte growth factor receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|GO:0017154|
GN019267.1	sp|K1QPN0|K1QPN0_CRAGI	1.1e-271	941.0	100.00%	91.54%	Solute carrier family 41 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008324|
GN019268.1	sp|K1QYZ4|K1QYZ4_CRAGI	6.8e-37	159.5	87.71%	68.99%	Uncharacterized protein C12orf45-like protein;OS=Crassostrea;PE=4;SV=1
GN019269.1	sp|K1R5T6|K1R5T6_CRAGI	0.0e+00	1207.2	97.78%	77.31%	Kelch-like protein 9;OS=Crassostrea;PE=4;SV=1
GN019270.1	sp|K1RJA9|K1RJA9_CRAGI	6.1e-134	482.6	88.75%	82.18%	PI-PLC X domain-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008081|	GO:0006629|
GN018752.1	sp|K1Q5Z1|K1Q5Z1_CRAGI	6.4e-74	282.7	92.63%	61.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019272.1	sp|K1PX70|K1PX70_CRAGI	8.3e-122	443.0	98.97%	50.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN019273.1	sp|K1Q3Y8|K1Q3Y8_CRAGI	7.0e-130	469.2	97.76%	74.43%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019274.1	sp|K1QQJ6|K1QQJ6_CRAGI	1.0e-09	71.2	14.87%	35.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019275.1	sp|K1RS14|K1RS14_CRAGI	2.6e-79	300.8	72.58%	69.83%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019276.1	sp|K1QEC5|K1QEC5_CRAGI	6.2e-83	312.8	89.22%	65.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019277.1	sp|K1R0D4|K1R0D4_CRAGI	1.4e-77	294.3	100.00%	83.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019278.1	sp|K1RA16|K1RA16_CRAGI	9.4e-172	608.6	97.50%	75.38%	Proton myo-inositol cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN019279.1	sp|K1Q902|K1Q902_CRAGI	1.2e-239	834.3	100.00%	87.04%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN019280.1	sp|K1QA93|K1QA93_CRAGI	1.6e-58	231.9	100.00%	63.81%	DnaJ-like protein subfamily B member 9;OS=Crassostrea;PE=4;SV=1
GN019281.1	sp|K1QPA3|K1QPA3_CRAGI	3.9e-42	177.6	51.03%	58.67%	Stress response protein nhaX;OS=Crassostrea;PE=4;SV=1
GN019282.1	sp|K1Q2N6|K1Q2N6_CRAGI	7.5e-37	159.8	90.31%	53.53%	Caspase-2;OS=Crassostrea;PE=4;SV=1	GO:0070513|GO:0002020|	GO:0042981|
GN019283.1	sp|A0A2G8K3T4|A0A2G8K3T4_STIJA	1.4e-86	326.2	69.58%	42.11%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0008270|
GN019284.1	sp|K1QUY2|K1QUY2_CRAGI	3.4e-103	380.2	82.40%	80.98%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN019285.1	sp|K1PLH9|K1PLH9_CRAGI	1.7e-44	185.3	80.08%	39.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019286.1	sp|K1R315|K1R315_CRAGI	3.8e-108	396.4	98.04%	92.96%	Calcium-independent phospholipase A2-gamma;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0016042|
GN019287.1	sp|K1PV61|K1PV61_CRAGI	6.7e-181	639.0	100.00%	83.50%	Inhibitor of growth protein;OS=Crassostrea;PE=3;SV=1	GO:0035267|GO:0000812|	GO:0046872|	GO:0006325|
GN019288.1	sp|K1QYX6|K1QYX6_CRAGI	2.5e-184	650.6	99.78%	73.45%	Uncharacterized protein C20orf54-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005887|	GO:0032217|
GN019289.1	sp|K1Q584|K1Q584_CRAGI	1.7e-152	545.8	90.57%	40.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019290.1	sp|K1Q584|K1Q584_CRAGI	6.7e-148	530.8	77.34%	39.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019291.1	sp|A0A210Q039|A0A210Q039_MIZYE	8.7e-149	533.1	89.75%	44.07%	Pseudouridylate synthase 7-like;OS=Mizuhopecten;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN019292.1	sp|K1QLK6|K1QLK6_CRAGI	0.0e+00	1230.7	99.83%	70.87%	E3 ubiquitin-protein ligase HUWE1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0004842|GO:0008270|
GN019293.1	sp|K1R7V5|K1R7V5_CRAGI	9.0e-149	531.9	93.75%	85.95%	Putative imidazolonepropionase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0016812|	GO:0019556|
GN019294.1	sp|K1R9N7|K1R9N7_CRAGI	4.7e-287	993.0	99.91%	74.39%	WD repeat-containing protein 51A;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN018697.1	sp|K1Q7N1|K1Q7N1_CRAGI	6.3e-17	93.2	43.68%	51.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018753.1	sp|K1RBU9|K1RBU9_CRAGI	2.2e-247	860.1	99.79%	91.48%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN019295.1	sp|A0A210PUW2|A0A210PUW2_MIZYE	4.2e-41	173.7	83.80%	47.87%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019296.1	sp|A0A210Q4D3|A0A210Q4D3_MIZYE	0.0e+00	1216.1	92.37%	49.46%	Tyrosine-protein phosphatase 99A;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004725|
GN019297.1	sp|K1R1B5|K1R1B5_CRAGI	9.5e-164	582.4	97.71%	78.08%	WD40 repeat-containing protein SMU1;OS=Crassostrea;PE=4;SV=1
GN019298.1	sp|K1R7W1|K1R7W1_CRAGI	7.1e-50	202.2	97.86%	69.85%	N-acetyltransferase ats1;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN019299.1	sp|K1QV78|K1QV78_CRAGI	1.9e-197	694.1	100.00%	75.61%	Complement C1q tumor necrosis factor-related protein 4;OS=Crassostrea;PE=4;SV=1
GN018754.1	sp|K1RBU9|K1RBU9_CRAGI	2.2e-212	743.8	99.79%	81.50%	Non-specific serine/threonine protein kinase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN019300.1	sp|K1QA94|K1QA94_CRAGI	7.9e-98	362.5	98.51%	66.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019301.1	sp|K1QL69|K1QL69_CRAGI	4.4e-81	308.1	26.39%	85.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019302.1	sp|K1PF64|K1PF64_CRAGI	9.4e-238	828.2	100.00%	87.17%	Rabenosyn-5;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003676|
GN019303.1	sp|K1Q9E5|K1Q9E5_CRAGI	2.2e-39	168.3	75.82%	56.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019304.1	sp|K1S3C0|K1S3C0_CRAGI	1.3e-09	68.6	53.69%	44.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019307.1	sp|K1QSV3|K1QSV3_CRAGI	1.7e-146	524.2	100.00%	89.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019308.1	sp|K1Q738|K1Q738_CRAGI	0.0e+00	1838.5	97.31%	75.08%	Scm-like with four MBT domains protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006355|
GN019309.1	sp|K1QSU7|K1QSU7_CRAGI	7.5e-128	462.6	99.72%	88.30%	DnaJ-like protein subfamily C member 2;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN018755.1	sp|K1QW70|K1QW70_CRAGI	7.3e-256	889.0	96.67%	87.50%	Bicaudal D-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008093|GO:0070840|
GN019310.1	sp|K1PYW0|K1PYW0_CRAGI	1.2e-234	818.9	72.05%	65.72%	TBC1 domain family member 30;OS=Crassostrea;PE=4;SV=1
GN019311.1	sp|K1R2S5|K1R2S5_CRAGI	1.0e-235	821.6	78.26%	87.53%	PX domain-containing protein kinase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0005524|GO:0035091|GO:0004672|
GN019312.1	sp|K1QH18|K1QH18_CRAGI	1.7e-266	923.7	100.00%	89.22%	Vacuolar fusion protein MON1-like protein A;OS=Crassostrea;PE=4;SV=1
GN019313.1	sp|K1Q2E5|K1Q2E5_CRAGI	1.9e-18	96.7	90.63%	78.95%	Uncharacterized protein C3orf67-like protein;OS=Crassostrea;PE=4;SV=1
GN019314.1	sp|K1Q2E5|K1Q2E5_CRAGI	1.9e-147	528.1	100.00%	72.65%	Uncharacterized protein C3orf67-like protein;OS=Crassostrea;PE=4;SV=1
GN019316.1	sp|K1QVI2|K1QVI2_CRAGI	4.8e-40	170.6	53.77%	53.16%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN019317.1	sp|A0A0B7BHX8|A0A0B7BHX8_9EUPU	2.2e-25	120.9	97.26%	44.37%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0003676|GO:0008276|
GN019318.1	sp|K1Q2E9|K1Q2E9_CRAGI	7.8e-184	648.7	92.88%	85.19%	Sulfatase-modifying factor 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019319.1	sp|K1PTB8|K1PTB8_CRAGI	1.1e-64	255.0	15.03%	56.50%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007219|GO:0016567|
GN018756.1	sp|R7TSC4|R7TSC4_CAPTE	6.9e-56	222.2	83.56%	86.78%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN019320.1	sp|K1R1A1|K1R1A1_CRAGI	7.2e-151	539.3	99.75%	86.95%	Xanthine dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0004553|GO:0046872|GO:0016491|GO:0003723|	GO:0005975|
GN019321.1	sp|A0A210QYJ7|A0A210QYJ7_MIZYE	1.6e-60	238.0	98.95%	57.45%	Monoacylglycerol lipase ABHD6;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0003824|
GN019322.1	sp|K1R1A1|K1R1A1_CRAGI	0.0e+00	1830.5	99.59%	72.03%	Xanthine dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0004553|GO:0046872|GO:0016491|GO:0003723|	GO:0005975|
GN019323.1	sp|K1Q0R6|K1Q0R6_CRAGI	0.0e+00	1085.5	100.00%	78.80%	EF-hand domain-containing protein C3orf25-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN018757.1	sp|K1RKR8|K1RKR8_CRAGI	2.6e-226	791.2	86.57%	82.08%	Pumilio-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003723|
GN019325.1	sp|K1PYH1|K1PYH1_CRAGI	4.7e-236	822.8	95.73%	75.18%	Glycerate kinase;OS=Crassostrea;PE=4;SV=1	GO:0008887|
GN019326.1	sp|A0A210PJC8|A0A210PJC8_MIZYE	3.3e-248	863.2	99.35%	65.35%	Leukotriene A(4) hydrolase;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0004463|GO:0008237|GO:0008270|	GO:0019370|
GN019327.1	sp|K1QME9|K1QME9_CRAGI	1.1e-58	233.4	65.20%	38.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019328.1	sp|K1QDL0|K1QDL0_CRAGI	9.3e-25	120.2	94.26%	32.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019329.1	sp|A0A3M6U3Y9|A0A3M6U3Y9_9CNID	1.7e-19	102.4	39.17%	45.08%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN019330.1	sp|A0A1S3JWK7|A0A1S3JWK7_LINUN	4.2e-114	417.5	57.64%	52.38%	tRNA-splicing ligase RtcB homolog;OS=Lingula;PE=3;SV=1	GO:0072669|	GO:0005524|GO:0046872|GO:0003972|	GO:0006388|
GN019331.1	sp|K1R624|K1R624_CRAGI	3.1e-204	716.8	79.32%	87.44%	Metabotropic glutamate receptor 3;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|
GN019332.1	sp|K1QZS8|K1QZS8_CRAGI	2.2e-263	913.3	93.15%	95.09%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004842|
GN019333.1	sp|K1PXQ1|K1PXQ1_CRAGI	0.0e+00	1215.3	98.67%	68.31%	Inter-alpha-trypsin inhibitor heavy chain H3;OS=Crassostrea;PE=4;SV=1	GO:0004867|	GO:0030212|
GN018698.1	sp|K1PGZ2|K1PGZ2_CRAGI	7.3e-14	83.2	54.25%	41.18%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN018758.1	sp|K1QGA5|K1QGA5_CRAGI	1.4e-106	391.3	89.22%	88.83%	Cyclin-related protein FAM58A;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN019334.1	sp|K1PZN9|K1PZN9_CRAGI	3.2e-47	194.9	54.96%	49.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019335.1	sp|K1Q768|K1Q768_CRAGI	4.7e-166	589.7	94.02%	95.15%	Intraflagellar transport protein 57-like protein;OS=Crassostrea;PE=4;SV=1	GO:0031514|
GN019336.1	sp|K1Q075|K1Q075_CRAGI	0.0e+00	1148.7	72.03%	68.64%	Plexin-A4;OS=Crassostrea;PE=4;SV=1	GO:0017154|
GN019337.1	sp|K1QER7|K1QER7_CRAGI	0.0e+00	1190.3	99.85%	87.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019338.1	sp|K1PSU6|K1PSU6_CRAGI	3.8e-91	340.1	87.08%	71.63%	Angiopoietin-related protein 6;OS=Crassostrea;PE=4;SV=1
GN019339.1	sp|K1PW86|K1PW86_CRAGI	5.2e-130	469.9	97.97%	58.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019341.1	sp|K1QVW5|K1QVW5_CRAGI	1.8e-231	807.4	100.00%	77.59%	Inositol-pentakisphosphate 2-kinase;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0035299|
GN019342.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	6.5e-75	286.2	99.17%	57.98%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN019343.1	sp|K1PXQ1|K1PXQ1_CRAGI	4.0e-233	813.1	99.84%	63.08%	Inter-alpha-trypsin inhibitor heavy chain H3;OS=Crassostrea;PE=4;SV=1	GO:0004867|	GO:0030212|
GN019344.1	sp|A0A210QWT8|A0A210QWT8_MIZYE	3.6e-105	389.0	41.28%	41.83%	Plexin-A3;OS=Mizuhopecten;PE=4;SV=1	GO:0016020|	GO:0017154|
GN019345.1	sp|K1RIF3|K1RIF3_CRAGI	4.6e-42	177.2	68.32%	43.26%	Semaphorin-5A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019346.1	sp|K1PZJ8|K1PZJ8_CRAGI	3.3e-104	384.4	62.86%	74.74%	Transient receptor potential cation channel subfamily V member 6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005216|
GN019347.1	sp|A0A210PJC8|A0A210PJC8_MIZYE	3.3e-248	863.2	99.35%	65.35%	Leukotriene A(4) hydrolase;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0004463|GO:0008237|GO:0008270|	GO:0019370|
GN019348.1	sp|K1QME9|K1QME9_CRAGI	1.1e-58	233.4	65.20%	38.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019349.1	sp|K1QDL0|K1QDL0_CRAGI	3.6e-23	114.8	93.53%	31.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019350.1	sp|K1RL29|K1RL29_CRAGI	0.0e+00	1129.4	97.87%	88.35%	Prickle-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN019351.1	sp|K1QFB8|K1QFB8_CRAGI	8.0e-50	203.8	66.67%	36.36%	Protein popC;OS=Crassostrea;PE=4;SV=1
GN018760.1	sp|K1QGB3|K1QGB3_CRAGI	1.6e-266	923.7	100.00%	88.57%	Cholesterol 7-alpha-monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN019352.1	sp|K1PYH1|K1PYH1_CRAGI	4.7e-236	822.8	95.73%	75.18%	Glycerate kinase;OS=Crassostrea;PE=4;SV=1	GO:0008887|
GN019353.1	sp|A0A210QYJ7|A0A210QYJ7_MIZYE	4.7e-99	366.7	98.67%	57.09%	Monoacylglycerol lipase ABHD6;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0003824|
GN019354.1	sp|K1R1A1|K1R1A1_CRAGI	1.0e-125	455.7	91.16%	85.32%	Xanthine dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0071949|GO:0004553|GO:0046872|GO:0016491|GO:0003723|	GO:0005975|
GN019355.1	sp|K1PVH6|K1PVH6_CRAGI	0.0e+00	1155.2	99.86%	38.49%	Uncharacterized protein C3orf63-like protein;OS=Crassostrea;PE=4;SV=1
GN019356.1	sp|K1R304|K1R304_CRAGI	2.8e-12	75.9	98.04%	65.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019357.1	sp|K1QL69|K1QL69_CRAGI	4.4e-81	308.1	26.39%	85.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019358.1	sp|K1PF64|K1PF64_CRAGI	9.4e-238	828.2	100.00%	87.17%	Rabenosyn-5;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0003676|
GN019359.1	sp|K1Q9E5|K1Q9E5_CRAGI	5.0e-39	167.2	75.82%	56.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019360.1	sp|A0A0L8ICQ2|A0A0L8ICQ2_OCTBM	4.5e-11	74.7	23.78%	45.98%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0005634|	GO:0006915|
GN019361.1	sp|K1R1B5|K1R1B5_CRAGI	4.5e-219	766.1	100.00%	90.84%	WD40 repeat-containing protein SMU1;OS=Crassostrea;PE=4;SV=1
GN019362.1	sp|K1QLK6|K1QLK6_CRAGI	0.0e+00	2704.9	99.19%	78.47%	E3 ubiquitin-protein ligase HUWE1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0004842|GO:0008270|
GN019363.1	sp|K1Q584|K1Q584_CRAGI	1.1e-139	503.1	97.81%	38.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019364.1	sp|K1Q584|K1Q584_CRAGI	3.8e-143	515.0	77.34%	38.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019365.1	sp|K1QLK6|K1QLK6_CRAGI	0.0e+00	2125.1	99.15%	86.52%	E3 ubiquitin-protein ligase HUWE1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0004842|GO:0008270|
GN019366.1	sp|K1R9N7|K1R9N7_CRAGI	4.7e-287	993.0	99.91%	74.39%	WD repeat-containing protein 51A;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN018761.1	sp|K1QLJ4|K1QLJ4_CRAGI	2.0e-38	163.7	98.04%	73.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019367.1	sp|K1R9N7|K1R9N7_CRAGI	3.9e-76	291.2	36.27%	88.10%	WD repeat-containing protein 51A;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN019368.1	sp|K1QKK2|K1QKK2_CRAGI	1.6e-59	234.6	97.06%	67.07%	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019369.1	sp|K1QMI8|K1QMI8_CRAGI	2.9e-96	357.5	86.80%	68.32%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN019370.1	sp|K1R1B0|K1R1B0_CRAGI	1.4e-28	134.0	15.50%	51.22%	Neurogenic locus notch-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|	GO:0007154|
GN019371.1	sp|K1R7V5|K1R7V5_CRAGI	1.1e-137	495.0	97.56%	84.95%	Putative imidazolonepropionase;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0016812|	GO:0019556|
GN018762.1	sp|A0A210R3L8|A0A210R3L8_MIZYE	5.5e-243	845.9	99.04%	62.56%	Beta-galactosidase;OS=Mizuhopecten;PE=3;SV=1	GO:0004565|	GO:0005975|
GN019372.1	sp|A0A210PZR3|A0A210PZR3_MIZYE	2.6e-133	481.1	70.78%	70.34%	Aminomethyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0005739|	GO:0004047|GO:0008483|	GO:0006546|
GN019373.1	sp|K1R315|K1R315_CRAGI	1.1e-230	805.1	66.26%	90.95%	Calcium-independent phospholipase A2-gamma;OS=Crassostrea;PE=4;SV=1	GO:0016787|	GO:0016042|
GN019374.1	sp|A0A224Z766|A0A224Z766_9ACAR	4.1e-82	310.8	81.28%	48.49%	Protein SHQ1;OS=Rhipicephalus;PE=4;SV=1	GO:0000493|
GN019375.1	sp|K1Q0B5|K1Q0B5_CRAGI	1.1e-10	74.3	35.27%	41.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019376.1	sp|K1Q0B5|K1Q0B5_CRAGI	3.2e-18	99.4	24.71%	31.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018763.1	sp|K1PRF0|K1PRF0_CRAGI	4.4e-37	160.2	94.92%	49.20%	HMG box-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003723|	GO:0006355|
GN019377.1	sp|K1PMC5|K1PMC5_CRAGI	1.2e-44	185.7	78.01%	54.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019378.1	sp|K1QPA3|K1QPA3_CRAGI	5.7e-45	185.7	99.13%	77.88%	Stress response protein nhaX;OS=Crassostrea;PE=4;SV=1
GN019379.1	sp|K1QEG0|K1QEG0_CRAGI	9.4e-113	412.5	98.69%	57.26%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN018764.1	sp|K1PRF0|K1PRF0_CRAGI	1.5e-116	424.9	98.43%	67.73%	HMG box-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003723|	GO:0006355|
GN019381.1	sp|K1Q6H8|K1Q6H8_CRAGI	9.0e-33	148.3	54.31%	24.62%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018765.1	sp|A0A210Q6Z1|A0A210Q6Z1_MIZYE	1.2e-105	389.4	77.93%	47.37%	MFS-type transporter SLC18B1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN019382.1	sp|K1R0D4|K1R0D4_CRAGI	1.4e-77	294.3	100.00%	83.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019384.1	sp|K1QPN5|K1QPN5_CRAGI	1.2e-112	411.4	100.00%	89.64%	Eukaryotic translation initiation factor 4E type 3;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0003743|
GN019385.1	sp|K1QYZ4|K1QYZ4_CRAGI	4.6e-15	86.3	80.36%	69.23%	Uncharacterized protein C12orf45-like protein;OS=Crassostrea;PE=4;SV=1
GN018766.1	sp|K1QG35|K1QG35_CRAGI	1.1e-142	513.5	85.69%	61.21%	Histone-lysine N-methyltransferase MLL5;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN019387.1	sp|K1RBC9|K1RBC9_CRAGI	9.1e-309	1064.3	100.00%	89.98%	Transketolase-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018767.1	sp|K1QTG4|K1QTG4_CRAGI	1.4e-307	1060.8	85.34%	76.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019388.1	sp|K1QVS6|K1QVS6_CRAGI	2.7e-213	747.3	88.94%	64.90%	Single-strand selective monofunctional uracil DNA glycosylase;OS=Crassostrea;PE=4;SV=1	GO:0017065|	GO:0006284|
GN019389.1	sp|K1PUT5|K1PUT5_CRAGI	3.3e-29	133.7	56.67%	66.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019390.1	sp|K1S151|K1S151_CRAGI	1.0e-55	221.5	89.43%	94.50%	Rab GDP dissociation inhibitor;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005096|GO:0005093|	GO:0015031|GO:0007264|
GN019391.1	sp|K1RD23|K1RD23_CRAGI	0.0e+00	1292.3	65.91%	78.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018768.1	sp|K1QMK9|K1QMK9_CRAGI	2.7e-97	361.7	92.35%	39.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0006801|
GN019392.1	sp|A0A3M6UAZ4|A0A3M6UAZ4_9CNID	5.3e-17	93.6	44.02%	47.42%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN018769.1	sp|K1RLX8|K1RLX8_CRAGI	5.3e-89	334.0	53.36%	68.09%	Serine/threonine-protein phosphatase 4 regulatory subunit 2-A;OS=Crassostrea;PE=4;SV=1	GO:0030289|	GO:0019888|
GN019393.1	sp|A0A2G8JNF8|A0A2G8JNF8_STIJA	1.7e-21	108.2	76.30%	46.27%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN018770.1	sp|K1P6P3|K1P6P3_CRAGI	1.8e-71	276.2	64.85%	45.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019394.1	sp|K1QKH0|K1QKH0_CRAGI	2.8e-51	207.6	82.61%	55.26%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN019395.1	sp|K1Q3W0|K1Q3W0_CRAGI	7.7e-11	73.9	19.57%	52.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019396.1	sp|K1QHT0|K1QHT0_CRAGI	6.3e-65	252.3	95.89%	85.61%	Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004170|GO:0005525|	GO:0046080|
GN019397.1	sp|K1QS28|K1QS28_CRAGI	3.0e-297	1026.5	100.00%	73.81%	Dystroglycan;OS=Crassostrea;PE=4;SV=1	GO:0016010|GO:0016021|	GO:0005509|	GO:0007016|
GN019398.1	sp|K1PPF3|K1PPF3_CRAGI	1.3e-214	751.5	87.65%	71.51%	JmjC domain-containing protein 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018771.1	sp|K1P0K4|K1P0K4_CRAGI	1.0e-242	845.1	100.00%	70.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019399.1	sp|K1PZN4|K1PZN4_CRAGI	1.6e-30	139.0	92.90%	29.80%	Prostaglandin E2 receptor EP4 subtype;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN019401.1	sp|K1QST0|K1QST0_CRAGI	2.2e-74	283.9	97.62%	80.37%	Stress response protein nhaX;OS=Crassostrea;PE=4;SV=1
GN018772.1	sp|K1QEQ1|K1QEQ1_CRAGI	4.4e-296	1024.2	23.73%	85.86%	Actin;OS=Crassostrea;PE=3;SV=1
GN019402.1	sp|K1RXH3|K1RXH3_CRAGI	3.5e-77	293.1	100.00%	89.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018773.1	sp|K1R8K6|K1R8K6_CRAGI	9.4e-132	475.7	98.48%	59.59%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN018774.1	sp|K1Q6Y2|K1Q6Y2_CRAGI	9.2e-182	643.3	100.00%	51.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019403.1	sp|K1Q3I4|K1Q3I4_CRAGI	0.0e+00	2969.5	89.18%	66.03%	Leucine-rich repeat serine/threonine-protein kinase 2;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0005525|GO:0004672|
GN019404.1	sp|K1R9K3|K1R9K3_CRAGI	2.8e-244	850.5	98.98%	60.38%	Vezatin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0017022|	GO:0098609|
GN019405.1	sp|K1QEF6|K1QEF6_CRAGI	7.3e-166	589.3	89.27%	78.56%	E3 ubiquitin-protein ligase Hakai;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|
GN019406.1	sp|K1PKP5|K1PKP5_CRAGI	6.0e-97	360.5	50.83%	64.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN019407.1	sp|K1QHK6|K1QHK6_CRAGI	5.7e-119	434.1	83.50%	44.41%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN019408.1	sp|K1PBT2|K1PBT2_CRAGI	2.0e-41	174.9	100.00%	74.78%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019409.1	sp|K1R849|K1R849_CRAGI	1.4e-308	1063.9	100.00%	93.22%	Kinesin-like protein;OS=Crassostrea;PE=3;SV=1	GO:0005874|	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN019411.1	sp|K1RE15|K1RE15_CRAGI	4.0e-96	357.1	67.49%	84.33%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019413.1	sp|K1RGY9|K1RGY9_CRAGI	0.0e+00	1924.1	82.97%	77.03%	Cortactin-binding protein 2;OS=Crassostrea;PE=4;SV=1
GN019414.1	sp|K1Q573|K1Q573_CRAGI	3.1e-52	210.3	92.12%	68.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019415.1	sp|A0A085M9A4|A0A085M9A4_9BILA	3.8e-10	69.3	90.54%	44.78%	Uncharacterized protein;OS=Trichuris;PE=4;SV=1	GO:0005576|	GO:0005509|
GN019416.1	sp|K1QKY6|K1QKY6_CRAGI	4.2e-95	354.0	100.00%	75.38%	Fibulin-2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005509|	GO:0000730|GO:0045002|
GN019417.1	sp|K1QS92|K1QS92_CRAGI	3.4e-122	443.4	100.00%	84.71%	Lipoma HMGIC fusion partner-like 3 protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019418.1	sp|K1RLV6|K1RLV6_CRAGI	2.1e-106	391.7	76.77%	62.75%	mRNA-decapping enzyme 1B;OS=Crassostrea;PE=4;SV=1	GO:0008047|	GO:0000290|
GN019419.1	sp|K1QWK9|K1QWK9_CRAGI	1.5e-48	198.0	88.16%	63.91%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN019420.1	sp|A0A210PZZ3|A0A210PZZ3_MIZYE	0.0e+00	1569.7	98.11%	45.97%	Plexin-B;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0017154|
GN019421.1	sp|A0A210PF36|A0A210PF36_MIZYE	2.5e-130	471.1	88.65%	59.89%	Ankyrin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0046872|
GN018775.1	sp|K1RM73|K1RM73_CRAGI	3.9e-58	231.9	50.38%	41.19%	OTU domain-containing protein 6B;OS=Crassostrea;PE=4;SV=1
GN019423.1	sp|K1P7X9|K1P7X9_CRAGI	1.0e-140	506.1	87.90%	64.86%	Delta-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0005509|GO:0008017|GO:0003777|	GO:0007154|GO:0007018|GO:0007275|
GN019424.1	sp|K1P7X9|K1P7X9_CRAGI	2.0e-150	537.3	93.46%	94.74%	Delta-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0005509|GO:0008017|GO:0003777|	GO:0007154|GO:0007018|GO:0007275|
GN019425.1	sp|K1P7X9|K1P7X9_CRAGI	8.1e-83	313.5	45.83%	56.12%	Delta-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0005509|GO:0008017|GO:0003777|	GO:0007154|GO:0007018|GO:0007275|
GN019426.1	sp|K1PE13|K1PE13_CRAGI	0.0e+00	3196.8	73.58%	79.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006914|
GN019428.1	sp|K1R5Z7|K1R5Z7_CRAGI	1.0e-169	602.1	97.89%	66.38%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019429.1	sp|K1PLN7|K1PLN7_CRAGI	4.6e-178	629.8	99.14%	65.74%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019430.1	sp|K1Q6I4|K1Q6I4_CRAGI	8.6e-140	502.7	100.00%	53.44%	Interferon-induced protein 44-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019431.1	sp|K1Q101|K1Q101_CRAGI	5.2e-64	249.2	100.00%	87.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019432.1	sp|V4CBN7|V4CBN7_LOTGI	4.2e-141	507.3	62.06%	69.63%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN019433.1	sp|A0A210QSE1|A0A210QSE1_MIZYE	2.8e-218	763.5	96.17%	82.05%	Cyclin-dependent kinase 16;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004674|
GN019435.1	sp|K1Q7R2|K1Q7R2_CRAGI	2.6e-282	976.9	99.87%	88.90%	Leucine-rich repeat and guanylate kinase domain-containing protein;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN019436.1	sp|K1PHY0|K1PHY0_CRAGI	2.2e-274	950.3	99.85%	74.92%	G/T mismatch-specific thymine DNA glycosylase;OS=Crassostrea;PE=4;SV=1	GO:0019104|	GO:0006281|
GN019437.1	sp|K1PN96|K1PN96_CRAGI	1.5e-13	82.4	49.80%	35.20%	PDZ and LIM domain protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019438.1	sp|K1R7C1|K1R7C1_CRAGI	2.4e-96	357.5	72.87%	89.30%	Neurocalcin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019439.1	sp|A0A210PZI4|A0A210PZI4_MIZYE	2.7e-225	787.3	80.11%	75.51%	ATP-binding cassette sub-family F member 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0016887|
GN019441.1	sp|K1QZU5|K1QZU5_CRAGI	0.0e+00	1140.2	97.90%	60.07%	Nuclear protein MDM1;OS=Crassostrea;PE=4;SV=1	GO:0008017|	GO:0046600|
GN019442.1	sp|K1Q7T7|K1Q7T7_CRAGI	1.9e-61	241.9	84.38%	47.45%	BTB and MATH domain-containing protein 42;OS=Crassostrea;PE=4;SV=1
GN019443.1	sp|K1R3X7|K1R3X7_CRAGI	6.8e-31	139.8	71.10%	48.05%	MAM domain-containing glycosylphosphatidylinositol anchor protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN019444.1	sp|K1PM59|K1PM59_CRAGI	5.6e-107	392.5	100.00%	90.38%	DNA/RNA-binding protein KIN17;OS=Crassostrea;PE=4;SV=1
GN019445.1	sp|K1PRV2|K1PRV2_CRAGI	0.0e+00	1214.1	93.50%	85.94%	Threonine synthase-like 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN019447.1	sp|A0A210PIS9|A0A210PIS9_MIZYE	4.4e-103	380.2	93.54%	58.64%	Cell division cycle protein 123;OS=Mizuhopecten;PE=4;SV=1	GO:0051301|
GN019448.1	sp|A0A1J0I8W7|A0A1J0I8W7_CRAHO	9.5e-200	701.4	100.00%	95.75%	Mitogen-activated protein kinase;OS=Crassostrea;PE=2;SV=1	GO:0005524|GO:0004707|
GN019449.1	sp|K1QEK3|K1QEK3_CRAGI	7.8e-76	289.3	98.37%	68.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019451.1	sp|K1PPD2|K1PPD2_CRAGI	2.7e-220	770.8	100.00%	86.94%	NACHT, LRR and PYD domains-containing protein 5;OS=Crassostrea;PE=4;SV=1
GN019452.1	sp|K1QFG9|K1QFG9_CRAGI	6.3e-80	302.4	100.00%	85.06%	Translocon-associated protein subunit delta;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0016021|
GN019453.1	sp|K1QP02|K1QP02_CRAGI	0.0e+00	1641.7	87.80%	62.56%	Metabotropic glutamate receptor 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN019454.1	sp|K1R3B1|K1R3B1_CRAGI	2.0e-96	357.5	100.00%	85.37%	Ubiquitin carboxyl-terminal hydrolase 48;OS=Crassostrea;PE=3;SV=1	GO:0004843|	GO:0016579|GO:0006511|
GN019455.1	sp|A0A210R3U8|A0A210R3U8_MIZYE	5.7e-79	300.4	77.70%	48.48%	DALR anticodon-binding domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0004814|GO:0005524|	GO:0006420|
GN019457.1	sp|K1RTW1|K1RTW1_CRAGI	0.0e+00	1128.2	100.00%	81.32%	Leucine-rich repeats and immunoglobulin-like domains protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019458.1	sp|A0A3B0KQG4|A0A3B0KQG4_DROGU	4.1e-09	67.8	77.49%	27.31%	Blast:Twinfilin;OS=Drosophila;PE=4;SV=1	GO:0016021|
GN018779.1	sp|K1Q5J2|K1Q5J2_CRAGI	3.7e-83	313.5	77.64%	88.59%	B-cell receptor-associated protein 31;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0016021|	GO:0006886|
GN019459.1	sp|A0A1W3JH44|A0A1W3JH44_CIOIN	1.0e-11	76.3	68.20%	31.74%	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8;OS=Ciona;PE=4;SV=1	GO:0005615|	GO:0004866|
GN019460.1	sp|K1PVU0|K1PVU0_CRAGI	1.7e-22	111.3	91.55%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019461.1	sp|K1Q853|K1Q853_CRAGI	0.0e+00	1245.7	99.46%	84.92%	G-protein coupled receptor 64;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|	GO:0007166|
GN018780.1	sp|K1RKE5|K1RKE5_CRAGI	0.0e+00	1354.0	96.00%	98.16%	IQ and AAA domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN019465.1	sp|K1R9Y8|K1R9Y8_CRAGI	4.4e-71	274.6	96.17%	31.00%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN019466.1	sp|K1PE97|K1PE97_CRAGI	1.5e-49	203.4	43.29%	59.18%	Zinc finger protein 26;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN019467.1	sp|K1P874|K1P874_CRAGI	0.0e+00	1096.6	80.24%	86.76%	F-box/LRR-repeat protein 13;OS=Crassostrea;PE=4;SV=1
GN019468.1	sp|K1QXZ9|K1QXZ9_CRAGI	2.8e-196	690.3	84.51%	90.79%	DNA-binding protein P3A2;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003700|	GO:0006357|
GN018781.1	sp|F8RU73|F8RU73_CRAGI	4.1e-63	246.9	67.11%	74.00%	Macrophage expressed protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN019469.1	sp|K1QNT3|K1QNT3_CRAGI	6.1e-77	292.7	81.31%	75.14%	L-rhamnose-binding lectin CSL3;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN019470.1	sp|K1Q596|K1Q596_CRAGI	7.3e-105	385.6	99.12%	82.51%	Phosphoserine phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0004647|	GO:0006564|
GN019471.1	sp|K1QCT3|K1QCT3_CRAGI	4.3e-49	199.1	97.00%	94.79%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=3;SV=1	GO:0003755|	GO:0006457|
GN019472.1	sp|K1R0C9|K1R0C9_CRAGI	3.2e-57	229.6	15.71%	66.87%	Kelch-like protein diablo;OS=Crassostrea;PE=4;SV=1
GN019473.1	sp|K1Q777|K1Q777_CRAGI	1.5e-185	654.8	99.81%	62.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018782.1	sp|K1PHJ6|K1PHJ6_CRAGI	1.7e-21	110.2	14.24%	56.04%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019475.1	sp|K1QLU9|K1QLU9_CRAGI	5.8e-82	310.5	55.86%	65.29%	Tetratricopeptide repeat protein 38;OS=Crassostrea;PE=4;SV=1
GN019477.1	sp|K1Q192|K1Q192_CRAGI	3.8e-165	587.0	90.63%	60.04%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN018783.1	sp|K1RSY3|K1RSY3_CRAGI	4.0e-62	243.8	87.74%	55.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019478.1	sp|K1QF25|K1QF25_CRAGI	7.1e-31	139.0	100.00%	81.34%	Microphthalmia-associated transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0006959|GO:0045893|
GN019479.1	sp|K1QF25|K1QF25_CRAGI	2.2e-155	554.3	100.00%	82.73%	Microphthalmia-associated transcription factor;OS=Crassostrea;PE=4;SV=1	GO:0046983|	GO:0006959|GO:0045893|
GN019480.1	sp|A0A210Q949|A0A210Q949_MIZYE	8.4e-77	292.7	77.74%	60.66%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019481.1	sp|K1QWG9|K1QWG9_CRAGI	3.4e-115	421.4	96.99%	45.22%	Forkhead box protein H1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN019482.1	sp|K1PQ33|K1PQ33_CRAGI	3.5e-17	93.6	89.05%	37.70%	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019483.1	sp|K1QCM2|K1QCM2_CRAGI	1.6e-51	208.4	75.45%	62.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019484.1	sp|K1PS50|K1PS50_CRAGI	2.5e-265	920.2	99.85%	61.86%	Putative tyrosinase-like protein tyr-1;OS=Crassostrea;PE=4;SV=1	GO:0046872|GO:0016491|
GN019485.1	sp|K1Q424|K1Q424_CRAGI	1.5e-24	118.2	78.34%	56.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018784.1	sp|K1Q2F1|K1Q2F1_CRAGI	3.7e-270	936.8	99.08%	50.20%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019486.1	sp|K1RPP1|K1RPP1_CRAGI	8.6e-83	312.4	90.28%	68.28%	Synaptophysin;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0008021|
GN019487.1	sp|A0A210QUX7|A0A210QUX7_MIZYE	2.6e-131	474.6	99.38%	48.76%	Protein-cysteine N-palmitoyltransferase porcupine;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0016740|
GN019488.1	sp|K1QRM0|K1QRM0_CRAGI	1.1e-196	691.4	95.23%	91.01%	Major facilitator superfamily domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015098|
GN019489.1	sp|K1QZ24|K1QZ24_CRAGI	0.0e+00	1232.6	99.90%	84.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019490.1	sp|A0A210PMW5|A0A210PMW5_MIZYE	9.6e-237	824.7	100.00%	92.98%	RuvB-like helicase;OS=Mizuhopecten;PE=3;SV=1	GO:0031011|GO:0035267|GO:0097255|	GO:0005524|GO:0043141|
GN019491.1	sp|K1QDB9|K1QDB9_CRAGI	4.6e-266	922.2	100.00%	98.32%	Transport protein Sec61 subunit alpha isoform 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0015031|
GN019493.1	sp|K1PYP9|K1PYP9_CRAGI	9.6e-10	68.2	58.33%	72.92%	Homeobox expressed in ES cells 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN019494.1	sp|A0A2B4SBE7|A0A2B4SBE7_STYPI	2.4e-15	90.5	15.20%	33.15%	Putative serine/threonine-protein kinase pats1;OS=Stylophora;PE=4;SV=1	GO:0016301|GO:0003723|	GO:0007165|
GN019495.1	sp|K1RA88|K1RA88_CRAGI	5.5e-11	72.8	41.18%	75.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019496.1	sp|K1RJF9|K1RJF9_CRAGI	5.8e-52	208.8	100.00%	93.40%	Urocanate hydratase;OS=Crassostrea;PE=3;SV=1	GO:0016153|
GN018785.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	1.0e-17	94.7	97.73%	52.94%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN019499.1	sp|K1QE72|K1QE72_CRAGI	0.0e+00	1248.8	72.64%	94.63%	IQ and ubiquitin-like domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN019500.1	sp|K1QKQ9|K1QKQ9_CRAGI	0.0e+00	7403.5	100.00%	92.50%	Dynein heavy chain 7, axonemal;OS=Crassostrea;PE=4;SV=1	GO:0030286|	GO:0005524|GO:0003777|	GO:0007018|
GN018786.1	sp|K1Q5Z1|K1Q5Z1_CRAGI	5.8e-66	256.1	97.96%	63.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019502.1	sp|K1QQ49|K1QQ49_CRAGI	3.4e-46	189.5	96.04%	94.79%	Putative ATP-dependent RNA helicase DDX20;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN019504.1	sp|K1QKY2|K1QKY2_CRAGI	2.2e-62	244.2	97.38%	60.43%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN018787.1	sp|K1PCV0|K1PCV0_CRAGI	6.3e-189	665.6	95.61%	86.67%	Severin;OS=Crassostrea;PE=4;SV=1	GO:0051015|
GN019505.1	sp|K1RXB8|K1RXB8_CRAGI	2.6e-118	430.6	96.92%	72.34%	F-box only protein 17;OS=Crassostrea;PE=4;SV=1
GN019506.1	sp|K1RMI7|K1RMI7_CRAGI	0.0e+00	1082.4	98.44%	79.22%	Ubiquitin carboxyl-terminal hydrolase 8;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0036459|	GO:0016579|GO:0006511|
GN019507.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	7.2e-90	336.7	82.49%	44.99%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN019508.1	sp|K1QNX3|K1QNX3_CRAGI	1.8e-171	607.4	100.00%	88.47%	Pre-mRNA-splicing factor 18;OS=Crassostrea;PE=4;SV=1	GO:0005681|	GO:0008380|
GN019512.1	sp|K1QIT8|K1QIT8_CRAGI	0.0e+00	1126.7	54.39%	57.75%	NACHT and WD repeat domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN019513.1	sp|K1QI36|K1QI36_CRAGI	0.0e+00	1359.7	100.00%	86.46%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN019514.1	sp|K1Q317|K1Q317_CRAGI	2.1e-248	864.0	91.72%	81.02%	Serine/threonine-protein kinase SRPK1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019515.1	sp|A0A210Q985|A0A210Q985_MIZYE	4.0e-230	803.5	96.91%	57.36%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019516.1	sp|A0A210Q985|A0A210Q985_MIZYE	0.0e+00	1548.9	99.84%	60.22%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019517.1	sp|A0A1S3IJV8|A0A1S3IJV8_LINUN	7.9e-26	123.6	92.71%	26.52%	uncharacterized protein LOC106165000;OS=Lingula;PE=4;SV=1
GN019518.1	sp|K1RA67|K1RA67_CRAGI	3.2e-28	130.2	99.24%	54.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018788.1	sp|K1PHM6|K1PHM6_CRAGI	6.1e-89	333.2	82.24%	70.63%	DNA excision repair protein ERCC-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|GO:0005840|	GO:0003684|GO:0004519|GO:0003735|	GO:0006281|GO:0006412|
GN019519.1	sp|A0A3L5TVI0|A0A3L5TVI0_MYTGA	8.5e-34	150.2	32.16%	57.85%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN019520.1	sp|K1QWC0|K1QWC0_CRAGI	4.5e-47	193.0	97.95%	69.01%	Universal stress protein A-like protein;OS=Crassostrea;PE=4;SV=1
GN019521.1	sp|K1QEZ1|K1QEZ1_CRAGI	1.3e-178	631.3	100.00%	77.49%	Peroxisomal sarcosine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN018789.1	sp|A0A2R5LER2|A0A2R5LER2_9ACAR	4.3e-58	230.3	98.79%	51.60%	Putative ribosomal protein l2;OS=Ornithodoros;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN019522.1	sp|K1Q8U5|K1Q8U5_CRAGI	5.3e-98	364.0	96.76%	40.96%	Heat shock protein STI1;OS=Crassostrea;PE=4;SV=1
GN019523.1	sp|K1R0H0|K1R0H0_CRAGI	1.3e-115	421.4	86.81%	94.09%	Glutamine synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004356|	GO:0006542|
GN019524.1	sp|K1QLS7|K1QLS7_CRAGI	1.6e-51	207.6	100.00%	71.88%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN019525.1	sp|K1QYY3|K1QYY3_CRAGI	6.4e-32	144.1	31.01%	54.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030414|
GN019526.1	sp|K1PZ08|K1PZ08_CRAGI	2.5e-112	410.2	100.00%	98.05%	Ras-related protein Rab-7a;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN019527.1	sp|K1RGA0|K1RGA0_CRAGI	4.0e-129	466.5	93.91%	93.49%	Ubiquitin carboxyl-terminal hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0004843|	GO:0006511|
GN019528.1	sp|K1RGA0|K1RGA0_CRAGI	4.7e-61	240.4	91.10%	65.15%	Ubiquitin carboxyl-terminal hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0004843|	GO:0006511|
GN019529.1	sp|K1QUE6|K1QUE6_CRAGI	1.6e-142	511.1	86.89%	94.32%	26S proteasome non-ATPase regulatory subunit 6;OS=Crassostrea;PE=4;SV=1	GO:0000502|	GO:0030234|
GN019530.1	sp|K1QG82|K1QG82_CRAGI	5.5e-59	233.0	84.39%	68.02%	Collagen alpha-2(VIII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN019538.1	sp|K1PLT0|K1PLT0_CRAGI	1.3e-39	167.5	100.00%	87.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019539.1	sp|K1QTS9|K1QTS9_CRAGI	1.8e-174	617.5	98.57%	84.59%	Betaine--homocysteine S-methyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN019540.1	sp|K1PKQ0|K1PKQ0_CRAGI	1.8e-21	107.5	65.05%	71.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019541.1	sp|K1PPH6|K1PPH6_CRAGI	1.1e-75	289.3	100.00%	87.54%	Kelch domain-containing protein 8B;OS=Crassostrea;PE=4;SV=1
GN019544.1	sp|A0A210Q181|A0A210Q181_MIZYE	4.6e-40	171.8	100.00%	41.37%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN019545.1	sp|K1Q8C2|K1Q8C2_CRAGI	2.6e-132	477.6	100.00%	82.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN019546.1	sp|K1PPK6|K1PPK6_CRAGI	0.0e+00	1124.0	98.33%	65.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005509|
GN019547.1	sp|A0A210PYJ1|A0A210PYJ1_MIZYE	9.7e-293	1012.3	98.61%	42.72%	Hepatocyte growth factor receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN019548.1	sp|K1QBB5|K1QBB5_CRAGI	3.4e-162	577.0	75.62%	80.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019549.1	sp|K1PPK8|K1PPK8_CRAGI	1.1e-23	117.1	14.09%	82.86%	Voltage-dependent calcium channel subunit alpha-2/delta-2;OS=Crassostrea;PE=4;SV=1
GN019550.1	sp|K1Q3X6|K1Q3X6_CRAGI	0.0e+00	2146.7	92.18%	66.05%	Neuropilin-1;OS=Crassostrea;PE=4;SV=1
GN019551.1	sp|K1R6N7|K1R6N7_CRAGI	5.0e-181	639.4	97.98%	75.00%	Mitochondrial tRNA-specific 2-thiouridylase 1;OS=Crassostrea;PE=3;SV=1	GO:0016783|	GO:0008033|
GN019552.1	sp|K1PTG9|K1PTG9_CRAGI	2.0e-50	204.1	100.00%	56.29%	Toll-like receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN019554.1	sp|K1Q4L3|K1Q4L3_CRAGI	2.2e-46	190.7	89.51%	62.20%	Neuronal acetylcholine receptor subunit alpha-3;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN019555.1	sp|K1S0P1|K1S0P1_CRAGI	0.0e+00	1506.9	88.75%	87.94%	Kinesin-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN019556.1	sp|A0A210PDW1|A0A210PDW1_MIZYE	2.1e-72	278.1	65.75%	66.67%	Transporter;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005328|
GN019557.1	sp|K1QVC3|K1QVC3_CRAGI	1.8e-105	387.5	93.49%	88.50%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN019558.1	sp|K1QPU0|K1QPU0_CRAGI	3.5e-09	67.0	36.03%	64.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019561.1	sp|K1R4A4|K1R4A4_CRAGI	5.5e-240	835.9	98.67%	65.71%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN019562.1	sp|K1PUB3|K1PUB3_CRAGI	2.3e-12	77.0	97.85%	48.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN019564.1	sp|A0A3M6UD05|A0A3M6UD05_9CNID	2.0e-20	103.6	100.00%	58.02%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN019565.1	sp|A0A210R4D1|A0A210R4D1_MIZYE	5.8e-154	550.1	99.66%	62.82%	p53-induced protein with a death domain;OS=Mizuhopecten;PE=4;SV=1
GN019566.1	sp|K1QG88|K1QG88_CRAGI	2.8e-195	686.8	96.81%	83.50%	Mannosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005788|GO:0005789|GO:0016021|	GO:0052824|	GO:0006488|
GN019567.1	sp|K1PU78|K1PU78_CRAGI	2.7e-99	367.9	52.55%	81.95%	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN019568.1	sp|K1RE59|K1RE59_CRAGI	6.0e-88	329.7	99.65%	61.13%	Heart-and neural crest derivatives-expressed protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN019570.1	sp|R7UCN5|R7UCN5_CAPTE	9.0e-12	75.9	76.07%	34.65%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN019571.1	sp|A0A210Q271|A0A210Q271_MIZYE	5.6e-18	95.1	98.44%	67.74%	RNA-binding protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005681|	GO:0046872|GO:0003723|	GO:0000381|GO:0042981|GO:0008380|
GN019572.1	sp|A0A210Q271|A0A210Q271_MIZYE	4.1e-39	168.3	26.04%	62.12%	RNA-binding protein 5;OS=Mizuhopecten;PE=4;SV=1	GO:0005681|	GO:0046872|GO:0003723|	GO:0000381|GO:0042981|GO:0008380|
GN019574.1	sp|A0A0P4VU74|A0A0P4VU74_9EUCA	5.7e-44	184.1	28.89%	69.30%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN019576.1	sp|A0A0B7BM85|A0A0B7BM85_9EUPU	6.9e-19	100.1	40.48%	46.53%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN019577.1	sp|K1PU81|K1PU81_CRAGI	2.3e-272	943.7	99.33%	63.10%	Protocadherin Fat 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019579.1	sp|K1PU86|K1PU86_CRAGI	1.5e-161	574.3	96.14%	90.94%	Thioredoxin reductase 3;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0009055|GO:0050660|GO:0004791|	GO:0045454|
GN019580.1	sp|A0A210PSR9|A0A210PSR9_MIZYE	4.5e-46	189.5	83.21%	80.73%	Thioredoxin reductase 3;OS=Mizuhopecten;PE=3;SV=1	GO:0005623|	GO:0009055|GO:0050660|GO:0015035|GO:0004791|	GO:0045454|
GN019581.1	sp|K1PE57|K1PE57_CRAGI	4.2e-152	543.1	100.00%	79.48%	Severin;OS=Crassostrea;PE=4;SV=1	GO:0051015|
GN019582.1	sp|K1PXN3|K1PXN3_CRAGI	1.5e-09	68.9	56.39%	34.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019583.1	sp|K1PJF4|K1PJF4_CRAGI	6.3e-14	81.6	100.00%	54.84%	Isoleucyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0002161|GO:0005524|GO:0004822|GO:0000049|	GO:0006428|
GN019584.1	sp|K1Q171|K1Q171_CRAGI	3.2e-81	308.1	98.14%	36.92%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0019013|	GO:0003723|
GN019586.1	sp|K1R1K0|K1R1K0_CRAGI	1.3e-09	70.5	22.12%	32.79%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN019587.1	sp|K1PRN5|K1PRN5_CRAGI	8.3e-193	679.5	76.87%	46.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019588.1	sp|K1PY93|K1PY93_CRAGI	1.1e-97	361.7	90.58%	76.56%	N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D;OS=Crassostrea;PE=4;SV=1	GO:0070290|GO:0008270|
GN019589.1	sp|K1RDZ7|K1RDZ7_CRAGI	7.7e-22	109.8	58.04%	38.17%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019590.1	sp|K1R2M0|K1R2M0_CRAGI	1.3e-174	617.8	96.53%	89.79%	Dual specificity protein phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0017017|GO:0004725|
GN019591.1	sp|K1S4L8|K1S4L8_CRAGI	0.0e+00	1586.6	60.07%	78.53%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018791.1	sp|W4Z9W9|W4Z9W9_STRPU	1.2e-19	102.4	69.34%	39.73%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN019592.1	sp|A0A2G8JRY6|A0A2G8JRY6_STIJA	2.9e-14	85.1	83.75%	26.41%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0004190|
GN019593.1	sp|K1RNK4|K1RNK4_CRAGI	2.6e-38	164.1	99.40%	47.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019595.1	sp|K1QDN8|K1QDN8_CRAGI	8.1e-71	271.9	100.00%	77.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019596.1	sp|K1QDN8|K1QDN8_CRAGI	2.7e-70	270.4	88.33%	81.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019597.1	sp|K1PDK4|K1PDK4_CRAGI	8.4e-219	765.4	95.31%	72.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019602.1	sp|K1QW62|K1QW62_CRAGI	7.5e-14	82.0	94.90%	48.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019603.1	sp|K1PVP7|K1PVP7_CRAGI	2.3e-127	460.7	99.31%	79.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019604.1	sp|K1QII5|K1QII5_CRAGI	1.9e-74	285.0	100.00%	43.81%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN019605.1	sp|K1R1Z2|K1R1Z2_CRAGI	4.9e-76	290.4	98.83%	43.57%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN019606.1	sp|K1QII5|K1QII5_CRAGI	1.5e-128	464.9	99.18%	60.82%	Tripartite motif-containing protein 45;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN019607.1	sp|K1PIW9|K1PIW9_CRAGI	1.6e-30	137.1	100.00%	74.07%	MAM domain-containing glycosylphosphatidylinositol anchor protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN019608.1	sp|K1PSY1|K1PSY1_CRAGI	2.2e-30	136.7	100.00%	75.31%	MAM domain-containing glycosylphosphatidylinositol anchor protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN019609.1	sp|K1Q9J8|K1Q9J8_CRAGI	4.2e-147	526.9	100.00%	60.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019611.1	sp|A0A210QBZ7|A0A210QBZ7_MIZYE	3.1e-22	111.3	92.05%	34.94%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018792.1	sp|W4YWW1|W4YWW1_STRPU	1.4e-23	115.2	79.65%	44.53%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|
GN019613.1	sp|K1R9S0|K1R9S0_CRAGI	1.6e-30	137.5	73.08%	80.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019616.1	sp|A0A210QEL8|A0A210QEL8_MIZYE	3.1e-10	70.5	95.59%	34.09%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016788|
GN019617.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	4.8e-51	207.2	98.67%	35.76%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN019618.1	sp|K1QUB9|K1QUB9_CRAGI	1.5e-147	528.1	99.46%	83.70%	Uncharacterized protein C3orf32;OS=Crassostrea;PE=4;SV=1
GN018793.1	sp|K1QUD4|K1QUD4_CRAGI	0.0e+00	1822.8	93.14%	73.40%	Metabotropic glutamate receptor 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN019619.1	sp|K1RZK6|K1RZK6_CRAGI	6.7e-122	442.6	99.67%	68.46%	UPF0249 protein ydjC-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|	GO:0005975|
GN019622.1	sp|K1RG72|K1RG72_CRAGI	1.4e-20	106.7	12.03%	84.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019624.1	sp|K1PKW3|K1PKW3_CRAGI	4.9e-205	719.2	95.47%	92.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0071203|
GN018794.1	sp|K1Q8F1|K1Q8F1_CRAGI	6.9e-199	700.3	51.94%	58.37%	Nucleolar protein 9;OS=Crassostrea;PE=4;SV=1
GN019626.1	sp|K1QE46|K1QE46_CRAGI	0.0e+00	1385.5	95.42%	91.44%	Conserved oligomeric Golgi complex subunit 5;OS=Crassostrea;PE=4;SV=1	GO:0017119|	GO:0006891|
GN019627.1	sp|K1R069|K1R069_CRAGI	7.2e-95	352.4	79.66%	90.37%	tRNA-dihydrouridine synthase;OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0017150|
GN019628.1	sp|K1PS47|K1PS47_CRAGI	0.0e+00	1661.7	93.33%	62.78%	Serine/threonine-protein kinase WNK1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN019630.1	sp|K1QE71|K1QE71_CRAGI	2.6e-51	206.8	97.60%	91.80%	DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0004386|	GO:0006270|GO:1905775|
GN019631.1	sp|K1Q742|K1Q742_CRAGI	7.0e-179	633.6	98.54%	36.15%	Mitosis inhibitor protein kinase wee1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019632.1	sp|A0A2H4UKL7|A0A2H4UKL7_CRAGI	1.1e-132	478.8	98.77%	61.29%	Leucine-rich repeat and fibronectin type-III domain-containing protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|
GN019633.1	sp|K1PHJ1|K1PHJ1_CRAGI	1.5e-74	285.0	87.01%	67.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0005634|	GO:0004861|GO:0017069|	GO:0000122|
GN019634.1	sp|A0A210PYJ6|A0A210PYJ6_MIZYE	2.6e-143	514.2	99.31%	63.34%	Interferon-related developmental regulator 1;OS=Mizuhopecten;PE=4;SV=1
GN019635.1	sp|K1RZN5|K1RZN5_CRAGI	2.3e-125	454.9	95.98%	47.44%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN019636.1	sp|K1P9D6|K1P9D6_CRAGI	2.8e-74	284.6	99.15%	41.64%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN019637.1	sp|K1Q0D0|K1Q0D0_CRAGI	0.0e+00	1158.3	79.18%	54.96%	Hepatocyte growth factor receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN019638.1	sp|K1PT23|K1PT23_CRAGI	4.5e-27	126.3	99.21%	51.20%	Multimerin-2;OS=Crassostrea;PE=4;SV=1
GN019639.1	sp|K1R4Z9|K1R4Z9_CRAGI	1.5e-13	82.8	33.82%	41.88%	Putative potassium channel regulatory protein;OS=Crassostrea;PE=4;SV=1	GO:0051260|
GN019640.1	sp|K1PT23|K1PT23_CRAGI	7.3e-29	133.3	52.40%	49.62%	Multimerin-2;OS=Crassostrea;PE=4;SV=1
GN019641.1	sp|K1Q7J0|K1Q7J0_CRAGI	2.3e-135	488.8	87.49%	39.65%	Hepatocyte growth factor receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004713|
GN019642.1	sp|K1PK61|K1PK61_CRAGI	6.7e-41	173.3	77.74%	50.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019643.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	1.2e-92	346.7	81.14%	34.12%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN019644.1	sp|K1Q390|K1Q390_CRAGI	6.6e-23	113.2	69.01%	38.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018795.1	sp|K1P8E8|K1P8E8_CRAGI	1.9e-54	217.6	100.00%	72.89%	Relaxin receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|GO:0016500|
GN019646.1	sp|K1QGT9|K1QGT9_CRAGI	0.0e+00	1380.2	99.63%	81.10%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN019647.1	sp|K1RNQ9|K1RNQ9_CRAGI	0.0e+00	1130.2	91.81%	83.18%	Transporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005328|
GN019648.1	sp|A0A210R5C7|A0A210R5C7_MIZYE	7.9e-145	518.8	100.00%	76.09%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019649.1	sp|K1QYR7|K1QYR7_CRAGI	9.9e-23	111.7	84.40%	60.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018796.1	sp|K1QDA8|K1QDA8_CRAGI	4.4e-46	189.5	99.22%	67.72%	Angiopoietin-4;OS=Crassostrea;PE=4;SV=1
GN019650.1	sp|K1RNQ1|K1RNQ1_CRAGI	3.1e-67	260.8	87.80%	56.31%	Kelch-like protein 28;OS=Crassostrea;PE=4;SV=1
GN019651.1	sp|K1R8K6|K1R8K6_CRAGI	1.4e-138	498.4	97.80%	61.25%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN019652.1	sp|K1R8K6|K1R8K6_CRAGI	8.9e-57	225.3	99.37%	65.45%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN019654.1	sp|K1QP74|K1QP74_CRAGI	2.4e-13	80.1	96.30%	50.65%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019655.1	sp|K1QP74|K1QP74_CRAGI	4.8e-27	126.3	92.54%	52.85%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019656.1	sp|K1QP74|K1QP74_CRAGI	3.5e-27	126.7	85.16%	55.56%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019657.1	sp|K1QNA5|K1QNA5_CRAGI	2.4e-206	724.2	99.84%	59.13%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019658.1	sp|K1QP74|K1QP74_CRAGI	8.8e-69	266.2	89.94%	52.54%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019659.1	sp|K1QP74|K1QP74_CRAGI	2.2e-59	234.6	95.36%	52.89%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019660.1	sp|C3Z0X5|C3Z0X5_BRAFL	6.8e-13	80.1	88.41%	28.91%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003676|
GN019661.1	sp|K1QS20|K1QS20_CRAGI	2.8e-26	124.4	68.78%	43.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019662.1	sp|K1R3A9|K1R3A9_CRAGI	1.6e-29	135.2	100.00%	38.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019663.1	sp|K1R2L7|K1R2L7_CRAGI	5.2e-35	152.1	95.35%	83.95%	Glutaminyl-tRNA synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004819|	GO:0006425|
GN019664.1	sp|K1R2L7|K1R2L7_CRAGI	1.1e-75	288.1	84.66%	97.08%	Glutaminyl-tRNA synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004819|	GO:0006425|
GN019665.1	sp|A0A210PS75|A0A210PS75_MIZYE	1.7e-66	258.1	96.23%	65.85%	Glutamine--tRNA ligase;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004819|	GO:0006425|
GN019666.1	sp|K1PMC5|K1PMC5_CRAGI	1.0e-37	161.8	97.73%	63.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019667.1	sp|K1R2M2|K1R2M2_CRAGI	2.1e-248	863.6	99.81%	81.25%	OTU domain-containing protein 5-B;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN019668.1	sp|K1QFZ6|K1QFZ6_CRAGI	7.0e-25	119.8	49.52%	48.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019670.1	sp|K1QKH0|K1QKH0_CRAGI	1.1e-49	202.6	69.85%	53.68%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN019671.1	sp|K1QTQ8|K1QTQ8_CRAGI	3.8e-32	143.7	91.06%	44.38%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019672.1	sp|K1PQ97|K1PQ97_CRAGI	3.7e-72	279.3	39.19%	34.94%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019676.1	sp|A0A210PYK1|A0A210PYK1_MIZYE	2.3e-114	417.9	99.48%	61.24%	Battenin;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|GO:0005765|
GN019677.1	sp|K1Q1V2|K1Q1V2_CRAGI	5.9e-111	406.8	88.48%	67.89%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019678.1	sp|K1Q1V2|K1Q1V2_CRAGI	2.6e-94	351.3	79.52%	68.79%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019679.1	sp|A0A210R729|A0A210R729_MIZYE	5.5e-73	280.0	94.43%	50.36%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019680.1	sp|K1Q1V2|K1Q1V2_CRAGI	5.9e-111	406.8	88.48%	67.89%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN018797.1	sp|K1PFY9|K1PFY9_CRAGI	2.2e-94	351.3	96.24%	52.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019681.1	sp|K1Q1V2|K1Q1V2_CRAGI	3.0e-18	97.8	65.92%	63.01%	GTPase IMAP family member 4;OS=Crassostrea;PE=4;SV=1	GO:0005525|
GN019682.1	sp|K1PQR0|K1PQR0_CRAGI	2.9e-66	257.3	99.07%	60.89%	Protein phosphatase 1H;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004722|
GN019683.1	sp|K1R7R6|K1R7R6_CRAGI	5.3e-260	902.1	98.84%	82.30%	Purple acid phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003993|GO:0046872|
GN019684.1	sp|K1PJF4|K1PJF4_CRAGI	0.0e+00	2298.9	96.87%	89.90%	Isoleucyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0002161|GO:0005524|GO:0004822|GO:0000049|	GO:0006428|
GN019685.1	sp|K1QJE1|K1QJE1_CRAGI	1.4e-199	701.0	96.93%	91.27%	MAP kinase-activated protein kinase 2;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN019686.1	sp|K1Q7Y0|K1Q7Y0_CRAGI	1.2e-63	249.2	46.29%	78.06%	Ankyrin repeat and SOCS box protein 8;OS=Crassostrea;PE=4;SV=1
GN019687.1	sp|K1QPY2|K1QPY2_CRAGI	1.0e-25	124.0	53.09%	32.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019688.1	sp|K1R9K5|K1R9K5_CRAGI	4.0e-65	254.2	58.64%	59.24%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019689.1	sp|A0A2T7NSG6|A0A2T7NSG6_POMCA	2.3e-46	191.0	93.75%	52.51%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0000350|
GN019692.1	sp|K1QZF9|K1QZF9_CRAGI	1.3e-24	118.6	86.71%	43.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019693.1	sp|K1PC63|K1PC63_CRAGI	3.4e-36	156.8	97.84%	58.52%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019695.1	sp|K1Q8Q1|K1Q8Q1_CRAGI	2.9e-285	986.5	85.49%	73.11%	Laccase-2;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN019696.1	sp|K1QU17|K1QU17_CRAGI	3.4e-52	210.7	80.83%	64.25%	NCK-interacting protein with SH3 domain;OS=Crassostrea;PE=4;SV=1
GN019697.1	sp|K1QU17|K1QU17_CRAGI	3.6e-52	209.9	81.08%	84.03%	NCK-interacting protein with SH3 domain;OS=Crassostrea;PE=4;SV=1
GN019698.1	sp|K1R9J2|K1R9J2_CRAGI	3.3e-257	893.3	90.29%	78.47%	Ras association domain-containing protein 5;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN019699.1	sp|K1RFZ5|K1RFZ5_CRAGI	1.8e-103	380.9	96.89%	83.41%	Adipocyte plasma membrane-associated protein;OS=Crassostrea;PE=4;SV=1	GO:0016844|	GO:0009058|
GN019701.1	sp|K1Q1L0|K1Q1L0_CRAGI	4.3e-28	130.2	57.95%	57.43%	Laccase-2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0016491|
GN019703.1	sp|V4BF99|V4BF99_LOTGI	2.3e-65	254.6	87.59%	52.59%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN019704.1	sp|K1Q8Q1|K1Q8Q1_CRAGI	2.9e-298	1029.6	95.20%	72.28%	Laccase-2;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN019705.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	7.0e-23	112.8	97.09%	37.02%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN019707.1	sp|K1Q1M0|K1Q1M0_CRAGI	0.0e+00	1116.7	100.00%	67.76%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN018798.1	sp|K1RYL4|K1RYL4_CRAGI	1.5e-38	164.9	93.17%	52.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019708.1	sp|K1S154|K1S154_CRAGI	1.4e-12	79.7	19.28%	59.42%	Ankyrin repeat domain-containing protein 16;OS=Crassostrea;PE=4;SV=1
GN019709.1	sp|K1Q697|K1Q697_CRAGI	8.3e-72	276.2	94.31%	50.53%	NAD(P)(+)--arginine ADP-ribosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0003956|	GO:0006471|
GN018799.1	sp|K1QSR0|K1QSR0_CRAGI	2.5e-49	200.3	99.22%	70.08%	Angiopoietin-4;OS=Crassostrea;PE=4;SV=1
GN019710.1	sp|K1RV76|K1RV76_CRAGI	2.0e-110	404.4	100.00%	62.24%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN019711.1	sp|A0A151IU93|A0A151IU93_9HYME	3.8e-100	371.7	97.67%	31.84%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN019712.1	sp|K1RV76|K1RV76_CRAGI	3.8e-31	141.7	26.71%	50.38%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN019713.1	sp|K1RV76|K1RV76_CRAGI	5.8e-110	402.9	100.00%	61.90%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN019714.1	sp|K1RV76|K1RV76_CRAGI	4.2e-18	95.5	98.41%	72.13%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN019715.1	sp|K1RV76|K1RV76_CRAGI	7.0e-21	104.8	100.00%	75.81%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN019716.1	sp|K1RV76|K1RV76_CRAGI	1.2e-118	431.8	100.00%	65.99%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN018801.1	sp|A0A210QYM3|A0A210QYM3_MIZYE	1.4e-22	112.1	67.32%	41.38%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018700.1	sp|W4XY62|W4XY62_STRPU	5.6e-39	167.5	45.57%	40.22%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0016788|GO:0003676|GO:0008270|	GO:0015074|
GN019719.1	sp|K1PVU0|K1PVU0_CRAGI	1.2e-10	71.2	95.35%	41.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019721.1	sp|K1RHZ3|K1RHZ3_CRAGI	0.0e+00	2317.0	76.85%	77.16%	Protocadherin Fat 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019722.1	sp|A0A210PF77|A0A210PF77_MIZYE	2.0e-22	111.3	83.83%	47.52%	Protocadherin Fat 4;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN019725.1	sp|K1R465|K1R465_CRAGI	6.6e-68	262.3	100.00%	74.21%	General transcription factor 3C polypeptide 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019726.1	sp|K1RKE0|K1RKE0_CRAGI	3.4e-64	250.0	98.14%	73.25%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019727.1	sp|K1P0L5|K1P0L5_CRAGI	9.4e-113	412.1	98.97%	71.43%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019728.1	sp|A0A210QF09|A0A210QF09_MIZYE	4.2e-26	125.6	48.78%	32.16%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019729.1	sp|K1QX30|K1QX30_CRAGI	3.6e-39	166.0	97.78%	97.73%	U4/U6 small nuclear ribonucleoprotein Prp3;OS=Crassostrea;PE=4;SV=1	GO:0046540|GO:0019013|	GO:0000398|
GN019730.1	sp|K1R068|K1R068_CRAGI	1.7e-169	601.3	100.00%	62.72%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN018802.1	sp|K1QP47|K1QP47_CRAGI	5.6e-232	808.9	94.92%	95.75%	Coiled-coil domain-containing protein 77;OS=Crassostrea;PE=4;SV=1
GN019731.1	sp|K1QHH8|K1QHH8_CRAGI	4.3e-31	139.0	87.80%	91.55%	Putative 10-formyltetrahydrofolate dehydrogenase ALDH1L2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0016155|GO:0016742|GO:0016620|	GO:0009258|GO:0009058|GO:0006730|GO:0016567|
GN019733.1	sp|K1RCK1|K1RCK1_CRAGI	1.1e-55	221.9	95.56%	69.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019734.1	sp|C3Y2X9|C3Y2X9_BRAFL	2.1e-24	118.6	77.46%	30.98%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN019736.1	sp|K1RMK2|K1RMK2_CRAGI	2.0e-20	104.0	63.46%	77.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019737.1	sp|K1RCK1|K1RCK1_CRAGI	3.3e-36	156.8	100.00%	65.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019741.1	sp|K1RTW7|K1RTW7_CRAGI	5.6e-16	89.7	98.68%	45.34%	Jumonji-C domain-containing protein Jarid1c;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003677|GO:0046872|GO:0008168|
GN019742.1	sp|K1QP47|K1QP47_CRAGI	5.6e-232	808.9	94.92%	95.75%	Coiled-coil domain-containing protein 77;OS=Crassostrea;PE=4;SV=1
GN019743.1	sp|A0A210PE80|A0A210PE80_MIZYE	0.0e+00	1272.7	95.99%	39.72%	Sterile alpha motif domain-containing protein 9-like;OS=Mizuhopecten;PE=4;SV=1	GO:0042981|
GN019744.1	sp|K1RCN1|K1RCN1_CRAGI	0.0e+00	1107.0	79.10%	67.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018803.1	sp|K1RTW7|K1RTW7_CRAGI	5.6e-16	89.7	98.68%	45.34%	Jumonji-C domain-containing protein Jarid1c;OS=Crassostrea;PE=2;SV=1	GO:0005634|	GO:0003677|GO:0046872|GO:0008168|
GN019747.1	sp|K1QVQ1|K1QVQ1_CRAGI	3.2e-36	156.4	92.08%	86.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019748.1	sp|K1RLP8|K1RLP8_CRAGI	6.0e-43	179.1	71.32%	86.81%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN019749.1	sp|K1RLP8|K1RLP8_CRAGI	5.9e-43	179.1	72.44%	86.81%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN019750.1	sp|K1QDA8|K1QDA8_CRAGI	1.6e-43	181.0	99.22%	65.35%	Angiopoietin-4;OS=Crassostrea;PE=4;SV=1
GN019751.1	sp|K1Q8F1|K1Q8F1_CRAGI	6.2e-199	700.3	58.32%	58.37%	Nucleolar protein 9;OS=Crassostrea;PE=4;SV=1
GN019752.1	sp|W4Z9W9|W4Z9W9_STRPU	1.2e-19	102.4	69.34%	39.73%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0046872|GO:0003676|	GO:0015074|
GN019753.1	sp|K1Q9P5|K1Q9P5_CRAGI	4.6e-64	249.6	83.64%	88.32%	Mitochondrial-processing peptidase subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0017087|	GO:0046872|GO:0004222|	GO:0006627|
GN019754.1	sp|K1Q9P5|K1Q9P5_CRAGI	2.2e-36	157.1	79.66%	82.80%	Mitochondrial-processing peptidase subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0017087|	GO:0046872|GO:0004222|	GO:0006627|
GN019755.1	sp|K1Q9P5|K1Q9P5_CRAGI	7.0e-51	205.3	100.00%	77.59%	Mitochondrial-processing peptidase subunit beta;OS=Crassostrea;PE=3;SV=1	GO:0017087|	GO:0046872|GO:0004222|	GO:0006627|
GN019756.1	sp|E9GEU2|E9GEU2_DAPPU	1.0e-19	100.9	98.46%	65.08%	Uncharacterized protein;OS=Daphnia;PE=3;SV=1	GO:0005743|GO:0017087|GO:0005739|	GO:0046872|GO:0004222|	GO:0006627|
GN019757.1	sp|K1PT09|K1PT09_CRAGI	1.7e-180	637.5	91.48%	96.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0060271|
GN019758.1	sp|A0A2T7NVX5|A0A2T7NVX5_POMCA	4.2e-52	210.3	94.59%	48.33%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN019759.1	sp|K1PHM6|K1PHM6_CRAGI	6.1e-89	333.2	82.24%	70.63%	DNA excision repair protein ERCC-1;OS=Crassostrea;PE=4;SV=1	GO:0005634|GO:0005840|	GO:0003684|GO:0004519|GO:0003735|	GO:0006281|GO:0006412|
GN018804.1	sp|K1RMC1|K1RMC1_CRAGI	6.1e-152	543.5	61.85%	61.07%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019761.1	sp|K1Q5Z1|K1Q5Z1_CRAGI	4.1e-66	256.9	87.66%	59.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019763.1	sp|K1Q5J2|K1Q5J2_CRAGI	3.7e-83	313.5	77.64%	88.59%	B-cell receptor-associated protein 31;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0016021|	GO:0006886|
GN019764.1	sp|K1Q8T7|K1Q8T7_CRAGI	3.2e-18	97.4	32.22%	80.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019765.1	sp|K1RKE5|K1RKE5_CRAGI	0.0e+00	1354.0	96.00%	98.16%	IQ and AAA domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|
GN019766.1	sp|K1PV02|K1PV02_CRAGI	3.0e-252	876.3	99.60%	86.00%	Succinate-semialdehyde dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0009013|	GO:0009450|
GN019767.1	sp|K1RSY3|K1RSY3_CRAGI	3.1e-51	207.2	98.98%	54.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019769.1	sp|K1PLG7|K1PLG7_CRAGI	6.5e-108	397.1	63.70%	53.60%	Interleukin-17 receptor D;OS=Crassostrea;PE=4;SV=1	GO:0030368|
GN019771.1	sp|K1RM73|K1RM73_CRAGI	3.6e-58	231.9	54.73%	41.19%	OTU domain-containing protein 6B;OS=Crassostrea;PE=4;SV=1
GN019774.1	sp|K1RSG7|K1RSG7_CRAGI	4.5e-271	939.5	99.36%	70.04%	Serine/threonine-protein kinase Nek4;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019775.1	sp|K1PT20|K1PT20_CRAGI	0.0e+00	1250.7	85.68%	84.09%	Prestin;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0008271|
GN019776.1	sp|K1QTG4|K1QTG4_CRAGI	1.4e-307	1060.8	85.34%	76.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019777.1	sp|K1QMK9|K1QMK9_CRAGI	2.7e-97	361.7	92.35%	39.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|	GO:0006801|
GN019778.1	sp|K1RLX8|K1RLX8_CRAGI	5.3e-89	334.0	53.36%	68.09%	Serine/threonine-protein phosphatase 4 regulatory subunit 2-A;OS=Crassostrea;PE=4;SV=1	GO:0030289|	GO:0019888|
GN019781.1	sp|A0A210R3L8|A0A210R3L8_MIZYE	5.5e-243	845.9	99.04%	62.56%	Beta-galactosidase;OS=Mizuhopecten;PE=3;SV=1	GO:0004565|	GO:0005975|
GN019782.1	sp|K1QGS1|K1QGS1_CRAGI	1.1e-114	419.9	90.00%	36.49%	Endothelin-converting enzyme 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|
GN019783.1	sp|A0A210Q6Z1|A0A210Q6Z1_MIZYE	1.2e-105	389.4	77.93%	47.37%	MFS-type transporter SLC18B1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN019785.1	sp|K1Q0S2|K1Q0S2_CRAGI	1.4e-147	528.1	100.00%	79.20%	NUAK family SNF1-like kinase 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019786.1	sp|K1Q7Z8|K1Q7Z8_CRAGI	1.4e-12	79.3	16.91%	84.44%	Wiskott-Aldrich syndrome protein;OS=Crassostrea;PE=4;SV=1	GO:0003779|	GO:0007015|GO:2000601|
GN019787.1	sp|K1QEE5|K1QEE5_CRAGI	1.9e-79	300.8	95.14%	95.45%	Calcium-dependent secretion activator 1;OS=Crassostrea;PE=4;SV=1	GO:0098793|	GO:1990504|GO:0016079|
GN019788.1	sp|K1QGB3|K1QGB3_CRAGI	1.6e-266	923.7	100.00%	88.57%	Cholesterol 7-alpha-monooxygenase;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN019790.1	sp|K1RFP7|K1RFP7_CRAGI	1.1e-35	155.6	53.09%	66.67%	UPF0595 protein C22orf40-like protein;OS=Crassostrea;PE=4;SV=1
GN019792.1	sp|A0A210QSG5|A0A210QSG5_MIZYE	0.0e+00	1657.9	99.70%	61.87%	ATP-binding cassette sub-family A member 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019794.1	sp|K1QGA5|K1QGA5_CRAGI	1.4e-106	391.3	89.22%	88.83%	Cyclin-related protein FAM58A;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN019795.1	sp|K1QWK4|K1QWK4_CRAGI	3.7e-66	258.1	97.04%	32.85%	Kelch-like protein 2;OS=Crassostrea;PE=4;SV=1
GN019796.1	sp|K1RKR8|K1RKR8_CRAGI	2.6e-226	791.2	86.57%	82.08%	Pumilio-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0003723|
GN019797.1	sp|K1Q831|K1Q831_CRAGI	0.0e+00	2087.0	99.82%	62.47%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|GO:0003723|	GO:0042981|
GN019798.1	sp|K1S1I0|K1S1I0_CRAGI	1.9e-223	780.8	93.27%	67.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019799.1	sp|A0A2T7NTG1|A0A2T7NTG1_POMCA	6.5e-127	459.9	93.33%	59.61%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0003700|	GO:0006357|
GN019800.1	sp|A0A210PZU7|A0A210PZU7_MIZYE	4.0e-111	407.1	98.18%	53.39%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019801.1	sp|T1FNE3|T1FNE3_HELRO	2.8e-233	813.1	100.00%	88.18%	Tubulin alpha chain;OS=Helobdella;PE=3;SV=1	GO:0005737|GO:0005874|	GO:0005525|GO:0003924|GO:0005200|	GO:0000226|GO:0007017|GO:0000278|
GN019802.1	sp|K1QD54|K1QD54_CRAGI	0.0e+00	1169.8	100.00%	88.01%	Nuclear receptor subfamily 2 group C member 2;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN019803.1	sp|A0A210PZU2|A0A210PZU2_MIZYE	4.8e-187	659.8	93.45%	57.66%	EGF domain-specific O-linked N-acetylglucosamine transferase;OS=Mizuhopecten;PE=4;SV=1	GO:0016757|
GN019804.1	sp|K1RL30|K1RL30_CRAGI	4.1e-63	246.1	100.00%	84.85%	Hepatocyte growth factor receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0004672|GO:0017154|
GN018810.1	sp|K1Q9V0|K1Q9V0_CRAGI	1.5e-180	637.5	99.03%	99.34%	WD repeat-containing protein 82;OS=Crassostrea;PE=4;SV=1	GO:0072357|GO:0048188|GO:0005802|GO:0031982|	GO:0005525|GO:0003924|	GO:0016192|
GN019805.1	sp|K1RLX8|K1RLX8_CRAGI	1.2e-12	79.3	50.86%	46.28%	Serine/threonine-protein phosphatase 4 regulatory subunit 2-A;OS=Crassostrea;PE=4;SV=1	GO:0030289|	GO:0019888|
GN019808.1	sp|K1QP25|K1QP25_CRAGI	1.5e-24	119.8	34.70%	46.71%	Brevican core protein;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN019809.1	sp|K1Q7L9|K1Q7L9_CRAGI	2.2e-107	394.4	99.37%	64.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019810.1	sp|K1RC34|K1RC34_CRAGI	1.4e-40	171.0	100.00%	76.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019811.1	sp|K1Q7L9|K1Q7L9_CRAGI	8.2e-110	402.5	99.37%	65.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019812.1	sp|K1QF83|K1QF83_CRAGI	3.6e-154	550.1	100.00%	71.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019814.1	sp|A0A2G8KA18|A0A2G8KA18_STIJA	1.3e-27	129.4	73.24%	34.09%	Retrovirus-related Pol polyprotein from transposon;OS=Stichopus;PE=4;SV=1	GO:0004190|
GN019815.1	sp|A0A2G8K0G5|A0A2G8K0G5_STIJA	4.9e-41	173.3	99.48%	45.26%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN019816.1	sp|K1PEP3|K1PEP3_CRAGI	2.9e-70	270.8	97.97%	57.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019817.1	sp|K1Q7U2|K1Q7U2_CRAGI	3.5e-71	274.2	78.74%	48.68%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019818.1	sp|A0A210Q993|A0A210Q993_MIZYE	1.9e-109	401.4	99.09%	64.62%	Phenylserine dehydratase;OS=Mizuhopecten;PE=4;SV=1	GO:0030170|	GO:0006520|
GN019819.1	sp|K1QN84|K1QN84_CRAGI	1.6e-115	421.4	82.14%	78.26%	Monoglyceride lipase;OS=Crassostrea;PE=4;SV=1
GN019820.1	sp|K1QYY5|K1QYY5_CRAGI	1.4e-47	194.9	98.86%	54.07%	Monoglyceride lipase;OS=Crassostrea;PE=4;SV=1
GN019821.1	sp|K1QXW9|K1QXW9_CRAGI	1.2e-103	381.7	85.71%	85.58%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN019822.1	sp|K1R5H7|K1R5H7_CRAGI	5.2e-131	472.6	94.94%	90.69%	Cell division cycle protein 20-like protein;OS=Crassostrea;PE=4;SV=1	GO:0010997|GO:0097027|	GO:0031145|GO:0051301|GO:1904668|
GN019823.1	sp|K1RC27|K1RC27_CRAGI	4.0e-44	183.0	73.02%	97.80%	Trafficking protein particle complex subunit 5;OS=Crassostrea;PE=3;SV=1	GO:0005783|GO:0005794|GO:0030008|	GO:0048193|
GN019825.1	sp|K1PU68|K1PU68_CRAGI	3.2e-70	270.4	100.00%	67.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019826.1	sp|K1QWY7|K1QWY7_CRAGI	3.8e-217	759.6	97.19%	66.85%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|	GO:0006004|
GN019828.1	sp|K1PPT3|K1PPT3_CRAGI	2.8e-70	272.3	42.05%	45.82%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019829.1	sp|K1Q6H8|K1Q6H8_CRAGI	2.4e-49	201.1	95.81%	50.96%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN019830.1	sp|K1QY88|K1QY88_CRAGI	3.2e-81	308.9	55.33%	39.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019831.1	sp|K1QDS1|K1QDS1_CRAGI	3.1e-94	350.1	98.56%	84.31%	3-hydroxyacyl-CoA dehydrogenase type-2;OS=Crassostrea;PE=3;SV=1	GO:0016491|
GN019833.1	sp|A0A1S3KIV2|A0A1S3KIV2_LINUN	7.3e-77	293.5	98.84%	38.30%	uncharacterized protein LOC106182054 isoform X2;OS=Lingula;PE=4;SV=2
GN019834.1	sp|K1QT45|K1QT45_CRAGI	8.4e-92	343.2	97.81%	67.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019835.1	sp|K1QT45|K1QT45_CRAGI	1.0e-145	522.3	87.97%	72.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019836.1	sp|A0A210PSN4|A0A210PSN4_MIZYE	3.6e-125	453.8	99.18%	55.79%	Sugar phosphate exchanger 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0022857|
GN019837.1	sp|K1Q178|K1Q178_CRAGI	4.7e-122	443.7	99.57%	48.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019838.1	sp|K1QIE5|K1QIE5_CRAGI	7.7e-130	469.5	97.34%	50.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019839.1	sp|K1QHE7|K1QHE7_CRAGI	1.5e-19	101.7	82.72%	42.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019840.1	sp|K1Q6H8|K1Q6H8_CRAGI	2.2e-16	92.0	47.95%	39.16%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN019841.1	sp|K1QRI0|K1QRI0_CRAGI	0.0e+00	2214.1	99.34%	81.51%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019842.1	sp|K1PZI5|K1PZI5_CRAGI	1.7e-42	179.5	36.83%	50.84%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019843.1	sp|W4XY62|W4XY62_STRPU	5.6e-39	167.5	45.57%	40.22%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0016788|GO:0003676|GO:0008270|	GO:0015074|
GN019844.1	sp|A0A1S3HLZ0|A0A1S3HLZ0_LINUN	1.8e-21	109.4	38.32%	35.33%	uncharacterized protein LOC106155992;OS=Lingula;PE=4;SV=1
GN019845.1	sp|K1PPT3|K1PPT3_CRAGI	4.4e-103	381.7	68.66%	36.77%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN019846.1	sp|K1PGZ2|K1PGZ2_CRAGI	7.3e-14	83.2	54.25%	41.18%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN019847.1	sp|K1Q7N1|K1Q7N1_CRAGI	6.3e-17	93.2	43.68%	51.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019848.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.6e-48	198.4	95.83%	48.56%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018701.1	sp|K1QRI0|K1QRI0_CRAGI	5.8e-244	849.0	98.22%	76.71%	ATP-binding cassette sub-family A member 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019850.1	sp|K1R993|K1R993_CRAGI	2.2e-31	141.4	78.92%	48.19%	Paired box protein Pax-8;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0007275|GO:0006355|
GN019852.1	sp|K1QVS0|K1QVS0_CRAGI	6.5e-182	642.1	95.25%	98.44%	Ras-like GTP-binding protein Rho1;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN018817.1	sp|K1RMK2|K1RMK2_CRAGI	2.0e-20	104.0	63.46%	77.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018819.1	sp|A0A210R559|A0A210R559_MIZYE	6.9e-24	116.3	83.42%	36.13%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018820.1	sp|A0A2B4S0M7|A0A2B4S0M7_STYPI	5.4e-10	70.5	90.13%	26.42%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN018702.1	sp|K1PHJ6|K1PHJ6_CRAGI	1.9e-109	402.1	91.43%	44.21%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN018822.1	sp|K1Q6H8|K1Q6H8_CRAGI	5.1e-55	219.9	96.74%	54.55%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018823.1	sp|A0A1S3KFK0|A0A1S3KFK0_LINUN	5.6e-45	187.2	61.28%	48.76%	uncharacterized protein LOC106181232;OS=Lingula;PE=4;SV=1
GN018824.1	sp|K1PHJ6|K1PHJ6_CRAGI	3.8e-115	422.2	52.35%	38.87%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN018825.1	sp|K1QIU8|K1QIU8_CRAGI	2.8e-64	250.0	100.00%	83.33%	Caveolin;OS=Crassostrea;PE=3;SV=1	GO:0005901|GO:0000139|GO:0016021|	GO:0070836|
GN018703.1	sp|K1Q6H8|K1Q6H8_CRAGI	2.2e-16	92.0	47.95%	39.16%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018827.1	sp|K1PBV0|K1PBV0_CRAGI	3.9e-257	892.5	100.00%	90.81%	UDP-glucose 6-dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0003979|
GN018829.1	sp|K1Q3P2|K1Q3P2_CRAGI	4.0e-66	256.1	100.00%	86.36%	Vitamin D(3) 25-hydroxylase;OS=Crassostrea;PE=3;SV=1	GO:0005901|GO:0000139|GO:0016021|	GO:0020037|GO:0005506|GO:0016705|	GO:0070836|
GN018830.1	sp|K1S5T3|K1S5T3_CRAGI	0.0e+00	1133.2	71.44%	74.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN018831.1	sp|K1R068|K1R068_CRAGI	1.6e-198	698.0	95.30%	63.31%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0016787|
GN018704.1	sp|K1PHJ6|K1PHJ6_CRAGI	3.4e-105	387.9	99.43%	41.40%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN018839.1	sp|K1RS12|K1RS12_CRAGI	1.5e-104	385.2	98.26%	66.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018692.1	sp|C3ZK91|C3ZK91_BRAFL	1.1e-79	303.5	67.38%	38.60%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN018705.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	3.7e-34	150.2	91.25%	52.38%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN018840.1	sp|K1RMA9|K1RMA9_CRAGI	3.1e-73	281.6	32.25%	89.19%	LIM domain-containing protein D;OS=Crassostrea;PE=4;SV=1
GN018842.1	sp|K1QXW9|K1QXW9_CRAGI	4.2e-154	550.4	99.45%	47.68%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018843.1	sp|K1QXW9|K1QXW9_CRAGI	7.5e-28	129.0	86.86%	48.31%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018844.1	sp|K1QXW9|K1QXW9_CRAGI	2.7e-153	547.7	99.45%	45.80%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018845.1	sp|K1QWM2|K1QWM2_CRAGI	4.4e-19	100.1	78.53%	38.58%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018846.1	sp|K1QXW9|K1QXW9_CRAGI	6.9e-157	559.7	99.09%	48.21%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018847.1	sp|K1QXW9|K1QXW9_CRAGI	2.2e-86	324.7	97.86%	47.18%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018706.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.1e-55	222.2	90.54%	54.46%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018849.1	sp|A0A210QF09|A0A210QF09_MIZYE	2.8e-26	125.6	73.33%	32.16%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018850.1	sp|K1QX25|K1QX25_CRAGI	7.1e-44	183.7	96.02%	34.61%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN018851.1	sp|K1PMC5|K1PMC5_CRAGI	2.7e-25	120.2	98.11%	58.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018852.1	sp|A0A210Q676|A0A210Q676_MIZYE	2.1e-37	161.4	97.12%	43.56%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018855.1	sp|K1R861|K1R861_CRAGI	8.7e-75	285.8	99.60%	46.13%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN018856.1	sp|K1RLP8|K1RLP8_CRAGI	6.1e-40	169.1	89.84%	67.54%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN018707.1	sp|K1QFL5|K1QFL5_CRAGI	3.1e-58	232.6	43.15%	36.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018858.1	sp|K1Q6H8|K1Q6H8_CRAGI	4.1e-33	149.1	32.96%	36.09%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018859.1	sp|A0A210Q676|A0A210Q676_MIZYE	3.7e-36	157.1	96.95%	44.21%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018861.1	sp|K1PF79|K1PF79_CRAGI	5.4e-154	551.2	85.61%	37.44%	Cadherin EGF LAG seven-pass G-type receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005509|GO:0004930|	GO:0007166|
GN018862.1	sp|K1RES3|K1RES3_CRAGI	6.0e-127	459.5	97.65%	67.47%	N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D;OS=Crassostrea;PE=4;SV=1	GO:0070290|GO:0008270|
GN018863.1	sp|K1RIG4|K1RIG4_CRAGI	3.4e-171	607.1	92.70%	58.81%	Carboxylic ester hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0004104|
GN018708.1	sp|K1QY88|K1QY88_CRAGI	3.2e-81	308.9	55.33%	39.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN018864.1	sp|K1QX30|K1QX30_CRAGI	1.6e-274	950.7	91.63%	89.17%	U4/U6 small nuclear ribonucleoprotein Prp3;OS=Crassostrea;PE=4;SV=1	GO:0046540|GO:0019013|	GO:0000398|
GN018868.1	sp|A0A210PW63|A0A210PW63_MIZYE	6.6e-12	76.6	60.29%	34.68%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018869.1	sp|K1QX25|K1QX25_CRAGI	8.1e-150	536.6	99.29%	42.23%	RBR-type E3 ubiquitin transferase;OS=Crassostrea;PE=3;SV=1	GO:0016874|GO:0046872|GO:0004842|
GN018870.1	sp|K1QXW9|K1QXW9_CRAGI	3.7e-22	109.8	96.33%	48.08%	Acyl-CoA synthetase family member 2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN018872.1	sp|K1R465|K1R465_CRAGI	1.2e-63	249.6	78.32%	40.94%	General transcription factor 3C polypeptide 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018873.1	sp|K1QQ60|K1QQ60_CRAGI	1.3e-296	1024.6	99.15%	61.16%	General transcription factor 3C polypeptide 1;OS=Crassostrea;PE=4;SV=1
GN018878.1	sp|A0A210PF77|A0A210PF77_MIZYE	2.0e-22	111.3	84.85%	47.52%	Protocadherin Fat 4;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN018880.1	sp|K1PVU0|K1PVU0_CRAGI	1.2e-10	71.2	95.35%	41.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018881.1	sp|K1PPD0|K1PPD0_CRAGI	2.0e-29	134.4	99.34%	42.67%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018882.1	sp|A0A2T7NVX4|A0A2T7NVX4_POMCA	2.4e-38	164.9	93.66%	36.11%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN018883.1	sp|K1QY65|K1QY65_CRAGI	5.7e-248	862.8	72.80%	78.43%	Uncharacterized protein C12orf56-like protein;OS=Crassostrea;PE=4;SV=1
GN018886.1	sp|A0A088ASR6|A0A088ASR6_APIME	2.6e-22	111.3	98.20%	34.22%	ATP-dependent DNA helicase PIF1;OS=Apis;PE=3;SV=1	GO:0005739|GO:0005634|	GO:0005524|GO:0043141|GO:0003677|	GO:0006310|GO:0006281|GO:0000002|GO:0000723|
GN018709.1	sp|K1QKH0|K1QKH0_CRAGI	1.1e-51	210.3	33.45%	55.26%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN018887.1	sp|K1RCU3|K1RCU3_CRAGI	1.3e-96	359.0	87.09%	52.97%	Poly [ADP-ribose] polymerase 12;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN018893.1	sp|K1RCC8|K1RCC8_CRAGI	3.8e-37	160.2	88.44%	55.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005739|	GO:0051607|
GN018895.1	sp|K1RV76|K1RV76_CRAGI	5.6e-119	433.0	92.14%	68.15%	Amine sulfotransferase;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN018897.1	sp|K1Q697|K1Q697_CRAGI	1.1e-67	262.3	98.16%	50.37%	NAD(P)(+)--arginine ADP-ribosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0003956|	GO:0006471|
GN018899.1	sp|K1QP33|K1QP33_CRAGI	1.8e-271	940.6	94.36%	68.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018901.1	sp|A0A210QPI8|A0A210QPI8_MIZYE	1.8e-67	261.2	91.58%	70.52%	Parkinson disease 7 domain-containing protein 1;OS=Mizuhopecten;PE=4;SV=1
GN018902.1	sp|K1Q1M0|K1Q1M0_CRAGI	0.0e+00	1128.6	100.00%	68.19%	Putative tyrosinase-like protein tyr-3;OS=Crassostrea;PE=4;SV=1	GO:0030246|GO:0046872|GO:0016491|
GN018903.1	sp|K1PU92|K1PU92_CRAGI	2.4e-232	811.2	56.22%	78.86%	Forkhead box protein P1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|
GN018904.1	sp|K1RFZ5|K1RFZ5_CRAGI	7.6e-116	422.9	73.12%	68.95%	Adipocyte plasma membrane-associated protein;OS=Crassostrea;PE=4;SV=1	GO:0016844|	GO:0009058|
GN018905.1	sp|K1Q8Q1|K1Q8Q1_CRAGI	2.1e-296	1023.5	94.07%	71.50%	Laccase-2;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN018906.1	sp|K1RDQ0|K1RDQ0_CRAGI	1.5e-19	102.1	38.89%	48.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018907.1	sp|K1RFZ1|K1RFZ1_CRAGI	2.4e-17	94.0	90.32%	43.24%	Cystatin-A2;OS=Crassostrea;PE=4;SV=1	GO:0004866|
GN018908.1	sp|K1RZA9|K1RZA9_CRAGI	4.4e-31	140.6	95.08%	93.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018909.1	sp|K1Q8Q1|K1Q8Q1_CRAGI	2.9e-285	986.5	85.49%	73.11%	Laccase-2;OS=Crassostrea;PE=3;SV=1	GO:0005507|GO:0016491|
GN018910.1	sp|K1QU17|K1QU17_CRAGI	3.5e-276	956.4	100.00%	74.77%	NCK-interacting protein with SH3 domain;OS=Crassostrea;PE=4;SV=1
GN018911.1	sp|K1Q6H8|K1Q6H8_CRAGI	8.3e-92	343.6	79.01%	40.98%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN018912.1	sp|K1QK61|K1QK61_CRAGI	1.3e-107	394.8	99.58%	78.01%	Prostaglandin reductase 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0047522|GO:0032440|
GN018914.1	sp|K1PG09|K1PG09_CRAGI	5.8e-75	286.2	99.08%	67.44%	Death domain-containing protein CRADD;OS=Crassostrea;PE=4;SV=1	GO:0042981|GO:0007165|
GN018915.1	sp|K1RCN4|K1RCN4_CRAGI	4.5e-158	562.8	97.01%	93.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018916.1	sp|K1R652|K1R652_CRAGI	7.7e-32	142.9	76.08%	81.82%	Uncharacterized protein C17orf59-like protein;OS=Crassostrea;PE=4;SV=1
GN018917.1	sp|K1Q7Y0|K1Q7Y0_CRAGI	1.2e-63	249.2	46.29%	78.06%	Ankyrin repeat and SOCS box protein 8;OS=Crassostrea;PE=4;SV=1
GN018918.1	sp|K1PJF4|K1PJF4_CRAGI	0.0e+00	2298.9	96.87%	89.90%	Isoleucyl-tRNA synthetase, cytoplasmic;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0002161|GO:0005524|GO:0004822|GO:0000049|	GO:0006428|
GN018919.1	sp|K1R7R6|K1R7R6_CRAGI	5.3e-260	902.1	98.84%	82.30%	Purple acid phosphatase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0003993|GO:0046872|
GN018920.1	sp|K1QTQ8|K1QTQ8_CRAGI	3.1e-55	222.6	38.52%	35.82%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN018922.1	sp|A0A210R729|A0A210R729_MIZYE	4.1e-28	130.6	67.43%	49.32%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018923.1	sp|A0A210R729|A0A210R729_MIZYE	9.3e-85	319.3	92.35%	51.78%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018925.1	sp|A0A210R729|A0A210R729_MIZYE	1.6e-51	208.4	84.42%	51.98%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018926.1	sp|A0A210R729|A0A210R729_MIZYE	1.8e-21	107.5	84.62%	56.18%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018927.1	sp|K1QWP4|K1QWP4_CRAGI	6.6e-48	195.7	80.58%	81.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018928.1	sp|A0A210R729|A0A210R729_MIZYE	4.6e-84	317.0	92.35%	51.46%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018931.1	sp|K1PMC5|K1PMC5_CRAGI	2.7e-25	120.2	98.11%	58.25%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018932.1	sp|K1QVY8|K1QVY8_CRAGI	1.1e-145	522.7	100.00%	59.20%	Armadillo repeat-containing X-linked protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018933.1	sp|K1R2M2|K1R2M2_CRAGI	2.5e-21	106.3	98.51%	84.62%	OTU domain-containing protein 5-B;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN018934.1	sp|K1R2M2|K1R2M2_CRAGI	2.7e-39	166.4	93.10%	95.00%	OTU domain-containing protein 5-B;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN018935.1	sp|K1QTQ8|K1QTQ8_CRAGI	5.9e-78	298.9	29.86%	37.14%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN018936.1	sp|A0A1X7TY35|A0A1X7TY35_AMPQE	1.1e-21	108.6	87.16%	43.75%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN018938.1	sp|K1R2L7|K1R2L7_CRAGI	6.7e-204	715.3	98.66%	92.39%	Glutaminyl-tRNA synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004819|	GO:0006425|
GN018939.1	sp|K1R2L7|K1R2L7_CRAGI	1.4e-97	361.3	100.00%	85.02%	Glutaminyl-tRNA synthetase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0004819|	GO:0006425|
GN018940.1	sp|K1QNA5|K1QNA5_CRAGI	3.7e-220	770.4	86.64%	58.38%	Protocadherin-like wing polarity protein stan;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005886|	GO:0005509|	GO:0007156|
GN018941.1	sp|K1Q7T3|K1Q7T3_CRAGI	1.6e-67	261.9	92.71%	47.21%	Beta-1,3-galactosyltransferase 5;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0008378|	GO:0006486|
GN018944.1	sp|K1RNQ1|K1RNQ1_CRAGI	3.1e-67	260.8	87.80%	56.31%	Kelch-like protein 28;OS=Crassostrea;PE=4;SV=1
GN018945.1	sp|A0A210R5C7|A0A210R5C7_MIZYE	7.9e-145	518.8	100.00%	76.09%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018946.1	sp|K1QXZ7|K1QXZ7_CRAGI	3.6e-75	287.3	88.37%	56.51%	VWFA and cache domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN018947.1	sp|K1QQG0|K1QQG0_CRAGI	0.0e+00	1493.4	99.86%	76.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018948.1	sp|K1PK61|K1PK61_CRAGI	6.7e-41	173.3	77.74%	50.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018949.1	sp|K1QE46|K1QE46_CRAGI	0.0e+00	1385.5	95.42%	91.44%	Conserved oligomeric Golgi complex subunit 5;OS=Crassostrea;PE=4;SV=1	GO:0017119|	GO:0006891|
GN018950.1	sp|K1R069|K1R069_CRAGI	1.4e-124	451.4	85.02%	89.71%	tRNA-dihydrouridine synthase;OS=Crassostrea;PE=3;SV=1	GO:0050660|GO:0017150|
GN018951.1	sp|K1PS47|K1PS47_CRAGI	0.0e+00	1656.0	93.38%	62.39%	Serine/threonine-protein kinase WNK1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004674|
GN018953.1	sp|K1QE71|K1QE71_CRAGI	0.0e+00	1570.4	99.77%	93.56%	DNA helicase;OS=Crassostrea;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0004386|	GO:0006270|GO:1905775|
GN018954.1	sp|K1Q742|K1Q742_CRAGI	0.0e+00	1572.4	97.57%	73.57%	Mitosis inhibitor protein kinase wee1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN018955.1	sp|K1Q742|K1Q742_CRAGI	3.6e-189	667.9	98.71%	36.58%	Mitosis inhibitor protein kinase wee1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN018956.1	sp|K1QE80|K1QE80_CRAGI	0.0e+00	1342.8	98.61%	63.74%	Uncharacterized protein in xynA 3'region;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN018957.1	sp|K1PSU8|K1PSU8_CRAGI	5.6e-119	432.6	100.00%	92.89%	Transmembrane BAX inhibitor motif-containing protein 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN018958.1	sp|K1PKV9|K1PKV9_CRAGI	2.8e-171	607.1	100.00%	83.08%	Uncharacterized protein C3orf32;OS=Crassostrea;PE=4;SV=1
GN018959.1	sp|K1RET6|K1RET6_CRAGI	3.1e-214	750.4	93.80%	64.64%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|
GN018960.1	sp|K1PKV9|K1PKV9_CRAGI	2.8e-171	607.1	100.00%	83.08%	Uncharacterized protein C3orf32;OS=Crassostrea;PE=4;SV=1
GN018961.1	sp|K1PSU8|K1PSU8_CRAGI	5.6e-119	432.6	100.00%	92.89%	Transmembrane BAX inhibitor motif-containing protein 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN018962.1	sp|K1R338|K1R338_CRAGI	4.0e-53	213.4	98.88%	55.68%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN018712.1	sp|K1PG51|K1PG51_CRAGI	5.5e-36	155.6	93.07%	82.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018713.1	sp|K1QHE7|K1QHE7_CRAGI	1.5e-19	101.7	82.72%	42.75%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018964.1	sp|W4ZKT7|W4ZKT7_STRPU	5.1e-09	68.2	48.65%	33.33%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN018966.1	sp|K1P112|K1P112_CRAGI	5.9e-72	275.8	100.00%	85.80%	ATP synthase subunit gamma, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0045261|	GO:0046933|	GO:0015986|
GN018967.1	sp|K1R5S1|K1R5S1_CRAGI	1.3e-41	175.3	54.17%	86.41%	ATP synthase subunit gamma;OS=Crassostrea;PE=3;SV=1	GO:0045261|	GO:0046933|	GO:0015986|
GN018968.1	sp|K1QUB9|K1QUB9_CRAGI	1.5e-147	528.1	99.46%	83.70%	Uncharacterized protein C3orf32;OS=Crassostrea;PE=4;SV=1
GN018969.1	sp|K1QQK9|K1QQK9_CRAGI	1.9e-152	544.7	100.00%	68.50%	RNA polymerase II-associated protein 3;OS=Crassostrea;PE=4;SV=1
GN018970.1	sp|K1PSY1|K1PSY1_CRAGI	2.2e-30	136.7	100.00%	75.31%	MAM domain-containing glycosylphosphatidylinositol anchor protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016020|
GN018971.1	sp|K1PLE4|K1PLE4_CRAGI	3.3e-122	443.7	85.58%	79.29%	Inter-alpha-trypsin inhibitor heavy chain H3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004867|	GO:0030212|
GN018972.1	sp|K1PDK4|K1PDK4_CRAGI	8.4e-219	765.4	95.31%	72.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018978.1	sp|K1Q171|K1Q171_CRAGI	2.6e-84	318.5	94.01%	36.15%	60 kDa SS-A/Ro ribonucleoprotein;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0019013|	GO:0003723|
GN018979.1	sp|K1S4L8|K1S4L8_CRAGI	0.0e+00	1586.6	58.41%	78.53%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN018981.1	sp|A0A210R4B7|A0A210R4B7_MIZYE	2.1e-67	263.1	80.45%	28.96%	Inter-alpha-trypsin inhibitor heavy chain H3;OS=Mizuhopecten;PE=4;SV=1	GO:0004867|	GO:0030212|
GN018982.1	sp|K1RHC5|K1RHC5_CRAGI	6.0e-70	269.2	97.74%	76.16%	UDP-N-acetylglucosamine transferase subunit ALG13-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016758|	GO:0006488|
GN018983.1	sp|K1RL61|K1RL61_CRAGI	5.5e-36	156.8	92.04%	38.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018984.1	sp|K1S449|K1S449_CRAGI	1.3e-16	92.4	56.64%	35.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018985.1	sp|K1PE57|K1PE57_CRAGI	4.2e-152	543.1	100.00%	79.48%	Severin;OS=Crassostrea;PE=4;SV=1	GO:0051015|
GN018714.1	sp|K1PG51|K1PG51_CRAGI	5.5e-36	155.6	93.07%	82.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN018987.1	sp|K1PU86|K1PU86_CRAGI	7.5e-35	151.8	98.95%	78.49%	Thioredoxin reductase 3;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0009055|GO:0050660|GO:0004791|	GO:0045454|
GN018988.1	sp|K1QGL9|K1QGL9_CRAGI	9.6e-58	228.4	100.00%	91.67%	Mannose-1-phosphate guanyltransferase beta;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN018989.1	sp|K1QQ79|K1QQ79_CRAGI	3.2e-90	336.7	97.85%	84.53%	4-aminobutyrate aminotransferase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0030170|GO:0008483|
GN018990.1	sp|W4ZKT7|W4ZKT7_STRPU	2.9e-09	67.8	70.47%	42.03%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0000124|GO:0046695|GO:0005669|	GO:0046982|GO:0001102|	GO:0006325|GO:0006357|GO:0051123|GO:0006366|
GN018991.1	sp|A0A1S3JF56|A0A1S3JF56_LINUN	1.7e-34	152.1	42.66%	53.06%	RNA-binding protein 5;OS=Lingula;PE=4;SV=1	GO:0046872|GO:0003723|
GN018992.1	sp|R7UCN5|R7UCN5_CAPTE	9.0e-12	75.9	76.07%	34.65%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN018993.1	sp|K1R0J2|K1R0J2_CRAGI	5.5e-51	206.1	75.48%	82.05%	PR domain zinc finger protein 14;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN018994.1	sp|K1RE59|K1RE59_CRAGI	6.0e-88	329.7	99.65%	61.13%	Heart-and neural crest derivatives-expressed protein 2;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN018995.1	sp|K1PKQ3|K1PKQ3_CRAGI	3.3e-164	583.6	84.54%	81.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN018996.1	sp|K1PKQ3|K1PKQ3_CRAGI	9.6e-165	585.1	98.26%	81.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN018997.1	sp|A0A210PEZ0|A0A210PEZ0_MIZYE	2.7e-31	140.6	96.03%	47.97%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN018716.1	sp|K1PU68|K1PU68_CRAGI	3.2e-70	270.4	100.00%	67.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN018999.1	sp|K1QLJ4|K1QLJ4_CRAGI	1.2e-19	101.3	96.91%	44.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0008061|	GO:0006030|
GN019000.1	sp|K1R0T8|K1R0T8_CRAGI	2.5e-150	537.7	75.00%	71.51%	Cytochrome P450 2B4;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0005506|GO:0016705|
GN019001.1	sp|A0A210R4D1|A0A210R4D1_MIZYE	3.9e-178	630.6	96.11%	63.34%	p53-induced protein with a death domain;OS=Mizuhopecten;PE=4;SV=1
GN019002.1	sp|K1QG88|K1QG88_CRAGI	2.8e-195	686.8	96.81%	83.50%	Mannosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005788|GO:0005789|GO:0016021|	GO:0052824|	GO:0006488|
GN019003.1	sp|K1PU78|K1PU78_CRAGI	1.2e-224	785.0	71.38%	80.13%	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN019004.1	sp|K1Q5X2|K1Q5X2_CRAGI	1.4e-115	422.2	68.34%	67.52%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN019005.1	sp|K1R500|K1R500_CRAGI	1.6e-144	518.1	77.17%	79.43%	4-hydroxybenzoate polyprenyltransferase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0031305|	GO:0002083|GO:0047293|	GO:0008299|GO:0006744|
GN019008.1	sp|A0A210PF02|A0A210PF02_MIZYE	2.9e-211	740.7	94.34%	55.59%	Serine/threonine-protein kinase B-raf;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0046872|GO:0004674|	GO:0035556|
GN019009.1	sp|A0A210R3D3|A0A210R3D3_MIZYE	3.1e-307	1060.1	96.16%	55.99%	Glutamate receptor-interacting protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0030159|
GN018717.1	sp|K1QG78|K1QG78_CRAGI	6.9e-24	114.8	96.92%	72.58%	Collectin-11;OS=Crassostrea;PE=4;SV=1
GN019010.1	sp|K1QVC3|K1QVC3_CRAGI	1.8e-105	387.5	93.49%	88.50%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN019011.1	sp|K1R4Y0|K1R4Y0_CRAGI	0.0e+00	1103.2	100.00%	68.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019012.1	sp|V5YTB4|V5YTB4_9BIVA	1.3e-250	871.3	93.14%	69.60%	Transporter;OS=Bathymodiolus;PE=2;SV=1	GO:0016021|	GO:0005328|
GN019013.1	sp|K1S0P1|K1S0P1_CRAGI	0.0e+00	1506.9	88.75%	87.94%	Kinesin-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0008017|GO:0003777|	GO:0007018|
GN019014.1	sp|K1R4Y5|K1R4Y5_CRAGI	7.2e-21	104.8	90.77%	82.76%	Putative helicase Mov10l1;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN019015.1	sp|K1PTG9|K1PTG9_CRAGI	2.0e-50	204.1	100.00%	56.29%	Toll-like receptor 1;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN019016.1	sp|K1R6N7|K1R6N7_CRAGI	5.0e-181	639.4	97.98%	75.00%	Mitochondrial tRNA-specific 2-thiouridylase 1;OS=Crassostrea;PE=3;SV=1	GO:0016783|	GO:0008033|
GN019017.1	sp|K1Q3X6|K1Q3X6_CRAGI	0.0e+00	2147.1	92.00%	66.13%	Neuropilin-1;OS=Crassostrea;PE=4;SV=1
GN019019.1	sp|V4A626|V4A626_LOTGI	2.5e-133	481.1	90.62%	58.48%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003676|
GN019020.1	sp|K1PLT7|K1PLT7_CRAGI	2.0e-183	648.3	94.74%	51.52%	Neprilysin-2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|
GN018718.1	sp|K1Q399|K1Q399_CRAGI	1.5e-105	387.9	100.00%	86.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019021.1	sp|A0A210PYJ1|A0A210PYJ1_MIZYE	9.7e-293	1012.3	98.61%	42.72%	Hepatocyte growth factor receptor;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004714|
GN019022.1	sp|K1QBB3|K1QBB3_CRAGI	2.1e-218	764.6	89.79%	56.33%	Methyl-CpG-binding domain protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0008263|	GO:0006281|
GN019023.1	sp|K1QBB0|K1QBB0_CRAGI	5.4e-236	822.4	99.62%	76.95%	DNA-(apurinic or apyrimidinic site) lyase;OS=Crassostrea;PE=3;SV=1	GO:0140078|GO:0003677|GO:0004519|GO:0008270|	GO:0006281|
GN019024.1	sp|K1QB97|K1QB97_CRAGI	1.1e-210	738.8	65.33%	77.19%	TBC1 domain family member 25;OS=Crassostrea;PE=4;SV=1	GO:0008146|
GN018719.1	sp|K1RH77|K1RH77_CRAGI	2.5e-229	800.0	100.00%	86.25%	Zinc finger MYND domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN019025.1	sp|K1QDG2|K1QDG2_CRAGI	0.0e+00	1118.2	100.00%	90.13%	Proton myo-inositol cotransporter;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN019026.1	sp|K1PPH6|K1PPH6_CRAGI	1.1e-75	289.3	100.00%	87.54%	Kelch domain-containing protein 8B;OS=Crassostrea;PE=4;SV=1
GN019027.1	sp|K1QK85|K1QK85_CRAGI	4.3e-245	852.4	97.59%	85.36%	Plasma alpha-L-fucosidase;OS=Crassostrea;PE=3;SV=1	GO:0004560|	GO:0006004|
GN019028.1	sp|K1RD08|K1RD08_CRAGI	2.9e-230	803.1	97.77%	91.30%	ATP-binding cassette sub-family D member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005778|	GO:0005524|GO:0042626|	GO:0006635|
GN019029.1	sp|K1PQ21|K1PQ21_CRAGI	1.5e-178	631.7	97.93%	60.80%	GRAM domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019030.1	sp|K1PVU0|K1PVU0_CRAGI	4.0e-28	130.2	97.56%	40.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019031.1	sp|K1Q718|K1Q718_CRAGI	5.4e-280	970.3	30.48%	90.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019034.1	sp|K1PLT0|K1PLT0_CRAGI	7.8e-109	398.7	100.00%	92.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019035.1	sp|K1PTH3|K1PTH3_CRAGI	1.1e-158	565.5	95.31%	72.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN019036.1	sp|K1Q800|K1Q800_CRAGI	1.7e-105	389.0	72.56%	46.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019037.1	sp|K1QTS9|K1QTS9_CRAGI	1.8e-174	617.5	98.57%	84.59%	Betaine--homocysteine S-methyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0047150|GO:0008270|	GO:0009086|
GN019038.1	sp|K1R250|K1R250_CRAGI	5.4e-60	236.9	99.31%	46.76%	Complement C1q subcomponent subunit A;OS=Crassostrea;PE=4;SV=1
GN019039.1	sp|K1Q937|K1Q937_CRAGI	1.0e-45	188.3	97.71%	66.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019040.1	sp|K1PD57|K1PD57_CRAGI	2.7e-78	297.7	100.00%	71.33%	Constitutive coactivator of PPAR-gamma-like protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN019041.1	sp|K1QJE4|K1QJE4_CRAGI	7.2e-64	249.2	75.25%	76.35%	Protein-lysine N-methyltransferase CGI_10003330;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0016279|
GN019042.1	sp|K1PZ08|K1PZ08_CRAGI	2.5e-112	410.2	100.00%	98.05%	Ras-related protein Rab-7a;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN019043.1	sp|K1RGA0|K1RGA0_CRAGI	4.0e-129	466.5	93.91%	93.49%	Ubiquitin carboxyl-terminal hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0004843|	GO:0006511|
GN019044.1	sp|K1PJF6|K1PJF6_CRAGI	7.3e-60	236.1	98.70%	56.72%	Homeobox expressed in ES cells 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN019045.1	sp|K1R2U8|K1R2U8_CRAGI	1.2e-55	221.5	98.60%	77.30%	Universal stress protein A-like protein;OS=Crassostrea;PE=4;SV=1
GN019046.1	sp|K1QEZ1|K1QEZ1_CRAGI	1.3e-178	631.3	100.00%	77.49%	Peroxisomal sarcosine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN019047.1	sp|F0V499|F0V499_MYTGA	5.2e-16	90.1	97.30%	29.89%	Putative C1q domain containing protein MgC1q62;OS=Mytilus;PE=2;SV=1
GN018720.1	sp|K1S024|K1S024_CRAGI	5.5e-87	326.6	94.16%	55.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019048.1	sp|K1QYY3|K1QYY3_CRAGI	7.6e-67	259.6	69.61%	59.18%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030414|
GN019049.1	sp|K1QYY3|K1QYY3_CRAGI	6.4e-32	144.1	31.01%	54.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030414|
GN019050.1	sp|K1QA54|K1QA54_CRAGI	0.0e+00	1476.8	88.49%	75.72%	Putative helicase MOV-10;OS=Crassostrea;PE=4;SV=1	GO:0032575|GO:0003723|	GO:0035194|
GN019051.1	sp|K1P2A2|K1P2A2_CRAGI	3.3e-33	146.4	99.00%	70.41%	Elongation factor Tu, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0003746|
GN019052.1	sp|K1QI33|K1QI33_CRAGI	0.0e+00	2457.6	98.27%	54.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN019053.1	sp|K1RA67|K1RA67_CRAGI	3.2e-28	130.2	99.24%	54.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019054.1	sp|K1QI36|K1QI36_CRAGI	0.0e+00	1817.7	100.00%	83.57%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN020129.1	sp|K1Q9T3|K1Q9T3_CRAGI	2.7e-40	171.8	98.11%	31.67%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020130.1	sp|K1Q2B0|K1Q2B0_CRAGI	1.9e-76	291.6	67.81%	65.99%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020132.1	sp|K1QH82|K1QH82_CRAGI	3.2e-48	197.6	90.91%	48.48%	Transient receptor potential cation channel subfamily M member 8;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005216|
GN020133.1	sp|K1Q3K8|K1Q3K8_CRAGI	1.6e-09	70.9	5.61%	61.22%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020135.1	sp|K1PJ38|K1PJ38_CRAGI	1.6e-173	614.8	86.49%	67.47%	Amiloride-sensitive cation channel 4;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN019895.1	sp|K1PB30|K1PB30_CRAGI	3.0e-56	224.6	34.62%	97.20%	WD repeat-containing protein 61;OS=Crassostrea;PE=4;SV=1
GN019854.1	sp|A0A2B4RAQ3|A0A2B4RAQ3_STYPI	8.8e-74	283.5	56.89%	45.67%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1	GO:0003676|
GN020141.1	sp|A0A3M6U888|A0A3M6U888_9CNID	3.0e-11	75.5	73.27%	24.57%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN020143.1	sp|A0A3M6U888|A0A3M6U888_9CNID	1.2e-09	70.5	36.89%	27.44%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN020144.1	sp|K1QDP1|K1QDP1_CRAGI	1.0e-55	221.9	94.48%	61.29%	Plasminogen;OS=Crassostrea;PE=4;SV=1
GN020145.1	sp|K1QMS5|K1QMS5_CRAGI	1.0e-86	325.1	98.97%	76.56%	Cysteine dioxygenase type 1;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0016702|
GN020148.1	sp|W4YPC4|W4YPC4_STRPU	1.9e-28	131.3	97.11%	38.24%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005829|	GO:0004748|	GO:0009263|
GN020150.1	sp|K1R9K5|K1R9K5_CRAGI	1.3e-60	239.2	62.13%	55.92%	Fibrinogen C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019896.1	sp|K1PQF5|K1PQF5_CRAGI	1.2e-102	380.2	64.28%	45.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020152.1	sp|K1QQD3|K1QQD3_CRAGI	9.4e-48	195.7	95.43%	51.87%	Complement C1q tumor necrosis factor-related protein 4;OS=Crassostrea;PE=4;SV=1
GN020153.1	sp|K1PTA0|K1PTA0_CRAGI	8.9e-73	279.6	80.90%	46.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020154.1	sp|K1PLJ8|K1PLJ8_CRAGI	3.3e-259	899.8	95.97%	76.44%	TBC1 domain family member 15;OS=Crassostrea;PE=4;SV=1
GN020155.1	sp|K1Q7S2|K1Q7S2_CRAGI	1.4e-28	132.5	54.71%	46.00%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN020156.1	sp|Q0KHB6|Q0KHB6_CRAGI	3.9e-286	989.2	88.71%	90.57%	Pyruvate kinase;OS=Crassostrea;PE=2;SV=1	GO:0016301|GO:0000287|GO:0030955|GO:0004743|
GN019897.1	sp|K1P4S4|K1P4S4_CRAGI	1.2e-122	444.9	93.07%	85.16%	DNA repair protein complementing XP-A cells-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003684|	GO:0006289|
GN020157.1	sp|K1PAU5|K1PAU5_CRAGI	7.5e-35	153.3	48.38%	54.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020158.1	sp|K1PHQ8|K1PHQ8_CRAGI	0.0e+00	1169.1	44.51%	86.88%	Metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN020159.1	sp|K1QGM5|K1QGM5_CRAGI	1.1e-36	159.8	50.27%	53.03%	Transcription factor 12;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN020160.1	sp|K1QKC9|K1QKC9_CRAGI	1.4e-48	199.1	75.31%	42.74%	Fibroleukin;OS=Crassostrea;PE=4;SV=1
GN020161.1	sp|K1PNS4|K1PNS4_CRAGI	1.2e-34	151.8	97.32%	63.01%	Inverted formin-2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN020162.1	sp|K1PNS4|K1PNS4_CRAGI	3.6e-162	577.0	91.21%	69.48%	Inverted formin-2;OS=Crassostrea;PE=4;SV=1	GO:0003779|GO:0017048|	GO:0030036|
GN020163.1	sp|K1QQ14|K1QQ14_CRAGI	2.9e-69	267.3	97.79%	61.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019898.1	sp|K1QAV9|K1QAV9_CRAGI	0.0e+00	2087.8	95.91%	86.82%	Paired amphipathic helix protein Sin3b;OS=Crassostrea;PE=4;SV=1	GO:0016580|	GO:0003714|	GO:0006355|
GN020164.1	sp|K1RGJ7|K1RGJ7_CRAGI	0.0e+00	1287.7	74.32%	63.88%	Neogenin;OS=Crassostrea;PE=4;SV=1
GN020165.1	sp|K1Q949|K1Q949_CRAGI	6.1e-169	599.0	100.00%	81.71%	Cyclopropane-fatty-acyl-phospholipid synthase;OS=Crassostrea;PE=4;SV=1
GN020166.1	sp|K1RV04|K1RV04_CRAGI	1.6e-238	830.9	97.52%	68.23%	Tyramine beta-hydroxylase;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN020167.1	sp|A0A1S3I398|A0A1S3I398_LINUN	2.9e-16	90.9	58.52%	43.69%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN020168.1	sp|K1Q1G8|K1Q1G8_CRAGI	9.8e-123	445.3	96.11%	72.32%	Dopamine beta-hydroxylase;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN020169.1	sp|A0A1S3I398|A0A1S3I398_LINUN	1.9e-15	88.2	58.52%	42.72%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN019899.1	sp|K1PIF1|K1PIF1_CRAGI	2.4e-301	1040.8	93.32%	68.45%	Zinc finger protein 99;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020170.1	sp|K1QGS1|K1QGS1_CRAGI	0.0e+00	1117.1	86.51%	75.00%	Endothelin-converting enzyme 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|
GN020171.1	sp|R9WWX3|R9WWX3_MYTCO	6.4e-12	76.3	86.93%	36.30%	C1q;OS=Mytilus;PE=2;SV=1
GN020172.1	sp|K1Q014|K1Q014_CRAGI	7.4e-225	785.4	100.00%	70.51%	Solute carrier family 22 member 21;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020173.1	sp|K1R701|K1R701_CRAGI	2.4e-24	117.9	74.87%	44.60%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN020174.1	sp|K1R701|K1R701_CRAGI	4.7e-24	117.5	49.12%	44.60%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN020175.1	sp|K1RIL4|K1RIL4_CRAGI	3.4e-10	70.5	95.30%	35.57%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN020176.1	sp|K1R338|K1R338_CRAGI	8.8e-46	189.1	84.85%	52.10%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN020177.1	sp|V3ZZR2|V3ZZR2_LOTGI	2.4e-72	277.7	91.73%	54.55%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN020178.1	sp|V4AE92|V4AE92_LOTGI	7.7e-119	433.3	77.74%	49.43%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN020179.1	sp|A0A1S3KFK0|A0A1S3KFK0_LINUN	8.2e-17	92.8	97.35%	31.07%	uncharacterized protein LOC106181232;OS=Lingula;PE=4;SV=1
GN020180.1	sp|K1R6U8|K1R6U8_CRAGI	1.6e-92	345.5	61.56%	75.10%	Testis-expressed sequence 9 protein;OS=Crassostrea;PE=4;SV=1
GN020182.1	sp|A0A210PSN0|A0A210PSN0_MIZYE	6.3e-21	109.8	20.39%	29.26%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020183.1	sp|K1Q708|K1Q708_CRAGI	4.7e-132	476.9	100.00%	66.07%	Mesoderm development candidate 1;OS=Crassostrea;PE=4;SV=1
GN020184.1	sp|K1QF12|K1QF12_CRAGI	7.5e-145	519.6	92.15%	87.35%	GA-binding protein subunit beta-1;OS=Crassostrea;PE=4;SV=1
GN020185.1	sp|K1R6V0|K1R6V0_CRAGI	1.9e-196	692.6	44.81%	56.82%	Pogo transposable element with ZNF domain;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020186.1	sp|K1QJJ3|K1QJJ3_CRAGI	3.7e-09	66.6	31.53%	88.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019900.1	sp|A0A1S3JFH1|A0A1S3JFH1_LINUN	6.2e-109	399.8	99.73%	54.64%	uncharacterized protein LOC106172806;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0003676|
GN020187.1	sp|K1R1H4|K1R1H4_CRAGI	1.9e-56	224.6	98.02%	55.56%	Cerebellin-3;OS=Crassostrea;PE=4;SV=1
GN020188.1	sp|K1PF05|K1PF05_CRAGI	8.5e-19	99.8	90.00%	28.63%	Beta-hexosaminidase;OS=Crassostrea;PE=4;SV=1	GO:0004563|GO:0030246|	GO:0005975|
GN020191.1	sp|K1QA62|K1QA62_CRAGI	1.2e-31	142.1	79.03%	47.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020192.1	sp|K1PMA2|K1PMA2_CRAGI	1.3e-180	639.0	93.71%	69.90%	Neurogenic locus notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020193.1	sp|A0A0B7AW50|A0A0B7AW50_9EUPU	1.7e-130	472.2	82.19%	47.55%	Uncharacterized protein;OS=Arion;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004222|
GN020194.1	sp|K1PU10|K1PU10_CRAGI	6.5e-47	194.9	33.21%	54.51%	Zinc finger protein 60;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020195.1	sp|K1S0I4|K1S0I4_CRAGI	5.5e-100	369.4	98.68%	73.66%	Methylthioribose-1-phosphate isomerase;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0046523|	GO:0019509|GO:0019284|
GN020196.1	sp|A0A2L2YQ29|A0A2L2YQ29_PARTP	6.5e-26	123.2	64.19%	46.38%	Uncharacterized protein;OS=Parasteatoda;PE=2;SV=1	GO:0055114|
GN020197.1	sp|K1QMS5|K1QMS5_CRAGI	6.5e-89	332.4	99.49%	76.53%	Cysteine dioxygenase type 1;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0016702|
GN020198.1	sp|A0A210QVR3|A0A210QVR3_MIZYE	3.8e-129	467.6	99.66%	43.16%	Protein RRNAD1;OS=Mizuhopecten;PE=4;SV=1
GN020200.1	sp|K1R6Y4|K1R6Y4_CRAGI	2.6e-247	860.1	76.57%	89.80%	F-box only protein 33;OS=Crassostrea;PE=4;SV=1	GO:0019005|	GO:0031146|
GN020201.1	sp|K1QLR4|K1QLR4_CRAGI	1.3e-120	438.3	100.00%	78.07%	Uncharacterized protein C2orf73-like protein;OS=Crassostrea;PE=4;SV=1
GN020202.1	sp|K1QF53|K1QF53_CRAGI	2.1e-151	540.8	100.00%	86.93%	Spermatogenesis-associated protein 17;OS=Crassostrea;PE=4;SV=1
GN020203.1	sp|K1Q737|K1Q737_CRAGI	6.6e-31	139.0	64.00%	89.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0030991|
GN020204.1	sp|A0A210PGW8|A0A210PGW8_MIZYE	6.9e-215	752.7	100.00%	57.91%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020205.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	1.8e-18	97.4	87.00%	46.51%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN020206.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	1.1e-18	98.6	91.24%	36.29%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN020207.1	sp|K1Q5P0|K1Q5P0_CRAGI	3.8e-104	384.0	97.50%	66.58%	60S ribosomal protein L17;OS=Crassostrea;PE=3;SV=1	GO:0005840|	GO:0003735|	GO:0006412|
GN020208.1	sp|A0A0B6ZVK9|A0A0B6ZVK9_9EUPU	2.3e-137	494.2	90.28%	76.15%	Uncharacterized protein;OS=Arion;PE=3;SV=1	GO:0005524|GO:0004674|
GN020209.1	sp|A0A210PXV5|A0A210PXV5_MIZYE	1.5e-90	337.8	100.00%	90.91%	60S ribosomal protein L17;OS=Mizuhopecten;PE=3;SV=1	GO:0015934|	GO:0003735|	GO:0006412|
GN020210.1	sp|K1QCW9|K1QCW9_CRAGI	1.2e-92	345.9	99.07%	48.46%	E3 ubiquitin-protein ligase MARCH2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0008270|
GN020211.1	sp|A0A2G8K889|A0A2G8K889_STIJA	1.9e-27	127.9	74.52%	50.42%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003677|
GN019901.1	sp|K1RHQ0|K1RHQ0_CRAGI	2.2e-303	1046.6	100.00%	81.55%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN020213.1	sp|A0A210QM88|A0A210QM88_MIZYE	4.4e-26	122.9	90.99%	57.69%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020215.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	5.9e-18	95.5	97.73%	52.94%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN020220.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	2.9e-20	104.8	59.16%	38.96%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019902.1	sp|K1PX63|K1PX63_CRAGI	9.7e-25	120.6	33.06%	50.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020226.1	sp|A0A2G8L4X1|A0A2G8L4X1_STIJA	6.1e-39	166.8	89.84%	41.63%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0055114|
GN019903.1	sp|K1QRD1|K1QRD1_CRAGI	2.7e-306	1056.2	100.00%	80.16%	EF-hand domain-containing protein D1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN020228.1	sp|K1PLC5|K1PLC5_CRAGI	6.0e-26	122.9	86.18%	46.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020229.1	sp|K1PLC5|K1PLC5_CRAGI	7.2e-24	116.7	100.00%	32.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020231.1	sp|K1Q794|K1Q794_CRAGI	7.8e-40	168.7	93.60%	61.21%	Fibroleukin;OS=Crassostrea;PE=4;SV=1	GO:0008233|
GN020234.1	sp|K1QME0|K1QME0_CRAGI	2.1e-75	287.7	98.21%	56.42%	Fibroleukin;OS=Crassostrea;PE=4;SV=1
GN020235.1	sp|K1QME0|K1QME0_CRAGI	7.1e-76	289.3	98.21%	56.88%	Fibroleukin;OS=Crassostrea;PE=4;SV=1
GN020238.1	sp|A0A210QLH6|A0A210QLH6_MIZYE	7.3e-106	390.2	99.82%	38.68%	Organic cation transporter protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020241.1	sp|K1PJX3|K1PJX3_CRAGI	0.0e+00	1291.2	100.00%	73.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020244.1	sp|K1QZ39|K1QZ39_CRAGI	7.1e-47	193.4	90.30%	42.09%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN020245.1	sp|K1QZ39|K1QZ39_CRAGI	8.3e-38	161.8	100.00%	71.30%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN020247.1	sp|K1QZ39|K1QZ39_CRAGI	2.2e-41	174.1	94.00%	60.71%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN020249.1	sp|K1QDD1|K1QDD1_CRAGI	9.2e-305	1052.0	100.00%	59.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020250.1	sp|K1P6P1|K1P6P1_CRAGI	6.0e-60	236.9	96.28%	39.82%	Amidase;OS=Crassostrea;PE=4;SV=1	GO:0004040|
GN020251.1	sp|A0A1X7T0L5|A0A1X7T0L5_AMPQE	3.3e-32	144.8	94.13%	28.17%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1
GN020252.1	sp|K1S0V2|K1S0V2_CRAGI	5.9e-17	93.2	72.47%	39.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020254.1	sp|K1PMD1|K1PMD1_CRAGI	1.1e-41	176.4	92.11%	34.55%	Acyl-coenzyme A amino acid N-acyltransferase 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|GO:0016790|GO:0016746|	GO:0006637|
GN020255.1	sp|K1PHH8|K1PHH8_CRAGI	4.4e-35	152.9	99.20%	54.47%	Caprin-2;OS=Crassostrea;PE=4;SV=1
GN020256.1	sp|V4BNP4|V4BNP4_LOTGI	3.9e-36	157.1	85.44%	45.71%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN020257.1	sp|K1QJ48|K1QJ48_CRAGI	1.1e-14	85.1	90.48%	52.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019907.1	sp|A0A1S3HXZ7|A0A1S3HXZ7_LINUN	3.7e-77	294.7	71.96%	44.88%	uncharacterized protein LOC106158870;OS=Lingula;PE=4;SV=1	GO:0004842|	GO:0015031|
GN020258.1	sp|K1QN42|K1QN42_CRAGI	4.1e-144	517.7	93.62%	42.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020259.1	sp|A0A210PQG6|A0A210PQG6_MIZYE	8.7e-121	439.1	97.73%	57.27%	Abhydrolase domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016787|
GN020260.1	sp|K1RLP8|K1RLP8_CRAGI	4.8e-46	189.9	72.43%	66.67%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN020261.1	sp|K1PMC5|K1PMC5_CRAGI	3.3e-42	177.2	76.96%	60.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020263.1	sp|A0A210PQH0|A0A210PQH0_MIZYE	9.2e-113	411.8	100.00%	96.30%	Ras-related protein Rab-11A;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|GO:0003924|
GN020264.1	sp|K1QYE4|K1QYE4_CRAGI	4.9e-28	129.4	99.14%	54.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019909.1	sp|A0A1S3HXZ7|A0A1S3HXZ7_LINUN	3.7e-77	294.7	71.96%	44.88%	uncharacterized protein LOC106158870;OS=Lingula;PE=4;SV=1	GO:0004842|	GO:0015031|
GN020265.1	sp|A0A210QAD6|A0A210QAD6_MIZYE	1.1e-96	358.6	100.00%	67.24%	Potassium channel subfamily K member 12;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0005267|
GN020266.1	sp|K1QTQ4|K1QTQ4_CRAGI	1.5e-09	69.7	20.10%	58.97%	Tenascin-X;OS=Crassostrea;PE=4;SV=1
GN020267.1	sp|K1R013|K1R013_CRAGI	7.8e-39	166.8	26.14%	82.35%	Tenascin-R;OS=Crassostrea;PE=4;SV=1
GN020274.1	sp|K1QFV9|K1QFV9_CRAGI	2.2e-10	70.1	98.61%	60.27%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN020278.1	sp|K1QFV9|K1QFV9_CRAGI	8.0e-09	65.1	100.00%	52.94%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN020282.1	sp|K1RBE8|K1RBE8_CRAGI	5.4e-76	289.7	96.85%	66.05%	Peptidoglycan recognition protein;OS=Crassostrea;PE=4;SV=1	GO:0008745|GO:0008270|	GO:0009253|
GN020283.1	sp|K1QHN3|K1QHN3_CRAGI	5.1e-118	430.6	96.41%	44.23%	SLIT and NTRK-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020285.1	sp|A0A210PN42|A0A210PN42_MIZYE	2.2e-35	156.0	99.04%	48.47%	Peroxidasin;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN020286.1	sp|K1S162|K1S162_CRAGI	1.6e-177	628.2	95.56%	82.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN020287.1	sp|K1QMT2|K1QMT2_CRAGI	2.5e-77	293.5	100.00%	99.32%	Signal peptidase complex catalytic subunit SEC11;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005787|	GO:0008236|	GO:0006465|
GN020288.1	sp|V4CIA8|V4CIA8_LOTGI	8.3e-39	165.2	92.56%	61.26%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0051537|GO:0008942|
GN020289.1	sp|C8BLQ9|C8BLQ9_9BIVA	1.1e-62	245.7	95.20%	48.70%	Uncharacterized protein;OS=Crassostrea;PE=2;SV=1
GN019910.1	sp|K1PI71|K1PI71_CRAGI	1.2e-26	124.8	52.07%	98.39%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020291.1	sp|K1R0W6|K1R0W6_CRAGI	3.9e-172	610.1	100.00%	62.99%	NADPH oxidase 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|GO:0016175|	GO:0042554|
GN020292.1	sp|K1QU26|K1QU26_CRAGI	0.0e+00	1201.4	100.00%	89.40%	Calpain-5;OS=Crassostrea;PE=3;SV=1	GO:0004198|	GO:0051493|
GN020298.1	sp|A0A210QP64|A0A210QP64_MIZYE	1.8e-17	94.4	80.67%	44.33%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020299.1	sp|A0A210PIK5|A0A210PIK5_MIZYE	2.6e-23	113.6	65.77%	79.17%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020304.1	sp|A0A3M6UAZ4|A0A3M6UAZ4_9CNID	5.3e-17	93.6	44.02%	47.42%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN020305.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	6.4e-105	386.7	98.18%	41.82%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN020306.1	sp|K1PPX8|K1PPX8_CRAGI	3.7e-65	254.2	65.96%	53.70%	Eppin;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0004867|
GN020307.1	sp|A0A3L5TV76|A0A3L5TV76_MYTGA	1.6e-49	204.1	27.71%	35.08%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN020309.1	sp|A0A109NI13|A0A109NI13_CRAGI	2.6e-287	993.0	100.00%	95.81%	Mothers against decapentaplegic homolog;OS=Crassostrea;PE=2;SV=1	GO:0005737|GO:0005634|GO:0005667|	GO:0003677|GO:0003700|	GO:0007179|
GN020310.1	sp|K1PYH9|K1PYH9_CRAGI	2.3e-189	667.2	100.00%	77.05%	Aminopeptidase N;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004177|GO:0008237|GO:0008270|
GN019911.1	sp|K1R7A9|K1R7A9_CRAGI	4.9e-223	779.2	98.55%	78.67%	Solute carrier family 2, facilitated glucose transporter member 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|	GO:0008643|
GN020314.1	sp|A3KDX3|A3KDX3_CRAGI	2.4e-22	109.8	97.18%	66.18%	Lysozyme 1M;OS=Crassostrea;PE=2;SV=1	GO:0003796|	GO:0008152|
GN020317.1	sp|A3KDX3|A3KDX3_CRAGI	3.2e-22	109.4	97.18%	66.18%	Lysozyme 1M;OS=Crassostrea;PE=2;SV=1	GO:0003796|	GO:0008152|
GN020318.1	sp|D8VNA2|D8VNA2_9BIVA	2.9e-17	94.7	55.47%	36.36%	C-type lectin 5;OS=Azumapecten;PE=2;SV=1	GO:0030246|
GN020319.1	sp|K1P0Y3|K1P0Y3_CRAGI	1.4e-33	149.4	67.31%	36.65%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN020323.1	sp|K1PYJ0|K1PYJ0_CRAGI	2.7e-42	178.3	82.30%	38.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN020326.1	sp|K1PUT2|K1PUT2_CRAGI	3.0e-22	111.3	43.60%	52.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN020329.1	sp|W4YR48|W4YR48_STRPU	2.6e-53	214.9	85.63%	41.72%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0003676|GO:0008270|
GN020330.1	sp|G3MGI1|G3MGI1_9ACAR	1.9e-18	98.2	91.44%	27.75%	Uncharacterized protein;OS=Amblyomma;PE=2;SV=1	GO:0008270|
GN020338.1	sp|A0A2B4SW31|A0A2B4SW31_STYPI	1.2e-107	396.7	84.04%	33.66%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN020340.1	sp|A0A2G8K3S6|A0A2G8K3S6_STIJA	3.7e-43	180.6	60.61%	59.29%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0008270|
GN020347.1	sp|K1PKF0|K1PKF0_CRAGI	1.4e-12	79.0	42.86%	43.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020349.1	sp|K1RC55|K1RC55_CRAGI	7.2e-15	85.9	85.19%	42.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020354.1	sp|K1PX51|K1PX51_CRAGI	1.7e-33	147.9	73.68%	65.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN020357.1	sp|K1QU46|K1QU46_CRAGI	5.1e-30	136.0	78.95%	67.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020364.1	sp|K1PVU0|K1PVU0_CRAGI	1.4e-28	131.7	97.56%	40.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020365.1	sp|A0A2S2NRW3|A0A2S2NRW3_SCHGA	1.3e-18	99.8	58.59%	30.29%	Gypsy retrotransposon integrase-like protein 1;OS=Schizaphis;PE=4;SV=1	GO:0003676|	GO:0015074|
GN020366.1	sp|A0A210PXY0|A0A210PXY0_MIZYE	3.3e-22	111.3	32.62%	73.40%	Chromatin target of PRMT1 protein;OS=Mizuhopecten;PE=4;SV=1
GN020368.1	sp|A0A210QML5|A0A210QML5_MIZYE	3.3e-98	364.0	88.79%	66.01%	Tropomodulin-1;OS=Mizuhopecten;PE=4;SV=1	GO:0005523|	GO:0051694|
GN020369.1	sp|K1R6G1|K1R6G1_CRAGI	2.6e-35	156.8	23.78%	34.96%	E3 ubiquitin-protein ligase MIB2;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0003950|GO:0004842|GO:0008270|
GN019917.1	sp|K1Q405|K1Q405_CRAGI	8.6e-112	410.2	99.71%	33.95%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN020372.1	sp|K1QL59|K1QL59_CRAGI	6.3e-41	172.6	90.34%	75.37%	Talin-1;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN020373.1	sp|A0A210PY34|A0A210PY34_MIZYE	0.0e+00	1526.5	99.74%	67.47%	WD repeat-containing protein 49;OS=Mizuhopecten;PE=4;SV=1
GN020374.1	sp|K1QZ27|K1QZ27_CRAGI	7.3e-118	429.5	80.97%	66.11%	Hexosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0000139|GO:0016021|	GO:0008378|	GO:0006486|
GN020375.1	sp|K1R861|K1R861_CRAGI	3.6e-96	357.5	99.47%	46.74%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0003677|
GN020376.1	sp|V4AE92|V4AE92_LOTGI	3.9e-90	337.8	76.73%	42.21%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN020377.1	sp|A0A2S2PQ34|A0A2S2PQ34_SCHGA	4.9e-19	99.8	91.24%	37.30%	Uncharacterized protein;OS=Schizaphis;PE=4;SV=1
GN020378.1	sp|K1QKH0|K1QKH0_CRAGI	4.9e-49	201.4	33.81%	54.74%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN020379.1	sp|K1QBD1|K1QBD1_CRAGI	1.1e-23	115.9	34.93%	65.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020381.1	sp|A0A131Y613|A0A131Y613_IXORI	3.3e-11	72.8	76.06%	60.38%	Putative maverick polb;OS=Ixodes;PE=2;SV=1	GO:0003677|GO:0003887|GO:0000166|	GO:0006260|
GN020384.1	sp|A0A1S3HNQ1|A0A1S3HNQ1_LINUN	1.1e-20	106.3	95.10%	33.10%	zinc finger and SCAN domain-containing protein 2;OS=Lingula;PE=4;SV=1	GO:0003677|
GN020385.1	sp|K1RLP8|K1RLP8_CRAGI	6.4e-45	185.7	97.69%	66.15%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN020387.1	sp|K1QQR2|K1QQR2_CRAGI	4.5e-20	102.4	100.00%	61.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020390.1	sp|A0A151IU93|A0A151IU93_9HYME	1.9e-31	142.1	93.31%	32.52%	Uncharacterized protein;OS=Trachymyrmex;PE=4;SV=1
GN020391.1	sp|C3Z7Z4|C3Z7Z4_BRAFL	7.2e-119	434.5	92.54%	30.70%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1
GN020393.1	sp|A0A210PH76|A0A210PH76_MIZYE	7.3e-11	73.6	56.18%	30.26%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|	GO:0015074|GO:0006310|
GN020394.1	sp|K1Q0U9|K1Q0U9_CRAGI	1.9e-26	125.6	39.05%	53.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020396.1	sp|V4BBQ4|V4BBQ4_LOTGI	5.5e-33	146.4	56.02%	72.83%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN020397.1	sp|K1PA93|K1PA93_CRAGI	4.4e-65	255.0	42.58%	44.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0046872|
GN020399.1	sp|K1Q7X0|K1Q7X0_CRAGI	2.4e-17	93.6	75.27%	62.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020407.1	sp|A0A1S3IM18|A0A1S3IM18_LINUN	1.6e-22	111.7	90.86%	36.48%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=2	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN020409.1	sp|K1Q027|K1Q027_CRAGI	2.0e-49	201.1	98.86%	50.58%	Histone-lysine N-methyltransferase PRDM9;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN020411.1	sp|K1Q027|K1Q027_CRAGI	1.5e-80	305.4	91.14%	44.21%	Histone-lysine N-methyltransferase PRDM9;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN020412.1	sp|K1Q027|K1Q027_CRAGI	6.5e-90	336.7	89.63%	47.62%	Histone-lysine N-methyltransferase PRDM9;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN020414.1	sp|K1Q9I6|K1Q9I6_CRAGI	3.5e-25	121.3	87.10%	37.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020416.1	sp|K1PUJ8|K1PUJ8_CRAGI	1.7e-127	461.1	96.82%	74.73%	Frizzled-5;OS=Crassostrea;PE=4;SV=1	GO:0007275|GO:0016055|
GN020417.1	sp|V4B0G7|V4B0G7_LOTGI	5.4e-106	391.3	29.20%	71.70%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005096|GO:0017160|	GO:0007264|
GN020417.1	sp|V4B0G7|V4B0G7_LOTGI	5.0e-11	75.9	9.22%	54.22%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0005096|GO:0017160|	GO:0007264|
GN020418.1	sp|K1QUP2|K1QUP2_CRAGI	1.2e-21	108.2	91.13%	43.86%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN020420.1	sp|A0A194AM13|A0A194AM13_PINFU	2.4e-34	150.6	99.26%	53.73%	Putative neurofilament heavy polypeptide-like protein;OS=Pinctada;PE=3;SV=1	GO:0008289|
GN020423.1	sp|K1P828|K1P828_CRAGI	1.1e-100	372.1	99.65%	63.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020428.1	sp|K1R985|K1R985_CRAGI	1.9e-30	139.4	22.91%	57.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020429.1	sp|K1QIM8|K1QIM8_CRAGI	8.7e-18	95.9	37.65%	69.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN020430.1	sp|K1QEY4|K1QEY4_CRAGI	6.2e-49	199.9	73.98%	55.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN020431.1	sp|K1Q405|K1Q405_CRAGI	1.4e-87	328.9	97.99%	45.38%	E3 ubiquitin-protein ligase DZIP3;OS=Crassostrea;PE=4;SV=1	GO:0016874|
GN020432.1	sp|K1QST7|K1QST7_CRAGI	1.8e-177	628.6	67.40%	56.24%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020433.1	sp|V4A2Z2|V4A2Z2_LOTGI	1.1e-100	372.9	75.41%	49.33%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0003677|
GN020435.1	sp|K1P0H4|K1P0H4_CRAGI	1.8e-18	98.6	75.22%	37.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019857.1	sp|K1QY88|K1QY88_CRAGI	3.5e-19	102.1	83.50%	26.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019858.1	sp|A0A210QJ34|A0A210QJ34_MIZYE	9.3e-16	90.5	35.27%	37.75%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0004842|
GN019928.1	sp|K1RM85|K1RM85_CRAGI	1.9e-216	758.1	82.02%	66.26%	Disintegrin and metalloproteinase domain-containing protein 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004222|	GO:0007229|
GN019929.1	sp|A0A2G8KZM8|A0A2G8KZM8_STIJA	4.4e-88	331.6	75.56%	33.61%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1	GO:0003676|
GN019930.1	sp|K1QZY9|K1QZY9_CRAGI	1.3e-36	158.7	93.53%	44.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019859.1	sp|K1Q5Z4|K1Q5Z4_CRAGI	1.9e-99	367.9	99.28%	59.39%	G2/M phase-specific E3 ubiquitin-protein ligase;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|
GN019932.1	sp|K1QF08|K1QF08_CRAGI	1.4e-24	117.1	100.00%	87.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019933.1	sp|K1QF08|K1QF08_CRAGI	5.3e-24	115.2	100.00%	84.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019935.1	sp|K1QRD1|K1QRD1_CRAGI	1.2e-216	759.2	48.09%	65.40%	EF-hand domain-containing protein D1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN019938.1	sp|K1RBC1|K1RBC1_CRAGI	5.8e-122	444.1	66.13%	46.29%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN019939.1	sp|K1R456|K1R456_CRAGI	0.0e+00	1263.8	99.65%	71.95%	ATP-binding cassette sub-family B member 6, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019940.1	sp|K1R5H4|K1R5H4_CRAGI	2.2e-17	94.4	73.83%	44.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005125|
GN019941.1	sp|K1RAG3|K1RAG3_CRAGI	1.7e-54	219.2	97.66%	33.41%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN019942.1	sp|K1QY33|K1QY33_CRAGI	1.5e-76	291.6	94.32%	60.00%	Ficolin-1;OS=Crassostrea;PE=4;SV=1
GN019943.1	sp|E4YGN2|E4YGN2_OIKDI	2.3e-47	195.7	57.72%	39.34%	Uncharacterized protein;OS=Oikopleura;PE=4;SV=1	GO:0005739|	GO:0051607|
GN019944.1	sp|K1Q068|K1Q068_CRAGI	4.6e-48	196.1	99.20%	71.20%	Ficolin-2;OS=Crassostrea;PE=4;SV=1
GN019862.1	sp|K1QY88|K1QY88_CRAGI	3.5e-19	102.1	94.41%	25.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019946.1	sp|K1QA72|K1QA72_CRAGI	9.0e-18	98.2	9.55%	66.67%	Double-strand-break repair protein rad21-like protein;OS=Crassostrea;PE=4;SV=1	GO:0008278|	GO:0007062|
GN019949.1	sp|K1QEN4|K1QEN4_CRAGI	5.9e-238	829.7	66.85%	71.17%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019950.1	sp|K1QEN4|K1QEN4_CRAGI	1.7e-245	854.0	99.03%	84.84%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN019951.1	sp|K1RBX8|K1RBX8_CRAGI	8.1e-26	123.6	47.31%	44.97%	GTPase-activating protein and VPS9 domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0043087|GO:0007165|
GN019953.1	sp|K1PXH5|K1PXH5_CRAGI	2.6e-45	187.6	92.42%	52.63%	Putative saccharopine dehydrogenase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016491|
GN019954.1	sp|A0A2R3SK17|A0A2R3SK17_ARGIR	1.2e-143	515.8	100.00%	67.33%	Leucine rich repeat only protein 9;OS=Argopecten;PE=2;SV=1
GN019955.1	sp|K1QTS6|K1QTS6_CRAGI	2.0e-76	291.6	59.74%	71.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019956.1	sp|K1QA94|K1QA94_CRAGI	2.0e-57	228.4	59.61%	53.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019957.1	sp|K1RE45|K1RE45_CRAGI	5.0e-75	286.2	96.28%	69.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019958.1	sp|K1RE45|K1RE45_CRAGI	3.6e-55	219.9	98.68%	67.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019959.1	sp|K1Q6K7|K1Q6K7_CRAGI	3.6e-28	131.0	71.94%	43.48%	BTB/POZ domain-containing protein 6-B;OS=Crassostrea;PE=4;SV=1
GN019960.1	sp|V4AE92|V4AE92_LOTGI	6.6e-84	316.2	97.44%	53.85%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN019863.1	sp|K1PKF0|K1PKF0_CRAGI	1.3e-20	105.9	45.93%	47.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019961.1	sp|K1RE36|K1RE36_CRAGI	0.0e+00	1113.2	95.95%	68.04%	Dipeptidyl peptidase 8;OS=Crassostrea;PE=3;SV=1	GO:0008236|
GN019962.1	sp|K1QTS1|K1QTS1_CRAGI	5.1e-87	327.8	84.62%	33.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019963.1	sp|K1Q3U3|K1Q3U3_CRAGI	3.8e-82	309.7	95.18%	89.17%	Protein ERGIC-53;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0016021|	GO:0005537|	GO:0006888|
GN019964.1	sp|K1Q3U3|K1Q3U3_CRAGI	3.7e-65	253.8	98.39%	75.41%	Protein ERGIC-53;OS=Crassostrea;PE=4;SV=1	GO:0005737|GO:0016021|	GO:0005537|	GO:0006888|
GN019965.1	sp|K1QFV9|K1QFV9_CRAGI	3.1e-257	893.3	86.35%	81.85%	Sodium-coupled monocarboxylate transporter 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN019966.1	sp|K1RNK4|K1RNK4_CRAGI	1.1e-35	155.2	97.52%	48.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019967.1	sp|K1QP55|K1QP55_CRAGI	2.7e-57	228.4	41.73%	82.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019864.1	sp|K1QY88|K1QY88_CRAGI	3.5e-19	102.1	94.41%	25.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019969.1	sp|K1QF88|K1QF88_CRAGI	6.2e-60	237.7	36.25%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019970.1	sp|A0A2B4RQ39|A0A2B4RQ39_STYPI	1.1e-09	67.8	63.16%	58.82%	Putative nuclease HARBI1;OS=Stylophora;PE=4;SV=1
GN019971.1	sp|K1PJI1|K1PJI1_CRAGI	7.5e-37	160.6	30.30%	53.73%	Scavenger receptor class F member 2;OS=Crassostrea;PE=4;SV=1
GN019865.1	sp|K1QVS7|K1QVS7_CRAGI	1.2e-22	110.5	100.00%	78.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019866.1	sp|K1Q6A9|K1Q6A9_CRAGI	1.1e-69	268.5	92.93%	67.06%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN019972.1	sp|K1PT52|K1PT52_CRAGI	1.1e-48	199.5	47.98%	59.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019973.1	sp|K1PC98|K1PC98_CRAGI	3.8e-56	224.6	98.50%	56.75%	Ankyrin repeat domain-containing protein 17;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019975.1	sp|V3ZX45|V3ZX45_LOTGI	4.9e-55	220.3	100.00%	44.53%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN019867.1	sp|K1PKF0|K1PKF0_CRAGI	8.7e-29	132.5	85.23%	47.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019976.1	sp|K1QJ48|K1QJ48_CRAGI	9.3e-70	268.5	92.50%	87.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019978.1	sp|K1PNE1|K1PNE1_CRAGI	3.9e-51	206.8	96.86%	51.63%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN019979.1	sp|K1RIW4|K1RIW4_CRAGI	1.9e-34	152.5	93.27%	23.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019981.1	sp|K1PNE1|K1PNE1_CRAGI	8.0e-52	209.1	88.48%	55.36%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN019982.1	sp|A0A1S3HNU4|A0A1S3HNU4_LINUN	8.5e-122	443.0	97.78%	45.31%	uncharacterized protein LOC106156821;OS=Lingula;PE=4;SV=1	GO:0008270|
GN019983.1	sp|A0A1S3I398|A0A1S3I398_LINUN	1.8e-13	81.6	57.63%	40.20%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN019984.1	sp|K1PNE1|K1PNE1_CRAGI	2.3e-51	207.6	91.62%	52.87%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN019985.1	sp|K1QTV0|K1QTV0_CRAGI	3.7e-37	160.6	78.34%	48.55%	Latent-transforming growth factor beta-binding protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN019986.1	sp|K1QJV3|K1QJV3_CRAGI	5.0e-17	92.0	100.00%	65.15%	N,N'-diacetylchitobiase;OS=Crassostrea;PE=4;SV=1	GO:0004563|GO:0030247|	GO:0005975|
GN019987.1	sp|K1PC98|K1PC98_CRAGI	1.2e-11	75.1	73.81%	47.92%	Ankyrin repeat domain-containing protein 17;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019988.1	sp|K1PC98|K1PC98_CRAGI	1.1e-19	101.3	63.83%	74.58%	Ankyrin repeat domain-containing protein 17;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019989.1	sp|K1PC98|K1PC98_CRAGI	3.3e-43	180.6	95.22%	50.99%	Ankyrin repeat domain-containing protein 17;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN019990.1	sp|K1PNE1|K1PNE1_CRAGI	8.0e-52	209.1	91.62%	53.45%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN019992.1	sp|K1P1T5|K1P1T5_CRAGI	3.9e-52	211.8	24.21%	69.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019869.1	sp|K1QY88|K1QY88_CRAGI	7.0e-20	104.4	85.06%	26.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN019994.1	sp|K1QKH0|K1QKH0_CRAGI	6.6e-21	107.5	28.24%	50.93%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN019996.1	sp|K1QKH0|K1QKH0_CRAGI	6.6e-21	107.5	28.24%	50.93%	Caspase-7;OS=Crassostrea;PE=3;SV=1	GO:0004197|
GN019998.1	sp|K1R4B0|K1R4B0_CRAGI	4.2e-57	226.5	98.80%	62.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020001.1	sp|K1QTV0|K1QTV0_CRAGI	5.5e-51	206.8	50.37%	73.88%	Latent-transforming growth factor beta-binding protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020004.1	sp|A0A210PI28|A0A210PI28_MIZYE	1.4e-89	335.9	64.87%	59.65%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN019870.1	sp|A0A210PIP1|A0A210PIP1_MIZYE	8.9e-17	92.4	89.10%	43.48%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020005.1	sp|A0A1S3H0Z4|A0A1S3H0Z4_LINUN	1.2e-22	112.1	97.09%	37.02%	ATP-dependent DNA helicase;OS=Lingula;PE=3;SV=1	GO:0005524|GO:0003678|	GO:0006310|GO:0006281|GO:0000723|
GN020008.1	sp|K1Q0I0|K1Q0I0_CRAGI	2.9e-09	67.4	75.84%	44.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019872.1	sp|A0A210PRU0|A0A210PRU0_MIZYE	1.5e-36	157.5	99.07%	67.62%	THAP domain-containing protein 4;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN020009.1	sp|K1Q2K0|K1Q2K0_CRAGI	9.1e-16	90.5	15.40%	76.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0098536|GO:0005815|	GO:0007099|GO:0098535|
GN020009.1	sp|K1Q2K0|K1Q2K0_CRAGI	4.4e-10	71.6	12.80%	62.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0098536|GO:0005815|	GO:0007099|GO:0098535|
GN020010.1	sp|K1PQH5|K1PQH5_CRAGI	1.3e-80	305.4	96.20%	54.13%	Toll-like receptor 13;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007165|
GN020014.1	sp|K1QPI1|K1QPI1_CRAGI	2.8e-09	66.6	73.49%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020016.1	sp|A0A1Y1M656|A0A1Y1M656_PHOPY	7.0e-09	67.4	87.36%	21.22%	Uncharacterized protein;OS=Photinus;PE=4;SV=1	GO:0008270|
GN020017.1	sp|K1QZ10|K1QZ10_CRAGI	9.2e-108	396.0	74.41%	64.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0019200|	GO:0006493|
GN020018.1	sp|K1RID2|K1RID2_CRAGI	3.8e-44	183.7	98.01%	44.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006353|
GN020019.1	sp|V4AE92|V4AE92_LOTGI	3.4e-64	250.8	97.77%	48.30%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN020020.1	sp|A0A1S3I398|A0A1S3I398_LINUN	4.5e-26	123.2	64.90%	58.42%	P2X purinoceptor 7-like;OS=Lingula;PE=4;SV=1
GN020021.1	sp|K1RF74|K1RF74_CRAGI	5.8e-19	100.5	33.93%	55.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020023.1	sp|K1RNK4|K1RNK4_CRAGI	9.4e-30	135.6	97.52%	45.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020025.1	sp|A0A1S3IHJ1|A0A1S3IHJ1_LINUN	1.0e-66	259.2	91.44%	47.64%	putative nuclease HARBI1;OS=Lingula;PE=4;SV=1
GN020027.1	sp|E9J352|E9J352_SOLIN	5.4e-52	210.7	73.67%	37.99%	Uncharacterized protein;OS=Solenopsis;PE=4;SV=1
GN020029.1	sp|K1QPD4|K1QPD4_CRAGI	2.3e-232	810.8	99.17%	60.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020030.1	sp|K1RGC0|K1RGC0_CRAGI	5.1e-65	253.8	100.00%	44.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020031.1	sp|K1R844|K1R844_CRAGI	1.7e-98	364.4	93.58%	89.71%	Ras-related protein Rab-21;OS=Crassostrea;PE=3;SV=1	GO:0005525|GO:0003924|
GN020032.1	sp|K1RKJ9|K1RKJ9_CRAGI	2.9e-19	101.3	44.30%	71.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0042981|
GN020035.1	sp|A0A2B4SSG5|A0A2B4SSG5_STYPI	8.8e-85	320.5	43.78%	55.96%	Putative E3 ubiquitin-protein ligase hulA;OS=Stylophora;PE=4;SV=1	GO:0016874|GO:0004842|
GN020037.1	sp|A0A1S3JNJ6|A0A1S3JNJ6_LINUN	2.8e-22	110.2	87.04%	55.32%	uncharacterized protein LOC106174793;OS=Lingula;PE=4;SV=1	GO:0008270|
GN020041.1	sp|A0A210QIA3|A0A210QIA3_MIZYE	2.1e-23	115.5	76.42%	29.01%	GTPase IMAP family member 7;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|
GN020042.1	sp|A0A0B7APY9|A0A0B7APY9_9EUPU	3.3e-12	77.4	80.92%	36.69%	Uncharacterized protein;OS=Arion;PE=4;SV=1
GN020043.1	sp|K1P6F2|K1P6F2_CRAGI	1.5e-18	99.0	59.76%	31.19%	Multiple epidermal growth factor-like domains 10;OS=Crassostrea;PE=4;SV=1
GN020044.1	sp|A0A210QGP2|A0A210QGP2_MIZYE	4.6e-12	78.2	18.23%	48.68%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020045.1	sp|K1QW69|K1QW69_CRAGI	1.0e-27	128.6	71.63%	52.48%	Amyloid-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN020046.1	sp|K1QEV0|K1QEV0_CRAGI	0.0e+00	1159.8	80.47%	86.91%	Colorectal mutant cancer protein;OS=Crassostrea;PE=4;SV=1
GN020047.1	sp|A0A3L5TQI2|A0A3L5TQI2_MYTGA	1.2e-17	96.3	70.61%	30.22%	Uncharacterized protein;OS=Mytilus;PE=4;SV=1
GN020048.1	sp|K1RG37|K1RG37_CRAGI	1.2e-16	92.8	81.72%	31.06%	GTPase IMAP family member 7;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0046872|
GN020050.1	sp|K1PCF9|K1PCF9_CRAGI	7.8e-231	805.4	100.00%	77.35%	Uncharacterized protein C5orf37-like protein;OS=Crassostrea;PE=4;SV=1
GN019880.1	sp|K1PFB3|K1PFB3_CRAGI	5.7e-33	147.5	33.68%	62.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020052.1	sp|K1PWM3|K1PWM3_CRAGI	3.0e-41	173.3	98.32%	73.95%	MICOS complex subunit MIC13;OS=complex;PE=3;SV=1	GO:0061617|
GN020053.1	sp|A0A210R0V5|A0A210R0V5_MIZYE	1.6e-26	125.9	31.92%	48.21%	Deleted in malignant brain tumors 1 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005044|
GN019881.1	sp|V3ZX45|V3ZX45_LOTGI	2.8e-83	315.1	84.81%	41.57%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0008270|
GN020055.1	sp|K1R1S9|K1R1S9_CRAGI	1.1e-170	605.1	99.77%	68.74%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN020056.1	sp|V4A8V5|V4A8V5_LOTGI	4.7e-148	531.2	87.00%	40.55%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0007165|
GN020057.1	sp|K1QIB5|K1QIB5_CRAGI	2.9e-178	630.2	100.00%	80.37%	UPF0586 protein C9orf41-like protein;OS=Crassostrea;PE=4;SV=1
GN020058.1	sp|A0A210PQ79|A0A210PQ79_MIZYE	9.9e-283	978.0	100.00%	72.43%	Dymeclin;OS=Mizuhopecten;PE=4;SV=1
GN020059.1	sp|K1Q216|K1Q216_CRAGI	3.7e-174	616.7	100.00%	71.96%	UPF0394 inner membrane protein yeeE;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020061.1	sp|K1RDA2|K1RDA2_CRAGI	2.4e-53	214.2	88.24%	59.76%	Calcium and integrin-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005509|	GO:0007229|
GN019883.1	sp|K1R1A2|K1R1A2_CRAGI	7.6e-70	270.8	41.59%	49.09%	Ras-related protein Rab-27A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN019883.1	sp|K1R1A2|K1R1A2_CRAGI	5.7e-17	95.1	9.79%	61.90%	Ras-related protein Rab-27A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN020063.1	sp|K1PQR5|K1PQR5_CRAGI	4.5e-115	421.4	44.15%	79.95%	F-box/LRR-repeat protein 17;OS=Crassostrea;PE=4;SV=1
GN020064.1	sp|K1R2A9|K1R2A9_CRAGI	3.2e-300	1036.2	99.86%	76.37%	Histidine decarboxylase;OS=Crassostrea;PE=4;SV=1	GO:0016831|GO:0030170|	GO:0006520|
GN020065.1	sp|K1RSX1|K1RSX1_CRAGI	4.2e-145	521.9	58.10%	61.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|	GO:0006355|
GN020066.1	sp|K1PK61|K1PK61_CRAGI	1.1e-38	166.0	77.74%	48.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020067.1	sp|K1R7H6|K1R7H6_CRAGI	2.0e-192	677.2	99.20%	87.84%	Phosphoserine aminotransferase;OS=Crassostrea;PE=3;SV=1	GO:0004648|	GO:0006564|
GN020068.1	sp|K1RWE5|K1RWE5_CRAGI	4.6e-152	542.7	100.00%	91.32%	Thioredoxin-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN020069.1	sp|K1R1A2|K1R1A2_CRAGI	1.5e-74	286.2	53.65%	48.47%	Ras-related protein Rab-27A;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN020070.1	sp|K1R6L9|K1R6L9_CRAGI	4.6e-43	180.6	49.83%	60.56%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN020071.1	sp|K1RWE0|K1RWE0_CRAGI	8.8e-92	343.2	48.01%	71.49%	Methionyl-tRNA formyltransferase, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016742|	GO:0009058|
GN020072.1	sp|A0A210QLL3|A0A210QLL3_MIZYE	1.7e-68	265.0	59.63%	81.87%	Ras-related protein Rab-11B;OS=Mizuhopecten;PE=4;SV=1	GO:0005525|GO:0003924|
GN020073.1	sp|K1PI09|K1PI09_CRAGI	3.4e-60	236.9	86.96%	76.30%	Abhydrolase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0016787|GO:0008270|
GN020074.1	sp|K1PBM3|K1PBM3_CRAGI	1.9e-61	240.7	95.33%	83.80%	HD domain-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN020075.1	sp|K1PLL5|K1PLL5_CRAGI	2.5e-53	216.5	24.56%	51.53%	Nidogen-2;OS=Crassostrea;PE=4;SV=1
GN020076.1	sp|K1QK87|K1QK87_CRAGI	1.9e-176	624.0	100.00%	87.32%	Solute carrier family 25 member 42;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|
GN020077.1	sp|K1RFX0|K1RFX0_CRAGI	9.8e-135	486.1	90.45%	49.80%	Receptor-type tyrosine-protein phosphatase mu;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN020078.1	sp|K1RFX0|K1RFX0_CRAGI	5.7e-135	486.9	90.45%	49.80%	Receptor-type tyrosine-protein phosphatase mu;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN020079.1	sp|K1R990|K1R990_CRAGI	2.5e-263	913.3	99.28%	77.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020080.1	sp|K1RYU6|K1RYU6_CRAGI	0.0e+00	1158.7	100.00%	87.17%	Potassium voltage-gated channel subfamily H member 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005249|
GN020081.1	sp|K1PJM9|K1PJM9_CRAGI	7.6e-145	520.0	85.69%	58.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN020082.1	sp|K1PJM9|K1PJM9_CRAGI	1.0e-35	156.4	84.08%	34.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0004867|
GN020083.1	sp|K1QRM9|K1QRM9_CRAGI	1.5e-57	228.4	52.63%	94.96%	Acidic leucine-rich nuclear phosphoprotein 32 family member A;OS=Crassostrea;PE=4;SV=1
GN020085.1	sp|K1PRE6|K1PRE6_CRAGI	7.1e-96	356.3	83.88%	66.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020086.1	sp|K1PRE6|K1PRE6_CRAGI	6.3e-86	323.9	59.71%	58.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN019884.1	sp|K1PT47|K1PT47_CRAGI	8.8e-47	192.6	70.64%	59.49%	Filamin-C;OS=Crassostrea;PE=4;SV=1
GN020088.1	sp|K1R7V0|K1R7V0_CRAGI	2.1e-44	186.4	49.02%	48.75%	Baculoviral IAP repeat-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020089.1	sp|K1R7V0|K1R7V0_CRAGI	3.5e-25	121.3	91.59%	55.02%	Baculoviral IAP repeat-containing protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020090.1	sp|K1RDR6|K1RDR6_CRAGI	4.5e-56	222.6	98.40%	87.70%	Ornithine decarboxylase antizyme 1;OS=Crassostrea;PE=4;SV=1	GO:0008073|
GN020091.1	sp|K1QTF1|K1QTF1_CRAGI	1.2e-103	382.5	61.00%	76.49%	Caspase-2;OS=Crassostrea;PE=4;SV=1	GO:0097200|	GO:0042981|
GN019885.1	sp|K1PLC2|K1PLC2_CRAGI	3.2e-280	970.3	64.15%	70.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN020093.1	sp|K1QWK4|K1QWK4_CRAGI	1.0e-124	453.0	94.09%	42.66%	Kelch-like protein 2;OS=Crassostrea;PE=4;SV=1
GN019886.1	sp|K1QBV9|K1QBV9_CRAGI	1.6e-22	112.1	95.69%	32.16%	Complement C1q subcomponent subunit B;OS=Crassostrea;PE=4;SV=1
GN020094.1	sp|K1PN12|K1PN12_CRAGI	1.5e-53	217.2	55.31%	28.60%	Receptor-type tyrosine-protein phosphatase T;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004725|
GN020095.1	sp|A0A210PI24|A0A210PI24_MIZYE	9.3e-166	589.3	95.85%	52.68%	Collagen alpha-5(VI) chain;OS=Mizuhopecten;PE=4;SV=1	GO:0005581|
GN019887.1	sp|K1PPC3|K1PPC3_CRAGI	1.3e-52	211.1	99.13%	92.92%	U6 snRNA-associated Sm-like protein LSm7;OS=Crassostrea;PE=4;SV=1	GO:0000398|GO:0000956|
GN020096.1	sp|K1QG37|K1QG37_CRAGI	1.2e-47	195.3	75.81%	65.96%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN020097.1	sp|A0A0P4VRI8|A0A0P4VRI8_9EUCA	5.9e-22	110.9	26.25%	48.48%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN020098.1	sp|K1PAP6|K1PAP6_CRAGI	4.0e-286	989.6	99.51%	69.40%	Interferon regulatory factor 2;OS=Crassostrea;PE=4;SV=1	GO:0044212|
GN020099.1	sp|K1Q107|K1Q107_CRAGI	2.9e-58	229.9	100.00%	83.33%	Histidine triad nucleotide-binding protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN020100.1	sp|K1Q105|K1Q105_CRAGI	1.3e-196	691.0	100.00%	90.98%	Ferrochelatase;OS=Crassostrea;PE=3;SV=1	GO:0004325|	GO:0006783|
GN020101.1	sp|K1Q875|K1Q875_CRAGI	3.7e-56	224.6	75.84%	45.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN019888.1	sp|A0A210QF19|A0A210QF19_MIZYE	6.2e-247	859.0	100.00%	66.09%	Vacuolar protein 8;OS=Mizuhopecten;PE=4;SV=1	GO:0007165|
GN020102.1	sp|K1Q105|K1Q105_CRAGI	1.3e-196	691.0	100.00%	90.98%	Ferrochelatase;OS=Crassostrea;PE=3;SV=1	GO:0004325|	GO:0006783|
GN019889.1	sp|K1Q432|K1Q432_CRAGI	2.5e-80	305.1	85.75%	44.96%	Nuclear receptor ROR-alpha;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0003707|GO:0008270|
GN019891.1	sp|K1PHE4|K1PHE4_CRAGI	4.2e-77	294.7	45.32%	57.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0016462|
GN020103.1	sp|A0A210Q706|A0A210Q706_MIZYE	6.6e-34	152.1	19.16%	40.76%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020104.1	sp|K1QH20|K1QH20_CRAGI	4.5e-48	197.6	42.13%	69.80%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020105.1	sp|K1QR89|K1QR89_CRAGI	1.2e-231	808.5	88.81%	66.37%	DC-STAMP domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020106.1	sp|K1QXJ0|K1QXJ0_CRAGI	3.7e-47	194.5	53.33%	55.74%	Collagen-like protein 4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN020107.1	sp|K1PS03|K1PS03_CRAGI	3.9e-46	191.4	49.77%	49.30%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020108.1	sp|K1R017|K1R017_CRAGI	2.1e-34	152.9	45.03%	35.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020109.1	sp|K1QDD0|K1QDD0_CRAGI	1.3e-178	632.1	60.73%	77.06%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN020110.1	sp|K1Q593|K1Q593_CRAGI	1.4e-182	644.4	93.82%	90.09%	Isopenicillin N synthetase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN020111.1	sp|K1Q593|K1Q593_CRAGI	1.3e-182	644.4	95.98%	90.09%	Isopenicillin N synthetase;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0016491|
GN020112.1	sp|K1Q6H8|K1Q6H8_CRAGI	5.6e-42	179.1	54.03%	24.89%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN020113.1	sp|K1RHL8|K1RHL8_CRAGI	1.7e-31	140.2	100.00%	88.89%	Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase;OS=Crassostrea;PE=4;SV=1	GO:0008375|	GO:0006486|
GN020114.1	sp|K1PXV1|K1PXV1_CRAGI	3.4e-27	127.9	98.58%	37.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020115.1	sp|K1QPX0|K1QPX0_CRAGI	5.4e-18	98.2	21.86%	43.33%	Endothelial cells scavenger receptor;OS=Crassostrea;PE=4;SV=1	GO:0004725|
GN020116.1	sp|A0A1S3IUZ4|A0A1S3IUZ4_LINUN	6.4e-22	111.7	49.57%	30.13%	uncharacterized protein LOC106167508;OS=Lingula;PE=4;SV=1
GN020117.1	sp|A0A1S3IUZ4|A0A1S3IUZ4_LINUN	5.6e-21	108.6	40.43%	29.17%	uncharacterized protein LOC106167508;OS=Lingula;PE=4;SV=1
GN019892.1	sp|K1P7H5|K1P7H5_CRAGI	1.1e-141	509.2	85.79%	54.51%	Sodium-dependent glucose transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008643|GO:0055085|
GN020118.1	sp|K1R145|K1R145_CRAGI	0.0e+00	1481.1	95.32%	70.86%	Aminopeptidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004177|GO:0008237|GO:0008270|
GN020120.1	sp|A0A1S3JNT2|A0A1S3JNT2_LINUN	1.8e-49	204.1	28.09%	30.47%	F-box/LRR-repeat protein 2-like;OS=Lingula;PE=4;SV=1
GN019893.1	sp|K1R432|K1R432_CRAGI	3.9e-103	379.8	97.73%	81.78%	Cysteine dioxygenase type 1;OS=Crassostrea;PE=4;SV=1	GO:0005506|GO:0016702|
GN019894.1	sp|A0A3G5ALD0|A0A3G5ALD0_CRAHO	1.8e-195	687.2	100.00%	96.60%	Guanine nucleotide-binding protein G(Q) subunit alpha;OS=Crassostrea;PE=2;SV=1
GN020121.1	sp|K1PG82|K1PG82_CRAGI	1.7e-150	537.7	97.87%	76.64%	Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C;OS=Crassostrea;PE=4;SV=1	GO:0016757|
GN020126.1	sp|K1RC55|K1RC55_CRAGI	8.2e-24	117.1	84.03%	29.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020127.1	sp|K1PZK5|K1PZK5_CRAGI	4.1e-27	127.9	94.36%	26.51%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN020489.1	sp|K1QBJ4|K1QBJ4_CRAGI	1.1e-69	268.1	99.31%	85.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020855.1	sp|K1QWA5|K1QWA5_CRAGI	1.9e-17	94.4	79.69%	43.40%	XK-related protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN020856.1	sp|K1QQQ3|K1QQQ3_CRAGI	1.1e-81	309.7	55.65%	61.11%	XK-related protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN020490.1	sp|K1QBJ4|K1QBJ4_CRAGI	4.5e-181	639.8	87.76%	79.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020857.1	sp|K1S490|K1S490_CRAGI	9.5e-222	775.8	92.71%	56.91%	Glycerol-3-phosphate acyltransferase 4;OS=Crassostrea;PE=4;SV=1	GO:0016746|
GN020858.1	sp|A0A210QD68|A0A210QD68_MIZYE	1.5e-124	453.0	87.51%	36.11%	E3 ubiquitin-protein ligase DTX3;OS=Mizuhopecten;PE=4;SV=1	GO:0016874|	GO:0007219|GO:0016567|
GN020859.1	sp|K1Q0N4|K1Q0N4_CRAGI	9.9e-91	340.9	62.75%	33.24%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN020860.1	sp|K1Q0N4|K1Q0N4_CRAGI	2.2e-185	655.2	91.37%	42.84%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN020861.1	sp|K1P996|K1P996_CRAGI	4.3e-21	106.3	51.33%	87.72%	Protein lap4;OS=Crassostrea;PE=4;SV=1
GN020862.1	sp|K1QFM0|K1QFM0_CRAGI	5.6e-153	545.8	100.00%	85.62%	Ribonuclease;OS=Crassostrea;PE=3;SV=1	GO:0003723|GO:0004523|
GN020863.1	sp|K1PFF2|K1PFF2_CRAGI	0.0e+00	1825.1	78.48%	50.84%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|GO:0003676|
GN020491.1	sp|K1QDU0|K1QDU0_CRAGI	1.2e-86	324.7	100.00%	81.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020870.1	sp|K1QQJ3|K1QQJ3_CRAGI	6.1e-294	1015.4	100.00%	68.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0002218|GO:0032481|
GN020871.1	sp|K1RWI3|K1RWI3_CRAGI	4.4e-267	926.0	95.10%	70.72%	Calpain-5;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN020872.1	sp|K1RSB8|K1RSB8_CRAGI	9.3e-122	442.2	100.00%	66.35%	Calpain-5;OS=Crassostrea;PE=3;SV=1	GO:0004198|	GO:0051493|
GN020873.1	sp|K1PM91|K1PM91_CRAGI	2.9e-191	673.3	100.00%	87.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0061630|
GN020874.1	sp|K1Q191|K1Q191_CRAGI	9.3e-51	204.9	97.46%	82.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0043066|
GN020875.1	sp|K1QS50|K1QS50_CRAGI	1.0e-83	315.8	78.12%	66.02%	Histone acetyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003700|GO:0004402|GO:0008270|
GN020876.1	sp|K1PE78|K1PE78_CRAGI	0.0e+00	1105.5	100.00%	71.95%	Hermansky-Pudlak syndrome 1-like protein;OS=Crassostrea;PE=4;SV=1
GN020877.1	sp|A0A210PPQ0|A0A210PPQ0_MIZYE	1.9e-41	174.9	69.72%	56.95%	Polycomb group RING finger protein 1;OS=Mizuhopecten;PE=4;SV=1
GN020878.1	sp|K1QI86|K1QI86_CRAGI	1.3e-306	1057.4	100.00%	78.35%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN020879.1	sp|K1QS55|K1QS55_CRAGI	6.6e-112	409.5	100.00%	76.27%	Homeobox protein HMX3-B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN020880.1	sp|K1PND9|K1PND9_CRAGI	8.3e-09	66.2	48.69%	34.38%	ATP-dependent helicase SGS1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN020882.1	sp|K1QZA0|K1QZA0_CRAGI	0.0e+00	2203.7	99.54%	85.17%	Serine/threonine-protein kinase 36;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN020883.1	sp|K1QS55|K1QS55_CRAGI	3.0e-112	410.6	100.00%	76.58%	Homeobox protein HMX3-B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN020884.1	sp|K1PXW4|K1PXW4_CRAGI	1.1e-98	366.3	87.02%	41.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|GO:0016787|	GO:0016042|
GN020886.1	sp|A0A210Q260|A0A210Q260_MIZYE	2.3e-112	411.0	93.08%	64.41%	Cyclic AMP receptor-like protein A;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004888|	GO:0007166|
GN020887.1	sp|K1RA90|K1RA90_CRAGI	3.6e-147	526.6	100.00%	83.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020888.1	sp|K1QMT0|K1QMT0_CRAGI	3.0e-221	773.9	67.09%	76.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN020889.1	sp|A0A210QLV8|A0A210QLV8_MIZYE	9.4e-88	328.6	100.00%	80.90%	COMM domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1
GN020890.1	sp|K1RA94|K1RA94_CRAGI	1.6e-116	426.0	98.52%	81.28%	Centrosomal protein of 63 kDa;OS=Crassostrea;PE=4;SV=1
GN020891.1	sp|K1RU24|K1RU24_CRAGI	1.7e-310	1070.5	100.00%	77.24%	Neurogenic locus Notch protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005509|
GN020892.1	sp|K1Q9Z1|K1Q9Z1_CRAGI	1.6e-14	84.7	51.82%	51.43%	Putative 2'-deoxynucleoside 5'-phosphate N-hydrolase 1;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0070694|	GO:0009159|GO:0009116|GO:0009117|
GN020893.1	sp|K1R467|K1R467_CRAGI	0.0e+00	1469.9	97.26%	61.13%	Interferon-induced helicase C domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003677|GO:0004386|
GN020894.1	sp|A0A210PYA1|A0A210PYA1_MIZYE	1.2e-84	319.3	61.00%	64.84%	BTB/POZ domain-containing protein KCTD9;OS=Mizuhopecten;PE=4;SV=1	GO:0035556|GO:0051260|
GN020895.1	sp|K1PQ84|K1PQ84_CRAGI	1.3e-64	251.1	99.24%	89.92%	Fumarylacetoacetate hydrolase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN020896.1	sp|A0A210PPE3|A0A210PPE3_MIZYE	5.6e-17	93.2	77.25%	40.63%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020897.1	sp|K1P8G6|K1P8G6_CRAGI	3.1e-160	570.1	87.05%	90.97%	Vesicular integral-membrane protein VIP36;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020898.1	sp|K1PKK3|K1PKK3_CRAGI	1.5e-97	361.3	93.30%	86.54%	PACRG-like protein;OS=Crassostrea;PE=4;SV=1
GN020899.1	sp|K1PTH8|K1PTH8_CRAGI	1.0e-62	245.0	94.04%	80.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020900.1	sp|K1QKN3|K1QKN3_CRAGI	1.3e-93	349.7	98.77%	51.72%	Growth inhibition and differentiation-related protein 88-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020901.1	sp|K1RS52|K1RS52_CRAGI	3.4e-114	416.8	100.00%	84.67%	Root phototropism protein 2;OS=Crassostrea;PE=4;SV=1
GN020902.1	sp|K1R7Y4|K1R7Y4_CRAGI	7.3e-180	635.6	85.01%	89.31%	Dual oxidase maturation factor 1;OS=Crassostrea;PE=4;SV=1	GO:0005789|GO:0016021|	GO:0015031|
GN020903.1	sp|K1PU70|K1PU70_CRAGI	6.0e-141	506.9	91.07%	50.52%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020906.1	sp|K1PKV7|K1PKV7_CRAGI	7.2e-155	552.4	98.61%	74.58%	3'-5' exoribonuclease 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020907.1	sp|K1QSZ6|K1QSZ6_CRAGI	3.0e-118	430.3	100.00%	78.33%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1
GN020908.1	sp|K1Q774|K1Q774_CRAGI	9.5e-264	915.2	95.90%	68.32%	Serine/threonine-protein kinase haspin;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN020910.1	sp|K1QF64|K1QF64_CRAGI	1.4e-12	77.4	84.00%	61.29%	A disintegrin and metalloproteinase with thrombospondin motifs 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007229|
GN020911.1	sp|K1Q2P1|K1Q2P1_CRAGI	1.7e-67	261.2	98.90%	66.67%	Neurocalcin-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020912.1	sp|K1PF62|K1PF62_CRAGI	3.5e-165	586.6	100.00%	73.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020913.1	sp|K1PF62|K1PF62_CRAGI	5.9e-31	138.7	100.00%	70.79%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020914.1	sp|K1QWJ9|K1QWJ9_CRAGI	2.5e-38	163.7	72.36%	90.91%	BCL2/adenovirus E1B 19 kDa protein-interacting protein 3;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005740|	GO:0043065|
GN020915.1	sp|K1Q318|K1Q318_CRAGI	2.7e-262	910.2	100.00%	88.51%	Splicing factor 3 subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|	GO:0006396|
GN020916.1	sp|K1QNX5|K1QNX5_CRAGI	2.9e-108	397.5	100.00%	58.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020917.1	sp|A0A2C9K9X3|A0A2C9K9X3_BIOGL	3.8e-288	996.5	97.70%	57.42%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0016021|	GO:0005216|
GN020492.1	sp|A0A2G8LMM1|A0A2G8LMM1_STIJA	8.9e-25	119.8	95.54%	30.35%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN020918.1	sp|K1QNW8|K1QNW8_CRAGI	9.9e-147	525.4	100.00%	82.41%	Dual specificity protein phosphatase 4;OS=Crassostrea;PE=3;SV=1	GO:0017017|GO:0004725|
GN020919.1	sp|K1PHJ6|K1PHJ6_CRAGI	9.8e-145	520.4	77.57%	35.13%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN020920.1	sp|K1QXD1|K1QXD1_CRAGI	4.9e-76	290.8	67.63%	55.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003682|	GO:0045892|GO:0007219|
GN020921.1	sp|K1QPP7|K1QPP7_CRAGI	1.6e-131	475.7	70.06%	57.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020922.1	sp|K1QG02|K1QG02_CRAGI	7.9e-281	972.2	90.38%	63.17%	Zinc finger B-box domain containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN020923.1	sp|K1PZF2|K1PZF2_CRAGI	0.0e+00	2009.2	98.81%	92.57%	Exportin-7;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0008536|	GO:0006886|GO:0051169|
GN020924.1	sp|K1PKA4|K1PKA4_CRAGI	7.4e-180	635.6	78.88%	95.68%	Casein kinase I isoform alpha;OS=Crassostrea;PE=3;SV=1	GO:0005524|GO:0004674|
GN020925.1	sp|K1R4H5|K1R4H5_CRAGI	2.5e-200	704.1	96.57%	76.51%	TNFAIP3-interacting protein 2;OS=Crassostrea;PE=4;SV=1	GO:0070530|	GO:0000281|GO:0014066|
GN020926.1	sp|K1QLR6|K1QLR6_CRAGI	2.3e-133	481.5	98.13%	51.13%	Tudor domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN020927.1	sp|K1QLR6|K1QLR6_CRAGI	2.2e-117	429.1	73.23%	44.39%	Tudor domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN020928.1	sp|K1QSW3|K1QSW3_CRAGI	1.4e-80	305.1	97.55%	65.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020929.1	sp|A0A210QVR4|A0A210QVR4_MIZYE	1.7e-36	158.3	86.22%	46.86%	C1q-related factor;OS=Mizuhopecten;PE=4;SV=1
GN020930.1	sp|K1RM98|K1RM98_CRAGI	1.7e-119	434.5	97.46%	93.28%	THO complex subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0000346|	GO:0006406|
GN020931.1	sp|K1QNN9|K1QNN9_CRAGI	1.5e-264	917.9	79.04%	71.88%	MICOS complex subunit MIC60;OS=complex;PE=3;SV=1	GO:0016021|GO:0005743|
GN020932.1	sp|A0A210PXE9|A0A210PXE9_MIZYE	4.9e-53	214.5	98.99%	29.86%	Monocarboxylate transporter 12;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020933.1	sp|A0A210PPB7|A0A210PPB7_MIZYE	4.5e-225	786.6	98.87%	66.95%	Dynactin subunit 1;OS=Mizuhopecten;PE=4;SV=1	GO:0005869|	GO:0070840|	GO:0010970|
GN020934.1	sp|A0A210Q392|A0A210Q392_MIZYE	5.4e-166	589.7	99.79%	62.89%	Equilibrative nucleoside transporter 3;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005337|
GN020937.1	sp|K1PTN1|K1PTN1_CRAGI	4.4e-218	763.5	99.87%	52.59%	Poly [ADP-ribose] polymerase 14;OS=Crassostrea;PE=4;SV=1
GN020938.1	sp|A0A210QRQ3|A0A210QRQ3_MIZYE	7.2e-126	456.1	94.31%	60.52%	Arsenite methyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN020939.1	sp|A0A2T7P9V6|A0A2T7P9V6_POMCA	2.4e-170	604.4	95.39%	57.01%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0003887|	GO:0006281|
GN020940.1	sp|K1QEF0|K1QEF0_CRAGI	1.1e-131	475.3	88.10%	78.21%	Serine protease HTRA2, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004252|
GN020941.1	sp|K1R0F4|K1R0F4_CRAGI	7.5e-155	552.4	100.00%	71.73%	StAR-related lipid transfer protein 7, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008289|
GN020943.1	sp|K1PBH1|K1PBH1_CRAGI	1.4e-74	284.6	100.00%	72.63%	Sarcoplasmic calcium-binding protein;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020944.1	sp|A0A210R1X6|A0A210R1X6_MIZYE	3.2e-27	126.7	96.61%	55.75%	MMS19 nucleotide excision repair protein-like;OS=Mizuhopecten;PE=4;SV=1	GO:0097428|
GN020945.1	sp|K1RMT3|K1RMT3_CRAGI	2.5e-59	233.4	99.18%	95.83%	Ubiquitin domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN020946.1	sp|K1R0P6|K1R0P6_CRAGI	3.4e-185	653.3	100.00%	81.77%	FMRFamide receptor;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008528|
GN020947.1	sp|K1RB04|K1RB04_CRAGI	1.8e-67	261.5	58.91%	86.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020948.1	sp|K1PSJ3|K1PSJ3_CRAGI	4.9e-205	719.2	100.00%	91.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020949.1	sp|K1PZX5|K1PZX5_CRAGI	6.8e-176	622.1	100.00%	89.73%	WD repeat-containing protein 54;OS=Crassostrea;PE=4;SV=1
GN020950.1	sp|K1Q7H3|K1Q7H3_CRAGI	3.1e-158	563.9	100.00%	65.25%	Docking protein 1;OS=Crassostrea;PE=4;SV=1
GN020951.1	sp|K1PSJ7|K1PSJ7_CRAGI	6.7e-159	566.2	96.61%	65.29%	Neuralized-like protein 1A;OS=Crassostrea;PE=4;SV=1
GN020952.1	sp|K1QWT8|K1QWT8_CRAGI	3.8e-30	137.5	81.78%	39.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020953.1	sp|K1Q6H8|K1Q6H8_CRAGI	3.4e-87	329.3	55.94%	30.84%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN020954.1	sp|K1PUG2|K1PUG2_CRAGI	1.8e-191	674.5	99.23%	65.83%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN020955.1	sp|R7V4V5|R7V4V5_CAPTE	2.6e-137	494.2	93.07%	60.00%	Uncharacterized protein;OS=Capitella;PE=3;SV=1	GO:0008061|	GO:0005975|
GN020956.1	sp|K1QYB6|K1QYB6_CRAGI	2.1e-287	993.8	91.69%	73.04%	Delta-1-pyrroline-5-carboxylate synthetase;OS=Crassostrea;PE=3;SV=1	GO:0004350|	GO:0006561|
GN020957.1	sp|A0A1I9W307|A0A1I9W307_HALDH	7.6e-219	765.8	70.69%	79.66%	Aminopeptidase;OS=Haliotis;PE=2;SV=1	GO:0004177|GO:0008237|GO:0008270|
GN020958.1	sp|K1RE25|K1RE25_CRAGI	3.9e-255	886.3	93.57%	74.22%	Basic immunoglobulin-like variable motif-containing protein;OS=Crassostrea;PE=4;SV=1
GN020960.1	sp|K1S3H6|K1S3H6_CRAGI	2.9e-55	221.1	84.44%	51.91%	Collagen alpha-2(VIII) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN020961.1	sp|K1R360|K1R360_CRAGI	1.1e-34	153.3	38.81%	55.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020962.1	sp|K1Q622|K1Q622_CRAGI	2.4e-119	434.1	91.78%	74.46%	Ribonuclease H2 subunit B;OS=Crassostrea;PE=4;SV=1	GO:0032299|
GN020963.1	sp|K1S3P6|K1S3P6_CRAGI	1.6e-202	711.8	91.93%	64.71%	LETM1 and EF-hand domain-containing protein 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016021|GO:0005739|	GO:0005509|GO:0043022|
GN020964.1	sp|K1QKR6|K1QKR6_CRAGI	8.9e-171	605.1	100.00%	80.94%	Carbohydrate sulfotransferase 15;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008146|
GN020965.1	sp|A0A210PI12|A0A210PI12_MIZYE	1.9e-151	541.6	96.00%	60.32%	Negative elongation factor A;OS=Mizuhopecten;PE=4;SV=1	GO:0032021|	GO:0003746|	GO:0034244|
GN020966.1	sp|K1R4P8|K1R4P8_CRAGI	1.7e-45	187.6	72.66%	97.83%	Peptidyl-prolyl cis-trans isomerase;OS=Crassostrea;PE=4;SV=1	GO:0003755|
GN020967.1	sp|K1PDV6|K1PDV6_CRAGI	5.1e-60	237.7	71.95%	43.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020968.1	sp|A0A210Q369|A0A210Q369_MIZYE	2.0e-120	438.0	98.31%	60.74%	Protein FAM45A;OS=Mizuhopecten;PE=4;SV=1
GN020969.1	sp|K1QXC6|K1QXC6_CRAGI	8.0e-47	191.8	100.00%	83.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020970.1	sp|A0A210QSP8|A0A210QSP8_MIZYE	7.9e-123	446.0	97.19%	56.54%	Palmitoyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0019706|
GN020971.1	sp|K1Q014|K1Q014_CRAGI	1.3e-144	518.8	99.61%	50.77%	Solute carrier family 22 member 21;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020972.1	sp|K1QFK9|K1QFK9_CRAGI	6.0e-123	446.4	99.49%	59.54%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN020973.1	sp|K1QRE1|K1QRE1_CRAGI	2.0e-169	600.5	100.00%	95.19%	COP9 signalosome complex subunit 6;OS=Crassostrea;PE=4;SV=1	GO:0008180|	GO:0000338|
GN020974.1	sp|A0A210PYL5|A0A210PYL5_MIZYE	1.9e-66	258.1	98.79%	61.33%	Transcription initiation factor TFIID subunit 9B;OS=Mizuhopecten;PE=4;SV=1	GO:0046982|GO:0003743|	GO:0006352|
GN020975.1	sp|K1RHQ7|K1RHQ7_CRAGI	1.9e-35	155.2	26.54%	88.24%	SCO-spondin;OS=Crassostrea;PE=4;SV=1
GN020976.1	sp|K1QZY2|K1QZY2_CRAGI	1.6e-151	541.2	96.81%	88.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020977.1	sp|K1RJK2|K1RJK2_CRAGI	1.2e-128	465.3	98.07%	63.43%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN020498.1	sp|K1QXB7|K1QXB7_CRAGI	7.3e-148	529.6	63.62%	78.98%	Ubiquitin-associated domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020978.1	sp|K1QWQ7|K1QWQ7_CRAGI	1.1e-77	297.0	56.44%	45.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020979.1	sp|K1RHL3|K1RHL3_CRAGI	5.5e-183	646.4	73.64%	81.42%	Organic cation transporter protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020499.1	sp|K1PPR1|K1PPR1_CRAGI	6.5e-266	921.8	100.00%	84.39%	Deoxyribodipyrimidine photo-lyase;OS=Crassostrea;PE=4;SV=1	GO:0003904|	GO:0006281|
GN020980.1	sp|K1R1G7|K1R1G7_CRAGI	1.3e-169	601.7	95.82%	68.12%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN020981.1	sp|A0A1S3JLN6|A0A1S3JLN6_LINUN	0.0e+00	1421.4	93.31%	51.38%	uncharacterized protein LOC106174328 isoform X1;OS=Lingula;PE=4;SV=1	GO:0016021|
GN020982.1	sp|K1QXR6|K1QXR6_CRAGI	8.7e-94	349.4	98.21%	86.02%	Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha;OS=Crassostrea;PE=4;SV=1	GO:0008318|	GO:0018342|
GN020983.1	sp|A0A210PQL2|A0A210PQL2_MIZYE	1.5e-75	288.1	97.62%	65.69%	Thymidylate kinase;OS=Mizuhopecten;PE=3;SV=1	GO:0005524|GO:0004798|	GO:0006233|
GN020984.1	sp|A0A2C9KEK2|A0A2C9KEK2_BIOGL	5.4e-165	587.0	82.77%	55.62%	Uncharacterized protein;OS=Biomphalaria;PE=4;SV=1	GO:0005524|GO:0004672|
GN020985.1	sp|A0A210R0J8|A0A210R0J8_MIZYE	1.7e-56	224.9	90.00%	59.71%	Mannose-P-dolichol utilization defect 1 protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN020986.1	sp|A0A210QKB5|A0A210QKB5_MIZYE	1.0e-124	452.2	93.31%	64.39%	Renin receptor;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0038023|
GN020989.1	sp|K1QTF6|K1QTF6_CRAGI	7.5e-29	135.6	9.86%	55.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020989.1	sp|K1QTF6|K1QTF6_CRAGI	8.3e-20	105.5	10.72%	37.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020500.1	sp|K1Q474|K1Q474_CRAGI	2.5e-54	216.9	100.00%	84.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020991.1	sp|A0A1S3IF14|A0A1S3IF14_LINUN	8.2e-37	159.1	96.97%	50.93%	uncharacterized protein LOC106163628;OS=Lingula;PE=4;SV=1
GN020992.1	sp|K1QXJ9|K1QXJ9_CRAGI	5.1e-182	642.5	97.41%	89.32%	Pantothenate kinase 3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004594|	GO:0015937|
GN020501.1	sp|K1QBK0|K1QBK0_CRAGI	2.1e-56	224.2	95.78%	65.41%	IL17-6;OS=Crassostrea;PE=2;SV=1	GO:0005576|	GO:0005125|
GN020993.1	sp|K1QEI9|K1QEI9_CRAGI	1.4e-100	372.5	70.29%	58.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN020994.1	sp|K1Q730|K1Q730_CRAGI	2.2e-66	258.1	89.86%	53.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004930|
GN020995.1	sp|K1R6W4|K1R6W4_CRAGI	2.8e-141	506.9	100.00%	87.29%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020996.1	sp|K1RR88|K1RR88_CRAGI	6.6e-191	672.2	99.74%	89.92%	5-hydroxytryptamine receptor 4;OS=Crassostrea;PE=3;SV=1	GO:0005887|	GO:0004993|	GO:0007268|GO:0032098|
GN020997.1	sp|K1QUH4|K1QUH4_CRAGI	1.4e-20	104.4	100.00%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020502.1	sp|K1PPR5|K1PPR5_CRAGI	4.5e-92	343.6	98.11%	66.05%	Homeobox protein ceh-9;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN020998.1	sp|K1QKM9|K1QKM9_CRAGI	3.9e-62	244.2	100.00%	93.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020999.1	sp|K1QYZ5|K1QYZ5_CRAGI	3.3e-182	644.0	89.88%	55.59%	Uncharacterized protein C4orf14-like protein;OS=Crassostrea;PE=4;SV=1	GO:0003896|GO:0005525|
GN021000.1	sp|K1RKV0|K1RKV0_CRAGI	0.0e+00	1501.5	99.13%	82.19%	Glutamate receptor, ionotropic kainate 2;OS=Crassostrea;PE=3;SV=1	GO:0030054|GO:0016021|GO:0045211|	GO:0004970|
GN021001.1	sp|K1REQ6|K1REQ6_CRAGI	8.4e-217	759.2	100.00%	73.08%	Transmembrane and TPR repeat-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021002.1	sp|K1QEY3|K1QEY3_CRAGI	1.9e-20	104.8	61.76%	69.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021003.1	sp|K1RSH8|K1RSH8_CRAGI	0.0e+00	3284.6	57.87%	64.88%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN021004.1	sp|K1PLF5|K1PLF5_CRAGI	1.0e-31	142.5	86.06%	43.33%	Complement C1q-like protein 3;OS=Crassostrea;PE=4;SV=1
GN021005.1	sp|K1PU36|K1PU36_CRAGI	1.8e-58	231.5	63.56%	71.81%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN021006.1	sp|V4B2Q3|V4B2Q3_LOTGI	2.3e-41	174.5	88.24%	45.81%	Uncharacterized protein;OS=Lottia;PE=3;SV=1
GN021007.1	sp|K1QZ80|K1QZ80_CRAGI	5.0e-142	510.4	92.59%	58.35%	Protein bunched, class 2/F isoform;OS=Crassostrea;PE=4;SV=1
GN021008.1	sp|K1PGC4|K1PGC4_CRAGI	9.3e-94	349.7	88.49%	48.20%	Monocarboxylate transporter 12-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021009.1	sp|K1PGC4|K1PGC4_CRAGI	1.0e-78	299.7	97.42%	38.74%	Monocarboxylate transporter 12-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021010.1	sp|A0A2L1K0V4|A0A2L1K0V4_CRAGI	2.4e-56	223.8	93.92%	71.72%	von Hippel-Lindau;OS=Crassostrea;PE=2;SV=1
GN020504.1	sp|A0A210PGR3|A0A210PGR3_MIZYE	3.5e-181	640.2	80.00%	78.81%	Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial;OS=Mizuhopecten;PE=3;SV=1	GO:0003995|GO:0050660|
GN021011.1	sp|K1S074|K1S074_CRAGI	1.7e-163	581.6	96.49%	59.01%	Monocarboxylate transporter 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0055085|
GN021012.1	sp|K1RTT4|K1RTT4_CRAGI	2.7e-104	384.0	96.86%	68.23%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021013.1	sp|K1PM26|K1PM26_CRAGI	5.6e-225	785.8	100.00%	74.71%	DNA polymerase mu;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0003887|GO:0046872|
GN021014.1	sp|K1PEA6|K1PEA6_CRAGI	0.0e+00	1137.9	94.59%	83.88%	Condensin complex subunit 2;OS=Crassostrea;PE=3;SV=1	GO:0000796|	GO:0051301|GO:0007076|
GN021015.1	sp|K1QEH9|K1QEH9_CRAGI	4.6e-155	553.5	91.50%	85.93%	Leucine zipper putative tumor suppressor 2-like protein;OS=Crassostrea;PE=4;SV=1
GN021016.1	sp|K1PK87|K1PK87_CRAGI	0.0e+00	1271.9	98.42%	80.13%	Putative E3 ubiquitin-protein ligase TRIP12;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN020505.1	sp|K1RPZ2|K1RPZ2_CRAGI	8.0e-103	378.6	99.50%	90.00%	ES1-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1
GN021017.1	sp|K1PK87|K1PK87_CRAGI	4.6e-247	859.0	98.27%	90.77%	Putative E3 ubiquitin-protein ligase TRIP12;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0004842|GO:0008270|
GN021018.1	sp|K1R4H7|K1R4H7_CRAGI	2.0e-273	947.6	63.72%	81.71%	Purine nucleoside phosphorylase;OS=Crassostrea;PE=4;SV=1	GO:0004731|	GO:0009116|
GN020506.1	sp|K1QG60|K1QG60_CRAGI	1.7e-113	414.8	76.79%	77.15%	Non-structural maintenance of chromosomes element 4;OS=Crassostrea;PE=3;SV=1	GO:0005634|GO:0030915|	GO:0006310|GO:0006281|
GN020507.1	sp|K1PAZ6|K1PAZ6_CRAGI	1.8e-121	441.0	100.00%	84.78%	Uncharacterized protein C10orf46-like protein;OS=Crassostrea;PE=4;SV=1	GO:0031625|	GO:0006511|
GN021020.1	sp|K1QJN2|K1QJN2_CRAGI	1.6e-55	221.5	73.20%	80.85%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006915|
GN021021.1	sp|K1R3F5|K1R3F5_CRAGI	3.4e-253	879.8	99.84%	75.28%	Zinc finger protein Pegasus;OS=Crassostrea;PE=4;SV=1	GO:0000981|GO:0003676|	GO:0040034|
GN021022.1	sp|K1QMF2|K1QMF2_CRAGI	2.2e-57	227.6	96.94%	61.46%	Transcription factor Sox-8;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN021023.1	sp|K1QWH6|K1QWH6_CRAGI	2.8e-158	563.5	100.00%	83.64%	Uracil-DNA glycosylase;OS=Crassostrea;PE=3;SV=1	GO:0005739|GO:0005634|	GO:0004844|	GO:0006284|
GN021025.1	sp|A0A210QGR7|A0A210QGR7_MIZYE	5.1e-72	277.3	86.20%	38.84%	Endoplasmic reticulum interferon stimulator;OS=Mizuhopecten;PE=4;SV=1	GO:0002218|GO:0032481|GO:0007165|
GN021029.1	sp|K1PYQ4|K1PYQ4_CRAGI	8.5e-239	832.4	99.88%	61.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN021030.1	sp|A0A210QTY0|A0A210QTY0_MIZYE	0.0e+00	1279.2	94.98%	60.42%	Inositol 1,4,5-trisphosphate receptor type 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005783|GO:0016021|	GO:0070679|GO:0005220|
GN021031.1	sp|K1QLV5|K1QLV5_CRAGI	7.6e-114	416.0	92.92%	53.62%	Inositol 1,4,5-trisphosphate receptor type 2;OS=Crassostrea;PE=4;SV=1	GO:0005783|GO:0016021|	GO:0070679|GO:0005220|
GN021032.1	sp|K1P6T1|K1P6T1_CRAGI	1.6e-71	275.8	78.78%	38.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020508.1	sp|K1PQ64|K1PQ64_CRAGI	7.8e-123	445.3	100.00%	92.41%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN021033.1	sp|K1RIR2|K1RIR2_CRAGI	4.8e-100	369.8	100.00%	62.21%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN021034.1	sp|K1QBR5|K1QBR5_CRAGI	9.1e-99	365.5	97.33%	63.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005319|
GN021035.1	sp|K1QPE9|K1QPE9_CRAGI	3.7e-47	193.7	70.10%	58.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021036.1	sp|A0A210QRQ3|A0A210QRQ3_MIZYE	5.1e-140	503.1	92.95%	69.88%	Arsenite methyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0008168|
GN021037.1	sp|A0A210PPI3|A0A210PPI3_MIZYE	5.2e-182	642.9	97.82%	73.21%	Major facilitator superfamily domain-containing protein 10;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0005215|	GO:0055085|
GN021038.1	sp|K1QVS7|K1QVS7_CRAGI	5.0e-22	108.6	100.00%	73.44%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020509.1	sp|K1QLP3|K1QLP3_CRAGI	2.7e-37	162.2	84.40%	37.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN021040.1	sp|K1RIR2|K1RIR2_CRAGI	1.6e-95	354.8	100.00%	60.46%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN021041.1	sp|K1RIR2|K1RIR2_CRAGI	1.2e-98	365.2	99.24%	61.30%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN021043.1	sp|K1RIR2|K1RIR2_CRAGI	5.5e-96	356.3	97.33%	61.57%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN021044.1	sp|K1RIR2|K1RIR2_CRAGI	1.0e-97	362.1	99.24%	62.07%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN020510.1	sp|A0A1S3IXC3|A0A1S3IXC3_LINUN	1.1e-154	552.4	98.67%	66.35%	cell division cycle protein 23 homolog;OS=Lingula;PE=4;SV=1	GO:0005680|	GO:0051301|GO:0030071|
GN021045.1	sp|K1RIR2|K1RIR2_CRAGI	5.3e-99	366.3	100.00%	62.98%	Short-chain collagen C4;OS=Crassostrea;PE=4;SV=1	GO:0005581|
GN021048.1	sp|K1R0H8|K1R0H8_CRAGI	5.5e-24	117.5	31.23%	55.34%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020511.1	sp|K1Q9H1|K1Q9H1_CRAGI	5.4e-104	383.3	100.00%	76.19%	Ankyrin repeat and protein kinase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016301|	GO:0035556|
GN021049.1	sp|K1RMM1|K1RMM1_CRAGI	1.1e-42	177.9	96.15%	89.22%	Homeobox protein Nkx-6.2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021050.1	sp|K1Q1Z5|K1Q1Z5_CRAGI	5.5e-178	629.8	100.00%	61.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021052.1	sp|K1QDC0|K1QDC0_CRAGI	1.3e-179	634.8	100.00%	73.89%	Arylacetamide deacetylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0052689|
GN021053.1	sp|K1RMM6|K1RMM6_CRAGI	2.6e-51	207.6	79.82%	67.05%	Centromere protein J;OS=Crassostrea;PE=4;SV=1
GN021054.1	sp|K1RAU7|K1RAU7_CRAGI	6.0e-123	446.4	100.00%	89.20%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021055.1	sp|K1PV16|K1PV16_CRAGI	0.0e+00	2105.5	100.00%	64.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN021056.1	sp|K1PMP0|K1PMP0_CRAGI	4.8e-311	1072.4	100.00%	54.63%	Glycerol-3-phosphate acyltransferase 1, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0008374|	GO:0044255|
GN021057.1	sp|K1PEX5|K1PEX5_CRAGI	0.0e+00	1235.3	96.31%	80.25%	Protein hu-li tai shao;OS=Crassostrea;PE=4;SV=1
GN020512.1	sp|K1PPS0|K1PPS0_CRAGI	2.2e-11	74.7	71.04%	33.10%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN021058.1	sp|K1P8S5|K1P8S5_CRAGI	0.0e+00	1701.8	99.82%	71.02%	Condensin complex subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0000796|	GO:0007076|
GN021059.1	sp|A0A210Q6H4|A0A210Q6H4_MIZYE	1.1e-12	78.2	77.32%	45.95%	D-dopachrome decarboxylase;OS=Mizuhopecten;PE=4;SV=1
GN021060.1	sp|K1Q835|K1Q835_CRAGI	5.6e-109	399.8	93.81%	72.87%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021064.1	sp|K1RAP6|K1RAP6_CRAGI	1.0e-121	441.8	99.62%	85.55%	T-cell leukemia homeobox protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021065.1	sp|K1QV43|K1QV43_CRAGI	2.2e-67	261.2	83.90%	67.32%	T-cell leukemia homeobox protein 3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021066.1	sp|K1PE49|K1PE49_CRAGI	1.0e-83	316.2	94.19%	43.66%	Arylacetamide deacetylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN021067.1	sp|K1PE49|K1PE49_CRAGI	4.8e-81	307.4	94.19%	42.58%	Arylacetamide deacetylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN021068.1	sp|K1PE49|K1PE49_CRAGI	1.2e-87	329.3	93.49%	43.21%	Arylacetamide deacetylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN021069.1	sp|A0A0L8HK79|A0A0L8HK79_OCTBM	1.7e-158	564.7	96.10%	63.40%	Uncharacterized protein;OS=Octopus;PE=4;SV=1	GO:0046872|
GN021070.1	sp|K1R641|K1R641_CRAGI	2.8e-223	780.4	93.77%	68.49%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN021071.1	sp|K1QG81|K1QG81_CRAGI	3.6e-53	213.4	100.00%	64.81%	Aristaless-related homeobox protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021072.1	sp|K1S2W0|K1S2W0_CRAGI	5.8e-31	139.0	99.08%	83.18%	Conopressin/neurophysin;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005185|
GN021073.1	sp|K1PH94|K1PH94_CRAGI	1.2e-270	937.9	79.12%	73.17%	Thyroid peroxidase;OS=Crassostrea;PE=4;SV=1	GO:0020037|GO:0004601|	GO:0006979|
GN021074.1	sp|K1Q9X9|K1Q9X9_CRAGI	1.1e-127	461.8	100.00%	72.30%	Integral membrane protein 2A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021075.1	sp|A0A210QY53|A0A210QY53_MIZYE	2.9e-75	288.5	91.54%	34.17%	Monocarboxylate transporter 5;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021076.1	sp|K1QGI4|K1QGI4_CRAGI	5.6e-157	559.3	94.17%	80.75%	Mannan endo-1,4-beta-mannosidase;OS=Crassostrea;PE=4;SV=1
GN021077.1	sp|K1QCP8|K1QCP8_CRAGI	1.2e-193	682.6	44.76%	80.74%	IgGFc-binding protein;OS=Crassostrea;PE=4;SV=1
GN020513.1	sp|K1PU06|K1PU06_CRAGI	1.4e-39	169.5	97.62%	36.41%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021079.1	sp|K1PWJ1|K1PWJ1_CRAGI	7.5e-74	282.0	99.33%	87.76%	Protein deltex-3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0007219|GO:0016567|
GN021080.1	sp|K1QLY6|K1QLY6_CRAGI	3.8e-145	520.0	91.84%	87.34%	Homeobox protein Nkx-2.6;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021081.1	sp|K1R2T5|K1R2T5_CRAGI	1.7e-86	324.7	91.20%	68.72%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005525|
GN021082.1	sp|K1QW20|K1QW20_CRAGI	0.0e+00	2003.8	100.00%	83.91%	Strawberry notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006355|
GN021084.1	sp|K1PCA9|K1PCA9_CRAGI	5.5e-36	156.4	90.12%	47.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020514.1	sp|K1PVY9|K1PVY9_CRAGI	7.9e-36	155.2	94.55%	65.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021085.1	sp|K1PUT5|K1PUT5_CRAGI	5.1e-30	136.3	56.67%	69.05%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021086.1	sp|K1PJP2|K1PJP2_CRAGI	0.0e+00	1423.3	100.00%	96.98%	Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN021087.1	sp|A0A1S3K9Y8|A0A1S3K9Y8_LINUN	1.5e-211	741.5	82.30%	75.24%	probable ATP-dependent RNA helicase DDX56 isoform X2;OS=Lingula;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN021088.1	sp|K1Q5M7|K1Q5M7_CRAGI	7.8e-262	908.3	100.00%	83.21%	D(2) dopamine receptor;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN021089.1	sp|K1QRP7|K1QRP7_CRAGI	4.4e-283	979.5	100.00%	64.04%	5-hydroxytryptamine receptor 2A;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN021090.1	sp|K1PJP9|K1PJP9_CRAGI	3.8e-289	999.2	99.51%	84.99%	26S proteasome non-ATPase regulatory subunit 1;OS=Crassostrea;PE=3;SV=1	GO:0008540|	GO:0030234|	GO:0042176|
GN021091.1	sp|K1QCM9|K1QCM9_CRAGI	1.2e-125	455.7	93.25%	52.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0008061|	GO:0006030|
GN021093.1	sp|K1PLC6|K1PLC6_CRAGI	1.7e-103	381.3	99.64%	72.73%	Nucleolar protein 14;OS=Crassostrea;PE=4;SV=1	GO:0032040|
GN021094.1	sp|K1PLC6|K1PLC6_CRAGI	7.7e-135	485.7	100.00%	78.61%	Nucleolar protein 14;OS=Crassostrea;PE=4;SV=1	GO:0032040|
GN020516.1	sp|K1R0I6|K1R0I6_CRAGI	6.0e-126	456.1	99.02%	84.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN021095.1	sp|K1Q7N0|K1Q7N0_CRAGI	2.5e-154	550.4	100.00%	86.40%	Transcription factor SOX-2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN021097.1	sp|A0A2T7P9I9|A0A2T7P9I9_POMCA	1.6e-42	177.9	99.36%	58.33%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0005730|	GO:0003723|
GN021098.1	sp|K1PVU5|K1PVU5_CRAGI	1.6e-134	485.0	92.04%	65.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021099.1	sp|K1QFU7|K1QFU7_CRAGI	3.1e-236	824.3	55.40%	67.71%	Uncharacterized protein C5orf34-like protein;OS=Crassostrea;PE=4;SV=1
GN021100.1	sp|A0A210QQE8|A0A210QQE8_MIZYE	9.3e-258	895.2	88.77%	62.50%	Melanotransferrin;OS=Mizuhopecten;PE=3;SV=1	GO:0005615|	GO:0046872|	GO:0006811|GO:0055072|
GN020517.1	sp|K1QL64|K1QL64_CRAGI	0.0e+00	1170.6	99.44%	60.17%	Putative ATP-dependent RNA helicase DDX58;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN021101.1	sp|K1RT39|K1RT39_CRAGI	2.8e-104	383.6	88.65%	90.59%	Glutaredoxin-3;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0005576|	GO:0009055|GO:0015035|GO:0036459|	GO:0045454|GO:0016579|
GN021102.1	sp|K1RT39|K1RT39_CRAGI	1.5e-46	191.0	95.42%	64.33%	Glutaredoxin-3;OS=Crassostrea;PE=4;SV=1	GO:0005623|GO:0005576|	GO:0009055|GO:0015035|GO:0036459|	GO:0045454|GO:0016579|
GN021103.1	sp|A0A210QUK6|A0A210QUK6_MIZYE	9.0e-14	84.7	21.11%	36.42%	Ribosome-binding protein 1;OS=Mizuhopecten;PE=4;SV=1
GN021104.1	sp|K1R9A7|K1R9A7_CRAGI	4.9e-235	819.3	95.68%	78.05%	Glycogenin-1;OS=Crassostrea;PE=2;SV=1	GO:0016757|
GN021105.1	sp|K1QVU3|K1QVU3_CRAGI	0.0e+00	1614.4	95.71%	93.33%	Gamma-tubulin complex component;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005874|GO:0005815|GO:0000922|	GO:0043015|	GO:0007020|
GN021107.1	sp|K1RAL8|K1RAL8_CRAGI	2.6e-46	192.6	84.96%	28.72%	Tripartite motif-containing protein 56;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN021108.1	sp|K1RWG6|K1RWG6_CRAGI	5.0e-178	629.8	89.04%	82.29%	Autophagy-related protein 16-1;OS=Crassostrea;PE=4;SV=1
GN021109.1	sp|K1QZW4|K1QZW4_CRAGI	1.6e-134	484.6	92.50%	81.08%	Retinol dehydrogenase 11;OS=Crassostrea;PE=3;SV=1
GN021110.1	sp|K1RD33|K1RD33_CRAGI	1.1e-127	462.6	57.59%	71.19%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|GO:0030170|	GO:0009058|
GN021111.1	sp|A0A0B6ZWB6|A0A0B6ZWB6_9EUPU	3.9e-46	190.3	86.08%	53.61%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0005739|	GO:0003735|	GO:0032543|
GN021112.1	sp|K1P966|K1P966_CRAGI	2.6e-115	421.4	51.66%	87.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:2000145|
GN021113.1	sp|K1PFC5|K1PFC5_CRAGI	9.5e-261	904.8	82.24%	90.61%	Fem-1-like protein C;OS=Crassostrea;PE=4;SV=1
GN021114.1	sp|K1PZ89|K1PZ89_CRAGI	0.0e+00	1401.0	100.00%	83.44%	Mannosyl-oligosaccharide glucosidase;OS=Crassostrea;PE=4;SV=1	GO:0004573|	GO:0009311|
GN021115.1	sp|K1QDS3|K1QDS3_CRAGI	0.0e+00	1164.8	78.69%	80.30%	Transcription factor AP-2 epsilon;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|
GN020518.1	sp|K1QL64|K1QL64_CRAGI	1.3e-192	679.1	94.61%	45.30%	Putative ATP-dependent RNA helicase DDX58;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN021116.1	sp|K1PN57|K1PN57_CRAGI	7.5e-198	695.7	72.85%	90.05%	Cytochrome c oxidase assembly protein COX15-like protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016627|	GO:0006784|
GN021117.1	sp|K1PRQ2|K1PRQ2_CRAGI	0.0e+00	1245.7	100.00%	91.31%	Ubiquitin thioesterase Zranb1;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN021118.1	sp|A0A210PYE1|A0A210PYE1_MIZYE	1.7e-180	637.9	99.57%	65.14%	Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase;OS=Mizuhopecten;PE=4;SV=1	GO:0005795|GO:0016021|	GO:0008455|	GO:0009312|
GN021119.1	sp|K1Q6Q0|K1Q6Q0_CRAGI	0.0e+00	1331.2	98.66%	74.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021121.1	sp|K1RHK8|K1RHK8_CRAGI	3.3e-124	450.3	99.02%	71.29%	Retinol dehydrogenase 11;OS=Crassostrea;PE=3;SV=1
GN020519.1	sp|K1QQ95|K1QQ95_CRAGI	8.6e-91	339.3	96.58%	65.50%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN021123.1	sp|K1P964|K1P964_CRAGI	1.0e-303	1048.1	100.00%	98.03%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021124.1	sp|K1PFC2|K1PFC2_CRAGI	1.7e-105	388.3	82.85%	66.55%	Putative transferase C1orf69-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN021125.1	sp|K1QFG6|K1QFG6_CRAGI	3.1e-28	131.0	94.91%	41.18%	Ninjurin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007155|GO:0042246|
GN021126.1	sp|K1QFG6|K1QFG6_CRAGI	4.3e-30	137.1	95.79%	42.38%	Ninjurin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007155|GO:0042246|
GN021127.1	sp|K1QFG6|K1QFG6_CRAGI	5.4e-33	146.7	92.02%	44.62%	Ninjurin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007155|GO:0042246|
GN021128.1	sp|K1RHG2|K1RHG2_CRAGI	3.5e-194	683.7	98.19%	60.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005328|
GN021129.1	sp|A0A210QKH3|A0A210QKH3_MIZYE	1.0e-66	260.4	99.69%	42.19%	Peroxisome proliferator-activated receptor gamma coactivator-related protein 1;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|GO:0003712|GO:0008134|
GN020520.1	sp|K1Q483|K1Q483_CRAGI	1.2e-79	302.0	100.00%	57.30%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN021130.1	sp|K1QVP7|K1QVP7_CRAGI	2.1e-95	354.0	97.98%	88.60%	3'-5' exoribonuclease CSL4-like protein;OS=Crassostrea;PE=4;SV=1	GO:0000178|	GO:0003723|	GO:0006396|
GN021131.1	sp|A0A1S3GY00|A0A1S3GY00_LINUN	2.3e-90	337.8	99.67%	56.72%	protein FRA10AC1 homolog;OS=Lingula;PE=4;SV=1
GN021132.1	sp|K1RXD5|K1RXD5_CRAGI	1.4e-54	218.8	100.00%	53.38%	Homeobox protein EMX1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021133.1	sp|K1Q2M0|K1Q2M0_CRAGI	5.2e-45	187.2	79.80%	45.34%	RFT1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005319|
GN021134.1	sp|A0A210PPF7|A0A210PPF7_MIZYE	1.3e-288	997.7	99.57%	75.76%	UPF0668 protein C10orf76;OS=Mizuhopecten;PE=4;SV=1
GN021135.1	sp|K1Q2M0|K1Q2M0_CRAGI	1.6e-218	764.6	73.26%	80.52%	RFT1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005319|
GN021136.1	sp|A0A210QQ25|A0A210QQ25_MIZYE	1.6e-262	910.6	99.27%	83.85%	T-complex protein 1 subunit eta;OS=Mizuhopecten;PE=3;SV=1	GO:0005737|	GO:0005524|GO:0051082|	GO:0006457|
GN020521.1	sp|K1QQ95|K1QQ95_CRAGI	2.8e-89	334.3	94.24%	65.18%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN021138.1	sp|K1QXJ5|K1QXJ5_CRAGI	1.1e-109	402.1	96.21%	72.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021139.1	sp|A0A210PPK9|A0A210PPK9_MIZYE	8.8e-233	812.4	90.80%	58.23%	Metal transporter CNNM2;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN021140.1	sp|K1R3L2|K1R3L2_CRAGI	1.1e-23	117.9	59.77%	24.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021141.1	sp|K1R3L2|K1R3L2_CRAGI	2.8e-22	113.2	59.77%	24.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020522.1	sp|K1Q483|K1Q483_CRAGI	6.1e-120	436.4	99.22%	57.81%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN021142.1	sp|K1PFP3|K1PFP3_CRAGI	7.6e-16	89.4	58.60%	57.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021143.1	sp|K1PVV6|K1PVV6_CRAGI	2.2e-261	906.7	99.42%	86.91%	Putative aminopeptidase W07G4.4;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0004177|GO:0030145|GO:0008235|
GN021144.1	sp|A0A210PYB4|A0A210PYB4_MIZYE	3.2e-129	466.8	100.00%	73.96%	Fumarylacetoacetate hydrolase domain-containing protein 2;OS=Mizuhopecten;PE=4;SV=1	GO:0016787|
GN020523.1	sp|K1QQ95|K1QQ95_CRAGI	1.7e-213	748.0	100.00%	60.40%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN021145.1	sp|K1QLX1|K1QLX1_CRAGI	1.2e-135	488.4	100.00%	74.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021146.1	sp|K1Q8Z8|K1Q8Z8_CRAGI	1.1e-109	401.4	100.00%	98.46%	Ras-related C3 botulinum toxin substrate 2;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|	GO:0007264|
GN021147.1	sp|K1QH01|K1QH01_CRAGI	1.4e-67	261.5	90.50%	67.78%	Calmodulin;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN021148.1	sp|K1QNJ5|K1QNJ5_CRAGI	6.5e-58	229.2	100.00%	64.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021149.1	sp|K1R8W1|K1R8W1_CRAGI	1.5e-127	461.5	92.33%	71.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021150.1	sp|K1Q203|K1Q203_CRAGI	1.0e-195	688.3	94.25%	73.11%	von Willebrand factor D and EGF domain-containing protein;OS=Crassostrea;PE=4;SV=1
GN021151.1	sp|K1Q903|K1Q903_CRAGI	8.1e-246	854.7	97.91%	96.19%	Suppressor of fused homolog;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0005634|	GO:0008134|
GN020524.1	sp|K1PPV5|K1PPV5_CRAGI	2.4e-226	790.0	100.00%	82.43%	Phosphatidylinositol 4-kinase type 2-beta;OS=Crassostrea;PE=4;SV=1	GO:0004430|
GN021152.1	sp|W4XIZ8|W4XIZ8_STRPU	8.8e-20	103.6	70.51%	27.80%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1	GO:0005634|	GO:0004190|GO:0003676|	GO:0015074|
GN021156.1	sp|K1R8W7|K1R8W7_CRAGI	2.6e-101	374.4	93.12%	68.52%	Fibronectin type 3 and ankyrin repeat domains protein 1;OS=Crassostrea;PE=4;SV=1
GN021157.1	sp|K1Q208|K1Q208_CRAGI	1.2e-62	244.6	100.00%	86.86%	TBC1 domain family member 14;OS=Crassostrea;PE=4;SV=1
GN021158.1	sp|K1Q208|K1Q208_CRAGI	4.2e-27	125.9	85.56%	77.63%	TBC1 domain family member 14;OS=Crassostrea;PE=4;SV=1
GN021159.1	sp|K1Q208|K1Q208_CRAGI	9.7e-42	175.3	76.71%	83.78%	TBC1 domain family member 14;OS=Crassostrea;PE=4;SV=1
GN020525.1	sp|K1PX56|K1PX56_CRAGI	6.3e-305	1053.1	46.01%	85.73%	Transcription elongation regulator 1;OS=Crassostrea;PE=4;SV=1
GN021160.1	sp|V4AI53|V4AI53_LOTGI	6.6e-70	269.2	95.92%	70.74%	Uncharacterized protein;OS=Lottia;PE=3;SV=1	GO:0016021|	GO:0016192|
GN021163.1	sp|K1RUE5|K1RUE5_CRAGI	1.6e-174	617.8	100.00%	79.13%	Protein FAM53A;OS=Crassostrea;PE=4;SV=1
GN021164.1	sp|T1J5B1|T1J5B1_STRMM	3.4e-40	171.4	84.24%	32.09%	Uncharacterized protein;OS=Strigamia;PE=3;SV=1	GO:0016021|	GO:0004983|
GN021165.1	sp|A0A210QRZ8|A0A210QRZ8_MIZYE	1.4e-182	646.4	99.41%	34.32%	Poly(ADP-ribose) glycohydrolase;OS=Mizuhopecten;PE=4;SV=1	GO:0004649|	GO:0005975|
GN021166.1	sp|K1Q208|K1Q208_CRAGI	2.7e-193	680.6	83.33%	78.68%	TBC1 domain family member 14;OS=Crassostrea;PE=4;SV=1
GN021168.1	sp|K1PNK2|K1PNK2_CRAGI	4.7e-49	200.3	90.04%	43.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021171.1	sp|K1R3U2|K1R3U2_CRAGI	1.1e-39	169.9	61.78%	41.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021172.1	sp|K1QX91|K1QX91_CRAGI	3.8e-211	740.0	100.00%	80.56%	Early growth response protein 3;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN021173.1	sp|K1Q9A1|K1Q9A1_CRAGI	4.5e-51	207.2	45.42%	79.84%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021175.1	sp|K1QMH2|K1QMH2_CRAGI	0.0e+00	2428.3	99.79%	85.58%	DNA polymerase;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0051539|GO:0003677|GO:0003887|GO:0046872|GO:0001882|GO:0000166|	GO:0006260|
GN021176.1	sp|K1Q0T1|K1Q0T1_CRAGI	2.9e-68	263.5	91.08%	85.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021177.1	sp|K1Q0T6|K1Q0T6_CRAGI	3.4e-73	280.8	61.18%	81.82%	Syntaxin-18;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021178.1	sp|A0A1S3J244|A0A1S3J244_LINUN	1.9e-70	272.3	87.58%	37.88%	piggyBac transposable element-derived protein 4-like;OS=Lingula;PE=4;SV=2
GN021179.1	sp|A6YRK7|A6YRK7_CRAGI	1.2e-229	801.2	97.80%	73.98%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021180.1	sp|A6YRK7|A6YRK7_CRAGI	1.1e-229	801.6	87.68%	72.64%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021181.1	sp|A0A1S3HEA1|A0A1S3HEA1_LINUN	1.8e-23	115.9	65.04%	31.69%	uncharacterized protein LOC106154126;OS=Lingula;PE=4;SV=1
GN021182.1	sp|A6YRK7|A6YRK7_CRAGI	6.6e-215	752.3	99.80%	68.41%	CYP356A1;OS=Crassostrea;PE=2;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021183.1	sp|K1RIW4|K1RIW4_CRAGI	5.2e-56	223.4	97.15%	48.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020528.1	sp|K1R200|K1R200_CRAGI	3.5e-203	714.1	99.89%	74.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN021184.1	sp|K1PAB9|K1PAB9_CRAGI	0.0e+00	2298.1	100.00%	76.76%	Filamin-C;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN021185.1	sp|K1PAB9|K1PAB9_CRAGI	7.0e-123	446.0	97.39%	66.20%	Filamin-C;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN021186.1	sp|K1PAB9|K1PAB9_CRAGI	0.0e+00	1105.9	99.57%	72.08%	Filamin-C;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN021188.1	sp|K1PWK4|K1PWK4_CRAGI	2.4e-46	190.3	94.17%	75.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021189.1	sp|K1PAB4|K1PAB4_CRAGI	1.1e-40	175.6	33.23%	26.05%	Putative 1-aminocyclopropane-1-carboxylate deaminase;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0008270|
GN021191.1	sp|K1PAB4|K1PAB4_CRAGI	9.5e-174	615.1	95.21%	81.23%	Putative 1-aminocyclopropane-1-carboxylate deaminase;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0008270|
GN021192.1	sp|K1QGK4|K1QGK4_CRAGI	4.5e-87	327.0	100.00%	58.64%	RAD52 motif-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN021193.1	sp|K1QGK4|K1QGK4_CRAGI	4.7e-51	206.1	96.97%	83.46%	RAD52 motif-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN021194.1	sp|K1PWK2|K1PWK2_CRAGI	2.0e-99	367.5	100.00%	77.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021195.1	sp|K1PPD6|K1PPD6_CRAGI	6.3e-46	189.5	98.91%	55.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021196.1	sp|K1R2I0|K1R2I0_CRAGI	0.0e+00	1992.2	99.65%	83.42%	Filamin-A;OS=Crassostrea;PE=4;SV=1	GO:0003779|
GN021197.1	sp|A0A210Q6R7|A0A210Q6R7_MIZYE	6.9e-75	286.2	91.80%	56.17%	Putative lipoyltransferase 2, mitochondrial;OS=Mizuhopecten;PE=3;SV=1	GO:0005739|	GO:0033819|GO:0102555|	GO:0009249|
GN021198.1	sp|K1R2I9|K1R2I9_CRAGI	2.3e-106	393.3	41.40%	36.99%	Ankyrin-3;OS=Crassostrea;PE=4;SV=1
GN021199.1	sp|K1Q6H8|K1Q6H8_CRAGI	1.7e-55	221.5	96.74%	53.59%	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A;OS=Crassostrea;PE=4;SV=1
GN021200.1	sp|K1R8I5|K1R8I5_CRAGI	4.7e-123	446.0	100.00%	90.48%	2-acylglycerol O-acyltransferase 2-A;OS=Crassostrea;PE=4;SV=1	GO:0016747|
GN021201.1	sp|K1QAE6|K1QAE6_CRAGI	6.4e-42	176.0	62.20%	69.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021202.1	sp|K1QWI3|K1QWI3_CRAGI	1.9e-220	771.2	79.19%	69.29%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN021203.1	sp|K1PXE5|K1PXE5_CRAGI	0.0e+00	1089.7	99.89%	76.02%	X-ray radiation resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0010165|
GN021204.1	sp|K1Q4Z1|K1Q4Z1_CRAGI	1.6e-222	777.3	100.00%	93.22%	Cytoplasmic protein NCK2;OS=Crassostrea;PE=4;SV=1
GN021207.1	sp|V4A6T0|V4A6T0_LOTGI	1.2e-11	75.1	51.59%	46.88%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN021208.1	sp|K1QMC6|K1QMC6_CRAGI	3.3e-48	197.6	98.48%	35.54%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021209.1	sp|A0A3M6TI11|A0A3M6TI11_9CNID	8.3e-27	126.3	85.96%	37.81%	Uncharacterized protein;OS=Pocillopora;PE=4;SV=1
GN020530.1	sp|K1Q1H7|K1Q1H7_CRAGI	2.1e-140	504.6	97.98%	60.54%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021211.1	sp|K1R514|K1R514_CRAGI	6.8e-32	142.9	51.89%	69.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021212.1	sp|K1RPI0|K1RPI0_CRAGI	6.4e-14	83.6	99.18%	32.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021213.1	sp|K1RPI0|K1RPI0_CRAGI	1.7e-14	85.5	99.18%	37.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021214.1	sp|K1RPI0|K1RPI0_CRAGI	6.2e-17	93.6	99.18%	39.02%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021216.1	sp|K1RTN3|K1RTN3_CRAGI	1.2e-47	194.5	99.12%	82.14%	Heparanase;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0016798|
GN021217.1	sp|K1QM92|K1QM92_CRAGI	2.8e-29	133.7	79.69%	70.64%	tRNA pseudouridine synthase A;OS=Crassostrea;PE=4;SV=1	GO:0009982|GO:0003723|	GO:0001522|
GN021218.1	sp|K1QWB7|K1QWB7_CRAGI	0.0e+00	1210.7	95.77%	67.82%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021219.1	sp|K1QM31|K1QM31_CRAGI	1.3e-119	434.9	100.00%	82.81%	Homeobox protein slou;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021220.1	sp|K1QDS7|K1QDS7_CRAGI	3.4e-44	184.5	67.86%	45.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021221.1	sp|K1QT51|K1QT51_CRAGI	1.8e-42	177.6	90.91%	73.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020532.1	sp|K1S306|K1S306_CRAGI	2.4e-140	503.8	96.62%	76.84%	Maltase-glucoamylase, intestinal;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0030246|GO:0004553|	GO:0005975|
GN021222.1	sp|K1QM31|K1QM31_CRAGI	5.5e-76	289.3	98.27%	87.57%	Homeobox protein slou;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021223.1	sp|K1QM34|K1QM34_CRAGI	9.9e-216	755.0	99.59%	86.90%	5-hydroxytryptamine receptor 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004930|
GN021224.1	sp|K1RDE2|K1RDE2_CRAGI	1.0e-90	339.0	99.32%	51.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021227.1	sp|K1QRW8|K1QRW8_CRAGI	5.0e-57	226.1	100.00%	72.19%	Pyruvate kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|GO:0000287|GO:0030955|GO:0004743|
GN021228.1	sp|K1QRW8|K1QRW8_CRAGI	1.9e-92	344.4	100.00%	76.44%	Pyruvate kinase;OS=Crassostrea;PE=3;SV=1	GO:0016301|GO:0000287|GO:0030955|GO:0004743|
GN021229.1	sp|K1RDF0|K1RDF0_CRAGI	4.6e-247	859.4	100.00%	75.61%	Transmembrane anterior posterior transformation protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020533.1	sp|A0A210Q4D4|A0A210Q4D4_MIZYE	2.4e-15	87.0	94.06%	39.36%	Maltase-glucoamylase, intestinal;OS=Mizuhopecten;PE=3;SV=1	GO:0030246|GO:0004553|	GO:0005975|
GN021230.1	sp|K1QT57|K1QT57_CRAGI	0.0e+00	1107.4	92.02%	70.00%	SEC23-interacting protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN021232.1	sp|A0A210PV19|A0A210PV19_MIZYE	1.7e-87	328.9	89.35%	43.10%	Monocarboxylate transporter 12;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021233.1	sp|A0A210PV19|A0A210PV19_MIZYE	2.5e-97	361.7	82.21%	45.66%	Monocarboxylate transporter 12;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021234.1	sp|K1Q4H7|K1Q4H7_CRAGI	1.4e-146	524.6	94.25%	80.27%	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8;OS=Crassostrea;PE=4;SV=1
GN021235.1	sp|K1QBS5|K1QBS5_CRAGI	3.6e-89	334.0	100.00%	59.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020534.1	sp|K1QXV3|K1QXV3_CRAGI	6.4e-109	399.4	92.86%	69.49%	Maltase-glucoamylase, intestinal;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0030246|GO:0004553|	GO:0005975|
GN021237.1	sp|K1QXI1|K1QXI1_CRAGI	1.1e-309	1068.9	86.31%	49.42%	BCL-6 corepressor;OS=Crassostrea;PE=4;SV=1
GN021238.1	sp|K1PPW7|K1PPW7_CRAGI	6.6e-277	958.7	100.00%	68.03%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021239.1	sp|K1PX19|K1PX19_CRAGI	2.8e-224	784.3	91.37%	45.07%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021240.1	sp|K1P696|K1P696_CRAGI	2.2e-48	199.9	15.21%	71.64%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN021241.1	sp|K1P696|K1P696_CRAGI	5.4e-40	169.1	88.50%	75.76%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN021242.1	sp|K1RUV3|K1RUV3_CRAGI	1.2e-102	378.6	91.18%	66.31%	Hemicentin-1;OS=Crassostrea;PE=4;SV=1
GN021243.1	sp|K1PJM1|K1PJM1_CRAGI	1.7e-163	581.6	57.80%	87.38%	Ubiquitin carboxyl-terminal hydrolase 15;OS=Crassostrea;PE=4;SV=1	GO:0004843|	GO:0016579|
GN021244.1	sp|K1R4Q0|K1R4Q0_CRAGI	4.1e-171	607.1	87.08%	63.45%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000015|	GO:0000287|GO:0004634|	GO:0006096|
GN021245.1	sp|K1QYD8|K1QYD8_CRAGI	2.9e-150	537.0	100.00%	74.62%	Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020535.1	sp|A0A2Z6G1A7|A0A2Z6G1A7_PINFU	1.0e-131	476.1	85.71%	71.06%	Matrix metalloproteinase;OS=Pinctada;PE=2;SV=1	GO:0031012|	GO:0004222|GO:0008270|
GN021246.1	sp|K1QV17|K1QV17_CRAGI	0.0e+00	1333.9	100.00%	96.04%	Poly [ADP-ribose] polymerase;OS=Crassostrea;PE=4;SV=1	GO:0003950|	GO:0032212|GO:0051225|GO:0016055|
GN021247.1	sp|K1QMK2|K1QMK2_CRAGI	5.7e-244	849.0	92.35%	82.71%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021248.1	sp|K1QMK2|K1QMK2_CRAGI	3.8e-142	510.0	98.81%	73.80%	Sialin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021250.1	sp|K1RL99|K1RL99_CRAGI	9.1e-88	329.3	69.00%	74.34%	Polycomb complex protein BMI-1-B;OS=Crassostrea;PE=4;SV=1
GN021251.1	sp|K1PEP3|K1PEP3_CRAGI	4.4e-15	85.9	78.05%	58.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021252.1	sp|A0A210PYA9|A0A210PYA9_MIZYE	2.8e-200	703.7	82.42%	80.69%	Nucleolar protein 56;OS=Mizuhopecten;PE=4;SV=1
GN021254.1	sp|A0A210R1E9|A0A210R1E9_MIZYE	2.1e-29	134.4	100.00%	40.78%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN021255.1	sp|K1R2P1|K1R2P1_CRAGI	1.5e-65	254.6	82.84%	82.73%	Diamine acetyltransferase 2;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN021256.1	sp|K1RMK6|K1RMK6_CRAGI	3.7e-102	378.3	54.49%	51.88%	Lysosome-associated membrane glycoprotein 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN021257.1	sp|K1PBR4|K1PBR4_CRAGI	1.8e-26	125.2	53.48%	52.03%	Tenascin;OS=Crassostrea;PE=4;SV=1
GN020536.1	sp|C3ZM17|C3ZM17_BRAFL	1.9e-13	81.3	55.41%	45.68%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003677|
GN021258.1	sp|V4BEU3|V4BEU3_LOTGI	1.5e-62	245.0	95.28%	57.97%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN021259.1	sp|K1R636|K1R636_CRAGI	0.0e+00	1760.3	26.72%	54.94%	Spermatogenesis-associated protein 13;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035556|GO:0035023|
GN021260.1	sp|K1QWF7|K1QWF7_CRAGI	1.7e-158	564.3	98.77%	84.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN021261.1	sp|K1RM35|K1RM35_CRAGI	7.9e-80	302.8	84.86%	60.64%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005164|	GO:0006955|
GN021262.1	sp|K1PVX3|K1PVX3_CRAGI	2.9e-66	257.3	95.85%	65.70%	Bridging integrator 3-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005737|
GN021263.1	sp|K1RUM6|K1RUM6_CRAGI	1.2e-102	378.3	95.34%	76.79%	Pancreatic lipase-related protein 1;OS=Crassostrea;PE=3;SV=1	GO:0005576|	GO:0052689|GO:0046872|	GO:0006629|
GN021264.1	sp|K1R4F4|K1R4F4_CRAGI	1.2e-36	157.9	96.30%	74.76%	Phospholipid scramblase;OS=Crassostrea;PE=3;SV=1
GN021265.1	sp|K1RB06|K1RB06_CRAGI	7.9e-298	1028.1	95.12%	77.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003824|
GN021266.1	sp|A0A210PPE5|A0A210PPE5_MIZYE	1.1e-37	162.9	75.00%	37.55%	Charged multivesicular body protein 7;OS=Mizuhopecten;PE=3;SV=1	GO:0007034|
GN021267.1	sp|K1QD78|K1QD78_CRAGI	6.4e-280	968.8	100.00%	77.17%	Lateral signaling target protein 2-like protein;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN021268.1	sp|A0A210R1V8|A0A210R1V8_MIZYE	1.5e-102	378.6	93.25%	58.73%	Zinc transporter ZIP13;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0046873|
GN021269.1	sp|K1PJL0|K1PJL0_CRAGI	7.6e-291	1004.6	100.00%	90.81%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021270.1	sp|K1QRL4|K1QRL4_CRAGI	0.0e+00	1876.7	100.00%	87.31%	Importin-5;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0006606|
GN020537.1	sp|A0A210PQK1|A0A210PQK1_MIZYE	1.4e-87	329.3	66.73%	53.29%	E3 ubiquitin-protein ligase RNF13;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0016874|
GN021271.1	sp|A0A210QEL6|A0A210QEL6_MIZYE	1.8e-134	485.0	94.04%	53.86%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN021272.1	sp|K1R2N6|K1R2N6_CRAGI	2.6e-91	340.5	100.00%	74.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021273.1	sp|A0A210R6K3|A0A210R6K3_MIZYE	0.0e+00	1078.5	85.51%	39.03%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN021274.1	sp|K1QNB7|K1QNB7_CRAGI	0.0e+00	1223.4	92.94%	66.77%	Eukaryotic translation initiation factor 2-alpha kinase 3;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|GO:0003743|
GN021275.1	sp|K1R2N6|K1R2N6_CRAGI	9.8e-66	255.0	100.00%	82.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021277.1	sp|K1Q534|K1Q534_CRAGI	1.0e-22	111.7	90.18%	48.00%	Starch-binding domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:2001070|
GN021279.1	sp|K1Q5Q4|K1Q5Q4_CRAGI	6.2e-108	397.5	95.36%	40.76%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0000723|
GN021280.1	sp|A0A210PVK0|A0A210PVK0_MIZYE	2.5e-145	521.2	92.49%	55.44%	cAMP-dependent protein kinase regulatory subunit;OS=Mizuhopecten;PE=4;SV=1	GO:0016301|
GN020538.1	sp|K1PEJ1|K1PEJ1_CRAGI	4.7e-154	549.7	90.78%	83.95%	Eukaryotic initiation factor 4A-8;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0003743|
GN021282.1	sp|K1Q4M0|K1Q4M0_CRAGI	6.6e-84	316.2	84.56%	65.07%	Sepiapterin reductase;OS=Crassostrea;PE=4;SV=1	GO:0004757|	GO:0006729|
GN021283.1	sp|K1PXL0|K1PXL0_CRAGI	0.0e+00	1525.0	100.00%	92.46%	Exocyst complex component;OS=Crassostrea;PE=3;SV=1	GO:0000145|	GO:0006904|
GN021284.1	sp|K1PQ90|K1PQ90_CRAGI	4.1e-146	523.1	100.00%	82.86%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021285.1	sp|K1QWD0|K1QWD0_CRAGI	0.0e+00	1215.3	98.63%	62.09%	Sedoheptulokinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN021286.1	sp|K1QMA4|K1QMA4_CRAGI	2.0e-47	193.7	94.64%	89.52%	RRP5-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003676|	GO:0006397|
GN021287.1	sp|K1Q3E1|K1Q3E1_CRAGI	1.6e-12	77.0	98.41%	60.66%	Hyaluronan mediated motility receptor;OS=Crassostrea;PE=4;SV=1	GO:0005540|
GN021288.1	sp|K1QD34|K1QD34_CRAGI	1.7e-121	441.8	100.00%	62.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021289.1	sp|K1PQV8|K1PQV8_CRAGI	1.2e-220	772.3	87.98%	55.50%	Lysyl oxidase-like protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016020|	GO:0005507|GO:0016641|GO:0005044|
GN021292.1	sp|A0A210Q4D5|A0A210Q4D5_MIZYE	2.0e-170	605.1	99.33%	41.26%	Tripartite motif-containing protein 45;OS=Mizuhopecten;PE=4;SV=1	GO:0008270|
GN021293.1	sp|K1QYP8|K1QYP8_CRAGI	2.8e-178	631.7	92.55%	51.22%	Zinc finger protein 62;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN021295.1	sp|K1PVT3|K1PVT3_CRAGI	2.4e-61	241.5	65.71%	56.60%	SAM domain and HD domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN021296.1	sp|A0A210R701|A0A210R701_MIZYE	7.1e-37	159.1	99.31%	53.10%	Werner syndrome ATP-dependent helicase;OS=Mizuhopecten;PE=4;SV=1	GO:0005524|GO:0004386|GO:0003676|
GN021297.1	sp|K1QWD8|K1QWD8_CRAGI	2.3e-59	235.3	80.85%	41.26%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN021298.1	sp|A0A2B4RUA7|A0A2B4RUA7_STYPI	8.8e-32	142.5	98.36%	39.78%	Exonuclease;OS=Stylophora;PE=4;SV=1	GO:0004527|
GN021299.1	sp|K1R2N1|K1R2N1_CRAGI	7.3e-237	825.1	100.00%	89.16%	Glutathione reductase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0009055|GO:0050660|GO:0004362|GO:0050661|	GO:0045454|GO:0006749|
GN021300.1	sp|K1QW05|K1QW05_CRAGI	2.2e-259	900.6	76.33%	78.21%	Guanylate cyclase soluble subunit beta-2;OS=Crassostrea;PE=4;SV=1	GO:0004383|	GO:0035556|
GN021302.1	sp|K1QE32|K1QE32_CRAGI	5.1e-292	1009.2	65.92%	91.04%	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0003995|GO:0050660|
GN021303.1	sp|K1RLG3|K1RLG3_CRAGI	8.0e-23	113.2	69.14%	60.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021304.1	sp|K1QMR3|K1QMR3_CRAGI	7.1e-107	392.9	100.00%	60.17%	Uncharacterized protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005164|	GO:0006955|
GN021305.1	sp|K1QMJ4|K1QMJ4_CRAGI	2.1e-64	251.9	100.00%	54.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021306.1	sp|K1QTL9|K1QTL9_CRAGI	0.0e+00	1318.5	100.00%	70.28%	Guanylate cyclase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005524|GO:0004383|GO:0004672|	GO:0035556|
GN021307.1	sp|K1RJ46|K1RJ46_CRAGI	2.4e-78	297.7	58.36%	90.38%	Protease-associated domain-containing protein of 21 kDa;OS=Crassostrea;PE=4;SV=1	GO:0008233|
GN021308.1	sp|K1RD80|K1RD80_CRAGI	1.0e-130	472.6	98.79%	67.60%	E3 ubiquitin-protein ligase KCMF1;OS=Crassostrea;PE=4;SV=1	GO:0016874|GO:0061630|GO:0008270|
GN021309.1	sp|A0A210QL72|A0A210QL72_MIZYE	7.3e-189	666.0	96.25%	69.20%	Poly(U)-binding-splicing factor PUF60;OS=Mizuhopecten;PE=4;SV=1	GO:0003723|
GN021310.1	sp|K1S2S0|K1S2S0_CRAGI	6.3e-51	206.5	82.05%	54.97%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1
GN021311.1	sp|K1S2S0|K1S2S0_CRAGI	2.2e-55	221.9	98.03%	48.72%	Putative ferric-chelate reductase 1;OS=Crassostrea;PE=4;SV=1
GN021312.1	sp|K1Q6Z4|K1Q6Z4_CRAGI	4.2e-36	156.8	58.72%	75.47%	Beta-1,3-galactosyltransferase 1;OS=Crassostrea;PE=4;SV=1	GO:0005794|GO:0016021|	GO:0008378|	GO:0006486|
GN021313.1	sp|A0A210QGL1|A0A210QGL1_MIZYE	3.3e-100	371.3	98.65%	73.37%	Ankyrin repeat domain-containing protein 42;OS=Mizuhopecten;PE=4;SV=1
GN021314.1	sp|K1R1W3|K1R1W3_CRAGI	0.0e+00	1617.8	96.11%	75.02%	Erythroid differentiation-related factor 1;OS=Crassostrea;PE=4;SV=1
GN021315.1	sp|K1QAW5|K1QAW5_CRAGI	0.0e+00	1271.9	96.02%	79.93%	Neuroligin-4, X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021316.1	sp|K1QS61|K1QS61_CRAGI	0.0e+00	1389.4	100.00%	81.60%	Neuroligin-4, X-linked;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0042043|
GN021317.1	sp|K1PK74|K1PK74_CRAGI	9.8e-49	198.4	99.25%	75.56%	Putative ankyrin repeat protein L93;OS=Crassostrea;PE=4;SV=1
GN021319.1	sp|K1PZB7|K1PZB7_CRAGI	3.9e-151	540.4	98.40%	52.54%	Cytochrome P450 2G1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021320.1	sp|K1PZB7|K1PZB7_CRAGI	3.3e-150	537.3	98.40%	52.33%	Cytochrome P450 2G1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021321.1	sp|K1PZB7|K1PZB7_CRAGI	2.4e-137	494.2	94.95%	61.56%	Cytochrome P450 2G1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN020539.1	sp|K1PZD8|K1PZD8_CRAGI	1.3e-110	404.8	100.00%	76.25%	Tumor necrosis factor ligand superfamily member 14;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005164|	GO:0006955|
GN021322.1	sp|K1PZB7|K1PZB7_CRAGI	4.8e-207	726.1	99.15%	72.69%	Cytochrome P450 2G1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021323.1	sp|K1PRW4|K1PRW4_CRAGI	2.4e-182	644.0	99.79%	61.49%	Cytochrome P450 2B19;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021324.1	sp|K1PYN8|K1PYN8_CRAGI	6.9e-185	652.5	100.00%	62.60%	Cytochrome P450 2B19;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0004497|GO:0016705|
GN021326.1	sp|K1QH71|K1QH71_CRAGI	2.1e-16	91.3	88.55%	84.35%	Complexin;OS=Crassostrea;PE=4;SV=1	GO:0019905|	GO:0006836|
GN021327.1	sp|A0A0N9EK95|A0A0N9EK95_CRAGI	6.9e-29	131.7	98.78%	75.00%	Inhibitor protein kappa B;OS=Crassostrea;PE=2;SV=1
GN021329.1	sp|K1QKJ2|K1QKJ2_CRAGI	3.1e-218	763.5	100.00%	84.17%	Ankyrin repeat domain-containing protein 53;OS=Crassostrea;PE=4;SV=1
GN021330.1	sp|K1Q092|K1Q092_CRAGI	2.6e-46	191.0	68.61%	79.61%	Neuropeptide Y receptor type 1;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004983|
GN021332.1	sp|K1R0R3|K1R0R3_CRAGI	8.8e-142	508.4	99.24%	97.32%	Lys-63-specific deubiquitinase BRCC36;OS=Crassostrea;PE=4;SV=1	GO:0070531|GO:0070552|	GO:0004843|	GO:0006281|GO:0070536|
GN021333.1	sp|K1QTW9|K1QTW9_CRAGI	1.2e-108	398.3	100.00%	77.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021334.1	sp|K1RLE3|K1RLE3_CRAGI	5.8e-26	122.9	44.22%	85.94%	U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0008380|
GN020540.1	sp|K1QZ95|K1QZ95_CRAGI	1.2e-78	298.1	100.00%	82.74%	Nuclear pore complex protein;OS=Crassostrea;PE=3;SV=1	GO:0031965|GO:0031080|	GO:0017056|	GO:0006406|GO:0000973|GO:0006606|
GN021335.1	sp|K1RK98|K1RK98_CRAGI	2.6e-121	440.7	100.00%	72.67%	Poly(ADP-ribose) glycohydrolase ARH3;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN021336.1	sp|K1R0Q9|K1R0Q9_CRAGI	5.5e-206	723.0	100.00%	51.65%	TATA box-binding protein-associated factor RNA polymerase I subunit B;OS=Crassostrea;PE=4;SV=1	GO:0070860|	GO:0001164|
GN021337.1	sp|K1RNY8|K1RNY8_CRAGI	2.8e-284	983.4	88.67%	67.59%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN021338.1	sp|K1R9I0|K1R9I0_CRAGI	3.5e-69	266.5	97.45%	78.13%	Myosin-VIIa;OS=Crassostrea;PE=4;SV=1	GO:0005856|
GN021339.1	sp|K1R9I0|K1R9I0_CRAGI	0.0e+00	2055.8	99.32%	76.27%	Myosin-VIIa;OS=Crassostrea;PE=4;SV=1	GO:0005856|
GN021340.1	sp|K1QZB0|K1QZB0_CRAGI	3.8e-165	587.4	99.25%	73.12%	Arfaptin-1;OS=Crassostrea;PE=4;SV=1	GO:0005096|GO:0046872|GO:0019904|
GN021341.1	sp|K1Q8A5|K1Q8A5_CRAGI	1.4e-102	379.8	29.91%	82.68%	Tetraspanin;OS=Crassostrea;PE=3;SV=1	GO:0016021|
GN021342.1	sp|K1P2G7|K1P2G7_CRAGI	5.4e-258	896.3	92.18%	54.51%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN021343.1	sp|K1PGI9|K1PGI9_CRAGI	6.1e-171	605.9	99.75%	75.76%	Multidrug resistance-associated protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|
GN021344.1	sp|K1PHN5|K1PHN5_CRAGI	5.1e-84	316.6	97.12%	61.40%	Mitochondrial intermediate peptidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005759|	GO:0046872|GO:0004222|	GO:0006627|
GN021345.1	sp|K1PB80|K1PB80_CRAGI	5.9e-73	280.8	56.43%	44.97%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021346.1	sp|K1QXT6|K1QXT6_CRAGI	6.6e-52	211.5	15.41%	78.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021347.1	sp|K1R447|K1R447_CRAGI	2.1e-118	431.8	65.01%	64.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021348.1	sp|K1QGW7|K1QGW7_CRAGI	1.1e-61	241.5	100.00%	78.57%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021349.1	sp|K1R766|K1R766_CRAGI	3.4e-65	254.6	74.81%	44.37%	BTB/POZ domain-containing protein 6;OS=Crassostrea;PE=4;SV=1
GN021350.1	sp|K1QTC3|K1QTC3_CRAGI	4.9e-53	212.6	96.12%	76.61%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021351.1	sp|K1QGH2|K1QGH2_CRAGI	6.1e-167	592.8	86.06%	80.40%	65 kDa Yes-associated protein;OS=Crassostrea;PE=4;SV=1
GN021352.1	sp|K1QST9|K1QST9_CRAGI	1.1e-95	355.5	77.74%	81.86%	Elongation factor G, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0005525|GO:0003924|GO:0003746|	GO:0070125|
GN021354.1	sp|K1QST9|K1QST9_CRAGI	4.9e-253	879.0	92.91%	89.26%	Elongation factor G, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0005739|	GO:0005525|GO:0003924|GO:0003746|	GO:0070125|
GN021355.1	sp|K1R9B6|K1R9B6_CRAGI	1.5e-219	767.7	84.39%	91.71%	H/ACA ribonucleoprotein complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0009982|GO:0003723|	GO:0001522|GO:0006396|
GN021356.1	sp|K1QUI9|K1QUI9_CRAGI	6.7e-91	340.1	58.92%	76.59%	Protein glass;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN021357.1	sp|K1R3C0|K1R3C0_CRAGI	3.0e-67	261.5	95.99%	43.34%	DNA repair protein complementing XP-G cells-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0004519|GO:0003697|	GO:0006289|
GN021358.1	sp|K1R9B6|K1R9B6_CRAGI	1.2e-172	611.3	100.00%	92.57%	H/ACA ribonucleoprotein complex subunit 4;OS=Crassostrea;PE=4;SV=1	GO:0019013|	GO:0009982|GO:0003723|	GO:0001522|GO:0006396|
GN021359.1	sp|K1PPL5|K1PPL5_CRAGI	2.9e-101	373.6	100.00%	73.57%	Glutathione S-transferase omega-1;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0004364|
GN021360.1	sp|K1QTZ2|K1QTZ2_CRAGI	1.0e-135	488.8	99.48%	62.17%	Aminoglycoside phosphotransferase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN021361.1	sp|K1Q3X9|K1Q3X9_CRAGI	8.0e-253	878.6	99.39%	69.77%	Phosphatidylinositide phosphatase SAC2;OS=Crassostrea;PE=4;SV=1	GO:0042578|
GN020541.1	sp|K1R7N6|K1R7N6_CRAGI	7.5e-16	89.7	29.41%	59.32%	Eukaryotic translation initiation factor 6;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0016021|GO:0005730|	GO:0043023|GO:0043022|GO:0003743|	GO:0042256|GO:0042273|
GN021362.1	sp|K1QBC1|K1QBC1_CRAGI	0.0e+00	1103.2	73.98%	84.81%	Protein slit;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|
GN021363.1	sp|K1Q3Y3|K1Q3Y3_CRAGI	7.1e-237	825.1	100.00%	92.13%	Metalloendopeptidase;OS=Crassostrea;PE=4;SV=1	GO:0004222|GO:0008270|
GN021364.1	sp|K1QK29|K1QK29_CRAGI	1.4e-82	311.6	100.00%	61.51%	Menaquinone biosynthesis methyltransferase ubiE;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN021365.1	sp|A0A2B4RYI2|A0A2B4RYI2_STYPI	5.5e-23	113.6	67.24%	38.46%	THAP domain-containing protein 11;OS=Stylophora;PE=4;SV=1	GO:0003677|
GN020542.1	sp|K1R7N6|K1R7N6_CRAGI	5.0e-17	94.4	20.42%	54.79%	Eukaryotic translation initiation factor 6;OS=Crassostrea;PE=3;SV=1	GO:0005737|GO:0016021|GO:0005730|	GO:0043023|GO:0043022|GO:0003743|	GO:0042256|GO:0042273|
GN021366.1	sp|K1QK29|K1QK29_CRAGI	4.9e-48	196.4	94.83%	55.49%	Menaquinone biosynthesis methyltransferase ubiE;OS=Crassostrea;PE=4;SV=1	GO:0008168|
GN021367.1	sp|K1PSL5|K1PSL5_CRAGI	0.0e+00	1174.1	51.06%	79.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021368.1	sp|K1QQP1|K1QQP1_CRAGI	3.0e-219	766.5	99.55%	86.10%	Programmed cell death protein 4;OS=Crassostrea;PE=4;SV=1	GO:0045892|
GN021369.1	sp|B3S3I3|B3S3I3_TRIAD	2.6e-46	190.7	84.71%	59.44%	Uncharacterized protein;OS=Trichoplax;PE=4;SV=1
GN021370.1	sp|K1QJ13|K1QJ13_CRAGI	3.3e-106	390.2	91.67%	80.51%	Phospholysine phosphohistidine inorganic pyrophosphate phosphatase;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN021371.1	sp|K1QB78|K1QB78_CRAGI	5.4e-105	387.9	81.11%	42.28%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021372.1	sp|K1Q3T8|K1Q3T8_CRAGI	1.2e-48	198.4	82.82%	70.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021373.1	sp|K1RAW1|K1RAW1_CRAGI	8.5e-86	322.0	98.96%	83.60%	HSPB1-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN021374.1	sp|K1PIA4|K1PIA4_CRAGI	0.0e+00	1619.0	100.00%	80.26%	Exocyst complex component 4;OS=Crassostrea;PE=4;SV=1	GO:0000145|	GO:0006904|GO:0090522|
GN021375.1	sp|K1RAV7|K1RAV7_CRAGI	1.4e-96	359.4	48.19%	67.27%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021375.1	sp|K1RAV7|K1RAV7_CRAGI	6.4e-12	78.2	12.61%	50.00%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021376.1	sp|K1QQN5|K1QQN5_CRAGI	3.3e-81	307.0	96.46%	68.66%	Arylacetamide deacetylase;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016787|
GN021377.1	sp|K1QB72|K1QB72_CRAGI	3.3e-70	270.0	97.02%	78.40%	Protein DPCD;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0005164|	GO:0006955|
GN021378.1	sp|K1QB72|K1QB72_CRAGI	5.5e-52	209.5	77.19%	81.68%	Protein DPCD;OS=Crassostrea;PE=3;SV=1	GO:0016020|	GO:0005164|	GO:0006955|
GN021379.1	sp|K1RAV4|K1RAV4_CRAGI	5.5e-172	609.8	69.48%	84.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021380.1	sp|K1Q3T2|K1Q3T2_CRAGI	1.9e-103	380.9	99.57%	75.32%	Williams-Beuren syndrome chromosomal region 27 protein;OS=Crassostrea;PE=4;SV=1
GN021381.1	sp|A0A1S3HAC7|A0A1S3HAC7_LINUN	5.2e-96	357.1	97.85%	42.08%	4-hydroxyphenylpyruvate dioxygenase;OS=Lingula;PE=3;SV=1	GO:0003868|GO:0046872|	GO:0009072|
GN021382.1	sp|K1Q817|K1Q817_CRAGI	1.8e-238	830.5	93.04%	87.73%	UPF0672 protein C3orf58;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021383.1	sp|K1P1A2|K1P1A2_CRAGI	1.6e-53	214.9	82.49%	56.98%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021384.1	sp|K1RAU9|K1RAU9_CRAGI	9.0e-239	833.2	98.36%	67.16%	Biorientation of chromosomes in cell division protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0051301|
GN021385.1	sp|K1QJ01|K1QJ01_CRAGI	6.8e-35	152.5	83.11%	63.41%	Brain-specific homeobox protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN021386.1	sp|A0A210QEN1|A0A210QEN1_MIZYE	0.0e+00	1203.7	99.33%	75.61%	EF-hand domain-containing family member C2;OS=Mizuhopecten;PE=4;SV=1	GO:0005509|
GN021387.1	sp|K1QG48|K1QG48_CRAGI	4.0e-68	264.2	57.81%	65.12%	Tripartite motif-containing protein 3;OS=Crassostrea;PE=4;SV=1
GN021388.1	sp|A0A0P5HBT0|A0A0P5HBT0_9CRUS	3.8e-66	256.9	71.30%	74.51%	TM2 domain-containing protein;OS=Daphnia;PE=4;SV=1	GO:0016021|
GN021389.1	sp|A0A2G8LMZ5|A0A2G8LMZ5_STIJA	9.7e-18	97.1	39.34%	32.35%	Uncharacterized protein;OS=Stichopus;PE=4;SV=1
GN021391.1	sp|K1QZN8|K1QZN8_CRAGI	1.1e-306	1057.7	88.15%	85.36%	Unc-93-like protein A;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021393.1	sp|K1Q9V2|K1Q9V2_CRAGI	1.8e-138	500.4	73.52%	49.27%	Antigen KI-67;OS=Crassostrea;PE=4;SV=1
GN021394.1	sp|A0A210QKH7|A0A210QKH7_MIZYE	6.4e-119	432.6	98.91%	71.27%	tRNA(His) guanylyltransferase;OS=Mizuhopecten;PE=3;SV=1	GO:0005525|GO:0000287|GO:0008193|	GO:0006400|
GN020546.1	sp|K1Q1H7|K1Q1H7_CRAGI	3.3e-15	87.0	49.64%	64.18%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN021395.1	sp|K1QS37|K1QS37_CRAGI	1.0e-196	692.2	98.08%	64.51%	HAUS augmin-like complex subunit 8;OS=Crassostrea;PE=4;SV=1
GN021396.1	sp|A0A210QI07|A0A210QI07_MIZYE	1.1e-61	243.0	99.76%	35.65%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN021397.1	sp|K1PTT5|K1PTT5_CRAGI	7.8e-90	337.0	38.84%	89.57%	Leucine-rich repeat-containing protein 27;OS=Crassostrea;PE=4;SV=1
GN020547.1	sp|K1Q8V9|K1Q8V9_CRAGI	7.3e-136	488.8	90.67%	92.98%	Agmatinase, mitochondrial;OS=Crassostrea;PE=3;SV=1	GO:0016813|GO:0046872|
GN021398.1	sp|A0A2T7NBD1|A0A2T7NBD1_POMCA	2.1e-31	141.7	89.11%	33.04%	Uncharacterized protein;OS=Pomacea;PE=4;SV=1	GO:0035556|
GN021399.1	sp|K1QJR5|K1QJR5_CRAGI	1.9e-263	913.7	99.82%	77.17%	Lipase maturation factor;OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|
GN021400.1	sp|A0A2R2MKS3|A0A2R2MKS3_LINUN	1.5e-14	85.5	98.17%	30.80%	uncharacterized protein LOC106168652;OS=Lingula;PE=4;SV=1
GN021401.1	sp|W4ZIE5|W4ZIE5_STRPU	8.3e-102	377.5	63.92%	36.32%	Uncharacterized protein;OS=Strongylocentrotus;PE=4;SV=1
GN021402.1	sp|K1QQ15|K1QQ15_CRAGI	1.1e-114	419.5	54.92%	68.12%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021403.1	sp|C3ZM17|C3ZM17_BRAFL	8.7e-14	82.4	55.41%	45.68%	Uncharacterized protein;OS=Branchiostoma;PE=4;SV=1	GO:0003677|
GN020548.1	sp|K1S621|K1S621_CRAGI	2.1e-258	897.1	98.90%	89.70%	Leucine-rich repeat-containing protein 63;OS=Crassostrea;PE=4;SV=1
GN021405.1	sp|K1QZN7|K1QZN7_CRAGI	0.0e+00	1401.0	100.00%	79.21%	Amine oxidase;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005507|GO:0008131|GO:0048038|	GO:0009308|
GN021406.1	sp|K1PIG2|K1PIG2_CRAGI	3.5e-281	973.4	75.08%	70.83%	Metabotropic glutamate receptor 5;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004930|
GN021407.1	sp|K1RNZ4|K1RNZ4_CRAGI	4.2e-53	214.2	100.00%	40.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021408.1	sp|K1RSI0|K1RSI0_CRAGI	2.3e-232	810.4	99.64%	72.91%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021409.1	sp|A0A210Q593|A0A210Q593_MIZYE	1.2e-35	155.6	92.44%	44.34%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN021410.1	sp|K1RHX1|K1RHX1_CRAGI	7.0e-104	382.5	99.61%	71.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN021411.1	sp|K1PV26|K1PV26_CRAGI	9.0e-17	92.8	76.70%	40.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021412.1	sp|K1PEX7|K1PEX7_CRAGI	7.0e-38	163.3	99.25%	83.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021413.1	sp|K1PMP3|K1PMP3_CRAGI	4.8e-164	583.2	98.89%	62.75%	Protoporphyrinogen oxidase;OS=Crassostrea;PE=3;SV=1	GO:0005743|	GO:0004729|	GO:0006782|
GN021414.1	sp|K1Q9R4|K1Q9R4_CRAGI	2.1e-50	206.5	50.44%	33.62%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021415.1	sp|K1Q9R4|K1Q9R4_CRAGI	1.3e-13	84.7	7.49%	46.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021416.1	sp|K1Q2A0|K1Q2A0_CRAGI	3.2e-67	261.5	78.60%	44.04%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021417.1	sp|K1Q0C8|K1Q0C8_CRAGI	4.7e-130	470.3	91.10%	62.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN021418.1	sp|K1PSZ4|K1PSZ4_CRAGI	1.7e-48	197.6	94.03%	92.00%	U6 snRNA-associated Sm-like protein LSm1;OS=Crassostrea;PE=3;SV=1	GO:1990726|GO:0005845|GO:0000932|	GO:0000339|	GO:0000290|GO:0006397|
GN021419.1	sp|K1S024|K1S024_CRAGI	1.1e-87	328.9	94.16%	56.16%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021420.1	sp|K1Q7S9|K1Q7S9_CRAGI	1.1e-61	244.2	32.60%	40.68%	Anosmin-1;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0030414|
GN021421.1	sp|K1Q7S9|K1Q7S9_CRAGI	7.5e-22	108.6	86.73%	54.12%	Anosmin-1;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0030414|
GN021422.1	sp|K1Q0C2|K1Q0C2_CRAGI	1.0e-268	931.4	100.00%	81.68%	Mushroom body large-type Kenyon cell-specific protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|
GN021423.1	sp|K1PSZ0|K1PSZ0_CRAGI	9.8e-18	95.5	98.63%	91.61%	MORN repeat-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN021424.1	sp|K1S5N3|K1S5N3_CRAGI	6.4e-204	715.7	99.57%	74.35%	Phosphotransferase;OS=Crassostrea;PE=3;SV=1	GO:0005623|	GO:0005524|GO:0005536|GO:0004396|	GO:0001678|GO:0006096|
GN021425.1	sp|K1R022|K1R022_CRAGI	1.5e-133	481.1	100.00%	81.68%	Transmembrane protease, serine 6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004252|
GN021426.1	sp|K1QCS1|K1QCS1_CRAGI	2.2e-249	867.1	75.49%	87.34%	Kyphoscoliosis peptidase;OS=Crassostrea;PE=4;SV=1
GN021427.1	sp|K1Q074|K1Q074_CRAGI	1.0e-71	275.8	71.27%	69.23%	Nucleotide exchange factor SIL1;OS=Crassostrea;PE=4;SV=1
GN021428.1	sp|K1R4S1|K1R4S1_CRAGI	4.7e-31	139.8	100.00%	51.33%	Nucleotide exchange factor SIL1;OS=Crassostrea;PE=4;SV=1
GN021429.1	sp|K4UA46|K4UA46_9BIVA	4.9e-266	922.2	100.00%	90.30%	Phosphotransferase;OS=Crassostrea;PE=2;SV=1	GO:0005623|	GO:0005524|GO:0005536|GO:0004396|	GO:0001678|GO:0006096|
GN021430.1	sp|K1R165|K1R165_CRAGI	1.1e-13	82.4	45.55%	47.13%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021431.1	sp|K1R4S1|K1R4S1_CRAGI	8.2e-31	138.7	99.16%	60.17%	Nucleotide exchange factor SIL1;OS=Crassostrea;PE=4;SV=1
GN021433.1	sp|K1QKG6|K1QKG6_CRAGI	1.4e-168	598.6	100.00%	58.95%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN021436.1	sp|A0A1S3I117|A0A1S3I117_LINUN	2.5e-60	238.0	89.83%	43.84%	uncharacterized protein LOC106159688;OS=Lingula;PE=4;SV=1	GO:0008270|
GN021437.1	sp|K1PKF0|K1PKF0_CRAGI	2.2e-29	135.2	55.67%	47.53%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN021439.1	sp|A0A096XIB2|A0A096XIB2_9ACAR	3.3e-86	324.7	99.37%	35.27%	Transposase;OS=Nuttalliella;PE=4;SV=1	GO:0046983|
GN021442.1	sp|A0A210PG43|A0A210PG43_MIZYE	7.6e-65	252.7	90.09%	52.23%	Palmitoyltransferase ZDHHC17;OS=Mizuhopecten;PE=3;SV=1	GO:0016021|	GO:0015095|GO:0016409|
GN020444.1	sp|K1QXM7|K1QXM7_CRAGI	1.1e-24	117.9	100.00%	62.92%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020552.1	sp|A0A0B7ASQ7|A0A0B7ASQ7_9EUPU	1.8e-68	264.6	100.00%	75.23%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0005681|	GO:0000398|
GN020553.1	sp|K1PA73|K1PA73_CRAGI	1.4e-39	167.9	68.42%	90.00%	Tctex1 domain-containing protein 2;OS=Crassostrea;PE=4;SV=1
GN020554.1	sp|K1QGG6|K1QGG6_CRAGI	1.3e-58	232.6	44.26%	88.54%	Myosin catalytic light chain LC-1, mantle muscle;OS=Crassostrea;PE=4;SV=1	GO:0005509|
GN020555.1	sp|K1PWG3|K1PWG3_CRAGI	0.0e+00	2034.2	91.88%	90.44%	Cohesin subunit SA-1;OS=Crassostrea;PE=4;SV=1
GN020556.1	sp|A0A0B7ASQ7|A0A0B7ASQ7_9EUPU	1.8e-68	264.6	100.00%	75.23%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0005681|	GO:0000398|
GN020557.1	sp|A0A0B6ZJZ1|A0A0B6ZJZ1_9EUPU	3.9e-25	120.2	54.55%	66.27%	Uncharacterized protein;OS=Arion;PE=4;SV=1	GO:0016829|
GN020558.1	sp|K1R0D9|K1R0D9_CRAGI	1.3e-12	78.6	84.21%	31.50%	Nuclear factor 7, brain;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN020559.1	sp|K1QU83|K1QU83_CRAGI	3.6e-79	301.6	99.32%	36.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004518|
GN020560.1	sp|K1QU83|K1QU83_CRAGI	4.0e-67	260.8	96.42%	46.70%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0004518|
GN020561.1	sp|K1Q898|K1Q898_CRAGI	4.8e-142	510.0	99.52%	77.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0035556|
GN020567.1	sp|K1Q183|K1Q183_CRAGI	6.9e-84	315.8	100.00%	83.80%	Charged multivesicular body protein 3;OS=Crassostrea;PE=3;SV=1	GO:0007034|
GN020568.1	sp|K1RK09|K1RK09_CRAGI	2.1e-87	328.6	71.24%	49.53%	Sodium/hydrogen exchanger 9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0015299|GO:0004888|
GN020569.1	sp|K1RAT2|K1RAT2_CRAGI	2.0e-38	163.7	100.00%	85.00%	Mitochondrial fission 1 protein;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005741|	GO:0000266|
GN020570.1	sp|K1PKR0|K1PKR0_CRAGI	3.1e-73	280.8	56.99%	91.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020445.1	sp|K1PX59|K1PX59_CRAGI	9.8e-100	369.8	57.09%	62.79%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020572.1	sp|K1Q724|K1Q724_CRAGI	1.3e-253	881.3	100.00%	78.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020573.1	sp|K1PZY8|K1PZY8_CRAGI	2.8e-142	510.8	98.10%	60.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020574.1	sp|K1QLK3|K1QLK3_CRAGI	6.1e-94	350.1	99.25%	47.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020446.1	sp|K1QHQ4|K1QHQ4_CRAGI	9.5e-293	1011.5	99.24%	66.50%	Zinc finger protein ZFAT;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020575.1	sp|K1PZZ9|K1PZZ9_CRAGI	2.4e-129	467.2	95.83%	77.45%	Protein-tyrosine sulfotransferase;OS=Crassostrea;PE=3;SV=1	GO:0008476|	GO:0006478|
GN020576.1	sp|K1PKR8|K1PKR8_CRAGI	1.8e-74	284.6	95.74%	57.14%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020447.1	sp|K1PBG0|K1PBG0_CRAGI	1.2e-113	414.8	100.00%	80.49%	Dynactin subunit 1;OS=Crassostrea;PE=4;SV=1
GN020578.1	sp|K1RDI3|K1RDI3_CRAGI	5.9e-187	659.1	95.60%	94.84%	IQ domain-containing protein G;OS=Crassostrea;PE=4;SV=1
GN020579.1	sp|K1QVY6|K1QVY6_CRAGI	0.0e+00	1325.1	99.91%	63.32%	PDZ domain-containing protein 7;OS=Crassostrea;PE=4;SV=1
GN020580.1	sp|K1QPR6|K1QPR6_CRAGI	9.3e-119	432.2	76.80%	94.02%	Homeobox protein XHOX-7.1;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN020581.1	sp|K1QFZ6|K1QFZ6_CRAGI	2.7e-27	127.9	58.45%	46.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020448.1	sp|K1PHU8|K1PHU8_CRAGI	0.0e+00	1436.4	97.05%	68.13%	Limbin;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0007224|
GN020449.1	sp|A0A210Q568|A0A210Q568_MIZYE	1.0e-48	200.7	77.99%	34.54%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0007224|
GN020583.1	sp|K1Q139|K1Q139_CRAGI	6.1e-13	79.3	57.38%	63.77%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020450.1	sp|K1PXJ8|K1PXJ8_CRAGI	4.1e-100	369.8	95.48%	87.14%	Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020584.1	sp|K1QXF9|K1QXF9_CRAGI	4.2e-30	136.7	70.25%	60.91%	Acyl-protein thioesterase 2;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN020585.1	sp|K1QSS7|K1QSS7_CRAGI	1.3e-212	745.0	99.02%	61.84%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN020451.1	sp|K1PXJ8|K1PXJ8_CRAGI	2.0e-152	544.3	93.51%	76.52%	Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020586.1	sp|K1Q726|K1Q726_CRAGI	0.0e+00	1116.7	100.00%	87.30%	Cytoplasmic polyadenylation element-binding protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003730|GO:0045182|
GN020587.1	sp|K1PNI1|K1PNI1_CRAGI	0.0e+00	1414.8	94.99%	85.52%	Bifunctional protein NCOAT;OS=Crassostrea;PE=4;SV=1
GN020588.1	sp|K1P2L7|K1P2L7_CRAGI	8.3e-192	675.6	99.81%	65.66%	Monocarboxylate transporter 12;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020452.1	sp|K1QHQ7|K1QHQ7_CRAGI	3.0e-14	84.3	39.18%	46.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020589.1	sp|K1Q7U8|K1Q7U8_CRAGI	8.3e-12	76.6	56.25%	32.17%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020590.1	sp|A0A2S2NY63|A0A2S2NY63_SCHGA	4.9e-53	214.2	84.31%	34.91%	Putative nuclease HARBI1;OS=Schizaphis;PE=4;SV=1
GN020591.1	sp|K1PX51|K1PX51_CRAGI	5.6e-33	147.5	49.33%	44.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|GO:0008270|
GN020592.1	sp|A0A2B4SSG5|A0A2B4SSG5_STYPI	7.8e-83	312.8	99.66%	56.46%	Putative E3 ubiquitin-protein ligase hulA;OS=Stylophora;PE=4;SV=1	GO:0016874|GO:0004842|
GN020593.1	sp|K1QZS3|K1QZS3_CRAGI	8.8e-23	112.8	98.16%	34.27%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN020453.1	sp|K1S021|K1S021_CRAGI	0.0e+00	1224.9	99.35%	70.46%	Putative ATP-dependent RNA helicase DDX11;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0005524|GO:0004003|GO:0003677|	GO:0006139|
GN020454.1	sp|K1RAG5|K1RAG5_CRAGI	0.0e+00	1187.9	99.21%	86.09%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020594.1	sp|K1PKQ4|K1PKQ4_CRAGI	2.7e-45	188.0	71.69%	48.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020595.1	sp|K1Q8S6|K1Q8S6_CRAGI	1.1e-282	978.4	90.89%	67.58%	AT-rich interactive domain-containing protein 5B;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|	GO:0006355|
GN020596.1	sp|K1QVZ4|K1QVZ4_CRAGI	0.0e+00	1086.6	100.00%	98.33%	Transcription factor collier;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0003677|GO:0046872|GO:0046983|	GO:0007275|GO:0006355|
GN020599.1	sp|K1PGW7|K1PGW7_CRAGI	1.2e-296	1025.0	56.28%	78.30%	Transmembrane protein 2;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005634|	GO:0003700|GO:0043565|
GN020600.1	sp|K1Q534|K1Q534_CRAGI	7.7e-28	129.4	95.08%	40.88%	Starch-binding domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:2001070|
GN020455.1	sp|K1R4B7|K1R4B7_CRAGI	5.1e-57	226.9	67.67%	65.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020601.1	sp|K1PKR4|K1PKR4_CRAGI	1.3e-73	281.2	98.66%	93.84%	A-kinase anchor protein 14;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN020602.1	sp|K1PSQ4|K1PSQ4_CRAGI	2.9e-84	317.4	63.12%	94.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020603.1	sp|K1PZZ5|K1PZZ5_CRAGI	2.9e-110	404.4	88.22%	61.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020605.1	sp|K1QVA2|K1QVA2_CRAGI	0.0e+00	1173.7	100.00%	73.71%	Rho guanine nucleotide exchange factor 7;OS=Crassostrea;PE=4;SV=1	GO:0005089|	GO:0035023|
GN020606.1	sp|K1QF69|K1QF69_CRAGI	2.7e-59	234.6	53.10%	74.51%	Complement C1q-like protein 4;OS=Crassostrea;PE=4;SV=1
GN020607.1	sp|V3ZVC0|V3ZVC0_LOTGI	7.1e-39	165.6	86.57%	72.17%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|
GN020609.1	sp|K1PIH9|K1PIH9_CRAGI	1.3e-21	109.0	75.11%	36.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020610.1	sp|K1R212|K1R212_CRAGI	4.4e-53	213.4	83.25%	65.45%	DNA polymerase delta subunit 3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0006260|
GN020611.1	sp|K1RLG8|K1RLG8_CRAGI	2.1e-123	447.6	86.53%	78.83%	Leucine carboxyl methyltransferase 1;OS=Crassostrea;PE=3;SV=1	GO:0018423|
GN020612.1	sp|K1QHL9|K1QHL9_CRAGI	3.0e-204	716.8	99.39%	76.31%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020613.1	sp|K1QRD4|K1QRD4_CRAGI	5.0e-145	519.2	96.25%	92.58%	S-formylglutathione hydrolase;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0052689|GO:0018738|	GO:0046294|
GN020456.1	sp|A0A1I8J146|A0A1I8J146_9PLAT	2.5e-10	70.1	57.14%	55.32%	Uncharacterized protein;OS=Macrostomum;PE=4;SV=1
GN020614.1	sp|A0A210PXH0|A0A210PXH0_MIZYE	1.3e-158	565.1	98.86%	68.14%	Uncharacterized protein CXorf58;OS=Mizuhopecten;PE=4;SV=1
GN020615.1	sp|K1QRD9|K1QRD9_CRAGI	8.2e-90	335.9	100.00%	65.72%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020616.1	sp|K1QV31|K1QV31_CRAGI	3.0e-218	764.6	100.00%	48.51%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020617.1	sp|K1QQG5|K1QQG5_CRAGI	1.2e-13	81.6	63.79%	53.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN020457.1	sp|A0A210QWB1|A0A210QWB1_MIZYE	4.5e-18	95.9	97.73%	52.94%	Neurofilament heavy polypeptide;OS=Mizuhopecten;PE=4;SV=1
GN020620.1	sp|K1RED4|K1RED4_CRAGI	5.3e-24	117.1	71.14%	43.43%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020622.1	sp|K1QK73|K1QK73_CRAGI	6.0e-78	296.6	99.67%	79.61%	DDRGK domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020623.1	sp|K1QSM6|K1QSM6_CRAGI	1.3e-270	937.6	99.66%	80.24%	Uncharacterized protein C2orf42;OS=Crassostrea;PE=4;SV=1
GN020624.1	sp|K1Q497|K1Q497_CRAGI	4.7e-265	919.1	93.36%	83.90%	Putative glycerol kinase 5;OS=Crassostrea;PE=4;SV=1	GO:0016301|GO:0016773|	GO:0005975|
GN020458.1	sp|K1RID2|K1RID2_CRAGI	1.9e-48	198.4	77.39%	50.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006353|
GN020625.1	sp|K1Q8A0|K1Q8A0_CRAGI	7.4e-105	386.0	67.68%	96.50%	Eukaryotic translation initiation factor 4E type 2;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0003743|
GN020626.1	sp|K1QXD8|K1QXD8_CRAGI	3.1e-81	307.0	100.00%	83.56%	Mediator of RNA polymerase II transcription subunit 4;OS=Crassostrea;PE=3;SV=1	GO:0016592|	GO:0003712|	GO:0006357|
GN020627.1	sp|K1QBL3|K1QBL3_CRAGI	5.2e-136	489.2	100.00%	91.60%	Putative phosphoglycerate mutase;OS=Crassostrea;PE=3;SV=1	GO:0004619|	GO:0006096|
GN020628.1	sp|K1Q1L2|K1Q1L2_CRAGI	4.9e-23	113.6	40.49%	67.07%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020629.1	sp|K1PHR7|K1PHR7_CRAGI	5.5e-91	340.1	69.34%	67.63%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020630.1	sp|K1PHR7|K1PHR7_CRAGI	4.1e-22	110.9	25.56%	70.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020631.1	sp|A0A210QKL3|A0A210QKL3_MIZYE	1.9e-16	90.9	95.65%	45.60%	Polyadenylate-binding protein-interacting protein 2B;OS=Mizuhopecten;PE=4;SV=1	GO:0000900|	GO:0045947|
GN020459.1	sp|V4AE92|V4AE92_LOTGI	7.0e-75	286.2	97.31%	51.28%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN020460.1	sp|K1Q3Q1|K1Q3Q1_CRAGI	8.8e-96	355.9	80.94%	63.64%	THAP domain-containing protein 4;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN020632.1	sp|K1Q4T7|K1Q4T7_CRAGI	6.6e-185	652.5	100.00%	68.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020633.1	sp|K1R4P9|K1R4P9_CRAGI	1.0e-151	542.0	100.00%	78.61%	WD repeat-containing protein 32;OS=Crassostrea;PE=4;SV=1
GN020634.1	sp|K1R4F7|K1R4F7_CRAGI	3.3e-98	363.2	98.94%	98.92%	Ras-related protein Rab-6B;OS=Crassostrea;PE=4;SV=1	GO:0005525|GO:0003924|
GN020635.1	sp|K1QRX4|K1QRX4_CRAGI	5.9e-19	99.4	78.13%	41.41%	C-type mannose receptor 2;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN020641.1	sp|K1PIL5|K1PIL5_CRAGI	1.9e-146	524.2	95.45%	82.86%	Lysine-specific demethylase 6A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0071558|GO:0046872|GO:0008168|	GO:0010468|
GN020642.1	sp|A0A210R6Y3|A0A210R6Y3_MIZYE	1.1e-49	202.2	93.78%	52.13%	Methylosome subunit pICln;OS=Mizuhopecten;PE=4;SV=1	GO:0005829|GO:0034709|GO:0034715|GO:0005886|	GO:0006884|GO:0006821|GO:0000387|
GN020643.1	sp|K1QF17|K1QF17_CRAGI	1.1e-12	79.7	90.51%	27.78%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020644.1	sp|A0A1X7TKE0|A0A1X7TKE0_AMPQE	4.0e-25	119.4	100.00%	59.38%	Uncharacterized protein;OS=Amphimedon;PE=4;SV=1	GO:0046983|
GN020462.1	sp|K1RID2|K1RID2_CRAGI	3.1e-26	124.4	74.46%	36.71%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0006353|
GN020645.1	sp|K1QQG5|K1QQG5_CRAGI	1.5e-13	81.6	48.68%	53.42%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN020647.1	sp|K1R4Q2|K1R4Q2_CRAGI	9.4e-81	305.4	100.00%	68.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020463.1	sp|V4AE92|V4AE92_LOTGI	7.3e-83	312.8	97.44%	53.11%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0006353|
GN020648.1	sp|K1QCG3|K1QCG3_CRAGI	7.8e-132	475.7	96.32%	85.35%	Sodium/hydrogen exchanger 7;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0015385|	GO:0006885|
GN020649.1	sp|K1RK09|K1RK09_CRAGI	5.9e-144	516.2	100.00%	74.12%	Sodium/hydrogen exchanger 9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0015299|GO:0004888|
GN020650.1	sp|K1RK09|K1RK09_CRAGI	3.3e-156	557.0	97.51%	69.62%	Sodium/hydrogen exchanger 9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0015299|GO:0004888|
GN020651.1	sp|K1RK09|K1RK09_CRAGI	8.9e-157	558.9	94.94%	69.62%	Sodium/hydrogen exchanger 9;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0015299|GO:0004888|
GN020652.1	sp|K1RCD4|K1RCD4_CRAGI	1.3e-70	272.3	46.77%	90.73%	Sperm flagellar protein 1;OS=Crassostrea;PE=4;SV=1	GO:0031514|
GN020653.1	sp|K1QPL7|K1QPL7_CRAGI	2.0e-103	382.9	26.60%	73.99%	Sperm flagellar protein 1;OS=Crassostrea;PE=4;SV=1	GO:0031514|
GN020654.1	sp|K1R5S0|K1R5S0_CRAGI	2.7e-224	783.9	65.15%	90.44%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020655.1	sp|K1R5S0|K1R5S0_CRAGI	1.5e-214	751.1	83.37%	86.28%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020656.1	sp|K1P7H5|K1P7H5_CRAGI	7.3e-135	486.5	93.37%	51.18%	Sodium-dependent glucose transporter 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008643|GO:0055085|
GN020657.1	sp|K1RVR5|K1RVR5_CRAGI	7.6e-43	180.3	45.65%	63.47%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020658.1	sp|K1R5S6|K1R5S6_CRAGI	3.2e-275	952.6	100.00%	93.22%	Spermine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020659.1	sp|A0A210PPF6|A0A210PPF6_MIZYE	1.3e-90	338.6	94.68%	62.55%	LRP2-binding protein;OS=Mizuhopecten;PE=4;SV=1
GN020660.1	sp|K1RCE1|K1RCE1_CRAGI	1.6e-128	466.1	93.94%	46.61%	Zinc finger protein Xfin;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020661.1	sp|K1RCE1|K1RCE1_CRAGI	4.3e-24	117.1	95.52%	46.60%	Zinc finger protein Xfin;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020464.1	sp|K1RDQ0|K1RDQ0_CRAGI	1.6e-33	148.7	100.00%	55.56%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020662.1	sp|K1RCE1|K1RCE1_CRAGI	6.2e-177	627.5	99.76%	51.88%	Zinc finger protein Xfin;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020663.1	sp|A0A210PPF6|A0A210PPF6_MIZYE	1.6e-130	471.5	100.00%	66.76%	LRP2-binding protein;OS=Mizuhopecten;PE=4;SV=1
GN020664.1	sp|K1Q6U8|K1Q6U8_CRAGI	1.4e-128	464.9	94.75%	67.58%	Membrane progestin receptor beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020665.1	sp|K1Q6U8|K1Q6U8_CRAGI	3.4e-130	470.3	94.75%	67.89%	Membrane progestin receptor beta;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020666.1	sp|A0A1Z5L4K9|A0A1Z5L4K9_ORNMO	7.6e-11	73.2	44.60%	37.23%	Uncharacterized protein;OS=Ornithodoros;PE=4;SV=1	GO:0008270|
GN020667.1	sp|K1PEH1|K1PEH1_CRAGI	2.1e-10	72.4	26.61%	45.74%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020668.1	sp|K1PZC7|K1PZC7_CRAGI	1.5e-117	429.5	92.54%	59.86%	Ankyrin repeat domain-containing protein 55;OS=Crassostrea;PE=4;SV=1
GN020669.1	sp|K1QZX2|K1QZX2_CRAGI	6.2e-82	309.3	76.08%	91.14%	Xaa-Pro aminopeptidase 1;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0070006|
GN020671.1	sp|K1QZX2|K1QZX2_CRAGI	8.1e-186	655.6	72.97%	89.14%	Xaa-Pro aminopeptidase 1;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0070006|
GN020672.1	sp|K1QDW7|K1QDW7_CRAGI	1.2e-172	611.3	98.43%	90.42%	L-Fucosyltransferase;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008107|	GO:0005975|GO:0006486|
GN020438.1	sp|K1Q5F6|K1Q5F6_CRAGI	8.8e-203	711.8	96.85%	82.11%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020673.1	sp|K1PZC0|K1PZC0_CRAGI	1.3e-97	361.3	97.99%	93.30%	Structural maintenance of chromosomes protein;OS=Crassostrea;PE=3;SV=1	GO:0005694|GO:0005634|	GO:0005524|	GO:0051276|
GN020674.1	sp|K1QZW5|K1QZW5_CRAGI	3.2e-224	783.1	98.92%	86.27%	Solute carrier family 2, facilitated glucose transporter member 8;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0022857|	GO:0008643|
GN020675.1	sp|K1PUY1|K1PUY1_CRAGI	8.2e-71	271.9	99.36%	85.81%	E3 ubiquitin-protein ligase MARCH5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0016874|GO:0008270|
GN020676.1	sp|K1Q2G2|K1Q2G2_CRAGI	3.2e-55	220.3	89.71%	67.95%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020677.1	sp|K1QA09|K1QA09_CRAGI	7.8e-129	465.7	99.68%	74.12%	Cyclin-J;OS=Crassostrea;PE=3;SV=1	GO:0005634|
GN020678.1	sp|K1QH41|K1QH41_CRAGI	7.3e-178	629.8	80.65%	76.04%	PWWP domain-containing protein 2A;OS=Crassostrea;PE=4;SV=1
GN020466.1	sp|K1PZL1|K1PZL1_CRAGI	0.0e+00	1398.6	89.59%	61.54%	Putative serine/threonine-protein kinase pats1;OS=Crassostrea;PE=4;SV=1	GO:0016301|	GO:0007165|
GN020685.1	sp|K1QFH9|K1QFH9_CRAGI	2.0e-38	163.7	86.27%	90.80%	Serine/threonine-protein kinase Nek1;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0004672|
GN020686.1	sp|K1QJA5|K1QJA5_CRAGI	6.3e-34	149.4	75.93%	67.48%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020687.1	sp|K1QHP8|K1QHP8_CRAGI	0.0e+00	1161.4	93.56%	96.15%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020688.1	sp|K1QCT0|K1QCT0_CRAGI	1.9e-166	590.9	82.68%	89.49%	Sideroflexin;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0031966|	GO:0015075|
GN020689.1	sp|K1PKH7|K1PKH7_CRAGI	4.1e-66	256.9	66.53%	83.65%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0008285|GO:0032007|
GN020690.1	sp|K1PTE8|K1PTE8_CRAGI	1.5e-73	281.6	97.81%	72.07%	Mediator of RNA polymerase II transcription subunit 28;OS=Crassostrea;PE=4;SV=1
GN020691.1	sp|K1R526|K1R526_CRAGI	1.8e-278	963.8	98.72%	76.68%	Ectonucleoside triphosphate diphosphohydrolase 7;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0016787|
GN020692.1	sp|K1RPJ0|K1RPJ0_CRAGI	5.0e-125	453.4	66.58%	79.01%	Telomerase Cajal body protein 1;OS=Crassostrea;PE=4;SV=1
GN020693.1	sp|K1RPJ0|K1RPJ0_CRAGI	1.4e-29	134.4	86.24%	70.83%	Telomerase Cajal body protein 1;OS=Crassostrea;PE=4;SV=1
GN020694.1	sp|K1QJ82|K1QJ82_CRAGI	4.3e-64	250.0	81.86%	71.10%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020695.1	sp|K1PTZ3|K1PTZ3_CRAGI	5.7e-70	271.6	42.87%	44.82%	Proline-, glutamic acid-and leucine-rich protein 1;OS=Crassostrea;PE=4;SV=1	GO:0006364|
GN020696.1	sp|A0A210R241|A0A210R241_MIZYE	0.0e+00	1340.9	99.83%	52.53%	Kyphoscoliosis peptidase;OS=Mizuhopecten;PE=4;SV=1
GN020697.1	sp|A0A210PYE6|A0A210PYE6_MIZYE	4.2e-48	196.1	100.00%	75.65%	Transmembrane protein 230;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN020700.1	sp|K1PK61|K1PK61_CRAGI	1.3e-19	100.9	95.24%	61.73%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020701.1	sp|A0A210QKK6|A0A210QKK6_MIZYE	1.5e-227	795.0	95.51%	49.06%	Endothelin-converting enzyme 1;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0004222|
GN020702.1	sp|K1QRA9|K1QRA9_CRAGI	1.6e-63	248.4	63.64%	73.99%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020703.1	sp|K1PR38|K1PR38_CRAGI	1.4e-76	291.6	90.09%	78.95%	TAR DNA-binding protein 43;OS=Crassostrea;PE=4;SV=1	GO:0003677|GO:0003723|
GN020704.1	sp|K1Q646|K1Q646_CRAGI	1.3e-255	887.9	99.04%	72.56%	NHL repeat-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0005623|	GO:0045454|
GN020705.1	sp|K1QD93|K1QD93_CRAGI	1.5e-13	81.3	45.05%	67.35%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020706.1	sp|K1RFG5|K1RFG5_CRAGI	2.9e-203	713.8	100.00%	76.01%	TWiK family of potassium channels protein 18;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005267|
GN020707.1	sp|A0A210QT46|A0A210QT46_MIZYE	6.9e-17	92.4	95.87%	41.38%	N-acetylated-alpha-linked acidic dipeptidase-like protein;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|
GN020468.1	sp|K1QZ10|K1QZ10_CRAGI	2.4e-107	394.4	84.07%	64.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0019200|	GO:0006493|
GN020709.1	sp|K1Q4M2|K1Q4M2_CRAGI	7.8e-127	459.1	99.70%	66.57%	N-acetylated-alpha-linked acidic dipeptidase-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005507|GO:0016715|
GN020710.1	sp|K1QZ10|K1QZ10_CRAGI	1.1e-107	395.6	84.07%	64.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0019200|	GO:0006493|
GN020711.1	sp|K1QLK4|K1QLK4_CRAGI	5.6e-60	237.7	95.87%	31.69%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020712.1	sp|K1QZ10|K1QZ10_CRAGI	1.1e-107	395.6	84.07%	64.08%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0019200|	GO:0006493|
GN020715.1	sp|J9KE05|J9KE05_ACYPI	2.3e-25	121.3	97.07%	33.84%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=2	GO:0046983|
GN020716.1	sp|A0A2B4S2P0|A0A2B4S2P0_STYPI	1.3e-56	226.1	98.24%	33.49%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN020717.1	sp|A0A210Q0W7|A0A210Q0W7_MIZYE	4.1e-57	226.9	100.00%	56.36%	G-protein coupled receptor B0563.6;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0008528|
GN020718.1	sp|V3YX33|V3YX33_LOTGI	9.5e-20	102.1	80.45%	47.17%	Uncharacterized protein;OS=Lottia;PE=4;SV=1
GN020719.1	sp|K1Q021|K1Q021_CRAGI	3.0e-86	324.3	78.98%	59.64%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020439.1	sp|K1Q5F6|K1Q5F6_CRAGI	2.6e-144	516.9	99.29%	88.93%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020720.1	sp|K1QCD7|K1QCD7_CRAGI	3.8e-60	236.5	89.74%	79.86%	Homeobox protein not2;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN020721.1	sp|A0A2B4SFR2|A0A2B4SFR2_STYPI	1.8e-15	87.8	96.88%	41.27%	Uncharacterized protein KIAA1958-like;OS=Stylophora;PE=4;SV=1	GO:0005739|	GO:0003677|	GO:0051607|GO:0015074|GO:0006310|
GN020722.1	sp|K1QT83|K1QT83_CRAGI	1.7e-161	574.7	96.47%	74.31%	Neuronal acetylcholine receptor subunit alpha-10;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|
GN020724.1	sp|K1RDI4|K1RDI4_CRAGI	2.8e-29	135.6	99.38%	38.55%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020725.1	sp|A0A2B4SK87|A0A2B4SK87_STYPI	5.3e-29	134.0	86.94%	28.99%	Uncharacterized protein;OS=Stylophora;PE=4;SV=1
GN020470.1	sp|K1QI28|K1QI28_CRAGI	1.9e-295	1020.0	91.67%	97.67%	V-type proton ATPase subunit B;OS=Crassostrea;PE=3;SV=1	GO:0033180|	GO:0005524|	GO:0015991|GO:0046034|
GN020728.1	sp|K1PS02|K1PS02_CRAGI	1.0e-117	429.1	91.46%	60.37%	Uncharacterized protein C10orf88-like protein;OS=Crassostrea;PE=4;SV=1
GN020731.1	sp|A0A210QVK7|A0A210QVK7_MIZYE	2.9e-103	381.7	47.92%	60.54%	ELMO domain-containing protein 3;OS=Mizuhopecten;PE=4;SV=1	GO:0005096|
GN020732.1	sp|K1RWJ1|K1RWJ1_CRAGI	1.6e-31	142.1	98.82%	37.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020472.1	sp|K1Q1D3|K1Q1D3_CRAGI	2.7e-13	81.6	37.96%	41.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020734.1	sp|K1PCA9|K1PCA9_CRAGI	1.4e-30	138.7	67.16%	50.00%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020735.1	sp|K1PHL0|K1PHL0_CRAGI	4.6e-224	782.3	100.00%	83.72%	LIM domain-containing protein unc-97;OS=Crassostrea;PE=4;SV=1	GO:0046872|
GN020736.1	sp|K1PB45|K1PB45_CRAGI	1.8e-52	211.1	100.00%	70.66%	Mid1-interacting protein 1;OS=Crassostrea;PE=4;SV=1
GN020737.1	sp|K1R1C6|K1R1C6_CRAGI	3.2e-246	856.3	97.75%	85.12%	Calpain-5;OS=Crassostrea;PE=3;SV=1	GO:0004198|
GN020739.1	sp|K1QYT2|K1QYT2_CRAGI	1.7e-166	591.7	91.55%	58.37%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020740.1	sp|K1PBN4|K1PBN4_CRAGI	1.3e-179	634.8	99.31%	71.69%	Ankyrin-1;OS=Crassostrea;PE=4;SV=1
GN020741.1	sp|K1QRG7|K1QRG7_CRAGI	2.2e-85	320.9	76.86%	86.86%	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005743|	GO:0046872|	GO:0006099|
GN020743.1	sp|K1QHR1|K1QHR1_CRAGI	2.2e-58	232.3	96.61%	29.85%	Amiloride-sensitive cation channel 1, neuronal;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005272|
GN020744.1	sp|K1QHQ3|K1QHQ3_CRAGI	8.3e-96	355.5	100.00%	79.40%	Rho GTPase-activating protein 19;OS=Crassostrea;PE=4;SV=1	GO:0007165|
GN020746.1	sp|K1RG21|K1RG21_CRAGI	5.0e-217	759.2	100.00%	77.75%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN020747.1	sp|K1RG21|K1RG21_CRAGI	1.4e-56	227.3	14.83%	77.37%	Heat shock 70 kDa protein 12A;OS=Crassostrea;PE=4;SV=1
GN020749.1	sp|K1QJV0|K1QJV0_CRAGI	1.9e-65	255.0	81.34%	70.39%	Neurogenic locus notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0005509|GO:0008061|	GO:0006030|
GN020750.1	sp|K1QJV0|K1QJV0_CRAGI	5.4e-84	315.8	98.24%	90.96%	Neurogenic locus notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0005576|GO:0016021|	GO:0005509|GO:0008061|	GO:0006030|
GN020751.1	sp|K1PDN7|K1PDN7_CRAGI	1.5e-114	419.5	54.97%	66.26%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020752.1	sp|K1P7L7|K1P7L7_CRAGI	0.0e+00	1163.7	100.00%	91.35%	Intraflagellar transport protein 81-like protein;OS=Crassostrea;PE=4;SV=1	GO:0030992|GO:0031514|	GO:0015631|	GO:0060271|GO:0042073|
GN020473.1	sp|K1R5G5|K1R5G5_CRAGI	0.0e+00	1142.5	94.04%	90.48%	Insulin-degrading enzyme;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004222|
GN020753.1	sp|K1PT96|K1PT96_CRAGI	2.9e-104	383.6	100.00%	76.50%	Metallo-beta-lactamase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1
GN020754.1	sp|K1QJT8|K1QJT8_CRAGI	2.4e-177	627.5	84.74%	70.59%	Steroid 17-alpha-hydroxylase/17,20 lyase;OS=Crassostrea;PE=3;SV=1	GO:0020037|GO:0005506|GO:0016829|GO:0004497|GO:0016705|
GN020755.1	sp|K1QRB4|K1QRB4_CRAGI	0.0e+00	1686.0	82.38%	80.83%	Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003677|GO:0018024|GO:0046872|
GN020474.1	sp|K1R5G5|K1R5G5_CRAGI	6.2e-175	619.0	100.00%	81.69%	Insulin-degrading enzyme;OS=Crassostrea;PE=3;SV=1	GO:0046872|GO:0004222|
GN020756.1	sp|K1R8G7|K1R8G7_CRAGI	2.4e-270	936.8	94.82%	77.92%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020757.1	sp|A0A210PPN3|A0A210PPN3_MIZYE	7.2e-73	279.6	54.90%	88.46%	Protein MAK16 homolog;OS=Mizuhopecten;PE=3;SV=1	GO:0005730|
GN020440.1	sp|K1Q5F6|K1Q5F6_CRAGI	0.0e+00	1577.8	96.80%	90.32%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020758.1	sp|K1QYI6|K1QYI6_CRAGI	0.0e+00	1350.9	99.44%	96.48%	Cullin-3-B;OS=Crassostrea;PE=3;SV=1	GO:0031461|	GO:0031625|	GO:0006511|
GN020759.1	sp|K1R095|K1R095_CRAGI	1.3e-190	671.8	99.83%	61.94%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020475.1	sp|K1QZ38|K1QZ38_CRAGI	5.9e-242	842.4	74.50%	91.31%	Rhotekin;OS=Crassostrea;PE=4;SV=1	GO:0017049|	GO:0007266|GO:0032185|
GN020760.1	sp|K1R5L0|K1R5L0_CRAGI	2.8e-158	563.9	78.57%	89.97%	Vitamin D3 receptor;OS=Crassostrea;PE=3;SV=1	GO:0005634|	GO:0004879|GO:0043565|GO:0003707|GO:0008270|
GN020476.1	sp|K1Q2A5|K1Q2A5_CRAGI	3.3e-49	200.3	95.38%	56.71%	Complement C1q tumor necrosis factor-related protein 3;OS=Crassostrea;PE=4;SV=1
GN020761.1	sp|K1RQ64|K1RQ64_CRAGI	1.5e-155	554.7	100.00%	71.69%	Aminoglycoside phosphotransferase domain-containing protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016740|
GN020762.1	sp|K1R9I2|K1R9I2_CRAGI	1.1e-92	345.5	100.00%	60.66%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020765.1	sp|K1PDE1|K1PDE1_CRAGI	0.0e+00	2748.4	83.50%	81.85%	WD repeat-containing protein C10orf79;OS=Crassostrea;PE=4;SV=1
GN020766.1	sp|K1QD82|K1QD82_CRAGI	1.5e-90	337.8	97.47%	85.42%	Activating signal cointegrator 1 complex subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0003723|
GN020767.1	sp|A0A210QSI0|A0A210QSI0_MIZYE	1.3e-12	77.4	89.71%	56.67%	WD repeat-containing protein 11;OS=Mizuhopecten;PE=4;SV=1
GN020477.1	sp|K1PAS1|K1PAS1_CRAGI	8.1e-11	73.2	49.78%	37.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020768.1	sp|K1Q2H3|K1Q2H3_CRAGI	3.0e-123	447.6	60.18%	83.97%	D-beta-hydroxybutyrate dehydrogenase;OS=Crassostrea;PE=3;SV=1
GN020769.1	sp|K1QQN7|K1QQN7_CRAGI	3.5e-197	694.9	89.12%	51.88%	SFI1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005813|
GN020770.1	sp|K1R641|K1R641_CRAGI	3.1e-256	890.2	73.54%	83.69%	Solute carrier family 23 member 2;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020771.1	sp|K1RPT8|K1RPT8_CRAGI	4.5e-46	190.7	72.60%	47.35%	Xaa-Pro aminopeptidase 2;OS=Crassostrea;PE=4;SV=1	GO:0004177|GO:0046872|
GN020772.1	sp|K1PUZ2|K1PUZ2_CRAGI	1.5e-178	631.3	99.77%	69.27%	Glycoprotein 3-alpha-L-fucosyltransferase A;OS=Crassostrea;PE=3;SV=1	GO:0032580|GO:0016021|	GO:0008417|	GO:0006486|
GN020773.1	sp|K1Q2H8|K1Q2H8_CRAGI	1.3e-300	1037.3	98.05%	85.24%	Atrial natriuretic peptide receptor A;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0004383|	GO:0035556|
GN020774.1	sp|K1QA35|K1QA35_CRAGI	1.6e-269	934.5	71.70%	78.16%	Guanylate cyclase 32E;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0004383|GO:0000166|	GO:0035556|
GN020775.1	sp|K1QRV6|K1QRV6_CRAGI	8.1e-75	286.6	96.21%	46.60%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020776.1	sp|K1QRV6|K1QRV6_CRAGI	1.2e-76	292.7	96.90%	41.89%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020777.1	sp|K1QRV6|K1QRV6_CRAGI	5.1e-77	293.9	97.25%	46.38%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020778.1	sp|K1QKI6|K1QKI6_CRAGI	3.1e-57	226.9	100.00%	62.50%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0061929|
GN020478.1	sp|R7V6Q1|R7V6Q1_CAPTE	2.8e-28	130.6	93.92%	46.38%	Uncharacterized protein;OS=Capitella;PE=4;SV=1
GN020779.1	sp|K1R934|K1R934_CRAGI	2.3e-138	497.3	96.71%	88.55%	Autophagy-related protein 3;OS=Crassostrea;PE=3;SV=1	GO:0005737|	GO:0006914|GO:0015031|
GN020780.1	sp|X1X991|X1X991_ACYPI	1.1e-23	115.2	84.62%	49.54%	Uncharacterized protein;OS=Acyrthosiphon;PE=4;SV=1
GN020781.1	sp|A0A1S3H799|A0A1S3H799_LINUN	1.2e-148	531.6	99.41%	80.42%	protein Mo25-like;OS=Lingula;PE=4;SV=1
GN020479.1	sp|K1Q1F5|K1Q1F5_CRAGI	1.4e-65	256.1	99.79%	32.94%	Tripartite motif-containing protein 2;OS=Crassostrea;PE=4;SV=1	GO:0008270|
GN020782.1	sp|K1PRN4|K1PRN4_CRAGI	1.3e-232	811.2	99.24%	72.92%	Dimethylaniline monooxygenase [N-oxide-forming];OS=Crassostrea;PE=3;SV=1	GO:0005789|GO:0016021|GO:0031090|	GO:0050660|GO:0004499|GO:0050661|
GN020783.1	sp|K1PZ23|K1PZ23_CRAGI	1.6e-181	641.3	90.54%	76.05%	DnaJ-like protein subfamily C member 3;OS=Crassostrea;PE=4;SV=1
GN020784.1	sp|K1QDD8|K1QDD8_CRAGI	1.2e-307	1061.2	100.00%	78.80%	Zinc finger protein DZIP1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020785.1	sp|K1PZS2|K1PZS2_CRAGI	9.3e-119	432.2	100.00%	72.67%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020786.1	sp|K1R1B8|K1R1B8_CRAGI	1.8e-71	274.2	87.36%	82.89%	Choline-phosphate cytidylyltransferase B;OS=Crassostrea;PE=4;SV=1	GO:0016779|	GO:0009058|
GN020787.1	sp|K1R1B8|K1R1B8_CRAGI	5.7e-135	486.5	75.29%	87.04%	Choline-phosphate cytidylyltransferase B;OS=Crassostrea;PE=4;SV=1	GO:0016779|	GO:0009058|
GN020788.1	sp|K1QM38|K1QM38_CRAGI	4.5e-295	1018.8	98.83%	86.95%	Monocarboxylate transporter 9;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020789.1	sp|K1QUH7|K1QUH7_CRAGI	0.0e+00	1412.9	75.75%	84.09%	Malignant fibrous histiocytoma-amplified sequence 1-like protein;OS=Crassostrea;PE=4;SV=1
GN020790.1	sp|K1RRV0|K1RRV0_CRAGI	9.0e-174	616.3	84.24%	50.56%	Putative deoxyribonuclease TATDN2;OS=Crassostrea;PE=4;SV=1	GO:0016788|
GN020791.1	sp|K1R7M1|K1R7M1_CRAGI	9.5e-86	322.8	86.41%	69.16%	Shootin-1;OS=Crassostrea;PE=4;SV=1
GN020792.1	sp|K1RDB3|K1RDB3_CRAGI	3.6e-94	349.7	92.93%	96.47%	F-box/WD repeat-containing protein 1A;OS=Crassostrea;PE=4;SV=1	GO:0046983|
GN020793.1	sp|K1QDR6|K1QDR6_CRAGI	2.7e-132	477.6	100.00%	61.21%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020794.1	sp|A0A210QU38|A0A210QU38_MIZYE	1.2e-157	561.6	96.46%	73.09%	Monocarboxylate transporter 12;OS=Mizuhopecten;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020796.1	sp|K1QDR8|K1QDR8_CRAGI	9.8e-68	265.0	15.94%	47.81%	Fibropellin-1;OS=Crassostrea;PE=4;SV=1	GO:0005576|	GO:0005509|GO:0008061|	GO:0006030|
GN020797.1	sp|K1QU52|K1QU52_CRAGI	0.0e+00	1742.2	99.46%	81.05%	HEAT repeat-containing protein 4;OS=Crassostrea;PE=4;SV=1
GN020798.1	sp|K1Q3T5|K1Q3T5_CRAGI	1.6e-132	478.0	100.00%	74.25%	Homeobox protein aristaless;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0043565|	GO:0006355|
GN020799.1	sp|K1QKW2|K1QKW2_CRAGI	3.0e-96	358.2	67.16%	54.55%	Monocarboxylate transporter 12-B;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020800.1	sp|A0A0P4WGA4|A0A0P4WGA4_9EUCA	2.2e-103	381.7	98.70%	41.29%	Uncharacterized protein;OS=Scylla;PE=4;SV=1
GN020801.1	sp|K1Q0K2|K1Q0K2_CRAGI	0.0e+00	3146.7	83.47%	77.01%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0005524|GO:0016887|
GN020480.1	sp|K1QAE5|K1QAE5_CRAGI	5.2e-121	441.0	100.00%	91.49%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020802.1	sp|K1RLP8|K1RLP8_CRAGI	2.8e-45	188.3	36.16%	65.93%	THAP domain-containing protein 10;OS=Crassostrea;PE=4;SV=1	GO:0003677|
GN020803.1	sp|K1RNA3|K1RNA3_CRAGI	3.0e-245	853.2	99.07%	78.88%	Solute carrier family 22 member 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020804.1	sp|K1RNA3|K1RNA3_CRAGI	4.5e-230	802.7	97.54%	76.44%	Solute carrier family 22 member 4;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0022857|
GN020805.1	sp|K1R1A5|K1R1A5_CRAGI	1.8e-122	445.7	33.24%	88.55%	Collagen alpha-1(IV) chain;OS=Crassostrea;PE=4;SV=1	GO:0005581|	GO:0005201|
GN020806.1	sp|A0A210QB58|A0A210QB58_MIZYE	6.7e-32	142.1	98.13%	60.58%	THAP domain-containing protein 6;OS=Mizuhopecten;PE=4;SV=1	GO:0003677|
GN020808.1	sp|K1RNE9|K1RNE9_CRAGI	1.2e-109	402.9	98.24%	36.15%	Neurogenic locus notch-like protein 1;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020481.1	sp|K1QJV2|K1QJV2_CRAGI	2.5e-137	494.2	99.21%	59.63%	Peroxisomal sarcosine oxidase;OS=Crassostrea;PE=4;SV=1	GO:0016491|
GN020809.1	sp|V3YXC0|V3YXC0_LOTGI	1.8e-89	335.5	75.37%	50.14%	Uncharacterized protein;OS=Lottia;PE=4;SV=1	GO:0016021|	GO:0055085|
GN020810.1	sp|K1R853|K1R853_CRAGI	5.4e-120	437.6	49.60%	79.95%	IWS1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0005634|
GN020482.1	sp|K1PX23|K1PX23_CRAGI	9.6e-250	867.8	100.00%	97.74%	Eukaryotic peptide chain release factor subunit 1;OS=Crassostrea;PE=4;SV=1	GO:0005737|	GO:0003747|
GN020811.1	sp|K1Q7K8|K1Q7K8_CRAGI	2.9e-20	105.1	81.18%	31.46%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020483.1	sp|K1PPW9|K1PPW9_CRAGI	5.3e-100	370.2	77.15%	62.15%	L-seryl-tRNA(Sec) kinase;OS=Crassostrea;PE=4;SV=1	GO:0016301|
GN020813.1	sp|K1QTE4|K1QTE4_CRAGI	1.4e-33	147.9	87.10%	66.36%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020814.1	sp|K1QJJ7|K1QJJ7_CRAGI	6.2e-93	345.9	91.74%	81.91%	Fumarylacetoacetate hydrolase domain-containing protein 1-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN020817.1	sp|K1QHD8|K1QHD8_CRAGI	9.2e-17	92.0	99.19%	43.90%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020818.1	sp|C3U1Y4|C3U1Y4_CRAVI	6.2e-152	542.3	100.00%	88.89%	Mitochondrial UCP5-like protein;OS=Crassostrea;PE=2;SV=1	GO:0016021|GO:0031966|	GO:0022857|	GO:0006839|
GN020819.1	sp|K1PE90|K1PE90_CRAGI	1.7e-52	211.8	97.35%	42.91%	Nuclear receptor subfamily 4 group A member 3;OS=Crassostrea;PE=4;SV=1	GO:0005634|	GO:0003700|GO:0043565|GO:0008270|
GN020820.1	sp|K1R057|K1R057_CRAGI	9.3e-230	801.6	90.43%	95.51%	C-terminal-binding protein;OS=Crassostrea;PE=3;SV=1	GO:0051287|GO:0016616|
GN020821.1	sp|K1PUG2|K1PUG2_CRAGI	3.5e-167	594.0	99.15%	50.34%	Heat shock 70 kDa protein 12B;OS=Crassostrea;PE=4;SV=1
GN020822.1	sp|K1RBT3|K1RBT3_CRAGI	4.9e-226	789.3	99.60%	76.10%	ATP-dependent RNA helicase SUV3-like protein, mitochondrial;OS=Crassostrea;PE=4;SV=1	GO:0004386|
GN020823.1	sp|K1RAW1|K1RAW1_CRAGI	2.7e-118	431.0	86.21%	58.38%	HSPB1-associated protein 1;OS=Crassostrea;PE=4;SV=1
GN020824.1	sp|K1PX54|K1PX54_CRAGI	2.7e-265	919.8	100.00%	92.86%	Pre-mRNA-splicing factor SLU7;OS=Crassostrea;PE=4;SV=1	GO:0030628|GO:0000386|	GO:0000398|
GN020825.1	sp|K1PQ55|K1PQ55_CRAGI	1.3e-122	446.0	95.91%	57.54%	Perlucin;OS=Crassostrea;PE=4;SV=1	GO:0030246|
GN020826.1	sp|K1R1D6|K1R1D6_CRAGI	4.5e-67	260.0	84.09%	72.28%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN020827.1	sp|K1QUI5|K1QUI5_CRAGI	1.1e-113	415.6	85.67%	66.77%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN020828.1	sp|K1PPF1|K1PPF1_CRAGI	2.2e-09	67.4	72.73%	54.88%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1
GN020829.1	sp|K1QUI5|K1QUI5_CRAGI	3.2e-89	334.0	81.12%	68.40%	Neuronal acetylcholine receptor subunit alpha-6;OS=Crassostrea;PE=3;SV=1	GO:0016021|	GO:0005230|GO:0004888|
GN020830.1	sp|K1QN02|K1QN02_CRAGI	2.9e-293	1013.1	79.83%	86.22%	Protein SERAC1;OS=Crassostrea;PE=4;SV=1
GN020831.1	sp|K1Q6Q3|K1Q6Q3_CRAGI	6.5e-101	372.5	86.03%	91.33%	Lipoma HMGIC fusion partner-like protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020832.1	sp|K1QU06|K1QU06_CRAGI	2.8e-204	716.8	100.00%	93.67%	Zinc finger protein ZIC 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020833.1	sp|K1QU06|K1QU06_CRAGI	2.8e-204	716.8	100.00%	93.67%	Zinc finger protein ZIC 1;OS=Crassostrea;PE=4;SV=1	GO:0003676|
GN020834.1	sp|K1QU05|K1QU05_CRAGI	4.1e-102	377.9	96.40%	37.40%	Hibernation-associated plasma protein HP-27;OS=Crassostrea;PE=4;SV=1
GN020835.1	sp|K1QMX8|K1QMX8_CRAGI	0.0e+00	1399.0	100.00%	95.85%	DNA replication licensing factor MCM7;OS=Crassostrea;PE=3;SV=1	GO:0042555|GO:0005634|	GO:0005524|GO:0003677|GO:0003678|	GO:0007049|GO:0006270|
GN020836.1	sp|A0A210R0D2|A0A210R0D2_MIZYE	3.2e-131	473.4	96.27%	86.82%	Defective in cullin neddylation protein;OS=Mizuhopecten;PE=4;SV=1
GN020838.1	sp|K1PP42|K1PP42_CRAGI	2.6e-100	370.5	98.76%	73.00%	Glutamate receptor delta-1 subunit;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN020839.1	sp|K1PP42|K1PP42_CRAGI	5.0e-197	692.6	94.99%	87.57%	Glutamate receptor delta-1 subunit;OS=Crassostrea;PE=3;SV=1	GO:0016021|GO:0005886|	GO:0004970|
GN020840.1	sp|K1RX71|K1RX71_CRAGI	1.1e-33	149.1	83.56%	82.97%	Ankyrin repeat domain-containing protein 39;OS=Crassostrea;PE=4;SV=1
GN020841.1	sp|K1RE08|K1RE08_CRAGI	9.5e-98	362.1	85.83%	81.52%	Haloacid dehalogenase-like hydrolase domain-containing protein 1A;OS=Crassostrea;PE=4;SV=1	GO:0016787|
GN020842.1	sp|A0A210PWN6|A0A210PWN6_MIZYE	1.2e-66	258.8	99.23%	51.56%	Uncharacterized protein;OS=Mizuhopecten;PE=4;SV=1
GN020843.1	sp|K1PQH0|K1PQH0_CRAGI	0.0e+00	2205.6	100.00%	80.34%	Multidrug resistance-associated protein 5;OS=Crassostrea;PE=4;SV=1	GO:0016021|	GO:0005524|GO:0042626|GO:0008514|
GN020844.1	sp|K1PUR8|K1PUR8_CRAGI	6.3e-97	359.4	98.81%	72.40%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
GN020845.1	sp|K1PUR8|K1PUR8_CRAGI	1.4e-117	427.9	100.00%	91.06%	Uncharacterized protein;OS=Crassostrea;PE=4;SV=1	GO:0016021|
